11058428
D013256_D013119 NONE steroid_2\NN\14727670|NONE (r_compound) myopathy_3\NN\14204950|naturally|,|Further|be|and (r_nsubj) recovers_4\VBZ\2210855|NONE (l_conj) be_15\VB\14625458|myopathy|naturally|,|Further|and (l_attr) recording_18\NN\6791372|may|.|improvement (l_cc) of_30\IN\0|,|just|a|of (l_pobj) protection_32\NN\407535|instead (l_relcl) methylprednisolone_34\NN\0|any (l_dobj) offers_35\VBZ\7160883|that (l_prep) to_36\IN\0|NONE (l_pobj) injury_40\NN\14052046|NONE
D013256_D013119 NONE steroid_26\NN\14727670|NONE (r_compound) myopathy_27\NNS\14204950|NONE (r_pobj) from_24\IN\0|this|motor|natural (r_prep) recovery_23\NN\7357388|NONE (r_pobj) of_19\IN\0|of|,|just|a (r_prep) recording_18\NN\6791372|may|.|improvement (l_cc) of_30\IN\0|,|just|a|of (l_pobj) protection_32\NN\407535|instead (l_relcl) methylprednisolone_34\NN\0|any (l_dobj) offers_35\VBZ\7160883|that (l_prep) to_36\IN\0|NONE (l_pobj) injury_40\NN\14052046|NONE
D013256_D009135 NONE steroid_2\NN\14727670|NONE (r_compound) myopathy_3\NN\14204950|naturally|,|Further|be|and
D013256_D009135 NONE steroid_2\NN\14727670|NONE (r_compound) myopathy_3\NN\14204950|naturally|,|Further|be|and (r_nsubj) recovers_4\VBZ\2210855|NONE (l_conj) be_15\VB\14625458|myopathy|naturally|,|Further|and (l_attr) recording_18\NN\6791372|may|.|improvement (l_prep) of_19\IN\0|of|,|just|a (l_pobj) recovery_23\NN\7357388|NONE (l_prep) from_24\IN\0|this|motor|natural (l_pobj) myopathy_27\NNS\14204950|NONE
D013256_D009135 NONE steroid_26\NN\14727670|NONE (r_compound) myopathy_27\NNS\14204950|NONE (r_pobj) from_24\IN\0|this|motor|natural (r_prep) recovery_23\NN\7357388|NONE (r_pobj) of_19\IN\0|of|,|just|a (r_prep) recording_18\NN\6791372|may|.|improvement (r_attr) be_15\VB\14625458|myopathy|naturally|,|Further|and (r_conj) recovers_4\VBZ\2210855|NONE (l_nsubj) myopathy_3\NN\14204950|naturally|,|Further|be|and
D013256_D009135 NONE steroid_26\NN\14727670|NONE (r_compound) myopathy_27\NNS\14204950|NONE
D000305_D009135 NONE corticosteroid_13\NN\14745635|NONE (r_pobj) of_11\IN\0|cause|myopathy|the (r_prep) possibility_10\NN\5944958|NONE (l_prep) myopathy_14\NNS\14204950|cause|of|the
D000305_D009135 NONE corticosteroid_21\NN\14745635|NONE (r_nsubj) myopathy_22\NNS\14204950|may|methylprednisolone|that
D008775_D009135 CID methylprednisolone_19\NN\0|that|may (r_nsubj) cause_21\VB\7323922|myopathy|of|the (r_acl) possibility_10\NN\5944958|NONE (l_prep) myopathy_14\NNS\14204950|cause|of|the
D008775_D009135 CID methylprednisolone_34\NN\0|any (r_relcl) protection_32\NN\407535|instead (r_pobj) of_30\IN\0|,|just|a|of (r_cc) recording_18\NN\6791372|may|.|improvement (r_attr) be_15\VB\14625458|myopathy|naturally|,|Further|and (r_conj) recovers_4\VBZ\2210855|NONE (l_nsubj) myopathy_3\NN\14204950|naturally|,|Further|be|and
D008775_D009135 CID methylprednisolone_34\NN\0|any (r_relcl) protection_32\NN\407535|instead (r_pobj) of_30\IN\0|,|just|a|of (r_cc) recording_18\NN\6791372|may|.|improvement (l_prep) of_19\IN\0|of|,|just|a (l_pobj) recovery_23\NN\7357388|NONE (l_prep) from_24\IN\0|this|motor|natural (l_pobj) myopathy_27\NNS\14204950|NONE
D008775_D009135 CID methylprednisolone_14\NN\0|myopathy|may|that (r_nsubj) cause_19\VB\7323922|the (l_ccomp) myopathy_22\NNS\14204950|may|methylprednisolone|that
D008775_D013119 NONE methylprednisolone_3\NN\0|harm|.|may (r_nsubj) do_5\VB\7447641|NONE (l_dobj) harm_7\NN\14052046|methylprednisolone|.|may (l_prep) for_8\IN\0|more (l_pobj) injury_11\NN\14052046|NONE
D008775_D013119 NONE methylprednisolone_16\NN\0|.|Because|standard (r_nsubj) became_17\VBD\146138|NONE (l_prep) because_0\IN\0|.|methylprednisolone|standard (l_pobj) studies_8\NNP\635850|of (l_compound) injury_7\NNP\14052046|(|the|,|National|NASCIS
D008775_D013119 NONE methylprednisolone_16\NN\0|.|Because|standard (r_nsubj) became_17\VBD\146138|NONE (l_attr) standard_19\NN\13577171|.|methylprednisolone|Because (l_prep) for_22\IN\0|of|the (l_pobj) injury_27\NN\14052046|NONE
D008775_D013119 NONE methylprednisolone_34\NN\0|any (l_dobj) offers_35\VBZ\7160883|that (l_prep) to_36\IN\0|NONE (l_pobj) injury_40\NN\14052046|NONE
7785794
D008790_D007022 CID metoprolol_32\NN\2832168|NONE (r_pobj) of_31\IN\0|concomitant (r_prep) use_30\NN\407535|NONE (r_pobj) with_28\IN\0|a|therapeutic|of (r_prep) dose_22\NN\3740161|days (r_pobj) after_19\IN\0|with|.|woman (r_prep) presented_9\VBN\2137132|NONE (l_prep) with_10\IN\0|after|.|woman (l_pobj) block_13\NN\21939|NONE (l_conj) hypotension_16\NN\14057371|heart|complete|and
D004298_D007022 NONE dopamine_28\NN\14807737|such (r_pobj) as_27\IN\14622893|pressor (r_prep) agents_25\NNS\7347|NONE (r_pobj) of_23\IN\0|high (r_prep) doses_22\NNS\3740161|of|multiple (r_conj) uses_14\NNS\407535|even (r_pobj) with_12\IN\0|to|,|hypotensive (r_prep) remain_4\VB\2604760|patient|. (l_acomp) hypotensive_5\JJ\10405694|to|,|with
D004280_D007022 NONE dobutamine_30\NN\0|and (r_conj) dopamine_28\NN\14807737|such (r_pobj) as_27\IN\14622893|pressor (r_prep) agents_25\NNS\7347|NONE (r_pobj) of_23\IN\0|high (r_prep) doses_22\NNS\3740161|of|multiple (r_conj) uses_14\NNS\407535|even (r_pobj) with_12\IN\0|to|,|hypotensive (r_prep) remain_4\VB\2604760|patient|. (l_acomp) hypotensive_5\JJ\10405694|to|,|with
D001285_D007022 NONE atropine_17\NN\14712692|NONE (r_pobj) of_15\IN\0|doses|multiple (r_prep) uses_14\NNS\407535|even (r_pobj) with_12\IN\0|to|,|hypotensive (r_prep) remain_4\VB\2604760|patient|. (l_acomp) hypotensive_5\JJ\10405694|to|,|with
D008790_D006327 CID metoprolol_11\NN\2832168|Refractory|after|.|block|and|and|cardiogenic (r_conj) shock_2\NN\7510495|NONE (l_conj) block_6\NN\21939|Refractory|after|metoprolol|.|and|and|cardiogenic
D008790_D006327 CID metoprolol_32\NN\2832168|NONE (r_pobj) of_31\IN\0|concomitant (r_prep) use_30\NN\407535|NONE (r_pobj) with_28\IN\0|a|therapeutic|of (r_prep) dose_22\NN\3740161|days (r_pobj) after_19\IN\0|with|.|woman (r_prep) presented_9\VBN\2137132|NONE (l_prep) with_10\IN\0|after|.|woman (l_pobj) block_13\NN\21939|NONE
D008790_D012770 NONE metoprolol_11\NN\2832168|Refractory|after|.|block|and|and|cardiogenic (r_conj) shock_2\NN\7510495|NONE
D004280_D006327 NONE dobutamine_30\NN\0|and (r_conj) dopamine_28\NN\14807737|such (r_pobj) as_27\IN\14622893|pressor (r_prep) agents_25\NNS\7347|NONE (r_pobj) of_23\IN\0|high (r_prep) doses_22\NNS\3740161|of|multiple (r_conj) uses_14\NNS\407535|even (r_pobj) with_12\IN\0|to|,|hypotensive (r_prep) remain_4\VB\2604760|patient|. (l_acomp) hypotensive_5\JJ\10405694|to|,|with (l_prep) with_6\IN\0|NONE (l_pobj) block_9\NN\21939|NONE
D002122_D006327 NONE chloride_9\NN\14818238|NONE (l_conj) hypotension_13\NN\14057371|intravenous|calcium|, (l_conj) block_17\NN\21939|the|and|refractory
D014700_D007022 CID verapamil_27\NN\2938514|NONE (r_pobj) of_23\IN\0|a|therapeutic|with (r_prep) dose_22\NN\3740161|days (r_pobj) after_19\IN\0|with|.|woman (r_prep) presented_9\VBN\2137132|NONE (l_prep) with_10\IN\0|after|.|woman (l_pobj) block_13\NN\21939|NONE (l_conj) hypotension_16\NN\14057371|heart|complete|and
D002122_D007022 NONE chloride_9\NN\14818238|NONE (l_conj) hypotension_13\NN\14057371|intravenous|calcium|,
D004298_D006327 NONE dopamine_28\NN\14807737|such (r_pobj) as_27\IN\14622893|pressor (r_prep) agents_25\NNS\7347|NONE (r_pobj) of_23\IN\0|high (r_prep) doses_22\NNS\3740161|of|multiple (r_conj) uses_14\NNS\407535|even (r_pobj) with_12\IN\0|to|,|hypotensive (r_prep) remain_4\VB\2604760|patient|. (l_acomp) hypotensive_5\JJ\10405694|to|,|with (l_prep) with_6\IN\0|NONE (l_pobj) block_9\NN\21939|NONE
D014700_D012770 NONE verapamil_8\NN\2938514|NONE (r_compound) sr_9\NNP\14625458|NONE (r_pobj) after_7\IN\0|Refractory|metoprolol|.|block|and|and|cardiogenic (r_prep) shock_2\NN\7510495|NONE
D001285_D006327 NONE atropine_17\NN\14712692|NONE (r_pobj) of_15\IN\0|doses|multiple (r_prep) uses_14\NNS\407535|even (r_pobj) with_12\IN\0|to|,|hypotensive (r_prep) remain_4\VB\2604760|patient|. (l_acomp) hypotensive_5\JJ\10405694|to|,|with (l_prep) with_6\IN\0|NONE (l_pobj) block_9\NN\21939|NONE
D014700_D006327 CID verapamil_8\NN\2938514|NONE (r_compound) sr_9\NNP\14625458|NONE (r_pobj) after_7\IN\0|Refractory|metoprolol|.|block|and|and|cardiogenic (r_prep) shock_2\NN\7510495|NONE (l_conj) block_6\NN\21939|Refractory|after|metoprolol|.|and|and|cardiogenic
D014700_D006327 CID verapamil_27\NN\2938514|NONE (r_pobj) of_23\IN\0|a|therapeutic|with (r_prep) dose_22\NN\3740161|days (r_pobj) after_19\IN\0|with|.|woman (r_prep) presented_9\VBN\2137132|NONE (l_prep) with_10\IN\0|after|.|woman (l_pobj) block_13\NN\21939|NONE
3057041
C020976_D006255 NONE azelastine_18\NN\0|NONE (r_pobj) of_17\IN\0|safety (r_prep) trial_16\NN\786195|,|groups|and|,|in|dose (r_conj) efficacy_13\NN\5199286|.|,|blind (l_prep) in_24\IN\13603305|trial|,|groups|and|,|dose (l_pobj) treatment_26\NN\654885|NONE (l_prep) of_27\IN\0|the (l_pobj) rhinitis_30\NN\14336539|NONE
C020976_D006255 NONE azelastine_0\NNP\0|with|.|was (r_nsubjpass) compared_8\VBN\644583|NONE (l_prep) with_9\IN\0|.|Azelastine|was (l_pobj) maleate_11\NN\2718811|NONE (l_prep) for_14\IN\0|chlorpheniramine|placebo|and (l_pobj) efficacy_15\NN\5199286|NONE (l_prep) in_18\IN\13603305|and|safety (l_pobj) treatment_20\NN\654885|NONE (l_prep) of_21\IN\0|the|in (l_pobj) rhinitis_24\NN\14336539|NONE
C020976_D006255 NONE azelastine_0\NNP\0|.|be (r_nsubj) appears_1\VBZ\2604760|NONE (l_xcomp) be_3\VB\14625458|Azelastine|. (l_attr) medication_8\NN\3247620|to (l_prep) for_9\IN\0|safe|,|efficacious|a (l_pobj) rhinitis_12\NN\14336539|NONE
C020976_D006970 CID azelastine_16\NN\0|dose|the (r_compound) group_17\NN\2137|only (r_pobj) in_11\IN\13603305|significantly|.|over|were|Drowsiness (r_prep) increased_6\VBN\169651|NONE (l_nsubjpass) drowsiness_0\VB\14015731|significantly|.|over|were|in
D002744_D006255 NONE chlorpheniramine_20\NN\0|, (r_conj) azelastine_18\NN\0|NONE (r_pobj) of_17\IN\0|safety (r_prep) trial_16\NN\786195|,|groups|and|,|in|dose (r_conj) efficacy_13\NN\5199286|.|,|blind (l_prep) in_24\IN\13603305|trial|,|groups|and|,|dose (l_pobj) treatment_26\NN\654885|NONE (l_prep) of_27\IN\0|the (l_pobj) rhinitis_30\NN\14336539|NONE
D002744_D006255 NONE maleate_11\NN\2718811|NONE (l_prep) for_14\IN\0|chlorpheniramine|placebo|and (l_pobj) efficacy_15\NN\5199286|NONE (l_prep) in_18\IN\13603305|and|safety (l_pobj) treatment_20\NN\654885|NONE (l_prep) of_21\IN\0|the|in (l_pobj) rhinitis_24\NN\14336539|NONE
C020976_D013651 CID azelastine_16\NN\0|dose|the (r_compound) group_17\NN\2137|only (r_pobj) in_11\IN\13603305|significantly|.|over|were|Drowsiness (r_prep) increased_6\VBN\169651|NONE (l_nsubjpass) drowsiness_0\VB\14015731|significantly|.|over|were|in (l_conj) perception_4\NN\5926676|and
9214597
D004967_D009369 NONE estrogen_14\NN\14745635| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) rat_17\NN\2329401|pituitary (r_nmod) tumors_19\NNS\14234074|NONE (r_pobj) of_13\IN\0|the (r_prep) development_12\NN\248977|NONE (r_pobj) during_10\IN\0|its (r_prep) receptor_9\NN\5225602|endothelial|and|growth|vascular (r_conj) factor_6\NN\7326557|NONE (r_pobj) of_2\IN\0|NONE (r_prep) expression_1\NN\4679549|NONE (r_pobj) over_0\IN\5867413|may|angiogenesis|. (r_prep) mediate_21\VB\761713|NONE (l_dobj) angiogenesis_26\NN\13489037|Over|may|. (l_compound) tumor_25\NN\14234074|initiated
D004967_D009369 NONE estrogen_22\NN\14745635| (r_npadvmod) initiated_24\VBN\1617192|tumor (r_amod) angiogenesis_26\NN\13489037|Over|may|. (l_compound) tumor_25\NN\14234074|initiated
D004967_D009369 NONE estrogens_0\NNP\14745635|in|.|can|angiogenesis (l_relcl) associated_5\VBN\628491|,|, (l_prep) with_6\IN\0|been|have|which (l_pobj) types_8\NNS\5839024|NONE (l_prep) of_9\IN\0|several (l_pobj) cancers_13\NNS\14239425|NONE
D004967_D009369 NONE estrogens_0\NNP\14745635|in|.|can|angiogenesis (r_nsubj) induce_16\VB\1627355|NONE (l_dobj) angiogenesis_18\NN\13489037|Estrogens|in|.|can (l_compound) tumor_17\NN\14234074|NONE
D004967_D009369 NONE estrogen_9\NN\14745635|NONE (r_compound) carcinogenesis_10\NN\0|NONE (r_pobj) during_8\IN\0|still|unknown|.|,|details|, (r_prep) are_12\VBP\13600404|NONE (l_nsubj) details_2\NNS\6634376|still|unknown|.|during|,|, (l_prep) of_3\IN\0|induction|mechanistic|The (l_pobj) angiogenesis_5\NN\13489037|NONE (l_compound) tumor_4\NN\14234074|NONE
D004967_D009369 NONE estrogen_5\NN\14745635|NONE (r_pobj) of_4\IN\0|the (r_prep) role_3\NN\719494|To|in (r_dobj) elucidate_1\VB\939277|was|density|,|using (l_prep) in_6\IN\13603305|role|To (l_pobj) regulation_8\NN\6652242|NONE (l_prep) of_9\IN\0|the|in (l_pobj) angiogenesis_11\NN\13489037|NONE (l_compound) tumor_10\NN\14234074|NONE
D004967_D009369 NONE estrogen_27\NN\14745635|NONE (r_pobj) of_26\IN\0|the (r_prep) regulation_25\NN\6652242|NONE (r_pobj) of_23\IN\0|the|initial (r_prep) step_22\NN\168237|NONE (r_pobj) in_19\IN\13603305|may|over|that|role (r_prep) play_15\VB\7007684|.|induced|findings (r_ccomp) suggest_2\VBP\1010118|NONE (l_ccomp) induced_28\VBN\1627355|.|findings|play (l_dobj) angiogenesis_30\NN\13489037|in (l_compound) tumor_29\NN\14234074|NONE
D004967_D010911 NONE estrogen_14\NN\14745635| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) rat_17\NN\2329401|pituitary (r_nmod) tumors_19\NNS\14234074|NONE
D004967_D010911 NONE estrogen_22\NN\14745635| (r_npadvmod) initiated_24\VBN\1617192|tumor (r_amod) angiogenesis_26\NN\13489037|Over|may|. (r_dobj) mediate_21\VB\761713|NONE (l_prep) over_0\IN\5867413|may|angiogenesis|. (l_pobj) expression_1\NN\4679549|NONE (l_prep) of_2\IN\0|NONE (l_pobj) factor_6\NN\7326557|NONE (l_conj) receptor_9\NN\5225602|endothelial|and|growth|vascular (l_prep) during_10\IN\0|its (l_pobj) development_12\NN\248977|NONE (l_prep) of_13\IN\0|the (l_pobj) tumors_19\NNS\14234074|NONE
D004967_D063646 NONE estrogen_9\NN\14745635|NONE (r_compound) carcinogenesis_10\NN\0|NONE
15893386
D015742_D008305 NONE propofol_5\JJ\0|NONE (r_amod) infusion_6\NN\14589223|NONE (r_pobj) with_4\IN\0|.|were|was|Anesthesia|uneventfully (r_prep) continued_2\VBN\2367363|NONE (l_advcl) were_10\VBD\0|.|was|Anesthesia|uneventfully|with (l_acomp) available_11\JJ\0|facilities|while (l_xcomp) detect_13\VB\2163746|NONE (l_conj) treat_15\VB\7570720|to|and (l_dobj) hyperthermia_17\NN\14034177|NONE
D013390_D014313 CID succinylcholine_0\NN\3800001| (r_npadvmod) induced_2\VBN\1627355|during|masseter|.|muscle (r_amod) rigidity_5\NN\5023233|NONE
D013390_D014313 CID succinylcholine_17\NN\3800001|)|Sch|(|during (r_nmod) administration_21\NN\1133281|NONE (r_pobj) after_16\IN\0|case|Here|we|.|, (r_prep) describe_3\VBP\1001294|NONE (l_dobj) case_5\NN\7283608|Here|we|.|,|after (l_prep) of_6\IN\0|a (l_pobj) rigidity_10\NN\5023233|NONE
D013390_D014313 CID succinylcholine_17\NN\3800001|)|Sch|(|during (r_nmod) administration_21\NN\1133281|NONE (r_pobj) after_16\IN\0|case|Here|we|.|, (r_prep) describe_3\VBP\1001294|NONE (l_dobj) case_5\NN\7283608|Here|we|.|,|after (l_prep) of_6\IN\0|a (l_pobj) rigidity_10\NN\5023233|NONE (l_appos) jaw_12\NN\5269901|masseter|severe|)|muscle|( (l_prep) of_13\IN\0|NONE (l_pobj) steel_14\NN\14586769|NONE
D013390_D014313 CID sch_19\NNP\0|)|(|succinylcholine|during (r_nmod) administration_21\NN\1133281|NONE (r_pobj) after_16\IN\0|case|Here|we|.|, (r_prep) describe_3\VBP\1001294|NONE (l_dobj) case_5\NN\7283608|Here|we|.|,|after (l_prep) of_6\IN\0|a (l_pobj) rigidity_10\NN\5023233|NONE
D013390_D014313 CID sch_19\NNP\0|)|(|succinylcholine|during (r_nmod) administration_21\NN\1133281|NONE (r_pobj) after_16\IN\0|case|Here|we|.|, (r_prep) describe_3\VBP\1001294|NONE (l_dobj) case_5\NN\7283608|Here|we|.|,|after (l_prep) of_6\IN\0|a (l_pobj) rigidity_10\NN\5023233|NONE (l_appos) jaw_12\NN\5269901|masseter|severe|)|muscle|( (l_prep) of_13\IN\0|NONE (l_pobj) steel_14\NN\14586769|NONE
3461217
D013739_D011471 NONE testosterone_21\NN\14747587|N||nitroso||and (r_conj) methylurea_19\NN\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatments_11\NNS\654885|NONE (r_pobj) by_10\IN\0|.|of (r_prep) production_0\NN\30358|NONE (l_prep) of_1\IN\0|.|by (l_pobj) cancer_4\NN\14239425|NONE
D043343_D009369 NONE tp_6\NNP\0|.|as|,|In|,|with (r_nsubj) acted_7\VBD\0|NONE (l_prep) as_8\IN\14622893|.|TP|,|In|,|with (l_pobj) agent_12\NN\7347|NONE (l_compound) enhancement_11\NN\248977|a (l_compound) tumor_10\NN\14234074|NONE
D043343_D011471 CID propionate_45\NN\0||(|and|)|: (r_conj) cas_35\NN\14625458|nitroso|N|| (r_appos) methylurea_33\NN\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treatments_25\NNS\654885|NONE (r_pobj) following_24\VBG\8180190|rats|PAs (r_prep) developed_15\VBD\1753788|% (l_dobj) pas_22\FW\285557|following|rats (l_nmod) adenocarcinomas_20\NNS\14242337|palpable|large|)|,|(|prostate
D043343_D011471 CID propionate_45\NN\0||(|and|)|: (r_conj) cas_35\NN\14625458|nitroso|N|| (r_appos) methylurea_33\NN\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treatments_25\NNS\654885|NONE (r_pobj) following_24\VBG\8180190|rats|PAs (r_prep) developed_15\VBD\1753788|% (l_dobj) pas_22\FW\285557|following|rats
D043343_D011471 CID tp_19\NNP\0|only (r_pobj) with_18\IN\0|when (r_prep) treated_16\VBN\2376958|PA|.|rat|,|Within (r_advcl) developed_10\VBD\1753788|NONE (l_dobj) pa_14\NNP\10080869|treated|.|rat|,|Within
D043343_D011471 CID tp_6\NNP\0|.|as|,|In|,|with (r_nsubj) acted_7\VBD\0|NONE (l_prep) with_14\IN\0|.|as|TP|,|In|, (l_pobj) emphasis_16\NN\14434681|NONE (l_prep) on_17\IN\0|primary (l_pobj) development_19\NN\248977|NONE (l_prep) of_20\IN\0|the (l_pobj) cancer_22\NN\14239425|NONE
D008770_D011471 CID methylurea_19\NN\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatments_11\NNS\654885|NONE (r_pobj) by_10\IN\0|.|of (r_prep) production_0\NN\30358|NONE (l_prep) of_1\IN\0|.|by (l_pobj) cancer_4\NN\14239425|NONE
D008770_D011471 CID methylurea_33\NN\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treatments_25\NNS\654885|NONE (r_pobj) following_24\VBG\8180190|rats|PAs (r_prep) developed_15\VBD\1753788|% (l_dobj) pas_22\FW\285557|following|rats (l_nmod) adenocarcinomas_20\NNS\14242337|palpable|large|)|,|(|prostate
D008770_D011471 CID methylurea_33\NN\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treatments_25\NNS\654885|NONE (r_pobj) following_24\VBG\8180190|rats|PAs (r_prep) developed_15\VBD\1753788|% (l_dobj) pas_22\FW\285557|following|rats
8251368
D017311_D013684 CID amlodipine_6\NN\0|One|later|with|,|. (r_dobj) commenced_1\VBD\0|NONE (l_prep) with_11\IN\0|One|later|amlodipine|,|. (l_pobj) recurrence_12\NN\7342049|NONE (l_prep) of_13\IN\0|NONE (l_pobj) telangiectasia_14\NN\0|NONE
D009543_D013684 CID nifedipine_1\RB\2938514| (r_advmod) induced_3\VBN\1627355|facial (r_amod) telangiectasia_5\NN\0|.
D009543_D013684 CID nifedipine_4\NN\2938514|Adalat (r_dobj) starting_3\VBG\457382|months (r_pcomp) after_2\IN\0|patients|,|.|telangiectasia (r_prep) developed_11\VBD\1753788|NONE (l_dobj) telangiectasia_14\NN\0|patients|,|after|.
D009543_D013684 CID adalat_6\NNP\0|nifedipine (r_oprd) starting_3\VBG\457382|months (r_pcomp) after_2\IN\0|patients|,|.|telangiectasia (r_prep) developed_11\VBD\1753788|NONE (l_dobj) telangiectasia_14\NN\0|patients|,|after|.
17019386
D008353_D009362 NONE mannitol_2\NN\3214670|: (r_appos) methods_0\NNS\5616786|was|had|.|as (r_nsubjpass) administered_14\VBN\2436349|NONE (l_parataxis) had_22\VBD\0|was|METHODS|.|as (l_dobj) glioma_24\NN\14236743|ten|(|before (l_conj) metastases_28\NNS\13533470|malignant|)|,
D008353_D009362 NONE mannitol_8\NN\3214670|NONE (r_pobj) of_7\IN\0|plasma|patients (r_prep) concentrations_6\NNS\4916342|higher|except|.|In (l_compound) patients_4\NNS\9898892|plasma|of (l_nmod) meningioma_1\NN\14235200|NONE (l_conj) metastases_3\NNS\13533470|and
D008353_D004487 NONE mannitol_13\NN\3214670|,|reversing|through|,|near|that|after|may (r_nsubj) leak_15\VB\9304465|of|.|The (l_advcl) reversing_23\VBG\109660|,|through|,|near|that|after|may|mannitol (l_conj) aggravating_34\VBG\126264|gradient|, (l_dobj) edema_36\NN\14315192|and|promoting
D008353_D005910 NONE mannitol_2\NN\3214670|NONE (r_pobj) of_1\IN\0|into (r_prep) passage_0\NN\199130|.|:|cause (r_nsubj) gliomas_7\NNS\14236743|NONE
D008353_D005910 NONE mannitol_2\NN\3214670|: (r_appos) methods_0\NNS\5616786|was|had|.|as (r_nsubjpass) administered_14\VBN\2436349|NONE (l_parataxis) had_22\VBD\0|was|METHODS|.|as (l_dobj) glioma_24\NN\14236743|ten|(|before
D008353_D005910 NONE mannitol_5\NN\3214670|in (r_amod) concentrations_6\NNS\4916342|mean|,|In|higher|. (r_nsubj) were_10\VBD\0|NONE (l_prep) in_0\IN\13603305|mean|,|higher|concentrations|. (l_pobj) patients_3\NNS\9898892|NONE (l_compound) glioma_2\NN\14236743|most
D008353_D005910 NONE mannitol_13\NN\3214670|,|reversing|through|,|near|that|after|may (r_nsubj) leak_15\VB\9304465|of|.|The (l_prep) near_20\IN\1849221|,|reversing|through|,|that|after|may|mannitol (l_pobj) gliomas_21\NNS\14236743|NONE
D008353_D019586 CID mannitol_5\NN\3214670|NONE (r_pobj) of_4\IN\0|reduce|Widespread (r_prep) use_3\NN\407535|continues|.|: (l_acl) reduce_7\VB\441445|of|Widespread (l_dobj) edema_9\NN\14315192|to (l_conj) icp_13\NNP\0|brain|and
D008353_D008579 NONE mannitol_2\NN\3214670|: (r_appos) methods_0\NNS\5616786|was|had|.|as (r_nsubjpass) administered_14\VBN\2436349|NONE (l_parataxis) had_22\VBD\0|was|METHODS|.|as (l_dobj) glioma_24\NN\14236743|ten|(|before (l_conj) metastases_28\NNS\13533470|malignant|)|, (l_conj) meningioma_31\NN\14235200|brain|seven|and
D008353_D008579 NONE mannitol_8\NN\3214670|NONE (r_pobj) of_7\IN\0|plasma|patients (r_prep) concentrations_6\NNS\4916342|higher|except|.|In (l_compound) patients_4\NNS\9898892|plasma|of (l_nmod) meningioma_1\NN\14235200|NONE
D008353_D001929 NONE mannitol_5\NN\3214670|NONE (r_pobj) of_4\IN\0|reduce|Widespread (r_prep) use_3\NN\407535|continues|.|: (l_acl) reduce_7\VB\441445|of|Widespread (l_dobj) edema_9\NN\14315192|to
D008353_D001932 NONE mannitol_5\NN\3214670|NONE (r_pobj) of_4\IN\0|reduce|Widespread (r_prep) use_3\NN\407535|continues|.|: (l_acl) reduce_7\VB\441445|of|Widespread (l_dobj) edema_9\NN\14315192|to (l_conj) icp_13\NNP\0|brain|and (l_prep) in_14\IN\13603305|lower|elevated (l_pobj) patients_17\NNS\9898892|NONE (l_compound) tumor_16\NN\14234074|NONE
D008353_D001932 NONE mannitol_14\NN\3214670|NONE (r_pobj) of_13\IN\0|the|into|possible (r_prep) passage_12\NN\199130|to|after|to (r_dobj) research_9\VB\633864|we|As|. (l_prep) to_20\IN\0|to|after|passage (l_pobj) patients_24\NNS\9898892|NONE (l_compound) tumor_23\NN\14234074|
9209318
D015215_D009190 CID azidothymidine_5\NN\0|NONE (r_pcomp) with_4\IN\0|Lifetime|AZT|of (r_prep) treatment_1\NN\654885|myelodysplasia|. (r_nsubj) produces_9\VBZ\7555863|NONE (l_dobj) myelodysplasia_10\NN\0|.|treatment
D015215_D009190 CID azt_7\NNP\3834836|Lifetime|with|of (r_appos) treatment_1\NN\654885|myelodysplasia|. (r_nsubj) produces_9\VBZ\7555863|NONE (l_dobj) myelodysplasia_10\NN\0|.|treatment
D015215_D009190 CID azt_2\NNP\3834836|NONE (r_compound) incorporation_3\NN\1237415|have|hemopoiesis|may (r_nsubj) induced_6\VBN\1627355|Above|. (l_dobj) hemopoiesis_9\NN\13526110|have|may|incorporation (l_prep) in_10\IN\13603305|ineffective|an (l_pobj) cells_15\NNS\3080309|NONE (l_relcl) known_19\VBN\0|the|primitive|progenitor|, (l_xcomp) seen_22\VBN\2106506|which|is (l_prep) in_24\IN\13603305|to|be|commonly (l_pobj) syndrome_27\NN\5870365|NONE
D015215_D000748 CID azt_0\NNP\3834836|.|anemia|has (r_nsubj) induced_2\VBN\1627355|NONE (l_dobj) anemia_5\NN\14189204|.|has|AZT
D015215_D000748 CID azt_12\NNP\3834836|NONE (r_compound) therapy_13\NN\657604|long (r_appos) term_11\NN\6286395|NONE (r_pobj) on_9\IN\0|a|macrocytic|in (r_prep) anemia_5\NN\14189204|.|has|AZT
D015215_D000163 NONE azt_0\NNP\3834836|.|anemia|has (r_nsubj) induced_2\VBN\1627355|NONE (l_dobj) anemia_5\NN\14189204|.|has|AZT (l_prep) in_6\IN\13603305|a|macrocytic|on (l_pobj) patients_8\NNS\9898892|NONE (l_compound) aids_7\NNP\13974317|NONE
D015215_D000163 NONE azt_12\NNP\3834836|NONE (r_compound) therapy_13\NN\657604|long (r_appos) term_11\NN\6286395|NONE (r_pobj) on_9\IN\0|a|macrocytic|in (r_prep) anemia_5\NN\14189204|.|has|AZT (l_prep) in_6\IN\13603305|a|macrocytic|on (l_pobj) patients_8\NNS\9898892|NONE (l_compound) aids_7\NNP\13974317|NONE
8514073
D003975_D010146 NONE diazepam_18\NN\2830852|the (r_compound) group_19\NN\2137|NONE (r_pobj) in_16\IN\13603305|NONE (r_prep) patients_15\NNS\9898892|NONE (r_pobj) of_14\IN\0|||(|) (r_prep) %_8\NN\0|NONE (r_pobj) in_6\IN\13603305|Pain|compared|. (r_prep) occurred_5\VBD\0|NONE (l_nsubj) pain_0\NN\14299637|in|compared|.
D000431_D014652 NONE alcohol_19\NN\7881800|and|pain|, (r_compound) use_20\NN\407535|of|,|dwell (r_conj) time_14\NN\7308889|intravenous|catheter|, (r_conj) site_11\NN\8673395|nonsteroidal|,|drug|inflammatory (r_conj) use_7\NN\407535|, (r_appos) smoking_0\NN\831191|effect|. (r_nsubj) had_27\VBD\0|NONE (l_dobj) effect_29\NN\34213|Smoking|. (l_prep) on_30\IN\0|no (l_pobj) incidence_32\NN\13821570|NONE (l_prep) of_33\IN\0|the (l_pobj) complications_35\NNS\1073995|NONE
D008874_D010146 NONE midazolam_32\JJ\2830852|the (r_amod) group_33\NN\2137|NONE (r_pobj) in_30\IN\13603305|)|patients|(||. (r_prep) %_23\NN\0|NONE (r_pobj) with_21\IN\0|NONE (r_prep) compared_20\VBN\644583|Pain|in|. (r_prep) occurred_5\VBD\0|NONE (l_nsubj) pain_0\NN\14299637|in|compared|.
D000431_D010146 NONE alcohol_19\NN\7881800|and|pain|, (r_compound) use_20\NN\407535|of|,|dwell (l_conj) pain_23\NN\14299637|and|alcohol|,
D008874_D014652 CID midazolam_3\FW\2830852|NONE (r_pobj) of_2\IN\0|.|Venous (r_prep) complications_1\NNS\1073995|NONE
D008874_D014652 CID midazolam_11\DT\2830852|NONE (r_pobj) with_10\IN\0|are|complications (r_prep) associated_9\VBN\628491|Although|have|studies (l_nsubjpass) complications_7\NNS\1073995|are|with
D008874_D014652 CID midazolam_14\NN\2830852|or (r_conj) diazepam_12\NN\2830852|NONE (r_pobj) of_11\IN\0|in|intravenous (r_prep) injection_10\NN\320852|NONE (r_pobj) after_8\IN\0|prospectively|.|We|incidence (r_prep) evaluated_2\VBD\670261|NONE (l_dobj) incidence_4\NN\13821570|prospectively|.|We|after (l_prep) of_5\IN\0|the (l_pobj) complications_7\NNS\1073995|NONE
D008874_D014652 CID midazolam_17\NNP\2830852|NONE (r_pobj) with_16\IN\0|. (r_prep) than_15\IN\0|(|of|) (r_prep) 22_10\CD\13745420|frequent|,|complications|Overall|. (r_npadvmod) were_4\VBD\0|NONE (l_nsubj) complications_3\NNS\1073995||frequent|,|Overall|.
D003975_D014652 CID diazepam_5\NN\2830852|NONE (r_pobj) versus_4\FW\0|NONE (r_prep) midazolam_3\FW\2830852|NONE (r_pobj) of_2\IN\0|.|Venous (r_prep) complications_1\NNS\1073995|NONE
D003975_D014652 CID diazepam_14\NN\2830852|NONE (r_pobj) with_13\IN\0|NONE (r_prep) than_12\IN\0|NONE (r_prep) midazolam_11\DT\2830852|NONE (r_pobj) with_10\IN\0|are|complications (r_prep) associated_9\VBN\628491|Although|have|studies (l_nsubjpass) complications_7\NNS\1073995|are|with
D003975_D014652 CID diazepam_12\NN\2830852|NONE (r_pobj) of_11\IN\0|in|intravenous (r_prep) injection_10\NN\320852|NONE (r_pobj) after_8\IN\0|prospectively|.|We|incidence (r_prep) evaluated_2\VBD\670261|NONE (l_dobj) incidence_4\NN\13821570|prospectively|.|We|after (l_prep) of_5\IN\0|the (l_pobj) complications_7\NNS\1073995|NONE
D003975_D014652 CID diazepam_8\NN\2830852|NONE (r_pobj) with_7\IN\0|more (r_prep) frequent_6\JJ\2556126||,|complications|Overall|. (r_acomp) were_4\VBD\0|NONE (l_nsubj) complications_3\NNS\1073995||frequent|,|Overall|.
6892185
D002122_D015878 NONE chloride_4\NN\14818238|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|)|fighting|injected|into|upon|, (r_nsubj) injected_5\VBD\81072|was|similarly|. (l_advcl) fighting_26\VBG\958896|)|injected|into|upon|,|effect (l_conj) mydriasis_43\NN\365995|attack|,
D002122_D015878 NONE chloride_24\NN\14818238|NONE (r_pobj) by_22\IN\0|significantly|On|not|were|mydriasis|.|, (r_agent) changed_21\VBN\0|NONE (l_nsubjpass) mydriasis_5\NN\365995|significantly|On|not|by|were|.|,
D002122_D015878 NONE chloride_5\NN\14818238|caused|"|can|that|from|"|vocalization (r_nsubj) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such
D002217_D004830 CID carbachol_53\NN\0|NONE (r_pobj) by_52\IN\0|NONE (r_agent) produced_51\VBN\1617192|tonic (r_acl) convulsions_50\NNS\14081375|and
D002217_D004830 CID carbachol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) evoked_13\VBN\1617192|tremor|, (r_acl) mydriasis_5\NN\365995|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN\345926|evoked|, (l_conj) convulsions_12\NNS\14081375|and
D002217_D004830 CID carbachol_30\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such (l_conj) tremor_22\NN\345926|, (l_conj) convulsions_27\NNS\14081375|and
D002122_D014202 NONE chloride_4\NN\14818238|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|)|fighting|injected|into|upon|, (r_nsubj) injected_5\VBD\81072|was|similarly|. (l_advcl) fighting_26\VBG\958896|)|injected|into|upon|,|effect (l_conj) mydriasis_43\NN\365995|attack|, (l_conj) tremor_45\NN\345926|,
D002122_D014202 NONE chloride_24\NN\14818238|NONE (r_pobj) by_22\IN\0|significantly|On|not|were|mydriasis|.|, (r_agent) changed_21\VBN\0|NONE (l_nsubjpass) mydriasis_5\NN\365995|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN\345926|evoked|,
D002122_D014202 NONE chloride_5\NN\14818238|caused|"|can|that|from|"|vocalization (r_nsubj) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such (l_conj) tremor_22\NN\345926|,
D010830_D015878 CID eserine_55\NN\0|and (r_conj) carbachol_53\NN\0|NONE (r_pobj) by_52\IN\0|NONE (r_agent) produced_51\VBN\1617192|tonic (r_acl) convulsions_50\NNS\14081375|and (r_conj) tremor_45\NN\345926|, (r_conj) mydriasis_43\NN\365995|attack|,
D010830_D015878 CID eserine_17\NN\0|and (r_conj) carbachol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) evoked_13\VBN\1617192|tremor|, (r_acl) mydriasis_5\NN\365995|significantly|On|not|by|were|.|,
D010830_D015878 CID eserine_32\NN\0|and (r_conj) carbachol_30\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such
D010830_D014202 CID eserine_55\NN\0|and (r_conj) carbachol_53\NN\0|NONE (r_pobj) by_52\IN\0|NONE (r_agent) produced_51\VBN\1617192|tonic (r_acl) convulsions_50\NNS\14081375|and (r_conj) tremor_45\NN\345926|,
D010830_D014202 CID eserine_17\NN\0|and (r_conj) carbachol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) evoked_13\VBN\1617192|tremor|, (r_acl) mydriasis_5\NN\365995|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN\345926|evoked|,
D010830_D014202 CID eserine_32\NN\0|and (r_conj) carbachol_30\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such (l_conj) tremor_22\NN\345926|,
D002217_D015878 CID carbachol_53\NN\0|NONE (r_pobj) by_52\IN\0|NONE (r_agent) produced_51\VBN\1617192|tonic (r_acl) convulsions_50\NNS\14081375|and (r_conj) tremor_45\NN\345926|, (r_conj) mydriasis_43\NN\365995|attack|,
D002217_D015878 CID carbachol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) evoked_13\VBN\1617192|tremor|, (r_acl) mydriasis_5\NN\365995|significantly|On|not|by|were|.|,
D002217_D015878 CID carbachol_30\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such
D002217_D014202 CID carbachol_53\NN\0|NONE (r_pobj) by_52\IN\0|NONE (r_agent) produced_51\VBN\1617192|tonic (r_acl) convulsions_50\NNS\14081375|and (r_conj) tremor_45\NN\345926|,
D002217_D014202 CID carbachol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) evoked_13\VBN\1617192|tremor|, (r_acl) mydriasis_5\NN\365995|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN\345926|evoked|,
D002217_D014202 CID carbachol_30\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such (l_conj) tremor_22\NN\345926|,
D002122_D004830 NONE chloride_4\NN\14818238|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|)|fighting|injected|into|upon|, (r_nsubj) injected_5\VBD\81072|was|similarly|. (l_advcl) fighting_26\VBG\958896|)|injected|into|upon|,|effect (l_conj) mydriasis_43\NN\365995|attack|, (l_conj) tremor_45\NN\345926|, (l_conj) convulsions_50\NNS\14081375|and
D002122_D004830 NONE chloride_24\NN\14818238|NONE (r_pobj) by_22\IN\0|significantly|On|not|were|mydriasis|.|, (r_agent) changed_21\VBN\0|NONE (l_nsubjpass) mydriasis_5\NN\365995|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN\345926|evoked|, (l_conj) convulsions_12\NNS\14081375|and
D002122_D004830 NONE chloride_5\NN\14818238|caused|"|can|that|from|"|vocalization (r_nsubj) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such (l_conj) tremor_22\NN\345926|, (l_conj) convulsions_27\NNS\14081375|and
D010830_D004830 CID eserine_55\NN\0|and (r_conj) carbachol_53\NN\0|NONE (r_pobj) by_52\IN\0|NONE (r_agent) produced_51\VBN\1617192|tonic (r_acl) convulsions_50\NNS\14081375|and
D010830_D004830 CID eserine_17\NN\0|and (r_conj) carbachol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) evoked_13\VBN\1617192|tremor|, (r_acl) mydriasis_5\NN\365995|significantly|On|not|by|were|.|, (l_conj) tremor_7\NN\345926|evoked|, (l_conj) convulsions_12\NNS\14081375|and
D010830_D004830 CID eserine_32\NN\0|and (r_conj) carbachol_30\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|"|chloride|can|that|from|"|vocalization (r_acl) dissociate_8\VB\2431320|apparent|.|It (l_prep) from_13\IN\0|caused|"|chloride|can|that|"|vocalization (l_pobj) phenomena_17\NNS\29677|NONE (l_prep) as_19\IN\14622893|autonomic (l_pobj) mydriasis_20\NN\365995|such (l_conj) tremor_22\NN\345926|, (l_conj) convulsions_27\NNS\14081375|and
11337188
D010068_D011693 NONE oxacillin_9\NN\3910417|NONE (r_pobj) with_8\IN\0|was|who|because|for (r_prep) treated_7\VBN\2376958|A|old (r_relcl) man_4\NN\9605289|failure|. (r_nsubj) developed_19\VBD\1753788|NONE (l_dobj) failure_21\NN\66216|man|. (l_appos) lesions_29\NNS\14204950|,|renal|diffuse|and
D010068_D051437 CID oxacillin_9\NN\3910417|NONE (r_pobj) with_8\IN\0|was|who|because|for (r_prep) treated_7\VBN\2376958|A|old (r_relcl) man_4\NN\9605289|failure|. (r_nsubj) developed_19\VBD\1753788|NONE (l_dobj) failure_21\NN\66216|man|.
D010068_D013203 NONE oxacillin_9\NN\3910417|NONE (r_pobj) with_8\IN\0|was|who|because|for (r_prep) treated_7\VBN\2376958|A|old (l_prep) because_13\IN\0|was|who|with|for (l_pobj) bacteremia_17\NN\14204950|of
D010068_D018366 CID oxacillin_5\NN\3910417|NONE (r_pobj) with_4\IN\0|NONE (r_prep) associated_3\VBN\628491|.|Cutaneous|leucocytoclastic (r_acl) vasculitis_2\NN\14336539|NONE
D010068_D018366 CID oxacillin_0\NNP\3910417|should|be|among|. (r_nsubjpass) included_3\VBN\0|NONE (l_prep) among_4\IN\0|should|Oxacillin|be|. (l_pobj) drugs_6\NNS\14778436|NONE (l_relcl) cause_9\VB\7323922|the (l_dobj) vasculitis_11\NN\14336539|that|can
D010068_D016470 NONE oxacillin_9\NN\3910417|NONE (r_pobj) with_8\IN\0|was|who|because|for (r_prep) treated_7\VBN\2376958|A|old (l_prep) because_13\IN\0|was|who|with|for (l_pobj) bacteremia_17\NN\14204950|of
6111982
D011433_D001145 NONE propranolol_6\NN\0|NONE (l_conj) pindolol_8\NN\2832168|and (l_xcomp) inhibiting_9\VBG\2510337|NONE (l_dobj) arrhythmia_12\NN\14103288|in
D010042_D001145 CID ouabain_11\JJ\0|the (r_compound) arrhythmia_12\NN\14103288|in
D010869_D001145 NONE pindolol_8\NN\2832168|and (l_xcomp) inhibiting_9\VBG\2510337|NONE (l_dobj) arrhythmia_12\NN\14103288|in
10533019
D004110_D013746 CID diltiazem_6\NN\2938514| (r_npadvmod) induced_8\VBN\1627355|threatening|with (r_amod) tetany_9\NN\14304060|NONE
D004110_D013746 CID diltiazem_16\NN\2938514|NONE (r_pobj) of_14\IN\0|the (r_prep) infusion_13\NN\14589223|NONE (r_pobj) after_11\IN\0|who|with|tetany (r_prep) developed_5\VBD\1753788|a (l_dobj) tetany_6\NN\14304060|after|who|with
D004110_D013746 CID diltiazem_17\NN\2938514|NONE (r_pobj) of_15\IN\0|the (r_prep) administration_14\NN\1133281|tetany|and|may|that|be (r_dobj) accompany_12\VB\0|NONE (l_nsubj) tetany_10\NN\14304060|and|administration|may|that|be
D004110_D012131 NONE diltiazem_16\NN\2938514|NONE (r_pobj) of_14\IN\0|the (r_prep) infusion_13\NN\14589223|NONE (r_pobj) after_11\IN\0|who|with|tetany (r_prep) developed_5\VBD\1753788|a (l_prep) with_7\IN\0|after|who|tetany (l_pobj) arrest_10\NN\88481|NONE
D002122_D013746 NONE chloride_12\NN\14818238|NONE (r_pobj) with_10\IN\0|threatening|induced (r_prep) tetany_9\NN\14304060|NONE
D002122_D013746 NONE chloride_4\NN\14818238|NONE (r_pobj) of_2\IN\0|The (r_prep) administration_1\NN\1133281|.|tetany|rapidly|,|averting (r_nsubj) resolved_6\VBD\352826|NONE (l_dobj) tetany_10\NN\14304060|.|rapidly|administration|,|averting
D002122_D013746 NONE chloride_21\NN\14818238|may|remedy|that (r_nsubj) be_23\VB\14625458|tetany|and|administration|may|that (r_conj) accompany_12\VB\0|NONE (l_nsubj) tetany_10\NN\14304060|and|administration|may|that|be
14982270
D011433_D006980 NONE propranolol_21\NN\0|(|)|tid|methimazole|and (l_prep) for_27\IN\0|tid (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|NONE (l_pobj) hyperthyroidism_30\NN\14059928|NONE
D008713_D011537 CID methimazole_14\NN\0|(|)|propranolol|tid|and (r_dobj) receiving_13\VBG\2210855|NONE (r_pcomp) after_12\IN\0|month (r_prep) itching_9\NN\5723210|woman|jaundice|and|.
D011433_D007565 NONE propranolol_21\NN\0|(|)|tid|methimazole|and (r_conj) receiving_13\VBG\2210855|NONE (r_pcomp) after_12\IN\0|month (r_prep) itching_9\NN\5723210|woman|jaundice|and|. (r_conj) had_5\VBD\0|NONE (l_dobj) jaundice_7\NN\14299637|woman|itching|and|.
D008713_D002779 NONE methimazole_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) cholestasis_3\NN\14052403|,|was|propranolol|and
D011433_D002779 NONE propranolol_8\NN\0|,|was|cholestasis|and (r_conj) diagnosed_5\VBN\644583|was|. (l_nsubjpass) cholestasis_3\NN\14052403|,|was|propranolol|and
D008713_D041781 CID methimazole_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|cholestatic|. (r_amod) jaundice_4\NN\14299637|NONE
D008713_D007565 NONE methimazole_14\NN\0|(|)|propranolol|tid|and (r_dobj) receiving_13\VBG\2210855|NONE (r_pcomp) after_12\IN\0|month (r_prep) itching_9\NN\5723210|woman|jaundice|and|. (r_conj) had_5\VBD\0|NONE (l_dobj) jaundice_7\NN\14299637|woman|itching|and|.
D008713_D006980 NONE methimazole_14\NN\0|(|)|propranolol|tid|and (r_dobj) receiving_13\VBG\2210855|NONE (l_conj) propranolol_21\NN\0|(|)|tid|methimazole|and (l_prep) for_27\IN\0|tid (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|NONE (l_pobj) hyperthyroidism_30\NN\14059928|NONE
D011433_D011537 NONE propranolol_21\NN\0|(|)|tid|methimazole|and (r_conj) receiving_13\VBG\2210855|NONE (r_pcomp) after_12\IN\0|month (r_prep) itching_9\NN\5723210|woman|jaundice|and|.
8638876
D011374_D012640 NONE progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (l_dobj) hemiparesis_17\NN\0|after (l_conj) seizure_19\NN\14081375|and
D011374_D014839 NONE progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (r_conj) developed_9\VBD\1753788|NONE (l_dobj) headache_10\NN\5829480|.|,|woman|left (l_conj) nausea_12\NN\14299637|, (l_conj) vomiting_14\NN\116687|and
D011374_D009325 NONE progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (r_conj) developed_9\VBD\1753788|NONE (l_dobj) headache_10\NN\5829480|.|,|woman|left (l_conj) nausea_12\NN\14299637|,
D011374_D002341 CID progesterone_13\NN\14747338|and (r_conj) estradiol_11\NN\14749794|NONE (r_pobj) of_10\IN\0|and|the|DM (r_prep) use_9\NN\407535|thrombogenicity|that (r_nsubj) increased_18\VBD\169651|authors|.|,|In (l_dobj) thrombogenicity_20\NN\0|use|that (l_relcl) provided_23\VBD\2199590|,|vascular (l_dobj) denominator_26\NN\13733167|which (l_prep) for_27\IN\0|common|a (l_pobj) thrombosis_28\NN\14100769|NONE (l_prep) of_29\IN\0|NONE (l_pobj) ica_32\NNP\0|NONE (l_conj) sinus_36\NN\5248181|and|both|the
D004958_D009325 NONE estradiol_28\NN\14749794|and (r_conj) progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (r_conj) developed_9\VBD\1753788|NONE (l_dobj) headache_10\NN\5829480|.|,|woman|left (l_conj) nausea_12\NN\14299637|,
D011374_D003920 NONE progesterone_13\NN\14747338|and (r_conj) estradiol_11\NN\14749794|NONE (r_pobj) of_10\IN\0|and|the|DM (r_prep) use_9\NN\407535|thrombogenicity|that (l_conj) dm_17\NNP\14117805|of|and|the
D004958_D010291 NONE estradiol_28\NN\14749794|and (r_conj) progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (l_dobj) hemiparesis_17\NN\0|after
D004958_D006261 NONE estradiol_28\NN\14749794|and (r_conj) progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (r_conj) developed_9\VBD\1753788|NONE (l_dobj) headache_10\NN\5829480|.|,|woman|left
D011374_D006261 NONE progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (r_conj) developed_9\VBD\1753788|NONE (l_dobj) headache_10\NN\5829480|.|,|woman|left
D004958_D002341 CID estradiol_11\NN\14749794|NONE (r_pobj) of_10\IN\0|and|the|DM (r_prep) use_9\NN\407535|thrombogenicity|that (r_nsubj) increased_18\VBD\169651|authors|.|,|In (l_dobj) thrombogenicity_20\NN\0|use|that (l_relcl) provided_23\VBD\2199590|,|vascular (l_dobj) denominator_26\NN\13733167|which (l_prep) for_27\IN\0|common|a (l_pobj) thrombosis_28\NN\14100769|NONE (l_prep) of_29\IN\0|NONE (l_pobj) ica_32\NNP\0|NONE (l_conj) sinus_36\NN\5248181|and|both|the
D004958_D014839 NONE estradiol_28\NN\14749794|and (r_conj) progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (r_conj) developed_9\VBD\1753788|NONE (l_dobj) headache_10\NN\5829480|.|,|woman|left (l_conj) nausea_12\NN\14299637|, (l_conj) vomiting_14\NN\116687|and
D011374_D010291 NONE progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (l_dobj) hemiparesis_17\NN\0|after
D004958_D003920 NONE estradiol_11\NN\14749794|NONE (r_pobj) of_10\IN\0|and|the|DM (r_prep) use_9\NN\407535|thrombogenicity|that (l_conj) dm_17\NNP\14117805|of|and|the
D011374_D012851 CID progesterone_13\NN\14747338|and (r_conj) estradiol_11\NN\14749794|NONE (r_pobj) of_10\IN\0|and|the|DM (r_prep) use_9\NN\407535|thrombogenicity|that (r_nsubj) increased_18\VBD\169651|authors|.|,|In (l_dobj) thrombogenicity_20\NN\0|use|that (l_relcl) provided_23\VBD\2199590|,|vascular (l_dobj) denominator_26\NN\13733167|which (l_prep) for_27\IN\0|common|a (l_pobj) thrombosis_28\NN\14100769|NONE (l_prep) of_29\IN\0|NONE (l_pobj) ica_32\NNP\0|NONE (l_conj) sinus_36\NN\5248181|and|both|the
D004958_D012851 CID estradiol_11\NN\14749794|NONE (r_pobj) of_10\IN\0|and|the|DM (r_prep) use_9\NN\407535|thrombogenicity|that (r_nsubj) increased_18\VBD\169651|authors|.|,|In (l_dobj) thrombogenicity_20\NN\0|use|that (l_relcl) provided_23\VBD\2199590|,|vascular (l_dobj) denominator_26\NN\13733167|which (l_prep) for_27\IN\0|common|a (l_pobj) thrombosis_28\NN\14100769|NONE (l_prep) of_29\IN\0|NONE (l_pobj) ica_32\NNP\0|NONE (l_conj) sinus_36\NN\5248181|and|both|the
D004958_D012640 NONE estradiol_28\NN\14749794|and (r_conj) progesterone_26\NN\14747338|NONE (r_pobj) of_25\IN\0|parenteral (r_prep) use_24\NN\407535|days (r_pobj) after_22\IN\0|hemiparesis (r_prep) left_16\VBD\8621598|headache|.|,|woman (l_dobj) hemiparesis_17\NN\0|after (l_conj) seizure_19\NN\14081375|and
6732043
D000728_D020181 CID androgen_12\JJ\14745635|exogenous (r_compound) administration_13\NN\1133281|NONE (r_pobj) by_10\IN\0|a (r_prep) woman_9\NN\9605289|NONE (r_pobj) in_7\IN\13603305|apnea|the (r_prep) syndrome_6\NN\5870365|NONE
D000728_D020181 CID androgens_36\NNS\14745635|being|while (r_dobj) administered_34\VBN\2436349|had|who|changes (r_advcl) developed_22\VBN\1753788|a|old (l_dobj) changes_24\NNS\7283608|had|administered|who (l_conj) syndrome_27\NN\5870365|and|physical (l_prep) of_28\IN\0|the (l_pobj) apnea_31\NN\14299637|NONE
D000728_D020181 CID androgen_3\NN\14745635|of|produced|abated (r_nmod) symptoms_5\NNS\5823932|NONE (l_prep) of_6\IN\0|androgen|produced|abated (l_pobj) apnea_9\NN\14299637|NONE
D000728_D020181 CID androgen_15\NN\14745635|NONE (r_compound) therapy_16\NN\657604|NONE (r_pobj) of_14\IN\0|side|a|possible (r_prep) effect_13\NN\34213|.|Development|be|must (r_oprd) considered_9\VBN\689344|NONE (l_nsubjpass) development_0\NN\248977|effect|.|be|must (l_prep) of_1\IN\0|NONE (l_pobj) syndrome_6\NN\5870365|NONE
D000728_D012891 NONE androgens_7\NNS\14745635|NONE (r_pobj) of_6\IN\0|a (r_prep) role_5\NN\719494|have|in|reports|. (r_dobj) favored_3\VBN\2397637|NONE (l_prep) in_8\IN\13603305|have|reports|role|. (l_pobj) pathogenesis_10\NN\13533470|NONE (l_prep) of_11\IN\0|the (l_pobj) apnea_13\NN\14299637|NONE
15814210
D003907_D009422 CID dexamethasone_19\NN\2721538|in (r_compound) treatment_20\NN\654885|NONE (r_pobj) after_18\IN\0|at|Minor|,|development|.|neurological (r_prep) dysfunction_2\NN\14204950|NONE
D003907_D009422 CID dexamethasone_19\NN\2721538|in (r_compound) therapy_20\NN\657604|NONE (r_pobj) after_18\IN\0|dysfunction|to (r_prep) assess_7\VB\5220461|.|objective (l_dobj) dysfunction_10\NN\14204950|after|to
D003907_D009422 CID dexamethasone_1\NN\2721538|NONE (r_compound) treatment_2\NN\654885|NONE (r_pobj) after_0\IN\0|rate|,|.|children (r_prep) showed_5\VBD\2137132|NONE (l_dobj) rate_8\NN\13815152|,|After|.|children (l_prep) of_9\IN\0|a|higher (l_pobj) dysfunctions_12\NNS\14204950|NONE
6153967
D004737_D012640 CID enflurane_4\NN\3299929|.|In|,|in (r_nsubj) resulted_10\VBD\2633881|NONE (l_prep) in_11\IN\13603305|.|enflurane|In|, (l_pobj) seizures_15\NNS\14081375|NONE
D004737_D012640 CID enflurane_6\NN\3299929|NONE (r_pobj) by_5\IN\0|NONE (r_agent) activated_4\VBN\1641914|are|and|ablated|and|foci (r_conj) delineated_2\VBN\2137132|NONE (l_conj) are_13\VBP\13600404|and|ablated|and|activated|foci (l_acomp) free_17\JJ\7942152|patients|now|. (l_npadvmod) seizure_15\NN\14081375|
D004737_D004827 NONE enflurane_6\NN\3299929|NONE (r_pobj) by_5\IN\0|NONE (r_agent) activated_4\VBN\1641914|are|and|ablated|and|foci (r_conj) delineated_2\VBN\2137132|NONE (l_nsubj) foci_1\NN\5704266|are|and|ablated|and|activated (l_amod) epileptic_0\JJ\10595647|NONE
D004737_D004827 NONE enflurane_5\NN\3299929|On|be|.|,|may (r_nsubj) prove_7\VB\2604760|NONE (l_xcomp) be_9\VB\14625458|On|.|,|enflurane|may (l_attr) activator_14\NN\19613|to (l_prep) of_15\IN\0|a|during|safe|fast|acting (l_pobj) foci_17\VBD\5704266|NONE (l_amod) epileptic_16\JJ\10595647|NONE
17574447
D010634_D004827 NONE pb_15\NNP\14625458|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|of|a|long (r_acl) history_10\NN\15120823|NONE (l_prep) of_11\IN\0|a|treated|long (l_pobj) epilepsy_12\NN\14085708|NONE
D010634_D006323 NONE pb_15\NNP\14625458|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|of|a|long (r_acl) history_10\NN\15120823|NONE (r_pobj) with_7\IN\0|:|we|Here|.|one|of (r_prep) report_2\VBP\6470073|NONE (l_appos) one_20\CD\13741022|:|we|with|Here|.|of (l_prep) as_21\IN\14622893|other|, (l_pobj) consequence_22\NN\34213|NONE (l_prep) of_23\IN\0|NONE (l_pobj) arrest_25\NN\88481|NONE
D010634_D056487 NONE pb_15\NNP\14625458| (r_npadvmod) related_17\VBN\628491|asymptomatic|chronic|enzyme (r_amod) dysfunction_22\NN\14204950|NONE
D010634_-1 NONE phenobarbital_8\JJ\2792049|term|report|: (r_amod) therapy_9\NN\657604|NONE (r_pobj) to_4\IN\0|NONE (r_prep) related_3\VBN\628491|cholangitis|.|and (r_acl) hepatonecrosis_0\NNP\0|NONE
D010634_D008107 CID phenobarbital_0\NNP\2792049|and|reputation|believed|, (r_nsubj) has_4\VBZ\13888491|NONE (l_conj) believed_14\VBN\686447|and|reputation|Phenobarbital|, (l_ccomp) indicate_26\VB\952524|it|is|.|commonly (l_conj) predict_28\VB\916909|increases|do|or|not|that (l_dobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) disease_35\NN\14061805|NONE
D010634_D008107 CID pb_2\NNP\14625458|(|) (r_appos) phenobarbital_0\NNP\2792049|and|reputation|believed|, (r_nsubj) has_4\VBZ\13888491|NONE (l_conj) believed_14\VBN\686447|and|reputation|Phenobarbital|, (l_ccomp) indicate_26\VB\952524|it|is|.|commonly (l_conj) predict_28\VB\916909|increases|do|or|not|that (l_dobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) disease_35\NN\14061805|NONE
D010634_D008107 CID pb_16\NNP\14625458| (r_npadvmod) related_18\VBN\628491|in (r_amod) increases_19\NNS\13576355|predict|do|or|not|that (r_nsubj) indicate_26\VB\952524|it|is|.|commonly (l_conj) predict_28\VB\916909|increases|do|or|not|that (l_dobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) disease_35\NN\14061805|NONE
D010634_D008107 CID pb_4\NNP\14625458|be|with|may|that (r_nsubjpass) associated_7\VBN\628491|.|findings (l_prep) with_8\IN\0|be|may|that|PB (l_pobj) damage_11\NN\7296428|NONE
D010634_D001996 NONE pb_15\NNP\14625458|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|of|a|long (r_acl) history_10\NN\15120823|NONE (r_pobj) with_7\IN\0|:|we|Here|.|one|of (r_prep) report_2\VBP\6470073|NONE (l_appos) one_20\CD\13741022|:|we|with|Here|.|of (l_appos) other_28\JJ\0|as|, (l_prep) of_29\IN\0|the (l_pobj) bronchopneumonia_31\NN\14147627|NONE
D010634_D002761 CID phenobarbital_8\JJ\2792049|term|report|: (r_amod) therapy_9\NN\657604|NONE (r_pobj) to_4\IN\0|NONE (r_prep) related_3\VBN\628491|cholangitis|.|and (r_acl) hepatonecrosis_0\NNP\0|NONE (l_conj) cholangitis_2\NN\14336539|related|.|and
2220369
C015173_D020246 CID epinephrine_6\NN\14807929|Central|vein|and|. (r_conj) thrombosis_2\NN\14100769|NONE
C015173_D020246 CID epinephrine_28\NN\14807929|NONE (r_pobj) with_26\IN\0|having|medication (r_prep) started_23\VBN\0|NONE (r_pcomp) after_21\IN\0|who|day|thrombosis|in (r_prep) acquired_11\VBD\0|an|old (l_dobj) thrombosis_14\NN\14100769|who|day|after|in
C015173_D005901 NONE epinephrine_28\NN\14807929|NONE (l_prep) for_29\IN\0|dipivalyl (l_pobj) glaucoma_31\NN\14252864|NONE
17366349
C092292_D009459 CID ziprasidone_5\NN\0|NONE (r_pobj) by_4\IN\0|syndrome|. (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) syndrome_2\NN\5870365|by|.
C092292_D009459 CID ziprasidone_16\NN\0|NONE (r_pobj) of_15\IN\0|the (r_prep) use_14\NN\407535|NONE (r_pobj) with_12\IN\0|NONE (r_prep) associated_11\VBN\628491|neuroleptic|NMS|malignant (r_acl) syndrome_7\NN\5870365|NONE
C092292_D009459 CID ziprasidone_16\NN\0|NONE (r_pobj) of_15\IN\0|the (r_prep) use_14\NN\407535|NONE (r_pobj) with_12\IN\0|NONE (r_prep) associated_11\VBN\628491|neuroleptic|NMS|malignant (r_acl) syndrome_7\NN\5870365|NONE (l_appos) nms_9\NNP\13649268|neuroleptic|malignant|associated
C092292_D009459 CID ziprasidone_14\NN\0|NONE (r_pobj) like_13\IN\5839024|NMS|,|atypical|antipsychotic (r_prep) drugs_12\NNS\14778436|NONE (l_nmod) nms_8\NNP\13649268|,|like|atypical|antipsychotic
C092292_D009459 CID ziprasidone_34\NNP\0|NONE (r_pobj) of_31\IN\0|an|day (r_prep) dose_30\NN\3740161|NONE (r_pobj) with_25\IN\0|NONE (r_prep) treatment_24\NN\654885|NONE (r_pobj) of_23\IN\0| (r_prep) days_22\NNS\15140892|NONE (r_pobj) after_20\IN\0|signs|who (r_prep) developed_14\VBD\1753788|NONE (l_dobj) signs_15\NNS\6643763|after|who (l_prep) of_18\IN\0|and|symptoms (l_pobj) nms_19\NNP\13649268|NONE
C092292_D009459 CID ziprasidone_3\NNP\0|NONE (r_xcomp) due_1\IN\5174653|NONE (r_amod) nms_0\NNP\13649268|.|in
C092292_D012559 NONE ziprasidone_34\NNP\0|NONE (r_pobj) of_31\IN\0|an|day (r_prep) dose_30\NN\3740161|NONE (r_pobj) with_25\IN\0|NONE (r_prep) treatment_24\NN\654885|NONE (r_pobj) of_23\IN\0| (r_prep) days_22\NNS\15140892|NONE (r_pobj) after_20\IN\0|signs|who (r_prep) developed_14\VBD\1753788|NONE (r_relcl) schizophrenia_12\NN\14398067|NONE
19370593
D004967_D001943 NONE oestrogen_3\NN\14745635|term (r_nmod) ht_6\NNP\0|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD\169651|NONE (l_conj) increase_42\VB\13576355|after|but|risk|HT|significantly|,|. (l_dobj) risk_44\NN\14541044|significantly|did|not (l_prep) of_45\IN\0|the (l_pobj) cancer_47\NN\14239425|NONE
D004967_D020521 CID oestrogen_3\NN\14745635|term (r_nmod) ht_6\NNP\0|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD\169651|NONE (l_dobj) risk_10\NN\14541044|after|but|HT|increase|significantly|,|. (l_prep) of_11\IN\0|the (l_pobj) embolism_15\NN\15269513|NONE (l_appos) disease_20\NN\14061805|venous||(|,|thrombo (l_nmod) stroke_17\NN\556313|gallbladder
D004967_D005705 CID oestrogen_3\NN\14745635|term (r_nmod) ht_6\NNP\0|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD\169651|NONE (l_dobj) risk_10\NN\14541044|after|but|HT|increase|significantly|,|. (l_prep) of_11\IN\0|the (l_pobj) embolism_15\NN\15269513|NONE (l_appos) disease_20\NN\14061805|venous||(|,|thrombo
D004967_D054556 CID oestrogen_3\NN\14745635|term (r_nmod) ht_6\NNP\0|after|but|risk|increase|significantly|,|. (r_nsubj) increased_8\VBD\169651|NONE (l_dobj) risk_10\NN\14541044|after|but|HT|increase|significantly|,|. (l_prep) of_11\IN\0|the (l_pobj) embolism_15\NN\15269513|NONE
2466960
D005472_D009369 NONE 5-fu_11\CD\0|for (r_compound) infusion_12\NN\14589223|NONE (l_prep) for_13\IN\0|FU (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|NONE (l_pobj) tumors_17\NNS\14234074|NONE
D005472_D003324 NONE 5-fu_3\CD\0|NONE (r_compound) infusion_4\NN\14589223|is|with|that (r_nsubjpass) associated_6\VBN\628491|We|. (l_prep) with_7\IN\0|is|infusion|that (l_pobj) increase_10\NN\13576355|NONE (l_prep) among_21\IN\0|in|significant|,|a (l_pobj) patients_22\NNS\9898892|particularly (l_prep) with_23\IN\0|NONE (l_pobj) disease_26\NN\14061805|NONE
D005472_D066126 NONE fluorouracil_11\NN\2722166|)|(|FU (r_nmod) therapy_15\NN\657604|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|cardiac (r_acl) toxicity_8\NN\13576101|NONE
D005472_D066126 NONE 5-fu_13\CD\0|fluorouracil|)|( (r_nmod) therapy_15\NN\657604|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|cardiac (r_acl) toxicity_8\NN\13576101|NONE
D005472_D000787 CID 5-fu_12\CD\0|NONE (r_nummod) infusion_13\NN\14589223|NONE (r_pobj) during_11\IN\0|:|angina|)|(|were|patient|. (r_prep) had_8\VBD\0|NONE (l_ccomp) were_2\VBD\0|:|during|angina|)|(|patient|. (l_nsubj) episodes_1\NNS\7283608|rare (l_compound) anginal_0\JJ\0|NONE
D005472_D000787 CID 5-fu_12\CD\0|NONE (r_nummod) infusion_13\NN\14589223|NONE (r_pobj) during_11\IN\0|:|angina|)|(|were|patient|. (r_prep) had_8\VBD\0|NONE (l_dobj) angina_9\NN\14171682|:|during|)|(|were|patient|.
D005472_D007511 CID 5-fu_11\CD\0|for (r_compound) infusion_12\NN\14589223|NONE (r_dobj) undergoing_10\VBG\109660| (r_acl) patients_9\NNS\9898892|NONE (r_pobj) on_7\IN\0|continuous|ECG (r_prep) monitoring_6\NN\879759|in|.|prospectively|We (r_dobj) performed_2\VBD\0|NONE (l_prep) in_18\IN\13603305|.|prospectively|We|monitoring (l_pobj) order_19\NN\7168131|NONE (l_acl) assess_21\VB\5220461|NONE (l_dobj) incidence_23\NN\13821570|to (l_prep) of_24\IN\0|the (l_pobj) changes_27\NNS\7283608|NONE (l_compound) st_26\NNP\0|NONE (l_amod) ischemic_25\JJ\0|NONE
D005472_D007511 CID 5-fu_15\CD\0|during|v (r_nummod) infusion_16\NN\14589223|NONE (r_pobj) to_14\IN\0|. (r_prep) prior_13\RB\10675876|incidence (r_advmod) was_9\VBD\0|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN\13821570|prior (l_prep) of_2\IN\0|The (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) ischemic_3\JJ\0|per|per
D005472_D007511 CID 5-fu_22\CD\0|(|P|) (r_nummod) infusion_23\NN\14589223|NONE (r_pobj) during_21\IN\0|FU|v (r_prep) infusion_16\NN\14589223|NONE (r_pobj) to_14\IN\0|. (r_prep) prior_13\RB\10675876|incidence (r_advmod) was_9\VBD\0|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN\13821570|prior (l_prep) of_2\IN\0|The (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) ischemic_3\JJ\0|per|per
D005472_D007511 CID 5-fu_46\CD\0|NONE (r_pobj) before_45\IN\0|v|was|;|duration|during|+/|. (r_prep) was_36\VBD\0|NONE (l_ccomp) was_9\VBD\0|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN\13821570|prior (l_prep) of_2\IN\0|The (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) ischemic_3\JJ\0|per|per
D005472_D007511 CID 5-fu_57\CD\0|NONE (r_pobj) during_56\IN\0|v|was|before|;|duration|+/|. (r_prep) was_36\VBD\0|NONE (l_ccomp) was_9\VBD\0|v|before|;|duration|during|+/|. (l_nsubj) incidence_1\NN\13821570|prior (l_prep) of_2\IN\0|The (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) ischemic_3\JJ\0|per|per
D005472_D007511 CID 5-fu_3\CD\0|NONE (r_compound) infusion_4\NN\14589223|is|with|that (r_nsubjpass) associated_6\VBN\628491|We|. (l_prep) with_7\IN\0|is|infusion|that (l_pobj) increase_10\NN\13576355|NONE (l_prep) in_11\IN\13603305|significant|,|among|a (l_pobj) deviation_15\NN\7337390|NONE (l_amod) suggestive_16\JJ\0|silent|segment (l_prep) of_17\IN\0|NONE (l_pobj) ischemia_18\NN\14195315|NONE
12448656
D013792_D002292 NONE thalidomide_5\NN\4166841|NONE (r_pobj) of_4\IN\0|A|in|II|phase|. (r_prep) study_3\NN\635850|NONE (l_prep) in_6\IN\13603305|A|of|II|phase|. (l_pobj) carcinoma_11\NN\14239918|NONE
D013792_D002292 NONE thalidomide_9\NN\4166841|NONE (r_pobj) of_8\IN\0|activity|the|and (r_prep) toxicity_5\NN\13576101|To|in (r_dobj) evaluate_3\VB\670261|.|: (l_prep) in_10\IN\13603305|To|toxicity (l_pobj) patients_11\NNS\9898892|and|measure (l_prep) with_12\IN\0|NONE (l_pobj) cancer_17\NN\14239425|NONE
D013792_D002292 NONE thalidomide_11\NN\4166841|NONE (r_pobj) of_10\IN\0|NONE (r_prep) activity_9\NN\30358|NONE (r_pobj) of_8\IN\0|a|in|low (r_prep) level_7\NN\4916342|NONE (l_prep) in_12\IN\13603305|of|a|low (l_pobj) carcinoma_15\NN\14239918|NONE
D013792_D002292 NONE thalidomide_10\NN\4166841|NONE (l_prep) for_11\IN\0|NONE (l_pobj) carcinoma_14\NN\14239918|NONE
D013792_D064420 NONE thalidomide_9\NN\4166841|NONE (r_pobj) of_8\IN\0|activity|the|and (r_prep) toxicity_5\NN\13576101|To|in
6942642
D011188_D007008 NONE potassium_13\NN\14625458|NONE (r_pobj) of_11\IN\0|NONE (r_prep) depletion_10\NN\351638|and (r_conj) hypokalemia_8\NN\14299637|that|thiazide
D049971_D001145 NONE thiazide_0\NNP\3214670|.|hypokalemia|, (r_compound) diuretics_1\NNS\3247620|NONE (l_conj) hypokalemia_3\JJ\14299637|.|,|Thiazide (l_conj) arrhythmias_6\NNS\14103288|and
D006852_C563897 NONE hydrochlorothiazide_18\NN\4423288|NONE (r_pobj) with_17\IN\0|moderate|diastolic (r_prep) hypertension_16\NN\14057371|NONE
D006852_C563897 NONE hctc_20\NNP\0|administered (r_appos) hydrochlorothiazide_18\NN\4423288|NONE (r_pobj) with_17\IN\0|moderate|diastolic (r_prep) hypertension_16\NN\14057371|NONE
D049971_D007008 NONE thiazide_0\NNP\3214670|.|hypokalemia|, (r_compound) diuretics_1\NNS\3247620|NONE (l_conj) hypokalemia_3\JJ\14299637|.|,|Thiazide
D049971_D007008 NONE thiazide_9\NN\3214670|chronic (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_7\IN\0|a|encountered|metabolic (r_prep) consequence_6\NN\34213|.|Hypokalemia (r_attr) is_1\VBZ\0|NONE (l_nsubj) hypokalemia_0\NNP\14299637|.|consequence
D049971_D007008 NONE thiazide_5\JJ\3214670|that|hypokalemia (r_csubj) cause_7\VBP\7323922|.|we|In (l_dobj) hypokalemia_8\NN\14299637|that|thiazide
2598570
D013496_D021501 CID suprofen_9\NN\0|NONE (r_pobj) from_8\IN\0|.|of|The (r_prep) epidemiology_1\NN\6043075|NONE (l_prep) of_2\IN\0|.|The|from (l_pobj) syndrome_7\NN\5870365|NONE (l_compound) pain_6\NN\14299637|flank
D007052_D007674 NONE ibuprofen_15\NNP\3828465|analgesic|)|other|( (r_appos) agents_12\NNS\7347|NONE (r_pobj) of_9\IN\0|concurrent (r_prep) use_8\NN\407535|,|disease|,|young (r_appos) age_5\NN\4916342|.|factors (l_conj) disease_20\NN\14061805|,|,|use|young
D007052_D006073 NONE ibuprofen_15\NNP\3828465|analgesic|)|other|( (r_appos) agents_12\NNS\7347|NONE (r_pobj) of_9\IN\0|concurrent (r_prep) use_8\NN\407535|,|disease|,|young (r_appos) age_5\NN\4916342|.|factors (l_conj) disease_20\NN\14061805|,|,|use|young (l_conj) history_29\NN\15120823|,|,|history|increase|,|renal|,|preexisting|increase (l_prep) of_30\IN\0|a (l_pobj) gout_31\NN\14186541|NONE
D000431_D006255 NONE alcohol_83\NN\7881800|to (r_dobj) use_82\VB\407535|were|;|to|.|;|and|in (r_conj) participate_47\VB\2367363|NONE (l_ccomp) were_2\VBD\0|;|to|.|;|use|and|in (l_conj) suffer_24\VB\2110220|likely|patients (l_prep) from_25\IN\0|NONE (l_pobj) fever_27\NN\14299637|NONE
D007052_D007669 NONE ibuprofen_15\NNP\3828465|analgesic|)|other|( (r_appos) agents_12\NNS\7347|NONE (r_pobj) of_9\IN\0|concurrent (r_prep) use_8\NN\407535|,|disease|,|young (r_appos) age_5\NN\4916342|.|factors (l_conj) disease_20\NN\14061805|,|,|use|young (l_conj) history_23\NN\15120823|,|,|history|increase|,|renal|,|preexisting|increase (l_prep) of_24\IN\0|a (l_pobj) stones_26\NNS\19128|NONE
D000431_D001249 NONE alcohol_83\NN\7881800|to (r_dobj) use_82\VB\407535|were|;|to|.|;|and|in (r_conj) participate_47\VB\2367363|NONE (l_ccomp) were_2\VBD\0|;|to|.|;|use|and|in (l_conj) suffer_24\VB\2110220|likely|patients (l_prep) from_25\IN\0|NONE (l_pobj) fever_27\NN\14299637|NONE (l_conj) asthma_29\NN\14145095|(|ratio|and|hay
458486
D063325_D010300 NONE tiapride_0\NNP\0|NONE (l_appos) movements_18\NNS\191142|.|, (l_prep) in_19\IN\13603305|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0| (l_pobj) disease_26\NN\14061805|NONE
D008787_D010300 NONE metoclopramide_9\NN\0|NONE (r_pobj) to_8\IN\0|closely (r_prep) related_7\JJ\628491|substituted|,|a|benzamide (r_acl) derivative_5\JJ\5802185|peak|in|involuntary|dose (r_amod) movements_18\NNS\191142|.|, (l_prep) in_19\IN\13603305|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0| (l_pobj) disease_26\NN\14061805|NONE
D007980_D004409 CID levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|involuntary (r_amod) movements_6\NNS\191142|NONE
D007980_D004409 CID levodopa_12\NN\14604959| (r_npadvmod) induced_14\VBN\1627355|reduced (r_amod) peak_15\NN\13758296|derivative|in|involuntary|dose (r_nmod) movements_18\NNS\191142|.|,
D007980_D004409 CID levodopa_8\RB\14604959| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) dyskinesias_11\NNS\14084880|are|by|that
C037689_D004409 NONE benzamide_4\RB\0|substituted|,|a|related (r_amod) derivative_5\JJ\5802185|peak|in|involuntary|dose (r_amod) movements_18\NNS\191142|.|,
C037689_D010300 NONE benzamide_4\RB\0|substituted|,|a|related (r_amod) derivative_5\JJ\5802185|peak|in|involuntary|dose (r_amod) movements_18\NNS\191142|.|, (l_prep) in_19\IN\13603305|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0| (l_pobj) disease_26\NN\14061805|NONE
D063325_D004421 NONE tiapride_0\NNP\0|.|effect|induced (r_nsubj) had_1\VBD\0|NONE (l_advcl) induced_7\VBN\1627355|Tiapride|.|effect (l_prep) of_10\IN\0|morning|levodopa| (l_pobj) dystonia_17\NN\0|NONE
D008787_D004409 NONE metoclopramide_9\NN\0|NONE (r_pobj) to_8\IN\0|closely (r_prep) related_7\JJ\628491|substituted|,|a|benzamide (r_acl) derivative_5\JJ\5802185|peak|in|involuntary|dose (r_amod) movements_18\NNS\191142|.|,
D007980_D004421 NONE levodopa_5\NN\14604959|morning|of| (r_npadvmod) induced_7\VBN\1627355|Tiapride|.|effect (l_prep) of_10\IN\0|morning|levodopa| (l_pobj) dystonia_17\NN\0|NONE
D004298_D004409 NONE dopamine_21\NN\14807737|NONE (r_compound) receptors_22\NNS\5225602|NONE (r_pobj) of_20\IN\0|separate|a (r_prep) group_19\NN\2137|NONE (r_pobj) of_16\IN\0|NONE (r_prep) overstimulation_15\NN\0|NONE (r_pobj) by_14\IN\0|dyskinesias|are|that (r_agent) caused_13\VBN\1617192|the (l_nsubjpass) dyskinesias_11\NNS\14084880|are|by|that
D063325_D004409 NONE tiapride_0\NNP\0|NONE (l_prep) in_1\IN\13603305|. (l_pobj) movements_6\NNS\191142|NONE
D063325_D004409 NONE tiapride_0\NNP\0|NONE (l_appos) movements_18\NNS\191142|.|,
D007980_D010300 NONE levodopa_12\NN\14604959| (r_npadvmod) induced_14\VBN\1627355|reduced (r_amod) peak_15\NN\13758296|derivative|in|involuntary|dose (r_nmod) movements_18\NNS\191142|.|, (l_prep) in_19\IN\13603305|derivative|peak|involuntary|dose (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0| (l_pobj) disease_26\NN\14061805|NONE
17786501
D004221_D000437 NONE disulfiram_15\NN\3740161|NONE (r_pobj) of_14\IN\0|for|chronic (r_prep) use_13\NN\407535|NONE (l_prep) for_16\IN\0|of|chronic (l_pobj) management_19\NN\1123598|NONE (l_compound) dependence_18\NN\24720|alcohol
D004221_D000437 NONE disulfiram_4\NN\3740161|.|for|been|had|He (r_dobj) taking_3\VBG\37396|NONE (l_prep) for_5\IN\0|disulfiram|.|been|had|He (l_pobj) dependence_7\NN\24720|NONE
D004221_D009901 NONE disulfiram_0\NNP\3740161| (r_npadvmod) induced_2\VBN\1627355|and|transient|neuropathy (r_amod) optic_4\JJ\5299178|:|case|a|. (l_conj) neuropathy_7\NN\14204950|and|transient|induced
D004221_D009901 NONE disulfiram_15\NN\3740161|NONE (r_pobj) of_14\IN\0|for|chronic (r_prep) use_13\NN\407535|NONE (r_pobj) after_11\IN\0|To|case (r_prep) report_3\VB\6470073|.|: (l_dobj) case_5\NN\7283608|after|To (l_prep) of_6\IN\0|a (l_pobj) optic_7\JJ\5299178|NONE (l_conj) neuropathy_10\NN\14204950|and
D004221_D010523 NONE disulfiram_0\NNP\3740161| (r_npadvmod) induced_2\VBN\1627355|and|transient|neuropathy (r_amod) optic_4\JJ\5299178|:|case|a|. (l_conj) neuropathy_7\NN\14204950|and|transient|induced
D004221_D010523 NONE disulfiram_15\NN\3740161|NONE (r_pobj) of_14\IN\0|for|chronic (r_prep) use_13\NN\407535|NONE (r_pobj) after_11\IN\0|To|case (r_prep) report_3\VB\6470073|.|: (l_dobj) case_5\NN\7283608|after|To (l_prep) of_6\IN\0|a (l_pobj) optic_7\JJ\5299178|NONE (l_conj) neuropathy_10\NN\14204950|and
3961813
C025541_D020258 NONE totp_6\NNP\0|hr (r_pobj) after_5\IN\0|esterase (r_prep) activities_2\NNS\30358|.|given|% (l_compound) esterase_1\NN\0|after (l_amod) neurotoxic_0\JJ\0|NONE
D003345_D009422 NONE corticosterone_9\NN\14752057|NONE (l_prep) on_10\IN\0|dietary (l_pobj) neuropathy_15\NN\14204950|NONE
D003345_D009422 NONE corticosterone_13\NN\14752057|NONE (r_pobj) of_12\IN\0|low|)|less|( (r_prep) concentrations_2\NNS\4916342|effects|Although|signs|. (r_nsubj) had_14\VBD\0|NONE (l_dobj) effects_16\NNS\13245626|concentrations|Although|signs|. (l_prep) on_17\IN\0|beneficial (l_pobj) neuropathy_21\NN\14204950|NONE
D007531_D009422 CID dfp_39\NNP\0|or|either (r_conj) totp_37\NNP\0|NONE (r_pobj) given_35\VBN\5892096|clinical|in|exacerbated (r_acl) signs_32\NNS\6643763|effects|concentrations|Although|. (r_dobj) had_14\VBD\0|NONE (l_dobj) effects_16\NNS\13245626|concentrations|Although|signs|. (l_prep) on_17\IN\0|beneficial (l_pobj) neuropathy_21\NN\14204950|NONE
C025541_D009410 CID totp_16\NNP\0|NONE (r_pobj) given_15\VBN\5892096|.|fibers|also|evident (r_prep) were_3\VBD\0|NONE (l_nsubj) fibers_2\NNS\14580897|.|given|also|evident
D010755_D020258 NONE organophosphorous_21\JJ\0|NONE (r_amod) compounds_22\NNS\5869584|not (r_dobj) given_20\VBN\5892096|.|%|activities (r_prep) were_9\VBD\0|NONE (l_nsubj) activities_2\NNS\30358|.|given|% (l_compound) esterase_1\NN\0|after (l_amod) neurotoxic_0\JJ\0|NONE
D007531_D009410 CID dfp_18\NNP\0|or (r_conj) totp_16\NNP\0|NONE (r_pobj) given_15\VBN\5892096|.|fibers|also|evident (r_prep) were_3\VBD\0|NONE (l_nsubj) fibers_2\NNS\14580897|.|given|also|evident
C025541_D009422 CID totp_18\NNP\0| (r_npadvmod) induced_20\VBN\1627355|greater|, (r_amod) neuropathy_21\NN\14204950|NONE
C025541_D009422 CID totp_37\NNP\0|NONE (r_pobj) given_35\VBN\5892096|clinical|in|exacerbated (r_acl) signs_32\NNS\6643763|effects|concentrations|Although|. (r_dobj) had_14\VBD\0|NONE (l_dobj) effects_16\NNS\13245626|concentrations|Although|signs|. (l_prep) on_17\IN\0|beneficial (l_pobj) neuropathy_21\NN\14204950|NONE
D010755_D009422 NONE organophosphorus_11\NN\0| (r_npadvmod) induced_13\VBN\1627355|delayed|in (r_amod) neuropathy_15\NN\14204950|NONE
D007531_D020258 NONE dfp_8\NNP\0|or (r_conj) totp_6\NNP\0|hr (r_pobj) after_5\IN\0|esterase (r_prep) activities_2\NNS\30358|.|given|% (l_compound) esterase_1\NN\0|after (l_amod) neurotoxic_0\JJ\0|NONE
1504402
D007741_D004342 CID dilevalol_7\NN\0| (r_npadvmod) associated_9\VBN\628491|NONE (r_amod) hepatitis_10\NN\14127211|NONE (r_pobj) for_6\IN\0|a (r_prep) mechanism_5\NN\13446390|NONE (r_pobj) as_3\IN\14622893|Hypersensitivity|immune|. (r_prep) reaction_2\NN\13446390|NONE (l_nmod) hypersensitivity_0\NN\14531772|immune|as|.
D007741_D056486 CID dilevalol_7\NN\0| (r_npadvmod) associated_9\VBN\628491|NONE (r_amod) hepatitis_10\NN\14127211|NONE
D007741_D056486 CID dilevalol_7\VB\0|To|reactivity (l_conj) serum_10\VB\5397468|to|and (l_prep) in_19\IN\13603305|to|containing (l_pobj) case_21\NN\7283608|NONE (l_prep) of_22\IN\0|a (l_pobj) injury_27\NN\14052046|NONE
D007741_D056486 CID dilevalol_15\JJ\0|or|ex|metabolites|putative|vivo (r_compound) antigens_16\NNS\20090|NONE (r_dobj) containing_11\VBG\2632940|to|in (r_xcomp) serum_10\VB\5397468|to|and (l_prep) in_19\IN\13603305|to|containing (l_pobj) case_21\NN\7283608|NONE (l_prep) of_22\IN\0|a (l_pobj) injury_27\NN\14052046|NONE
D007741_D056486 CID dilevalol_23\NN\0| (r_npadvmod) induced_25\VBN\1627355|liver (r_amod) injury_27\NN\14052046|NONE
D007741_D056486 CID dilevalol_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|liver (r_amod) injury_14\NN\14052046|NONE
D007741_D056486 CID dilevalol_16\JJ\0|prepared|ex (r_compound) antigens_17\NNS\20090|NONE (r_dobj) containing_11\VBG\2632940|NONE (r_acl) sera_10\NN\5397468|NONE (r_pobj) to_9\IN\0|lymphocyte (r_prep) sensitization_8\NN\14531772|NONE (r_pobj) of_6\IN\0|the (r_prep) detection_5\NN\5708432|,|.|suggesting|methodology (r_dobj) allowed_3\VBD\0|NONE (l_advcl) suggesting_19\VBG\1010118|,|detection|.|methodology (l_dobj) involvement_21\NN\1080366|NONE (l_prep) of_22\IN\0|the (l_pobj) mechanism_25\NN\13446390|NONE (l_prep) in_26\IN\13603305|an|immunologic (l_pobj) injury_31\NN\14052046|NONE
D007741_D056486 CID dilevalol_27\NN\0| (r_npadvmod) induced_29\VBN\1627355|liver (r_amod) injury_31\NN\14052046|NONE
12760988
D003907_D063806 NONE dexamethasone_18\NN\2721538|or (r_conj) saline_16\NN\14849367|NONE (r_pobj) with_15\IN\0|before (r_prep) pretreated_14\VBN\0| (r_acl) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|incidence|.|was (r_prep) determined_10\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|in (l_prep) of_4\IN\0|and|severity|The (l_pobj) myalgia_8\NN\14322699|NONE
D003907_D063806 NONE dexamethasone_18\NN\2721538|the (r_compound) group_19\NN\2137|NONE (r_pobj) in_16\IN\13603305| (r_prep) patients_15\NNS\9898892|,|reported|compared|of|and (r_nsubj) complained_20\VBD\0|two|the|: (r_acl) groups_12\NNS\2137|NONE (r_pobj) between_9\IN\0|not|Incidence|did|significantly (r_prep) differ_7\VB\0|NONE (l_nsubj) incidence_0\NN\13821570|not|did|between|significantly (l_conj) severity_2\NN\5036394|and (l_prep) of_3\IN\0|NONE (l_pobj) myalgia_4\NN\14322699|NONE
D003907_D063806 NONE dexamethasone_18\NN\2721538|the (r_compound) group_19\NN\2137|NONE (r_pobj) in_16\IN\13603305| (r_prep) patients_15\NNS\9898892|,|reported|compared|of|and (r_nsubj) complained_20\VBD\0|two|the|: (l_prep) of_21\IN\0|,|reported|compared|and|patients (l_pobj) myalgia_22\NN\14322699|NONE
D003907_D063806 NONE dexamethasone_18\NN\2721538|the (r_compound) group_19\NN\2137|NONE (r_pobj) in_16\IN\13603305| (r_prep) patients_15\NNS\9898892|,|reported|compared|of|and (r_nsubj) complained_20\VBD\0|two|the|: (l_conj) reported_36\VBN\831651|,|compared|of|and|patients (l_nsubjpass) myalgia_34\NN\14322699|by|was|.
D003907_D010149 NONE dexamethasone_4\NN\2721538|NONE (r_pobj) of_3\IN\0|NONE (r_prep) administration_2\NN\1133281|:|before (r_appos) implications_0\NNS\5774614|not|effective|. (r_nsubj) was_7\VBD\0|NONE (l_acomp) effective_9\JJ\0|IMPLICATIONS|not|. (l_prep) in_10\IN\13603305|NONE (l_pcomp) decreasing_11\VBG\169651|NONE (l_dobj) incidence_13\NN\13821570|NONE (l_conj) severity_16\NN\5036394|the|or (l_prep) of_17\IN\0|the (l_pobj) myalgia_22\NN\14322699|NONE
D003907_D010149 NONE dexamethasone_2\NN\2721538|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|not|justified|. (r_nsubj) is_3\VBZ\0|NONE (l_acomp) justified_5\VBN\1012073|Pretreatment|not|. (l_xcomp) prevent_7\VB\0|NONE (l_dobj) myalgia_9\NN\14322699|after|to
D013390_D010149 CID succinylcholine_3\NN\3800001|NONE (r_pobj) after_2\IN\0|Postoperative|:|evidence|. (r_prep) myalgia_1\NN\14322699|NONE
D013390_D010149 CID succinylcholine_6\NN\3800001|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|A|common|side (r_acl) effect_3\NN\34213|myalgia|. (r_nsubj) is_7\VBZ\0|NONE (l_attr) myalgia_9\NN\14322699|.|effect
D013390_D010149 CID succinylcholine_6\NN\3800001|NONE (r_pobj) before_5\IN\0|:|Administration (r_punct) implications_0\NNS\5774614|not|effective|. (r_nsubj) was_7\VBD\0|NONE (l_acomp) effective_9\JJ\0|IMPLICATIONS|not|. (l_prep) in_10\IN\13603305|NONE (l_pcomp) decreasing_11\VBG\169651|NONE (l_dobj) incidence_13\NN\13821570|NONE (l_conj) severity_16\NN\5036394|the|or (l_prep) of_17\IN\0|the (l_pobj) myalgia_22\NN\14322699|NONE
D013390_D010149 CID succinylcholine_18\NN\3800001| (r_npadvmod) induced_20\VBN\1627355|postoperative (r_amod) myalgia_22\NN\14322699|NONE
D013390_D010149 CID succinylcholine_11\NN\3800001|NONE (r_pobj) after_10\IN\0|myalgia|to (r_prep) prevent_7\VB\0|NONE (l_dobj) myalgia_9\NN\14322699|after|to
D013390_D063806 CID succinylcholine_5\NN\3800001| (r_npadvmod) associated_7\VBN\628491|NONE (r_amod) myalgia_8\NN\14322699|NONE
D013390_D063806 CID succinylcholine_20\NN\3800001|NONE (r_pobj) before_19\IN\0|with (r_prep) pretreated_14\VBN\0| (r_acl) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|incidence|.|was (r_prep) determined_10\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|in (l_prep) of_4\IN\0|and|severity|The (l_pobj) myalgia_8\NN\14322699|NONE
D013390_D063806 CID succinylcholine_12\NN\3800001| (r_npadvmod) associated_14\VBN\628491|NONE (r_amod) myalgia_15\NN\14322699|NONE
11827497
D006493_D013921 CID heparin_3\NN\2718259| (r_npadvmod) induced_5\VBN\1627355|onset|. (r_amod) thrombocytopenia_6\NN\14189204|NONE
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) thrombocytopenia_3\NN\14189204|after|.
D006493_D013921 CID heparin_10\JJ\2718259|,|with (r_compound) exposure_11\NN\5042871|days (r_pobj) after_9\IN\0|.|thrombocytopenia (r_prep) presents_4\VBZ\28270|NONE (l_nsubj) thrombocytopenia_3\NN\14189204|after|.
D006493_D013921 CID heparin_5\NN\2718259| (r_npadvmod) induced_7\VBN\1627355|NONE (r_amod) thrombocytopenia_8\NN\14189204|NONE
D006493_D013921 CID heparin_16\NN\2718259| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) thrombocytopenia_19\NN\14189204|NONE
D006493_D013921 CID heparin_9\NN\2718259| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) thrombocytopenia_12\NN\14189204|on|in|apparent
D006493_D013921 CID heparin_9\JJ\2718259|NONE (r_compound) exposure_10\NN\5042871|had|that (r_dobj) included_8\VBN\0|NONE (r_relcl) hospitalizations_5\NNS\15113229|NONE (r_pobj) after_4\IN\0|||home|Patients|,|:|with|return|.|in (r_prep) went_2\VBD\0|NONE (l_prep) with_16\IN\0||after||home|Patients|,|:|return|.|in (l_pobj) thrombocytopenia_18\NN\14189204|NONE
D006493_D013921 CID heparin_3\NN\2718259| (r_npadvmod) induced_5\VBN\1627355|onset (r_amod) thrombocytopenia_6\NN\14189204|.|increasingly|being|is
D006493_D013921 CID heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) thrombocytopenia_11\NN\14189204|must|physicians|avoid|,|returns
D006493_D013921 CID heparin_27\VBN\2718259|alternative|not|, (r_appos) anticoagulants_24\NNS\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) therapy_21\NN\657604|consider|.|should|;|,|be (r_nsubjpass) initiated_31\VBN\1617192|NONE (l_ccomp) consider_7\VB\689344|.|should|;|therapy|,|be (l_dobj) thrombocytopenia_11\NN\14189204|must|physicians|avoid|,|returns
D006493_D001157 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) thrombocytopenia_3\NN\14189204|after|. (r_nsubj) presents_4\VBZ\28270|NONE (l_prep) after_9\IN\0|.|thrombocytopenia (l_pobj) exposure_11\NN\5042871|days (l_prep) with_13\IN\0|,|heparin (l_conj) without_15\IN\0|or (l_pobj) thromboemboli_19\NN\0|NONE
D006493_D001157 CID heparin_10\JJ\2718259|,|with (r_compound) exposure_11\NN\5042871|days (l_prep) with_13\IN\0|,|heparin (l_conj) without_15\IN\0|or (l_pobj) thromboemboli_19\NN\0|NONE
D006493_D054556 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) thrombocytopenia_3\NN\14189204|after|. (r_nsubj) presents_4\VBZ\28270|NONE (l_prep) after_9\IN\0|.|thrombocytopenia (l_pobj) exposure_11\NN\5042871|days (l_prep) with_13\IN\0|,|heparin (l_conj) without_15\IN\0|or (l_pobj) thromboemboli_19\NN\0|NONE
D006493_D054556 CID heparin_10\JJ\2718259|,|with (r_compound) exposure_11\NN\5042871|days (l_prep) with_13\IN\0|,|heparin (l_conj) without_15\IN\0|or (l_pobj) thromboemboli_19\NN\0|NONE
D006493_D013923 NONE heparin_9\NN\2718259| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) thrombocytopenia_12\NN\14189204|on|in|apparent (r_nsubj) became_13\VBD\146138|year|a (l_prep) on_15\IN\0|thrombocytopenia|in|apparent (l_pobj) presentation_17\NN\1027379|NONE (l_prep) with_18\IN\0|delayed (l_pobj) complications_20\NNS\1073995|NONE (l_compound) thromboembolic_19\JJ\0|NONE
D006493_D013923 NONE heparin_13\NN\2718259| (r_npadvmod) induced_15\VBN\1627355|platelet|tests (r_nmod) factor_17\NN\7326557|NONE (r_pobj) of_12\IN\0|NONE (r_prep) results_11\NNS\34213|Platelet|,|onset|, (r_appos) counts_3\VBZ\13582013|:|. (l_appos) onset_5\NN\7325190|results|Platelet|,|, (l_prep) of_6\IN\0|NONE (l_pobj) thromboembolism_9\NN\14100769|NONE
D006493_D013923 NONE heparin_9\JJ\2718259|NONE (r_compound) exposure_10\NN\5042871|had|that (r_dobj) included_8\VBN\0|NONE (r_relcl) hospitalizations_5\NNS\15113229|NONE (r_pobj) after_4\IN\0|||home|Patients|,|:|with|return|.|in (r_prep) went_2\VBD\0|NONE (l_advcl) return_23\VB\6479665||after||home|Patients|,|:|with|.|in (l_prep) with_33\IN\0|only|to|to (l_pobj) complications_35\NNS\1073995|NONE (l_compound) thromboembolic_34\JJ\0|NONE
D006493_D013923 NONE heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) thrombocytopenia_11\NN\14189204|must|physicians|avoid|,|returns (r_dobj) consider_7\VB\689344|.|should|;|therapy|,|be (l_advcl) returns_17\NNS\6479665|thrombocytopenia|must|physicians|avoid|, (l_prep) with_18\IN\0|whenever|patient|hospitalized|a (l_pobj) thromboembolism_19\NN\14100769|NONE
D006493_D013923 NONE heparin_27\VBN\2718259|alternative|not|, (r_appos) anticoagulants_24\NNS\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) therapy_21\NN\657604|consider|.|should|;|,|be (r_nsubjpass) initiated_31\VBN\1617192|NONE (l_ccomp) consider_7\VB\689344|.|should|;|therapy|,|be (l_advcl) returns_17\NNS\6479665|thrombocytopenia|must|physicians|avoid|, (l_prep) with_18\IN\0|whenever|patient|hospitalized|a (l_pobj) thromboembolism_19\NN\14100769|NONE
1355091
D009638_D001919 CID noradrenaline_33\NN\14807929|bradycardia|kg|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor (r_conj) responses_2\NNS\11410625|with|were|in|. (l_conj) bradycardia_4\NNS\14110674|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
D009638_D001919 CID noradrenaline_7\NN\14807929| (r_npadvmod) induced_9\VBN\1627355|in|pressor|the (r_amod) effect_11\NN\34213|that (r_dobj) accompanied_5\VBD\0|the (r_relcl) bradycardia_3\NN\14110674|despite|similar|,|Furthermore
C014282_D001919 CID cirazoline_9\NN\0|NONE (r_pobj) to_5\IN\0|NONE (r_prep) bradycardia_4\NNS\14110674|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
C014282_D001919 CID cirazoline_7\NN\0|NONE (r_pobj) of_6\IN\0|bradycardia (r_prep) effects_5\NNS\13245626|and|Both|the (l_amod) bradycardia_4\NN\14110674|of
D015016_D007024 NONE rauwolscine_33\JJ\0|NONE (r_pobj) with_32\IN\0|NONE (r_prep) treated_31\VBN\2376958|the (r_acl) shr_30\NN\0|not (r_pobj) in_28\IN\13603305|.|hypotension|but|,|,|However|tilt (r_conj) induced_7\VBN\1627355|NONE (l_dobj) hypotension_9\NN\14057371|.|in|but|,|,|However|tilt
D011224_D006973 NONE prazosin_9\NN\2698769| (r_npadvmod) pretreated_11\VBN\0|NONE (r_amod) conscious_12\JJ\0|hypertensive (r_amod) rats_15\NNS\2329401|NONE (l_amod) hypertensive_14\JJ\10405694|conscious
D011224_D006973 NONE prazosin_7\NN\2698769|chronic (r_compound) treatment_8\NN\654885|function|whether|for (r_nsubj) alters_9\VBZ\0|to (l_prep) for_14\IN\0|function|whether|treatment (l_pobj) control_16\NN\5190804|NONE (l_prep) in_21\IN\13603305|of|orthostatic (l_pobj) rats_25\NNS\2329401|NONE (l_amod) hypertensive_24\JJ\10405694|(|)|SHR|conscious
D011224_D001919 NONE prazosin_51\NN\2698769|chronic (r_compound) pretreatment_52\NN\0|NONE (r_pobj) without_49\IN\0|and (r_conj) with_47\IN\0|responses|were|in|. (r_prep) determined_43\VBN\0|NONE (l_nsubjpass) responses_2\NNS\11410625|with|were|in|. (l_conj) bradycardia_4\NNS\14110674|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
D011224_D001919 NONE prazosin_12\NN\2698769|NONE (r_pobj) in_10\IN\13603305|.|were|pressor|treated|compared (r_prep) abolished_9\VBN\0|NONE (l_nsubjpass) pressor_2\NN\9190918|.|were|in|treated|compared (l_conj) effects_5\NNS\13245626|and|Both|the (l_amod) bradycardia_4\NN\14110674|of
D011224_D001919 NONE prazosin_28\NN\2698769|chronic (r_compound) treatment_29\NN\654885|NONE (r_pobj) with_26\IN\0|NONE (r_prep) shr_25\NNP\0|NONE (r_pobj) in_24\IN\13603305|than (r_prep) greater_23\JJR\0|.|bradycardia (r_acomp) was_22\VBD\0|similar|,|but|On|effects|, (l_nsubj) bradycardia_21\NN\14110674|.|greater
D011224_D001919 NONE prazosin_20\NN\2698769|chronic (r_compound) treatment_21\NN\654885|NONE (r_pobj) without_18\IN\0|and (r_conj) with_16\IN\0|NONE (r_prep) similar_15\JJ\0|bradycardia|despite|,|Furthermore (r_acomp) was_14\VBD\0|NONE (l_nsubj) bradycardia_3\NN\14110674|despite|similar|,|Furthermore
D011224_D007024 CID prazosin_9\NN\2698769| (r_npadvmod) pretreated_11\VBN\0|NONE (r_amod) conscious_12\JJ\0|hypertensive (r_amod) rats_15\NNS\2329401|NONE (r_pobj) in_7\IN\13603305|adrenoceptor|alpha (r_prep) blockade_6\NN\952963|NONE (r_pobj) following_3\VBG\8180190|hypotension|. (r_prep) occurs_2\VBZ\0|NONE (l_nsubj) hypotension_1\NN\14057371|.|following
D011224_D007024 CID prazosin_15\NN\2698769|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|orthostatic|in (r_acl) hypotension_9\NN\14057371|.|in|but|,|,|However|tilt
D011224_D007024 CID prazosin_22\NN\2698769|NONE (r_pobj) of_21\IN\0|acute (r_prep) dosing_20\NN\515154|NONE (r_pobj) after_18\IN\0|or (r_conj) to_16\IN\0|either (r_prep) prior_15\RB\10675876|when (r_advmod) performed_13\VBN\0|not|tilts|hypotension|.|did (r_advcl) produce_9\VB\7555863|NONE (l_dobj) hypotension_11\NN\14057371|not|tilts|.|performed|did
C056299_D001919 CID abbott-53693_22\NNP\0|bradycardia|kg|noradrenaline|i.v.|and|,|and|,|micrograms|)|kg|The|pressor (r_appos) responses_2\NNS\11410625|with|were|in|. (l_conj) bradycardia_4\NNS\14110674|kg|noradrenaline|i.v.|and|,|Abbott|and|,|micrograms|)|kg|The|pressor
C056299_D001919 CID abbott-53693_9\NNP\0|NONE (r_pobj) of_8\IN\0|the|pressor (r_prep) effects_7\NNS\13245626|similar|,|was|but|On|, (r_nsubj) were_10\VBD\0|NONE (l_conj) was_22\VBD\0|similar|,|but|On|effects|, (l_nsubj) bradycardia_21\NN\14110674|.|greater
15579441
D011692_D000860 CID aminonucleoside_15\NN\0| (r_advmod) induced_17\VBN\1627355|nephrotic|hypoxia|and (r_amod) syndrome_19\NN\5870365|the (r_appos) puromycin_14\NNS\0|NONE (r_pobj) in_12\IN\13603305|to|hypoxia (r_prep) identify_8\VB\699815|NONE (l_dobj) hypoxia_11\NN\14035298|in|to
D011692_D000860 CID aminonucleoside_15\NN\0| (r_advmod) induced_17\VBN\1627355|nephrotic|hypoxia|and (r_amod) syndrome_19\NN\5870365|the (l_conj) hypoxia_24\NN\14035298|nephrotic|and|induced
D011692_D000860 CID aminonucleoside_21\NN\0|puromycin (r_compound) model_22\NN\5888929|and|.fold (r_pobj) in_18\IN\13603305|,|at|showed|.fold (r_prep) reaching_13\VBG\331950|Expression|,|.|throughout (r_advcl) increased_7\VBD\169651|NONE (l_nsubj) expression_0\NN\4679549|,|.|throughout|reaching (l_prep) of_1\IN\0|NONE (l_pobj) transgene_6\NN\5436752|NONE (l_amod) responsive_5\JJ\0|the (l_npadvmod) hypoxia_3\NN\14035298|
D011692_D009404 CID aminonucleoside_15\NN\0| (r_advmod) induced_17\VBN\1627355|nephrotic|hypoxia|and (r_amod) syndrome_19\NN\5870365|the
8988571
D003042_D064420 NONE cocaine_4\NN\3492717|NONE (r_compound) use_5\NN\407535|NONE (r_dobj) following_3\VBG\8180190|Fatal|excited (r_acl) delirium_2\NN\14391660|findings|evidence|:|. (r_dep) provide_9\VBP\2199590|NONE (l_dobj) evidence_11\NN\5816287|findings|:|delirium|. (l_prep) for_12\IN\0|new (l_pobj) mechanisms_13\NNS\13446390|NONE (l_prep) of_14\IN\0|NONE (l_pobj) toxicity_16\NN\13576101|NONE
D003042_D064420 NONE cocaine_15\NN\3492717|NONE (r_compound) toxicity_16\NN\13576101|NONE
D003042_D003645 CID cocaine_11\NN\3492717|chronic (r_compound) use_12\NN\407535|function|that|and (r_nsubj) disrupts_13\VBZ\362348|the (r_acl) hypothesis_8\NN\7162194|NONE (r_pobj) with_6\IN\0|most (r_prep) consistent_5\JJ\0|precipitate|.|,|findings (r_acomp) are_3\VBP\13600404|NONE (l_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may (l_conj) delirium_29\NN\14391660|, (l_conj) thermoregulation_32\NN\0|, (l_conj) rhabdomyolysis_34\NN\0|,|aberrant (l_conj) death_38\NN\7296428|and|,
D003042_D003645 CID cocaine_22\NN\3492717|recent (r_compound) use_23\NN\407535|NONE (r_pobj) with_20\IN\0|when (r_prep) coupled_19\VBN\1295275|,|agitation|may (r_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may (l_conj) delirium_29\NN\14391660|, (l_conj) thermoregulation_32\NN\0|, (l_conj) rhabdomyolysis_34\NN\0|,|aberrant (l_conj) death_38\NN\7296428|and|,
D003042_D062787 NONE cocaine_5\NN\3492717| (r_npadvmod) related_7\VBN\628491|all|in (r_amod) deaths_8\NNS\7296428|NONE (r_pobj) of_3\IN\0|a (r_prep) registry_2\NN\6502378|NONE (r_pobj) from_0\IN\0|,|from|,|EDDs|.|were|with (r_prep) compared_23\VBN\644583|NONE (l_prep) with_24\IN\0|,|from|,|EDDs|From|.|were (l_pobj) victims_26\NNS\9630641|NONE (l_prep) of_27\IN\0|without| (l_pobj) overdose_30\NN\84738|NONE
D003042_D062787 NONE cocaine_29\NN\3492717|accidental (r_compound) overdose_30\NN\84738|NONE
C005618_D003693 NONE benzoylecgonine_6\NN\0|and (r_conj) cocaine_4\NN\3492717|NONE (r_pobj) of_3\IN\0|in|were (r_prep) concentrations_2\NNS\4916342|.|EDDs (r_dobj) had_1\VBD\0|NONE (l_nsubj) edds_0\NNS\6702458|.|concentrations
D003042_D012206 CID cocaine_11\NN\3492717|chronic (r_compound) use_12\NN\407535|function|that|and (r_nsubj) disrupts_13\VBZ\362348|the (r_acl) hypothesis_8\NN\7162194|NONE (r_pobj) with_6\IN\0|most (r_prep) consistent_5\JJ\0|precipitate|.|,|findings (r_acomp) are_3\VBP\13600404|NONE (l_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may (l_conj) delirium_29\NN\14391660|, (l_conj) thermoregulation_32\NN\0|, (l_conj) rhabdomyolysis_34\NN\0|,|aberrant
D003042_D012206 CID cocaine_22\NN\3492717|recent (r_compound) use_23\NN\407535|NONE (r_pobj) with_20\IN\0|when (r_prep) coupled_19\VBN\1295275|,|agitation|may (r_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may (l_conj) delirium_29\NN\14391660|, (l_conj) thermoregulation_32\NN\0|, (l_conj) rhabdomyolysis_34\NN\0|,|aberrant
D003042_D003693 CID cocaine_4\NN\3492717|NONE (r_compound) use_5\NN\407535|NONE (r_dobj) following_3\VBG\8180190|Fatal|excited (r_acl) delirium_2\NN\14391660|findings|evidence|:|.
D003042_D003693 CID cocaine_15\NN\3492717|NONE (r_compound) toxicity_16\NN\13576101|NONE (r_pobj) of_14\IN\0|NONE (r_prep) mechanisms_13\NNS\13446390|NONE (r_pobj) for_12\IN\0|new (r_prep) evidence_11\NN\5816287|findings|:|delirium|. (r_dobj) provide_9\VBP\2199590|NONE (l_dep) delirium_2\NN\14391660|findings|evidence|:|.
D003042_D003693 CID cocaine_7\NN\3492717| (r_npadvmod) induced_9\VBN\1627355|between|EDDs|excited|( (r_amod) delirium_11\NN\14391660|NONE
D003042_D003693 CID cocaine_7\NN\3492717| (r_npadvmod) induced_9\VBN\1627355|between|EDDs|excited|( (r_amod) delirium_11\NN\14391660|NONE (l_appos) edds_13\NNP\6702458|induced|between|excited|(
D003042_D003693 CID cocaine_5\NN\3492717| (r_npadvmod) related_7\VBN\628491|all|in (r_amod) deaths_8\NNS\7296428|NONE (r_pobj) of_3\IN\0|a (r_prep) registry_2\NN\6502378|NONE (r_pobj) from_0\IN\0|,|from|,|EDDs|.|were|with (r_prep) compared_23\VBN\644583|NONE (l_nsubjpass) edds_21\NNS\6702458|,|from|,|From|.|were|with
D003042_D003693 CID cocaine_5\NN\3492717| (r_npadvmod) related_7\VBN\628491|all|in (r_amod) deaths_8\NNS\7296428|NONE (r_pobj) of_3\IN\0|a (r_prep) registry_2\NN\6502378|NONE (r_pobj) from_0\IN\0|,|from|,|EDDs|.|were|with (r_prep) compared_23\VBN\644583|NONE (l_prep) with_24\IN\0|,|from|,|EDDs|From|.|were (l_pobj) victims_26\NNS\9630641|NONE (l_prep) without_31\IN\0||of (l_pobj) delirium_33\NN\14391660|NONE
D003042_D003693 CID cocaine_29\NN\3492717|accidental (r_compound) overdose_30\NN\84738|NONE (r_pobj) of_27\IN\0|without| (r_prep) victims_26\NNS\9630641|NONE (r_pobj) with_24\IN\0|,|from|,|EDDs|From|.|were (r_prep) compared_23\VBN\644583|NONE (l_nsubjpass) edds_21\NNS\6702458|,|from|,|From|.|were|with
D003042_D003693 CID cocaine_29\NN\3492717|accidental (r_compound) overdose_30\NN\84738|NONE (r_pobj) of_27\IN\0|without| (r_prep) victims_26\NNS\9630641|NONE (l_prep) without_31\IN\0||of (l_pobj) delirium_33\NN\14391660|NONE
D003042_D003693 CID cocaine_4\NN\3492717|NONE (r_pobj) of_3\IN\0|in|were (r_prep) concentrations_2\NNS\4916342|.|EDDs (r_dobj) had_1\VBD\0|NONE (l_nsubj) edds_0\NNS\6702458|.|concentrations
D003042_D003693 CID cocaine_11\NN\3492717|chronic (r_compound) use_12\NN\407535|function|that|and (r_nsubj) disrupts_13\VBZ\362348|the (r_acl) hypothesis_8\NN\7162194|NONE (r_pobj) with_6\IN\0|most (r_prep) consistent_5\JJ\0|precipitate|.|,|findings (r_acomp) are_3\VBP\13600404|NONE (l_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may (l_conj) delirium_29\NN\14391660|,
D003042_D003693 CID cocaine_22\NN\3492717|recent (r_compound) use_23\NN\407535|NONE (r_pobj) with_20\IN\0|when (r_prep) coupled_19\VBN\1295275|,|agitation|may (r_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may (l_conj) delirium_29\NN\14391660|,
D003042_D011595 NONE cocaine_11\NN\3492717|chronic (r_compound) use_12\NN\407535|function|that|and (r_nsubj) disrupts_13\VBZ\362348|the (r_acl) hypothesis_8\NN\7162194|NONE (r_pobj) with_6\IN\0|most (r_prep) consistent_5\JJ\0|precipitate|.|,|findings (r_acomp) are_3\VBP\13600404|NONE (l_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may
D003042_D011595 NONE cocaine_22\NN\3492717|recent (r_compound) use_23\NN\407535|NONE (r_pobj) with_20\IN\0|when (r_prep) coupled_19\VBN\1295275|,|agitation|may (r_advcl) precipitate_26\VB\15046900|.|consistent|,|findings (l_dobj) agitation_27\NN\14373582|,|coupled|may
3934126
D000617_D006311 NONE aminoglycoside_18\NN\0|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) to_14\IN\0|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN\2510337|NONE (l_nsubjpass) nephrotoxicity_9\NN\0|to|.|occurred|;|were (l_conj) ototoxicity_11\NN\0|and
D014640_D006311 CID vancomycin_20\NNP\2716866|an|plus (r_appos) aminoglycoside_18\NN\0|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) to_14\IN\0|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN\2510337|NONE (l_nsubjpass) nephrotoxicity_9\NN\0|to|.|occurred|;|were (l_conj) ototoxicity_11\NN\0|and
D014640_D007674 NONE vancomycin_20\NNP\2716866|an|plus (r_appos) aminoglycoside_18\NN\0|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) to_14\IN\0|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN\2510337|NONE (l_nsubjpass) nephrotoxicity_9\NN\0|to|.|occurred|;|were
D000617_D007674 NONE aminoglycoside_18\NN\0|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) to_14\IN\0|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN\2510337|NONE (l_nsubjpass) nephrotoxicity_9\NN\0|to|.|occurred|;|were
D014640_D013924 CID vancomycin_20\NNP\2716866|an|plus (r_appos) aminoglycoside_18\NN\0|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) to_14\IN\0|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN\2510337|NONE (l_ccomp) occurred_1\VBD\0|to|nephrotoxicity|.|;|were (l_nsubj) thrombophlebitis_0\NNP\14352890|with
D014640_D007239 NONE vancomycin_0\NNP\2716866|curative|. (r_nsubj) was_1\VBD\0|NONE (l_acomp) curative_2\JJ\3740161|Vancomycin|. (l_prep) in_3\IN\13603305|NONE (l_pobj) %_5\NN\0|NONE (l_prep) of_6\IN\0| (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0| (l_pobj) infection_11\NN\14052046|NONE
D014640_D007239 NONE vancomycin_3\NNP\2716866|therapy|administered|that|,|, (r_nsubj) constitutes_8\VBZ\0|.|We (l_dobj) therapy_12\NN\657604|administered|that|vancomycin|,|, (l_prep) for_13\IN\0|safe|,|effective (l_pobj) infections_14\NNS\14052046|NONE
D000617_D013924 NONE aminoglycoside_18\NN\0|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) to_14\IN\0|nephrotoxicity|.|occurred|;|were (r_prep) confined_13\VBN\2510337|NONE (l_ccomp) occurred_1\VBD\0|to|nephrotoxicity|.|;|were (l_nsubj) thrombophlebitis_0\NNP\14352890|with
16844102
D003676_D009422 NONE dfo_7\NNP\0||alpha|and (r_conj) tc_5\NNP\14625458|by|that|damage (r_nsubj) ameliorate_8\VB\126264|This|. (l_dobj) damage_14\NN\7296428|by|that|TC
D008694_D020258 NONE methamphetamine_8\NN\2704153| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) neurotoxicity_11\NN\0|NONE
D008694_D020258 NONE methamphetamine_0\NN\2704153|is|.|associated (l_appos) neurotoxicity_4\NN\0|NONE
D008694_D020258 NONE ma)-induced_2\VBN\0|dopaminergic (r_amod) neurotoxicity_4\NN\0|NONE
D008694_D020258 NONE ma_34\NNP\10332385| (r_npadvmod) induced_36\VBN\1627355|the (r_amod) neurotoxicity_37\NN\0|NONE
D003676_D005334 NONE dfo_4\NNP\0|alpha|and| (r_conj) tc_2\NNP\14625458|alterations|as|.|hyperthermia (r_nsubj) attenuated_5\VBD\224901|NONE (l_dobj) hyperthermia_10\NN\14034177|alterations|as|.|TC
D024502_D009422 NONE tc_5\NNP\14625458|by|that|damage (r_nsubj) ameliorate_8\VB\126264|This|. (l_dobj) damage_14\NN\7296428|by|that|TC
D024502_D020258 NONE tocopherol_4\NN\14724645|NONE (l_conj) deferoxamine_6\NN\0|alpha|and| (l_prep) on_7\IN\0|NONE (l_pobj) neurotoxicity_11\NN\0|NONE
D024502_D020258 NONE tocopherol_8\NN\14724645|NONE (r_pobj) of_5\IN\0|the|on (r_prep) effect_4\NN\34213|.|study (l_prep) on_32\IN\0|of|the (l_pobj) neurotoxicity_37\NN\0|NONE
D024502_D020258 NONE tc_12\NNP\14625458|(|scavenger|chelator|,|,|)|alpha||, (r_appos) tocopherol_8\NN\14724645|NONE (r_pobj) of_5\IN\0|the|on (r_prep) effect_4\NN\34213|.|study (l_prep) on_32\IN\0|of|the (l_pobj) neurotoxicity_37\NN\0|NONE
D008694_D005334 CID ma_7\NNP\10332385| (r_npadvmod) induced_9\VBN\1627355|the (r_amod) hyperthermia_10\NN\14034177|alterations|as|.|TC
D010100_D020258 NONE oxygen_19\NN\14622893|reactive (r_compound) species_20\NNS\7992450|NONE (r_pobj) of_17\IN\0|a|and|DFO|, (r_prep) scavenger_16\NN\14779550|(|chelator|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN\14724645|NONE (r_pobj) of_5\IN\0|the|on (r_prep) effect_4\NN\34213|.|study (l_prep) on_32\IN\0|of|the (l_pobj) neurotoxicity_37\NN\0|NONE
D007501_D020258 NONE iron_29\NN\14625458|an (r_compound) chelator_30\NN\0|(|scavenger|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN\14724645|NONE (r_pobj) of_5\IN\0|the|on (r_prep) effect_4\NN\34213|.|study (l_prep) on_32\IN\0|of|the (l_pobj) neurotoxicity_37\NN\0|NONE
D024502_D005334 NONE tc_2\NNP\14625458|alterations|as|.|hyperthermia (r_nsubj) attenuated_5\VBD\224901|NONE (l_dobj) hyperthermia_10\NN\14034177|alterations|as|.|TC
D003676_D020258 NONE deferoxamine_6\NN\0|alpha|and| (l_prep) on_7\IN\0|NONE (l_pobj) neurotoxicity_11\NN\0|NONE
D003676_D020258 NONE deferoxamine_23\NN\0|)|( (r_nmod) dfo_25\NNP\0|a|of|and|, (r_conj) scavenger_16\NN\14779550|(|chelator|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN\14724645|NONE (r_pobj) of_5\IN\0|the|on (r_prep) effect_4\NN\34213|.|study (l_prep) on_32\IN\0|of|the (l_pobj) neurotoxicity_37\NN\0|NONE
D003676_D020258 NONE dfo_25\NNP\0|a|of|and|, (r_conj) scavenger_16\NN\14779550|(|chelator|,|TC|,|)|alpha||, (r_appos) tocopherol_8\NN\14724645|NONE (r_pobj) of_5\IN\0|the|on (r_prep) effect_4\NN\34213|.|study (l_prep) on_32\IN\0|of|the (l_pobj) neurotoxicity_37\NN\0|NONE
D008694_D009422 CID ma_10\NNP\10332385| (r_npadvmod) induced_12\VBN\1627355|the|neuronal (r_amod) damage_14\NN\7296428|by|that|TC
15867025
D006514_D012409 NONE antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (r_pobj) to_38\IN\0|who|were|to (r_prep) born_37\VBN\0|NONE (r_relcl) infants_34\NNS\9918248|NONE (r_pobj) to_33\IN\0|of (r_prep) administration_27\NN\1133281|to|,|administration (r_conj) dose_22\NN\3740161|for|prenatal|, (r_conj) screening_8\NN\6887726|on|Assessment|was|.|: (l_prep) for_9\IN\0|dose|prenatal|, (l_pobj) b_11\NNP\1355326|NONE (l_conj) rubella_13\NN\14123044|hepatitis|and
D006514_D012409 NONE antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (l_conj) immunity_48\NN\13920835|B|positive|,|surface (l_compound) rubella_47\NN\14123044|administration|and|,
D006514_D012409 NONE antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (l_conj) immunity_48\NN\13920835|B|positive|,|surface (l_conj) administration_51\NN\1133281|rubella|and|, (l_prep) of_52\IN\0|NONE (l_pobj) vaccine_58\NN\3562739|NONE (l_compound) rubella_57\NN\14123044|in
D006514_D012409 NONE antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (r_pobj) to_38\IN\0|who|were|to (r_prep) born_37\VBN\0|NONE (l_prep) to_59\TO\0|who|to|were (l_pobj) women_62\NNS\9605289|NONE (l_compound) rubella_60\VB\14123044|nonimmune
D006514_D006509 CID antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (r_pobj) to_38\IN\0|who|were|to (r_prep) born_37\VBN\0|NONE (r_relcl) infants_34\NNS\9918248|NONE (r_pobj) to_33\IN\0|of (r_prep) administration_27\NN\1133281|to|,|administration (r_conj) dose_22\NN\3740161|for|prenatal|, (r_conj) screening_8\NN\6887726|on|Assessment|was|.|: (l_prep) for_9\IN\0|dose|prenatal|, (l_pobj) b_11\NNP\1355326|NONE
D006514_D006509 CID antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (r_pobj) to_38\IN\0|who|were|to (r_prep) born_37\VBN\0|NONE (r_relcl) infants_34\NNS\9918248|NONE (r_pobj) to_33\IN\0|of (r_prep) administration_27\NN\1133281|to|,|administration (r_conj) dose_22\NN\3740161|for|prenatal|, (l_nsubj) administration_15\NN\1133281|to|,|administration (l_prep) of_16\IN\0|NONE (l_pobj) birth_21\NN\15265518|NONE (l_compound) vaccine_20\NN\3562739|the (l_compound) b_19\NNP\1355326|NONE
D006514_D006509 CID antigen_42\NN\20090| (r_npadvmod) positive_44\JJ\6321702|immunity|B|,|surface (r_amod) mothers_45\NNS\10399491|NONE (r_pobj) to_38\IN\0|who|were|to (r_prep) born_37\VBN\0|NONE (r_relcl) infants_34\NNS\9918248|NONE (r_pobj) to_33\IN\0|of (r_prep) administration_27\NN\1133281|to|,|administration (l_prep) of_28\IN\0|to (l_pobj) globulin_32\NN\14736972|NONE (l_compound) b_30\NNP\1355326|immune
D006514_D006509 CID antigen_9\NN\20090| (r_npadvmod) positive_11\JJ\6321702|B|surface (r_amod) mothers_12\NNS\10399491|NONE (r_pobj) to_5\IN\0|were|who (r_prep) born_4\VBN\0|All (r_relcl) infants_1\NNS\9918248|.|globulin|also (r_nsubj) received_14\VBD\2210855|NONE (l_dobj) globulin_18\NN\14736972|infants|.|also (l_compound) b_16\NN\1355326|immune
16471092
C099041_D053201 NONE tolterodine_14\JJ\0|NONE (r_amod) treatment_15\NN\654885|NONE (r_pobj) after_13\IN\0|.|Urinary|quality|and (r_prep) symptoms_1\NNS\5823932|NONE (l_conj) quality_3\NN\24264|.|Urinary|after|and (l_prep) of_4\IN\0|NONE (l_pobj) changes_6\NNS\7283608|NONE (l_prep) with_10\IN\0|life|in (l_pobj) bladder_12\NN\5515670|NONE
C099041_D053201 NONE tolterodine_22\JJ\0|NONE (r_amod) treatment_23\NN\654885|NONE (r_pobj) after_21\IN\0|To|symptoms (r_prep) study_3\VB\635850|:|. (l_dobj) symptoms_6\NNS\5823932|To|after (l_conj) quality_8\NN\24264|and|the|urinary (l_prep) of_9\IN\0|NONE (l_pobj) changes_11\NNS\7283608|NONE (l_prep) with_15\IN\0|life|in (l_pobj) bladder_17\NN\5515670|NONE
C099041_D053201 NONE tolterodine_22\JJ\0|NONE (r_amod) treatment_23\NN\654885|NONE (r_pobj) after_21\IN\0|To|symptoms (r_prep) study_3\VB\635850|:|. (l_dobj) symptoms_6\NNS\5823932|To|after (l_conj) quality_8\NN\24264|and|the|urinary (l_prep) of_9\IN\0|NONE (l_pobj) changes_11\NNS\7283608|NONE (l_prep) with_15\IN\0|life|in (l_pobj) bladder_17\NN\5515670|NONE (l_appos) oab_19\NNP\0|)|(|overactive
C099041_D053201 NONE tolterodine_0\NNP\0|well|was|and|improved (r_nsubjpass) tolerated_3\VBN\802318|NONE (l_conj) improved_7\VBD\126264|Tolterodine|well|was|and (l_dobj) quality_9\NN\24264|effects|. (l_prep) with_15\IN\0|in|the|of (l_pobj) oab_16\NNP\0|NONE
15974569
D005557_D006930 NONE formalin_17\NN\14589223| (r_npadvmod) induced_19\VBN\1627355|paw (r_amod) licking_21\NN\7291312|NONE (r_pobj) of_16\IN\0|hyperalgesia|, (r_prep) reversal_15\NN\199130|:|three|of (l_conj) hyperalgesia_27\NN\0|,|of
D005557_D006930 NONE formalin_17\NN\14589223| (r_npadvmod) induced_19\VBN\1627355|paw (r_amod) licking_21\NN\7291312|NONE (r_pobj) of_16\IN\0|hyperalgesia|, (r_prep) reversal_15\NN\199130|:|three|of (l_conj) hyperalgesia_27\NN\0|,|of (l_conj) hyperalgesia_34\NN\0|,|and|thermal|induced
D002211_D006930 CID capsaicin_30\NN\15032661| (r_npadvmod) induced_32\VBN\1627355|mechanical (r_amod) hyperalgesia_34\NN\0|,|and|thermal|induced (r_conj) hyperalgesia_27\NN\0|,|of
D002211_D006930 CID capsaicin_30\NN\15032661| (r_npadvmod) induced_32\VBN\1627355|mechanical (r_amod) hyperalgesia_34\NN\0|,|and|thermal|induced
D002351_D006930 CID carrageenan_23\NN\14898470| (r_npadvmod) induced_25\VBN\1627355|,|and|thermal|hyperalgesia (r_amod) hyperalgesia_27\NN\0|,|of
D002351_D006930 CID carrageenan_23\NN\14898470| (r_npadvmod) induced_25\VBN\1627355|,|and|thermal|hyperalgesia (r_amod) hyperalgesia_27\NN\0|,|of (l_conj) hyperalgesia_34\NN\0|,|and|thermal|induced
D002351_D010146 NONE carrageenan_23\NN\14898470| (r_npadvmod) induced_25\VBN\1627355|,|and|thermal|hyperalgesia (r_amod) hyperalgesia_27\NN\0|,|of (r_conj) reversal_15\NN\199130|:|three|of (r_appos) models_11\NNS\5888929|NONE (l_prep) of_12\IN\0|:|three|reversal (l_pobj) pain_13\NN\14299637|NONE
D007608_D010146 NONE kainate_7\NN\0|GluR|potent|receptor (r_compound) antagonists_9\NNS\7846|in (r_compound) actives_10\NNS\14779550|NONE (l_prep) in_11\IN\13603305|antagonists (l_pobj) models_14\NNS\5888929|NONE (l_prep) of_15\IN\0|animal|three (l_pobj) pain_16\NN\14299637|NONE
D005557_D010146 NONE formalin_17\NN\14589223| (r_npadvmod) induced_19\VBN\1627355|paw (r_amod) licking_21\NN\7291312|NONE (r_pobj) of_16\IN\0|hyperalgesia|, (r_prep) reversal_15\NN\199130|:|three|of (r_appos) models_11\NNS\5888929|NONE (l_prep) of_12\IN\0|:|three|reversal (l_pobj) pain_13\NN\14299637|NONE
D002211_D010146 NONE capsaicin_30\NN\15032661| (r_npadvmod) induced_32\VBN\1627355|mechanical (r_amod) hyperalgesia_34\NN\0|,|and|thermal|induced (r_conj) hyperalgesia_27\NN\0|,|of (r_conj) reversal_15\NN\199130|:|three|of (r_appos) models_11\NNS\5888929|NONE (l_prep) of_12\IN\0|:|three|reversal (l_pobj) pain_13\NN\14299637|NONE
6504332
D010634_D004409 CID phenobarbital_0\NN\2792049| (r_npadvmod) induced_2\VBN\1627355|.|in (r_amod) dyskinesia_3\NN\14084880|NONE
D010634_D004409 CID phenobarbital_15\JJ\2792049|for (r_amod) therapy_16\NN\657604|NONE (r_dobj) starting_14\VBG\457382|soon (r_pcomp) after_13\IN\0|child|dyskinesia|. (r_prep) developed_9\VBD\1753788|NONE (l_dobj) dyskinesia_11\JJ\14084880|child|after|.
D010634_D004409 CID phenobarbital_4\JJ\2792049|NONE (r_pobj) with_3\IN\0|repeat (r_prep) challenge_2\NN\13927383|NONE (r_pobj) on_0\IN\0|,|.|dyskinesia (r_prep) recurred_8\VBD\339934|NONE (l_nsubj) dyskinesia_7\NN\14084880|,|.|On
D010634_D009069 NONE phenobarbital_0\NN\2792049|be|.|to|should (r_nsubjpass) added_3\VBN\156601|NONE (l_prep) to_4\IN\0|be|Phenobarbital|.|should (l_pobj) list_6\NN\6637824|NONE (l_prep) of_7\IN\0|the (l_pobj) drugs_9\NNS\14778436|NONE (l_relcl) cause_12\VB\7323922|anticonvulsant (l_dobj) disorders_14\NNS\14034177|that|can
D010634_D012640 NONE phenobarbital_15\JJ\2792049|for (r_amod) therapy_16\NN\657604|NONE (l_prep) for_17\IN\0|phenobarbital (l_pobj) seizures_18\NNS\14081375|NONE
D010634_D009422 NONE phenobarbital_0\NN\2792049| (r_npadvmod) induced_2\VBN\1627355|.|in (r_amod) dyskinesia_3\NN\14084880|NONE (l_prep) in_4\IN\13603305|induced|. (l_pobj) child_9\NN\9622049|NONE (l_amod) impaired_8\VBN\258857|a
D010634_D009422 NONE phenobarbital_15\JJ\2792049|for (r_amod) therapy_16\NN\657604|NONE (r_dobj) starting_14\VBG\457382|soon (r_pcomp) after_13\IN\0|child|dyskinesia|. (r_prep) developed_9\VBD\1753788|NONE (l_nsubj) child_4\NN\9622049|after|dyskinesia|. (l_prep) with_5\IN\0|old|A (l_pobj) impairment_8\NN\7296428|NONE
18356633
D000583_D007674 CID amikacin_3\JJ\0|in (r_amod) nephrotoxicity_4\NN\0|NONE
D000583_D007674 CID amikacin_2\RB\0| (r_npadvmod) associated_4\VBN\628491|NONE (r_amod) nephrotoxicity_5\NN\0|To|in
D000583_D007674 CID amikacin_17\JJ\0|NONE (r_prep) via_16\IN\0|of (r_prep) evaluation_13\NN\874067|serum|and (r_conj) creatinine_11\NN\0|NONE (r_pobj) in_9\IN\13603305|an (r_prep) increase_8\NN\13576355|NONE (r_pobj) of_6\IN\0|NONE (r_prep) means_5\NNS\44150|NONE (r_pobj) by_4\IN\0|The|of (r_prep) occurrence_1\NN\29378|.|were (l_prep) of_2\IN\0|by|The (l_pobj) nephrotoxicity_3\NN\0|NONE
D000617_D009369 NONE aminoglycoside_17\NN\0|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treatment_14\NN\654885|that (r_dobj) required_13\VBD\0|oncologic|a (r_relcl) disorder_11\NN\14034177|NONE
D000583_D009503 NONE amikacin_0\NNP\0|.|aminoglycoside (r_nsubj) is_1\VBZ\0|NONE (l_attr) aminoglycoside_3\NN\0|.|Amikacin (l_acl) used_5\VBN\0|an (l_xcomp) provide_7\VB\2199590|commonly (l_dobj) treatment_13\NN\654885|to (l_prep) for_14\IN\0|empirical|double|negative (l_pobj) neutropenia_16\NN\14196405|NONE
D003404_D007674 NONE creatinine_11\NN\0|NONE (r_pobj) in_9\IN\13603305|an (r_prep) increase_8\NN\13576355|NONE (r_pobj) of_6\IN\0|NONE (r_prep) means_5\NNS\44150|NONE (r_pobj) by_4\IN\0|The|of (r_prep) occurrence_1\NN\29378|.|were (l_prep) of_2\IN\0|by|The (l_pobj) nephrotoxicity_3\NN\0|NONE
D000583_D007239 NONE amikacin_0\NNP\0|.|aminoglycoside (r_nsubj) is_1\VBZ\0|NONE (l_attr) aminoglycoside_3\NN\0|.|Amikacin (l_acl) used_5\VBN\0|an (l_xcomp) provide_7\VB\2199590|commonly (l_dobj) treatment_13\NN\654885|to (l_prep) for_14\IN\0|empirical|double|negative (l_pobj) neutropenia_16\NN\14196405|NONE (l_conj) infections_20\NNS\14052046|febrile|and
D000617_D007239 NONE aminoglycoside_3\NN\0|.|Amikacin (l_acl) used_5\VBN\0|an (l_xcomp) provide_7\VB\2199590|commonly (l_dobj) treatment_13\NN\654885|to (l_prep) for_14\IN\0|empirical|double|negative (l_pobj) neutropenia_16\NN\14196405|NONE (l_conj) infections_20\NNS\14052046|febrile|and
D000617_D006402 NONE aminoglycoside_17\NN\0|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treatment_14\NN\654885|that (r_dobj) required_13\VBD\0|oncologic|a (r_relcl) disorder_11\NN\14034177|NONE
D000583_D006402 NONE amikacin_27\JJ\0|NONE (r_pobj) to_20\IN\0|.|were|patients (r_prep) randomized_19\VBN\278117|NONE (l_nsubjpass) patients_1\NNS\9898892|.|were|to (l_prep) with_2\IN\0|Forty (l_pobj) diagnosis_4\NN\152018|NONE (l_amod) consistent_5\JJ\0|a (l_prep) with_6\IN\0|NONE (l_pobj) disorder_11\NN\14034177|NONE
D000617_D009503 NONE aminoglycoside_3\NN\0|.|Amikacin (l_acl) used_5\VBN\0|an (l_xcomp) provide_7\VB\2199590|commonly (l_dobj) treatment_13\NN\654885|to (l_prep) for_14\IN\0|empirical|double|negative (l_pobj) neutropenia_16\NN\14196405|NONE
D000583_D009369 NONE amikacin_27\JJ\0|NONE (r_pobj) to_20\IN\0|.|were|patients (r_prep) randomized_19\VBN\278117|NONE (l_nsubjpass) patients_1\NNS\9898892|.|were|to (l_prep) with_2\IN\0|Forty (l_pobj) diagnosis_4\NN\152018|NONE (l_amod) consistent_5\JJ\0|a (l_prep) with_6\IN\0|NONE (l_pobj) disorder_11\NN\14034177|NONE
1564236
D013793_D023921 NONE thallium-201_18\JJ\0|emission (r_amod) tomography_23\NN\900375|NONE (r_pobj) with_17\IN\0|NONE (r_prep) correlation_16\NN\13841213|Relation|with|:|. (r_appos) observed_4\VBN\2163746|NONE (l_prep) with_5\IN\0|Relation|correlation|:|. (l_pobj) contrast_7\NN\13854649|NONE (l_prep) to_9\IN\0|echocardiography|myocardial (l_pobj) severity_11\NN\5036394|NONE (l_prep) of_12\IN\0|the (l_pobj) stenosis_14\NN\14204950|NONE
D004176_D023921 NONE dipyridamole_1\NN\0| (r_npadvmod) induced_3\VBN\1627355|NONE (r_amod) hyperemia_4\NN\14320394|NONE (r_pobj) during_0\IN\0|area|,||.|by (r_prep) had_16\VBD\0|NONE (l_nsubj) 12_6\CD\13745420|area|During|,|.|by (l_prep) of_7\IN\0|NONE (l_pobj) dogs_10\NNS\2083346|NONE (l_prep) with_11\IN\0||the (l_pobj) stenosis_15\NN\14204950|NONE
D004176_D006940 CID dipyridamole_1\NN\0| (r_npadvmod) induced_3\VBN\1627355|NONE (r_amod) hyperemia_4\NN\14320394|NONE
D004176_D006940 CID dipyridamole_24\NN\0| (r_npadvmod) induced_26\VBN\1627355|NONE (r_amod) hyperemia_27\NN\14320394|NONE
D004176_D006940 CID dipyridamole_11\NN\0| (r_npadvmod) induced_13\VBN\1627355|NONE (r_amod) hyperemia_14\NN\14320394|NONE
9305828
D010862_D012640 NONE pilocarpine_1\NN\14712692|model|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|pilocarpine|model|is|. (l_pobj) period_13\NN\13575869|NONE (l_acl) followed_17\VBN\1835496|an|acute|of (l_agent) by_18\IN\0|NONE (l_pobj) seizures_21\NNS\14081375|NONE
D010862_D012640 NONE pilo_3\NNP\0|)|(|of (r_nmod) model_5\NN\5888929|pilocarpine|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|pilocarpine|model|is|. (l_pobj) period_13\NN\13575869|NONE (l_acl) followed_17\VBN\1835496|an|acute|of (l_agent) by_18\IN\0|NONE (l_pobj) seizures_21\NNS\14081375|NONE
D010862_D004827 NONE pilocarpine_1\NN\14712692|model|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_nsubjpass) model_5\NN\5888929|pilocarpine|is|by|. (l_prep) of_6\IN\0|)|(|PILO (l_pobj) epilepsy_7\NN\14085708|NONE
D010862_D004827 NONE pilo_3\NNP\0|)|(|of (r_nmod) model_5\NN\5888929|pilocarpine|is|by|. (l_prep) of_6\IN\0|)|(|PILO (l_pobj) epilepsy_7\NN\14085708|NONE
D010862_D013226 NONE pilocarpine_1\NN\14712692|model|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|pilocarpine|model|is|. (l_pobj) period_13\NN\13575869|NONE (l_prep) of_14\IN\0|an|acute|followed (l_pobj) epilepticus_16\NN\0|NONE
D010862_D013226 NONE pilo_3\NNP\0|)|(|of (r_nmod) model_5\NN\5888929|pilocarpine|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|pilocarpine|model|is|. (l_pobj) period_13\NN\13575869|NONE (l_prep) of_14\IN\0|an|acute|followed (l_pobj) epilepticus_16\NN\0|NONE
D010862_D004833 CID pilocarpine_6\NN\14712692|of|the (r_amod) model_7\NN\5888929|NONE (l_prep) of_8\IN\0|the|pilocarpine (l_pobj) epilepsy_11\NN\14085708|NONE
D010862_D004833 CID pilo_30\NNP\0|the|of (r_amod) model_31\NN\5888929|NONE (l_prep) of_32\IN\0|the|PILO (l_pobj) tle_33\NNP\0|NONE
D010862_D001930 NONE pilocarpine_1\NN\14712692|model|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|pilocarpine|model|is|. (l_pobj) period_13\NN\13575869|NONE (l_acl) followed_17\VBN\1835496|an|acute|of (l_agent) by_18\IN\0|NONE (l_pobj) seizures_21\NNS\14081375|NONE (l_conj) damage_25\NN\7296428|spontaneous|and|recurrent
D010862_D001930 NONE pilo_3\NNP\0|)|(|of (r_nmod) model_5\NN\5888929|pilocarpine|is|by|. (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|pilocarpine|model|is|. (l_pobj) period_13\NN\13575869|NONE (l_acl) followed_17\VBN\1835496|an|acute|of (l_agent) by_18\IN\0|NONE (l_pobj) seizures_21\NNS\14081375|NONE (l_conj) damage_25\NN\7296428|spontaneous|and|recurrent
7791169
D016595_D010146 NONE misoprostol_2\NNP\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) addition_0\NN\3081021|can|without|impairment|. (r_nsubj) minimize_4\VB\441445|NONE (l_prep) without_8\IN\0|can|impairment|.|Addition (l_pcomp) affecting_9\VBG\126264|NONE (l_dobj) control_11\NN\5190804|NONE (l_compound) pain_10\NN\14299637|NONE
D016595_D007674 NONE misoprostol_3\NNP\0|NONE (r_pobj) of_2\IN\0|Protective (r_prep) effect_1\NN\34213|dysfunction|. (r_nsubj) induced_6\VBD\1627355|NONE (l_dobj) dysfunction_8\NN\14204950|effect|.
D016595_D007674 NONE misoprostol_2\NNP\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) addition_0\NN\3081021|can|without|impairment|. (r_nsubj) minimize_4\VB\441445|NONE (l_dobj) impairment_7\NN\7296428|can|without|.|Addition
D007213_D007674 CID indomethacin_5\NN\3828465|NONE (r_pobj) on_4\IN\0|NONE (r_prep) misoprostol_3\NNP\0|NONE (r_pobj) of_2\IN\0|Protective (r_prep) effect_1\NN\34213|dysfunction|. (r_nsubj) induced_6\VBD\1627355|NONE (l_dobj) dysfunction_8\NN\14204950|effect|.
D007213_D007674 CID indomethacin_8\NN\3828465|related|renal (r_nmod) dysfunction_11\NN\14204950|NONE
2021202
D007530_D007022 CID isoflurane_6\RB\3570838| (r_npadvmod) induced_8\VBN\1627355|prolonged|in (r_amod) hypotension_9\NN\14057371|NONE
D007530_D007022 CID isoflurane_3\RB\3570838| (r_npadvmod) induced_5\VBN\1627355|on (r_amod) hypotension_6\NN\14057371|NONE
D007530_D007022 CID isoflurane_11\NN\3570838|the|inspired (r_amod) concentration_13\NN\4916342|maintain (r_dobj) increasing_9\VBG\169651|NONE (r_pcomp) by_8\IN\0|.|was|mmHg|for|Hypotension (r_prep) induced_2\VBN\1627355|NONE (l_nsubjpass) hypotension_0\NNP\14057371|.|was|mmHg|by|for
D007530_D007022 CID isoflurane_9\RB\3570838| (r_npadvmod) induced_11\VBN\1627355|and (r_amod) hypotension_12\NN\14057371|NONE
17285209
D000809_D000799 NONE angiotensin_3\NN\4522421| (r_npadvmod) converting_5\VBG\126264|(|)|ACE|and|blocker (r_amod) enzyme_6\NN\14723628|NONE (r_pobj) of_2\IN\0|The (r_prep) recognition_1\NN\13932421|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ\0|NONE (l_nsubj) angioedema_18\NN\14316714|.|(|recognition|challenge
D000809_D000799 NONE angiotensin_11\NN\4522421|receptor (r_compound) blocker_13\NN\10101634|(|)|ACE|and|converting (r_conj) enzyme_6\NN\14723628|NONE (r_pobj) of_2\IN\0|The (r_prep) recognition_1\NN\13932421|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ\0|NONE (l_nsubj) angioedema_18\NN\14316714|.|(|recognition|challenge
D000809_D007410 NONE angiotensin_3\NN\4522421| (r_npadvmod) converting_5\VBG\126264|(|)|ACE|and|blocker (r_amod) enzyme_6\NN\14723628|NONE (r_pobj) of_2\IN\0|The (r_prep) recognition_1\NN\13932421|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ\0|NONE (l_nsubj) angioedema_18\NN\14316714|.|(|recognition|challenge
D000809_D007410 NONE angiotensin_11\NN\4522421|receptor (r_compound) blocker_13\NN\10101634|(|)|ACE|and|converting (r_conj) enzyme_6\NN\14723628|NONE (r_pobj) of_2\IN\0|The (r_prep) recognition_1\NN\13932421|angioedema|.|(|challenge (r_nsubj) constitutes_19\VBZ\0|NONE (l_nsubj) angioedema_18\NN\14316714|.|(|recognition|challenge
C044946_D006973 NONE benazapril_28\NN\0|/ (r_compound) mg._30\CD\0|/|a|of|combination (r_appos) pill_24\NN\4424218|NONE (r_pobj) on_21\IN\0|who|was (r_prep) started_20\VBN\0|old|,|American|with|year|a (r_relcl) female_12\NN\15388|NONE (l_prep) with_13\IN\0|old|,|American|started|year|a (l_pobj) hypertension_16\NN\14057371|NONE
D017311_D006973 NONE amlodipine_26\NN\0|NONE (r_pobj) of_25\IN\0|/|a|combination|mg. (r_prep) pill_24\NN\4424218|NONE (r_pobj) on_21\IN\0|who|was (r_prep) started_20\VBN\0|old|,|American|with|year|a (r_relcl) female_12\NN\15388|NONE (l_prep) with_13\IN\0|old|,|American|started|year|a (l_pobj) hypertension_16\NN\14057371|NONE
7752389
D011453_D053201 NONE prostanoids_0\NNS\0|to|.|,|,|via|may (r_nsubj) contribute_8\VBP\126264|NONE (l_prep) to_9\IN\0|Prostanoids|.|,|,|via|may (l_pobj) urge_11\VB\23773|NONE (l_conj) hyperactivity_14\NN\14052403|seen|both|and
D015232_D053201 CID e2-induced_1\JJ\0|in|?|bladder|Prostaglandin (r_amod) hyperactivity_3\NN\14052403|NONE
D015320_D053201 NONE tachykinins_12\NNS\0|NONE (r_pobj) of_11\IN\0|NONE (r_prep) involvement_10\NN\1080366|:|conscious|normal|, (r_appos) rats_8\NNS\2329401|NONE (r_pobj) in_4\IN\13603305|?|Einduced|bladder|Prostaglandin (r_prep) hyperactivity_3\NN\14052403|NONE
D015320_D053201 NONE tachykinins_6\NNS\0|NONE (r_pobj) of_5\IN\0|NONE (r_prep) release_4\NN\3748886|NONE (r_pobj) via_3\IN\0|to|Prostanoids|.|,|,|may (r_prep) contribute_8\VBP\126264|NONE (l_prep) to_9\IN\0|Prostanoids|.|,|,|via|may (l_pobj) urge_11\VB\23773|NONE (l_conj) hyperactivity_14\NN\14052403|seen|both|and
12907924
D008774_D000544 NONE methylphenidate_18\NN\4320126|NONE (r_pobj) on_17\IN\0|was|man|. (r_prep) started_16\VBN\0|NONE (l_nsubjpass) man_4\NN\9605289|on|was|. (l_prep) with_5\IN\0|An|old (l_pobj) depression_9\NN\14373582|NONE (l_conj) disease_14\NN\14061805|and|resistant
D008774_D009771 CID methylphenidate_0\NNP\4320126| (r_npadvmod) induced_2\VBN\1627355|compulsive|in|. (r_amod) symptoms_6\NNS\5823932|NONE
D008774_D009771 CID methylphenidate_12\NN\4320126|was|by|when (r_nsubjpass) replaced_14\VBN\1631072|over (r_advcl) diminished_7\VBN\169651|but|.|behavior (r_conj) ensued_5\VBD\2633881|NONE (l_nsubj) behavior_4\NN\407535|but|.|diminished
D016666_D009771 NONE fluvoxamine_16\NN\0|NONE (r_pobj) by_15\IN\0|was|methylphenidate|when (r_agent) replaced_14\VBN\1631072|over (r_advcl) diminished_7\VBN\169651|but|.|behavior (r_conj) ensued_5\VBD\2633881|NONE (l_nsubj) behavior_4\NN\407535|but|.|diminished
D008774_D061218 NONE methylphenidate_18\NN\4320126|NONE (r_pobj) on_17\IN\0|was|man|. (r_prep) started_16\VBN\0|NONE (l_nsubjpass) man_4\NN\9605289|on|was|. (l_prep) with_5\IN\0|An|old (l_pobj) depression_9\NN\14373582|NONE
8643973
D017239_D010051 NONE paclitaxel_0\NNP\0|NONE (l_acl) combined_1\VBD\2630189|. (l_prep) in_4\IN\13603305|with (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the|line (l_pobj) cancer_13\NN\14239425|NONE
D017239_D010051 NONE paclitaxel_12\NN\0|NONE (r_pobj) of_11\IN\0|maximum|Taxol|tolerated|the (r_prep) dose_10\NN\3740161|given|to (r_dobj) determine_6\VB\0|escalated|I|In (l_prep) given_26\VBN\5892096|to|dose (l_prep) as_27\IN\14622893|NONE (l_pobj) infusion_30\NN\14589223|NONE (l_acl) administered_35\VBN\2436349|a|in|hour (l_prep) to_39\IN\0|days (l_pobj) women_40\NNS\9605289|NONE (l_prep) with_41\IN\0|NONE (l_pobj) cancer_44\NN\14239425|NONE
D017239_D010051 NONE taxol_14\NNP\0|maximum|tolerated|of|the (r_appos) dose_10\NN\3740161|given|to (r_dobj) determine_6\VB\0|escalated|I|In (l_prep) given_26\VBN\5892096|to|dose (l_prep) as_27\IN\14622893|NONE (l_pobj) infusion_30\NN\14589223|NONE (l_acl) administered_35\VBN\2436349|a|in|hour (l_prep) to_39\IN\0|days (l_pobj) women_40\NNS\9605289|NONE (l_prep) with_41\IN\0|NONE (l_pobj) cancer_44\NN\14239425|NONE
D017239_D010051 NONE paclitaxel_46\NN\0|NONE (r_compound) doses_47\NNS\3740161|level|.|were|follows (r_nsubjpass) escalated_49\VBN\153263|I|determine|In (r_conj) study_4\VBP\635850|NONE (l_xcomp) determine_6\VB\0|escalated|I|In (l_prep) given_26\VBN\5892096|to|dose (l_prep) as_27\IN\14622893|NONE (l_pobj) infusion_30\NN\14589223|NONE (l_acl) administered_35\VBN\2436349|a|in|hour (l_prep) to_39\IN\0|days (l_pobj) women_40\NNS\9605289|NONE (l_prep) with_41\IN\0|NONE (l_pobj) cancer_44\NN\14239425|NONE
D016190_D010051 NONE carboplatin_3\NN\0|NONE (r_pobj) with_2\IN\0|in (r_prep) combined_1\VBD\2630189|. (l_prep) in_4\IN\13603305|with (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the|line (l_pobj) cancer_13\NN\14239425|NONE
D016190_D010051 NONE carboplatin_34\NN\0|NONE (r_pobj) with_33\IN\0|NONE (r_prep) combination_32\NN\7951464|NONE (r_pobj) in_31\IN\13603305|a|administered|hour (r_prep) infusion_30\NN\14589223|NONE (l_acl) administered_35\VBN\2436349|a|in|hour (l_prep) to_39\IN\0|days (l_pobj) women_40\NNS\9605289|NONE (l_prep) with_41\IN\0|NONE (l_pobj) cancer_44\NN\14239425|NONE
11912119
D007980_D004409 CID levodopa_3\RB\14604959| (r_npadvmod) induced_5\VBN\1627355|in (r_amod) dyskinesias_6\NNS\14084880|Force|.|and
D007980_D004409 CID levodopa_18\NN\14604959|NONE (r_compound) therapy_19\NN\657604|NONE (r_pobj) of_17\IN\0|motor (r_prep) complications_16\NNS\1073995|NONE (r_pobj) to_14\IN\0|its (r_prep) relationship_13\NN\31921|Parkinson|and (r_conj) disease_10\NN\14061805|NONE (r_pobj) in_7\IN\13603305|coordination|We|,|to|. (r_prep) assessed_1\VBD\670261|NONE (l_prep) to_22\IN\0|coordination|We|,|in|. (l_pobj) dyskinesias_26\NNS\14084880|particularly
D007980_D004409 CID levodopa_18\NN\14604959|NONE (r_compound) therapy_19\NN\657604|NONE (r_pobj) of_17\IN\0|motor (r_prep) complications_16\NNS\1073995|NONE (r_pobj) to_14\IN\0|its (r_prep) relationship_13\NN\31921|Parkinson|and (r_conj) disease_10\NN\14061805|NONE (r_pobj) in_7\IN\13603305|coordination|We|,|to|. (r_prep) assessed_1\VBD\670261|NONE (l_prep) to_22\IN\0|coordination|We|,|in|. (l_pobj) dyskinesias_26\NNS\14084880|particularly (l_appos) lid_28\NNP\5313679|)|induced|(
D007980_D004409 CID levodopa_23\VB\14604959| (r_npadvmod) induced_25\VBN\1627355|)|LID|( (r_amod) dyskinesias_26\NNS\14084880|particularly
D007980_D004409 CID levodopa_23\VB\14604959| (r_npadvmod) induced_25\VBN\1627355|)|LID|( (r_amod) dyskinesias_26\NNS\14084880|particularly (l_appos) lid_28\NNP\5313679|)|induced|(
D007980_D004409 CID levodopa_23\NN\14604959| (r_npadvmod) induced_25\VBN\1627355|(|LID (r_amod) dyskinesias_26\NNS\14084880|NONE (r_pobj) without_22\IN\0|)|and|disease (r_conj) with_9\IN\0|We|.|groups (l_pobj) disease_13\NN\14061805|without|)|and (l_conj) lid_15\NNP\5313679||(|Parkinson|n|+|,
D007980_D004409 CID levodopa_23\NN\14604959| (r_npadvmod) induced_25\VBN\1627355|(|LID (r_amod) dyskinesias_26\NNS\14084880|NONE
D007980_D004409 CID levodopa_23\NN\14604959| (r_npadvmod) induced_25\VBN\1627355|(|LID (r_amod) dyskinesias_26\NNS\14084880|NONE (l_appos) lid_32\NNP\5313679|(|induced
D007980_D004409 CID levodopa_28\RB\14604959|score|.|were (r_dobj) assessed_24\VBN\670261|NONE (l_nsubjpass) score_2\NN\5736149|levodopa|.|were (l_prep) of_3\IN\0|motor|The (l_pobj) scale_10\NNP\7260623|NONE (l_appos) score_14\NN\5736149|Parkinson|,|Rating (l_compound) dyskinesia_13\JJ\14084880|force|and|a|in
D007980_D004409 CID levodopa_21\NN\14604959|NONE (r_pobj) by_20\IN\0|.|significantly|)|was|force|In|, (r_agent) increased_19\VBN\169651|NONE (l_prep) in_0\IN\13603305|.|significantly|)|was|force|by|, (l_pobj) disease_3\NN\14061805|NONE (l_conj) lid_5\NNP\5313679|+|Parkinson
D007980_D010300 NONE levodopa_3\RB\14604959| (r_npadvmod) induced_5\VBN\1627355|in (r_amod) dyskinesias_6\NNS\14084880|Force|.|and (l_prep) in_7\IN\13603305|induced (l_pobj) disease_10\NN\14061805|NONE
D007980_D010300 NONE levodopa_18\NN\14604959|NONE (r_compound) therapy_19\NN\657604|NONE (r_pobj) of_17\IN\0|motor (r_prep) complications_16\NNS\1073995|NONE (r_pobj) to_14\IN\0|its (r_prep) relationship_13\NN\31921|Parkinson|and (r_conj) disease_10\NN\14061805|NONE
D007980_D010300 NONE levodopa_23\VB\14604959| (r_npadvmod) induced_25\VBN\1627355|)|LID|( (r_amod) dyskinesias_26\NNS\14084880|particularly (r_pobj) to_22\IN\0|coordination|We|,|in|. (r_prep) assessed_1\VBD\670261|NONE (l_prep) in_7\IN\13603305|coordination|We|,|to|. (l_pobj) disease_10\NN\14061805|NONE
D007980_D010300 NONE levodopa_23\NN\14604959| (r_npadvmod) induced_25\VBN\1627355|(|LID (r_amod) dyskinesias_26\NNS\14084880|NONE (r_pobj) without_22\IN\0|)|and|disease (r_conj) with_9\IN\0|We|.|groups (r_prep) studied_1\VBD\0|NONE (l_dobj) groups_3\NNS\2137|We|with|. (l_prep) of_4\IN\0|two (l_pobj) patients_8\NNS\9898892|NONE (l_compound) disease_7\NN\14061805|Parkinson
D007980_D010300 NONE levodopa_23\NN\14604959| (r_npadvmod) induced_25\VBN\1627355|(|LID (r_amod) dyskinesias_26\NNS\14084880|NONE (r_pobj) without_22\IN\0|)|and|disease (r_conj) with_9\IN\0|We|.|groups (l_pobj) disease_13\NN\14061805|without|)|and
D007980_D010300 NONE levodopa_23\NN\14604959| (r_npadvmod) induced_25\VBN\1627355|(|LID (r_amod) dyskinesias_26\NNS\14084880|NONE (l_appos) lid_32\NNP\5313679|(|induced (l_compound) disease_30\NN\14061805|)|Parkinson|controls|,|and|||n|,
D007980_D010300 NONE levodopa_28\RB\14604959|score|.|were (r_dobj) assessed_24\VBN\670261|NONE (l_nsubjpass) score_2\NN\5736149|levodopa|.|were (l_prep) of_3\IN\0|motor|The (l_pobj) scale_10\NNP\7260623|NONE (l_compound) rating_9\NNP\5733583|score|Parkinson|, (l_compound) disease_8\NNP\14061805|NONE
D007980_D010300 NONE levodopa_21\NN\14604959|NONE (r_pobj) by_20\IN\0|.|significantly|)|was|force|In|, (r_agent) increased_19\VBN\169651|NONE (l_prep) in_0\IN\13603305|.|significantly|)|was|force|by|, (l_pobj) disease_3\NN\14061805|NONE
3108839
D016685_D013274 NONE c_29\NN\13714184|NONE (r_pobj) with_27\IN\0|NONE (r_prep) treatment_26\NN\654885|while (r_pobj) on_25\IN\0|.|course|We|and|died|in (r_advcl) describe_1\VBP\1001294|NONE (l_prep) in_8\IN\13603305|.|on|course|We|and|died (l_pobj) man_14\NN\9605289|NONE (l_prep) with_15\IN\0|old|developed||a (l_pobj) adenocarcinoma_17\NN\14242337|NONE
D016685_D000743 NONE c_15\NN\13714184|mitomycin (r_compound) treatment_16\NN\654885|NONE (r_pobj) with_13\IN\0|and (r_prep) associated_12\VBN\628491|progressive|renal (r_acl) failure_11\NN\66216|and (r_conj) thrombocytopenia_7\JJ\14189204|,|microangiopathic|hemolytic (r_conj) anemia_5\NN\14189204|NONE
D016685_D011654 NONE c_14\NN\13714184|mitomycin (r_compound) treatment_15\NN\654885|NONE (r_pobj) of_12\IN\0|NONE (r_prep) start_11\NN\7290905|NONE (r_pobj) after_10\IN\0|usually|is|mth|and|failure (r_prep) develops_4\VBZ\1753788|NONE (l_conj) is_19\VBZ\0|usually|after|mth|and|failure (l_attr) %_22\NN\0|.|mortality (l_prep) from_23\IN\0| (l_pobj) failure_25\NN\66216|NONE (l_conj) edema_28\NN\14315192|renal|or
D016685_D011654 NONE c_29\NN\13714184|NONE (r_pobj) with_27\IN\0|NONE (r_prep) treatment_26\NN\654885|while (r_pobj) on_25\IN\0|.|course|We|and|died|in (r_advcl) describe_1\VBP\1001294|NONE (l_conj) died_31\VBD\146138|.|on|course|We|and|in (l_prep) in_32\IN\13603305|NONE (l_pobj) edema_34\NN\14315192|NONE
D016685_D006463 CID c_1\NNP\13714184|syndrome|. (r_nsubj) associated_2\VBD\628491|NONE (l_dobj) syndrome_5\NN\5870365|C|.
D016685_D006463 CID c_1\NNP\13714184|Syndrome (r_nsubj) associated_2\VBD\628491|.|condition (l_dobj) syndrome_5\NNP\5870365|C
D016685_D006463 CID c_1\NNP\13714184|Syndrome (r_nsubj) associated_2\VBD\628491|.|condition (l_dobj) syndrome_5\NNP\5870365|C (l_appos) hus_7\NNP\0|Hemolytic|Uremic|)
D016685_D051437 CID c_15\NN\13714184|mitomycin (r_compound) treatment_16\NN\654885|NONE (r_pobj) with_13\IN\0|and (r_prep) associated_12\VBN\628491|progressive|renal (r_acl) failure_11\NN\66216|and
D016685_D051437 CID c_14\NN\13714184|mitomycin (r_compound) treatment_15\NN\654885|NONE (r_pobj) of_12\IN\0|NONE (r_prep) start_11\NN\7290905|NONE (r_pobj) after_10\IN\0|usually|is|mth|and|failure (r_prep) develops_4\VBZ\1753788|NONE (l_nsubj) failure_2\NN\66216|usually|is|after|mth|and
D016685_D051437 CID c_14\NN\13714184|mitomycin (r_compound) treatment_15\NN\654885|NONE (r_pobj) of_12\IN\0|NONE (r_prep) start_11\NN\7290905|NONE (r_pobj) after_10\IN\0|usually|is|mth|and|failure (r_prep) develops_4\VBZ\1753788|NONE (l_conj) is_19\VBZ\0|usually|after|mth|and|failure (l_attr) %_22\NN\0|.|mortality (l_prep) from_23\IN\0| (l_pobj) failure_25\NN\66216|NONE
D016685_D051437 CID c_29\NN\13714184|NONE (r_pobj) with_27\IN\0|NONE (r_prep) treatment_26\NN\654885|while (r_pobj) on_25\IN\0|.|course|We|and|died|in (r_advcl) describe_1\VBP\1001294|NONE (l_prep) in_8\IN\13603305|.|on|course|We|and|died (l_pobj) man_14\NN\9605289|NONE (l_relcl) developed_19\VBD\1753788|with|old||a (l_dobj) failure_21\NN\66216|who|thrombocytopenia|and
D016685_D013921 NONE c_15\NN\13714184|mitomycin (r_compound) treatment_16\NN\654885|NONE (r_pobj) with_13\IN\0|and (r_prep) associated_12\VBN\628491|progressive|renal (r_acl) failure_11\NN\66216|and (r_conj) thrombocytopenia_7\JJ\14189204|,|microangiopathic|hemolytic
D016685_D013921 NONE c_29\NN\13714184|NONE (r_pobj) with_27\IN\0|NONE (r_prep) treatment_26\NN\654885|while (r_pobj) on_25\IN\0|.|course|We|and|died|in (r_advcl) describe_1\VBP\1001294|NONE (l_prep) in_8\IN\13603305|.|on|course|We|and|died (l_pobj) man_14\NN\9605289|NONE (l_relcl) developed_19\VBD\1753788|with|old||a (l_conj) thrombocytopenia_23\NN\14189204|failure|who|and
17682013
D008727_D002544 NONE methotrexate_21\NN\2722166|NONE (r_pobj) of_19\IN\0|NONE (r_prep) recipients_18\NNS\9764201|commonly (r_pobj) in_17\IN\13603305|has|leukoencephalopathy|as|,|.|been (r_prep) described_8\VBN\1001294|NONE (l_nsubjpass) leukoencephalopathy_2\JJ\0|has|as|,|.|been|in (l_acl) mimicking_3\VBG\1742886|A|transient (l_dobj) accident_5\NN\7314427|NONE
D008727_D056784 CID methotrexate_21\NN\2722166|NONE (r_pobj) of_19\IN\0|NONE (r_prep) recipients_18\NNS\9764201|commonly (r_pobj) in_17\IN\13603305|has|leukoencephalopathy|as|,|.|been (r_prep) described_8\VBN\1001294|NONE (l_nsubjpass) leukoencephalopathy_2\JJ\0|has|as|,|.|been|in
D008727_D056784 CID methotrexate_12\NNP\2722166|NONE (r_pobj) with_11\IN\0|NONE (r_prep) treated_10\VBN\2376958|NONE (r_acl) patients_9\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|toxic (r_prep) leukoencephalopathy_7\JJ\0|NONE
C017367_D056784 CID carmofur_23\NN\0|and|fluorouracil|.|:|reports|We (r_conj) identified_2\VBD\699815|NONE (l_dobj) reports_4\NNS\6470073|and|fluorouracil|.|:|We|carmofur (l_prep) of_5\IN\0| (l_pobj) leukoencephalopathy_7\JJ\0|NONE
D005472_D056784 CID 5-fluorouracil_19\CD\0|and|.|:|reports|We|carmofur (r_punct) identified_2\VBD\699815|NONE (l_dobj) reports_4\NNS\6470073|and|fluorouracil|.|:|We|carmofur (l_prep) of_5\IN\0| (l_pobj) leukoencephalopathy_7\JJ\0|NONE
C110904_D056784 CID capecitabine_26\NN\0|its|,|and|derivative (r_conj) carmofur_23\NN\0|and|fluorouracil|.|:|reports|We (r_conj) identified_2\VBD\699815|NONE (l_dobj) reports_4\NNS\6470073|and|fluorouracil|.|:|We|carmofur (l_prep) of_5\IN\0| (l_pobj) leukoencephalopathy_7\JJ\0|NONE
D008727_D007938 NONE methotrexate_21\NN\2722166|NONE (l_prep) for_22\IN\0|intrathecal (l_pobj) leukaemia_24\NN\14239918|NONE
6216862
D010396_D006527 NONE penicillamine_32\NN\3740161|NONE (r_pobj) with_31\IN\0|NONE (r_prep) treated_30\VBN\2376958|with (r_acl) patients_26\NNS\9898892|not (r_pobj) in_25\IN\13603305|but|as|been|has|which (r_conj) reported_11\VBN\831651|,|elastosis|perforans (l_prep) as_12\IN\14622893|in|but|been|has|which (l_pobj) effect_16\NN\34213|NONE (l_prep) in_17\IN\13603305|side|a|rare (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) disease_22\NN\14061805|NONE
D010396_D017285 CID penicillamine_20\NN\3740161|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|in (r_prep) complications_18\NNS\1073995|NONE (r_pobj) as_17\IN\14622893|been|all|.|have|rashes (r_prep) recorded_16\VBN\2225492|NONE (l_nsubjpass) rashes_1\NNS\14321469|been|all|.|have|as (l_conj) proteinuria_3\NN\14299637|,|Skin (l_conj) erythematosus_7\NN\0|, (l_conj) polymyositis_9\NN\14350292|lupus|,|systemic
D010396_D005076 CID penicillamine_20\NN\3740161|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|in (r_prep) complications_18\NNS\1073995|NONE (r_pobj) as_17\IN\14622893|been|all|.|have|rashes (r_prep) recorded_16\VBN\2225492|NONE (l_nsubjpass) rashes_1\NNS\14321469|been|all|.|have|as
D010396_D001172 NONE penicillamine_4\NN\3740161|NONE (r_compound) therapy_5\NN\657604|NONE (r_pobj) of_3\IN\0|in|Multiple|side|. (r_prep) effects_2\NNS\13245626|NONE (l_prep) in_6\IN\13603305|of|Multiple|side|. (l_pobj) patient_8\NN\9898892|NONE (l_prep) with_9\IN\0|one (l_pobj) arthritis_11\NN\14171682|NONE
D010396_D001172 NONE penicillamine_20\NN\3740161|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|in (r_prep) complications_18\NNS\1073995|NONE (l_prep) in_22\IN\13603305|of (l_pobj) patients_23\NNS\9898892|NONE (l_prep) with_24\IN\0|NONE (l_pobj) arthritis_26\NN\14171682|NONE
D010396_D001172 NONE penicillamine_32\NN\3740161|NONE (r_pobj) with_31\IN\0|NONE (r_prep) treated_30\VBN\2376958|with (r_acl) patients_26\NNS\9898892|not (l_prep) with_27\IN\0|treated (l_pobj) arthritis_29\NN\14171682|NONE
D010396_D012871 NONE penicillamine_32\NN\3740161|NONE (r_pobj) with_31\IN\0|NONE (r_prep) treated_30\VBN\2376958|with (r_acl) patients_26\NNS\9898892|not (r_pobj) in_25\IN\13603305|but|as|been|has|which (r_conj) reported_11\VBN\831651|,|elastosis|perforans (r_relcl) serpiginosa_6\NN\0|lesion|. (r_dobj) resembled_3\VBD\2657219|NONE (l_nsubj) lesion_2\NN\14204950|serpiginosa|.
D010396_D011507 CID penicillamine_20\NN\3740161|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|in (r_prep) complications_18\NNS\1073995|NONE (r_pobj) as_17\IN\14622893|been|all|.|have|rashes (r_prep) recorded_16\VBN\2225492|NONE (l_nsubjpass) rashes_1\NNS\14321469|been|all|.|have|as (l_conj) proteinuria_3\NN\14299637|,|Skin
D010396_D008180 CID penicillamine_20\NN\3740161|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|in (r_prep) complications_18\NNS\1073995|NONE (r_pobj) as_17\IN\14622893|been|all|.|have|rashes (r_prep) recorded_16\VBN\2225492|NONE (l_nsubjpass) rashes_1\NNS\14321469|been|all|.|have|as (l_conj) proteinuria_3\NN\14299637|,|Skin (l_conj) erythematosus_7\NN\0|,
D010396_C536202 NONE penicillamine_32\NN\3740161|NONE (r_pobj) with_31\IN\0|NONE (r_prep) treated_30\VBN\2376958|with (r_acl) patients_26\NNS\9898892|not (r_pobj) in_25\IN\13603305|but|as|been|has|which (r_conj) reported_11\VBN\831651|,|elastosis|perforans (r_relcl) serpiginosa_6\NN\0|lesion|.
D010396_D009157 CID penicillamine_20\NN\3740161|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|in (r_prep) complications_18\NNS\1073995|NONE (r_pobj) as_17\IN\14622893|been|all|.|have|rashes (r_prep) recorded_16\VBN\2225492|NONE (l_nsubjpass) rashes_1\NNS\14321469|been|all|.|have|as (l_conj) proteinuria_3\NN\14299637|,|Skin (l_conj) erythematosus_7\NN\0|, (l_conj) polymyositis_9\NN\14350292|lupus|,|systemic (l_conj) gravis_12\NN\0|and|myasthenia
9636837
D016190_D010523 CID cbdca_5\NNP\0|intensity|association|and (r_nmod) schedules_9\NNS\5898568|NONE (r_pobj) of_4\IN\0|the (r_prep) use_3\NN\407535|concern|may|.|,|However (r_nsubj) cause_20\VB\7323922|NONE (l_dobj) concern_22\NN\5682950|use|may|.|,|However (l_prep) about_23\IN\0|some (l_pobj) safety_25\NN\13920835|NONE (l_prep) with_26\IN\0|its (l_pobj) respect_27\NN\5817845|NONE (l_prep) to_28\IN\0|NONE (l_pobj) damage_32\NN\7296428|NONE
D016190_D010523 CID cbdca_0\JJ\0|NONE (r_compound) administration_1\NN\1133281|.|neurotoxicity (r_nsubj) induced_2\VBD\1627355|NONE (l_dobj) neurotoxicity_7\NN\0|administration|.
D016190_D020258 NONE carboplatin_4\NN\0|)|CBDCA|( (r_poss) advantages_6\NNS\5154517|NONE (r_pobj) of_3\IN\0|The|over|most (r_prep) striking_2\JJ\7283608|)|rate|. (r_nsubj) is_15\VBZ\0|NONE (l_attr) rate_19\NN\13815152|)|.|striking (l_prep) of_20\IN\0|reduced|its (l_pobj) effects_22\NNS\13245626|NONE (l_amod) neurotoxic_21\JJ\0|NONE
D016190_D020258 NONE cbdca_8\NNP\0|carboplatin|)|( (r_appos) advantages_6\NNS\5154517|NONE (r_pobj) of_3\IN\0|The|over|most (r_prep) striking_2\JJ\7283608|)|rate|. (r_nsubj) is_15\VBZ\0|NONE (l_attr) rate_19\NN\13815152|)|.|striking (l_prep) of_20\IN\0|reduced|its (l_pobj) effects_22\NNS\13245626|NONE (l_amod) neurotoxic_21\JJ\0|NONE
D016190_D020258 NONE cbdca_5\NNP\0|intensity|association|and (r_nmod) schedules_9\NNS\5898568|NONE (l_conj) association_12\NN\8008335|intensity|CBDCA|and (l_prep) with_13\IN\0|in|the (l_pobj) drugs_16\NNS\14778436|NONE (l_amod) neurotoxic_15\JJ\0|other
D016190_D020258 NONE cbdca_0\NNP\0|in|,|are|neurotoxic|and (r_nsubj) is_1\VBZ\0|NONE (l_acomp) neurotoxic_2\JJ\0|in|,|are|and|CBDCA
D016190_D020258 NONE cbdca_0\NNP\0|in|,|are|neurotoxic|and (r_nsubj) is_1\VBZ\0|NONE (l_conj) are_15\VBP\13600404|in|,|neurotoxic|and|CBDCA (l_ccomp) is_26\VBZ\0|.|similar|type (l_ccomp) induced_31\VBN\1627355|that|probable|it (l_nsubjpass) neurotoxicity_29\NN\0|by|that|is|in
D002945_D020258 NONE cisplatin_11\NN\0|( (r_nmod) cddp_13\NNP\0|NONE (r_pobj) over_10\IN\5867413|The|of|most (r_prep) striking_2\JJ\7283608|)|rate|. (r_nsubj) is_15\VBZ\0|NONE (l_attr) rate_19\NN\13815152|)|.|striking (l_prep) of_20\IN\0|reduced|its (l_pobj) effects_22\NNS\13245626|NONE (l_amod) neurotoxic_21\JJ\0|NONE
D002945_D020258 NONE cddp_13\NNP\0|NONE (r_pobj) over_10\IN\5867413|The|of|most (r_prep) striking_2\JJ\7283608|)|rate|. (r_nsubj) is_15\VBZ\0|NONE (l_attr) rate_19\NN\13815152|)|.|striking (l_prep) of_20\IN\0|reduced|its (l_pobj) effects_22\NNS\13245626|NONE (l_amod) neurotoxic_21\JJ\0|NONE
D002945_D020258 NONE cddp_23\NNP\0|NONE (r_pobj) by_22\IN\0|NONE (r_agent) caused_21\VBN\1617192|NONE (r_acl) those_20\DT\0|NONE (r_pobj) to_19\IN\0|closely (r_prep) similar_18\JJ\0|is|.|type (r_acomp) are_15\VBP\13600404|in|,|neurotoxic|and|CBDCA (r_conj) is_1\VBZ\0|NONE (l_acomp) neurotoxic_2\JJ\0|in|,|are|and|CBDCA
D002945_D020258 NONE cddp_23\NNP\0|NONE (r_pobj) by_22\IN\0|NONE (r_agent) caused_21\VBN\1617192|NONE (r_acl) those_20\DT\0|NONE (r_pobj) to_19\IN\0|closely (r_prep) similar_18\JJ\0|is|.|type (r_acomp) are_15\VBP\13600404|in|,|neurotoxic|and|CBDCA (l_ccomp) is_26\VBZ\0|.|similar|type (l_ccomp) induced_31\VBN\1627355|that|probable|it (l_nsubjpass) neurotoxicity_29\NN\0|by|that|is|in
1728915
D002220_D062787 NONE carbamazepine_12\NN\0|a|massive (r_compound) overdose_13\NN\84738|NONE
D002220_D001523 NONE carbamazepine_1\NN\0|widely|in|Because|is (r_nsubjpass) used_4\VBN\0|,|implications|.|recognition (l_prep) in_5\IN\13603305|widely|carbamazepine|Because|is (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) conditions_13\NNS\14512817|NONE (l_amod) neurologic_10\JJ\0|many (l_conj) psychiatric_12\JJ\0|and
D002220_D013616 CID carbamazepine_12\NN\0|a|massive (r_compound) overdose_13\NN\84738|NONE (r_pobj) of_9\IN\0|the (r_prep) setting_8\NN\8567235|NONE (r_pobj) in_6\IN\13603305|.|group|tachycardias (r_prep) developed_3\VBD\1753788|NONE (l_dobj) tachycardias_5\NNS\14110674|in|.|group
D002220_D001919 CID carbamazepine_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|,|,|A|with (r_acl) patient_1\NN\9898892|review|. (l_prep) with_2\IN\0|induced|,|,|A (l_pobj) bradycardia_4\NNP\14110674|NONE
D002220_D001919 CID carbamazepine_28\NN\0|therapeutic|serum (r_compound) levels_30\NNS\4916342|NONE (r_pobj) with_22\IN\0|NONE (r_prep) associated_21\VBN\628491|exclusively|group|. (r_advcl) consisted_3\VBD\2603699|NONE (l_advmod) exclusively_5\RB\0|associated|group|. (l_prep) of_6\IN\0|almost (l_pobj) women_8\NNS\9605289|NONE (l_relcl) developed_10\VBD\1753788|elderly|, (l_dobj) bradyarrhythmias_15\NNS\0|who
D002220_D054537 CID carbamazepine_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|,|,|A|with (r_acl) patient_1\NN\9898892|review|. (l_prep) with_2\IN\0|induced|,|,|A (l_pobj) bradycardia_4\NNP\14110674|NONE (l_conj) block_7\NN\21939|sinus|and
D002220_D054537 CID carbamazepine_28\NN\0|therapeutic|serum (r_compound) levels_30\NNS\4916342|NONE (r_pobj) with_22\IN\0|NONE (r_prep) associated_21\VBN\628491|exclusively|group|. (r_advcl) consisted_3\VBD\2603699|NONE (l_advmod) exclusively_5\RB\0|associated|group|. (l_prep) of_6\IN\0|almost (l_pobj) women_8\NNS\9605289|NONE (l_relcl) developed_10\VBD\1753788|elderly|, (l_dobj) bradyarrhythmias_15\NNS\0|who (l_conj) delay_19\NN\15271008|threatening|or
D002220_D006331 NONE carbamazepine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|.|cardiac (r_amod) dysfunction_4\NN\14204950|NONE
D002220_D006331 NONE carbamazepine_11\NN\0| (r_npadvmod) associated_13\VBN\628491|cardiac (r_amod) dysfunction_15\NN\14204950|NONE
6323692
D009020_D000699 NONE morphine_11\NN\2707683|NHAc (r_appos) pretreatment_9\NN\0|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN\2938514|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ\0|NONE
D014700_D000699 NONE verapamil_1\NN\2938514|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ\0|NONE
D014700_D000699 NONE verapamil_29\NN\2938514|action|. (r_nsubj) affected_32\VBD\126264|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ\0|NONE
D002118_D022124 NONE calcium_7\NN\14625458|a|blocking|enhances (r_compound) channel_8\NN\6251781|hyperammonemia (r_dobj) exerts_5\VBZ\1158872|.|data (l_nsubj) hyperammonemia_4\NN\0|channel
D000079_D003866 NONE acetaldehyde_18\NN\14584765|NONE (r_pobj) by_17\IN\0|catecholamine|independent (r_prep) release_16\NN\3748886|was|.|by|not (r_nsubjpass) blocked_21\VBN\1476483|depression|Addition|,|but (r_conj) reversed_4\VBD\109660|NONE (l_dobj) depression_6\NN\14373582|Addition|blocked|,|but
D003975_D000699 NONE diazepam_14\NN\2830852| (r_npadvmod) induced_16\VBN\1627355|muscular (r_amod) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|, (r_conj) analgesia-_12\JJ\0|NONE
D002395_D003866 NONE catecholamine_15\NN\5407119|by|independent (r_compound) release_16\NN\3748886|was|.|by|not (r_nsubjpass) blocked_21\VBN\1476483|depression|Addition|,|but (r_conj) reversed_4\VBD\109660|NONE (l_dobj) depression_6\NN\14373582|Addition|blocked|,|but
C018824_D003866 NONE nh4ac_23\NNPS\0|NONE (r_pobj) by_22\IN\0|release|was|.|not (r_agent) blocked_21\VBN\1476483|depression|Addition|,|but (r_conj) reversed_4\VBD\109660|NONE (l_dobj) depression_6\NN\14373582|Addition|blocked|,|but
D014700_D001259 NONE verapamil_1\NN\2938514|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
D014700_D001259 NONE verapamil_29\NN\2938514|action|. (r_nsubj) affected_32\VBD\126264|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
D010433_D000699 NONE metrazol_37\NN\3740161|NONE (r_pobj) of_36\IN\0|convulsant|the (r_prep) action_35\NN\30358|.|verapamil (r_dobj) affected_32\VBD\126264|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ\0|NONE
D000661_D000699 NONE amphetamine_21\NN\3248958| (r_npadvmod) induced_23\VBN\1627355|motor (r_amod) activity_25\NN\30358|NONE (r_dobj) antagonized_20\VBN\1787955|and|and|incoordination|verapamil|affected|and|, (r_conj) analgesia-_12\JJ\0|NONE
D010433_D001259 NONE metrazol_37\NN\3740161|NONE (r_pobj) of_36\IN\0|convulsant|the (r_prep) action_35\NN\30358|.|verapamil (r_dobj) affected_32\VBD\126264|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
C018824_D000699 NONE nh4ac_8\NNP\0|morphine (r_nmod) pretreatment_9\NN\0|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN\2938514|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ\0|NONE
C018824_D000699 NONE nh4ac_31\NNP\0|neither|nor (r_conj) verapamil_29\NN\2938514|action|. (r_nsubj) affected_32\VBD\126264|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ\0|NONE
C018824_D001259 CID acetate_3\NN\15010703|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|time|.|approximately (r_nsubj) doubled_15\VBD\247390|NONE (l_npadvmod) time_17\NN\7308889|Pretreatment|.|approximately (l_relcl) remained_22\VBD\2604760|the (l_conj) incoordination_31\NN\5648247|on|had|and|mice
C018824_D001259 CID nh4ac_5\NNP\0|ammonium|(|)|s.c. (r_appos) acetate_3\NN\15010703|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|time|.|approximately (r_nsubj) doubled_15\VBD\247390|NONE (l_npadvmod) time_17\NN\7308889|Pretreatment|.|approximately (l_relcl) remained_22\VBD\2604760|the (l_conj) incoordination_31\NN\5648247|on|had|and|mice
C018824_D001259 CID nh4ac_36\NNP\0|alone (r_compound) treatment_37\NN\654885|effect (r_nsubj) had_39\VBD\0|on|and|mice|incoordination (r_conj) remained_22\VBD\2604760|the (l_conj) incoordination_31\NN\5648247|on|had|and|mice
C018824_D001259 CID nh4ac_8\NNP\0|morphine (r_nmod) pretreatment_9\NN\0|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN\2938514|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
C018824_D001259 CID nh4ac_31\NNP\0|neither|nor (r_conj) verapamil_29\NN\2938514|action|. (r_nsubj) affected_32\VBD\126264|and|antagonized|and|incoordination|verapamil|and|, (r_conj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
D009020_D001259 NONE morphine_18\NN\2707683| (r_npadvmod) treated_20\VBN\2376958|NONE (r_amod) mice_21\NNS\2329401|on|had|and|incoordination (r_nsubj) remained_22\VBD\2604760|the (l_conj) incoordination_31\NN\5648247|on|had|and|mice
D009020_D001259 NONE morphine_11\NN\2707683|NHAc (r_appos) pretreatment_9\NN\0|mg/kg|i.p.|(|)|and|Both (r_conj) verapamil_1\NN\2938514|and|antagonized|and|incoordination|affected|and|, (r_nsubj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
D000661_D001259 NONE amphetamine_21\NN\3248958| (r_npadvmod) induced_23\VBN\1627355|motor (r_amod) activity_25\NN\30358|NONE (r_dobj) antagonized_20\VBN\1787955|and|and|incoordination|verapamil|affected|and|, (r_conj) analgesia-_12\JJ\0|NONE (l_conj) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
D003975_D001259 CID diazepam_33\NN\2830852|NONE (r_pobj) by_32\IN\0|muscular|but|increased|, (r_prep) incoordination_31\NN\5648247|on|had|and|mice
D003975_D001259 CID diazepam_14\NN\2830852| (r_npadvmod) induced_16\VBN\1627355|muscular (r_amod) incoordination_18\NN\5648247|and|antagonized|and|verapamil|affected|and|,
D002118_D003866 NONE calcium_3\NN\14625458|NONE (r_pobj) of_1\IN\0|NONE (r_prep) addition_0\NN\3081021|depression|blocked|,|but (r_nsubj) reversed_4\VBD\109660|NONE (l_dobj) depression_6\NN\14373582|Addition|blocked|,|but
D002118_D003866 NONE calcium_12\NN\14625458| (r_npadvmod) independent_14\JJ\9619824|by|catecholamine (r_amod) release_16\NN\3748886|was|.|by|not (r_nsubjpass) blocked_21\VBN\1476483|depression|Addition|,|but (r_conj) reversed_4\VBD\109660|NONE (l_dobj) depression_6\NN\14373582|Addition|blocked|,|but
7072798
D002701_D001855 NONE chloramphenicol_13\NN\2716866|NONE (r_pobj) with_12\IN\0|topical|for (r_prep) treatment_11\NN\654885|NONE (r_pobj) after_9\IN\0|of|second|the (r_prep) report_4\NN\6470073|.|reported|,|This (r_attr) was_1\VBD\0|NONE (l_advcl) reported_29\VBN\831651|.|,|report|This (l_nsubjpass) cases_20\NNS\7283608|although|been|also|have (l_prep) of_21\IN\0|two (l_pobj) hypoplasia_25\NN\14365950|NONE
D002701_D002386 NONE chloramphenicol_22\NN\2716866|NONE (r_pobj) with_21\IN\0|topical (r_prep) therapy_20\NN\657604|NONE (r_dobj) beginning_18\VBG\7283608|extraction|and (r_conj) undergoing_14\VBG\109660|months (l_dobj) extraction_16\NN\13518963|beginning|and (l_compound) cataract_15\NN\14252864|NONE
D002701_D005128 NONE chloramphenicol_11\NN\2716866|NONE (r_pobj) with_8\IN\0|NONE (r_prep) associated_7\VBN\628491|ocular (r_acl) toxicity_6\NN\13576101|NONE
D002701_D000741 CID chloramphenicol_8\NN\2716866|NONE (r_pobj) of_6\IN\0|topical (r_prep) administration_5\NN\1133281|NONE (r_pobj) following_3\VBG\8180190|Fatal|.|aplastic (r_prep) anemia_2\NN\14189204|NONE
D002701_D000741 CID chloramphenicol_22\NN\2716866|NONE (r_pobj) with_21\IN\0|topical (r_prep) therapy_20\NN\657604|NONE (r_dobj) beginning_18\VBG\7283608|extraction|and (r_conj) undergoing_14\VBG\109660|months (r_pcomp) after_13\IN\0|woman|.|of (r_prep) died_5\VBD\146138|NONE (l_prep) of_6\IN\0|woman|.|after (l_pobj) anemia_8\NN\14189204|NONE
D002701_D000741 CID chloramphenicol_13\NN\2716866|an|idiosyncratic (r_acl) response_11\NN\11410625|NONE (r_pobj) with_8\IN\0|was|.|pattern (r_prep) associated_7\VBN\628491|NONE (l_nsubjpass) pattern_1\NN\5726345|was|.|with (l_prep) of_2\IN\0|The (l_pobj) anemia_5\NN\14189204|NONE
D002701_D000741 CID chloramphenicol_13\NN\2716866|NONE (r_pobj) with_12\IN\0|topical|for (r_prep) treatment_11\NN\654885|NONE (r_pobj) after_9\IN\0|of|second|the (r_prep) report_4\NN\6470073|.|reported|,|This (l_prep) of_5\IN\0|after|second|the (l_pobj) anemia_8\NN\14189204|NONE
8441146
D010396_D000741 CID penicillamine_19\NN\3740161|and|one|in (r_conj) case_15\NN\7283608|NONE (r_pobj) in_13\IN\13603305|was|which|by (r_prep) caused_10\VBN\1617192|aplastic|severe (r_relcl) anemia_7\NN\14189204|to
D006046_D000741 CID gold_12\NN\13371489|NONE (r_pobj) by_11\IN\0|was|which|in (r_agent) caused_10\VBN\1617192|aplastic|severe (r_relcl) anemia_7\NN\14189204|to
8911359
D003520_D014523 NONE cyclophosphamide_13\NN\0|NONE (r_pobj) of_12\IN\0|,|treatment|the (r_prep) etiology_7\NN\7326557|NONE (r_pobj) of_5\IN\0|NONE (r_prep) knowledge_4\NN\23100|We|cancer|. (r_dobj) gained_3\VBD\2238085|: (l_dobj) cancer_16\NN\14239425|We|.|knowledge
D003520_D001749 CID cyclophosphamide_0\NN\0|.|associated|bladder|disease| (r_nmod) cancer_3\NN\14239425|NONE
D003520_D001749 CID cyclophosphamide_17\NN\0|cancer (r_pobj) with_16\IN\0|The|of|age|medical (l_pobj) cancer_20\NN\14239425|cyclophosphamide
D003520_D001749 CID cyclophosphamide_0\NN\0|bladder|associated (r_nmod) tumor_3\NN\14234074|.|disease
10193809
D011692_D011507 CID aminonucleoside_1\NN\0|NONE (r_amod) puromycin_0\NNP\0|was|.|to|induce (r_nsubjpass) administered_6\VBN\2436349|NONE (l_advcl) induce_12\VB\1627355|was|.|to|Puromycin (l_dobj) proteinuria_13\NN\14299637|to
D011692_D011507 CID pan_3\NNP\3101986|NONE (r_appos) aminonucleoside_1\NN\0|NONE (r_amod) puromycin_0\NNP\0|was|.|to|induce (r_nsubjpass) administered_6\VBN\2436349|NONE (l_advcl) induce_12\VB\1627355|was|.|to|Puromycin (l_dobj) proteinuria_13\NN\14299637|to
3780814
D010634_D011230 NONE pb_22\NNP\14625458|was|when|for|simultaneously|with (r_nsubjpass) given_24\VBN\5892096|significantly|.|number|After|,|was (r_advcl) reduced_20\VBN\441445|NONE (l_nsubjpass) number_8\NN\5107765|significantly|.|After|given|,|was (l_conj) size_11\NN\5090441|and|the (l_prep) of_12\IN\0|the (l_pcomp) induced_13\VBN\1627355|NONE (l_dobj) foci_17\NN\5704266|NONE
D010634_D063646 NONE phenobarbital_5\JJ\2792049|NONE (r_pobj) of_4\IN\0|carcinogenic|.|given (r_prep) action_3\NN\30358|NONE (l_amod) carcinogenic_2\JJ\0|.|of|given
D010634_D063646 NONE phenobarbital_13\JJ\2792049|NONE (r_pobj) of_12\IN\0|on|the (r_prep) effect_11\NN\34213|administered|to (l_prep) on_25\IN\0|of|the (l_pobj) carcinogenesis_26\NN\0|NONE
D010634_D063646 NONE pb_15\NNP\14625458|(|) (r_appos) phenobarbital_13\JJ\2792049|NONE (r_pobj) of_12\IN\0|on|the (r_prep) effect_11\NN\34213|administered|to (l_prep) on_25\IN\0|of|the (l_pobj) carcinogenesis_26\NN\0|NONE
D010634_D063646 NONE pb_15\NNP\14625458|+ (r_conj) den_13\NNP\8580803|NONE (r_pobj) by_12\IN\0|or|DEN (r_conj) by_8\IN\0|rats|were|according|.|during (r_agent) treated_7\VBN\2376958|NONE (l_prep) according_23\VBG\2657219|rats|by|were|.|during (l_prep) to_24\IN\0|NONE (l_pobj) schedule_26\NN\5898568|NONE (l_prep) for_27\IN\0|our (l_pobj) hepatocarcinogenesis_28\NN\0|NONE
D010634_D063646 NONE pb_4\NNP\14625458|given|effect|that (l_relcl) promotes_7\VBZ\2556126|,|, (l_dobj) carcinogenesis_8\NN\0|which|administered
D004052_D011230 CID den_27\NNP\8580803|NONE (r_pobj) with_26\IN\0|PB|was|when|for|simultaneously (r_prep) given_24\VBN\5892096|significantly|.|number|After|,|was (r_advcl) reduced_20\VBN\441445|NONE (l_nsubjpass) number_8\NN\5107765|significantly|.|After|given|,|was (l_conj) size_11\NN\5090441|and|the (l_prep) of_12\IN\0|the (l_pcomp) induced_13\VBN\1627355|NONE (l_dobj) foci_17\NN\5704266|NONE
D004052_D009369 NONE den_1\NNP\8580803|rats (r_nsubj) treated_4\VBN\2376958|survival|prolonged|In|,|decreased|and (r_ccomp) was_9\VBD\0|NONE (l_conj) decreased_15\VBD\169651|survival|prolonged|treated|In|,|and (l_nsubj) incidence_14\NN\13821570|.|as (l_compound) tumor_13\NN\14234074|the
D004052_D009369 NONE den_23\NNP\8580803|NONE (r_pobj) by_22\IN\0|alone (r_agent) obtained_21\VBN\2210855|the (r_acl) results_20\NNS\34213|NONE (r_pobj) with_18\IN\0|NONE (r_prep) compared_17\VBN\644583|NONE (r_prep) as_16\IN\14622893|incidence|. (r_prep) decreased_15\VBD\169651|survival|prolonged|treated|In|,|and (l_nsubj) incidence_14\NN\13821570|.|as (l_compound) tumor_13\NN\14234074|the
D004052_D063646 NONE diethylnitrosamine_9\NN\0|NONE (r_pobj) with_8\IN\0|simultaneously (r_prep) given_6\VBN\5892096|carcinogenic|.|of (r_prep) action_3\NN\30358|NONE (l_amod) carcinogenic_2\JJ\0|.|of|given
D004052_D063646 NONE diethylnitrosamine_33\JJ\0|NONE (r_pobj) with_32\IN\0|simultaneously|it|when|is (r_prep) administered_30\VBN\2436349|effect|to (r_advcl) elucidate_9\VB\939277|NONE (l_dobj) effect_11\NN\34213|administered|to (l_prep) on_25\IN\0|of|the (l_pobj) carcinogenesis_26\NN\0|NONE
D004052_D063646 NONE den_35\NNP\8580803|work|has|.|been|in (r_parataxis) planned_5\VBN\708538|NONE (l_prep) in_6\IN\13603305|work|DEN|has|.|been (l_pobj) order_7\NN\7168131|NONE (l_acl) elucidate_9\VB\939277|NONE (l_dobj) effect_11\NN\34213|administered|to (l_prep) on_25\IN\0|of|the (l_pobj) carcinogenesis_26\NN\0|NONE
D004052_D063646 NONE den_9\NNP\8580803|by|or (r_pobj) by_8\IN\0|rats|were|according|.|during (r_agent) treated_7\VBN\2376958|NONE (l_prep) according_23\VBG\2657219|rats|by|were|.|during (l_prep) to_24\IN\0|NONE (l_pobj) schedule_26\NN\5898568|NONE (l_prep) for_27\IN\0|our (l_pobj) hepatocarcinogenesis_28\NN\0|NONE
D004052_D063646 NONE den_13\NNP\8580803|NONE (r_pobj) by_12\IN\0|or|DEN (r_conj) by_8\IN\0|rats|were|according|.|during (r_agent) treated_7\VBN\2376958|NONE (l_prep) according_23\VBG\2657219|rats|by|were|.|during (l_prep) to_24\IN\0|NONE (l_pobj) schedule_26\NN\5898568|NONE (l_prep) for_27\IN\0|our (l_pobj) hepatocarcinogenesis_28\NN\0|NONE
D004052_D063646 NONE den_13\NNP\8580803|the (r_compound) treatment_14\NN\654885|NONE (r_pobj) after_11\IN\0|when (r_prep) administered_10\VBN\2436349|which|carcinogenesis (r_advcl) promotes_7\VBZ\2556126|,|, (l_dobj) carcinogenesis_8\NN\0|which|administered
D004052_D063646 NONE den_24\NNP\8580803|NONE (r_pobj) with_23\IN\0|simultaneously|when (r_prep) given_21\VBN\5892096|effect|that|PB (r_advcl) reduces_16\VBZ\441445|is|It|. (l_nsubj) pb_4\NNP\14625458|given|effect|that (l_relcl) promotes_7\VBZ\2556126|,|, (l_dobj) carcinogenesis_8\NN\0|which|administered
D010634_D009369 NONE pb_3\NNP\14625458|+ (r_conj) den_1\NNP\8580803|rats (r_nsubj) treated_4\VBN\2376958|survival|prolonged|In|,|decreased|and (r_ccomp) was_9\VBD\0|NONE (l_conj) decreased_15\VBD\169651|survival|prolonged|treated|In|,|and (l_nsubj) incidence_14\NN\13821570|.|as (l_compound) tumor_13\NN\14234074|the
20683499
C029036_D008569 NONE crocin_3\NNS\0|NONE (l_prep) in_4\IN\13603305|In|,|. (l_pobj) impairment_14\NN\7296428|NONE
C029036_D007859 NONE crocin_3\NNS\0|NONE (l_prep) in_4\IN\13603305|In|,|. (l_pobj) impairment_14\NN\7296428|NONE
D013311_D008569 NONE stz_17\NNP\0| (r_npadvmod) injected_19\VBN\81072|in|treated (r_amod) group_20\NN\2137|NONE (r_pobj) in_15\IN\13603305|learning|attenuated|dose (r_prep) impairment_14\NN\7296428|NONE
D013311_D000544 CID streptozocin_11\NNS\0| (r_npadvmod) induced_13\VBN\1627355|of (r_amod) model_14\NN\5888929|NONE (l_prep) of_15\IN\0|induced (l_pobj) disease_19\NN\14061805|NONE
D013311_D000544 CID streptozocin_20\NNP\0|of|the (r_appos) effect_6\NN\34213|was|In|,|. (l_prep) of_7\IN\0|the|streptozocin (l_pobj) crocins_8\NNS\0|NONE (l_prep) on_9\IN\0|NONE (l_pobj) disease_13\NN\14061805|NONE
D013311_D000544 CID stz_22\NNP\0|icv|(|) (r_appos) streptozocin_20\NNP\0|of|the (r_appos) effect_6\NN\34213|was|In|,|. (l_prep) of_7\IN\0|the|streptozocin (l_pobj) crocins_8\NNS\0|NONE (l_prep) on_9\IN\0|NONE (l_pobj) disease_13\NN\14061805|NONE
D013311_D000544 CID stz_10\NNP\0| (r_compound) icv_12\NN\0|NONE (r_pobj) with_9\IN\0|bilaterally|in|)|rats|,|were|In (r_prep) injected_8\VBN\81072|was|,|application|. (l_prep) in_0\IN\13603305|bilaterally|in|with|)|rats|,|were (l_pobj) groups_4\NNS\2137|NONE (l_compound) disease_3\NN\14061805|Alzheimer
D013311_D000544 CID stz_28\NNP\0| (r_compound) icv_30\NN\0|a|similar (r_compound) application_31\NN\947128|was|,|.|injected (r_nsubjpass) repeated_33\VBN\952524|NONE (l_ccomp) injected_8\VBN\81072|was|,|application|. (l_prep) in_0\IN\13603305|bilaterally|in|with|)|rats|,|were (l_pobj) groups_4\NNS\2137|NONE (l_compound) disease_3\NN\14061805|Alzheimer
D013311_D000544 CID stz_20\NNP\0| (r_compound) icv_22\NN\0|NONE (r_pobj) by_19\IN\0|in (r_agent) caused_18\VBN\1617192|the|cognitive (l_prep) in_23\IN\13603305|by (l_pobj) rats_24\NNS\2329401|NONE (l_conj) potential_27\NN\14481929|and (l_prep) in_28\IN\13603305|its (l_pobj) treatment_30\NN\654885|NONE (l_prep) of_31\IN\0|the (l_pobj) diseases_33\NNS\14061805|NONE (l_prep) as_35\IN\14622893|neurodegenerative (l_pobj) disease_38\NN\14061805|such
C029036_D000544 NONE crocin_9\NNS\0|,|sativus (l_prep) on_10\IN\0|NONE (l_pobj) model_14\NN\5888929|NONE (l_prep) of_15\IN\0|induced (l_pobj) disease_19\NN\14061805|NONE
C029036_D000544 NONE crocins_8\NNS\0|NONE (l_prep) on_9\IN\0|NONE (l_pobj) disease_13\NN\14061805|NONE
C029036_D000544 NONE crocin_8\NNS\0|NONE (r_pobj) of_7\IN\0|the|)|mg/kg|in|( (r_prep) effectiveness_6\NN\5190804|Therefore|,|results|. (l_prep) in_13\IN\13603305|the|)|mg/kg|of|( (l_pcomp) antagonizing_14\VBG\1787955|NONE (l_dobj) deficits_17\NNS\5113133|NONE (l_acl) caused_18\VBN\1617192|the|cognitive (l_prep) in_23\IN\13603305|by (l_pobj) rats_24\NNS\2329401|NONE (l_conj) potential_27\NN\14481929|and (l_prep) in_28\IN\13603305|its (l_pobj) treatment_30\NN\654885|NONE (l_prep) of_31\IN\0|the (l_pobj) diseases_33\NNS\14061805|NONE (l_prep) as_35\IN\14622893|neurodegenerative (l_pobj) disease_38\NN\14061805|such
D013311_D019636 NONE stz_20\NNP\0| (r_compound) icv_22\NN\0|NONE (r_pobj) by_19\IN\0|in (r_agent) caused_18\VBN\1617192|the|cognitive (l_prep) in_23\IN\13603305|by (l_pobj) rats_24\NNS\2329401|NONE (l_conj) potential_27\NN\14481929|and (l_prep) in_28\IN\13603305|its (l_pobj) treatment_30\NN\654885|NONE (l_prep) of_31\IN\0|the (l_pobj) diseases_33\NNS\14061805|NONE
D013311_D003072 CID stz_20\NNP\0| (r_compound) icv_22\NN\0|NONE (r_pobj) by_19\IN\0|in (r_agent) caused_18\VBN\1617192|the|cognitive (r_acl) deficits_17\NNS\5113133|NONE
C029036_D019636 NONE crocin_8\NNS\0|NONE (r_pobj) of_7\IN\0|the|)|mg/kg|in|( (r_prep) effectiveness_6\NN\5190804|Therefore|,|results|. (l_prep) in_13\IN\13603305|the|)|mg/kg|of|( (l_pcomp) antagonizing_14\VBG\1787955|NONE (l_dobj) deficits_17\NNS\5113133|NONE (l_acl) caused_18\VBN\1617192|the|cognitive (l_prep) in_23\IN\13603305|by (l_pobj) rats_24\NNS\2329401|NONE (l_conj) potential_27\NN\14481929|and (l_prep) in_28\IN\13603305|its (l_pobj) treatment_30\NN\654885|NONE (l_prep) of_31\IN\0|the (l_pobj) diseases_33\NNS\14061805|NONE
D013311_D007859 NONE stz_17\NNP\0| (r_npadvmod) injected_19\VBN\81072|in|treated (r_amod) group_20\NN\2137|NONE (r_pobj) in_15\IN\13603305|learning|attenuated|dose (r_prep) impairment_14\NN\7296428|NONE
C029036_D003072 NONE crocin_8\NNS\0|NONE (r_pobj) of_7\IN\0|the|)|mg/kg|in|( (r_prep) effectiveness_6\NN\5190804|Therefore|,|results|. (l_prep) in_13\IN\13603305|the|)|mg/kg|of|( (l_pcomp) antagonizing_14\VBG\1787955|NONE (l_dobj) deficits_17\NNS\5113133|NONE
19674115
D011718_D033461 NONE pyrazinamide_0\NNP\0|effects|can|. (r_nsubj) have_2\VB\7846|NONE (l_dobj) effects_4\NNS\13245626|can|.|Pyrazinamide (l_prep) as_6\IN\14622893|adverse (l_pobj) toxicity_8\NN\13576101|such (l_conj) disorders_13\NNS\14034177|hepatic|, (l_nmod) hyperuricemia_10\NN\0|NONE
D011718_D000857 CID pyrazinamide_4\NN\0|NONE (r_pobj) by_3\IN\0|dysosmia|. (r_agent) induced_2\VBN\1627355|NONE (l_nsubj) dysosmia_1\NN\14052403|by|.
D011718_D000857 CID pyrazinamide_10\VB\0|NONE (r_xcomp) related_8\VBN\628491|reversible|olfactory (r_acl) disorder_7\NN\14034177|NONE
D011718_D000857 CID pyrazinamide_4\JJ\0|NONE (r_compound) withdrawal_5\NN\7206096|completely (r_pobj) after_3\IN\0|recurred|and|Dysosmia|. (r_prep) disappeared_1\VBD\0|NONE (l_nsubj) dysosmia_0\NNP\14052403|recurred|and|after|.
D011718_D056486 NONE pyrazinamide_0\NNP\0|effects|can|. (r_nsubj) have_2\VB\7846|NONE (l_dobj) effects_4\NNS\13245626|can|.|Pyrazinamide (l_prep) as_6\IN\14622893|adverse (l_pobj) toxicity_8\NN\13576101|such
19944736
D018021_D012640 CID licl_4\NNP\0|NONE (r_pobj) in_3\IN\13603305|NONE (r_prep) administered_2\VBN\2436349|rats|,|, (r_acl) tacrine_0\NNP\0|and|seizures|.|delayed (r_nsubj) induces_10\VBZ\1627355|NONE (l_dobj) seizures_12\NNS\14081375|and|.|Tacrine|delayed
D013619_D004827 NONE tacrine_5\NN\0| (r_npadvmod) loaded_7\VBN\452512|NONE (r_amod) nanoparticles_8\NNS\0|NONE (r_pobj) with_4\IN\0|animals (r_prep) treated_3\VBN\2376958|.|outcome (r_csubj) showed_9\VBD\2137132|NONE (l_dobj) outcome_12\NN\7291312|treated|. (l_prep) of_13\IN\0|an|earlier|with (l_pobj) symptoms_16\NNS\5823932|NONE (l_appos) onset_20\NN\7325190|CNS|,|adverse|, (l_amod) epileptic_19\JJ\10595647|i.e.
D013619_D004827 NONE tacrine_22\NN\0| (r_compound) lithium_24\NN\14625458|the|in|of (r_compound) model_25\NN\5888929|NONE (l_prep) of_26\IN\0|the|in|lithium (l_pobj) epilepsy_27\NN\14085708|NONE
D008094_D004827 NONE lithium_24\NN\14625458|the|in|of (r_compound) model_25\NN\5888929|NONE (l_prep) of_26\IN\0|the|in|lithium (l_pobj) epilepsy_27\NN\14085708|NONE
D013619_D001930 CID tacrine_0\NNP\0|and|seizures|.|delayed (r_nsubj) induces_10\VBZ\1627355|NONE (l_conj) delayed_14\VBD\439958|and|seizures|.|Tacrine (l_dobj) damage_16\NN\7296428|NONE
D013619_D001930 CID tacrine_3\NN\0| (r_npadvmod) loaded_5\VBN\452512|nanoparticles (r_amod) administration_7\NN\1133281|,|.|In|solution|damage|, (r_nsubj) induced_8\VBD\1627355|NONE (l_dobj) damage_9\NN\7296428|administration|,|.|In|solution|, (l_prep) of_10\IN\0|in (l_pobj) cells_12\NNS\3080309|NONE
D013619_D001930 CID tacrine_29\NN\0|NONE (r_pobj) of_28\IN\0|the|%|while|saline (r_prep) solution_27\NN\14586258|administration|,|.|In|damage|, (r_advcl) induced_8\VBD\1627355|NONE (l_dobj) damage_9\NN\7296428|administration|,|.|In|solution|, (l_prep) of_10\IN\0|in (l_pobj) cells_12\NNS\3080309|NONE
D018021_D001930 CID licl_4\NNP\0|NONE (r_pobj) in_3\IN\13603305|NONE (r_prep) administered_2\VBN\2436349|rats|,|, (r_acl) tacrine_0\NNP\0|and|seizures|.|delayed (r_nsubj) induces_10\VBZ\1627355|NONE (l_conj) delayed_14\VBD\439958|and|seizures|.|Tacrine (l_dobj) damage_16\NN\7296428|NONE
D013619_D012640 CID tacrine_0\NNP\0|and|seizures|.|delayed (r_nsubj) induces_10\VBZ\1627355|NONE (l_dobj) seizures_12\NNS\14081375|and|.|Tacrine|delayed
1141447
D008094_D003919 CID lithium_7\NN\14625458| (r_npadvmod) induced_9\VBN\1627355|diabetes (r_amod) insipidus_11\NN\0|NONE
D008094_D003919 CID lithium_3\NN\14625458| (r_npadvmod) induced_5\VBN\1627355|diabetes (r_amod) insipidus_7\NN\0|NONE
8686832
D000431_D010146 NONE alcohol_27\NN\7881800|a|high|,|be (r_compound) intake_28\NN\13440063|NONE (r_pobj) to_24\IN\0|NONE (r_prep) admitted_23\VBD\822367|NONE (r_acl) pain_22\NN\14299637|NONE (r_pobj) without_21\IN\0|seven|and (r_prep) pain_10\NN\14299637|NONE
D000431_D010146 NONE alcohol_27\NN\7881800|a|high|,|be (r_compound) intake_28\NN\13440063|NONE (r_pobj) to_24\IN\0|NONE (r_prep) admitted_23\VBD\822367|NONE (r_acl) pain_22\NN\14299637|NONE
D008012_D001416 CID lignocaine_11\NN\0|NONE (r_dobj) involving_7\VBG\2676054|spinal (r_acl) anaesthesia_6\NN\14034177|NONE (r_pobj) after_4\IN\0|back (r_prep) pain_3\NN\14299637|.|and
D008012_D001416 CID lignocaine_14\NN\0|NONE (r_pobj) of_10\IN\0|intrathecal|the (r_prep) use_9\NN\407535|NONE (r_pobj) with_6\IN\0|is|.|Leg (r_prep) associated_5\VBN\628491|NONE (l_nsubjpass) leg_0\NNP\5560244|is|with|. (l_conj) pain_3\NN\14299637|back|and/or
11185967
D000431_D019969 NONE alcohol_8\NN\7881800| (r_npadvmod) related_10\VBN\628491|seizure (r_amod) disorder_12\NN\14034177|or|underlying (r_conj) drug_6\NN\14778436|NONE (r_pobj) of_4\IN\0|NONE (r_prep) history_3\NN\15120823|,|,|Patient (r_appos) demographics_1\NNS\6021499|from|time|,|results|.|recorded (r_nsubj) estimated_14\VBN\637259|NONE (l_prep) from_16\IN\0|demographics|time|,|results|.|recorded (l_prep) to_18\IN\0|seizure (l_pobj) collection_20\NN\31264|NONE (l_conj) history_22\NN\15120823|,|sample (l_conj) suspicion_24\NN\5916739|or (l_prep) of_25\IN\0|NONE (l_pobj) cocaine_26\NN\3492717|NONE (l_conj) abuse_29\NN\418025|or
D000431_D012640 NONE alcohol_8\NN\7881800| (r_npadvmod) related_10\VBN\628491|seizure (r_amod) disorder_12\NN\14034177|or|underlying (l_compound) seizure_11\NN\14081375|related
D000431_D012640 NONE alcohol_8\NN\7881800| (r_npadvmod) related_10\VBN\628491|seizure (r_amod) disorder_12\NN\14034177|or|underlying (r_conj) drug_6\NN\14778436|NONE (r_pobj) of_4\IN\0|NONE (r_prep) history_3\NN\15120823|,|,|Patient (r_appos) demographics_1\NNS\6021499|from|time|,|results|.|recorded (r_nsubj) estimated_14\VBN\637259|NONE (l_prep) from_16\IN\0|demographics|time|,|results|.|recorded (l_pobj) seizure_17\NN\14081375|to
D000431_D019970 NONE alcohol_8\NN\7881800| (r_npadvmod) related_10\VBN\628491|seizure (r_amod) disorder_12\NN\14034177|or|underlying (r_conj) drug_6\NN\14778436|NONE (r_pobj) of_4\IN\0|NONE (r_prep) history_3\NN\15120823|,|,|Patient (r_appos) demographics_1\NNS\6021499|from|time|,|results|.|recorded (r_nsubj) estimated_14\VBN\637259|NONE (l_prep) from_16\IN\0|demographics|time|,|results|.|recorded (l_prep) to_18\IN\0|seizure (l_pobj) collection_20\NN\31264|NONE (l_conj) history_22\NN\15120823|,|sample (l_conj) suspicion_24\NN\5916739|or (l_prep) of_25\IN\0|NONE (l_pobj) cocaine_26\NN\3492717|NONE (l_conj) abuse_29\NN\418025|or
D003042_D012640 NONE cocaine_16\NN\3492717|NONE (l_prep) in_19\IN\13603305|or|amphetamine (l_pobj) patients_24\NNS\9898892|NONE (l_compound) seizure_23\NN\14081375|emergency
D003042_D012640 NONE cocaine_9\NN\3492717|NONE (l_prep) in_12\IN\13603305|and|amphetamines (l_pobj) patients_15\NNS\9898892|NONE (l_compound) seizure_14\NN\14081375|NONE
D000661_D012640 NONE amphetamine_18\NN\3248958|or|in (r_conj) cocaine_16\NN\3492717|NONE (l_prep) in_19\IN\13603305|or|amphetamine (l_pobj) patients_24\NNS\9898892|NONE (l_compound) seizure_23\NN\14081375|emergency
D000662_D012640 NONE amphetamines_11\NNS\3248958|and|in (r_conj) cocaine_9\NN\3492717|NONE (l_prep) in_12\IN\13603305|and|amphetamines (l_pobj) patients_15\NNS\9898892|NONE (l_compound) seizure_14\NN\14081375|NONE
9564988
D064704_D012852 NONE levofloxacin_5\NN\0|NONE (r_pobj) of_4\IN\0|label|for|. (r_prep) assessment_3\NN\5732756|NONE (l_prep) for_6\IN\0|of|label|. (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|in|the (l_pobj) sinusitis_12\NN\14336539|NONE
D064704_D012852 NONE levofloxacin_7\NN\0|NONE (r_pobj) of_6\IN\0|and|safety|the (r_prep) efficacy_3\NN\5199286|in|To|.|daily (r_dobj) evaluate_1\VB\670261|NONE (l_prep) in_20\IN\13603305|To|efficacy|.|daily (l_pcomp) treating_21\VBG\2376958|NONE (l_prep) with_24\IN\0|outpatients (l_pobj) sinusitis_27\NN\14336539|NONE
D064704_D012852 NONE levofloxacin_7\VBZ\0|.|is|results (r_ccomp) indicate_5\VBP\952524|NONE (l_ccomp) is_12\VBZ\0|levofloxacin|.|results (l_attr) treatment_17\NN\654885|NONE (l_prep) for_18\IN\0|effective|an (l_pobj) sinusitis_21\NN\14336539|NONE
10565806
C076029_D001714 CID olanzapine_6\NN\0|NONE (r_pobj) by_5\IN\0|Hypomania|. (r_prep) induced_4\VBN\1627355|NONE (l_nsubj) hypomania_0\NNP\0|by|.
C076029_D001714 CID olanzapine_28\JJ\0|NONE (r_compound) treatment_29\NN\654885|NONE (r_pobj) of_27\IN\0|the (r_prep) introduction_26\NN\235435|shortly (r_pobj) after_24\IN\0|who|hypomania (r_prep) developed_21\VBD\1753788|a|IV|specified|psychotic (l_dobj) hypomania_22\NN\0|who|after
C076029_D011618 NONE olanzapine_28\JJ\0|NONE (r_compound) treatment_29\NN\654885|NONE (r_pobj) of_27\IN\0|the (r_prep) introduction_26\NN\235435|shortly (r_pobj) after_24\IN\0|who|hypomania (r_prep) developed_21\VBD\1753788|a|IV|specified|psychotic (r_relcl) disorder_14\NN\14034177|NONE
9672273
D013629_D014652 CID tamoxifen_20\NN\2714883|NONE (r_pobj) on_19\IN\0|NONE (r_prep) women_18\NNS\9605289|NONE (r_pobj) among_17\IN\0|hypertriglyceridaemia|and|vascular (r_prep) events_14\NNS\23100|NONE
D013629_D016889 NONE tamoxifen_0\NNP\2714883|agent|,|associated|. (r_nsubj) is_1\VBZ\0|NONE (l_advcl) associated_15\VBN\628491|agent|Tamoxifen|,|. (l_prep) with_16\IN\0|may|drug|although|be (l_pobj) development_18\NN\248977|NONE (l_prep) of_19\IN\0|the (l_pobj) cancer_21\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_5\NN\2714883|NONE (r_pobj) with_4\IN\0|:|of|.|findings (r_prep) prevention_0\NN\1073995|NONE (l_prep) of_1\IN\0|with|:|.|findings (l_pobj) cancer_3\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_0\NNP\2714883|agent|,|associated|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_5\NN\7347|Tamoxifen|,|associated|. (l_prep) in_6\IN\13603305|a|chemopreventive|candidate (l_pobj) cancer_8\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_18\NN\2714883|NONE (r_pobj) of_17\IN\0|blind|a|randomised|controlled|,|)|(|have|in|in (r_prep) trial_16\NN\786195|,|.|we|In (l_relcl) have_29\VB\7846|blind|a|randomised|controlled|,|)|(|in|of|in (l_dobj) cancer_31\NN\14239425|and|did|who|not|had
D013629_D001943 NONE tamoxifen_17\NN\2714883||(|) (r_nmod) arms_21\NNS\3575240|the|cases|(|)|and (r_conj) placebo_11\NN\3740161|NONE (r_pobj) between_9\IN\0|cancer (r_prep) frequency_8\NN\15286249|NONE (l_compound) cancer_7\NN\14239425|between
D013629_D001943 NONE tamoxifen_12\NN\2714883|NONE (r_dobj) receiving_11\VBG\2210855|used (r_acl) women_10\NNS\9605289|NONE (r_pobj) among_9\IN\0|among|of|:|a|significant (r_prep) reduction_5\NN\351485|There (l_prep) of_6\IN\0|among|:|among|a|significant (l_pobj) cancer_8\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_12\NN\2714883|NONE (r_dobj) receiving_11\VBG\2210855|used (r_acl) women_10\NNS\9605289|NONE (r_pobj) among_9\IN\0|among|of|:|a|significant (r_prep) reduction_5\NN\351485|There (r_attr) is_1\VBZ\0|we|compared|.|cases|, (r_ccomp) found_36\VBD\13279262|NONE (l_dobj) cases_38\NNS\7283608|we|compared|is|.|, (l_prep) of_39\IN\0|eight (l_pobj) cancer_41\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_51\NN\2714883|NONE (r_pobj) to_50\IN\0|NONE (r_prep) allocated_49\VBN\2228698| (r_acl) women_48\NNS\9605289|NONE (r_pobj) among_46\IN\0|one (r_prep) case_45\NN\7283608|NONE (r_pobj) with_43\IN\0|NONE (r_prep) compared_42\VBN\644583|we|is|.|cases|, (r_prep) found_36\VBD\13279262|NONE (l_ccomp) is_1\VBZ\0|we|compared|.|cases|, (l_attr) reduction_5\NN\351485|There (l_prep) of_6\IN\0|among|:|among|a|significant (l_pobj) cancer_8\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_51\NN\2714883|NONE (r_pobj) to_50\IN\0|NONE (r_prep) allocated_49\VBN\2228698| (r_acl) women_48\NNS\9605289|NONE (r_pobj) among_46\IN\0|one (r_prep) case_45\NN\7283608|NONE (r_pobj) with_43\IN\0|NONE (r_prep) compared_42\VBN\644583|we|is|.|cases|, (r_prep) found_36\VBD\13279262|NONE (l_dobj) cases_38\NNS\7283608|we|compared|is|.|, (l_prep) of_39\IN\0|eight (l_pobj) cancer_41\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_29\NN\2714883|NONE (r_pobj) of_28\IN\0|postulated|the|protective (r_prep) effects_27\NNS\13245626|in|has|,|,|apparent|.|not (r_nsubj) are_30\VBP\13600404|NONE (l_prep) in_8\IN\13603305|effects|has|,|,|apparent|.|not (l_prep) at_13\IN\14622893|cohort (l_pobj) risk_19\NN\14541044|NONE (l_prep) of_20\IN\0|low (l_pobj) cancer_22\NN\14239425|NONE
D013629_D015228 CID tamoxifen_20\NN\2714883|NONE (r_pobj) on_19\IN\0|NONE (r_prep) women_18\NNS\9605289|NONE (r_pobj) among_17\IN\0|hypertriglyceridaemia|and|vascular (r_prep) events_14\NNS\23100|NONE (l_conj) hypertriglyceridaemia_16\NN\0|and|vascular|among
11077455
D020888_D014786 CID vigabatrin_16\NN\0| (r_npadvmod) attributed_18\VBN\670261|field (r_amod) constriction_21\NN\5071027|NONE
D020888_D014786 CID vigabatrin_9\NN\0|NONE (r_pobj) with_8\IN\0|to|be (r_prep) associated_7\VBN\628491|constriction (r_xcomp) thought_4\NN\5809192|.|been|has (l_nsubj) constriction_3\NN\5071027|associated
D020888_D014786 CID vigabatrin_15\NN\0| (r_npadvmod) attributed_17\VBN\670261|known|field (r_amod) loss_20\NN\13252973|NONE
D020888_D014786 CID vigabatrin_9\NN\0|NONE (r_compound) therapy_10\NN\657604|NONE (r_pobj) with_8\IN\0|to|be (r_prep) associated_7\VBN\628491|.|constriction (r_xcomp) appears_4\VBZ\2604760|NONE (l_nsubj) constriction_3\NN\5071027|.|associated
1423339
D011433_D064420 NONE propranolol_4\JJ\0|NONE (r_amod) toxicity_5\NN\13576101|NONE
D011433_D064420 NONE propranolol_14\JJ\0|NONE (r_amod) toxicity_15\NN\13576101|NONE
D011433_D003704 NONE propranolol_14\JJ\0|NONE (r_amod) toxicity_15\NN\13576101|NONE (r_pobj) of_13\IN\0|a (r_prep) result_12\NN\34213|NONE (r_pobj) as_10\IN\14622893|woman|dementia|. (r_prep) developed_3\VBD\1753788|NONE (l_dobj) dementia_9\NN\14395018|as|woman|.
D011433_D000647 CID propranolol_4\JJ\0|NONE (r_amod) toxicity_5\NN\13576101|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBN\628491|Amnestic|.|report|: (r_acl) syndrome_1\NN\5870365|NONE
D011433_D000544 NONE propranolol_14\JJ\0|NONE (r_amod) toxicity_15\NN\13576101|NONE (r_pobj) of_13\IN\0|a (r_prep) result_12\NN\34213|NONE (r_pobj) as_10\IN\14622893|woman|dementia|. (r_prep) developed_3\VBD\1753788|NONE (l_dobj) dementia_9\NN\14395018|as|woman|. (l_amod) like_7\JJ\5839024|subacute|an (l_npadvmod) alzheimer_5\NNP\0|
7710775
D001241_D007511 NONE acetylsalicylate_4\VBP\0|NONE (l_prep) before_7\IN\0|other|.|,|of (l_pobj) ischemia_8\NN\14195315|intravenously|immediately
D008315_D007022 NONE malondialdehyde_23\NN\0|NONE (r_pobj) in_19\IN\13603305|higher|although (r_prep) was_24\VBD\0|.|of|/|during|,|intravenously (r_advcl) min_13\NN\15154774|NONE (l_prep) of_0\IN\0|.|/|during|,|intravenously|was (l_pobj) drug_3\NN\14778436|NONE (l_amod) hypotensive_2\JJ\10405694|the|nitroprusside
D009705_D002545 NONE nucleosides_9\NNS\14887305|dependence|.|and|, (l_prep) during_10\IN\0|NONE (l_pobj) ischemia_13\NN\14195315|NONE
-1_D007511 NONE oxypurines_10\NNS\0|NONE (r_pobj) of_8\IN\0|dependent|a (r_prep) increase_7\NN\13576355|was|.|,|During (r_nsubjpass) observed_14\VBN\2163746|NONE (l_prep) during_0\IN\0|was|.|increase|, (l_pobj) ischemia_1\NN\14195315|NONE
-1_D007511 NONE oxypurines_10\NNS\0|, (r_conj) malondialdehyde_8\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) determination_6\NN\43195|,|that|may|monitor|be (r_nsubjpass) used_20\VBN\0|data|. (l_xcomp) monitor_22\VB\10676877|,|that|may|determination|be (l_dobj) alterations_25\NNS\7283608|to (l_acl) occurring_28\VBG\0|the|metabolic|of (l_prep) during_29\IN\0|NONE (l_pobj) phenomena_31\NNS\29677|NONE (l_amod) ischemic_30\JJ\0|NONE
D008315_D007511 NONE malondialdehyde_1\NN\0|after|,|resulting|. (r_nsubj) increased_23\VBD\169651|NONE (l_prep) after_24\IN\0|,|malondialdehyde|resulting|. (l_pobj) min_26\NN\15154774|NONE (l_prep) of_27\IN\0| (l_pobj) ischemia_28\NN\14195315|NONE
D008315_D007511 NONE malondialdehyde_23\NN\0|NONE (r_pobj) in_19\IN\13603305|higher|although (r_prep) was_24\VBD\0|.|of|/|during|,|intravenously (r_advcl) min_13\NN\15154774|NONE (l_prep) during_15\IN\0|.|of|/|,|intravenously|was (l_pobj) ischemia_16\NN\14195315|NONE
D008315_D007511 NONE malondialdehyde_8\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) determination_6\NN\43195|,|that|may|monitor|be (r_nsubjpass) used_20\VBN\0|data|. (l_xcomp) monitor_22\VB\10676877|,|that|may|determination|be (l_dobj) alterations_25\NNS\7283608|to (l_acl) occurring_28\VBG\0|the|metabolic|of (l_prep) during_29\IN\0|NONE (l_pobj) phenomena_31\NNS\29677|NONE (l_amod) ischemic_30\JJ\0|NONE
-1_D002545 NONE oxypurines_6\NNS\0|NONE (l_conj) nucleosides_9\NNS\14887305|dependence|.|and|, (l_prep) during_10\IN\0|NONE (l_pobj) ischemia_13\NN\14195315|NONE
D008315_D002545 CID malondialdehyde_4\NN\0|NONE (r_pobj) of_2\IN\0|Time (r_prep) dependence_1\NN\24720|.|and|,|nucleosides (r_nsubj) oxypurines_6\NNS\0|NONE (l_conj) nucleosides_9\NNS\14887305|dependence|.|and|, (l_prep) during_10\IN\0|NONE (l_pobj) ischemia_13\NN\14195315|NONE
D009599_D007511 NONE nitroprusside_4\NN\0|the|hypotensive (r_acl) drug_3\NN\14778436|NONE (r_pobj) of_0\IN\0|.|/|during|,|intravenously|was (r_prep) min_13\NN\15154774|NONE (l_prep) during_15\IN\0|.|of|/|,|intravenously|was (l_pobj) ischemia_16\NN\14195315|NONE
D009705_D007511 NONE nucleosides_12\NNS\14887305|plasma|and (r_conj) oxypurines_10\NNS\0|NONE (r_pobj) of_8\IN\0|dependent|a (r_prep) increase_7\NN\13576355|was|.|,|During (r_nsubjpass) observed_14\VBN\2163746|NONE (l_prep) during_0\IN\0|was|.|increase|, (l_pobj) ischemia_1\NN\14195315|NONE
D009705_D007511 NONE nucleosides_13\NNS\14887305|and|, (r_conj) oxypurines_10\NNS\0|, (r_conj) malondialdehyde_8\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) determination_6\NN\43195|,|that|may|monitor|be (r_nsubjpass) used_20\VBN\0|data|. (l_xcomp) monitor_22\VB\10676877|,|that|may|determination|be (l_dobj) alterations_25\NNS\7283608|to (l_acl) occurring_28\VBG\0|the|metabolic|of (l_prep) during_29\IN\0|NONE (l_pobj) phenomena_31\NNS\29677|NONE (l_amod) ischemic_30\JJ\0|NONE
D009599_D007022 NONE nitroprusside_4\NN\0|the|hypotensive (r_acl) drug_3\NN\14778436|NONE (l_amod) hypotensive_2\JJ\10405694|the|nitroprusside
8888541
D012701_D011595 NONE serotonin_3\NN\14807737|HTA (r_nmod) receptors_5\NNS\5225602|NONE (r_pobj) of_2\IN\0|Excessive (r_prep) stimulation_1\NN\242808|.|syndrome (r_nsubj) causes_6\VBZ\7323922|NONE (l_dobj) syndrome_8\NN\5870365|.|stimulation (l_prep) of_9\IN\0|a (l_pobj) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle (l_conj) confusion_22\NN\13972797|, (l_conj) agitation_24\NN\14373582|,
D012701_D011595 NONE serotonin_10\NN\14807737|consists (r_compound) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle (l_conj) confusion_22\NN\13972797|, (l_conj) agitation_24\NN\14373582|,
D014191_D003866 NONE tranylcypromine_22\NN\3783017|who|was (l_prep) for_23\IN\0|NONE (l_pobj) depression_24\NN\14373582|NONE
D012701_D012798 NONE serotonin_3\NN\14807737|HTA (r_nmod) receptors_5\NNS\5225602|NONE (r_pobj) of_2\IN\0|Excessive (r_prep) stimulation_1\NN\242808|.|syndrome (r_nsubj) causes_6\VBZ\7323922|NONE (l_dobj) syndrome_8\NN\5870365|.|stimulation (l_prep) of_9\IN\0|a (l_pobj) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle
D012701_D012798 NONE serotonin_10\NN\14807737|consists (r_compound) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle
C047426_D020230 CID venlafaxine_3\NNP\0| (r_compound) tranylcypromine_5\NN\3783017|NONE (r_compound) interaction_6\NN\37396|NONE (r_pobj) from_2\IN\0|.|Serotonin (r_prep) syndrome_1\NN\5870365|NONE
C047426_D020230 CID venlafaxine_3\NNP\0| (r_compound) maoi_5\NNP\2718811|resulted|a (r_compound) interaction_6\NN\37396|.|We (l_relcl) resulted_8\VBD\2633881|MAOI|a (l_prep) in_9\IN\13603305|in|that (l_pobj) syndrome_12\NN\5870365|NONE
D012701_D005334 NONE serotonin_3\NN\14807737|HTA (r_nmod) receptors_5\NNS\5225602|NONE (r_pobj) of_2\IN\0|Excessive (r_prep) stimulation_1\NN\242808|.|syndrome (r_nsubj) causes_6\VBZ\7323922|NONE (l_dobj) syndrome_8\NN\5870365|.|stimulation (l_prep) of_9\IN\0|a (l_pobj) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle (l_conj) confusion_22\NN\13972797|, (l_conj) agitation_24\NN\14373582|, (l_conj) hyperthermia_26\NN\14034177|and
D012701_D005334 NONE serotonin_10\NN\14807737|consists (r_compound) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle (l_conj) confusion_22\NN\13972797|, (l_conj) agitation_24\NN\14373582|, (l_conj) hyperthermia_26\NN\14034177|and
D012701_D003221 NONE serotonin_3\NN\14807737|HTA (r_nmod) receptors_5\NNS\5225602|NONE (r_pobj) of_2\IN\0|Excessive (r_prep) stimulation_1\NN\242808|.|syndrome (r_nsubj) causes_6\VBZ\7323922|NONE (l_dobj) syndrome_8\NN\5870365|.|stimulation (l_prep) of_9\IN\0|a (l_pobj) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle (l_conj) confusion_22\NN\13972797|,
D012701_D003221 NONE serotonin_10\NN\14807737|consists (r_compound) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|, (l_conj) salivation_20\NN\13553916|,|muscle (l_conj) confusion_22\NN\13972797|,
D012701_D009127 NONE serotonin_3\NN\14807737|HTA (r_nmod) receptors_5\NNS\5225602|NONE (r_pobj) of_2\IN\0|Excessive (r_prep) stimulation_1\NN\242808|.|syndrome (r_nsubj) causes_6\VBZ\7323922|NONE (l_dobj) syndrome_8\NN\5870365|.|stimulation (l_prep) of_9\IN\0|a (l_pobj) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|,
D012701_D009127 NONE serotonin_10\NN\14807737|consists (r_compound) excess_11\NN\5119367|NONE (l_relcl) consists_13\VBZ\2603699|serotonin (l_prep) of_14\IN\0|that (l_pcomp) shivering_15\VBG\14299637|NONE (l_conj) rigidity_18\NN\5023233|,
C047426_D003866 NONE venlafaxine_3\NNP\0| (r_compound) maoi_5\NNP\2718811|resulted|a (r_compound) interaction_6\NN\37396|.|We (l_relcl) resulted_8\VBD\2633881|MAOI|a (l_prep) in_13\IN\13603305|in|that (l_pobj) male_18\NN\15388|NONE (l_relcl) taking_21\VBG\37396|a|old (l_dobj) tranylcypromine_22\NN\3783017|who|was (l_prep) for_23\IN\0|NONE (l_pobj) depression_24\NN\14373582|NONE
D003975_D009127 NONE diazepam_4\NN\2830852|NONE (r_pobj) of_3\IN\0|i.v.| (r_prep) mg_2\NN\13717155|NONE (r_pobj) after_0\IN\0|.|he|tremulous (r_prep) remained_7\VBD\2604760|NONE (l_acomp) tremulous_8\JJ\0|.|he|After (l_prep) with_9\IN\0|NONE (l_pobj) rigidity_11\NN\5023233|NONE
D014191_D020230 CID tranylcypromine_5\NN\3783017|NONE (r_compound) interaction_6\NN\37396|NONE (r_pobj) from_2\IN\0|.|Serotonin (r_prep) syndrome_1\NN\5870365|NONE
D014191_D020230 CID tranylcypromine_22\NN\3783017|who|was (r_dobj) taking_21\VBG\37396|a|old (r_relcl) male_18\NN\15388|NONE (r_pobj) in_13\IN\13603305|in|that (r_prep) resulted_8\VBD\2633881|MAOI|a (l_prep) in_9\IN\13603305|in|that (l_pobj) syndrome_12\NN\5870365|NONE
7282516
D004317_D009202 CID doxorubicin_9\NN\2716866|NONE (r_compound) cardiomyopathy_10\NN\14103288|NONE
D004317_D009202 CID doxorubicin_10\NN\2716866|NONE (l_nsubj) cm_3\NNP\13649268|)|DXR (l_amod) cardiomyopathy_1\NN\14103288|)|produced|(|The
D004317_D009202 CID doxorubicin_10\NN\2716866|NONE (l_nsubj) cm_3\NNP\13649268|)|DXR
D004317_D009202 CID dxr_12\NN\0|)|CM (r_appos) doxorubicin_10\NN\2716866|NONE (l_nsubj) cm_3\NNP\13649268|)|DXR (l_amod) cardiomyopathy_1\NN\14103288|)|produced|(|The
D004317_D009202 CID dxr_12\NN\0|)|CM (r_appos) doxorubicin_10\NN\2716866|NONE (l_nsubj) cm_3\NNP\13649268|)|DXR
D004317_D009202 CID adriamycin_1\NNP\0|opportunity|)|(|. (r_nsubj) provides_3\VBZ\2199590|NONE (l_dobj) opportunity_6\NN\14481929|)|Adriamycin|(|. (l_acl) analyze_8\VB\0|a|unique (l_dobj) relationships_16\NNS\31921|to (l_prep) during_17\IN\0|effect (l_pobj) development_18\NN\248977|NONE (l_prep) of_19\IN\0|NONE (l_pobj) disease_21\NN\14061805|NONE
D004317_D009202 CID dxr_1\NNP\0| (r_compound) cm_3\NNP\13649268|myocardial
D004317_D009202 CID dxr_1\NNP\0| (r_compound) cm_3\NNP\13649268|myocardial (r_nmod) damage_5\NN\7296428|NONE
D004317_D009202 CID dxr_15\NNP\0|NONE (r_compound) dose_16\NN\3740161|)|(|cytotoxic (r_appos) insult_13\NN\6714976|NONE (r_pobj) of_11\IN\0|the (r_prep) degree_10\NN\4916342|NONE (r_pobj) to_8\IN\0|NONE (r_prep) proportional_7\JJ\5855125|.|preserved|In (r_acomp) is_6\VBZ\0|NONE (l_prep) in_0\IN\13603305|proportional|.|preserved (l_pobj) damage_5\NN\7296428|NONE (l_nmod) cm_3\NNP\13649268|myocardial
D004317_D009202 CID dxr_15\NNP\0|NONE (r_compound) dose_16\NN\3740161|)|(|cytotoxic (r_appos) insult_13\NN\6714976|NONE (r_pobj) of_11\IN\0|the (r_prep) degree_10\NN\4916342|NONE (r_pobj) to_8\IN\0|NONE (r_prep) proportional_7\JJ\5855125|.|preserved|In (r_acomp) is_6\VBZ\0|NONE (l_prep) in_0\IN\13603305|proportional|.|preserved (l_pobj) damage_5\NN\7296428|NONE
11838826
C047047_D011605 NONE cabergoline_55\NN\0|NONE (r_pobj) with_54\IN\0|were|)|.|dose|males (r_prep) treated_53\VBN\2376958|NONE (l_nsubjpass) males_1\NNS\15388|were|)|.|with|dose (l_prep) with_9\IN\0|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN\14034177|NONE (l_conj) psychoses_24\NNS\14380140|edition|Diagnostic|or|bipolar
D018967_D001714 NONE risperidone_27\NN\0| (r_npadvmod) induced_29\VBN\1627355|in (r_amod) elevations_30\NNS\7445480|NONE (r_pobj) with_26\IN\0|Four|mL|(|age|with|,|(|,|)|) (r_prep) males_1\NNS\15388|were|)|.|with|dose (l_prep) with_9\IN\0|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN\14034177|NONE
D018967_D001523 NONE risperidone_27\NN\0| (r_npadvmod) induced_29\VBN\1627355|in (r_amod) elevations_30\NNS\7445480|NONE (r_pobj) with_26\IN\0|Four|mL|(|age|with|,|(|,|)|) (r_prep) males_1\NNS\15388|were|)|.|with|dose (l_prep) with_9\IN\0|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN\14034177|NONE (l_amod) diagnostic_10\NNP\0|edition|or|psychoses|bipolar (l_conj) manual_13\NNP\6421301|and (l_prep) of_14\IN\0|Statistical (l_pobj) disorders_16\NNPS\14034177|NONE
C047047_D001714 NONE cabergoline_55\NN\0|NONE (r_pobj) with_54\IN\0|were|)|.|dose|males (r_prep) treated_53\VBN\2376958|NONE (l_nsubjpass) males_1\NNS\15388|were|)|.|with|dose (l_prep) with_9\IN\0|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN\14034177|NONE
C047047_D006966 NONE cabergoline_11\NN\0|NONE (r_pobj) with_10\IN\0|induced (r_prep) hyperprolactinemia_9\NN\0|NONE
C047047_D006966 NONE cabergoline_16\NN\0|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treated_14\VBN\2376958|induced (r_acl) hyperprolactinemia_13\NN\0|NONE
C047047_D006966 NONE cabergoline_0\NNP\0|may|for|useful (r_nsubj) be_2\VB\14625458|,|however|is|;|.|research (l_prep) for_4\IN\0|may|Cabergoline|useful (l_pobj) treatment_6\NN\654885|NONE (l_prep) of_7\IN\0|the|in (l_pobj) hyperprolactinemia_11\NN\0|NONE
D004298_D006966 NONE dopamine_8\NN\14807737|a|in (r_compound) agonist_9\NN\0|NONE (r_pobj) with_6\IN\0|induced (r_prep) hyperprolactinemia_5\NN\0|NONE
D018967_D006966 CID risperidone_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|with (r_amod) hyperprolactinemia_5\NN\0|NONE
D018967_D006966 CID risperidone_0\NNP\0|.|is|with (r_nsubjpass) associated_16\VBN\628491|NONE (l_prep) with_17\IN\0|.|is|Risperidone (l_pobj) hyperprolactinemia_18\NN\0|NONE
D018967_D006966 CID risperidone_6\NN\0| (r_npadvmod) induced_8\VBN\1627355|with (r_amod) hyperprolactinemia_9\NN\0|NONE
D018967_D006966 CID risperidone_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|treated (r_amod) hyperprolactinemia_13\NN\0|NONE
D018967_D006966 CID risperidone_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hyperprolactinemia_11\NN\0|NONE
D018967_D011605 NONE risperidone_27\NN\0| (r_npadvmod) induced_29\VBN\1627355|in (r_amod) elevations_30\NNS\7445480|NONE (r_pobj) with_26\IN\0|Four|mL|(|age|with|,|(|,|)|) (r_prep) males_1\NNS\15388|were|)|.|with|dose (l_prep) with_9\IN\0|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN\14034177|NONE (l_conj) psychoses_24\NNS\14380140|edition|Diagnostic|or|bipolar
C047047_D001523 NONE cabergoline_55\NN\0|NONE (r_pobj) with_54\IN\0|were|)|.|dose|males (r_prep) treated_53\VBN\2376958|NONE (l_nsubjpass) males_1\NNS\15388|were|)|.|with|dose (l_prep) with_9\IN\0|Four|mL|(|age|,|(|,|with|)|) (l_pobj) disorder_22\NN\14034177|NONE (l_amod) diagnostic_10\NNP\0|edition|or|psychoses|bipolar (l_conj) manual_13\NNP\6421301|and (l_prep) of_14\IN\0|Statistical (l_pobj) disorders_16\NNPS\14034177|NONE
16192988
D008694_D001523 CID methamphetamine_0\NN\2704153|.|alterations (r_nsubj) causes_1\VBZ\7323922|NONE (l_dobj) alterations_2\NNS\7283608|Methamphetamine|. (l_relcl) display_16\VBP\6879180|in (l_dobj) aggressiveness_18\NN\4835724|that
D008694_D001523 CID methamphetamine_18\NN\2704153|NONE (r_pobj) in_17\IN\13603305|NONE (r_prep) common_16\JJ\8673395|NONE (r_acomp) are_15\VBP\13600404|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN\831651|NONE (l_nsubjpass) behaviors_1\NNS\407535|are|,|in|been|and|have|.
D008694_D001523 CID methamphetamine_18\NN\2704153|NONE (r_pobj) in_17\IN\13603305|NONE (r_prep) common_16\JJ\8673395|NONE (r_acomp) are_15\VBP\13600404|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN\831651|NONE (l_prep) in_5\IN\13603305|are|,|been|and|behaviors|have|. (l_pobj) patients_6\NNS\9898892|NONE (l_relcl) suffer_8\VBP\2110220|NONE (l_prep) from_9\IN\0|who (l_pobj) disorders_12\NNS\14034177|NONE
D008694_D001523 CID meth_20\NN\2704153|NONE (r_nmod) abusers_22\NNS\9633969|( (r_appos) methamphetamine_18\NN\2704153|NONE (r_pobj) in_17\IN\13603305|NONE (r_prep) common_16\JJ\8673395|NONE (r_acomp) are_15\VBP\13600404|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN\831651|NONE (l_nsubjpass) behaviors_1\NNS\407535|are|,|in|been|and|have|.
D008694_D001523 CID meth_20\NN\2704153|NONE (r_nmod) abusers_22\NNS\9633969|( (r_appos) methamphetamine_18\NN\2704153|NONE (r_pobj) in_17\IN\13603305|NONE (r_prep) common_16\JJ\8673395|NONE (r_acomp) are_15\VBP\13600404|,|in|been|and|behaviors|have|. (r_conj) reported_4\VBN\831651|NONE (l_prep) in_5\IN\13603305|are|,|been|and|behaviors|have|. (l_pobj) patients_6\NNS\9898892|NONE (l_relcl) suffer_8\VBP\2110220|NONE (l_prep) from_9\IN\0|who (l_pobj) disorders_12\NNS\14034177|NONE
D008694_D001523 CID meth_13\NNP\2704153|NONE (r_pobj) of_12\IN\0|)|single|multiple|( (r_prep) injections_11\NNS\320852|that|aggressiveness|significantly (r_nsubj) increased_15\VBD\169651|we|Herein|,|. (l_dobj) aggressiveness_16\NN\4835724|that|injections|significantly
D008694_D001523 CID meth_8\NNP\2704153| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hyperactivity_11\NN\14052403|NONE (r_pobj) to_7\IN\0|NONE (r_prep) secondary_6\JJ\8426461|.|increase|not (r_acomp) was_4\VBD\0|NONE (l_nsubj) increase_1\NN\13576355|secondary|.|not (l_prep) in_2\IN\13603305|This (l_pobj) aggressiveness_3\NN\4835724|NONE
D008694_D006948 NONE meth_8\NNP\2704153| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hyperactivity_11\NN\14052403|NONE
1732442
D004317_D009202 CID adriamycin_8\NNS\0| (r_npadvmod) induced_10\VBN\1627355|with (r_amod) cardiomyopathy_11\NN\14103288|NONE
D004317_D009202 CID adriamycin_5\NNS\0| (r_amod) induced_7\VBN\1627355|NONE (r_amod) cardiomyopathy_8\NN\14103288|NONE
D004317_D009202 CID adriamycin_5\NNS\0| (r_amod) induced_7\VBN\1627355|NONE (r_amod) cardiomyopathy_8\NN\14103288|NONE (r_pobj) of_4\IN\0|rat|a (r_prep) model_3\NN\5888929|NONE (r_dobj) using_0\VBG\418025|.|we|hypothesis|, (r_advcl) tested_11\VBD\670261|NONE (l_dobj) hypothesis_13\NN\7162194|Using|.|we|, (l_acl) appear_21\VB\2604760|the (l_conj) exacerbated_24\VBN\126264|activity|and|may|that (l_advmod) dependently_27\RB\0|be (l_prep) in_28\IN\13603305||dose (l_pobj) cardiomyopathy_30\NN\14103288|NONE
D004317_D009202 CID adriamycin_29\FW\0|NONE (r_amod) cardiomyopathy_30\NN\14103288|NONE (r_pobj) in_28\IN\13603305||dose (r_prep) dependently_27\RB\0|be (r_advmod) exacerbated_24\VBN\126264|activity|and|may|that (r_conj) appear_21\VB\2604760|the (r_acl) hypothesis_13\NN\7162194|Using|.|we|, (r_dobj) tested_11\VBD\670261|NONE (l_advcl) using_0\VBG\418025|.|we|hypothesis|, (l_dobj) model_3\NN\5888929|NONE (l_prep) of_4\IN\0|rat|a (l_pobj) cardiomyopathy_8\NN\14103288|NONE
D004317_D009202 CID adriamycin_29\FW\0|NONE (r_amod) cardiomyopathy_30\NN\14103288|NONE
D004317_D009202 CID adriamycin_34\NNS\0| (r_amod) induced_36\VBN\1627355|NONE (r_amod) cardiomyopathy_37\NN\14103288|NONE (r_pobj) of_33\IN\0|NONE (r_prep) detection_32\NN\5708432|NONE (r_pobj) for_31\IN\0|a|useful (r_prep) method_30\NN\5616786|that|may|scintigraphy (r_attr) be_27\VB\14625458|appearance|. (r_ccomp) indicates_22\VBZ\952524|NONE (l_nsubj) appearance_1\NN\4723816|be|. (l_prep) of_2\IN\0|The (l_pobj) activity_7\NN\30358|NONE (l_prep) in_8\IN\13603305|neuron|impaired|cardiac (l_pobj) presence_10\NN\13954253|NONE (l_prep) of_11\IN\0|the (l_pobj) impairment_14\NN\7296428|NONE
D004317_D009202 CID adriamycin_34\NNS\0| (r_amod) induced_36\VBN\1627355|NONE (r_amod) cardiomyopathy_37\NN\14103288|NONE
D004317_C536522 NONE adriamycin_16\JJ\0|NONE (r_amod) treatment_17\NN\654885|NONE (r_pobj) of_15\IN\0|the (r_prep) duration_14\NN\15113229|NONE (r_pobj) to_12\IN\0|NONE (r_prep) relation_11\NN\2137|NONE (r_pobj) in_10\IN\13603305|mg/kg|was|degree|. (r_prep) analyzed_9\VBN\0|NONE (l_nsubjpass) degree_1\NN\4916342|mg/kg|was|in|. (l_prep) of_2\IN\0|The (l_pobj) degeneration_4\NN\29677|NONE (l_prep) of_5\IN\0|vacuolar (l_pobj) cells_7\NNS\3080309|NONE
D004317_C536522 NONE adriamycin_34\NNS\0| (r_amod) induced_36\VBN\1627355|NONE (r_amod) cardiomyopathy_37\NN\14103288|NONE (r_pobj) of_33\IN\0|NONE (r_prep) detection_32\NN\5708432|NONE (r_pobj) for_31\IN\0|a|useful (r_prep) method_30\NN\5616786|that|may|scintigraphy (r_attr) be_27\VB\14625458|appearance|. (r_ccomp) indicates_22\VBZ\952524|NONE (l_nsubj) appearance_1\NN\4723816|be|. (l_prep) of_2\IN\0|The (l_pobj) activity_7\NN\30358|NONE (l_prep) in_8\IN\13603305|neuron|impaired|cardiac (l_pobj) presence_10\NN\13954253|NONE (l_prep) of_11\IN\0|the (l_pobj) impairment_14\NN\7296428|NONE (l_appos) degeneration_20\NN\29677|myocardial|)|slight|(
D019797_C536522 NONE mibg_24\NNP\0|NONE (r_compound) scintigraphy_25\NN\0|that|may|method (r_nsubj) be_27\VB\14625458|appearance|. (r_ccomp) indicates_22\VBZ\952524|NONE (l_nsubj) appearance_1\NN\4723816|be|. (l_prep) of_2\IN\0|The (l_pobj) activity_7\NN\30358|NONE (l_prep) in_8\IN\13603305|neuron|impaired|cardiac (l_pobj) presence_10\NN\13954253|NONE (l_prep) of_11\IN\0|the (l_pobj) impairment_14\NN\7296428|NONE (l_appos) degeneration_20\NN\29677|myocardial|)|slight|(
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_13\NNP\0|NONE (r_pcomp) with_12\IN\0|induced (r_prep) cardiomyopathy_11\NN\14103288|NONE
D019797_D009202 NONE mibg_24\NNP\0|NONE (r_compound) scintigraphy_25\NN\0|that|may|method (r_nsubj) be_27\VB\14625458|appearance|. (r_ccomp) indicates_22\VBZ\952524|NONE (l_nsubj) appearance_1\NN\4723816|be|. (l_prep) of_2\IN\0|The (l_pobj) activity_7\NN\30358|NONE (l_prep) in_8\IN\13603305|neuron|impaired|cardiac (l_pobj) presence_10\NN\13954253|NONE (l_prep) of_11\IN\0|the (l_pobj) impairment_14\NN\7296428|NONE
D019797_D009202 NONE mibg_24\NNP\0|NONE (r_compound) scintigraphy_25\NN\0|that|may|method (r_nsubj) be_27\VB\14625458|appearance|. (l_attr) method_30\NN\5616786|that|may|scintigraphy (l_prep) for_31\IN\0|a|useful (l_pobj) detection_32\NN\5708432|NONE (l_prep) of_33\IN\0|NONE (l_pobj) cardiomyopathy_37\NN\14103288|NONE
11890511
33969
D011352_D001008 NONE procyclindine_17\JJ\0|NONE (r_compound) treatment_18\NN\654885|NONE (r_pobj) during_16\IN\0|their (r_prep) condition_15\NN\24720|NONE (r_pobj) to_13\IN\0|NONE (r_prep) compared_12\VBN\644583|increase|,|,|However|benztropine|and|treated (r_prep) had_5\VBD\0|NONE (l_conj) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN\14373582|than|.|patients
D011352_D010302 NONE procyclidine_18\NN\3800001|NONE (r_pobj) as_17\IN\14622893|as (r_prep) efficacious_16\JJ\0|,|drug (r_acomp) were_14\VBD\0|were|Ethopropazine|.|be|and (r_conj) found_4\VBN\13279262|NONE (l_xcomp) be_6\VB\14625458|were|Ethopropazine|.|were|and (l_acomp) effective_8\JJ\0|to (l_prep) in_9\IN\13603305|equally (l_pcomp) controlling_10\VBG\0|NONE (l_dobj) symptoms_12\NNS\5823932|NONE
C084820_D003866 NONE ethopropazine_27\NN\0|NONE (r_pobj) than_26\IN\0|anxiety|.|patients (r_mark) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN\14373582|than|.|patients (l_conj) depression_25\NN\14373582|and|more
C017610_D010302 CID enanthate_18\NN\0|NONE (r_amod) fluphenazine_17\JJ\3713736|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|to|in (r_advcl) benztropine_9\VB\0|.|In|was (l_prep) in_10\IN\13603305|induced|to (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) parkinsonism_14\NN\14085708|NONE
C084820_D004409 NONE ethopropazine_27\NN\0|NONE (r_pobj) than_26\IN\0|anxiety|.|patients (r_mark) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (r_conj) had_5\VBD\0|NONE (l_dobj) increase_8\NN\13576355|,|,|However|benztropine|and|treated|compared (l_prep) in_9\IN\13603305|a|significant (l_pobj) dyskinesia_11\JJ\14084880|NONE
C084820_D001008 NONE ethopropazine_27\NN\0|NONE (r_pobj) than_26\IN\0|anxiety|.|patients (r_mark) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN\14373582|than|.|patients
D001590_D010302 NONE benztropine_2\NN\0|.|and (l_prep) in_3\IN\13603305|NONE (l_pobj) parkinsonism_7\NN\14085708|NONE
D001590_D010302 NONE benztropine_9\VB\0|.|In|was (l_prep) in_10\IN\13603305|induced|to (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) parkinsonism_14\NN\14085708|NONE
D001590_D010302 NONE benztropine_2\NN\0|and (r_conj) ethopropazine_0\NN\0|were|.|were|be|and (r_nsubjpass) found_4\VBN\13279262|NONE (l_xcomp) be_6\VB\14625458|were|Ethopropazine|.|were|and (l_acomp) effective_8\JJ\0|to (l_prep) in_9\IN\13603305|equally (l_pcomp) controlling_10\VBG\0|NONE (l_dobj) symptoms_12\NNS\5823932|NONE
D001590_D010302 NONE benztropine_3\NN\0|,|that|not|because|drug (r_nsubj) is_4\VBZ\0|.|This (l_attr) drug_8\NN\14778436|benztropine|,|that|not|because (l_prep) in_11\IN\13603305|of|anticholinergic|the (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the (l_pobj) symptoms_19\NNS\5823932|NONE
C084820_D012559 NONE ethopropazine_5\NN\0|NONE (r_pobj) in_0\IN\13603305|.|benztropine|was (r_prep) compared_7\VBN\644583|NONE (l_xcomp) benztropine_9\VB\0|.|In|was (l_advcl) induced_15\VBN\1627355|to|in (l_agent) by_16\IN\0|NONE (l_pobj) fluphenazine_17\JJ\3713736|NONE (l_amod) enanthate_18\NN\0|NONE (l_prep) in_19\IN\13603305|NONE (l_pobj) outpatients_22\NNS\10405694|NONE (l_amod) schizophrenic_21\JJ\10490141|
D011352_D003866 NONE procyclindine_17\JJ\0|NONE (r_compound) treatment_18\NN\654885|NONE (r_pobj) during_16\IN\0|their (r_prep) condition_15\NN\24720|NONE (r_pobj) to_13\IN\0|NONE (r_prep) compared_12\VBN\644583|increase|,|,|However|benztropine|and|treated (r_prep) had_5\VBD\0|NONE (l_conj) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN\14373582|than|.|patients (l_conj) depression_25\NN\14373582|and|more
D011352_D004409 NONE procyclindine_17\JJ\0|NONE (r_compound) treatment_18\NN\654885|NONE (r_pobj) during_16\IN\0|their (r_prep) condition_15\NN\24720|NONE (r_pobj) to_13\IN\0|NONE (r_prep) compared_12\VBN\644583|increase|,|,|However|benztropine|and|treated (r_prep) had_5\VBD\0|NONE (l_dobj) increase_8\NN\13576355|,|,|However|benztropine|and|treated|compared (l_prep) in_9\IN\13603305|a|significant (l_pobj) dyskinesia_11\JJ\14084880|NONE
C017610_D012559 NONE enanthate_18\NN\0|NONE (l_prep) in_19\IN\13603305|NONE (l_pobj) outpatients_22\NNS\10405694|NONE (l_amod) schizophrenic_21\JJ\10490141|
D001590_D004409 CID benztropine_2\NN\0|increase|,|,|However|and|treated|compared (r_nsubj) had_5\VBD\0|NONE (l_dobj) increase_8\NN\13576355|,|,|However|benztropine|and|treated|compared (l_prep) in_9\IN\13603305|a|significant (l_pobj) dyskinesia_11\JJ\14084880|NONE
C084820_D010302 NONE ethopropazine_0\NN\0|NONE (l_conj) benztropine_2\NN\0|.|and (l_prep) in_3\IN\13603305|NONE (l_pobj) parkinsonism_7\NN\14085708|NONE
C084820_D010302 NONE ethopropazine_5\NN\0|NONE (r_pobj) in_0\IN\13603305|.|benztropine|was (r_prep) compared_7\VBN\644583|NONE (l_xcomp) benztropine_9\VB\0|.|In|was (l_prep) in_10\IN\13603305|induced|to (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) parkinsonism_14\NN\14085708|NONE
C084820_D010302 NONE ethopropazine_0\NN\0|were|.|were|be|and (r_nsubjpass) found_4\VBN\13279262|NONE (l_xcomp) be_6\VB\14625458|were|Ethopropazine|.|were|and (l_acomp) effective_8\JJ\0|to (l_prep) in_9\IN\13603305|equally (l_pcomp) controlling_10\VBG\0|NONE (l_dobj) symptoms_12\NNS\5823932|NONE
D001590_D001008 CID benztropine_2\NN\0|increase|,|,|However|and|treated|compared (r_nsubj) had_5\VBD\0|NONE (l_conj) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN\14373582|than|.|patients
D001590_D012559 NONE benztropine_9\VB\0|.|In|was (l_advcl) induced_15\VBN\1627355|to|in (l_agent) by_16\IN\0|NONE (l_pobj) fluphenazine_17\JJ\3713736|NONE (l_amod) enanthate_18\NN\0|NONE (l_prep) in_19\IN\13603305|NONE (l_pobj) outpatients_22\NNS\10405694|NONE (l_amod) schizophrenic_21\JJ\10490141|
D001590_D003866 CID benztropine_2\NN\0|increase|,|,|However|and|treated|compared (r_nsubj) had_5\VBD\0|NONE (l_conj) treated_28\VBN\2376958|increase|,|,|However|benztropine|and|compared (l_nsubj) anxiety_23\NN\14373582|than|.|patients (l_conj) depression_25\NN\14373582|and|more
591536
D006493_D001791 NONE heparin_8\VBN\2718259| (r_npadvmod) induced_10\VBN\1627355|platelet (r_amod) aggregation_12\NN\31264|factor|.
D006493_D013921 CID heparin_6\JJ\2718259|systemic (r_compound) therapy_7\NN\657604|NONE (r_dobj) receiving_4\VBG\2210855|NONE (r_acl) patients_3\NNS\9898892|NONE (r_pobj) in_2\IN\13603305|Arterial|:|complication|. (r_prep) thromboembolism_1\NN\14100769|NONE (l_appos) complication_10\NN\1073995|Arterial|:|in|. (l_acl) associated_11\VBN\628491|a (l_prep) with_12\IN\0|NONE (l_pobj) thrombocytopenia_16\NN\14189204|NONE
D006493_D013921 CID heparin_13\NN\2718259| (r_npadvmod) induced_15\VBN\1627355|NONE (r_amod) thrombocytopenia_16\NN\14189204|NONE
D006493_D013921 CID heparin_24\JJ\2718259|NONE (r_compound) therapy_25\NN\657604|NONE (r_pobj) of_23\IN\0|the (r_prep) initiation_22\NN\7450842|days (r_pobj) after_20\IN\0|NONE (r_prep) occurring_15\VBG\0|thrombi (r_pcomp) by_7\IN\0|preceded|arterial|, (r_prep) occlusion_6\NN\14081375|.|Characteristic (l_acl) preceded_27\VBN\0|by|arterial|, (l_agent) by_28\IN\0|NONE (l_pobj) thrombocytopenia_30\NN\14189204|NONE
D006493_D013921 CID heparin_8\VBN\2718259| (r_npadvmod) induced_10\VBN\1627355|platelet (r_amod) aggregation_12\NN\31264|factor|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) factor_2\NN\7326557|aggregation|. (l_acl) relating_3\VBG\628491|common|The (l_dobj) thromboembolism_4\NN\14100769|NONE (l_conj) thrombocytopenia_6\NN\14189204|and
D006493_D001157 CID heparin_24\JJ\2718259|NONE (r_compound) therapy_25\NN\657604|NONE (r_pobj) of_23\IN\0|the (r_prep) initiation_22\NN\7450842|days (r_pobj) after_20\IN\0|NONE (r_prep) occurring_15\VBG\0|thrombi (r_pcomp) by_7\IN\0|preceded|arterial|, (r_prep) occlusion_6\NN\14081375|.|Characteristic
D006493_D013923 NONE heparin_6\JJ\2718259|systemic (r_compound) therapy_7\NN\657604|NONE (r_dobj) receiving_4\VBG\2210855|NONE (r_acl) patients_3\NNS\9898892|NONE (r_pobj) in_2\IN\13603305|Arterial|:|complication|. (r_prep) thromboembolism_1\NN\14100769|NONE
D006493_D013923 NONE heparin_13\NN\2718259| (r_npadvmod) induced_15\VBN\1627355|NONE (r_amod) thrombocytopenia_16\NN\14189204|NONE (r_pobj) with_12\IN\0|NONE (r_prep) associated_11\VBN\628491|a (r_acl) complication_10\NN\1073995|Arterial|:|in|. (r_appos) thromboembolism_1\NN\14100769|NONE
D006493_D013923 NONE heparin_8\JJ\2718259|systemic (r_compound) therapy_9\NN\657604|NONE (r_pobj) of_6\IN\0|recognized|a (r_prep) complication_5\NN\1073995|.|thromboembolism (r_attr) is_2\VBZ\0|NONE (l_nsubj) thromboembolism_1\NN\14100769|complication|.
D006493_D013923 NONE heparin_8\VBN\2718259| (r_npadvmod) induced_10\VBN\1627355|platelet (r_amod) aggregation_12\NN\31264|factor|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) factor_2\NN\7326557|aggregation|. (l_acl) relating_3\VBG\628491|common|The (l_dobj) thromboembolism_4\NN\14100769|NONE
D006493_D013927 NONE heparin_24\JJ\2718259|NONE (r_compound) therapy_25\NN\657604|NONE (r_pobj) of_23\IN\0|the (r_prep) initiation_22\NN\7450842|days (r_pobj) after_20\IN\0|NONE (r_prep) occurring_15\VBG\0|thrombi (r_pcomp) by_7\IN\0|preceded|arterial|, (l_pobj) thrombi_11\NN\5402091|occurring
D006493_D007511 NONE heparin_24\JJ\2718259|NONE (r_compound) therapy_25\NN\657604|NONE (r_pobj) of_23\IN\0|the (r_prep) initiation_22\NN\7450842|days (r_pobj) after_20\IN\0|NONE (r_prep) occurring_15\VBG\0|thrombi (r_pcomp) by_7\IN\0|preceded|arterial|, (l_pobj) thrombi_11\NN\5402091|occurring (l_prep) with_12\IN\0|fibrin (l_pobj) ischemia_14\NN\14195315|NONE
133615
D003276_D013923 NONE contraceptive_6\NN\3183080|oral (r_amod) therapy_7\NN\657604|NONE (r_pobj) of_4\IN\0|Thromboembolic|in|report|.|: (r_prep) complications_3\NNS\1073995|NONE (l_amod) thromboembolic_0\JJ\0|of|in|report|.|:
D003276_D001778 CID contraceptive_6\NN\3183080|oral (r_amod) therapy_7\NN\657604|NONE (r_pobj) of_4\IN\0|Thromboembolic|in|report|.|: (r_prep) complications_3\NNS\1073995|NONE (l_prep) in_8\IN\13603305|of|Thromboembolic|report|.|: (l_pobj) relationship_9\NN\31921|NONE (l_prep) to_10\IN\0|NONE (l_pobj) levels_12\NNS\4916342|NONE (l_prep) of_13\IN\0|pretreatment (l_pobj) factors_16\NNS\7326557|NONE (l_compound) coagulation_15\NN\13518963|NONE
19944333
C471405_D003329 CID sorafenib_0\NNP\0||infarction|.|due (r_npadvmod) induced_2\VBN\1627355|NONE (l_prep) due_6\IN\5174653||Sorafenib|infarction|. (l_pobj) spasm_10\NN\14299637|to
C471405_D003329 CID sorafenib_6\NN\0| (r_npadvmod) induced_8\VBN\1627355|coronary|artery (r_amod) spasm_11\NN\14299637|NONE
D020108_D060050 NONE nicorandil_3\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) addition_0\NN\3081021|and|maintained|.|symptoms (r_nsubj) reduced_4\VBD\441445|NONE (l_conj) maintained_8\VBD\0|and|Addition|.|symptoms (l_dobj) status_11\NN\24720|NONE (l_compound) angina_10\NN\14171682|NONE
C471405_D009203 NONE sorafenib_0\NNP\0||infarction|.|due (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) infarction_5\NN\14204950||Sorafenib|.|due
16174948
D003042_D013345 CID cocaine_6\NN\3492717| (r_npadvmod) associated_8\VBN\628491|subarachnoid (r_amod) hemorrhage_10\NN\14285662|NONE
D003042_D013345 CID cocaine_12\NN\3492717| (r_npadvmod) associated_14\VBN\628491|subarachnoid|SAH|underwent (r_amod) hemorrhage_16\NN\14285662|NONE
D003042_D013345 CID cocaine_12\NN\3492717| (r_npadvmod) associated_14\VBN\628491|subarachnoid|SAH|underwent (r_amod) hemorrhage_16\NN\14285662|NONE (l_appos) sah_18\NNP\0|subarachnoid|underwent|associated
D003042_D013345 CID cocaine_25\NN\3492717|NONE (r_compound) use_26\NN\407535|shortly (r_pobj) after_24\IN\0|angiography|who (r_prep) underwent_21\VBD\109660|subarachnoid|SAH|associated (r_relcl) hemorrhage_16\NN\14285662|NONE
D003042_D013345 CID cocaine_25\NN\3492717|NONE (r_compound) use_26\NN\407535|shortly (r_pobj) after_24\IN\0|angiography|who (r_prep) underwent_21\VBD\109660|subarachnoid|SAH|associated (r_relcl) hemorrhage_16\NN\14285662|NONE (l_appos) sah_18\NNP\0|subarachnoid|underwent|associated
D003042_D013345 CID cocaine_14\NN\3492717|NONE (r_pobj) for_13\IN\0|urine|positive (r_prep) toxicology_12\NN\6054892|NONE (r_pobj) with_9\IN\0|NONE (r_prep) those_8\DT\0|NONE (r_dobj) identified_7\VBD\699815|retrospectively|and|.|patients|We (r_conj) screened_1\VBD\2533282|NONE (l_dobj) patients_2\NNS\9898892|retrospectively|and|.|We|identified (l_prep) with_3\IN\0|NONE (l_pobj) sah_4\NNP\0|NONE
D003042_D013345 CID cocaine_31\NN\3492717|NONE (r_compound) use_32\NN\407535|NONE (r_pobj) with_30\IN\0|NONE (r_prep) associated_29\VBN\628491|aneurysmal (r_acl) sah_28\NNP\0|NONE
D003042_D014657 NONE cocaine_0\NN\3492717|NONE (r_compound) use_1\NN\407535|.|has|with|been (r_nsubjpass) associated_4\VBN\628491|NONE (l_prep) with_5\IN\0|.|has|use|been (l_pobj) complications_7\NNS\1073995|NONE (l_prep) including_9\VBG\0|,|neurovascular (l_pobj) vasoconstriction_11\NN\1149911|NONE (l_conj) vasculitis_13\NN\14336539|arterial|and
D003042_D014657 NONE cocaine_31\NN\3492717|NONE (r_compound) use_32\NN\407535|NONE (r_pobj) with_30\IN\0|NONE (r_prep) associated_29\VBN\628491|aneurysmal (r_acl) sah_28\NNP\0|NONE (r_pobj) after_26\IN\0|who|angiography (r_prep) underwent_24\VBD\109660|NONE (r_relcl) patients_22\NNS\9898892|NONE (r_pobj) in_21\IN\13603305|be|.|evidence|could (r_prep) found_20\VBN\13279262|NONE (l_nsubjpass) evidence_2\NN\5816287|be|.|in|could (l_prep) for_3\IN\0|quantitative|No (l_pobj) narrowing_4\VBG\5064037|NONE (l_prep) of_5\IN\0|NONE (l_pobj) arteries_8\NNS\5417975|NONE (l_conj) evidence_12\NN\5816287|large|cerebral|or (l_prep) for_13\IN\0|angiographic|qualitative (l_pobj) narrowing_15\NN\5064037|NONE (l_conj) vasculitis_17\NN\14336539|distal|or
D003042_D017542 CID cocaine_31\NN\3492717|NONE (r_compound) use_32\NN\407535|NONE (r_pobj) with_30\IN\0|NONE (r_prep) associated_29\VBN\628491|aneurysmal (r_acl) sah_28\NNP\0|NONE (l_amod) aneurysmal_27\NN\0|associated
D003042_D013901 NONE cocaine_0\NN\3492717|NONE (r_compound) use_1\NN\407535|.|has|with|been (r_nsubjpass) associated_4\VBN\628491|NONE (l_prep) with_5\IN\0|.|has|use|been (l_pobj) complications_7\NNS\1073995|NONE
8267029
D010396_D001172 NONE penicillamine_0\NN\3740161|.||glomerulonephritis|in (r_nsubj) induced_2\VBN\1627355|NONE (l_prep) in_6\IN\13603305|.||glomerulonephritis|Penicillamine (l_pobj) patient_8\NN\9898892|NONE (l_prep) with_9\IN\0|a (l_pobj) arthritis_11\NN\14171682|NONE
D010396_D001172 NONE penicillamine_21\NN\3740161|)|(|day (r_nmod) treatment_28\NN\654885|NONE (r_pobj) of_18\IN\0| (r_prep) months_17\NNS\15113229|NONE (r_pobj) after_15\IN\0|woman|glomerulonephritis|. (r_prep) presented_8\VBD\2137132|NONE (l_nsubj) woman_4\NN\9605289|after|glomerulonephritis|. (l_prep) with_5\IN\0|A|old (l_pobj) arthritis_7\NN\14171682|NONE
D010396_D005921 CID penicillamine_0\NN\3740161|.||glomerulonephritis|in (r_nsubj) induced_2\VBN\1627355|NONE (l_dobj) glomerulonephritis_5\NN\14113798|.||in|Penicillamine
D010396_D005921 CID penicillamine_21\NN\3740161|)|(|day (r_nmod) treatment_28\NN\654885|NONE (r_pobj) of_18\IN\0| (r_prep) months_17\NNS\15113229|NONE (r_pobj) after_15\IN\0|woman|glomerulonephritis|. (r_prep) presented_8\VBD\2137132|NONE (l_dobj) glomerulonephritis_11\NN\14113798|woman|after|.
D010396_D005921 CID penicillamine_21\NN\3740161|)|(|day (r_nmod) treatment_28\NN\654885|NONE (r_pobj) of_18\IN\0| (r_prep) months_17\NNS\15113229|NONE (r_pobj) after_15\IN\0|woman|glomerulonephritis|. (r_prep) presented_8\VBD\2137132|NONE (l_dobj) glomerulonephritis_11\NN\14113798|woman|after|. (l_appos) rpgn_13\NNP\0|progressive
D010396_D005921 CID penicillamine_11\NN\3740161|NONE (r_compound) treatment_12\NN\654885|NONE (r_pobj) of_8\IN\0|the (r_prep) course_7\NN\883297|NONE (r_pobj) in_5\IN\13603305|new|of|This (r_prep) case_2\NN\7283608|need|. (l_prep) of_3\IN\0|in|new|This (l_pobj) rpgn_4\NNP\0|NONE
D010396_D011507 NONE penicillamine_11\NN\3740161|NONE (r_compound) treatment_12\NN\654885|NONE (r_pobj) of_8\IN\0|the (r_prep) course_7\NN\883297|NONE (r_pobj) in_5\IN\13603305|new|of|This (r_prep) case_2\NN\7283608|need|. (r_nsubj) emphasizes_13\VBZ\943837|NONE (l_dobj) need_15\NN\13920835|case|. (l_prep) for_16\IN\0|the (l_pobj) monitoring_18\NN\879759|NONE (l_prep) of_19\IN\0|frequent (l_pobj) function_21\NN\13783581|NONE (l_conj) evaluation_23\NN\874067|and|renal (l_prep) of_24\IN\0|NONE (l_pobj) sediment_26\NN\20827|NONE (l_conj) proteinuria_28\NN\14299637|urinary|in|and
2435991
D004837_D001145 CID adrenaline_10\RB\14807929| (r_npadvmod) induced_12\VBN\1627355|and|, (r_conj) digitalis-_7\NN\0|coronary|stage|, (r_conj) ligation-_5\JJ\0|ventricular|canine (r_nmod) arrhythmias_15\NNS\14103288|NONE
D004837_D001145 CID adrenaline_10\RB\14807929| (r_npadvmod) induced_12\VBN\1627355|and|, (r_conj) digitalis-_7\NN\0|coronary|stage|, (r_conj) ligation-_5\JJ\0|ventricular|canine (r_nmod) arrhythmias_15\NNS\14103288|NONE (r_dobj) using_0\VBG\418025|were|determined|effects|and|, (r_advcl) examined_22\VBN\0|NONE (l_conj) determined_34\VBN\0|were|effects|and|Using|, (l_nsubjpass) concentration_28\NN\4916342|.|was (l_prep) for_29\IN\0|effective|minimum|the|plasma (l_pobj) model_32\NN\5888929|NONE (l_compound) arrhythmia_31\NN\14103288|each
D004837_D001145 CID adrenaline_27\NN\14807929|and|, (r_conj) digitalis_24\NN\15059939|,|h|coronary (r_conj) ligation_22\NN\149084|h|coronary|, (r_appos) ligation_18\NN\149084|NONE (r_pobj) by_15\IN\0|concentrations (r_agent) induced_14\VBN\1627355|.|Cibenzoline|were|arrhythmias|,|and (r_conj) suppressed_1\VBD\2510337|NONE (l_dobj) arrhythmias_4\NNS\14103288|.|Cibenzoline|induced|were|,|and
D004837_D001145 CID adrenaline_27\NN\14807929|and|, (r_conj) digitalis_24\NN\15059939|,|h|coronary (r_conj) ligation_22\NN\149084|h|coronary|, (r_appos) ligation_18\NN\149084|NONE (r_pobj) by_15\IN\0|concentrations (r_agent) induced_14\VBN\1627355|.|Cibenzoline|were|arrhythmias|,|and (l_nsubj) concentrations_11\NNS\4916342|by (l_prep) for_12\IN\0|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS\14103288|NONE
D004837_D001145 CID adrenaline_3\NN\14807929| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) arrhythmia_6\NN\14103288|NONE
D004837_D001145 CID adrenaline_3\NN\14807929| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) arrhythmia_6\NN\14103288|NONE (r_pobj) for_2\IN\0|The (r_prep) concentration_1\NN\4916342|higher|. (r_nsubj) was_7\VBD\0|NONE (l_acomp) higher_9\JJR\0|concentration|. (l_prep) than_10\IN\0|significantly (l_pobj) those_11\DT\0|NONE (l_prep) for_12\IN\0|NONE (l_pobj) types_15\NNS\5839024|NONE (l_prep) of_16\IN\0|other|the (l_pobj) arrhythmias_17\NNS\14103288|NONE
C032151_D007022 NONE cibenzoline_1\NN\0|effects|found|Because|given|and (r_nsubj) had_2\VBD\0|.|,|usefulness|is (l_dobj) effects_10\NNS\13245626|found|cibenzoline|Because|given|and (l_nmod) node_8\NN\13870805|depressive (l_amod) hypotensive_5\JJ\10405694|weak|only
D004071_D001145 CID digitalis-_7\NN\0|coronary|stage|, (r_conj) ligation-_5\JJ\0|ventricular|canine (r_nmod) arrhythmias_15\NNS\14103288|NONE
D004071_D001145 CID digitalis-_7\NN\0|coronary|stage|, (r_conj) ligation-_5\JJ\0|ventricular|canine (r_nmod) arrhythmias_15\NNS\14103288|NONE (r_dobj) using_0\VBG\418025|were|determined|effects|and|, (r_advcl) examined_22\VBN\0|NONE (l_conj) determined_34\VBN\0|were|effects|and|Using|, (l_nsubjpass) concentration_28\NN\4916342|.|was (l_prep) for_29\IN\0|effective|minimum|the|plasma (l_pobj) model_32\NN\5888929|NONE (l_compound) arrhythmia_31\NN\14103288|each
D004071_D001145 CID digitalis_24\NN\15059939|,|h|coronary (r_conj) ligation_22\NN\149084|h|coronary|, (r_appos) ligation_18\NN\149084|NONE (r_pobj) by_15\IN\0|concentrations (r_agent) induced_14\VBN\1627355|.|Cibenzoline|were|arrhythmias|,|and (r_conj) suppressed_1\VBD\2510337|NONE (l_dobj) arrhythmias_4\NNS\14103288|.|Cibenzoline|induced|were|,|and
D004071_D001145 CID digitalis_24\NN\15059939|,|h|coronary (r_conj) ligation_22\NN\149084|h|coronary|, (r_appos) ligation_18\NN\149084|NONE (r_pobj) by_15\IN\0|concentrations (r_agent) induced_14\VBN\1627355|.|Cibenzoline|were|arrhythmias|,|and (l_nsubj) concentrations_11\NNS\4916342|by (l_prep) for_12\IN\0|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS\14103288|NONE
C032151_D003866 NONE cibenzoline_1\NN\0|effects|found|Because|given|and (r_nsubj) had_2\VBD\0|.|,|usefulness|is (l_dobj) effects_10\NNS\13245626|found|cibenzoline|Because|given|and (l_amod) depressive_9\JJ\10595647|node
C032151_D001145 NONE cibenzoline_4\NN\0|NONE (r_pobj) of_3\IN\0|Antiarrhythmic|plasma|on|. (r_prep) concentrations_2\NNS\4916342|NONE (l_prep) on_5\IN\0|Antiarrhythmic|plasma|of|. (l_pobj) arrhythmias_8\NNS\14103288|NONE
C032151_D001145 NONE cibenzoline_20\NN\0|NONE (r_pobj) of_19\IN\0|antiarrhythmic (r_prep) effects_18\NNS\13245626|were|determined|and|Using|, (r_nsubjpass) examined_22\VBN\0|NONE (l_advcl) using_0\VBG\418025|were|determined|effects|and|, (l_dobj) arrhythmias_15\NNS\14103288|NONE
C032151_D001145 NONE cibenzoline_20\NN\0|NONE (r_pobj) of_19\IN\0|antiarrhythmic (r_prep) effects_18\NNS\13245626|were|determined|and|Using|, (r_nsubjpass) examined_22\VBN\0|NONE (l_conj) determined_34\VBN\0|were|effects|and|Using|, (l_nsubjpass) concentration_28\NN\4916342|.|was (l_prep) for_29\IN\0|effective|minimum|the|plasma (l_pobj) model_32\NN\5888929|NONE (l_compound) arrhythmia_31\NN\14103288|each
C032151_D001145 NONE cibenzoline_0\NNP\0|.|induced|were|arrhythmias|,|and (r_nsubj) suppressed_1\VBD\2510337|NONE (l_dobj) arrhythmias_4\NNS\14103288|.|Cibenzoline|induced|were|,|and
C032151_D001145 NONE cibenzoline_0\NNP\0|.|induced|were|arrhythmias|,|and (r_nsubj) suppressed_1\VBD\2510337|NONE (l_conj) induced_14\VBN\1627355|.|Cibenzoline|were|arrhythmias|,|and (l_nsubj) concentrations_11\NNS\4916342|by (l_prep) for_12\IN\0|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS\14103288|NONE
C032151_D001145 NONE cibenzoline_1\NN\0|effects|found|Because|given|and (r_nsubj) had_2\VBD\0|.|,|usefulness|is (l_advcl) given_19\VBN\5892096|effects|found|cibenzoline|Because|and (l_prep) to_20\IN\0|when (l_pobj) dogs_24\NNS\2083346|NONE (l_compound) arrhythmia_23\NN\14103288|coronary
7102237
D012601_D001049 NONE scopolamine_4\NN\14712692|NONE (r_pobj) with_3\IN\0|NONE (r_prep) premedicated_2\VBN\0|NONE (r_acl) patients_1\NNS\9898892|NONE (r_pobj) in_0\IN\13603305|,|,|occurred|effect|)|.|found|,|slower|but|mg/kg (r_prep) was_28\VBD\0|NONE (l_advcl) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
D009567_D001049 NONE nitrazepam_11\NN\2830852|evening| (r_amod) mg_10\IN\13717155|(|+|+|morphine (r_conj) scopolamine_4\NN\14712692|NONE (r_pobj) with_3\IN\0|NONE (r_prep) premedicated_2\VBN\0|NONE (r_acl) patients_1\NNS\9898892|NONE (r_pobj) in_0\IN\13603305|,|,|occurred|effect|)|.|found|,|slower|but|mg/kg (r_prep) was_28\VBD\0|NONE (l_advcl) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
D009020_D001049 NONE morphine_6\NN\2707683|mg|(|+|+ (r_conj) scopolamine_4\NN\14712692|NONE (r_pobj) with_3\IN\0|NONE (r_prep) premedicated_2\VBN\0|NONE (r_acl) patients_1\NNS\9898892|NONE (r_pobj) in_0\IN\13603305|,|,|occurred|effect|)|.|found|,|slower|but|mg/kg (r_prep) was_28\VBD\0|NONE (l_advcl) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
D008874_D001049 CID midazolam_24\JJ\2830852|NONE (r_pobj) of_23\IN\0|the|inducing (r_prep) effect_22\NN\34213|,|,|occurred|)|.|found|,|In|slower|but|mg/kg (r_nsubj) was_28\VBD\0|NONE (l_advcl) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
D008874_D001049 CID midazolam_50\JJ\2830852|the (r_amod) group_51\NN\2137|NONE (r_pobj) in_48\IN\13603305|sequelae|were (r_prep) found_47\VBN\13279262|,|,|occurred|effect|)|.|,|In|slower|but|mg/kg (r_conj) was_28\VBD\0|NONE (l_advcl) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
D008874_D001049 CID midazolam_62\JJ\2830852|lasted|the (r_amod) group_63\NN\2137|NONE (r_pobj) in_60\IN\13603305|apnoea|often|although (r_prep) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
D013874_D001049 CID thiopentone_36\NN\0|NONE (r_pobj) of_35\IN\0|NONE (r_prep) that_34\DT\0|NONE (r_pobj) than_33\IN\0|NONE (r_prep) onset_32\NN\7325190|NONE (r_pobj) in_31\IN\13603305|clearly (r_prep) slower_30\JJR\0|,|,|occurred|effect|)|.|found|,|In|but|mg/kg (r_acomp) was_28\VBD\0|NONE (l_advcl) occurred_57\VBD\0|,|,|effect|)|.|found|,|In|slower|but|mg/kg (l_nsubj) apnoea_56\NN\0|often|in|although
2051906
D001379_D017285 NONE azathioprine_30\NN\3740161|NONE (r_amod) therapy_31\NN\657604|NONE (r_pobj) of_29\IN\0|NONE (r_prep) initiation_28\NN\7450842|months (r_pobj) after_27\IN\0|.|patient|features (r_prep) developed_17\VBD\1753788|NONE (l_nsubj) patient_4\NN\9898892|.|after|features (l_prep) with_6\IN\0|,|A|old (l_pobj) polymyositis_8\NN\14350292|without|and
D001379_D002779 CID azathioprine_7\JJ\3740161|NONE (r_amod) therapy_8\NN\657604|NONE (r_pobj) following_6\VBG\8180190|Reversible|with|. (r_prep) cholestasis_1\NN\14052403|NONE
D001379_D002779 CID azathioprine_7\JJ\3740161|NONE (r_amod) therapy_8\NN\657604|NONE (r_pobj) following_6\VBG\8180190|Reversible|with|. (r_prep) cholestasis_1\NN\14052403|NONE (l_prep) with_2\IN\0|Reversible|following|. (l_pobj) injury_5\NN\14052046|NONE
D001379_D002779 CID azathioprine_30\NN\3740161|NONE (r_amod) therapy_31\NN\657604|NONE (r_pobj) of_29\IN\0|NONE (r_prep) initiation_28\NN\7450842|months (r_pobj) after_27\IN\0|.|patient|features (r_prep) developed_17\VBD\1753788|NONE (l_dobj) features_21\NNS\5849040|.|after|patient (l_prep) of_22\IN\0|clinical (l_pobj) cholestasis_24\NN\14052403|NONE
D001379_D002779 CID azathioprine_12\RB\3740161| (r_advmod) induced_14\VBN\1627355|associated|reversible (r_amod) cholestasis_15\NN\14052403|NONE
D001379_D002779 CID azathioprine_12\RB\3740161| (r_advmod) induced_14\VBN\1627355|associated|reversible (r_amod) cholestasis_15\NN\14052403|NONE (l_acl) associated_16\VBN\628491|reversible|induced (l_prep) with_17\IN\0|NONE (l_pobj) evidence_19\NN\5816287|NONE (l_prep) of_20\IN\0|histological (l_pobj) injury_23\NN\14052046|NONE
D001379_D008107 NONE azathioprine_30\NN\3740161|NONE (r_amod) therapy_31\NN\657604|NONE (r_pobj) of_29\IN\0|NONE (r_prep) initiation_28\NN\7450842|months (r_pobj) after_27\IN\0|.|patient|features (r_prep) developed_17\VBD\1753788|NONE (l_nsubj) patient_4\NN\9898892|.|after|features (l_prep) with_6\IN\0|,|A|old (l_conj) without_10\IN\0|and|polymyositis (l_pobj) evidence_12\NN\5816287|NONE (l_prep) of_13\IN\0|previous (l_pobj) disease_15\NN\14061805|NONE
803783
D010121_D001247 NONE oxytocin_0\NN\5407119|during (r_compound) administration_1\NN\1133281|.|carried|is (r_nsubjpass) advocated_8\VBN\875394|NONE (l_advcl) carried_14\VBN\1850315|.|administration|is (l_conj) instructed_33\VBD\831651|,|out|can|be|if|only|and|aware|under|it (l_xcomp) watch_35\VB\4437953|NONE (l_conj) report_39\VB\6470073|and|diuresis|to (l_dobj) signs_42\NNS\6643763|NONE (l_prep) as_46\IN\14622893|such|of|early (l_pobj) asthenia_47\NNP\14547643|NONE
D010121_D001523 NONE oxytocin_0\NN\5407119|during (r_compound) administration_1\NN\1133281|.|carried|is (r_nsubjpass) advocated_8\VBN\875394|NONE (l_advcl) carried_14\VBN\1850315|.|administration|is (l_conj) instructed_33\VBD\831651|,|out|can|be|if|only|and|aware|under|it (l_xcomp) watch_35\VB\4437953|NONE (l_conj) report_39\VB\6470073|and|diuresis|to (l_dobj) signs_42\NNS\6643763|NONE (l_prep) as_46\IN\14622893|such|of|early (l_pobj) asthenia_47\NNP\14547643|NONE (l_conj) irritability_50\NN\7552087|,
D010121_D000031 NONE oxytocin_4\NN\5407119|NONE (r_compound) administration_5\NN\1133281|NONE (r_pobj) with_3\IN\0|during (r_prep) associated_2\VBN\628491|Water|. (l_prep) during_6\IN\0|with (l_pobj) abortion_10\NN\209943|NONE
D010121_D000031 NONE oxytocin_8\NN\5407119|NONE (r_compound) administration_9\NN\1133281|NONE (r_pobj) with_7\IN\0|during (r_prep) connection_6\NN\31921|NONE (l_prep) during_10\IN\0|with (l_pobj) abortions_14\NNS\209943|NONE
D010121_D000031 NONE oxytocin_0\NN\5407119|during (r_compound) administration_1\NN\1133281|.|carried|is (l_prep) during_2\IN\0|Oxytocin (l_pobj) abortions_6\NNS\209943|NONE
D010121_D014869 CID oxytocin_4\NN\5407119|NONE (r_compound) administration_5\NN\1133281|NONE (r_pobj) with_3\IN\0|during (r_prep) associated_2\VBN\628491|Water|. (r_acl) intoxication_1\NN\14034177|NONE
D010121_D014869 CID oxytocin_8\NN\5407119|NONE (r_compound) administration_9\NN\1133281|NONE (r_pobj) with_7\IN\0|during (r_prep) connection_6\NN\31921|NONE (r_pobj) in_5\IN\13603305|water (r_prep) intoxication_4\NN\14034177|NONE
D010121_D014869 CID oxytocin_0\NN\5407119|during (r_compound) administration_1\NN\1133281|.|carried|is (r_nsubjpass) advocated_8\VBN\875394|NONE (l_advcl) carried_14\VBN\1850315|.|administration|is (l_advcl) aware_25\JJ\0|,|out|can|instructed|be|if|only|and|under|it (l_prep) of_26\IN\0|NONE (l_pobj) symptoms_28\NNS\5823932|NONE (l_prep) of_29\IN\0|the (l_pobj) intoxication_31\NN\14034177|NONE
D010121_D006261 NONE oxytocin_0\NN\5407119|during (r_compound) administration_1\NN\1133281|.|carried|is (r_nsubjpass) advocated_8\VBN\875394|NONE (l_advcl) carried_14\VBN\1850315|.|administration|is (l_conj) instructed_33\VBD\831651|,|out|can|be|if|only|and|aware|under|it (l_xcomp) watch_35\VB\4437953|NONE (l_conj) report_39\VB\6470073|and|diuresis|to (l_dobj) signs_42\NNS\6643763|NONE (l_prep) as_46\IN\14622893|such|of|early (l_pobj) asthenia_47\NNP\14547643|NONE (l_conj) irritability_50\NN\7552087|, (l_conj) headaches_53\NNS\5829480|,|or|muscular
3001299
D008094_D007037 CID lithium_22\NN\14625458|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) during_21\IN\0|of|the (r_prep) development_13\NN\248977|NONE (l_prep) of_14\IN\0|the|during (l_pobj) insipidus_18\NN\0|NONE (l_conj) hypothyroidism_20\NN\14059928|nephrogenic|and|both|diabetes
D008094_D007037 CID lithium_9\NN\14625458|they|were|while (r_dobj) taking_8\VBG\37396|in|Hypothyroidism|. (r_advcl) developed_1\VBD\1753788|NONE (l_nsubj) hypothyroidism_0\NN\14059928|in|taking|.
D008094_D018500 NONE lithium_22\NN\14625458|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) during_21\IN\0|of|the (r_prep) development_13\NN\248977|NONE (l_prep) of_14\IN\0|the|during (l_pobj) insipidus_18\NN\0|NONE
1711760
D010656_D006973 CID phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate
D007530_D006973 NONE isoflurane_1\JJ\3570838|NONE (r_amod) anesthesia_2\NN\14034177|NONE (r_pobj) under_0\IN\0|.|MCA|was|, (r_prep) occluded_12\VBN\2451370|NONE (l_nsubjpass) mca_5\NNP\0|.|Under|was|, (l_prep) of_6\IN\0|the (l_pobj) rats_10\NNS\2329401| (l_amod) hypertensive_9\JJ\10405694|NONE
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8\CD\0|NONE (r_nummod) staining_9\VBG\275424|NONE (r_pobj) by_7\IN\0|was|extent|. (r_agent) determined_6\VBN\0|NONE (l_nsubjpass) extent_1\NN\13939892|was|by|. (l_prep) of_2\IN\0|The (l_pobj) injury_4\NN\14052046|NONE
D010656_D009410 NONE phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate (r_nsubj) instituted_8\VBD\1641914|data|. (l_advcl) aggravate_15\VB\126264|hypertension|h|,|that (l_dobj) edema_16\NN\14315192|does|after|MCAO|not (l_acl) improves_24\VBZ\126264|in (l_conj) reduces_37\VBZ\441445|it|edema|,|that|and (l_dobj) area_39\NN\8630985|that|it (l_prep) of_40\IN\0|the (l_pobj) dysfunction_43\NN\14204950|NONE
D010656_D007511 NONE phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate (r_nsubj) instituted_8\VBD\1641914|data|. (l_advcl) aggravate_15\VB\126264|hypertension|h|,|that (l_dobj) edema_16\NN\14315192|does|after|MCAO|not (l_prep) in_17\IN\13603305|improves (l_pobj) core_20\NN\7996689|NONE (l_amod) ischemic_19\JJ\0|the
D010656_D007511 NONE phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate (r_nsubj) instituted_8\VBD\1641914|data|. (l_advcl) aggravate_15\VB\126264|hypertension|h|,|that (l_dobj) edema_16\NN\14315192|does|after|MCAO|not (l_acl) improves_24\VBZ\126264|in (l_dobj) edema_25\NN\14315192|reduces|it|,|that|and (l_prep) in_26\IN\13603305|NONE (l_pobj) periphery_28\NN\13903079|NONE (l_prep) of_29\IN\0|the (l_pobj) territory_32\NN\8630985|NONE (l_amod) ischemic_31\JJ\0|the
D010656_D020244 NONE phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate (r_nsubj) instituted_8\VBD\1641914|data|. (l_advcl) aggravate_15\VB\126264|hypertension|h|,|that (l_nsubj) mcao_12\NNP\0|does|after|edema|not
D010656_D004487 NONE phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate (r_nsubj) instituted_8\VBD\1641914|data|. (l_advcl) aggravate_15\VB\126264|hypertension|h|,|that (l_dobj) edema_16\NN\14315192|does|after|MCAO|not
D010656_D004487 NONE phenylephrine_4\NN\2682038| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypertension_7\NN\14057371|h|,|that|aggravate (r_nsubj) instituted_8\VBD\1641914|data|. (l_advcl) aggravate_15\VB\126264|hypertension|h|,|that (l_dobj) edema_16\NN\14315192|does|after|MCAO|not (l_acl) improves_24\VBZ\126264|in (l_dobj) edema_25\NN\14315192|reduces|it|,|that|and
20735774
D000082_D056486 NONE paracetamol_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|acute|liver (r_amod) injury_14\NN\14052046|NONE
D000082_D056486 NONE paracetamol_16\RB\0| (r_npadvmod) induced_18\VBN\1627355|whose|liver (r_amod) injury_20\NN\14052046|had|failure
D000082_D017114 CID paracetamol_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|acute|liver (r_amod) failure_15\NN\66216|NONE
D000082_D017114 CID paracetamol_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|liver|acute (r_amod) failure_13\NN\66216|NONE
D000082_D017114 CID paracetamol_5\NN\0||whether (r_advmod) induced_7\VBN\1627355|failure|mortality (r_nmod) increases_11\VBZ\13576355|To (l_nsubj) failure_10\NN\66216|induced|mortality
D000082_D017114 CID paracetamol_16\RB\0| (r_npadvmod) induced_18\VBN\1627355|whose|liver (r_amod) injury_20\NN\14052046|had|failure (r_nsubj) caused_22\VBN\1617192||the (l_dobj) failure_26\NN\66216|had|injury
D000082_D017114 CID paracetamol_16\RB\0| (r_npadvmod) induced_18\VBN\1627355|whose|liver (r_amod) injury_20\NN\14052046|had|failure (r_nsubj) caused_22\VBN\1617192||the (r_relcl) patients_14\NNS\9898892|NONE (r_pobj) for_11\IN\0|slightly (r_prep) higher_10\JJR\0|was|but|rates|On|,|, (r_acomp) were_8\VBD\0|NONE (l_conj) was_46\VBD\0|higher|but|rates|On|,|, (l_conj) died_58\VBD\146138|,|and|association|dependent (l_nsubj) survivors_53\NNS\9630641|of|,|.|were (l_prep) of_54\IN\0|no (l_pobj) failure_57\NN\66216|NONE
D000082_D017114 CID paracetamol_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|liver|acute (r_amod) failure_5\NN\66216|did|not|.|mortality
D000082_D008107 NONE paracetamol_16\RB\0| (r_npadvmod) induced_18\VBN\1627355|whose|liver (r_amod) injury_20\NN\14052046|had|failure (r_nsubj) caused_22\VBN\1617192||the (r_relcl) patients_14\NNS\9898892|NONE (r_pobj) for_11\IN\0|slightly (r_prep) higher_10\JJR\0|was|but|rates|On|,|, (r_acomp) were_8\VBD\0|NONE (l_conj) was_46\VBD\0|higher|but|rates|On|,|, (l_conj) died_58\VBD\146138|,|and|association|dependent (l_prep) of_59\IN\0|,|.|were|survivors (l_pobj) disease_61\NN\14061805|NONE
20705401
D012701_D006948 NONE serotonin_1\NN\14807737|therapeutically|is|corrected|by|. (r_nsubjpass) targeted_9\VBN\1151110|NONE (l_agent) by_10\IN\0|serotonin|therapeutically|is|corrected|. (l_pobj) antipsychotics_14\NNS\4470232|NONE (l_prep) as_17\IN\14622893|several|,|generation (l_pobj) clozapine_18\NN\3713736|such (l_conj) hyperactivity_28\NN\14052403|induced|,|olanzapine|and|and
D012701_D006948 NONE 5-ht6_4\CD\0|(||) (r_nummod) receptor_6\NN\5225602|The (r_appos) serotonin_1\NN\14807737|therapeutically|is|corrected|by|. (r_nsubjpass) targeted_9\VBN\1151110|NONE (l_agent) by_10\IN\0|serotonin|therapeutically|is|corrected|. (l_pobj) antipsychotics_14\NNS\4470232|NONE (l_prep) as_17\IN\14622893|several|,|generation (l_pobj) clozapine_18\NN\3713736|such (l_conj) hyperactivity_28\NN\14052403|induced|,|olanzapine|and|and
D012701_D006948 NONE 5-ht6_39\CD\0|a|receptor|selective (r_nummod) antagonist_41\NN\7846|NONE (r_pobj) of_36\IN\0|the (r_prep) use_35\NN\407535|NONE (r_pobj) with_33\IN\0|is (r_prep) corrected_32\VBN\138508|serotonin|therapeutically|is|by|. (r_conj) targeted_9\VBN\1151110|NONE (l_agent) by_10\IN\0|serotonin|therapeutically|is|corrected|. (l_pobj) antipsychotics_14\NNS\4470232|NONE (l_prep) as_17\IN\14622893|several|,|generation (l_pobj) clozapine_18\NN\3713736|such (l_conj) hyperactivity_28\NN\14052403|induced|,|olanzapine|and|and
D012701_D012559 NONE 5-ht6_20\CD\0|altered (r_nummod) receptors_21\NNS\5225602|that|are|in (r_nsubjpass) involved_23\VBN\2676054|evidence|. (r_ccomp) suggests_17\VBZ\1010118|models|,|and|reflect|were (r_conj) considered_4\VBN\689344|NONE (l_xcomp) reflect_6\VB\923793|models|suggests|,|and|were (l_dobj) symptoms_9\NNS\5823932|to (l_prep) of_10\IN\0|the|positive (l_pobj) schizophrenia_11\NN\14398067|NONE
C076029_D006948 NONE olanzapine_20\NN\0|hyperactivity|induced|,|and|and (r_conj) clozapine_18\NN\3713736|such (l_conj) hyperactivity_28\NN\14052403|induced|,|olanzapine|and|and
D008694_D011605 CID methamphetamine_7\NN\2704153| (r_npadvmod) induced_9\VBN\1627355|in (r_amod) psychosis_10\NN\14380140|NONE
D008694_D011605 CID methamphetamine_3\NN\2704153|NONE (r_pobj) of_2\IN\0|psychosis|The (r_prep) symptoms_1\NNS\5823932|similar|. (l_appos) psychosis_6\NN\14380140|The|of
D008694_D011605 CID meth)-induced_5\JJ\0|( (r_amod) psychosis_6\NN\14380140|The|of
D008694_D011605 CID meth_17\NNP\2704153| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) psychosis_20\NN\14380140|NONE
D008694_D011605 CID meth_29\NN\2704153| (r_npadvmod) induced_31\VBN\1627355|in|)|and|(|psychosis||controls (r_amod) patients_33\NNS\9898892|control (l_compound) psychosis_32\NN\14380140|in|)|and|(|induced||controls
D008694_D011605 CID meth_4\NNP\2704153| (r_npadvmod) induced_6\VBN\1627355|psychosis|in (r_amod) patients_8\NNS\9898892|NONE (l_compound) psychosis_7\NN\14380140|induced|in
D008694_D011605 CID meth_32\NNP\2704153| (r_npadvmod) induced_34\VBN\1627355|psychosis (r_amod) patients_36\NNS\9898892|between|,|an (l_compound) psychosis_35\NN\14380140|induced
D008694_D011605 CID meth_10\NNP\2704153| (r_npadvmod) induced_12\VBN\1627355|in (r_amod) psychosis_13\NN\14380140|NONE
D012701_D011605 NONE serotonin_0\NN\14807737||receptor (r_nmod) gene_3\NN\8459252|with|is|. (r_nsubjpass) associated_5\VBN\628491|NONE (l_prep) with_6\IN\0|is|gene|. (l_pobj) psychosis_10\NN\14380140|NONE
D012701_D011605 NONE 5-ht6_20\CD\0|altered (r_nummod) receptors_21\NNS\5225602|that|are|in (r_nsubjpass) involved_23\VBN\2676054|evidence|. (l_prep) in_24\IN\13603305|that|receptors|are (l_pobj) pathophysiology_26\NN\0|NONE (l_prep) of_27\IN\0|the (l_pobj) disorders_29\NNS\14034177|NONE
D012701_D011605 NONE 5-ht6_11\CD\0|the|with|(|HTR|) (r_nummod) gene_12\NN\8459252|NONE (l_prep) with_16\IN\0|the|(|HT|HTR|) (l_pobj) psychosis_20\NN\14380140|NONE
D003024_D006948 NONE clozapine_18\NN\3713736|such (l_conj) hyperactivity_28\NN\14052403|induced|,|olanzapine|and|and
D003913_D006948 NONE amphetamine_25\NN\3248958|||d (r_npadvmod) induced_27\VBN\1627355|hyperactivity|,|olanzapine|and|and (r_conj) clozapine_18\NN\3713736|such (l_conj) hyperactivity_28\NN\14052403|induced|,|olanzapine|and|and
D008694_D012563 NONE methamphetamine_3\NN\2704153|NONE (r_pobj) of_2\IN\0|psychosis|The (r_prep) symptoms_1\NNS\5823932|similar|. (r_nsubj) are_7\VBP\13600404|NONE (l_acomp) similar_8\JJ\0|.|symptoms (l_prep) to_9\IN\0|NONE (l_pobj) those_10\DT\0|NONE (l_prep) of_11\IN\0|NONE (l_pobj) schizophrenia_14\NN\14398067|NONE
D008694_D012563 NONE meth)-induced_5\JJ\0|( (r_amod) psychosis_6\NN\14380140|The|of (r_appos) symptoms_1\NNS\5823932|similar|. (r_nsubj) are_7\VBP\13600404|NONE (l_acomp) similar_8\JJ\0|.|symptoms (l_prep) to_9\IN\0|NONE (l_pobj) those_10\DT\0|NONE (l_prep) of_11\IN\0|NONE (l_pobj) schizophrenia_14\NN\14398067|NONE
14704468
C066440_D012640 NONE loreclezole_0\NNP\0|.|action|reducing|, (r_nsubj) exerted_5\VBD\1158872|NONE (l_advcl) reducing_16\VBG\13447361|.|action|Loreclezole|, (l_dobj) seizure_18\NN\14081375|NONE
18006530
D015742_D010146 CID propofol_9\NN\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) induction_4\NN\7450842|NONE (r_pobj) during_3\IN\0|.|of (r_prep) reduction_0\NN\351485|NONE (l_prep) of_1\IN\0|during|. (l_pobj) pain_2\NN\14299637|NONE
D015742_D010146 CID propofol_4\NN\0|NONE (r_pobj) of_3\IN\0|NONE (r_prep) injection_2\NN\320852|NONE (r_pobj) on_1\IN\0|NONE (r_prep) pain_0\NN\14299637|.|unpleasant
D015742_D010146 CID propofol_3\JJ\0|infusion (r_amod) pain_5\NN\14299637|be|that|might|by
D015742_D010146 CID propofol_15\JJ\0|the|in (r_amod) infusion_16\NN\14589223|NONE (r_dobj) starting_13\VBG\457382|NONE (r_pcomp) before_12\IN\0|remifentanil (r_prep) infusing_10\VBG\606335|NONE (r_pcomp) by_9\IN\0|be|that|might|pain (r_prep) prevented_8\VBN\0|.|We (l_nsubjpass) pain_5\NN\14299637|be|that|might|by
D015742_D010146 CID propofol_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) caused_13\VBN\1617192|NONE (r_acl) pain_12\NN\14299637|was|using|.
D015742_D010146 CID propofol_26\JJ\0|the (r_amod) infusion_27\NN\14589223|NONE (r_pobj) during_24\IN\0|scale (r_prep) using_18\VBG\418025|was|pain|. (r_advcl) evaluated_17\VBN\670261|,|and|complications|during|were (l_nsubjpass) pain_12\NN\14299637|was|using|.
D015742_D010146 CID propofol_7\NN\0|NONE (r_pobj) of_6\IN\0|with (r_prep) anaesthesia_3\NN\14034177|NONE (r_pobj) of_2\IN\0|NONE (r_prep) induction_1\NN\7450842|NONE (r_pobj) during_0\IN\0|without|was|,|.|reduction|) (r_prep) achieved_19\VBN\2524171|NONE (l_nsubjpass) reduction_13\NN\351485|without|was|,|During|.|) (l_prep) in_14\IN\13603305|significant|a (l_pobj) pain_17\NN\14299637|NONE
D015742_D010146 CID propofol_15\JJ\0|infusion (r_amod) pain_17\NN\14299637|NONE
C071741_D010146 NONE remifentanil_11\NN\0|controlled|and (r_conj) propofol_9\NN\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) induction_4\NN\7450842|NONE (r_pobj) during_3\IN\0|.|of (r_prep) reduction_0\NN\351485|NONE (l_prep) of_1\IN\0|during|. (l_pobj) pain_2\NN\14299637|NONE
C071741_D010146 NONE remifentanil_11\NN\0|before (r_dobj) infusing_10\VBG\606335|NONE (r_pcomp) by_9\IN\0|be|that|might|pain (r_prep) prevented_8\VBN\0|.|We (l_nsubjpass) pain_5\NN\14299637|be|that|might|by
C071741_D010146 NONE remifentanil_26\NN\0|NONE (r_pobj) of_25\IN\0|)|( (r_prep) ce_23\NNP\14625458|prevent|site|the (r_appos) concentration_21\NN\4916342|to (l_relcl) prevent_28\VB\0|Ce|site|the (l_dobj) pain_30\NN\14299637|without|to
C071741_D010146 NONE remifentanil_0\NN\0| (r_npadvmod) related_2\VBN\628491|NONE (r_amod) complications_3\NNS\1073995|evaluated|,|and|during|were (r_nsubjpass) assessed_5\VBN\670261|NONE (l_conj) evaluated_17\VBN\670261|,|and|complications|during|were (l_nsubjpass) pain_12\NN\14299637|was|using|.
C071741_D010146 NONE remifentanil_8\NN\0|the (r_compound) infusion_9\NN\14589223|NONE (r_pobj) during_6\IN\0|evaluated|,|and|complications|were (r_prep) assessed_5\VBN\670261|NONE (l_conj) evaluated_17\VBN\670261|,|and|complications|during|were (l_nsubjpass) pain_12\NN\14299637|was|using|.
C071741_D010146 NONE remifentanil_9\NN\0|and (r_conj) propofol_7\NN\0|NONE (r_pobj) of_6\IN\0|with (r_prep) anaesthesia_3\NN\14034177|NONE (r_pobj) of_2\IN\0|NONE (r_prep) induction_1\NN\7450842|NONE (r_pobj) during_0\IN\0|without|was|,|.|reduction|) (r_prep) achieved_19\VBN\2524171|NONE (l_nsubjpass) reduction_13\NN\351485|without|was|,|During|.|) (l_prep) in_14\IN\13603305|significant|a (l_pobj) pain_17\NN\14299637|NONE
C071741_D010146 NONE remifentanil_27\NN\0|NONE (r_pobj) of_26\IN\0|prior (r_prep) administration_25\NN\1133281|NONE (r_pobj) by_23\IN\0|at|significant (r_prep) complications_22\NNS\1073995|NONE (r_pobj) without_20\IN\0|was|,|During|.|reduction|) (r_prep) achieved_19\VBN\2524171|NONE (l_nsubjpass) reduction_13\NN\351485|without|was|,|During|.|) (l_prep) in_14\IN\13603305|significant|a (l_pobj) pain_17\NN\14299637|NONE
8045270
C061282_D002375 CID 21680_29\CD\0|(|)|micrograms (r_nummod) cgs_28\NNP\13577934|adenosine|an|,|AA|receptor (r_appos) agonist_26\NN\0|NONE (r_pobj) of_21\IN\0|intracerebroventricular (r_prep) administration_20\NN\1133281|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|the|cataleptic (r_acl) responses_16\NNS\11410625|.|,|significantly|administration|in (l_amod) cataleptic_15\JJ\10490141|the|induced
D006220_D002375 CID haloperidol_7\NN\3713736|and|by (r_pobj) by_6\IN\0|NONE (r_agent) induced_5\VBN\1627355|the (r_acl) catalepsy_4\NN\14023236|also|.|KF
D000241_D002375 NONE adenosine_23\NN\14964367|an|,|CGS|AA|receptor (r_amod) agonist_26\NN\0|NONE (r_pobj) of_21\IN\0|intracerebroventricular (r_prep) administration_20\NN\1133281|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|the|cataleptic (r_acl) responses_16\NNS\11410625|.|,|significantly|administration|in (l_amod) cataleptic_15\JJ\10490141|the|induced
C081198_D010302 NONE kf17837_2\NN\0|Furthermore|,|may|drug|. (r_nsubj) be_4\VB\14625458|NONE (l_attr) drug_7\NN\14778436|Furthermore|,|may|.|KF (l_prep) in_8\IN\13603305|useful|a (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_11\IN\0|the (l_pobj) parkinsonism_12\NN\14085708|NONE
C081198_D002375 NONE kf17837_3\NNP\0|NONE (r_pobj) of_2\IN\0|.|Oral (r_prep) administration_1\NN\1133281|.|,|significantly|responses|in (r_nsubj) ameliorated_13\VBD\126264|NONE (l_dobj) responses_16\NNS\11410625|.|,|significantly|administration|in (l_amod) cataleptic_15\JJ\10490141|the|induced
C081198_D002375 NONE kf17837_0\NN\0|catalepsy|also|. (r_nsubj) reduced_2\VBD\441445|NONE (l_dobj) catalepsy_4\NN\14023236|also|.|KF
D012110_D002375 CID reserpine_15\NN\2721160|NONE (r_pobj) by_14\IN\0|haloperidol|and (r_conj) by_6\IN\0|NONE (r_agent) induced_5\VBN\1627355|the (r_acl) catalepsy_4\NN\14023236|also|.|KF
17344330
D008691_D008133 CID methadone_8\NN\3808564|NONE (r_pobj) with_7\IN\0|for (r_prep) treated_6\VBN\2376958|NONE (r_acl) patients_5\NNS\9898892|NONE (r_pobj) among_4\IN\0|prolongation|.|and (r_prep) syncope_0\NNP\7478169|NONE (l_conj) prolongation_3\NN\1017987|.|and|among
D008691_D008133 CID methadone_5\NN\3808564|NONE (r_pobj) with_4\IN\0|NONE (r_prep) treated_3\VBN\2376958|the (r_acl) subjects_2\NNS\6598915|NONE (r_pobj) among_0\IN\0|.|interval (r_prep) had_14\VBD\0|NONE (l_dobj) interval_17\NN\33615|.|Among
D008691_D008133 CID methadone_0\NNP\3808564|.|is|with (r_nsubjpass) associated_2\VBN\628491|NONE (l_prep) with_3\IN\0|.|is|Methadone (l_pobj) prolongation_5\NN\1017987|NONE
D003932_D016171 NONE heroin_1\NN\3492717|NONE (r_compound) addicts_2\NNS\10059582|using|As|sometimes (r_nsubj) faint_4\JJ\7478169|and|episodes|doctors|,|and|caused|,|underestimate|might (r_advcl) attribute_12\VB\5835747|NONE (l_conj) underestimate_24\VBP\5803379|and|episodes|faint|doctors|,|and|caused|,|might (l_dobj) incidence_26\NN\13821570|thereby (l_prep) of_27\IN\0|the|in (l_pobj) tdp_28\NNP\0|NONE
D003932_D013575 NONE heroin_10\NN\3492717|in (r_compound) dependence_11\NN\24720|NONE (r_pobj) for_9\IN\0|with (r_prep) treated_6\VBN\2376958|NONE (r_acl) patients_5\NNS\9898892|NONE (r_pobj) among_4\IN\0|prolongation|.|and (r_prep) syncope_0\NNP\7478169|NONE
D003932_D013575 NONE heroin_1\NN\3492717|NONE (r_compound) addicts_2\NNS\10059582|using|As|sometimes (r_nsubj) faint_4\JJ\7478169|and|episodes|doctors|,|and|caused|,|underestimate|might (r_advcl) attribute_12\VB\5835747|NONE (l_dobj) episodes_15\NNS\7283608|and|faint|doctors|,|and|caused|,|underestimate|might (l_prep) of_16\IN\0|many (l_pobj) syncope_17\NN\7478169|NONE
D003932_D013575 NONE heroin_15\NN\3492717|NONE (r_compound) addicts_16\NNS\10059582|NONE (r_pobj) of_14\IN\0|a (r_prep) population_13\NN\7942152|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) syncope_10\NN\7478169|NONE
D008691_D013575 CID methadone_8\NN\3808564|NONE (r_pobj) with_7\IN\0|for (r_prep) treated_6\VBN\2376958|NONE (r_acl) patients_5\NNS\9898892|NONE (r_pobj) among_4\IN\0|prolongation|.|and (r_prep) syncope_0\NNP\7478169|NONE
D008691_D013575 CID methadone_53\NN\3808564|NONE (r_pobj) of_52\IN\0|proarrhythmic|the (r_prep) effect_51\NN\34213|NONE (r_pobj) by_48\IN\0|,|.|may|,|be|mortality|in (r_agent) caused_47\VBN\1617192|and|episodes|faint|doctors|,|and|,|underestimate|might (r_conj) attribute_12\VB\5835747|NONE (l_dobj) episodes_15\NNS\7283608|and|faint|doctors|,|and|caused|,|underestimate|might (l_prep) of_16\IN\0|many (l_pobj) syncope_17\NN\7478169|NONE
D008691_D013575 CID methadone_9\NN\3808564|and|reporting (r_compound) dose_10\NN\3740161|QT|opioid|and|,|and (l_conj) reporting_12\NN\6681177|methadone|and (l_prep) of_13\IN\0|NONE (l_pobj) syncope_14\NN\7478169|NONE
D008691_D013575 CID methadone_4\NN\3808564|NONE (r_compound) dose_5\NN\3740161|was|with|. (r_nsubjpass) associated_7\VBN\628491|NONE (l_prep) with_8\IN\0|dose|was|. (l_pobj) ci_14\NNP\13635336|NONE (l_appos) odds_21\NNS\4756635|%|)|to|a|. (l_prep) for_22\IN\0|higher (l_pobj) syncope_23\NN\7478169|NONE
D008691_D013575 CID methadone_0\NNP\3808564|.|is|with (r_nsubjpass) associated_2\VBN\628491|NONE (l_prep) with_3\IN\0|.|is|Methadone (l_pobj) prolongation_5\NN\1017987|NONE (l_conj) reporting_8\NN\6681177|and|QT (l_prep) of_9\IN\0|higher (l_pobj) syncope_10\NN\7478169|NONE
D003932_D008133 NONE heroin_10\NN\3492717|in (r_compound) dependence_11\NN\24720|NONE (r_pobj) for_9\IN\0|with (r_prep) treated_6\VBN\2376958|NONE (r_acl) patients_5\NNS\9898892|NONE (r_pobj) among_4\IN\0|prolongation|.|and (r_prep) syncope_0\NNP\7478169|NONE (l_conj) prolongation_3\NN\1017987|.|and|among
D003932_D008133 NONE heroin_15\NN\3492717|NONE (r_compound) addicts_16\NNS\10059582|NONE (r_pobj) of_14\IN\0|a (r_prep) population_13\NN\7942152|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) syncope_10\NN\7478169|NONE (r_pobj) of_9\IN\0|higher (r_prep) reporting_8\NN\6681177|and|QT (r_conj) prolongation_5\NN\1017987|NONE
D008691_D016171 NONE methadone_21\NN\3808564|NONE (r_compound) users_22\NNS\7846|NONE (r_pobj) in_20\IN\13603305|Prolongation|has|been|. (r_prep) reported_19\VBN\831651|NONE (l_nsubjpass) prolongation_0\NN\1017987|in|has|been|. (l_prep) of_1\IN\0|NONE (l_pobj) interval_4\NN\33615|NONE (l_prep) in_5\IN\13603305|the|QT (l_pobj) ecg_7\NNP\7000195|NONE (l_prep) of_8\IN\0|the (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) pointes_13\FW\831651|NONE
D008691_D016171 NONE methadone_21\NN\3808564|NONE (r_compound) users_22\NNS\7846|NONE (r_pobj) in_20\IN\13603305|Prolongation|has|been|. (r_prep) reported_19\VBN\831651|NONE (l_nsubjpass) prolongation_0\NN\1017987|in|has|been|. (l_prep) of_1\IN\0|NONE (l_pobj) interval_4\NN\33615|NONE (l_prep) in_5\IN\13603305|the|QT (l_pobj) ecg_7\NNP\7000195|NONE (l_prep) of_8\IN\0|the (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) pointes_13\FW\831651|NONE (l_appos) tdp_15\NN\0|)|(|torsade|de
D008691_D016171 NONE methadone_53\NN\3808564|NONE (r_pobj) of_52\IN\0|proarrhythmic|the (r_prep) effect_51\NN\34213|NONE (r_pobj) by_48\IN\0|,|.|may|,|be|mortality|in (r_agent) caused_47\VBN\1617192|and|episodes|faint|doctors|,|and|,|underestimate|might (r_conj) attribute_12\VB\5835747|NONE (l_conj) underestimate_24\VBP\5803379|and|episodes|faint|doctors|,|and|caused|,|might (l_dobj) incidence_26\NN\13821570|thereby (l_prep) of_27\IN\0|the|in (l_pobj) tdp_28\NNP\0|NONE
9799166
D000661_D020521 CID amphetamine_4\NN\3248958|or (r_conj) cocaine_2\NN\3492717|and (r_conj) stroke_0\NN\556313|.
D000661_D020521 CID amphetamine_5\NN\3248958|NONE (r_compound) use_6\NN\407535|and (r_conj) cocaine_3\NN\3492717|NONE (r_pobj) of_2\IN\0|with|The (r_prep) association_1\NN\8008335|is|on|. (l_prep) with_7\IN\0|of|The (l_pobj) stroke_11\NN\556313|NONE
D000661_D020521 CID amphetamine_13\NN\3248958|and/or (r_conj) cocaine_11\NN\3492717|NONE (r_pobj) of_10\IN\0|NONE (r_prep) use_9\NN\407535|and (r_conj) stroke_7\NN\556313|NONE
D000661_D020521 CID amphetamine_15\NN\3248958|and/or (r_conj) cocaine_13\NN\3492717|NONE (r_dobj) using_12\VBG\418025|NONE (r_pcomp) to_11\IN\0|who (r_prep) admitted_10\VBD\822367|in (r_relcl) stroke_6\NN\556313|NONE
D000661_D020521 CID amphetamine_5\NN\3248958|and/or (r_conj) cocaine_3\NN\3492717|NONE (r_pobj) of_2\IN\0|The (r_prep) use_1\NN\407535|.|factor (r_nsubj) is_6\VBZ\0|NONE (l_attr) factor_10\NN\7326557|.|use (l_prep) for_11\IN\0|strong|risk|a (l_pobj) stroke_12\NN\556313|NONE
D003042_D007511 NONE cocaine_3\NN\3492717|NONE (r_pobj) of_2\IN\0|with|The (r_prep) association_1\NN\8008335|is|on|. (l_prep) with_7\IN\0|of|The (l_pobj) stroke_11\NN\556313|NONE (l_amod) hemorrhagic_8\JJ\0|NONE (l_conj) ischemic_10\JJ\0|and
D000661_D007511 NONE amphetamine_5\NN\3248958|NONE (r_compound) use_6\NN\407535|and (r_conj) cocaine_3\NN\3492717|NONE (r_pobj) of_2\IN\0|with|The (r_prep) association_1\NN\8008335|is|on|. (l_prep) with_7\IN\0|of|The (l_pobj) stroke_11\NN\556313|NONE (l_amod) hemorrhagic_8\JJ\0|NONE (l_conj) ischemic_10\JJ\0|and
D003042_D020521 CID cocaine_2\NN\3492717|and (r_conj) stroke_0\NN\556313|.
D003042_D020521 CID cocaine_3\NN\3492717|NONE (r_pobj) of_2\IN\0|with|The (r_prep) association_1\NN\8008335|is|on|. (l_prep) with_7\IN\0|of|The (l_pobj) stroke_11\NN\556313|NONE
D003042_D020521 CID cocaine_11\NN\3492717|NONE (r_pobj) of_10\IN\0|NONE (r_prep) use_9\NN\407535|and (r_conj) stroke_7\NN\556313|NONE
D003042_D020521 CID cocaine_13\NN\3492717|NONE (r_dobj) using_12\VBG\418025|NONE (r_pcomp) to_11\IN\0|who (r_prep) admitted_10\VBD\822367|in (r_relcl) stroke_6\NN\556313|NONE
D003042_D020521 CID cocaine_3\NN\3492717|NONE (r_pobj) of_2\IN\0|The (r_prep) use_1\NN\407535|.|factor (r_nsubj) is_6\VBZ\0|NONE (l_attr) factor_10\NN\7326557|.|use (l_prep) for_11\IN\0|strong|risk|a (l_pobj) stroke_12\NN\556313|NONE
11226639
D008550_D053608 CID melatonin_3\NN\5407119|NONE (l_prep) on_4\IN\0|NONE (l_pobj) narcosis_8\NN\5678932|NONE
D008550_D053608 CID melatonin_0\NNP\5407119|cycle|but|,|is (r_nsubj) affects_1\VBZ\26192|NONE (l_conj) is_11\VBZ\0|cycle|Melatonin|but|, (l_ccomp) influence_17\VB\5190804|.|it|clear|not (l_dobj) narcosis_21\NN\5678932|whether|it|may
D008550_D053608 CID melatonin_0\NNP\5407119|correlation|,|.|,|however|was (r_nsubjpass) found_20\VBN\13279262|NONE (l_punct) ,_11\,\0|correlation|.|,|Melatonin|however|was (l_punct) affected_4\VBN\126264|NONE (l_prep) in_5\IN\13603305|treatment (l_pobj) narcosis_10\NN\5678932|NONE
D008550_D053608 CID melatonin_7\NN\5407119|NONE (r_pobj) of_6\IN\0|the|highest (r_prep) dose_5\NN\3740161|.|reduction|produced|and|and|increase|,|In (r_nsubj) caused_12\VBD\1617192|NONE (l_conj) produced_20\VBD\1617192|dose|.|reduction|and|and|increase|,|In (l_dobj) reduction_23\NN\351485|, (l_prep) of_24\IN\0|sustained|a (l_pobj) duration_26\NN\15113229|NONE (l_prep) of_27\IN\0|the (l_pobj) narcosis_28\NN\5678932|NONE
D008550_D053608 CID melatonin_0\NNP\5407119|.|duration (r_nsubj) influenced_5\VBD\137313|NONE (l_dobj) duration_7\NN\15113229|.|Melatonin (l_conj) latency_11\NN\15269513|the|but (l_prep) of_12\IN\0|not|the (l_pobj) narcosis_18\NN\5678932|NONE
D008550_D053608 CID melatonin_6\NN\5407119|NONE (l_prep) on_7\IN\0|NONE (l_pobj) narcosis_9\NN\5678932|NONE
D007649_D053608 CID ketamine-_13\NNS\0|NONE (r_nmod) narcosis_18\NN\5678932|NONE
C032232_D053608 NONE barbiturate_5\NN\4166841| (r_npadvmod) induced_7\VBN\1627355|in (r_amod) narcosis_8\NN\5678932|NONE
C032232_D053608 NONE barbiturate_9\NN\4166841|a|manner (r_compound) narcosis_10\NN\5678932|NONE
C032232_D053608 NONE barbiturate_14\NN\4166841|NONE (r_compound) narcosis_15\NN\5678932|NONE
C032232_D053608 NONE barbiturate_16\JJ\4166841|of|the (r_compound) mechanism_17\NN\13446390|NONE (r_pobj) for_14\IN\0|NONE (r_prep) specific_13\JJ\5817396|to (r_acomp) be_12\VB\14625458|action|.|,|Thus (r_xcomp) seems_10\VBZ\2604760|NONE (l_nsubj) action_4\NN\30358|.|be|,|Thus (l_prep) of_5\IN\0|dual|the (l_pobj) melatonin_6\NN\5407119|NONE (l_prep) on_7\IN\0|NONE (l_pobj) narcosis_9\NN\5678932|NONE
D003975_D053608 CID diazepam_15\NN\2830852| (r_npadvmod) induced_17\VBN\1627355|or (r_conj) ketamine-_13\NNS\0|NONE (r_nmod) narcosis_18\NN\5678932|NONE
2894433
D001569_D001919 NONE benzodiazepine_36\JJ\3771443|macromolecular|chloride|channel|the (r_amod) complex_43\NN\5869584|NONE (r_pobj) with_34\IN\0|NONE (r_prep) associated_33\VBN\628491|NONE (r_acl) sites_32\NNS\8673395|NONE (r_pobj) to_31\IN\0|NONE (r_prep) binding_30\VBG\4688246|NONE (r_pcomp) by_29\IN\0|agent|channels (r_prep) blocks_26\NNS\21939|)|( (r_appos) picrotoxin_22\NN\0|NONE (r_pobj) of_21\IN\0|intravenous|an (r_prep) dose_20\NN\3740161|NONE (r_pobj) with_17\IN\0|of (r_prep) pretreatment_14\NN\0|NONE (r_pobj) by_13\IN\0|was|enhancement|,|.|However (r_agent) antagonized_12\VBN\1787955|NONE (l_nsubjpass) enhancement_4\NN\248977|by|was|,|.|However (l_prep) of_5\IN\0|diazepam|the (l_pobj) bradycardia_10\NN\14110674|NONE
D001569_D001919 NONE benzodiazepine_8\JJ\3771443|the|channel|macromolecular|chloride|within (r_amod) complex_15\NN\5869584|NONE (r_pobj) through_6\IN\0|that|facilitate|diazepam (r_prep) acts_5\VBZ\0|.|data (l_advcl) facilitate_22\VB\2547586|that|through|diazepam (l_dobj) bradycardia_24\NN\14110674|to
D005680_D001919 NONE gaba_38\NNP\14601829|| (r_compound) chloride_40\NN\14818238|macromolecular|benzodiazepine|channel|the (r_compound) complex_43\NN\5869584|NONE (r_pobj) with_34\IN\0|NONE (r_prep) associated_33\VBN\628491|NONE (r_acl) sites_32\NNS\8673395|NONE (r_pobj) to_31\IN\0|NONE (r_prep) binding_30\VBG\4688246|NONE (r_pcomp) by_29\IN\0|agent|channels (r_prep) blocks_26\NNS\21939|)|( (r_appos) picrotoxin_22\NN\0|NONE (r_pobj) of_21\IN\0|intravenous|an (r_prep) dose_20\NN\3740161|NONE (r_pobj) with_17\IN\0|of (r_prep) pretreatment_14\NN\0|NONE (r_pobj) by_13\IN\0|was|enhancement|,|.|However (r_agent) antagonized_12\VBN\1787955|NONE (l_nsubjpass) enhancement_4\NN\248977|by|was|,|.|However (l_prep) of_5\IN\0|diazepam|the (l_pobj) bradycardia_10\NN\14110674|NONE
D005680_D001919 NONE gaba_10\NNP\14601829|| (r_compound) chloride_12\NN\14818238|benzodiazepine|the|channel|macromolecular|within (r_compound) complex_15\NN\5869584|NONE (r_pobj) through_6\IN\0|that|facilitate|diazepam (r_prep) acts_5\VBZ\0|.|data (l_advcl) facilitate_22\VB\2547586|that|through|diazepam (l_dobj) bradycardia_24\NN\14110674|to
D004837_D001919 CID adrenaline_12\NN\14807929|NONE (r_pobj) of_11\IN\0|intravenous|(|)|micrograms (r_prep) infusion_10\NN\14589223|NONE (r_pobj) by_8\IN\0|.|was|Also|in|bradycardia|, (r_agent) produced_5\VBN\1617192|NONE (l_nsubjpass) bradycardia_3\NN\14110674|.|was|Also|in|,|by
D004837_D001919 CID adrenaline_14\NN\14807929| (r_npadvmod) induced_16\VBN\1627355|pressor|the (r_amod) effect_18\NN\34213|NONE (r_pobj) in_12\IN\13603305|no (r_prep) change_11\NN\7283608|although (r_dobj) causing_9\VBG\30358|with|of|Intravenous|, (r_advcl) pretreatment_1\NN\0|did|bradycardia|.|, (r_nsubj) enhance_21\VB\227165|NONE (l_dobj) bradycardia_27\NN\14110674|did|.|,|pretreatment
D004837_D001919 CID adrenaline_23\NN\14807929| (r_npadvmod) induced_25\VBN\1627355|reflex|the (r_amod) bradycardia_27\NN\14110674|did|.|,|pretreatment
D004837_D001919 CID adrenaline_6\NN\14807929| (r_npadvmod) induced_8\VBN\1627355|reflex (r_amod) bradycardia_10\NN\14110674|NONE
D010852_D001919 NONE picrotoxin_22\NN\0|NONE (r_pobj) of_21\IN\0|intravenous|an (r_prep) dose_20\NN\3740161|NONE (r_pobj) with_17\IN\0|of (r_prep) pretreatment_14\NN\0|NONE (r_pobj) by_13\IN\0|was|enhancement|,|.|However (r_agent) antagonized_12\VBN\1787955|NONE (l_nsubjpass) enhancement_4\NN\248977|by|was|,|.|However (l_prep) of_5\IN\0|diazepam|the (l_pobj) bradycardia_10\NN\14110674|NONE
D002712_D001919 NONE chloride_27\NN\14818238|NONE (r_compound) channels_28\NNS\6251781|agent|by (r_dobj) blocks_26\NNS\21939|)|( (r_appos) picrotoxin_22\NN\0|NONE (r_pobj) of_21\IN\0|intravenous|an (r_prep) dose_20\NN\3740161|NONE (r_pobj) with_17\IN\0|of (r_prep) pretreatment_14\NN\0|NONE (r_pobj) by_13\IN\0|was|enhancement|,|.|However (r_agent) antagonized_12\VBN\1787955|NONE (l_nsubjpass) enhancement_4\NN\248977|by|was|,|.|However (l_prep) of_5\IN\0|diazepam|the (l_pobj) bradycardia_10\NN\14110674|NONE
D002712_D001919 NONE chloride_40\NN\14818238|macromolecular|benzodiazepine|channel|the (r_compound) complex_43\NN\5869584|NONE (r_pobj) with_34\IN\0|NONE (r_prep) associated_33\VBN\628491|NONE (r_acl) sites_32\NNS\8673395|NONE (r_pobj) to_31\IN\0|NONE (r_prep) binding_30\VBG\4688246|NONE (r_pcomp) by_29\IN\0|agent|channels (r_prep) blocks_26\NNS\21939|)|( (r_appos) picrotoxin_22\NN\0|NONE (r_pobj) of_21\IN\0|intravenous|an (r_prep) dose_20\NN\3740161|NONE (r_pobj) with_17\IN\0|of (r_prep) pretreatment_14\NN\0|NONE (r_pobj) by_13\IN\0|was|enhancement|,|.|However (r_agent) antagonized_12\VBN\1787955|NONE (l_nsubjpass) enhancement_4\NN\248977|by|was|,|.|However (l_prep) of_5\IN\0|diazepam|the (l_pobj) bradycardia_10\NN\14110674|NONE
D002712_D001919 NONE chloride_12\NN\14818238|benzodiazepine|the|channel|macromolecular|within (r_compound) complex_15\NN\5869584|NONE (r_pobj) through_6\IN\0|that|facilitate|diazepam (r_prep) acts_5\VBZ\0|.|data (l_advcl) facilitate_22\VB\2547586|that|through|diazepam (l_dobj) bradycardia_24\NN\14110674|to
D003975_D001919 CID diazepam_0\NNP\2830852|bradycardia|. (r_nsubj) facilitates_1\VBZ\2547586|NONE (l_dobj) bradycardia_3\NN\14110674|Diazepam|.
D003975_D001919 CID diazepam_6\NN\2830852|NONE (r_pobj) with_5\IN\0|causing|of|Intravenous|, (r_prep) pretreatment_1\NN\0|did|bradycardia|.|, (r_nsubj) enhance_21\VB\227165|NONE (l_dobj) bradycardia_27\NN\14110674|did|.|,|pretreatment
D003975_D001919 CID diazepam_3\NN\2830852|the|of (r_compound) enhancement_4\NN\248977|by|was|,|.|However (l_prep) of_5\IN\0|diazepam|the (l_pobj) bradycardia_10\NN\14110674|NONE
D003975_D001919 CID diazepam_4\NN\2830852|that|facilitate|through (r_nsubj) acts_5\VBZ\0|.|data (l_advcl) facilitate_22\VB\2547586|that|through|diazepam (l_dobj) bradycardia_24\NN\14110674|to
7905523
D015215_D015658 NONE zidovudine_15\NN\3834836|||butyl|N|and|SC (l_prep) in_16\IN\13603305|NONE (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|and (l_pobj) infection_20\NN\14052046|NONE
C059896_D007153 NONE sc-48334_2\VBP\0|mean|The|trough|ml|state (r_nmod) level_7\NN\4916342|below|. (r_nsubj) was_16\VBD\0|NONE (l_prep) below_17\IN\0|level|. (l_pobj) concentration_22\NN\4916342|NONE (l_prep) for_23\IN\0|the|vitro|inhibitory (l_pobj) virus_26\NN\9312843|NONE (l_compound) immunodeficiency_25\NN\13973990|HIV|)|human|(
C059896_D015658 NONE deoxynojirimycin_10\NNP\0|.|/|cells|safety (l_conj) zidovudine_15\NN\3834836|||butyl|N|and|SC (l_prep) in_16\IN\13603305|NONE (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|and (l_pobj) infection_20\NN\14052046|NONE
C059896_D015658 NONE sc-48334_12\NNP\0|||butyl|zidovudine|N|and (r_appos) deoxynojirimycin_10\NNP\0|.|/|cells|safety (l_conj) zidovudine_15\NN\3834836|||butyl|N|and|SC (l_prep) in_16\IN\13603305|NONE (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|and (l_pobj) infection_20\NN\14052046|NONE
19289093
D002809_D007022 CID sulfate_19\NN\15010703|an|oversulfated|elicit (r_nmod) derivative_23\NN\5802185|NONE (l_relcl) elicit_26\VB\1617192|an|sulfate|oversulfated (l_dobj) response_29\NN\11410625|could|that|following (l_amod) hypotensive_28\JJ\10405694|a|in
D006493_D007022 NONE heparin_8\JJ\2718259|NONE (r_compound) products_9\NNS\3076708|NONE (r_pobj) of_7\IN\0|commercial (r_prep) lots_6\NNS\13757724|NONE (r_pobj) of_4\IN\0|a (r_prep) number_3\NN\5107765|Recently|,|.|were|contaminated (r_nsubjpass) found_11\VBN\13279262|NONE (l_xcomp) contaminated_14\VBN\1534147|Recently|,|number|.|were (l_prep) with_15\IN\0|to|be (l_pobj) derivative_23\NN\5802185|NONE (l_relcl) elicit_26\VB\1617192|an|sulfate|oversulfated (l_dobj) response_29\NN\11410625|could|that|following (l_amod) hypotensive_28\JJ\10405694|a|in
D006493_D007022 NONE heparin_3\JJ\2718259|both|contaminated|derivative|and (r_compound) products_4\NNS\3076708|NONE (r_dobj) using_0\VBG\418025|.|,|produces|we (r_advcl) showed_12\VBD\2137132|NONE (l_ccomp) produces_16\VBZ\7555863|.|Using|,|we (l_dobj) hypotension_20\NN\14057371|OSCS|that
12231232
C095756_D009127 NONE aida_0\NNP\0|rigidity|. (r_nsubj) diminished_9\VBD\169651|NONE (l_dobj) rigidity_15\NN\5023233|AIDA|.
D006220_D009127 CID haloperidol_0\NN\3713736|.|rigidity (r_nsubj) induced_6\VBD\1627355|NONE (l_dobj) rigidity_11\NN\5023233|.|Haloperidol
D006220_D009127 CID haloperidol_11\NN\3713736| (r_npadvmod) induced_13\VBN\1627355|the|muscle (r_amod) rigidity_15\NN\5023233|AIDA|.
D006220_D010300 NONE haloperidol_0\NN\3713736|.|rigidity (r_nsubj) induced_6\VBD\1627355|NONE (l_dobj) rigidity_11\NN\5023233|.|Haloperidol (l_amod) parkinsonian_7\JJ\0|measured|,|muscle
871943
D013390_D001049 CID succinylcholine_6\NN\3800001|NONE (r_compound) apnoea_7\NN\0|NONE
D013390_D001049 CID succinylcholine_10\NN\3800001|by|have|after|hours|been (r_nsubjpass) treated_13\VBN\2376958|.|apnoea|patients (r_advcl) demonstrating_2\VBG\2137132|NONE (l_dobj) apnoea_5\NN\0|.|patients|treated
D013390_D001049 CID succinylcholine_6\NN\3800001|NONE (r_compound) apnoea_7\NN\0|NONE
19692487
D015232_D011141 NONE )_29\-RRB-\0|NONE (r_punct) pge(2_28\NNP\0|and|high|output (r_appos) urine_27\NN\14853947|NONE (r_pobj) of_25\IN\0|complete (r_prep) blockade_24\NN\952963|NONE (r_pobj) by_21\IN\0|NONE (r_agent) accompanied_20\VBN\0|resistant|.|mPGES|,|,|mice|In (r_advcl) were_6\VBD\0|NONE (l_acomp) resistant_8\JJ\0|.|mPGES|,|,|mice|In|accompanied (l_prep) to_9\IN\0|largely (l_pobj) polyuria_13\NN\14113228|NONE
D015232_D011141 NONE )_5\-RRB-\0|mPGESderived (r_punct) pge(2_4\NNP\0|via|that|polyuria (r_nsubj) mediates_6\VBZ\761713|We|. (l_dobj) polyuria_10\NN\14113228|via|that|PGE(
D008094_D011141 NONE lithium_6\NN\14625458| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) polyuria_9\NN\14113228|NONE
D008094_D011141 NONE lithium_8\NN\14625458| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) polyuria_11\NN\14113228|NONE
D008094_D011141 NONE lithium_7\NN\14625458| (r_npadvmod) induced_9\VBN\1627355|in (r_amod) polyuria_10\NN\14113228|to
D008094_D011141 NONE lithium_10\NN\14625458| (r_npadvmod) induced_12\VBN\1627355|and|urine (r_amod) polyuria_13\NN\14113228|NONE
D008094_D011141 NONE lithium_7\NN\14625458| (r_npadvmod) induced_9\VBN\1627355|likely (r_amod) polyuria_10\NN\14113228|via|that|PGE(
D011458_D011141 NONE e_17\NN\14724645|NONE (r_appos) microsomal_15\JJ\0|NONE (r_pobj) in_14\IN\13603305|mice (r_prep) deficient_13\JJ\0|NONE (r_pobj) in_11\IN\13603305|induced (r_prep) polyuria_10\NN\14113228|to
2907585
-1_D002375 NONE piperazine_10\NN\4528630|novel|anxiolytic (r_nmod) drugs_12\NNS\14778436|NONE (r_pobj) by_6\IN\0|of|. (r_prep) reversal_0\NN\199130|NONE (l_prep) of_1\IN\0|.|by (l_pobj) catalepsy_5\NN\14023236|NONE
-1_D002375 NONE piperazine_5\NN\4528630|of (r_compound) analogues_6\NNS\4743605|NONE (r_pobj) of_2\IN\0|A (r_prep) series_1\NN\8456993|.|were|induced|for (r_nsubjpass) tested_14\VBN\670261|NONE (l_conj) induced_21\VBN\1627355|.|were|series|for (l_dobj) catalepsy_22\NN\14023236|NONE
D006220_D002375 CID haloperidol_11\NN\3713736|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|NONE (r_acl) catalepsy_8\NN\14023236|.|drug
D006220_D002375 CID haloperidol_20\NN\3713736|to (r_dobj) reverse_19\VB\13854649|their (r_acl) ability_17\NN\4723816|NONE (r_pobj) for_15\IN\0|.|were|induced|series (r_prep) tested_14\VBN\670261|NONE (l_conj) induced_21\VBN\1627355|.|were|series|for (l_dobj) catalepsy_22\NN\14023236|NONE
D002065_D002375 NONE buspirone_5\NN\3771443|,|,|anxiolytic|novel|The (r_appos) drug_3\NN\14778436|catalepsy|. (r_nsubj) reverses_7\VBZ\13854649|NONE (l_dobj) catalepsy_8\NN\14023236|.|drug
D002065_D002375 NONE buspirone_8\NN\3771443|NONE (r_pobj) of_7\IN\0|piperazine (r_prep) analogues_6\NNS\4743605|NONE (r_pobj) of_2\IN\0|A (r_prep) series_1\NN\8456993|.|were|induced|for (r_nsubjpass) tested_14\VBN\670261|NONE (l_conj) induced_21\VBN\1627355|.|were|series|for (l_dobj) catalepsy_22\NN\14023236|NONE
D058825_D002375 NONE agonists_12\NNS\0|and (r_conj) buspirone_8\NN\3771443|NONE (r_pobj) of_7\IN\0|piperazine (r_prep) analogues_6\NNS\4743605|NONE (r_pobj) of_2\IN\0|A (r_prep) series_1\NN\8456993|.|were|induced|for (r_nsubjpass) tested_14\VBN\670261|NONE (l_conj) induced_21\VBN\1627355|.|were|series|for (l_dobj) catalepsy_22\NN\14023236|NONE
D012701_D002375 NONE 5-hydroxytryptamine1a_6\CD\0|NONE (r_compound) receptors_7\NNS\5225602|NONE (r_pobj) for_5\IN\0|strong (r_prep) affinity_4\NN\11426530|NONE (r_pobj) with_2\IN\0|Those (r_prep) drugs_1\NNS\14778436|able|. (r_nsubj) were_8\VBD\0|NONE (l_acomp) able_9\JJ\0|drugs|. (l_xcomp) reverse_11\VB\13854649|NONE (l_dobj) catalepsy_12\NN\14023236|to
D012701_D002375 NONE 5-ht_5\CD\0|postsynaptic (r_compound) receptors_6\NNS\5225602|NONE (r_pobj) of_3\IN\0|NONE (r_prep) inhibition_2\NN\1068773|.|,|neither|potentiated|However|nor (r_nsubj) inhibited_8\VBN\2510337|NONE (l_conj) potentiated_10\VBN\229605|inhibition|.|,|neither|However|nor (l_dobj) reversal_11\NN\199130|leaves|and (l_prep) of_12\IN\0|NONE (l_pobj) catalepsy_13\NN\14023236|NONE
9098464
D005473_D062788 CID hydrochloride_13\NN\14817592|NONE (r_pobj) by_11\IN\0|on (r_agent) induced_10\VBN\1627355|of|the (r_acl) effects_7\NNS\13245626|murine|.|A|:|of (r_appos) model_2\NN\5888929|NONE (l_prep) of_3\IN\0|effects|murine|.|A|: (l_pobj) adenomyosis_4\NN\14204950|NONE
D005473_D062788 CID hydrochloride_13\NN\14817592|NONE (r_pobj) by_11\IN\0|on (r_agent) induced_10\VBN\1627355|of|the (l_prep) on_21\IN\0|by (l_pobj) induction_23\NN\7450842|NONE (l_compound) adenomyosis_22\NN\14204950|in
D005473_D062788 CID fluoxetine_9\NN\4169152|whether|hyperprolactinemia (r_nsubj) caused_16\VBD\1617192|to (l_dobj) hyperprolactinemia_17\NN\0|whether|fluoxetine (l_conj) effects_20\NNS\13245626|and (l_prep) with_21\IN\0|its (l_pobj) respect_22\NN\5817845|NONE (l_prep) to_23\IN\0|NONE (l_pobj) adenomyosis_24\NN\14204950|NONE
D005473_D062788 CID fluoxetine_14\NN\4169152|NONE (r_dobj) receiving_13\VBG\2210855|noncastrated|the (r_acl) group_12\NN\2137|all (r_pobj) within_9\IN\0|.|cases|studies (r_prep) revealed_2\VBD\2137132|NONE (l_dobj) cases_4\NNS\7283608|.|within|studies (l_prep) of_5\IN\0||, (l_pobj) adenomyosis_6\NN\14204950|NONE
D005473_D006966 CID hydrochloride_13\NN\14817592|NONE (r_pobj) by_11\IN\0|on (r_agent) induced_10\VBN\1627355|of|the (r_acl) effects_7\NNS\13245626|murine|.|A|:|of (l_prep) of_8\IN\0|induced|the (l_pobj) hyperprolactinemia_9\NN\0|NONE
D005473_D006966 CID fluoxetine_9\NN\4169152|whether|hyperprolactinemia (r_nsubj) caused_16\VBD\1617192|to (l_dobj) hyperprolactinemia_17\NN\0|whether|fluoxetine
D005473_D006966 CID fluoxetine_0\NNP\4169152|was|produce|for|.|to (r_nsubjpass) given_8\VBN\5892096|NONE (l_advcl) produce_17\VB\7555863|Fluoxetine|was|for|.|to (l_dobj) hyperprolactinemia_18\NN\0|to
D012701_D062788 NONE serotonin_17\NN\14807737|a|selective|reuptake (r_compound) inhibitor_19\NN\20090|fluoxetine|,|, (r_appos) hydrochloride_13\NN\14817592|NONE (r_pobj) by_11\IN\0|on (r_agent) induced_10\VBN\1627355|of|the (r_acl) effects_7\NNS\13245626|murine|.|A|:|of (r_appos) model_2\NN\5888929|NONE (l_prep) of_3\IN\0|effects|murine|.|A|: (l_pobj) adenomyosis_4\NN\14204950|NONE
D012701_D062788 NONE serotonin_17\NN\14807737|a|selective|reuptake (r_compound) inhibitor_19\NN\20090|fluoxetine|,|, (r_appos) hydrochloride_13\NN\14817592|NONE (r_pobj) by_11\IN\0|on (r_agent) induced_10\VBN\1627355|of|the (l_prep) on_21\IN\0|by (l_pobj) induction_23\NN\7450842|NONE (l_compound) adenomyosis_22\NN\14204950|in
D012701_D006966 NONE serotonin_17\NN\14807737|a|selective|reuptake (r_compound) inhibitor_19\NN\20090|fluoxetine|,|, (r_appos) hydrochloride_13\NN\14817592|NONE (r_pobj) by_11\IN\0|on (r_agent) induced_10\VBN\1627355|of|the (r_acl) effects_7\NNS\13245626|murine|.|A|:|of (l_prep) of_8\IN\0|induced|the (l_pobj) hyperprolactinemia_9\NN\0|NONE
D012701_D006966 NONE serotonin_3\NN\14807737|a|reuptake (r_compound) inhibitor_5\NN\20090|,|, (r_appos) fluoxetine_0\NNP\4169152|was|produce|for|.|to (r_nsubjpass) given_8\VBN\5892096|NONE (l_advcl) produce_17\VB\7555863|Fluoxetine|was|for|.|to (l_dobj) hyperprolactinemia_18\NN\0|to
28952
D011188_D007008 NONE potassium_1\NN\14625458|influence|:|and|.|hypokalaemia|Initial (r_compound) loss_2\NN\13252973|NONE (l_conj) hypokalaemia_4\NN\0|influence|:|and|.|potassium|Initial
D011188_D007008 NONE potassium_4\NN\14625458|development|and|initial|during|the (r_compound) loss_5\NN\13252973|To (l_conj) development_7\NN\248977|potassium|and|initial|during|the (l_prep) of_8\IN\0|NONE (l_pobj) hypokalaemia_9\NN\0|NONE
D011188_D007008 NONE potassium_4\NN\14625458|development|and|initial|during|the (r_compound) loss_5\NN\13252973|To (r_dobj) investigate_1\VB\644583|.|were|in (r_csubjpass) performed_22\VBN\0|NONE (l_prep) in_23\IN\13603305|.|were|investigate (l_pobj) patients_25\NNS\9898892|NONE (l_prep) with_26\IN\0|ten (l_pobj) hypertension_28\NN\14057371|NONE (l_relcl) shown_31\VBN\2137132|essential (l_dobj) hypokalaemia_32\NN\0|who|under|had
D002752_D006973 NONE chlorthalidone_6\NN\3214670|in (r_compound) administration_7\NN\1133281|NONE (l_prep) in_8\IN\13603305|chlorthalidone (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
D012964_D007008 NONE sodium_18\NN\14625458|dietary (r_compound) restriction_19\NN\5846054|NONE (r_pobj) of_16\IN\0|the (r_prep) influence_15\NN\5190804|:|and|.|potassium|hypokalaemia|Initial (r_appos) loss_2\NN\13252973|NONE (l_conj) hypokalaemia_4\NN\0|influence|:|and|.|potassium|Initial
D011188_D006973 NONE potassium_1\NN\14625458|influence|:|and|.|hypokalaemia|Initial (r_compound) loss_2\NN\13252973|NONE (l_conj) hypokalaemia_4\NN\0|influence|:|and|.|potassium|Initial (l_prep) during_5\IN\0|NONE (l_pobj) administration_7\NN\1133281|NONE (l_prep) in_8\IN\13603305|chlorthalidone (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
D011188_D006973 NONE potassium_4\NN\14625458|development|and|initial|during|the (r_compound) loss_5\NN\13252973|To (r_dobj) investigate_1\VB\644583|.|were|in (r_csubjpass) performed_22\VBN\0|NONE (l_prep) in_23\IN\13603305|.|were|investigate (l_pobj) patients_25\NNS\9898892|NONE (l_prep) with_26\IN\0|ten (l_pobj) hypertension_28\NN\14057371|NONE
D002752_D007008 CID chlorthalidone_6\NN\3214670|in (r_compound) administration_7\NN\1133281|NONE (r_pobj) during_5\IN\0|NONE (r_prep) hypokalaemia_4\NN\0|influence|:|and|.|potassium|Initial
D012964_D006973 NONE sodium_18\NN\14625458|dietary (r_compound) restriction_19\NN\5846054|NONE (r_pobj) of_16\IN\0|the (r_prep) influence_15\NN\5190804|:|and|.|potassium|hypokalaemia|Initial (r_appos) loss_2\NN\13252973|NONE (l_conj) hypokalaemia_4\NN\0|influence|:|and|.|potassium|Initial (l_prep) during_5\IN\0|NONE (l_pobj) administration_7\NN\1133281|NONE (l_prep) in_8\IN\13603305|chlorthalidone (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
12042105
C052342_D053040 CID topiramate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|. (r_amod) nephrolithiasis_3\NN\14115914|NONE
C052342_D053040 CID topiramate_7\RB\0| (r_npadvmod) induced_9\VBN\1627355|in (r_amod) nephrolithiasis_10\NN\14115914|NONE
C052342_D004827 NONE topiramate_0\NNP\0|.|medication (r_nsubj) is_1\VBZ\0|NONE (l_attr) medication_6\NN\3247620|.|Topiramate (l_relcl) becoming_9\VBG\146138|a|antiepileptic|developed (l_prep) because_13\IN\0|prescribed|is|that (l_pobj) efficacy_16\NN\5199286|of (l_prep) in_17\IN\13603305|its (l_pcomp) treating_18\VBG\2376958|NONE (l_dobj) seizures_20\NNS\14081375|NONE
C020243_D053040 NONE phosphate_29\NN\15010703|NONE (r_compound) nephrolithiasis_30\NN\14115914|NONE
15858223
D005978_D056486 NONE glutathione_11\NN\0|)||GST|(|S (r_compound) transferase_14\NNP\14732946|NONE (r_pobj) of_8\IN\0|serum (r_prep) levels_7\NNS\4916342|and|by (r_pobj) on_5\IN\0|NONE (r_prep) based_4\VBN\0|toxicity|was|. (r_prep) evaluated_3\VBN\670261|NONE (l_nsubjpass) toxicity_1\NN\13576101|was|based|.
C075750_D009336 NONE 15-f(2t)-isop_18\CD\0|NONE (r_pobj) of_17\IN\0|,|precedes (r_prep) levels_16\NNS\4916342|NONE (l_relcl) precedes_21\VBZ\0|,|of (l_dobj) onset_23\NN\7325190|which (l_prep) of_24\IN\0|the (l_pobj) necrosis_25\NN\11444117|NONE
D014635_D005234 CID vpa_6\NNP\0|treatment|,|that|in|measured (r_compound) results_8\NNS\34213|.|,|findings|Overall (l_advcl) measured_14\VBN\697589|treatment|VPA|,|that|in (l_agent) by_15\IN\0|as (l_pobj) levels_16\NNS\4916342|NONE (l_relcl) precedes_21\VBZ\0|,|of (l_dobj) onset_23\NN\7325190|which (l_prep) of_24\IN\0|the (l_pobj) necrosis_25\NN\11444117|NONE (l_conj) steatosis_27\NN\0|,
D014635_D056486 CID acid_14\NN\14818238|NONE (r_compound) metabolite_15\NN\20090|valproic|in (r_amod) levels_16\NNS\4916342|liver|,|and (r_conj) toxicity_10\NN\13576101|,|peroxidation
D014635_D056486 CID vpa_9\NNP\0| (r_npadvmod) associated_11\VBN\628491|and|oxidative|hepatotoxicity|, (r_amod) stress_13\NN\7083732|NONE (l_conj) hepatotoxicity_15\NN\0|and|oxidative|associated|,
D014635_D056486 CID vpa_27\NNP\0|NONE (r_pobj) with_26\IN\0|rats|ip|were|.|daily|for|determine (r_prep) treated_24\VBN\2376958|NONE (l_advcl) determine_1\VB\0|rats|ip|with|were|.|daily|for (l_ccomp) was_4\VBD\0|To (l_attr) relationship_7\NN\31921|whether|there (l_prep) between_8\IN\0|a|temporal (l_pobj) stress_13\NN\7083732|NONE (l_conj) hepatotoxicity_15\NN\0|and|oxidative|associated|,
D014635_D009336 CID vpa_6\NNP\0|treatment|,|that|in|measured (r_compound) results_8\NNS\34213|.|,|findings|Overall (l_advcl) measured_14\VBN\697589|treatment|VPA|,|that|in (l_agent) by_15\IN\0|as (l_pobj) levels_16\NNS\4916342|NONE (l_relcl) precedes_21\VBZ\0|,|of (l_dobj) onset_23\NN\7325190|which (l_prep) of_24\IN\0|the (l_pobj) necrosis_25\NN\11444117|NONE
C075750_D005234 NONE 15-f(2t)-isop_18\CD\0|NONE (r_pobj) of_17\IN\0|,|precedes (r_prep) levels_16\NNS\4916342|NONE (l_relcl) precedes_21\VBZ\0|,|of (l_dobj) onset_23\NN\7325190|which (l_prep) of_24\IN\0|the (l_pobj) necrosis_25\NN\11444117|NONE (l_conj) steatosis_27\NN\0|,
16820346
D013481_D006973 NONE superoxide_25\RB\14971519|plasma (r_advmod) decreased_23\VBD\169651|)|mmHg|,|mmHg|hypertension|and|Atorva|vs. (r_conj) reversed_1\VBN\109660|NONE (l_dobj) hypertension_5\NN\14057371|)|mmHg|,|mmHg|decreased|and|Atorva|vs.
D003907_D006973 CID dexamethasone_4\NN\2721538| (r_npadvmod) induced_6\VBN\1627355|in (r_amod) hypertension_7\NN\14057371|NONE
D003907_D006973 CID dexamethasone_11\NN\2721538|NONE (l_appos) hypertension_14\NN\14057371|(
D003907_D006973 CID dex)-induced_13\VBN\0|, (r_amod) hypertension_14\NN\14057371|(
D003907_D006973 CID dex_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|+/ (r_amod) hypertension_5\NN\14057371|)|mmHg|,|mmHg|decreased|and|Atorva|vs.
D003907_D006973 CID dexamethasone_6\NN\2721538| (r_npadvmod) induced_8\VBN\1627355|in (r_amod) hypertension_9\NN\14057371|NONE
C065179_D006973 NONE atorvastatin_0\NNS\3676175|reversed|and|. (r_nsubj) prevented_1\VBD\0|NONE (l_conj) reversed_3\VBD\109660|and|.|Atorvastatin (l_dobj) hypertension_7\NN\14057371|NONE
C065179_D006973 NONE atorvastatin_6\NN\3676175|)|( (r_nmod) atorva_8\NN\0|NONE (r_pobj) of_5\IN\0|antioxidant|on|the (r_prep) effects_4\NNS\13245626|To (l_prep) on_10\IN\0|antioxidant|the|of (l_pobj) dexamethasone_11\NN\2721538|NONE (l_appos) hypertension_14\NN\14057371|(
C065179_D006973 NONE atorva_8\NN\0|NONE (r_pobj) of_5\IN\0|antioxidant|on|the (r_prep) effects_4\NNS\13245626|To (l_prep) on_10\IN\0|antioxidant|the|of (l_pobj) dexamethasone_11\NN\2721538|NONE (l_appos) hypertension_14\NN\14057371|(
C065179_D006973 NONE atorva_25\NN\0|tap|kg (r_nmod) water_34\NN\14618834|NONE (r_pobj) with_24\IN\0|were|assess|.|for|rats (r_prep) treated_23\VBN\2376958|NONE (l_advcl) assess_1\VB\5220461|were|with|.|for|rats (l_dobj) effects_4\NNS\13245626|To (l_prep) on_10\IN\0|antioxidant|the|of (l_pobj) dexamethasone_11\NN\2721538|NONE (l_appos) hypertension_14\NN\14057371|(
C065179_D006973 NONE atorva_0\NN\0|)|mmHg|,|mmHg|decreased|hypertension|and|vs. (r_nsubj) reversed_1\VBN\109660|NONE (l_dobj) hypertension_5\NN\14057371|)|mmHg|,|mmHg|decreased|and|Atorva|vs.
C065179_D006973 NONE atorvastatin_2\NN\3676175|,|.|and|reversed|Thus (r_nsubj) prevented_3\VBN\0|NONE (l_conj) reversed_5\VBN\109660|,|.|atorvastatin|and|Thus (l_dobj) hypertension_9\NN\14057371|NONE
18674790
D004317_D009765 NONE doxorubicin_11\RB\2716866| (r_npadvmod) induced_13\VBN\1627355|NONE (r_compound) cardiotoxicity_14\NN\0|NONE (r_pobj) to_10\IN\0|highly (r_prep) sensitive_9\JJ\10488309|rats|. (r_acomp) are_7\VBP\13600404|NONE (l_nsubj) rats_6\NNS\2329401|sensitive|. (l_amod) obese_5\JJ\0|fed|fat|High
D004317_D009765 NONE doxorubicin_40\RB\2716866| (r_npadvmod) induced_42\VBN\1627355|NONE (r_compound) cardiotoxicity_43\NN\0|NONE (r_pobj) to_39\IN\0|intervention|,|whether (r_prep) sensitizes_38\VBZ\126264|we|.|,|In (l_nsubj) intervention_10\NN\1239064|to|,|whether (l_prep) by_11\IN\0|physiological|a (l_pcomp) feeding_12\VBG\838098|NONE (l_dobj) diet_17\NN\7560652|NONE (l_relcl) induces_23\VBZ\1627355|,|HFD|fat|)|(|high|% (l_dobj) obesity_24\NN\4999401|g|which
D004317_D009765 NONE doxorubicin_7\NN\2716866|/|mg|ip|(|)|, (r_nmod) kg_9\NNS\13717155|.|LD(|administered|A (r_appos) dose_3\NN\3740161|NONE (l_acl) administered_13\VBN\2436349|.|LD(|kg|A (l_prep) on_14\IN\0|NONE (l_pobj) day_15\NN\15154774|NONE (l_nummod) 43_16\CD\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimen_21\NN\5898568|NONE (l_acl) led_22\VBD\3202760|the|HFD|feeding (l_prep) to_23\IN\0|NONE (l_pobj) cardiotoxicity_25\NN\0|NONE (l_conj) dysfunction_28\NN\14204950|higher|, (l_conj) peroxidation_31\NN\0|,|cardiac (l_conj) mortality_36\NN\5054863|lipid|,|and (l_prep) in_37\IN\13603305|in|% (l_pobj) rats_43\NNS\2329401|NONE (l_amod) obese_39\JJ\0|the|)|OB|(
D004317_D009765 NONE doxorubicin_7\NN\2716866|/|mg|ip|(|)|, (r_nmod) kg_9\NNS\13717155|.|LD(|administered|A (r_appos) dose_3\NN\3740161|NONE (l_acl) administered_13\VBN\2436349|.|LD(|kg|A (l_prep) on_14\IN\0|NONE (l_pobj) day_15\NN\15154774|NONE (l_nummod) 43_16\CD\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimen_21\NN\5898568|NONE (l_acl) led_22\VBD\3202760|the|HFD|feeding (l_prep) to_23\IN\0|NONE (l_pobj) cardiotoxicity_25\NN\0|NONE (l_conj) dysfunction_28\NN\14204950|higher|, (l_conj) peroxidation_31\NN\0|,|cardiac (l_conj) mortality_36\NN\5054863|lipid|,|and (l_prep) in_37\IN\13603305|in|% (l_pobj) rats_43\NNS\2329401|NONE (l_nmod) ob_41\NNP\0|the|)|obese|(
D004317_D009765 NONE doxorubicin_0\NNP\2716866|NONE (r_compound) toxicokinetics_1\NNS\0|NONE (r_compound) studies_2\NNS\635850|.|change (r_nsubj) revealed_3\VBD\2137132|NONE (l_dobj) change_5\NN\7283608|.|studies (l_conj) hearts_27\NNS\496167|no|and|in|)|in (l_compound) ob_26\NNP\0|NONE
D004317_D009765 NONE doxorubicin_9\NN\2716866|NONE (r_pobj) of_8\IN\0|NONE (r_prep) accumulation_7\NN\13497135|NONE (r_pobj) in_6\IN\13603305|hearts|no|and|in|) (r_prep) change_5\NN\7283608|.|studies (l_conj) hearts_27\NNS\496167|no|and|in|)|in (l_compound) ob_26\NNP\0|NONE
D004317_D009765 NONE doxorubicin_109\NN\2716866|NONE (r_compound) administration_110\NN\1133281|NONE (r_pobj) after_108\IN\0|ADP|decreased (r_prep) ratio_107\NN\13815152|NONE (r_pobj) by_102\IN\0|NONE (r_agent) accompanied_101\VBN\0|%|)|in||( (r_acl) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (r_ccomp) revealed_2\VBD\2137132|NONE (l_ccomp) sensitized_7\VBN\126264|studies|decreased|. (l_nsubjpass) rats_5\NNS\2329401|that|due|are (l_compound) ob_4\NNP\0|NONE
D004317_D009765 NONE doxorubicin_109\NN\2716866|NONE (r_compound) administration_110\NN\1133281|NONE (r_pobj) after_108\IN\0|ADP|decreased (r_prep) ratio_107\NN\13815152|NONE (r_pobj) by_102\IN\0|NONE (r_agent) accompanied_101\VBN\0|%|)|in||( (r_acl) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (l_nsubj) stress_16\NN\7083732|drop|,|and|kinase (l_acl) activated_35\VBN\1641914|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN\13447361|alpha|downregulation (l_appos) heart_64\NN\5919034|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN\0|min|g|)|in (l_pobj) heart_74\NN\5919034|NONE (l_prep) in_75\IN\13603305|g|.+/. (l_pobj) ob_76\NNP\0|NONE
D004317_D009765 NONE doxorubicin_12\RB\2716866| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) cardiotoxicity_15\NN\0|NONE (r_pobj) to_11\IN\0|highly|by (r_prep) sensitized_10\JJ\126264|.|,|In|rats (r_acomp) are_8\VBP\13600404|NONE (l_nsubj) rats_7\NNS\2329401|.|sensitized|,|In (l_amod) obese_6\JJ\0|induced
D004317_D066126 NONE doxorubicin_11\RB\2716866| (r_npadvmod) induced_13\VBN\1627355|NONE (r_compound) cardiotoxicity_14\NN\0|NONE
D004317_D066126 NONE doxorubicin_4\NN\2716866|NONE (r_pobj) by_3\IN\0|NONE (r_prep) chemotherapy_2\NN\661091|due|Often|,|is|. (r_nsubjpass) limited_9\VBN\4019101|NONE (l_prep) due_10\IN\5174653|Often|,|chemotherapy|is|. (l_pobj) life_12\NN\13954253|to (l_acl) threatening_13\VBG\2603699|NONE (l_dobj) cardiotoxicity_14\NN\0|during
D004317_D066126 NONE adriamycin_6\NNP\0|NONE (r_punct) )_7\-RRB-\0|NONE (r_punct) is_8\VBZ\0|due|Often|,|chemotherapy|. (r_auxpass) limited_9\VBN\4019101|NONE (l_prep) due_10\IN\5174653|Often|,|chemotherapy|is|. (l_pobj) life_12\NN\13954253|to (l_acl) threatening_13\VBG\2603699|NONE (l_dobj) cardiotoxicity_14\NN\0|during
D004317_D066126 NONE doxorubicin_12\RB\2716866| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) cardiotoxicity_15\NN\0|NONE
D004317_D066126 NONE doxorubicin_40\RB\2716866| (r_npadvmod) induced_42\VBN\1627355|NONE (r_compound) cardiotoxicity_43\NN\0|NONE
D004317_D066126 NONE doxorubicin_7\NN\2716866|/|mg|ip|(|)|, (r_nmod) kg_9\NNS\13717155|.|LD(|administered|A (r_appos) dose_3\NN\3740161|NONE (l_acl) administered_13\VBN\2436349|.|LD(|kg|A (l_prep) on_14\IN\0|NONE (l_pobj) day_15\NN\15154774|NONE (l_nummod) 43_16\CD\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimen_21\NN\5898568|NONE (l_acl) led_22\VBD\3202760|the|HFD|feeding (l_prep) to_23\IN\0|NONE (l_pobj) cardiotoxicity_25\NN\0|NONE
D004317_D066126 NONE doxorubicin_12\RB\2716866| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) cardiotoxicity_15\NN\0|NONE
C010013_D009765 NONE doxorubicinol_11\NN\0|and (r_conj) doxorubicin_9\NN\2716866|NONE (r_pobj) of_8\IN\0|NONE (r_prep) accumulation_7\NN\13497135|NONE (r_pobj) in_6\IN\13603305|hearts|no|and|in|) (r_prep) change_5\NN\7283608|.|studies (l_conj) hearts_27\NNS\496167|no|and|in|)|in (l_compound) ob_26\NNP\0|NONE
D004317_D056486 NONE doxorubicin_7\NN\2716866|/|mg|ip|(|)|, (r_nmod) kg_9\NNS\13717155|.|LD(|administered|A (r_appos) dose_3\NN\3740161|NONE (l_acl) administered_13\VBN\2436349|.|LD(|kg|A (l_prep) on_14\IN\0|NONE (l_pobj) day_15\NN\15154774|NONE (l_nummod) 43_16\CD\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimen_21\NN\5898568|NONE (l_acl) led_22\VBD\3202760|the|HFD|feeding (l_prep) to_23\IN\0|NONE (l_pobj) cardiotoxicity_25\NN\0|NONE (l_conj) dysfunction_28\NN\14204950|higher|, (l_conj) peroxidation_31\NN\0|,|cardiac (l_conj) mortality_36\NN\5054863|lipid|,|and (l_prep) in_44\IN\13603305|%|in (l_pobj) absence_46\NN\14449405|NONE (l_prep) of_47\IN\0|the (l_pobj) toxicity_53\NN\13576101|NONE
D000255_D066126 NONE atp_21\NNP\14964590|mitochondrial|cardiac (r_compound) generation_22\NN\7942152|substantially|,|increasing (r_dobj) downregulating_18\VBG\0|NONE (r_pcomp) by_16\IN\0|to|highly (r_prep) sensitized_10\JJ\126264|.|,|In|rats (l_prep) to_11\IN\0|highly|by (l_pobj) cardiotoxicity_15\NN\0|NONE
D004041_D066126 NONE fat_1\JJ\14938907|fed|High|obese (r_amod) rats_6\NNS\2329401|sensitive|. (r_nsubj) are_7\VBP\13600404|NONE (l_acomp) sensitive_9\JJ\10488309|rats|. (l_prep) to_10\IN\0|highly (l_pobj) cardiotoxicity_14\NN\0|NONE
D004041_D066126 NONE fat_16\JJ\14938907|,|HFD|)|(|high|%|induces (r_amod) diet_17\NN\7560652|NONE (r_dobj) feeding_12\VBG\838098|NONE (r_pcomp) by_11\IN\0|physiological|a (r_prep) intervention_10\NN\1239064|to|,|whether (r_nsubj) sensitizes_38\VBZ\126264|we|.|,|In (l_prep) to_39\IN\0|intervention|,|whether (l_pobj) cardiotoxicity_43\NN\0|NONE
D004317_D007674 NONE doxorubicin_7\NN\2716866|/|mg|ip|(|)|, (r_nmod) kg_9\NNS\13717155|.|LD(|administered|A (r_appos) dose_3\NN\3740161|NONE (l_acl) administered_13\VBN\2436349|.|LD(|kg|A (l_prep) on_14\IN\0|NONE (l_pobj) day_15\NN\15154774|NONE (l_nummod) 43_16\CD\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimen_21\NN\5898568|NONE (l_acl) led_22\VBD\3202760|the|HFD|feeding (l_prep) to_23\IN\0|NONE (l_pobj) cardiotoxicity_25\NN\0|NONE (l_conj) dysfunction_28\NN\14204950|higher|, (l_conj) peroxidation_31\NN\0|,|cardiac (l_conj) mortality_36\NN\5054863|lipid|,|and (l_prep) in_44\IN\13603305|%|in (l_pobj) absence_46\NN\14449405|NONE (l_prep) of_47\IN\0|the (l_pobj) toxicity_53\NN\13576101|NONE
D000244_D009765 NONE adp_106\NNP\14964590|after|decreased (r_compound) ratio_107\NN\13815152|NONE (r_pobj) by_102\IN\0|NONE (r_agent) accompanied_101\VBN\0|%|)|in||( (r_acl) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (r_ccomp) revealed_2\VBD\2137132|NONE (l_ccomp) sensitized_7\VBN\126264|studies|decreased|. (l_nsubjpass) rats_5\NNS\2329401|that|due|are (l_compound) ob_4\NNP\0|NONE
D000244_D009765 NONE adp_106\NNP\14964590|after|decreased (r_compound) ratio_107\NN\13815152|NONE (r_pobj) by_102\IN\0|NONE (r_agent) accompanied_101\VBN\0|%|)|in||( (r_acl) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (l_nsubj) stress_16\NN\7083732|drop|,|and|kinase (l_acl) activated_35\VBN\1641914|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN\13447361|alpha|downregulation (l_appos) heart_64\NN\5919034|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN\0|min|g|)|in (l_pobj) heart_74\NN\5919034|NONE (l_prep) in_75\IN\13603305|g|.+/. (l_pobj) ob_76\NNP\0|NONE
D004041_D009765 CID fat_1\JJ\14938907|fed|High|obese (r_amod) rats_6\NNS\2329401|sensitive|. (l_amod) obese_5\JJ\0|fed|fat|High
D004041_D009765 CID fat_16\JJ\14938907|,|HFD|)|(|high|%|induces (r_amod) diet_17\NN\7560652|NONE (l_relcl) induces_23\VBZ\1627355|,|HFD|fat|)|(|high|% (l_dobj) obesity_24\NN\4999401|g|which
D004317_D006331 CID doxorubicin_7\NN\2716866|/|mg|ip|(|)|, (r_nmod) kg_9\NNS\13717155|.|LD(|administered|A (r_appos) dose_3\NN\3740161|NONE (l_acl) administered_13\VBN\2436349|.|LD(|kg|A (l_prep) on_14\IN\0|NONE (l_pobj) day_15\NN\15154774|NONE (l_nummod) 43_16\CD\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimen_21\NN\5898568|NONE (l_acl) led_22\VBD\3202760|the|HFD|feeding (l_prep) to_23\IN\0|NONE (l_pobj) cardiotoxicity_25\NN\0|NONE (l_conj) dysfunction_28\NN\14204950|higher|,
D000255_D009765 NONE atp_99\NNP\14964590|cardiac (r_compound) levels_100\NNS\4916342|NONE (r_pobj) in_97\IN\13603305|%|)||accompanied|( (r_prep) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (r_ccomp) revealed_2\VBD\2137132|NONE (l_ccomp) sensitized_7\VBN\126264|studies|decreased|. (l_nsubjpass) rats_5\NNS\2329401|that|due|are (l_compound) ob_4\NNP\0|NONE
D000255_D009765 NONE atp_99\NNP\14964590|cardiac (r_compound) levels_100\NNS\4916342|NONE (r_pobj) in_97\IN\13603305|%|)||accompanied|( (r_prep) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (l_nsubj) stress_16\NN\7083732|drop|,|and|kinase (l_acl) activated_35\VBN\1641914|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN\13447361|alpha|downregulation (l_appos) heart_64\NN\5919034|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN\0|min|g|)|in (l_pobj) heart_74\NN\5919034|NONE (l_prep) in_75\IN\13603305|g|.+/. (l_pobj) ob_76\NNP\0|NONE
D000255_D009765 NONE atp_104\NNP\14964590|/ (r_nmod) adp_106\NNP\14964590|after|decreased (r_compound) ratio_107\NN\13815152|NONE (r_pobj) by_102\IN\0|NONE (r_agent) accompanied_101\VBN\0|%|)|in||( (r_acl) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (r_ccomp) revealed_2\VBD\2137132|NONE (l_ccomp) sensitized_7\VBN\126264|studies|decreased|. (l_nsubjpass) rats_5\NNS\2329401|that|due|are (l_compound) ob_4\NNP\0|NONE
D000255_D009765 NONE atp_104\NNP\14964590|/ (r_nmod) adp_106\NNP\14964590|after|decreased (r_compound) ratio_107\NN\13815152|NONE (r_pobj) by_102\IN\0|NONE (r_agent) accompanied_101\VBN\0|%|)|in||( (r_acl) drop_96\NN\13899200|stress|,|and|kinase (r_conj) decreased_82\VBD\169651|studies|sensitized|. (l_nsubj) stress_16\NN\7083732|drop|,|and|kinase (l_acl) activated_35\VBN\1641914|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN\13447361|alpha|downregulation (l_appos) heart_64\NN\5919034|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN\0|min|g|)|in (l_pobj) heart_74\NN\5919034|NONE (l_prep) in_75\IN\13603305|g|.+/. (l_pobj) ob_76\NNP\0|NONE
D000255_D009765 NONE atp_21\NNP\14964590|mitochondrial|cardiac (r_compound) generation_22\NN\7942152|substantially|,|increasing (r_dobj) downregulating_18\VBG\0|NONE (r_pcomp) by_16\IN\0|to|highly (r_prep) sensitized_10\JJ\126264|.|,|In|rats (r_acomp) are_8\VBP\13600404|NONE (l_nsubj) rats_7\NNS\2329401|.|sensitized|,|In (l_amod) obese_6\JJ\0|induced
D000249_D009765 NONE amp_84\NN\13633375| (r_compound) alpha2_86\NN\0|mitochondrial|protein (r_compound) kinase_88\NN\14732946|drop|stress|,|and (r_dobj) decreased_82\VBD\169651|studies|sensitized|. (r_ccomp) revealed_2\VBD\2137132|NONE (l_ccomp) sensitized_7\VBN\126264|studies|decreased|. (l_nsubjpass) rats_5\NNS\2329401|that|due|are (l_compound) ob_4\NNP\0|NONE
D000249_D009765 NONE amp_84\NN\13633375| (r_compound) alpha2_86\NN\0|mitochondrial|protein (r_compound) kinase_88\NN\14732946|drop|stress|,|and (r_dobj) decreased_82\VBD\169651|studies|sensitized|. (l_nsubj) stress_16\NN\7083732|drop|,|and|kinase (l_acl) activated_35\VBN\1641914|higher|oxyradical||)|(|leading (l_dobj) oxidation_56\NN\13447361|alpha|downregulation (l_appos) heart_64\NN\5919034|acid|)|(|cardiac||decreased|, (l_prep) versus_67\IN\0|min|g|)|in (l_pobj) heart_74\NN\5919034|NONE (l_prep) in_75\IN\13603305|g|.+/. (l_pobj) ob_76\NNP\0|NONE
8424298
D007530_D007022 CID isoflurane_8\NN\3570838|NONE (r_pobj) with_7\IN\0|NONE (r_prep) labetalol_6\NN\2721160|NONE (r_pobj) by_5\IN\0|NONE (r_agent) induced_4\VBN\1627355|deliberate (r_acl) hypotension_3\NN\14057371|NONE
D007530_D007022 CID isoflurane_18\JJ\3570838|(|hypotensive (r_amod) group_21\NN\2137|NONE (r_pobj) with_17\IN\0|NONE (r_prep) labetalol_16\NN\2721160|NONE (r_pobj) by_15\IN\0|NONE (r_agent) induced_14\VBN\1627355|deliberate (r_acl) hypotension_13\NN\14057371|NONE
D007530_D007022 CID isoflurane_18\JJ\3570838|(|hypotensive (r_amod) group_21\NN\2137|NONE (l_amod) hypotensive_20\JJ\10405694|(|isoflurane
D007530_D007022 CID isoflurane_9\NN\3570838|NONE (r_pobj) with_8\IN\0|NONE (r_prep) labetalol_7\NN\2721160|NONE (r_pobj) by_6\IN\0|hypotension|that (r_prep) induced_5\VBN\1627355|has|.|results (l_nsubj) hypotension_4\NN\14057371|that|by
D007741_D007022 CID labetalol_6\NN\2721160|NONE (r_pobj) by_5\IN\0|NONE (r_agent) induced_4\VBN\1627355|deliberate (r_acl) hypotension_3\NN\14057371|NONE
D007741_D007022 CID labetalol_16\NN\2721160|NONE (r_pobj) by_15\IN\0|NONE (r_agent) induced_14\VBN\1627355|deliberate (r_acl) hypotension_13\NN\14057371|NONE
D007741_D007022 CID labetalol_16\NN\2721160|NONE (l_prep) with_17\IN\0|NONE (l_pobj) group_21\NN\2137|NONE (l_amod) hypotensive_20\JJ\10405694|(|isoflurane
D007741_D007022 CID labetalol_7\NN\2721160|NONE (r_pobj) by_6\IN\0|hypotension|that (r_prep) induced_5\VBN\1627355|has|.|results (l_nsubj) hypotension_4\NN\14057371|that|by
9758264
D005492_D008180 CID acid_4\NN\14818238|NONE (r_pobj) of_2\IN\0|Epileptogenic (r_prep) activity_1\NN\30358|SLE|after|) (r_nsubj) induces_7\VBZ\1627355|NONE (l_dobj) sle_8\NNP\14229912|activity|after|)
D005492_D008180 CID acid_11\NN\14818238|( (r_appos) sle_8\NNP\14229912|activity|after|)
D005492_D008180 CID acid_35\NN\14818238|NONE (r_pobj) of_33\IN\0|>|(|therapeutic|the|) (r_prep) dose_25\NN\3740161|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD\1641914|NONE (l_ccomp) damage_15\VB\7296428|cluster|therefore|.|,|dose (l_nsubj) disease_6\NN\14061805|barrier|could (l_appos) lupus_12\NN\14219661|)|(|autoimmune|patient
D005492_D012640 CID acid_35\NN\14818238|NONE (r_pobj) of_33\IN\0|>|(|therapeutic|the|) (r_prep) dose_25\NN\3740161|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD\1641914|NONE (l_dobj) cluster_38\NN\7959269|damage|therefore|.|,|dose (l_prep) of_39\IN\0|a (l_pobj) seizures_40\NNS\14081375|NONE
D005492_D001327 NONE acid_35\NN\14818238|NONE (r_pobj) of_33\IN\0|>|(|therapeutic|the|) (r_prep) dose_25\NN\3740161|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD\1641914|NONE (l_ccomp) damage_15\VB\7296428|cluster|therefore|.|,|dose (l_nsubj) disease_6\NN\14061805|barrier|could
D005492_D001327 NONE acid_9\NN\14818238|NONE (r_pobj) of_7\IN\0|(|)|<| (r_prep) mg_5\NN\13717155|,|in|,|Physiological|without (r_appos) dose_1\NN\3740161|did|not|risk|. (l_prep) without_19\IN\0|mg|,|in|,|Physiological (l_pobj) disease_22\NN\14061805|all
D005492_D004827 NONE acid_4\NN\14818238|NONE (r_pobj) of_2\IN\0|Epileptogenic (r_prep) activity_1\NN\30358|SLE|after|) (r_nsubj) induces_7\VBZ\1627355|NONE (l_dobj) sle_8\NNP\14229912|activity|after|) (l_appos) acid_11\NN\14818238|( (l_conj) epilepsy_13\NN\14085708|folic|and
D005492_D004827 NONE acid_11\NN\14818238|( (l_conj) epilepsy_13\NN\14085708|folic|and
D005492_D004827 NONE acid_6\NN\14818238| (r_npadvmod) containing_8\VBG\2632940|folic|multivitamin|in (r_amod) supplementation_10\NN\5108947|NONE (l_prep) in_11\IN\13603305|folic|multivitamin|containing (l_pobj) women_13\NNS\9605289|NONE (l_amod) epileptic_12\JJ\10595647|NONE
D005492_D004827 NONE acid_6\NN\14818238| (r_npadvmod) containing_8\VBG\2632940|folic|multivitamin|in (r_amod) supplementation_10\NN\5108947|NONE (r_pobj) of_4\IN\0|the (r_prep) effect_3\NN\34213|To|in|.|before (r_dobj) study_1\VB\635850|NONE (l_prep) in_18\IN\13603305|effect|To|.|before (l_pobj) order_19\NN\7168131|NONE (l_acl) determine_21\VB\0|NONE (l_dobj) rate_23\NN\13815152|to (l_prep) of_24\IN\0|the (l_pobj) defects_27\NNS\14462666|NONE (l_conj) effects_33\NNS\13245626|and|birth|structural (l_amod) related_31\VBN\628491|side (l_npadvmod) epilepsy_29\NN\14085708|
D005492_D004827 NONE acid_7\NN\14818238|NONE (r_pobj) with_4\IN\0|.||epileptic (r_prep) women_3\NNS\9605289|NONE (l_amod) epileptic_2\JJ\10595647|.||with
D005492_D004827 NONE acid_7\NN\14818238|NONE (l_appos) effects_21\NNS\13245626|supplementation|folic|,|periconceptional|( (l_amod) related_19\VBN\628491|during|developed|side (l_npadvmod) epilepsy_17\NN\14085708|
D005492_D004827 NONE acid_14\NN\14818238|and (r_conj) carbamazepine_10\NN\0|NONE (r_pobj) by_9\IN\0|was|.|continuously|woman (r_agent) treated_7\VBN\2376958|NONE (l_nsubjpass) woman_5\NN\9605289|by|was|.|continuously (l_amod) epileptic_4\JJ\10595647|old|This
D005492_D004827 NONE acid_35\NN\14818238|NONE (r_pobj) of_33\IN\0|>|(|therapeutic|the|) (r_prep) dose_25\NN\3740161|damage|cluster|therefore|.|, (r_nsubj) triggered_36\VBD\1641914|NONE (l_ccomp) damage_15\VB\7296428|cluster|therefore|.|,|dose (l_nsubj) disease_6\NN\14061805|barrier|could (l_poss) patient_3\NN\9898892|)|lupus|(|autoimmune (l_amod) epileptic_1\JJ\10595647|'s|pregnant|The
D005492_D004827 NONE acid_9\NN\14818238|NONE (r_pobj) of_7\IN\0|(|)|<| (r_prep) mg_5\NN\13717155|,|in|,|Physiological|without (r_appos) dose_1\NN\3740161|did|not|risk|. (l_prep) in_11\IN\13603305|mg|,|,|Physiological|without (l_pobj) women_16\NNS\9605289|both (l_amod) epileptic_15\JJ\10595647|healthy|
D005492_D004827 NONE acid_9\NN\14818238|NONE (r_pobj) of_7\IN\0|(|)|<| (r_prep) mg_5\NN\13717155|,|in|,|Physiological|without (r_appos) dose_1\NN\3740161|did|not|risk|. (r_nsubj) increase_26\VB\13576355|NONE (l_dobj) risk_28\NN\14541044|did|not|.|dose (l_prep) for_29\IN\0|the (l_pobj) seizures_31\NNS\14081375|NONE
D002220_D004827 NONE carbamazepine_10\NN\0|NONE (r_pobj) by_9\IN\0|was|.|continuously|woman (r_agent) treated_7\VBN\2376958|NONE (l_nsubjpass) woman_5\NN\9605289|by|was|.|continuously (l_amod) epileptic_4\JJ\10595647|old|This
D005492_D000014 NONE acid_6\NN\14818238| (r_npadvmod) containing_8\VBG\2632940|folic|multivitamin|in (r_amod) supplementation_10\NN\5108947|NONE (r_pobj) of_4\IN\0|the (r_prep) effect_3\NN\34213|To|in|.|before (r_dobj) study_1\VB\635850|NONE (l_prep) in_18\IN\13603305|effect|To|.|before (l_pobj) order_19\NN\7168131|NONE (l_acl) determine_21\VB\0|NONE (l_dobj) rate_23\NN\13815152|to (l_prep) of_24\IN\0|the (l_pobj) defects_27\NNS\14462666|NONE
9875685
D014031_D064420 NONE tobramicyn_17\NN\0|NONE (l_prep) on_18\IN\0|NONE (l_pobj) concentrations_23\NNS\4916342|NONE (l_conj) toxicity_25\NN\13576101|and|serum|state
D003404_D007674 NONE creatinine_2\NN\0|.|was|versus|in|,|without (r_nsubjpass) observed_4\VBN\2163746|NONE (l_prep) without_20\IN\0|.|creatinine|was|versus|in|, (l_pobj) evidence_21\NN\5816287|NONE (l_prep) of_22\IN\0|NONE (l_pobj) nephrotoxicity_23\NN\0|NONE
20331935
D013739_D006966 NONE testosterone_1\NN\14747587|Serum (r_compound) concentration_2\NN\4916342|.|affected|but|with (r_nsubj) increased_3\VBD\169651|NONE (l_conj) affected_10\VBN\126264|.|but|with|concentration (l_agent) by_11\IN\0|was|not (l_pobj) hyperprolactinemia_12\NN\0|NONE
D018967_D050723 NONE risperidone_8\NN\0|were|after (r_nsubjpass) started_12\VBN\0||and|occurred|fractures|, (r_advcl) occurred_6\VBD\0|NONE (l_nsubj) fractures_3\NNS\14285662||and|occurred|started|,
D018967_D006966 CID risperidone_12\NN\0| (r_npadvmod) induced_14\VBN\1627355|on (r_amod) hyperprolactinemia_15\NN\0|NONE
D018967_D006966 CID risperidone_17\NN\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) treated_15\VBN\2376958|of| (r_acl) %_6\NN\0|NONE (r_pobj) in_4\IN\13603305|NONE (r_prep) present_3\JJ\28270|:|Hyperprolactinemia|. (r_acomp) was_2\VBD\0|NONE (l_nsubj) hyperprolactinemia_1\NNP\0|:|.|present
D018967_D006966 CID risperidone_8\NN\0|were|after (r_nsubjpass) started_12\VBN\0||and|occurred|fractures|, (r_advcl) occurred_6\VBD\0|NONE (l_conj) occurred_16\VBD\0||and|fractures|started|, (l_prep) in_17\IN\13603305|none|. (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) hyperprolactinemia_20\NN\0|NONE
D018967_D006966 CID risperidone_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|treatment|and (r_amod) hyperprolactinemia_10\NN\0|to|lower
16225977
C076029_D013981 NONE olanzapine_13\NN\0|, (r_conj) risperidone_11\NN\0|such (r_pobj) as_10\IN\14622893|atypical (r_prep) antipsychotics_8\NNS\4470232|NONE (r_pobj) by_6\IN\0|can|disorders|be|.|effectively (r_agent) treated_5\VBN\2376958|NONE (l_nsubjpass) disorders_1\NNS\14034177|can|by|be|.|effectively
C092292_D013981 NONE ziprasidone_15\NN\0|and (r_conj) olanzapine_13\NN\0|, (r_conj) risperidone_11\NN\0|such (r_pobj) as_10\IN\14622893|atypical (r_prep) antipsychotics_8\NNS\4470232|NONE (r_pobj) by_6\IN\0|can|disorders|be|.|effectively (r_agent) treated_5\VBN\2376958|NONE (l_nsubjpass) disorders_1\NNS\14034177|can|by|be|.|effectively
C012052_D012559 NONE amisulpride_0\NNP\0|.|in|like|related (r_amod) symptoms_5\NNS\5823932|NONE (l_prep) in_6\IN\13603305|Amisulpride|.|like|related (l_pobj) schizophrenic_9\NN\10490141|NONE
C012052_D012559 NONE amisulpride_20\JJ\0|NONE (r_amod) treatment_21\NN\654885|NONE (r_pobj) of_19\IN\0| (r_prep) months_18\NNS\15113229|NONE (r_pobj) after_16\IN\0|movements|who (r_prep) developed_9\VBD\1753788|mg|old|girl|a (r_relcl) schizophrenic_7\NN\10490141|We|.
C012052_D020820 NONE amisulpride_20\JJ\0|NONE (r_amod) treatment_21\NN\654885|NONE (r_pobj) of_19\IN\0| (r_prep) months_18\NNS\15113229|NONE (r_pobj) after_16\IN\0|movements|who (r_prep) developed_9\VBD\1753788|mg|old|girl|a (l_dobj) movements_15\NNS\191142|after|who
D003024_D013981 NONE clozapine_26\NN\3713736|or (r_conj) quetiapine_24\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) during_21\IN\0|NONE (r_prep) occurring_20\VBG\0|symptoms|that (r_xcomp) show_8\VBP\429048|case (l_dobj) symptoms_12\NNS\5823932|occurring|that
D003024_D013981 NONE clozapine_29\NN\3713736|, (r_conj) quetiapine_27\NN\0|such (r_pobj) as_26\IN\14622893|atypical (r_prep) antipsychotics_24\NNS\4470232|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) during_20\IN\0|in|that|might|symptoms (r_prep) occur_15\VB\0|with|,|patient|. (l_nsubj) symptoms_13\NNS\5823932|in|during|that|might
C069541_D013981 NONE quetiapine_24\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) during_21\IN\0|NONE (r_prep) occurring_20\VBG\0|symptoms|that (r_xcomp) show_8\VBP\429048|case (l_dobj) symptoms_12\NNS\5823932|occurring|that
C069541_D013981 NONE quetiapine_27\NN\0|such (r_pobj) as_26\IN\14622893|atypical (r_prep) antipsychotics_24\NNS\4470232|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) during_20\IN\0|in|that|might|symptoms (r_prep) occur_15\VB\0|with|,|patient|. (l_nsubj) symptoms_13\NNS\5823932|in|during|that|might
C012052_D013981 CID amisulpride_0\NNP\0|.|in|like|related (r_amod) symptoms_5\NNS\5823932|NONE
C012052_D013981 CID amisulpride_13\NN\0|NONE (r_pobj) of_12\IN\0|the|mg (r_prep) dose_11\NN\3740161|we|completely|after (r_dobj) reduced_9\VBD\441445|symptoms|. (r_advcl) resolved_5\VBN\352826|NONE (l_nsubj) symptoms_4\NNS\5823932|.|reduced
C012052_D013981 CID amisulpride_32\NN\0|,|or (r_conj) clozapine_29\NN\3713736|, (r_conj) quetiapine_27\NN\0|such (r_pobj) as_26\IN\14622893|atypical (r_prep) antipsychotics_24\NNS\4470232|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) during_20\IN\0|in|that|might|symptoms (r_prep) occur_15\VB\0|with|,|patient|. (l_nsubj) symptoms_13\NNS\5823932|in|during|that|might
D018967_D013981 NONE risperidone_11\NN\0|such (r_pobj) as_10\IN\14622893|atypical (r_prep) antipsychotics_8\NNS\4470232|NONE (r_pobj) by_6\IN\0|can|disorders|be|.|effectively (r_agent) treated_5\VBN\2376958|NONE (l_nsubjpass) disorders_1\NNS\14034177|can|by|be|.|effectively
6540303
D007649_D002389 CID ketamine_5\NN\3054098|NONE (r_compound) catatonia_6\NN\14544672|NONE
D007649_D002389 CID ketamine_15\NN\3054098| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) catatonia_18\NN\14544672|NONE
D007649_D002389 CID ketamine_17\NN\3054098|NONE (r_pobj) after_16\IN\0|duration|,|but|In|,|pretreatment|did (r_prep) increased_8\VBD\169651|NONE (l_dobj) duration_10\NN\15113229|,|but|In|,|pretreatment|did|after (l_prep) of_11\IN\0|the (l_pobj) catatonia_12\NNP\14544672|NONE
D007649_D002389 CID ketamine_15\NN\3054098|than (r_compound) catatonia_16\NNP\14544672|NONE
D004298_D002389 CID dopamine_7\NN\14807737|NONE (r_pobj) with_6\IN\0|NONE (r_prep) pretreatment_5\NN\0|duration|,|but|In|,|did|after (r_nsubj) increased_8\VBD\169651|NONE (l_dobj) duration_10\NN\15113229|,|but|In|,|pretreatment|did|after (l_prep) of_11\IN\0|the (l_pobj) catatonia_12\NNP\14544672|NONE
D004298_D002389 CID dopamine_2\NN\14807737|.|act|,|Furthermore (r_nsubj) appeared_3\VBD\2604760|NONE (l_xcomp) act_5\VB\6479665|.|dopamine|,|Furthermore (l_prep) on_6\IN\0|to (l_pobj) systems_7\NNS\3575240|NONE (l_acl) involved_10\JJ\2676054|NONE (l_prep) with_11\IN\0|closely (l_pobj) induction_13\NN\7450842|NONE (l_prep) of_14\IN\0|on|the (l_pobj) catatonia_16\NNP\14544672|NONE
D002395_D002389 NONE catecholamines_10\NNS\5407119|NONE (r_pobj) of_9\IN\0|the|on (r_prep) role_8\NN\719494|to|in (l_prep) on_14\IN\0|the|of (l_pobj) catatonia_18\NN\14544672|NONE
D009638_D002389 NONE norepinephrine_22\NN\14807929|NONE (r_pobj) with_21\IN\0|NONE (r_prep) pretreatment_20\NN\0|.|not (r_nsubj) did_23\VBD\0|duration|,|but|In|,|pretreatment|after (r_conj) increased_8\VBD\169651|NONE (l_dobj) duration_10\NN\15113229|,|but|In|,|pretreatment|did|after (l_prep) of_11\IN\0|the (l_pobj) catatonia_12\NNP\14544672|NONE
D000588_D002389 NONE amine_2\NN\14951377|on (r_compound) pretreatment_3\NN\0|NONE (l_prep) on_4\IN\0|amine (l_pobj) catatonia_6\NN\14544672|NONE
6292680
D004317_D009202 CID doxorubicin_0\JJ\2716866|.|in (r_nsubj) cardiomyopathy_1\NN\14103288|NONE
D004317_D009202 CID doxorubicin_23\NN\2716866|NONE (r_pobj) of_22\IN\0|conventional (r_prep) dosage_21\NN\13576355|tumor|the|and (r_conj) bed_18\NN\2821943|NONE (r_pobj) to_15\IN\0|NONE (r_prep) irradiation_14\NN\13920835|NONE (r_pobj) after_13\IN\0|.|children|cardiomyopathy (r_prep) experienced_9\VBD\2108377|NONE (l_dobj) cardiomyopathy_12\NN\14103288|.|after|children
D004317_D009202 CID doxorubicin_30\NN\2716866|NONE (r_pobj) of_29\IN\0|the|on (r_prep) interaction_28\NN\37396|NONE (r_pobj) to_26\IN\0|fields|that|portion (r_prep) include_16\VBP\0|the (r_acl) fact_8\NN\5816287|NONE (r_pobj) to_6\IN\0|cardiomyopathy||)|.|is (r_prep) attributed_3\VBN\670261|NONE (l_nsubjpass) cardiomyopathy_1\NN\14103288||to|)|.|is
D018943_D009202 NONE anthracycline_11\NN\0|severe (r_amod) cardiomyopathy_12\NN\14103288|.|after|children
D004317_D009369 NONE doxorubicin_23\NN\2716866|NONE (r_pobj) of_22\IN\0|conventional (r_prep) dosage_21\NN\13576355|tumor|the|and (r_conj) bed_18\NN\2821943|NONE (l_compound) tumor_17\NN\14234074|dosage|the|and
D004317_D009396 NONE doxorubicin_0\JJ\2716866|.|in (r_nsubj) cardiomyopathy_1\NN\14103288|NONE (l_prep) in_2\IN\13603305|.|Doxorubicin (l_pobj) children_3\NNS\9622049|NONE (l_prep) with_4\IN\0|NONE (l_pobj) tumor_9\NN\14234074|NONE
D004317_D009396 NONE doxorubicin_23\NN\2716866|NONE (r_pobj) of_22\IN\0|conventional (r_prep) dosage_21\NN\13576355|tumor|the|and (r_conj) bed_18\NN\2821943|NONE (r_pobj) to_15\IN\0|NONE (r_prep) irradiation_14\NN\13920835|NONE (r_pobj) after_13\IN\0|.|children|cardiomyopathy (r_prep) experienced_9\VBD\2108377|NONE (l_nsubj) children_1\NNS\9622049|.|after|cardiomyopathy (l_prep) with_2\IN\0|Two (l_pobj) tumor_4\NN\14234074|NONE
D004317_D009396 NONE doxorubicin_30\NN\2716866|NONE (r_pobj) of_29\IN\0|the|on (r_prep) interaction_28\NN\37396|NONE (r_pobj) to_26\IN\0|fields|that|portion (r_prep) include_16\VBP\0|the (l_nsubj) fields_11\VBZ\0|that|to|portion (l_prep) for_12\IN\0|radiation (l_pobj) tumor_15\NN\14234074|NONE
D004317_D009396 NONE doxorubicin_4\NN\2716866|NONE (r_compound) dosage_5\NN\13576355|sharply|in|be|that (r_nsubjpass) restricted_8\VBN\235368|is|.|It (l_prep) in_9\IN\13603305|sharply|dosage|be|that (l_pobj) children_10\NNS\9622049|NONE (l_prep) with_11\IN\0|NONE (l_pobj) tumor_13\NN\14234074|NONE
D018943_D009369 NONE anthracycline_11\NN\0|severe (r_amod) cardiomyopathy_12\NN\14103288|.|after|children (r_dobj) experienced_9\VBD\2108377|NONE (l_prep) after_13\IN\0|.|children|cardiomyopathy (l_pobj) irradiation_14\NN\13920835|NONE (l_prep) to_15\IN\0|NONE (l_pobj) bed_18\NN\2821943|NONE (l_compound) tumor_17\NN\14234074|dosage|the|and
D018943_D009396 NONE anthracycline_11\NN\0|severe (r_amod) cardiomyopathy_12\NN\14103288|.|after|children (r_dobj) experienced_9\VBD\2108377|NONE (l_nsubj) children_1\NNS\9622049|.|after|cardiomyopathy (l_prep) with_2\IN\0|Two (l_pobj) tumor_4\NN\14234074|NONE
2826064
D013726_D007008 CID terbutaline_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) hypokalemia_12\NN\14299637|NONE
D013726_D007008 CID terbutaline_4\JJ\0|higher|after (r_compound) concentrations_5\NNS\4916342|NONE (r_pobj) of_2\IN\0|NONE (r_prep) spite_1\NN\7550369|NONE (r_pobj) in_0\IN\13603305|.|,|was|completely|by|hypokalemia (r_prep) antagonized_15\VBN\1787955|NONE (l_nsubjpass) hypokalemia_11\NN\14299637|.|In|,|was|completely|by
D010096_D007008 NONE oxprenolol_8\NN\0|NONE (r_pobj) by_7\IN\0|its (r_prep) abolishment_6\NN\209943|mediated|and|. (r_conj) hypokalemia_3\NN\14299637|NONE
D010096_D007008 NONE oxprenolol_6\NN\0|NONE (r_pobj) of_5\IN\0|the (r_prep) efficacy_4\NN\5199286|.|we|with|,|in|Subsequently (r_dobj) investigated_2\VBD\644583|NONE (l_prep) in_7\IN\13603305|.|we|with|,|Subsequently|efficacy (l_pcomp) antagonizing_8\VBG\1787955|NONE (l_dobj) hypokalemia_10\NN\14299637|NONE
D010096_D007008 NONE oxprenolol_7\NN\0|NONE (r_amod) pretreatment_8\NN\0|NONE (r_pobj) after_6\IN\0|higher|terbutaline (r_prep) concentrations_5\NNS\4916342|NONE (r_pobj) of_2\IN\0|NONE (r_prep) spite_1\NN\7550369|NONE (r_pobj) in_0\IN\13603305|.|,|was|completely|by|hypokalemia (r_prep) antagonized_15\VBN\1787955|NONE (l_nsubjpass) hypokalemia_11\NN\14299637|.|In|,|was|completely|by
9915601
D005680_D001919 NONE acid_29\NN\14818238|NONE (r_pobj) of_24\IN\0|decreased (r_prep) synthesis_23\NN\13446390|NONE (r_pobj) to_21\IN\0|NONE (r_prep) attributed_20\VBN\670261|an (r_acl) interaction_19\NN\37396|.|,|of|High|hypotension (r_appos) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High (l_conj) change_10\VB\7283608|induced|increase|and (l_prep) to_15\IN\0|tachycardia (l_pobj) bradycardia_16\NNP\14110674|NONE
D005680_D001919 NONE gaba_31\NNP\14601829|aminobutyric|brain (r_appos) acid_29\NN\14818238|NONE (r_pobj) of_24\IN\0|decreased (r_prep) synthesis_23\NN\13446390|NONE (r_pobj) to_21\IN\0|NONE (r_prep) attributed_20\VBN\670261|an (r_acl) interaction_19\NN\37396|.|,|of|High|hypotension (r_appos) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High (l_conj) change_10\VB\7283608|induced|increase|and (l_prep) to_15\IN\0|tachycardia (l_pobj) bradycardia_16\NNP\14110674|NONE
D007538_D001919 CID isoniazid_12\NN\2716205|NONE (r_pobj) with_11\IN\0|NONE (r_prep) pretreated_10\VBD\0|NONE (r_acl) rats_9\NNS\2329401|NONE (r_pobj) in_8\IN\13603305|adrenoceptor (r_prep) antagonists_7\NNS\7846|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|.|Enhanced (r_acl) bradycardia_1\NNS\14110674|NONE
D007538_D001919 CID isoniazid_3\NN\2716205|NONE (r_pobj) of_2\IN\0|.|,|interaction|High|hypotension (r_prep) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High (l_conj) change_10\VB\7283608|induced|increase|and (l_prep) to_15\IN\0|tachycardia (l_pobj) bradycardia_16\NNP\14110674|NONE
D007538_D001919 CID isoniazid_9\NN\2716205|NONE (l_prep) of_10\IN\0|NONE (l_pobj) bradycardia_11\NN\14110674|NONE
D007538_D001919 CID isoniazid_0\NNP\2716205|,|bradycardia|significantly|,|but|propranolol|as|after|. (r_nsubj) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D018738_D001919 NONE hexamethonium_22\NN\0|not (r_pobj) after_21\IN\0|,|bradycardia|significantly|,|but|propranolol|Isoniazid|as|. (r_conj) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D001262_D001919 NONE atenolol_11\NN\2832168|and (r_conj) labetalol_9\JJ\2721160|, (r_conj) pindolol_7\NN\2832168|after|, (r_conj) propranolol_5\NN\0|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D003000_D001919 NONE clonidine_17\NN\2721160|NONE (r_pobj) after_16\IN\0|as|well (r_prep) as_15\IN\14622893|,|bradycardia|significantly|,|but|propranolol|Isoniazid|after|. (r_cc) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D007538_D013610 NONE isoniazid_3\NN\2716205|NONE (r_pobj) of_2\IN\0|.|,|interaction|High|hypotension (r_prep) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High (l_conj) change_10\VB\7283608|induced|increase|and (l_dobj) tachycardia_14\NN\14110674|to
D007538_D007022 CID isoniazid_3\NN\2716205|NONE (r_pobj) of_2\IN\0|.|,|interaction|High|hypotension (r_prep) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High
D011433_D001919 NONE propranolol_5\NN\0|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D007741_D001919 NONE labetalol_9\JJ\2721160|, (r_conj) pindolol_7\NN\2832168|after|, (r_conj) propranolol_5\NN\0|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D010869_D001919 NONE pindolol_7\NN\2832168|after|, (r_conj) propranolol_5\NN\0|,|bradycardia|significantly|,|but|Isoniazid|as|after|. (r_advcl) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D014520_D001919 NONE urethane_26\NN\14850483|NONE (r_pobj) with_23\IN\0|NONE (r_prep) anaesthetised_22\VBN\84738|NONE (r_acl) rats_21\NNS\2329401|NONE (r_pobj) in_20\IN\13603305|.|was|In|,|enhancement (r_prep) determined_19\VBN\0|NONE (l_nsubjpass) enhancement_7\NN\248977|.|was|In|in|, (l_prep) by_8\IN\0|induced|the|possible (l_pobj) isoniazid_9\NN\2716205|NONE (l_prep) of_10\IN\0|NONE (l_pobj) bradycardia_11\NN\14110674|NONE
D005680_D007022 NONE acid_29\NN\14818238|NONE (r_pobj) of_24\IN\0|decreased (r_prep) synthesis_23\NN\13446390|NONE (r_pobj) to_21\IN\0|NONE (r_prep) attributed_20\VBN\670261|an (r_acl) interaction_19\NN\37396|.|,|of|High|hypotension (r_appos) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High
D005680_D007022 NONE gaba_31\NNP\14601829|aminobutyric|brain (r_appos) acid_29\NN\14818238|NONE (r_pobj) of_24\IN\0|decreased (r_prep) synthesis_23\NN\13446390|NONE (r_pobj) to_21\IN\0|NONE (r_prep) attributed_20\VBN\670261|an (r_acl) interaction_19\NN\37396|.|,|of|High|hypotension (r_appos) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High
D002217_D001919 NONE carbachol_24\NN\0|or (r_conj) hexamethonium_22\NN\0|not (r_pobj) after_21\IN\0|,|bradycardia|significantly|,|but|propranolol|Isoniazid|as|. (r_conj) increased_2\VBD\169651|NONE (l_acomp) bradycardia_3\NNP\14110674|,|significantly|,|but|propranolol|Isoniazid|as|after|.
D002698_D001919 NONE chloralose_24\NN\0| (r_compound) urethane_26\NN\14850483|NONE (r_pobj) with_23\IN\0|NONE (r_prep) anaesthetised_22\VBN\84738|NONE (r_acl) rats_21\NNS\2329401|NONE (r_pobj) in_20\IN\13603305|.|was|In|,|enhancement (r_prep) determined_19\VBN\0|NONE (l_nsubjpass) enhancement_7\NN\248977|.|was|In|in|, (l_prep) by_8\IN\0|induced|the|possible (l_pobj) isoniazid_9\NN\2716205|NONE (l_prep) of_10\IN\0|NONE (l_pobj) bradycardia_11\NN\14110674|NONE
D005680_D013610 NONE acid_29\NN\14818238|NONE (r_pobj) of_24\IN\0|decreased (r_prep) synthesis_23\NN\13446390|NONE (r_pobj) to_21\IN\0|NONE (r_prep) attributed_20\VBN\670261|an (r_acl) interaction_19\NN\37396|.|,|of|High|hypotension (r_appos) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High (l_conj) change_10\VB\7283608|induced|increase|and (l_dobj) tachycardia_14\NN\14110674|to
D005680_D013610 NONE gaba_31\NNP\14601829|aminobutyric|brain (r_appos) acid_29\NN\14818238|NONE (r_pobj) of_24\IN\0|decreased (r_prep) synthesis_23\NN\13446390|NONE (r_pobj) to_21\IN\0|NONE (r_prep) attributed_20\VBN\670261|an (r_acl) interaction_19\NN\37396|.|,|of|High|hypotension (r_appos) doses_1\NNS\3740161|NONE (l_appos) hypotension_5\NN\14057371|.|,|of|interaction|High (l_conj) change_10\VB\7283608|induced|increase|and (l_dobj) tachycardia_14\NN\14110674|to
6496797
D014196_D006327 CID trazodone_8\NN\3829085|NONE (r_pobj) of_7\IN\0|a|single (r_prep) dose_6\NN\3740161|NONE (r_pobj) following_3\VBG\8180190|heart|Complete|. (r_prep) block_2\NN\21939|NONE
D014196_D006327 CID trazodone_9\NN\3829085|NONE (r_pobj) of_8\IN\0|a|single|starting (r_prep) dose_7\NN\3740161|NONE (r_dobj) receiving_3\VBG\2210855|minutes (r_pcomp) after_2\IN\0|block|.|,|patient (r_prep) developed_13\VBD\1753788|NONE (l_dobj) block_16\NN\21939|after|.|,|patient
7604176
D017035_D009220 CID pravastatin_11\NN\3676175|NONE (r_pobj) of_10\IN\0|the (r_prep) use_9\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491|of|,|A|inhibitor (r_acl) case_1\NN\7283608|is|.|, (l_prep) of_2\IN\0|associated|,|A|inhibitor (l_pobj) myopathy_5\NNS\14204950|NONE
D017035_D009135 NONE pravastatin_0\NNP\3676175| (r_npadvmod) associated_2\VBN\628491|. (r_amod) myopathy_3\NN\14204950|NONE
D017035_D009135 NONE pravastatin_17\JJ\3676175|NONE (r_amod) discontinuation_18\NN\209943|NONE (r_pobj) after_16\IN\0|in|which (r_prep) resolved_11\VBD\352826|lower|the (r_relcl) limbs_9\NNS\5559908|NONE (r_pobj) of_6\IN\0|acute (r_prep) myopathy_5\NN\14204950|NONE
D017035_D009135 NONE pravastatin_11\RB\3676175| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) myopathy_14\NNS\14204950|entity|associated|.|,|could (r_nsubj) represent_16\VB\2664769|NONE (l_advcl) associated_6\VBN\628491|entity|myopathy|.|,|could (l_prep) with_7\IN\0|have|been|While|lovastatin (l_pobj) myopathy_9\NNS\14204950|NONE
D017035_D009135 NONE pravastatin_11\RB\3676175| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) myopathy_14\NNS\14204950|entity|associated|.|,|could
D019821_D009135 NONE simvastatin_3\NN\3676175|and (r_conj) lovastatin_1\NN\3676175|with|have|been|While (r_nsubjpass) associated_6\VBN\628491|entity|myopathy|.|,|could (l_prep) with_7\IN\0|have|been|While|lovastatin (l_pobj) myopathy_9\NNS\14204950|NONE
D019821_D009135 NONE simvastatin_3\NN\3676175|and (r_conj) lovastatin_1\NN\3676175|with|have|been|While (r_nsubjpass) associated_6\VBN\628491|entity|myopathy|.|,|could (r_advcl) represent_16\VB\2664769|NONE (l_nsubj) myopathy_14\NNS\14204950|entity|associated|.|,|could
D008148_D009135 NONE lovastatin_1\NN\3676175|with|have|been|While (r_nsubjpass) associated_6\VBN\628491|entity|myopathy|.|,|could (l_prep) with_7\IN\0|have|been|While|lovastatin (l_pobj) myopathy_9\NNS\14204950|NONE
D008148_D009135 NONE lovastatin_1\NN\3676175|with|have|been|While (r_nsubjpass) associated_6\VBN\628491|entity|myopathy|.|,|could (r_advcl) represent_16\VB\2664769|NONE (l_nsubj) myopathy_14\NNS\14204950|entity|associated|.|,|could
D017035_D006937 NONE pravastatin_2\RB\3676175|.|day|He|because (r_dobj) assumed_1\VBD\719734|NONE (l_prep) because_9\IN\0|pravastatin|.|day|He (l_pobj) hypercholesterolemia_11\NN\14299637|of
20466178
D016559_D003872 NONE tacrolimus_5\NN\0|topical (r_compound) treatment_6\NN\654885|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBN\628491|Rosaceiform|. (r_acl) dermatitis_1\NN\14226056|NONE
D016559_D003872 NONE tacrolimus_19\NN\0|% (r_compound) ointment_20\NN\4074482|while|for (r_dobj) using_13\VBG\418025|eruptions|who (r_advcl) developed_6\VBD\1753788| (l_dobj) eruptions_11\NNS\7307754|who|using (l_compound) dermatitis_10\NN\14226056|like
D016559_D003872 NONE tacrolimus_7\NN\0|such (r_pobj) as_6\IN\14622893|NONE (r_prep) immunomodulators_4\NNS\0|NONE (r_pobj) of_3\IN\0|Continuous|topical (r_prep) use_2\NN\407535|.|as|should|reported|,|be (r_nsubjpass) regarded_12\VBN\689344|NONE (l_prep) as_13\IN\14622893|use|.|should|reported|,|be (l_pobj) cause_16\NN\7323922|NONE (l_prep) of_17\IN\0|potential|a (l_pobj) dermatitis_19\NN\14226056|NONE
C117268_D003872 CID pimecrolimus_9\NN\0|or (r_conj) tacrolimus_7\NN\0|such (r_pobj) as_6\IN\14622893|NONE (r_prep) immunomodulators_4\NNS\0|NONE (r_pobj) of_3\IN\0|Continuous|topical (r_prep) use_2\NN\407535|.|as|should|reported|,|be (r_nsubjpass) regarded_12\VBN\689344|NONE (l_prep) as_13\IN\14622893|use|.|should|reported|,|be (l_pobj) cause_16\NN\7323922|NONE (l_prep) of_17\IN\0|potential|a (l_pobj) dermatitis_19\NN\14226056|NONE
D016559_D003875 NONE tacrolimus_19\NN\0|% (r_compound) ointment_20\NN\4074482|while|for (r_dobj) using_13\VBG\418025|eruptions|who (r_advcl) developed_6\VBD\1753788| (l_dobj) eruptions_11\NNS\7307754|who|using
D016559_D005148 NONE tacrolimus_19\NN\0|% (r_compound) ointment_20\NN\4074482|while|for (r_dobj) using_13\VBG\418025|eruptions|who (l_prep) for_21\IN\0|ointment|while (l_pobj) dermatitis_23\NN\14226056|NONE
D016559_D012393 NONE tacrolimus_19\NN\0|% (r_compound) ointment_20\NN\4074482|while|for (r_dobj) using_13\VBG\418025|eruptions|who (r_advcl) developed_6\VBD\1753788| (l_dobj) eruptions_11\NNS\7307754|who|using (l_amod) like_9\JJ\5839024|dermatitis (l_npadvmod) rosacea_7\NN\14222112|
663266
D003974_D014693 NONE renografin_7\NNP\0|NONE (r_pobj) with_6\IN\0|.|often|,|fibrillation|suggesting (r_prep) occurred_2\VBD\0|NONE (l_nsubj) fibrillation_1\NN\14361664|.|often|,|with|suggesting
C027278_D064420 NONE %_5\NN\0|The|of (r_appos) toxicity_1\NN\13576101|.|into|%|was|with
C027278_D064420 NONE %_13\NN\0|.|into|toxicity|was|with (r_npadvmod) compared_7\VBN\644583|NONE (l_nsubjpass) toxicity_1\NN\13576101|.|into|%|was|with
D003973_D014693 NONE diatrizoate_3\JJ\0|with (r_pobj) from_2\IN\0|Ventricular|. (r_prep) fibrillation_1\NN\14361664|NONE
D003974_D064420 NONE renografin_7\NNP\0|NONE (r_pobj) with_6\IN\0|.|often|,|fibrillation|suggesting (r_prep) occurred_2\VBD\0|NONE (l_advcl) suggesting_9\VBG\1010118|.|often|,|fibrillation|with (l_ccomp) contribute_13\VBP\126264|NONE (l_prep) to_14\IN\0|in|that|agents (l_pobj) toxicity_15\NN\13576101|NONE
15638391
D006220_D006966 CID haloperidol_16\NN\3713736|NONE (r_pobj) by_15\IN\0|.|process (r_agent) induced_14\VBN\1627355|NONE (l_nsubj) process_1\NN\407535|by|. (l_prep) of_2\IN\0|Aging (l_pobj) cells_4\NNS\3080309|NONE (l_prep) of_5\IN\0|epithelial (l_pobj) lobe_10\NN\5220461|NONE (l_prep) in_11\IN\13603305|the|rat|lateral|prostate (l_pobj) hyperprolactinemia_13\NN\0|NONE
D006220_D006966 CID haloperidol_15\NN\3713736|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|examine|aim|. (r_advcl) was_5\VBD\0|NONE (l_xcomp) examine_7\VB\0|aim|induced|. (l_dobj) influence_9\NN\5190804|,|to (l_prep) of_10\IN\0|the (l_pobj) hyperprolactinemia_11\NN\0|NONE
D006220_D006966 CID hal_17\NNP\0|on (r_appos) haloperidol_15\NN\3713736|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|examine|aim|. (r_advcl) was_5\VBD\0|NONE (l_xcomp) examine_7\VB\0|aim|induced|. (l_dobj) influence_9\NN\5190804|,|to (l_prep) of_10\IN\0|the (l_pobj) hyperprolactinemia_11\NN\0|NONE
15266362
D004280_D004342 CID dobutamine_13\NN\0|hypersensitivity|that|was (r_xcomp) related_11\VBN\628491|NONE (l_nsubjpass) hypersensitivity_5\NN\14531772|that|was|dobutamine
D004280_D004802 CID dobutamine_13\NN\0|hypersensitivity|that|was (r_xcomp) related_11\VBN\628491|NONE (l_nsubjpass) hypersensitivity_5\NN\14531772|that|was|dobutamine (l_amod) eosinophilic_7\JJ\0|the|(|myocarditis|)
D004280_D018754 NONE dobutamine_22\NN\0|drugs|and (r_compound) infusion_23\NN\14589223|NONE (r_pobj) with_21\IN\0|assessed|aggressively (r_prep) managed_19\VBD\2524171|.|and|was|patient|with (r_conj) admitted_14\VBN\822367|NONE (l_prep) with_15\IN\0|managed|.|and|was|patient (l_pobj) failure_17\NN\66216|NONE
D004280_D009205 CID dobutamine_13\NN\0|hypersensitivity|that|was (r_xcomp) related_11\VBN\628491|NONE (l_nsubjpass) hypersensitivity_5\NN\14531772|that|was|dobutamine (l_amod) myocarditis_9\NN\14338942|the|eosinophilic|(|)
D004280_D002312 NONE dobutamine_22\NN\0|drugs|and (r_compound) infusion_23\NN\14589223|NONE (r_pobj) with_21\IN\0|assessed|aggressively (r_prep) managed_19\VBD\2524171|.|and|was|patient|with (r_conj) admitted_14\VBN\822367|NONE (l_nsubjpass) patient_5\NN\9898892|managed|.|and|was|with (l_acl) known_7\VBN\0|The|old|female|,|, (l_xcomp) have_9\VB\7846|NONE (l_dobj) cardiomyopathy_11\NN\14103288|to
2004015
D015215_D007239 NONE azt_28\NNP\3834836| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) anaemia_31\NN\14299637|due|if|in|, (r_nsubj) is_32\VBZ\0|to (r_ccomp) determine_26\VB\0|have|.|model|We|,|decreased (r_xcomp) used_2\VBN\0|NONE (l_dobj) model_5\NN\5888929|have|determine|.|We|,|decreased (l_prep) of_6\IN\0|a|murine (l_pobj) aids_7\NNP\13974317|NONE (l_appos) infection_9\NN\14052046|,
D015215_C565469 NONE azidothymidine_8\NN\0|Sensitivity|.|mice (r_advmod) treated_9\VBN\2376958|NONE (l_dobj) mice_11\NNS\2329401|Sensitivity|.|azidothymidine (l_amod) immunodeficient_10\JJ\0|NONE
D015215_D000163 NONE azt_28\NNP\3834836| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) anaemia_31\NN\14299637|due|if|in|, (r_nsubj) is_32\VBZ\0|to (r_ccomp) determine_26\VB\0|have|.|model|We|,|decreased (r_xcomp) used_2\VBN\0|NONE (l_dobj) model_5\NN\5888929|have|determine|.|We|,|decreased (l_prep) of_6\IN\0|a|murine (l_pobj) aids_7\NNP\13974317|NONE
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4\NN\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|The (r_acl) anaemia_1\NN\14299637|.|poorly|is
D015215_D000740 CID azt_6\NNP\3834836|NONE (r_appos) 3'-azido-3'dideoxythymidine_4\NN\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|The (r_acl) anaemia_1\NN\14299637|.|poorly|is
D015215_D000740 CID azt_28\NNP\3834836| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) anaemia_31\NN\14299637|due|if|in|,
D015215_D000740 CID azt_0\NNP\3834836|.|anaemia|in|,|in (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) anaemia_2\NN\14299637|.|in|,|in|AZT
D015215_D000740 CID azt_15\NNP\3834836|NONE (r_pobj) in_14\IN\13603305|BFU||marrow (r_prep) e_13\NNP\14724645|NONE (r_pobj) of_6\IN\0|the (r_prep) number_5\NN\5107765|,|mice|Despite (r_nsubj) treated_16\VBD\2376958|.|up|to|observed|over (l_prep) despite_0\IN\7501545|,|number|mice (l_pobj) anaemia_2\NN\14299637|NONE
D015215_D000740 CID azt_8\NNP\3834836|NONE (r_pobj) in_7\IN\13603305|treated|levels|were|treated|. (r_prep) observed_6\VBD\2163746|NONE (l_conj) were_11\VBD\0|treated|levels|in|treated|. (l_acomp) appropriate_12\JJ\2228698|NONE (l_prep) for_13\IN\0|NONE (l_pobj) degree_15\NN\4916342|NONE (l_prep) of_16\IN\0|observed|the (l_pobj) anaemia_17\NN\14299637|NONE
D015215_D000740 CID azt_17\NNP\3834836|with|mice (r_nsubj) treated_20\VBD\2376958|numbers|.|were (l_prep) with_22\IN\0|AZT|mice (l_pobj) degrees_24\NNS\4916342|NONE (l_prep) of_25\IN\0|similar (l_pobj) anaemia_26\NN\14299637|NONE
D015215_D000740 CID azt_12\NNP\3834836|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) observed_10\VBN\2163746|of|the (r_acl) degree_7\NN\4916342|NONE (l_prep) of_8\IN\0|the|observed (l_pobj) anaemia_9\NN\14299637|NONE
D015215_D000740 CID azt_0\NNP\3834836|and||in|levels|anaemia (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) anaemia_4\NN\14299637|and||in|levels|AZT
D015215_D007938 NONE azt_28\NNP\3834836| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) anaemia_31\NN\14299637|due|if|in|, (r_nsubj) is_32\VBZ\0|to (r_ccomp) determine_26\VB\0|have|.|model|We|,|decreased (r_xcomp) used_2\VBN\0|NONE (l_dobj) model_5\NN\5888929|have|determine|.|We|,|decreased (l_prep) of_6\IN\0|a|murine (l_pobj) aids_7\NNP\13974317|NONE (l_appos) infection_9\NN\14052046|, (l_prep) of_10\IN\0|NONE (l_pobj) mice_13\NNS\2329401|NONE (l_prep) with_14\IN\0|female|CBL/ (l_pobj) leukaemia_19\NN\14239918|NONE
D015215_D045262 NONE azt_12\NNP\3834836|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) observed_10\VBN\2163746|of|the (r_acl) degree_7\NN\4916342|NONE (r_pobj) for_5\IN\0|NONE (r_prep) inappropriate_4\JJ\0|treated|.|However|,|reticulocytosis (r_acomp) was_3\VBD\0|NONE (l_nsubj) reticulocytosis_2\NN\0|treated|.|However|inappropriate|,
C030299_D000740 NONE phenylhydrazine_22\NN\0|PHZ|mice|(|) (r_npadvmod) treated_26\VBD\2376958|levels|were|in|treated|. (r_conj) observed_6\VBD\2163746|NONE (l_conj) were_11\VBD\0|treated|levels|in|treated|. (l_acomp) appropriate_12\JJ\2228698|NONE (l_prep) for_13\IN\0|NONE (l_pobj) degree_15\NN\4916342|NONE (l_prep) of_16\IN\0|observed|the (l_pobj) anaemia_17\NN\14299637|NONE
C030299_D000740 NONE phz_24\NNP\0|mice|(|phenylhydrazine|) (r_nsubj) treated_26\VBD\2376958|levels|were|in|treated|. (r_conj) observed_6\VBD\2163746|NONE (l_conj) were_11\VBD\0|treated|levels|in|treated|. (l_acomp) appropriate_12\JJ\2228698|NONE (l_prep) for_13\IN\0|NONE (l_pobj) degree_15\NN\4916342|NONE (l_prep) of_16\IN\0|observed|the (l_pobj) anaemia_17\NN\14299637|NONE
C030299_D000740 NONE phz_19\NNP\0|and (r_conj) azt_17\NNP\3834836|with|mice (r_nsubj) treated_20\VBD\2376958|numbers|.|were (l_prep) with_22\IN\0|AZT|mice (l_pobj) degrees_24\NNS\4916342|NONE (l_prep) of_25\IN\0|similar (l_pobj) anaemia_26\NN\14299637|NONE
188339
D013256_D008113 NONE steroids_19\NNS\14727670|NONE (r_dobj) using_16\VBG\418025|have|,|been|previously|tumors|in|.|Within (r_advcl) seen_12\VBN\2106506|NONE (l_nsubjpass) tumors_9\NNS\14234074|have|,|been|previously|using|in|.|Within
D003276_D008113 CID contraceptives_11\NNS\3183080|NONE (r_pobj) with_9\IN\0|NONE (r_prep) associated_8\VBN\628491|liver (r_acl) tumors_7\NNS\14234074|NONE
D003276_D008113 CID contraceptive_18\JJ\3183080|oral (r_amod) steroids_19\NNS\14727670|NONE (r_dobj) using_16\VBG\418025|have|,|been|previously|tumors|in|.|Within (r_advcl) seen_12\VBN\2106506|NONE (l_nsubjpass) tumors_9\NNS\14234074|have|,|been|previously|using|in|.|Within
6293644
D006220_D002375 CID haloperidol_7\NN\3713736| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) catalepsy_10\NN\14023236|NONE
D001058_D006948 CID apomorphine_16\NN\3786417| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) hyperactivity_19\NN\14052403|NONE
D001058_D002375 NONE apomorphine_16\NN\3786417| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) hyperactivity_19\NN\14052403|NONE (r_pobj) of_15\IN\0|partial|a (r_prep) prevention_14\NN\1073995|a|of|and (r_conj) potentiation_5\NN\13564910|NONE (l_prep) of_6\IN\0|a|and|prevention (l_pobj) catalepsy_10\NN\14023236|NONE
D006220_D006948 NONE haloperidol_7\NN\3713736| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) catalepsy_10\NN\14023236|NONE (r_pobj) of_6\IN\0|a|and|prevention (r_prep) potentiation_5\NN\13564910|NONE (l_conj) prevention_14\NN\1073995|a|of|and (l_prep) of_15\IN\0|partial|a (l_pobj) hyperactivity_19\NN\14052403|NONE
11243580
D009569_D012640 NONE oxide_20\NN\14818238|methyl|)|(|NAME (r_appos) ester_12\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|on|,|.|were (r_nsubjpass) investigated_36\VBN\644583|NONE (l_prep) on_37\IN\0|effects|,|.|were (l_pobj) convulsions_41\NNS\14081375|NONE
D009569_D012640 NONE no_22\NNP\7204911|)|and|arginine|synthase (r_intj) inhibitor_25\NN\20090|a|,|precursor|nitric|( (r_appos) oxide_20\NN\14818238|methyl|)|(|NAME (r_appos) ester_12\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|on|,|.|were (r_nsubjpass) investigated_36\VBN\644583|NONE (l_prep) on_37\IN\0|effects|,|.|were (l_pobj) convulsions_41\NNS\14081375|NONE
D009569_D012640 NONE no_32\JJ\7204911|a (r_det) precursor_33\NN\14580897|inhibitor|a|,|nitric|( (r_appos) oxide_20\NN\14818238|methyl|)|(|NAME (r_appos) ester_12\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|on|,|.|were (r_nsubjpass) investigated_36\VBN\644583|NONE (l_prep) on_37\IN\0|effects|,|.|were (l_pobj) convulsions_41\NNS\14081375|NONE
D009569_D012640 NONE no_5\DT\7204911|mediator|that (r_nsubj) is_6\VBZ\0|results|may|. (l_attr) mediator_9\NN\10351874|that|NO (l_prep) in_10\IN\13603305|proconvulsant|a (l_pobj) convulsions_14\NNS\14081375|NONE
D001120_D012640 NONE arginine_29\NN\14605787|)|NO|and|synthase (r_conj) inhibitor_25\NN\20090|a|,|precursor|nitric|( (r_appos) oxide_20\NN\14818238|methyl|)|(|NAME (r_appos) ester_12\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|on|,|.|were (r_nsubjpass) investigated_36\VBN\644583|NONE (l_prep) on_37\IN\0|effects|,|.|were (l_pobj) convulsions_41\NNS\14081375|NONE
D001120_D012640 NONE arginine_6\NN\14605787|the (r_compound) treatment_7\NN\654885|incidence|.|,|In (r_nsubj) increased_8\VBD\169651|NONE (l_dobj) incidence_10\NN\13821570|treatment|.|,|In (l_appos) convulsions_18\NNS\14081375|of|the|mg/kg|(|,
D019331_D012640 NONE ester_12\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|on|,|.|were (r_nsubjpass) investigated_36\VBN\644583|NONE (l_prep) on_37\IN\0|effects|,|.|were (l_pobj) convulsions_41\NNS\14081375|NONE
D019331_D012640 NONE name_16\NN\6284225|oxide|methyl|)|( (r_appos) ester_12\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|on|,|.|were (r_nsubjpass) investigated_36\VBN\644583|NONE (l_prep) on_37\IN\0|effects|,|.|were (l_pobj) convulsions_41\NNS\14081375|NONE
D019331_D012640 NONE name_2\NNP\6284225|.|incidence|significantly (r_nsubj) decreased_16\VBD\169651|NONE (l_dobj) incidence_18\NN\13821570|NAME|.|significantly (l_appos) convulsions_26\NNS\14081375|of|the
D003975_D012640 NONE diazepam_10\NN\2830852|and|i.p.|L|)|mg/kg| (r_conj) name_2\NNP\6284225|.|incidence|significantly (r_nsubj) decreased_16\VBD\169651|NONE (l_dobj) incidence_18\NN\13821570|NAME|.|significantly (l_appos) convulsions_26\NNS\14081375|of|the
D008012_D012640 CID lidocaine_6\NN\3681148| (r_npadvmod) induced_8\VBN\1627355|in (r_amod) convulsion_9\NN\14081375|NONE
D008012_D012640 CID lidocaine_38\NN\3681148| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) convulsions_41\NNS\14081375|NONE
D008012_D012640 CID lidocaine_20\NN\3681148|NONE (r_pobj) of_19\IN\0|convulsions|the (r_prep) incidence_18\NN\13821570|NAME|.|significantly (l_appos) convulsions_26\NNS\14081375|of|the
D008012_D012640 CID lidocaine_12\NN\3681148|NONE (r_pobj) of_11\IN\0|the|mg/kg|(|,|convulsions (r_prep) incidence_10\NN\13821570|treatment|.|,|In (l_appos) convulsions_18\NNS\14081375|of|the|mg/kg|(|,
D008012_D012640 CID lidocaine_11\NN\3681148| (r_npadvmod) induced_13\VBN\1627355|NONE (r_amod) convulsions_14\NNS\14081375|NONE
326460
D001539_D007008 CID bendrofluazide_2\NN\0| (r_advmod) induced_4\VBN\1627355|NONE (r_amod) hypokalemia_5\NN\14299637|NONE
D001539_D007008 CID bendrofluazide_17\NN\0|in|term (r_amod) treatment_18\NN\654885|NONE (r_pobj) of_13\IN\0|the (r_prep) hypokalemia_12\NN\14299637|to
D013999_D007008 NONE timolol_7\NN\2832168|NONE (r_pobj) by_6\IN\0|.|of (r_prep) amelioration_0\NN\248977|NONE (l_prep) of_1\IN\0|.|by (l_pobj) hypokalemia_5\NN\14299637|NONE
D013999_D007008 NONE timolol_6\NN\2832168|blocking|The|beta|,|, (r_appos) drug_4\NN\14778436|correct|was|and (r_nsubj) tended_8\VBD\2604760|NONE (l_xcomp) correct_10\VB\138508|was|drug|and (l_dobj) hypokalemia_12\NN\14299637|to
17923537
D005446_D009798 CID acetonide_21\NN\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|with (r_acl) patients_14\NNS\9898892|NONE (r_pobj) in_13\IN\13603305|and|of|the|management (r_prep) incidence_3\NN\13821570|To|. (l_prep) of_6\IN\0|and|the|management|in (l_pobj) pressure_9\NN\11419404|NONE
D005446_D009798 CID fa_23\NNP\6868043|(|)|intravitreal (r_nmod) implant_26\NN\4013729|the|fluocinolone (r_appos) acetonide_21\NN\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|with (r_acl) patients_14\NNS\9898892|NONE (r_pobj) in_13\IN\13603305|and|of|the|management (r_prep) incidence_3\NN\13821570|To|. (l_prep) of_6\IN\0|and|the|management|in (l_pobj) pressure_9\NN\11419404|NONE
D005446_D014605 NONE acetonide_9\NN\0|fluocinolone (r_compound) implants_10\NNS\4013729|NONE (r_pobj) with_7\IN\0|NONE (r_prep) treated_6\VBN\2376958|in|.|Intraocular (r_acl) pressure_1\NN\11419404|NONE (l_prep) in_2\IN\13603305|.|Intraocular|treated (l_pobj) patients_3\NNS\9898892|NONE (l_prep) with_4\IN\0|NONE (l_pobj) uveitis_5\NN\14336539|NONE
D005446_D014605 NONE acetonide_21\NN\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|with (r_acl) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|treated (l_pobj) uveitis_16\NN\14336539|NONE
D005446_D014605 NONE fa_23\NNP\6868043|(|)|intravitreal (r_nmod) implant_26\NN\4013729|the|fluocinolone (r_appos) acetonide_21\NN\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|with (r_acl) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|treated (l_pobj) uveitis_16\NN\14336539|NONE
14736955
D013481_D007674 NONE superoxide_41\JJ\14971519|and|activities (r_amod) production_42\NN\30358|NONE (r_pobj) with_40\IN\0|positively|Injury|.|was (r_prep) correlated_39\VBN\2657219|were|activities|inversely|with|Among (r_conj) correlated_10\VBN\2657219|NONE (l_prep) among_0\IN\0|were|activities|inversely|correlated|with (l_pobj) injury_7\NN\14052046|animals
D013481_D007674 NONE superoxide_25\NN\14971519|NONE (l_prep) in_26\IN\13603305|NONE (l_pobj) lesions_31\NNS\14204950|NONE
C102006_D007674 NONE citrate_32\NN\14850483|NONE (r_compound) synthase_33\NN\0|increased (r_compound) activity_34\NN\30358|depressed|of|and (r_conj) activities_15\NNS\30358|,|significant|glomerular (r_appos) lesions_12\NNS\14204950|group|.
D004317_D009401 CID doxorubicin_10\NN\2716866|NONE (r_compound) nephrosis_11\NN\14304060|NONE
D004317_D007674 NONE doxorubicin_0\NNP\2716866|nephropathy|. (r_nsubj) induces_1\VBZ\1627355|NONE (l_dobj) nephropathy_6\NN\14573196|Doxorubicin|.
D004317_D007674 NONE doxorubicin_0\NNP\2716866|nephropathy|. (r_nsubj) induces_1\VBZ\1627355|NONE (l_dobj) nephropathy_6\NN\14573196|Doxorubicin|. (l_acl) characterized_7\VBN\609683|a|perpetuating (l_agent) by_8\IN\0|NONE (l_pobj) lesions_16\NNS\14204950|NONE
D004317_D007674 NONE doxorubicin_27\RB\2716866| (r_npadvmod) induced_29\VBN\1627355|renal (r_amod) lesions_31\NNS\14204950|NONE
20727411
-1_D011605 NONE ketamine_5\NN\3054098|NONE (r_pobj) of_2\IN\0|Neural (r_prep) correlates_1\NNS\5857459|psychosis|during|. (r_nsubj) induced_6\VBD\1627355|NONE (l_dobj) psychosis_7\NN\14380140|correlates|during|.
D016202_D012559 NONE aspartate_8\NNP\0|glutamatergic|)|(|NMDA|The (r_nmod) receptor_12\NN\5225602|been|has|in|. (r_nsubjpass) implicated_15\VBN\2677097|NONE (l_prep) in_16\IN\13603305|been|has|receptor|. (l_pobj) pathophysiology_18\NN\0|NONE (l_prep) of_19\IN\0|the (l_pobj) schizophrenia_20\NN\14398067|NONE
D016202_D012559 NONE nmda_10\NNP\0|aspartate|glutamatergic|)|(|The (r_nmod) receptor_12\NN\5225602|been|has|in|. (r_nsubjpass) implicated_15\VBN\2677097|NONE (l_prep) in_16\IN\13603305|been|has|receptor|. (l_pobj) pathophysiology_18\NN\0|NONE (l_prep) of_19\IN\0|the (l_pobj) schizophrenia_20\NN\14398067|NONE
D016202_D012559 NONE nmda_13\NNP\0|competitive|receptor (r_compound) antagonist_15\NN\7846|the (r_compound) ketamine_16\NN\3054098|NONE (r_pobj) of_8\IN\0|a|subanesthetic (r_prep) dose_7\NN\3740161|Administered|.|to|, (r_nsubj) leads_17\VBZ\5155821|NONE (l_prep) to_18\IN\0|Administered|dose|.|, (l_pobj) symptoms_20\NNS\5823932|NONE (l_amod) similar_21\JJ\0|psychopathological (l_prep) to_22\IN\0|NONE (l_pobj) those_23\DT\0|NONE (l_acl) observed_24\VBN\2163746|NONE (l_prep) in_25\IN\13603305|NONE (l_pobj) schizophrenia_26\NN\14398067|NONE
D016202_D012559 NONE nmda_10\NNP\0|an|receptor|in (r_compound) dysfunction_12\NN\14204950|NONE (l_prep) in_13\IN\13603305|NMDA|an|receptor (l_pobj) pathophysiology_15\NN\0|NONE (l_prep) of_16\IN\0|the (l_pobj) schizophrenia_17\NN\14398067|NONE
D007649_D011605 CID ketamine_0\NN\3054098|psychosis|. (r_nsubj) elicited_1\VBD\1617192|NONE (l_dobj) psychosis_2\NN\14380140|Ketamine|.
D007649_D012559 NONE ketamine_16\NN\3054098|NONE (r_pobj) of_8\IN\0|a|subanesthetic (r_prep) dose_7\NN\3740161|Administered|.|to|, (r_nsubj) leads_17\VBZ\5155821|NONE (l_prep) to_18\IN\0|Administered|dose|.|, (l_pobj) symptoms_20\NNS\5823932|NONE (l_amod) similar_21\JJ\0|psychopathological (l_prep) to_22\IN\0|NONE (l_pobj) those_23\DT\0|NONE (l_acl) observed_24\VBN\2163746|NONE (l_prep) in_25\IN\13603305|NONE (l_pobj) schizophrenia_26\NN\14398067|NONE
D007649_D012559 NONE ketamine_5\NN\3054098|symptoms|.|In|supporting|,|, (r_nsubj) exacerbates_6\VBZ\126264|NONE (l_prep) in_0\IN\13603305|symptoms|.|supporting|,|,|ketamine (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) schizophrenia_3\NN\14398067|NONE
D007649_D012559 NONE ketamine_0\NN\3054098|,|in|changes|. (r_nsubj) induces_1\VBZ\1627355|NONE (l_dobj) changes_3\NNS\7283608|,|in|.|Ketamine (l_prep) in_4\IN\13603305|activation (l_pobj) subjects_6\NNS\6598915|NONE (l_amod) similar_7\JJ\0|healthy (l_prep) to_8\IN\0|NONE (l_pobj) those_9\DT\0|NONE (l_acl) observed_10\VBN\2163746|NONE (l_prep) in_11\IN\13603305|NONE (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|NONE (l_pobj) schizophrenia_14\NN\14398067|NONE
D007649_D018754 NONE ketamine_5\NN\3054098|symptoms|.|In|supporting|,|, (r_nsubj) exacerbates_6\VBZ\126264|NONE (l_advcl) supporting_13\VBG\407535|symptoms|.|In|,|,|ketamine (l_dobj) hypothesis_15\NN\7162194|NONE (l_prep) of_16\IN\0|the (l_pobj) dysfunction_19\NN\14204950|NONE
3969369
D013739_D063646 NONE testosterone_3\NN\14747587|NONE (r_pobj) of_2\IN\0|.|on|Promotional (r_prep) effects_1\NNS\13245626|NONE (l_prep) on_7\IN\0|.|Promotional|of (l_pobj) carcinogenesis_9\NN\0|NONE
D013739_D011471 CID testosterone_6\NN\14747587|NONE (r_pobj) with_5\IN\0|at|months (r_prep) implanted_4\VBN\1421622|,|LW|, (r_acl) rats_2\NNS\2329401|incidence|after (r_nsubj) developed_12\VBD\1753788|%|,|:|%|and|.|tumors|had (l_dobj) incidence_15\NN\13821570|rats|after (l_prep) of_16\IN\0|higher|a (l_pobj) cancer_18\NN\14239425|NONE
D013739_D011471 CID testosterone_4\NN\14747587| (r_npadvmod) treated_6\VBN\2376958|LW|that|fed (r_amod) rats_8\NNS\2329401|results|. (l_relcl) fed_11\VBN\10373801|LW|treated|that (l_dobj) diet_14\NN\7560652|were|that (l_relcl) supplemented_18\VBN\182406|same|,|the (l_dobj) fat_26\NN\14938907|was|with|which (l_conj) cancer_30\NN\14239425|%|,
D013739_D009369 NONE testosterone_6\NN\14747587|NONE (r_pobj) with_5\IN\0|at|months (r_prep) implanted_4\VBN\1421622|,|LW|, (r_acl) rats_2\NNS\2329401|incidence|after (r_nsubj) developed_12\VBD\1753788|%|,|:|%|and|.|tumors|had (r_ccomp) developed_30\VBN\1753788|NONE (l_dobj) tumors_32\NNS\14234074|%|,|:|%|developed|and|.|had
D013739_D009369 NONE testosterone_6\NN\14747587|NONE (r_pobj) with_5\IN\0|at|months (r_prep) implanted_4\VBN\1421622|,|LW|, (r_acl) rats_2\NNS\2329401|incidence|after (r_nsubj) developed_12\VBD\1753788|%|,|:|%|and|.|tumors|had (r_ccomp) developed_30\VBN\1753788|NONE (l_conj) %_36\NN\0|%|,|:|developed|and|.|tumors|had (l_advcl) included_39\VBD\0| (l_dobj) tumors_41\NNS\14234074|when|it
D013739_D011472 CID testosterone_9\NN\14747587|NONE (r_pobj) with_8\IN\0|developed (r_prep) treated_7\VBN\2376958|rats|and|L|.|diet (l_advcl) developed_10\VBD\1753788|with (l_dobj) prostatitis_12\NN\14336539|NONE
2339463
D015119_D008595 NONE acid_22\NN\14818238|prolonged|for|aminocaproic (r_compound) therapy_23\NN\657604|NONE (l_prep) for_24\IN\0|acid|prolonged|aminocaproic (l_pobj) menorrhagia_25\NN\13513747|NONE
D015119_D020227 NONE acid_22\NN\14818238|prolonged|for|aminocaproic (r_compound) therapy_23\NN\657604|NONE (r_pobj) with_17\IN\0|NONE (r_prep) associated_16\VBN\628491|transverse|sinus (r_acl) thrombosis_15\NN\14100769|NONE
D015119_D020225 NONE acid_22\NN\14818238|prolonged|for|aminocaproic (r_compound) therapy_23\NN\657604|NONE (r_pobj) with_17\IN\0|NONE (r_prep) associated_16\VBN\628491|transverse|sinus (r_acl) thrombosis_15\NN\14100769|NONE
D015119_D012851 NONE acid_15\NN\14818238|NONE (l_appos) thrombosis_19\NN\14100769|,|aminocaproic
D015119_D013923 NONE acid_15\NN\14818238|NONE (r_pobj) with_11\IN\0|NONE (r_prep) treatment_10\NN\654885|NONE (r_pobj) during_9\IN\0|has|been|risk|increased (r_prep) reported_8\VBN\831651|been|.|has|previously|not (l_nsubjpass) risk_2\NN\14541044|during|has|been|increased (l_prep) of_3\IN\0|NONE (l_pobj) disease_5\NN\14061805|NONE
8268147
D010396_D003882 NONE penicillamine_14\NN\3740161|NONE (r_compound) treatment_15\NN\654885|NONE (r_pobj) of_11\IN\0|autoimmune|the (r_prep) complications_10\NNS\1073995|NONE (r_pobj) of_7\IN\0|NONE (r_prep) one_6\CD\13741022|NONE (r_pobj) as_5\IN\14622893|remains|but|,|dermatomyositis|can (r_prep) develop_4\VB\1753788|NONE (l_nsubj) dermatomyositis_2\NN\14350292|remains|but|,|as|can
D010396_D003882 NONE penicillamine_4\NN\3740161|NONE (r_compound) therapy_5\NN\657604|NONE (r_dobj) receiving_1\VBG\2210855|NONE (r_acl) patients_0\NNS\9898892|carefully|.|should|for|be (r_nsubjpass) followed_8\VBN\1835496|NONE (l_prep) for_10\IN\0|carefully|Patients|.|should|be (l_pobj) development_12\NN\248977|NONE (l_prep) of_13\IN\0|the (l_pobj) complications_15\NNS\1073995|NONE (l_prep) like_16\IN\5839024|autoimmune (l_pobj) dermatomyositis_19\NN\14350292|NONE
D010396_D017285 CID penicillamine_15\NN\3740161|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treated_11\VBN\2376958|primary|biliary (r_acl) cirrhosis_10\NN\14116321|NONE (r_pobj) with_7\IN\0|a (r_prep) patient_6\NN\9898892|NONE (r_pobj) in_4\IN\13603305|A|of|. (r_prep) case_1\NN\7283608|NONE (l_prep) of_2\IN\0|A|in|. (l_pobj) polymyositis_3\NN\14350292|NONE
D010396_D017285 CID penicillamine_14\NN\3740161|NONE (r_compound) treatment_15\NN\654885|NONE (r_pobj) of_11\IN\0|autoimmune|the (r_prep) complications_10\NNS\1073995|NONE (r_pobj) of_7\IN\0|NONE (r_prep) one_6\CD\13741022|NONE (r_pobj) as_5\IN\14622893|remains|but|,|dermatomyositis|can (r_prep) develop_4\VB\1753788|NONE (l_nsubj) dermatomyositis_2\NN\14350292|remains|but|,|as|can (l_nmod) polymyositis_0\NNP\14350292|/
D010396_D017285 CID penicillamine_16\NN\3740161|NONE (r_compound) therapy_17\NN\657604|while (r_dobj) receiving_13\VBG\2210855|polymyositis|who (r_advcl) developed_10\VBD\1753788|,|biliary|primary (l_dobj) polymyositis_11\NN\14350292|receiving|who
D010396_D017285 CID penicillamine_4\NN\3740161|NONE (r_compound) therapy_5\NN\657604|NONE (r_dobj) receiving_1\VBG\2210855|NONE (r_acl) patients_0\NNS\9898892|carefully|.|should|for|be (r_nsubjpass) followed_8\VBN\1835496|NONE (l_prep) for_10\IN\0|carefully|Patients|.|should|be (l_pobj) development_12\NN\248977|NONE (l_prep) of_13\IN\0|the (l_pobj) complications_15\NNS\1073995|NONE (l_prep) like_16\IN\5839024|autoimmune (l_pobj) dermatomyositis_19\NN\14350292|NONE (l_nmod) polymyositis_17\NN\14350292|/
D010396_D012216 NONE penicillamine_3\NN\3740161|been|Although|for|has (r_nsubjpass) used_6\VBN\0|.|,|usefulness|toxicity (l_prep) for_7\IN\0|been|Although|penicillamine|has (l_pobj) diseases_10\NNS\14061805|NONE
D010396_D008105 NONE penicillamine_15\NN\3740161|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treated_11\VBN\2376958|primary|biliary (r_acl) cirrhosis_10\NN\14116321|NONE
D010396_D008105 NONE penicillamine_16\NN\3740161|NONE (r_compound) therapy_17\NN\657604|while (r_dobj) receiving_13\VBG\2210855|polymyositis|who (r_advcl) developed_10\VBD\1753788|,|biliary|primary (r_relcl) cirrhosis_7\NN\14116321|NONE
D010396_D064420 NONE penicillamine_3\NN\3740161|been|Although|for|has (r_nsubjpass) used_6\VBN\0|.|,|usefulness|toxicity (r_advcl) limits_13\VBZ\5123416|NONE (l_nsubj) toxicity_12\NN\13576101|.|,|used|usefulness
9165568
D018967_D001480 NONE risperidone_14\NN\0|NONE (r_pobj) with_13\IN\0|the|low|of (r_prep) frequency_9\NN\15286249|to (l_prep) of_10\IN\0|the|with|low (l_pobj) symptoms_12\NNS\5823932|NONE
D004298_D009459 NONE dopamine_10\NN\14807737|receptor|D|in (r_compound) blockade_13\NN\952963|NONE (r_pobj) of_9\IN\0|a (r_prep) result_8\NN\34213|to (r_attr) be_6\VB\14625458|syndrome|is|. (r_xcomp) thought_4\VBN\5809192|NONE (l_nsubjpass) syndrome_2\NN\5870365|be|is|.
D018967_D009459 CID risperidone_4\NN\0|NONE (r_pobj) with_3\IN\0|.|Neuroleptic|malignant (r_prep) syndrome_2\NN\5870365|NONE
D018967_D009459 CID risperidone_12\NN\0|NONE (r_pobj) with_11\IN\0|NONE (r_prep) monotherapy_10\NN\0|NONE (r_pobj) after_9\IN\0|woman|syndrome|. (r_prep) developed_5\VBD\1753788|NONE (l_dobj) syndrome_8\NN\5870365|woman|.|after
D018967_D009459 CID risperidone_11\NN\0|NONE (r_pobj) with_10\IN\0|protection|that (r_prep) observed_9\VBN\2163746|.|It|ensure (r_ccomp) appears_1\VBZ\2604760|NONE (l_conj) ensure_14\VB\0|.|It|observed (l_dobj) protection_15\NN\407535|not|does (l_prep) from_16\IN\0|NONE (l_pobj) syndrome_19\NN\5870365|NONE
20164825
D008687_D014652 NONE metformin_3\NN\2719105|apoptosis|induced|can|.|and|prevent (r_nsubj) diminish_5\VB\169651|NONE (l_conj) prevent_15\VB\0|apoptosis|induced|can|metformin|.|and (l_dobj) dysfunction_17\NN\14204950|in
D005839_D058186 CID gentamicin_4\NN\2716866| (r_npadvmod) mediated_6\VBN\761713|renal|acute (r_amod) failure_9\NN\66216|fully|treatment|.
D005839_D007674 NONE gentamicin_3\NN\2716866| (r_npadvmod) induced_5\VBN\1627355|experimental (r_amod) nephropathy_6\NN\14573196|Metformin|by|.
D005839_D007674 NONE gentamicin_12\NN\2716866|NONE (r_amod) nephrotoxicity_13\NN\0|can|and|improve|effects|that
D008687_D007674 NONE metformin_0\NNP\2719105|by|nephropathy|. (r_nsubj) prevents_1\VBZ\0|NONE (l_dobj) nephropathy_6\NN\14573196|Metformin|by|.
D008687_D007674 NONE metformin_11\NN\2719105|NONE (r_pobj) by_10\IN\0|their (r_prep) correction_9\NN\248977|of|vivo|and (r_conj) markers_3\NNS\21939|NONE (l_prep) of_4\IN\0|vivo|and|correction (l_pobj) dysfunction_6\NN\14204950|NONE
D008687_D007674 NONE metformin_9\NN\2719105|NONE (r_pobj) of_8\IN\0|pleiotropic (r_prep) effects_7\NNS\13245626|can|and|improve|that|nephrotoxicity (r_nsubj) lessen_11\VB\169651|.|study|,|Thus (l_dobj) nephrotoxicity_13\NN\0|can|and|improve|effects|that
D005839_D064420 NONE gentamicin_14\NN\2716866|NONE (r_amod) toxicity_15\NN\13576101|NONE
D008687_D058186 NONE metformin_0\NNP\2719105|NONE (r_compound) treatment_1\NN\654885|fully|.|failure (r_nsubj) blocked_3\VBD\1476483|NONE (l_dobj) failure_9\NN\66216|fully|treatment|.
6728084
D000617_D007674 NONE aminoglycoside_3\NN\0|on (r_compound) treatment_4\NN\654885|NONE (r_pobj) of_2\IN\0|.|Nephrotoxic (r_prep) effects_1\NNS\13245626|NONE (l_amod) nephrotoxic_0\JJ\0|.|of
D000617_D007674 NONE aminoglycosides_2\NNS\0|,|.|may|as|Thus (r_nsubj) act_4\VB\6479665|NONE (l_prep) as_5\IN\14622893|,|.|may|aminoglycosides|Thus (l_pobj) nephrotoxicants_6\NNS\0|NONE (l_prep) at_7\IN\14622893|NONE (l_pobj) impairment_13\NN\7296428|NONE (l_prep) of_14\IN\0|glomerular|inducing (l_pobj) reabsorption_16\NN\13526110|NONE
625456
D002119_D006934 CID ate_24\VBN\0|carbon|| (r_amod) sodium_26\NN\14625458|calcium|bicarbonate (r_compound) powders_28\NNS\15046900|NONE (r_pobj) of_20\IN\0|large (r_prep) amounts_19\NNS\13329641|for|who|had|regularly (r_dobj) consumed_17\VBN\1168468|NONE (r_relcl) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|case|.|two|are (r_prep) reported_11\VBN\831651|NONE (l_nsubjpass) case_1\NN\7283608|in|.|two|are (l_prep) of_2\IN\0|One|and (l_pobj) hypercalcaemia_4\NN\14299637|NONE
D017693_D006934 CID bicarbonate_27\NN\14798450|calcium|sodium (r_compound) powders_28\NNS\15046900|NONE (r_pobj) of_20\IN\0|large (r_prep) amounts_19\NNS\13329641|for|who|had|regularly (r_dobj) consumed_17\VBN\1168468|NONE (r_relcl) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|case|.|two|are (r_prep) reported_11\VBN\831651|NONE (l_nsubjpass) case_1\NN\7283608|in|.|two|are (l_prep) of_2\IN\0|One|and (l_pobj) hypercalcaemia_4\NN\14299637|NONE
D002119_D053040 CID ate_24\VBN\0|carbon|| (r_amod) sodium_26\NN\14625458|calcium|bicarbonate (r_compound) powders_28\NNS\15046900|NONE (r_pobj) of_20\IN\0|large (r_prep) amounts_19\NNS\13329641|for|who|had|regularly (r_dobj) consumed_17\VBN\1168468|NONE (r_relcl) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|case|.|two|are (r_prep) reported_11\VBN\831651|NONE (l_nsubjpass) two_6\CD\13741022|in|case|.|are (l_prep) of_7\IN\0|NONE (l_pobj) nephrolithiasis_9\NN\14115914|NONE
D017693_D053040 CID bicarbonate_27\NN\14798450|calcium|sodium (r_compound) powders_28\NNS\15046900|NONE (r_pobj) of_20\IN\0|large (r_prep) amounts_19\NNS\13329641|for|who|had|regularly (r_dobj) consumed_17\VBN\1168468|NONE (r_relcl) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|case|.|two|are (r_prep) reported_11\VBN\831651|NONE (l_nsubjpass) two_6\CD\13741022|in|case|.|are (l_prep) of_7\IN\0|NONE (l_pobj) nephrolithiasis_9\NN\14115914|NONE
18363626
D010100_D001919 NONE oxygen_30\NN\14622893|NONE (r_compound) saturations_31\NNS\13534954|adjusted|and|normal (r_conj) range_28\NN\5123416|NONE (r_pobj) of_23\IN\0| (r_prep) %_22\NN\0|NONE (r_pobj) within_20\IN\0|,|associated|were|pressures|. (r_prep) were_19\VBD\0|NONE (l_advcl) associated_4\VBN\628491|,|within|were|pressures|. (l_prep) with_5\IN\0|sedation|Although|was (l_pobj) incidence_9\NN\13821570|NONE (l_prep) of_10\IN\0|a|% (l_pobj) bradycardia_11\NN\14110674|NONE
D020927_D001919 CID dexmedetomidine_1\NN\0|NONE (r_amod) sedation_2\NN\14034177|with|Although|was (r_nsubjpass) associated_4\VBN\628491|,|within|were|pressures|. (l_prep) with_5\IN\0|sedation|Although|was (l_pobj) incidence_9\NN\13821570|NONE (l_prep) of_10\IN\0|a|% (l_pobj) bradycardia_11\NN\14110674|NONE
1286498
D005442_D009325 CID flumazenil_11\JJ\0|the|and|pain (r_compound) group_12\NN\2137|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) vomiting_8\VBG\116687|and (r_conj) nausea_6\NN\14299637|.|effects
D005442_D009325 CID flumazenil_11\JJ\0|the|and|pain (r_compound) group_12\NN\2137|NONE (l_conj) pain_19\NN\14299637|the|flumazenil|and (l_nmod) nausea_14\NN\14299637|in
D005442_D010146 NONE flumazenil_11\JJ\0|the|and|pain (r_compound) group_12\NN\2137|NONE (l_conj) pain_19\NN\14299637|the|flumazenil|and
D005442_D014839 CID flumazenil_11\JJ\0|the|and|pain (r_compound) group_12\NN\2137|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) vomiting_8\VBG\116687|and
8599504
D004329_D000799 CID droperidol_3\NN\0|NONE (r_compound) administration_4\NN\1133281|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBD\628491|. (r_acl) angioedema_0\NNP\14316714|NONE
D004329_D000799 CID droperidol_39\NN\0|NONE (r_pobj) of_38\IN\0|a|single|IV (r_prep) dose_37\NN\3740161|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) of_30\IN\0| (r_prep) minutes_29\NNS\6502378|NONE (r_pobj) within_27\IN\0|angioedema|in (r_prep) developed_26\VBN\1753788|no|drug|known (l_nsubj) angioedema_19\NN\14316714|within|in
D004329_D004487 NONE droperidol_39\NN\0|NONE (r_pobj) of_38\IN\0|a|single|IV (r_prep) dose_37\NN\3740161|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) of_30\IN\0| (r_prep) minutes_29\NNS\6502378|NONE (r_pobj) within_27\IN\0|angioedema|in (r_prep) developed_26\VBN\1753788|no|drug|known (l_nsubj) angioedema_19\NN\14316714|within|in (l_prep) with_20\IN\0|NONE (l_pobj) swelling_23\NN\14315071|NONE
D004329_D004342 NONE droperidol_39\NN\0|NONE (r_pobj) of_38\IN\0|a|single|IV (r_prep) dose_37\NN\3740161|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) of_30\IN\0| (r_prep) minutes_29\NNS\6502378|NONE (r_pobj) within_27\IN\0|angioedema|in (r_prep) developed_26\VBN\1753788|no|drug|known (r_relcl) allergies_16\NNS\14533203|NONE
D004329_D014060 NONE droperidol_39\NN\0|NONE (r_pobj) of_38\IN\0|a|single|IV (r_prep) dose_37\NN\3740161|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) of_30\IN\0| (r_prep) minutes_29\NNS\6502378|NONE (r_pobj) within_27\IN\0|angioedema|in (r_prep) developed_26\VBN\1753788|no|drug|known (l_nsubj) angioedema_19\NN\14316714|within|in (l_prep) with_20\IN\0|NONE (l_pobj) swelling_23\NN\14315071|NONE
9514561
D002211_D010146 CID capsaicin_5\NN\15032661|NONE (r_pobj) by_4\IN\0|NONE (r_agent) elicited_3\VBN\1617192|study|cranial|.|:|Experimental (r_acl) pain_2\NN\14299637|NONE
D002211_D010146 CID capsaicin_4\NN\15032661|NONE (r_pobj) of_3\IN\0|small|A (r_prep) amount_2\NN\13329641|evoke|was|in|subcutaneously|. (r_nsubjpass) administered_6\VBN\2436349|NONE (l_advcl) evoke_13\VB\1617192|amount|was|in|subcutaneously|. (l_dobj) sensation_17\NN\5708432|to (l_amod) painful_16\JJ\0|in|burning|a
9848575
D004317_D009202 CID doxorubicin_15\RB\2716866| (r_npadvmod) induced_17\VBN\1627355|in (r_amod) cardiomyopathy_18\NN\14103288|normal|and
D004317_D009202 CID doxorubicin_7\NN\2716866|NONE (r_pobj) of_6\IN\0|six (r_prep) courses_5\NNS\883297|which (r_dobj) received_2\VBD\2210855|NONE (r_relcl) animals_0\NNS\4475|.|electrocardiogram|show|decrease|, (r_nsubj) demonstrated_8\VBD\2137132|NONE (l_dobj) decrease_16\NN\7296428|.|electrocardiogram|show|,|Animals (l_prep) of_17\IN\0|NONE (l_pobj) pressure_19\NN\11419404|NONE (l_conj) cardiomyopathy_25\NN\14103288|and|blood
D004317_D009202 CID doxorubicin_22\NN\2716866|NONE (r_pobj) of_21\IN\0|four|mg/kg|)|( (r_prep) courses_20\NNS\883297|NONE (r_pobj) by_18\IN\0|examine|in|.|was (r_agent) induced_15\VBN\1627355|NONE (l_csubjpass) examine_1\VB\0|by|in|.|was (l_dobj) effect_6\NN\34213|To (l_prep) of_7\IN\0|deteriorating|a|cardiotoxic (l_pobj) cardiomyopathy_13\NN\14103288|NONE
D018943_D009202 NONE anthracycline_6\NN\0|(|SM|a|novel|)|synthetic (r_amod) derivative_7\JJ\5802185|NONE (r_pobj) of_2\IN\0|Chronic|on|. (r_prep) effects_1\NNS\13245626|NONE (l_prep) on_11\IN\0|Chronic|of|. (l_pobj) heart_13\NN\5919034|NONE (l_conj) cardiomyopathy_18\NN\14103288|normal|and
D004317_D066126 NONE doxorubicin_28\NN\2716866|effect|of|cardiotoxic|chronic|and|the (r_appos) potential_9\NN\14481929|to (l_amod) cardiotoxic_8\JJ\0|effect|of|doxorubicin|chronic|and|the
D004317_D066126 NONE doxorubicin_28\NN\2716866|effect|of|cardiotoxic|chronic|and|the (r_appos) potential_9\NN\14481929|to (l_conj) effect_16\NN\34213|of|cardiotoxic|doxorubicin|chronic|and|the (l_prep) on_19\IN\0|a|of|deteriorating|possible (l_pobj) cardiotoxicity_23\NN\0|NONE
D004317_D066126 NONE doxorubicin_22\NN\2716866|NONE (r_pobj) of_21\IN\0|four|mg/kg|)|( (r_prep) courses_20\NNS\883297|NONE (r_pobj) by_18\IN\0|examine|in|.|was (r_agent) induced_15\VBN\1627355|NONE (l_csubjpass) examine_1\VB\0|by|in|.|was (l_dobj) effect_6\NN\34213|To (l_amod) cardiotoxic_5\JJ\0|deteriorating|a|of
D004317_D066126 NONE doxorubicin_11\NN\2716866|additional|the (r_compound) treatment_12\NN\654885|NONE (r_pobj) by_8\IN\0|were|changes|. (r_agent) enhanced_7\VBN\227165|NONE (l_nsubjpass) changes_5\NNS\7283608|were|by|. (l_amod) cardiotoxic_4\JJ\0|grade|The
D004317_D066126 NONE doxorubicin_16\RB\2716866| (r_npadvmod) induced_18\VBN\1627355|in (r_amod) cardiotoxicity_19\NN\0|NONE (r_pobj) on_15\IN\0|deteriorating (r_prep) effect_14\NN\34213|chronic|and (r_conj) cardiotoxicity_11\NN\0|NONE
D004317_D066126 NONE doxorubicin_16\RB\2716866| (r_npadvmod) induced_18\VBN\1627355|in (r_amod) cardiotoxicity_19\NN\0|NONE
C055866_D009202 NONE sm-5887_9\NNP\0|(|a|novel|anthracycline|)|synthetic (r_appos) derivative_7\JJ\5802185|NONE (r_pobj) of_2\IN\0|Chronic|on|. (r_prep) effects_1\NNS\13245626|NONE (l_prep) on_11\IN\0|Chronic|of|. (l_pobj) heart_13\NN\5919034|NONE (l_conj) cardiomyopathy_18\NN\14103288|normal|and
C055866_D009202 NONE sm-5887_35\NNP\0|the (r_compound) administration_36\NN\1133281|animals|while|not|changes|did (r_nsubj) show_39\VB\429048|.|electrocardiogram|decrease|,|Animals (r_advcl) demonstrated_8\VBD\2137132|NONE (l_dobj) decrease_16\NN\7296428|.|electrocardiogram|show|,|Animals (l_prep) of_17\IN\0|NONE (l_pobj) pressure_19\NN\11419404|NONE (l_conj) cardiomyopathy_25\NN\14103288|and|blood
C055866_D009202 NONE sm-5887_8\NNP\0|grade|, (r_nmod) cardiomyopathy_13\NN\14103288|NONE
C055866_D009202 NONE sm-5887_5\NNP\0|the (r_compound) treatment_6\NN\654885|,|On|.|did|not|grade (r_nsubj) progress_9\VB\250259|NONE (l_dobj) grade_11\NN\7975026|,|On|.|did|not|treatment (l_prep) of_12\IN\0|the (l_pobj) cardiomyopathy_13\NN\14103288|NONE
C055866_D066126 NONE sm-5887_11\NNP\0|NONE (r_pobj) of_10\IN\0|effect|cardiotoxic|doxorubicin|chronic|and|the (r_prep) potential_9\NN\14481929|to (l_amod) cardiotoxic_8\JJ\0|effect|of|doxorubicin|chronic|and|the
C055866_D066126 NONE sm-5887_11\NNP\0|NONE (r_pobj) of_10\IN\0|effect|cardiotoxic|doxorubicin|chronic|and|the (r_prep) potential_9\NN\14481929|to (l_conj) effect_16\NN\34213|of|cardiotoxic|doxorubicin|chronic|and|the (l_prep) on_19\IN\0|a|of|deteriorating|possible (l_pobj) cardiotoxicity_23\NN\0|NONE
C055866_D066126 NONE sm-5887_18\NNP\0|NONE (r_pobj) of_17\IN\0|a|deteriorating|possible|on (r_prep) effect_16\NN\34213|of|cardiotoxic|doxorubicin|chronic|and|the (r_conj) potential_9\NN\14481929|to (l_amod) cardiotoxic_8\JJ\0|effect|of|doxorubicin|chronic|and|the
C055866_D066126 NONE sm-5887_18\NNP\0|NONE (r_pobj) of_17\IN\0|a|deteriorating|possible|on (r_prep) effect_16\NN\34213|of|cardiotoxic|doxorubicin|chronic|and|the (l_prep) on_19\IN\0|a|of|deteriorating|possible (l_pobj) cardiotoxicity_23\NN\0|NONE
C055866_D066126 NONE sm-5887_8\NNP\0|grade|, (r_nmod) cardiomyopathy_13\NN\14103288|NONE (r_pobj) of_7\IN\0|deteriorating|a|cardiotoxic (r_prep) effect_6\NN\34213|To (l_amod) cardiotoxic_5\JJ\0|deteriorating|a|of
C055866_D066126 NONE sm-5887_3\NNP\0|does|.|potential|In|,|not (r_nsubj) have_6\VB\7846|NONE (l_dobj) potential_8\NN\14481929|does|SM|.|In|,|not (l_prep) of_9\IN\0|any (l_pobj) cardiotoxicity_11\NN\0|NONE
C055866_D066126 NONE sm-5887_3\NNP\0|does|.|potential|In|,|not (r_nsubj) have_6\VB\7846|NONE (l_dobj) potential_8\NN\14481929|does|SM|.|In|,|not (l_prep) of_9\IN\0|any (l_pobj) cardiotoxicity_11\NN\0|NONE (l_conj) effect_14\NN\34213|chronic|and (l_prep) on_15\IN\0|deteriorating (l_pobj) cardiotoxicity_19\NN\0|NONE
11573852
D000666_D004830 NONE b_18\NNP\1355326|NONE (r_pobj) of_16\IN\0|intravenous (r_prep) infusion_15\NN\14589223|NONE (r_pobj) during_13\IN\0|man|,|seizures|stopped|then|. (r_prep) experienced_8\VBD\2108377|NONE (l_dobj) seizures_12\NNS\14081375|man|,|stopped|then|.|during
D000666_D012640 CID b_1\NN\1355326| (r_npadvmod) induced_3\VBN\1627355|in|. (r_amod) seizures_4\NNS\14081375|NONE
D000666_D012640 CID b_16\NNP\1355326|NONE (r_compound) infusion_17\NN\14589223|NONE (r_pobj) following_14\VBG\8180190|a|of (r_prep) case_3\NN\7283608|.|To (l_prep) of_4\IN\0|following|a (l_pobj) episodes_6\NNS\7283608|NONE (l_prep) of_7\IN\0|in|multiple (l_pobj) activity_9\NN\30358|NONE (l_compound) seizure_8\NN\14081375|NONE
D000666_D012640 CID b_18\NNP\1355326|NONE (r_pobj) of_16\IN\0|intravenous (r_prep) infusion_15\NN\14589223|NONE (r_pobj) during_13\IN\0|man|,|seizures|stopped|then|. (r_prep) experienced_8\VBD\2108377|NONE (l_conj) stopped_28\VBN\0|man|,|seizures|then|.|during (l_nsubjpass) seizures_23\NNS\14081375|and|decreased|was
D000666_D012640 CID b_15\NNP\1355326|amphotercin (r_compound) administration_16\NN\1133281|only (r_pobj) during_13\IN\0|NONE (r_prep) occurred_11\VBD\0|.|,|and|seizures|Despite (r_conj) persisted_9\VBD\118523|NONE (l_nsubj) seizures_8\NNS\14081375|.|,|and|occurred|Despite
D000666_D012640 CID b_8\NNP\1355326|cause|that (r_nsubj) was_9\VBD\0|.|course (l_attr) cause_11\NN\7323922|B|that (l_prep) of_12\IN\0|the (l_pobj) seizures_14\NNS\14081375|NONE
D000666_D012640 CID b_1\NNP\1355326|be|. (r_nsubj) seems_2\VBZ\2604760|NONE (l_xcomp) be_4\VB\14625458|B|. (l_attr) cause_7\NN\7323922|to (l_prep) of_8\IN\0|probable|the (l_pobj) seizures_10\NNS\14081375|NONE
D000666_D012640 CID b_11\NNP\1355326|NONE (r_pobj) with_9\IN\0|NONE (r_prep) associated_8\VBN\628491|NONE (r_acl) seizures_7\NNS\14081375|NONE
D000431_D012640 NONE alcohol_9\NN\7881800|as|withdrawal (r_compound) intake_10\NN\13440063|a|of|; (r_conj) history_4\NN\15120823|patient|.|cause (r_dobj) had_2\VBD\0|NONE (l_conj) cause_17\VB\7323922|patient|.|history (l_dobj) seizures_18\NNS\14081375|can|also
D016049_D012640 NONE didanosine_0\NNP\2725367|potential|also|. (r_nsubj) has_2\VBZ\13888491|NONE (l_dobj) potential_4\NN\14481929|Didanosine|also|. (l_prep) for_5\IN\0|a (l_pcomp) inducing_6\VBG\42311|NONE (l_dobj) seizures_7\NNS\14081375|NONE
D000666_D000163 NONE b_1\NN\1355326| (r_npadvmod) induced_3\VBN\1627355|in|. (r_amod) seizures_4\NNS\14081375|NONE (l_prep) in_5\IN\13603305|induced|. (l_pobj) patient_7\NN\9898892|NONE (l_prep) with_8\IN\0|a (l_pobj) aids_9\NNP\13974317|NONE
D000666_D000163 NONE b_16\NNP\1355326|NONE (r_compound) infusion_17\NN\14589223|NONE (r_pobj) following_14\VBG\8180190|a|of (r_prep) case_3\NN\7283608|.|To (l_prep) of_4\IN\0|following|a (l_pobj) episodes_6\NNS\7283608|NONE (l_prep) in_10\IN\13603305|multiple|of (l_pobj) patent_13\NN\6470073|NONE (l_compound) aids_12\NNP\13974317|an
D000666_D000163 NONE b_8\NNP\1355326|cause|that (r_nsubj) was_9\VBD\0|.|course (l_attr) cause_11\NN\7323922|B|that (l_prep) of_12\IN\0|the (l_pobj) seizures_14\NNS\14081375|NONE (l_prep) in_15\IN\13603305|the (l_pobj) patient_18\NN\9898892|NONE (l_compound) aids_17\NNP\13974317|this
D000431_D000437 NONE alcohol_9\NN\7881800|as|withdrawal (r_compound) intake_10\NN\13440063|a|of|; (r_conj) history_4\NN\15120823|patient|.|cause (l_prep) of_5\IN\0|a|;|intake (l_pobj) abuse_7\NN\418025|NONE
D008140_D012640 NONE lorazepam_5\NN\2830852|and (r_conj) phenytoin_3\NN\3550533|NONE (r_pobj) of_2\IN\0|NONE (r_prep) administration_1\NN\1133281|NONE (r_pobj) despite_0\IN\7501545|.|,|and|seizures|occurred (r_prep) persisted_9\VBD\118523|NONE (l_nsubj) seizures_8\NNS\14081375|.|,|and|occurred|Despite
D010672_D012640 NONE phenytoin_3\NN\3550533|NONE (r_pobj) of_2\IN\0|NONE (r_prep) administration_1\NN\1133281|NONE (r_pobj) despite_0\IN\7501545|.|,|and|seizures|occurred (r_prep) persisted_9\VBD\118523|NONE (l_nsubj) seizures_8\NNS\14081375|.|,|and|occurred|Despite
8012887
D006493_D013927 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|arterial (r_amod) thrombosis_11\NN\14100769|NONE
D006493_D013927 CID heparin_6\NN\2718259| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) thrombosis_9\NN\14100769|NONE
D006493_D013927 CID heparin_14\JJ\2718259|NONE (r_pobj) with_13\IN\0|NONE (r_prep) patients_12\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|successfully|induced|,|defined|has|been|but|for|Ancrod (r_prep) used_3\VBN\0|NONE (l_prep) for_5\IN\0|successfully|induced|,|defined|has|been|but|in|Ancrod (l_pobj) prophylaxis_6\NN\1077350|NONE (l_prep) against_7\IN\0|NONE (l_pobj) development_8\NN\248977|NONE (l_prep) of_9\IN\0|NONE (l_pobj) thrombosis_10\NN\14100769|NONE
D006493_D013927 CID heparin_14\JJ\2718259|NONE (r_pobj) with_13\IN\0|NONE (r_prep) patients_12\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|successfully|induced|,|defined|has|been|but|for|Ancrod (r_prep) used_3\VBN\0|NONE (l_conj) defined_39\VBN\2604760|successfully|induced|,|has|been|but|for|in|Ancrod (l_auxpass) is_36\VBZ\0|not|well|. (l_nsubj) success_27\NN\7283608|NONE (l_prep) in_28\IN\13603305|its (l_pobj) patients_29\NNS\9898892|NONE (l_relcl) developed_32\VBN\1753788|NONE (l_dobj) syndrome_35\NN\5870365|who|have (l_compound) thrombosis_34\NN\14100769|the
D006493_D013927 CID heparin_23\NN\2718259|NONE (r_pobj) to_22\IN\0|brief (r_prep) reexposure_21\NN\0|who (r_dobj) require_19\VBP\0|platelet (r_relcl) aggregation_17\NN\31264|NONE (r_dobj) induced_15\VBN\1627355|successfully|,|defined|has|been|but|for|in|Ancrod (r_advcl) used_3\VBN\0|NONE (l_prep) for_5\IN\0|successfully|induced|,|defined|has|been|but|in|Ancrod (l_pobj) prophylaxis_6\NN\1077350|NONE (l_prep) against_7\IN\0|NONE (l_pobj) development_8\NN\248977|NONE (l_prep) of_9\IN\0|NONE (l_pobj) thrombosis_10\NN\14100769|NONE
D006493_D013927 CID heparin_23\NN\2718259|NONE (r_pobj) to_22\IN\0|brief (r_prep) reexposure_21\NN\0|who (r_dobj) require_19\VBP\0|platelet (r_relcl) aggregation_17\NN\31264|NONE (r_dobj) induced_15\VBN\1627355|successfully|,|defined|has|been|but|for|in|Ancrod (r_advcl) used_3\VBN\0|NONE (l_conj) defined_39\VBN\2604760|successfully|induced|,|has|been|but|for|in|Ancrod (l_auxpass) is_36\VBZ\0|not|well|. (l_nsubj) success_27\NN\7283608|NONE (l_prep) in_28\IN\13603305|its (l_pobj) patients_29\NNS\9898892|NONE (l_relcl) developed_32\VBN\1753788|NONE (l_dobj) syndrome_35\NN\5870365|who|have (l_compound) thrombosis_34\NN\14100769|the
D006493_D013927 CID heparin_14\NN\2718259| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) thrombosis_17\NN\14100769|NONE
D006493_D001791 NONE heparin_14\JJ\2718259|NONE (r_pobj) with_13\IN\0|NONE (r_prep) patients_12\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|successfully|induced|,|defined|has|been|but|for|Ancrod (r_prep) used_3\VBN\0|NONE (l_advcl) induced_15\VBN\1627355|successfully|,|defined|has|been|but|for|in|Ancrod (l_dobj) aggregation_17\NN\31264|NONE
D006493_D001791 NONE heparin_23\NN\2718259|NONE (r_pobj) to_22\IN\0|brief (r_prep) reexposure_21\NN\0|who (r_dobj) require_19\VBP\0|platelet (r_relcl) aggregation_17\NN\31264|NONE
8766220
D017374_-1 NONE paroxetine_7\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) association_5\NN\8008335|NONE (r_pobj) in_4\IN\13603305|.|was|dosulepine|drug|and (r_prep) initiated_3\VBN\1617192|NONE (l_conj) dosulepine_9\JJ\0|.|was|drug|and|in (l_prep) in_11\IN\13603305|hydrochloride (l_pobj) patient_14\NN\9898892|NONE (l_amod) tetraparetic_13\JJ\0|with|a
D014147_D006212 CID tramadol_9\NN\0|NONE (r_pobj) of_8\IN\0|term (r_prep) intake_7\NN\13440063|NONE (r_pobj) after_3\IN\0|hallucinations|and|combined|. (r_prep) nightmares_0\NNS\14411243|NONE (l_conj) hallucinations_2\NNS\14376855|and|combined|after|.
D014147_D006212 CID tramadol_25\NN\0|active|and (r_conj) drugs_23\NNS\14778436|NONE (r_pobj) of_19\IN\0|the (r_prep) withdrawal_18\NN\7206096|NONE (r_pobj) after_16\IN\0|only|that (r_prep) stopped_15\VBD\0|NONE (r_relcl) hallucinations_12\NNS\14376855|after|patient|.
D004308_D059350 NONE hydrochloride_10\NN\14817592|in (r_dobj) dosulepine_9\JJ\0|.|was|drug|and|in (l_prep) in_11\IN\13603305|hydrochloride (l_pobj) patient_14\NN\9898892|NONE (l_prep) with_15\IN\0|a|tetraparetic (l_pobj) pain_17\NN\14299637|NONE
D004308_-1 NONE hydrochloride_10\NN\14817592|in (r_dobj) dosulepine_9\JJ\0|.|was|drug|and|in (l_prep) in_11\IN\13603305|hydrochloride (l_pobj) patient_14\NN\9898892|NONE (l_amod) tetraparetic_13\JJ\0|with|a
D017374_D059350 NONE paroxetine_7\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) association_5\NN\8008335|NONE (r_pobj) in_4\IN\13603305|.|was|dosulepine|drug|and (r_prep) initiated_3\VBN\1617192|NONE (l_conj) dosulepine_9\JJ\0|.|was|drug|and|in (l_prep) in_11\IN\13603305|hydrochloride (l_pobj) patient_14\NN\9898892|NONE (l_prep) with_15\IN\0|a|tetraparetic (l_pobj) pain_17\NN\14299637|NONE
D014147_D010146 NONE tramadol_0\NNP\0|.|opioid (r_nsubj) is_1\VBZ\0|NONE (l_attr) opioid_4\NN\0|.|Tramadol (l_prep) with_5\IN\0|a|weak (l_pobj) effects_6\NNS\13245626|NONE (l_relcl) used_14\VBN\0|on (l_xcomp) treat_16\VB\7570720|that|is (l_dobj) pain_18\NN\14299637|to
D014147_D010146 NONE tramadol_0\NNP\0|.|opioid (r_nsubj) is_1\VBZ\0|NONE (l_attr) opioid_4\NN\0|.|Tramadol (l_prep) with_5\IN\0|a|weak (l_pobj) effects_6\NNS\13245626|NONE (l_relcl) used_14\VBN\0|on (l_xcomp) treat_16\VB\7570720|that|is (l_dobj) pain_18\NN\14299637|to (l_conj) pain_23\NN\14299637|and|cancer
D014147_D009369 NONE tramadol_0\NNP\0|.|opioid (r_nsubj) is_1\VBZ\0|NONE (l_attr) opioid_4\NN\0|.|Tramadol (l_prep) with_5\IN\0|a|weak (l_pobj) effects_6\NNS\13245626|NONE (l_relcl) used_14\VBN\0|on (l_xcomp) treat_16\VB\7570720|that|is (l_dobj) pain_18\NN\14299637|to (l_compound) cancer_17\NN\14239425|and|pain
3088349
D000661_-1 NONE amphetamine_17\NN\3248958|NONE (r_pobj) by_16\IN\0|NONE (r_prep) exhaustion_15\NN\14016361|NONE (r_pobj) to_14\TO\0|rotation|susceptibility|. (r_prep) reflects_8\VBZ\923793|NONE (l_nsubj) rotation_2\NN\331950|to|susceptibility|. (l_prep) following_3\VBG\8180190|Transient|contralateral (l_pobj) lesion_7\NN\14204950|NONE
D000661_D009069 CID amphetamine_17\NN\3248958|NONE (r_pobj) by_16\IN\0|NONE (r_prep) exhaustion_15\NN\14016361|NONE (r_pobj) to_14\TO\0|rotation|susceptibility|. (r_prep) reflects_8\VBZ\923793|NONE (l_nsubj) rotation_2\NN\331950|to|susceptibility|.
D000661_D009069 CID amphetamine_26\NN\3248958| (r_npadvmod) induced_28\VBN\1627355|rotational (r_amod) behavior_30\NN\407535|NONE (r_pobj) on_25\IN\0|,|we|effect|In|. (r_prep) examined_12\VBD\0|NONE (l_prep) in_0\IN\13603305|,|we|effect|on|. (l_pobj) order_1\NN\7168131|NONE (l_acl) clarify_3\VB\939277|NONE (l_dobj) nature_5\NN\4723816|to (l_prep) of_6\IN\0|the (l_pobj) rotation_10\NN\331950|NONE
D000661_D009069 CID amphetamine_26\NN\3248958| (r_npadvmod) induced_28\VBN\1627355|rotational (r_amod) behavior_30\NN\407535|NONE
D000661_D009069 CID amphetamine_10\NN\3248958|was|for|when (r_nsubjpass) administered_12\VBN\2436349|evident|still|indicating|degree|.|, (r_advcl) was_6\VBD\0|NONE (l_advcl) indicating_22\VBG\952524|administered|evident|still|degree|.|, (l_dobj) involvement_23\NN\1080366|NONE (l_prep) of_24\IN\0|NONE (l_pobj) cells_26\NNS\3080309|NONE (l_prep) in_27\IN\13603305|spared (l_pobj) rotation_30\NN\331950|NONE
D000661_D009069 CID amphetamine_16\NN\3248958|or|exercise|, (r_compound) dose_17\NN\3740161|either|,|lesion (r_conj) volume_14\NN\33615|NONE (r_pobj) of_11\IN\0|NONE (r_prep) irrespective_10\RB\0|and|(|of|the (r_conj) duration_5\NN\15113229|NONE (r_pobj) of_3\IN\0|NONE (r_prep) regardless_2\RB\0|become|,|,|rotation|and|,|However|circled (r_advmod) tended_31\VBD\2604760|NONE (l_nsubj) rotation_30\NN\331950|become|,|,|and|,|regardless|However|circled
D000661_D009069 CID amphetamine_27\NN\3248958| (r_npadvmod) induced_29\VBN\1627355|NONE (r_amod) rotation_30\NN\331950|become|,|,|and|,|regardless|However|circled
D000661_D009069 CID amphetamine_55\NN\3248958|further (r_compound) injections_56\NNS\320852|NONE (r_pobj) to_53\IN\0|NONE (r_prep) response_52\NN\11410625|NONE (r_pobj) in_51\IN\13603305|to|rats|.|ipsilaterally (r_prep) circled_46\VBD\1835496|become|,|,|rotation|and|,|regardless|However (r_conj) tended_31\VBD\2604760|NONE (l_nsubj) rotation_30\NN\331950|become|,|,|and|,|regardless|However|circled
D000661_D009069 CID amphetamine_4\NN\3248958|effect|that (r_nsubj) has_5\VBZ\13888491|findings|. (l_dobj) effect_8\NN\34213|amphetamine|that (l_prep) on_9\IN\0|irreversible|an (l_pobj) pool_15\NN\3302121|NONE (l_acl) contributing_16\VBG\126264|lesion|the|DA (l_prep) to_17\IN\0|NONE (l_pobj) rotation_19\NN\331950|NONE
D016627_-1 NONE 6-ohda_2\CD\0|NONE (r_pobj) following_0\VBG\8180190|lesion (r_prep) induced_3\VBN\1627355|has|period|been|precede|. (l_dobj) lesion_5\NN\14204950|Following
D016627_D009069 NONE 6-ohda_2\CD\0|NONE (r_pobj) following_0\VBG\8180190|lesion (r_prep) induced_3\VBN\1627355|has|period|been|precede|. (r_ccomp) reported_15\VBN\831651|NONE (l_nsubjpass) period_9\NN\13575869|induced|has|been|precede|. (l_prep) of_10\IN\0|a|transient (l_pobj) rotation_12\NN\331950|NONE
D016627_D009069 NONE 6-ohda_2\CD\0|NONE (r_pobj) following_0\VBG\8180190|lesion (r_prep) induced_3\VBN\1627355|has|period|been|precede|. (r_ccomp) reported_15\VBN\831651|NONE (l_xcomp) precede_17\VB\0|induced|has|period|been|. (l_dobj) circling_21\NN\1835496|to
12739036
D003401_D008180 NONE creatine_5\NN\14601829|kinase|in (r_compound) levels_7\NNS\4916342|NONE (l_prep) in_8\IN\13603305|creatine|kinase (l_pobj) erythematosus_11\NN\0|NONE
D003520_D007674 NONE cyclophosphamide_25\NN\0|and (r_conj) azathioprine_23\NN\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) of_20\IN\0|NONE (r_prep) periods_19\NNS\13575869|NONE (r_dobj) undergone_18\JJ\109660|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG\14322699|NONE (l_prep) with_14\IN\0|from|and|Since|,|had|undergone|been|she|. (l_pobj) involvement_16\NN\1080366|NONE
D001379_D007674 NONE azathioprine_23\NN\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) of_20\IN\0|NONE (r_prep) periods_19\NNS\13575869|NONE (r_dobj) undergone_18\JJ\109660|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG\14322699|NONE (l_prep) with_14\IN\0|from|and|Since|,|had|undergone|been|she|. (l_pobj) involvement_16\NN\1080366|NONE
D013256_D009220 NONE steroids_10\NNS\14727670|NONE (r_pobj) with_9\IN\0|was|.|patient (r_prep) treated_8\VBN\2376958|,|Myositis|and|was (r_conj) suspected_2\VBN\916909|NONE (l_nsubjpass) myositis_0\NNP\14336539|treated|,|and|was
D002738_D009135 NONE chloroquine_15\NN\2721948| (r_advmod) induced_17\VBN\1627355|severe (r_amod) myopathy_18\NN\14204950|NONE
D002738_D009135 NONE chloroquine_3\NN\2721948| (r_npadvmod) induced_5\VBN\1627355|NONE (r_compound) myopathy_6\NN\14204950|As|it
D003520_D008180 NONE cyclophosphamide_25\NN\0|and (r_conj) azathioprine_23\NN\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) of_20\IN\0|NONE (r_prep) periods_19\NNS\13575869|NONE (r_dobj) undergone_18\JJ\109660|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG\14322699|NONE (l_prep) from_7\IN\0|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN\0|NONE
D003520_D008180 NONE cyclophosphamide_25\NN\0|and (r_conj) azathioprine_23\NN\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) of_20\IN\0|NONE (r_prep) periods_19\NNS\13575869|NONE (r_dobj) undergone_18\JJ\109660|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG\14322699|NONE (l_prep) from_7\IN\0|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN\0|NONE (l_appos) sle_12\NNP\14229912|(|systemic|lupus|)
D002738_D018771 NONE chloroquine_3\NN\2721948|( (r_amod) cq_5\NNP\0|NONE (r_pobj) with_2\IN\0|)|Additional (r_prep) therapy_1\NN\657604|was|because|. (r_nsubjpass) started_8\VBN\0|NONE (l_prep) because_9\IN\0|was|therapy|. (l_pobj) arthralgia_11\NN\14322699|of
D002738_D018771 NONE cq_5\NNP\0|NONE (r_pobj) with_2\IN\0|)|Additional (r_prep) therapy_1\NN\657604|was|because|. (r_nsubjpass) started_8\VBN\0|NONE (l_prep) because_9\IN\0|was|therapy|. (l_pobj) arthralgia_11\NN\14322699|of
D001379_D008180 NONE azathioprine_23\NN\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) of_20\IN\0|NONE (r_prep) periods_19\NNS\13575869|NONE (r_dobj) undergone_18\JJ\109660|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG\14322699|NONE (l_prep) from_7\IN\0|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN\0|NONE
D001379_D008180 NONE azathioprine_23\NN\3740161|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) of_20\IN\0|NONE (r_prep) periods_19\NNS\13575869|NONE (r_dobj) undergone_18\JJ\109660|from|and|Since|,|had|with|been|she|. (r_conj) suffering_6\VBG\14322699|NONE (l_prep) from_7\IN\0|and|Since|,|had|with|undergone|been|she|. (l_pobj) erythematosus_10\NN\0|NONE (l_appos) sle_12\NNP\14229912|(|systemic|lupus|)
3220106
D009538_D006948 CID nicotine_3\NN\14712692| (r_npadvmod) induced_5\VBN\1627355|in|locomotor (r_amod) hyperactivity_7\NN\14052403|NONE
D009538_D006948 CID nicotine_10\NN\14712692| (r_npadvmod) treated_12\VBN\2376958|chronic (r_amod) rats_13\NNS\2329401|NONE (r_pobj) in_8\IN\13603305|induced|locomotor (r_prep) hyperactivity_7\NN\14052403|NONE
D009538_D006948 CID nicotine_5\NN\14712692| (r_npadvmod) treated_7\VBN\2376958|chronic (r_amod) rats_8\NNS\2329401|initially|hyperactivity|that|,|due|in (r_nsubj) develop_9\VBP\1753788|results|followed|. (l_dobj) hyperactivity_11\NN\14052403|initially|rats|that|,|due|in
D009538_D006948 CID nicotine_15\NN\14712692|NONE (r_pobj) to_14\IN\0|NONE (r_prep) response_13\NN\11410625|NONE (r_pobj) in_12\IN\13603305|initially|hyperactivity|rats|that|,|due (r_prep) develop_9\VBP\1753788|results|followed|. (l_dobj) hyperactivity_11\NN\14052403|initially|rats|that|,|due|in
D004298_D006948 NONE da_28\NNP\10484858|NONE (r_compound) concentration_29\NN\4916342|and|nicotinic (r_conj) receptors_26\NNS\5225602|NONE (r_pobj) of_24\IN\0|the|both (r_prep) density_23\NN\4941325|NONE (r_pobj) of_20\IN\0|NONE (r_prep) increases_19\NNS\13576355|to (r_pobj) due_17\JJ\5174653|initially|hyperactivity|rats|that|,|in (r_prep) develop_9\VBP\1753788|results|followed|. (l_dobj) hyperactivity_11\NN\14052403|initially|rats|that|,|due|in
D004298_D006948 NONE da_34\NNP\10484858|in|receptor (r_compound) supersensitivity_36\NN\0|NONE (r_dobj) inducing_33\VBG\42311|NONE (r_pcomp) by_32\IN\0|NONE (r_agent) followed_31\VBN\1835496|results|.|develop (r_advcl) suggest_2\VBP\1010118|NONE (l_ccomp) develop_9\VBP\1753788|results|followed|. (l_dobj) hyperactivity_11\NN\14052403|initially|rats|that|,|due|in
2790457
D003042_D012640 CID cocaine_11\NN\3492717|NONE (r_pobj) by_10\IN\0|NONE (r_agent) kindled_9\VBN\2764245|local|anesthetic (r_acl) seizures_8\NNS\14081375|NONE
D003042_D012640 CID cocaine_10\NN\3492717| (r_npadvmod) induced_12\VBN\1627355|both|and (r_conj) lidocaine-_8\NN\0|NONE (r_nmod) seizures_13\NNS\14081375|NONE
D003042_D012640 CID cocaine_10\NN\3492717| (r_npadvmod) induced_12\VBN\1627355|both|and (r_conj) lidocaine-_8\NN\0|NONE (r_nmod) seizures_13\NNS\14081375|NONE (r_pobj) of_6\IN\0|the (r_prep) development_5\NN\248977|CBZ|,|.|but|had (r_dobj) inhibited_3\VBD\2510337|NONE (l_conj) had_16\VBD\0|CBZ|development|,|.|but (l_dobj) effect_18\NN\34213|NONE (l_prep) on_19\IN\0|little (l_pobj) seizures_25\NNS\14081375|NONE
D003042_D012640 CID cocaine_13\NN\3492717| (r_npadvmod) injected_15\VBN\81072|the (r_amod) rats_16\NNS\2329401|NONE (r_pobj) in_11\IN\13603305|related (r_prep) mortality_10\NN\5054863|NONE (l_amod) related_9\VBN\628491|in (l_npadvmod) seizure_7\NN\14081375|
D003042_D012640 CID cocaine_23\NN\3492717| (r_npadvmod) induced_25\VBN\1627355|kindled|completed (r_amod) seizures_26\NNS\14081375|NONE
D003042_D012640 CID cocaine_19\NN\3492717| (r_npadvmod) kindled_21\VBN\2764245|lidocaine (r_amod) seizures_22\NNS\14081375|NONE
D002220_D012640 NONE carbamazepine_1\NN\0|development|. (r_nsubj) inhibits_2\VBZ\2510337|NONE (l_dobj) development_4\NN\248977|carbamazepine|. (l_prep) of_5\IN\0|the (l_pobj) seizures_8\NNS\14081375|NONE
D002220_D012640 NONE carbamazepine_3\NN\0|NONE (l_appos) treatment_7\NN\654885|NONE (l_prep) on_8\IN\0|)|CBZ|( (l_pobj) seizures_13\NNS\14081375|NONE
D002220_D012640 NONE cbz_5\NNP\0|)|on|( (r_nmod) treatment_7\NN\654885|NONE (l_prep) on_8\IN\0|)|CBZ|( (l_pobj) seizures_13\NNS\14081375|NONE
D002220_D012640 NONE cbz_30\NNP\0|NONE (r_compound) administration_31\NN\1133281|NONE (r_pobj) of_29\IN\0|different (r_prep) methods_28\NNS\5616786|NONE (r_pobj) under_26\IN\0|and|stages (r_conj) in_18\IN\13603305|effects|were|. (r_prep) evaluated_17\VBN\670261|NONE (l_nsubjpass) effects_1\NNS\13245626|were|in|. (l_prep) of_2\IN\0|The (l_pobj) carbamazepine_3\NN\0|NONE (l_appos) treatment_7\NN\654885|NONE (l_prep) on_8\IN\0|)|CBZ|( (l_pobj) seizures_13\NNS\14081375|NONE
D002220_D012640 NONE cbz_2\NN\0|development|,|.|but|had (r_nsubj) inhibited_3\VBD\2510337|NONE (l_dobj) development_5\NN\248977|CBZ|,|.|but|had (l_prep) of_6\IN\0|the (l_pobj) seizures_13\NNS\14081375|NONE
D002220_D012640 NONE cbz_2\NN\0|development|,|.|but|had (r_nsubj) inhibited_3\VBD\2510337|NONE (l_conj) had_16\VBD\0|CBZ|development|,|.|but (l_dobj) effect_18\NN\34213|NONE (l_prep) on_19\IN\0|little (l_pobj) seizures_25\NNS\14081375|NONE
D002220_D012640 NONE cbz_1\NN\0|incidence|also|. (r_nsubj) decreased_3\VBD\169651|NONE (l_dobj) incidence_5\NN\13821570|CBZ|also|. (l_prep) of_6\IN\0|the (l_pobj) mortality_10\NN\5054863|NONE (l_amod) related_9\VBN\628491|in (l_npadvmod) seizure_7\NN\14081375|
D002220_D012640 NONE cbz_1\NN\0|.|effect (r_nsubj) had_13\VBD\0|NONE (l_dobj) effect_15\NN\34213|.|CBZ (l_prep) on_16\IN\0|no (l_pobj) seizures_26\NNS\14081375|NONE
D002220_D012640 NONE cbz_4\NNP\0|NONE (r_pobj) of_3\IN\0|Repeated|)|i.p. (r_prep) injection_2\NN\320852|without|.|also (r_nsubj) was_10\VBD\0|NONE (l_prep) without_11\IN\0|injection|.|also (l_pobj) effect_12\NN\34213|NONE (l_prep) on_13\IN\0|NONE (l_pobj) development_15\NN\248977|NONE (l_prep) of_16\IN\0|the (l_pobj) seizures_22\NNS\14081375|NONE
D002220_D012640 NONE cbz_4\NN\0|NONE (r_pobj) of_3\IN\0|differential|The|depending (r_prep) effects_2\NNS\13245626|.|underlie (l_prep) depending_5\VBG\2604760|of|differential|The (l_prep) upon_6\IN\0|NONE (l_pobj) stage_7\NN\15113229|NONE (l_prep) of_8\IN\0|NONE (l_pobj) development_10\NN\248977|NONE (l_compound) seizure_9\NN\14081375|NONE
D002220_D012640 NONE cbz_4\NN\0|NONE (r_pobj) of_3\IN\0|differential|The|depending (r_prep) effects_2\NNS\13245626|.|underlie (r_nsubj) suggest_11\VBP\1010118|NONE (l_ccomp) underlie_15\VBP\2604760|.|effects (l_dobj) development_17\NN\248977|that|mechanisms (l_prep) versus_18\IN\0|the (l_pobj) maintenance_19\NN\266806|NONE (l_prep) of_20\IN\0|NONE (l_pobj) seizures_25\NNS\14081375|NONE
D008012_D012640 CID lidocaine_13\NN\3681148|and (r_conj) cocaine_11\NN\3492717|NONE (r_pobj) by_10\IN\0|NONE (r_agent) kindled_9\VBN\2764245|local|anesthetic (r_acl) seizures_8\NNS\14081375|NONE
D008012_D012640 CID lidocaine-_8\NN\0|NONE (r_nmod) seizures_13\NNS\14081375|NONE
D008012_D012640 CID lidocaine-_8\NN\0|NONE (r_nmod) seizures_13\NNS\14081375|NONE (r_pobj) of_6\IN\0|the (r_prep) development_5\NN\248977|CBZ|,|.|but|had (r_dobj) inhibited_3\VBD\2510337|NONE (l_conj) had_16\VBD\0|CBZ|development|,|.|but (l_dobj) effect_18\NN\34213|NONE (l_prep) on_19\IN\0|little (l_pobj) seizures_25\NNS\14081375|NONE
D008012_D012640 CID lidocaine_18\NN\3681148|acute||or (r_npadvmod) kindled_20\VBN\2764245|induced|completed (r_amod) seizures_26\NNS\14081375|NONE
D008012_D012640 CID lidocaine-_17\NN\0|kindled (r_nmod) seizures_22\NNS\14081375|NONE
16116131
D007980_D004409 CID levodopa_7\RB\14604959| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) dyskinesia_10\NN\14084880|NONE
D001058_D004409 NONE apomorphine_46\NN\3786417|continuous (r_compound) infusion_47\NN\14589223|NONE (r_pobj) by_44\IN\0|NONE (r_agent) induced_43\VBN\1627355|a|dyskinetic (r_acl) state_42\NN\8491826|NONE (l_amod) dyskinetic_41\JJ\0|a|induced
D001058_D010300 NONE apomorphine_46\NN\3786417|continuous (r_compound) infusion_47\NN\14589223|NONE (r_pobj) by_44\IN\0|NONE (r_agent) induced_43\VBN\1627355|a|dyskinetic (r_acl) state_42\NN\8491826|NONE (r_pobj) of_39\IN\0|a (r_prep) modification_38\NN\191142|NONE (r_pobj) in_36\IN\13603305|modulation|whether|may (r_prep) result_35\VB\34213|,|Using|authors|. (r_ccomp) investigated_28\VBN\644583|NONE (l_advcl) using_0\VBG\418025|result|,|authors|. (l_parataxis) rtms_6\NN\0|stimulation (l_prep) over_8\IN\5867413|(|) (l_pobj) area_12\NN\8630985|NONE (l_prep) in_16\IN\13603305|supplementary|SMA|the|motor (l_pobj) group_18\NN\2137|NONE (l_prep) of_19\IN\0|a (l_pobj) patients_20\NNS\9898892|NONE (l_prep) with_21\IN\0|NONE (l_pobj) disease_24\NN\14061805|NONE
9867728
D005277_D006349 NONE fenfluramine_8\NN\0|NONE (r_pobj) of_7\IN\0|underwent (r_prep) users_6\NNS\7846|NONE (r_pobj) among_5\IN\0|valvular|heart (r_prep) disease_4\NN\14061805|NONE
D005277_D006349 NONE fenfluramine_16\NN\0|NONE (r_pobj) of_15\IN\0|NONE (r_prep) users_14\NNS\7846|NONE (r_pobj) of_13\IN\0| (r_prep) %_12\NN\0|disease (r_nsubj) had_19\VBD\0|Because|surveys (l_dobj) disease_21\NN\14061805|%
D005277_D006349 NONE fenfluramine_13\NN\0|NONE (r_pobj) of_12\IN\0|underwent (r_prep) users_11\NNS\7846|NONE (r_pobj) among_10\IN\0|new|valvular (r_prep) abnormalities_9\NNS\14034177|NONE
D005277_D006349 NONE fenfluramine_18\JJ\0| (r_compound) phentermine_20\NN\0|NONE (r_dobj) receiving_17\VBG\2210855|%|(|]|Two|) (r_acl) patients_1\NNS\9898892|.|disease (r_nsubj) developed_21\VBD\1753788|NONE (l_dobj) disease_24\NN\14061805|.|patients
D010645_D006349 NONE phentermine_20\NN\0|NONE (r_dobj) receiving_17\VBG\2210855|%|(|]|Two|) (r_acl) patients_1\NNS\9898892|.|disease (r_nsubj) developed_21\VBD\1753788|NONE (l_dobj) disease_24\NN\14061805|.|patients
D020372_D006349 NONE dexfenfluramine_10\NN\0|and (r_conj) fenfluramine_8\NN\0|NONE (r_pobj) of_7\IN\0|underwent (r_prep) users_6\NNS\7846|NONE (r_pobj) among_5\IN\0|valvular|heart (r_prep) disease_4\NN\14061805|NONE
D020372_D006349 NONE dexfenfluramine_18\NN\0|and (r_conj) fenfluramine_16\NN\0|NONE (r_pobj) of_15\IN\0|NONE (r_prep) users_14\NNS\7846|NONE (r_pobj) of_13\IN\0| (r_prep) %_12\NN\0|disease (r_nsubj) had_19\VBD\0|Because|surveys (l_dobj) disease_21\NN\14061805|%
D020372_D006349 NONE dexfenfluramine_15\NN\0|or (r_conj) fenfluramine_13\NN\0|NONE (r_pobj) of_12\IN\0|underwent (r_prep) users_11\NNS\7846|NONE (r_pobj) among_10\IN\0|new|valvular (r_prep) abnormalities_9\NNS\14034177|NONE
804391
D012293_D011507 CID rifampin_8\NN\2716205|NONE (r_advmod) treated_9\VBN\2376958|with (r_amod) patients_10\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|chain|.|Light|and|immunity (r_prep) proteinuria_2\NN\14299637|NONE
D012293_D011507 CID rifampin_13\NN\2716205|NONE (r_pobj) with_12\IN\0|patients (r_prep) treated_11\VBN\2376958|in|was|proteinuria|. (r_advcl) found_4\VBN\13279262|NONE (l_nsubjpass) proteinuria_2\NN\14299637|in|treated|was|.
D012293_D014376 NONE rifampin_8\NN\2716205|NONE (r_advmod) treated_9\VBN\2376958|with (r_amod) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|treated (l_pobj) tuberculosis_12\NN\14127211|NONE
D012293_D014376 NONE rifampin_13\NN\2716205|NONE (r_pobj) with_12\IN\0|patients (r_prep) treated_11\VBN\2376958|in|was|proteinuria|. (l_nsubj) patients_10\NNS\9898892|with (l_compound) tuberculosis_9\NN\14127211|
9523850
D008775_D063806 NONE methylprednisolone_2\NN\0|NONE (r_pobj) of_1\IN\0|:|in|.|trial (r_prep) value_0\NN\5856066|NONE (l_prep) in_3\IN\13603305|:|.|trial|of (l_pobj) prevention_4\NN\1073995|NONE (l_prep) of_5\IN\0|NONE (l_pobj) syndrome_10\NN\5870365|NONE (l_compound) myalgia_9\NN\14322699|the|associated
D008775_D063806 NONE mp_6\NNP\10249459|NONE (r_pobj) of_5\IN\0|before (r_prep) administration_4\NN\1133281|frequency|after|TDI|that (r_nsubj) reduces_11\VBZ\441445|.|data (l_dobj) frequency_13\NN\15286249|administration|after|TDI|that (l_prep) of_16\IN\0|severity|and|the (l_pobj) syndrome_21\NN\5870365|NONE (l_compound) myalgia_20\NN\14322699|the
D008775_D018771 NONE methylprednisolone_2\NN\0|NONE (r_pobj) of_1\IN\0|:|in|.|trial (r_prep) value_0\NN\5856066|NONE (l_prep) in_3\IN\13603305|:|.|trial|of (l_pobj) prevention_4\NN\1073995|NONE (l_prep) of_5\IN\0|NONE (l_pobj) syndrome_10\NN\5870365|NONE (l_compound) myalgia_9\NN\14322699|the|associated (l_compound) arthralgia_7\JJ\14322699|
D008775_D018771 NONE mp_6\NNP\10249459|NONE (r_pobj) of_5\IN\0|before (r_prep) administration_4\NN\1133281|frequency|after|TDI|that (r_nsubj) reduces_11\VBZ\441445|.|data (l_dobj) frequency_13\NN\15286249|administration|after|TDI|that (l_prep) of_16\IN\0|severity|and|the (l_pobj) syndrome_21\NN\5870365|NONE (l_compound) myalgia_20\NN\14322699|the (l_compound) arthralgia_18\JJ\14322699|
D007505_D018771 CID dextran_19\NN\0|NONE (r_pobj) of_17\IN\0|total|the|dose (r_prep) infusion_16\NN\14589223|NONE (r_pobj) with_12\IN\0|NONE (r_prep) associated_11\VBN\628491|myalgia|the (r_acl) syndrome_10\NN\5870365|NONE (l_compound) myalgia_9\NN\14322699|the|associated (l_compound) arthralgia_7\JJ\14322699|
D007505_D063806 NONE dextran_19\NN\0|NONE (r_pobj) of_17\IN\0|total|the|dose (r_prep) infusion_16\NN\14589223|NONE (r_pobj) with_12\IN\0|NONE (r_prep) associated_11\VBN\628491|myalgia|the (r_acl) syndrome_10\NN\5870365|NONE (l_compound) myalgia_9\NN\14322699|the|associated
2569282
D020927_D009123 NONE dexmedetomidine_7\NN\0|capable|. (r_nsubj) is_13\VBZ\0|NONE (l_acomp) capable_14\JJ\0|dexmedetomidine|. (l_prep) of_15\IN\0|NONE (l_pcomp) inducing_16\VBG\42311|NONE (l_dobj) flaccidity_18\NN\4938228|NONE
D020927_D009123 NONE med_11\NNP\6700447|agonist|The|selective|alpha (r_appos) dexmedetomidine_7\NN\0|capable|. (r_nsubj) is_13\VBZ\0|NONE (l_acomp) capable_14\JJ\0|dexmedetomidine|. (l_prep) of_15\IN\0|NONE (l_pcomp) inducing_16\VBG\42311|NONE (l_dobj) flaccidity_18\NN\4938228|NONE
D015760_D009127 CID alfentanil_23\NN\0|dose|in (r_compound) anesthesia_24\NN\14034177|NONE (r_pobj) by_19\IN\0|NONE (r_agent) caused_18\VBN\1617192|muscle|the (r_acl) rigidity_17\NN\5023233|treatment|if
D015760_D009127 CID alfentanil_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|in|muscle (r_amod) rigidity_11\NN\5023233|.|,|MED|In
D020927_D009127 NONE dexmedetomidine_0\NNP\0|rigidity|,|.|,|acting (r_nsubj) prevents_8\VBZ\0|NONE (l_dobj) rigidity_13\NN\5023233|,|.|Dexmedetomidine|,|acting
D020927_D009127 NONE med_13\NNP\6700447|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|rigidity|if (r_nsubj) prevents_14\VBZ\0|.|authors|,|In (l_dobj) rigidity_17\NN\5023233|treatment|if
D020927_D009127 NONE med_5\NNP\6700447|.|,|In|rigidity (r_nsubj) prevented_6\VBD\0|NONE (l_dobj) rigidity_11\NN\5023233|.|,|MED|In
D020927_D018476 NONE med_6\NNP\6700447|The|dose (r_compound) animals_7\NNS\4475|flaccid|,|and|lacked|. (r_nsubj) were_8\VBD\0|NONE (l_acomp) flaccid_9\JJ\0|,|and|lacked|animals|. (l_conj) akinetic_11\JJ\0|,
D020927_D012021 NONE med_6\NNP\6700447|The|dose (r_compound) animals_7\NNS\4475|flaccid|,|and|lacked|. (r_nsubj) were_8\VBD\0|NONE (l_conj) lacked_14\VBD\0|flaccid|,|and|animals|. (l_dobj) response_17\NN\11410625|NONE (l_compound) startle_16\JJ\863513|during|a
12481039
D012964_D012640 NONE sodium_1\NN\14625458|NONE (r_compound) channel_2\NN\6251781|dependence|.|Reduced|, (r_compound) density_3\NN\4941325|NONE (l_appos) dependence_7\NN\24720|.|Reduced|channel|, (l_conj) susceptibility_13\NN\13920835|,|voltage|of|and|altered (l_prep) to_14\IN\0|increased (l_pobj) seizures_15\NNS\14081375|NONE
D012964_D012640 NONE sodium_19\NN\14625458|NONE (r_compound) channel_20\NN\6251781|beta (r_compound) 2-subunits_22\NNS\0|mice (r_dobj) lacking_18\VBG\0|NONE (r_pcomp) in_16\IN\13603305|NONE (r_prep) seizures_15\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_17\NN\14712692| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) seizures_20\NNS\14081375|NONE (r_pobj) for_16\IN\0|NONE (r_prep) threshold_15\NN\15265518|reduced|and (r_conj) latency_13\NN\15269513|NONE (r_pobj) by_11\IN\0|as (r_agent) indicated_10\VBN\952524|mice|,|.|but|seemed|,|susceptibility (r_advcl) displayed_3\VBD\2137132|NONE (l_dobj) susceptibility_5\NN\13920835|mice|,|.|but|seemed|,|indicated (l_prep) to_6\IN\0|increased (l_pobj) seizures_7\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_17\NN\14712692| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) seizures_20\NNS\14081375|NONE
20195852
C038192_D003490 NONE iopromide_17\JJ\0|,|two|CM|(|contrast (r_appos) media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (r_dobj) determined_3\VBD\0|NONE (l_prep) among_21\IN\0|incidence|,|.|study (l_conj) compared_29\VBD\644583|patients|and (l_dobj) rates_31\NNS\13308999|NONE (l_prep) for_32\IN\0|the (l_pobj) complication_34\NN\1073995|NONE (l_prep) in_35\IN\13603305|this (l_pobj) relation_36\NN\2137|NONE (l_prep) to_37\IN\0|NONE (l_pobj) type_39\NN\5839024|NONE (l_conj) presence_46\NN\13954253|of|dosage|the|and|and (l_prep) of_47\IN\0|the (l_pobj) cyanosis_48\NN\14299637|NONE
D007472_D003490 NONE iohexol_19\NN\0|and (r_conj) iopromide_17\JJ\0|,|two|CM|(|contrast (r_appos) media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (r_dobj) determined_3\VBD\0|NONE (l_prep) among_21\IN\0|incidence|,|.|study (l_conj) compared_29\VBD\644583|patients|and (l_dobj) rates_31\NNS\13308999|NONE (l_prep) for_32\IN\0|the (l_pobj) complication_34\NN\1073995|NONE (l_prep) in_35\IN\13603305|this (l_pobj) relation_36\NN\2137|NONE (l_prep) to_37\IN\0|NONE (l_pobj) type_39\NN\5839024|NONE (l_conj) presence_46\NN\13954253|of|dosage|the|and|and (l_prep) of_47\IN\0|the (l_pobj) cyanosis_48\NN\14299637|NONE
D007472_D007674 CID iohexol_19\NN\0|and (r_conj) iopromide_17\JJ\0|,|two|CM|(|contrast (r_appos) media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (l_prep) of_6\IN\0|the|for (l_pobj) cin_7\NNP\0|NONE
C038192_D007674 CID iopromide_17\JJ\0|,|two|CM|(|contrast (r_appos) media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (l_prep) of_6\IN\0|the|for (l_pobj) cin_7\NNP\0|NONE
D003287_D007674 CID media_8\NNS\3575240|Risk|by|. (r_dobj) contrast_7\NN\13854649|NONE (l_nsubj) risk_0\NN\14541044|media|by|. (l_prep) of_1\IN\0|after (l_pobj) nephropathy_2\NN\14573196|NONE
D003287_D007674 CID media_6\NNS\3575240| (r_npadvmod) induced_8\VBN\1627355|in|CIN|( (r_amod) nephropathy_9\NN\14573196|nonionic
D003287_D007674 CID media_6\NNS\3575240| (r_npadvmod) induced_8\VBN\1627355|in|CIN|( (r_amod) nephropathy_9\NN\14573196|nonionic (l_appos) cin_11\NNP\0|in|induced|(
D003287_D007674 CID media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (l_prep) of_6\IN\0|the|for (l_pobj) cin_7\NNP\0|NONE
D003287_D007674 CID cm_14\NNP\13649268|,|two|(|iopromide|contrast (r_appos) media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (l_prep) of_6\IN\0|the|for (l_pobj) cin_7\NNP\0|NONE
D003287_D007674 CID cm_43\NNP\13649268|NONE (r_pobj) of_42\IN\0|presence|dosage|the|and|and (r_prep) type_39\NN\5839024|NONE (r_pobj) to_37\IN\0|NONE (r_prep) relation_36\NN\2137|NONE (r_pobj) in_35\IN\13603305|this (r_prep) complication_34\NN\1073995|NONE (r_pobj) for_32\IN\0|the (r_prep) rates_31\NNS\13308999|NONE (r_dobj) compared_29\VBD\644583|patients|and (r_conj) among_21\IN\0|incidence|,|.|study (r_prep) determined_3\VBD\0|NONE (l_dobj) incidence_5\NN\13821570|among|,|.|study (l_prep) of_6\IN\0|the|for (l_pobj) cin_7\NNP\0|NONE
D003287_D007674 CID cm_17\NNP\13649268|NONE (r_pobj) of_16\IN\0|the|proper (r_prep) dosage_15\NN\13576355|who (r_dobj) received_12\VBD\2210855|NONE (r_relcl) those_10\DT\0|NONE (r_pobj) among_9\IN\0|Whereas|% (r_prep) were_8\VBD\0|percentage|,|.|among|with|,|to|) (l_nsubj) %_2\NN\0|among|Whereas (l_prep) of_3\IN\0|. (l_pobj) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|the (l_pobj) cin_7\NNP\0|NONE
D003287_D007674 CID cm_17\NNP\13649268|NONE (r_pobj) of_16\IN\0|the|proper (r_prep) dosage_15\NN\13576355|who (r_dobj) received_12\VBD\2210855|NONE (r_relcl) those_10\DT\0|NONE (r_pobj) among_9\IN\0|Whereas|% (r_prep) were_8\VBD\0|percentage|,|.|among|with|,|to|) (r_advcl) increased_21\VBD\169651|NONE (l_prep) with_32\IN\0|percentage|,|.|among|were|,|to|) (l_pobj) difference_35\NN\4723816|NONE (l_prep) in_36\IN\13603305|significant|a (l_pobj) incidence_38\NN\13821570|NONE (l_prep) of_39\IN\0|related|the (l_pobj) cin_40\NNP\0|NONE
D003287_D007674 CID cm_47\NNP\13649268|NONE (r_pobj) of_46\IN\0|the|different (r_prep) dosages_45\NNS\13576355|NONE (r_pobj) to_42\IN\0|NONE (r_prep) related_41\VBN\628491|of|the (r_acl) incidence_38\NN\13821570|NONE (r_pobj) in_36\IN\13603305|significant|a (r_prep) difference_35\NN\4723816|NONE (r_pobj) with_32\IN\0|percentage|,|.|among|were|,|to|) (r_prep) increased_21\VBD\169651|NONE (l_advcl) were_8\VBD\0|percentage|,|.|among|with|,|to|) (l_nsubj) %_2\NN\0|among|Whereas (l_prep) of_3\IN\0|. (l_pobj) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|the (l_pobj) cin_7\NNP\0|NONE
D003287_D007674 CID cm_47\NNP\13649268|NONE (r_pobj) of_46\IN\0|the|different (r_prep) dosages_45\NNS\13576355|NONE (r_pobj) to_42\IN\0|NONE (r_prep) related_41\VBN\628491|of|the (r_acl) incidence_38\NN\13821570|NONE (l_prep) of_39\IN\0|related|the (l_pobj) cin_40\NNP\0|NONE
D003287_D007674 CID cm_13\NNP\13649268|NONE (r_pobj) of_10\IN\0|the (r_prep) type_9\NN\5839024|on|not|nor|, (r_pobj) on_7\IN\0|dosage|but (r_conj) on_3\IN\0|and|incidence|needed|, (r_prep) depends_2\VBZ\2604760|NONE (l_conj) needed_32\VBN\0|and|incidence|on|, (l_advcl) is_26\VBZ\0|concern|for|.|is|, (l_nsubj) cin_24\NNP\0|although|usually|reversible
D003287_D003490 NONE media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (r_dobj) determined_3\VBD\0|NONE (l_prep) among_21\IN\0|incidence|,|.|study (l_conj) compared_29\VBD\644583|patients|and (l_dobj) rates_31\NNS\13308999|NONE (l_prep) for_32\IN\0|the (l_pobj) complication_34\NN\1073995|NONE (l_prep) in_35\IN\13603305|this (l_pobj) relation_36\NN\2137|NONE (l_prep) to_37\IN\0|NONE (l_pobj) type_39\NN\5839024|NONE (l_conj) presence_46\NN\13954253|of|dosage|the|and|and (l_prep) of_47\IN\0|the (l_pobj) cyanosis_48\NN\14299637|NONE
D003287_D003490 NONE cm_14\NNP\13649268|,|two|(|iopromide|contrast (r_appos) media_12\NNS\3575240|NONE (r_pobj) for_8\IN\0|the|of (r_prep) incidence_5\NN\13821570|among|,|.|study (r_dobj) determined_3\VBD\0|NONE (l_prep) among_21\IN\0|incidence|,|.|study (l_conj) compared_29\VBD\644583|patients|and (l_dobj) rates_31\NNS\13308999|NONE (l_prep) for_32\IN\0|the (l_pobj) complication_34\NN\1073995|NONE (l_prep) in_35\IN\13603305|this (l_pobj) relation_36\NN\2137|NONE (l_prep) to_37\IN\0|NONE (l_pobj) type_39\NN\5839024|NONE (l_conj) presence_46\NN\13954253|of|dosage|the|and|and (l_prep) of_47\IN\0|the (l_pobj) cyanosis_48\NN\14299637|NONE
D003287_D003490 NONE cm_43\NNP\13649268|NONE (r_pobj) of_42\IN\0|presence|dosage|the|and|and (r_prep) type_39\NN\5839024|NONE (l_conj) presence_46\NN\13954253|of|dosage|the|and|and (l_prep) of_47\IN\0|the (l_pobj) cyanosis_48\NN\14299637|NONE
D003287_D003490 NONE cm_13\NNP\13649268|NONE (r_pobj) of_10\IN\0|the (r_prep) type_9\NN\5839024|on|not|nor|, (r_pobj) on_7\IN\0|dosage|but (l_conj) on_16\IN\0|not|nor|type|, (l_pobj) presence_18\NN\13954253|NONE (l_prep) of_19\IN\0|the (l_pobj) cyanosis_20\NN\14299637|NONE
15673851
D016202_D020760 NONE aspartate_10\NN\0|spinal (r_compound) receptors_11\NNS\5225602|NONE (r_pobj) of_2\IN\0|The (r_prep) activation_1\NN\13561719|.|may|to (r_nsubj) contribute_13\VB\126264|NONE (l_prep) to_14\IN\0|activation|.|may (l_pobj) degeneration_15\NN\29677|NONE (l_acl) induced_20\VBN\1627355|of (l_prep) after_24\IN\0|by (l_pobj) interval_27\NN\33615|NONE (l_prep) of_28\IN\0|a|noninjurious (l_pobj) ischemia_31\NN\14195315|NONE
D016202_D020760 NONE nmda_15\NNP\0|receptor (r_compound) activation_17\NN\13561719|NONE (r_pobj) via_14\IN\0|cord (r_prep) ischemia_13\NN\14195315|NONE
D016202_D020258 NONE nmda_15\NNP\0|receptor (r_compound) activation_17\NN\13561719|NONE (r_pobj) via_14\IN\0|cord (r_prep) ischemia_13\NN\14195315|NONE (r_pobj) of_10\IN\0|the (r_prep) setting_9\NN\8567235|NONE (r_pobj) in_7\IN\13603305|neurotoxic|that|may|opioids (r_prep) be_5\VB\14625458|We|. (l_acomp) neurotoxic_6\JJ\0|that|may|in|opioids
D016202_D001157 NONE aspartate_20\NNP\0|(|)|NMDA (r_nmod) receptors_24\NNS\5225602|NONE (r_pobj) of_13\IN\0|NONE (r_prep) activation_12\NN\13561719|motor|spinal|and (r_conj) neurons_10\NNS\5430628|NONE (r_pobj) of_7\IN\0|after|the|following (r_prep) degeneration_6\NN\29677|NONE (l_prep) following_28\VBG\8180190|of|after|the (l_pobj) interval_31\NN\33615|NONE (l_prep) of_32\IN\0|noninjurious|a (l_pobj) occlusion_34\NN\14081375|NONE
D016202_D001157 NONE nmda_22\NNP\0|(|)|aspartate (r_nmod) receptors_24\NNS\5225602|NONE (r_pobj) of_13\IN\0|NONE (r_prep) activation_12\NN\13561719|motor|spinal|and (r_conj) neurons_10\NNS\5430628|NONE (r_pobj) of_7\IN\0|after|the|following (r_prep) degeneration_6\NN\29677|NONE (l_prep) following_28\VBG\8180190|of|after|the (l_pobj) interval_31\NN\33615|NONE (l_prep) of_32\IN\0|noninjurious|a (l_pobj) occlusion_34\NN\14081375|NONE
D018698_D020336 NONE glutamate_15\NN\15010703|NONE (r_pobj) in_13\IN\13603305|concomitant|a (r_prep) increase_12\NN\13576355|NONE (r_pobj) with_9\IN\0|that|morphine|paraparesis (r_prep) induces_6\VBZ\1627355|.|data (l_dobj) paraparesis_8\NN\14558599|that|morphine|with
D016202_D020336 NONE nmda_21\NNP\0|receptor (r_compound) activation_23\NN\13561719|NONE (r_pobj) in_20\IN\13603305|is|which (r_prep) involved_19\VBN\2676054|CSF|, (r_relcl) glutamate_15\NN\15010703|NONE (r_pobj) in_13\IN\13603305|concomitant|a (r_prep) increase_12\NN\13576355|NONE (r_pobj) with_9\IN\0|that|morphine|paraparesis (r_prep) induces_6\VBZ\1627355|.|data (l_dobj) paraparesis_8\NN\14558599|that|morphine|with
D009020_D020760 NONE morphine_23\NN\2707683|NONE (r_pobj) by_21\IN\0|after (r_agent) induced_20\VBN\1627355|of (l_prep) after_24\IN\0|by (l_pobj) interval_27\NN\33615|NONE (l_prep) of_28\IN\0|a|noninjurious (l_pobj) ischemia_31\NN\14195315|NONE
D016291_D020336 NONE mk-801_8\NNP\0|NONE (r_punct) (_9\-LRB-\0|on|)| (r_punct) mug_11\NN\13756125|Second|,|we|.|effect (l_prep) on_13\IN\0|)|(| (l_pobj) changes_16\NNS\7283608|NONE (l_prep) after_21\IN\0|the|in|histopathologic (l_pobj) paraparesis_26\NN\14558599|NONE
D016291_D020336 NONE mk-801_1\NNP\0|.|number|after|significantly|IT|compared (r_punct) reduced_3\VBD\441445|NONE (l_prep) after_13\IN\0|.|number|significantly|MK|IT|compared (l_pobj) paraparesis_18\NN\14558599|NONE
D009020_D020336 CID morphine_22\NN\2707683| (r_npadvmod) induced_24\VBN\1627355|spastic (r_amod) paraparesis_26\NN\14558599|NONE
D009020_D020336 CID morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|spastic (r_amod) paraparesis_18\NN\14558599|NONE
D009020_D020336 CID morphine_5\NN\2707683|that|with|paraparesis (r_nsubj) induces_6\VBZ\1627355|.|data (l_dobj) paraparesis_8\NN\14558599|that|morphine|with
D009020_D001157 NONE morphine_27\NN\2707683|NONE (r_pobj) after_25\IN\0|of|the|following (r_prep) degeneration_6\NN\29677|NONE (l_prep) following_28\VBG\8180190|of|after|the (l_pobj) interval_31\NN\33615|NONE (l_prep) of_32\IN\0|noninjurious|a (l_pobj) occlusion_34\NN\14081375|NONE
7647582
D014269_D056486 NONE trifluoroacetyl_11\JJ\0|NONE (r_compound) adduct_12\NN\14818238|a|biotransformation|)|bound|( (r_appos) product_9\NN\3076708|NONE (r_pobj) to_3\IN\0|An|antibody (r_prep) response_2\NN\11410625|has|on|been|. (r_nsubjpass) detected_16\VBN\2163746|NONE (l_prep) on_17\IN\0|has|been|response|. (l_pobj) patients_20\NNS\9898892|NONE (l_compound) hepatitis_19\NN\14127211|halothane
D006221_D056486 CID halothane_25\NN\3570838|previous (r_relcl) exposure_23\NN\5042871|NONE (r_pobj) following_21\VBG\8180190|alone|with|anesthetics|have|been|. (r_agent) associated_10\VBN\628491|NONE (l_prep) with_11\IN\0|following|alone|anesthetics|have|been|. (l_pobj) injury_17\NN\14052046|NONE
D006221_D056486 CID halothane_0\NNP\3570838|NONE (r_compound) hepatitis_1\NN\14127211|.|involve
D006221_D056486 CID halothane_18\NN\3570838|hepatitis (r_amod) patients_20\NNS\9898892|NONE (l_compound) hepatitis_19\NN\14127211|halothane
D006221_D056486 CID halothane_23\NN\3570838|NONE (r_compound) hepatitis_24\NN\14127211|NONE
D006221_D056486 CID halothane_30\NN\3570838|alone|could|condition|supports|enflurane|. (r_advcl) produce_15\VB\7555863|NONE (l_dobj) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_amod) similar_19\JJ\0|hypersensitivity|a (l_prep) to_20\IN\0|NONE (l_pobj) that_21\DT\0|NONE (l_prep) of_22\IN\0|NONE (l_pobj) hepatitis_24\NN\14127211|NONE
D004737_D004342 NONE enflurane_10\NN\3299929|NONE (l_conj) isoflurane_12\RB\3570838|and (l_prep) with_13\IN\0|NONE (l_pobj) hypersensitivity_15\NN\14531772|NONE
D004737_D004342 NONE enflurane_11\NN\3299929|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB\7555863|NONE (l_dobj) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN\14531772|a|similar
D007530_D056486 CID isoflurane_6\RB\3570838|and (r_conj) enflurane_4\NN\3299929|halogenated|,|Two|, (r_conj) anesthetics_2\NNS\3247620|following|alone|with|have|been|. (r_nsubjpass) associated_10\VBN\628491|NONE (l_prep) with_11\IN\0|following|alone|anesthetics|have|been|. (l_pobj) injury_17\NN\14052046|NONE
D007530_D056486 CID isoflurane_13\NN\3570838|by|and/or (r_conj) enflurane_11\NN\3299929|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB\7555863|NONE (l_dobj) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_amod) similar_19\JJ\0|hypersensitivity|a (l_prep) to_20\IN\0|NONE (l_pobj) that_21\DT\0|NONE (l_prep) of_22\IN\0|NONE (l_pobj) hepatitis_24\NN\14127211|NONE
D007530_D004342 NONE isoflurane_12\RB\3570838|and (l_prep) with_13\IN\0|NONE (l_pobj) hypersensitivity_15\NN\14531772|NONE
D007530_D004342 NONE isoflurane_13\NN\3570838|by|and/or (r_conj) enflurane_11\NN\3299929|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB\7555863|NONE (l_dobj) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN\14531772|a|similar
D006221_D004342 NONE halothane_18\NN\3570838|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|the (r_acl) hypersensitivity_15\NN\14531772|NONE
D006221_D004342 NONE halothane_23\NN\3570838|NONE (r_compound) hepatitis_24\NN\14127211|NONE (r_pobj) of_22\IN\0|NONE (r_prep) that_21\DT\0|NONE (r_pobj) to_20\IN\0|NONE (r_prep) similar_19\JJ\0|hypersensitivity|a (r_amod) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN\14531772|a|similar
D006221_D004342 NONE halothane_30\NN\3570838|alone|could|condition|supports|enflurane|. (r_advcl) produce_15\VB\7555863|NONE (l_dobj) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_compound) hypersensitivity_17\NN\14531772|a|similar
D004737_D056486 CID enflurane_4\NN\3299929|halogenated|,|Two|, (r_conj) anesthetics_2\NNS\3247620|following|alone|with|have|been|. (r_nsubjpass) associated_10\VBN\628491|NONE (l_prep) with_11\IN\0|following|alone|anesthetics|have|been|. (l_pobj) injury_17\NN\14052046|NONE
D004737_D056486 CID enflurane_11\NN\3299929|alone|could|condition|supports|.|halothane (r_nsubj) produce_15\VB\7555863|NONE (l_dobj) condition_18\NN\24720|alone|could|supports|enflurane|.|halothane (l_amod) similar_19\JJ\0|hypersensitivity|a (l_prep) to_20\IN\0|NONE (l_pobj) that_21\DT\0|NONE (l_prep) of_22\IN\0|NONE (l_pobj) hepatitis_24\NN\14127211|NONE
7059267
D002747_D003924 NONE chlorpropamide_12\NN\0|NONE (r_pobj) with_11\IN\0|woman (r_prep) treated_10\VBN\2376958|neuropathy|. (l_nsubj) woman_4\NN\9605289|with (l_prep) with_5\IN\0|A|old (l_pobj) diabetes_9\NNS\14075199|NONE
D002747_D003924 NONE diabenese_14\NNP\0|(|) (r_appos) chlorpropamide_12\NN\0|NONE (r_pobj) with_11\IN\0|woman (r_prep) treated_10\VBN\2376958|neuropathy|. (l_nsubj) woman_4\NN\9605289|with (l_prep) with_5\IN\0|A|old (l_pobj) diabetes_9\NNS\14075199|NONE
D002747_D003924 NONE chlorpropamide_26\NN\0|NONE (r_amod) therapy_27\NN\657604|NONE (r_pobj) of_25\IN\0|NONE (r_prep) discontinuation_24\NN\209943|NONE (r_pobj) with_23\IN\0|that (r_prep) resolved_22\VBD\352826|a|toxic|optic (r_relcl) neuropathy_20\NN\14204950|treated|. (r_dobj) had_16\VBD\0|NONE (l_csubj) treated_10\VBN\2376958|neuropathy|. (l_nsubj) woman_4\NN\9605289|with (l_prep) with_5\IN\0|A|old (l_pobj) diabetes_9\NNS\14075199|NONE
D002747_D009901 CID chlorpropamide_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|.|optic (r_amod) neuropathy_4\NN\14204950|NONE
D002747_D009901 CID chlorpropamide_12\NN\0|NONE (r_pobj) with_11\IN\0|woman (r_prep) treated_10\VBN\2376958|neuropathy|. (r_csubj) had_16\VBD\0|NONE (l_dobj) neuropathy_20\NN\14204950|treated|.
D002747_D009901 CID diabenese_14\NNP\0|(|) (r_appos) chlorpropamide_12\NN\0|NONE (r_pobj) with_11\IN\0|woman (r_prep) treated_10\VBN\2376958|neuropathy|. (r_csubj) had_16\VBD\0|NONE (l_dobj) neuropathy_20\NN\14204950|treated|.
D002747_D009901 CID chlorpropamide_26\NN\0|NONE (r_amod) therapy_27\NN\657604|NONE (r_pobj) of_25\IN\0|NONE (r_prep) discontinuation_24\NN\209943|NONE (r_pobj) with_23\IN\0|that (r_prep) resolved_22\VBD\352826|a|toxic|optic (r_relcl) neuropathy_20\NN\14204950|treated|.
2528969
11208990
D000109_D007674 NONE acetylcholine_5\NN\14807558|NONE (r_npadvmod) related_6\VBN\628491|IPRK|and (r_conj) phenylephrine_3\NN\2682038|the (r_nmod) responses_7\NNS\11410625|NONE (r_pobj) in_0\IN\13603305|impaired|. (r_prep) were_8\VBD\0|NONE (l_acomp) impaired_10\VBN\258857|In|. (l_prep) in_11\IN\13603305|significantly (l_pobj) group_16\NN\2137|NONE (l_compound) nephropathy_15\NN\14573196|the
D004317_D009401 NONE adr_15\NNP\0| (r_npadvmod) induced_17\VBN\1627355|the (r_amod) nephrosis_18\NN\14304060|NONE
D009569_D007674 NONE oxide_3\NN\14818238|NONE (r_compound) production_4\NN\30358|NONE (r_pobj) of_1\IN\0|.|apoptosis|and (r_prep) association_0\NN\8008335|NONE (l_conj) apoptosis_6\NN\11486178|of|.|and (l_prep) in_7\IN\13603305|NONE (l_pobj) model_9\NN\5888929|NONE (l_prep) of_10\IN\0|a (l_pobj) nephropathy_12\NN\14573196|NONE
D004317_D009395 NONE adr_9\NNP\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treated_7\VBN\2376958|NONE (r_acl) rats_6\NNS\2329401|NONE (r_pobj) of_5\IN\0|the (r_prep) kidneys_4\NNS\5333259|NONE (r_pobj) of_2\IN\0|Histopathological (r_prep) examination_1\NN\633864|areas|. (r_nsubj) revealed_10\VBD\2137132|NONE (l_dobj) areas_12\NNS\8630985|examination|. (l_prep) of_13\IN\0|focal (l_pobj) proliferation_15\NN\13489037|NONE (l_conj) inflammation_19\NN\14299637|and|mesangial
D009569_D009401 NONE no_5\UH\7204911|NONE (r_intj) between_4\IN\0|NONE (r_prep) interactions_3\NNS\37396|important|in|that (r_nsubj) are_8\VBP\13600404|.|We (l_prep) in_10\IN\13603305|interactions|important|that (l_pobj) pathogenesis_12\NN\13533470|NONE (l_prep) of_13\IN\0|the (l_pobj) nephrosis_18\NN\14304060|NONE
D010656_D007674 NONE phenylephrine_3\NN\2682038|the (r_nmod) responses_7\NNS\11410625|NONE (r_pobj) in_0\IN\13603305|impaired|. (r_prep) were_8\VBD\0|NONE (l_acomp) impaired_10\VBN\258857|In|. (l_prep) in_11\IN\13603305|significantly (l_pobj) group_16\NN\2137|NONE (l_compound) nephropathy_15\NN\14573196|the
D004317_D007674 NONE adr_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) nephropathy_10\NN\14573196|NONE
D004317_D007674 NONE adr_8\NNP\0| (r_compound) nephropathy_10\NN\14573196|(|P|the|)
D004317_D007674 NONE adr_13\NNP\0| (r_compound) nephropathy_15\NN\14573196|the
D004317_D007674 NONE adr_4\NNP\0| (r_compound) nephropathy_6\NN\14573196|the
D009569_D009404 NONE no_6\DT\7204911|association (r_intj) of_5\IN\0|the (l_pobj) association_9\NN\8008335|NO (l_prep) with_10\IN\0|its (l_pobj) apoptosis_11\NN\11486178|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) model_15\NN\5888929|NONE (l_prep) of_16\IN\0|experimental|induced|an (l_pobj) syndrome_18\NN\5870365|NONE
D009573_D007674 NONE nitrite_1\NN\14621446|Urine (r_compound) levels_2\NNS\4916342|were|in|.|significantly (r_nsubjpass) increased_5\VBN\169651|NONE (l_prep) in_6\IN\13603305|levels|were|.|significantly (l_pobj) group_11\NN\2137|NONE (l_compound) nephropathy_10\NN\14573196|(|P|the|)
D004317_D009404 CID adriamycin_25\NNS\0|NONE (r_pobj) of_24\IN\0|single|a (r_prep) injection_23\NN\320852|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|experimental|of|an (r_acl) model_15\NN\5888929|NONE (l_prep) of_16\IN\0|experimental|induced|an (l_pobj) syndrome_18\NN\5870365|NONE
D004317_D009404 CID adr_27\NNP\0|)|( (r_appos) adriamycin_25\NNS\0|NONE (r_pobj) of_24\IN\0|single|a (r_prep) injection_23\NN\320852|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|experimental|of|an (r_acl) model_15\NN\5888929|NONE (l_prep) of_16\IN\0|experimental|induced|an (l_pobj) syndrome_18\NN\5870365|NONE
D004317_C537346 NONE adr_9\NNP\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treated_7\VBN\2376958|NONE (r_acl) rats_6\NNS\2329401|NONE (r_pobj) of_5\IN\0|the (r_prep) kidneys_4\NNS\5333259|NONE (r_pobj) of_2\IN\0|Histopathological (r_prep) examination_1\NN\633864|areas|. (r_nsubj) revealed_10\VBD\2137132|NONE (l_dobj) areas_12\NNS\8630985|examination|. (l_prep) of_13\IN\0|focal (l_pobj) proliferation_15\NN\13489037|NONE
16634859
D000431_D006130 CID alcohol_9\NN\7881800| (r_npadvmod) related_11\VBN\628491|growth (r_amod) impairment_14\NN\7296428|NONE
D000431_D006130 CID alcohol_1\NN\7881800|NONE (r_compound) consumption_2\NN\13440063|postpregnancy|among|Any (r_compound) recognition_4\NN\13932421|.|in (r_nsubj) resulted_9\VBD\2633881|NONE (l_prep) in_10\IN\13603305|recognition|. (l_pobj) growth_13\NN\13526110|NONE
D000431_D006130 CID alcohol_1\NN\7881800|NONE (r_compound) consumption_2\NN\13440063|postpregnancy|among|Any (r_compound) recognition_4\NN\13932421|.|in (r_nsubj) resulted_9\VBD\2633881|NONE (l_prep) in_10\IN\13603305|recognition|. (l_pobj) growth_13\NN\13526110|NONE (l_conj) cranial_18\JJ\0|cerebellar|as|reduced (l_acl) body_20\NN\19128|decreased (l_dobj) growth_21\NN\13526110|in|to
16428827
D012601_D007859 NONE scopolamine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|of (r_amod) impairments_15\NNS\7296428|NONE (l_prep) of_16\IN\0|induced (l_pobj) learning_17\NN\5701944|NONE (l_conj) memory_19\NN\5926676|and
D012601_D000647 CID scopolamine_16\NN\14712692| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) amnesia_19\NN\5669934|to
D012601_D000647 CID scopolamine_22\NN\14712692| (r_npadvmod) induced_24\VBN\1627355|NONE (r_amod) amnesia_25\NN\5669934|also|it|that
D000109_D000544 NONE acetylcholine_20\NN\14807558|( (r_nmod) ach_22\NNS\0|NONE (r_pobj) of_19\IN\0|enzymatic|the (r_prep) production_18\NN\30358|NONE (r_pobj) of_15\IN\0|an (r_prep) augmentation_14\NN\7356676|NONE (r_pobj) via_12\IN\0|transmission|which (r_prep) enhances_9\VBZ\227165|)|(|ChAT|,|) (r_relcl) activator_6\NN\19613|The|choline|, (r_appos) acetyltransferase_2\NN\0|factor|. (r_nsubj) is_25\VBZ\0|NONE (l_attr) factor_28\NN\7326557|acetyltransferase|. (l_prep) in_29\IN\13603305|an|important (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) disease_35\NN\14061805|NONE
D000109_D000544 NONE acetylcholine_20\NN\14807558|( (r_nmod) ach_22\NNS\0|NONE (r_pobj) of_19\IN\0|enzymatic|the (r_prep) production_18\NN\30358|NONE (r_pobj) of_15\IN\0|an (r_prep) augmentation_14\NN\7356676|NONE (r_pobj) via_12\IN\0|transmission|which (r_prep) enhances_9\VBZ\227165|)|(|ChAT|,|) (r_relcl) activator_6\NN\19613|The|choline|, (r_appos) acetyltransferase_2\NN\0|factor|. (r_nsubj) is_25\VBZ\0|NONE (l_attr) factor_28\NN\7326557|acetyltransferase|. (l_prep) in_29\IN\13603305|an|important (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) disease_35\NN\14061805|NONE (l_appos) ad_37\NN\7247071|)|Alzheimer
D000109_D000544 NONE ach_22\NNS\0|NONE (r_pobj) of_19\IN\0|enzymatic|the (r_prep) production_18\NN\30358|NONE (r_pobj) of_15\IN\0|an (r_prep) augmentation_14\NN\7356676|NONE (r_pobj) via_12\IN\0|transmission|which (r_prep) enhances_9\VBZ\227165|)|(|ChAT|,|) (r_relcl) activator_6\NN\19613|The|choline|, (r_appos) acetyltransferase_2\NN\0|factor|. (r_nsubj) is_25\VBZ\0|NONE (l_attr) factor_28\NN\7326557|acetyltransferase|. (l_prep) in_29\IN\13603305|an|important (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) disease_35\NN\14061805|NONE
D000109_D000544 NONE ach_22\NNS\0|NONE (r_pobj) of_19\IN\0|enzymatic|the (r_prep) production_18\NN\30358|NONE (r_pobj) of_15\IN\0|an (r_prep) augmentation_14\NN\7356676|NONE (r_pobj) via_12\IN\0|transmission|which (r_prep) enhances_9\VBZ\227165|)|(|ChAT|,|) (r_relcl) activator_6\NN\19613|The|choline|, (r_appos) acetyltransferase_2\NN\0|factor|. (r_nsubj) is_25\VBZ\0|NONE (l_attr) factor_28\NN\7326557|acetyltransferase|. (l_prep) in_29\IN\13603305|an|important (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) disease_35\NN\14061805|NONE (l_appos) ad_37\NN\7247071|)|Alzheimer
D000109_D000647 NONE acetylcholine_10\NN\14807558|NONE (r_compound) biosynthesis_11\NN\13565379|NONE (r_pobj) in_9\IN\13603305|a (r_prep) role_8\NN\719494|and|as|daidzein|might|ameliorates|that|, (r_dobj) play_6\VB\7007684|results|. (l_conj) ameliorates_21\VBZ\126264|and|as|daidzein|role|might|that|, (l_dobj) amnesia_25\NN\5669934|also|it|that
C004742_D008569 NONE daidzein_7\NN\0|NONE (r_pobj) of_6\IN\0|from|the (r_prep) effects_5\NNS\13245626|to (l_prep) from_8\IN\0|the|of (l_pobj) thunbergiana_10\NNS\0|NONE (l_prep) on_11\IN\0|Pueraria (l_pobj) impairments_15\NNS\7296428|NONE (l_prep) of_16\IN\0|induced (l_pobj) learning_17\NN\5701944|NONE (l_conj) memory_19\NN\5926676|and
D002794_D000647 NONE choline_2\NN\15090742|NONE (r_compound) acetyltransferase_3\NN\0|and|Daidzein|from|.|improves (r_dobj) activates_1\VBZ\1641914|NONE (l_conj) improves_10\VBZ\126264|and|Daidzein|from|.|acetyltransferase (l_dobj) amnesia_14\NN\5669934|NONE
D012601_D008569 NONE scopolamine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|of (r_amod) impairments_15\NNS\7296428|NONE (l_prep) of_16\IN\0|induced (l_pobj) learning_17\NN\5701944|NONE (l_conj) memory_19\NN\5926676|and
D002794_D000544 NONE choline_1\NN\15090742|The|,|activator (r_compound) acetyltransferase_2\NN\0|factor|. (r_nsubj) is_25\VBZ\0|NONE (l_attr) factor_28\NN\7326557|acetyltransferase|. (l_prep) in_29\IN\13603305|an|important (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) disease_35\NN\14061805|NONE
D002794_D000544 NONE choline_1\NN\15090742|The|,|activator (r_compound) acetyltransferase_2\NN\0|factor|. (r_nsubj) is_25\VBZ\0|NONE (l_attr) factor_28\NN\7326557|acetyltransferase|. (l_prep) in_29\IN\13603305|an|important (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) disease_35\NN\14061805|NONE (l_appos) ad_37\NN\7247071|)|Alzheimer
C004742_D000647 NONE daidzein_0\NNP\0|and|from|.|improves|acetyltransferase (r_nsubj) activates_1\VBZ\1641914|NONE (l_conj) improves_10\VBZ\126264|and|Daidzein|from|.|acetyltransferase (l_dobj) amnesia_14\NN\5669934|NONE
C004742_D000647 NONE daidzein_2\NN\0|NONE (r_pobj) of_1\IN\0|weight|to (r_prep) administration_0\NN\1133281|reverse|,|.|was|according|significantly (r_nsubjpass) shown_12\VBN\2137132|NONE (l_xcomp) reverse_15\VB\13854649|,|Administration|.|was|according|significantly (l_dobj) amnesia_19\NN\5669934|to
C004742_D000647 NONE daidzein_4\NN\0|and|as|role|might|ameliorates|that|, (r_nsubj) play_6\VB\7007684|results|. (l_conj) ameliorates_21\VBZ\126264|and|as|daidzein|role|might|that|, (l_dobj) amnesia_25\NN\5669934|also|it|that
C004742_D007859 NONE daidzein_7\NN\0|NONE (r_pobj) of_6\IN\0|from|the (r_prep) effects_5\NNS\13245626|to (l_prep) from_8\IN\0|the|of (l_pobj) thunbergiana_10\NNS\0|NONE (l_prep) on_11\IN\0|Pueraria (l_pobj) impairments_15\NNS\7296428|NONE (l_prep) of_16\IN\0|induced (l_pobj) learning_17\NN\5701944|NONE (l_conj) memory_19\NN\5926676|and
7910951
D003473_D009468 CID nmba_21\NNP\0|to (r_pobj) due_17\IN\5174653|likely|(|most (r_prep) likely_16\JJ\0|at (r_parataxis) pathology_8\NN\6045562|to (l_prep) at_9\IN\14622893|likely (l_pobj) junction_13\NN\8664443|NONE
D000305_D009468 NONE corticosteroids_30\NNS\14745635|to (r_pobj) due_28\IN\5174653|)|most|( (r_prep) likely_27\JJ\0|(|due|most (r_parataxis) likely_16\JJ\0|at (r_parataxis) pathology_8\NN\6045562|to (l_prep) at_9\IN\14622893|likely (l_pobj) junction_13\NN\8664443|NONE
D003473_D018908 CID agents_9\NNS\7347|NONE (r_pobj) of_5\IN\0|term|The (r_prep) use_4\NN\407535|been|recently|,|been|.|as|has (r_nsubjpass) implicated_18\VBN\2677097|NONE (l_prep) as_19\IN\14622893|been|use|recently|,|been|.|has (l_pobj) cause_21\NN\7323922|NONE (l_prep) of_22\IN\0|a (l_pobj) weakness_25\NN\14462666|NONE
D003473_D018908 CID nmba_13\NNP\0|)|neuromuscular|(|blocking (r_appos) agents_9\NNS\7347|NONE (r_pobj) of_5\IN\0|term|The (r_prep) use_4\NN\407535|been|recently|,|been|.|as|has (r_nsubjpass) implicated_18\VBN\2677097|NONE (l_prep) as_19\IN\14622893|been|use|recently|,|been|.|has (l_pobj) cause_21\NN\7323922|NONE (l_prep) of_22\IN\0|a (l_pobj) weakness_25\NN\14462666|NONE
D003473_D018908 CID nmbas_25\NNP\0|NONE (r_pobj) of_22\IN\0|the (r_prep) discontinuation_21\NN\209943|NONE (r_pobj) following_19\VBG\8180190|prolonged (r_prep) weakness_18\NN\14462666|who
D003473_D018908 CID nmba_21\NNP\0|to (r_pobj) due_17\IN\5174653|likely|(|most (r_prep) likely_16\JJ\0|at (r_parataxis) pathology_8\NN\6045562|to (r_pobj) due_6\JJ\5174653|.|weakness (r_acomp) is_5\VBZ\0|NONE (l_nsubj) weakness_1\NN\14462666|.|due
D000305_D018908 NONE corticosteroids_30\NNS\14745635|to (r_pobj) due_28\IN\5174653|)|most|( (r_prep) likely_27\JJ\0|(|due|most (r_parataxis) likely_16\JJ\0|at (r_parataxis) pathology_8\NN\6045562|to (r_pobj) due_6\JJ\5174653|.|weakness (r_acomp) is_5\VBZ\0|NONE (l_nsubj) weakness_1\NN\14462666|.|due
D003473_D012131 NONE nmbas_25\NNP\0|NONE (r_pobj) of_22\IN\0|the (r_prep) discontinuation_21\NN\209943|NONE (r_pobj) following_19\VBG\8180190|prolonged (r_prep) weakness_18\NN\14462666|who (r_dobj) developed_16\VBD\1753788|acute|respiratory (r_relcl) insufficiency_14\NN\14462946|NONE
D003473_D010243 NONE agents_7\NNS\7347|nondepolarizing (r_appos) neuromuscular_5\JJ\0|to (r_pobj) due_2\IN\5174653|.|Prolonged (r_prep) paralysis_1\NN\14557898|NONE
D000305_D010243 NONE corticosteroids_9\NNS\14745635|and|blocking (r_conj) agents_7\NNS\7347|nondepolarizing (r_appos) neuromuscular_5\JJ\0|to (r_pobj) due_2\IN\5174653|.|Prolonged (r_prep) paralysis_1\NN\14557898|NONE
7437994
6127992
D014700_D007022 CID verapamil_18\NN\2938514|blocking (r_nmod) drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and (r_conj) hypotension_11\NN\14057371|,|cardiac|profound
D014700_D001919 CID verapamil_18\NN\2938514|blocking (r_nmod) drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and
D000319_D007022 CID drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and (r_conj) hypotension_11\NN\14057371|,|cardiac|profound
D000319_D006333 CID drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and (r_conj) hypotension_11\NN\14057371|,|cardiac|profound (r_conj) failure_9\NN\66216|.|patients
D014700_D006333 CID verapamil_18\NN\2938514|blocking (r_nmod) drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and (r_conj) hypotension_11\NN\14057371|,|cardiac|profound (r_conj) failure_9\NN\66216|.|patients
D000319_D017202 NONE drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and (r_conj) hypotension_11\NN\14057371|,|cardiac|profound (r_conj) failure_9\NN\66216|.|patients (r_dobj) developed_6\VBD\1753788|NONE (l_nsubj) patients_1\NNS\9898892|failure|. (l_prep) with_2\IN\0|Three (l_pobj) disease_5\NN\14061805|NONE
D014700_D017202 NONE verapamil_18\NN\2938514|blocking (r_nmod) drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and (r_conj) hypotension_11\NN\14057371|,|cardiac|profound (r_conj) failure_9\NN\66216|.|patients (r_dobj) developed_6\VBD\1753788|NONE (l_nsubj) patients_1\NNS\9898892|failure|. (l_prep) with_2\IN\0|Three (l_pobj) disease_5\NN\14061805|NONE
D000319_D001919 CID drugs_24\NNS\14778436|NONE (r_pobj) with_17\IN\0|combined (r_prep) therapy_16\NN\657604|NONE (r_pobj) during_14\IN\0|NONE (r_prep) bradycardia_13\NN\14110674|and
15764424
D000661_D006948 CID amphetamine_2\NN\3248958|NONE (r_compound) levels_3\NNS\4916342|or (r_conj) methamphetamine_0\NN\2704153|were|to|. (r_nsubjpass) related_5\VBN\628491|NONE (l_prep) to_6\IN\0|were|.|Methamphetamine (l_pobj) scores_9\NNS\13757724|NONE (l_conj) rating_14\NN\5733583|several|psychopathology|and (l_compound) hyperkinesia_13\NN\0|global|the
D002395_D006948 NONE catecholamines_12\NNS\5407119|,|symptom (l_conj) hyperkinesia_14\NN\0|and
D002395_D011605 NONE catecholamines_12\NNS\5407119|,|symptom (r_conj) severity_10\NN\5036394|NONE (r_pobj) to_8\IN\0|NONE (r_prep) relationship_7\NN\31921|Quantitative|in|drug|:|. (r_appos) levels_2\NNS\4916342|NONE (l_prep) in_3\IN\13603305|Quantitative|relationship|drug|:|. (l_pobj) psychosis_5\NN\14380140|NONE
D002395_D011605 NONE catecholamines_10\NNS\5407119|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS\5823932|,|and
D002395_D011605 NONE catecholamines_10\NNS\5407119|,|drug|quantitative|stimulant (r_conj) levels_8\NNS\4916342|NONE (r_pobj) between_4\IN\0|the (r_prep) relationship_3\NN\31921|To (r_dobj) examine_1\VB\0|patients|were|,|and|,|collected (r_advcl) interviewed_34\VBN\964694|NONE (l_nsubjpass) patients_17\NNS\9898892|examine|were|,|and|,|collected (l_prep) in_18\IN\13603305|nineteen (l_pobj) service_22\NN\575741|NONE (l_prep) with_23\IN\0|emergency|a|psychiatric (l_pobj) diagnosis_25\NN\152018|NONE (l_prep) of_26\IN\0|a (l_pobj) psychosis_32\NN\14380140|NONE
D002395_D011605 NONE catecholamine_49\NN\5407119|stimulant|and (r_conj) drug_47\NN\14778436|metabolite (r_nmod) levels_51\NNS\4916342|NONE (r_pobj) of_45\IN\0|quantitative (r_prep) assays_44\NNS\5733583|NONE (r_pobj) for_42\IN\0|.|plasma|were (r_prep) collected_41\VBN\2281093|patients|examine|were|,|and|, (r_conj) interviewed_34\VBN\964694|NONE (l_advcl) examine_1\VB\0|patients|were|,|and|,|collected (l_dobj) relationship_3\NN\31921|To (l_prep) between_4\IN\0|the (l_pobj) levels_8\NNS\4916342|NONE (l_conj) catecholamines_10\NNS\5407119|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS\5823932|,|and
D002395_D011605 NONE catecholamine_49\NN\5407119|stimulant|and (r_conj) drug_47\NN\14778436|metabolite (r_nmod) levels_51\NNS\4916342|NONE (r_pobj) of_45\IN\0|quantitative (r_prep) assays_44\NNS\5733583|NONE (r_pobj) for_42\IN\0|.|plasma|were (r_prep) collected_41\VBN\2281093|patients|examine|were|,|and|, (r_conj) interviewed_34\VBN\964694|NONE (l_nsubjpass) patients_17\NNS\9898892|examine|were|,|and|,|collected (l_prep) in_18\IN\13603305|nineteen (l_pobj) service_22\NN\575741|NONE (l_prep) with_23\IN\0|emergency|a|psychiatric (l_pobj) diagnosis_25\NN\152018|NONE (l_prep) of_26\IN\0|a (l_pobj) psychosis_32\NN\14380140|NONE
D003042_D001523 NONE cocaine_29\NN\3492717|or (r_conj) amphetamine-_27\JJ\0| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) psychosis_32\NN\14380140|NONE (r_pobj) of_26\IN\0|a (r_prep) diagnosis_25\NN\152018|NONE (r_pobj) with_23\IN\0|emergency|a|psychiatric (r_prep) service_22\NN\575741|NONE (l_amod) psychiatric_20\JJ\0|emergency|a|with
D000661_D001523 NONE amphetamine-_27\JJ\0| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) psychosis_32\NN\14380140|NONE (r_pobj) of_26\IN\0|a (r_prep) diagnosis_25\NN\152018|NONE (r_pobj) with_23\IN\0|emergency|a|psychiatric (r_prep) service_22\NN\575741|NONE (l_amod) psychiatric_20\JJ\0|emergency|a|with
D003042_D011605 CID cocaine_29\NN\3492717|or (r_conj) amphetamine-_27\JJ\0| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) psychosis_32\NN\14380140|NONE (r_pobj) of_26\IN\0|a (r_prep) diagnosis_25\NN\152018|NONE (r_pobj) with_23\IN\0|emergency|a|psychiatric (r_prep) service_22\NN\575741|NONE (r_pobj) in_18\IN\13603305|nineteen (r_prep) patients_17\NNS\9898892|examine|were|,|and|,|collected (r_nsubjpass) interviewed_34\VBN\964694|NONE (l_advcl) examine_1\VB\0|patients|were|,|and|,|collected (l_dobj) relationship_3\NN\31921|To (l_prep) between_4\IN\0|the (l_pobj) levels_8\NNS\4916342|NONE (l_conj) catecholamines_10\NNS\5407119|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS\5823932|,|and
D003042_D011605 CID cocaine_29\NN\3492717|or (r_conj) amphetamine-_27\JJ\0| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) psychosis_32\NN\14380140|NONE
D008694_D006948 CID methamphetamine_0\NN\2704153|were|to|. (r_nsubjpass) related_5\VBN\628491|NONE (l_prep) to_6\IN\0|were|.|Methamphetamine (l_pobj) scores_9\NNS\13757724|NONE (l_conj) rating_14\NN\5733583|several|psychopathology|and (l_compound) hyperkinesia_13\NN\0|global|the
D002395_D001523 NONE catecholamines_10\NNS\5407119|,|drug|quantitative|stimulant (r_conj) levels_8\NNS\4916342|NONE (r_pobj) between_4\IN\0|the (r_prep) relationship_3\NN\31921|To (r_dobj) examine_1\VB\0|patients|were|,|and|,|collected (r_advcl) interviewed_34\VBN\964694|NONE (l_nsubjpass) patients_17\NNS\9898892|examine|were|,|and|,|collected (l_prep) in_18\IN\13603305|nineteen (l_pobj) service_22\NN\575741|NONE (l_amod) psychiatric_20\JJ\0|emergency|a|with
D002395_D001523 NONE catecholamine_49\NN\5407119|stimulant|and (r_conj) drug_47\NN\14778436|metabolite (r_nmod) levels_51\NNS\4916342|NONE (r_pobj) of_45\IN\0|quantitative (r_prep) assays_44\NNS\5733583|NONE (r_pobj) for_42\IN\0|.|plasma|were (r_prep) collected_41\VBN\2281093|patients|examine|were|,|and|, (r_conj) interviewed_34\VBN\964694|NONE (l_nsubjpass) patients_17\NNS\9898892|examine|were|,|and|,|collected (l_prep) in_18\IN\13603305|nineteen (l_pobj) service_22\NN\575741|NONE (l_amod) psychiatric_20\JJ\0|emergency|a|with
D000661_D011605 CID amphetamine-_27\JJ\0| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) psychosis_32\NN\14380140|NONE (r_pobj) of_26\IN\0|a (r_prep) diagnosis_25\NN\152018|NONE (r_pobj) with_23\IN\0|emergency|a|psychiatric (r_prep) service_22\NN\575741|NONE (r_pobj) in_18\IN\13603305|nineteen (r_prep) patients_17\NNS\9898892|examine|were|,|and|,|collected (r_nsubjpass) interviewed_34\VBN\964694|NONE (l_advcl) examine_1\VB\0|patients|were|,|and|,|collected (l_dobj) relationship_3\NN\31921|To (l_prep) between_4\IN\0|the (l_pobj) levels_8\NNS\4916342|NONE (l_conj) catecholamines_10\NNS\5407119|,|drug|quantitative|stimulant (l_conj) symptoms_14\NNS\5823932|,|and
D000661_D011605 CID amphetamine-_27\JJ\0| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) psychosis_32\NN\14380140|NONE
2343592
C044650_D006259 NONE cilastatin_32\NN\0|NONE (r_pobj) of_29\IN\0|maximum (r_prep) doses_28\NNS\3740161|while (r_dobj) receiving_26\VBG\2210855|seizures|evidence|. (r_advcl) developed_23\VBN\1753788|trauma|and|patients (r_conj) head_15\NN\5225090|NONE (l_dobj) trauma_16\NN\14052046|and|patients|developed
C044650_D012640 CID cilastatin_32\NN\0|NONE (r_pobj) of_29\IN\0|maximum (r_prep) doses_28\NNS\3740161|while (r_dobj) receiving_26\VBG\2210855|seizures|evidence|. (r_advcl) developed_23\VBN\1753788|trauma|and|patients (l_dobj) seizures_24\NNS\14081375|receiving|evidence|.
C044650_D020521 NONE cilastatin_32\NN\0|NONE (r_pobj) of_29\IN\0|maximum (r_prep) doses_28\NNS\3740161|while (r_dobj) receiving_26\VBG\2210855|seizures|evidence|. (r_advcl) developed_23\VBN\1753788|trauma|and|patients (r_conj) head_15\NN\5225090|NONE (l_nsubj) patients_2\NNS\9898892|trauma|and|developed (l_prep) with_3\IN\0|elderly|Two (l_pobj) history_5\NN\15120823|NONE (l_prep) of_6\IN\0|a (l_pobj) accident_10\NN\7314427|NONE
C044650_D020521 NONE cilastatin_32\NN\0|NONE (r_pobj) of_29\IN\0|maximum (r_prep) doses_28\NNS\3740161|while (r_dobj) receiving_26\VBG\2210855|seizures|evidence|. (r_advcl) developed_23\VBN\1753788|trauma|and|patients (r_conj) head_15\NN\5225090|NONE (l_nsubj) patients_2\NNS\9898892|trauma|and|developed (l_prep) with_3\IN\0|elderly|Two (l_pobj) history_5\NN\15120823|NONE (l_prep) of_6\IN\0|a (l_pobj) accident_10\NN\7314427|NONE (l_appos) cva_12\NNP\14081375|either|cerebral|vascular|or|(
D047090_D012640 NONE lactam_10\NN\0|other (r_compound) antibiotics_11\NNS\2716205|NONE (r_pobj) of_6\IN\0|maximum (r_prep) doses_5\NNS\3740161|.|had|without|patients (r_dobj) received_3\VBN\2210855|NONE (l_prep) without_12\IN\0|.|had|doses|patients (l_pobj) evidence_13\NN\5816287|NONE (l_prep) of_14\IN\0|NONE (l_pobj) activity_16\NN\30358|NONE (l_compound) seizure_15\NN\14081375|NONE
C044650_D007674 NONE cilastatin_32\NN\0|NONE (r_pobj) of_29\IN\0|maximum (r_prep) doses_28\NNS\3740161|while (r_dobj) receiving_26\VBG\2210855|seizures|evidence|. (r_advcl) developed_23\VBN\1753788|trauma|and|patients (l_nsubj) evidence_19\NN\5816287|receiving|seizures|. (l_prep) of_20\IN\0|no (l_pobj) disease_22\NN\14061805|NONE
D015378_D012640 NONE imipenem_3\NN\0|:|factors (r_compound) therapy_4\NN\657604|NONE (r_pobj) with_2\IN\0|Seizure|. (r_prep) activity_1\NN\30358|NONE (l_compound) seizure_0\NN\14081375|.|with
D010672_D012640 NONE phenytoin_8\NN\3550533|NONE (r_pobj) of_7\IN\0|therapeutic (r_prep) doses_6\NNS\3740161|NONE (r_pobj) with_4\IN\0|were|.|seizures (r_prep) controlled_3\VBN\0|NONE (l_nsubjpass) seizures_1\NNS\14081375|were|.|with
18161408
D002996_D013927 NONE cc_9\NN\13616054|NONE (r_pobj) of_8\IN\0|a|rare (r_prep) complication_7\NN\1073995|.|might|Thrombosis (r_attr) be_2\VB\14625458|NONE (l_nsubj) thrombosis_0\NN\14100769|complication|.|might
D002996_D013923 CID cc_17\NN\13616054|NONE (r_pobj) with_16\IN\0|ovulation (r_prep) induction_15\NN\7450842|NONE (r_pobj) after_13\IN\0|been|has|that (r_prep) reported_12\VBN\831651|a|rare (r_relcl) complication_8\NN\1073995|.|Thromboembolism (r_attr) is_1\VBZ\0|NONE (l_nsubj) thromboembolism_0\NN\14100769|.|complication
D002996_D009203 CID citrate_7\NN\14850483|NONE (r_pobj) with_5\IN\0|for (r_prep) associated_4\VBN\628491|report|:|in|Myocardial|. (r_acl) infarction_1\NN\14204950|NONE
D002996_D009203 CID cc_13\NN\13616054|NONE (l_conj) infarction_16\NN\14204950|and
D002996_D002637 NONE cc_12\NN\13616054|woman|recently|.|presented|had|and|for (r_dobj) received_11\VBN\2210855|NONE (l_conj) presented_17\VBD\2137132|woman|recently|.|CC|had|and|for (l_prep) with_18\IN\0|NONE (l_pobj) pain_20\NN\14299637|NONE
16960342
D019259_D005355 NONE lamivudine_17\NN\3834836|NONE (r_amod) monotherapy_18\NN\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) treatment_15\NN\654885|NONE (r_pobj) after_14\IN\0|clinical|Sustained|of|. (r_prep) improvement_2\NN\7359599|NONE (l_prep) of_3\IN\0|clinical|Sustained|.|after (l_pobj) patient_5\NN\9898892|NONE (l_prep) with_6\IN\0|a (l_pobj) cirrhosis_13\NN\14116321|NONE
D019259_D005355 NONE lamivudine_3\NN\3834836|NONE (r_pobj) of_2\IN\0|The|to (r_prep) administration_1\NN\1133281|like|,|in|,|be|.|,|should|as (l_prep) to_4\IN\0|of|The (l_pobj) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|NONE (l_pobj) cirrhosis_10\NN\14116321|NONE
D019259_D006509 NONE lamivudine_17\NN\3834836|NONE (r_amod) monotherapy_18\NN\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) treatment_15\NN\654885|NONE (r_pobj) after_14\IN\0|clinical|Sustained|of|. (r_prep) improvement_2\NN\7359599|NONE (l_prep) of_3\IN\0|clinical|Sustained|.|after (l_pobj) patient_5\NN\9898892|NONE (l_prep) with_6\IN\0|a (l_pobj) cirrhosis_13\NN\14116321|NONE (l_amod) related_12\VBN\628491|decompensated (l_npadvmod) virus_10\NN\9312843| (l_compound) b_9\NNP\1355326|NONE
3300918
D004876_D008881 CID ergot_6\NN\14276936|NONE (r_pobj) of_5\IN\0|the (r_prep) history_4\NN\15120823|NONE (r_pobj) of_2\IN\0|A (r_prep) discussion_1\NN\6252138|discovery|. (r_nsubj) includes_7\VBZ\0|NONE (l_dobj) discovery_10\NN\30358|.|discussion (l_appos) epidemics_13\NNS\7435273|,|original|its (l_relcl) caused_19\VBN\1617192|the|of (l_prep) through_20\IN\0|has|it|that (l_pobj) ages_22\NNS\4916342|NONE (l_conj) role_28\NN\719494|the|and (l_prep) in_29\IN\13603305|past|its (l_pobj) management_31\NN\1123598|NONE (l_prep) of_32\IN\0|the (l_pobj) headache_34\NN\5829480|NONE
D004876_D008881 CID ergot_13\NN\14276936|NONE (r_compound) preparations_14\NNS\407535|.|persists|play|,|Despite|, (r_nsubj) continue_15\VBP\2367363|NONE (l_xcomp) play_17\VB\7007684|.|persists|,|Despite|preparations|, (l_dobj) role_20\NN\719494|to (l_prep) in_21\IN\13603305|a|major (l_pobj) therapy_23\NN\657604|NONE (l_compound) migraine_22\NN\14326607|NONE
D002118_D004881 NONE calcium_4\NN\14625458|NONE (r_compound) channel_5\NN\6251781|and|antagonists (r_compound) blockers_6\NNS\10101634|NONE (r_pobj) of_3\IN\0|the (r_prep) advent_2\NN\48225|NONE (r_pobj) despite_0\IN\7501545|.|persists|play|,|preparations|, (r_prep) continue_15\VBP\2367363|NONE (l_advcl) persists_34\VBZ\118523|.|play|,|Despite|preparations|, (l_nsubj) danger_28\NN\13920835|so|that (l_prep) of_29\IN\0|the (l_pobj) fire_33\NN\7283608|NONE
D004876_D004881 NONE ergot_13\NN\14276936|NONE (r_compound) preparations_14\NNS\407535|.|persists|play|,|Despite|, (r_nsubj) continue_15\VBP\2367363|NONE (l_advcl) persists_34\VBZ\118523|.|play|,|Despite|preparations|, (l_nsubj) danger_28\NN\13920835|so|that (l_prep) of_29\IN\0|the (l_pobj) fire_33\NN\7283608|NONE
D002118_D008881 NONE calcium_4\NN\14625458|NONE (r_compound) channel_5\NN\6251781|and|antagonists (r_compound) blockers_6\NNS\10101634|NONE (r_pobj) of_3\IN\0|the (r_prep) advent_2\NN\48225|NONE (r_pobj) despite_0\IN\7501545|.|persists|play|,|preparations|, (r_prep) continue_15\VBP\2367363|NONE (l_xcomp) play_17\VB\7007684|.|persists|,|Despite|preparations|, (l_dobj) role_20\NN\719494|to (l_prep) in_21\IN\13603305|a|major (l_pobj) therapy_23\NN\657604|NONE (l_compound) migraine_22\NN\14326607|NONE
D008784_D014652 CID methysergide_20\NN\0|NONE (r_pobj) of_19\IN\0|the|by (r_prep) ingestion_18\NN\13440063|NONE (r_pobj) to_16\IN\0|secondary|,|case|is|. (r_prep) described_14\VBN\1001294|NONE (l_nsubjpass) case_2\NN\7283608|secondary|to|,|is|. (l_prep) of_3\IN\0|rare|with|,|A (l_pobj) vasospasm_5\NN\0|NONE
D004876_D005734 NONE ergot_6\NN\14276936|NONE (r_pobj) of_5\IN\0|the (r_prep) history_4\NN\15120823|NONE (r_pobj) of_2\IN\0|A (r_prep) discussion_1\NN\6252138|discovery|. (r_nsubj) includes_7\VBZ\0|NONE (l_dobj) discovery_10\NN\30358|.|discussion (l_appos) epidemics_13\NNS\7435273|,|original|its (l_prep) of_14\IN\0|the|caused (l_pobj) gangrene_15\NN\14204950|NONE
19642243
D014640_D051437 NONE vancomycin_8\NNP\2716866|NONE (r_amod) therapy_9\NN\657604|NONE (r_pobj) of_7\IN\0|prolonged|a|in (r_prep) course_6\NN\883297|NONE (r_pobj) after_3\IN\0|.|failure (r_prep) developed_2\VBD\1753788|NONE (l_nsubj) failure_1\NN\66216|after|.
D014640_D051437 NONE vancomycin_17\NNP\2716866|NONE (r_pobj) of_16\IN\0|prolonged (r_prep) administration_15\NN\1133281|NONE (r_pobj) during_13\IN\0|tenofovir|that|may|risk (r_prep) raise_7\VB\5108947|NONE (l_dobj) risk_9\NN\14541044|tenofovir|that|may|during (l_prep) of_10\IN\0|the (l_pobj) failure_12\NN\66216|NONE
C418563_D051437 NONE fumarate_18\NN\0|as|who|were (r_dobj) receiving_15\VBG\2210855| (r_relcl) patients_12\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|prolonged|a|of (r_prep) course_6\NN\883297|NONE (r_pobj) after_3\IN\0|.|failure (r_prep) developed_2\VBD\1753788|NONE (l_nsubj) failure_1\NN\66216|after|.
D014640_D007674 NONE vancomycin_0\NNP\2716866|NONE (r_compound) nephrotoxicity_1\NN\0|result|infrequent|but|.
D014640_D007674 NONE vancomycin_0\NNP\2716866|NONE (r_compound) nephrotoxicity_1\NN\0|result|infrequent|but|. (r_nsubj) is_2\VBZ\0|NONE (l_conj) result_6\VB\34213|infrequent|nephrotoxicity|but|. (l_prep) from_7\IN\0|may (l_pobj) coadministration_8\NN\0|NONE (l_prep) with_9\IN\0|NONE (l_pobj) agent_12\NN\7347|NONE (l_amod) nephrotoxic_11\JJ\0|a
D014640_D058186 CID vancomycin_12\NNP\2716866|prolonged (r_amod) course_13\NN\883297|while|for (r_dobj) receiving_10\VBG\2210855|.|in|Acute|renal (r_advcl) failure_2\NN\66216|NONE
C096918_D005198 NONE tenofovir_0\NNP\0|because|in|been|has|. (r_nsubjpass) implicated_3\VBN\2677097|NONE (l_prep) in_4\IN\13603305|because|Tenofovir|been|has|. (l_pobj) development_6\NN\248977|NONE (l_prep) of_7\IN\0|the (l_pobj) syndrome_9\NN\5870365|NONE
D014640_D010019 NONE vancomycin_12\NNP\2716866|prolonged (r_amod) course_13\NN\883297|while|for (r_dobj) receiving_10\VBG\2210855|.|in|Acute|renal (l_prep) for_14\IN\0|while|course (l_pobj) osteomyelitis_15\NN\14351321|NONE
C096918_D058186 NONE tenofovir_8\NNS\0|NONE (r_pobj) on_7\IN\0|with (r_prep) patients_4\NNS\9898892|NONE (r_pobj) in_3\IN\13603305|.|Acute|receiving|renal (r_prep) failure_2\NN\66216|NONE
D014640_D000163 NONE vancomycin_12\NNP\2716866|prolonged (r_amod) course_13\NN\883297|while|for (r_dobj) receiving_10\VBG\2210855|.|in|Acute|renal (r_advcl) failure_2\NN\66216|NONE (l_prep) in_3\IN\13603305|.|Acute|receiving|renal (l_pobj) patients_4\NNS\9898892|NONE (l_prep) with_5\IN\0|on (l_pobj) aids_6\NNP\13974317|NONE
C096918_D010019 NONE tenofovir_8\NNS\0|NONE (r_pobj) on_7\IN\0|with (r_prep) patients_4\NNS\9898892|NONE (r_pobj) in_3\IN\13603305|.|Acute|receiving|renal (r_prep) failure_2\NN\66216|NONE (l_advcl) receiving_10\VBG\2210855|.|in|Acute|renal (l_prep) for_14\IN\0|while|course (l_pobj) osteomyelitis_15\NN\14351321|NONE
C096918_D000163 NONE tenofovir_8\NNS\0|NONE (r_pobj) on_7\IN\0|with (r_prep) patients_4\NNS\9898892|NONE (l_prep) with_5\IN\0|on (l_pobj) aids_6\NNP\13974317|NONE
C096918_D051437 NONE tenofovir_0\NNP\0|because|in|been|has|. (r_nsubjpass) implicated_3\VBN\2677097|NONE (l_prep) in_4\IN\13603305|because|Tenofovir|been|has|. (l_pobj) development_6\NN\248977|NONE (l_prep) of_7\IN\0|the (l_pobj) syndrome_9\NN\5870365|NONE (l_conj) insufficiency_12\NN\14462946|Fanconi|and
C096918_D051437 NONE tenofovir_5\NNS\0|that|may|risk|during (r_nsubj) raise_7\VB\5108947|NONE (l_dobj) risk_9\NN\14541044|tenofovir|that|may|during (l_prep) of_10\IN\0|the (l_pobj) failure_12\NN\66216|NONE
6454943
D002216_D011507 NONE captopril_2\NN\2673637|NONE (r_pobj) of_1\IN\0|on (r_prep) effect_0\NN\34213|.||proteinuria|in (r_nsubj) induced_10\VBN\1627355|NONE (l_dobj) proteinuria_11\NN\14299637|.||Effect|in
D002216_D011507 NONE captopril_6\NN\2673637|in (r_compound) treatment_7\NN\654885|NONE (r_pobj) of_5\IN\0|side|a (r_prep) effect_4\NN\34213|.|Proteinuria (r_attr) is_1\VBZ\0|NONE (l_nsubj) proteinuria_0\NNP\14299637|.|effect
D002216_D011507 NONE captopril_3\NN\2673637|NONE (r_pobj) of_2\IN\0|Oral|for|at (r_prep) administration_1\NN\1133281|.|aggravate (r_nsubj) failed_10\VBD\0|NONE (l_xcomp) aggravate_12\VB\126264|.|administration (l_dobj) proteinuria_13\JJ\14299637|to
D002216_D011507 NONE captopril_2\NN\2673637|NONE (r_compound) treatment_3\NN\654885|.|Also|potentiate|, (r_nsubj) failed_4\VBD\0|NONE (l_xcomp) potentiate_6\VB\229605|.|Also|,|treatment (l_conj) facilitate_8\VB\2547586|or|to (l_dobj) development_9\NN\248977|NONE (l_prep) of_10\IN\0|NONE (l_pobj) proteinuria_12\NN\14299637|NONE
D011692_D006973 NONE aminonucleoside_8\RB\0|existing (r_punct) -_9\HYPH\0|.|proteinuria|Effect|in (r_punct) induced_10\VBN\1627355|NONE (l_prep) in_12\IN\13603305|.||proteinuria|Effect (l_pobj) rats_15\NNS\2329401|NONE (l_amod) hypertensive_14\JJ\10405694|NONE
D002216_D007674 NONE captopril_9\NN\2673637|NONE (r_pobj) with_8\IN\0|same|renal|the (r_prep) abnormality_7\NN\14034177|NONE
D002216_D006973 NONE captopril_2\NN\2673637|NONE (r_pobj) of_1\IN\0|on (r_prep) effect_0\NN\34213|.||proteinuria|in (r_nsubj) induced_10\VBN\1627355|NONE (l_prep) in_12\IN\13603305|.||proteinuria|Effect (l_pobj) rats_15\NNS\2329401|NONE (l_amod) hypertensive_14\JJ\10405694|NONE
D002216_D006973 NONE captopril_6\NN\2673637|in (r_compound) treatment_7\NN\654885|NONE (l_prep) in_8\IN\13603305|captopril (l_pobj) patients_10\NNS\9898892|NONE (l_amod) hypertensive_9\JJ\10405694|NONE
D011692_D011507 CID aminonucleoside_8\RB\0|existing (r_punct) -_9\HYPH\0|.|proteinuria|Effect|in (r_punct) induced_10\VBN\1627355|NONE (l_dobj) proteinuria_11\NN\14299637|.||Effect|in
D011692_D011507 CID aminonucleoside_16\NN\0|NONE (r_amod) puromycin_15\NNS\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) invoked_13\VBN\1617192|massive (r_acl) proteinuria_12\NN\14299637|NONE
10328196
D003907_D011565 NONE dexamethasone_15\NN\2721538| (r_npadvmod) induced_17\VBN\1627355|greater|or (r_conj) spontaneous_13\JJ\0|did (r_amod) apoptosis_18\NN\11486178|to (r_oprd) exhibit_11\VB\6733939|NONE (r_xcomp) tended_9\VBD\2604760|.|cells (r_ccomp) activated_0\VBN\1641914|NONE (l_dobj) cells_4\NNS\3080309|tended|. (l_prep) from_5\IN\0|peripheral|T (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) psoriasis_8\NN\14219661|NONE
D020123_D011565 NONE sirolimus_5\NN\0|NONE (r_pobj) of_4\IN\0|NONE (r_prep) administration_3\NN\1133281|NONE (r_dobj) following_2\VBG\8180190|)|(|association|Systemic|for|.|:|rapamycin (r_prep) toxicity_1\NN\13576101|NONE (l_prep) for_10\IN\0|)|(|following|association|Systemic|.|:|rapamycin (l_pobj) psoriasis_11\NN\14219661|NONE
D020123_D011565 NONE rapamycin_8\VBZ\0|)|(|following|association|Systemic|for|.|: (r_appos) toxicity_1\NN\13576101|NONE (l_prep) for_10\IN\0|)|(|following|association|Systemic|.|:|rapamycin (l_pobj) psoriasis_11\NN\14219661|NONE
D020123_D011565 NONE sirolimus_14\NN\0|skin|lesional (r_nmod) cells_17\NNS\3080309|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatment_11\NN\654885|NONE (r_pobj) following_10\VBG\8180190|a|leak (r_acl) syndrome_9\NN\5870365|analyzed|individuals|After|.|and (r_dobj) developed_5\VBD\1753788|NONE (l_nsubj) individuals_2\NNS\7347|analyzed|syndrome|After|.|and (l_prep) with_3\IN\0| (l_pobj) psoriasis_4\NN\14219661|NONE
D020123_D011565 NONE sirolimus_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|leak (r_amod) syndrome_13\NN\5870365|NONE (r_pobj) with_7\IN\0| (r_prep) patient_6\NN\9898892|NONE (r_pobj) from_4\IN\0|keratome|skin|A (r_prep) specimen_3\NN\5820620|compared|.|increase (r_nsubj) had_14\VBD\0|NONE (l_prep) compared_28\VBN\644583|.|specimen|increase (l_prep) with_29\IN\0|NONE (l_pobj) patient_35\NN\9898892|NONE (l_prep) with_36\IN\0|unaffected|%|treated|)|an|( (l_pobj) psoriasis_37\NN\14219661|NONE
D020123_D011565 NONE sirolimus_32\NN\0| (r_npadvmod) treated_34\VBN\2376958|unaffected|%|)|an|with|( (r_amod) patient_35\NN\9898892|NONE (l_prep) with_36\IN\0|unaffected|%|treated|)|an|( (l_pobj) psoriasis_37\NN\14219661|NONE
D020123_D011565 NONE sirolimus_30\NN\0|NONE (r_pobj) of_29\IN\0|the (r_prep) presence_28\NN\13954253|particularly (r_pobj) in_26\IN\13603305|cells|,|than (r_prep) did_20\VBD\0|spontaneous (r_advcl) apoptosis_18\NN\11486178|to (r_oprd) exhibit_11\VB\6733939|NONE (r_xcomp) tended_9\VBD\2604760|.|cells (r_ccomp) activated_0\VBN\1641914|NONE (l_dobj) cells_4\NNS\3080309|tended|. (l_prep) from_5\IN\0|peripheral|T (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) psoriasis_8\NN\14219661|NONE
D020123_D019559 CID sirolimus_5\NN\0|NONE (r_pobj) of_4\IN\0|NONE (r_prep) administration_3\NN\1133281|NONE (r_dobj) following_2\VBG\8180190|)|(|association|Systemic|for|.|:|rapamycin (r_prep) toxicity_1\NN\13576101|NONE (l_appos) association_13\NN\8008335|)|(|following|Systemic|for|.|:|rapamycin (l_prep) of_14\IN\0|with (l_pobj) syndrome_17\NN\5870365|NONE
D020123_D019559 CID rapamycin_8\VBZ\0|)|(|following|association|Systemic|for|.|: (r_appos) toxicity_1\NN\13576101|NONE (l_appos) association_13\NN\8008335|)|(|following|Systemic|for|.|:|rapamycin (l_prep) of_14\IN\0|with (l_pobj) syndrome_17\NN\5870365|NONE
D020123_D019559 CID sirolimus_14\NN\0|skin|lesional (r_nmod) cells_17\NNS\3080309|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatment_11\NN\654885|NONE (r_pobj) following_10\VBG\8180190|a|leak (r_acl) syndrome_9\NN\5870365|analyzed|individuals|After|.|and
D020123_D019559 CID sirolimus_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|leak (r_amod) syndrome_13\NN\5870365|NONE
D020123_D019559 CID sirolimus_32\NN\0| (r_npadvmod) treated_34\VBN\2376958|unaffected|%|)|an|with|( (r_amod) patient_35\NN\9898892|NONE (r_pobj) with_29\IN\0|NONE (r_prep) compared_28\VBN\644583|.|specimen|increase (r_prep) had_14\VBD\0|NONE (l_nsubj) specimen_3\NN\5820620|compared|.|increase (l_prep) from_4\IN\0|keratome|skin|A (l_pobj) patient_6\NN\9898892|NONE (l_prep) with_7\IN\0| (l_pobj) syndrome_13\NN\5870365|NONE
D020123_D019559 CID sirolimus_4\NN\0|NONE (r_pobj) of_3\IN\0|Severe|adverse (r_prep) effects_2\NNS\13245626|fever|. (r_nsubj) include_5\VBP\0|NONE (l_dobj) fever_6\NN\14299637|effects|. (l_conj) anemia_8\NN\14189204|, (l_conj) syndrome_13\NN\5870365|,|and
D020123_D005334 NONE sirolimus_4\NN\0|NONE (r_pobj) of_3\IN\0|Severe|adverse (r_prep) effects_2\NNS\13245626|fever|. (r_nsubj) include_5\VBP\0|NONE (l_dobj) fever_6\NN\14299637|effects|.
D020123_D000740 NONE sirolimus_4\NN\0|NONE (r_pobj) of_3\IN\0|Severe|adverse (r_prep) effects_2\NNS\13245626|fever|. (r_nsubj) include_5\VBP\0|NONE (l_dobj) fever_6\NN\14299637|effects|. (l_conj) anemia_8\NN\14189204|,
D020123_D064420 NONE sirolimus_5\NN\0|NONE (r_pobj) of_4\IN\0|NONE (r_prep) administration_3\NN\1133281|NONE (r_dobj) following_2\VBG\8180190|)|(|association|Systemic|for|.|:|rapamycin (r_prep) toxicity_1\NN\13576101|NONE
D020123_D064420 NONE rapamycin_8\VBZ\0|)|(|following|association|Systemic|for|.|: (r_appos) toxicity_1\NN\13576101|NONE
2716967
D009020_D009127 NONE morphine_21\NN\2707683|or (r_conj) ketamine_19\NN\3054098|NONE (r_pobj) of_18\IN\0|the|relative|in (r_prep) predominance_17\NN\14441825|Latency|.|, (r_dobj) reflected_14\VBD\923793|NONE (l_nsubj) latency_0\NN\15269513|.|,|predominance (l_prep) to_1\IN\0|NONE (l_pobj) loss_3\NN\13252973|NONE (l_prep) of_4\IN\0|the (l_pobj) reflex_6\NN\859001|NONE (l_conj) rigidity_8\NN\5023233|,|righting
D009270_D002375 NONE naloxone_0\NN\3808977|.|effects (r_nsubj) inhibited_1\VBD\2510337|NONE (l_dobj) effects_5\NNS\13245626|Naloxone|. (l_amod) cataleptic_4\JJ\10490141|induced|the
D009270_D002375 NONE naloxone_36\NN\3808977|NONE (r_pobj) for_35\IN\0|different|a (r_prep) id50_34\NNP\0|of|and (r_conj) asymmetry_24\NN\5062748|in|, (r_conj) differences_16\NNS\4723816|the|induced|, (r_conj) catalepsy_14\NN\14023236|NONE
D009020_D000699 NONE morphine_7\NN\2707683|and|both (r_conj) ketamine_5\NN\3054098|analgesia|that (r_nsubj) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D009020_D000699 NONE morphine_26\NN\2707683|NONE (r_pobj) to_25\IN\0||cross|produced (r_prep) tolerance_24\NN\5032565|studies|,|induce|induced (r_dobj) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D009020_D000699 NONE morphine_31\NN\2707683|NONE (r_pobj) with_30\IN\0|NONE (r_prep) pretreatment_29\NN\0|but|tolerance|not|did|augmented|whereas (r_nsubj) induce_34\VB\1627355|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D009020_D000699 NONE morphine_53\NN\2707683|NONE (r_pobj) to_51\IN\0|was|;|demonstrated|.|augmentation (r_prep) attributed_50\VBN\670261|NONE (l_ccomp) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D007649_D000699 NONE ketamine_5\NN\3054098|analgesia|that (r_nsubj) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D007649_D000699 NONE ketamine_20\NN\3054098|NONE (r_pobj) with_19\IN\0| (r_prep) treatment_18\NN\654885|NONE (r_nsubj) produced_21\VBD\1617192||cross|to (r_amod) tolerance_24\NN\5032565|studies|,|induce|induced (r_dobj) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D007649_D000699 NONE ketamine_39\NN\3054098|NONE (r_pobj) to_38\IN\0||cross (r_prep) tolerance_37\NN\5032565|but|pretreatment|not|did|augmented|whereas (r_dobj) induce_34\VB\1627355|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that
D009270_D009127 NONE naloxone_36\NN\3808977|NONE (r_pobj) for_35\IN\0|different|a (r_prep) id50_34\NNP\0|of|and (r_conj) asymmetry_24\NN\5062748|in|, (r_conj) differences_16\NNS\4723816|the|induced|, (l_prep) in_17\IN\13603305|asymmetry|, (l_pobj) latency_18\NN\15269513|NONE (l_conj) rigidity_20\NN\5023233|,
D007649_D002375 CID ketamine_5\NN\3054098|NONE (r_pobj) of_4\IN\0|potentiation|: (r_prep) combinations_3\NNS\7951464|NONE (r_pobj) by_2\IN\0|.|Catalepsy (r_agent) induced_1\VBN\1627355|NONE (l_nsubj) catalepsy_0\NNP\14023236|by|.
D007649_D002375 CID ketamine_5\NN\3054098|analgesia|that (r_nsubj) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D007649_D002375 CID ketamine_5\NN\3054098|analgesia|that (r_nsubj) induced_8\VBN\1627355|studies|,|induce|tolerance (r_ccomp) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_advcl) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D007649_D002375 CID ketamine_20\NN\3054098|NONE (r_pobj) with_19\IN\0| (r_prep) treatment_18\NN\654885|NONE (r_nsubj) produced_21\VBD\1617192||cross|to (r_amod) tolerance_24\NN\5032565|studies|,|induce|induced (r_dobj) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D007649_D002375 CID ketamine_20\NN\3054098|NONE (r_pobj) with_19\IN\0| (r_prep) treatment_18\NN\654885|NONE (r_nsubj) produced_21\VBD\1617192||cross|to (r_amod) tolerance_24\NN\5032565|studies|,|induce|induced (r_dobj) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_advcl) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D007649_D002375 CID ketamine_39\NN\3054098|NONE (r_pobj) to_38\IN\0||cross (r_prep) tolerance_37\NN\5032565|but|pretreatment|not|did|augmented|whereas (r_dobj) induce_34\VB\1627355|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D007649_D002375 CID ketamine_39\NN\3054098|NONE (r_pobj) to_38\IN\0||cross (r_prep) tolerance_37\NN\5032565|but|pretreatment|not|did|augmented|whereas (r_dobj) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D009020_D002375 CID morphine_7\NN\2707683|and (r_conj) ketamine_5\NN\3054098|NONE (r_pobj) of_4\IN\0|potentiation|: (r_prep) combinations_3\NNS\7951464|NONE (r_pobj) by_2\IN\0|.|Catalepsy (r_agent) induced_1\VBN\1627355|NONE (l_nsubj) catalepsy_0\NNP\14023236|by|.
D009020_D002375 CID morphine_7\NN\2707683|and|both (r_conj) ketamine_5\NN\3054098|analgesia|that (r_nsubj) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D009020_D002375 CID morphine_7\NN\2707683|and|both (r_conj) ketamine_5\NN\3054098|analgesia|that (r_nsubj) induced_8\VBN\1627355|studies|,|induce|tolerance (r_ccomp) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_advcl) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D009020_D002375 CID morphine_26\NN\2707683|NONE (r_pobj) to_25\IN\0||cross|produced (r_prep) tolerance_24\NN\5032565|studies|,|induce|induced (r_dobj) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D009020_D002375 CID morphine_26\NN\2707683|NONE (r_pobj) to_25\IN\0||cross|produced (r_prep) tolerance_24\NN\5032565|studies|,|induce|induced (r_dobj) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_advcl) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D009020_D002375 CID morphine_31\NN\2707683|NONE (r_pobj) with_30\IN\0|NONE (r_prep) pretreatment_29\NN\0|but|tolerance|not|did|augmented|whereas (r_nsubj) induce_34\VB\1627355|studies|,|induced|tolerance (r_advcl) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D009020_D002375 CID morphine_31\NN\2707683|NONE (r_pobj) with_30\IN\0|NONE (r_prep) pretreatment_29\NN\0|but|tolerance|not|did|augmented|whereas (r_nsubj) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D009020_D002375 CID morphine_53\NN\2707683|NONE (r_pobj) to_51\IN\0|was|;|demonstrated|.|augmentation (r_prep) attributed_50\VBN\670261|NONE (l_ccomp) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_ccomp) induced_8\VBN\1627355|studies|,|induce|tolerance (l_dobj) analgesia_9\NN\14034177|ketamine|that (l_conj) catalepsy_11\NN\14023236|in|and
D009020_D002375 CID morphine_53\NN\2707683|NONE (r_pobj) to_51\IN\0|was|;|demonstrated|.|augmentation (r_prep) attributed_50\VBN\670261|NONE (l_ccomp) demonstrated_2\VBD\2137132|was|;|to|.|augmentation (l_advcl) induce_34\VB\1627355|studies|,|induced|tolerance (l_conj) augmented_42\VBD\153263|but|tolerance|pretreatment|not|did|whereas (l_dobj) response_45\NN\11410625|rather (l_amod) cataleptic_44\JJ\10490141|the
D007649_D009127 NONE ketamine_19\NN\3054098|NONE (r_pobj) of_18\IN\0|the|relative|in (r_prep) predominance_17\NN\14441825|Latency|.|, (r_dobj) reflected_14\VBD\923793|NONE (l_nsubj) latency_0\NN\15269513|.|,|predominance (l_prep) to_1\IN\0|NONE (l_pobj) loss_3\NN\13252973|NONE (l_prep) of_4\IN\0|the (l_pobj) reflex_6\NN\859001|NONE (l_conj) rigidity_8\NN\5023233|,|righting
11861791
D004317_D006333 CID doxorubicin_11\NN\2716866| (r_npadvmod) induced_13\VBN\1627355|heart (r_amod) failure_15\NN\66216|NONE
D004317_D006331 NONE dox_36\NNP\0|NONE (r_pobj) by_35\IN\0|NONE (r_agent) induced_34\VBN\1627355|cardiac (r_acl) dysfunction_33\NN\14204950|NONE
D004317_D005117 NONE dox_16\NNP\0|the (r_compound) treatment_17\NN\654885|NONE (r_pobj) with_14\IN\0|NONE (r_prep) associated_13\VBN\628491|severe|cardiac (r_acl) complications_12\NNS\1073995|NONE
D004317_D066126 NONE doxorubicin_12\NN\2716866|NONE (r_pobj) of_11\IN\0|the (r_prep) cardiotoxicity_10\NN\0|NONE
D004317_D066126 NONE dox_14\NNP\0|,|antibiotic (r_appos) doxorubicin_12\NN\2716866|NONE (r_pobj) of_11\IN\0|the (r_prep) cardiotoxicity_10\NN\0|NONE
D004317_D066126 NONE dox_13\NNP\0| (r_npadvmod) induced_15\VBN\1627355|the (r_amod) cardiotoxicity_16\NN\0|NONE
D004317_D066126 NONE dox_9\NNP\0|NONE (r_pobj) of_8\IN\0|the (r_prep) cardiotoxicity_7\NN\0|NONE
C434926_D006331 NONE pj34_19\NNP\0|NONE (r_pobj) with_14\IN\0|pharmacological (r_prep) inhibition_13\NN\1068773|genetic|or (r_conj) deletion_10\NN\13508333|NONE (r_pobj) by_8\IN\0|,|approach (r_prep) using_0\VBG\418025|.|role|we|,|now (r_advcl) demonstrate_23\VBP\2137132|NONE (l_dobj) role_25\NN\719494|Using|.|we|,|now (l_prep) in_28\IN\13603305|of|the (l_pobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) dysfunction_33\NN\14204950|NONE
C434926_D006331 NONE pj34_3\NNP\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|significantly|and|.|dysfunction|increased (r_nsubj) improved_5\VBD\126264|NONE (l_dobj) dysfunction_7\NN\14204950|significantly|and|.|Treatment|increased
D018943_D066126 NONE anthracycline_21\NN\0|used|a|antitumor (r_amod) antibiotic_22\NN\2716205|,|DOX (r_appos) doxorubicin_12\NN\2716866|NONE (r_pobj) of_11\IN\0|the (r_prep) cardiotoxicity_10\NN\0|NONE
D011064_D006333 NONE )_5\-RRB-\0|ribose (r_punct) polymerase_6\NN\14732946|NONE (r_pobj) of_1\IN\0|NONE (r_prep) activation_0\NN\13561719|.|to (r_nsubj) contributes_7\VBZ\126264|NONE (l_prep) to_8\IN\0|Activation|. (l_pobj) development_9\NN\248977|NONE (l_prep) of_10\IN\0|NONE (l_pobj) failure_15\NN\66216|NONE
12109865
3131282
C009166_D013274 NONE acetate_6\NN\15010703|NONE (r_pobj) of_4\IN\0|on|carcinogenic (r_prep) effect_3\NN\34213|with|. (l_prep) on_7\IN\0|carcinogenic|of (l_pobj) carcinogenesis_9\NN\0|NONE
C009166_D013274 NONE acetate_6\NN\15010703|NONE (r_pobj) of_4\IN\0|on|potential|modifying|The (r_prep) effect_3\NN\34213|tumorigenesis|was|(|. (r_nsubjpass) examined_19\VBN\0|NONE (l_nsubjpass) tumorigenesis_17\NN\0|was|(|.|effect
C009166_D013274 NONE ra_8\NNP\14625458|retinyl (r_appos) acetate_6\NN\15010703|NONE (r_pobj) of_4\IN\0|on|potential|modifying|The (r_prep) effect_3\NN\34213|tumorigenesis|was|(|. (r_nsubjpass) examined_19\VBN\0|NONE (l_nsubjpass) tumorigenesis_17\NN\0|was|(|.|effect
C009166_D013274 NONE ra_27\NNP\14625458|from|incidence|to (r_nsubj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_prep) of_38\IN\0|)|papilloma|the|( (l_pobj) tumors_40\NNS\14234074|NONE
C009166_D013274 NONE ra_74\NNP\14625458| (r_npadvmod) free_76\JJ\7942152|NONE (r_amod) water_77\NN\14618834|NONE (r_dobj) given_73\VBN\5892096|the (r_acl) group_72\NN\2137|NONE (r_pobj) in_70\IN\13603305|% (r_prep) from_59\IN\0|incidence|to|RA (r_prep) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_prep) of_38\IN\0|)|papilloma|the|( (l_pobj) tumors_40\NNS\14234074|NONE
C009166_D013274 NONE ra_4\NNP\14625458|carcinogenesis|that|as (r_nsubj) acted_5\VBD\0|findings|. (l_dobj) carcinogenesis_15\NN\0|RA|that|as
D002083_D063646 NONE hydroxyanisole_17\NN\0|NONE (r_pobj) with_15\IN\0|effect|. (r_prep) induced_14\VBN\1627355|NONE (l_nsubj) effect_3\NN\34213|with|. (l_amod) carcinogenic_2\JJ\0|on|of
D002083_D013274 CID hydroxyanisole_17\NN\0|NONE (r_pobj) with_15\IN\0|effect|. (r_prep) induced_14\VBN\1627355|NONE (l_nsubj) effect_3\NN\34213|with|. (l_prep) on_7\IN\0|carcinogenic|of (l_pobj) carcinogenesis_9\NN\0|NONE
D002083_D013274 CID hydroxyanisole_12\NN\0|NONE (r_pobj) on_10\IN\0|of|potential|modifying|The (r_prep) effect_3\NN\34213|tumorigenesis|was|(|. (r_nsubjpass) examined_19\VBN\0|NONE (l_nsubjpass) tumorigenesis_17\NN\0|was|(|.|effect
D002083_D013274 CID bha)-induced_14\JJ\0|NONE (r_amod) rat_15\NN\2329401|forestomach (r_compound) tumorigenesis_17\NN\0|was|(|.|effect
D002083_D013274 CID bha_5\NNP\0|NONE (r_dobj) given_2\VBN\5892096|NONE (r_acl) groups_1\NNS\2137|NONE (r_pobj) in_0\IN\13603305|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN\2163746|NONE (l_conj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_prep) of_38\IN\0|)|papilloma|the|( (l_pobj) tumors_40\NNS\14234074|NONE
D002083_D013274 CID bha_13\NNP\0|of|the|forestomach (r_compound) carcinogenesis_15\NN\0|RA|that|as
C009166_D063646 NONE acetate_6\NN\15010703|NONE (r_pobj) of_4\IN\0|on|carcinogenic (r_prep) effect_3\NN\34213|with|. (l_amod) carcinogenic_2\JJ\0|on|of
C009166_D017573 NONE ra_7\NNP\14625458|NONE (r_punct) co_8\NNP\14954601|NONE (r_punct) -_9\HYPH\0|NONE (r_punct) administered_10\VBN\2436349|dose (r_punct) at_11\IN\14622893|BHA (r_prep) given_2\VBN\5892096|NONE (r_acl) rats_1\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|effect|%|. (r_prep) showed_23\VBD\2137132|NONE (l_dobj) effect_29\NN\34213|%|In|. (l_prep) on_30\IN\0|dependent|a|enhancing (l_pobj) development_32\NN\248977|NONE (l_prep) of_33\IN\0|the (l_pobj) hyperplasia_39\NN\14365950|NONE
D002083_D017573 NONE bha_5\NNP\0|at (r_dobj) given_2\VBN\5892096|NONE (r_acl) rats_1\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|effect|%|. (r_prep) showed_23\VBD\2137132|NONE (l_dobj) effect_29\NN\34213|%|In|. (l_prep) on_30\IN\0|dependent|a|enhancing (l_pobj) development_32\NN\248977|NONE (l_prep) of_33\IN\0|the (l_pobj) hyperplasia_39\NN\14365950|NONE
D002083_D017573 NONE bha_35\NNP\0| (r_npadvmod) induced_37\VBN\1627355|epithelial|the (r_amod) hyperplasia_39\NN\14365950|NONE
C009166_D002277 NONE ra_27\NNP\14625458|from|incidence|to (r_nsubj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_appos) papilloma_44\NN\14236226|)|of|the|( (l_conj) carcinoma_46\NN\14239918|squamous|cell|and
C009166_D002277 NONE ra_27\NNP\14625458|from|incidence|to (r_nsubj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_prep) to_48\IN\0|from|incidence|RA (l_pobj) %_50\NN\0|NONE (l_appos) rats_55\NNS\2329401| (l_prep) with_56\IN\0||/|)|,|( (l_pobj) carcinoma_57\NN\14239918|NONE
C009166_D002277 NONE ra_27\NNP\14625458|from|incidence|to (r_nsubj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_prep) from_59\IN\0|incidence|to|RA (l_pobj) %_61\NN\0|in (l_appos) rat_66\NN\2329401||,|(|/|) (l_prep) with_67\IN\0|one (l_pobj) carcinoma_68\NN\14239918|NONE
C009166_D002277 NONE ra_74\NNP\14625458| (r_npadvmod) free_76\JJ\7942152|NONE (r_amod) water_77\NN\14618834|NONE (r_dobj) given_73\VBN\5892096|the (r_acl) group_72\NN\2137|NONE (r_pobj) in_70\IN\13603305|% (r_prep) from_59\IN\0|incidence|to|RA (r_prep) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_appos) papilloma_44\NN\14236226|)|of|the|( (l_conj) carcinoma_46\NN\14239918|squamous|cell|and
C009166_D002277 NONE ra_74\NNP\14625458| (r_npadvmod) free_76\JJ\7942152|NONE (r_amod) water_77\NN\14618834|NONE (r_dobj) given_73\VBN\5892096|the (r_acl) group_72\NN\2137|NONE (r_pobj) in_70\IN\13603305|% (r_prep) from_59\IN\0|incidence|to|RA (r_prep) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_prep) to_48\IN\0|from|incidence|RA (l_pobj) %_50\NN\0|NONE (l_appos) rats_55\NNS\2329401| (l_prep) with_56\IN\0||/|)|,|( (l_pobj) carcinoma_57\NN\14239918|NONE
C009166_D002277 NONE ra_74\NNP\14625458| (r_npadvmod) free_76\JJ\7942152|NONE (r_amod) water_77\NN\14618834|NONE (r_dobj) given_73\VBN\5892096|the (r_acl) group_72\NN\2137|NONE (r_pobj) in_70\IN\13603305|% (r_prep) from_59\IN\0|incidence|to|RA (l_pobj) %_61\NN\0|in (l_appos) rat_66\NN\2329401||,|(|/|) (l_prep) with_67\IN\0|one (l_pobj) carcinoma_68\NN\14239918|NONE
C009166_D009369 NONE ra_17\NN\14625458|and|in (r_pobj) with_14\IN\0|)|%|(| (r_prep) rats_9\NNS\2329401|NONE (r_pobj) in_7\IN\13603305|Tumors|were|. (r_prep) induced_6\VBN\1627355|NONE (l_nsubjpass) tumors_0\NNS\14234074|in|were|.
C009166_D009369 NONE ra_29\NNP\14625458|%| (r_compound) administration_32\NN\1133281|NONE (r_punct) ._33\.\0|in|Tumors|were (r_punct) induced_6\VBN\1627355|NONE (l_nsubjpass) tumors_0\NNS\14234074|in|were|.
D002083_D002277 NONE bha_5\NNP\0|NONE (r_dobj) given_2\VBN\5892096|NONE (r_acl) groups_1\NNS\2137|NONE (r_pobj) in_0\IN\13603305|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN\2163746|NONE (l_conj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_appos) papilloma_44\NN\14236226|)|of|the|( (l_conj) carcinoma_46\NN\14239918|squamous|cell|and
D002083_D002277 NONE bha_5\NNP\0|NONE (r_dobj) given_2\VBN\5892096|NONE (r_acl) groups_1\NNS\2137|NONE (r_pobj) in_0\IN\13603305|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN\2163746|NONE (l_conj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_prep) to_48\IN\0|from|incidence|RA (l_pobj) %_50\NN\0|NONE (l_appos) rats_55\NNS\2329401| (l_prep) with_56\IN\0||/|)|,|( (l_pobj) carcinoma_57\NN\14239918|NONE
D002083_D002277 NONE bha_5\NNP\0|NONE (r_dobj) given_2\VBN\5892096|NONE (r_acl) groups_1\NNS\2137|NONE (r_pobj) in_0\IN\13603305|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN\2163746|NONE (l_conj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_prep) from_59\IN\0|incidence|to|RA (l_pobj) %_61\NN\0|in (l_appos) rat_66\NN\2329401||,|(|/|) (l_prep) with_67\IN\0|one (l_pobj) carcinoma_68\NN\14239918|NONE
D002083_D010212 NONE bha_5\NNP\0|NONE (r_dobj) given_2\VBN\5892096|NONE (r_acl) groups_1\NNS\2137|NONE (r_pobj) in_0\IN\13603305|were|in|marked|,|increased|changes|. (r_prep) observed_16\VBN\2163746|NONE (l_conj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_appos) papilloma_44\NN\14236226|)|of|the|(
C009166_D010212 NONE ra_27\NNP\14625458|from|incidence|to (r_nsubj) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_appos) papilloma_44\NN\14236226|)|of|the|(
C009166_D010212 NONE ra_74\NNP\14625458| (r_npadvmod) free_76\JJ\7942152|NONE (r_amod) water_77\NN\14618834|NONE (r_dobj) given_73\VBN\5892096|the (r_acl) group_72\NN\2137|NONE (r_pobj) in_70\IN\13603305|% (r_prep) from_59\IN\0|incidence|to|RA (r_prep) increased_35\VBD\169651|were|in|marked|,|changes|.|In (l_dobj) incidence_37\NN\13821570|from|to|RA (l_appos) papilloma_44\NN\14236226|)|of|the|(
C009166_D010212 NONE ra_17\NN\14625458|and|in (r_pobj) with_14\IN\0|)|%|(| (r_prep) rats_9\NNS\2329401|NONE (r_pobj) in_7\IN\13603305|Tumors|were|. (r_prep) induced_6\VBN\1627355|NONE (l_nsubjpass) tumors_0\NNS\14234074|in|were|. (l_appos) papillomas_3\NNS\14236226|,|,
C009166_D010212 NONE ra_29\NNP\14625458|%| (r_compound) administration_32\NN\1133281|NONE (r_punct) ._33\.\0|in|Tumors|were (r_punct) induced_6\VBN\1627355|NONE (l_nsubjpass) tumors_0\NNS\14234074|in|were|. (l_appos) papillomas_3\NNS\14236226|,|,
19234905
D014635_D006423 NONE valproate_33\NNP\0|NONE (r_pobj) with_32\IN\0|partly|within|which (r_prep) improved_28\VBD\126264|after|one|movements (r_advcl) developed_18\VBN\1753788|hemianopsia|observed|after|one|and|:|. (r_conj) had_8\VBD\0|NONE (l_dobj) hemianopsia_12\NN\14552802|observed|after|one|and|:|.|developed
D007980_D004409 CID levodopa_55\RB\14604959| (r_npadvmod) induced_57\VBN\1627355|NONE (r_amod) dyskinesias_58\NNS\14084880|were|.
8600333
C053519_D001859 NONE protocol_23\NN\6652242|NONE (r_pobj) to_17\IN\0|NONE (r_prep) according_16\VBG\2657219|were|who (r_prep) treated_15\VBN\2376958|term|of (r_relcl) survivors_8\NNS\9630641|NONE (l_prep) of_9\IN\0|term|treated (l_pobj) tumors_12\NNS\14234074|NONE
D004317_D066126 NONE doxorubicin_3\NN\2716866| (r_npadvmod) induced_5\VBN\1627355|NONE (r_compound) cardiotoxicity_6\NN\0|NONE
D004317_D001859 NONE doxorubicin_27\NN\2716866|NONE (r_pobj) including_26\VBG\0|NONE (r_prep) both_25\DT\0|T|,|Rosen (r_appos) protocol_23\NN\6652242|NONE (r_pobj) to_17\IN\0|NONE (r_prep) according_16\VBG\2657219|were|who (r_prep) treated_15\VBN\2376958|term|of (r_relcl) survivors_8\NNS\9630641|NONE (l_prep) of_9\IN\0|term|treated (l_pobj) tumors_12\NNS\14234074|NONE
6308526
D009020_D007035 CID morphine_5\NN\2707683|Pretreatment|at|significantly|analgesia|. (r_dobj) blocked_4\VBD\1476483|NONE (l_npadvmod) analgesia_6\NN\14034177|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN\14023236|, (l_conj) hypothermia_10\VBN\14034177|and
D009020_D000699 NONE morphine_5\NN\2707683|Pretreatment|at|significantly|analgesia|. (r_dobj) blocked_4\VBD\1476483|NONE (l_npadvmod) analgesia_6\NN\14034177|Pretreatment|at|significantly|.|morphine
D009020_D012131 NONE morphine_6\NN\2707683| (r_npadvmod) induced_8\VBN\1627355|hypotension|the (r_amod) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone
D009020_D012131 NONE morphine_15\NN\2707683| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) bradycardia_18\NN\14110674|whereas|affected (r_nsubj) was_19\VBD\0|,|Moreover|depression|significantly|,|.|naloxazone (r_advcl) attenuated_4\VBD\224901|NONE (l_dobj) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone
D009020_D007022 CID morphine_6\NN\2707683| (r_npadvmod) induced_8\VBN\1627355|hypotension|the (r_amod) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone (l_nmod) hypotension_9\NN\14057371|induced|the
D009020_D007022 CID morphine_15\NN\2707683| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) bradycardia_18\NN\14110674|whereas|affected (r_nsubj) was_19\VBD\0|,|Moreover|depression|significantly|,|.|naloxazone (r_advcl) attenuated_4\VBD\224901|NONE (l_dobj) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone (l_nmod) hypotension_9\NN\14057371|induced|the
C024224_D007022 NONE naloxazone_2\NN\0|,|Moreover|depression|significantly|,|was|. (r_nsubj) attenuated_4\VBD\224901|NONE (l_dobj) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone (l_nmod) hypotension_9\NN\14057371|induced|the
D009020_D002375 CID morphine_5\NN\2707683|Pretreatment|at|significantly|analgesia|. (r_dobj) blocked_4\VBD\1476483|NONE (l_npadvmod) analgesia_6\NN\14034177|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN\14023236|,
C024224_D002375 NONE naloxazone_2\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|at|significantly|analgesia|.|morphine (r_nsubj) blocked_4\VBD\1476483|NONE (l_npadvmod) analgesia_6\NN\14034177|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN\14023236|,
C024224_D000699 NONE naloxazone_2\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|at|significantly|analgesia|.|morphine (r_nsubj) blocked_4\VBD\1476483|NONE (l_npadvmod) analgesia_6\NN\14034177|Pretreatment|at|significantly|.|morphine
C024224_D007035 NONE naloxazone_2\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|at|significantly|analgesia|.|morphine (r_nsubj) blocked_4\VBD\1476483|NONE (l_npadvmod) analgesia_6\NN\14034177|Pretreatment|at|significantly|.|morphine (l_conj) catalepsy_8\NN\14023236|, (l_conj) hypothermia_10\VBN\14034177|and
D009020_D001919 CID morphine_6\NN\2707683| (r_npadvmod) induced_8\VBN\1627355|hypotension|the (r_amod) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone (r_dobj) attenuated_4\VBD\224901|NONE (l_advcl) was_19\VBD\0|,|Moreover|depression|significantly|,|.|naloxazone (l_nsubj) bradycardia_18\NN\14110674|whereas|affected
D009020_D001919 CID morphine_15\NN\2707683| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) bradycardia_18\NN\14110674|whereas|affected
C024224_D001919 NONE naloxazone_2\NN\0|,|Moreover|depression|significantly|,|was|. (r_nsubj) attenuated_4\VBD\224901|NONE (l_advcl) was_19\VBD\0|,|Moreover|depression|significantly|,|.|naloxazone (l_nsubj) bradycardia_18\NN\14110674|whereas|affected
C024224_D012131 NONE naloxazone_2\NN\0|,|Moreover|depression|significantly|,|was|. (r_nsubj) attenuated_4\VBD\224901|NONE (l_dobj) depression_12\NN\14373582|,|Moreover|significantly|,|was|.|naloxazone
9326871
D004917_D005759 CID erythromycin_7\NNP\2716866|NONE (r_pobj) of_6\IN\0|effect|the (r_prep) profile_5\NN\6999802|Although|is (r_nsubjpass) established_9\VBN\2426171|.|still|being|experience|is (r_advcl) recorded_35\VBN\2225492|NONE (l_nsubjpass) experience_27\NN\5984287|.|still|being|established|is (l_prep) including_11\VBG\0|with|,|, (l_pobj) gastroenteritis_12\JJ\14171682|NONE
D004917_D066126 NONE erythromycin_11\NNP\2716866|NONE (r_pobj) of_10\IN\0|intravenous (r_prep) administration_9\NN\1133281|NONE (r_pobj) after_4\IN\0|but|Cardiotoxicity|reported|been|.|has (r_prep) demonstrated_3\VBN\2137132|NONE (l_nsubjpass) cardiotoxicity_0\NN\0|but|reported|been|.|after|has
D017291_D001145 NONE clarithromycin_14\NN\0|NONE (r_pobj) of_13\IN\0|six|therapeutic (r_prep) doses_12\NNS\3740161|NONE (r_pobj) after_9\IN\0|that (r_prep) occurred_8\VBD\0|ventricular (r_relcl) dysrhythmias_6\NNS\0|NONE
D018942_D005759 NONE macrolides_31\NNS\0|NONE (r_pobj) with_28\IN\0|including|,|, (r_prep) experience_27\NN\5984287|.|still|being|established|is (l_prep) including_11\VBG\0|with|,|, (l_pobj) gastroenteritis_12\JJ\14171682|NONE
D017291_D017180 CID clarithromycin_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|ventricular|. (r_amod) tachycardia_4\NN\14110674|NONE
D018942_D066126 NONE macrolides_20\NNS\0|NONE (r_pobj) with_17\IN\0|been|never|has (r_prep) reported_16\VBN\831651|but|Cardiotoxicity|been|.|after|has (r_conj) demonstrated_3\VBN\2137132|NONE (l_nsubjpass) cardiotoxicity_0\NN\0|but|reported|been|.|after|has
2594614
D002045_D007022 CID bupivacaine_5\NN\0|NONE (r_pobj) of_1\IN\0|mg/kg|(|to|) (r_prep) administration_0\NN\1133281|.|decrease (r_nsubj) elicited_16\VBD\1617192|NONE (l_dobj) decrease_19\NN\7296428|Administration|. (l_prep) of_20\IN\0|marked|)|(|in|a (l_pobj) pressure_24\NN\11419404|NONE (l_appos) mbp_26\NNP\0|(|blood|mean|arterial|leading (l_conj) rate_30\NN\13815152|)|and (l_punct) )_33\-RRB-\0|(|heart|HR
D002045_D007022 CID bupivacaine_23\NN\0|NONE (r_compound) administration_24\NN\1133281|NONE (r_pobj) before_22\IN\0||)|i.v. (r_prep) min_21\NN\15154774|Intravenous|antagonist|of|, (r_appos) injection_1\NN\320852|.|decrease (r_nsubj) suppressed_30\VBD\2510337|NONE (l_dobj) decrease_33\NN\7296428|injection|. (l_prep) of_34\IN\0|both|the (l_pobj) mbp_35\NNP\0|NONE (l_conj) hr_37\NN\15154774|and
D002045_D007022 CID bupivacaine_12\NN\0|NONE (r_pobj) after_11\IN\0|mg/kg|was|BN|When|immediately (r_prep) injected_9\VBN\81072|was|reversion|,|,|.|was (r_advcl) observed_29\VBN\2163746|NONE (l_nsubjpass) reversion_20\NN\13286801|injected|was|,|,|.|was (l_prep) of_21\IN\0|a|partial (l_pobj) decrease_23\NN\7296428|NONE (l_prep) of_24\IN\0|the (l_pobj) mbp_25\NNP\0|NONE (l_conj) hr_27\NN\15154774|and
D002045_D002318 NONE bupivacaine_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|in|cardiovascular (r_amod) impairments_19\NNS\7296428|NONE
D002045_D002318 NONE bupivacaine_44\NN\0| (r_npadvmod) induced_46\VBN\1627355|cardiovascular (r_amod) toxicity_48\NN\13576101|NONE
C045856_D002318 NONE 52021_12\CD\0|NONE (r_nummod) bn_11\NNP\0|,|on|factor|,|a|activating|specific (r_appos) antagonist_9\NN\7846|NONE (l_prep) on_14\IN\0|,|factor|BN|,|a|activating|specific (l_pobj) impairments_19\NNS\7296428|NONE
C045856_D002318 NONE 52021_5\CD\0|NONE (r_nummod) bn_4\NNP\0|NONE (r_pobj) of_3\IN\0|the (r_prep) administration_2\NN\1133281|not|Since|at|MBP|at|,|,|did (r_nsubj) alter_14\VB\0|clearly|bulk|action|.|, (r_advcl) demonstrate_29\VBP\2137132|NONE (l_dobj) action_32\NN\30358|clearly|bulk|alter|.|, (l_prep) against_43\IN\0|of|,|protective|,|a|antagonist (l_pobj) toxicity_48\NN\13576101|NONE
C045856_D002318 NONE 52021_35\CD\0|NONE (r_nummod) bn_34\NNP\0|NONE (r_pobj) of_33\IN\0|,|protective|,|a|against|antagonist (r_prep) action_32\NN\30358|clearly|bulk|alter|.|, (l_prep) against_43\IN\0|of|,|protective|,|a|antagonist (l_pobj) toxicity_48\NN\13576101|NONE
C045856_D001919 NONE 52021_14\CD\0|)|mg/kg|)|PAF|( (r_appos) antagonist_12\NN\7846|min|Intravenous|of|, (r_appos) injection_1\NN\320852|.|decrease (r_nsubj) suppressed_30\VBD\2510337|NONE (l_dobj) decrease_33\NN\7296428|injection|. (l_prep) of_34\IN\0|both|the (l_pobj) mbp_35\NNP\0|NONE (l_conj) hr_37\NN\15154774|and
C045856_D001919 NONE 52021_2\CD\0|mg/kg|)|i.v. (r_nummod) bn_1\NNP\0|mg/kg|was|after|When|immediately (r_nsubjpass) injected_9\VBN\81072|was|reversion|,|,|.|was (r_advcl) observed_29\VBN\2163746|NONE (l_nsubjpass) reversion_20\NN\13286801|injected|was|,|,|.|was (l_prep) of_21\IN\0|a|partial (l_pobj) decrease_23\NN\7296428|NONE (l_prep) of_24\IN\0|the (l_pobj) mbp_25\NNP\0|NONE (l_conj) hr_27\NN\15154774|and
D002045_D018376 NONE bupivacaine_16\NN\0| (r_npadvmod) induced_18\VBN\1627355|cardiovascular (r_amod) alterations_20\NNS\7283608|NONE
D002045_D001919 CID bupivacaine_5\NN\0|NONE (r_pobj) of_1\IN\0|mg/kg|(|to|) (r_prep) administration_0\NN\1133281|.|decrease (r_nsubj) elicited_16\VBD\1617192|NONE (l_dobj) decrease_19\NN\7296428|Administration|. (l_prep) of_20\IN\0|marked|)|(|in|a (l_pobj) pressure_24\NN\11419404|NONE (l_appos) mbp_26\NNP\0|(|blood|mean|arterial|leading (l_conj) rate_30\NN\13815152|)|and (l_punct) )_33\-RRB-\0|(|heart|HR
D002045_D001919 CID bupivacaine_23\NN\0|NONE (r_compound) administration_24\NN\1133281|NONE (r_pobj) before_22\IN\0||)|i.v. (r_prep) min_21\NN\15154774|Intravenous|antagonist|of|, (r_appos) injection_1\NN\320852|.|decrease (r_nsubj) suppressed_30\VBD\2510337|NONE (l_dobj) decrease_33\NN\7296428|injection|. (l_prep) of_34\IN\0|both|the (l_pobj) mbp_35\NNP\0|NONE (l_conj) hr_37\NN\15154774|and
D002045_D001919 CID bupivacaine_12\NN\0|NONE (r_pobj) after_11\IN\0|mg/kg|was|BN|When|immediately (r_prep) injected_9\VBN\81072|was|reversion|,|,|.|was (r_advcl) observed_29\VBN\2163746|NONE (l_nsubjpass) reversion_20\NN\13286801|injected|was|,|,|.|was (l_prep) of_21\IN\0|a|partial (l_pobj) decrease_23\NN\7296428|NONE (l_prep) of_24\IN\0|the (l_pobj) mbp_25\NNP\0|NONE (l_conj) hr_27\NN\15154774|and
C045856_D007022 NONE 52021_14\CD\0|)|mg/kg|)|PAF|( (r_appos) antagonist_12\NN\7846|min|Intravenous|of|, (r_appos) injection_1\NN\320852|.|decrease (r_nsubj) suppressed_30\VBD\2510337|NONE (l_dobj) decrease_33\NN\7296428|injection|. (l_prep) of_34\IN\0|both|the (l_pobj) mbp_35\NNP\0|NONE (l_conj) hr_37\NN\15154774|and
C045856_D007022 NONE 52021_2\CD\0|mg/kg|)|i.v. (r_nummod) bn_1\NNP\0|mg/kg|was|after|When|immediately (r_nsubjpass) injected_9\VBN\81072|was|reversion|,|,|.|was (r_advcl) observed_29\VBN\2163746|NONE (l_nsubjpass) reversion_20\NN\13286801|injected|was|,|,|.|was (l_prep) of_21\IN\0|a|partial (l_pobj) decrease_23\NN\7296428|NONE (l_prep) of_24\IN\0|the (l_pobj) mbp_25\NNP\0|NONE (l_conj) hr_27\NN\15154774|and
9061311
D010100_D017114 NONE oxygen_5\NN\14622893|radical|in|due (r_nmod) production_7\NN\30358|with|,|was|In|. (l_prep) in_8\IN\13603305|oxygen|radical|due (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) alf_11\NNP\0|NONE
D013481_D001424 NONE superoxide_2\NN\14971519|peroxide (r_amod) production_6\NN\30358|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) defects_0\NNS\14462666|may|be|.|in (r_nsubjpass) implicated_9\VBN\2677097|NONE (l_prep) in_10\IN\13603305|Defects|may|be|. (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|high|the (l_pobj) infections_16\NNS\14052046|NONE
D006861_D001424 NONE peroxide_5\NN\14780040|superoxide (r_compound) production_6\NN\30358|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) defects_0\NNS\14462666|may|be|.|in (r_nsubjpass) implicated_9\VBN\2677097|NONE (l_prep) in_10\IN\13603305|Defects|may|be|. (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|high|the (l_pobj) infections_16\NNS\14052046|NONE
D009240_D017114 NONE phenylalanine_15\NN\14605787|(|) (r_nmod) fmlp_17\NN\0|NONE (r_pobj) with_8\IN\0|from (r_prep) stimulated_7\VBN\137313|NONE (l_prep) from_19\IN\0|with (l_pobj) patients_24\NNS\9898892|NONE (l_compound) alf_23\NNP\0|further||a
D009240_D017114 NONE fmlp_17\NN\0|NONE (r_pobj) with_8\IN\0|from (r_prep) stimulated_7\VBN\137313|NONE (l_prep) from_19\IN\0|with (l_pobj) patients_24\NNS\9898892|NONE (l_compound) alf_23\NNP\0|further||a
D000082_D017114 CID paracetamol_14\JJ\0|NONE (r_compound) overdose_15\NN\84738|to (r_pobj) due_12\IN\5174653|oxygen|radical|in (r_amod) production_7\NN\30358|with|,|was|In|. (l_prep) in_8\IN\13603305|oxygen|radical|due (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) alf_11\NNP\0|NONE
D000082_D017114 CID paracetamol_10\JJ\0|NONE (r_compound) overdose_11\NN\84738|to (r_pobj) due_8\IN\5174653|results|defect|.|,|complement (r_prep) demonstrate_2\VBP\2137132|NONE (l_dobj) defect_5\NN\14462666|due|results|.|,|complement (l_prep) in_6\IN\13603305|neutrophil|a (l_pobj) alf_7\NNP\0|NONE
D010100_D062787 NONE oxygen_5\NN\14622893|radical|in|due (r_nmod) production_7\NN\30358|with|,|was|In|. (l_amod) due_12\IN\5174653|oxygen|radical|in (l_pobj) overdose_15\NN\84738|to
D006861_D017114 NONE peroxide_4\NN\14780040|and (r_conj) superoxide_1\NN\14971519|in|.|Neutrophil (r_nmod) production_5\NN\30358|NONE (l_prep) in_6\IN\13603305|.|superoxide|Neutrophil (l_pobj) patients_7\NNS\9898892|NONE (l_prep) with_8\IN\0|NONE (l_pobj) failure_11\NN\66216|NONE
D006861_D017114 NONE peroxide_5\NN\14780040|superoxide (r_compound) production_6\NN\30358|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) defects_0\NNS\14462666|may|be|.|in (r_nsubjpass) implicated_9\VBN\2677097|NONE (l_prep) in_10\IN\13603305|Defects|may|be|. (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|high|the (l_pobj) infections_16\NNS\14052046|NONE (l_prep) in_17\IN\13603305|bacterial (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) failure_22\NN\66216|NONE
D006861_D017114 NONE peroxide_5\NN\14780040|superoxide (r_compound) production_6\NN\30358|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) defects_0\NNS\14462666|may|be|.|in (r_nsubjpass) implicated_9\VBN\2677097|NONE (l_prep) in_10\IN\13603305|Defects|may|be|. (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|high|the (l_pobj) infections_16\NNS\14052046|NONE (l_prep) in_17\IN\13603305|bacterial (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) failure_22\NN\66216|NONE (l_appos) alf_24\NNP\0|(|acute|liver|)
D006861_D017114 NONE peroxide_3\NN\14780040|NONE (r_compound) production_4\NN\30358|by|and (r_conj) superoxide_0\NN\14971519|reduced|with|.|opsonized (l_prep) by_5\IN\0|and|production (l_pobj) neutrophils_7\NNS\5449959|NONE (l_compound) alf_6\NNP\0|NONE
D006861_D017114 NONE peroxide_3\NN\14780040|NONE (r_compound) production_4\NN\30358|by|and (r_conj) superoxide_0\NN\14971519|reduced|with|.|opsonized (r_nsubj) stimulated_8\VBN\137313|NONE (l_dobj) opsonized_11\VBN\126264|reduced|Superoxide|with|. (l_prep) with_12\IN\0|NONE (l_pobj) serum_14\NN\5397468|NONE (l_compound) alf_13\NNP\0|NONE
D006861_D017114 NONE peroxide_3\NN\14780040|NONE (r_compound) production_4\NN\30358|in|and (r_conj) superoxide_0\NN\14971519|.|compared|unaffected (l_prep) in_5\IN\13603305|and|production (l_pobj) neutrophils_6\NNS\5449959|NONE (l_acl) stimulated_7\VBN\137313|NONE (l_prep) from_19\IN\0|with (l_pobj) patients_24\NNS\9898892|NONE (l_compound) alf_23\NNP\0|further||a
D013481_D017114 NONE superoxide_1\NN\14971519|in|.|Neutrophil (r_nmod) production_5\NN\30358|NONE (l_prep) in_6\IN\13603305|.|superoxide|Neutrophil (l_pobj) patients_7\NNS\9898892|NONE (l_prep) with_8\IN\0|NONE (l_pobj) failure_11\NN\66216|NONE
D013481_D017114 NONE superoxide_2\NN\14971519|peroxide (r_amod) production_6\NN\30358|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) defects_0\NNS\14462666|may|be|.|in (r_nsubjpass) implicated_9\VBN\2677097|NONE (l_prep) in_10\IN\13603305|Defects|may|be|. (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|high|the (l_pobj) infections_16\NNS\14052046|NONE (l_prep) in_17\IN\13603305|bacterial (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) failure_22\NN\66216|NONE
D013481_D017114 NONE superoxide_2\NN\14971519|peroxide (r_amod) production_6\NN\30358|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) defects_0\NNS\14462666|may|be|.|in (r_nsubjpass) implicated_9\VBN\2677097|NONE (l_prep) in_10\IN\13603305|Defects|may|be|. (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|high|the (l_pobj) infections_16\NNS\14052046|NONE (l_prep) in_17\IN\13603305|bacterial (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) failure_22\NN\66216|NONE (l_appos) alf_24\NNP\0|(|acute|liver|)
D013481_D017114 NONE superoxide_0\NN\14971519|reduced|with|.|opsonized (l_prep) by_5\IN\0|and|production (l_pobj) neutrophils_7\NNS\5449959|NONE (l_compound) alf_6\NNP\0|NONE
D013481_D017114 NONE superoxide_0\NN\14971519|reduced|with|.|opsonized (r_nsubj) stimulated_8\VBN\137313|NONE (l_dobj) opsonized_11\VBN\126264|reduced|Superoxide|with|. (l_prep) with_12\IN\0|NONE (l_pobj) serum_14\NN\5397468|NONE (l_compound) alf_13\NNP\0|NONE
D013481_D017114 NONE superoxide_0\NN\14971519|.|compared|unaffected (l_prep) in_5\IN\13603305|and|production (l_pobj) neutrophils_6\NNS\5449959|NONE (l_acl) stimulated_7\VBN\137313|NONE (l_prep) from_19\IN\0|with (l_pobj) patients_24\NNS\9898892|NONE (l_compound) alf_23\NNP\0|further||a
D000082_D062787 NONE paracetamol_14\JJ\0|NONE (r_compound) overdose_15\NN\84738|to
D000082_D062787 NONE paracetamol_10\JJ\0|NONE (r_compound) overdose_11\NN\84738|to
18483878
D003520_D001745 NONE cyp_22\NNP\0|NONE (r_pobj) with_21\IN\0|NONE (r_prep) wt_20\NNP\0|NONE (r_pobj) in_19\IN\13603305|that (r_prep) observed_18\VBD\2163746|,|are|mediators|above|mice (r_advcl) increased_15\VBN\169651|.|data (l_advcl) mice_7\NNS\2329401|,|are|mediators|above|observed (l_prep) with_8\IN\0|in|that (l_pobj) inflammation_10\NN\14299637|NONE
D003520_D003556 CID cyclophosphamide_15\NN\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) mice_13\NNS\2329401|(|cystitis|polypeptide|)|VIP/ (r_appos) knockout_9\NN\10787470|NONE (l_appos) cystitis_18\NN\14566129|mice|(|polypeptide|)|VIP/
D003520_D003556 CID cyp)-induced_17\VBN\0|NONE (r_compound) cystitis_18\NN\14566129|mice|(|polypeptide|)|VIP/
D003520_D003556 CID cyclophosphamide_14\NN\0|NONE (r_pobj) after_13\IN\0|cystitis|function|.|VIP(/ (r_prep) altered_4\JJ\0|NONE (l_dobj) cystitis_17\NN\14566129|function|after|.|VIP(/
D003520_D003556 CID cyp)-induced_16\VBN\0|( (r_amod) cystitis_17\NN\14566129|function|after|.|VIP(/
D003520_D003556 CID cyp_32\NNP\0| (r_npadvmod) induced_34\VBN\1627355|;|i.p.|(|)|h|;|mg/kg (r_amod) cystitis_35\NN\14566129|NONE
19300240
D002395_D054549 NONE catecholamines_9\NNS\5407119|NONE (r_pobj) of_7\IN\0|both|supraphysiologic|caused (r_prep) levels_6\NNS\4916342|may|development|have|.|In|, (r_nsubj) contributed_24\VBN\126264|NONE (l_dobj) development_26\NN\248977|may|have|levels|.|In|, (l_prep) of_27\IN\0|the (l_pobj) abs_28\NN\14592610|NONE
D002395_D009369 NONE catecholamines_9\NNS\5407119|NONE (r_pobj) of_7\IN\0|both|supraphysiologic|caused (r_prep) levels_6\NNS\4916342|may|development|have|.|In|, (l_acl) caused_14\VBN\1617192|both|of|supraphysiologic (l_agent) by_15\IN\0|NONE (l_pobj) diagnosis_17\NN\152018|NONE (l_compound) cancer_16\NN\14239425|chemotherapy|as
D005472_D015179 NONE fluorouracil_5\NN\2722166|NONE (r_pobj) with_4\IN\0|She|for|chemotherapy|. (r_prep) underwent_1\VBD\109660|NONE (l_prep) for_6\IN\0|She|chemotherapy|.|with (l_pobj) cancer_9\NN\14239425|NONE
D005472_D054549 CID flourouracil_1\NN\0| (r_npadvmod) induced_3\VBN\1627355|ballooning|.||report|: (r_amod) syndrome_6\NN\5870365|NONE
11078231
D000109_D023921 NONE acetylcholine_8\NN\14807558|NONE (r_pobj) of_7\IN\0|intracoronary (r_prep) injection_6\NN\320852|NONE (r_pobj) by_4\IN\0|spasm|,|was|and|documented (r_agent) induced_3\VBN\1627355|NONE (l_conj) documented_17\VBN\1000214|spasm|,|by|was|and (l_nsubjpass) stenosis_15\NN\14204950|was|.|on
D004280_D003329 CID dobutamine_8\NN\0|NONE (r_compound) stress_9\NN\7083732|NONE (r_compound) echocardiography_10\RB\177127|NONE (r_pobj) during_7\IN\0|artery|coronary (r_prep) spasm_6\NN\14299637|to
D004280_D003329 CID dobutamine_19\NN\0|NONE (r_pobj) by_18\IN\0|ischemia|is|whether (r_agent) induced_17\VBN\1627355|to (l_nsubjpass) ischemia_11\NN\14195315|is|whether|by (l_amod) due_12\IN\5174653|myocardial (l_pcomp) to_13\IN\0|NONE (l_pobj) spasm_15\NN\14299637|NONE
D004280_D003329 CID dobutamine_4\NN\0|can|spasm|in (r_nsubj) provoke_6\VB\1617192|.|findings (l_dobj) spasm_8\NN\14299637|can|dobutamine|in
D004280_D000788 CID dobutamine_4\NN\0|can|spasm|in (r_nsubj) provoke_6\VB\1617192|.|findings (l_prep) in_9\IN\13603305|can|spasm|dobutamine (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|some (l_pobj) angina_15\NN\14171682|NONE
D004280_D017202 NONE dobutamine_8\NN\0|NONE (r_compound) stress_9\NN\7083732|NONE (r_compound) echocardiography_10\RB\177127|NONE (r_pobj) during_7\IN\0|artery|coronary (r_prep) spasm_6\NN\14299637|to (r_pobj) due_2\IN\5174653|Myocardial|. (r_amod) ischemia_1\NN\14195315|NONE
D004280_D017202 NONE dobutamine_0\NNP\0|echocardiography (r_nsubj) stress_1\NN\7083732|.|test (r_nsubj) is_6\VBZ\0|NONE (l_attr) test_12\NN\5798043|.|stress (l_prep) for_13\IN\0|useful|a|provocation (l_pobj) ischemia_15\NN\14195315|NONE
D004280_D017202 NONE dobutamine_19\NN\0|NONE (r_pobj) by_18\IN\0|ischemia|is|whether (r_agent) induced_17\VBN\1627355|to (l_nsubjpass) ischemia_11\NN\14195315|is|whether|by
9630698
D006220_D009127 CID haloperidol_5\NN\3713736|NONE (r_pobj) by_4\IN\0|.|)|rigidity|was (r_agent) induced_3\VBN\1627355|NONE (l_nsubjpass) rigidity_1\NN\5023233|.|)|by|was
D006220_D009127 CID haloperidol_34\NN\3713736| (r_advmod) induced_36\VBN\1627355|and|the|activity|(|muscle|)|MMG|both (r_amod) rigidity_38\NN\5023233|NONE
C066192_D009127 NONE acid_1\NN\14818238|in|decreased|,|into|.|, (r_nsubj) injected_12\VBN\81072|NONE (l_conj) decreased_31\VBD\169651|in|acid|,|into|.|, (l_dobj) rigidity_38\NN\5023233|NONE
C066192_D009127 NONE 5,7-dcka_3\CD\0|,|,dichlorokynurenic|,|)|antagonist (r_appos) acid_1\NN\14818238|in|decreased|,|into|.|, (r_nsubj) injected_12\VBN\81072|NONE (l_conj) decreased_31\VBD\169651|in|acid|,|into|.|, (l_dobj) rigidity_38\NN\5023233|NONE
D005998_D009127 NONE glycine_8\NN\14601829|NONE (r_compound) site_9\NN\8673395|a|selective (r_compound) antagonist_10\NN\7846|,|,dichlorokynurenic|,DCKA|,|) (r_appos) acid_1\NN\14818238|in|decreased|,|into|.|, (r_nsubj) injected_12\VBN\81072|NONE (l_conj) decreased_31\VBD\169651|in|acid|,|into|.|, (l_dobj) rigidity_38\NN\5023233|NONE
12139551
D008787_D006323 CID metoclopramide_4\NN\0|intravenous|of|a|causing (r_compound) case_7\NN\7283608|NONE (r_pobj) after_2\IN\0|.|Cardiac (r_prep) arrest_1\NN\88481|NONE
D008787_D006323 CID metoclopramide_4\NN\0|intravenous|of|a|causing (r_compound) case_7\NN\7283608|NONE (l_acl) causing_14\VBG\30358|intravenous|of|metoclopramide|a (l_dobj) episodes_16\NNS\7283608|NONE (l_prep) of_17\IN\0|five (l_pobj) arrest_19\NN\88481|NONE
D008787_D006323 CID metoclopramide_13\NN\0|NONE (r_pobj) of_12\IN\0|repeated|five (r_prep) injections_11\NNS\320852|NONE (r_pobj) of_8\IN\0|intravenous|metoclopramide|a|causing (r_prep) case_7\NN\7283608|NONE (r_pobj) after_2\IN\0|.|Cardiac (r_prep) arrest_1\NN\88481|NONE
D008787_D006323 CID metoclopramide_13\NN\0|NONE (r_pobj) of_12\IN\0|repeated|five (r_prep) injections_11\NNS\320852|NONE (r_pobj) of_8\IN\0|intravenous|metoclopramide|a|causing (r_prep) case_7\NN\7283608|NONE (l_acl) causing_14\VBG\30358|intravenous|of|metoclopramide|a (l_dobj) episodes_16\NNS\7283608|NONE (l_prep) of_17\IN\0|five (l_pobj) arrest_19\NN\88481|NONE
D008787_D006323 CID metoclopramide_8\NN\0|NONE (r_pobj) of_7\IN\0|intravenous (r_prep) injection_6\NN\320852|by|immediately|was|where|repeatedly (r_nsubjpass) followed_11\VBN\1835496|a (l_agent) by_12\IN\0|immediately|injection|was|where|repeatedly (l_pobj) asystole_13\NN\14204950|NONE
D008787_D006323 CID metoclopramide_3\JJ\0|patient|during|After|mg (r_dobj) received_2\VBD\2210855|it|followed|,|clear|.|was (r_ccomp) is_24\VBZ\0|NONE (l_advcl) followed_37\VBN\1835496|it|,|received|clear|.|was (l_agent) by_38\IN\0|NONE (l_pobj) asystole_39\NN\14204950|NONE
D008787_D006323 CID metoclopramide_30\NN\0|NONE (r_pobj) of_29\IN\0|every (r_prep) administration_28\NN\1133281|)|(|immediately|within|that (r_nsubj) was_31\VBD\0|it|followed|,|received|clear|. (r_ccomp) is_24\VBZ\0|NONE (l_advcl) followed_37\VBN\1835496|it|,|received|clear|.|was (l_agent) by_38\IN\0|NONE (l_pobj) asystole_39\NN\14204950|NONE
D008787_D006323 CID metoclopramide_10\NN\0|NONE (r_pobj) by_9\IN\0|NONE (r_agent) caused_8\VBN\1617192|of (r_acl) episodes_4\NNS\7283608|NONE (l_prep) of_5\IN\0|caused (l_pobj) arrest_7\NN\88481|NONE
11022397
D010862_D008569 NONE pilocarpine_10\NN\14712692|and (r_conj) tropicamide_8\NN\0|NONE (r_pobj) of_7\IN\0|NONE (r_prep) administration_6\NN\1133281|NONE (r_pobj) after_5\IN\0|Pupil|at (r_prep) size_1\NN\5090441|in|induced|;|. (r_ccomp) impairment_15\NN\7296428|NONE (l_prep) in_16\IN\13603305|induced|size|;|. (l_pobj) recall_18\NN\7185325|NONE
D014331_D008569 NONE tropicamide_8\NN\0|NONE (r_pobj) of_7\IN\0|NONE (r_prep) administration_6\NN\1133281|NONE (r_pobj) after_5\IN\0|Pupil|at (r_prep) size_1\NN\5090441|in|induced|;|. (r_ccomp) impairment_15\NN\7296428|NONE (l_prep) in_16\IN\13603305|induced|size|;|. (l_pobj) recall_18\NN\7185325|NONE
D012601_D008569 CID scopolamine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|in|size|;|. (r_amod) impairment_15\NN\7296428|NONE (l_prep) in_16\IN\13603305|induced|size|;|. (l_pobj) recall_18\NN\7185325|NONE
D012601_D008569 CID scopolamine_11\NN\14712692| (r_npadvmod) induced_13\VBN\1627355|greater|in (r_amod) impairment_14\NN\7296428|,|after|.|Compared|group|)|recall (r_dobj) had_9\VBD\0|NONE (l_dobj) recall_17\NN\7185325|,|after|.|Compared|group|)|impairment
16047871
D014859_D012871 NONE warfarin_11\NN\2718259|for (r_dobj) receiving_10\VBG\2210855|NONE (r_pcomp) after_9\IN\0|that (r_prep) developed_8\VBD\1753788|skin (r_relcl) eruptions_6\NNS\7307754|NONE
D014859_D012871 NONE warfarin_21\NN\2718259|after|was (r_nsubjpass) discontinued_23\VBN\0|in (r_advcl) resolved_16\VBD\352826|Cutaneous|LV (r_acl) lesions_15\NNS\14204950|NONE (r_dobj) confirming_12\VBG\0|,|available|results|. (r_advcl) were_6\VBD\0|NONE (l_nsubj) results_1\NNS\34213|,|available|confirming|. (l_prep) of_2\IN\0|The (l_pobj) biopsies_5\NNS\5739043|NONE (l_compound) lesion_4\NN\14204950|NONE
D014859_D018366 CID warfarin_21\NN\2718259|after|was (r_nsubjpass) discontinued_23\VBN\0|in (r_advcl) resolved_16\VBD\352826|Cutaneous|LV (r_acl) lesions_15\NNS\14204950|NONE
D014859_C535509 NONE warfarin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|leukocytoclastic|. (r_amod) vasculitis_4\NN\14336539|NONE
D014859_C535509 NONE warfarin_12\NN\2718259|probably|to (r_pobj) due_10\JJ\5174653|with| (r_amod) patients_3\NNS\9898892|.|We (l_prep) with_4\IN\0|due| (l_pobj) lv_8\NNP\0|NONE
D014859_C535509 NONE warfarin_11\JJ\2718259|NONE (r_compound) therapy_12\NN\657604|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|a|adverse|onset (r_acl) reaction_8\NN\13446390|.|may|LV (r_attr) be_2\VB\14625458|NONE (l_nsubj) lv_0\NNP\0|reaction|.|may
16364460
D012601_D000647 CID scopolamine_10\NN\14712692| (r_npadvmod) induced_12\VBN\1627355|in (r_amod) amnesia_13\NN\5669934|.|Microinjection
D012601_D000647 CID scopolamine_9\NN\14712692|antagonist)induced|(|muscarinic|cholinergic|in (r_nmod) amnesia_14\NN\5669934|NONE
D012601_D000647 CID scopolamine_16\NN\14712692| (r_npadvmod) induced_18\VBN\1627355|the (r_amod) amnesia_19\NN\5669934|that|microinjection
D016713_D000647 NONE ritanserin_2\NN\0|NONE (r_pobj) of_1\IN\0|into (r_prep) microinjection_0\NN\0|.|amnesia (r_nsubj) improves_9\VBZ\126264|NONE (l_dobj) amnesia_13\NN\5669934|.|Microinjection
D016713_D000647 NONE ritanserin_3\NN\0|NONE (r_pobj) of_2\IN\0|antagonist|The|on (r_prep) effect_1\NN\34213|was|.|MWM (l_prep) on_8\IN\0|antagonist|The|of (l_pobj) amnesia_14\NN\5669934|NONE
D016713_D000647 NONE ritanserin_6\NN\0|NONE (r_pobj) of_5\IN\0|into (r_prep) microinjection_4\NN\0|that|amnesia (r_nsubj) improves_14\VBZ\126264|findings|. (l_dobj) amnesia_19\NN\5669934|that|microinjection
16418614
D011441_D014424 NONE ptu_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|.|in (r_amod) vasculitis_3\NN\14336539|NONE (l_prep) in_4\IN\13603305|.|associated (l_pobj) girl_6\NN\10787470|NONE (l_prep) with_7\IN\0|a (l_pobj) syndrome_9\NNP\5870365|NONE
D011441_D006111 NONE ptu_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|.|in (r_amod) vasculitis_3\NN\14336539|NONE (l_prep) in_4\IN\13603305|.|associated (l_pobj) girl_6\NN\10787470|NONE (l_prep) with_7\IN\0|a (l_pobj) syndrome_9\NNP\5870365|NONE (l_conj) disease_13\NN\14061805|Turner|and
D011441_D014657 CID ptu_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|.|in (r_amod) vasculitis_3\NN\14336539|NONE
D011441_D014657 CID propylthiouracil_3\NN\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) diagnosis_1\NN\152018|.|by|detection|(|vasculitis|was|, (r_nsubjpass) made_8\VBN\0|NONE (l_nsubjpass) vasculitis_6\NN\14336539|diagnosis|.|by|detection|(|was|,
D011441_D014657 CID ptu)-associated_5\VBN\0|NONE (r_amod) vasculitis_6\NN\14336539|diagnosis|.|by|detection|(|was|,
D011441_D014657 CID ptu_37\NNP\0|NONE (r_pobj) of_36\IN\0|NONE (r_prep) withdrawal_35\NN\7206096|NONE (r_dobj) following_34\VBG\8180190|clinical|observed|of|the (r_acl) resolution_31\NN\6470073|and|,|of|the (r_conj) detection_17\NN\5708432|diagnosis|.|by|(|vasculitis|was|, (r_appos) made_8\VBN\0|NONE (l_nsubjpass) vasculitis_6\NN\14336539|diagnosis|.|by|detection|(|was|,
7263204
D000493_D000741 NONE allopurinol_14\NN\3740161|NONE (r_pobj) than_13\IN\0|NONE (r_prep) other_12\JJ\0|no (r_amod) drugs_11\NNS\14778436|were|in (r_nsubjpass) given_18\VBN\5892096|.|is|case (r_relcl) described_7\VBN\1001294|NONE (l_nsubjpass) case_1\NN\7283608|.|is|given (l_prep) of_2\IN\0|A (l_pobj) anemia_5\NN\14189204|NONE
D007213_D000741 CID indomethacin_5\NN\3828465|to (r_pobj) due_3\IN\5174653|Fatal|.|lymphocyte|aplastic| (r_amod) anemia_2\NN\14189204|NONE
D007213_D000741 CID indomethacin_1\NN\3828465|as|Although|been|has (r_nsubjpass) implicated_4\VBN\2677097|been|.|role|definitely|not|has|, (l_prep) as_5\IN\14622893|Although|been|has|indomethacin (l_pobj) cause_8\NN\7323922|NONE (l_prep) of_9\IN\0|a|possible (l_pobj) anemia_11\NN\14189204|NONE
D007213_D000741 CID indomethacin_16\NN\3828465|and (r_conj) allopurinol_14\NN\3740161|NONE (r_pobj) than_13\IN\0|NONE (r_prep) other_12\JJ\0|no (r_amod) drugs_11\NNS\14778436|were|in (r_nsubjpass) given_18\VBN\5892096|.|is|case (r_relcl) described_7\VBN\1001294|NONE (l_nsubjpass) case_1\NN\7283608|.|is|given (l_prep) of_2\IN\0|A (l_pobj) anemia_5\NN\14189204|NONE
D007213_D000741 CID indomethacin_6\NN\3828465|NONE (r_pobj) with_5\IN\0|positive|transformation|A (r_prep) test_4\NN\5798043|role|.|further (r_nsubj) substantiates_10\VBZ\0|NONE (l_dobj) role_13\NN\719494|test|.|further (l_prep) in_17\IN\13603305|of|potential|the (l_pcomp) causing_18\VBG\30358|NONE (l_dobj) anemia_20\NN\14189204|in
9545159
D001393_D016171 CID azole_22\JJ\0|antifungal (r_amod) agents_24\NNS\7347|or (r_conj) erythromycin_20\NNP\2716866|NONE (r_pobj) with_19\IN\0|concomitant (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_16\IN\0|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) torsades_5\NNS\0|,|.|but|have|been|after|with (l_dobj) pointes_7\FW\831651|Prolongation
D001393_D008133 CID azole_22\JJ\0|antifungal (r_amod) agents_24\NNS\7347|or (r_conj) erythromycin_20\NNP\2716866|NONE (r_pobj) with_19\IN\0|concomitant (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_16\IN\0|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) torsades_5\NNS\0|,|.|but|have|been|after|with (l_nsubj) prolongation_0\NN\1017987|pointes (l_prep) of_1\IN\0|, (l_pobj) interval_3\NN\33615|NONE
D004110_D008133 CID diltiazem_9\NN\2938514|NONE (r_compound) interaction_10\NN\37396|NONE (r_pobj) to_6\IN\0|NONE (r_prep) related_5\VBN\628491|the|QT (r_acl) interval_4\NN\33615|NONE
D004110_D005764 NONE diltiazem_20\NN\2938514|and|gastroesophageal|reflux|,|agent (r_conj) disorder_18\NN\14034177|NONE
D004917_D008133 CID erythromycin_20\NNP\2716866|NONE (r_pobj) with_19\IN\0|concomitant (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_16\IN\0|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) torsades_5\NNS\0|,|.|but|have|been|after|with (l_nsubj) prolongation_0\NN\1017987|pointes (l_prep) of_1\IN\0|, (l_pobj) interval_3\NN\33615|NONE
D020117_D006973 NONE cisapride_14\NN\0|for|was|who|,|for (r_dobj) taking_13\VBG\37396|a|old (l_prep) for_31\IN\0|cisapride|was|who|,|for (l_pobj) hypertension_32\NN\14057371|NONE
D020117_D008133 CID cisapride_7\NN\0| (r_compound) diltiazem_9\NN\2938514|NONE (r_compound) interaction_10\NN\37396|NONE (r_pobj) to_6\IN\0|NONE (r_prep) related_5\VBN\628491|the|QT (r_acl) interval_4\NN\33615|NONE
D020117_D005764 NONE cisapride_14\NN\0|for|was|who|,|for (r_dobj) taking_13\VBG\37396|a|old (l_prep) for_15\IN\0|cisapride|for|was|who|, (l_pobj) disorder_18\NN\14034177|NONE
D004110_D006973 NONE diltiazem_20\NN\2938514|and|gastroesophageal|reflux|,|agent (r_conj) disorder_18\NN\14034177|NONE (r_pobj) for_15\IN\0|cisapride|for|was|who|, (r_prep) taking_13\VBG\37396|a|old (l_prep) for_31\IN\0|cisapride|was|who|,|for (l_pobj) hypertension_32\NN\14057371|NONE
D004917_D016171 CID erythromycin_20\NNP\2716866|NONE (r_pobj) with_19\IN\0|concomitant (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_16\IN\0|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) torsades_5\NNS\0|,|.|but|have|been|after|with (l_dobj) pointes_7\FW\831651|Prolongation
D001393_D016757 CID azole_22\JJ\0|antifungal (r_amod) agents_24\NNS\7347|or (r_conj) erythromycin_20\NNP\2716866|NONE (r_pobj) with_19\IN\0|concomitant (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_16\IN\0|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) torsades_5\NNS\0|,|.|but|have|been|after|with (l_dobj) pointes_7\FW\831651|Prolongation (l_conj) death_12\NN\7296428|de|and|,
D020117_D015835 NONE cisapride_0\NNP\0|.|widely|for|is (r_nsubjpass) prescribed_13\VBN\748282|NONE (l_prep) for_14\IN\0|.|widely|Cisapride|is (l_pobj) treatment_16\NN\654885|NONE (l_prep) of_17\IN\0|the (l_pobj) disorders_20\NNS\14034177|NONE
D004917_D016757 CID erythromycin_20\NNP\2716866|NONE (r_pobj) with_19\IN\0|concomitant (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_16\IN\0|,|.|torsades|but|have|been|with (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) torsades_5\NNS\0|,|.|but|have|been|after|with (l_dobj) pointes_7\FW\831651|Prolongation (l_conj) death_12\NN\7296428|de|and|,
2320800
D007069_D051437 NONE ifosfamide_34\NN\0| (r_pobj) after_28\IN\0|the (r_prep) day_27\NN\15154774|failure|.|woman|, (r_npadvmod) developed_17\VBD\1753788|NONE (l_dobj) failure_22\NN\66216|.|woman|,|day
D007069_D001943 NONE ifosfamide_5\JJ\0|dose (r_compound) chemotherapy_6\NN\661091|anuria|.|in (r_dobj) complicating_2\VBG\126264|NONE (l_prep) in_7\IN\13603305|anuria|chemotherapy|. (l_pobj) patient_11\NN\9898892|NONE (l_compound) cancer_10\NN\14239425|with|a
D007069_D001943 NONE ifosfamide_34\NN\0| (r_pobj) after_28\IN\0|the (r_prep) day_27\NN\15154774|failure|.|woman|, (r_npadvmod) developed_17\VBD\1753788|NONE (l_nsubj) woman_6\NN\9605289|failure|.|,|day (l_prep) with_7\IN\0|treated|,|old|A|, (l_pobj) cancer_10\NN\14239425|NONE
D002945_D001002 NONE cisplatin_15\NN\0|NONE (r_pobj) with_14\IN\0|previously (r_prep) treated_13\VBN\2376958|with|,|old|A|, (r_acl) woman_6\NN\9605289|failure|.|,|day (r_nsubj) developed_17\VBD\1753788|NONE (l_dobj) failure_22\NN\66216|.|woman|,|day (l_prep) with_23\IN\0|irreversible|an|renal|lethal (l_pobj) anuria_24\NN\14061805|NONE
D002945_D001002 NONE cisplatin_20\NN\0|previous (r_amod) chemotherapy_21\NN\661091|having|with|and (r_dobj) received_18\VBN\2210855|in (r_advcl) occurring_13\VBG\0|,|that|anuria|mainly|due (r_advcl) was_7\VBD\0|We|strongly|. (l_nsubj) anuria_6\NN\14061805|,|that|occurring|mainly|due
D007069_D007022 NONE ifosfamide_11\NN\0|NONE (r_xcomp) due_9\JJ\5174653|,|that|anuria|occurring|mainly (r_acomp) was_7\VBD\0|We|strongly|. (l_advcl) occurring_13\VBG\0|,|that|anuria|mainly|due (l_advcl) received_18\VBN\2210855|in (l_prep) with_23\IN\0|having|chemotherapy|and (l_pobj) perfusion_26\NN\320852|NONE (l_prep) due_27\IN\5174653|poor|kidney (l_pcomp) to_28\IN\0|NONE (l_pobj) hypotension_30\NN\14057371|NONE
D002945_D007022 NONE cisplatin_20\NN\0|previous (r_amod) chemotherapy_21\NN\661091|having|with|and (r_dobj) received_18\VBN\2210855|in (l_prep) with_23\IN\0|having|chemotherapy|and (l_pobj) perfusion_26\NN\320852|NONE (l_prep) due_27\IN\5174653|poor|kidney (l_pcomp) to_28\IN\0|NONE (l_pobj) hypotension_30\NN\14057371|NONE
D002945_D001943 NONE cisplatin_15\NN\0|NONE (r_pobj) with_14\IN\0|previously (r_prep) treated_13\VBN\2376958|with|,|old|A|, (r_acl) woman_6\NN\9605289|failure|.|,|day (l_prep) with_7\IN\0|treated|,|old|A|, (l_pobj) cancer_10\NN\14239425|NONE
D002945_D051437 NONE cisplatin_15\NN\0|NONE (r_pobj) with_14\IN\0|previously (r_prep) treated_13\VBN\2376958|with|,|old|A|, (r_acl) woman_6\NN\9605289|failure|.|,|day (r_nsubj) developed_17\VBD\1753788|NONE (l_dobj) failure_22\NN\66216|.|woman|,|day
D007069_D001002 CID ifosfamide_5\JJ\0|dose (r_compound) chemotherapy_6\NN\661091|anuria|.|in (r_dobj) complicating_2\VBG\126264|NONE (l_nsubj) anuria_1\NN\14061805|chemotherapy|.|in
D007069_D001002 CID ifosfamide_34\NN\0| (r_pobj) after_28\IN\0|the (r_prep) day_27\NN\15154774|failure|.|woman|, (r_npadvmod) developed_17\VBD\1753788|NONE (l_dobj) failure_22\NN\66216|.|woman|,|day (l_prep) with_23\IN\0|irreversible|an|renal|lethal (l_pobj) anuria_24\NN\14061805|NONE
D007069_D001002 CID ifosfamide_11\NN\0|NONE (r_xcomp) due_9\JJ\5174653|,|that|anuria|occurring|mainly (r_acomp) was_7\VBD\0|We|strongly|. (l_nsubj) anuria_6\NN\14061805|,|that|occurring|mainly|due
D007069_D007674 CID ifosfamide_5\JJ\0|dose (r_compound) chemotherapy_6\NN\661091|anuria|.|in (r_dobj) complicating_2\VBG\126264|NONE (l_prep) in_7\IN\13603305|anuria|chemotherapy|. (l_pobj) patient_11\NN\9898892|NONE (l_prep) with_12\IN\0|cancer|a (l_pobj) function_16\NN\13783581|NONE
D007069_D007674 CID ifosfamide_0\NNP\0|.|drug (r_nsubj) is_1\VBZ\0|NONE (l_attr) drug_5\NN\14778436|.|Ifosfamide (l_amod) nephrotoxic_4\JJ\0|known|a|with
D007069_D007674 CID ifosfamide_0\NNP\0|.|drug (r_nsubj) is_1\VBZ\0|NONE (l_attr) drug_5\NN\14778436|.|Ifosfamide (l_prep) with_6\IN\0|known|nephrotoxic|a (l_pobj) tubulopathies_8\NNS\0|NONE
D007069_D007674 CID ifosfamide_5\NN\0|NONE (r_pobj) of_4\IN\0|in|careful (r_prep) use_3\NN\407535|We|. (l_prep) in_6\IN\13603305|careful|of (l_pobj) patients_7\NNS\9898892|NONE (l_acl) pretreated_8\VBN\0|NONE (l_prep) with_9\IN\0|NONE (l_pobj) chemotherapy_11\NN\661091|NONE (l_amod) nephrotoxic_10\JJ\0|perfusion|and
16586083
C109794_D002318 NONE peptide_10\NN\14724264|such (r_pobj) as_3\IN\14622893|Diagnostic (r_prep) markers_1\NNS\21939|might|.|in|avoiding|, (r_nsubj) help_25\VB\407535|NONE (l_advcl) avoiding_36\VBG\0|might|.|in|markers|, (l_dobj) occurrence_38\NN\29378|thus (l_prep) of_39\IN\0|the (l_pobj) toxicity_42\NN\13576101|NONE
C109794_D002318 NONE probnp_14\NNP\0|brain|terminal|or|natriuretic|protein|(|) (r_appos) peptide_10\NN\14724264|such (r_pobj) as_3\IN\14622893|Diagnostic (r_prep) markers_1\NNS\21939|might|.|in|avoiding|, (r_nsubj) help_25\VB\407535|NONE (l_advcl) avoiding_36\VBG\0|might|.|in|markers|, (l_dobj) occurrence_38\NN\29378|thus (l_prep) of_39\IN\0|the (l_pobj) toxicity_42\NN\13576101|NONE
D016861_D006973 CID inhibitors_25\NNS\20090|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) during_21\IN\0|hypertension|, (r_prep) stroke_15\NN\556313|myocardial|, (l_conj) hypertension_17\NN\14057371|during|,
D016861_D006333 CID inhibitors_25\NNS\20090|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) during_21\IN\0|hypertension|, (r_prep) stroke_15\NN\556313|myocardial|, (l_conj) hypertension_17\NN\14057371|during|, (l_conj) failure_20\NN\66216|and
D016861_D020521 CID inhibitors_25\NNS\20090|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) during_21\IN\0|hypertension|, (r_prep) stroke_15\NN\556313|myocardial|,
D016861_D009203 CID inhibitors_25\NNS\20090|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) during_21\IN\0|hypertension|, (r_prep) stroke_15\NN\556313|myocardial|, (r_conj) infarction_13\NN\14204950|NONE
6615052
D006493_D013927 NONE heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|,|thrombosis|. (r_amod) thrombocytopenia_3\NN\14189204|NONE (l_conj) thrombosis_5\NN\14100769|induced|,|.
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|,|thrombosis|. (r_amod) thrombocytopenia_3\NN\14189204|NONE
D006493_D013921 CID heparin_6\NN\2718259| (r_npadvmod) induced_8\VBN\1627355|a (r_amod) thrombocytopenia_9\NN\14189204|NONE
D006493_D013923 CID heparin_17\VBN\2718259|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|thromboembolic (r_prep) events_13\NNS\23100|or|frequently|,|, (l_compound) thromboembolic_12\JJ\0|in
D006493_D001791 NONE heparin_12\NN\2718259|NONE (r_pobj) to_11\IN\0|NONE (r_prep) resistance_10\NN\37396|and|,|added (r_dobj) increased_9\VBN\169651|has|count|testing|.|, (r_conj) revealed_3\VBN\2137132|NONE (l_dobj) count_7\NN\13582013|has|testing|increased|.|,
D006493_D001791 NONE heparin_24\NN\2718259|aggregation|is|when (r_nsubjpass) added_26\VBN\156601|resistance|and|, (r_conj) increased_9\VBN\169651|has|count|testing|.|, (r_conj) revealed_3\VBN\2137132|NONE (l_dobj) count_7\NN\13582013|has|testing|increased|.|,
D006493_D001791 NONE heparin_15\JJ\2718259|patient|using|,|while|is (l_appos) testing_19\NN\639556|, (l_compound) aggregation_18\NN\31264|NONE
D006493_D006470 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|,|thrombosis|. (r_amod) thrombocytopenia_3\NN\14189204|NONE (l_conj) thrombosis_5\NN\14100769|induced|,|. (l_conj) hemorrhage_8\NN\14285662|and|,
D006493_D006470 CID heparin_17\VBN\2718259|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|thromboembolic (r_prep) events_13\NNS\23100|or|frequently|,|, (r_appos) hemorrhage_6\NN\14285662|manifestations|.
14648024
D014212_D015473 NONE acid_4\NN\14818238| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) erythema_7\NN\14227218|in|retinoic (r_compound) nodosum_8\NN\0|. (l_prep) in_9\IN\13603305|retinoic|erythema (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|NONE (l_pobj) leukemia_14\NN\14239918|NONE
D014212_D015473 NONE acid_8\NN\14818238|NONE (r_pobj) with_3\IN\0|for (r_prep) associated_2\VBD\628491|Erythema (l_prep) for_12\IN\0|with (l_pobj) leukemia_15\NN\14239918|NONE
D014212_D015473 NONE acid_8\NN\14818238|NONE (r_pobj) with_3\IN\0|for (r_prep) associated_2\VBD\628491|Erythema (l_prep) for_12\IN\0|with (l_pobj) leukemia_15\NN\14239918|NONE (l_appos) apl_17\NNP\0|acute|(|)|promyelocytic
D014212_D015473 NONE atra_10\NNP\0|(|retinoic|)|all (r_appos) acid_8\NN\14818238|NONE (r_pobj) with_3\IN\0|for (r_prep) associated_2\VBD\628491|Erythema (l_prep) for_12\IN\0|with (l_pobj) leukemia_15\NN\14239918|NONE
D014212_D015473 NONE atra_10\NNP\0|(|retinoic|)|all (r_appos) acid_8\NN\14818238|NONE (r_pobj) with_3\IN\0|for (r_prep) associated_2\VBD\628491|Erythema (l_prep) for_12\IN\0|with (l_pobj) leukemia_15\NN\14239918|NONE (l_appos) apl_17\NNP\0|acute|(|)|promyelocytic
D014212_D015473 NONE atra_12\NNP\0|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_11\IN\0|who|nodosum (r_prep) developed_8\VBD\1753788|classic (r_relcl) apl_6\NNP\0|NONE
D014212_D010146 NONE atra_23\NNP\0|NONE (r_compound) therapy_24\NN\657604|NONE (r_pobj) after_22\IN\0|,|over|erythematous|multiple|subsequent|painful (r_prep) nodules_6\NNS\5264913|.|and (l_amod) painful_4\JJ\0|,|over|erythematous|multiple|subsequent|after
D014212_D005334 CID atra_23\NNP\0|NONE (r_compound) therapy_24\NN\657604|NONE (r_pobj) after_22\IN\0|,|over|erythematous|multiple|subsequent|painful (r_prep) nodules_6\NNS\5264913|.|and (r_conj) fever_0\NN\14299637|NONE
D013256_D004893 NONE steroid_5\NN\14727670|NONE (r_pobj) of_4\IN\0|term (r_prep) use_3\NN\407535|in|.|effective (r_nsubj) is_6\VBZ\0|NONE (l_prep) in_9\IN\13603305|use|.|effective (l_pobj) nodosum_14\NN\0|NONE
D014212_D004893 CID acid_4\NN\14818238| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) erythema_7\NN\14227218|in|retinoic (r_compound) nodosum_8\NN\0|.
D014212_D004893 CID acid_8\NN\14818238|NONE (r_pobj) with_3\IN\0|for (r_prep) associated_2\VBD\628491|Erythema (r_acl) nodosum_1\NN\0|.|rare
D014212_D004893 CID atra_10\NNP\0|(|retinoic|)|all (r_appos) acid_8\NN\14818238|NONE (r_pobj) with_3\IN\0|for (r_prep) associated_2\VBD\628491|Erythema (r_acl) nodosum_1\NN\0|.|rare
D014212_D004893 CID atra_12\NNP\0|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_11\IN\0|who|nodosum (r_prep) developed_8\VBD\1753788|classic (l_dobj) nodosum_10\NN\0|who|during
D014212_D004893 CID atra_23\NNP\0|NONE (r_compound) therapy_24\NN\657604|NONE (r_pobj) after_22\IN\0|,|over|erythematous|multiple|subsequent|painful (r_prep) nodules_6\NNS\5264913|.|and
D014212_D004893 CID atra_0\NNP\0|.|be (r_nsubj) seemed_1\VBD\2604760|NONE (l_xcomp) be_3\VB\14625458|.|ATRA (l_attr) etiology_7\NN\7326557|to (l_prep) of_8\IN\0|the|possible (l_pobj) nodosum_10\NN\0|NONE
D014212_D004893 CID atra_10\NNP\0| (r_npadvmod) induced_12\VBN\1627355|erythema (r_amod) nodosum_14\NN\0|NONE
17490864
D000661_D006948 CID amphetamine_0\NN\3248958| (r_npadvmod) induced_2\VBN\1627355|locomotor (r_amod) hyperactivity_4\NN\14052403|similar|.
21418164
D008130_D015620 NONE ccnu_0\NNP\0|.|in|commonly|was (r_nsubjpass) used_2\VBN\0|NONE (l_prep) in_5\IN\13603305|.|commonly|was|CCNU (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) lymphoma_9\NN\14239918|NONE (l_conj) tumour_13\NN\14234074|, (l_conj) tumour_16\NN\14234074|,|mast|cell (l_conj) tumours_19\NNS\14234074|brain|,
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|( (r_nmod) ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D056486 NONE ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D064420 NONE ccnu_0\NNP\0|.|(|)|toxicity (r_npadvmod) lomustine_2\NN\2722458|NONE (l_dobj) toxicity_4\NN\13576101|.|(|)|CCNU
D008130_D064420 NONE lomustine_2\NN\2722458|NONE (l_dobj) toxicity_4\NN\13576101|.|(|)|CCNU
D008130_D064420 NONE ccnu_6\NNP\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) treated_4\VBN\2376958|the| (r_acl) dogs_3\NNS\2083346|NONE (r_pobj) of_0\IN\0|.||,|criteria (r_prep) met_9\VBD\0|NONE (l_dobj) criteria_12\NNS\13577171|.|Of||, (l_prep) for_13\IN\0|the|inclusion (l_pobj) class_17\NN\7951464|NONE (l_prep) of_18\IN\0|one (l_pobj) toxicity_19\NN\13576101|NONE
D008130_D064420 NONE ccnu_0\NN\0| (r_npadvmod) associated_2\VBN\628491|in (r_amod) toxicity_3\NN\13576101|but|.|common|,|is
D008130_D008223 NONE ccnu_0\NNP\0|.|in|commonly|was (r_nsubjpass) used_2\VBN\0|NONE (l_prep) in_5\IN\13603305|.|commonly|was|CCNU (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) lymphoma_9\NN\14239918|NONE
D008130_D008223 NONE ccnu_0\NNP\0|.|in|commonly|was (r_nsubjpass) used_2\VBN\0|NONE (l_prep) in_5\IN\13603305|.|commonly|was|CCNU (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) lymphoma_9\NN\14239918|NONE (l_conj) tumour_13\NN\14234074|, (l_conj) tumour_16\NN\14234074|,|mast|cell (l_conj) tumours_19\NNS\14234074|brain|, (l_conj) lymphoma_22\NN\14239918|and|histiocytic
D000409_D064420 NONE alanine_5\NN\14601829|elevated (r_compound) transaminase_6\NN\15077571|ALT|( (r_nmod) concentration_10\NN\4916342|Potential|renal|and (r_conj) toxicity_2\NN\13576101|.|were|in
D008130_D001932 NONE ccnu_0\NNP\0|.|in|commonly|was (r_nsubjpass) used_2\VBN\0|NONE (l_prep) in_5\IN\13603305|.|commonly|was|CCNU (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) lymphoma_9\NN\14239918|NONE (l_conj) tumour_13\NN\14234074|, (l_conj) tumour_16\NN\14234074|,|mast|cell
D008130_D034801 NONE ccnu_0\NNP\0|.|in|commonly|was (r_nsubjpass) used_2\VBN\0|NONE (l_prep) in_5\IN\13603305|.|commonly|was|CCNU (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) lymphoma_9\NN\14239918|NONE (l_conj) tumour_13\NN\14234074|,
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|( (r_nmod) ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D007674 NONE ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|( (r_nmod) ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D005767 NONE ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|( (r_nmod) ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
D008130_D006402 NONE ccnu_21\NNP\0|NONE (r_dobj) receiving_18\VBG\2210855|bearing (r_acl) dogs_17\NNS\2083346|NONE (r_pobj) in_13\IN\13603305|haematological (r_prep) toxicities_12\NNS\13576101|NONE
9022662
D008774_D001289 NONE methylphenidate_14\NN\4320126|NONE (r_pobj) with_13\IN\0|without|previously (r_prep) treated_12\VBN\2376958|deficit (r_acl) disorder_10\NN\14034177|NONE
D010389_D001289 NONE pemoline_0\NNP\0|derivative|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) derivative_4\NN\5802185|.|Pemoline (l_relcl) is_6\VBZ\0|an|oxazolidine (l_conj) used_12\VBN\0|and|that|different (l_prep) in_13\IN\13603305|NONE (l_pobj) treatment_15\NN\654885|NONE (l_prep) of_16\IN\0|the (l_pobj) disorder_19\NN\14034177|NONE
D001569_D001264 NONE benzodiazepines_10\NNS\3771443|NONE (r_pobj) of_8\IN\0|high (r_prep) doses_7\NNS\3740161|gastrointestinal|and (r_conj) decontamination_4\NN\391599|.|in|children (r_dobj) received_2\VBD\2210855|NONE (l_prep) in_11\IN\13603305|decontamination|.|children (l_pobj) attempt_13\NN\407535|NONE (l_acl) control_15\VB\5190804|an (l_dobj) movements_18\NNS\191142|to (l_compound) choreoathetoid_17\JJ\0|the
C064210_D001289 NONE oxazolidine_3\JJ\0|an|is (r_compound) derivative_4\NN\5802185|.|Pemoline (l_relcl) is_6\VBZ\0|an|oxazolidine (l_conj) used_12\VBN\0|and|that|different (l_prep) in_13\IN\13603305|NONE (l_pobj) treatment_15\NN\654885|NONE (l_prep) of_16\IN\0|the (l_pobj) disorder_19\NN\14034177|NONE
D010389_D001264 CID pemoline_0\NNP\0|choreoathetosis (r_nsubj) induced_1\VBD\1627355|case|.|of|and|review|: (l_dobj) choreoathetosis_3\NN\0|Pemoline
D010389_D001264 CID pemoline_9\NN\0|NONE (l_relcl) experienced_11\VBD\2108377|NONE (l_dobj) choreoathetosis_13\NN\0|who
D010389_D001264 CID pemoline_12\NN\0|NONE (r_compound) overdose_13\NN\84738|NONE (r_pobj) after_11\IN\0|NONE (r_prep) presenting_10\VBG\2137132|NONE (r_acl) patients_9\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|.|should|possibility|be (r_prep) considered_7\VBN\689344|NONE (l_nsubjpass) possibility_1\NN\5944958|.|in|should|be (l_prep) of_2\IN\0|The (l_pobj) movements_4\NNS\191142|NONE (l_compound) choreoathetoid_3\JJ\0|NONE
D010389_D062787 CID pemoline_12\NN\0|NONE (r_compound) overdose_13\NN\84738|NONE
D001569_D002819 NONE benzodiazepines_10\NNS\3771443|NONE (r_pobj) of_8\IN\0|high (r_prep) doses_7\NNS\3740161|gastrointestinal|and (r_conj) decontamination_4\NN\391599|.|in|children (r_dobj) received_2\VBD\2210855|NONE (l_prep) in_11\IN\13603305|decontamination|.|children (l_pobj) attempt_13\NN\407535|NONE (l_acl) control_15\VB\5190804|an (l_dobj) movements_18\NNS\191142|to (l_compound) choreoathetoid_17\JJ\0|the
D000662_D001289 NONE amphetamines_10\NNS\3248958|NONE (r_pobj) from_9\IN\0|structurally (r_prep) different_8\JJ\0|used|and|that (r_acomp) is_6\VBZ\0|an|oxazolidine (l_conj) used_12\VBN\0|and|that|different (l_prep) in_13\IN\13603305|NONE (l_pobj) treatment_15\NN\654885|NONE (l_prep) of_16\IN\0|the (l_pobj) disorder_19\NN\14034177|NONE
D010389_D009069 NONE pemoline_0\NNP\0|has|not|commonly|as|been|in|. (r_nsubjpass) associated_5\VBN\628491|NONE (l_prep) as_9\IN\14622893|Pemoline|has|not|commonly|been|in|. (l_pobj) cause_11\NN\7323922|NONE (l_prep) of_12\IN\0|a (l_pobj) disorders_15\NNS\14034177|NONE
D010389_D009069 NONE pemoline_0\NN\0|associated|movement (r_nmod) disorder_3\NN\14034177|been|has|.|rarely|in
D010389_D002819 CID pemoline_0\NNP\0|choreoathetosis (r_nsubj) induced_1\VBD\1627355|case|.|of|and|review|: (l_dobj) choreoathetosis_3\NN\0|Pemoline
D010389_D002819 CID pemoline_9\NN\0|NONE (l_relcl) experienced_11\VBD\2108377|NONE (l_dobj) choreoathetosis_13\NN\0|who
D010389_D002819 CID pemoline_12\NN\0|NONE (r_compound) overdose_13\NN\84738|NONE (r_pobj) after_11\IN\0|NONE (r_prep) presenting_10\VBG\2137132|NONE (r_acl) patients_9\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|.|should|possibility|be (r_prep) considered_7\VBN\689344|NONE (l_nsubjpass) possibility_1\NN\5944958|.|in|should|be (l_prep) of_2\IN\0|The (l_pobj) movements_4\NNS\191142|NONE (l_compound) choreoathetoid_3\JJ\0|NONE
839274
D003276_D020518 CID contraceptives_14\NNS\3183080|NONE (r_pobj) on_12\IN\0|of|focal|nodular (r_prep) hyperplasia_5\NN\14365950|Hepatic|and
D003276_D020518 CID contraceptives_18\NNS\3183080|NONE (r_pobj) of_16\IN\0|the (r_prep) use_15\NN\407535|NONE (r_pobj) with_13\IN\0|presumably (r_prep) associated_12\VBD\628491|of (r_acl) one_6\CD\13741022|of|Two|and (l_prep) of_7\IN\0|associated (l_pobj) hyperplasia_10\NN\14365950|NONE
D003276_D000236 CID contraceptives_14\NNS\3183080|NONE (r_pobj) on_12\IN\0|of|focal|nodular (r_prep) hyperplasia_5\NN\14365950|Hepatic|and (r_conj) adenomas_1\NNS\14236226|.|:|case
D003276_D000236 CID contraceptives_18\NNS\3183080|NONE (r_pobj) of_16\IN\0|the (r_prep) use_15\NN\407535|NONE (r_pobj) with_13\IN\0|presumably (r_prep) associated_12\VBD\628491|of (r_acl) one_6\CD\13741022|of|Two|and (r_conj) cases_1\NNS\7283608|.|are|, (l_prep) of_2\IN\0|one|Two|and (l_pobj) adenoma_4\NN\14236226|NONE
18177388
D000661_D054549 CID amphetamine_21\NN\3248958|NONE (r_compound) use_22\NN\407535|NONE (r_pobj) of_20\IN\0|the (r_prep) setting_19\NN\8567235|NONE (r_pobj) in_17\IN\13603305|a|young (r_prep) woman_16\NN\9605289|NONE (r_pobj) in_13\IN\13603305|cardiomyopathy|syndrome|Reverse|.|) (r_prep) left_3\VBN\8621598|NONE (l_dobj) syndrome_7\NN\5870365|cardiomyopathy|Reverse|.|in|)
D000661_D054549 CID amphetamine_21\NN\3248958|NONE (r_compound) use_22\NN\407535|NONE (r_pobj) of_20\IN\0|the (r_prep) setting_19\NN\8567235|NONE (r_pobj) in_17\IN\13603305|a|young (r_prep) woman_16\NN\9605289|NONE (r_pobj) in_13\IN\13603305|cardiomyopathy|syndrome|Reverse|.|) (r_prep) left_3\VBN\8621598|NONE (l_oprd) cardiomyopathy_11\NN\14103288|syndrome|Reverse|.|in|)
D000661_D054549 CID amphetamine_26\NN\3248958|NONE (r_compound) use_27\NN\407535|NONE (r_pobj) after_25\IN\0|NONE (r_prep) occurring_24\VBG\0|rare|this|of (r_acl) type_18\NN\5839024|NONE (l_prep) of_19\IN\0|rare|this|occurring (l_pobj) syndrome_23\NN\5870365|NONE
12851669
D016912_D054556 NONE levonorgestrel_42\NN\0| (r_npadvmod) containing_44\VBG\2632940|NONE (r_amod) cocs_45\NNS\0|NONE (r_pobj) on_41\IN\0|NONE (r_prep) women_40\NNS\9605289|NONE (r_pobj) among_39\IN\0|women (r_prep) years_38\NNS\15144371|NONE (r_pobj) per_34\IN\0|.|and|(|range|,|,|range (r_prep) range_9\NN\5123416|.|risk (r_attr) was_6\VBD\0|NONE (l_nsubj) risk_3\NN\14541044|.|range (l_prep) of_4\IN\0|corresponding|The|absolute (l_pobj) vte_5\NNP\0|NONE
D003277_D054556 CID contraceptives_30\NNS\3183080|NONE (r_pobj) on_27\IN\0|NONE (r_prep) women_26\NNS\9605289|NONE (r_pobj) among_25\IN\0|and|estimates|,|.|To (r_conj) achieve_1\VB\2524171|NONE (l_dobj) estimates_4\NNS\5802185|and|among|,|.|To (l_prep) of_5\IN\0|risk|absolute (l_pobj) thromboembolism_7\NN\14100769|NONE
D003277_D054556 CID contraceptives_30\NNS\3183080|NONE (r_pobj) on_27\IN\0|NONE (r_prep) women_26\NNS\9605289|NONE (r_pobj) among_25\IN\0|and|estimates|,|.|To (r_conj) achieve_1\VB\2524171|NONE (l_dobj) estimates_4\NNS\5802185|and|among|,|.|To (l_prep) of_5\IN\0|risk|absolute (l_pobj) thromboembolism_7\NN\14100769|NONE (l_appos) vte_9\NNP\0|among|venous|)|(
D003277_D054556 CID cocs_32\NNPS\0|)|oral|combined|( (r_appos) contraceptives_30\NNS\3183080|NONE (r_pobj) on_27\IN\0|NONE (r_prep) women_26\NNS\9605289|NONE (r_pobj) among_25\IN\0|and|estimates|,|.|To (r_conj) achieve_1\VB\2524171|NONE (l_dobj) estimates_4\NNS\5802185|and|among|,|.|To (l_prep) of_5\IN\0|risk|absolute (l_pobj) thromboembolism_7\NN\14100769|NONE
D003277_D054556 CID cocs_32\NNPS\0|)|oral|combined|( (r_appos) contraceptives_30\NNS\3183080|NONE (r_pobj) on_27\IN\0|NONE (r_prep) women_26\NNS\9605289|NONE (r_pobj) among_25\IN\0|and|estimates|,|.|To (r_conj) achieve_1\VB\2524171|NONE (l_dobj) estimates_4\NNS\5802185|and|among|,|.|To (l_prep) of_5\IN\0|risk|absolute (l_pobj) thromboembolism_7\NN\14100769|NONE (l_appos) vte_9\NNP\0|among|venous|)|(
D003277_D054556 CID cocs_19\NNS\0|while (r_pobj) on_18\IN\0|to|have|VTE (r_advcl) had_15\VBN\0|were|women|,|.|:|During (l_dobj) vte_16\NNP\0|on|to|have
D003277_D054556 CID cocs_24\NNS\0|NONE (r_pobj) on_23\IN\0|the (r_prep) women_22\NNS\9605289|NONE (r_pobj) among_20\IN\0|women (r_prep) years_19\NNS\15144371|NONE (r_pobj) per_15\IN\0|.|) (r_prep) 3.1_11\CD\0|.|(|,|,|.|) (r_npadvmod) range_28\NN\5123416|.|and|per|(|,|,|range (r_appos) range_9\NN\5123416|.|risk (r_attr) was_6\VBD\0|NONE (l_nsubj) risk_3\NN\14541044|.|range (l_prep) of_4\IN\0|corresponding|The|absolute (l_pobj) vte_5\NNP\0|NONE
D003277_D054556 CID cocs_45\NNS\0|NONE (r_pobj) on_41\IN\0|NONE (r_prep) women_40\NNS\9605289|NONE (r_pobj) among_39\IN\0|women (r_prep) years_38\NNS\15144371|NONE (r_pobj) per_34\IN\0|.|and|(|range|,|,|range (r_prep) range_9\NN\5123416|.|risk (r_attr) was_6\VBD\0|NONE (l_nsubj) risk_3\NN\14541044|.|range (l_prep) of_4\IN\0|corresponding|The|absolute (l_pobj) vte_5\NNP\0|NONE
D003277_D054556 CID cocs_12\NNS\0|NONE (r_pobj) on_11\IN\0|Danish (r_prep) women_10\NNS\9605289|NONE (r_pobj) among_8\IN\0|absolute|of|the (r_prep) risk_5\NN\14541044|.|results|is (l_prep) of_6\IN\0|absolute|the|among (l_pobj) vte_7\NNP\0|NONE
D017373_D054556 NONE acetate_12\NN\15010703|NONE (r_pobj) on_9\IN\0|NONE (r_prep) women_8\NNS\9605289|NONE (r_pobj) in_7\IN\13603305|venous (r_prep) thromboembolism_6\NN\14100769|NONE
D017373_D054556 NONE acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE
D017373_D054556 NONE acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE (l_appos) vte_9\NNP\0|among|venous|)|(
D017373_D054556 NONE cpa_19\NNP\9761403|(|)|/ (r_nmod) ee_21\NNP\6125041|NONE (r_appos) ethinylestradiol_17\NN\0|cyproterone|plus (r_conj) acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE
D017373_D054556 NONE cpa_19\NNP\9761403|(|)|/ (r_nmod) ee_21\NNP\6125041|NONE (r_appos) ethinylestradiol_17\NN\0|cyproterone|plus (r_conj) acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE (l_appos) vte_9\NNP\0|among|venous|)|(
D017373_D054556 NONE cpa_65\NNP\9761403|/ (r_nmod) ee_67\NNP\6125041|NONE (r_pobj) on_64\IN\0|the (r_prep) women_63\NNS\9605289|NONE (r_pobj) among_61\IN\0|women (r_prep) years_60\NNS\15144371|NONE (r_pobj) per_56\IN\0|.|,|)|(|. (r_prep) range_50\NN\5123416|.|and|per|(|range|,|, (r_conj) range_9\NN\5123416|.|risk (r_attr) was_6\VBD\0|NONE (l_nsubj) risk_3\NN\14541044|.|range (l_prep) of_4\IN\0|corresponding|The|absolute (l_pobj) vte_5\NNP\0|NONE
D017373_D054556 NONE cpa_20\NNP\9761403|/ (r_nmod) ee_22\NNP\6125041|NONE (r_dobj) taking_19\VBG\37396|NONE (r_acl) women_18\NNS\9605289|NONE (r_pobj) among_17\IN\0|NONE (r_prep) that_16\DT\0|NONE (r_pobj) to_15\IN\0|NONE (r_prep) similar_14\JJ\0|NONE (r_acomp) is_13\VBZ\0|.|risk|results (r_ccomp) suggest_2\VBP\1010118|NONE (l_dobj) risk_5\NN\14541044|.|results|is (l_prep) of_6\IN\0|absolute|the|among (l_pobj) vte_7\NNP\0|NONE
D004997_D054556 NONE ethinylestradiol_14\NN\0|combined|cyproterone|and (r_conj) acetate_12\NN\15010703|NONE (r_pobj) on_9\IN\0|NONE (r_prep) women_8\NNS\9605289|NONE (r_pobj) in_7\IN\13603305|venous (r_prep) thromboembolism_6\NN\14100769|NONE
D004997_D054556 NONE ethinylestradiol_17\NN\0|cyproterone|plus (r_conj) acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE
D004997_D054556 NONE ethinylestradiol_17\NN\0|cyproterone|plus (r_conj) acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE (l_appos) vte_9\NNP\0|among|venous|)|(
D004997_D054556 NONE ee_21\NNP\6125041|NONE (r_appos) ethinylestradiol_17\NN\0|cyproterone|plus (r_conj) acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE
D004997_D054556 NONE ee_21\NNP\6125041|NONE (r_appos) ethinylestradiol_17\NN\0|cyproterone|plus (r_conj) acetate_15\NN\15010703|NONE (r_pobj) on_13\IN\0|NONE (r_prep) women_12\NNS\9605289|NONE (r_pobj) among_11\IN\0|VTE|venous|)|( (r_prep) thromboembolism_7\NN\14100769|NONE (l_appos) vte_9\NNP\0|among|venous|)|(
D004997_D054556 NONE ee_67\NNP\6125041|NONE (r_pobj) on_64\IN\0|the (r_prep) women_63\NNS\9605289|NONE (r_pobj) among_61\IN\0|women (r_prep) years_60\NNS\15144371|NONE (r_pobj) per_56\IN\0|.|,|)|(|. (r_prep) range_50\NN\5123416|.|and|per|(|range|,|, (r_conj) range_9\NN\5123416|.|risk (r_attr) was_6\VBD\0|NONE (l_nsubj) risk_3\NN\14541044|.|range (l_prep) of_4\IN\0|corresponding|The|absolute (l_pobj) vte_5\NNP\0|NONE
D004997_D054556 NONE ee_22\NNP\6125041|NONE (r_dobj) taking_19\VBG\37396|NONE (r_acl) women_18\NNS\9605289|NONE (r_pobj) among_17\IN\0|NONE (r_prep) that_16\DT\0|NONE (r_pobj) to_15\IN\0|NONE (r_prep) similar_14\JJ\0|NONE (r_acomp) is_13\VBZ\0|.|risk|results (r_ccomp) suggest_2\VBP\1010118|NONE (l_dobj) risk_5\NN\14541044|.|results|is (l_prep) of_6\IN\0|absolute|the|among (l_pobj) vte_7\NNP\0|NONE
3670965
D001241_D012202 CID aspirin_16\JJ\2707683|NONE (r_compound) ingestion_17\NN\13440063|or (r_conj) salicylates_14\NNS\3828465|NONE (r_pobj) with_13\IN\0|NONE (r_prep) association_12\NN\8008335|NONE (r_pobj) of_11\IN\0|a|total (r_prep) lack_10\NN\14449126|NONE (r_pobj) despite_7\IN\7501545|.|may|be|,|from|were|syndrome (r_prep) disappearing_4\VBG\42757|NONE (l_nsubj) syndrome_1\NN\5870365|.|may|be|,|despite|from|were
D012459_D012202 NONE salicylates_14\NNS\3828465|NONE (r_pobj) with_13\IN\0|NONE (r_prep) association_12\NN\8008335|NONE (r_pobj) of_11\IN\0|a|total (r_prep) lack_10\NN\14449126|NONE (r_pobj) despite_7\IN\7501545|.|may|be|,|from|were|syndrome (r_prep) disappearing_4\VBG\42757|NONE (l_nsubj) syndrome_1\NN\5870365|.|may|be|,|despite|from|were
10692744
D000086_D003221 NONE acetazolamide_4\NN\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|Acute (r_acl) confusion_1\NN\13972797|.|reaction
D000086_D005862 CID acetazolamide_0\RB\0| (r_npadvmod) induced_2\VBN\1627355|Gerstmann|. (r_amod) syndrome_4\NN\5870365|NONE
D000086_D005862 CID acetazolamide_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|Gerstmann (r_amod) syndrome_9\NN\5870365|NONE
D000086_D007674 NONE acetazolamide_4\NN\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|Acute (r_acl) confusion_1\NN\13972797|.|reaction (r_nsubj) is_5\VBZ\0|NONE (l_attr) reaction_11\NN\13446390|.|confusion (l_prep) in_12\IN\13603305|a|adverse|drug|known (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) impairment_16\NN\7296428|NONE
19940105
D006220_D002375 CID haloperidol_22\NN\3713736| (r_npadvmod) induced_24\VBN\1627355|in (r_amod) catalepsy_25\NN\14023236|that|intrastriatal
D006220_D002375 CID haloperidol_8\NN\3713736| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) catalepsy_11\NN\14023236|NONE
D018698_D010300 NONE glutamate_1\NN\15010703||receptor (r_nmod) subtype_4\NN\0|.|in|symptoms (r_nsubj) modulates_5\VBZ\1724459|NONE (l_prep) in_8\IN\13603305|.|subtype|symptoms (l_pobj) models_10\NNS\5888929|NONE (l_prep) of_11\IN\0|rodent (l_pobj) disease_14\NN\14061805|NONE
D018698_D010300 NONE glutamate_1\NN\15010703|mGlu (r_nmod) receptors_5\NNS\5225602|transmission|and|.|represent (r_nsubj) modulate_6\VBP\1724459|NONE (l_conj) represent_15\VBP\2664769|transmission|receptors|and|. (l_dobj) targets_18\NNS\7258332|NONE (l_prep) for_19\IN\0|therapeutic|promising (l_pobj) treatment_21\NN\654885|NONE (l_prep) of_22\IN\0|symptomatic (l_pobj) disease_25\NN\14061805|NONE
D018698_D010300 NONE glutamate_1\NN\15010703|mGlu (r_nmod) receptors_5\NNS\5225602|transmission|and|.|represent (r_nsubj) modulate_6\VBP\1724459|NONE (l_conj) represent_15\VBP\2664769|transmission|receptors|and|. (l_dobj) targets_18\NNS\7258332|NONE (l_prep) for_19\IN\0|therapeutic|promising (l_pobj) treatment_21\NN\654885|NONE (l_prep) of_22\IN\0|symptomatic (l_pobj) disease_25\NN\14061805|NONE (l_appos) pd_27\NNP\14625458|)|(|Parkinson
C507346_D010300 NONE amn082_1\NNP\0|.|in|thus|were (r_nsubjpass) tested_15\VBN\670261|NONE (l_prep) in_16\IN\13603305|.|thus|were|AMN (l_pobj) models_19\NNS\5888929|NONE (l_prep) of_20\IN\0|rodent|different (l_pobj) pd_21\NNP\14625458|NONE
C507346_D010300 NONE amn082_18\NNP\0|respond|.|time|,|In (r_nsubj) reverses_19\VBZ\13854649|NONE (l_prep) in_0\IN\13603305|respond|.|time|,|AMN (l_pobj) task_4\NN\575741|NONE (l_acl) used_6\VBN\0|a|complex (l_xcomp) evaluate_8\VB\670261|commonly (l_dobj) symptoms_11\NNS\5823932|to (l_prep) of_12\IN\0|major|akinetic (l_pobj) patients_14\NNS\9898892|NONE (l_compound) pd_13\NNP\14625458|NONE
C507346_D010300 NONE amn082_3\NNP\0|NONE (r_pobj) of_2\IN\0|Higher (r_prep) doses_1\NNS\3740161|.|effect (r_nsubj) have_11\VBP\7846|NONE (l_dobj) effect_13\NN\34213|.|doses (l_prep) on_14\IN\0|no (l_pobj) models_17\NNS\5888929|NONE (l_prep) of_18\IN\0|the|same (l_pobj) pd_19\NNP\14625458|NONE
C507346_D002375 NONE amn082_20\NNP\0|NONE (r_pobj) of_19\IN\0|.|(|)|nmol (r_prep) administration_12\NN\1133281|NONE (r_dobj) intrastriatal_11\JJ\0|catalepsy|that (r_csubj) reverses_21\VBZ\13854649|Here|we|.|, (l_dobj) catalepsy_25\NN\14023236|that|intrastriatal
C507346_D002375 NONE amn082_3\NNP\0|,|duration|In|. (r_nsubj) reduces_4\VBZ\441445|NONE (l_dobj) duration_6\NN\15113229|,|AMN|In|. (l_prep) of_7\IN\0|in|the (l_pobj) catalepsy_11\NN\14023236|NONE
C507346_D018476 NONE amn082_18\NNP\0|respond|.|time|,|In (r_nsubj) reverses_19\VBZ\13854649|NONE (l_prep) in_0\IN\13603305|respond|.|time|,|AMN (l_pobj) task_4\NN\575741|NONE (l_acl) used_6\VBN\0|a|complex (l_xcomp) evaluate_8\VB\670261|commonly (l_dobj) symptoms_11\NNS\5823932|to (l_amod) akinetic_10\JJ\0|major|of
D016627_D010300 NONE 6-ohda_31\CD\0| (r_advmod) lesioned_33\VBN\0|bilateral (r_amod) rats_34\NNS\2329401|NONE (r_pobj) of_29\IN\0|a (r_prep) cue_28\NN\7010821|NONE (r_pobj) to_26\IN\0|to (r_prep) respond_25\VB\2367363|.|time|,|AMN|In (r_xcomp) reverses_19\VBZ\13854649|NONE (l_prep) in_0\IN\13603305|respond|.|time|,|AMN (l_pobj) task_4\NN\575741|NONE (l_acl) used_6\VBN\0|a|complex (l_xcomp) evaluate_8\VB\670261|commonly (l_dobj) symptoms_11\NNS\5823932|to (l_prep) of_12\IN\0|major|akinetic (l_pobj) patients_14\NNS\9898892|NONE (l_compound) pd_13\NNP\14625458|NONE
D016627_D018476 NONE 6-ohda_31\CD\0| (r_advmod) lesioned_33\VBN\0|bilateral (r_amod) rats_34\NNS\2329401|NONE (r_pobj) of_29\IN\0|a (r_prep) cue_28\NN\7010821|NONE (r_pobj) to_26\IN\0|to (r_prep) respond_25\VB\2367363|.|time|,|AMN|In (r_xcomp) reverses_19\VBZ\13854649|NONE (l_prep) in_0\IN\13603305|respond|.|time|,|AMN (l_pobj) task_4\NN\575741|NONE (l_acl) used_6\VBN\0|a|complex (l_xcomp) evaluate_8\VB\670261|commonly (l_dobj) symptoms_11\NNS\5823932|to (l_amod) akinetic_10\JJ\0|major|of
2980315
C053571_D014693 NONE iopentol_14\NN\0|NONE (r_pobj) after_13\IN\0|)|than|p|(|less (r_prep) 0.05_11\CD\0|.|than|lower|Frequencies (r_parataxis) were_4\VBD\0|NONE (l_nsubj) frequencies_0\NNS\15286249|.|.|than|lower (l_prep) of_1\IN\0|NONE (l_pobj) fibrillation_3\NN\14361664|NONE
D007472_D014693 NONE iohexol_20\NN\0|%|and (r_conj) iopentol_14\NN\0|NONE (r_pobj) after_13\IN\0|)|than|p|(|less (r_prep) 0.05_11\CD\0|.|than|lower|Frequencies (r_parataxis) were_4\VBD\0|NONE (l_nsubj) frequencies_0\NNS\15286249|.|.|than|lower (l_prep) of_1\IN\0|NONE (l_pobj) fibrillation_3\NN\14361664|NONE
D008794_D014693 CID metrizoate_27\NN\0|NONE (r_pobj) after_26\IN\0|NONE (r_prep) than_25\IN\0|.|.|lower|Frequencies (r_prep) were_4\VBD\0|NONE (l_nsubj) frequencies_0\NNS\15286249|.|.|than|lower (l_prep) of_1\IN\0|NONE (l_pobj) fibrillation_3\NN\14361664|NONE
6433367
D011453_D012640 NONE prostaglandin_2\JJ\5414534|synthetase (r_amod) inhibitors_4\NNS\20090|NONE (r_pobj) of_1\IN\0|on|. (r_prep) effect_0\NN\34213|NONE (l_prep) on_5\IN\0|of|. (l_pobj) convulsions_8\NNS\14081375|NONE
D011453_D012640 NONE prostaglandins_5\NNS\5414534|NONE (r_pobj) of_4\IN\0|the (r_prep) relationship_3\NN\31921|To|to (r_dobj) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D011453_D012640 NONE prostaglandins_5\NNS\5414534|NONE (r_pobj) of_4\IN\0|the (r_prep) relationship_3\NN\31921|To|to (r_dobj) investigate_1\VB\644583|were|,|.|effects (r_advcl) evaluated_37\VBN\670261|NONE (l_nsubjpass) effects_14\NNS\13245626|were|,|.|investigate (l_prep) on_20\IN\0|of|the (l_pobj) convulsions_21\NNS\14081375|NONE
D011453_D012640 NONE pgs_7\NNS\0|(|) (r_appos) prostaglandins_5\NNS\5414534|NONE (r_pobj) of_4\IN\0|the (r_prep) relationship_3\NN\31921|To|to (r_dobj) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D011453_D012640 NONE pgs_7\NNS\0|(|) (r_appos) prostaglandins_5\NNS\5414534|NONE (r_pobj) of_4\IN\0|the (r_prep) relationship_3\NN\31921|To|to (r_dobj) investigate_1\VB\644583|were|,|.|effects (r_advcl) evaluated_37\VBN\670261|NONE (l_nsubjpass) effects_14\NNS\13245626|were|,|.|investigate (l_prep) on_20\IN\0|of|the (l_pobj) convulsions_21\NNS\14081375|NONE
D011453_D012640 NONE pgs_4\NNS\0|picrotoxin|that|in|,|but|are (r_nsubjpass) involved_6\VBN\2676054|.|results (l_prep) in_7\IN\13603305|picrotoxin|PGs|that|,|but|are (l_pobj) fluorthyl-_12\NNS\0|NONE (l_conj) convulsions_17\NNS\14081375|)|the|and|underlying
D011453_D012640 NONE pgs_4\NNS\0|picrotoxin|that|in|,|but|are (r_nsubjpass) involved_6\VBN\2676054|.|results (l_conj) picrotoxin-_21\XX\0|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS\14081375|not|,|electroshock
D010433_D012640 CID pentetrazol_28\NNP\0|)|electroshock|,|( (r_nmod) ptz_30\NNP\0|, (r_conj) picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE (r_pobj) on_20\IN\0|of|the (r_prep) effects_14\NNS\13245626|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN\670261|NONE (l_advcl) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D010433_D012640 CID pentetrazol_28\NNP\0|)|electroshock|,|( (r_nmod) ptz_30\NNP\0|, (r_conj) picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE
D010433_D012640 CID ptz_30\NNP\0|, (r_conj) picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE (r_pobj) on_20\IN\0|of|the (r_prep) effects_14\NNS\13245626|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN\670261|NONE (l_advcl) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D010433_D012640 CID ptz_30\NNP\0|, (r_conj) picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE
D010433_D012640 CID ptz_14\NNP\0| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) convulsions_17\NNS\14081375|)|the|and|underlying
D010433_D012640 CID ptz_14\NNP\0| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) convulsions_17\NNS\14081375|)|the|and|underlying (r_conj) fluorthyl-_12\NNS\0|NONE (r_pobj) in_7\IN\13603305|picrotoxin|PGs|that|,|but|are (r_prep) involved_6\VBN\2676054|.|results (l_conj) picrotoxin-_21\XX\0|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS\14081375|not|,|electroshock
D001640_D012640 CID bicuculline_35\NN\0|or (r_conj) electroshock_33\NN\662681|)|pentetrazol|,|( (r_conj) ptz_30\NNP\0|, (r_conj) picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE (r_pobj) on_20\IN\0|of|the (r_prep) effects_14\NNS\13245626|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN\670261|NONE (l_advcl) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D001640_D012640 CID bicuculline_35\NN\0|or (r_conj) electroshock_33\NN\662681|)|pentetrazol|,|( (r_conj) ptz_30\NNP\0|, (r_conj) picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE
D001640_D012640 CID bicuculline_26\NN\0| (r_advmod) induced_28\VBN\1627355|or|, (r_conj) electroshock-_23\XX\0|not|,|convulsions (r_conj) picrotoxin-_21\XX\0|PGs|that|in|,|but|are (r_conj) involved_6\VBN\2676054|.|results (l_prep) in_7\IN\13603305|picrotoxin|PGs|that|,|but|are (l_pobj) fluorthyl-_12\NNS\0|NONE (l_conj) convulsions_17\NNS\14081375|)|the|and|underlying
D001640_D012640 CID bicuculline_26\NN\0| (r_advmod) induced_28\VBN\1627355|or|, (r_conj) electroshock-_23\XX\0|not|,|convulsions (r_conj) picrotoxin-_21\XX\0|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS\14081375|not|,|electroshock
D010852_D012640 CID picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE (r_pobj) on_20\IN\0|of|the (r_prep) effects_14\NNS\13245626|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN\670261|NONE (l_advcl) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D010852_D012640 CID picrotoxin_26\JJ\0|, (r_conj) flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE
D010852_D012640 CID picrotoxin-_21\XX\0|PGs|that|in|,|but|are (r_conj) involved_6\VBN\2676054|.|results (l_prep) in_7\IN\13603305|picrotoxin|PGs|that|,|but|are (l_pobj) fluorthyl-_12\NNS\0|NONE (l_conj) convulsions_17\NNS\14081375|)|the|and|underlying
D010852_D012640 CID picrotoxin-_21\XX\0|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS\14081375|not|,|electroshock
D005481_D012640 CID flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE (r_pobj) on_20\IN\0|of|the (r_prep) effects_14\NNS\13245626|were|,|.|investigate (r_nsubjpass) evaluated_37\VBN\670261|NONE (l_advcl) investigate_1\VB\644583|were|,|.|effects (l_prep) to_9\TO\0|To|relationship (l_pobj) induction_11\NN\7450842|NONE (l_compound) seizure_10\NN\14081375|NONE
D005481_D012640 CID flurothyl_24\JJ\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|NONE (r_acl) convulsions_21\NNS\14081375|NONE
D005481_D012640 CID fluorthyl-_12\NNS\0|NONE (l_conj) convulsions_17\NNS\14081375|)|the|and|underlying
D005481_D012640 CID fluorthyl-_12\NNS\0|NONE (r_pobj) in_7\IN\13603305|picrotoxin|PGs|that|,|but|are (r_prep) involved_6\VBN\2676054|.|results (l_conj) picrotoxin-_21\XX\0|PGs|that|in|,|but|are (l_pobj) convulsions_29\NNS\14081375|not|,|electroshock
16600756
D011453_D053201 NONE prostaglandins_4\NNS\5414534|in|and|growth|Nerve|. (r_conj) factor_2\NN\7326557|NONE (l_prep) in_5\IN\13603305|and|growth|prostaglandins|Nerve|. (l_pobj) urine_7\NN\14853947|NONE (l_prep) of_8\IN\0|the (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|female (l_pobj) bladder_13\NN\5515670|NONE
D011453_D053201 NONE pgs_7\NNS\0|urinary|and (l_prep) in_8\IN\13603305|NONE (l_pobj) women_9\NNS\9605289|NONE (l_prep) with_10\IN\0|NONE (l_pobj) oab_11\NNP\0|NONE
D011453_D053201 NONE pg_8\NNP\0|and|urinary (r_conj) ngf_6\NNP\14734348|NONE (r_pobj) between_4\IN\0|,|and|parameters (r_prep) correlations_3\NNS\13841213|In|,|were|. (l_conj) parameters_12\NNS\5858936|between|,|and (l_prep) in_13\IN\13603305|urodynamic (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|NONE (l_pobj) oab_16\NNP\0|NONE
D011453_D053201 NONE pgs_2\NNS\0|and (r_conj) ngf_0\NNP\14734348|roles|. (r_nsubj) have_3\VBP\7846|NONE (l_dobj) roles_5\NNS\719494|NGF|. (l_prep) in_6\IN\13603305|important (l_pobj) development_8\NN\248977|NONE (l_prep) of_9\IN\0|the (l_pobj) symptoms_11\NNS\5823932|NONE (l_compound) oab_10\NNP\0|in
D011464_D053201 NONE pgi2_3\NNP\0|However|different|,|not|. (r_nsubj) was_4\VBD\0|NONE (l_acomp) different_6\JJ\0|However|,|not|PGI|. (l_prep) between_7\IN\0|NONE (l_pobj) controls_8\NNS\5190804|NONE (l_prep) with_11\IN\0|patients|and (l_pobj) oab_12\NNP\0|NONE
D011464_D053201 NONE pgi2_5\NNP\0|and (r_conj) pgf2alpha_3\NNP\0|Urinary|, (r_appos) ngf_1\NNP\14734348|did|.|with|not (r_nsubj) correlate_8\VB\5857459|NONE (l_prep) with_9\IN\0|did|.|not|NGF (l_pobj) parameters_11\NNS\5858936|NONE (l_prep) in_12\IN\13603305|urodynamic (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) oab_15\NNP\0|NONE
D015232_D053201 CID pge2_3\NNP\0|Urinary|, (r_conj) ngf_1\NNP\14734348|significantly|were|)|compared|.|in (r_nsubjpass) increased_8\VBN\169651|NONE (l_prep) in_9\IN\13603305|significantly|were|)|compared|.|NGF (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|NONE (l_pobj) oab_12\NNP\0|NONE
D015232_D053201 CID pge2_5\NNP\0|NONE (l_compound) oab_3\NNP\0|urinary
D015237_D053201 CID pgf2alpha_5\NNP\0|and (r_conj) pge2_3\NNP\0|Urinary|, (r_conj) ngf_1\NNP\14734348|significantly|were|)|compared|.|in (r_nsubjpass) increased_8\VBN\169651|NONE (l_prep) in_9\IN\13603305|significantly|were|)|compared|.|NGF (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|NONE (l_pobj) oab_12\NNP\0|NONE
D015237_D053201 CID pgf2alpha_3\NNP\0|Urinary|, (r_appos) ngf_1\NNP\14734348|did|.|with|not (r_nsubj) correlate_8\VB\5857459|NONE (l_prep) with_9\IN\0|did|.|not|NGF (l_pobj) parameters_11\NNS\5858936|NONE (l_prep) in_12\IN\13603305|urodynamic (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) oab_15\NNP\0|NONE
8410199
D010862_D012640 CID pilocarpine_14\NN\14712692| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) seizures_17\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_8\NN\14712692|NONE (r_pobj) with_7\IN\0|studied|intraperitoneally|,|were|and|rats (r_prep) injected_5\VBN\81072|NONE (l_conj) studied_15\VBN\0|intraperitoneally|,|were|and|with|rats (l_conj) intervals_27\NNS\33615|,|was|at|and|formation|.|histologically (l_prep) after_28\IN\0|week (l_pobj) seizures_32\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_29\NN\14712692| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) seizures_32\NNS\14081375|NONE
D018698_D012640 NONE glutamate_2\NN\15010703|NONE (r_compound) decarboxylase_3\NN\14732946|containing|in (r_nmod) neurons_7\NNS\5430628|NONE (r_pobj) of_1\IN\0|.|following (r_prep) loss_0\NN\13252973|NONE (l_prep) following_13\VBG\8180190|of|. (l_pobj) seizures_17\NNS\14081375|NONE
D018698_D012640 NONE acid_10\NN\14818238|neurons|(|glutamic (r_compound) decarboxylase_11\NN\14732946|if|vulnerable (r_nsubj) are_26\VBP\13600404|to (l_acomp) vulnerable_27\JJ\0|decarboxylase|if (l_prep) to_28\IN\0|NONE (l_pobj) damage_32\NN\7296428|NONE (l_amod) induced_31\VBN\1627355|in (l_npadvmod) seizure_29\NN\14081375|
D018698_D012640 NONE acid_10\NN\14818238|neurons|(|glutamic (r_compound) decarboxylase_11\NN\14732946|if|vulnerable (r_nsubj) are_26\VBP\13600404|to (l_acomp) vulnerable_27\JJ\0|decarboxylase|if (l_prep) to_28\IN\0|NONE (l_pobj) damage_32\NN\7296428|NONE (l_prep) in_33\IN\13603305|induced (l_pobj) model_35\NN\5888929|NONE (l_prep) of_36\IN\0|a (l_pobj) seizures_38\NNS\14081375|NONE
C028911_D009410 NONE violet_6\NN\12387633|cresyl|,|methods (r_compound) staining_7\NN\275424|NONE (l_conj) methods_11\NNS\5616786|cresyl|,|violet (l_compound) degeneration_10\NN\29677|and|neuronal|localization|,
C028911_D009410 NONE violet_6\NN\12387633|cresyl|,|methods (r_compound) staining_7\NN\275424|NONE (r_pobj) including_4\VBG\0|Additional|,|neuronanatomical|, (r_prep) studies_2\NNS\635850|.|related (r_nsubj) suggested_22\VBD\1010118|NONE (l_ccomp) related_36\VBN\628491|.|studies (l_prep) to_37\IN\0|decrease|was|that (l_pobj) loss_39\NN\13252973|than|to
1636026
D014527_D007674 NONE acid_39\NN\14818238|NONE (r_pobj) of_37\IN\0||/|mg (r_prep) dl_36\NN\13616054|NONE (r_pobj) of_32\IN\0|the (r_prep) addition_31\NN\3081021|NONE (r_pobj) without_29\IN\0|or (r_conj) with_27\IN\0|free (r_prep) buffer_26\NN\14818238|NONE (r_pobj) with_22\IN\0|NONE (r_prep) perfused_21\VBN\454868|recirculating|isolated|rat|the (r_acl) kidney_20\NN\5333259|NONE (r_pobj) in_15\IN\13603305|.|mg|effects|were (r_prep) compared_14\VBN\644583|NONE (l_nsubjpass) effects_3\NNS\13245626|.|mg|in|were (l_amod) nephrotoxic_2\JJ\0|of|direct|The
D013496_D058186 CID suprofen_1\NN\0|been|has|Although|with (r_nsubjpass) associated_4\VBN\628491|.|,|mechanism|unclear (l_prep) with_5\IN\0|been|has|Although|suprofen (l_pobj) development_7\NN\248977|NONE (l_prep) of_8\IN\0|the|in (l_pobj) failure_11\NN\66216|NONE
D013496_D058186 CID suprofen_3\VB\0|,|,|declines|.|likely|In (r_nsubj) causes_4\VBZ\7323922|NONE (l_dobj) declines_6\NNS\13458571|suprofen|,|,|.|likely|In (l_prep) in_7\IN\13603305|acute (l_pobj) function_9\NN\13783581|NONE
D013496_D007674 NONE suprofen_12\NN\0|NONE (r_pobj) of_11\IN\0|NONE (r_prep) mg_10\NN\13717155|.|in|effects|were (r_nsubjpass) compared_14\VBN\644583|NONE (l_nsubjpass) effects_3\NNS\13245626|.|mg|in|were (l_amod) nephrotoxic_2\JJ\0|of|direct|The
D014527_D058186 NONE acid_21\NN\14818238|NONE (r_pobj) of_19\IN\0|the|intrarenal (r_prep) distribution_18\NN\5726596|directly (r_dobj) altering_15\VBG\692130|NONE (r_pcomp) by_13\IN\0|most (r_prep) likely_12\JJ\0|suprofen|,|,|declines|.|In (r_advcl) causes_4\VBZ\7323922|NONE (l_dobj) declines_6\NNS\13458571|suprofen|,|,|.|likely|In (l_prep) in_7\IN\13603305|acute (l_pobj) function_9\NN\13783581|NONE
6637851
D000638_D064420 NONE amiodarone_10\NN\2715941|dose (r_compound) therapy_11\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) toxicity_5\NN\13576101|and|.|term|for
D000638_D064420 NONE amiodarone_4\NN\2715941|in|Although|effective (r_nsubj) is_5\VBZ\0|,|.|it|toxicity (r_advcl) causes_25\VBZ\7323922|NONE (l_dobj) toxicity_27\NN\13576101|,|is|.|it
D000638_D006323 NONE amiodarone_0\NNP\2715941|.|was|to (r_nsubjpass) administered_2\VBN\2436349|NONE (l_prep) to_3\IN\0|.|was|Amiodarone (l_pobj) patients_5\NNS\9898892|NONE (l_conj) arrest_24\NN\88481|or|sustained||
D000638_D014693 NONE amiodarone_10\NN\2715941|dose (r_compound) therapy_11\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) toxicity_5\NN\13576101|and|.|term|for (r_conj) efficacy_3\NN\5199286|NONE (l_prep) for_12\IN\0|toxicity|and|.|term (l_pobj) tachycardia_14\NN\14110674|NONE (l_conj) fibrillation_17\NN\14361664|or|ventricular
D000638_D014693 NONE amiodarone_9\NN\2715941|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treatment_7\NN\654885|.|and|percent|had (r_dobj) continued_6\VBD\2367363|NONE (l_conj) had_11\VBD\0|.|and|percent|treatment (l_dobj) recurrence_13\NN\7342049|NONE (l_prep) of_14\IN\0|over|no (l_pobj) vt_16\NNP\0|NONE (l_conj) fibrillation_19\NN\14361664|VF|)|symptomatic|or|(
D000638_D014693 NONE amiodarone_9\NN\2715941|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treatment_7\NN\654885|.|and|percent|had (r_dobj) continued_6\VBD\2367363|NONE (l_conj) had_11\VBD\0|.|and|percent|treatment (l_dobj) recurrence_13\NN\7342049|NONE (l_prep) of_14\IN\0|over|no (l_pobj) vt_16\NNP\0|NONE (l_appos) vf_21\NNP\0|)|symptomatic|or|fibrillation|(
D000638_D014693 NONE amiodarone_4\NN\2715941|in|Although|effective (r_nsubj) is_5\VBZ\0|,|.|it|toxicity (l_prep) in_8\IN\13603305|amiodarone|Although|effective (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the|term (l_pobj) vt_15\NNP\0|NONE (l_conj) refractory_18\NN\3673767|or (l_compound) vf_17\NNP\0|to
D000638_D014693 NONE amiodarone_31\NN\2715941|NONE (r_pobj) with_30\IN\0|can|,|be|,|successfully|However|adjusted|.|% (r_prep) managed_29\VBN\2524171|NONE (l_nsubjpass) %_19\NN\0|can|,|be|,|successfully|However|adjusted|with|. (l_prep) of_20\IN\0| (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0|NONE (l_pobj) vt_23\NNP\0|NONE (l_conj) vf_25\NNP\0|or
D000638_D017180 NONE amiodarone_10\NN\2715941|dose (r_compound) therapy_11\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) toxicity_5\NN\13576101|and|.|term|for (r_conj) efficacy_3\NN\5199286|NONE (l_prep) for_12\IN\0|toxicity|and|.|term (l_pobj) tachycardia_14\NN\14110674|NONE
D000638_D017180 NONE amiodarone_0\NNP\2715941|.|was|to (r_nsubjpass) administered_2\VBN\2436349|NONE (l_prep) to_3\IN\0|.|was|Amiodarone (l_pobj) patients_5\NNS\9898892|NONE (l_relcl) sustained_8\VBN\2679899|arrest|or|| (l_dobj) tachycardia_12\NN\14110674|,|had|who
D000638_D017180 NONE amiodarone_0\NNP\2715941|.|was|to (r_nsubjpass) administered_2\VBN\2436349|NONE (l_prep) to_3\IN\0|.|was|Amiodarone (l_pobj) patients_5\NNS\9898892|NONE (l_relcl) sustained_8\VBN\2679899|arrest|or|| (l_dobj) tachycardia_12\NN\14110674|,|had|who (l_appos) vt_14\NNP\0|symptomatic|(|ventricular|)
D000638_D017180 NONE amiodarone_9\NN\2715941|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treatment_7\NN\654885|.|and|percent|had (r_dobj) continued_6\VBD\2367363|NONE (l_conj) had_11\VBD\0|.|and|percent|treatment (l_dobj) recurrence_13\NN\7342049|NONE (l_prep) of_14\IN\0|over|no (l_pobj) vt_16\NNP\0|NONE
D000638_D017180 NONE amiodarone_17\NN\2715941|NONE (r_pobj) by_15\IN\0|were|successfully (r_agent) managed_14\VBN\2524171|recurrence|and|percent|. (r_conj) had_5\VBD\0|NONE (l_dobj) recurrence_8\NN\7342049|managed|and|percent|. (l_prep) of_9\IN\0|a|nonfatal (l_pobj) vt_10\NNP\0|NONE
D000638_D017180 NONE amiodarone_4\NN\2715941|in|Although|effective (r_nsubj) is_5\VBZ\0|,|.|it|toxicity (l_prep) in_8\IN\13603305|amiodarone|Although|effective (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the|term (l_pobj) vt_15\NNP\0|NONE
D000638_D017180 NONE amiodarone_31\NN\2715941|NONE (r_pobj) with_30\IN\0|can|,|be|,|successfully|However|adjusted|.|% (r_prep) managed_29\VBN\2524171|NONE (l_nsubjpass) %_19\NN\0|can|,|be|,|successfully|However|adjusted|with|. (l_prep) of_20\IN\0| (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0|NONE (l_pobj) vt_23\NNP\0|NONE
12734532
D010665_D009202 NONE ppa_7\NNP\0|NONE (r_pobj) of_6\IN\0|with|the (r_prep) abuse_5\NN\418025|reports|involved|.|have|, (l_prep) with_8\IN\0|the|of (l_pobj) injury_10\NN\14052046|NONE
D010665_D009202 NONE dexatrim_7\NNP\0|in|PPA)induced|myocardial (r_nmod) injury_11\NN\14052046|NONE
D010665_D009202 NONE ppa)-induced_9\VBN\0|Dexatrim|in|myocardial (r_amod) injury_11\NN\14052046|NONE
D010665_D009202 NONE ppa_10\NN\0|NONE (r_pobj) of_9\IN\0|the||related|other (r_prep) cases_8\NNS\7283608|we|,|In|. (l_acl) related_11\VBN\628491|of|the||other (l_dobj) injury_13\NN\14052046|NONE
D010665_D009203 CID dexatrim_3\NNP\0|Case|.|: (l_prep) as_7\IN\14622893|(|Phenylpropanolamine|) (l_pobj) cause_9\NN\7323922|NONE (l_prep) of_10\IN\0|a (l_pobj) infarction_12\NN\14204950|NONE
D010665_D009203 CID phenylpropanolamine_5\NNP\2682038|(|)|as (r_appos) dexatrim_3\NNP\0|Case|.|: (l_prep) as_7\IN\14622893|(|Phenylpropanolamine|) (l_pobj) cause_9\NN\7323922|NONE (l_prep) of_10\IN\0|a (l_pobj) infarction_12\NN\14204950|NONE
D010665_D062787 NONE ppa_7\NNP\0|NONE (r_pobj) of_6\IN\0|with|the (r_prep) abuse_5\NN\418025|reports|involved|.|have|, (r_dobj) linked_3\VBN\628491|NONE (l_advcl) involved_16\VBN\2676054|reports|.|have|abuse|, (l_nsubjpass) overdose_14\NN\84738|when|especially|is
3535719
D014031_D064420 NONE tobramycin_7\JJ\2716866|NONE (l_nsubj) efficacy_1\NN\5199286|in|. (l_conj) toxicity_3\NN\13576101|Relative|and
D009428_D007239 NONE sulfate_9\NN\15010703|NONE (r_pobj) of_7\IN\0|safety|and|the (r_prep) efficacy_4\NN\5199286|prospectively|.|We|in (r_dobj) compared_2\VBD\644583|NONE (l_prep) in_13\IN\13603305|prospectively|.|efficacy|We (l_pobj) conjunction_14\NN\5048123|NONE (l_prep) in_18\IN\13603305|with (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0||immunocompromised (l_pobj) infections_25\NNS\14052046|NONE
D010878_D006311 CID piperacillin_12\VB\3910033||and (r_conj) netilmicin_10\NNS\0|NONE (r_pobj) of_8\IN\0|)|.|four|( (r_prep) %_6\NN\0|in|and (r_pobj) in_2\IN\13603305|Ototoxicity|. (r_prep) occurred_1\VBD\0|NONE (l_nsubj) ototoxicity_0\NN\0|.|in
D010878_D006311 CID piperacillin_24\NN\3910033| (r_npadvmod) treated_26\VBN\2376958|NONE (r_amod) patients_27\NNS\9898892|and| (r_conj) tobramycin_22\NNS\2716866|NONE (r_pobj) of_20\IN\0|||(|) (r_prep) %_18\NN\0|NONE (r_pobj) in_14\IN\13603305|and|% (r_conj) in_2\IN\13603305|Ototoxicity|. (r_prep) occurred_1\VBD\0|NONE (l_nsubj) ototoxicity_0\NN\0|.|in
D014031_D006311 CID tobramycin_22\NNS\2716866|NONE (r_pobj) of_20\IN\0|||(|) (r_prep) %_18\NN\0|NONE (r_pobj) in_14\IN\13603305|and|% (r_conj) in_2\IN\13603305|Ototoxicity|. (r_prep) occurred_1\VBD\0|NONE (l_nsubj) ototoxicity_0\NN\0|.|in
D014031_D006311 CID tobramycin_18\NNS\2716866|NONE (r_pobj) with_17\IN\0|NONE (r_prep) than_16\IN\0|with|often (r_prep) reversible_13\JJ\3419014|less|and (r_conj) severe_9\JJ\0|that|ototoxicity (r_acomp) was_7\VBD\0|.|We (l_nsubj) ototoxicity_6\NN\0|that|severe
D009428_D006311 CID netilmicin_10\NNS\0|NONE (r_pobj) of_8\IN\0|)|.|four|( (r_prep) %_6\NN\0|in|and (r_pobj) in_2\IN\13603305|Ototoxicity|. (r_prep) occurred_1\VBD\0|NONE (l_nsubj) ototoxicity_0\NN\0|.|in
D009428_D006311 CID netilmicin_15\NNS\0|NONE (r_pobj) with_14\IN\0|often|than (r_prep) reversible_13\JJ\3419014|less|and (r_conj) severe_9\JJ\0|that|ototoxicity (r_acomp) was_7\VBD\0|.|We (l_nsubj) ototoxicity_6\NN\0|that|severe
D009428_D007674 CID netilmicin_10\NNS\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) treated_8\VBN\2376958|NONE (r_acl) patients_7\NNS\9898892|NONE (r_pobj) in_6\IN\13603305|)|similar|a|%|( (r_prep) proportion_5\NN\13824815|NONE (r_pobj) in_2\IN\13603305|.|Nephrotoxicity (r_prep) occurred_1\VBD\0|NONE (l_nsubj) nephrotoxicity_0\NN\0|.|in
D000617_D006311 NONE aminoglycoside_3\NN\0| (r_npadvmod) associated_5\VBN\628491|NONE (r_amod) ototoxicity_6\NN\0|that|severe
D010878_D007239 NONE sodium_17\NN\14625458|NONE (r_pobj) with_15\IN\0|in (r_prep) conjunction_14\NN\5048123|NONE (l_prep) in_18\IN\13603305|with (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0||immunocompromised (l_pobj) infections_25\NNS\14052046|NONE
D014031_D007674 CID tobramycin_12\JJ\2716866|and (r_conj) netilmicin_10\NNS\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) treated_8\VBN\2376958|NONE (r_acl) patients_7\NNS\9898892|NONE (r_pobj) in_6\IN\13603305|)|similar|a|%|( (r_prep) proportion_5\NN\13824815|NONE (r_pobj) in_2\IN\13603305|.|Nephrotoxicity (r_prep) occurred_1\VBD\0|NONE (l_nsubj) nephrotoxicity_0\NN\0|.|in
D009428_D064420 NONE netilmicin_5\NNS\0|NONE (r_pobj) of_4\IN\0|and (r_prep) toxicity_3\NN\13576101|Relative|and
D014031_D007239 NONE sulfate_12\NN\15010703|or|netilmicin (r_conj) sulfate_9\NN\15010703|NONE (r_pobj) of_7\IN\0|safety|and|the (r_prep) efficacy_4\NN\5199286|prospectively|.|We|in (r_dobj) compared_2\VBD\644583|NONE (l_prep) in_13\IN\13603305|prospectively|.|efficacy|We (l_pobj) conjunction_14\NN\5048123|NONE (l_prep) in_18\IN\13603305|with (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0||immunocompromised (l_pobj) infections_25\NNS\14052046|NONE
6115999
D011433_D003316 NONE propranolol_10\NN\0|the (r_amod) group_11\NN\2137|NONE (r_pobj) in_8\IN\13603305|to|have (r_prep) occurred_7\VBN\0|.|disease|is (r_xcomp) known_4\VBN\0|NONE (l_nsubjpass) disease_2\NN\14061805|.|occurred|is
D011433_D011928 CID propranolol_37\NN\0|NONE (r_dobj) taking_36\VBG\37396|women|and (r_acl) men_33\NNS\8208016|NONE (r_pobj) in_32\IN\13603305|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN\29677|glucose|and|impaired|in|associated|,|,
D001539_D007172 CID bendrofluazide_6\JJ\0|and|impotence (r_amod) treatment_7\NN\654885|NONE (l_conj) impotence_9\NN\4723816|bendrofluazide|and
D001539_D007172 CID bendrofluazide_6\JJ\0|and|impotence (r_amod) treatment_7\NN\654885|NONE (r_pobj) between_5\IN\0|an (r_prep) association_4\NN\8008335|occurred|,|results|and (r_dobj) show_2\VBP\429048|NONE (l_conj) occurred_14\VBD\0|association|,|results|and (l_nsubj) impotence_12\NN\4723816|.|frequently|in|also
D001539_D006973 NONE bendrofluazide_3\VB\0|.|Adverse (l_conj) propranolol_5\NN\0|and|to (l_prep) for_6\IN\0|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) hypertension_11\NN\14057371|NONE
D001539_D006973 NONE bendrofluazide_21\NN\0|four|treatment|: (r_amod) groups_19\NNS\2137|NONE (r_pobj) of_16\IN\0|NONE (r_prep) one_15\CD\13741022|NONE (r_pobj) to_14\IN\0|are|.|randomly|Participants (r_prep) allocated_13\VBN\2228698|NONE (l_nsubjpass) participants_0\NNS\9816771|are|.|randomly|to (l_prep) in_1\IN\13603305|NONE (l_pobj) trial_7\NN\786195|NONE (l_prep) for_8\IN\0|the|treatment|Council (l_pobj) hypertension_10\NN\14057371|NONE
D001539_D018149 CID bendrofluazide_23\NN\0|NONE (r_amod) treatment_24\NN\654885|NONE (r_pobj) with_22\IN\0|NONE (r_prep) associated_21\VBN\628491|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN\5032565|NONE
D001539_D004417 NONE bendrofluazide_23\NN\0|NONE (r_amod) treatment_24\NN\654885|NONE (r_pobj) with_22\IN\0|NONE (r_prep) associated_21\VBN\628491|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN\5032565|NONE (l_conj) phenomenon_29\NN\29677|glucose|and|impaired|in|associated|,|, (l_conj) dyspnoea_31\NN\14299637|Raynaud|and|in
D001539_D011928 NONE bendrofluazide_23\NN\0|NONE (r_amod) treatment_24\NN\654885|NONE (r_pobj) with_22\IN\0|NONE (r_prep) associated_21\VBN\628491|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN\5032565|NONE (l_conj) phenomenon_29\NN\29677|glucose|and|impaired|in|associated|,|,
D011433_D004417 CID propranolol_37\NN\0|NONE (r_dobj) taking_36\VBG\37396|women|and (r_acl) men_33\NNS\8208016|NONE (r_pobj) in_32\IN\13603305|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN\29677|glucose|and|impaired|in|associated|,|, (l_conj) dyspnoea_31\NN\14299637|Raynaud|and|in
D011433_D007172 CID propranolol_20\RB\0|than (r_dobj) taking_19\VBG\37396|NONE (r_acl) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|.|frequently|impotence|also (r_prep) occurred_14\VBD\0|association|,|results|and (r_conj) show_2\VBP\429048|NONE (l_dobj) association_4\NN\8008335|occurred|,|results|and (l_prep) between_5\IN\0|an (l_pobj) treatment_7\NN\654885|NONE (l_conj) impotence_9\NN\4723816|bendrofluazide|and
D011433_D007172 CID propranolol_20\RB\0|than (r_dobj) taking_19\VBG\37396|NONE (r_acl) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|.|frequently|impotence|also (r_prep) occurred_14\VBD\0|association|,|results|and (l_nsubj) impotence_12\NN\4723816|.|frequently|in|also
D011433_D006973 NONE propranolol_5\NN\0|and|to (l_prep) for_6\IN\0|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) hypertension_11\NN\14057371|NONE
D011433_D006973 NONE propranolol_23\NN\0|, (r_conj) bendrofluazide_21\NN\0|four|treatment|: (r_amod) groups_19\NNS\2137|NONE (r_pobj) of_16\IN\0|NONE (r_prep) one_15\CD\13741022|NONE (r_pobj) to_14\IN\0|are|.|randomly|Participants (r_prep) allocated_13\VBN\2228698|NONE (l_nsubjpass) participants_0\NNS\9816771|are|.|randomly|to (l_prep) in_1\IN\13603305|NONE (l_pobj) trial_7\NN\786195|NONE (l_prep) for_8\IN\0|the|treatment|Council (l_pobj) hypertension_10\NN\14057371|NONE
D001539_D006073 CID bendrofluazide_23\NN\0|NONE (r_amod) treatment_24\NN\654885|NONE (r_pobj) with_22\IN\0|NONE (r_prep) associated_21\VBN\628491|glucose|and|phenomenon|impaired|in|,|, (r_acl) tolerance_11\NN\5032565|NONE (l_prep) in_12\IN\13603305|glucose|and|phenomenon|impaired|associated|,|, (l_pobj) men_13\NNS\8208016|NONE (l_conj) women_15\NNS\9605289|in|and (l_conj) gout_17\NN\14186541|and
D011433_D018149 NONE propranolol_37\NN\0|NONE (r_dobj) taking_36\VBG\37396|women|and (r_acl) men_33\NNS\8208016|NONE (r_pobj) in_32\IN\13603305|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN\29677|glucose|and|impaired|in|associated|,|, (r_conj) tolerance_11\NN\5032565|NONE
D011433_D006073 NONE propranolol_37\NN\0|NONE (r_dobj) taking_36\VBG\37396|women|and (r_acl) men_33\NNS\8208016|NONE (r_pobj) in_32\IN\13603305|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN\29677|glucose|and|impaired|in|associated|,|, (r_conj) tolerance_11\NN\5032565|NONE (l_prep) in_12\IN\13603305|glucose|and|phenomenon|impaired|associated|,|, (l_pobj) men_13\NNS\8208016|NONE (l_conj) women_15\NNS\9605289|in|and (l_conj) gout_17\NN\14186541|and
11847945
D007530_D056486 CID isoflurane_6\RB\3570838|NONE (r_pobj) to_5\IN\0|NONE (r_prep) exposure_4\NN\5042871|NONE (r_pobj) after_3\IN\0|Acute|cholestatic|. (r_prep) hepatitis_2\NN\14127211|NONE
D007530_D056486 CID isoflurane_14\RB\3570838|NONE (r_pobj) to_10\IN\0|NONE (r_prep) exposure_9\NN\5042871|NONE (r_pobj) following_8\VBG\8180190|a|of (r_prep) case_3\NN\7283608|.|To (l_prep) of_4\IN\0|a|following (l_pobj) hepatitis_7\NN\14127211|NONE
D007530_D056486 CID isoflurane_0\NNP\3570838|.|hepatitis|,|can (r_nsubj) cause_8\VB\7323922|NONE (l_dobj) hepatitis_11\NN\14127211|Isoflurane|.|,|can
D004177_D000699 NONE dipyrone_7\NN\0|NONE (l_prep) for_8\IN\0|NONE (l_pobj) analgesia_9\NN\14034177|NONE
D007530_D002779 CID isoflurane_6\RB\3570838|NONE (r_pobj) to_5\IN\0|NONE (r_prep) exposure_4\NN\5042871|NONE (r_pobj) after_3\IN\0|Acute|cholestatic|. (r_prep) hepatitis_2\NN\14127211|NONE
D007530_D002779 CID isoflurane_14\RB\3570838|NONE (r_pobj) to_10\IN\0|NONE (r_prep) exposure_9\NN\5042871|NONE (r_pobj) following_8\VBG\8180190|a|of (r_prep) case_3\NN\7283608|.|To (l_prep) of_4\IN\0|a|following (l_pobj) hepatitis_7\NN\14127211|NONE
D007530_D002779 CID isoflurane_0\NNP\3570838|.|hepatitis|,|can (r_nsubj) cause_8\VB\7323922|NONE (l_dobj) hepatitis_11\NN\14127211|Isoflurane|.|,|can
12013711
D018967_D001480 NONE risperidone_26\NN\0|NONE (r_pobj) with_25\IN\0|.|were|successfully|patients (r_prep) treated_24\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|.|were|successfully|with (l_relcl) had_5\VBD\0|,|schizophrenic|,|Two (l_conj) developed_16\VBN\1753788|history|and|who (l_dobj) eps_17\NNP\0|with|had|previously|who
D008238_D010468 NONE lsd_16\NNP\3097890|NONE (r_compound) abuse_17\NN\418025|NONE (r_pobj) of_15\IN\0|past|a (r_prep) history_14\NN\15120823|NONE (r_pobj) with_11\IN\0|,|benign|.|visual|transient|in|associated (r_prep) disturbances_7\NNS\407535|NONE
D008238_D010468 NONE lsd_14\NNP\3097890|prior (r_compound) consumption_15\NN\13440063|NONE (r_pobj) to_12\IN\0|NONE (r_prep) related_11\VBN\628491|"|" (r_acl) flashbacks_9\NNS\6401328|NONE (r_pobj) as_7\IN\14622893|previously (r_prep) experienced_6\VBN\2108377|visual (r_acl) disturbances_4\NNS\407535|imagery|.
D018967_D012559 NONE risperidone_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|,|benign|.|visual|transient|in|with (r_amod) disturbances_7\NNS\407535|NONE (l_prep) in_8\IN\13603305|,|benign|.|visual|transient|with|associated (l_pobj) patients_10\NNS\9898892|NONE (l_amod) schizophrenic_9\JJ\10490141|NONE
D018967_D012559 NONE risperidone_26\NN\0|NONE (r_pobj) with_25\IN\0|.|were|successfully|patients (r_prep) treated_24\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|.|were|successfully|with (l_amod) schizophrenic_1\JJ\10490141|,|had|,|Two
D008238_D001480 NONE lsd_10\NNP\3097890|NONE (r_compound) abuse_11\NN\418025|NONE (r_pobj) of_9\IN\0|a|prior (r_prep) history_8\NN\15120823|developed|and|who (r_dobj) had_5\VBD\0|,|schizophrenic|,|Two (l_conj) developed_16\VBN\1753788|history|and|who (l_dobj) eps_17\NNP\0|with|had|previously|who
D008238_D012559 NONE lsd_16\NNP\3097890|NONE (r_compound) abuse_17\NN\418025|NONE (r_pobj) of_15\IN\0|past|a (r_prep) history_14\NN\15120823|NONE (r_pobj) with_11\IN\0|,|benign|.|visual|transient|in|associated (r_prep) disturbances_7\NNS\407535|NONE (l_prep) in_8\IN\13603305|,|benign|.|visual|transient|with|associated (l_pobj) patients_10\NNS\9898892|NONE (l_amod) schizophrenic_9\JJ\10490141|NONE
D008238_D012559 NONE lsd_10\NNP\3097890|NONE (r_compound) abuse_11\NN\418025|NONE (r_pobj) of_9\IN\0|a|prior (r_prep) history_8\NN\15120823|developed|and|who (r_dobj) had_5\VBD\0|,|schizophrenic|,|Two (r_relcl) patients_2\NNS\9898892|.|were|successfully|with (l_amod) schizophrenic_1\JJ\10490141|,|had|,|Two
D018967_D010468 CID risperidone_0\NNP\0| (r_npadvmod) associated_2\VBN\628491|,|benign|.|visual|transient|in|with (r_amod) disturbances_7\NNS\407535|NONE
D018967_D010468 CID risperidone_17\NN\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) treatment_15\NN\654885|NONE (r_dobj) starting_14\VBG\457382|NONE (r_pcomp) after_13\IN\0|immediately|which (r_prep) appeared_11\VBD\2604760|visual|transient|, (r_relcl) disturbances_8\NNS\407535|NONE
D018967_D010468 CID risperidone_0\NNP\0|NONE (r_compound) administration_1\NN\1133281|was|wore|and (r_nsubjpass) continued_3\VBN\2367363|NONE (l_conj) wore_9\VBD\0|administration|was|and (l_nsubj) disturbances_7\NNS\407535|.|gradually|off
19923525
D009553_D008569 NONE nimodipine_0\NNP\0|impairment|. (r_nsubj) prevents_1\VBZ\0|NONE (l_dobj) impairment_3\NN\7296428|Nimodipine|.
D002118_D007022 NONE calcium_13\NN\14625458|NONE (r_compound) homeostasis_14\NN\13934900|NONE (r_pobj) of_12\IN\0|the|during (r_prep) preservation_11\NN\817680|NONE (l_prep) during_15\IN\0|the|of (l_pobj) hypotension_16\NN\14057371|NONE
D005996_D008569 CID nitroglycerin_6\NN\15015501| (r_npadvmod) induced_8\VBN\1627355|in (r_amod) hypotension_9\NN\14057371|NONE (r_pobj) by_5\IN\0|NONE (r_agent) caused_4\VBN\1617192|memory (r_acl) impairment_3\NN\7296428|Nimodipine|.
D009553_D007022 NONE nimodipine_0\NNP\0|impairment|. (r_nsubj) prevents_1\VBZ\0|NONE (l_dobj) impairment_3\NN\7296428|Nimodipine|. (l_acl) caused_4\VBN\1617192|memory (l_agent) by_5\IN\0|NONE (l_pobj) hypotension_9\NN\14057371|NONE
D009553_D007022 NONE nimodipine_5\NN\0|at (r_nsubj) administered_9\VBN\2436349|the (r_acl) hypothesis_3\NN\7162194|We (r_dobj) tested_1\VBD\670261|memory|(|would|.|hypotension (r_ccomp) preserve_19\VB\14514039|NONE (l_nsubj) hypotension_17\NN\14057371|memory|(|would|.|tested
D009553_D007022 NONE nimo_7\NNP\0|that|(|) (r_appos) nimodipine_5\NN\0|at (r_nsubj) administered_9\VBN\2436349|the (r_acl) hypothesis_3\NN\7162194|We (r_dobj) tested_1\VBD\670261|memory|(|would|.|hypotension (r_ccomp) preserve_19\VB\14514039|NONE (l_nsubj) hypotension_17\NN\14057371|memory|(|would|.|tested
D009553_D007022 NONE nimo_27\NN\0|+ (r_conj) ntg_25\NNP\0|, (r_appos) saline_23\NN\14849367|NONE (r_pobj) with_22\IN\0|NONE (r_prep) injected_21\VBN\81072|NONE (r_acl) those_20\DT\0|NONE (r_pobj) with_19\IN\0|NONE (r_prep) compared_18\VBN\644583|or|delayed|decrease|, (r_prep) showed_5\VBD\2137132|Mice|to|. (r_conj) subjected_1\VBN\137313|NONE (l_prep) to_2\IN\0|showed|Mice|. (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) hypotensive_3\JJ\10405694|NONE
D009553_D007022 NONE nimo_0\NN\0|disruption|improve|but|. (r_advmod) attenuated_1\VBD\224901|NONE (l_conj) improve_17\VB\126264|disruption|but|.|NIMO (l_prep) in_19\IN\13603305|latency|not|did (l_pobj) absence_21\NN\14449405|NONE (l_prep) of_22\IN\0|the (l_pobj) hypotension_23\NN\14057371|NONE
D009553_D007022 NONE nimo_4\NNP\0|NONE (r_pobj) of_3\IN\0|The|observed (r_prep) effect_2\NN\34213|,|attributable|.|were|may|have (r_nsubj) been_7\VBN\0|NONE (l_acomp) attributable_8\JJ\0|,|effect|.|were|may|have (l_prep) to_9\IN\0|NONE (l_pobj) preservation_11\NN\817680|NONE (l_prep) during_15\IN\0|the|of (l_pobj) hypotension_16\NN\14057371|NONE
D005996_D007022 CID nitroglycerin_6\NN\15015501| (r_npadvmod) induced_8\VBN\1627355|in (r_amod) hypotension_9\NN\14057371|NONE
D005996_D007022 CID nitroglycerin_14\NN\15015501|NONE (r_pobj) of_13\IN\0|the (r_prep) onset_12\NN\7325190|NONE (r_pobj) at_10\IN\14622893|nimodipine (r_prep) administered_9\VBN\2436349|the (r_acl) hypothesis_3\NN\7162194|We (r_dobj) tested_1\VBD\670261|memory|(|would|.|hypotension (r_ccomp) preserve_19\VB\14514039|NONE (l_nsubj) hypotension_17\NN\14057371|memory|(|would|.|tested
D005996_D007022 CID ntg)-induced_16\JJ\0|NONE (r_amod) hypotension_17\NN\14057371|memory|(|would|.|tested
D005996_D007022 CID ntg_25\NNP\0|, (r_appos) saline_23\NN\14849367|NONE (r_pobj) with_22\IN\0|NONE (r_prep) injected_21\VBN\81072|NONE (r_acl) those_20\DT\0|NONE (r_pobj) with_19\IN\0|NONE (r_prep) compared_18\VBN\644583|or|delayed|decrease|, (r_prep) showed_5\VBD\2137132|Mice|to|. (r_conj) subjected_1\VBN\137313|NONE (l_prep) to_2\IN\0|showed|Mice|. (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) hypotensive_3\JJ\10405694|NONE
D005996_D007022 CID ntg_31\NNP\0|respectively|) (r_dobj) delayed_30\VBN\439958|or|compared|decrease|, (r_conj) showed_5\VBD\2137132|Mice|to|. (r_conj) subjected_1\VBN\137313|NONE (l_prep) to_2\IN\0|showed|Mice|. (l_pobj) episodes_4\NNS\7283608|NONE (l_amod) hypotensive_3\JJ\10405694|NONE
D005996_D007022 CID ntg_9\NNP\0|NONE (r_pobj) of_8\IN\0|the (r_prep) injection_7\NN\320852|impairment|,|had|In|.|after|, (r_nsubj) produced_13\VBD\1617192|NONE (l_conj) had_30\VBD\0|injection|impairment|,|In|.|after|, (l_advcl) delayed_27\VBN\439958|effect (l_dobj) hypotension_29\NN\14057371|whereas
D005996_D007022 CID ntg_13\NNP\0|NONE (r_pobj) by_12\IN\0|NONE (r_agent) caused_11\VBN\1617192|term (r_acl) memory_10\NN\5926676|NONE (r_pobj) of_6\IN\0|NONE (r_prep) consolidation_5\NN\7373803|NONE (r_pobj) in_4\IN\13603305|the (r_prep) disruption_3\NN\1066163|improve|but|.|NIMO (r_dobj) attenuated_1\VBD\224901|NONE (l_conj) improve_17\VB\126264|disruption|but|.|NIMO (l_prep) in_19\IN\13603305|latency|not|did (l_pobj) absence_21\NN\14449405|NONE (l_prep) of_22\IN\0|the (l_pobj) hypotension_23\NN\14057371|NONE
6436733
D000641_D006970 CID ammonia_0\NN\14940386|higher|in|.|,|)|were (r_nsubj) was_4\VBD\0|NONE (l_prep) in_6\IN\13603305|higher|.|Ammonia|,|)|were (l_pobj) patients_7\NNS\9898892|NONE (l_relcl) complained_14\VBD\0|NONE (l_prep) of_15\IN\0|during|,|,|who|than (l_pobj) drowsiness_16\NN\14015731|NONE
D000641_D006970 CID nh3_2\NNP\0|NONE (r_appos) ammonia_0\NN\14940386|higher|in|.|,|)|were (r_nsubj) was_4\VBD\0|NONE (l_prep) in_6\IN\13603305|higher|.|Ammonia|,|)|were (l_pobj) patients_7\NNS\9898892|NONE (l_relcl) complained_14\VBD\0|NONE (l_prep) of_15\IN\0|during|,|,|who|than (l_pobj) drowsiness_16\NN\14015731|NONE
D014635_D006970 CID vpa_35\NNP\0|plasma (r_compound) levels_37\NNS\4916342|similar|although (r_nsubj) were_38\VBD\0|higher|in|.|Ammonia|,|) (r_advcl) was_4\VBD\0|NONE (l_prep) in_6\IN\13603305|higher|.|Ammonia|,|)|were (l_pobj) patients_7\NNS\9898892|NONE (l_relcl) complained_14\VBD\0|NONE (l_prep) of_15\IN\0|during|,|,|who|than (l_pobj) drowsiness_16\NN\14015731|NONE
D014635_D004827 NONE acid_1\NN\14818238|.|to|was (r_nsubjpass) given_6\VBN\5892096|NONE (l_dative) to_7\IN\0|.|acid|was (l_pobj) patients_10\NNS\9898892|NONE (l_amod) epileptic_9\JJ\10595647||treated
D014635_D004827 NONE vpa_3\NNP\0|)|(|Valproic (r_appos) acid_1\NN\14818238|.|to|was (r_nsubjpass) given_6\VBN\5892096|NONE (l_dative) to_7\IN\0|.|acid|was (l_pobj) patients_10\NNS\9898892|NONE (l_amod) epileptic_9\JJ\10595647||treated
20533999
D004298_D020258 NONE dopamine_0\NN\14807737|essential|not|. (r_nsubj) is_1\VBZ\0|NONE (l_acomp) essential_3\JJ\2452|Dopamine|not|. (l_prep) for_4\IN\0|NONE (l_pobj) development_6\NN\248977|NONE (l_prep) of_7\IN\0|the (l_pobj) neurotoxicity_11\NN\0|NONE
D004298_D020258 NONE da_29\NNP\10484858|induced (r_compound) neurotoxicity_30\NN\0|NONE
D004298_D020258 NONE da_13\NN\10484858|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) deficient_10\JJ\0|to (r_acomp) be_9\VB\14625458|genetically|develop|that|mice (r_xcomp) engineered_7\VBN\1639714|Further|,|.|we (l_conj) develop_14\VBP\1753788|genetically|that|be|mice (l_dobj) neurotoxicity_16\NN\0|long|,
D004298_D020258 NONE da_7\NNP\10484858|not|and|essential|suggest|that (r_nsubj) is_8\VBZ\0|.|Taken|findings|, (l_acomp) essential_10\JJ\2452|not|and|DA|suggest|that (l_prep) for_11\IN\0|NONE (l_pobj) development_13\NN\248977|NONE (l_prep) of_14\IN\0|the (l_pobj) neurotoxicity_19\NN\0|NONE
D004298_D020258 NONE da_26\JJ\10484858|NONE (r_pobj) of_25\IN\0|NONE (r_prep) independent_24\JJ\9619824|NONE (r_amod) mechanisms_23\NNS\13446390|investigation|that (r_nsubj) warrant_27\NN\6552984|NONE (r_ccomp) suggest_21\VBP\1010118|not|and|essential|DA|that (r_conj) is_8\VBZ\0|.|Taken|findings|, (l_acomp) essential_10\JJ\2452|not|and|DA|suggest|that (l_prep) for_11\IN\0|NONE (l_pobj) development_13\NN\248977|NONE (l_prep) of_14\IN\0|the (l_pobj) neurotoxicity_19\NN\0|NONE
D004298_D009461 NONE da_13\NNP\10484858|unilateral (r_compound) deficits_14\NNS\5113133|to (r_dobj) have_10\VB\7846|genetically|mice|that|develop (r_xcomp) engineered_8\VBN\1639714|we|,|.|In (l_conj) develop_15\VBP\1753788|genetically|mice|that|have (l_dobj) deficits_20\NNS\5113133|NONE
D019805_D020258 NONE tyrosine_24\NN\14601829|NONE (l_prep) on_25\IN\0||para (l_pobj) neurotoxicity_30\NN\0|NONE
D008694_D020258 CID methamphetamine_8\NN\2704153| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) neurotoxicity_11\NN\0|NONE
D008694_D020258 CID meth_26\NNP\2704153| (r_npadvmod) induced_28\VBN\1627355|DA (r_amod) neurotoxicity_30\NN\0|NONE
D008694_D020258 CID meth_15\NNP\2704153|NONE (r_compound) neurotoxicity_16\NN\0|long|,
D008694_D020258 CID meth_25\NNP\2704153|NONE (r_pobj) of_24\IN\0|the|thermic (r_prep) effects_23\NNS\13245626|are|as (r_nsubjpass) preserved_27\VBN\2681795|as (r_advcl) long_19\RB\1825237|neurotoxicity|, (r_advmod) develop_14\VBP\1753788|genetically|that|be|mice (l_dobj) neurotoxicity_16\NN\0|long|,
D008694_D020258 CID meth_15\NNP\2704153| (r_npadvmod) induced_17\VBN\1627355|dopaminergic (r_amod) neurotoxicity_19\NN\0|NONE
D007980_D020258 NONE dihydroxyphenylalanine_11\NN\14601829|NONE (r_pobj) of_8\IN\0|the|reverse|reported (r_prep) ability_7\NN\4723816|also|is|by|that (l_acl) reverse_13\VB\13854649|of|the|reported (l_dobj) effect_16\NN\34213|to (l_prep) of_17\IN\0|protective|the (l_pobj) tyrosine_24\NN\14601829|NONE (l_prep) on_25\IN\0||para (l_pobj) neurotoxicity_30\NN\0|NONE
D008694_D009461 NONE meth_16\NN\2704153| (r_npadvmod) induced_18\VBN\1627355|are|dopaminergic (r_amod) deficits_20\NNS\5113133|NONE
D004298_D064420 NONE dopamine_5\NN\14807737|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ\761713|It|widely|.|is (l_dobj) methamphetamine_10\NN\2704153|decrease|dopamine|that (l_acl) meth)-induced_12\JJ\0|(|, (l_dobj) toxicity_13\NN\13576101|brain
D004298_D064420 NONE dopamine_5\NN\14807737|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN\13576101|because|drugs|enhance|,
D004298_D064420 NONE dopamine_5\NN\14807737|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_advcl) enhance_35\VB\227165|because|drugs|toxicity|, (l_dobj) toxicity_36\NN\13576101|drugs|whereas
D004298_D064420 NONE da_7\NNP\10484858|NONE (r_appos) dopamine_5\NN\14807737|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ\761713|It|widely|.|is (l_dobj) methamphetamine_10\NN\2704153|decrease|dopamine|that (l_acl) meth)-induced_12\JJ\0|(|, (l_dobj) toxicity_13\NN\13576101|brain
D004298_D064420 NONE da_7\NNP\10484858|NONE (r_appos) dopamine_5\NN\14807737|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN\13576101|because|drugs|enhance|,
D004298_D064420 NONE da_7\NNP\10484858|NONE (r_appos) dopamine_5\NN\14807737|decrease|that|methamphetamine (r_nsubj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_advcl) enhance_35\VB\227165|because|drugs|toxicity|, (l_dobj) toxicity_36\NN\13576101|drugs|whereas
D004298_D064420 NONE da_24\NNP\10484858|NONE (r_compound) neurotransmission_25\NN\0|NONE (r_pobj) with_23\IN\0|that (r_prep) interfere_22\VBP\2451370|NONE (r_relcl) drugs_20\NNS\14778436|because|toxicity|enhance|, (r_nsubj) decrease_26\NN\7296428|dopamine|that|methamphetamine (r_advcl) mediates_9\VBZ\761713|It|widely|.|is (l_dobj) methamphetamine_10\NN\2704153|decrease|dopamine|that (l_acl) meth)-induced_12\JJ\0|(|, (l_dobj) toxicity_13\NN\13576101|brain
D004298_D064420 NONE da_24\NNP\10484858|NONE (r_compound) neurotransmission_25\NN\0|NONE (r_pobj) with_23\IN\0|that (r_prep) interfere_22\VBP\2451370|NONE (r_relcl) drugs_20\NNS\14778436|because|toxicity|enhance|, (r_nsubj) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN\13576101|because|drugs|enhance|,
D004298_D064420 NONE da_24\NNP\10484858|NONE (r_compound) neurotransmission_25\NN\0|NONE (r_pobj) with_23\IN\0|that (r_prep) interfere_22\VBP\2451370|NONE (r_relcl) drugs_20\NNS\14778436|because|toxicity|enhance|, (r_nsubj) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_advcl) enhance_35\VB\227165|because|drugs|toxicity|, (l_dobj) toxicity_36\NN\13576101|drugs|whereas
D004298_D064420 NONE da_33\NNP\10484858|NONE (r_compound) neurotransmission_34\NN\0|that (r_dobj) increase_32\VBP\13576355|NONE (r_relcl) drugs_30\NNS\14778436|whereas|toxicity (r_nsubj) enhance_35\VB\227165|because|drugs|toxicity|, (r_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (r_advcl) mediates_9\VBZ\761713|It|widely|.|is (l_dobj) methamphetamine_10\NN\2704153|decrease|dopamine|that (l_acl) meth)-induced_12\JJ\0|(|, (l_dobj) toxicity_13\NN\13576101|brain
D004298_D064420 NONE da_33\NNP\10484858|NONE (r_compound) neurotransmission_34\NN\0|that (r_dobj) increase_32\VBP\13576355|NONE (r_relcl) drugs_30\NNS\14778436|whereas|toxicity (r_nsubj) enhance_35\VB\227165|because|drugs|toxicity|, (r_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN\13576101|because|drugs|enhance|,
D004298_D064420 NONE da_33\NNP\10484858|NONE (r_compound) neurotransmission_34\NN\0|that (r_dobj) increase_32\VBP\13576355|NONE (r_relcl) drugs_30\NNS\14778436|whereas|toxicity (r_nsubj) enhance_35\VB\227165|because|drugs|toxicity|, (l_dobj) toxicity_36\NN\13576101|drugs|whereas
D008694_D064420 NONE methamphetamine_10\NN\2704153|decrease|dopamine|that (l_acl) meth)-induced_12\JJ\0|(|, (l_dobj) toxicity_13\NN\13576101|brain
D008694_D064420 NONE methamphetamine_10\NN\2704153|decrease|dopamine|that (r_dobj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN\13576101|because|drugs|enhance|,
D008694_D064420 NONE methamphetamine_10\NN\2704153|decrease|dopamine|that (r_dobj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_advcl) enhance_35\VB\227165|because|drugs|toxicity|, (l_dobj) toxicity_36\NN\13576101|drugs|whereas
D008694_D064420 NONE meth)-induced_12\JJ\0|(|, (l_dobj) toxicity_13\NN\13576101|brain
D008694_D064420 NONE meth)-induced_12\JJ\0|(|, (r_acl) methamphetamine_10\NN\2704153|decrease|dopamine|that (r_dobj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_dobj) toxicity_27\NN\13576101|because|drugs|enhance|,
D008694_D064420 NONE meth)-induced_12\JJ\0|(|, (r_acl) methamphetamine_10\NN\2704153|decrease|dopamine|that (r_dobj) mediates_9\VBZ\761713|It|widely|.|is (l_advcl) decrease_26\NN\7296428|dopamine|that|methamphetamine (l_advcl) enhance_35\VB\227165|because|drugs|toxicity|, (l_dobj) toxicity_36\NN\13576101|drugs|whereas
15517007
D018943_D006331 NONE anthracyclines_8\NNS\0|or (r_conj) cyclophosphamide_6\NN\0|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN\0|caution|,|is|However|. (l_prep) in_14\IN\13603305|are|patients|cyclophosphamide|for|,|when|, (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) damage_21\NN\7296428|NONE
D008942_D012595 NONE mitoxantrone_11\NN\0|such (r_pobj) as_10\IN\14622893|NONE (r_prep) anthracyclines_8\NNS\0|or (r_conj) cyclophosphamide_6\NN\0|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN\0|caution|,|is|However|. (l_dobj) patients_28\NNS\9898892|in|are|cyclophosphamide|for|,|when|, (l_compound) sclerosis_27\NN\14204950|systemic
D003520_D006331 CID cyclophosphamide_6\NN\0|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN\0|caution|,|is|However|. (l_prep) in_14\IN\13603305|are|patients|cyclophosphamide|for|,|when|, (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) damage_21\NN\7296428|NONE
D018943_D012595 NONE anthracyclines_8\NNS\0|or (r_conj) cyclophosphamide_6\NN\0|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN\0|caution|,|is|However|. (l_dobj) patients_28\NNS\9898892|in|are|cyclophosphamide|for|,|when|, (l_compound) sclerosis_27\NN\14204950|systemic
D008942_D006331 CID mitoxantrone_11\NN\0|such (r_pobj) as_10\IN\14622893|NONE (r_prep) anthracyclines_8\NNS\0|or (r_conj) cyclophosphamide_6\NN\0|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN\0|caution|,|is|However|. (l_prep) in_14\IN\13603305|are|patients|cyclophosphamide|for|,|when|, (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) damage_21\NN\7296428|NONE
D003520_D012595 NONE cyclophosphamide_6\NN\0|in|are|patients|for|,|when|, (r_nsubjpass) used_13\VBN\0|caution|,|is|However|. (l_dobj) patients_28\NNS\9898892|in|are|cyclophosphamide|for|,|when|, (l_compound) sclerosis_27\NN\14204950|systemic
16157917
C047781_C562694 NONE lamotrigine_0\NNP\0|NONE (l_acl) associated_1\VBD\628491|. (l_prep) with_2\IN\0|NONE (l_pobj) exacerbation_3\NN\374224|NONE (l_prep) in_8\IN\13603305|or|myoclonus (l_pobj) epilepsies_11\NNS\14085708|NONE
C047781_C562694 NONE lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_nsubj) patients_1\NNS\9898892|with|experienced|. (l_prep) with_2\IN\0|Five (l_pobj) epilepsies_5\NNS\14085708|NONE
C047781_C562694 NONE lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_nsubj) patients_1\NNS\9898892|with|experienced|. (l_prep) with_2\IN\0|Five (l_pobj) epilepsies_5\NNS\14085708|NONE (l_appos) ige_7\NNP\15030481|)|generalized|idiopathic|(
C047781_C562694 NONE ltg_13\NNP\0|(|) (r_appos) lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_nsubj) patients_1\NNS\9898892|with|experienced|. (l_prep) with_2\IN\0|Five (l_pobj) epilepsies_5\NNS\14085708|NONE
C047781_C562694 NONE ltg_13\NNP\0|(|) (r_appos) lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_nsubj) patients_1\NNS\9898892|with|experienced|. (l_prep) with_2\IN\0|Five (l_pobj) epilepsies_5\NNS\14085708|NONE (l_appos) ige_7\NNP\15030481|)|generalized|idiopathic|(
C047781_D009207 CID lamotrigine_0\NNP\0|NONE (l_acl) associated_1\VBD\628491|. (l_prep) with_2\IN\0|NONE (l_pobj) exacerbation_3\NN\374224|NONE (l_conj) myoclonus_7\NN\14360459|or|in
C047781_D009207 CID lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_advcl) experienced_15\VBD\2108377|with|.|patients (l_dobj) exacerbation_16\NN\374224|NONE (l_conj) appearance_20\NN\4723816|or (l_prep) of_21\IN\0|novo|de (l_pobj) jerks_23\NNS\10322238|NONE
C047781_D009207 CID lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_advcl) experienced_15\VBD\2108377|with|.|patients (l_dobj) exacerbation_16\NN\374224|NONE (l_conj) appearance_20\NN\4723816|or (l_prep) of_21\IN\0|novo|de (l_pobj) jerks_23\NNS\10322238|NONE (l_appos) mj_25\NNP\0|(|)|myoclonic
C047781_D009207 CID ltg_13\NNP\0|(|) (r_appos) lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_advcl) experienced_15\VBD\2108377|with|.|patients (l_dobj) exacerbation_16\NN\374224|NONE (l_conj) appearance_20\NN\4723816|or (l_prep) of_21\IN\0|novo|de (l_pobj) jerks_23\NNS\10322238|NONE
C047781_D009207 CID ltg_13\NNP\0|(|) (r_appos) lamotrigine_11\NNP\0|NONE (r_pobj) with_10\IN\0|experienced|.|patients (r_prep) treated_9\VBN\2376958|NONE (l_advcl) experienced_15\VBD\2108377|with|.|patients (l_dobj) exacerbation_16\NN\374224|NONE (l_conj) appearance_20\NN\4723816|or (l_prep) of_21\IN\0|novo|de (l_pobj) jerks_23\NNS\10322238|NONE (l_appos) mj_25\NNP\0|(|)|myoclonic
C047781_D009207 CID ltg_4\NNP\0|in|MJ|In|.|, (r_nsubj) exacerbated_5\VBD\126264|NONE (l_dobj) mj_6\NNP\0|in|In|.|LTG|,
C047781_D009207 CID ltg_3\NNP\0|NONE (r_compound) dose_4\NN\3740161|was|when|by (r_nsubjpass) decreased_6\VBN\169651|MJ|. (r_advcl) disappeared_1\VBD\0|NONE (l_nsubj) mj_0\NNP\0|.|decreased
C047781_D009207 CID ltg_4\NNP\0|MJ|,|in|,|In|.|with (r_nsubj) exacerbated_5\VBD\126264|NONE (l_dobj) mj_6\NNP\0|,|LTG|in|,|In|.|with
C047781_D009207 CID ltg_4\NNP\0|MJ|,|in|,|In|.|with (r_nsubj) exacerbated_5\VBD\126264|NONE (l_prep) with_15\IN\0|MJ|,|LTG|in|,|In|. (l_pobj) status_17\NN\24720|NONE
C047781_D009207 CID ltg_22\NNP\0|NONE (r_compound) withdrawal_23\NN\7206096|NONE (r_pobj) after_21\IN\0|that|only (r_prep) ceased_20\VBD\0|myoclonic (r_relcl) status_17\NN\24720|NONE (r_pobj) with_15\IN\0|MJ|,|LTG|in|,|In|. (r_prep) exacerbated_5\VBD\126264|NONE (l_dobj) mj_6\NNP\0|,|LTG|in|,|In|.|with
C047781_D009207 CID ltg_22\NNP\0|NONE (r_compound) withdrawal_23\NN\7206096|NONE (r_pobj) after_21\IN\0|that|only (r_prep) ceased_20\VBD\0|myoclonic (r_relcl) status_17\NN\24720|NONE
12911170
D002939_D000744 NONE ciprofloxacin_0\NNP\2716866|nephritis|.| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) nephritis_5\NN\14113228|.|Ciprofloxacin| (l_conj) anemia_9\NN\14189204|interstitial|acute|and
D002939_D000744 NONE ciprofloxacin_9\NNS\2716866| (r_npadvmod) induced_11\VBN\1627355|and|anemia|interstitial (r_amod) nephritis_13\NN\14113228|NONE (l_conj) anemia_17\NN\14189204|and|induced|interstitial
D002939_D000743 CID ciprofloxacin_0\NNP\2716866|been|has|.|with (r_nsubjpass) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|been|has|.|Ciprofloxacin (l_pobj) effects_7\NNS\13245626|NONE (l_prep) including_8\VBG\0|several|side (l_pobj) nephritis_10\NN\14113228|NONE (l_conj) anemia_13\NN\14189204|and|interstitial
D002939_D009395 CID ciprofloxacin_0\NNP\2716866|nephritis|.| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) nephritis_5\NN\14113228|.|Ciprofloxacin|
D002939_D009395 CID ciprofloxacin_0\NNP\2716866|been|has|.|with (r_nsubjpass) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|been|has|.|Ciprofloxacin (l_pobj) effects_7\NNS\13245626|NONE (l_prep) including_8\VBG\0|several|side (l_pobj) nephritis_10\NN\14113228|NONE
D002939_D009395 CID ciprofloxacin_9\NNS\2716866| (r_npadvmod) induced_11\VBN\1627355|and|anemia|interstitial (r_amod) nephritis_13\NN\14113228|NONE
D013256_D000743 NONE steroid_10\NN\14727670|NONE (r_compound) therapy_11\NN\657604|NONE (r_pobj) of_9\IN\0|NONE (r_prep) initiation_8\NN\7450842|and|the (r_conj) drug_6\NN\14778436|NONE (r_dobj) stopping_4\VBG\3323703|NONE (r_pcomp) after_3\IN\0|.|anemia (r_prep) improved_2\VBD\126264|NONE (l_nsubj) anemia_1\NN\14189204|after|.
2886572
D004837_D006973 CID epinephrine_7\NN\14807929| (r_npadvmod) induced_9\VBN\1627355|hypertensive (r_amod) rats_11\NNS\2329401|NONE (l_amod) hypertensive_10\JJ\10405694|induced
2322844
D015232_D006930 CID e2_1\NNP\0|lasted|,|effect|but (r_nsubj) showed_2\VBD\2137132|NONE (l_dobj) effect_5\NN\34213|lasted|,|E|but (l_amod) hyperalgesic_4\JJ\0|a|at
D015232_D006930 CID e2-induced_3\NNP\0|prostaglandin (r_amod) hyperalgesia_4\NN\0|but|,|was|Conversely|by|by|.
D015232_D006930 CID e2_9\NNP\0|both|prostaglandin|and (r_conj) d2_6\NN\0|hyperalgesia|that|in|but|, (r_nsubj) exert_10\VBP\1158872|results|. (l_dobj) hyperalgesia_11\NN\0|that|in|D|but|,
C053876_D006930 NONE ah6809_28\NN\0|not (r_pobj) by_27\IN\0|by|effect|was|.|but (r_agent) blocked_7\VBN\1476483|NONE (l_nsubjpass) effect_2\NN\34213|by|was|.|but|by (l_amod) hyperalgesic_1\JJ\0|The|of
C053876_D006930 NONE ah6809_8\NN\0|NONE (r_pobj) by_7\IN\0|but|,|was|Conversely|hyperalgesia|by|. (r_agent) blocked_6\VBN\1476483|NONE (l_nsubjpass) hyperalgesia_4\NN\0|but|,|was|Conversely|by|by|.
D011453_D006930 NONE pg_10\NN\0|NONE (r_pobj) of_8\IN\0|to (r_prep) doses_7\NNS\3740161|NONE (r_pobj) at_6\IN\14622893|a|hyperalgesic (r_prep) effect_5\NN\34213|lasted|,|E|but (l_amod) hyperalgesic_4\JJ\0|a|at
D015237_D010146 NONE alpha_2\NN\6828818|effect|. (r_nsubj) had_3\VBD\0|NONE (l_dobj) effect_5\NN\34213|alpha|. (l_prep) on_6\IN\0|little (l_pobj) responses_8\NNS\11410625|NONE (l_compound) pain_7\NN\14299637|NONE
D019342_D010146 NONE acid_21\NN\14818238|hot|and (r_conj) plate_18\NN\2797881|writhing (r_dobj) using_16\VBG\418025|NONE (r_pcomp) by_15\IN\0|effects|were|. (r_prep) evaluated_14\VBN\670261|NONE (l_nsubjpass) effects_1\NNS\13245626|by|were|. (l_prep) on_7\IN\0|of|The (l_pobj) responses_9\NNS\11410625|NONE (l_compound) pain_8\NN\14299637|in
D011453_D010146 NONE prostaglandins_6\NNS\5414534|NONE (r_pobj) of_5\IN\0|intrathecal (r_prep) administration_4\NN\1133281|NONE (r_pobj) of_2\IN\0|The|on (r_prep) effects_1\NNS\13245626|by|were|. (l_prep) on_7\IN\0|of|The (l_pobj) responses_9\NNS\11410625|NONE (l_compound) pain_8\NN\14299637|in
D015230_D006930 CID d2_1\NN\0|during|action|. (r_nsubj) had_10\VBD\0|NONE (l_dobj) action_13\NN\30358|D|during|. (l_amod) hyperalgesic_12\JJ\0|a|on
D015230_D006930 CID d2_32\NN\0|NONE (r_pobj) of_30\IN\0|NONE (r_prep) that_29\DT\0|NONE (r_pobj) than_28\IN\0|shorter|)|(| (r_prep) min_26\NN\15154774|effect|. (r_dobj) lasted_20\VBD\2704349|,|E|effect|but (r_conj) showed_2\VBD\2137132|NONE (l_dobj) effect_5\NN\34213|lasted|,|E|but (l_amod) hyperalgesic_4\JJ\0|a|at
D015230_D006930 CID d2_5\NN\0|NONE (r_pobj) of_3\IN\0|hyperalgesic|The (r_prep) effect_2\NN\34213|by|was|.|but|by (l_amod) hyperalgesic_1\JJ\0|The|of
D015230_D006930 CID d2_6\NN\0|hyperalgesia|that|in|but|, (r_nsubj) exert_10\VBP\1158872|results|. (l_dobj) hyperalgesia_11\NN\0|that|in|D|but|,
6150641
D002927_D006402 NONE cimetidine_5\NN\14778019|NONE (r_pobj) of_4\IN\0|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D002927_D006402 NONE cimetidine_60\NN\14778019|NONE (r_compound) therapy_61\NN\657604|NONE (r_pobj) with_59\IN\0|than (r_prep) seen_58\VBN\2106506|a|lower|creatinine (r_advcl) level_56\NN\4916342|NONE (r_pobj) with_50\IN\0|.|therapy|was (r_prep) associated_49\VBN\628491|,|was|but|Treatment|not|with (r_conj) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D002927_D007172 CID cimetidine_12\NN\14778019|while|and|disappeared (r_dobj) taking_11\VBG\37396|changes|percent|. (r_advcl) developed_5\VBD\1753788|NONE (l_dobj) changes_7\NNS\7283608|taking|percent|. (l_conj) impotence_9\NN\4723816|breast|or
D002927_D007172 CID cimetidine_21\NN\14778019|was|by|when (r_nsubjpass) replaced_23\VBN\1631072|changes|in (r_advcl) disappeared_19\VBD\0|while|cimetidine|and (r_conj) taking_11\VBG\37396|changes|percent|. (r_advcl) developed_5\VBD\1753788|NONE (l_dobj) changes_7\NNS\7283608|taking|percent|. (l_conj) impotence_9\NN\4723816|breast|or
D002927_D056486 NONE cimetidine_5\NN\14778019|NONE (r_pobj) of_4\IN\0|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D002927_D056486 NONE cimetidine_60\NN\14778019|NONE (r_compound) therapy_61\NN\657604|NONE (r_pobj) with_59\IN\0|than (r_prep) seen_58\VBN\2106506|a|lower|creatinine (r_advcl) level_56\NN\4916342|NONE (r_pobj) with_50\IN\0|.|therapy|was (r_prep) associated_49\VBN\628491|,|was|but|Treatment|not|with (r_conj) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D003404_D006402 NONE creatinine_55\NN\0|a|lower|seen (r_compound) level_56\NN\4916342|NONE (r_pobj) with_50\IN\0|.|therapy|was (r_prep) associated_49\VBN\628491|,|was|but|Treatment|not|with (r_conj) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D003404_D056486 NONE creatinine_55\NN\0|a|lower|seen (r_compound) level_56\NN\4916342|NONE (r_pobj) with_50\IN\0|.|therapy|was (r_prep) associated_49\VBN\628491|,|was|but|Treatment|not|with (r_conj) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D011899_D056486 NONE ranitidine_18\NN\14778019|,|months|)|or (r_conj) median_12\NN\6021761|(|months|; (r_conj) cimetidine_5\NN\14778019|NONE (r_pobj) of_4\IN\0|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D011899_D056486 NONE ranitidine_46\NN\14778019|NONE (r_compound) therapy_47\NN\657604|.|with|was (r_nsubjpass) associated_49\VBN\628491|,|was|but|Treatment|not|with (r_conj) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D011899_D007172 NONE ranitidine_25\NN\14778019|NONE (r_pobj) by_24\IN\0|cimetidine|was|when (r_agent) replaced_23\VBN\1631072|changes|in (r_advcl) disappeared_19\VBD\0|while|cimetidine|and (r_conj) taking_11\VBG\37396|changes|percent|. (r_advcl) developed_5\VBD\1753788|NONE (l_dobj) changes_7\NNS\7283608|taking|percent|. (l_conj) impotence_9\NN\4723816|breast|or
D011899_D006402 NONE ranitidine_18\NN\14778019|,|months|)|or (r_conj) median_12\NN\6021761|(|months|; (r_conj) cimetidine_5\NN\14778019|NONE (r_pobj) of_4\IN\0|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|,|was|but|associated|not|with (r_nsubjpass) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
D011899_D006402 NONE ranitidine_46\NN\14778019|NONE (r_compound) therapy_47\NN\657604|.|with|was (r_nsubjpass) associated_49\VBN\628491|,|was|but|Treatment|not|with (r_conj) associated_32\VBN\628491|NONE (l_prep) with_33\IN\0|,|was|but|associated|Treatment|not (l_pobj) toxicity_37\NN\13576101|NONE
15075188
D011692_D001201 CID pan_4\NNP\3101986|NONE (r_compound) treatment_5\NN\654885|proteinuria|After|, (r_nsubj) induced_6\VBD\1627355|.|,|excretion (r_advcl) decreased_12\VBD\169651|NONE (l_dobj) excretion_15\NN\13466586|.|,|induced (l_conj) ascites_19\NNS\14204950|,|sodium|and
D012964_D001201 NONE sodium_14\NN\14625458|,|and|ascites (r_compound) excretion_15\NN\13466586|.|,|induced (l_conj) ascites_19\NNS\14204950|,|sodium|and
D012964_D004487 NONE sodium_6\NN\14625458|and|edema (r_compound) retention_7\NN\809465|NONE (l_conj) edema_10\NN\14315192|and|sodium
D012964_D009404 NONE sodium_6\NN\14625458|and|edema (r_compound) retention_7\NN\809465|NONE (r_pobj) by_5\IN\0|often|.|syndrome|is (r_agent) accompanied_4\VBN\0|NONE (l_nsubjpass) syndrome_1\NN\5870365|often|.|by|is
D012964_D009404 NONE sodium_34\NN\14625458|the|associated (r_compound) retention_35\NN\809465|NONE (l_acl) associated_36\VBN\628491|sodium|the (l_prep) with_37\IN\0|NONE (l_pobj) syndrome_42\NN\5870365|NONE
D011692_D034141 CID pan_4\NNP\3101986|NONE (r_compound) treatment_5\NN\654885|proteinuria|After|, (r_nsubj) induced_6\VBD\1627355|.|,|excretion (l_dobj) proteinuria_8\NN\14299637|treatment|After|, (l_appos) hypoalbuminemia_10\NN\0|,|significant
D012964_D011507 NONE sodium_14\NN\14625458|,|and|ascites (r_compound) excretion_15\NN\13466586|.|,|induced (r_dobj) decreased_12\VBD\169651|NONE (l_advcl) induced_6\VBD\1627355|.|,|excretion (l_dobj) proteinuria_8\NN\14299637|treatment|After|,
D012964_D034141 NONE sodium_14\NN\14625458|,|and|ascites (r_compound) excretion_15\NN\13466586|.|,|induced (r_dobj) decreased_12\VBD\169651|NONE (l_advcl) induced_6\VBD\1627355|.|,|excretion (l_dobj) proteinuria_8\NN\14299637|treatment|After|, (l_appos) hypoalbuminemia_10\NN\0|,|significant
D011692_D009404 CID aminonucleoside_11\RB\0| (r_advmod) induced_13\VBN\1627355|puromycin|nephrotic|in (r_amod) syndrome_15\NN\5870365|NONE
D011692_D009404 CID pan_38\NNP\3101986| (r_npadvmod) induced_40\VBN\1627355|nephrotic (r_amod) syndrome_42\NN\5870365|NONE
D011692_D011507 CID pan_4\NNP\3101986|NONE (r_compound) treatment_5\NN\654885|proteinuria|After|, (r_nsubj) induced_6\VBD\1627355|.|,|excretion (l_dobj) proteinuria_8\NN\14299637|treatment|After|,
16006300
C019248_D006934 NONE pamidronate_0\JJ\0|NONE (r_compound) treatment_1\NN\654885|is|,|in|with|. (r_nsubjpass) associated_3\VBN\628491|NONE (l_prep) in_11\IN\13603305|is|,|with|treatment|. (l_pobj) cases_12\NNS\7283608|even (l_prep) of_13\IN\0|NONE (l_pobj) hypercalcemia_16\NN\14299637|NONE
D002118_D006934 NONE calcium_18\NN\14625458|>|(|and|review (r_dobj) corrected_16\VBN\138508|We|.|data (r_parataxis) report_1\VBP\6470073|NONE (l_dobj) data_6\NNS\7951464|We|.|corrected (l_prep) in_7\IN\13603305|the|clinical (l_pobj) patients_9\NNS\9898892|NONE (l_relcl) presented_11\VBD\2137132| (l_prep) with_12\IN\0|who (l_pobj) hypercalcemia_14\NN\14299637|NONE
D002118_D006934 NONE calcium_18\NN\14625458|>|(|and|review (r_dobj) corrected_16\VBN\138508|We|.|data (l_conj) review_28\VB\5733583|>|(|calcium|and (l_dobj) literature_31\NN\6362953|NONE (l_prep) on_32\IN\0|pertinent|the (l_pobj) syndrome_36\NN\5870365|NONE
D002119_D064420 NONE carbonate_1\NN\15010703|:|syndrome|. (r_compound) toxicity_2\NN\13576101|NONE
C019248_D006996 CID pamidronate_10\JJ\0|NONE (l_relcl) caused_22\VBD\1617192|.|mg|intravenously|patients|, (l_dobj) hypocalcemia_24\NN\14299637|which
C019248_D006996 CID pamidronate_0\JJ\0|NONE (r_compound) treatment_1\NN\654885|is|,|in|with|. (r_nsubjpass) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|is|,|in|treatment|. (l_pobj) risk_6\NN\14541044|NONE (l_prep) for_7\IN\0|considerable (l_pobj) hypocalcemia_8\NN\14299637|NONE
D002119_D006934 CID carbonate_1\NN\15010703|:|syndrome|. (r_compound) toxicity_2\NN\13576101|NONE (l_appos) syndrome_9\NN\5870365|carbonate|:|.
D002119_D006934 CID carbonate_6\NN\15010703| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) hypercalcemia_9\NN\14299637|NONE
D002119_D006934 CID carbonate_6\NN\15010703| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) hypercalcemia_9\NN\14299637|NONE (r_pobj) with_4\IN\0| (r_prep) patients_3\NNS\9898892|gain|and|.|To (r_dobj) describe_1\VB\1001294|NONE (l_conj) gain_11\VB\13576355|patients|and|.|To (l_dobj) insights_12\NNS\5710020|NONE (l_prep) into_13\IN\0|NONE (l_pobj) cause_15\NN\7323922|NONE (l_prep) of_18\IN\0|and|management|the (l_pobj) syndrome_23\NN\5870365|NONE
D002119_D006934 CID carbonate_23\NN\15010703|NONE (r_pobj) of_19\IN\0|in|small (r_prep) amounts_18\NNS\13329641|NONE (r_pobj) by_16\IN\0|can|be (r_agent) precipitated_15\VBN\1642924|cause|and|.|may|syndrome (r_conj) be_5\VB\14625458|NONE (l_nsubj) syndrome_3\NN\5870365|precipitated|cause|and|.|may
D002119_D006934 CID carbonate_23\NN\15010703|NONE (r_pobj) of_19\IN\0|in|small (r_prep) amounts_18\NNS\13329641|NONE (r_pobj) by_16\IN\0|can|be (r_agent) precipitated_15\VBN\1642924|cause|and|.|may|syndrome (r_conj) be_5\VB\14625458|NONE (l_attr) cause_8\NN\7323922|precipitated|and|.|may|syndrome (l_prep) of_9\IN\0|common|a (l_pobj) hypercalcemia_11\NN\14299637|NONE
D002118_D006996 NONE calcium_7\NN\14625458|higher|received|the (r_compound) concentrations_8\NNS\4916342|NONE (r_pobj) with_3\IN\0|The| (r_prep) patients_2\NNS\9898892|.|mg|intravenously|caused|, (r_nsubj) pamidronate_10\JJ\0|NONE (l_relcl) caused_22\VBD\1617192|.|mg|intravenously|patients|, (l_dobj) hypocalcemia_24\NN\14299637|which
C097949_D000471 NONE d_27\JJ\15089472|NONE (r_compound) concentrations_28\NNS\4916342|,|and|related (r_conj) peptide_23\NN\14724264|(|,|low|PTH|parathyroid|) (r_conj) hormone_15\NN\5404728|metabolic|,|relative|and (r_conj) alkalosis_10\NN\14204950|acute|renal|,
C097949_D058186 NONE d_27\JJ\15089472|NONE (r_compound) concentrations_28\NNS\4916342|,|and|related (r_conj) peptide_23\NN\14724264|(|,|low|PTH|parathyroid|) (r_conj) hormone_15\NN\5404728|metabolic|,|relative|and (r_conj) alkalosis_10\NN\14204950|acute|renal|, (r_conj) insufficiency_6\NN\14462946|patients|.
3115150
D015760_D009127 CID alfentanil_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|muscle (r_amod) rigidity_7\NN\5023233|pretreatment|.
D015760_D009127 CID alfentanil_29\NN\0|pretreatment|significantly|.|rigidity (r_advcl) attenuated_14\VBD\224901|NONE (l_dobj) rigidity_17\NN\5023233|alfentanil|pretreatment|significantly|.
D015760_D009127 CID alfentanil_15\NNS\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) produced_13\VBN\1617192|the (r_acl) rigidity_12\NN\5023233|to|significantly
D015760_D009127 CID alfentanil_19\NNS\0|NONE (r_pobj) by_18\IN\0|,|Despite|animals (r_agent) followed_17\VBN\1835496|.|motionless (l_prep) despite_0\IN\7501545|by|,|animals (l_pobj) absence_2\NN\14449405|NONE (l_prep) of_3\IN\0|the (l_pobj) rigidity_4\NN\5023233|NONE
D015760_D009127 CID alfentanil_35\NN\0|alone (r_advmod) receiving_34\VBG\2210855|NONE (r_acl) animals_33\NNS\4475|than (r_nsubj) were_32\VBD\0|less|to (r_advcl) responsive_27\JJ\0|,|,|and (r_conj) flaccid_23\JJ\0|NONE (r_conj) motionless_21\JJ\0|.|followed (r_acomp) were_20\VBD\0|NONE (l_csubj) followed_17\VBN\1835496|.|motionless (l_prep) despite_0\IN\7501545|by|,|animals (l_pobj) absence_2\NN\14449405|NONE (l_prep) of_3\IN\0|the (l_pobj) rigidity_4\NN\5023233|NONE
D007650_D009127 NONE ketanserin_0\JJ\0|NONE (r_compound) pretreatment_1\NN\0|rigidity|. (r_nsubj) reverses_2\VBZ\13854649|NONE (l_dobj) rigidity_7\NN\5023233|pretreatment|.
D007650_D009127 NONE ketanserin_3\NN\0|NONE (r_pobj) with_2\IN\0|antagonist|,|,|Systemic (r_prep) pretreatment_1\NN\0|alfentanil|significantly|.|rigidity (r_nsubj) attenuated_14\VBD\224901|NONE (l_dobj) rigidity_17\NN\5023233|alfentanil|pretreatment|significantly|.
D007650_D009127 NONE ketanserin_9\JJ\0|that (r_dobj) received_8\VBD\2210855|mg/kg (r_relcl) animals_6\NNS\4475|by|,|Despite (r_nsubj) followed_17\VBN\1835496|.|motionless (l_prep) despite_0\IN\7501545|by|,|animals (l_pobj) absence_2\NN\14449405|NONE (l_prep) of_3\IN\0|the (l_pobj) rigidity_4\NN\5023233|NONE
D012701_D002318 NONE serotonin_3\NN\14807737|NONE (r_compound) antagonists_4\NNS\7846|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|.|,|may|useful|be (r_nsubj) be_6\VB\14625458|NONE (l_advcl) be_20\VB\14625458|Pretreatment|.|,|may|useful (l_xcomp) assess_23\VB\5220461|studies|although|will|necessary (l_dobj) interaction_25\NN\37396|to (l_prep) of_26\IN\0|the (l_pobj) cns_29\NNP\5237227|NONE (l_conj) cardiovascular_31\JJ\0|,|enhanced (l_conj) depression_35\NN\14373582|and|,
D002707_D009127 NONE chlordiazepoxide_0\VB\2830852|.|influence (r_nsubj) failed_7\VBD\0|NONE (l_xcomp) influence_10\VB\5190804|.|Chlordiazepoxide (l_dobj) rigidity_12\NN\5023233|to|significantly
D012701_D009127 NONE serotonin_9\NN\14807737|specific|receptor|a (r_compound) antagonist_11\NN\7846|,|,|with|Systemic (r_appos) pretreatment_1\NN\0|alfentanil|significantly|.|rigidity (r_nsubj) attenuated_14\VBD\224901|NONE (l_dobj) rigidity_17\NN\5023233|alfentanil|pretreatment|significantly|.
D012701_D009127 NONE serotonin_3\NN\14807737|NONE (r_compound) antagonists_4\NNS\7846|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|.|,|may|useful|be (r_nsubj) be_6\VB\14625458|NONE (l_acomp) useful_8\JJ\0|Pretreatment|.|,|may|be (l_prep) in_9\IN\13603305|clinically (l_pcomp) attenuating_10\VBG\224901|NONE (l_dobj) rigidity_14\NN\5023233|NONE
D012701_D012131 NONE serotonin_3\NN\14807737|NONE (r_compound) antagonists_4\NNS\7846|NONE (r_pobj) with_1\IN\0|NONE (r_prep) pretreatment_0\NN\0|.|,|may|useful|be (r_nsubj) be_6\VB\14625458|NONE (l_advcl) be_20\VB\14625458|Pretreatment|.|,|may|useful (l_xcomp) assess_23\VB\5220461|studies|although|will|necessary (l_dobj) interaction_25\NN\37396|to (l_prep) of_26\IN\0|the (l_pobj) cns_29\NNP\5237227|NONE (l_conj) cardiovascular_31\JJ\0|,|enhanced (l_conj) depression_35\NN\14373582|and|,
18513945
D010121_D007022 CID oxytocin_0\NN\5407119|uterotonic|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) uterotonic_5\NN\0|.|Oxytocin (l_relcl) cause_8\VB\7323922|a|used (l_dobj) hypotension_13\NN\14057371|that|can|,|given
D010121_D007022 CID oxytocin_0\NN\5407119| (r_npadvmod) induced_2\VBN\1627355|at (r_amod) hypotension_3\NN\14057371|incorrectly|may|be|.|to
D010121_D007022 CID oxytocin_4\NN\5407119|NONE (r_pobj) to_3\IN\0|NONE (r_prep) response_2\NN\11410625|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) hypotension_0\NN\14057371|with|was|.
D010121_D020521 NONE oxytocin_4\NN\5407119|NONE (r_pobj) to_3\IN\0|NONE (r_prep) response_2\NN\11410625|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) hypotension_0\NN\14057371|with|was|. (r_nsubjpass) associated_6\VBN\628491|NONE (l_prep) with_7\IN\0|was|Hypotension|. (l_pobj) decrease_9\NN\7296428|NONE (l_conj) increase_17\NN\13576355|in|a|and (l_prep) in_18\IN\13603305|compensatory|a (l_pobj) volume_20\NN\33615|NONE (l_compound) stroke_19\NN\556313|rate|,
D010121_D006473 NONE oxytocin_0\NN\5407119| (r_npadvmod) induced_2\VBN\1627355|at (r_amod) hypotension_3\NN\14057371|incorrectly|may|be|.|to (r_nsubjpass) attributed_10\VBN\670261|NONE (l_prep) to_11\IN\0|incorrectly|hypotension|may|be|. (l_pobj) loss_13\NN\13252973|NONE
2722224
D006854_D006973 CID hydrocortisone_0\NNP\14751417|:||hypertension|responsiveness|. (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) hypertension_3\NN\14057371|:||Hydrocortisone|responsiveness|.
D006854_D006973 CID hydrocortisone_7\NN\14751417|NONE (r_pobj) with_6\IN\0|blood (r_prep) pressure_5\NN\11419404|NONE
D006854_D016534 NONE hydrocortisone_7\NN\14751417|NONE (r_pobj) with_6\IN\0|blood (r_prep) pressure_5\NN\11419404|NONE (r_dobj) resting_3\VBG\2604760|NONE (r_pcomp) in_2\IN\13603305|The (r_prep) rise_1\NN\7324673|.|is|with (r_nsubjpass) associated_9\VBN\628491|NONE (l_prep) with_10\IN\0|rise|.|is (l_pobj) output_14\NN\4007894|NONE
16720068
D000525_D014202 NONE alprazolam_7\NN\2830852|NONE (r_compound) treatment_8\NN\654885|and (r_conj) paroxetine_5\NN\0|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|.|patient|retardation|, (r_prep) exhibited_12\VBD\2632167|NONE (l_dobj) retardation_15\NN\7296428|On|.|patient|, (l_conj) disorientation_17\NN\5896733|marked|,|psychomotor (l_conj) rigidity_22\NN\5023233|and|, (l_prep) with_23\IN\0|severe|muscle (l_pobj) tremors_24\NNS\345926|NONE
D000525_D009127 NONE alprazolam_7\NN\2830852|NONE (r_compound) treatment_8\NN\654885|and (r_conj) paroxetine_5\NN\0|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|.|patient|retardation|, (r_prep) exhibited_12\VBD\2632167|NONE (l_dobj) retardation_15\NN\7296428|On|.|patient|, (l_conj) disorientation_17\NN\5896733|marked|,|psychomotor (l_conj) rigidity_22\NN\5023233|and|,
D017374_D009127 NONE paroxetine_5\NN\0|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|.|patient|retardation|, (r_prep) exhibited_12\VBD\2632167|NONE (l_dobj) retardation_15\NN\7296428|On|.|patient|, (l_conj) disorientation_17\NN\5896733|marked|,|psychomotor (l_conj) rigidity_22\NN\5023233|and|,
D017374_D009459 CID paroxetine_9\NN\0|NONE (r_pobj) with_8\IN\0|concomitant (r_prep) treatment_7\NN\654885|NONE (r_pobj) to_5\IN\0|NONE (r_prep) related_4\VBN\628491|neuroleptic|malignant|Possible|. (r_acl) syndrome_3\NN\5870365|NONE
D017374_D009459 CID paroxetine_24\NN\0|NONE (r_pobj) after_22\IN\0|that|symptoms|can (r_prep) occur_21\VB\0|thus (r_ccomp) demonstrating_14\VBG\2137132|.|with|,|patient (r_advcl) presented_2\VBN\2137132|NONE (l_prep) with_3\IN\0|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS\5823932|NONE (l_prep) of_5\IN\0|NONE (l_pobj) syndrome_8\NN\5870365|NONE
D017374_D009459 CID paroxetine_24\NN\0|NONE (r_pobj) after_22\IN\0|that|symptoms|can (r_prep) occur_21\VB\0|thus (r_ccomp) demonstrating_14\VBG\2137132|.|with|,|patient (r_advcl) presented_2\VBN\2137132|NONE (l_prep) with_3\IN\0|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS\5823932|NONE (l_prep) of_5\IN\0|NONE (l_pobj) syndrome_8\NN\5870365|NONE (l_appos) nms_10\NNP\13649268|malignant|neuroleptic
D017374_D009459 CID paroxetine_24\NN\0|NONE (r_pobj) after_22\IN\0|that|symptoms|can (r_prep) occur_21\VB\0|thus (l_nsubj) symptoms_19\NNS\5823932|that|after|can (l_amod) like_18\JJ\5839024|NONE (l_npadvmod) nms_16\NNP\13649268|
D000525_D009459 CID alprazolam_11\NN\2830852|and (r_conj) paroxetine_9\NN\0|NONE (r_pobj) with_8\IN\0|concomitant (r_prep) treatment_7\NN\654885|NONE (r_pobj) to_5\IN\0|NONE (r_prep) related_4\VBN\628491|neuroleptic|malignant|Possible|. (r_acl) syndrome_3\NN\5870365|NONE
D000525_D009459 CID alprazolam_26\NN\2830852|NONE (r_compound) treatment_27\NN\654885|and|combined (r_conj) paroxetine_24\NN\0|NONE (r_pobj) after_22\IN\0|that|symptoms|can (r_prep) occur_21\VB\0|thus (r_ccomp) demonstrating_14\VBG\2137132|.|with|,|patient (r_advcl) presented_2\VBN\2137132|NONE (l_prep) with_3\IN\0|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS\5823932|NONE (l_prep) of_5\IN\0|NONE (l_pobj) syndrome_8\NN\5870365|NONE
D000525_D009459 CID alprazolam_26\NN\2830852|NONE (r_compound) treatment_27\NN\654885|and|combined (r_conj) paroxetine_24\NN\0|NONE (r_pobj) after_22\IN\0|that|symptoms|can (r_prep) occur_21\VB\0|thus (r_ccomp) demonstrating_14\VBG\2137132|.|with|,|patient (r_advcl) presented_2\VBN\2137132|NONE (l_prep) with_3\IN\0|demonstrating|.|,|patient (l_pobj) symptoms_4\NNS\5823932|NONE (l_prep) of_5\IN\0|NONE (l_pobj) syndrome_8\NN\5870365|NONE (l_appos) nms_10\NNP\13649268|malignant|neuroleptic
D000525_D009459 CID alprazolam_26\NN\2830852|NONE (r_compound) treatment_27\NN\654885|and|combined (r_conj) paroxetine_24\NN\0|NONE (r_pobj) after_22\IN\0|that|symptoms|can (r_prep) occur_21\VB\0|thus (l_nsubj) symptoms_19\NNS\5823932|that|after|can (l_amod) like_18\JJ\5839024|NONE (l_npadvmod) nms_16\NNP\13649268|
D017374_D011596 NONE paroxetine_5\NN\0|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|.|patient|retardation|, (r_prep) exhibited_12\VBD\2632167|NONE (l_dobj) retardation_15\NN\7296428|On|.|patient|,
D017374_D014202 NONE paroxetine_5\NN\0|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|.|patient|retardation|, (r_prep) exhibited_12\VBD\2632167|NONE (l_dobj) retardation_15\NN\7296428|On|.|patient|, (l_conj) disorientation_17\NN\5896733|marked|,|psychomotor (l_conj) rigidity_22\NN\5023233|and|, (l_prep) with_23\IN\0|severe|muscle (l_pobj) tremors_24\NNS\345926|NONE
D000525_D011596 NONE alprazolam_7\NN\2830852|NONE (r_compound) treatment_8\NN\654885|and (r_conj) paroxetine_5\NN\0|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|.|patient|retardation|, (r_prep) exhibited_12\VBD\2632167|NONE (l_dobj) retardation_15\NN\7296428|On|.|patient|,
19721134
D010862_D001145 NONE pilocarpine_9\NN\14712692|NONE (r_pobj) of_8\IN\0|the (r_prep) effects_7\NNS\13245626|to|and|explore (r_dobj) evaluate_5\VB\670261|was|.|study (l_conj) explore_11\VB\789138|to|effects|and (l_conj) using_17\VBG\418025|,|mechanism (l_dobj) rat_22\NN\2329401|NONE (l_conj) models_30\NNS\5888929|induced|both|and (l_compound) arrhythmia_29\NN\14103288|induced
D010862_D001145 NONE pilocarpine_5\NN\14712692|delayed|of|that (r_amod) onset_8\NN\7325190|data (l_prep) of_9\IN\0|delayed|pilocarpine|that (l_pobj) arrhythmias_10\NNS\14103288|NONE
D010862_D001145 NONE pilocarpine_5\NN\14712692|delayed|of|that (r_amod) onset_8\NN\7325190|data (r_dobj) showed_3\VBD\2137132|.|,|,|course|score (r_ccomp) decreased_12\VBD\169651|NONE (l_npadvmod) score_24\NN\5736149|.|showed|,|,|course (l_compound) arrhythmia_23\NN\14103288|reduced|and|increased|,
D010862_D001145 NONE pilocarpine_5\NN\14712692|delayed|of|that (r_amod) onset_8\NN\7325190|data (r_dobj) showed_3\VBD\2137132|.|,|,|course|score (r_ccomp) decreased_12\VBD\169651|NONE (l_npadvmod) score_24\NN\5736149|.|showed|,|,|course (l_conj) increased_27\VBD\169651|reduced|arrhythmia|and|, (l_dobj) time_30\NN\7308889|NONE (l_prep) of_31\IN\0|the|survival (l_pobj) rats_33\NNS\2329401|NONE (l_amod) arrhythmic_32\JJ\0|pigs|and
D010862_D001145 NONE pilocarpine_4\NN\14712692|that|actions (r_nsubj) produced_5\VBD\1617192|.|data (l_dobj) actions_7\NNS\30358|pilocarpine|that (l_prep) on_8\IN\0|antiarrhythmic (l_pobj) models_14\NNS\5888929|NONE (l_nmod) rat_10\NN\2329401|induced|pig (l_amod) arrhythmic_9\JJ\0|and
D010042_D001145 CID ouabain_24\NN\0| (r_npadvmod) induced_26\VBN\1627355|arrhythmia (r_amod) models_30\NNS\5888929|induced|both|and (l_compound) arrhythmia_29\NN\14103288|induced
D010042_D001145 CID ouabain_19\RB\0|or (r_conj) aconitine_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|rat|pig (r_acl) models_14\NNS\5888929|NONE (l_nmod) rat_10\NN\2329401|induced|pig (l_amod) arrhythmic_9\JJ\0|and
D010862_D014693 NONE pilocarpine_5\NN\14712692|delayed|of|that (r_amod) onset_8\NN\7325190|data (r_dobj) showed_3\VBD\2137132|.|,|,|course|score (r_ccomp) decreased_12\VBD\169651|NONE (l_dobj) course_15\NN\883297|.|showed|,|,|score (l_prep) of_16\IN\0|the|time (l_pobj) tachycardia_18\NN\14110674|NONE (l_conj) fibrillation_20\NN\14361664|ventricular|and
D010862_D017180 NONE pilocarpine_5\NN\14712692|delayed|of|that (r_amod) onset_8\NN\7325190|data (r_dobj) showed_3\VBD\2137132|.|,|,|course|score (r_ccomp) decreased_12\VBD\169651|NONE (l_dobj) course_15\NN\883297|.|showed|,|,|score (l_prep) of_16\IN\0|the|time (l_pobj) tachycardia_18\NN\14110674|NONE (l_conj) fibrillation_20\NN\14361664|ventricular|and
D000157_D001145 CID aconitine_19\NN\0| (r_npadvmod) induced_21\VBN\1627355|both|and|models (r_amod) rat_22\NN\2329401|NONE (l_conj) models_30\NNS\5888929|induced|both|and (l_compound) arrhythmia_29\NN\14103288|induced
D000157_D001145 CID aconitine_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|rat|pig (r_acl) models_14\NNS\5888929|NONE (l_nmod) rat_10\NN\2329401|induced|pig (l_amod) arrhythmic_9\JJ\0|and
D002118_D001145 NONE ca(2_34\NNP\0|NONE (r_pobj) of_33\IN\0|the (r_prep) improvement_32\NN\7359599|NONE (r_pobj) to_30\IN\0|may|mechanism|be (r_prep) related_29\VBN\628491|the (r_relcl) cardiac_23\JJ\0|NONE (r_dobj) stimulating_21\VBG\137313|NONE (r_pcomp) via_20\IN\0|NONE (r_prep) ouabain_19\RB\0|or (r_conj) aconitine_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|rat|pig (r_acl) models_14\NNS\5888929|NONE (l_nmod) rat_10\NN\2329401|induced|pig (l_amod) arrhythmic_9\JJ\0|and
21294084
D010406_D004827 NONE penicillin_12\NN\2716866| (r_npadvmod) induced_14\VBN\1627355|epilepsy|in (r_amod) model_16\NN\5888929|NONE (r_pobj) in_11\IN\13603305|epileptic|cortical (r_prep) discharges_10\NNS\7283608|NONE (l_amod) epileptic_9\JJ\10595647|cortical|in
D010406_D004827 NONE penicillin_12\NN\2716866| (r_npadvmod) induced_14\VBN\1627355|epilepsy|in (r_amod) model_16\NN\5888929|NONE (l_compound) epilepsy_15\NN\14085708|induced|in
D010406_D004827 NONE penicillin_17\NN\2716866| (r_npadvmod) induced_19\VBN\1627355|epilepsy (r_amod) model_21\NN\5888929|NONE (r_pobj) in_16\IN\13603305|cortical|epileptic (r_prep) activity_15\NN\30358|NONE (l_amod) epileptic_14\JJ\10595647|cortical|in
D010406_D004827 NONE penicillin_17\NN\2716866| (r_npadvmod) induced_19\VBN\1627355|epilepsy (r_amod) model_21\NN\5888929|NONE (l_compound) epilepsy_20\NN\14085708|induced
D010406_D004827 NONE penicillin_7\NN\2716866| (r_npadvmod) induced_9\VBN\1627355|independent|the|cortical|acute|epileptic (r_amod) activity_12\NN\30358|DBS|. (l_amod) epileptic_11\JJ\10595647|independent|the|cortical|acute|induced
14742097
D020280_D020018 CID sertraline_8\NN\4169152|,|either (r_conj) fluoxetine_6\NN\4169152|NONE (r_dobj) receiving_4\VBG\2210855|dysfunctional|Nineteen (r_acl) women_3\NNS\9605289|in|. (l_amod) dysfunctional_2\JJ\0|receiving|Nineteen
D004809_D020018 NONE ephedrine_10\NN\14712692|NONE (r_pobj) of_9\IN\0|A|,|controlled|.|,|randomized|for|crossover (r_prep) study_8\NN\635850|NONE (l_prep) for_11\IN\0|A|,|controlled|.|of|,|randomized|crossover (l_pobj) dysfunction_17\NN\14204950|NONE
D004809_D020018 NONE ephedrine_9\NN\14712692|effects|whether|, (r_nsubj) has_28\VBZ\13888491|to (l_dobj) effects_30\NNS\13245626|whether|ephedrine|, (l_prep) in_31\IN\13603305|beneficial (l_pcomp) reversing_32\VBG\109660|NONE (l_dobj) dysfunction_37\NN\14204950|NONE
D004809_D020018 NONE ephedrine_35\NN\14712692|NONE (r_pobj) of_34\IN\0|the|on|mg (r_prep) effects_33\NNS\13245626|NONE (r_pobj) of_31\IN\0|blind|cross|controlled|week|,|,|,|an (r_prep) study_30\NN\635850|NONE (r_pobj) in_13\IN\13603305|.|women (r_prep) participated_12\VBD\2367363|NONE (l_nsubj) women_3\NNS\9605289|in|. (l_amod) dysfunctional_2\JJ\0|receiving|Nineteen
D005473_D020018 CID fluoxetine_6\NN\4169152|NONE (r_dobj) receiving_4\VBG\2210855|dysfunctional|Nineteen (r_acl) women_3\NNS\9605289|in|. (l_amod) dysfunctional_2\JJ\0|receiving|Nineteen
D017374_D020018 CID paroxetine_11\NN\0|,|or (r_conj) sertraline_8\NN\4169152|,|either (r_conj) fluoxetine_6\NN\4169152|NONE (r_dobj) receiving_4\VBG\2210855|dysfunctional|Nineteen (r_acl) women_3\NNS\9605289|in|. (l_amod) dysfunctional_2\JJ\0|receiving|Nineteen
11868798
D013148_D009503 NONE spironolactone_9\NN\2721160|NONE (r_pobj) of_8\IN\0|reduce|the (r_prep) ability_7\NN\4723816|to (l_acl) reduce_11\VB\441445|of|the (l_conj) prevent_16\VB\0|to|requirements|and (l_dobj) hypokalemia_17\NN\14299637|to (l_prep) in_18\IN\13603305|NONE (l_pobj) patients_20\NNS\9898892|NONE (l_amod) neutropenic_19\JJ\0|on
D013148_D009503 NONE spironolactone_4\NN\2721160|requirements|and|prevent|that|can (r_nsubj) reduce_6\VB\441445|.|study (l_conj) prevent_10\VBP\0|requirements|and|spironolactone|that|can (l_prep) by_12\IN\0|hypokalemia (l_pcomp) reducing_13\VBG\13447361|NONE (l_dobj) loss_16\NN\13252973|NONE (l_prep) in_17\IN\13603305|potassium|urinary (l_pobj) patients_19\NNS\9898892|NONE (l_amod) neutropenic_18\JJ\0|on
D011188_D007008 NONE potassium_12\NN\14625458|NONE (r_compound) requirements_13\NNS\1129920|to|and|prevent (r_dobj) reduce_11\VB\441445|of|the (l_conj) prevent_16\VB\0|to|requirements|and (l_dobj) hypokalemia_17\NN\14299637|to
D011188_D007008 NONE potassium_7\NN\14625458|NONE (r_compound) requirements_8\NNS\1129920|and|prevent|spironolactone|that|can (r_dobj) reduce_6\VB\441445|.|study (l_conj) prevent_10\VBP\0|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN\14299637|by
D011188_D007008 NONE potassium_15\NN\14625458|in|urinary (r_compound) loss_16\NN\13252973|NONE (r_dobj) reducing_13\VBG\13447361|NONE (r_pcomp) by_12\IN\0|hypokalemia (r_prep) prevent_10\VBP\0|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN\14299637|by
D013148_D007008 NONE spironolactone_0\NNP\2721160|it|drug|:|? (r_npadvmod) is_2\VBZ\0|NONE (l_attr) drug_6\NN\14778436|Spironolactone|it|:|? (l_prep) for_7\IN\0|a|novel (l_pobj) prevention_9\NN\1073995|NONE (l_prep) of_10\IN\0|the (l_pobj) hypokalemia_15\NN\14299637|NONE
D013148_D007008 NONE spironolactone_9\NN\2721160|NONE (r_pobj) of_8\IN\0|reduce|the (r_prep) ability_7\NN\4723816|to (l_acl) reduce_11\VB\441445|of|the (l_conj) prevent_16\VB\0|to|requirements|and (l_dobj) hypokalemia_17\NN\14299637|to
D013148_D007008 NONE spironolactone_4\NN\2721160|requirements|and|prevent|that|can (r_nsubj) reduce_6\VB\441445|.|study (l_conj) prevent_10\VBP\0|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN\14299637|by
D000666_D009369 NONE b_12\NN\1355326| (r_npadvmod) related_14\VBN\628491|in (r_amod) hypokalemia_15\NN\14299637|NONE (l_prep) in_16\IN\13603305|related (l_pobj) patients_18\NNS\9898892|NONE (l_compound) cancer_17\NN\14239425|NONE
D000666_D009503 NONE amb_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) on_21\IN\0|neutropenic (r_prep) patients_20\NNS\9898892|NONE (l_amod) neutropenic_19\JJ\0|on
D000666_D009503 NONE amb_21\JJ\0|NONE (r_compound) treatment_22\NN\654885|NONE (r_pobj) on_20\IN\0|neutropenic (r_prep) patients_19\NNS\9898892|NONE (l_amod) neutropenic_18\JJ\0|on
D013148_D006402 NONE spironolactone_21\NN\2721160|alone|either|AmB|or|intravenous (r_conj) amb_15\VB\0|to|twice|developing|daily (r_dobj) receive_12\VB\2210855|patients|were|.|In (r_xcomp) randomized_10\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|were|.|In|receive (l_prep) with_5\IN\0| (l_pobj) disorders_8\NNS\14034177|NONE
D013148_D009369 NONE spironolactone_0\NNP\2721160|it|drug|:|? (r_npadvmod) is_2\VBZ\0|NONE (l_attr) drug_6\NN\14778436|Spironolactone|it|:|? (l_prep) for_7\IN\0|a|novel (l_pobj) prevention_9\NN\1073995|NONE (l_prep) of_10\IN\0|the (l_pobj) hypokalemia_15\NN\14299637|NONE (l_prep) in_16\IN\13603305|related (l_pobj) patients_18\NNS\9898892|NONE (l_compound) cancer_17\NN\14239425|NONE
D000666_D007674 NONE b_9\NNP\1355326|NONE (r_pobj) of_7\IN\0|major|the|adverse (r_prep) effect_6\NN\34213|,|Nephrotoxicity|.|:|limiting (r_attr) is_2\VBZ\0|NONE (l_nsubj) nephrotoxicity_1\NN\0|effect|,|.|:|limiting
D000666_D007674 NONE amb_11\NNP\0|amphotericin (r_appos) b_9\NNP\1355326|NONE (r_pobj) of_7\IN\0|major|the|adverse (r_prep) effect_6\NN\34213|,|Nephrotoxicity|.|:|limiting (r_attr) is_2\VBZ\0|NONE (l_nsubj) nephrotoxicity_1\NN\0|effect|,|.|:|limiting
D000666_D064420 NONE amb._24\NNP\0|NONE (r_compound) potassium_25\NN\14625458|NONE (r_compound) depletion_26\NN\351638|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0|major|side|a (r_prep) effect_20\NN\34213|that (r_attr) is_15\VBZ\0|profound|the|potassium (r_relcl) wasting_13\VBG\14547643|NONE (r_pobj) for_9\IN\0|NONE (r_prep) responsible_8\JJ\0|to (r_acomp) be_7\VB\14625458|toxicity|potentiates (r_xcomp) seems_5\VBZ\2604760|NONE (l_nsubj) toxicity_4\NN\13576101|be|potentiates
D000666_D064420 NONE amb._24\NNP\0|NONE (r_compound) potassium_25\NN\14625458|NONE (r_compound) depletion_26\NN\351638|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0|major|side|a (r_prep) effect_20\NN\34213|that (r_attr) is_15\VBZ\0|profound|the|potassium (r_relcl) wasting_13\VBG\14547643|NONE (r_pobj) for_9\IN\0|NONE (r_prep) responsible_8\JJ\0|to (r_acomp) be_7\VB\14625458|toxicity|potentiates (r_xcomp) seems_5\VBZ\2604760|NONE (l_conj) potentiates_28\VBZ\229605|toxicity|be (l_dobj) toxicity_31\NN\13576101|also
D000666_D064420 NONE amb._33\NN\0|NONE (r_pobj) of_32\IN\0|tubular|the (r_prep) toxicity_31\NN\13576101|also (r_dobj) potentiates_28\VBZ\229605|toxicity|be (r_conj) seems_5\VBZ\2604760|NONE (l_nsubj) toxicity_4\NN\13576101|be|potentiates
D000666_D064420 NONE amb._33\NN\0|NONE (r_pobj) of_32\IN\0|tubular|the (r_prep) toxicity_31\NN\13576101|also
D000666_D007008 CID b_12\NN\1355326| (r_npadvmod) related_14\VBN\628491|in (r_amod) hypokalemia_15\NN\14299637|NONE
D000666_D007008 CID amb_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) on_21\IN\0|neutropenic (r_prep) patients_20\NNS\9898892|NONE (r_pobj) in_18\IN\13603305|NONE (r_prep) hypokalemia_17\NN\14299637|to
D000666_D007008 CID amb_21\JJ\0|NONE (r_compound) treatment_22\NN\654885|NONE (r_pobj) on_20\IN\0|neutropenic (r_prep) patients_19\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|potassium|urinary (r_prep) loss_16\NN\13252973|NONE (r_dobj) reducing_13\VBG\13447361|NONE (r_pcomp) by_12\IN\0|hypokalemia (r_prep) prevent_10\VBP\0|requirements|and|spironolactone|that|can (l_dobj) hypokalemia_11\NN\14299637|by
D000666_D006402 NONE amb_15\VB\0|to|twice|developing|daily (r_dobj) receive_12\VB\2210855|patients|were|.|In (r_xcomp) randomized_10\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|were|.|In|receive (l_prep) with_5\IN\0| (l_pobj) disorders_8\NNS\14034177|NONE
D000666_D006402 NONE amb_18\JJ\0|alone|either|spironolactone|or|intravenous (r_conj) amb_15\VB\0|to|twice|developing|daily (r_dobj) receive_12\VB\2210855|patients|were|.|In (r_xcomp) randomized_10\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|were|.|In|receive (l_prep) with_5\IN\0| (l_pobj) disorders_8\NNS\14034177|NONE
D011188_D009503 NONE potassium_12\NN\14625458|NONE (r_compound) requirements_13\NNS\1129920|to|and|prevent (r_dobj) reduce_11\VB\441445|of|the (l_conj) prevent_16\VB\0|to|requirements|and (l_dobj) hypokalemia_17\NN\14299637|to (l_prep) in_18\IN\13603305|NONE (l_pobj) patients_20\NNS\9898892|NONE (l_amod) neutropenic_19\JJ\0|on
D011188_D009503 NONE potassium_7\NN\14625458|NONE (r_compound) requirements_8\NNS\1129920|and|prevent|spironolactone|that|can (r_dobj) reduce_6\VB\441445|.|study (l_conj) prevent_10\VBP\0|requirements|and|spironolactone|that|can (l_prep) by_12\IN\0|hypokalemia (l_pcomp) reducing_13\VBG\13447361|NONE (l_dobj) loss_16\NN\13252973|NONE (l_prep) in_17\IN\13603305|potassium|urinary (l_pobj) patients_19\NNS\9898892|NONE (l_amod) neutropenic_18\JJ\0|on
D011188_D009503 NONE potassium_15\NN\14625458|in|urinary (r_compound) loss_16\NN\13252973|NONE (l_prep) in_17\IN\13603305|potassium|urinary (l_pobj) patients_19\NNS\9898892|NONE (l_amod) neutropenic_18\JJ\0|on
D000666_D009181 NONE amb_15\VB\0|to|twice|developing|daily (r_dobj) receive_12\VB\2210855|patients|were|.|In (l_advcl) developing_27\VBG\13541167|to|twice|AmB|daily (l_dobj) infection_33\NN\14052046|when
D000666_D009181 NONE amb_18\JJ\0|alone|either|spironolactone|or|intravenous (r_conj) amb_15\VB\0|to|twice|developing|daily (r_dobj) receive_12\VB\2210855|patients|were|.|In (l_advcl) developing_27\VBG\13541167|to|twice|AmB|daily (l_dobj) infection_33\NN\14052046|when
D013148_D009181 NONE spironolactone_21\NN\2721160|alone|either|AmB|or|intravenous (r_conj) amb_15\VB\0|to|twice|developing|daily (r_dobj) receive_12\VB\2210855|patients|were|.|In (l_advcl) developing_27\VBG\13541167|to|twice|AmB|daily (l_dobj) infection_33\NN\14052046|when
D011188_D064420 NONE potassium_12\NN\14625458|profound|is|the (r_compound) wasting_13\VBG\14547643|NONE (r_pobj) for_9\IN\0|NONE (r_prep) responsible_8\JJ\0|to (r_acomp) be_7\VB\14625458|toxicity|potentiates (r_xcomp) seems_5\VBZ\2604760|NONE (l_nsubj) toxicity_4\NN\13576101|be|potentiates
D011188_D064420 NONE potassium_12\NN\14625458|profound|is|the (r_compound) wasting_13\VBG\14547643|NONE (r_pobj) for_9\IN\0|NONE (r_prep) responsible_8\JJ\0|to (r_acomp) be_7\VB\14625458|toxicity|potentiates (r_xcomp) seems_5\VBZ\2604760|NONE (l_conj) potentiates_28\VBZ\229605|toxicity|be (l_dobj) toxicity_31\NN\13576101|also
D011188_D064420 NONE potassium_25\NN\14625458|NONE (r_compound) depletion_26\NN\351638|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0|major|side|a (r_prep) effect_20\NN\34213|that (r_attr) is_15\VBZ\0|profound|the|potassium (r_relcl) wasting_13\VBG\14547643|NONE (r_pobj) for_9\IN\0|NONE (r_prep) responsible_8\JJ\0|to (r_acomp) be_7\VB\14625458|toxicity|potentiates (r_xcomp) seems_5\VBZ\2604760|NONE (l_nsubj) toxicity_4\NN\13576101|be|potentiates
D011188_D064420 NONE potassium_25\NN\14625458|NONE (r_compound) depletion_26\NN\351638|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0|major|side|a (r_prep) effect_20\NN\34213|that (r_attr) is_15\VBZ\0|profound|the|potassium (r_relcl) wasting_13\VBG\14547643|NONE (r_pobj) for_9\IN\0|NONE (r_prep) responsible_8\JJ\0|to (r_acomp) be_7\VB\14625458|toxicity|potentiates (r_xcomp) seems_5\VBZ\2604760|NONE (l_conj) potentiates_28\VBZ\229605|toxicity|be (l_dobj) toxicity_31\NN\13576101|also
12549952
D016642_D017114 CID bupropion_5\NN\0|NONE (r_pobj) with_3\IN\0|.|Acute|liver (r_prep) failure_2\NN\66216|NONE
D016642_D017114 CID bupropion_9\NN\0|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|of (r_acl) evidence_4\NN\5816287|is (r_dobj) increasing_3\VBG\169651|,|.|case|this (r_advcl) is_12\VBZ\0|NONE (l_attr) case_15\NN\7283608|,|.|increasing|this (l_relcl) resulted_21\VBN\2633881|first|of|the (l_prep) from_22\IN\0|on|could|that|have (l_pobj) failure_25\NN\66216|NONE
D016642_D017114 CID bupropion_30\NN\0|NONE (r_dobj) receiving_29\VBG\2210855|a (r_acl) patient_28\JJ\9898892|NONE (r_pobj) in_26\IN\13603305|liver|acute (r_prep) failure_25\NN\66216|NONE
D016642_D017114 CID bupropion_13\NN\0|NONE (r_pobj) by_12\IN\0|NONE (r_agent) induced_11\VBN\1627355|acute|liver (r_acl) insult_10\NN\6714976|NONE
D016642_D056486 CID bupropion_3\NN\0|in|that|hepatotoxicity (r_nsubj) induced_4\VBD\1627355|The (l_dobj) hepatotoxicity_5\NN\0|in|that|bupropion
D016642_D056486 CID bupropion_9\NN\0|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|of (r_acl) evidence_4\NN\5816287|is (l_prep) of_5\IN\0|induced (l_pobj) hepatotoxicity_6\NN\0|NONE
D016642_D056486 CID bupropion_30\NN\0|NONE (r_dobj) receiving_29\VBG\2210855|a (r_acl) patient_28\JJ\9898892|NONE (r_pobj) in_26\IN\13603305|liver|acute (r_prep) failure_25\NN\66216|NONE (r_pobj) from_22\IN\0|on|could|that|have (r_prep) resulted_21\VBN\2633881|first|of|the (r_relcl) case_15\NN\7283608|,|.|increasing|this (r_attr) is_12\VBZ\0|NONE (l_advcl) increasing_3\VBG\169651|,|.|case|this (l_dobj) evidence_4\NN\5816287|is (l_prep) of_5\IN\0|induced (l_pobj) hepatotoxicity_6\NN\0|NONE
D016642_D056486 CID bupropion_13\NN\0|NONE (l_acl) given_14\VBN\5892096|NONE (l_prep) with_16\IN\0|concurrently (l_pobj) drugs_19\NNS\14778436|NONE (l_amod) hepatotoxic_18\JJ\0|other
D002231_D017093 NONE carbimazole_16\NN\0|and (r_conj) bupropion_14\NN\0|NONE (r_pobj) of_13\IN\0|concurrent (r_prep) use_12\NN\407535|NONE (r_pobj) with_10\IN\0|possibly (r_prep) associated_9\VBN\628491|liver|fatal (r_acl) failure_7\NN\66216|NONE
D011433_D006980 NONE propranolol_17\NN\0|man|had|with|.|and|been (r_conj) treated_13\VBN\2376958|NONE (l_nsubjpass) man_5\NN\9605289|had|with|propranolol|.|and|been (l_prep) with_6\IN\0|Chinese|A|old (l_pobj) history_8\NN\15120823|NONE (l_prep) of_9\IN\0|a (l_pobj) hyperthyroidism_10\NN\14059928|NONE
D002231_D017114 CID carbimazole_7\NN\0|NONE (r_compound) therapy_8\NN\657604|and|concurrent (r_conj) bupropion_5\NN\0|NONE (r_pobj) with_3\IN\0|.|Acute|liver (r_prep) failure_2\NN\66216|NONE
D002231_D017114 CID carbimazole_36\NN\0|NONE (r_pobj) with_35\IN\0|concomitant (r_prep) treatment_34\NN\654885|while (r_pobj) on_32\IN\0|from|could|that|have (r_prep) resulted_21\VBN\2633881|first|of|the (l_prep) from_22\IN\0|on|could|that|have (l_pobj) failure_25\NN\66216|NONE
D002231_D006980 NONE carbimazole_15\NN\0|NONE (r_pobj) with_14\IN\0|man|had|propranolol|.|and|been (r_prep) treated_13\VBN\2376958|NONE (l_nsubjpass) man_5\NN\9605289|had|with|propranolol|.|and|been (l_prep) with_6\IN\0|Chinese|A|old (l_pobj) history_8\NN\15120823|NONE (l_prep) of_9\IN\0|a (l_pobj) hyperthyroidism_10\NN\14059928|NONE
D016642_D017093 NONE bupropion_14\NN\0|NONE (r_pobj) of_13\IN\0|concurrent (r_prep) use_12\NN\407535|NONE (r_pobj) with_10\IN\0|possibly (r_prep) associated_9\VBN\628491|liver|fatal (r_acl) failure_7\NN\66216|NONE
D002231_D056486 CID carbimazole_36\NN\0|NONE (r_pobj) with_35\IN\0|concomitant (r_prep) treatment_34\NN\654885|while (r_pobj) on_32\IN\0|from|could|that|have (r_prep) resulted_21\VBN\2633881|first|of|the (r_relcl) case_15\NN\7283608|,|.|increasing|this (r_attr) is_12\VBZ\0|NONE (l_advcl) increasing_3\VBG\169651|,|.|case|this (l_dobj) evidence_4\NN\5816287|is (l_prep) of_5\IN\0|induced (l_pobj) hepatotoxicity_6\NN\0|NONE
7197363
D011814_D009069 CID quipazine_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) head_18\NN\5225090|in (r_compound) twitches_19\NNS\14360459|and|induced
D011814_D009069 CID quipazine_31\NN\0|NONE (r_pobj) of_28\IN\0|NONE (r_prep) completing_27\VBG\352826|NONE (r_pcomp) after_26\IN\0|hr (r_prep) increased_22\VBN\169651|)|(|or|after (r_conj) reduced_13\VBN\441445|aggressiveness|twitches|.|,|and|hr (r_conj) increased_6\VBD\169651|NONE (l_conj) twitches_35\NNS\14360459|aggressiveness|.|,|reduced|and|hr
D001058_D009069 NONE apomorphine_10\NN\3786417| (r_npadvmod) induced_12\VBN\1627355|twitches|and (r_amod) aggressiveness_13\NN\4835724|NONE (l_conj) twitches_19\NNS\14360459|and|induced
D001058_D009069 NONE apomorphine_7\NN\3786417| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) aggressiveness_10\NN\4835724|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD\169651|NONE (l_conj) twitches_35\NNS\14360459|aggressiveness|.|,|reduced|and|hr
D011814_D012892 NONE quipazine_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) head_18\NN\5225090|in (r_compound) twitches_19\NNS\14360459|and|induced (r_conj) aggressiveness_13\NN\4835724|NONE (r_pobj) on_9\IN\0|of|The (r_prep) effects_1\NNS\13245626|.|were (l_prep) of_2\IN\0|The|on (l_pobj) deprivation_5\NN\14493145|NONE
D011814_D012892 NONE quipazine_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) head_18\NN\5225090|in (r_compound) twitches_19\NNS\14360459|and|induced (r_conj) aggressiveness_13\NN\4835724|NONE (r_pobj) on_9\IN\0|of|The (r_prep) effects_1\NNS\13245626|.|were (l_prep) of_2\IN\0|The|on (l_pobj) deprivation_5\NN\14493145|NONE (l_appos) remd_7\NNP\0|sleep|(|REM|)
D011814_D012892 NONE quipazine_31\NN\0|NONE (r_pobj) of_28\IN\0|NONE (r_prep) completing_27\VBG\352826|NONE (r_pcomp) after_26\IN\0|hr (r_prep) increased_22\VBN\169651|)|(|or|after (r_conj) reduced_13\VBN\441445|aggressiveness|twitches|.|,|and|hr (r_conj) increased_6\VBD\169651|NONE (l_nsubj) hr_3\NN\15154774|aggressiveness|twitches|.|,|reduced|and (l_prep) of_4\IN\0|eight (l_pobj) remd_5\NNP\0|NONE
D011814_D012892 NONE quipazine_31\NN\0|NONE (r_pobj) of_28\IN\0|NONE (r_prep) completing_27\VBG\352826|NONE (r_pcomp) after_26\IN\0|hr (r_prep) increased_22\VBN\169651|)|(|or|after (r_conj) reduced_13\VBN\441445|aggressiveness|twitches|.|,|and|hr (l_prep) after_16\IN\0|)|(|or|increased (l_pcomp) completing_17\VBG\352826|immediately (l_prep) of_18\IN\0|NONE (l_pobj) remd_19\NNP\0|NONE
D011814_D012892 NONE quipazine_31\NN\0|NONE (l_nmod) remd_29\NNP\0|)|
D011814_D001523 NONE quipazine_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) head_18\NN\5225090|in (r_compound) twitches_19\NNS\14360459|and|induced (r_conj) aggressiveness_13\NN\4835724|NONE
D011814_D001523 NONE quipazine_31\NN\0|NONE (r_pobj) of_28\IN\0|NONE (r_prep) completing_27\VBG\352826|NONE (r_pcomp) after_26\IN\0|hr (r_prep) increased_22\VBN\169651|)|(|or|after (r_conj) reduced_13\VBN\441445|aggressiveness|twitches|.|,|and|hr (r_conj) increased_6\VBD\169651|NONE (l_dobj) aggressiveness_10\NN\4835724|twitches|.|,|reduced|and|hr
D001058_D001523 CID apomorphine_10\NN\3786417| (r_npadvmod) induced_12\VBN\1627355|twitches|and (r_amod) aggressiveness_13\NN\4835724|NONE
D001058_D001523 CID apomorphine_7\NN\3786417| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) aggressiveness_10\NN\4835724|twitches|.|,|reduced|and|hr
D001058_D012892 NONE apomorphine_10\NN\3786417| (r_npadvmod) induced_12\VBN\1627355|twitches|and (r_amod) aggressiveness_13\NN\4835724|NONE (r_pobj) on_9\IN\0|of|The (r_prep) effects_1\NNS\13245626|.|were (l_prep) of_2\IN\0|The|on (l_pobj) deprivation_5\NN\14493145|NONE
D001058_D012892 NONE apomorphine_10\NN\3786417| (r_npadvmod) induced_12\VBN\1627355|twitches|and (r_amod) aggressiveness_13\NN\4835724|NONE (r_pobj) on_9\IN\0|of|The (r_prep) effects_1\NNS\13245626|.|were (l_prep) of_2\IN\0|The|on (l_pobj) deprivation_5\NN\14493145|NONE (l_appos) remd_7\NNP\0|sleep|(|REM|)
D001058_D012892 NONE apomorphine_7\NN\3786417| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) aggressiveness_10\NN\4835724|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD\169651|NONE (l_nsubj) hr_3\NN\15154774|aggressiveness|twitches|.|,|reduced|and (l_prep) of_4\IN\0|eight (l_pobj) remd_5\NNP\0|NONE
D001058_D012892 NONE apomorphine_7\NN\3786417| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) aggressiveness_10\NN\4835724|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD\169651|NONE (l_conj) reduced_13\VBN\441445|aggressiveness|twitches|.|,|and|hr (l_prep) after_16\IN\0|)|(|or|increased (l_pcomp) completing_17\VBG\352826|immediately (l_prep) of_18\IN\0|NONE (l_pobj) remd_19\NNP\0|NONE
D001058_D012892 NONE apomorphine_7\NN\3786417| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) aggressiveness_10\NN\4835724|twitches|.|,|reduced|and|hr (r_dobj) increased_6\VBD\169651|NONE (l_conj) reduced_13\VBN\441445|aggressiveness|twitches|.|,|and|hr (l_conj) increased_22\VBN\169651|)|(|or|after (l_prep) after_26\IN\0|hr (l_pcomp) completing_27\VBG\352826|NONE (l_prep) of_28\IN\0|NONE (l_pobj) quipazine_31\NN\0|NONE (l_nmod) remd_29\NNP\0|)|
8665051
D013256_D009336 NONE steroid_18\NN\14727670|the (r_compound) groups_19\NNS\2137|NONE (r_pobj) in_16\IN\13603305|atrophy|and|fiber|IIb (r_prep) atrophy_15\NN\14299637|ATPase|revealed|.|, (r_dobj) showed_11\VBD\2137132|NONE (l_advcl) revealed_32\VBD\2137132|ATPase|.|,|atrophy (l_dobj) pattern_36\NN\5726345|examinations|whereas (l_prep) with_37\IN\0|a|normal|muscular (l_pobj) absence_38\NN\14449405|NONE (l_prep) of_39\IN\0|NONE (l_pobj) necrosis_40\NN\11444117|NONE
D013256_D009336 NONE steroids_14\NNS\14727670|NONE (r_pobj) of_13\IN\0|massive (r_prep) doses_12\NNS\3740161|NONE (r_pobj) with_10\IN\0|term||)|( (r_prep) treatment_9\NN\654885|wasting|that (r_nsubj) induced_15\VBD\1627355|We (r_ccomp) conclude_1\VBP\628491|atrophy|resulting|;||,|types (r_ccomp) induced_30\VBD\1627355|steroid||;|necrosis (r_ccomp) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (l_dobj) necrosis_53\NN\11444117|steroid|induced||;
D013256_D009336 NONE steroids_29\NNS\14727670|NONE (r_pobj) of_28\IN\0|both (r_prep) types_27\NNS\5839024|atrophy|resulting|;||conclude|, (r_nsubj) induced_30\VBD\1627355|steroid||;|necrosis (r_ccomp) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (l_dobj) necrosis_53\NN\11444117|steroid|induced||;
D013256_D009336 NONE steroid_50\NN\14727670|induced||;|necrosis (r_nsubj) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (l_dobj) necrosis_53\NN\11444117|steroid|induced||;
D013256_D013746 NONE steroid_8\NN\14727670|both (r_compound) groups_9\NNS\2137|NONE (r_pobj) in_6\IN\13603305|was|,|was|time|and (r_prep) prolonged_5\VBN\317700|NONE (l_conj) was_16\VBD\0|in|,|was|time|and (l_advcl) were_24\VBD\0|tension|.|longer|,|with (l_nsubj) tensions_23\NNS\14375890|whereas|similar (l_compound) tetanic_22\JJ\0|NONE
D013256_D009133 NONE steroid_18\NN\14727670|the (r_compound) groups_19\NNS\2137|NONE (r_pobj) in_16\IN\13603305|atrophy|and|fiber|IIb (r_prep) atrophy_15\NN\14299637|ATPase|revealed|.|,
D013256_D009133 NONE steroid_18\NN\14727670|the (r_compound) groups_19\NNS\2137|NONE (r_pobj) in_16\IN\13603305|atrophy|and|fiber|IIb (r_prep) atrophy_15\NN\14299637|ATPase|revealed|.|, (l_conj) atrophy_25\NN\14299637|and|in|fiber|IIb
D013256_D009133 NONE steroids_14\NNS\14727670|NONE (r_pobj) of_13\IN\0|massive (r_prep) doses_12\NNS\3740161|NONE (r_pobj) with_10\IN\0|term||)|( (r_prep) treatment_9\NN\654885|wasting|that (r_nsubj) induced_15\VBD\1627355|We (r_ccomp) conclude_1\VBP\628491|atrophy|resulting|;||,|types (r_ccomp) induced_30\VBD\1627355|steroid||;|necrosis (r_ccomp) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (r_ccomp) caused_63\VBN\1617192|NONE (l_nsubjpass) atrophy_60\NN\14299637|(|;|caused|by|was|.|alone|not
D013256_D009133 NONE steroids_29\NNS\14727670|NONE (r_pobj) of_28\IN\0|both (r_prep) types_27\NNS\5839024|atrophy|resulting|;||conclude|, (r_nsubj) induced_30\VBD\1627355|steroid||;|necrosis (r_ccomp) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (r_ccomp) caused_63\VBN\1617192|NONE (l_nsubjpass) atrophy_60\NN\14299637|(|;|caused|by|was|.|alone|not
D013256_D009133 NONE steroid_50\NN\14727670|induced||;|necrosis (r_nsubj) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (r_ccomp) caused_63\VBN\1617192|NONE (l_nsubjpass) atrophy_60\NN\14299637|(|;|caused|by|was|.|alone|not
D014221_D000855 CID triamcinolone_24\NN\14751417|or|,|M (r_conj) methylprednisolone_18\NN\0|(|saline|)|, (r_appos) c_15\NNP\13714184|NONE (r_pobj) of_12\IN\0|daily (r_prep) injection_11\NN\320852|to (r_dobj) receive_9\VB\2210855|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN\2475922|NONE (l_conj) showed_46\VBD\2137132|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D014221_D000855 CID t_26\NNP\14999913|NONE (r_appos) triamcinolone_24\NN\14751417|or|,|M (r_conj) methylprednisolone_18\NN\0|(|saline|)|, (r_appos) c_15\NNP\13714184|NONE (r_pobj) of_12\IN\0|daily (r_prep) injection_11\NN\320852|to (r_dobj) receive_9\VB\2210855|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN\2475922|NONE (l_conj) showed_46\VBD\2137132|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D014221_D000855 CID t_67\NNP\14999913|and|, (r_conj) m_65\NNP\13649268|NONE (r_pobj) in_64\IN\13603305|NONE (r_prep) %_63\NN\0|treated||(|the (r_appos) groups_58\NNS\2137|NONE (r_pobj) in_53\IN\13603305|a|significant|of (r_prep) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D008775_D000855 CID methylprednisolone_18\NN\0|(|saline|)|, (r_appos) c_15\NNP\13714184|NONE (r_pobj) of_12\IN\0|daily (r_prep) injection_11\NN\320852|to (r_dobj) receive_9\VB\2210855|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN\2475922|NONE (l_conj) showed_46\VBD\2137132|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D008775_D000855 CID m_20\NNP\13649268|or|,|triamcinolone (r_appos) methylprednisolone_18\NN\0|(|saline|)|, (r_appos) c_15\NNP\13714184|NONE (r_pobj) of_12\IN\0|daily (r_prep) injection_11\NN\320852|to (r_dobj) receive_9\VB\2210855|Therefore|randomly|were|d|measured|.|rats|,|showed|,|, (r_xcomp) assigned_7\VBN\2475922|NONE (l_conj) showed_46\VBD\2137132|Therefore|randomly|were|receive|d|measured|.|rats|,|,|, (l_dobj) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D008775_D000855 CID m_65\NNP\13649268|NONE (r_pobj) in_64\IN\13603305|NONE (r_prep) %_63\NN\0|treated||(|the (r_appos) groups_58\NNS\2137|NONE (r_pobj) in_53\IN\13603305|a|significant|of (r_prep) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D013256_D001284 NONE steroids_14\NNS\14727670|NONE (r_pobj) of_13\IN\0|massive (r_prep) doses_12\NNS\3740161|NONE (r_pobj) with_10\IN\0|term||)|( (r_prep) treatment_9\NN\654885|wasting|that (r_nsubj) induced_15\VBD\1627355|We (r_ccomp) conclude_1\VBP\628491|atrophy|resulting|;||,|types (r_ccomp) induced_30\VBD\1627355|steroid||;|necrosis (l_dobj) atrophy_34\NN\14299637|resulting|;||conclude|,|types
D013256_D001284 NONE steroids_29\NNS\14727670|NONE (r_pobj) of_28\IN\0|both (r_prep) types_27\NNS\5839024|atrophy|resulting|;||conclude|, (r_nsubj) induced_30\VBD\1627355|steroid||;|necrosis (l_dobj) atrophy_34\NN\14299637|resulting|;||conclude|,|types
D013256_D001284 NONE steroid_50\NN\14727670|induced||;|necrosis (r_nsubj) caused_51\VBD\1617192|atrophy|(|;|by|was|.|alone|not (l_ccomp) induced_30\VBD\1627355|steroid||;|necrosis (l_dobj) atrophy_34\NN\14299637|resulting|;||conclude|,|types
D014221_D009133 CID t_27\NNP\14999913|NONE (r_pobj) with_26\IN\0|IIa|also (r_prep) atrophy_25\NN\14299637|and|in|fiber|IIb (r_conj) atrophy_15\NN\14299637|ATPase|revealed|.|,
D014221_D009133 CID t_27\NNP\14999913|NONE (r_pobj) with_26\IN\0|IIa|also (r_prep) atrophy_25\NN\14299637|and|in|fiber|IIb
D014221_D009133 CID t_18\NNP\14999913|, (r_conj) c_16\NNP\13714184||(|) (r_appos) rats_14\NNS\2329401|NONE (r_pobj) in_12\IN\13603305|NONE (r_prep) performed_11\VBN\0|PF|(|,|)|,|fed|a (r_acl) study_9\NN\635850|was|.|,|Finally (r_nsubj) showed_24\VBD\2137132|NONE (l_ccomp) was_28\VBD\0|study|.|,|Finally (l_nsubj) atrophy_27\NN\14299637|pronounced|that
D014221_D009133 CID t_37\NNP\14999913| (r_npadvmod) treated_39\VBN\2376958|NONE (r_amod) animals_40\NNS\4475|NONE (r_pobj) in_36\IN\13603305|NONE (r_prep) than_35\IN\0|in|less (r_prep) pronounced_31\VBN\0|atrophy|that (r_acomp) was_28\VBD\0|study|.|,|Finally (l_nsubj) atrophy_27\NN\14299637|pronounced|that
D013256_D000855 NONE steroid_55\NN\14727670| (r_npadvmod) treated_57\VBN\2376958||(|the|% (r_amod) groups_58\NNS\2137|NONE (r_pobj) in_53\IN\13603305|a|significant|of (r_prep) reduction_49\NN\351485|)|respectively (l_prep) of_50\IN\0|in|a|significant (l_pobj) intake_52\NN\13440063|NONE
D008775_D013746 NONE m_19\NNP\13649268|NONE (r_pobj) with_18\IN\0|tension|were|.|longer|, (r_prep) was_16\VBD\0|in|,|was|time|and (l_advcl) were_24\VBD\0|tension|.|longer|,|with (l_nsubj) tensions_23\NNS\14375890|whereas|similar (l_compound) tetanic_22\JJ\0|NONE
D014221_D009336 NONE t_27\NNP\14999913|NONE (r_pobj) with_26\IN\0|IIa|also (r_prep) atrophy_25\NN\14299637|and|in|fiber|IIb (r_conj) atrophy_15\NN\14299637|ATPase|revealed|.|, (r_dobj) showed_11\VBD\2137132|NONE (l_advcl) revealed_32\VBD\2137132|ATPase|.|,|atrophy (l_dobj) pattern_36\NN\5726345|examinations|whereas (l_prep) with_37\IN\0|a|normal|muscular (l_pobj) absence_38\NN\14449405|NONE (l_prep) of_39\IN\0|NONE (l_pobj) necrosis_40\NN\11444117|NONE
D000305_D009135 NONE corticosteroids_17\NNS\14745635|NONE (r_pobj) of_16\IN\0|massive (r_prep) doses_15\NNS\3740161|NONE (r_pobj) with_13\IN\0|NONE (r_prep) treated_12\VBN\2376958|NONE (r_acl) patients_11\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|may|myopathy|that (r_prep) occur_9\VB\0|reports|have|. (l_nsubj) myopathy_7\NN\14204950|may|that|in
2709684
D005839_D058186 CID gentamicin_41\NN\2716866| (r_npadvmod) induced_43\VBN\1627355|ARF|acute|renal (r_amod) failure_46\NN\66216|NONE
D005839_D058186 CID gentamicin_41\NN\2716866| (r_npadvmod) induced_43\VBN\1627355|ARF|acute|renal (r_amod) failure_46\NN\66216|NONE (l_appos) arf_48\NNP\0|acute|renal|induced
D005839_D058186 CID gentamicin_8\NN\2716866|,|decrease|P|(| (r_compound) arf_10\NNP\0|;|.|,|less|did|not|In|day|P
D013311_D003920 CID streptozotocin_3\NNS\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) diabetes_6\NN\14075199|DM (r_compound) mellitus_7\NN\0|NONE
D013311_D003920 CID streptozotocin_3\NNS\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) diabetes_6\NN\14075199|DM (r_compound) mellitus_7\NN\0|NONE (l_appos) dm_9\NNP\14117805|diabetes
D010695_D006029 NONE phlorizin_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) glycosuria_3\NN\14299637|nephrotoxicity|.|does|not
D010695_D006029 NONE p_13\NN\14622893|treated|the (r_nmod) animals_15\NNS\4475|NONE (r_pobj) of_11\IN\0|NONE (r_prep) that_10\DT\0|NONE (r_pobj) to_9\IN\0|NONE (r_prep) degree_8\NN\4916342|NONE (r_pobj) in_7\IN\13603305|NONE (r_prep) similar_6\JJ\0|)|mild|( (r_amod) glycosuria_4\NN\14299637|NONE
D010695_D006029 NONE p_4\NN\14622893|CCr|glycosuria|,|I|In|and (r_nsubj) induced_5\VBD\1627355|NONE (l_dobj) glycosuria_10\NN\14299637|CCr|P|,|I|In|and
D005839_D007674 NONE gentamicin_7\NN\2716866|in (r_compound) nephrotoxicity_8\NN\0|.|glycosuria|does|not
D005839_D007674 NONE gentamicin_3\NN\2716866|NONE (r_amod) nephrotoxicity_4\NN\0|NONE
D005839_D007674 NONE gentamicin_11\NN\2716866|NONE (r_pobj) of_10\IN\0|)|Nephrotoxic|(|body (r_prep) doses_1\NNS\3740161|to|.|during|to|were (l_amod) nephrotoxic_0\JJ\0|of|)|(|body
D013311_D006029 NONE streptozotocin_3\NNS\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) diabetes_6\NN\14075199|DM (r_compound) mellitus_7\NN\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) rats_1\NNS\2329401|Because|diuresis (r_nsubj) have_11\VBP\7846|have|,|.|be|we (l_dobj) diuresis_15\NN\14299637|rats|Because (l_appos) glycosuria_17\NN\14299637|solute|)|(|a
D005839_D009956 NONE gentamicin_8\NN\2716866|,|decrease|P|(| (r_compound) arf_10\NNP\0|;|.|,|less|did|not|In|day|P (r_dobj) prevent_7\VB\0|NONE (l_conj) day_34\NN\15154774|;|.|,|less|did|not|In|ARF|P (l_conj) score_39\NN\5736149|;|micrograms|and|/ (l_compound) necrosis_38\NN\11444117|.|)|,|tubular
D005947_D003920 NONE glucose_21\NN\14710501|with|tubular (r_compound) reabsorption_22\NN\13526110|NONE (r_pobj) of_19\IN\0|NONE (r_prep) blockage_18\NN\14034177|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|diabetic|with (r_acl) rats_11\NNS\2329401|NONE (l_amod) diabetic_10\JJ\10595647|induced|with
D010695_D007674 NONE phlorizin_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) glycosuria_3\NN\14299637|nephrotoxicity|.|does|not (r_nsubj) prevent_6\VB\0|NONE (l_dobj) nephrotoxicity_8\NN\0|.|glycosuria|does|not
D010695_D007674 NONE phlorizin_24\NN\0|NONE (r_pobj) with_23\IN\0|tubular|glucose (r_prep) reabsorption_22\NN\13526110|NONE (r_pobj) of_19\IN\0|NONE (r_prep) blockage_18\NN\14034177|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|diabetic|with (r_acl) rats_11\NNS\2329401|NONE (r_pobj) in_7\IN\13603305|protection|.|was (r_prep) studied_6\VBN\0|NONE (l_nsubjpass) protection_1\NN\407535|in|.|was (l_prep) from_2\IN\0|The (l_pobj) nephrotoxicity_4\NN\0|NONE
D010695_D007674 NONE p_26\NN\14622893|(|) (r_appos) phlorizin_24\NN\0|NONE (r_pobj) with_23\IN\0|tubular|glucose (r_prep) reabsorption_22\NN\13526110|NONE (r_pobj) of_19\IN\0|NONE (r_prep) blockage_18\NN\14034177|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|diabetic|with (r_acl) rats_11\NNS\2329401|NONE (r_pobj) in_7\IN\13603305|protection|.|was (r_prep) studied_6\VBN\0|NONE (l_nsubjpass) protection_1\NN\407535|in|.|was (l_prep) from_2\IN\0|The (l_pobj) nephrotoxicity_4\NN\0|NONE
D010695_D007674 NONE p_4\NN\14622893|CCr|glycosuria|,|I|In|and (r_nsubj) induced_5\VBD\1627355|NONE (l_conj) ccr_33\IN\0|P|glycosuria|,|I|In|and (l_nsubj) evidence_27\NN\5816287|min|.|score|baseline (l_prep) of_28\IN\0|no|functional (l_pobj) dysfunction_30\NN\14204950|NONE
D010695_D003920 NONE phlorizin_24\NN\0|NONE (r_pobj) with_23\IN\0|tubular|glucose (r_prep) reabsorption_22\NN\13526110|NONE (r_pobj) of_19\IN\0|NONE (r_prep) blockage_18\NN\14034177|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|diabetic|with (r_acl) rats_11\NNS\2329401|NONE (l_amod) diabetic_10\JJ\10595647|induced|with
D010695_D003920 NONE p_26\NN\14622893|(|) (r_appos) phlorizin_24\NN\0|NONE (r_pobj) with_23\IN\0|tubular|glucose (r_prep) reabsorption_22\NN\13526110|NONE (r_pobj) of_19\IN\0|NONE (r_prep) blockage_18\NN\14034177|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|diabetic|with (r_acl) rats_11\NNS\2329401|NONE (l_amod) diabetic_10\JJ\10595647|induced|with
D010695_D003920 NONE p_13\NN\14622893|treated|the (r_nmod) animals_15\NNS\4475|NONE (r_pobj) of_11\IN\0|NONE (r_prep) that_10\DT\0|NONE (r_pobj) to_9\IN\0|NONE (r_prep) degree_8\NN\4916342|NONE (r_pobj) in_7\IN\13603305|NONE (r_prep) similar_6\JJ\0|)|mild|( (r_amod) glycosuria_4\NN\14299637|NONE (r_pobj) with_2\IN\0|DM (r_prep) rats_1\NNS\2329401|.|were|also (l_compound) dm_0\NNP\14117805|with
D010695_D003920 NONE p_3\NN\14622893|Group|P|for|;|II (r_nsubj) received_6\VBD\2210855|NONE (l_conj) ii_19\NNP\13741022|Group|P|for|P|; (l_conj) iii_27\NNP\13741022|Group|P|;|( (l_acl) gentamicin_29\NN\2716866|.|Group|( (l_conj) iv_34\NNP\13741022|alone|and|) (l_appos) dm_37\NNP\14117805|Group
D010695_D003920 NONE p_7\NN\14622893|Group|for|P|;|II (r_dobj) received_6\VBD\2210855|NONE (l_conj) ii_19\NNP\13741022|Group|P|for|P|; (l_conj) iii_27\NNP\13741022|Group|P|;|( (l_acl) gentamicin_29\NN\2716866|.|Group|( (l_conj) iv_34\NNP\13741022|alone|and|) (l_appos) dm_37\NNP\14117805|Group
D010695_D003920 NONE p_21\NN\14622893|III|Group|;|( (r_appos) ii_19\NNP\13741022|Group|P|for|P|; (l_conj) iii_27\NNP\13741022|Group|P|;|( (l_acl) gentamicin_29\NN\2716866|.|Group|( (l_conj) iv_34\NNP\13741022|alone|and|) (l_appos) dm_37\NNP\14117805|Group
D010695_D058186 NONE p_4\NN\14622893|;|.|,|less|did|not|In|ARF|day (r_nsubj) prevent_7\VB\0|NONE (l_dobj) arf_10\NNP\0|;|.|,|less|did|not|In|day|P
D010695_D058186 NONE p_21\NN\14622893|,|decrease|(||gentamicin (r_appos) arf_10\NNP\0|;|.|,|less|did|not|In|day|P
D005839_D006029 NONE gentamicin_7\NN\2716866|in (r_compound) nephrotoxicity_8\NN\0|.|glycosuria|does|not (r_dobj) prevent_6\VB\0|NONE (l_nsubj) glycosuria_3\NN\14299637|nephrotoxicity|.|does|not
D005839_D006029 NONE gentamicin_41\NN\2716866| (r_npadvmod) induced_43\VBN\1627355|ARF|acute|renal (r_amod) failure_46\NN\66216|NONE (r_pobj) to_40\IN\0|their (r_prep) resistance_39\NN\37396|NONE (r_pobj) for_37\IN\0|NONE (r_prep) responsible_36\JJ\0|that|may|in|this (r_acomp) be_35\VB\14625458|have|have|,|.|we (r_ccomp) suggested_29\VBN\1010118|NONE (l_advcl) have_11\VBP\7846|have|,|.|be|we (l_dobj) diuresis_15\NN\14299637|rats|Because (l_appos) glycosuria_17\NN\14299637|solute|)|(|a
D005839_D003920 NONE gentamicin_41\NN\2716866| (r_npadvmod) induced_43\VBN\1627355|ARF|acute|renal (r_amod) failure_46\NN\66216|NONE (r_pobj) to_40\IN\0|their (r_prep) resistance_39\NN\37396|NONE (r_pobj) for_37\IN\0|NONE (r_prep) responsible_36\JJ\0|that|may|in|this (r_acomp) be_35\VB\14625458|have|have|,|.|we (r_ccomp) suggested_29\VBN\1010118|NONE (l_advcl) have_11\VBP\7846|have|,|.|be|we (l_nsubj) rats_1\NNS\2329401|Because|diuresis (l_prep) with_2\IN\0|NONE (l_pobj) mellitus_7\NN\0|NONE
D005839_D003920 NONE gentamicin_41\NN\2716866| (r_npadvmod) induced_43\VBN\1627355|ARF|acute|renal (r_amod) failure_46\NN\66216|NONE (r_pobj) to_40\IN\0|their (r_prep) resistance_39\NN\37396|NONE (r_pobj) for_37\IN\0|NONE (r_prep) responsible_36\JJ\0|that|may|in|this (r_acomp) be_35\VB\14625458|have|have|,|.|we (r_ccomp) suggested_29\VBN\1010118|NONE (l_advcl) have_11\VBP\7846|have|,|.|be|we (l_nsubj) rats_1\NNS\2329401|Because|diuresis (l_prep) with_2\IN\0|NONE (l_pobj) mellitus_7\NN\0|NONE (l_appos) dm_9\NNP\14117805|diabetes
D005839_D003920 NONE gentamicin_3\NN\2716866|NONE (r_amod) nephrotoxicity_4\NN\0|NONE (r_pobj) from_2\IN\0|The (r_prep) protection_1\NN\407535|in|.|was (r_nsubjpass) studied_6\VBN\0|NONE (l_prep) in_7\IN\13603305|protection|.|was (l_pobj) rats_11\NNS\2329401|NONE (l_amod) diabetic_10\JJ\10595647|induced|with
D005839_D003920 NONE gentamicin_23\NN\2716866|+|) (r_conj) p_21\NN\14622893|III|Group|;|( (r_appos) ii_19\NNP\13741022|Group|P|for|P|; (l_conj) iii_27\NNP\13741022|Group|P|;|( (l_acl) gentamicin_29\NN\2716866|.|Group|( (l_conj) iv_34\NNP\13741022|alone|and|) (l_appos) dm_37\NNP\14117805|Group
D005839_D003920 NONE gentamicin_29\NN\2716866|.|Group|( (l_conj) iv_34\NNP\13741022|alone|and|) (l_appos) dm_37\NNP\14117805|Group
D005839_D003920 NONE gentamicin_39\NN\2716866|mild|(|+|) (r_conj) dm_37\NNP\14117805|Group
D013311_D058186 NONE streptozotocin_3\NNS\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) diabetes_6\NN\14075199|DM (r_compound) mellitus_7\NN\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) rats_1\NNS\2329401|Because|diuresis (r_nsubj) have_11\VBP\7846|have|,|.|be|we (r_advcl) suggested_29\VBN\1010118|NONE (l_ccomp) be_35\VB\14625458|have|have|,|.|we (l_acomp) responsible_36\JJ\0|that|may|in|this (l_prep) for_37\IN\0|NONE (l_pobj) resistance_39\NN\37396|NONE (l_prep) to_40\IN\0|their (l_pobj) failure_46\NN\66216|NONE
D013311_D058186 NONE streptozotocin_3\NNS\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) diabetes_6\NN\14075199|DM (r_compound) mellitus_7\NN\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) rats_1\NNS\2329401|Because|diuresis (r_nsubj) have_11\VBP\7846|have|,|.|be|we (r_advcl) suggested_29\VBN\1010118|NONE (l_ccomp) be_35\VB\14625458|have|have|,|.|we (l_acomp) responsible_36\JJ\0|that|may|in|this (l_prep) for_37\IN\0|NONE (l_pobj) resistance_39\NN\37396|NONE (l_prep) to_40\IN\0|their (l_pobj) failure_46\NN\66216|NONE (l_appos) arf_48\NNP\0|acute|renal|induced
D010695_D009956 NONE p_4\NN\14622893|CCr|glycosuria|,|I|In|and (r_nsubj) induced_5\VBD\1627355|NONE (l_conj) ccr_33\IN\0|P|glycosuria|,|I|In|and (l_dobj) score_49\NN\5736149|evidence|min|.|baseline (l_compound) necrosis_48\NN\11444117|zero|(|)|[|tubular||]|maximum|,
D010695_D009956 NONE p_4\NN\14622893|;|.|,|less|did|not|In|ARF|day (r_nsubj) prevent_7\VB\0|NONE (l_conj) day_34\NN\15154774|;|.|,|less|did|not|In|ARF|P (l_conj) score_39\NN\5736149|;|micrograms|and|/ (l_compound) necrosis_38\NN\11444117|.|)|,|tubular
D010695_D009956 NONE p_21\NN\14622893|,|decrease|(||gentamicin (r_appos) arf_10\NNP\0|;|.|,|less|did|not|In|day|P (r_dobj) prevent_7\VB\0|NONE (l_conj) day_34\NN\15154774|;|.|,|less|did|not|In|ARF|P (l_conj) score_39\NN\5736149|;|micrograms|and|/ (l_compound) necrosis_38\NN\11444117|.|)|,|tubular
D005947_D007674 NONE glucose_21\NN\14710501|with|tubular (r_compound) reabsorption_22\NN\13526110|NONE (r_pobj) of_19\IN\0|NONE (r_prep) blockage_18\NN\14034177|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|diabetic|with (r_acl) rats_11\NNS\2329401|NONE (r_pobj) in_7\IN\13603305|protection|.|was (r_prep) studied_6\VBN\0|NONE (l_nsubjpass) protection_1\NN\407535|in|.|was (l_prep) from_2\IN\0|The (l_pobj) nephrotoxicity_4\NN\0|NONE
15531665
D001205_D050197 NONE c_12\NN\13714184|NONE (r_pobj) of_10\IN\0|high|in|a (r_prep) intake_9\NN\13440063|might|that|atherosclerosis (r_nsubj) promote_17\VB\2556126|to (l_dobj) atherosclerosis_18\NN\14108324|might|that|intake
D005492_D002318 NONE folate_21\NN\15090742|,|,|and|vitamin|carotene (r_nmod) e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (r_conj) type_8\NN\5839024|risk|, (r_appos) factors_6\NNS\7326557|NONE (l_compound) risk_5\NN\14541044|type|, (l_compound) disease_4\NN\14061805|NONE
D005492_D002318 NONE folate_21\NN\15090742|,|,|and|vitamin|carotene (r_nmod) e_24\NN\14724645|NONE (l_conj) carotene_29\NN\15090379|,|,|and|folate|vitamin (l_appos) risks_34\NNS\14541044|,|beta| (l_prep) of_35\IN\0|relative|adjusted|the (l_pobj) mortality_39\NN\5054863|NONE (l_compound) disease_38\NN\14061805|cardiovascular|total
D014810_D002318 NONE e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (r_conj) type_8\NN\5839024|risk|, (r_appos) factors_6\NNS\7326557|NONE (l_compound) risk_5\NN\14541044|type|, (l_compound) disease_4\NN\14061805|NONE
D014810_D002318 NONE e_24\NN\14724645|NONE (l_conj) carotene_29\NN\15090379|,|,|and|folate|vitamin (l_appos) risks_34\NNS\14541044|,|beta| (l_prep) of_35\IN\0|relative|adjusted|the (l_pobj) mortality_39\NN\5054863|NONE (l_compound) disease_38\NN\14061805|cardiovascular|total
D019207_D003920 NONE carotene_29\NN\15090379|,|,|and|folate|vitamin (r_conj) e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (r_conj) type_8\NN\5839024|risk|, (l_prep) of_9\IN\0|used|duration (l_pobj) medication_11\NN\3247620|NONE (l_compound) diabetes_10\NN\14075199|NONE
D019207_D003920 NONE carotene_29\NN\15090379|,|,|and|folate|vitamin (r_conj) e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (l_prep) of_15\IN\0|,|and|intakes (l_pobj) diabetes_16\NNS\14075199|NONE
D019207_D002318 NONE carotene_29\NN\15090379|,|,|and|folate|vitamin (r_conj) e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (r_conj) type_8\NN\5839024|risk|, (r_appos) factors_6\NNS\7326557|NONE (l_compound) risk_5\NN\14541044|type|, (l_compound) disease_4\NN\14061805|NONE
D019207_D002318 NONE carotene_29\NN\15090379|,|,|and|folate|vitamin (l_appos) risks_34\NNS\14541044|,|beta| (l_prep) of_35\IN\0|relative|adjusted|the (l_pobj) mortality_39\NN\5054863|NONE (l_compound) disease_38\NN\14061805|cardiovascular|total
D001205_D003324 NONE c_6\NN\13714184|from|and|mortality (r_compound) intake_7\NN\13440063|NONE (r_pobj) between_4\IN\0|the (r_prep) relation_3\NN\2137|We|,|)|disease|. (r_dobj) studied_1\VBD\0|NONE (l_dep) disease_22\NN\14061805|We|relation|,|)|.
D001205_D002318 CID c_3\NN\13714184|Does|risk|? (r_nsubj) increase_4\VB\13576355|NONE (l_dobj) risk_7\NN\14541044|Does|?|C (l_compound) disease_6\NN\14061805|in
D001205_D002318 CID c_10\NN\13714184|mortality|from|and (r_compound) intake_11\NN\13440063|NONE (l_prep) from_14\IN\0|C|mortality|and (l_pobj) disease_16\NN\14061805|NONE
D001205_D002318 CID c_6\NN\13714184|from|and|mortality (r_compound) intake_7\NN\13440063|NONE (l_prep) from_10\IN\0|C|and|mortality (l_pobj) disease_13\NN\14061805|NONE
D001205_D002318 CID c_63\NN\13714184|total|from (r_compound) intake_64\NN\13440063|NONE (r_pobj) of_60\IN\0|NONE (r_prep) quintiles_59\NNS\0|NONE (r_pobj) across_58\IN\0|,|,|.|P|.|( (r_prep) 1.0_41\CD\0|adjustment|.|After (r_attr) were_40\VBD\0|NONE (l_nsubj) adjustment_1\NN\7357388|.|.|After (l_prep) for_2\IN\0|NONE (l_pobj) factors_6\NNS\7326557|NONE (l_compound) risk_5\NN\14541044|type|, (l_compound) disease_4\NN\14061805|NONE
D001205_D002318 CID c_63\NN\13714184|total|from (r_compound) intake_64\NN\13440063|NONE (r_pobj) of_60\IN\0|NONE (r_prep) quintiles_59\NNS\0|NONE (r_pobj) across_58\IN\0|,|,|.|P|.|( (r_prep) 1.0_41\CD\0|adjustment|.|After (r_attr) were_40\VBD\0|NONE (l_nsubj) adjustment_1\NN\7357388|.|.|After (l_prep) for_2\IN\0|NONE (l_pobj) factors_6\NNS\7326557|NONE (l_appos) type_8\NN\5839024|risk|, (l_conj) duration_14\NN\15113229|used|of (l_conj) intakes_19\NNS\13440063|,|and|of (l_prep) of_20\IN\0|NONE (l_pobj) e_24\NN\14724645|NONE (l_conj) carotene_29\NN\15090379|,|,|and|folate|vitamin (l_appos) risks_34\NNS\14541044|,|beta| (l_prep) of_35\IN\0|relative|adjusted|the (l_pobj) mortality_39\NN\5054863|NONE (l_compound) disease_38\NN\14061805|cardiovascular|total
D001205_D002318 CID c_1\NN\13714184|NONE (r_compound) intake_2\NN\13440063|.|unrelated (r_nsubj) was_3\VBD\0|NONE (l_acomp) unrelated_4\JJ\0|intake|. (l_prep) to_5\IN\0|NONE (l_pobj) mortality_6\NN\5054863|NONE (l_prep) from_7\IN\0|in (l_pobj) disease_9\NN\14061805|NONE
D001205_D002318 CID c_3\NN\13714184|A|high|from (r_compound) intake_4\NN\13440063|is|with|. (r_nsubjpass) associated_8\VBN\628491|NONE (l_prep) with_9\IN\0|is|intake|. (l_pobj) risk_12\NN\14541044|NONE (l_prep) of_13\IN\0|increased|an (l_pobj) mortality_16\NN\5054863|NONE (l_compound) disease_15\NN\14061805|in|cardiovascular
D005492_D003920 NONE folate_21\NN\15090742|,|,|and|vitamin|carotene (r_nmod) e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (r_conj) type_8\NN\5839024|risk|, (l_prep) of_9\IN\0|used|duration (l_pobj) medication_11\NN\3247620|NONE (l_compound) diabetes_10\NN\14075199|NONE
D005492_D003920 NONE folate_21\NN\15090742|,|,|and|vitamin|carotene (r_nmod) e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (l_prep) of_15\IN\0|,|and|intakes (l_pobj) diabetes_16\NNS\14075199|NONE
D001205_D020521 NONE c_6\NN\13714184|from|and|mortality (r_compound) intake_7\NN\13440063|NONE (r_pobj) between_4\IN\0|the (r_prep) relation_3\NN\2137|We|,|)|disease|. (r_dobj) studied_1\VBD\0|NONE (l_dep) disease_22\NN\14061805|We|relation|,|)|. (l_conj) stroke_30\NN\556313|and|coronary|,||artery|n
D014810_D003920 NONE e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (r_conj) type_8\NN\5839024|risk|, (l_prep) of_9\IN\0|used|duration (l_pobj) medication_11\NN\3247620|NONE (l_compound) diabetes_10\NN\14075199|NONE
D014810_D003920 NONE e_24\NN\14724645|NONE (r_pobj) of_20\IN\0|NONE (r_prep) intakes_19\NNS\13440063|,|and|of (r_conj) duration_14\NN\15113229|used|of (l_prep) of_15\IN\0|,|and|intakes (l_pobj) diabetes_16\NNS\14075199|NONE
D001205_D003920 NONE c_3\NN\13714184|Does|risk|? (r_nsubj) increase_4\VB\13576355|NONE (l_dobj) risk_7\NN\14541044|Does|?|C (l_prep) in_8\IN\13603305|disease (l_pobj) women_9\NNS\9605289|NONE (l_prep) with_10\IN\0|NONE (l_pobj) diabetes_11\NNS\14075199|NONE
D001205_D003920 NONE c_12\NN\13714184|NONE (r_pobj) of_10\IN\0|high|in|a (r_prep) intake_9\NN\13440063|might|that|atherosclerosis (l_prep) in_13\IN\13603305|high|of|a (l_pobj) persons_15\NNS\7347|NONE (l_amod) diabetic_14\JJ\10595647|NONE
D001205_D003920 NONE c_6\NN\13714184|from|and|mortality (r_compound) intake_7\NN\13440063|NONE (r_pobj) between_4\IN\0|the (r_prep) relation_3\NN\2137|We|,|)|disease|. (r_dobj) studied_1\VBD\0|NONE (l_dep) disease_22\NN\14061805|We|relation|,|)|. (l_conj) stroke_30\NN\556313|and|coronary|,||artery|n (l_prep) in_36\IN\13603305|)||(|n (l_pobj) women_39\NNS\9605289|NONE (l_relcl) reported_41\VBD\831651||postmenopausal (l_xcomp) being_42\VBG\24720|who (l_acomp) diabetic_43\JJ\10595647|NONE
D001205_D003920 NONE c_63\NN\13714184|total|from (r_compound) intake_64\NN\13440063|NONE (r_pobj) of_60\IN\0|NONE (r_prep) quintiles_59\NNS\0|NONE (r_pobj) across_58\IN\0|,|,|.|P|.|( (r_prep) 1.0_41\CD\0|adjustment|.|After (r_attr) were_40\VBD\0|NONE (l_nsubj) adjustment_1\NN\7357388|.|.|After (l_prep) for_2\IN\0|NONE (l_pobj) factors_6\NNS\7326557|NONE (l_appos) type_8\NN\5839024|risk|, (l_prep) of_9\IN\0|used|duration (l_pobj) medication_11\NN\3247620|NONE (l_compound) diabetes_10\NN\14075199|NONE
D001205_D003920 NONE c_63\NN\13714184|total|from (r_compound) intake_64\NN\13440063|NONE (r_pobj) of_60\IN\0|NONE (r_prep) quintiles_59\NNS\0|NONE (r_pobj) across_58\IN\0|,|,|.|P|.|( (r_prep) 1.0_41\CD\0|adjustment|.|After (r_attr) were_40\VBD\0|NONE (l_nsubj) adjustment_1\NN\7357388|.|.|After (l_prep) for_2\IN\0|NONE (l_pobj) factors_6\NNS\7326557|NONE (l_appos) type_8\NN\5839024|risk|, (l_conj) duration_14\NN\15113229|used|of (l_prep) of_15\IN\0|,|and|intakes (l_pobj) diabetes_16\NNS\14075199|NONE
D001205_D003920 NONE c_3\NN\13714184|A|high|from (r_compound) intake_4\NN\13440063|is|with|. (r_nsubjpass) associated_8\VBN\628491|NONE (l_prep) with_9\IN\0|is|intake|. (l_pobj) risk_12\NN\14541044|NONE (l_prep) of_13\IN\0|increased|an (l_pobj) mortality_16\NN\5054863|NONE (l_prep) in_17\IN\13603305|disease|cardiovascular (l_pobj) women_19\NNS\9605289|NONE (l_prep) with_20\IN\0|postmenopausal (l_pobj) diabetes_21\NNS\14075199|NONE
16563323
D005045_D011537 NONE etomidate_10\NN\0|NONE (l_prep) without_12\IN\0|Pretreatment|.|induction|after (l_pobj) effects_14\NNS\13245626|NONE (l_prep) as_16\IN\14622893|side (l_pobj) sedation_17\NN\14034177|such (l_conj) apnea_19\NN\14299637|, (l_conj) nausea_21\NN\14299637|, (l_conj) pruritus_24\NN\5723563|or|,
C071741_D001049 NONE remifentanil_2\NN\0|NONE (r_pobj) with_1\IN\0|myoclonus (r_prep) pretreatment_0\NN\0|.|induction|without|after (r_nsubj) etomidate_10\NN\0|NONE (l_prep) without_12\IN\0|Pretreatment|.|induction|after (l_pobj) effects_14\NNS\13245626|NONE (l_prep) as_16\IN\14622893|side (l_pobj) sedation_17\NN\14034177|such (l_conj) apnea_19\NN\14299637|,
D005045_D001049 NONE etomidate_10\NN\0|NONE (l_prep) without_12\IN\0|Pretreatment|.|induction|after (l_pobj) effects_14\NNS\13245626|NONE (l_prep) as_16\IN\14622893|side (l_pobj) sedation_17\NN\14034177|such (l_conj) apnea_19\NN\14299637|,
C071741_D011537 NONE remifentanil_2\NN\0|NONE (r_pobj) with_1\IN\0|myoclonus (r_prep) pretreatment_0\NN\0|.|induction|without|after (r_nsubj) etomidate_10\NN\0|NONE (l_prep) without_12\IN\0|Pretreatment|.|induction|after (l_pobj) effects_14\NNS\13245626|NONE (l_prep) as_16\IN\14622893|side (l_pobj) sedation_17\NN\14034177|such (l_conj) apnea_19\NN\14299637|, (l_conj) nausea_21\NN\14299637|, (l_conj) pruritus_24\NN\5723563|or|,
C071741_D009325 NONE remifentanil_2\NN\0|NONE (r_pobj) with_1\IN\0|myoclonus (r_prep) pretreatment_0\NN\0|.|induction|without|after (r_nsubj) etomidate_10\NN\0|NONE (l_prep) without_12\IN\0|Pretreatment|.|induction|after (l_pobj) effects_14\NNS\13245626|NONE (l_prep) as_16\IN\14622893|side (l_pobj) sedation_17\NN\14034177|such (l_conj) apnea_19\NN\14299637|, (l_conj) nausea_21\NN\14299637|,
D005045_D009325 NONE etomidate_10\NN\0|NONE (l_prep) without_12\IN\0|Pretreatment|.|induction|after (l_pobj) effects_14\NNS\13245626|NONE (l_prep) as_16\IN\14622893|side (l_pobj) sedation_17\NN\14034177|such (l_conj) apnea_19\NN\14299637|, (l_conj) nausea_21\NN\14299637|,
D005045_D009207 CID etomidate_5\NN\0|.|myoclonus|pretreatment (r_advcl) reduces_2\VBZ\441445|NONE (l_dobj) myoclonus_3\NN\14360459|etomidate|.|pretreatment
D005045_D009207 CID etomidate_32\NN\0|NONE (r_pobj) with_31\IN\0|NONE (r_prep) induction_30\NN\7450842|NONE (r_amod) anesthesia_29\NN\14034177|NONE (r_pobj) after_28\IN\0|on|the|of (r_prep) effect_20\NN\34213|and|with (l_prep) on_23\IN\0|the|after|of (l_pobj) incidence_25\NN\13821570|NONE (l_prep) of_26\IN\0|the (l_pobj) myoclonus_27\NN\14360459|NONE
D005045_D009207 CID etomidate_16\NN\0|,|In|.|with|were|patients (r_advcl) associated_8\VBN\628491|NONE (l_prep) with_9\IN\0|,|In|.|were|patients|etomidate (l_pobj) incidence_12\NN\13821570|NONE (l_prep) of_13\IN\0|increased (l_pobj) myoclonus_14\NN\14360459|NONE
D005045_D009207 CID etomidate_10\NN\0|NONE (l_nsubj) pretreatment_0\NN\0|.|induction|without|after (l_appos) myoclonus_8\NN\14360459|with
D005045_D009207 CID etomidate_9\NN\0|.|incidence|experience (r_advcl) increased_2\VBD\169651|NONE (l_dobj) incidence_3\NN\13821570|etomidate|.|experience (l_prep) of_4\IN\0|NONE (l_pobj) myoclonus_5\NN\14360459|NONE
C071741_D009207 NONE remifentanil_0\NNP\0|NONE (r_compound) pretreatment_1\NN\0|etomidate|.|myoclonus (r_nsubj) reduces_2\VBZ\441445|NONE (l_dobj) myoclonus_3\NN\14360459|etomidate|.|pretreatment
C071741_D009207 NONE remifentanil_13\NN\0|/|microg| (r_nmod) kg_17\NNS\13717155|NONE (r_pobj) with_12\IN\0|and|effect (r_prep) pretreatment_11\NN\0|NONE (l_conj) effect_20\NN\34213|and|with (l_prep) on_23\IN\0|the|after|of (l_pobj) incidence_25\NN\13821570|NONE (l_prep) of_26\IN\0|the (l_pobj) myoclonus_27\NN\14360459|NONE
C071741_D009207 NONE remifentanil_9\NN\0|%|)|(|the (r_compound) group_10\NN\2137|NONE (r_pobj) in_7\IN\13603305|than|significantly (r_prep) lower_6\JJR\2831724|P|incidence|(|. (r_acomp) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|P|(|.|lower (l_prep) of_2\IN\0|The (l_pobj) myoclonus_3\NN\14360459|NONE
C071741_D009207 NONE remifentanil_2\NN\0|NONE (r_pobj) with_1\IN\0|myoclonus (r_prep) pretreatment_0\NN\0|.|induction|without|after (l_appos) myoclonus_8\NN\14360459|with
16584858
C009591_D017202 NONE chloride_10\NN\14818238|used|TTC (r_nmod) test_14\NN\5798043|NONE (l_acl) used_15\VBN\0|TTC|chloride (l_prep) for_16\IN\0|NONE (l_pobj) assay_20\NN\5733583|NONE (l_prep) of_21\IN\0|mapping|macroscopic (l_pobj) myocardium_24\NN\5389939|NONE
C009591_D017202 NONE ttc_12\NNP\0|used|chloride (r_nmod) test_14\NN\5798043|NONE (l_acl) used_15\VBN\0|TTC|chloride (l_prep) for_16\IN\0|NONE (l_pobj) assay_20\NN\5733583|NONE (l_prep) of_21\IN\0|mapping|macroscopic (l_pobj) myocardium_24\NN\5389939|NONE
D007501_D009202 NONE iron_58\NN\14625458|binding|reduced (r_nmod) capacity_60\NN\5202497|and|acid|uric (r_conj) level_54\NN\4916342|.|caused|, (r_dobj) increased_51\VBN\169651|NONE (l_ccomp) caused_20\VBD\1617192|.|level|, (l_dobj) damage_22\NN\7296428|injection|creatine
C013592_D017202 NONE mangiferin_4\NN\0|NONE (r_pobj) of_3\IN\0|The|protective (r_prep) role_2\NN\719494|was|by|. (r_nsubjpass) analyzed_6\VBN\0|NONE (l_agent) by_7\IN\0|was|role|. (l_pobj) test_14\NN\5798043|NONE (l_acl) used_15\VBN\0|TTC|chloride (l_prep) for_16\IN\0|NONE (l_pobj) assay_20\NN\5733583|NONE (l_prep) of_21\IN\0|mapping|macroscopic (l_pobj) myocardium_24\NN\5389939|NONE
C013592_D009203 NONE mangiferin_2\NN\0|NONE (l_prep) on_3\IN\0|NONE (l_pobj) alterations_5\NNS\7283608|NONE (l_prep) in_9\IN\13603305|biochemical|and|status (l_pobj) infarction_14\NN\14204950|NONE
C013592_D009203 NONE mangiferin_3\NN\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) pretreatment_1\NN\0|NONE (r_pobj) upon_0\IN\0|weight|.|in|given|(|protected (r_prep) suspended_9\VBN\1481360|NONE (l_prep) given_17\VBN\5892096|weight|.|in|Upon|(|protected (l_prep) to_22\IN\0|for|intraperitoneally (l_pobj) rats_24\NNS\2329401|NONE (l_compound) mi_23\NNP\14207561|NONE
C013592_D009203 NONE mangiferin_16\JJ\0|NONE (r_compound) administration_17\NN\1133281|NONE (r_pobj) upon_15\IN\0|significantly|tissue|.|compared (r_prep) rose_13\VBD\13112664|NONE (l_prep) compared_19\VBN\644583|significantly|tissue|.|upon (l_prep) to_20\IN\0|as (l_pobj) rats_25\NNS\2329401|NONE (l_compound) mi_24\NNP\14207561|induced
C013592_D009203 NONE mangiferin_8\NN\0|due|that|effect (r_nsubj) exerts_9\VBZ\1158872|is|.|From|it (l_dobj) effect_12\NN\34213|due|that|mangiferin (l_prep) against_13\IN\0|beneficial|a (l_pobj) mi_17\NNP\14207561|NONE
D014527_D009202 NONE acid_53\NN\14818238|and|capacity|uric (r_compound) level_54\NN\4916342|.|caused|, (r_dobj) increased_51\VBN\169651|NONE (l_ccomp) caused_20\VBD\1617192|.|level|, (l_dobj) damage_22\NN\7296428|injection|creatine
C013592_D006331 NONE mangiferin_8\NN\0|due|that|effect (r_nsubj) exerts_9\VBZ\1158872|is|.|From|it (l_prep) due_18\IN\5174653|that|mangiferin|effect (l_pcomp) to_19\IN\0|NONE (l_pobj) potential_22\NN\14481929|NONE (l_relcl) regulated_25\VBD\296178|its|antioxidant|, (l_prep) against_30\IN\0|which|system (l_pobj) damage_32\NN\7296428|NONE
D001205_D009203 NONE c_31\NN\13714184|, (r_conj) cerruloplasmin_28\NN\0|such (r_pobj) as_27\IN\14622893|enzymic|levels (r_prep) antioxidants_25\NNS\14724436|,|catalase|superoxide|, (r_appos) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D019344_D009202 NONE lactate_36\NN\14850483|LDH|(|) (r_compound) dehydrogenase_37\NN\0|NONE (r_pobj) of_34\IN\0|increased|the (r_prep) activity_33\NN\30358|NONE (r_pobj) by_30\IN\0|was|which|and (r_agent) determined_29\VBN\0|rat|, (r_relcl) heart_25\NN\5919034|NONE (r_pobj) in_23\IN\13603305|myocardial (r_prep) damage_22\NN\7296428|injection|creatine
D005978_D009203 NONE glutathione_12\NN\0|,|transferase (r_compound) peroxidase_13\NN\14971234|, (r_conj) catalase_10\NNP\14732946|antioxidants|,|superoxide|, (r_conj) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D005978_D009203 NONE glutathione_15\NN\0|and|activities (r_compound) transferase_16\NN\14732946|,|glutathione (r_conj) peroxidase_13\NN\14971234|, (r_conj) catalase_10\NNP\14732946|antioxidants|,|superoxide|, (r_conj) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D005978_D009203 NONE glutathione_18\NN\0|NONE (r_compound) reductase_19\NN\14732946|NONE (r_compound) activities_20\NNS\30358|glutathione|and (r_conj) transferase_16\NN\14732946|,|glutathione (r_conj) peroxidase_13\NN\14971234|, (r_conj) catalase_10\NNP\14732946|antioxidants|,|superoxide|, (r_conj) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D005978_D009203 NONE glutathione_36\NN\0|and|Vitamin (r_conj) e_34\NN\14724645|,|Vitamin (r_conj) c_31\NN\13714184|, (r_conj) cerruloplasmin_28\NN\0|such (r_pobj) as_27\IN\14622893|enzymic|levels (r_prep) antioxidants_25\NNS\14724436|,|catalase|superoxide|, (r_appos) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D007545_D009202 NONE isph_3\NNP\0|NONE (r_pobj) of_2\IN\0|to|Subcutaneous (r_prep) injection_1\NN\320852|damage|creatine (r_nsubj) caused_20\VBD\1617192|.|level|, (l_dobj) damage_22\NN\7296428|injection|creatine
D003401_D009202 NONE creatine_42\NN\14601829|injection|damage (r_conj) caused_20\VBD\1617192|.|level|, (l_dobj) damage_22\NN\7296428|injection|creatine
D014810_D009203 NONE e_34\NN\14724645|,|Vitamin (r_conj) c_31\NN\13714184|, (r_conj) cerruloplasmin_28\NN\0|such (r_pobj) as_27\IN\14622893|enzymic|levels (r_prep) antioxidants_25\NNS\14724436|,|catalase|superoxide|, (r_appos) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D004121_D009203 NONE sulphoxide_15\RB\0|NONE (r_pobj) of_13\IN\0|)| (r_prep) ml_12\NNS\13616054|NONE (r_pobj) in_10\IN\13603305|weight|.|given|Upon|(|protected (r_prep) suspended_9\VBN\1481360|NONE (l_prep) given_17\VBN\5892096|weight|.|in|Upon|(|protected (l_prep) to_22\IN\0|for|intraperitoneally (l_pobj) rats_24\NNS\2329401|NONE (l_compound) mi_23\NNP\14207561|NONE
D013481_D009203 NONE superoxide_7\JJ\14971519|antioxidants|,|catalase|, (r_amod) dismutase_8\NN\0|such (r_pobj) as_6\IN\14622893|antioxidant (r_prep) enzymes_4\NNS\14723628|heart (r_dobj) tissue_2\NN\5220461|in|were|. (r_nsubjpass) altered_39\VBN\0|NONE (l_prep) in_40\IN\13603305|tissue|were|. (l_pobj) rats_42\NNS\2329401|NONE (l_compound) mi_41\NNP\14207561|NONE
D007545_D006331 NONE isph_14\NNP\0| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) mi_17\NNP\14207561|NONE (r_pobj) against_13\IN\0|beneficial|a (r_prep) effect_12\NN\34213|due|that|mangiferin (r_dobj) exerts_9\VBZ\1158872|is|.|From|it (l_prep) due_18\IN\5174653|that|mangiferin|effect (l_pcomp) to_19\IN\0|NONE (l_pobj) potential_22\NN\14481929|NONE (l_relcl) regulated_25\VBD\296178|its|antioxidant|, (l_prep) against_30\IN\0|which|system (l_pobj) damage_32\NN\7296428|NONE
D007545_D009203 CID isoproterenol_10\NN\3740161| (r_npadvmod) induced_12\VBN\1627355|in|myocardial (r_amod) infarction_14\NN\14204950|NONE
D007545_D009203 CID isoproterenol_5\NN\3740161|NONE (r_pobj) on_4\IN\0|MI|(|in|)|(|through|myocardial|ISPH)induced (r_prep) infarction_9\NN\14204950|,|)|.|(
D007545_D009203 CID isoproterenol_5\NN\3740161|NONE (r_pobj) on_4\IN\0|MI|(|in|)|(|through|myocardial|ISPH)induced (r_prep) infarction_9\NN\14204950|,|)|.|( (l_appos) mi_11\NNP\14207561|(|in|)|(|through|myocardial|on|ISPH)induced
D007545_D009203 CID isph)-induced_7\JJ\0|MI|(|in|)|(|through|myocardial|on (r_amod) infarction_9\NN\14204950|,|)|.|(
D007545_D009203 CID isph)-induced_7\JJ\0|MI|(|in|)|(|through|myocardial|on (r_amod) infarction_9\NN\14204950|,|)|.|( (l_appos) mi_11\NNP\14207561|(|in|)|(|through|myocardial|on|ISPH)induced
D007545_D009203 CID isph_21\NNP\0| (r_npadvmod) induced_23\VBN\1627355|MI (r_amod) rats_25\NNS\2329401|NONE (l_compound) mi_24\NNP\14207561|induced
D007545_D009203 CID isph_14\NNP\0| (r_npadvmod) induced_16\VBN\1627355|NONE (r_amod) mi_17\NNP\14207561|NONE
2004
D000639_D002037 CID elavil_5\NNP\4482543|nortriptyline (r_conj) aventyl_0\NNP\0|left|produced|branch|each|in|. (r_nsubj) block_14\NN\21939|NONE
D000639_D002037 CID amitriptyline_7\FW\4482543|NONE (r_appos) elavil_5\NNP\4482543|nortriptyline (r_conj) aventyl_0\NNP\0|left|produced|branch|each|in|. (r_nsubj) block_14\NN\21939|NONE
D013881_D017180 CID mellaril_8\NNP\3713736|,|was|receiving|be|. (r_nsubj) appeared_12\VBD\2604760|NONE (l_xcomp) be_14\VB\14625458|,|was|receiving|Mellaril|. (l_acomp) responsible_15\JJ\0|to (l_prep) for_16\IN\0|NONE (l_pobj) cases_18\NNS\7283608|NONE (l_prep) of_19\IN\0|,|five (l_pobj) tachycardia_21\NN\14110674|NONE
D013881_D017180 CID thioridazine_10\NNP\3713736|) (r_appos) mellaril_8\NNP\3713736|,|was|receiving|be|. (r_nsubj) appeared_12\VBD\2604760|NONE (l_xcomp) be_14\VB\14625458|,|was|receiving|Mellaril|. (l_acomp) responsible_15\JJ\0|to (l_prep) for_16\IN\0|NONE (l_pobj) cases_18\NNS\7283608|NONE (l_prep) of_19\IN\0|,|five (l_pobj) tachycardia_21\NN\14110674|NONE
D010640_D005117 NONE phenothiazines_16\NNS\14771088|NONE (r_dobj) receiving_15\VBG\2210855|NONE (r_acl) patients_14\NNS\9898892|NONE (r_pobj) to_13\IN\0|cardiac (r_prep) complications_12\NNS\1073995|NONE
D008012_D001145 NONE lidocaine_8\NN\3681148|NONE (r_pobj) of_7\IN\0|intravenous (r_prep) administration_6\NN\1133281|and (r_pobj) to_4\IN\0|arrhythmias|direct (r_prep) responded_3\VBD\2367363|was|;|in|pacing|. (l_nsubj) arrhythmias_2\NNS\14103288|to|direct
D011433_D001145 NONE propranolol_27\NN\0|NONE (r_pobj) of_26\IN\0|combined|and|some|administration (r_prep) instances_22\NNS\7283608|NONE (r_pobj) in_20\IN\13603305|was|;|responded|pacing|. (r_prep) required_19\VBN\0|NONE (l_ccomp) responded_3\VBD\2367363|was|;|in|pacing|. (l_nsubj) arrhythmias_2\NNS\14103288|to|direct
D002746_D013617 NONE thorazine_7\NN\3713736|NONE (r_dobj) receiving_6\VBG\2210855|one (r_acl) patient_5\NN\9898892|NONE (r_pobj) in_3\IN\13603305|tachycardia|. (r_prep) developed_2\VBN\1753788|NONE (l_nsubj) tachycardia_1\NN\14110674|in|.
D002746_D013617 NONE chlorpromazine_9\NN\3713736|NONE (r_appos) thorazine_7\NN\3713736|NONE (r_dobj) receiving_6\VBG\2210855|one (r_acl) patient_5\NN\9898892|NONE (r_pobj) in_3\IN\13603305|tachycardia|. (r_prep) developed_2\VBN\1753788|NONE (l_nsubj) tachycardia_1\NN\14110674|in|.
D009661_D002037 CID aventyl_0\NNP\0|left|produced|branch|each|in|. (r_nsubj) block_14\NN\21939|NONE
D009661_D002037 CID nortriptyline_2\NN\4482543|Elavil (r_appos) aventyl_0\NNP\0|left|produced|branch|each|in|. (r_nsubj) block_14\NN\21939|NONE
12745515
D016642_D012892 NONE bupropion_9\NN\0|and|sleep (r_conj) deprivation_4\NN\14493145|NONE
D016642_D012892 NONE bupropion_12\NN\0|and|release|deprivation (r_compound) use_13\NN\407535|NONE (l_conj) deprivation_16\NN\14493145|and|bupropion|release
D016642_D012892 NONE bupropion_11\NN\0| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) seizures_14\NNS\14081375|NONE (r_pobj) of_10\IN\0|the (r_prep) risk_9\NN\14541044|NONE (r_pobj) to_7\IN\0|deprivation|that|may (r_prep) add_6\VB\14304060|We|. (l_nsubj) deprivation_4\NN\14493145|that|may|to
D016642_D012640 CID bupropion_9\NN\0|and|sleep (r_conj) deprivation_4\NN\14493145|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBN\628491|. (r_acl) seizure_0\NN\14081375|NONE
D016642_D012640 CID bupropion_12\NN\0|and|release|deprivation (r_compound) use_13\NN\407535|NONE (r_pobj) with_8\IN\0|NONE (r_prep) associated_7\VBN\628491|a|generalized (r_acl) seizure_6\NN\14081375|.|report
D016642_D012640 CID bupropion_4\NN\0|NONE (r_compound) use_5\NN\407535|NONE (r_pobj) of_3\IN\0| (r_prep) weeks_2\NNS\15113229|NONE (r_pobj) after_0\IN\0|seizure|subject|,|.|after (r_prep) experienced_9\VBD\2108377|NONE (l_dobj) seizure_14\NN\14081375|After|subject|,|.|after
D016642_D012640 CID bupropion_11\NN\0| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) seizures_14\NNS\14081375|NONE
3708922
D000666_D007674 NONE b_24\NN\1355326|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN\2716866|such (r_pobj) as_15\IN\14622893|,|a|nephrotoxic (r_prep) potential_12\NN\14481929|NONE (l_amod) nephrotoxic_11\JJ\0|,|as|a
D000666_D064420 NONE b_24\NN\1355326|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN\2716866|such (r_pobj) as_15\IN\14622893|,|a|nephrotoxic (r_prep) potential_12\NN\14481929|NONE (r_pobj) with_9\IN\0|The|combined|drugs|of (r_prep) administration_2\NN\1133281|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB\126264|NONE (l_ccomp) induced_41\VBN\1627355|administration|.|not|did|CSA (l_dobj) toxicity_42\NN\13576101|NONE
D007654_D007674 NONE ketoconazole_26\NN\0|amphothericin|and (r_conj) b_24\NN\1355326|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN\2716866|such (r_pobj) as_15\IN\14622893|,|a|nephrotoxic (r_prep) potential_12\NN\14481929|NONE (l_amod) nephrotoxic_11\JJ\0|,|as|a
D016572_D064420 NONE csa_4\NNP\0|NONE (r_pobj) of_3\IN\0|The|with|combined|drugs (r_prep) administration_2\NN\1133281|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB\126264|NONE (l_ccomp) induced_41\VBN\1627355|administration|.|not|did|CSA (l_dobj) toxicity_42\NN\13576101|NONE
D016572_D064420 NONE csa_40\NNP\0|administration|induced|.|not|did (r_dobj) aggravate_38\VB\126264|NONE (l_ccomp) induced_41\VBN\1627355|administration|.|not|did|CSA (l_dobj) toxicity_42\NN\13576101|NONE
D007654_D064420 NONE ketoconazole_26\NN\0|amphothericin|and (r_conj) b_24\NN\1355326|used|)|,|,|(|at|, (r_conj) gentamicin_16\NN\2716866|such (r_pobj) as_15\IN\14622893|,|a|nephrotoxic (r_prep) potential_12\NN\14481929|NONE (r_pobj) with_9\IN\0|The|combined|drugs|of (r_prep) administration_2\NN\1133281|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB\126264|NONE (l_ccomp) induced_41\VBN\1627355|administration|.|not|did|CSA (l_dobj) toxicity_42\NN\13576101|NONE
D005839_D007674 NONE gentamicin_16\NN\2716866|such (r_pobj) as_15\IN\14622893|,|a|nephrotoxic (r_prep) potential_12\NN\14481929|NONE (l_amod) nephrotoxic_11\JJ\0|,|as|a
D005839_D007674 NONE gentamicin_0\NNP\2716866|,|however|.|nephrotoxicity|, (r_nsubj) increased_7\VBD\169651|NONE (l_dobj) nephrotoxicity_9\NN\0|,|however|.|,|Gentamicin
D016572_D007674 CID cyclosporine_1\NN\0|Experimental|.|risk|: (r_compound) nephrotoxicity_2\NN\0|NONE
D016572_D007674 CID cyclosporine_3\NN\0|in|or (r_pobj) of_2\IN\0|The (l_conj) in_9\IN\13603305|cyclosporine|or (l_pobj) combination_10\NN\7951464|NONE (l_prep) with_11\IN\0|NONE (l_pobj) chemotherapeutics_13\NNS\0|NONE (l_prep) in_14\IN\13603305|various (l_pobj) development_16\NN\248977|NONE (l_prep) of_17\IN\0|the (l_pobj) toxicity_19\NN\13576101|NONE
D016572_D007674 CID csa_5\NNP\0|NONE (r_appos) cyclosporine_3\NN\0|in|or (r_pobj) of_2\IN\0|The (l_conj) in_9\IN\13603305|cyclosporine|or (l_pobj) combination_10\NN\7951464|NONE (l_prep) with_11\IN\0|NONE (l_pobj) chemotherapeutics_13\NNS\0|NONE (l_prep) in_14\IN\13603305|various (l_pobj) development_16\NN\248977|NONE (l_prep) of_17\IN\0|the (l_pobj) toxicity_19\NN\13576101|NONE
D016572_D007674 CID csa_4\NNP\0|NONE (r_pobj) of_3\IN\0|The|with|combined|drugs (r_prep) administration_2\NN\1133281|induced|.|not|did|CSA (l_prep) with_9\IN\0|The|combined|drugs|of (l_pobj) potential_12\NN\14481929|NONE (l_amod) nephrotoxic_11\JJ\0|,|as|a
D016572_D007674 CID csa_40\NNP\0|administration|induced|.|not|did (r_dobj) aggravate_38\VB\126264|NONE (l_nsubj) administration_2\NN\1133281|induced|.|not|did|CSA (l_prep) with_9\IN\0|The|combined|drugs|of (l_pobj) potential_12\NN\14481929|NONE (l_amod) nephrotoxic_11\JJ\0|,|as|a
D016572_D007674 CID csa_8\NNP\0|NONE (r_compound) nephrotoxicity_9\NN\0|,|however|.|,|Gentamicin
D016572_D007674 CID csa_6\NNP\0|NONE (r_pobj) by_5\IN\0|NONE (r_agent) induced_4\VBN\1627355|the (r_acl) nephrotoxicity_3\NN\0|,|mechanism|Thus|.
D005839_D064420 NONE gentamicin_16\NN\2716866|such (r_pobj) as_15\IN\14622893|,|a|nephrotoxic (r_prep) potential_12\NN\14481929|NONE (r_pobj) with_9\IN\0|The|combined|drugs|of (r_prep) administration_2\NN\1133281|induced|.|not|did|CSA (r_nsubj) aggravate_38\VB\126264|NONE (l_ccomp) induced_41\VBN\1627355|administration|.|not|did|CSA (l_dobj) toxicity_42\NN\13576101|NONE
15266215
C406224_D001168 NONE valdecoxib_6\NNS\3124700|NONE (l_prep) versus_7\IN\0|inhibitor|the|specific|cyclooxygenase (l_pobj) agents_10\NNS\7347|NONE (l_conj) placebo_12\NN\3740161|antiinflammatory|and|nonsteroidal (l_prep) on_13\IN\0|NONE (l_pobj) events_16\NNS\23100|NONE (l_prep) in_17\IN\13603305|cardiovascular|thrombotic (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) arthritis_20\NN\14171682|NONE
D009288_D013927 NONE naproxen_46\NN\3828465|and|,|tid|or|data (r_conj) ibuprofen_40\VBD\3828465|(|nonselective|bid (r_npadvmod) nsaid_33\NNP\2721538|.|incidence|was|by|, (r_appos) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_amod) thrombotic_4\JJ\0|cardiovascular|(|)|thrombotic
D009288_D013927 NONE naproxen_46\NN\3828465|and|,|tid|or|data (r_conj) ibuprofen_40\VBD\3828465|(|nonselective|bid (r_npadvmod) nsaid_33\NNP\2721538|.|incidence|was|by|, (r_appos) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_appos) thrombotic_16\JJ\0|cardiovascular|(|)|thrombotic
D009288_D010003 NONE naproxen_46\NN\3828465|and|,|tid|or|data (r_conj) ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_nmod) osteoarthritis_57\NN\14186541|arthritis|were
D007052_D010003 NONE ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_nmod) osteoarthritis_57\NN\14186541|arthritis|were
C406224_D010003 NONE valdecoxib_6\NNS\3124700|NONE (r_pobj) for_5\IN\0|cardiovascular|event|inhibitor|, (r_prep) data_4\NNS\7951464|We|. (l_appos) inhibitor_11\NN\20090|cardiovascular|event|for|, (l_prep) in_12\IN\13603305|COXspecific|treated|a|new (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0| (l_pobj) osteoarthritis_17\NN\14186541|NONE
C406224_D010003 NONE valdecoxib_23\NNS\3124700|NONE (r_dobj) analyzing_21\VBG\0|NONE (r_pcomp) by_20\IN\0|.|incidence|was|NSAID|, (r_prep) determined_19\VBN\0|NONE (l_appos) nsaid_33\NNP\2721538|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_nmod) osteoarthritis_57\NN\14186541|arthritis|were
C406224_D010003 NONE valdecoxib_24\NN\3124700|NONE (r_compound) doses_25\NNS\3740161|term|Short|with (r_conj) treatment_5\NN\654885|not|was|.|with (r_nsubjpass) associated_28\VBN\628491|NONE (l_prep) with_29\IN\0|not|treatment|was|. (l_pobj) incidence_32\NN\13821570|NONE (l_prep) of_33\IN\0|an|increased (l_pobj) events_35\NNS\23100|NONE (l_amod) relative_36\JJ\7846|thrombotic (l_prep) to_37\IN\0|NONE (l_pobj) nsaids_39\NNPS\2721538|NONE (l_prep) in_42\IN\13603305|placebo|in|nonselective|or (l_pobj) patients_47\NNS\9898892|NONE (l_nmod) osteoarthritis_43\NN\14186541|arthritis
D004008_D013927 NONE diclofenac_35\NN\0|,|mg (r_nmod) bid_38\NN\7160883|(|ibuprofen|nonselective (r_appos) nsaid_33\NNP\2721538|.|incidence|was|by|, (r_appos) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_amod) thrombotic_4\JJ\0|cardiovascular|(|)|thrombotic
D004008_D013927 NONE diclofenac_35\NN\0|,|mg (r_nmod) bid_38\NN\7160883|(|ibuprofen|nonselective (r_appos) nsaid_33\NNP\2721538|.|incidence|was|by|, (r_appos) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_appos) thrombotic_16\JJ\0|cardiovascular|(|)|thrombotic
D004008_D001172 NONE diclofenac_35\NN\0|,|mg (r_nmod) bid_38\NN\7160883|(|ibuprofen|nonselective (r_appos) nsaid_33\NNP\2721538|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_compound) arthritis_60\NN\14171682|osteoarthritis|were
C406224_D001172 NONE valdecoxib_6\NNS\3124700|NONE (r_pobj) for_5\IN\0|cardiovascular|event|inhibitor|, (r_prep) data_4\NNS\7951464|We|. (l_appos) inhibitor_11\NN\20090|cardiovascular|event|for|, (l_prep) in_12\IN\13603305|COXspecific|treated|a|new (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0| (l_pobj) osteoarthritis_17\NN\14186541|NONE (l_conj) arthritis_20\NN\14171682|and
C406224_D001172 NONE valdecoxib_23\NNS\3124700|NONE (r_dobj) analyzing_21\VBG\0|NONE (r_pcomp) by_20\IN\0|.|incidence|was|NSAID|, (r_prep) determined_19\VBN\0|NONE (l_appos) nsaid_33\NNP\2721538|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_compound) arthritis_60\NN\14171682|osteoarthritis|were
C406224_D001172 NONE valdecoxib_24\NN\3124700|NONE (r_compound) doses_25\NNS\3740161|term|Short|with (r_conj) treatment_5\NN\654885|not|was|.|with (r_nsubjpass) associated_28\VBN\628491|NONE (l_prep) with_29\IN\0|not|treatment|was|. (l_pobj) incidence_32\NN\13821570|NONE (l_prep) of_33\IN\0|an|increased (l_pobj) events_35\NNS\23100|NONE (l_amod) relative_36\JJ\7846|thrombotic (l_prep) to_37\IN\0|NONE (l_pobj) nsaids_39\NNPS\2721538|NONE (l_prep) in_42\IN\13603305|placebo|in|nonselective|or (l_pobj) patients_47\NNS\9898892|NONE (l_compound) arthritis_46\NN\14171682|osteoarthritis
C406224_D013927 NONE valdecoxib_6\NNS\3124700|NONE (l_prep) versus_7\IN\0|inhibitor|the|specific|cyclooxygenase (l_pobj) agents_10\NNS\7347|NONE (l_conj) placebo_12\NN\3740161|antiinflammatory|and|nonsteroidal (l_prep) on_13\IN\0|NONE (l_pobj) events_16\NNS\23100|NONE (l_amod) thrombotic_15\JJ\0|in|cardiovascular
C406224_D013927 NONE valdecoxib_23\NNS\3124700|NONE (r_dobj) analyzing_21\VBG\0|NONE (r_pcomp) by_20\IN\0|.|incidence|was|NSAID|, (r_prep) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_amod) thrombotic_4\JJ\0|cardiovascular|(|)|thrombotic
C406224_D013927 NONE valdecoxib_23\NNS\3124700|NONE (r_dobj) analyzing_21\VBG\0|NONE (r_pcomp) by_20\IN\0|.|incidence|was|NSAID|, (r_prep) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_appos) thrombotic_16\JJ\0|cardiovascular|(|)|thrombotic
C406224_D013927 NONE valdecoxib_12\NNS\3124700|NONE (r_pobj) for_11\IN\0|NONE (r_prep) similar_10\JJ\0|incidences|. (r_acomp) were_9\VBD\0|NONE (l_nsubj) incidences_5\NNS\13821570|.|similar (l_prep) of_6\IN\0|Crude|adjusted (l_pobj) events_8\NNS\23100|NONE (l_amod) thrombotic_7\JJ\0|NONE
C406224_D013927 NONE valdecoxib_11\NN\3124700|each (r_compound) dose_12\NN\3740161|NONE (r_pobj) for_9\IN\0|NONE (r_prep) similar_8\JJ\0|.|risk|also (r_acomp) was_6\VBD\0|NONE (l_nsubj) risk_1\NN\14541044|.|similar|also (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_amod) thrombotic_4\JJ\0|serious
C406224_D013927 NONE valdecoxib_23\NN\3124700|;|,|% (r_conj) placebo_15\NN\3740161|)|(|of (r_appos) nonusers_11\NNS\0|NONE (r_pobj) than_10\IN\0|aspirin (r_prep) users_9\NNS\7846|NONE (r_pobj) of_7\IN\0|NONE (r_prep) users_6\NNS\7846|NONE (r_pobj) for_5\IN\0|risk|higher|. (r_prep) was_2\VBD\0|NONE (l_nsubj) risk_1\NN\14541044|for|higher|. (l_amod) thrombotic_0\JJ\0|NONE
C406224_D013927 NONE valdecoxib_24\NN\3124700|NONE (r_compound) doses_25\NNS\3740161|term|Short|with (r_conj) treatment_5\NN\654885|not|was|.|with (r_nsubjpass) associated_28\VBN\628491|NONE (l_prep) with_29\IN\0|not|treatment|was|. (l_pobj) incidence_32\NN\13821570|NONE (l_prep) of_33\IN\0|an|increased (l_pobj) events_35\NNS\23100|NONE (l_amod) thrombotic_34\JJ\0|relative
D007052_D013927 NONE ibuprofen_40\VBD\3828465|(|nonselective|bid (r_npadvmod) nsaid_33\NNP\2721538|.|incidence|was|by|, (r_appos) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_amod) thrombotic_4\JJ\0|cardiovascular|(|)|thrombotic
D007052_D013927 NONE ibuprofen_40\VBD\3828465|(|nonselective|bid (r_npadvmod) nsaid_33\NNP\2721538|.|incidence|was|by|, (r_appos) determined_19\VBN\0|NONE (l_nsubjpass) incidence_1\NN\13821570|.|was|by|NSAID|, (l_prep) of_2\IN\0|The (l_pobj) events_5\NNS\23100|NONE (l_appos) thrombotic_16\JJ\0|cardiovascular|(|)|thrombotic
D001241_D013927 CID aspirin_8\NN\2707683|than (r_compound) users_9\NNS\7846|NONE (r_pobj) of_7\IN\0|NONE (r_prep) users_6\NNS\7846|NONE (r_pobj) for_5\IN\0|risk|higher|. (r_prep) was_2\VBD\0|NONE (l_nsubj) risk_1\NN\14541044|for|higher|. (l_amod) thrombotic_0\JJ\0|NONE
D001241_D013927 CID aspirin_13\NN\2707683|NONE (r_pobj) of_12\IN\0|)|placebo|( (r_prep) nonusers_11\NNS\0|NONE (r_pobj) than_10\IN\0|aspirin (r_prep) users_9\NNS\7846|NONE (r_pobj) of_7\IN\0|NONE (r_prep) users_6\NNS\7846|NONE (r_pobj) for_5\IN\0|risk|higher|. (r_prep) was_2\VBD\0|NONE (l_nsubj) risk_1\NN\14541044|for|higher|. (l_amod) thrombotic_0\JJ\0|NONE
D009288_D001172 NONE naproxen_46\NN\3828465|and|,|tid|or|data (r_conj) ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_compound) arthritis_60\NN\14171682|osteoarthritis|were
D007052_D001172 NONE ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_compound) arthritis_60\NN\14171682|osteoarthritis|were
D004008_D010003 NONE diclofenac_35\NN\0|,|mg (r_nmod) bid_38\NN\7160883|(|ibuprofen|nonselective (r_appos) nsaid_33\NNP\2721538|.|incidence|was|by|, (l_npadvmod) ibuprofen_40\VBD\3828465|(|nonselective|bid (l_conj) data_53\NNS\7951464|and|,|tid|naproxen|or (l_prep) from_54\IN\0|placebo (l_pobj) trials_61\NNS\786195|NONE (l_nmod) osteoarthritis_57\NN\14186541|arthritis|were
3311455
D016572_D007674 CID cyclosporine_17\NN\0|NONE (r_pobj) with_16\IN\0|term (r_prep) therapy_15\NN\657604|NONE (r_pobj) to_11\IN\0|NONE (r_prep) secondary_10\JJ\8426461|chronic (r_amod) nephrotoxicity_9\NN\0|NONE
D016572_D007674 CID cyclosporine_8\NN\0|NONE (r_pobj) of_7\IN\0|lower|these|even (r_prep) dosages_6\NNS\13576355|required|that|nephrotoxicity|can (r_nsubj) cause_10\VB\7323922|We|. (l_dobj) nephrotoxicity_12\NN\0|required|dosages|that|can
20635749
D000638_D009230 CID amiodarone_6\NN\2715941|presenting (r_pobj) on_5\IN\0|Severe|report|failure|.|: (l_pcomp) presenting_7\VBG\2137132|amiodarone (l_prep) with_8\IN\0|NONE (l_pobj) coma_10\NN\5678932|NONE
D000638_D009230 CID amiodarone_10\NN\2715941| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hypothyroidism_13\NN\14059928|NONE (r_pobj) to_9\IN\0|secondary|in (r_prep) coma_7\NN\5678932|.|report|This
D000638_D009230 CID amiodarone_19\NN\2715941|term (r_compound) therapy_20\NN\657604|NONE (r_pobj) during_16\IN\0|case|one|of (r_prep) report_12\NN\6470073|.|there|To (l_prep) of_13\IN\0|during|case|one (l_pobj) coma_15\NN\5678932|NONE
D000638_D003128 CID amiodarone_6\NN\2715941|presenting (r_pobj) on_5\IN\0|Severe|report|failure|.|: (l_pcomp) presenting_7\VBG\2137132|amiodarone (l_prep) with_8\IN\0|NONE (l_pobj) coma_10\NN\5678932|NONE
D000638_D003128 CID amiodarone_10\NN\2715941| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hypothyroidism_13\NN\14059928|NONE (r_pobj) to_9\IN\0|secondary|in (r_prep) coma_7\NN\5678932|.|report|This
D000638_D003128 CID amiodarone_19\NN\2715941|term (r_compound) therapy_20\NN\657604|NONE (r_pobj) during_16\IN\0|case|one|of (r_prep) report_12\NN\6470073|.|there|To (l_prep) of_13\IN\0|during|case|one (l_pobj) coma_15\NN\5678932|NONE
D000638_D006333 NONE amiodarone_6\NN\2715941|presenting (r_pobj) on_5\IN\0|Severe|report|failure|.|: (r_prep) patient_4\NN\9898892|NONE (l_compound) failure_3\NN\66216|Severe|report|.|on|:
D000638_D006333 NONE amiodarone_10\NN\2715941| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hypothyroidism_13\NN\14059928|NONE (r_pobj) to_9\IN\0|secondary|in (r_prep) coma_7\NN\5678932|.|report|This (l_prep) in_14\IN\13603305|to|secondary (l_pobj) patient_16\NN\9898892|NONE (l_prep) with_17\IN\0|a (l_pobj) failure_21\NN\66216|NONE
D000638_D006333 NONE amiodarone_10\NN\2715941| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hypothyroidism_13\NN\14059928|NONE (r_pobj) to_9\IN\0|secondary|in (r_prep) coma_7\NN\5678932|.|report|This (l_prep) in_14\IN\13603305|to|secondary (l_pobj) patient_16\NN\9898892|NONE (l_prep) with_17\IN\0|a (l_pobj) failure_21\NN\66216|NONE (l_appos) chf_23\NNP\0|heart|severe
D000638_D006333 NONE amiodarone_4\NN\2715941|NONE (r_pobj) on_3\IN\0|with (r_prep) patients_0\NNS\9898892|,|morbidity|.|and|deserve|may (l_prep) with_1\IN\0|on (l_pobj) chf_2\NNP\0|NONE
D000638_D006333 NONE amiodarone_13\NN\2715941|NONE (l_prep) among_14\IN\0|NONE (l_pobj) patients_16\NNS\9898892|NONE (l_compound) chf_15\NNP\0|NONE
D000638_D007037 CID amiodarone_10\NN\2715941| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hypothyroidism_13\NN\14059928|NONE
D000638_D007037 CID amiodarone_4\NN\2715941|NONE (r_pobj) on_3\IN\0|with (r_prep) patients_0\NNS\9898892|,|morbidity|.|and|deserve|may (r_nsubj) suffer_6\VB\2110220|NONE (l_dobj) morbidity_8\NN\13826959|,|Patients|.|and|deserve|may (l_prep) from_11\IN\0|serious|and|mortality (l_pobj) hypothyroidism_12\NN\14059928|NONE
17042884
C069541_D017109 NONE quetiapine_14\NN\0|NONE (r_pobj) with_13\IN\0|,|akathisia (r_prep) including_10\VBG\0|symptoms|,|To (l_pobj) akathisia_11\NN\0|,|with
C069541_D017109 NONE quetiapine_16\NN\0|%|)|( (r_amod) monotherapy_17\NN\0|NONE (r_pobj) with_15\IN\0|than|no (r_prep) different_14\JJ\0|incidence|. (r_acomp) was_12\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|different|. (l_prep) including_9\VBG\0|,|The|,|of (l_pobj) akathisia_10\NN\0|NONE
C069541_D017109 NONE quetiapine_9\NN\0|(|)|placebo|and|% (r_amod) monotherapy_10\NN\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) similar_7\JJ\0|and (r_conj) low_5\JJ\14520518|,|incidence|with|.|and (r_acomp) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|,|with|low|.|and (l_prep) of_2\IN\0|The (l_pobj) akathisia_3\NN\0|NONE
C069541_D017109 NONE qtp_24\NNP\0|NONE (r_pobj) with_23\IN\0|,|incidence|low|.|and (r_conj) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|,|with|low|.|and (l_prep) of_2\IN\0|The (l_pobj) akathisia_3\NN\0|NONE
C069541_D017109 NONE quetiapine_41\NN\0|NONE (r_pcomp) than_40\IN\0|,|%|and|,|syndrome|)|( (r_prep) tremor_21\NN\345926|incidence|.|Haloperidol (r_npadvmod) induced_1\VBD\1627355|NONE (l_dobj) incidence_5\NN\13821570|.|tremor|Haloperidol (l_appos) 0.001_9\CD\0|a|higher (l_prep) of_11\IN\0|<|p|(|) (l_pobj) akathisia_12\NN\0|NONE
C069541_D017109 NONE quetiapine_13\NN\0|NONE (r_amod) therapy_14\NN\657604|.|In|,|with|incidence|similar (r_nsubj) is_15\VBZ\0|NONE (l_nsubj) incidence_5\NN\13821570|.|In|,|with|therapy|similar (l_prep) including_9\VBG\0|the|,|of|, (l_pobj) akathisia_10\NN\0|NONE
D006220_D017109 CID haloperidol_0\NNP\3713736|incidence|.|tremor (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) incidence_5\NN\13821570|.|tremor|Haloperidol (l_appos) 0.001_9\CD\0|a|higher (l_prep) of_11\IN\0|<|p|(|) (l_pobj) akathisia_12\NN\0|NONE
D006220_D014202 CID haloperidol_0\NNP\3713736|incidence|.|tremor (r_nsubj) induced_1\VBD\1627355|NONE (l_npadvmod) tremor_21\NN\345926|incidence|.|Haloperidol
C069541_D014202 NONE quetiapine_20\NN\0|NONE (r_pobj) than_19\IN\0|.|)|%|(|higher|a|%|)|( (r_prep) incidence_7\NN\13821570|NONE (l_appos) 0.05_11\CD\0|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN\0|<|)|p|( (l_pobj) tremor_14\NN\345926|NONE
C069541_D014202 NONE quetiapine_20\NN\0|NONE (r_pobj) than_19\IN\0|.|)|%|(|higher|a|%|)|( (r_prep) incidence_7\NN\13821570|NONE (r_pobj) with_3\IN\0|was|Lithium (r_prep) associated_2\VBN\628491|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN\126264|NONE (l_nsubj) tremor_27\NN\345926|may|have|.|;|to|associated
C069541_D014202 NONE quetiapine_20\NN\0|NONE (r_pobj) than_19\IN\0|.|)|%|(|higher|a|%|)|( (r_prep) incidence_7\NN\13821570|NONE (r_pobj) with_3\IN\0|was|Lithium (r_prep) associated_2\VBN\628491|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN\126264|NONE (l_prep) to_41\IN\0|may|have|.|;|tremor|associated (l_pobj) rate_44\NN\13815152|NONE (l_prep) of_45\IN\0|the|in|elevated (l_pobj) tremor_46\NN\345926|NONE
C069541_D014202 NONE quetiapine_41\NN\0|NONE (r_pcomp) than_40\IN\0|,|%|and|,|syndrome|)|( (r_prep) tremor_21\NN\345926|incidence|.|Haloperidol
D006220_D001480 CID haloperidol_13\NN\3713736|NONE (r_pobj) with_12\IN\0|whereas (r_prep) treated_11\VBN\2376958|NONE (r_acl) patients_10\NNS\9898892|NONE (r_pobj) of_9\IN\0|. (r_prep) %_8\NN\0|NONE (r_pobj) in_6\IN\13603305|)|events (r_prep) occurred_5\VBD\0|NONE (l_nsubj) events_1\NNS\23100|)|in (l_acl) related_2\VBN\628491|Adverse (l_prep) to_3\IN\0|NONE (l_pobj) eps_4\NNP\0|NONE
D006220_D001480 CID haloperidol_0\NNP\3713736|incidence|.|tremor (r_nsubj) induced_1\VBD\1627355|NONE (l_npadvmod) tremor_21\NN\345926|incidence|.|Haloperidol (l_conj) syndrome_32\NN\5870365|,|than|%|and|,|)|(
C069541_D001480 NONE quetiapine_11\NN\0|NONE (r_pobj) with_10\IN\0|of|.|level (r_prep) incidence_3\NN\13821570|NONE (l_prep) of_4\IN\0|with|.|level (l_pobj) symptoms_6\NNS\5823932|NONE
C069541_D001480 NONE quetiapine_11\NN\0|NONE (r_pobj) with_10\IN\0|of|.|level (r_prep) incidence_3\NN\13821570|NONE (l_prep) of_4\IN\0|with|.|level (l_pobj) symptoms_6\NNS\5823932|NONE (l_appos) eps_8\NNP\0|extrapyramidal
C069541_D001480 NONE quetiapine_14\NN\0|NONE (r_pobj) with_13\IN\0|,|akathisia (r_prep) including_10\VBG\0|symptoms|,|To (r_prep) evaluate_3\VB\670261|:|. (l_dobj) symptoms_5\NNS\5823932|including|,|To
C069541_D001480 NONE quetiapine_14\NN\0|NONE (r_pobj) with_13\IN\0|,|akathisia (r_prep) including_10\VBG\0|symptoms|,|To (r_prep) evaluate_3\VB\670261|:|. (l_dobj) symptoms_5\NNS\5823932|including|,|To (l_appos) eps_7\NNP\0|extrapyramidal
C069541_D001480 NONE quetiapine_16\NN\0|%|)|( (r_amod) monotherapy_17\NN\0|NONE (r_pobj) with_15\IN\0|than|no (r_prep) different_14\JJ\0|incidence|. (r_acomp) was_12\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|different|. (l_prep) of_2\IN\0|,|The|,|including (l_pobj) events_7\NNS\23100|NONE (l_amod) related_5\VBN\628491|adverse (l_npadvmod) eps_3\NNP\0|
C069541_D001480 NONE qtp_8\NNP\0|NONE (r_pobj) with_7\IN\0|related|adverse (r_prep) events_6\NNS\23100|,|different|Similarly|. (l_amod) related_4\VBN\628491|adverse|with (l_npadvmod) eps_2\NNP\0|
C069541_D001480 NONE quetiapine_41\NN\0|NONE (r_pcomp) than_40\IN\0|,|%|and|,|syndrome|)|( (r_prep) tremor_21\NN\345926|incidence|.|Haloperidol (l_conj) syndrome_32\NN\5870365|,|than|%|and|,|)|(
C069541_D001480 NONE quetiapine_13\NN\0|NONE (r_amod) therapy_14\NN\657604|.|In|,|with|incidence|similar (r_nsubj) is_15\VBZ\0|NONE (l_nsubj) incidence_5\NN\13821570|.|In|,|with|therapy|similar (l_prep) of_6\IN\0|the|,|including|, (l_pobj) eps_7\NNP\0|NONE
C069541_D001714 NONE quetiapine_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) studies_14\NNS\635850|NONE (l_prep) of_15\IN\0|controlled (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) mania_19\NN\9180259|NONE
C069541_D001714 NONE quetiapine_14\NN\0|NONE (l_prep) in_15\IN\13603305|NONE (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) mania_19\NN\9180259|NONE
C069541_D001714 NONE quetiapine_13\NN\0|NONE (r_amod) therapy_14\NN\657604|.|In|,|with|incidence|similar (r_nsubj) is_15\VBZ\0|NONE (l_prep) in_0\IN\13603305|.|,|with|incidence|therapy|similar (l_pobj) mania_2\NN\9180259|NONE
D008094_D001480 CID li_10\NNP\14625458|)|%|(|/ (r_nmod) dvp_12\NNP\0|+ (r_conj) qtp_8\NNP\0|NONE (r_pobj) with_7\IN\0|related|adverse (r_prep) events_6\NNS\23100|,|different|Similarly|. (l_amod) related_4\VBN\628491|adverse|with (l_npadvmod) eps_2\NNP\0|
D008094_D001480 CID li_24\NNP\14625458|/|)|(|% (r_nmod) dvp_26\NNP\0|+ (r_conj) pbo_22\NNP\0|NONE (r_pobj) with_21\IN\0|NONE (r_prep) than_20\IN\0|no (r_prep) different_19\JJ\0|,|Similarly|.|events (r_acomp) were_17\VBD\0|NONE (l_nsubj) events_6\NNS\23100|,|different|Similarly|. (l_amod) related_4\VBN\628491|adverse|with (l_npadvmod) eps_2\NNP\0|
D008094_D001480 CID lithium_28\NN\14625458|NONE (r_pobj) with_27\IN\0|NONE (r_prep) treated_26\VBN\2376958|NONE (r_acl) patients_25\NNS\9898892|NONE (r_pobj) of_24\IN\0|. (r_prep) %_23\NN\0|NONE (r_pobj) whereas_21\IN\0|with (r_prep) treated_11\VBN\2376958|NONE (r_acl) patients_10\NNS\9898892|NONE (r_pobj) of_9\IN\0|. (r_prep) %_8\NN\0|NONE (r_pobj) in_6\IN\13603305|)|events (r_prep) occurred_5\VBD\0|NONE (l_nsubj) events_1\NNS\23100|)|in (l_acl) related_2\VBN\628491|Adverse (l_prep) to_3\IN\0|NONE (l_pobj) eps_4\NNP\0|NONE
D008094_D017109 NONE li_26\NNP\14625458|/|%|)|(|and|PBO (r_nmod) dvp_28\NNP\0|+ (r_conj) qtp_24\NNP\0|NONE (r_pobj) with_23\IN\0|,|incidence|low|.|and (r_conj) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|,|with|low|.|and (l_prep) of_2\IN\0|The (l_pobj) akathisia_3\NN\0|NONE
D008094_D017109 NONE li_36\NNP\14625458|/ (r_compound) dvp_38\NNP\0|(|+|)|% (r_conj) pbo_34\NNP\0|Li|/|%|)|(|and (r_conj) dvp_28\NNP\0|+ (r_conj) qtp_24\NNP\0|NONE (r_pobj) with_23\IN\0|,|incidence|low|.|and (r_conj) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|,|with|low|.|and (l_prep) of_2\IN\0|The (l_pobj) akathisia_3\NN\0|NONE
D008094_D014202 CID lithium_0\NN\14625458|was|with (r_nsubjpass) associated_2\VBN\628491|may|have|.|;|to|tremor (l_prep) with_3\IN\0|was|Lithium (l_pobj) incidence_7\NN\13821570|NONE (l_appos) 0.05_11\CD\0|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN\0|<|)|p|( (l_pobj) tremor_14\NN\345926|NONE
D008094_D014202 CID lithium_0\NN\14625458|was|with (r_nsubjpass) associated_2\VBN\628491|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN\126264|NONE (l_nsubj) tremor_27\NN\345926|may|have|.|;|to|associated
D008094_D014202 CID lithium_0\NN\14625458|was|with (r_nsubjpass) associated_2\VBN\628491|may|have|.|;|to|tremor (r_ccomp) contributed_40\VBN\126264|NONE (l_prep) to_41\IN\0|may|have|.|;|tremor|associated (l_pobj) rate_44\NN\13815152|NONE (l_prep) of_45\IN\0|the|in|elevated (l_pobj) tremor_46\NN\345926|NONE
D008094_D014202 CID lithium_36\NN\14625458|NONE (r_pobj) of_35\IN\0|a|known|adverse (r_prep) effect_34\NN\34213|which (r_attr) is_30\VBZ\0|,|cerebellar|, (r_relcl) tremor_27\NN\345926|may|have|.|;|to|associated (r_nsubj) contributed_40\VBN\126264|NONE (l_ccomp) associated_2\VBN\628491|may|have|.|;|to|tremor (l_prep) with_3\IN\0|was|Lithium (l_pobj) incidence_7\NN\13821570|NONE (l_appos) 0.05_11\CD\0|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN\0|<|)|p|( (l_pobj) tremor_14\NN\345926|NONE
D008094_D014202 CID lithium_36\NN\14625458|NONE (r_pobj) of_35\IN\0|a|known|adverse (r_prep) effect_34\NN\34213|which (r_attr) is_30\VBZ\0|,|cerebellar|, (r_relcl) tremor_27\NN\345926|may|have|.|;|to|associated
D008094_D014202 CID lithium_36\NN\14625458|NONE (r_pobj) of_35\IN\0|a|known|adverse (r_prep) effect_34\NN\34213|which (r_attr) is_30\VBZ\0|,|cerebellar|, (r_relcl) tremor_27\NN\345926|may|have|.|;|to|associated (r_nsubj) contributed_40\VBN\126264|NONE (l_prep) to_41\IN\0|may|have|.|;|tremor|associated (l_pobj) rate_44\NN\13815152|NONE (l_prep) of_45\IN\0|the|in|elevated (l_pobj) tremor_46\NN\345926|NONE
D008094_D014202 CID lithium_50\NN\14625458|NONE (r_compound) therapy_51\NN\657604|NONE (r_dobj) receiving_49\VBG\2210855|NONE (r_acl) patients_48\NNS\9898892|NONE (r_pobj) in_47\IN\13603305|of|the|elevated (r_prep) rate_44\NN\13815152|NONE (r_pobj) to_41\IN\0|may|have|.|;|tremor|associated (r_prep) contributed_40\VBN\126264|NONE (l_ccomp) associated_2\VBN\628491|may|have|.|;|to|tremor (l_prep) with_3\IN\0|was|Lithium (l_pobj) incidence_7\NN\13821570|NONE (l_appos) 0.05_11\CD\0|)|than|%|(|higher|a|%|)|( (l_prep) of_13\IN\0|<|)|p|( (l_pobj) tremor_14\NN\345926|NONE
D008094_D014202 CID lithium_50\NN\14625458|NONE (r_compound) therapy_51\NN\657604|NONE (r_dobj) receiving_49\VBG\2210855|NONE (r_acl) patients_48\NNS\9898892|NONE (r_pobj) in_47\IN\13603305|of|the|elevated (r_prep) rate_44\NN\13815152|NONE (r_pobj) to_41\IN\0|may|have|.|;|tremor|associated (r_prep) contributed_40\VBN\126264|NONE (l_nsubj) tremor_27\NN\345926|may|have|.|;|to|associated
D008094_D014202 CID lithium_50\NN\14625458|NONE (r_compound) therapy_51\NN\657604|NONE (r_dobj) receiving_49\VBG\2210855|NONE (r_acl) patients_48\NNS\9898892|NONE (r_pobj) in_47\IN\13603305|of|the|elevated (r_prep) rate_44\NN\13815152|NONE (l_prep) of_45\IN\0|the|in|elevated (l_pobj) tremor_46\NN\345926|NONE
D014635_D001480 NONE dvp_12\NNP\0|+ (r_conj) qtp_8\NNP\0|NONE (r_pobj) with_7\IN\0|related|adverse (r_prep) events_6\NNS\23100|,|different|Similarly|. (l_amod) related_4\VBN\628491|adverse|with (l_npadvmod) eps_2\NNP\0|
D014635_D001480 NONE dvp_26\NNP\0|+ (r_conj) pbo_22\NNP\0|NONE (r_pobj) with_21\IN\0|NONE (r_prep) than_20\IN\0|no (r_prep) different_19\JJ\0|,|Similarly|.|events (r_acomp) were_17\VBD\0|NONE (l_nsubj) events_6\NNS\23100|,|different|Similarly|. (l_amod) related_4\VBN\628491|adverse|with (l_npadvmod) eps_2\NNP\0|
D014635_D017109 NONE dvp_28\NNP\0|+ (r_conj) qtp_24\NNP\0|NONE (r_pobj) with_23\IN\0|,|incidence|low|.|and (r_conj) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|,|with|low|.|and (l_prep) of_2\IN\0|The (l_pobj) akathisia_3\NN\0|NONE
D014635_D017109 NONE dvp_38\NNP\0|(|+|)|% (r_conj) pbo_34\NNP\0|Li|/|%|)|(|and (r_conj) dvp_28\NNP\0|+ (r_conj) qtp_24\NNP\0|NONE (r_pobj) with_23\IN\0|,|incidence|low|.|and (r_conj) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|,|with|low|.|and (l_prep) of_2\IN\0|The (l_pobj) akathisia_3\NN\0|NONE
85485
D001556_D006528 CID hexachloride_15\NN\0|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|.|in (r_acl) changes_0\NNS\7283608|NONE (l_prep) in_1\IN\13603305|induced|. (l_pobj) peroxisomes_2\NNS\0|NONE (l_prep) in_3\IN\13603305|NONE (l_pobj) liver_5\NN\5298729|NONE (l_conj) hepatoma_7\NN\14242337|preneoplastic|and
D001556_D006528 CID hexachloride_17\NN\0|NONE (r_pobj) by_11\IN\0|examined|.|in|Peroxisomes (r_prep) induced_8\VBN\1627355|NONE (l_nsubj) peroxisomes_0\NNS\0|examined|.|in|by (l_prep) in_1\IN\13603305|NONE (l_pobj) hepatomas_2\NNS\14242337|lesions
D001556_D017093 NONE hexachloride_17\NN\0|NONE (r_pobj) by_11\IN\0|examined|.|in|Peroxisomes (r_prep) induced_8\VBN\1627355|NONE (l_nsubj) peroxisomes_0\NNS\0|examined|.|in|by (l_prep) in_1\IN\13603305|NONE (l_pobj) lesions_7\NNS\14204950|hepatomas
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN\0| (r_appos) alpha_27\NN\6828818|NONE (r_appos) ethyl_25\NN\14617189|NONE (r_pobj) to_24\IN\0|.|did|not|,|were|cells|with (r_prep) respond_23\VB\2367363|NONE (l_advcl) were_5\VBD\0|.|did|not|,|cells|to|with (l_attr) tumors_9\NNS\14234074|contained|most|Although|and
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN\0| (r_appos) alpha_27\NN\6828818|NONE (r_appos) ethyl_25\NN\14617189|NONE (r_pobj) to_24\IN\0|.|did|not|,|were|cells|with (r_prep) respond_23\VB\2367363|NONE (l_nsubj) cells_20\NNS\3080309|.|did|not|,|were|to|with (l_compound) tumor_19\NN\14234074|the
C012282_D006528 NONE chlorophenoxyisobutyrate_31\NN\0| (r_appos) alpha_27\NN\6828818|NONE (r_appos) ethyl_25\NN\14617189|NONE (r_pobj) to_24\IN\0|.|did|not|,|were|cells|with (r_prep) respond_23\VB\2367363|NONE (l_advcl) were_5\VBD\0|.|did|not|,|cells|to|with (l_nsubj) most_1\JJS\0|contained|Although|and|tumors (l_prep) of_2\IN\0|NONE (l_pobj) hepatomas_4\NNS\14242337|NONE
14975762
D004317_D006333 CID doxorubicin_11\RB\2716866| (r_compound) induced_13\VBN\1627355|NONE (r_pobj) from_10\IN\0|cardiac|p|protects (r_prep) myocytes_9\NNS\0|NONE (r_pobj) of_5\IN\0|that (r_prep) overexpression_4\NN\0|reduces|and (r_nsubj) apoptosis_14\NN\11486178|findings|. (l_conj) reduces_16\VBZ\441445|overexpression|and (l_dobj) extent_18\NN\13939892|NONE (l_prep) of_19\IN\0|the (l_pobj) failure_22\NN\66216|NONE
D004317_D009369 NONE doxorubicin_0\NNP\2716866|agent (r_nsubj) is_1\VBZ\0|. (l_attr) agent_6\NN\7347|Doxorubicin (l_compound) tumor_5\NN\14234074|represses|an
15930398
D015742_D000647 CID propofol_12\NN\0|NONE (r_pobj) with_11\IN\0|procedural (r_prep) sedation_10\NN\14034177|NONE (r_pobj) during_8\IN\0|the|of|persistence|and (r_prep) onset_3\NN\7325190|NONE (l_prep) of_6\IN\0|the|during|persistence|and (l_pobj) amnesia_7\NN\5669934|NONE
18201582
C084178_D006973 NONE telmisartan_32\NN\0|monotherapy (r_pobj) of_31\IN\0|a|with|dose (r_prep) combination_30\NN\7951464|NONE (l_prep) with_41\IN\0|a|of|dose (l_pobj) hypertension_44\NN\14057371|NONE
C084178_D006973 NONE telmisartan_23\NNP\0|NONE (r_pobj) of_22\IN\0|FDC|new|a|dose|)|( (r_prep) combination_18\NN\7951464|NONE (r_pobj) of_12\IN\0|and|tolerability|the (r_prep) efficacy_9\NN\5199286|amlodipine|+|mg|to (r_dobj) evaluate_7\VB\670261|.|aim (l_conj) amlodipine_27\NN\0|+|efficacy|mg|to (l_prep) compared_33\VBN\644583|mg|) (l_prep) with_34\IN\0|NONE (l_pobj) amlodipine_35\NN\0|NONE (l_appos) monotherapy_37\NN\0|NONE (l_prep) in_41\IN\13603305|mg|A (l_pobj) patients_44\NNS\9898892|NONE (l_prep) with_45\IN\0|Indian|adult (l_pobj) hypertension_48\NN\14057371|NONE
D017311_D006973 NONE amlodipine_34\NN\0|and|versus (r_conj) telmisartan_32\NN\0|monotherapy (r_pobj) of_31\IN\0|a|with|dose (r_prep) combination_30\NN\7951464|NONE (l_prep) with_41\IN\0|a|of|dose (l_pobj) hypertension_44\NN\14057371|NONE
D017311_D006973 NONE amlodipine_36\NN\0|NONE (r_pobj) versus_35\IN\0|and|amlodipine (r_prep) telmisartan_32\NN\0|monotherapy (r_pobj) of_31\IN\0|a|with|dose (r_prep) combination_30\NN\7951464|NONE (l_prep) with_41\IN\0|a|of|dose (l_pobj) hypertension_44\NN\14057371|NONE
D017311_D006973 NONE amlodipine_27\NN\0|+|efficacy|mg|to (l_prep) compared_33\VBN\644583|mg|) (l_prep) with_34\IN\0|NONE (l_pobj) amlodipine_35\NN\0|NONE (l_appos) monotherapy_37\NN\0|NONE (l_prep) in_41\IN\13603305|mg|A (l_pobj) patients_44\NNS\9898892|NONE (l_prep) with_45\IN\0|Indian|adult (l_pobj) hypertension_48\NN\14057371|NONE
D017311_D006973 NONE amlodipine_35\NN\0|NONE (l_appos) monotherapy_37\NN\0|NONE (l_prep) in_41\IN\13603305|mg|A (l_pobj) patients_44\NNS\9898892|NONE (l_prep) with_45\IN\0|Indian|adult (l_pobj) hypertension_48\NN\14057371|NONE
19917396
D016559_D006332 CID tacrolimus_5\NNS\0|NONE (r_pobj) by_4\IN\0|NONE (r_agent) induced_3\VBN\1627355|Reversible|myocardial (r_acl) hypertrophy_2\NN\14365950|.|:|case
D016559_D006332 CID tacrolimus_8\NNS\0|NONE (r_pobj) by_7\IN\0|NONE (r_agent) induced_6\VBN\1627355|myocardial|transient (r_acl) hypertrophy_5\NN\14365950|Herein|.|we
D016559_D006332 CID tacrolimus_10\NN\0|NONE (r_pobj) of_9\IN\0|the|target (r_prep) concentration_8\NN\4916342|NONE (r_dobj) reducing_5\VBG\13447361|NONE (r_pcomp) upon_4\IN\0|hypertrophy|.|and|recur|completely (r_prep) resolved_3\VBN\352826|NONE (l_nsubj) hypertrophy_1\NN\14365950|upon|.|and|recur|completely
D016559_D006332 CID tacrolimus_5\NN\0|hypertrophy|that (r_nsubj) induces_6\VBZ\1627355|.|,|we|Thus (l_dobj) hypertrophy_9\NN\14365950|that|tacrolimus
10074612
D008775_D007022 CID methylprednisolone_11\NN\0|NONE (r_pobj) after_6\IN\0|NONE (r_prep) asystole_5\NN\14204950|and|, (r_conj) bradycardia_2\NNP\14110674|,|. (r_conj) hypotension_0\NN\14057371|NONE
D008775_D007022 CID methylprednisolone_18\NN\0|NONE (r_pobj) of_14\IN\0|intravenous|in (r_prep) administration_13\NN\1133281|NONE (r_pobj) after_11\IN\0|NONE (r_prep) asystole_10\NN\14204950|and|, (r_conj) bradycardia_7\NNP\14110674|, (r_conj) hypotension_5\NN\14057371|NONE
D008775_D003645 NONE methylprednisolone_16\NN\0|NONE (r_pobj) of_14\IN\0|a|high (r_prep) dose_13\NN\3740161|NONE (r_pobj) after_10\IN\0|.|study|mechanisms (r_prep) reviews_2\VBZ\5733583|NONE (l_dobj) mechanisms_6\NNS\13446390|.|after|study (l_prep) of_7\IN\0|current|proposed|the (l_pobj) death_9\NN\7296428|NONE
D008775_D003645 NONE ivmp_18\NN\0|intravenous (r_appos) methylprednisolone_16\NN\0|NONE (r_pobj) of_14\IN\0|a|high (r_prep) dose_13\NN\3740161|NONE (r_pobj) after_10\IN\0|.|study|mechanisms (r_prep) reviews_2\VBZ\5733583|NONE (l_dobj) mechanisms_6\NNS\13446390|.|after|study (l_prep) of_7\IN\0|current|proposed|the (l_pobj) death_9\NN\7296428|NONE
D008775_D006323 CID methylprednisolone_11\NN\0|NONE (r_pobj) after_6\IN\0|NONE (r_prep) asystole_5\NN\14204950|and|,
D008775_D006323 CID methylprednisolone_18\NN\0|NONE (r_pobj) of_14\IN\0|intravenous|in (r_prep) administration_13\NN\1133281|NONE (r_pobj) after_11\IN\0|NONE (r_prep) asystole_10\NN\14204950|and|,
D008775_D001919 CID methylprednisolone_11\NN\0|NONE (r_pobj) after_6\IN\0|NONE (r_prep) asystole_5\NN\14204950|and|, (r_conj) bradycardia_2\NNP\14110674|,|.
D008775_D001919 CID methylprednisolone_18\NN\0|NONE (r_pobj) of_14\IN\0|intravenous|in (r_prep) administration_13\NN\1133281|NONE (r_pobj) after_11\IN\0|NONE (r_prep) asystole_10\NN\14204950|and|, (r_conj) bradycardia_7\NNP\14110674|,
11704023
D013999_D005901 NONE timolol_6\NN\2832168|NONE (l_prep) on_9\IN\0|ophthalmic|with|aqueous (l_pobj) response_14\NN\11410625|NONE (l_prep) in_15\IN\13603305|the|hour|rate (l_pobj) patients_16\NNS\9898892|NONE (l_prep) on_17\IN\0|NONE (l_pobj) treatment_18\NN\654885|NONE (l_prep) for_19\IN\0|NONE (l_pobj) glaucoma_20\NN\14252864|NONE
D013999_D005901 NONE timolol_11\NN\2832168|of|the|, (l_conj) suspension_21\NN\14586258|%|)|aqueous|solution|and|( (l_relcl) forms_23\VBZ\6286395|a|%|timolol (l_prep) on_26\IN\0|that|gel (l_pobj) application_27\NN\947128|NONE (l_prep) on_35\IN\0|to (l_pobj) rate_39\NN\13815152|NONE (l_prep) in_40\IN\13603305|the|hour|heart (l_pobj) patients_41\NNS\9898892|NONE (l_acl) treated_44\VBN\2376958|NONE (l_prep) for_45\IN\0|currently|quantify|being (l_pobj) glaucoma_46\NN\14252864|NONE
D013999_D005901 NONE timolol_13\NN\2832168|NONE (r_compound) solution_14\NN\14586258|%|)|aqueous|and|suspension|( (r_appos) timolol_11\NN\2832168|of|the|, (l_conj) suspension_21\NN\14586258|%|)|aqueous|solution|and|( (l_relcl) forms_23\VBZ\6286395|a|%|timolol (l_prep) on_26\IN\0|that|gel (l_pobj) application_27\NN\947128|NONE (l_prep) on_35\IN\0|to (l_pobj) rate_39\NN\13815152|NONE (l_prep) in_40\IN\13603305|the|hour|heart (l_pobj) patients_41\NNS\9898892|NONE (l_acl) treated_44\VBN\2376958|NONE (l_prep) for_45\IN\0|currently|quantify|being (l_pobj) glaucoma_46\NN\14252864|NONE
D013999_D005901 NONE timolol_20\NN\2832168|a|forms|% (r_compound) suspension_21\NN\14586258|%|)|aqueous|solution|and|( (l_relcl) forms_23\VBZ\6286395|a|%|timolol (l_prep) on_26\IN\0|that|gel (l_pobj) application_27\NN\947128|NONE (l_prep) on_35\IN\0|to (l_pobj) rate_39\NN\13815152|NONE (l_prep) in_40\IN\13603305|the|hour|heart (l_pobj) patients_41\NNS\9898892|NONE (l_acl) treated_44\VBN\2376958|NONE (l_prep) for_45\IN\0|currently|quantify|being (l_pobj) glaucoma_46\NN\14252864|NONE
D013999_D005901 NONE timolol_32\NN\2832168|)|( (r_compound) gellan_33\NN\0|the (r_appos) conjunctiva_30\NN\5327134|NONE (r_pobj) to_28\IN\0|on (r_prep) application_27\NN\947128|NONE (l_prep) on_35\IN\0|to (l_pobj) rate_39\NN\13815152|NONE (l_prep) in_40\IN\13603305|the|hour|heart (l_pobj) patients_41\NNS\9898892|NONE (l_acl) treated_44\VBN\2376958|NONE (l_prep) for_45\IN\0|currently|quantify|being (l_pobj) glaucoma_46\NN\14252864|NONE
D013999_D009798 NONE timolol_56\NN\2832168|gellan|morning|,|or|(|) (r_compound) solution_57\NN\14586258|over|)|in|to|, (r_conj) crossed_32\VBN\2050132|patients|were|.|and (r_conj) randomized_30\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|crossed|were|.|and (l_prep) with_5\IN\0|Caucasian|three (l_pobj) glaucoma_10\NN\14252864|NONE (l_conj) hypertension_13\NN\14057371|or|angle|primary
D013999_D009798 NONE timolol_68\NN\2832168|morning|)|( (r_compound) gellan_69\NN\0|morning|timolol|,|or|(|) (r_conj) solution_57\NN\14586258|over|)|in|to|, (r_conj) crossed_32\VBN\2050132|patients|were|.|and (r_conj) randomized_30\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|crossed|were|.|and (l_prep) with_5\IN\0|Caucasian|three (l_pobj) glaucoma_10\NN\14252864|NONE (l_conj) hypertension_13\NN\14057371|or|angle|primary
D013999_D005902 NONE timolol_56\NN\2832168|gellan|morning|,|or|(|) (r_compound) solution_57\NN\14586258|over|)|in|to|, (r_conj) crossed_32\VBN\2050132|patients|were|.|and (r_conj) randomized_30\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|crossed|were|.|and (l_prep) with_5\IN\0|Caucasian|three (l_pobj) glaucoma_10\NN\14252864|NONE
D013999_D005902 NONE timolol_68\NN\2832168|morning|)|( (r_compound) gellan_69\NN\0|morning|timolol|,|or|(|) (r_conj) solution_57\NN\14586258|over|)|in|to|, (r_conj) crossed_32\VBN\2050132|patients|were|.|and (r_conj) randomized_30\VBN\278117|NONE (l_nsubjpass) patients_4\NNS\9898892|crossed|were|.|and (l_prep) with_5\IN\0|Caucasian|three (l_pobj) glaucoma_10\NN\14252864|NONE
19135948
C107135_D009190 NONE everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE
C107135_D009190 NONE everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE (l_appos) leukemia_33\NN\14239918|undergoing|myelodysplastic|either (l_nmod) mds_24\NNP\14622893|(|myeloid|AML|(|)
D016559_D006504 CID tacrolimus_10\NN\0|and (r_conj) everolimus_8\NN\0|NONE (r_pobj) with_7\IN\0|disease|Graft (r_prep) prophylaxis_6\VBN\1077350|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN\628491|NONE (l_prep) with_13\IN\0|is|.|microangiopathy|prophylaxis|and (l_pobj) incidence_16\NN\13821570|NONE (l_prep) of_17\IN\0|a|high (l_pobj) syndrome_20\NN\5870365|NONE
C107135_D015470 NONE everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE (l_appos) leukemia_33\NN\14239918|undergoing|myelodysplastic|either
C107135_D015470 NONE everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE (l_appos) leukemia_33\NN\14239918|undergoing|myelodysplastic|either (l_appos) aml_35\NNP\0|(|MDS|myeloid|(|)
D016559_D006086 NONE tacrolimus_10\NN\0|and (r_conj) everolimus_8\NN\0|NONE (r_pobj) with_7\IN\0|disease|Graft (r_prep) prophylaxis_6\VBN\1077350|is|.|with|microangiopathy|and (l_compound) disease_5\NN\14061805|Graft|with
D016559_D015470 NONE tacrolimus_8\NN\0|and (r_conj) everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE (l_appos) leukemia_33\NN\14239918|undergoing|myelodysplastic|either
D016559_D015470 NONE tacrolimus_8\NN\0|and (r_conj) everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE (l_appos) leukemia_33\NN\14239918|undergoing|myelodysplastic|either (l_appos) aml_35\NNP\0|(|MDS|myeloid|(|)
C107135_D006504 CID everolimus_8\NN\0|NONE (r_pobj) with_7\IN\0|disease|Graft (r_prep) prophylaxis_6\VBN\1077350|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN\628491|NONE (l_prep) with_13\IN\0|is|.|microangiopathy|prophylaxis|and (l_pobj) incidence_16\NN\13821570|NONE (l_prep) of_17\IN\0|a|high (l_pobj) syndrome_20\NN\5870365|NONE
D008727_D006086 NONE methotrexate_5\NNP\2722166|NONE (r_pobj) with_4\IN\0|NONE (r_prep) combined_3\VBN\2630189|calcineurin|A (r_acl) inhibitor_2\NN\20090|prophylaxis|. (r_nsubj) is_6\VBZ\0|NONE (l_attr) prophylaxis_9\NN\1077350|.|inhibitor (l_prep) for_10\IN\0|standard|the|after (l_pobj) disease_16\NN\14061805|NONE
D008727_D006086 NONE methotrexate_5\NNP\2722166|NONE (r_pobj) with_4\IN\0|NONE (r_prep) combined_3\VBN\2630189|calcineurin|A (r_acl) inhibitor_2\NN\20090|prophylaxis|. (r_nsubj) is_6\VBZ\0|NONE (l_attr) prophylaxis_9\NN\1077350|.|inhibitor (l_prep) for_10\IN\0|standard|the|after (l_pobj) disease_16\NN\14061805|NONE (l_appos) gvhd_18\NNP\0|graft|)|(
D016559_D009190 NONE tacrolimus_8\NN\0|and (r_conj) everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE
D016559_D009190 NONE tacrolimus_8\NN\0|and (r_conj) everolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|a|in|with (r_prep) combination_4\NN\7951464|NONE (l_prep) with_19\IN\0|of|a|in (l_pobj) syndrome_22\NN\5870365|NONE (l_appos) leukemia_33\NN\14239918|undergoing|myelodysplastic|either (l_nmod) mds_24\NNP\14622893|(|myeloid|AML|(|)
C107135_D006086 NONE everolimus_8\NN\0|NONE (r_pobj) with_7\IN\0|disease|Graft (r_prep) prophylaxis_6\VBN\1077350|is|.|with|microangiopathy|and (l_compound) disease_5\NN\14061805|Graft|with
D016559_D014652 CID tacrolimus_10\NN\0|and (r_conj) everolimus_8\NN\0|NONE (r_pobj) with_7\IN\0|disease|Graft (r_prep) prophylaxis_6\VBN\1077350|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN\628491|NONE (l_conj) microangiopathy_22\NN\0|is|.|with|prophylaxis|and
C107135_D014652 CID everolimus_8\NN\0|NONE (r_pobj) with_7\IN\0|disease|Graft (r_prep) prophylaxis_6\VBN\1077350|is|.|with|microangiopathy|and (r_nsubjpass) associated_12\VBN\628491|NONE (l_conj) microangiopathy_22\NN\0|is|.|with|prophylaxis|and
10091616
D007980_D004409 CID levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|by (r_amod) dyskinesias_5\NNS\14084880|NONE
D001058_D004409 CID apomorphine_69\NN\3786417|NONE (r_pobj) of_68\IN\0|single|effective|an (r_prep) dose_67\NN\3740161|NONE (r_pobj) of_63\IN\0|NONE (r_prep) administration_62\NN\1133281|NONE (r_pobj) following_61\VBG\8180190|the|of (r_prep) worsening_55\VBG\13457378|NONE (r_pobj) on_53\IN\0|) (r_prep) tasks_52\NNS\575741|aloud (r_dobj) speaking_49\VBG\7109847|role|to|, (r_dep) evaluate_16\VB\670261|in|were|.|patients (r_advcl) included_11\VBN\0|NONE (l_nsubjpass) patients_1\NNS\9898892|in|were|evaluate|. (l_relcl) had_3\VBD\0|Ten (l_prep) with_7\IN\0|who|disease (l_pcomp) disabling_8\VBG\126264|NONE (l_dobj) dyskinesia_9\NN\14084880|NONE
D001058_D004409 CID apomorphine_69\NN\3786417|NONE (r_pobj) of_68\IN\0|single|effective|an (r_prep) dose_67\NN\3740161|NONE (r_pobj) of_63\IN\0|NONE (r_prep) administration_62\NN\1133281|NONE (r_pobj) following_61\VBG\8180190|the|of (r_prep) worsening_55\VBG\13457378|NONE (l_prep) of_56\IN\0|following|the (l_pobj) dyskinesia_60\JJ\14084880|NONE
D001058_D010300 NONE apomorphine_69\NN\3786417|NONE (r_pobj) of_68\IN\0|single|effective|an (r_prep) dose_67\NN\3740161|NONE (r_pobj) of_63\IN\0|NONE (r_prep) administration_62\NN\1133281|NONE (r_pobj) following_61\VBG\8180190|the|of (r_prep) worsening_55\VBG\13457378|NONE (r_pobj) on_53\IN\0|) (r_prep) tasks_52\NNS\575741|aloud (r_dobj) speaking_49\VBG\7109847|role|to|, (r_dep) evaluate_16\VB\670261|in|were|.|patients (r_advcl) included_11\VBN\0|NONE (l_nsubjpass) patients_1\NNS\9898892|in|were|evaluate|. (l_relcl) had_3\VBD\0|Ten (l_dobj) disease_6\NN\14061805|who|with
950631
D010396_D007674 CID penicillamine_2\NN\3740161| (r_npadvmod) induced_4\VBN\1627355|glomerular (r_amod) disease_6\NN\14061805|NONE
D010396_D001172 NONE penicillamine_18\NN\3740161|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treatment_14\NN\654885|NONE (r_pobj) of_13\IN\0| (r_prep) months_12\NNS\15113229|NONE (r_pobj) after_8\IN\0|.|patients|proteinuria (r_prep) developed_5\VBD\1753788|NONE (l_nsubj) patients_1\NNS\9898892|.|after|proteinuria (l_prep) with_2\IN\0|Four (l_pobj) arthritis_4\NN\14171682|NONE
D010396_D011507 CID penicillamine_18\NN\3740161|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treatment_14\NN\654885|NONE (r_pobj) of_13\IN\0| (r_prep) months_12\NNS\15113229|NONE (r_pobj) after_8\IN\0|.|patients|proteinuria (r_prep) developed_5\VBD\1753788|NONE (l_dobj) proteinuria_7\NN\14299637|.|patients|after
7803371
D003915_D003072 CID dextromethorphan_8\NN\0|NONE (r_pobj) of_7\IN\0|term (r_prep) abuse_6\NN\418025|NONE (r_pobj) from_2\IN\0|.|:|report|Cognitive (r_prep) deterioration_1\NN\14560612|NONE
D003915_D003072 CID dm_13\NN\14117805|NONE (r_pobj) of_12\IN\0|prolonged (r_prep) use_11\NN\407535|NONE (r_pobj) from_9\IN\0|NONE (r_prep) resulting_8\VBG\2633881|cognitive (r_acl) deterioration_7\NN\14560612|NONE
9105126
D013256_D018658 CID steroid_9\NN\14727670|term (r_compound) therapy_10\NN\657604|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|ventricular|septal|Postinfarction|. (r_acl) defect_3\NN\14462666|NONE
D013256_D018658 CID steroid_13\NN\14727670|term (r_compound) therapy_14\NN\657604|NONE (r_pobj) on_9\IN\0|NONE (r_prep) patients_8\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|septal|postinfarction|ventricular (r_prep) rupture_6\NN\14285662|NONE
D013256_D018658 CID steroid_4\NN\14727670|rupture|and (r_compound) therapy_5\NN\657604|NONE (l_conj) rupture_10\NN\14285662|steroid|and
15276120
D014859_D006470 CID warfarin_3\RB\2718259| (r_npadvmod) associated_5\VBN\628491|NONE (r_amod) hemorrhage_6\NN\14285662|NONE
D014859_D006470 CID warfarin_4\RB\2718259| (r_npadvmod) related_6\VBN\628491|at (r_amod) bleeding_7\NN\14285662|NONE
11694026
D000082_D014581 NONE paracetamol_4\NN\0|and (r_conj) nimesulide_2\NN\0|NONE (r_pobj) of_1\IN\0|in|. (r_prep) tolerability_0\DT\0|NONE (l_prep) in_5\IN\13603305|.|of (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) angioedema_13\NN\14316714|NONE (l_nmod) urticaria_11\NN\14533203|NONE
D000082_D014581 NONE paracetamol_11\NN\0|and (r_conj) nimesulide_9\NN\0|NONE (r_pobj) of_8\IN\0|reliability|and (r_prep) tolerability_5\NN\0|we|.|In|in (r_dobj) investigated_4\VBD\644583|NONE (l_prep) in_12\IN\13603305|we|tolerability|.|In (l_pobj) number_16\NN\5107765|NONE (l_prep) of_17\IN\0|large|a (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) history_25\NN\15120823|NONE (l_prep) of_26\IN\0|documented|an|exclusive (l_pobj) angioedema_32\NN\14316714|NONE (l_nmod) urticaria_30\NN\14533203|/
D000082_D014581 NONE paracetamol_12\NNP\0|or (r_conj) nimesulide_10\NN\0|NONE (r_pobj) with_9\IN\0|oral|challenge|A|controlled (r_prep) procedure_8\NN\407535|was|to|with|. (r_nsubjpass) applied_14\VBN\0|NONE (l_prep) with_18\IN\0|was|to|procedure|. (l_pobj) history_20\NN\15120823|NONE (l_prep) of_21\IN\0|a (l_pobj) angioedema_27\NN\14316714|NONE (l_nmod) urticaria_25\NN\14533203|/
D000082_D014581 NONE paracetamol_12\NN\0|and (r_conj) nimesulide_10\NN\0|NONE (r_pobj) of_9\IN\0|the|in|good (r_prep) tolerability_8\NN\0|results|,|.|Taken (l_prep) in_13\IN\13603305|the|of|good (l_pobj) patients_14\NNS\9898892|NONE (l_relcl) experienced_16\VBD\2108377|NONE (l_dobj) angioedema_19\NNP\14316714|who (l_nmod) urticaria_17\NN\14533203|caused
D000894_D014581 NONE nsaid_8\NNP\2721538| (r_npadvmod) induced_10\VBN\1627355|/ (r_amod) urticaria_11\NN\14533203|NONE
D000894_D014581 NONE nsaid_27\NNP\2721538| (r_npadvmod) induced_29\VBN\1627355|NONE (r_amod) urticaria_30\NN\14533203|/
D000894_D014581 NONE nsaid_22\NNP\2721538| (r_npadvmod) induced_24\VBN\1627355|NONE (r_amod) urticaria_25\NN\14533203|/
D000894_D014581 NONE nsaid_21\NNP\2721538| (r_npadvmod) induced_23\VBN\1627355|/ (r_amod) urticaria_24\NN\14533203|or|(|alone|angioedema (r_nmod) angioedema_26\NN\14316714|NONE (r_pobj) of_20\IN\0|with|an (r_prep) history_19\NN\15120823|NONE (r_pobj) with_17\IN\0|NONE (r_prep) subjects_16\NNS\6598915|NONE (r_pobj) of_15\IN\0|. (r_prep) %_14\NN\0|of|and|a (r_conj) history_8\NN\15120823|NONE (l_prep) of_9\IN\0|and|a|% (l_pobj) urticaria_11\NN\14533203|NONE
D000894_D014581 NONE nsaid_21\NNP\2721538| (r_npadvmod) induced_23\VBN\1627355|/ (r_amod) urticaria_24\NN\14533203|or|(|alone|angioedema
D000894_D014581 NONE nsaid_21\NNP\2721538| (r_npadvmod) induced_23\VBN\1627355|/ (r_amod) urticaria_24\NN\14533203|or|(|alone|angioedema (r_nmod) angioedema_26\NN\14316714|NONE (r_pobj) of_20\IN\0|with|an (r_prep) history_19\NN\15120823|NONE (l_prep) with_31\IN\0|of|an (l_conj) without_33\IN\0|or (l_pobj) urticaria_35\NN\14533203|NONE
D000894_D014581 NONE nsaids_22\NNS\2721538|NONE (r_pobj) by_21\IN\0|NONE (r_agent) caused_20\VBN\1617192|urticaria (r_acl) angioedema_19\NNP\14316714|who (l_nmod) urticaria_17\NN\14533203|caused
D000894_D014581 NONE nsaid_29\NNP\2721538| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) angioedema_32\NN\14316714|NONE (r_pobj) of_28\IN\0|a (r_prep) history_27\NN\15120823|NONE (r_pobj) by_25\IN\0|,|.|by|,|all|However|risk|and|statistically|,|is (r_prep) increased_13\VBN\169651|NONE (l_agent) by_14\IN\0|,|.|by|,|all|However|risk|and|statistically|,|is (l_pobj) history_16\NN\15120823|NONE (l_prep) of_17\IN\0|a (l_pobj) urticaria_19\NN\14533203|NONE
D000082_D000799 CID paracetamol_4\NN\0|and (r_conj) nimesulide_2\NN\0|NONE (r_pobj) of_1\IN\0|in|. (r_prep) tolerability_0\DT\0|NONE (l_prep) in_5\IN\13603305|.|of (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) angioedema_13\NN\14316714|NONE
D000082_D000799 CID paracetamol_11\NN\0|and (r_conj) nimesulide_9\NN\0|NONE (r_pobj) of_8\IN\0|reliability|and (r_prep) tolerability_5\NN\0|we|.|In|in (r_dobj) investigated_4\VBD\644583|NONE (l_prep) in_12\IN\13603305|we|tolerability|.|In (l_pobj) number_16\NN\5107765|NONE (l_prep) of_17\IN\0|large|a (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) history_25\NN\15120823|NONE (l_prep) of_26\IN\0|documented|an|exclusive (l_pobj) angioedema_32\NN\14316714|NONE
D000082_D000799 CID paracetamol_12\NNP\0|or (r_conj) nimesulide_10\NN\0|NONE (r_pobj) with_9\IN\0|oral|challenge|A|controlled (r_prep) procedure_8\NN\407535|was|to|with|. (r_nsubjpass) applied_14\VBN\0|NONE (l_prep) with_18\IN\0|was|to|procedure|. (l_pobj) history_20\NN\15120823|NONE (l_prep) of_21\IN\0|a (l_pobj) angioedema_27\NN\14316714|NONE
D000082_D000799 CID paracetamol_12\NN\0|and (r_conj) nimesulide_10\NN\0|NONE (r_pobj) of_9\IN\0|the|in|good (r_prep) tolerability_8\NN\0|results|,|.|Taken (l_prep) in_13\IN\13603305|the|of|good (l_pobj) patients_14\NNS\9898892|NONE (l_relcl) experienced_16\VBD\2108377|NONE (l_dobj) angioedema_19\NNP\14316714|who
C012655_D000799 CID nimesulide_2\NN\0|NONE (r_pobj) of_1\IN\0|in|. (r_prep) tolerability_0\DT\0|NONE (l_prep) in_5\IN\13603305|.|of (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) angioedema_13\NN\14316714|NONE
C012655_D000799 CID nimesulide_9\NN\0|NONE (r_pobj) of_8\IN\0|reliability|and (r_prep) tolerability_5\NN\0|we|.|In|in (r_dobj) investigated_4\VBD\644583|NONE (l_prep) in_12\IN\13603305|we|tolerability|.|In (l_pobj) number_16\NN\5107765|NONE (l_prep) of_17\IN\0|large|a (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) history_25\NN\15120823|NONE (l_prep) of_26\IN\0|documented|an|exclusive (l_pobj) angioedema_32\NN\14316714|NONE
C012655_D000799 CID nimesulide_10\NN\0|NONE (r_pobj) with_9\IN\0|oral|challenge|A|controlled (r_prep) procedure_8\NN\407535|was|to|with|. (r_nsubjpass) applied_14\VBN\0|NONE (l_prep) with_18\IN\0|was|to|procedure|. (l_pobj) history_20\NN\15120823|NONE (l_prep) of_21\IN\0|a (l_pobj) angioedema_27\NN\14316714|NONE
C012655_D000799 CID nimesulide_10\NN\0|NONE (r_pobj) of_9\IN\0|the|in|good (r_prep) tolerability_8\NN\0|results|,|.|Taken (l_prep) in_13\IN\13603305|the|of|good (l_pobj) patients_14\NNS\9898892|NONE (l_relcl) experienced_16\VBD\2108377|NONE (l_dobj) angioedema_19\NNP\14316714|who
C012655_D014581 NONE nimesulide_2\NN\0|NONE (r_pobj) of_1\IN\0|in|. (r_prep) tolerability_0\DT\0|NONE (l_prep) in_5\IN\13603305|.|of (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) angioedema_13\NN\14316714|NONE (l_nmod) urticaria_11\NN\14533203|NONE
C012655_D014581 NONE nimesulide_9\NN\0|NONE (r_pobj) of_8\IN\0|reliability|and (r_prep) tolerability_5\NN\0|we|.|In|in (r_dobj) investigated_4\VBD\644583|NONE (l_prep) in_12\IN\13603305|we|tolerability|.|In (l_pobj) number_16\NN\5107765|NONE (l_prep) of_17\IN\0|large|a (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) history_25\NN\15120823|NONE (l_prep) of_26\IN\0|documented|an|exclusive (l_pobj) angioedema_32\NN\14316714|NONE (l_nmod) urticaria_30\NN\14533203|/
C012655_D014581 NONE nimesulide_10\NN\0|NONE (r_pobj) with_9\IN\0|oral|challenge|A|controlled (r_prep) procedure_8\NN\407535|was|to|with|. (r_nsubjpass) applied_14\VBN\0|NONE (l_prep) with_18\IN\0|was|to|procedure|. (l_pobj) history_20\NN\15120823|NONE (l_prep) of_21\IN\0|a (l_pobj) angioedema_27\NN\14316714|NONE (l_nmod) urticaria_25\NN\14533203|/
C012655_D014581 NONE nimesulide_10\NN\0|NONE (r_pobj) of_9\IN\0|the|in|good (r_prep) tolerability_8\NN\0|results|,|.|Taken (l_prep) in_13\IN\13603305|the|of|good (l_pobj) patients_14\NNS\9898892|NONE (l_relcl) experienced_16\VBD\2108377|NONE (l_dobj) angioedema_19\NNP\14316714|who (l_nmod) urticaria_17\NN\14533203|caused
D000894_D000799 CID nsaid_8\NNP\2721538| (r_npadvmod) induced_10\VBN\1627355|/ (r_amod) urticaria_11\NN\14533203|NONE (r_nmod) angioedema_13\NN\14316714|NONE
D000894_D000799 CID nsaid_27\NNP\2721538| (r_npadvmod) induced_29\VBN\1627355|NONE (r_amod) urticaria_30\NN\14533203|/ (r_nmod) angioedema_32\NN\14316714|NONE
D000894_D000799 CID nsaid_22\NNP\2721538| (r_npadvmod) induced_24\VBN\1627355|NONE (r_amod) urticaria_25\NN\14533203|/ (r_nmod) angioedema_27\NN\14316714|NONE
D000894_D000799 CID nsaid_21\NNP\2721538| (r_npadvmod) induced_23\VBN\1627355|/ (r_amod) urticaria_24\NN\14533203|or|(|alone|angioedema (r_nmod) angioedema_26\NN\14316714|NONE
D000894_D000799 CID nsaid_21\NNP\2721538| (r_npadvmod) induced_23\VBN\1627355|/ (r_amod) urticaria_24\NN\14533203|or|(|alone|angioedema (r_nmod) angioedema_26\NN\14316714|NONE (l_conj) angioedema_28\NN\14316714|or|urticaria|(|alone
D000894_D000799 CID nsaids_22\NNS\2721538|NONE (r_pobj) by_21\IN\0|NONE (r_agent) caused_20\VBN\1617192|urticaria (r_acl) angioedema_19\NNP\14316714|who
D000894_D000799 CID nsaid_29\NNP\2721538| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) angioedema_32\NN\14316714|NONE
19707748
D064704_D012640 CID levofloxacin_3\NNS\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBN\628491|:|presentation|. (r_acl) seizures_0\NNS\14081375|NONE
D064704_D012640 CID levofloxacin_15\NNS\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treatment_13\NN\654885|discuss|and (r_dobj) initiating_12\VBG\1617192|shortly|as (r_pcomp) after_11\IN\0|who|seizures (r_prep) developed_8\VBD\1753788|,|of|a (l_dobj) seizures_9\NNS\14081375|after|who
D064704_D012640 CID levofloxacin_15\NNS\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treatment_13\NN\654885|discuss|and (r_dobj) initiating_12\VBG\1617192|shortly|as (r_pcomp) after_11\IN\0|who|seizures (r_prep) developed_8\VBD\1753788|,|of|a (r_relcl) patient_6\NN\9898892|NONE (l_prep) of_47\IN\0|developed|,|a (l_pobj) seizures_51\NNS\14081375|NONE
D064704_D012640 CID levofloxacin_48\NN\0| (r_npadvmod) induced_50\VBN\1627355|NONE (r_amod) seizures_51\NNS\14081375|NONE (r_pobj) of_47\IN\0|developed|,|a (r_prep) patient_6\NN\9898892|NONE (l_relcl) developed_8\VBD\1753788|,|of|a (l_dobj) seizures_9\NNS\14081375|after|who
D064704_D012640 CID levofloxacin_48\NN\0| (r_npadvmod) induced_50\VBN\1627355|NONE (r_amod) seizures_51\NNS\14081375|NONE
D064704_D012640 CID levofloxacin_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) seizures_6\NNS\14081375|NONE
15811908
C037689_D010673 NONE benzamide_14\JJ\0|substituted (r_amod) drugs_15\NNS\14778436|NONE (r_pobj) of_12\IN\0|the (r_prep) use_11\NN\407535|NONE (r_pobj) with_9\IN\0|symptoms|often|but|are|,|is (r_prep) associated_8\VBN\628491|NONE (l_nsubjpass) symptoms_3\NNS\5823932|often|but|are|,|is|with (l_prep) of_4\IN\0|induced (l_pobj) pheochromocytoma_5\NN\14235200|NONE
D063325_D006973 CID tiapride_21\NN\0|NONE (r_compound) therapy_22\NN\657604|and (r_conj) amisulpride_19\NN\0|the|hypertensive|and (r_conj) crisis_17\NN\14411243|NONE (l_amod) hypertensive_16\JJ\10405694|the|and|amisulpride
D063325_D006973 CID tiapride_16\NN\0| (r_npadvmod) induced_18\VBN\1627355|hypertensive (r_amod) crisis_20\NN\14411243|and (l_amod) hypertensive_19\JJ\10405694|induced
D063325_D010673 NONE tiapride_5\NN\0|and (r_conj) amisulpride_3\NN\0|NONE (r_pobj) by_2\IN\0|Pheochromocytoma|. (r_prep) unmasked_1\VBD\853195|NONE (l_nsubj) pheochromocytoma_0\NNP\14235200|by|.
D063325_D010673 NONE tiapride_13\NN\0|and (r_conj) amisulpride_11\NN\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treated_9\VBN\2376958|a (r_acl) patient_8\NN\9898892|NONE (r_pobj) in_6\IN\13603305|of|the (r_prep) unmasking_3\NN\7215377|.|To (l_prep) of_4\IN\0|in|the (l_pobj) pheochromocytoma_5\NN\14235200|NONE
D063325_D010673 NONE tiapride_16\NN\0| (r_npadvmod) induced_18\VBN\1627355|hypertensive (r_amod) crisis_20\NN\14411243|and (r_conj) amisulpride-_14\JJ\0|NONE (r_pobj) of_13\IN\0|first|the|reported|in (r_prep) case_12\NN\7283608|As|,|this|. (l_prep) in_21\IN\13603305|first|the|reported|of (l_pobj) patient_23\NN\9898892|NONE (l_prep) with_24\IN\0|a (l_pobj) pheochromocytoma_25\NN\14235200|NONE
C012052_D014839 CID amisulpride_21\NN\0|NONE (r_pobj) of_20\IN\0|the|first (r_prep) doses_19\NNS\3740161|hours (r_pobj) after_16\IN\0|NONE (r_prep) vomiting_13\NN\116687|man|hypertension|and
C012052_D006261 CID amisulpride_21\NN\0|NONE (r_pobj) of_20\IN\0|the|first (r_prep) doses_19\NNS\3740161|hours (r_pobj) after_16\IN\0|NONE (r_prep) vomiting_13\NN\116687|man|hypertension|and (r_conj) developed_6\VBD\1753788|NONE (l_dobj) hypertension_8\NN\14057371|man|and|vomiting (l_prep) with_9\IN\0|acute (l_pobj) headache_11\NN\5829480|NONE
C012052_D010673 NONE amisulpride_3\NN\0|NONE (r_pobj) by_2\IN\0|Pheochromocytoma|. (r_prep) unmasked_1\VBD\853195|NONE (l_nsubj) pheochromocytoma_0\NNP\14235200|by|.
C012052_D010673 NONE amisulpride_11\NN\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treated_9\VBN\2376958|a (r_acl) patient_8\NN\9898892|NONE (r_pobj) in_6\IN\13603305|of|the (r_prep) unmasking_3\NN\7215377|.|To (l_prep) of_4\IN\0|in|the (l_pobj) pheochromocytoma_5\NN\14235200|NONE
C012052_D010673 NONE amisulpride-_14\JJ\0|NONE (r_pobj) of_13\IN\0|first|the|reported|in (r_prep) case_12\NN\7283608|As|,|this|. (l_prep) in_21\IN\13603305|first|the|reported|of (l_pobj) patient_23\NN\9898892|NONE (l_prep) with_24\IN\0|a (l_pobj) pheochromocytoma_25\NN\14235200|NONE
C012052_D006973 CID amisulpride_21\NN\0|NONE (r_pobj) of_20\IN\0|the|first (r_prep) doses_19\NNS\3740161|hours (r_pobj) after_16\IN\0|NONE (r_prep) vomiting_13\NN\116687|man|hypertension|and (r_conj) developed_6\VBD\1753788|NONE (l_dobj) hypertension_8\NN\14057371|man|and|vomiting
C012052_D006973 CID amisulpride_19\NN\0|the|hypertensive|and (r_conj) crisis_17\NN\14411243|NONE (l_amod) hypertensive_16\JJ\10405694|the|and|amisulpride
C012052_D006973 CID amisulpride-_14\JJ\0|NONE (l_conj) crisis_20\NN\14411243|and (l_amod) hypertensive_19\JJ\10405694|induced
19719056
D002351_D010146 CID carrageenan_17\NN\14898470| (r_npadvmod) induced_19\VBN\1627355|paw|edema|,|rat (r_amod) model_23\NN\5888929|)|and (r_conj) mice_14\NNS\2329401|( (r_appos) model_12\NN\5888929|respectively (r_attr) writhing_11\VBG\1831531|NONE
D019342_D010146 NONE acid_9\NN\14818238|NONE (r_dobj) using_7\VBG\418025|.|activities|induced|were (r_advcl) ascertained_6\VBN\0|NONE (l_conj) induced_10\VBD\1627355|.|activities|using|were (l_xcomp) writhing_11\VBG\1831531|NONE
D019342_D004487 NONE acid_9\NN\14818238|NONE (r_dobj) using_7\VBG\418025|.|activities|induced|were (r_advcl) ascertained_6\VBN\0|NONE (l_conj) induced_10\VBD\1627355|.|activities|using|were (l_xcomp) writhing_11\VBG\1831531|NONE (l_attr) model_12\NN\5888929|respectively (l_appos) mice_14\NNS\2329401|( (l_conj) model_23\NN\5888929|)|and (l_compound) edema_22\NN\14315192|induced|paw|,|rat
D002351_D004487 CID carrageenan_17\NN\14898470| (r_npadvmod) induced_19\VBN\1627355|paw|edema|,|rat (r_amod) model_23\NN\5888929|)|and (l_compound) edema_22\NN\14315192|induced|paw|,|rat
7707116
D015474_D064420 NONE ra_24\NNP\14625458|NONE (r_pobj) of_21\IN\0|,|and|pharmacokinetics|administered (r_prep) toxicities_17\NNS\13576101|following|tolerated|the|,|)|(|MTD
D015474_D064420 NONE ra_6\NNP\14625458|after|was (r_nsubjpass) discontinued_8\VBN\0|toxicities|. (r_advcl) resolved_2\VBD\352826|NONE (l_nsubj) toxicities_1\NNS\13576101|discontinued|.
D015474_D009447 NONE acid_7\NN\14818238|NONE (r_pobj) of_3\IN\0|in|following (r_prep) trial_2\NN\786195|.|Phase (l_prep) in_8\IN\13603305|of|following (l_pobj) children_9\NNS\9622049|NONE (l_prep) with_10\IN\0|NONE (l_pobj) neuroblastoma_11\NN\14239425|NONE
D015474_D009447 NONE acid_11\NN\14818238|NONE (r_pobj) with_7\IN\0|cell|neuroblastoma (r_prep) lines_6\NNS\8426461|NONE (l_compound) neuroblastoma_4\NN\14239425|cell|with
D015474_D009447 NONE ra_15\NNP\14625458|retinoic (r_appos) acid_11\NN\14818238|NONE (r_pobj) with_7\IN\0|cell|neuroblastoma (r_prep) lines_6\NNS\8426461|NONE (l_compound) neuroblastoma_4\NN\14239425|cell|with
D015474_D009447 NONE ra_3\NNP\14625458|responses|Since|has (r_nsubj) demonstrated_5\VBN\2137132|may|,|it|.|effective (l_dobj) responses_7\NNS\11410625|RA|Since|has (l_prep) in_8\IN\13603305|clinical (l_pobj) patients_10\NNS\9898892|NONE (l_compound) neuroblastoma_9\NN\14239425|NONE
D015474_D009447 NONE ra_24\NNP\14625458|NONE (r_pobj) of_21\IN\0|,|and|pharmacokinetics|administered (r_prep) toxicities_17\NNS\13576101|following|tolerated|the|,|)|(|MTD (l_acl) administered_25\VBD\2436349|,|of|and|pharmacokinetics (l_prep) on_26\IN\0|NONE (l_pobj) schedule_29\NN\5898568|NONE (l_prep) in_30\IN\13603305|an|intermittent (l_pobj) children_31\NNS\9622049|NONE (l_prep) with_32\IN\0|NONE (l_pobj) neuroblastoma_33\NN\14239425|NONE
D015474_D006934 CID ra_13\NNP\14625458|serum (r_compound) levels_14\NNS\4916342|NONE (r_pobj) by_9\IN\0|be|may (r_agent) predicted_8\VBN\916909|DLT|hypercalcemia|and|,|. (r_conj) included_2\VBD\0|NONE (l_dobj) hypercalcemia_3\NN\14299637|DLT|and|,|predicted|.
11858397
D008787_D002037 NONE metoclopramide_5\NN\0|NONE (r_pobj) by_4\IN\0|with|in (r_agent) induced_3\VBN\1627355|.|Torsade|de (l_prep) with_10\IN\0|by|in (l_pobj) block_16\NN\21939|NONE
D008787_D002037 NONE metoclopramide_26\NN\0|NONE (r_pobj) of_25\IN\0|intravenous (r_prep) administration_24\NN\1133281|NONE (r_pobj) after_20\IN\0|who|pointes (r_prep) developed_16\VBD\1753788|old|with|a (r_relcl) woman_7\NN\9605289|NONE (l_prep) with_8\IN\0|old|developed|a (l_pobj) block_14\NN\21939|NONE
D020117_D016171 CID cisapride_8\RB\0|were|simultaneously|when (r_nsubjpass) given_12\VBN\5892096|pointes|also|.|patient (r_advcl) developed_3\VBD\1753788|NONE (l_dobj) pointes_6\FW\831651|given|also|.|patient
D008787_D016171 CID metoclopramide_5\NN\0|NONE (r_pobj) by_4\IN\0|with|in (r_agent) induced_3\VBN\1627355|.|Torsade|de (r_acl) pointes_2\NNS\831651|NONE
D008787_D016171 CID metoclopramide_26\NN\0|NONE (r_pobj) of_25\IN\0|intravenous (r_prep) administration_24\NN\1133281|NONE (r_pobj) after_20\IN\0|who|pointes (r_prep) developed_16\VBD\1753788|old|with|a (l_dobj) pointes_19\NNS\831651|who|after
D008787_D016171 CID metoclopramide_6\NN\0|that|pointes|clinically (r_nsubj) provokes_7\VBZ\1617192|the|first (l_dobj) pointes_10\FW\831651|that|metoclopramide|clinically
D008787_D016171 CID metoclopramide_0\NNP\0|be|cautiously|in|.|should (r_nsubjpass) used_3\VBN\0|NONE (l_prep) in_5\IN\13603305|Metoclopramide|be|cautiously|.|should (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) risk_9\NN\14541044|NONE (l_prep) of_10\IN\0|a (l_pobj) pointes_13\FW\831651|NONE
D004917_D016171 CID erythromycin_10\NNP\2716866|and (r_conj) cisapride_8\RB\0|were|simultaneously|when (r_nsubjpass) given_12\VBN\5892096|pointes|also|.|patient (r_advcl) developed_3\VBD\1753788|NONE (l_dobj) pointes_6\FW\831651|given|also|.|patient
7007443
D000082_D017114 CID paracetamol_26\JJ\0|NONE (r_compound) overdose_27\NN\84738|NONE (r_pobj) after_25\IN\0|who|failure (r_prep) survived_21\VBD\0|NONE (l_dobj) failure_24\NN\66216|who|after
D000082_D017114 CID paracetamol_26\JJ\0|NONE (r_compound) overdose_27\NN\84738|NONE (r_pobj) after_25\IN\0|who|failure (r_prep) survived_21\VBD\0|NONE (r_relcl) those_19\DT\0|NONE (r_pobj) in_18\IN\13603305|nearly (r_prep) fourfold_17\RB\0|who|and (r_conj) died_14\VBD\146138|NONE (r_relcl) patients_12\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|.|tenfold|was|increased|activity|, (r_prep) increased_8\VBN\169651|NONE (l_advcl) increased_32\VBN\169651|.|in|tenfold|was|activity|, (l_prep) in_34\IN\13603305|survived|equally|whereas|activities|were (l_pobj) patients_35\NNS\9898892|NONE (l_prep) with_36\IN\0|NONE (l_pobj) failure_39\NN\66216|NONE
D000082_D006525 NONE paracetamol_26\JJ\0|NONE (r_compound) overdose_27\NN\84738|NONE (r_pobj) after_25\IN\0|who|failure (r_prep) survived_21\VBD\0|NONE (r_relcl) those_19\DT\0|NONE (r_pobj) in_18\IN\13603305|nearly (r_prep) fourfold_17\RB\0|who|and (r_conj) died_14\VBD\146138|NONE (r_relcl) patients_12\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|.|tenfold|was|increased|activity|, (r_prep) increased_8\VBN\169651|NONE (l_advcl) increased_32\VBN\169651|.|in|tenfold|was|activity|, (l_prep) in_34\IN\13603305|survived|equally|whereas|activities|were (l_pobj) patients_35\NNS\9898892|NONE (l_prep) with_36\IN\0|NONE (l_pobj) failure_39\NN\66216|NONE (l_amod) due_40\IN\5174653|fulminant|hepatic (l_pcomp) to_41\IN\0|NONE (l_pobj) hepatitis_43\NN\14127211|NONE
D000082_D062787 NONE paracetamol_26\JJ\0|NONE (r_compound) overdose_27\NN\84738|NONE
3653576
C001335_D007674 NONE hcbd_4\NNP\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) produced_2\VBN\1617192|Tubular (r_acl) damage_1\NN\7296428|quantitatively|.|was|from (r_nsubjpass) discriminated_8\VBN\650353|NONE (l_prep) from_13\IN\0|quantitatively|.|was|damage (l_pobj) damage_15\NN\7296428|NONE
C004504_D058186 CID 2-bromoethylamine_36\NN\0|NONE (r_punct) ._42\.\0|PAN|,|produced|and (r_punct) puromycin_29\NNS\0|NONE (l_ccomp) produced_20\VBN\1617192|.|PAN|,|and (l_nsubjpass) models_2\NNS\5888929|were|,|by (l_prep) of_3\IN\0|Acute|experimental (l_pobj) damage_5\NN\7296428|NONE
C004504_D058186 CID bea_38\NNP\0|respectively|, (r_nmod) 2-bromoethylamine_36\NN\0|NONE (r_punct) ._42\.\0|PAN|,|produced|and (r_punct) puromycin_29\NNS\0|NONE (l_ccomp) produced_20\VBN\1617192|.|PAN|,|and (l_nsubjpass) models_2\NNS\5888929|were|,|by (l_prep) of_3\IN\0|Acute|experimental (l_pobj) damage_5\NN\7296428|NONE
C004504_D007674 NONE bea_6\NNP\0|or (r_conj) hcbd_4\NNP\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) produced_2\VBN\1617192|Tubular (r_acl) damage_1\NN\7296428|quantitatively|.|was|from (r_nsubjpass) discriminated_8\VBN\650353|NONE (l_prep) from_13\IN\0|quantitatively|.|was|damage (l_pobj) damage_15\NN\7296428|NONE
D011692_D058186 CID aminonucleoside_30\NN\0|(|) (r_nmod) pan_32\NNP\3101986|.|,|produced|and (r_npadvmod) puromycin_29\NNS\0|NONE (l_ccomp) produced_20\VBN\1617192|.|PAN|,|and (l_nsubjpass) models_2\NNS\5888929|were|,|by (l_prep) of_3\IN\0|Acute|experimental (l_pobj) damage_5\NN\7296428|NONE
D011692_D058186 CID pan_32\NNP\3101986|.|,|produced|and (r_npadvmod) puromycin_29\NNS\0|NONE (l_ccomp) produced_20\VBN\1617192|.|PAN|,|and (l_nsubjpass) models_2\NNS\5888929|were|,|by (l_prep) of_3\IN\0|Acute|experimental (l_pobj) damage_5\NN\7296428|NONE
C001335_D058186 CID hexachloro-1:3-butadiene_24\,\0|NONE (r_pobj) of_23\IN\0|NONE (r_prep) administration_22\NN\1133281|NONE (r_pobj) by_21\IN\0|were|models|, (r_agent) produced_20\VBN\1617192|.|PAN|,|and (l_nsubjpass) models_2\NNS\5888929|were|,|by (l_prep) of_3\IN\0|Acute|experimental (l_pobj) damage_5\NN\7296428|NONE
C001335_D058186 CID hcbd_26\NNP\0|)|( (r_appos) hexachloro-1:3-butadiene_24\,\0|NONE (r_pobj) of_23\IN\0|NONE (r_prep) administration_22\NN\1133281|NONE (r_pobj) by_21\IN\0|were|models|, (r_agent) produced_20\VBN\1617192|.|PAN|,|and (l_nsubjpass) models_2\NNS\5888929|were|,|by (l_prep) of_3\IN\0|Acute|experimental (l_pobj) damage_5\NN\7296428|NONE
D011692_D007674 NONE pan_18\NNP\3101986|NONE (r_pobj) by_17\IN\0|NONE (r_agent) produced_16\VBN\1617192|glomerular (r_acl) damage_15\NN\7296428|NONE
3084782
D008625_D003872 CID tiopronin_12\NNP\0|NONE (r_pobj) to_11\IN\0|NONE (r_pcomp) due_10\IN\5174653|been|.|association|between|and|between|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE (l_conj) dermatitis_9\NN\14226056|and
D008625_D003872 CID tiopronin_12\NNP\0|NONE (r_pobj) to_11\IN\0|NONE (r_pcomp) due_10\IN\5174653|been|.|association|between|and|between|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_28\IN\0|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN\14226056|due
D006046_D009393 NONE gold_32\NN\13371489|and|B (r_compound) thiosulphate_33\NN\0|to (r_pobj) due_30\IN\5174653|dermatitis (r_prep) between_28\IN\0|been|.|association|due|between|and|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE
-1_D009393 NONE thiosulphate_33\NN\0|to (r_pobj) due_30\IN\5174653|dermatitis (r_prep) between_28\IN\0|been|.|association|due|between|and|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE
D006046_D003872 CID gold_32\NN\13371489|and|B (r_compound) thiosulphate_33\NN\0|to (r_pobj) due_30\IN\5174653|dermatitis (r_prep) between_28\IN\0|been|.|association|due|between|and|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE (l_conj) dermatitis_9\NN\14226056|and
D006046_D003872 CID gold_32\NN\13371489|and|B (r_compound) thiosulphate_33\NN\0|to (r_pobj) due_30\IN\5174653|dermatitis (r_prep) between_28\IN\0|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN\14226056|due
D008625_D009393 CID tiopronin_12\NNP\0|NONE (r_pobj) to_11\IN\0|NONE (r_pcomp) due_10\IN\5174653|been|.|association|between|and|between|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE
D008625_D009393 CID tiopronin_17\NNP\0|NONE (r_npadvmod) related_18\VBN\628491|the|nephritis (r_amod) group_20\NN\2137|NONE (l_compound) nephritis_19\NN\14113228|the|related
D008625_D001172 NONE tiopronin_17\NNP\0|NONE (r_npadvmod) related_18\VBN\628491|the|nephritis (r_amod) group_20\NN\2137|NONE (r_pobj) for_15\IN\0|NONE (r_prep) except_14\IN\807461|with (r_prep) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|except (l_pobj) ra_13\NNP\14625458|NONE
D010396_D003872 NONE penicillamine_17\NN\3740161|)|(|class|BCw|and (r_appos) tiopronin_12\NNP\0|NONE (r_pobj) to_11\IN\0|NONE (r_pcomp) due_10\IN\5174653|been|.|association|between|and|between|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE (l_conj) dermatitis_9\NN\14226056|and
D010396_D003872 NONE penicillamine_17\NN\3740161|)|(|class|BCw|and (r_appos) tiopronin_12\NNP\0|NONE (r_pobj) to_11\IN\0|NONE (r_pcomp) due_10\IN\5174653|been|.|association|between|and|between|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_28\IN\0|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN\14226056|due
D010396_D009393 NONE penicillamine_17\NN\3740161|)|(|class|BCw|and (r_appos) tiopronin_12\NNP\0|NONE (r_pobj) to_11\IN\0|NONE (r_pcomp) due_10\IN\5174653|been|.|association|between|and|between|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE
-1_D003872 NONE thiosulphate_33\NN\0|to (r_pobj) due_30\IN\5174653|dermatitis (r_prep) between_28\IN\0|been|.|association|due|between|and|has|, (r_prep) found_5\VBN\13279262|NONE (l_prep) between_6\IN\0|been|.|association|due|and|between|has|, (l_pobj) nephritis_7\NN\14113228|NONE (l_conj) dermatitis_9\NN\14226056|and
-1_D003872 NONE thiosulphate_33\NN\0|to (r_pobj) due_30\IN\5174653|dermatitis (r_prep) between_28\IN\0|been|.|association|due|between|and|has|, (l_pobj) dermatitis_29\NN\14226056|due
3703509
D011241_D011141 NONE prednisone_5\NN\2721538|NONE (r_pobj) to_3\IN\0|short (r_prep) exposure_2\NN\5042871|NONE (r_pobj) following_0\VBG\8180190|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD\1753788|NONE (l_advcl) increasing_12\VBG\169651|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN\14015731|NONE (l_conj) polydipsia_15\NN\14040660|, (l_conj) polyphagia_17\NN\0|, (l_conj) polyuria_20\NN\14113228|and|,
D019344_D007662 NONE lactate_13\NN\14850483|a|known (r_compound) level_14\NN\4916342|NONE (r_pobj) without_9\IN\0|in (r_prep) present_4\JJ\28270|.|was|acidosis (l_prep) in_5\IN\13603305|without (l_pobj) one_6\CD\13741022|NONE (l_conj) ketosis_8\NN\14299637|and
D011241_D006963 NONE prednisone_5\NN\2721538|NONE (r_pobj) to_3\IN\0|short (r_prep) exposure_2\NN\5042871|NONE (r_pobj) following_0\VBG\8180190|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD\1753788|NONE (l_advcl) increasing_12\VBG\169651|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN\14015731|NONE (l_conj) polydipsia_15\NN\14040660|, (l_conj) polyphagia_17\NN\0|,
D011241_D053609 NONE prednisone_5\NN\2721538|NONE (r_pobj) to_3\IN\0|short (r_prep) exposure_2\NN\5042871|NONE (r_pobj) following_0\VBG\8180190|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD\1753788|NONE (l_dobj) lethargy_10\NN\14014621|increasing|Following|,|.|,|boys
D011241_D059606 NONE prednisone_5\NN\2721538|NONE (r_pobj) to_3\IN\0|short (r_prep) exposure_2\NN\5042871|NONE (r_pobj) following_0\VBG\8180190|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD\1753788|NONE (l_advcl) increasing_12\VBG\169651|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN\14015731|NONE (l_conj) polydipsia_15\NN\14040660|,
D011241_D006970 NONE prednisone_5\NN\2721538|NONE (r_pobj) to_3\IN\0|short (r_prep) exposure_2\NN\5042871|NONE (r_pobj) following_0\VBG\8180190|increasing|,|lethargy|.|,|boys (r_prep) developed_9\VBD\1753788|NONE (l_advcl) increasing_12\VBG\169651|Following|,|lethargy|.|,|boys (l_dobj) somnolence_13\NN\14015731|NONE
D019344_D000140 NONE lactate_13\NN\14850483|a|known (r_compound) level_14\NN\4916342|NONE (r_pobj) without_9\IN\0|in (r_prep) present_4\JJ\28270|.|was|acidosis (r_acomp) was_3\VBD\0|NONE (l_nsubj) acidosis_2\NN\14204950|present|.|was
1687392
D015647_D002375 NONE 38393_5\CD\0|agonist|or|agonist||D (r_nummod) skf_4\NNP\0|NONE (r_nmod) quinpirole_9\NN\0|catalepsy|. (r_nsubj) decreased_10\VBD\169651|NONE (l_dobj) catalepsy_12\NN\14023236|quinpirole|.
D015647_D002375 NONE 38393_3\CD\0|NONE (r_nummod) skf_2\NNP\0|NONE (r_pobj) of_1\IN\0|with (r_prep) combination_0\NN\7951464|not|.|did|potentiated (r_nsubj) cause_8\VB\7323922|NONE (l_ccomp) potentiated_9\VBN\229605|Combination|not|.|did (l_dobj) effect_11\NN\34213|NONE (l_prep) on_12\IN\0|induced|inhibitory (l_pobj) catalepsy_13\NN\14023236|NONE
D005476_D002375 CID fluphenazine_2\NN\3713736|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD\1627355|NONE (l_dobj) catalepsy_13\NN\14023236|.|sulpiride|fluphenazine
D005476_D002375 CID fluphenazine_15\NN\3713736|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|the (r_acl) catalepsy_12\NN\14023236|quinpirole|.
C534628_D002375 CID 23390_7\CD\0|antagonist|D|or (r_nummod) sch_6\NNP\0|Dopamine|antagonist|, (r_appos) fluphenazine_2\NN\3713736|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD\1627355|NONE (l_dobj) catalepsy_13\NN\14023236|.|sulpiride|fluphenazine
C534628_D002375 CID 23390_3\CD\0|NONE (r_nummod) sch_2\NNP\0|NONE (r_pobj) of_1\IN\0|with (r_prep) combination_0\NN\7951464|.|did|potentiation|not (r_nsubj) induce_8\VB\1627355|NONE (l_dobj) potentiation_10\NN\13564910|.|did|Combination|not (l_compound) catalepsy_9\NN\14023236|NONE
C534628_D002375 CID 23390_18\CD\0|or|sulpiride (r_nummod) sch_17\NNP\0|, (r_appos) fluphenazine_15\NN\3713736|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|the (r_acl) catalepsy_12\NN\14023236|quinpirole|.
D019257_D002375 NONE quinpirole_9\NN\0|catalepsy|. (r_nsubj) decreased_10\VBD\169651|NONE (l_dobj) catalepsy_12\NN\14023236|quinpirole|.
D019257_D002375 NONE quinpirole_5\NN\0|NONE (r_pobj) with_4\IN\0|of (r_prep) combination_0\NN\7951464|not|.|did|potentiated (r_nsubj) cause_8\VB\7323922|NONE (l_ccomp) potentiated_9\VBN\229605|Combination|not|.|did (l_dobj) effect_11\NN\34213|NONE (l_prep) on_12\IN\0|induced|inhibitory (l_pobj) catalepsy_13\NN\14023236|NONE
D004298_D002375 NONE dopamine_6\NN\14807737|both (r_compound) receptors_7\NNS\5225602|NONE (r_pobj) of_1\IN\0|NONE (r_prep) blockade_0\NN\952963|.|catalepsy|may|in (r_nsubj) induce_9\VB\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|.|may|in|Blockade
D004298_D002375 NONE dopamine_4\NN\14807737|NONE (r_compound) antagonists_5\NNS\7846|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|The (r_acl) catalepsy_1\NN\14023236|been|determined|and|has
D004298_D002375 NONE dopamine_4\NN\14807737|NONE (r_compound) antagonists_5\NNS\7846|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|The (r_acl) catalepsy_1\NN\14023236|been|determined|and|has (r_nsubjpass) tested_8\VBN\670261|NONE (l_conj) determined_18\VBN\0|been|and|has|catalepsy (l_nsubjpass) subtypes_13\NNS\0|.|was (l_acl) involved_14\VBN\2676054|the|possible|dopamine (l_prep) in_15\IN\13603305|NONE (l_pobj) catalepsy_16\NN\14023236|NONE
D004298_D002375 NONE dopamine_12\NN\14807737|the|possible|involved (r_compound) subtypes_13\NNS\0|.|was (r_nsubjpass) determined_18\VBN\0|been|and|has|catalepsy (r_conj) tested_8\VBN\670261|NONE (l_nsubjpass) catalepsy_1\NN\14023236|been|determined|and|has
D004298_D002375 NONE dopamine_12\NN\14807737|the|possible|involved (r_compound) subtypes_13\NNS\0|.|was (l_acl) involved_14\VBN\2676054|the|possible|dopamine (l_prep) in_15\IN\13603305|NONE (l_pobj) catalepsy_16\NN\14023236|NONE
D004298_D002375 NONE dopamine_0\NN\14807737|antagonist|,|SCH (r_compound) fluphenazine_2\NN\3713736|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD\1627355|NONE (l_dobj) catalepsy_13\NN\14023236|.|sulpiride|fluphenazine
D004298_D002375 NONE dopamine_16\NN\14807737|NONE (r_compound) antagonists_17\NNS\7846|NONE (r_pobj) by_15\IN\0|NONE (r_agent) induced_14\VBN\1627355|inhibitory|on (r_acl) effect_11\NN\34213|NONE (l_prep) on_12\IN\0|induced|inhibitory (l_pobj) catalepsy_13\NN\14023236|NONE
D013469_D002375 CID sulpiride_11\NN\0|.|catalepsy|fluphenazine (r_npadvmod) induced_12\VBD\1627355|NONE (l_dobj) catalepsy_13\NN\14023236|.|sulpiride|fluphenazine
D013469_D002375 CID sulpiride_5\NN\0|NONE (r_pobj) with_4\IN\0|of (r_prep) combination_0\NN\7951464|.|did|potentiation|not (r_nsubj) induce_8\VB\1627355|NONE (l_dobj) potentiation_10\NN\13564910|.|did|Combination|not (l_compound) catalepsy_9\NN\14023236|NONE
D013469_D002375 CID sulpiride_20\NN\0||or (r_conj) sch_17\NNP\0|, (r_appos) fluphenazine_15\NN\3713736|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|the (r_acl) catalepsy_12\NN\14023236|quinpirole|.
4090988
D000082_D008113 CID paracetamol_2\NN\0|NONE (l_prep) of_3\IN\0|in (l_pobj) tumours_7\NNS\14234074|NONE
D000082_D008113 CID paracetamol_8\NN\0| (r_npadvmod) treated_10\VBN\2376958|NONE (r_amod) rats_11\NNS\2329401|NONE (r_pobj) of_7\IN\0|the (r_prep) livers_6\NNS\5298729|NONE (r_pobj) of_4\IN\0|An|microscope (r_prep) study_3\NN\635850|changes|. (r_nsubj) revealed_12\VBD\2137132|NONE (l_dobj) changes_14\NNS\7283608|.|study (l_relcl) resemble_19\VBP\2657219|in|ultrastructural (l_dobj) those_20\DT\0|that (l_relcl) result_22\NN\34213|NONE (l_prep) from_23\IN\0|that (l_pobj) exposure_24\NN\5042871|NONE (l_prep) to_25\IN\0|NONE (l_pobj) variety_27\NN\7951464|NONE (l_prep) of_28\IN\0|a (l_pobj) hepatocarcinogens_30\NNS\0|NONE
D000082_D009369 NONE paracetamol_12\JJ\0|NONE (r_compound) feeding_13\NN\838098|NONE (r_dobj) following_11\VBG\8180190|yield|also|. (r_prep) arose_10\VBD\2623529|NONE (l_nsubj) yield_2\NN\913705|following|also|. (l_prep) of_3\IN\0|low|A|at (l_pobj) tumours_4\NNS\14234074|NONE
D000082_D001749 CID paracetamol_2\NN\0|NONE (l_prep) of_3\IN\0|in (l_pobj) tumours_7\NNS\14234074|NONE
D000082_D001749 CID paracetamol_11\RB\0| (r_npadvmod) treated_13\VBN\2376958|all (r_amod) groups_14\NNS\2137|NONE (r_pobj) in_9\IN\13603305|and|bore|,|Papillomas (r_prep) developed_8\VBN\1753788|NONE (l_conj) bore_19\VBD\9631463|and|in|,|Papillomas (l_dobj) carcinomas_21\NNS\14239918|.|rats
D000082_D006965 CID paracetamol_7\NN\0| (r_npadvmod) treated_9\VBN\2376958|NONE (r_amod) rats_10\NNS\2329401|NONE (r_pobj) of_6\IN\0| (r_prep) %_5\NN\0|hyperplasia|Additionally|,|. (r_nsubj) developed_11\VBD\1753788|NONE (l_dobj) hyperplasia_12\NN\14365950|%|Additionally|,|.
D000082_D001744 NONE paracetamol_7\NN\0| (r_npadvmod) treated_9\VBN\2376958|NONE (r_amod) rats_10\NNS\2329401|NONE (r_pobj) of_6\IN\0| (r_prep) %_5\NN\0|hyperplasia|Additionally|,|. (r_nsubj) developed_11\VBD\1753788|NONE (l_dobj) hyperplasia_12\NN\14365950|%|Additionally|,|. (l_prep) of_13\IN\0|NONE (l_pobj) epithelium_16\NN\5267548|NONE (l_relcl) was_19\VBD\0|bladder|,|the (l_acomp) coincident_21\JJ\0|not|which (l_prep) with_22\IN\0|NONE (l_pobj) presence_24\NN\13954253|NONE (l_prep) of_25\IN\0|the (l_pobj) calculi_27\NNS\9416076|NONE
D000082_D010212 NONE paracetamol_11\RB\0| (r_npadvmod) treated_13\VBN\2376958|all (r_amod) groups_14\NNS\2137|NONE (r_pobj) in_9\IN\13603305|and|bore|,|Papillomas (r_prep) developed_8\VBN\1753788|NONE (l_nsubj) papillomas_0\NNP\14236226|and|in|bore|,
11524350
C037663_D012640 CID ropivacaine_6\VBP\0|and (r_conj) levobupivacaine_4\NN\0|NONE (r_pobj) of_3\IN\0|cumulative|The (r_prep) doses_2\NNS\3740161|and|similar|.|seizures|were (r_nsubj) were_10\VBD\0|NONE (l_nsubj) seizures_9\NNS\14081375|and|similar|doses|.|were
D002045_D064420 NONE bupivacaine-_5\DT\0|NONE (r_nmod) rats_13\NNS\2329401|NONE (r_pobj) in_4\IN\13603305|.|Systemic|and|resuscitation (r_prep) toxicity_1\NN\13576101|NONE
D002045_D064420 NONE bupivacaine_6\NN\0|NONE (r_pobj) of_5\IN\0|systemic|the|levobupivacaine|, (r_prep) toxicity_4\NN\13576101|We|.
D002045_D064420 NONE bupivacaine_15\NN\0|and (r_conj) ropivacaine_13\NN\0|NONE (r_pobj) of_12\IN\0|NONE (r_prep) that_11\DT\0|NONE (r_pobj) between_10\IN\0|NONE (r_prep) intermediate_9\JJ\14806838|that|toxicity|administered (r_acomp) is_8\VBZ\0|We (l_nsubj) toxicity_5\NN\13576101|intermediate|that|administered
D002045_D064420 NONE bupivacaine_40\NN\0|NONE (r_pobj) by_39\IN\0|NONE (r_agent) induced_38\VBN\1627355|NONE (r_acl) that_37\DT\0|NONE (r_pobj) than_36\IN\0|more|to (r_prep) susceptible_33\JJ\0|to (r_acomp) be_31\VB\14625458|.|arrest (r_xcomp) appears_29\VBZ\2604760|when|at|and (r_conj) administered_17\VBN\2436349|intermediate|that|toxicity (r_advcl) is_8\VBZ\0|We (l_nsubj) toxicity_5\NN\13576101|intermediate|that|administered
C476513_D001145 CID levobupivacaine_4\NN\0|NONE (r_pobj) of_3\IN\0|The|cumulative|produced (r_prep) doses_2\NNS\3740161|were|smaller|but|, (l_relcl) produced_6\VBD\1617192|of|The|cumulative (l_dobj) dysrhythmias_7\NNS\0|that
D002045_D012640 NONE bupivacaine_18\NN\0|NONE (r_pobj) of_17\IN\0|NONE (r_prep) those_16\DT\0|NONE (r_pobj) than_15\IN\0|NONE (r_prep) larger_14\JJR\0|NONE (r_acomp) were_13\VBD\0|and|similar|doses|.|seizures (r_conj) were_10\VBD\0|NONE (l_nsubj) seizures_9\NNS\14081375|and|similar|doses|.|were
C476513_D006323 CID levobupivacaine_4\NN\0|NONE (r_pobj) of_3\IN\0|The|cumulative|produced (r_prep) doses_2\NNS\3740161|were|smaller|but|, (l_relcl) produced_6\VBD\1617192|of|The|cumulative (l_dobj) dysrhythmias_7\NNS\0|that (l_conj) asystole_9\NN\14204950|and
C476513_D006323 CID levobupivacaine_7\NN\0|NONE (r_pobj) of_6\IN\0|systemic|the (r_prep) toxicity_5\NN\13576101|intermediate|that|administered (r_nsubj) is_8\VBZ\0|We (l_advcl) administered_17\VBN\2436349|intermediate|that|toxicity (l_conj) appears_29\VBZ\2604760|when|at|and (l_nsubj) arrest_28\NN\88481|be|.
C476513_D006323 CID levobupivacaine_42\NN\0|or (r_conj) bupivacaine_40\NN\0|NONE (r_pobj) by_39\IN\0|NONE (r_agent) induced_38\VBN\1627355|NONE (r_acl) that_37\DT\0|NONE (r_pobj) than_36\IN\0|more|to (r_prep) susceptible_33\JJ\0|to (r_acomp) be_31\VB\14625458|.|arrest (r_xcomp) appears_29\VBZ\2604760|when|at|and (l_nsubj) arrest_28\NN\88481|be|.
D002045_D001145 NONE bupivacaine_26\NN\0|NONE (r_pobj) of_25\IN\0|NONE (r_prep) those_24\DT\0|NONE (r_pobj) than_23\IN\0|NONE (r_prep) larger_22\JJR\0|.|they (r_acomp) were_21\VBD\0|smaller|but|,|doses (r_conj) were_10\VBD\0|NONE (l_nsubj) doses_2\NNS\3740161|were|smaller|but|, (l_relcl) produced_6\VBD\1617192|of|The|cumulative (l_dobj) dysrhythmias_7\NNS\0|that
C476513_D064420 NONE levobupivacaine-_7\JJ\0|, (r_conj) bupivacaine-_5\DT\0|NONE (r_nmod) rats_13\NNS\2329401|NONE (r_pobj) in_4\IN\13603305|.|Systemic|and|resuscitation (r_prep) toxicity_1\NN\13576101|NONE
C476513_D064420 NONE levobupivacaine_8\NN\0|systemic|the|of|, (r_conj) toxicity_4\NN\13576101|We|.
C476513_D064420 NONE levobupivacaine_7\NN\0|NONE (r_pobj) of_6\IN\0|systemic|the (r_prep) toxicity_5\NN\13576101|intermediate|that|administered
C476513_D064420 NONE levobupivacaine_42\NN\0|or (r_conj) bupivacaine_40\NN\0|NONE (r_pobj) by_39\IN\0|NONE (r_agent) induced_38\VBN\1627355|NONE (r_acl) that_37\DT\0|NONE (r_pobj) than_36\IN\0|more|to (r_prep) susceptible_33\JJ\0|to (r_acomp) be_31\VB\14625458|.|arrest (r_xcomp) appears_29\VBZ\2604760|when|at|and (r_conj) administered_17\VBN\2436349|intermediate|that|toxicity (r_advcl) is_8\VBZ\0|We (l_nsubj) toxicity_5\NN\13576101|intermediate|that|administered
C476513_D012640 CID levobupivacaine_4\NN\0|NONE (r_pobj) of_3\IN\0|cumulative|The (r_prep) doses_2\NNS\3740161|and|similar|.|seizures|were (r_nsubj) were_10\VBD\0|NONE (l_nsubj) seizures_9\NNS\14081375|and|similar|doses|.|were
C037663_D064420 NONE ropivacaine_10\NN\0| (r_npadvmod) infused_12\VBN\606335|,|or (r_conj) levobupivacaine-_7\JJ\0|, (r_conj) bupivacaine-_5\DT\0|NONE (r_nmod) rats_13\NNS\2329401|NONE (r_pobj) in_4\IN\13603305|.|Systemic|and|resuscitation (r_prep) toxicity_1\NN\13576101|NONE
C037663_D064420 NONE ropivacaine_11\NN\0|and|, (r_conj) levobupivacaine_8\NN\0|systemic|the|of|, (r_conj) toxicity_4\NN\13576101|We|.
C037663_D064420 NONE ropivacaine_13\NN\0|NONE (r_pobj) of_12\IN\0|NONE (r_prep) that_11\DT\0|NONE (r_pobj) between_10\IN\0|NONE (r_prep) intermediate_9\JJ\14806838|that|toxicity|administered (r_acomp) is_8\VBZ\0|We (l_nsubj) toxicity_5\NN\13576101|intermediate|that|administered
C037663_D064420 NONE ropivacaine_24\NN\0| (r_npadvmod) induced_26\VBN\1627355|cardiac|that (r_amod) arrest_28\NN\88481|be|. (r_nsubj) appears_29\VBZ\2604760|when|at|and (r_conj) administered_17\VBN\2436349|intermediate|that|toxicity (r_advcl) is_8\VBZ\0|We (l_nsubj) toxicity_5\NN\13576101|intermediate|that|administered
C037663_D006323 CID ropivacaine_17\NN\0|NONE (r_pobj) of_16\IN\0|the|corresponding (r_prep) doses_15\NNS\3740161|NONE (r_pobj) than_12\IN\0|NONE (r_prep) smaller_11\JJR\0|were|but|,|doses (r_acomp) were_10\VBD\0|NONE (l_nsubj) doses_2\NNS\3740161|were|smaller|but|, (l_relcl) produced_6\VBD\1617192|of|The|cumulative (l_dobj) dysrhythmias_7\NNS\0|that (l_conj) asystole_9\NN\14204950|and
C037663_D006323 CID ropivacaine_13\NN\0|NONE (r_pobj) of_12\IN\0|NONE (r_prep) that_11\DT\0|NONE (r_pobj) between_10\IN\0|NONE (r_prep) intermediate_9\JJ\14806838|that|toxicity|administered (r_acomp) is_8\VBZ\0|We (l_advcl) administered_17\VBN\2436349|intermediate|that|toxicity (l_conj) appears_29\VBZ\2604760|when|at|and (l_nsubj) arrest_28\NN\88481|be|.
C037663_D006323 CID ropivacaine_24\NN\0| (r_npadvmod) induced_26\VBN\1627355|cardiac|that (r_amod) arrest_28\NN\88481|be|.
C037663_D001145 CID ropivacaine_17\NN\0|NONE (r_pobj) of_16\IN\0|the|corresponding (r_prep) doses_15\NNS\3740161|NONE (r_pobj) than_12\IN\0|NONE (r_prep) smaller_11\JJR\0|were|but|,|doses (r_acomp) were_10\VBD\0|NONE (l_nsubj) doses_2\NNS\3740161|were|smaller|but|, (l_relcl) produced_6\VBD\1617192|of|The|cumulative (l_dobj) dysrhythmias_7\NNS\0|that
D002045_D006323 NONE bupivacaine_26\NN\0|NONE (r_pobj) of_25\IN\0|NONE (r_prep) those_24\DT\0|NONE (r_pobj) than_23\IN\0|NONE (r_prep) larger_22\JJR\0|.|they (r_acomp) were_21\VBD\0|smaller|but|,|doses (r_conj) were_10\VBD\0|NONE (l_nsubj) doses_2\NNS\3740161|were|smaller|but|, (l_relcl) produced_6\VBD\1617192|of|The|cumulative (l_dobj) dysrhythmias_7\NNS\0|that (l_conj) asystole_9\NN\14204950|and
D002045_D006323 NONE bupivacaine_15\NN\0|and (r_conj) ropivacaine_13\NN\0|NONE (r_pobj) of_12\IN\0|NONE (r_prep) that_11\DT\0|NONE (r_pobj) between_10\IN\0|NONE (r_prep) intermediate_9\JJ\14806838|that|toxicity|administered (r_acomp) is_8\VBZ\0|We (l_advcl) administered_17\VBN\2436349|intermediate|that|toxicity (l_conj) appears_29\VBZ\2604760|when|at|and (l_nsubj) arrest_28\NN\88481|be|.
D002045_D006323 NONE bupivacaine_40\NN\0|NONE (r_pobj) by_39\IN\0|NONE (r_agent) induced_38\VBN\1627355|NONE (r_acl) that_37\DT\0|NONE (r_pobj) than_36\IN\0|more|to (r_prep) susceptible_33\JJ\0|to (r_acomp) be_31\VB\14625458|.|arrest (r_xcomp) appears_29\VBZ\2604760|when|at|and (l_nsubj) arrest_28\NN\88481|be|.
8106150
D016291_D004409 NONE mk-801_15\NNP\0|NONE (r_punct) ,_16\,\0|markedly|movements|drugs|at|.|but (r_punct) reduced_18\VBD\441445|NONE (l_dobj) movements_21\NNS\191142|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ\0|the
D015632_D004409 NONE mptp_12\NNP\0| (r_npadvmod) treated_14\VBN\2376958|NONE (r_amod) monkeys_15\NNS\2469914|NONE (r_pobj) in_11\IN\13603305|induced (r_prep) dyskinesias_10\NNS\14084880|NONE
D010830_D004409 NONE physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) movements_21\NNS\191142|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ\0|the
D008614_D004409 NONE meperidine_4\RB\3808564|and (r_conj) yohimbine_2\NN\0|.|movements|However|,|predominantly (r_nsubj) reduced_5\VBN\441445|NONE (l_dobj) movements_9\NNS\191142|.|yohimbine|However|,|predominantly (l_amod) dyskinetic_8\JJ\0|the
D003000_D020734 NONE clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_conj) at_23\IN\14622893|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN\13275288|NONE (l_prep) of_26\IN\0|the (l_pobj) return_28\NN\6479665|NONE (l_prep) of_29\IN\0|a (l_pobj) symptomatology_31\NN\0|NONE (l_amod) parkinsonian_30\JJ\0|NONE
D001418_D004409 NONE baclofen_0\NNP\0|also|.|useful (r_nsubj) was_1\VBD\0|NONE (l_acomp) useful_3\JJ\0|also|.|Baclofen (l_prep) against_7\IN\0|in (l_pobj) form_11\NN\6286395|NONE (l_prep) of_12\IN\0|a|dystonic (l_pobj) dyskinesia_13\NN\14084880|NONE
D001418_D020821 NONE baclofen_0\NNP\0|also|.|useful (r_nsubj) was_1\VBD\0|NONE (l_acomp) useful_3\JJ\0|also|.|Baclofen (l_prep) against_7\IN\0|in (l_pobj) form_11\NN\6286395|NONE (l_amod) dystonic_10\JJ\0|a|of
D001285_D002819 NONE atropine_0\NNP\14712692|into|movements|. (r_nsubj) converted_1\VBD\126264|NONE (l_prep) into_5\IN\0|movements|.|Atropine (l_pobj) chorea_6\NN\14253124|NONE
D011433_D004409 NONE propranolol_12\NN\0|MDOT|, (r_conj) methysergide_8\NN\0|, (r_conj) physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) movements_21\NNS\191142|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ\0|the
D016291_D020734 NONE mk-801_15\NNP\0|NONE (r_punct) ,_16\,\0|markedly|movements|drugs|at|.|but (r_punct) reduced_18\VBD\441445|NONE (l_conj) at_23\IN\14622893|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN\13275288|NONE (l_prep) of_26\IN\0|the (l_pobj) return_28\NN\6479665|NONE (l_prep) of_29\IN\0|a (l_pobj) symptomatology_31\NN\0|NONE (l_amod) parkinsonian_30\JJ\0|NONE
D008784_D020734 NONE methysergide_8\NN\0|, (r_conj) physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_conj) at_23\IN\14622893|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN\13275288|NONE (l_prep) of_26\IN\0|the (l_pobj) return_28\NN\6479665|NONE (l_prep) of_29\IN\0|a (l_pobj) symptomatology_31\NN\0|NONE (l_amod) parkinsonian_30\JJ\0|NONE
D008784_D004409 NONE methysergide_8\NN\0|, (r_conj) physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) movements_21\NNS\191142|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ\0|the
D007980_D004409 NONE dopa_7\NN\14601829| (r_npadvmod) induced_9\VBN\1627355|in (r_amod) dyskinesias_10\NNS\14084880|NONE
D007980_D004409 NONE dopa_19\NNP\14601829|NONE (r_pobj) with_16\IN\0|NONE (r_prep) combination_15\NN\7951464|NONE (r_pobj) in_14\IN\13603305|were|.|then|see|series (r_prep) tested_13\VBN\670261|NONE (l_advcl) see_21\VB\8647945|were|.|then|in|series (l_ccomp) modified_28\VBN\109660|to (l_nsubjpass) movements_25\NNS\191142|would|be|if (l_amod) dyskinetic_24\JJ\0|the
D003000_D004409 NONE clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) movements_21\NNS\191142|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ\0|the
D011433_D020734 NONE propranolol_12\NN\0|MDOT|, (r_conj) methysergide_8\NN\0|, (r_conj) physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_conj) at_23\IN\14622893|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN\13275288|NONE (l_prep) of_26\IN\0|the (l_pobj) return_28\NN\6479665|NONE (l_prep) of_29\IN\0|a (l_pobj) symptomatology_31\NN\0|NONE (l_amod) parkinsonian_30\JJ\0|NONE
-1_D020734 NONE 5-mdot_10\CD\0|propranolol|, (r_conj) methysergide_8\NN\0|, (r_conj) physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_conj) at_23\IN\14622893|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN\13275288|NONE (l_prep) of_26\IN\0|the (l_pobj) return_28\NN\6479665|NONE (l_prep) of_29\IN\0|a (l_pobj) symptomatology_31\NN\0|NONE (l_amod) parkinsonian_30\JJ\0|NONE
D015632_D020734 CID mptp_11\NNP\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) parkinsonian_7\NN\0|was|.|group
D001285_D020821 NONE atropine_0\NNP\14712692|into|movements|. (r_nsubj) converted_1\VBD\126264|NONE (l_dobj) movements_4\NNS\191142|into|.|Atropine (l_amod) dystonic_3\JJ\0|the
D015016_D004409 NONE yohimbine_2\NN\0|.|movements|However|,|predominantly (r_nsubj) reduced_5\VBN\441445|NONE (l_dobj) movements_9\NNS\191142|.|yohimbine|However|,|predominantly (l_amod) dyskinetic_8\JJ\0|the
-1_D004409 NONE 5-mdot_10\CD\0|propranolol|, (r_conj) methysergide_8\NN\0|, (r_conj) physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) movements_21\NNS\191142|markedly|drugs|at|,|.|but (l_amod) dyskinetic_20\JJ\0|the
D004298_D004409 NONE dopamine_10\NN\14807737|NONE (r_pobj) than_9\IN\0|NONE (r_prep) other_8\JJ\0|NONE (r_amod) neurotransmitters_7\NNS\14807410|NONE (r_pobj) on_6\IN\0|primarily (r_prep) acting_4\VBG\407535|NONE (r_acl) agents_3\NNS\7347|NONE (r_pobj) of_2\IN\0|A (r_prep) series_1\NN\8456993|were|.|then|in|see (r_nsubjpass) tested_13\VBN\670261|NONE (l_advcl) see_21\VB\8647945|were|.|then|in|series (l_ccomp) modified_28\VBN\109660|to (l_nsubjpass) movements_25\NNS\191142|would|be|if (l_amod) dyskinetic_24\JJ\0|the
D010830_D020734 NONE physostigmine_6\NN\14712692|, (r_conj) clonidine_4\NN\2721160|NONE (r_pobj) including_3\VBG\0|Several|, (r_prep) drugs_1\NNS\14778436|markedly|movements|at|,|.|but (r_nsubj) reduced_18\VBD\441445|NONE (l_conj) at_23\IN\14622893|markedly|movements|drugs|,|.|but (l_pobj) cost_25\NN\13275288|NONE (l_prep) of_26\IN\0|the (l_pobj) return_28\NN\6479665|NONE (l_prep) of_29\IN\0|a (l_pobj) symptomatology_31\NN\0|NONE (l_amod) parkinsonian_30\JJ\0|NONE
3431591
C031662_D064420 NONE 3717_1\CD\0|acid|,|, (r_nummod) cb_0\NN\0|.|inhibitor (r_nsubj) is_6\VBZ\0|NONE (l_attr) inhibitor_11\NN\20090|.|CB (l_relcl) mediated_21\VBN\761713|of|binding|a (l_nsubjpass) cytotoxicity_19\NN\13583478|through|is
C031662_D064420 NONE acid_4\NN\14818238|,|,| (r_appos) cb_0\NN\0|.|inhibitor (r_nsubj) is_6\VBZ\0|NONE (l_attr) inhibitor_11\NN\20090|.|CB (l_relcl) mediated_21\VBN\761713|of|binding|a (l_nsubjpass) cytotoxicity_19\NN\13583478|through|is
C031662_D064420 NONE 3717_28\CD\0|, (r_nummod) cb_27\NNP\0|NONE (r_pobj) than_26\IN\0|more (r_prep) potent_25\JJ\0||,|,| (r_amod) 26-_17\NNPS\0|,|respectively|As|and|be (r_attr) are_16\VBP\13600404|NONE (l_conj) be_39\VB\14625458|,||respectively|As|and (l_attr) determinant_42\NN\5686481|formation|,|may|.|therefore|, (l_prep) of_43\IN\0|an|important (l_pobj) cytotoxicity_46\NN\13583478|NONE
C031662_D064420 NONE 3717_45\CD\0|CB (r_nummod) cytotoxicity_46\NN\13583478|NONE
C031662_D010051 NONE 3717_6\CD\0|NONE (r_nummod) cb_5\NNP\0|NONE (r_pobj) with_4\IN\0|clinical|early (r_prep) studies_3\NNS\635850|NONE (r_pobj) in_0\IN\13603305|,|in|been|has|activity|. (r_prep) seen_11\VBN\2106506|NONE (l_prep) in_12\IN\13603305|,|In|been|has|activity|. (l_pobj) cancer_14\NN\14239425|NONE (l_conj) cancer_17\NN\14239425|breast|,
C031662_D001943 NONE 3717_6\CD\0|NONE (r_nummod) cb_5\NNP\0|NONE (r_pobj) with_4\IN\0|clinical|early (r_prep) studies_3\NNS\635850|NONE (r_pobj) in_0\IN\13603305|,|in|been|has|activity|. (r_prep) seen_11\VBN\2106506|NONE (l_prep) in_12\IN\13603305|,|In|been|has|activity|. (l_pobj) cancer_14\NN\14239425|NONE
C031662_D008654 NONE 3717_6\CD\0|NONE (r_nummod) cb_5\NNP\0|NONE (r_pobj) with_4\IN\0|clinical|early (r_prep) studies_3\NNS\635850|NONE (r_pobj) in_0\IN\13603305|,|in|been|has|activity|. (r_prep) seen_11\VBN\2106506|NONE (l_prep) in_12\IN\13603305|,|In|been|has|activity|. (l_pobj) cancer_14\NN\14239425|NONE (l_conj) cancer_17\NN\14239425|breast|, (l_conj) hepatoma_19\NN\14242337|ovarian|, (l_conj) mesothelioma_22\NN\14242337|,|and
C031662_D006528 NONE 3717_6\CD\0|NONE (r_nummod) cb_5\NNP\0|NONE (r_pobj) with_4\IN\0|clinical|early (r_prep) studies_3\NNS\635850|NONE (r_pobj) in_0\IN\13603305|,|in|been|has|activity|. (r_prep) seen_11\VBN\2106506|NONE (l_prep) in_12\IN\13603305|,|In|been|has|activity|. (l_pobj) cancer_14\NN\14239425|NONE (l_conj) cancer_17\NN\14239425|breast|, (l_conj) hepatoma_19\NN\14242337|ovarian|,
18589141
D006493_D013927 NONE sodium_2\NN\14625458|is|prevent|at|in|. (r_nsubjpass) used_16\VBN\0|NONE (l_xcomp) prevent_24\VB\0|is|at|in|sodium|. (l_dobj) thrombosis_25\NN\14100769|to|after
D006493_D013927 NONE ufh_4\NNP\0|heparin|Unfractionated|(|or|)|heparin (r_appos) sodium_2\NN\14625458|is|prevent|at|in|. (r_nsubjpass) used_16\VBN\0|NONE (l_xcomp) prevent_24\VB\0|is|at|in|sodium|. (l_dobj) thrombosis_25\NN\14100769|to|after
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|.|after (r_amod) thrombocytopenia_3\NN\14189204|NONE
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|HIT (r_amod) thrombocytopenia_3\NN\14189204|decreases|reaction|,|.|resulting
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|HIT (r_amod) thrombocytopenia_3\NN\14189204|decreases|reaction|,|.|resulting (l_appos) hit_5\NNP\36762|induced
D006493_D013921 CID heparin_15\NN\2718259|NONE (r_pobj) to_14\IN\0|an|mediated|adverse (r_prep) reaction_13\NN\13446390|decreases|,|thrombocytopenia|.|resulting (r_attr) is_7\VBZ\0|NONE (l_nsubj) thrombocytopenia_3\NN\14189204|decreases|reaction|,|.|resulting
D006493_D013921 CID heparin_15\NN\2718259|NONE (r_pobj) to_14\IN\0|an|mediated|adverse (r_prep) reaction_13\NN\13446390|decreases|,|thrombocytopenia|.|resulting (r_attr) is_7\VBZ\0|NONE (l_nsubj) thrombocytopenia_3\NN\14189204|decreases|reaction|,|.|resulting (l_appos) hit_5\NNP\36762|induced
D006493_D013921 CID 4/heparin_10\NN\0| (r_nummod) reactive_12\JJ\0|NONE (r_amod) antibody_13\NN\14728724|)|in|(|antibody (r_nmod) positivity_18\NN\13856574|The|after|of (r_conj) frequencies_1\NNS\15286249|.|however|,|unknown|, (l_prep) of_2\IN\0|The|after|positivity (l_pobj) hit_3\NN\36762|NONE
D006493_D013921 CID 4/heparin_10\NN\0| (r_nummod) reactive_12\JJ\0|NONE (r_amod) antibody_13\NN\14728724|)|in|(|antibody (r_nmod) positivity_18\NN\13856574|The|after|of (l_nmod) antibody_16\NN\14728724|)|in|(|antibody (l_nmod) hit_15\NNP\36762|NONE
D006493_D013921 CID ufh_7\NN\0| (r_npadvmod) related_9\VBN\628491|NONE (r_amod) hit_10\NN\36762|.|None
D006493_D001791 NONE heparin_1\NN\2718259| (r_npadvmod) induced_3\VBN\1627355|aggregation|The (r_amod) test_6\NN\5798043|.|in|negative (l_compound) aggregation_5\NN\31264|induced|The
D006495_D013927 NONE heparin_11\NN\2718259|heparin|Unfractionated|(|or|)|UFH (r_conj) sodium_2\NN\14625458|is|prevent|at|in|. (r_nsubjpass) used_16\VBN\0|NONE (l_xcomp) prevent_24\VB\0|is|at|in|sodium|. (l_dobj) thrombosis_25\NN\14100769|to|after
7337133
D000082_D017093 CID acetaminophen_9\NN\2707683|NONE (r_compound) overdose_10\NN\84738|NONE (r_pobj) in_8\IN\13603305|fulminant|hepatic (r_prep) failure_7\NN\66216|NONE
D000082_D017093 CID acetaminophen_6\RB\2707683| (r_advmod) induced_8\VBN\1627355|hepatic|fatal|fulminant (r_amod) failure_11\NN\66216|NONE
D000082_D001929 CID acetaminophen_9\NN\2707683|NONE (r_compound) overdose_10\NN\84738|NONE (r_pobj) in_8\IN\13603305|fulminant|hepatic (r_prep) failure_7\NN\66216|NONE (r_pobj) with_4\IN\0|NONE (r_prep) associated_3\VBN\628491|:|role|.|Massive|cerebral (r_acl) edema_2\NN\14315192|NONE
D000082_D001929 CID acetaminophen_6\RB\2707683| (r_advmod) induced_8\VBN\1627355|hepatic|fatal|fulminant (r_amod) failure_11\NN\66216|NONE (r_pobj) with_4\IN\0|a (r_prep) patient_3\NN\9898892|We|with|.|, (r_dobj) present_1\VBP\28270|NONE (l_prep) with_13\IN\0|We|.|,|patient (l_pobj) signs_14\NNS\6643763|NONE (l_prep) of_17\IN\0|and|symptoms (l_pobj) edema_19\NN\14315192|NONE
D000082_D062787 NONE acetaminophen_9\NN\2707683|NONE (r_compound) overdose_10\NN\84738|NONE
10539815
D004232_D003920 NONE diuretic_49\JJ\3247620|, (r_conj) antiplatelet_47\JJ\0|NONE (r_pobj) of_46\IN\0|NONE (r_prep) use_45\NN\407535|,|and (r_conj) diabetes_42\NNS\14075199|,
D004232_D003920 NONE diuretic_14\JJ\3247620|,|diabetes|and (r_amod) therapy_15\NN\657604|,|older (l_conj) diabetes_18\NNS\14075199|,|and|diuretic
D004656_D018487 NONE enalapril_26\NN\2673637|NONE (r_pobj) of_25\IN\0|controlled|randomized|,|blind|a|for|, (r_prep) trial_24\NN\786195|SOLVD|,|(|)|Ventricular|Left (r_appos) dysfunction_9\NNP\14204950|NONE
D003404_D051437 NONE creatinine_10\NN\0|NONE (r_pobj) in_8\IN\13603305|a (r_prep) rise_7\NN\7324673|NONE (r_pobj) as_5\IN\14622893|was|>|function|/=. (r_prep) defined_4\VBN\2604760|NONE (l_nsubjpass) function_2\NN\13783581|was|>|as|/=.
D003404_D003920 NONE creatinine_25\NN\0|,|ejection (r_conj) fraction_22\NN\14806838|history|,|, (r_conj) age_18\NN\4916342|NONE (l_appos) history_38\NN\15120823|fraction|,|, (l_prep) of_39\IN\0|NONE (l_pobj) hypertension_40\NN\14057371|NONE (l_conj) diabetes_42\NNS\14075199|,
D004656_D051437 CID enalapril_4\NN\2673637|NONE (r_pobj) to_3\IN\0|randomly (r_prep) assigned_2\VBN\2475922|NONE (r_acl) patients_0\NNS\9898892|.|likelihood (r_nsubj) had_5\VBD\0|NONE (l_dobj) likelihood_10\NN\4756172|.|Patients (l_prep) of_11\IN\0|a|greater (l_pobj) function_14\NN\13783581|NONE
D004656_D051437 CID enalapril_9\NN\2673637|NONE (r_compound) groups_10\NNS\2137|age|both|and|the (r_conj) placebo_7\NN\3740161|NONE (r_pobj) in_4\IN\13603305|,|with|were|were|.|,|By (r_prep) associated_20\VBN\628491|NONE (l_prep) with_21\IN\0|,|in|were|were|.|,|By (l_pobj) function_24\NN\13783581|NONE
D004656_D051437 CID enalapril_23\JJ\2673637|ratio|the (r_compound) group_24\NN\2137|NONE (r_pobj) in_21\IN\13603305|significantly|,|so|interval (r_prep) more_19\RBR\0|,|but|was|age|with (r_conj) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|,|but|was|age|more (l_pobj) risk_7\NN\14541044|NONE (l_prep) of_8\IN\0|a|greater (l_pcomp) developing_9\VBG\13541167|NONE (l_dobj) function_12\NN\13783581|NONE
D004656_D051437 CID enalapril_26\NN\2673637|RR|[|(|]|risk|:|years (r_dep) ratio_29\NN\13815152|the|enalapril (r_appos) group_24\NN\2137|NONE (r_pobj) in_21\IN\13603305|significantly|,|so|interval (r_prep) more_19\RBR\0|,|but|was|age|with (r_conj) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|,|but|was|age|more (l_pobj) risk_7\NN\14541044|NONE (l_prep) of_8\IN\0|a|greater (l_pcomp) developing_9\VBG\13541167|NONE (l_dobj) function_12\NN\13783581|NONE
D004656_D051437 CID enalapril_15\JJ\2673637|)|%|(|the (r_compound) group_16\NN\2137|NONE (r_pobj) in_13\IN\13603305|renal|decreased (r_prep) function_12\NN\13783581|NONE
D004656_D051437 CID enalapril_0\NNP\2673637|NONE (r_compound) use_1\NN\407535|.|increase (r_nsubj) caused_2\VBD\1617192|NONE (l_dobj) increase_6\NN\13576355|.|use (l_prep) in_7\IN\13603305|%|a (l_pobj) risk_9\NN\14541044|NONE (l_prep) of_10\IN\0|the (l_pobj) function_13\NN\13783581|NONE
D004656_D051437 CID enalapril_23\JJ\2673637|the (r_compound) group_24\NN\2137|NONE (r_pobj) in_21\IN\13603305|compared|.|risk|was (r_prep) reduced_20\VBN\441445|but|,|Diabetes|with|was (r_conj) associated_2\VBN\628491|NONE (l_prep) with_3\IN\0|but|,|Diabetes|reduced|was (l_pobj) risk_6\NN\14541044|NONE (l_prep) of_7\IN\0|increased|an (l_pobj) impairment_9\NN\7296428|NONE
D004232_D051437 CID diuretic_14\JJ\3247620|,|diabetes|and (r_amod) therapy_15\NN\657604|,|older (r_conj) age_12\NN\4916342|both|and|groups|the (r_conj) placebo_7\NN\3740161|NONE (r_pobj) in_4\IN\13603305|,|with|were|were|.|,|By (r_prep) associated_20\VBN\628491|NONE (l_prep) with_21\IN\0|,|in|were|were|.|,|By (l_pobj) function_24\NN\13783581|NONE
D004232_D051437 CID diuretic_0\JJ\3247620|NONE (r_compound) therapy_1\NN\657604|likewise|was|.|with (r_nsubjpass) associated_4\VBN\628491|NONE (l_prep) with_5\IN\0|likewise|therapy|was|. (l_pobj) risk_8\NN\14541044|NONE (l_prep) of_9\IN\0|greater|a|than (l_pobj) function_12\NN\13783581|NONE
D004656_D006333 NONE enalapril_26\NN\2673637|NONE (r_pobj) of_25\IN\0|controlled|randomized|,|blind|a|for|, (r_prep) trial_24\NN\786195|SOLVD|,|(|)|Ventricular|Left (l_prep) for_27\IN\0|controlled|randomized|,|blind|a|,|of (l_pobj) treatment_29\NN\654885|NONE (l_prep) of_30\IN\0|the (l_pobj) chf_31\NNP\0|NONE
D004656_D006333 NONE enalapril_0\NNP\2673637|NONE (r_compound) use_1\NN\407535|.|increase (r_nsubj) caused_2\VBD\1617192|NONE (l_dobj) increase_6\NN\13576355|.|use (l_prep) in_7\IN\13603305|%|a (l_pobj) risk_9\NN\14541044|NONE (l_prep) of_10\IN\0|the (l_pobj) function_13\NN\13783581|NONE (l_prep) in_14\IN\13603305|decreased|renal (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) chf_17\NNP\0|NONE
D004656_D006333 NONE enalapril_23\JJ\2673637|the (r_compound) group_24\NN\2137|NONE (r_pobj) in_21\IN\13603305|compared|.|risk|was (r_prep) reduced_20\VBN\441445|but|,|Diabetes|with|was (r_conj) associated_2\VBN\628491|NONE (l_prep) with_3\IN\0|but|,|Diabetes|reduced|was (l_pobj) risk_6\NN\14541044|NONE (l_prep) of_7\IN\0|increased|an (l_pobj) impairment_9\NN\7296428|NONE (l_prep) in_10\IN\13603305|renal (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|all (l_pobj) chf_14\NNP\0|NONE
D003404_D006973 NONE creatinine_25\NN\0|,|ejection (r_conj) fraction_22\NN\14806838|history|,|, (r_conj) age_18\NN\4916342|NONE (l_appos) history_38\NN\15120823|fraction|,|, (l_prep) of_39\IN\0|NONE (l_pobj) hypertension_40\NN\14057371|NONE
D000809_D051437 NONE angiotensin_11\NN\4522421| (r_npadvmod) converting_13\VBG\126264|NONE (r_amod) enzyme_14\NN\14723628|inhibitor (r_compound) therapy_16\NN\657604|NONE (r_pobj) during_10\IN\0|with (r_prep) patients_6\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|renal|decreased (r_prep) function_4\NN\13783581|NONE
D000809_D051437 NONE angiotensin_1\NN\4522421| (r_npadvmod) converting_3\VBG\126264|NONE (r_amod) enzyme_4\NN\14723628|inhibitor (r_compound) therapy_6\NN\657604|rates|Although|in (r_nsubj) reduces_7\VBZ\441445|also|it|,|.|function|may (r_advcl) cause_23\VB\7323922|NONE (l_dobj) function_26\NN\13783581|also|reduces|it|,|.|may
D000809_D051437 NONE angiotensin_17\NN\4522421| (r_npadvmod) converting_19\VBG\126264|NONE (r_amod) enzyme_20\NN\14723628|inhibitor (r_compound) therapy_22\NN\657604|who|are (r_dobj) prescribed_16\VBN\748282|NONE (r_relcl) chf_13\NNP\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) patients_11\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|in (r_prep) reduction_6\NN\351485|NONE (l_prep) in_7\IN\13603305|in (l_pobj) function_9\NN\13783581|NONE
D000809_D018487 NONE angiotensin_11\NN\4522421| (r_npadvmod) converting_13\VBG\126264|NONE (r_amod) enzyme_14\NN\14723628|inhibitor (r_compound) therapy_16\NN\657604|NONE (r_pobj) during_10\IN\0|with (r_prep) patients_6\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|renal|decreased (r_prep) function_4\NN\13783581|NONE (r_pobj) of_1\IN\0|NONE (r_prep) predictors_0\NNS\10756433|from|: (r_dep) results_18\NNS\34213|NONE (l_prep) from_19\IN\0|Predictors|: (l_pobj) studies_21\NNS\635850|NONE (l_prep) of_22\IN\0|the (l_pobj) dysfunction_25\NN\14204950|NONE
D004232_D006973 NONE diuretic_49\JJ\3247620|, (r_conj) antiplatelet_47\JJ\0|NONE (r_pobj) of_46\IN\0|NONE (r_prep) use_45\NN\407535|,|and (r_conj) diabetes_42\NNS\14075199|, (r_conj) hypertension_40\NN\14057371|NONE
D004656_D003920 NONE enalapril_9\NN\2673637|NONE (r_compound) groups_10\NNS\2137|age|both|and|the (r_conj) placebo_7\NN\3740161|NONE (l_conj) age_12\NN\4916342|both|and|groups|the (l_conj) therapy_15\NN\657604|,|older (l_conj) diabetes_18\NNS\14075199|,|and|diuretic
D004656_D003920 NONE enalapril_2\NN\2673637|RR|effect|.|,|Conversely (r_nsubj) had_3\VBD\0|NONE (l_npadvmod) rr_9\NN\0|enalapril|effect|.|,|Conversely (l_nummod) 1.33_10\CD\0|( (l_prep) compared_19\VBN\644583|NONE (l_prep) with_20\IN\0|, (l_pobj) placebo_21\NN\3740161|NONE (l_appos) ci_28\NNP\13635336|( (l_prep) in_33\IN\13603305|)|%|RR|,|. (l_pobj) patients_34\NNS\9898892|NONE (l_prep) with_35\IN\0|NONE (l_pobj) diabetes_36\NNS\14075199|NONE
D004656_D003920 NONE enalapril_23\JJ\2673637|the (r_compound) group_24\NN\2137|NONE (r_pobj) in_21\IN\13603305|compared|.|risk|was (r_prep) reduced_20\VBN\441445|but|,|Diabetes|with|was (r_conj) associated_2\VBN\628491|NONE (l_nsubjpass) diabetes_0\NN\14075199|but|,|with|reduced|was
D000809_D006333 NONE angiotensin_11\NN\4522421| (r_npadvmod) converting_13\VBG\126264|NONE (r_amod) enzyme_14\NN\14723628|inhibitor (r_compound) therapy_16\NN\657604|NONE (r_pobj) during_10\IN\0|with (r_prep) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|during (l_pobj) failure_9\NN\66216|NONE
D000809_D006333 NONE angiotensin_1\NN\4522421| (r_npadvmod) converting_3\VBG\126264|NONE (r_amod) enzyme_4\NN\14723628|inhibitor (r_compound) therapy_6\NN\657604|rates|Although|in (r_nsubj) reduces_7\VBZ\441445|also|it|,|.|function|may (l_prep) in_10\IN\13603305|rates|therapy|Although (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) failure_15\NN\66216|NONE
D000809_D006333 NONE angiotensin_1\NN\4522421| (r_npadvmod) converting_3\VBG\126264|NONE (r_amod) enzyme_4\NN\14723628|inhibitor (r_compound) therapy_6\NN\657604|rates|Although|in (r_nsubj) reduces_7\VBZ\441445|also|it|,|.|function|may (l_prep) in_10\IN\13603305|rates|therapy|Although (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) failure_15\NN\66216|NONE (l_appos) chf_17\NNP\0|congestive|heart
D000809_D006333 NONE angiotensin_17\NN\4522421| (r_npadvmod) converting_19\VBG\126264|NONE (r_amod) enzyme_20\NN\14723628|inhibitor (r_compound) therapy_22\NN\657604|who|are (r_dobj) prescribed_16\VBN\748282|NONE (r_relcl) chf_13\NNP\0|NONE
18441470
D008094_D012804 CID lithium_14\NN\14625458|NONE (r_pobj) of_13\IN\0|cardiovascular|the|adverse (r_prep) effects_12\NNS\13245626|NONE (r_pobj) among_8\IN\0|has|dysfunction|.|been|frequently (r_prep) reported_5\VBN\831651|NONE (l_nsubjpass) dysfunction_2\NN\14204950|among|has|.|been|frequently
D008094_D013575 NONE lithium_17\NN\14625458|NONE (r_compound) therapy_18\NN\657604|NONE (r_pobj) to_16\IN\0|,|necessitating|block|.|,|secondary|In (r_prep) developed_14\VBD\1753788|NONE (l_nsubj) block_10\NN\21939|,|necessitating|to|.|,|secondary|In (l_prep) with_11\IN\0|)|(|AV|complete|atrioventricular (l_pobj) attacks_13\NNS\955060|NONE
D008094_D013575 NONE lithium_1\NN\14625458|NONE (r_compound) levels_2\NNS\4916342|during|.|under (r_nsubj) remained_3\VBD\2604760|NONE (l_prep) during_10\IN\0|levels|.|under (l_pobj) attacks_13\NNS\955060|NONE
D008094_D054537 CID lithium_5\NN\14625458|NONE (r_compound) therapy_6\NN\657604|NONE (r_pobj) to_4\IN\0|NONE (r_prep) secondary_3\JJ\8426461|atrioventricular|Complete|. (r_amod) block_2\NN\21939|NONE
D008094_D054537 CID lithium_17\NN\14625458|NONE (r_compound) therapy_18\NN\657604|NONE (r_pobj) to_16\IN\0|,|necessitating|block|.|,|secondary|In (r_prep) developed_14\VBD\1753788|NONE (l_nsubj) block_10\NN\21939|,|necessitating|to|.|,|secondary|In
3973521
11230490
D003520_D001943 NONE cyclophosphamide_12\NN\0|and|encapsulated (r_conj) doxorubicin_10\NN\2716866|NONE (r_pobj) of_6\IN\0|preserved|antitumor (r_prep) efficacy_5\NN\5199286|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN\0|NONE (l_prep) compared_13\VBN\644583|.|Reduced|and|efficacy (l_prep) in_19\IN\13603305|with (l_pobj) trial_24\NN\786195|NONE (l_prep) of_25\IN\0|multicenter|a|randomized|, (l_pobj) cancer_28\NN\14239425|NONE
D003520_D001943 NONE cyclophosphamide_18\NN\0|conventional|and (r_conj) doxorubicin_16\NN\2716866|NONE (r_pobj) with_14\IN\0|in (r_prep) compared_13\VBN\644583|.|Reduced|and|efficacy (l_prep) in_19\IN\13603305|with (l_pobj) trial_24\NN\786195|NONE (l_prep) of_25\IN\0|multicenter|a|randomized|, (l_pobj) cancer_28\NN\14239425|NONE
D003520_D001943 NONE cyclophosphamide_24\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) combination_22\NN\7951464|NONE (r_pobj) in_21\IN\13603305|Corporation|,|Liposome|)|The (r_prep) company_12\NNP\8053576|determine|providing|.|significantly|cardiotoxicity|; (r_nsubj) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE
D003520_D001943 NONE cyclophosphamide_24\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) combination_22\NN\7951464|NONE (r_pobj) in_21\IN\13603305|Corporation|,|Liposome|)|The (r_prep) company_12\NNP\8053576|determine|providing|.|significantly|cardiotoxicity|; (r_nsubj) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE (l_appos) mbc_44\NNP\0|breast|metastatic
D003520_D001943 NONE cyclophosphamide_46\NN\0|NONE (r_pobj) of_45\IN\0|)|with (r_prep) combination_38\NN\7951464|NONE (r_pobj) in_37\IN\13603305|doxorubicin|to|,|,|m(|weeks (r_prep) receive_18\VB\2210855|.|patients|were (r_xcomp) randomized_16\VBN\278117|NONE (l_nsubjpass) patients_5\NNS\9898892|receive|.|were (l_prep) with_6\IN\0|seven|and|chemotherapy (l_pobj) mbc_7\NNP\0|NONE
D003520_D001943 NONE cyclophosphamide_26\NN\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) combination_24\NN\7951464|NONE (r_pobj) in_23\IN\13603305|when|as (r_prep) used_22\VBN\0|efficacy|, (l_prep) as_27\IN\14622893|when|in (l_pobj) therapy_31\NN\657604|NONE (l_prep) for_32\IN\0|line (l_pobj) mbc_33\NNP\0|NONE
D003520_D064420 NONE cyclophosphamide_46\NN\0|NONE (r_pobj) of_45\IN\0|)|with (r_prep) combination_38\NN\7951464|NONE (r_pobj) in_37\IN\13603305|doxorubicin|to|,|,|m(|weeks (r_prep) receive_18\VB\2210855|.|patients|were (l_npadvmod) weeks_53\NNS\15113229|doxorubicin|in|to|,|,|m( (l_prep) until_54\IN\0|every| (l_pobj) progression_56\NN\8457976|NONE (l_conj) toxicity_59\NN\13576101|disease|or
D003520_D009503 CID cyclophosphamide_26\NN\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) combination_24\NN\7951464|NONE (r_pobj) in_23\IN\13603305|when|as (r_prep) used_22\VBN\0|efficacy|, (r_advcl) provides_16\VBZ\2199590|Myocet|neutropenia|and|by|index|. (r_conj) improves_1\VBZ\126264|NONE (l_dobj) neutropenia_14\NN\14196405|Myocet|provides|and|by|index|.
D004317_D066126 NONE doxorubicin_10\NN\2716866|NONE (r_pobj) of_6\IN\0|preserved|antitumor (r_prep) efficacy_5\NN\5199286|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN\0|NONE
D004317_D066126 NONE doxorubicin_16\NN\2716866|NONE (r_pobj) with_14\IN\0|in (r_prep) compared_13\VBN\644583|.|Reduced|and|efficacy (r_prep) cardiotoxicity_1\NN\0|NONE
D004317_D066126 NONE myocet_3\NNP\0|whether|encapsulated (r_nmod) doxorubicin_8\NN\2716866|To (r_dobj) determine_1\VB\0|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ\441445|NONE (l_dobj) cardiotoxicity_28\NN\0|Company|determine|providing|.|significantly|;
D004317_D066126 NONE doxorubicin_8\NN\2716866|To (r_dobj) determine_1\VB\0|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ\441445|NONE (l_dobj) cardiotoxicity_28\NN\0|Company|determine|providing|.|significantly|;
D004317_D066126 NONE doxorubicin_27\NN\2716866|NONE (r_compound) cardiotoxicity_28\NN\0|Company|determine|providing|.|significantly|;
D004317_D066126 NONE myocet_0\NNP\0|provides|neutropenia|and|by|index|. (r_nsubj) improves_1\VBZ\126264|NONE (l_prep) by_7\IN\0|Myocet|provides|neutropenia|and|index|. (l_pcomp) reducing_9\VBG\13447361|NONE (l_dobj) cardiotoxicity_10\NN\0|significantly
D004317_D066126 NONE doxorubicin_6\NN\2716866|NONE (r_pobj) of_5\IN\0|the|therapeutic (r_prep) index_4\NN\13850304|Myocet|provides|neutropenia|and|by|. (r_dobj) improves_1\VBZ\126264|NONE (l_prep) by_7\IN\0|Myocet|provides|neutropenia|and|index|. (l_pcomp) reducing_9\VBG\13447361|NONE (l_dobj) cardiotoxicity_10\NN\0|significantly
D004317_D001943 NONE doxorubicin_10\NN\2716866|NONE (r_pobj) of_6\IN\0|preserved|antitumor (r_prep) efficacy_5\NN\5199286|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN\0|NONE (l_prep) compared_13\VBN\644583|.|Reduced|and|efficacy (l_prep) in_19\IN\13603305|with (l_pobj) trial_24\NN\786195|NONE (l_prep) of_25\IN\0|multicenter|a|randomized|, (l_pobj) cancer_28\NN\14239425|NONE
D004317_D001943 NONE doxorubicin_16\NN\2716866|NONE (r_pobj) with_14\IN\0|in (r_prep) compared_13\VBN\644583|.|Reduced|and|efficacy (l_prep) in_19\IN\13603305|with (l_pobj) trial_24\NN\786195|NONE (l_prep) of_25\IN\0|multicenter|a|randomized|, (l_pobj) cancer_28\NN\14239425|NONE
D004317_D001943 NONE myocet_3\NNP\0|whether|encapsulated (r_nmod) doxorubicin_8\NN\2716866|To (r_dobj) determine_1\VB\0|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE
D004317_D001943 NONE myocet_3\NNP\0|whether|encapsulated (r_nmod) doxorubicin_8\NN\2716866|To (r_dobj) determine_1\VB\0|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE (l_appos) mbc_44\NNP\0|breast|metastatic
D004317_D001943 NONE doxorubicin_8\NN\2716866|To (r_dobj) determine_1\VB\0|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE
D004317_D001943 NONE doxorubicin_8\NN\2716866|To (r_dobj) determine_1\VB\0|Company|providing|.|significantly|cardiotoxicity|; (r_advcl) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE (l_appos) mbc_44\NNP\0|breast|metastatic
D004317_D001943 NONE doxorubicin_27\NN\2716866|NONE (r_compound) cardiotoxicity_28\NN\0|Company|determine|providing|.|significantly|; (r_dobj) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE
D004317_D001943 NONE doxorubicin_27\NN\2716866|NONE (r_compound) cardiotoxicity_28\NN\0|Company|determine|providing|.|significantly|; (r_dobj) reduces_26\VBZ\441445|NONE (l_advcl) providing_30\VBG\2199590|Company|determine|.|significantly|cardiotoxicity|; (l_prep) in_34\IN\13603305|while|efficacy (l_pobj) treatment_38\NN\654885|NONE (l_prep) of_39\IN\0|line (l_pobj) cancer_42\NN\14239425|NONE (l_appos) mbc_44\NNP\0|breast|metastatic
D004317_D001943 NONE myocet_26\NNP\0|(|) (r_nmod) m_28\NNP\13649268|NONE (r_pobj) of_25\IN\0|)|/||mg|or|either (r_prep) m(2_23\NN\0|doxorubicin|in|to|,|,|weeks (r_dobj) receive_18\VB\2210855|.|patients|were (r_xcomp) randomized_16\VBN\278117|NONE (l_nsubjpass) patients_5\NNS\9898892|receive|.|were (l_prep) with_6\IN\0|seven|and|chemotherapy (l_pobj) mbc_7\NNP\0|NONE
D004317_D001943 NONE doxorubicin_32\NN\2716866|in|to|,|,|m(|weeks (r_dobj) receive_18\VB\2210855|.|patients|were (r_xcomp) randomized_16\VBN\278117|NONE (l_nsubjpass) patients_5\NNS\9898892|receive|.|were (l_prep) with_6\IN\0|seven|and|chemotherapy (l_pobj) mbc_7\NNP\0|NONE
D004317_D001943 NONE myocet_0\NNP\0|provides|neutropenia|and|by|index|. (r_nsubj) improves_1\VBZ\126264|NONE (l_conj) provides_16\VBZ\2199590|Myocet|neutropenia|and|by|index|. (l_advcl) used_22\VBN\0|efficacy|, (l_prep) as_27\IN\14622893|when|in (l_pobj) therapy_31\NN\657604|NONE (l_prep) for_32\IN\0|line (l_pobj) mbc_33\NNP\0|NONE
D004317_D001943 NONE doxorubicin_6\NN\2716866|NONE (r_pobj) of_5\IN\0|the|therapeutic (r_prep) index_4\NN\13850304|Myocet|provides|neutropenia|and|by|. (r_dobj) improves_1\VBZ\126264|NONE (l_conj) provides_16\VBZ\2199590|Myocet|neutropenia|and|by|index|. (l_advcl) used_22\VBN\0|efficacy|, (l_prep) as_27\IN\14622893|when|in (l_pobj) therapy_31\NN\657604|NONE (l_prep) for_32\IN\0|line (l_pobj) mbc_33\NNP\0|NONE
D004317_D009503 CID myocet_0\NNP\0|provides|neutropenia|and|by|index|. (r_nsubj) improves_1\VBZ\126264|NONE (l_dobj) neutropenia_14\NN\14196405|Myocet|provides|and|by|index|.
D004317_D009503 CID doxorubicin_6\NN\2716866|NONE (r_pobj) of_5\IN\0|the|therapeutic (r_prep) index_4\NN\13850304|Myocet|provides|neutropenia|and|by|. (r_dobj) improves_1\VBZ\126264|NONE (l_dobj) neutropenia_14\NN\14196405|Myocet|provides|and|by|index|.
D003520_D066126 NONE cyclophosphamide_12\NN\0|and|encapsulated (r_conj) doxorubicin_10\NN\2716866|NONE (r_pobj) of_6\IN\0|preserved|antitumor (r_prep) efficacy_5\NN\5199286|.|compared|Reduced|and (r_conj) cardiotoxicity_1\NN\0|NONE
D003520_D066126 NONE cyclophosphamide_18\NN\0|conventional|and (r_conj) doxorubicin_16\NN\2716866|NONE (r_pobj) with_14\IN\0|in (r_prep) compared_13\VBN\644583|.|Reduced|and|efficacy (r_prep) cardiotoxicity_1\NN\0|NONE
D003520_D066126 NONE cyclophosphamide_24\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) combination_22\NN\7951464|NONE (r_pobj) in_21\IN\13603305|Corporation|,|Liposome|)|The (r_prep) company_12\NNP\8053576|determine|providing|.|significantly|cardiotoxicity|; (r_nsubj) reduces_26\VBZ\441445|NONE (l_dobj) cardiotoxicity_28\NN\0|Company|determine|providing|.|significantly|;
D003520_D066126 NONE cyclophosphamide_26\NN\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) combination_24\NN\7951464|NONE (r_pobj) in_23\IN\13603305|when|as (r_prep) used_22\VBN\0|efficacy|, (r_advcl) provides_16\VBZ\2199590|Myocet|neutropenia|and|by|index|. (r_conj) improves_1\VBZ\126264|NONE (l_prep) by_7\IN\0|Myocet|provides|neutropenia|and|index|. (l_pcomp) reducing_9\VBG\13447361|NONE (l_dobj) cardiotoxicity_10\NN\0|significantly
D004317_D064420 NONE myocet_26\NNP\0|(|) (r_nmod) m_28\NNP\13649268|NONE (r_pobj) of_25\IN\0|)|/||mg|or|either (r_prep) m(2_23\NN\0|doxorubicin|in|to|,|,|weeks (r_dobj) receive_18\VB\2210855|.|patients|were (l_npadvmod) weeks_53\NNS\15113229|doxorubicin|in|to|,|,|m( (l_prep) until_54\IN\0|every| (l_pobj) progression_56\NN\8457976|NONE (l_conj) toxicity_59\NN\13576101|disease|or
D004317_D064420 NONE doxorubicin_32\NN\2716866|in|to|,|,|m(|weeks (r_dobj) receive_18\VB\2210855|.|patients|were (l_npadvmod) weeks_53\NNS\15113229|doxorubicin|in|to|,|,|m( (l_prep) until_54\IN\0|every| (l_pobj) progression_56\NN\8457976|NONE (l_conj) toxicity_59\NN\13576101|disease|or
11467664
D008687_D056486 NONE metformin_12\NN\2719105|NONE (r_pobj) of_11\IN\0|the (r_prep) initiation_10\NN\7450842|wk (r_pobj) after_8\IN\0|the|of (r_prep) onset_2\NN\7325190|NONE (r_pobj) given_0\VBN\5892096|represents|,|we (r_prep) believe_15\VBP\686447|case|.|, (l_ccomp) represents_19\VBZ\2664769|Given|,|we (l_dobj) example_21\NN\5816287|that|case (l_prep) of_22\IN\0|an (l_pobj) hepatotoxicity_26\NN\0|NONE
D008687_D056486 NONE metformin_23\NN\2719105| (r_npadvmod) associated_25\VBN\628491|NONE (r_amod) hepatotoxicity_26\NN\0|NONE
D008687_D041781 CID metformin_7\NN\2719105|NONE (r_pobj) of_6\IN\0|the (r_prep) use_5\NN\407535|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBN\628491|Cholestatic|. (r_acl) jaundice_1\NN\14299637|NONE
D008687_D041781 CID hydrochloride_15\NN\14817592|NONE (r_pobj) with_13\IN\0|NONE (r_prep) treatment_12\NN\654885|NONE (r_pobj) of_11\IN\0|NONE (r_prep) initiation_10\NN\7450842|shortly (r_pobj) after_9\IN\0|who|jaundice (r_prep) developed_5\VBD\1753788|a (l_dobj) jaundice_7\NN\14299637|who|after
D008687_D007565 NONE hydrochloride_1\NN\14817592|resolved|,|was|and (r_nsubjpass) discontinued_3\VBN\0|NONE (l_conj) resolved_10\VBN\352826|,|hydrochloride|was|and (l_nsubj) jaundice_9\NN\14299637|.|slowly|over
D008687_D007565 NONE metformin_12\NN\2719105|NONE (r_pobj) of_11\IN\0|the (r_prep) initiation_10\NN\7450842|wk (r_pobj) after_8\IN\0|the|of (r_prep) onset_2\NN\7325190|NONE (l_prep) of_3\IN\0|the|after (l_pobj) jaundice_5\NN\14299637|NONE
D008687_D007565 NONE metformin_23\NN\2719105| (r_npadvmod) associated_25\VBN\628491|NONE (r_amod) hepatotoxicity_26\NN\0|NONE (r_pobj) of_22\IN\0|an (r_prep) example_21\NN\5816287|that|case (r_dobj) represents_19\VBZ\2664769|Given|,|we (r_ccomp) believe_15\VBP\686447|case|.|, (l_prep) given_0\VBN\5892096|represents|,|we (l_pobj) onset_2\NN\7325190|NONE (l_prep) of_3\IN\0|the|after (l_pobj) jaundice_5\NN\14299637|NONE
19319147
D014859_D006470 NONE warfarin_12\RB\2718259| (r_npadvmod) associated_14\VBN\628491|intracerebral (r_amod) hemorrhage_16\NN\14285662|NONE (r_pobj) of_11\IN\0|mouse|a (r_prep) model_10\NN\5888929|NONE (r_pobj) in_7\IN\13603305|volume|reversal|. (r_prep) reduces_4\VBZ\441445|NONE (l_dobj) volume_6\NN\33615|in|reversal|. (l_compound) hemorrhage_5\NN\14285662|NONE
C025667_D002543 NONE pcc_5\NNP\0|treatment|to|in (r_nsubj) be_7\VB\14625458|NONE (l_attr) treatment_11\NN\654885|to|PCC|in (l_prep) for_12\IN\0|an|effective|acute (l_pobj) ich_15\NNP\0|NONE
D014859_D002543 CID warfarin_12\RB\2718259| (r_npadvmod) associated_14\VBN\628491|intracerebral (r_amod) hemorrhage_16\NN\14285662|NONE
D014859_D002543 CID warfarin_0\NNP\2718259| (r_npadvmod) associated_2\VBN\628491|ICH|intracerebral|) (r_amod) hemorrhage_4\NN\14285662|.|type
D014859_D002543 CID warfarin_0\NNP\2718259| (r_npadvmod) associated_2\VBN\628491|ICH|intracerebral|) (r_amod) hemorrhage_4\NN\14285662|.|type (l_appos) ich_8\NNP\0|intracerebral|)|associated
D014859_D020521 NONE warfarin_0\NNP\2718259| (r_npadvmod) associated_2\VBN\628491|ICH|intracerebral|) (r_amod) hemorrhage_4\NN\14285662|.|type (r_nsubj) is_10\VBZ\0|NONE (l_attr) type_13\NN\5839024|.|hemorrhage (l_prep) of_14\IN\0|a|severe (l_pobj) stroke_15\NN\556313|NONE
2557556
D009020_D006930 NONE morphine_0\NNP\2707683|did|hyperalgesia|,|not|,|however|. (r_nsubj) alter_6\VB\0|NONE (l_dobj) hyperalgesia_8\NN\0|Morphine|did|,|not|,|however|.
D015232_D006930 CID e2-induced_23\VBN\0|prostaglandin (r_amod) hyperalgesia_24\NN\0|NONE
D015124_D006930 CID monophosphate_14\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|the (r_acl) hyperalgesia_8\NN\0|Morphine|did|,|not|,|however|.
4069770
D005839_D058186 CID gentamicin_18\NN\2716866|NONE (r_pobj) with_17\IN\0|day|penicillin|and (r_prep) therapy_16\NN\657604|NONE (r_pobj) after_15\IN\0|of|who (r_prep) died_10\VBD\146138|a|premature (l_prep) of_11\IN\0|who|after (l_pobj) failure_14\NN\66216|NONE
D005839_D007674 NONE gentamicin_0\NNP\2716866|.|in (r_amod) nephropathy_1\NN\14573196|NONE
D010406_D058186 NONE penicillin_28\NN\2716866|with|day|and (r_conj) therapy_16\NN\657604|NONE (r_pobj) after_15\IN\0|of|who (r_prep) died_10\VBD\146138|a|premature (l_prep) of_11\IN\0|who|after (l_pobj) failure_14\NN\66216|NONE
D005839_D001002 NONE gentamicin_2\NN\2716866|The|serum (r_compound) concentration_3\NN\4916342|.|levels|had|developed (r_nsubj) reached_5\VBN\0|NONE (l_advcl) developed_10\VBD\1753788|concentration|.|levels|had (l_nsubj) anuria_9\NN\14061805|when
2840807
D000324_D004421 CID acth_10\NNP\5407119|of|neuropeptide|) (r_nmod) stimulation_12\NN\242808|NONE (r_pobj) after_5\IN\0|A|like|. (r_prep) syndrome_4\NN\5870365|NONE (l_amod) like_3\JJ\5839024|A|.|after (l_npadvmod) dystonia_1\NN\0|
D009074_D004421 CID msh_8\NNP\5407119|/|( (r_nmod) acth_10\NNP\5407119|of|neuropeptide|) (r_nmod) stimulation_12\NN\242808|NONE (r_pobj) after_5\IN\0|A|like|. (r_prep) syndrome_4\NN\5870365|NONE (l_amod) like_3\JJ\5839024|A|.|after (l_npadvmod) dystonia_1\NN\0|
D000324_D009069 NONE acth_20\NNP\5407119||N (r_compound) terminal_23\NN\4306080|at|resulted|the (r_compound) fragments_24\NNS\9385911|NONE (r_pobj) by_18\IN\0|;|were|(|receptors|)|a (r_agent) stimulated_17\VBN\137313|,|However|certain|not|it|cause|.|,|released (r_ccomp) is_3\VBZ\0|NONE (l_conj) cause_57\VB\7323922|,|However|certain|not|it|stimulated|.|,|released (l_ccomp) resulted_94\VBD\2633881|indeed|did (l_nsubj) depression_62\NN\14373582|in|inhibition|,|c|whether (l_relcl) resulted_74\VBD\2633881|term|the|at|targets|(|described|)|; (l_prep) in_75\IN\13603305|that (l_pobj) duration_78\NN\15113229|NONE (l_prep) of_79\IN\0|long|the (l_pobj) disorder_82\NN\14034177|NONE
D000324_D003866 NONE acth_20\NNP\5407119||N (r_compound) terminal_23\NN\4306080|at|resulted|the (r_compound) fragments_24\NNS\9385911|NONE (r_pobj) by_18\IN\0|;|were|(|receptors|)|a (r_agent) stimulated_17\VBN\137313|,|However|certain|not|it|cause|.|,|released (r_ccomp) is_3\VBZ\0|NONE (l_conj) cause_57\VB\7323922|,|However|certain|not|it|stimulated|.|,|released (l_ccomp) resulted_94\VBD\2633881|indeed|did (l_nsubj) depression_62\NN\14373582|in|inhibition|,|c|whether
2533791
D017325_D006509 NONE vaccine_25\NN\3562739|.|injections (r_dobj) derived_22\VBN\634472|and|infants|with|are (r_conj) treated_3\VBN\2376958|NONE (l_prep) with_4\IN\0|derived|and|infants|are (l_pobj) injections_6\NNS\320852|NONE (l_prep) of_7\IN\0|two (l_pobj) globulin_11\NN\14736972|NONE (l_compound) b_9\NNP\1355326|immune|HBIG
18808529
D007545_D007022 NONE isoproterenol_3\NN\3740161| (r_npadvmod) induced_5\VBN\1627355|myocardial (r_amod) damage_7\NN\7296428|NONE (r_pobj) of_2\IN\0|The (r_prep) mechanism_1\NN\13446390|but|is|unknown|, (r_nsubj) is_8\VBZ\0|NONE (l_conj) is_25\VBZ\0|but|unknown|mechanism|, (l_nsubj) mismatch_13\NN\5695806|.|explanation (l_prep) vs._17\IN\0|of|a (l_pobj) demand_18\NN\6513366|NONE (l_prep) following_19\VBG\8180190|NONE (l_pobj) hyperactivity_24\NN\14052403|NONE (l_nmod) hypotension_21\NN\14057371|myocardial
D010100_D007022 NONE oxygen_15\NN\14622893|NONE (r_compound) supply_16\NN\13576355|NONE (r_pobj) of_14\IN\0|vs.|a (r_prep) mismatch_13\NN\5695806|.|explanation (l_prep) vs._17\IN\0|of|a (l_pobj) demand_18\NN\6513366|NONE (l_prep) following_19\VBG\8180190|NONE (l_pobj) hyperactivity_24\NN\14052403|NONE (l_nmod) hypotension_21\NN\14057371|myocardial
D010100_D009202 NONE oxygen_15\NN\14622893|NONE (r_compound) supply_16\NN\13576355|NONE (r_pobj) of_14\IN\0|vs.|a (r_prep) mismatch_13\NN\5695806|.|explanation (r_nsubj) is_25\VBZ\0|but|unknown|mechanism|, (r_conj) is_8\VBZ\0|NONE (l_nsubj) mechanism_1\NN\13446390|but|is|unknown|, (l_prep) of_2\IN\0|The (l_pobj) damage_7\NN\7296428|NONE
D010100_D009202 NONE oxygen_15\NN\14622893|NONE (r_compound) supply_16\NN\13576355|NONE (r_pobj) of_14\IN\0|vs.|a (r_prep) mismatch_13\NN\5695806|.|explanation (l_prep) vs._17\IN\0|of|a (l_pobj) demand_18\NN\6513366|NONE (l_prep) following_19\VBG\8180190|NONE (l_pobj) hyperactivity_24\NN\14052403|NONE
D007545_D009202 CID isoproterenol_0\NN\3740161|correlation|:|loss|. (r_nsubj) induces_1\VBZ\1627355|NONE (l_dobj) correlation_10\NN\13841213|Isoproterenol|:|loss|. (l_prep) with_11\IN\0|NONE (l_pobj) injury_13\NN\14052046|NONE
D007545_D009202 CID isoproterenol_3\NN\3740161| (r_npadvmod) induced_5\VBN\1627355|myocardial (r_amod) damage_7\NN\7296428|NONE
D007545_D009202 CID isoproterenol_3\NN\3740161| (r_npadvmod) induced_5\VBN\1627355|myocardial (r_amod) damage_7\NN\7296428|NONE (r_pobj) of_2\IN\0|The (r_prep) mechanism_1\NN\13446390|but|is|unknown|, (r_nsubj) is_8\VBZ\0|NONE (l_conj) is_25\VBZ\0|but|unknown|mechanism|, (l_nsubj) mismatch_13\NN\5695806|.|explanation (l_prep) vs._17\IN\0|of|a (l_pobj) demand_18\NN\6513366|NONE (l_prep) following_19\VBG\8180190|NONE (l_pobj) hyperactivity_24\NN\14052403|NONE
D007545_D007511 CID isoproterenol_29\NN\3740161|NONE (r_pobj) by_28\IN\0|NONE (r_agent) induced_27\VBN\1627355|severe|the|in (r_acl) alterations_11\NNS\7283608|changes|. (r_dobj) explain_8\VBP\831651|NONE (l_nsubj) changes_1\NNS\7283608|alterations|. (l_acl) related_3\VBN\628491|These|,|, (l_prep) to_4\IN\0|NONE (l_pobj) injury_6\NN\14052046|NONE
9952311
D004317_D009202 NONE adriamycin_7\NNS\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) cardiomyopathy_10\NN\14103288|NONE
D004317_D028361 CID adriamycin_7\NNS\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) cardiomyopathy_10\NN\14103288|NONE (r_pobj) in_6\IN\13603305|suppression|:|Structural|.|of|in (r_prep) impairment_3\NN\7296428|NONE (l_prep) of_4\IN\0|in|suppression|:|Structural|.|in (l_pobj) mitochondria_5\NN\5445668|NONE
D004317_D028361 CID adr_21\NNP\0|NONE (r_pobj) of_20\IN\0|the|deteriorating|on (r_prep) effects_19\NNS\13245626|impairment|that (r_nsubj) involve_25\VBP\2676054|.|,|we|Knowing (l_dobj) impairment_30\NN\7296428|that|effects
D004317_D009369 NONE adriamycin_3\NNS\0|NONE (r_pobj) of_2\IN\0|in|The (r_prep) use_1\NN\407535|has|due|.|been (l_prep) in_7\IN\13603305|of|The (l_pobj) chemotherapy_9\NN\661091|NONE (l_compound) cancer_8\NN\14239425|NONE
D004317_D009369 NONE adr_5\NNP\0|(|) (r_appos) adriamycin_3\NNS\0|NONE (r_pobj) of_2\IN\0|in|The (r_prep) use_1\NN\407535|has|due|.|been (l_prep) in_7\IN\13603305|of|The (l_pobj) chemotherapy_9\NN\661091|NONE (l_compound) cancer_8\NN\14239425|NONE
D004317_D002318 NONE adriamycin_3\NNS\0|NONE (r_pobj) of_2\IN\0|in|The (r_prep) use_1\NN\407535|has|due|.|been (r_nsubjpass) limited_12\VBN\4019101|NONE (l_prep) due_13\IN\5174653|has|use|.|been (l_pcomp) to_14\IN\0|NONE (l_pobj) toxicity_18\NN\13576101|NONE
D004317_D002318 NONE adr_5\NNP\0|(|) (r_appos) adriamycin_3\NNS\0|NONE (r_pobj) of_2\IN\0|in|The (r_prep) use_1\NN\407535|has|due|.|been (r_nsubjpass) limited_12\VBN\4019101|NONE (l_prep) due_13\IN\5174653|has|use|.|been (l_pcomp) to_14\IN\0|NONE (l_pobj) toxicity_18\NN\13576101|NONE
D004317_D001145 NONE adr_10\NNP\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) mice_8\NNS\2329401|NONE (r_pobj) of_7\IN\0| (r_prep) treatment_6\NN\654885|arrhythmias|swelling|that (r_nsubj) caused_11\VBD\1617192|results|. (l_dobj) arrhythmias_13\NNS\14103288|swelling|that|treatment
D004317_D004487 NONE adr_10\NNP\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) mice_8\NNS\2329401|NONE (r_pobj) of_7\IN\0| (r_prep) treatment_6\NN\654885|arrhythmias|swelling|that (r_nsubj) caused_11\VBD\1617192|results|. (l_ccomp) swelling_51\NN\14315071|arrhythmias|that|treatment
D004317_D001919 CID adr_10\NNP\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) mice_8\NNS\2329401|NONE (r_pobj) of_7\IN\0| (r_prep) treatment_6\NN\654885|arrhythmias|swelling|that (r_nsubj) caused_11\VBD\1617192|results|. (l_dobj) arrhythmias_13\NNS\14103288|swelling|that|treatment (l_acl) characterized_14\VBN\609683|cardiovascular (l_agent) by_15\IN\0|NONE (l_pobj) bradycardia_16\NNP\14110674|NONE
10523326
D009569_D006973 NONE oxide_1\NN\14818238|NONE (r_compound) synthase_2\NN\0|Nitric|in|. (r_compound) expression_3\NN\4679549|NONE (l_prep) in_4\IN\13603305|Nitric|synthase|. (l_pobj) course_6\NN\883297|NONE (l_prep) of_7\IN\0|the (l_pobj) hypertension_11\NN\14057371|NONE
D009569_D006973 NONE no_15\DT\7204911|)|NOx|( (r_det) metabolites_16\NNS\20090|NONE (r_pobj) of_14\IN\0|reduced|urinary (r_prep) excretion_13\NN\13466586|species|increased|and|,|We|.|recently (r_dobj) showed_2\VBD\2137132|NONE (l_conj) increased_22\VBD\169651|species|and|,|We|.|recently|excretion (l_dobj) sequestration_24\NN\1201021|NONE (l_prep) as_25\IN\14622893|NO (l_pobj) nitrotyrosine_26\JJ\0|NONE (l_prep) in_27\IN\13603305|NONE (l_pobj) tissues_29\NNS\5220461|NONE (l_prep) in_30\IN\13603305|various (l_pobj) rats_31\NNS\2329401|NONE (l_prep) with_32\IN\0|NONE (l_pobj) hypertension_36\NN\14057371|NONE
D009569_D006973 NONE no_23\DT\7204911|as (r_det) sequestration_24\NN\1201021|NONE (l_prep) as_25\IN\14622893|NO (l_pobj) nitrotyrosine_26\JJ\0|NONE (l_prep) in_27\IN\13603305|NONE (l_pobj) tissues_29\NNS\5220461|NONE (l_prep) in_30\IN\13603305|various (l_pobj) rats_31\NNS\2329401|NONE (l_prep) with_32\IN\0|NONE (l_pobj) hypertension_36\NN\14057371|NONE
D009569_D006973 NONE no_25\DT\7204911|depressed (r_det) synthase_26\NN\0|NOS|(|) (r_nmod) expression_30\NN\4679549|to (r_pobj) due_22\IN\5174653|,|reduction|whether|in|, (r_prep) is_17\VBZ\0|to (l_nsubj) reduction_8\NN\351485|,|whether|in|,|due (l_prep) in_12\IN\13603305|the|in (l_pobj) hypertension_16\NN\14057371|NONE
D009569_D006973 NONE no_11\DT\7204911|,|inhibition|mediated (r_compound) inactivation_12\NN\13518963|to (l_appos) inhibition_17\NN\1068773|,|NO|mediated (l_conj) actions_25\NNS\30358|,|and|associated|of (l_prep) of_26\IN\0|stimulatory|perhaps (l_pobj) stress_29\NN\7083732|NONE (l_acl) associated_30\VBN\628491|shear|increased (l_prep) with_31\IN\0|NONE (l_pobj) hypertension_32\NN\14057371|NONE
C002744_D006973 NONE nitrotyrosine_26\JJ\0|NONE (l_prep) in_27\IN\13603305|NONE (l_pobj) tissues_29\NNS\5220461|NONE (l_prep) in_30\IN\13603305|various (l_pobj) rats_31\NNS\2329401|NONE (l_prep) with_32\IN\0|NONE (l_pobj) hypertension_36\NN\14057371|NONE
D007854_D006973 CID lead_8\NN\5155821| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hypertension_11\NN\14057371|NONE
D007854_D006973 CID lead_33\NN\5155821| (r_npadvmod) induced_35\VBN\1627355|NONE (r_amod) hypertension_36\NN\14057371|NONE
D007854_D006973 CID lead_13\NN\5155821| (r_npadvmod) induced_15\VBN\1627355|NONE (r_amod) hypertension_16\NN\14057371|NONE
D007854_D006973 CID lead_3\NN\5155821| (r_npadvmod) induced_5\VBN\1627355|in (r_amod) hypertension_6\NN\14057371|with|was|.|,|In
D007854_D006973 CID lead_14\NN\5155821| (r_npadvmod) associated_16\VBN\628491|,|and|actions|of (r_amod) inhibition_17\NN\1068773|,|NO|mediated (l_conj) actions_25\NNS\30358|,|and|associated|of (l_prep) of_26\IN\0|stimulatory|perhaps (l_pobj) stress_29\NN\7083732|NONE (l_acl) associated_30\VBN\628491|shear|increased (l_prep) with_31\IN\0|NONE (l_pobj) hypertension_32\NN\14057371|NONE
D010100_D006973 NONE oxygen_5\NN\14622893|reactive|(|,|)|elevated|ROS (r_compound) species_6\NNS\7992450|increased|and|,|We|.|recently|excretion (r_dobj) showed_2\VBD\2137132|NONE (l_conj) increased_22\VBD\169651|species|and|,|We|.|recently|excretion (l_dobj) sequestration_24\NN\1201021|NONE (l_prep) as_25\IN\14622893|NO (l_pobj) nitrotyrosine_26\JJ\0|NONE (l_prep) in_27\IN\13603305|NONE (l_pobj) tissues_29\NNS\5220461|NONE (l_prep) in_30\IN\13603305|various (l_pobj) rats_31\NNS\2329401|NONE (l_prep) with_32\IN\0|NONE (l_pobj) hypertension_36\NN\14057371|NONE
D014810_D006973 NONE e_1\NN\14724645|NONE (r_compound) supplementation_2\NN\5108947|hypertension|lowered|,|. (r_nsubj) ameliorated_3\VBD\126264|NONE (l_dobj) hypertension_4\NN\14057371|supplementation|lowered|,|.
D008315_D006973 NONE mda_8\NNP\0|plasma (r_compound) concentration_9\NN\4916342|raised|,|eNOS|and (r_dobj) lowered_6\VBD\1850315|hypertension|supplementation|,|. (r_conj) ameliorated_3\VBD\126264|NONE (l_dobj) hypertension_4\NN\14057371|supplementation|lowered|,|.
1610717
D003042_D012640 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|behavior|.|and|brainstem (r_amod) seizures_4\NNS\14081375|NONE
783197
D010042_D006333 NONE ouabain_5\NN\0|NONE (r_pobj) of_4\IN\0|)|on|weight|the (r_prep) effects_3\NNS\13245626|We|. (l_prep) on_12\IN\0|)|of|weight|the (l_pobj) parameters_19\NNS\5858936|NONE (l_prep) without_29\IN\0|in|metabolic|volumetric (l_pobj) failure_33\NN\66216|NONE
D010042_D006333 NONE ouabain_26\JJ\0|NONE (r_compound) administration_27\NN\1133281|NONE (r_pobj) after_25\IN\0|is (r_prep) falls_24\VBZ\11692265|We|.|left (r_conj) conclude_1\VBP\628491|NONE (l_ccomp) left_18\VBD\8621598|We|falls|. (l_nsubj) patients_4\NNS\9898892|volume|in|that (l_prep) with_5\IN\0|NONE (l_pobj) disease_9\NN\14061805|NONE (l_relcl) are_11\VBP\13600404|chronic|coronary|artery (l_prep) in_13\IN\13603305|not|who (l_pobj) failure_17\NN\66216|NONE
D010042_D003324 NONE ouabain_2\NN\0|NONE (l_prep) on_3\IN\0|NONE (l_pobj) supply_6\NN\13576355|NONE (l_conj) demand_8\NN\6513366|oxygen|myocardial|and (l_prep) in_9\IN\13603305|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|NONE (l_pobj) disease_15\NN\14061805|NONE
D010042_D003324 NONE ouabain_5\NN\0|NONE (r_pobj) of_4\IN\0|)|on|weight|the (r_prep) effects_3\NNS\13245626|We|. (l_prep) on_12\IN\0|)|of|weight|the (l_pobj) parameters_19\NNS\5858936|NONE (l_prep) in_20\IN\13603305|metabolic|without|volumetric (l_pobj) patients_22\NNS\9898892|NONE (l_prep) with_23\IN\0| (l_pobj) disease_28\NN\14061805|NONE
D010042_D003324 NONE ouabain_26\JJ\0|NONE (r_compound) administration_27\NN\1133281|NONE (r_pobj) after_25\IN\0|is (r_prep) falls_24\VBZ\11692265|We|.|left (r_conj) conclude_1\VBP\628491|NONE (l_ccomp) left_18\VBD\8621598|We|falls|. (l_nsubj) patients_4\NNS\9898892|volume|in|that (l_prep) with_5\IN\0|NONE (l_pobj) disease_9\NN\14061805|NONE
D010100_D003324 NONE oxygen_5\NN\14622893|demand|myocardial|and (r_compound) supply_6\NN\13576355|NONE (l_conj) demand_8\NN\6513366|oxygen|myocardial|and (l_prep) in_9\IN\13603305|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|NONE (l_pobj) disease_15\NN\14061805|NONE
D010100_D003324 NONE oxygen_7\NN\14622893|and|demand|myocardial (r_compound) supply_8\NN\13576355|NONE (r_pobj) on_5\IN\0|digitalis (r_prep) glycosides_4\NNS\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|.|measured|of|but|, (r_nsubj) are_11\VBP\13600404|NONE (l_prep) of_12\IN\0|.|effects|measured|but|, (l_pobj) interest_14\NN\5682570|NONE (l_prep) in_15\IN\13603305|particular (l_pobj) presence_17\NN\13954253|NONE (l_prep) of_18\IN\0|the (l_pobj) disease_22\NN\14061805|NONE
D004071_D003324 NONE glycosides_4\NNS\14727670|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|.|measured|of|but|, (r_nsubj) are_11\VBP\13600404|NONE (l_prep) of_12\IN\0|.|effects|measured|but|, (l_pobj) interest_14\NN\5682570|NONE (l_prep) in_15\IN\13603305|particular (l_pobj) presence_17\NN\13954253|NONE (l_prep) of_18\IN\0|the (l_pobj) disease_22\NN\14061805|NONE
D010042_D002303 CID ouabain_26\JJ\0|NONE (r_compound) administration_27\NN\1133281|NONE (r_pobj) after_25\IN\0|is (r_prep) falls_24\VBZ\11692265|We|.|left
2893236
D018698_D012133 NONE glutamate_11\NN\15010703|,|respiratory (r_conj) paralysis_9\NN\14557898|control|Naloxone|.
D005680_D012133 NONE gaba_0\NNP\14601829|in (r_compound) involvement_1\NN\1080366|reversal|. (r_nsubj) induced_4\VBN\1627355|NONE (l_dobj) reversal_5\NN\199130|involvement|. (l_prep) of_6\IN\0|NONE (l_pobj) paralysis_8\NN\14557898|NONE
D005680_D012133 NONE gaba_13\NNP\14601829|and|levels (r_conj) glutamate_11\NN\15010703|,|respiratory (r_conj) paralysis_9\NN\14557898|control|Naloxone|.
D005680_D012133 NONE gaba_12\NNP\14601829|in (r_dobj) involves_11\VBZ\2676054|and|naloxone|paralysis (r_conj) reverses_4\VBZ\13854649|data|. (l_dobj) paralysis_6\NN\14557898|involves|and|naloxone
D005680_D012131 NONE gaba_12\NNP\14601829|NONE (r_pobj) in_11\IN\13603305|decrease|further|and (r_prep) increase_10\NN\13576355|NONE (r_pobj) with_8\IN\0|produced|,|respiratory|i.v.|mg/kg (r_prep) arrest_7\NN\88481|without|.
D018698_D012131 NONE glutamate_16\NN\15010703|NONE (r_pobj) in_15\IN\13603305|in|again (r_prep) decrease_14\NN\7296428|further|in|and (r_conj) increase_10\NN\13576355|NONE (r_pobj) with_8\IN\0|produced|,|respiratory|i.v.|mg/kg (r_prep) arrest_7\NN\88481|without|.
D009270_D012133 NONE naloxone_3\NN\3808977|NONE (r_pobj) in_2\IN\13603305|GABA (r_prep) involvement_1\NN\1080366|reversal|. (r_nsubj) induced_4\VBN\1627355|NONE (l_dobj) reversal_5\NN\199130|involvement|. (l_prep) of_6\IN\0|NONE (l_pobj) paralysis_8\NN\14557898|NONE
D009270_D012133 NONE naloxone_3\NN\3808977|.|paralysis|In (r_nsubj) reversed_4\VBD\109660|NONE (l_dobj) paralysis_6\NN\14557898|naloxone|.|In
D009270_D012133 NONE naloxone_0\NN\3808977|paralysis|control|. (r_nsubj) reversed_7\VBD\109660|NONE (l_dobj) paralysis_9\NN\14557898|control|Naloxone|.
D009270_D012133 NONE naloxone_3\NN\3808977|involves|and|paralysis (r_nsubj) reverses_4\VBZ\13854649|data|. (l_dobj) paralysis_6\NN\14557898|involves|and|naloxone
D013874_D012133 CID thiopental_11\NN\2792049|NONE (r_pobj) by_10\IN\0|NONE (r_agent) produced_9\VBN\1617192|respiratory (r_acl) paralysis_8\NN\14557898|NONE
D013874_D012133 CID thiopental_9\NN\2792049|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|respiratory (r_acl) paralysis_6\NN\14557898|naloxone|.|In
D013874_D012133 CID thiopental_9\NN\2792049|NONE (r_pobj) by_8\IN\0|NONE (r_agent) produced_7\VBN\1617192|respiratory (r_acl) paralysis_6\NN\14557898|involves|and|naloxone
D000596_D012131 NONE acids_29\NNS\14818238|NONE (r_pobj) of_26\IN\0|NONE (r_prep) any_25\DT\0|NONE (r_dobj) affecting_24\VBG\126264|NONE (r_pcomp) without_23\IN\0|arrest|. (r_prep) stem_22\NN\6290637|NONE (l_nsubj) arrest_7\NN\88481|without|.
D013874_D012131 NONE thiopental_4\NN\2792049|NONE (r_npadvmod) produced_5\VBD\1617192|,|with|respiratory|i.v.|mg/kg (r_amod) arrest_7\NN\88481|without|.
8677458
D015080_D064420 NONE mesna_15\NN\0|along (r_dobj) administering_14\VBG\2436349|NONE (r_pcomp) by_13\IN\0|can|be|that (r_agent) prevented_12\VBN\0|of|a|major|potential (r_relcl) toxicity_6\NN\13576101|cystitis|.
D007069_D006470 CID ifosfamide_7\RB\0| (r_advmod) induced_9\VBN\1627355|hemorrhagic (r_amod) cystitis_11\NN\14566129|to
D007069_D006470 CID ifosfamide_8\NN\0|NONE (r_pobj) of_7\IN\0|prevented|a|major|potential (r_prep) toxicity_6\NN\13576101|cystitis|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) cystitis_1\NN\14566129|toxicity|.
D015080_D003556 CID mesna_4\NN\0|NONE (r_pobj) of_3\IN\0|Continuous|subcutaneous|prevent|. (r_prep) administration_2\NN\1133281|NONE (l_relcl) prevent_6\VB\0|Continuous|of|subcutaneous|. (l_dobj) cystitis_11\NN\14566129|to
D015080_D003556 CID mesna_15\NN\0|along (r_dobj) administering_14\VBG\2436349|NONE (r_pcomp) by_13\IN\0|can|be|that (r_agent) prevented_12\VBN\0|of|a|major|potential (r_relcl) toxicity_6\NN\13576101|cystitis|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) cystitis_1\NN\14566129|toxicity|.
D007069_D003556 CID ifosfamide_7\RB\0| (r_advmod) induced_9\VBN\1627355|hemorrhagic (r_amod) cystitis_11\NN\14566129|to
D007069_D003556 CID ifosfamide_8\NN\0|NONE (r_pobj) of_7\IN\0|prevented|a|major|potential (r_prep) toxicity_6\NN\13576101|cystitis|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) cystitis_1\NN\14566129|toxicity|.
D015080_D006470 CID mesna_4\NN\0|NONE (r_pobj) of_3\IN\0|Continuous|subcutaneous|prevent|. (r_prep) administration_2\NN\1133281|NONE (l_relcl) prevent_6\VB\0|Continuous|of|subcutaneous|. (l_dobj) cystitis_11\NN\14566129|to
D015080_D006470 CID mesna_15\NN\0|along (r_dobj) administering_14\VBG\2436349|NONE (r_pcomp) by_13\IN\0|can|be|that (r_agent) prevented_12\VBN\0|of|a|major|potential (r_relcl) toxicity_6\NN\13576101|cystitis|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) cystitis_1\NN\14566129|toxicity|.
D007069_D064420 NONE ifosfamide_8\NN\0|NONE (r_pobj) of_7\IN\0|prevented|a|major|potential (r_prep) toxicity_6\NN\13576101|cystitis|.
D007069_D014839 NONE ifosfamide_33\RB\0| (r_advmod) induced_35\VBN\1627355|severe (r_amod) emesis_36\NN\116687|and|who|is
D015080_D014839 NONE mesna_19\NN\0|,|inadequate|as (r_compound) concentrations_20\NNS\4916342|NONE (l_prep) as_23\IN\14622893|,|inadequate|mesna (l_prep) in_24\IN\13603305|such (l_pobj) patient_26\NN\9898892|NONE (l_relcl) experiences_31\VBZ\5984287|a|taking (l_dobj) emesis_36\NN\116687|and|who|is
D015080_D014839 NONE mesna_29\NN\0|NONE (r_dobj) taking_27\VBG\37396|a|experiences (r_acl) patient_26\NN\9898892|NONE (l_relcl) experiences_31\VBZ\5984287|a|taking (l_dobj) emesis_36\NN\116687|and|who|is
3411101
D011802_D056486 NONE quinidine_0\NN\2715941|.|responsible|may (r_nsubj) be_5\VB\14625458|NONE (l_acomp) responsible_6\JJ\0|Quinidine|.|may (l_prep) for_7\IN\0|NONE (l_pobj) hepatitis_9\NN\14127211|NONE
C033457_D056486 CID phenylethylbarbiturate_1\NN\0|Quinidine|hepatitis|.|in| (r_npadvmod) induced_3\VBN\1627355|NONE (l_dobj) hepatitis_5\NN\14127211|Quinidine|.|phenylethylbarbiturate|in|
C033457_D056486 CID phenylethylbarbiturate_28\NN\0|NONE (r_pobj) of_26\IN\0|a|month (r_prep) administration_25\NN\1133281|NONE (r_pobj) after_22\IN\0|by|during (r_prep) affected_11\VBN\126264|a|old|Laotian (l_agent) by_12\IN\0|after|during (l_pobj) hepatitis_14\NN\14127211|NONE
C033457_D056486 CID phenylethylbarbiturate_3\NN\0|or|itself (r_conj) quinidine_0\NN\2715941|.|responsible|may (r_nsubj) be_5\VB\14625458|NONE (l_acomp) responsible_6\JJ\0|Quinidine|.|may (l_prep) for_7\IN\0|NONE (l_pobj) hepatitis_9\NN\14127211|NONE
17943461
D015215_D002311 CID zidovudine_12\NNP\3834836|HAART|AZT|;|the (r_appos) component_11\NN\5867413|whether|pathway|and|cause (r_nsubj) triggers_18\VBZ\3659292|to (l_conj) cause_28\VB\7323922|whether|component|pathway|and (l_dobj) disruption_30\NN\1066163|NONE (l_prep) in_31\IN\13603305|cytoskeletal (l_pobj) model_34\NN\5888929|NONE (l_prep) of_35\IN\0|a|murine (l_pobj) dcm_36\NNP\0|NONE
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14\CD\0|NONE (r_appos) zidovudine_12\NNP\3834836|HAART|AZT|;|the (r_appos) component_11\NN\5867413|whether|pathway|and|cause (r_nsubj) triggers_18\VBZ\3659292|to (l_conj) cause_28\VB\7323922|whether|component|pathway|and (l_dobj) disruption_30\NN\1066163|NONE (l_prep) in_31\IN\13603305|cytoskeletal (l_pobj) model_34\NN\5888929|NONE (l_prep) of_35\IN\0|a|murine (l_pobj) dcm_36\NNP\0|NONE
D015215_D002311 CID azt_16\NNP\3834836|HAART|;|zidovudine|the (r_appos) component_11\NN\5867413|whether|pathway|and|cause (r_nsubj) triggers_18\VBZ\3659292|to (l_conj) cause_28\VB\7323922|whether|component|pathway|and (l_dobj) disruption_30\NN\1066163|NONE (l_prep) in_31\IN\13603305|cytoskeletal (l_pobj) model_34\NN\5888929|NONE (l_prep) of_35\IN\0|a|murine (l_pobj) dcm_36\NNP\0|NONE
D015215_D002311 CID azt_69\NNP\3834836|NONE (r_pobj) of_68\IN\0|different (r_prep) concentrations_67\NNS\4916342|NONE (r_dobj) containing_65\VBG\2632940|ad (r_acl) libitum_64\NN\0|mice|In|METHODS|.|: (r_dobj) received_61\VBD\2210855|NONE (l_prep) in_4\IN\13603305|mice|libitum|METHODS|.|: (l_pobj) order_5\NN\7168131|NONE (l_acl) investigate_7\VB\644583|NONE (l_ccomp) triggers_18\VBZ\3659292|to (l_conj) cause_28\VB\7323922|whether|component|pathway|and (l_dobj) disruption_30\NN\1066163|NONE (l_prep) in_31\IN\13603305|cytoskeletal (l_pobj) model_34\NN\5888929|NONE (l_prep) of_35\IN\0|a|murine (l_pobj) dcm_36\NNP\0|NONE
D015215_D002311 CID azt_3\NNP\3834836| (r_npadvmod) treated_5\VBN\2376958|NONE (r_amod) fasl_6\NNPS\0|Tg (r_compound) mice_8\NNS\2329401|with|.|in|,|,|dilation|In (r_nsubj) developed_9\VBD\1753788|NONE (l_dobj) dilation_11\NN\7138085|with|.|in|mice|,|,|In
D015215_D009202 CID azt_7\NNP\3834836| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) cardiomyopathy_10\NN\14103288|NONE
11027904
D020910_D010146 NONE ketorolac_48\RB\3828465|analgesic (r_nmod) agents_53\NNS\7347|,|before|.|was|By (r_conj) examined_23\VBN\0|NONE (l_prep) by_0\IN\0|,|before|.|agents|was (l_pcomp) using_1\VBG\418025|NONE (l_dobj) tolerance_13\NN\5032565|,|design (l_prep) to_14\IN\0|NONE (l_pobj) pain_21\NN\14299637|NONE
D008691_D010146 NONE methadone_3\NN\3808564| (r_npadvmod) maintained_5\VBN\0|opioid (r_amod) abusers_7\NNS\9633969|NONE (r_pobj) in_2\IN\13603305|Pain|. (r_prep) responses_1\NNS\11410625|NONE (l_compound) pain_0\NN\14299637|in|.
D008691_D010146 NONE methadone_19\NN\3808564| (r_compound) maintenance_21\NN\266806|(|)|n|MM|(||) (r_nmod) treatment_25\NN\654885|NONE (r_pobj) in_18\IN\13603305|in (r_prep) stabilized_17\VBD\126264|of|a (r_acl) sample_13\NN\5820620|NONE (r_pobj) in_11\IN\13603305|and|response|pain (r_prep) tolerance_7\NN\5032565|to (l_compound) pain_6\NN\14299637|in|and|response
D004091_D010146 NONE hydromorphone_38\NN\2707683|common (r_parataxis) opioid_36\NN\0|NONE (r_pobj) of_34\IN\0|therapeutic (r_prep) doses_33\NNS\3740161|NONE (r_pobj) of_31\IN\0|oral (r_prep) administration_30\NN\1133281|NONE (r_pobj) after_28\IN\0|both|and (r_conj) before_26\IN\0|,|.|agents|was|By (r_advmod) examined_23\VBN\0|NONE (l_prep) by_0\IN\0|,|before|.|agents|was (l_pcomp) using_1\VBG\418025|NONE (l_dobj) tolerance_13\NN\5032565|,|design (l_prep) to_14\IN\0|NONE (l_pobj) pain_21\NN\14299637|NONE
D008691_D009293 NONE methadone_19\NN\3808564| (r_compound) maintenance_21\NN\266806|(|)|n|MM|(||) (r_nmod) treatment_25\NN\654885|NONE (r_pobj) in_18\IN\13603305|in (r_prep) stabilized_17\VBD\126264|of|a (r_acl) sample_13\NN\5820620|NONE (l_prep) of_14\IN\0|stabilized|a (l_pobj) addicts_16\NNS\10059582|NONE
11705128
D012254_D019698 NONE ribavirin_19\RB\2725367|and (r_conj) interferon_15\NN\2725367|NONE (r_pobj) with_14\IN\0|combination (r_prep) therapy_13\NN\657604|NONE (r_pobj) of_11\IN\0|increased|and|effectiveness (r_prep) efficacy_6\NN\5199286|studies|compared|.|have (r_dobj) demonstrated_4\VBN\2137132|NONE (l_prep) compared_20\VBN\644583|efficacy|studies|.|have (l_prep) with_21\IN\0|NONE (l_pobj) monotherapy_25\NN\0|NONE (l_prep) in_26\IN\13603305|alpha (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|the (l_pobj) c_32\NNP\13714184|NONE
D012254_D019698 NONE ribavirin_19\RB\2725367|and (r_conj) interferon_15\NN\2725367|NONE (r_pobj) with_14\IN\0|combination (r_prep) therapy_13\NN\657604|NONE (r_pobj) of_11\IN\0|increased|and|effectiveness (r_prep) efficacy_6\NN\5199286|studies|compared|.|have (r_dobj) demonstrated_4\VBN\2137132|NONE (l_prep) compared_20\VBN\644583|efficacy|studies|.|have (l_prep) with_21\IN\0|NONE (l_pobj) monotherapy_25\NN\0|NONE (l_prep) in_26\IN\13603305|alpha (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|the (l_pobj) c_32\NNP\13714184|NONE (l_appos) chc_34\NNP\0|(|)|hepatitis|chronic
D012254_D000743 CID ribavirin_3\RB\2725367| (r_npadvmod) induced_5\VBN\1627355|hemolytic|in (r_amod) anemia_7\NN\14189204|NONE
D012254_D000743 CID ribavirin_11\RB\2725367||anemia|.|associated|: (r_npadvmod) induced_13\VBN\1627355|NONE (l_dobj) anemia_15\NN\14189204|ribavirin||.|associated|:
D012254_D000743 CID ribavirin_11\RB\2725367||anemia|.|associated|: (r_npadvmod) induced_13\VBN\1627355|NONE (l_dobj) anemia_15\NN\14189204|ribavirin||.|associated|: (l_appos) riha_17\NNP\0|hemolytic|(|)
D012254_D000743 CID ribavirin_14\JJ\2725367|the (r_compound) dosage_15\NN\13576355|NONE (r_pobj) of_12\IN\0|discontinuation|or (r_prep) reduction_9\NN\351485|.|standard (r_attr) is_8\VBZ\0|NONE (l_nsubj) standard_1\NN\13577171|reduction|. (l_prep) for_4\IN\0|The|of (l_pobj) management_5\NN\1123598|NONE (l_prep) of_6\IN\0|NONE (l_pobj) riha_7\NNP\0|NONE
D012254_D000743 CID ribavirin_7\NN\2725367|NONE (r_pobj) of_6\IN\0|optimal|incidence|the|and (r_prep) dose_5\NN\3740161|NONE (l_conj) incidence_10\NN\13821570|optimal|of|the|and (l_prep) of_11\IN\0|in|the (l_pobj) riha_12\NNP\0|NONE
D012254_D006526 NONE ribavirin_3\RB\2725367| (r_npadvmod) induced_5\VBN\1627355|hemolytic|in (r_amod) anemia_7\NN\14189204|NONE (l_prep) in_8\IN\13603305|hemolytic|induced (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_11\IN\0|the (l_pobj) c_13\NNP\13714184|NONE
D016898_D019698 NONE alpha_24\NN\6828818|in (r_compound) monotherapy_25\NN\0|NONE (l_prep) in_26\IN\13603305|alpha (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|the (l_pobj) c_32\NNP\13714184|NONE
D016898_D019698 NONE alpha_24\NN\6828818|in (r_compound) monotherapy_25\NN\0|NONE (l_prep) in_26\IN\13603305|alpha (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|the (l_pobj) c_32\NNP\13714184|NONE (l_appos) chc_34\NNP\0|(|)|hepatitis|chronic
17975693
D002939_D001008 CID ciprofloxacin-_5\JJ\0|NONE (r_nmod) rats_10\NNS\2329401|in|behaviour|that (r_nsubj) showed_11\VBD\2137132|.|results|:|studied (l_dobj) behaviour_13\NN\14006945|in|rats|that
D009643_D001008 CID norfloxacin_7\NNS\0| (r_npadvmod) treated_9\VBN\2376958|and (r_conj) ciprofloxacin-_5\JJ\0|NONE (r_nmod) rats_10\NNS\2329401|in|behaviour|that (r_nsubj) showed_11\VBD\2137132|.|results|:|studied (l_dobj) behaviour_13\NN\14006945|in|rats|that
18627295
D004317_D009202 CID doxorubicin_0\NNP\2716866|.|are|by (l_dobj) inflammation_4\NN\14299637|and|apoptosis (l_amod) induced_3\VBN\1627355|NONE (l_npadvmod) cardiomyopathy_1\NN\14103288|
D004317_D009202 CID dox_17\NNP\0|NONE (r_compound) cardiomyopathy_18\NN\14103288|NONE
D004317_D009202 CID dox_17\NNP\0|NONE (r_compound) cardiomyopathy_18\NN\14103288|NONE (r_pobj) of_16\IN\0|the (r_prep) development_15\NN\248977|NONE (r_pobj) during_13\IN\0|role|To|) (r_prep) elucidate_1\VB\939277|mice|by|.|,|we (r_advcl) studied_21\VBD\0|NONE (l_prep) by_29\IN\0|mice|.|,|elucidate|we (l_pcomp) investigating_30\VBG\575741|NONE (l_conj) apoptosis_34\NN\11486178|inflammation|and (l_prep) after_35\IN\0|NONE (l_pobj) induction_36\NN\7450842|NONE (l_prep) of_37\IN\0|NONE (l_pobj) cardiomyopathy_41\NN\14103288|NONE
D004317_D009202 CID dox_38\NNP\0| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) cardiomyopathy_41\NN\14103288|NONE (r_pobj) of_37\IN\0|NONE (r_prep) induction_36\NN\7450842|NONE (r_pobj) after_35\IN\0|NONE (r_prep) apoptosis_34\NN\11486178|inflammation|and (r_conj) investigating_30\VBG\575741|NONE (r_pcomp) by_29\IN\0|mice|.|,|elucidate|we (r_prep) studied_21\VBD\0|NONE (l_advcl) elucidate_1\VB\939277|mice|by|.|,|we (l_prep) during_13\IN\0|role|To|) (l_pobj) development_15\NN\248977|NONE (l_prep) of_16\IN\0|the (l_pobj) cardiomyopathy_18\NN\14103288|NONE
D004317_D009202 CID dox_38\NNP\0| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) cardiomyopathy_41\NN\14103288|NONE
D004317_D009202 CID dox_8\NNP\0|NONE (r_pobj) in_7\IN\13603305|that|BR|detrimental|cardiomyopathy|mediates (r_prep) is_5\VBZ\0|findings|. (l_acl) cardiomyopathy_9\NN\14103288|in|that|BR|detrimental|mediates
D004317_D009202 CID dox_16\NNP\0|NONE (r_compound) cardiomyopathy_17\NN\14103288|NONE
D004317_D007249 NONE doxorubicin_0\NNP\2716866|.|are|by (l_dobj) inflammation_4\NN\14299637|and|apoptosis
D004317_D007249 NONE dox_17\NNP\0|NONE (r_compound) cardiomyopathy_18\NN\14103288|NONE (r_pobj) of_16\IN\0|the (r_prep) development_15\NN\248977|NONE (r_pobj) during_13\IN\0|role|To|) (r_prep) elucidate_1\VB\939277|mice|by|.|,|we (r_advcl) studied_21\VBD\0|NONE (l_prep) by_29\IN\0|mice|.|,|elucidate|we (l_pcomp) investigating_30\VBG\575741|NONE (l_dobj) inflammation_32\NN\14299637|and|apoptosis
D004317_D007249 NONE dox_38\NNP\0| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) cardiomyopathy_41\NN\14103288|NONE (r_pobj) of_37\IN\0|NONE (r_prep) induction_36\NN\7450842|NONE (r_pobj) after_35\IN\0|NONE (r_prep) apoptosis_34\NN\11486178|inflammation|and (r_conj) investigating_30\VBG\575741|NONE (l_dobj) inflammation_32\NN\14299637|and|apoptosis
D004317_D066126 NONE doxorubicin_5\NN\2716866|NONE (r_pobj) of_2\IN\0|Clinical (r_prep) use_1\NN\407535|is|by|. (r_nsubjpass) limited_10\VBN\4019101|NONE (l_agent) by_11\IN\0|is|use|. (l_pobj) effects_14\NNS\13245626|NONE (l_amod) cardiotoxic_13\JJ\0|its|,|attributed
D004317_D066126 NONE dox_7\NNP\0|the|anthracycline|) (r_appos) doxorubicin_5\NN\2716866|NONE (r_pobj) of_2\IN\0|Clinical (r_prep) use_1\NN\407535|is|by|. (r_nsubjpass) limited_10\VBN\4019101|NONE (l_agent) by_11\IN\0|is|use|. (l_pobj) effects_14\NNS\13245626|NONE (l_amod) cardiotoxic_13\JJ\0|its|,|attributed
D004317_D006331 NONE dox_0\NN\0|NONE (r_compound) control_1\NN\5190804|NONE (r_compound) mice_2\NNS\2329401|.|dysfunction (r_nsubj) showed_3\VBD\2137132|NONE (l_dobj) dysfunction_5\NN\14204950|.|mice
D004317_D006331 NONE dox_1\NNP\0|BR(/|) (r_nmod) mice_4\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|compared|dysfunction|was|,|. (r_prep) improved_9\VBN\126264|NONE (l_nsubjpass) dysfunction_7\NN\14204950|compared|was|,|In|.
D004317_D006331 NONE dox_12\NNP\0|control|,|associated (r_compound) mice_14\NNS\2329401|NONE (r_pobj) to_11\IN\0|NONE (r_prep) compared_10\VBN\644583|dysfunction|was|,|In|. (r_prep) improved_9\VBN\126264|NONE (l_nsubjpass) dysfunction_7\NN\14204950|compared|was|,|In|.
D018943_D066126 NONE anthracycline_4\NN\0|the|)|DOX (r_amod) doxorubicin_5\NN\2716866|NONE (r_pobj) of_2\IN\0|Clinical (r_prep) use_1\NN\407535|is|by|. (r_nsubjpass) limited_10\VBN\4019101|NONE (l_agent) by_11\IN\0|is|use|. (l_pobj) effects_14\NNS\13245626|NONE (l_amod) cardiotoxic_13\JJ\0|its|,|attributed
2564649
D011224_D009127 NONE prazosin_32\NN\2698769|NONE (r_pobj) with_25\IN\0|of|prior|electrolytic (r_prep) lesions_18\NNS\14204950|NONE (r_pobj) by_15\IN\0|even (r_agent) reduced_14\VBN\441445|rigidity|was|.|or|significantly (r_conj) antagonized_11\VBN\1787955|NONE (l_nsubjpass) rigidity_4\NN\5023233|was|.|reduced|or|significantly
D005283_D009127 CID fentanyl_8\NN\2707683| (r_npadvmod) induced_10\VBN\1627355|in|muscular (r_amod) rigidity_12\NN\5023233|NONE
D005283_D009127 CID fentanyl_17\NN\2707683|dose (r_compound) anesthesia_18\NN\14034177|NONE (r_pobj) with_13\IN\0|is|that (r_prep) associated_12\VBN\628491|side|known|a (r_relcl) effect_9\NN\34213|rigidity|Whereas (r_attr) is_3\VBZ\0|,|paucity|)|with|. (l_nsubj) rigidity_2\NN\5023233|Whereas|effect
D005283_D009127 CID fentanyl_10\NN\2707683|NONE (r_pobj) by_9\IN\0|muscular (r_prep) rigidity_8\NN\5023233|NONE
7542793
D016559_D007674 CID fk506_5\NNP\0|and|:|inhibition|.|of (r_conj) nephrotoxicity_0\NN\0|NONE
D016559_D007674 CID fk506_10\NNP\0|that|likely|is|through|effects (r_nsubjpass) mediated_13\VBN\761713|results|. (l_nsubjpass) effects_6\NNS\13245626|FK|that|likely|is|through (l_amod) nephrotoxic_5\JJ\0|the|of|and
D016572_D064420 NONE csa_4\NNP\0|NONE (l_conj) toxicity_7\NN\13576101|and
D018942_D006984 NONE macrolide_21\NN\0|(|not|mg/kg|immunosuppressant|related|the|) (r_amod) rapamycin_23\NNS\0|but|,|FK|mg/kg|(|; (r_conj) fujimycine_9\NNP\0|and||) (r_conj) mg/kg_6\NN\0|CsA|,|Cyclosporin|; (r_appos) a_1\NNP\13649268|given|.|reduction (r_nsubj) caused_29\VBD\1617192|NONE (l_dobj) reduction_31\NN\351485|A|given|. (l_prep) of_32\IN\0|a (l_pobj) rate_35\NN\13815152|NONE (l_appos) changes_38\NNS\7283608|filtration|glomerular|, (l_conj) hypertrophy_45\NN\14365950|of|degenerative|,|and
D016572_D006984 NONE a_1\NNP\13649268|given|.|reduction (r_nsubj) caused_29\VBD\1617192|NONE (l_dobj) reduction_31\NN\351485|A|given|. (l_prep) of_32\IN\0|a (l_pobj) rate_35\NN\13815152|NONE (l_appos) changes_38\NNS\7283608|filtration|glomerular|, (l_conj) hypertrophy_45\NN\14365950|of|degenerative|,|and
D016572_D006984 NONE csa_3\NNP\0|,|Cyclosporin|;|mg/kg (r_appos) a_1\NNP\13649268|given|.|reduction (r_nsubj) caused_29\VBD\1617192|NONE (l_dobj) reduction_31\NN\351485|A|given|. (l_prep) of_32\IN\0|a (l_pobj) rate_35\NN\13815152|NONE (l_appos) changes_38\NNS\7283608|filtration|glomerular|, (l_conj) hypertrophy_45\NN\14365950|of|degenerative|,|and
D016572_D007674 CID a_3\NNP\13649268|NONE (r_pobj) of_1\IN\0|and|:|inhibition|.|FK (r_prep) nephrotoxicity_0\NN\0|NONE
D016572_D007674 CID csa_8\NNP\0|NONE (r_pobj) of_7\IN\0|the|nephrotoxic|and (r_prep) effects_6\NNS\13245626|FK|that|likely|is|through (l_amod) nephrotoxic_5\JJ\0|the|of|and
D016559_D064420 NONE fk506_6\NNP\0|NONE (r_compound) toxicity_7\NN\13576101|and
D016559_D006984 NONE fujimycine_9\NNP\0|and||) (r_conj) mg/kg_6\NN\0|CsA|,|Cyclosporin|; (r_appos) a_1\NNP\13649268|given|.|reduction (r_nsubj) caused_29\VBD\1617192|NONE (l_dobj) reduction_31\NN\351485|A|given|. (l_prep) of_32\IN\0|a (l_pobj) rate_35\NN\13815152|NONE (l_appos) changes_38\NNS\7283608|filtration|glomerular|, (l_conj) hypertrophy_45\NN\14365950|of|degenerative|,|and
D016559_D006984 NONE fk506_11\NNP\0|but|,|mg/kg|(|rapamycin|; (r_appos) fujimycine_9\NNP\0|and||) (r_conj) mg/kg_6\NN\0|CsA|,|Cyclosporin|; (r_appos) a_1\NNP\13649268|given|.|reduction (r_nsubj) caused_29\VBD\1617192|NONE (l_dobj) reduction_31\NN\351485|A|given|. (l_prep) of_32\IN\0|a (l_pobj) rate_35\NN\13815152|NONE (l_appos) changes_38\NNS\7283608|filtration|glomerular|, (l_conj) hypertrophy_45\NN\14365950|of|degenerative|,|and
D020123_D006984 NONE rapamycin_23\NNS\0|but|,|FK|mg/kg|(|; (r_conj) fujimycine_9\NNP\0|and||) (r_conj) mg/kg_6\NN\0|CsA|,|Cyclosporin|; (r_appos) a_1\NNP\13649268|given|.|reduction (r_nsubj) caused_29\VBD\1617192|NONE (l_dobj) reduction_31\NN\351485|A|given|. (l_prep) of_32\IN\0|a (l_pobj) rate_35\NN\13815152|NONE (l_appos) changes_38\NNS\7283608|filtration|glomerular|, (l_conj) hypertrophy_45\NN\14365950|of|degenerative|,|and
1300436
D003404_D058186 NONE creatinine_46\NN\0|NONE (r_pobj) in_44\IN\13603305|from|a (r_prep) rise_43\NN\7324673|NONE (r_pobj) with_41\IN\0|,|significantly|)|in|were|occurred|,|. (r_prep) deteriorated_26\VBD\208836|NONE
D005665_D007674 NONE furosemide_4\NN\3214670|NONE (r_pobj) of_3\IN\0|deleterious|Potential|.|in (r_prep) effect_2\NN\34213|NONE (l_prep) in_5\IN\13603305|of|deleterious|Potential|. (l_pobj) nephropathy_7\NN\14573196|NONE
D005665_D007674 NONE furosemide_11\NN\3214670|NONE (r_pobj) of_10\IN\0|the (r_prep) efficacy_9\NN\5199286|to|in (r_dobj) determine_7\VB\0|purpose|. (l_prep) in_12\IN\13603305|to|efficacy (l_pobj) addition_13\NN\3081021|NONE (l_prep) in_17\IN\13603305|to (l_pobj) prevention_19\NN\1073995|NONE (l_prep) of_20\IN\0|the (l_pobj) nephropathy_22\NN\14573196|NONE
D005665_D007674 NONE furosemide_0\NNP\3214670|.|may|deleterious|in (r_nsubj) be_2\VB\14625458|NONE (l_prep) in_4\IN\13603305|.|may|deleterious|Furosemide (l_pobj) prevention_6\NN\1073995|NONE (l_prep) of_7\IN\0|the (l_pobj) nephropathy_9\NN\14573196|NONE
D005665_D015431 NONE furosemide_9\NN\3214670| (r_npadvmod) treated_11\VBN\2376958|the (r_amod) group_12\NN\2137|NONE (r_pobj) in_7\IN\13603305|weight (r_prep) loss_6\NN\13252973|NONE
D005665_D051437 NONE furosemide_9\NN\3214670| (r_npadvmod) treated_11\VBN\2376958|the (r_amod) group_12\NN\2137|NONE (r_pobj) in_7\IN\13603305|weight (r_prep) loss_6\NN\13252973|NONE (r_pobj) with_4\IN\0|.|failure|was (r_prep) associated_3\VBN\628491|NONE (l_nsubjpass) failure_1\NN\66216|.|with|was
D005665_D058186 CID furosemide_32\NN\3214670|NONE (r_pobj) with_31\IN\0|NONE (r_prep) pretreated_30\VBN\0|the (r_acl) group_29\NN\2137|NONE (r_pobj) in_27\IN\13603305|,|with|significantly|)|were|occurred|,|. (r_prep) deteriorated_26\VBD\208836|NONE
12101159
D002118_D006323 NONE calcium_13\NN\14625458|NONE (r_pobj) with_9\IN\0|NONE (r_prep) resuscitation_8\NN\1047338|arrest|;|. (r_dep) delayed_0\VBN\439958|NONE (l_dobj) arrest_3\NN\88481|;|.|resuscitation (l_amod) asystolic_1\JJ\0|after|cardiac
D002118_D006323 NONE calcium_13\NN\14625458|NONE (r_pobj) with_9\IN\0|NONE (r_prep) resuscitation_8\NN\1047338|arrest|;|. (r_dep) delayed_0\VBN\439958|NONE (l_dobj) arrest_3\NN\88481|;|.|resuscitation
D002118_D006323 NONE calcium_12\NN\14625458|aggressive|dose|in|intravenous (r_compound) therapy_13\NN\657604|NONE (r_pobj) for_7\IN\0|,|with|a (r_prep) role_6\NN\719494|there (l_prep) with_20\IN\0|,|for|a (l_pobj) onset_22\NN\7325190|particularly (l_prep) of_23\IN\0|the (l_pobj) asystole_24\NN\14204950|NONE
D004110_D062787 CID diltiazem_5\NN\2938514|NONE (r_compound) overdose_6\NN\84738|NONE
D004110_D062787 CID diltiazem_15\NN\2938514|NONE (r_pobj) of_14\IN\0|. (r_prep) g_13\NN\13717155|NONE (r_pobj) including_9\VBG\0|a|mixed (r_prep) overdose_8\NN\84738|man|.
D004110_D062787 CID diltiazem_16\NN\2938514|severe (r_compound) overdose_17\NN\84738|NONE
D004110_D062787 CID diltiazem_11\NN\2938514|NONE (r_compound) overdose_12\NN\84738|NONE
D000431_D062787 NONE alcohol_25\NN\7881800|isosorbide|,|and (r_conj) nitrate_22\NN\14818238|, (r_conj) aspirin_19\NN\2707683|, (r_conj) paracetamol_17\JJ\0|, (r_conj) diltiazem_15\NN\2938514|NONE (r_pobj) of_14\IN\0|. (r_prep) g_13\NN\13717155|NONE (r_pobj) including_9\VBG\0|a|mixed (r_prep) overdose_8\NN\84738|man|.
D002118_D062787 NONE calcium_13\NN\14625458|NONE (r_pobj) with_9\IN\0|NONE (r_prep) resuscitation_8\NN\1047338|arrest|;|. (r_dep) delayed_0\VBN\439958|NONE (l_dobj) arrest_3\NN\88481|;|.|resuscitation (l_prep) after_4\IN\0|asystolic|cardiac (l_pobj) overdose_6\NN\84738|NONE
D002118_D062787 NONE calcium_12\NN\14625458|aggressive|dose|in|intravenous (r_compound) therapy_13\NN\657604|NONE (l_prep) in_14\IN\13603305|calcium|aggressive|dose|intravenous (l_pobj) overdose_17\NN\84738|NONE
D004110_D006323 CID diltiazem_5\NN\2938514|NONE (r_compound) overdose_6\NN\84738|NONE (r_pobj) after_4\IN\0|asystolic|cardiac (r_prep) arrest_3\NN\88481|;|.|resuscitation (l_amod) asystolic_1\JJ\0|after|cardiac
D004110_D006323 CID diltiazem_5\NN\2938514|NONE (r_compound) overdose_6\NN\84738|NONE (r_pobj) after_4\IN\0|asystolic|cardiac (r_prep) arrest_3\NN\88481|;|.|resuscitation
D004110_D006323 CID diltiazem_16\NN\2938514|severe (r_compound) overdose_17\NN\84738|NONE (r_pobj) in_14\IN\13603305|calcium|aggressive|dose|intravenous (r_prep) therapy_13\NN\657604|NONE (r_pobj) for_7\IN\0|,|with|a (r_prep) role_6\NN\719494|there (l_prep) with_20\IN\0|,|for|a (l_pobj) onset_22\NN\7325190|particularly (l_prep) of_23\IN\0|the (l_pobj) asystole_24\NN\14204950|NONE
D004110_D006323 CID diltiazem_11\NN\2938514|NONE (r_compound) overdose_12\NN\84738|NONE (r_pobj) after_10\IN\0|of (r_prep) cases_6\NNS\7283608|NONE (l_prep) of_7\IN\0|after (l_pobj) arrest_9\NN\88481|NONE
D009566_D062787 NONE nitrate_22\NN\14818238|, (r_conj) aspirin_19\NN\2707683|, (r_conj) paracetamol_17\JJ\0|, (r_conj) diltiazem_15\NN\2938514|NONE (r_pobj) of_14\IN\0|. (r_prep) g_13\NN\13717155|NONE (r_pobj) including_9\VBG\0|a|mixed (r_prep) overdose_8\NN\84738|man|.
D001241_D062787 NONE aspirin_19\NN\2707683|, (r_conj) paracetamol_17\JJ\0|, (r_conj) diltiazem_15\NN\2938514|NONE (r_pobj) of_14\IN\0|. (r_prep) g_13\NN\13717155|NONE (r_pobj) including_9\VBG\0|a|mixed (r_prep) overdose_8\NN\84738|man|.
D007547_D062787 NONE isosorbide_21\JJ\3740161|alcohol|,|and (r_compound) nitrate_22\NN\14818238|, (r_conj) aspirin_19\NN\2707683|, (r_conj) paracetamol_17\JJ\0|, (r_conj) diltiazem_15\NN\2938514|NONE (r_pobj) of_14\IN\0|. (r_prep) g_13\NN\13717155|NONE (r_pobj) including_9\VBG\0|a|mixed (r_prep) overdose_8\NN\84738|man|.
D000082_D062787 NONE paracetamol_17\JJ\0|, (r_conj) diltiazem_15\NN\2938514|NONE (r_pobj) of_14\IN\0|. (r_prep) g_13\NN\13717155|NONE (r_pobj) including_9\VBG\0|a|mixed (r_prep) overdose_8\NN\84738|man|.
11099450
D007980_D004409 CID levodopa_33\RB\14604959| (r_npadvmod) induced_35\VBN\1627355|LID|)|( (r_amod) dyskinesias_36\NNS\14084880|off|and|parkinsonian
D007980_D004409 CID levodopa_33\RB\14604959| (r_npadvmod) induced_35\VBN\1627355|LID|)|( (r_amod) dyskinesias_36\NNS\14084880|off|and|parkinsonian (l_appos) lid_38\NNP\5313679|induced|)|(
D007980_D004409 CID levodopa_8\JJ\14604959|of|responsiveness|the|preoperative|and (r_compound) responsiveness_9\NN\5652926|NONE (r_pobj) between_5\IN\0|positive|significant|Program (r_prep) correlations_4\NNS\13841213|We|was|.|in|, (r_dobj) found_1\VBD\13279262|NONE (l_advcl) was_45\VBD\0|We|.|correlations|in|, (l_attr) correlation_47\NN\13841213|whereas|there (l_prep) with_48\IN\0|no (l_pobj) improvement_50\NN\7359599|NONE (l_prep) in_51\IN\13603305|the (l_pobj) lid_52\NNP\5313679|NONE
D007980_D004409 CID levodopa_15\JJ\14604959|of|the (r_compound) responsiveness_16\NN\5652926|of|the|levodopa|preoperative|and (r_conj) responsiveness_9\NN\5652926|NONE (r_pobj) between_5\IN\0|positive|significant|Program (r_prep) correlations_4\NNS\13841213|We|was|.|in|, (r_dobj) found_1\VBD\13279262|NONE (l_advcl) was_45\VBD\0|We|.|correlations|in|, (l_attr) correlation_47\NN\13841213|whereas|there (l_prep) with_48\IN\0|no (l_pobj) improvement_50\NN\7359599|NONE (l_prep) in_51\IN\13603305|the (l_pobj) lid_52\NNP\5313679|NONE
D007980_D004409 CID levodopa_5\JJ\14604959|for (r_compound) responsiveness_6\NN\5652926|NONE (l_prep) for_7\IN\0|levodopa (l_pobj) outcome_9\NN\7291312|NONE (l_prep) of_10\IN\0|the (l_pobj) signs_15\NNS\6643763|NONE (l_conj) lid_17\NNP\5313679|parkinsonian|off|and
D007980_D004409 CID levodopa_5\JJ\14604959|for (r_compound) responsiveness_6\NN\5652926|NONE (l_prep) for_7\IN\0|levodopa (l_pobj) outcome_9\NN\7291312|NONE (l_prep) of_10\IN\0|the (l_pobj) signs_15\NNS\6643763|NONE (l_conj) lid_17\NNP\5313679|parkinsonian|off|and (l_conj) correlations_21\NNS\13841213|and (l_prep) of_22\IN\0|the|different (l_pobj) volume_25\NN\33615|NONE (l_prep) with_26\IN\0|ventral|lesion (l_pobj) dyskinesias_27\NNS\14084880|NONE
D007980_D004409 CID levodopa_5\JJ\14604959|for (r_compound) responsiveness_6\NN\5652926|NONE (r_pobj) of_4\IN\0|differential|predictive|The (r_prep) value_3\NN\5856066|.|be (r_nsubj) indicate_34\VBP\952524|NONE (l_ccomp) be_42\VB\14625458|.|value (l_acomp) responsible_43\JJ\0|may|substrates|that (l_prep) for_44\IN\0|NONE (l_pobj) signs_52\NNS\6643763|generation (l_conj) dyskinesias_54\NNS\14084880|off|and
D007980_D010300 NONE levodopa_33\RB\14604959| (r_npadvmod) induced_35\VBN\1627355|LID|)|( (r_amod) dyskinesias_36\NNS\14084880|off|and|parkinsonian (r_conj) signs_31\NNS\6643763|NONE (l_poss) parkinsonian_27\NN\0|off|and|dyskinesias
D007980_D010300 NONE levodopa_5\JJ\14604959|for (r_compound) responsiveness_6\NN\5652926|NONE (l_prep) for_7\IN\0|levodopa (l_pobj) outcome_9\NN\7291312|NONE (l_prep) of_10\IN\0|the (l_pobj) signs_15\NNS\6643763|NONE (l_poss) parkinsonian_11\NN\0|LID|off|and
D007980_D010300 NONE levodopa_5\JJ\14604959|for (r_compound) responsiveness_6\NN\5652926|NONE (l_prep) for_7\IN\0|levodopa (l_pobj) outcome_9\NN\7291312|NONE (l_prep) of_10\IN\0|the (l_pobj) signs_15\NNS\6643763|NONE (l_conj) lid_17\NNP\5313679|parkinsonian|off|and (l_conj) correlations_21\NNS\13841213|and (l_prep) of_22\IN\0|the|different (l_pobj) volume_25\NN\33615|NONE (l_prep) with_26\IN\0|ventral|lesion (l_pobj) dyskinesias_27\NNS\14084880|NONE (l_conj) parkinsonian_29\NN\0|and|signs
D007980_D010300 NONE levodopa_5\JJ\14604959|for (r_compound) responsiveness_6\NN\5652926|NONE (r_pobj) of_4\IN\0|differential|predictive|The (r_prep) value_3\NN\5856066|.|be (r_nsubj) indicate_34\VBP\952524|NONE (l_ccomp) be_42\VB\14625458|.|value (l_acomp) responsible_43\JJ\0|may|substrates|that (l_prep) for_44\IN\0|NONE (l_pobj) generation_46\NN\7942152|signs (l_prep) of_47\IN\0|the (l_pobj) parkinsonian_48\NN\0|NONE
1079693
D002738_D012164 NONE chloroquine_2\NN\2721948|found|.|and|We (r_xcomp) used_1\VBD\0|NONE (l_conj) found_11\VBD\13279262|.|chloroquine|and|We (l_dobj) case_14\NN\7283608|NONE (l_prep) of_15\IN\0|one (l_pobj) chorioretinopathy_16\JJ\0|NONE
D000305_D014605 NONE corticosteroids_27\NNS\14745635|NONE (r_pobj) with_26\IN\0|intensive|topical (r_prep) treatment_25\NN\654885|NONE (r_pobj) of_22\IN\0|six (r_prep) months_21\NNS\15113229|NONE (r_pobj) to_17\IN\0|not|did|after|.|,|% (r_prep) respond_16\VB\2367363|NONE (l_nsubj) %_9\NN\0|to|not|did|after|.|, (l_prep) of_10\IN\0| (l_pobj) cases_11\NNS\7283608|NONE (l_prep) of_12\IN\0|NONE (l_pobj) uveitis_13\NN\14336539|NONE
D000305_D002386 NONE corticosteroids_2\NNS\14745635|Systemically (r_dobj) administered_1\VBN\2436349|were|in (r_csubjpass) used_4\VBN\0|;|.|number|was (r_ccomp) found_19\VBN\13279262|NONE (l_nsubjpass) number_13\NN\5107765|;|used|.|was (l_prep) of_14\IN\0|a|significant (l_pobj) cataracts_17\NNS\14252864|NONE
D006886_D012164 CID hydroxychloroquine_4\NN\2721538|or (r_conj) chloroquine_2\NN\2721948|found|.|and|We (r_xcomp) used_1\VBD\0|NONE (l_conj) found_11\VBD\13279262|.|chloroquine|and|We (l_dobj) case_14\NN\7283608|NONE (l_prep) of_15\IN\0|one (l_pobj) chorioretinopathy_16\JJ\0|NONE
11195262
D014635_D004830 NONE vpa_4\NNP\0|was|.|had|been|for|He (r_dobj) taking_3\VBG\37396|NONE (l_prep) for_5\IN\0|VPA|was|.|had|been|He (l_pobj) treatment_6\NN\654885|NONE (l_prep) of_7\IN\0|NONE (l_pobj) convulsions_13\NNS\14081375|NONE
D014635_D007177 CID valproate_3\NN\0|NONE (l_prep) to_4\IN\0|.|Contribution (l_pobj) syndrome_6\NN\5870365|NONE (l_prep) of_7\IN\0|the (l_pobj) secretion_9\NN\13526110|NONE (l_prep) of_10\IN\0|inappropriate (l_pobj) hormone_12\NN\5404728|NONE
D014635_D007177 CID valproate_14\NN\0|of|the (l_conj) developed_21\VBD\1753788|)|VPA|and|( (l_dobj) syndrome_23\NN\5870365|who|subsequently (l_prep) of_24\IN\0|the (l_pobj) secretion_26\NN\13526110|NONE (l_prep) of_27\IN\0|inappropriate (l_pobj) hormone_29\NN\5404728|NONE
D014635_D007177 CID valproate_14\NN\0|of|the (l_conj) developed_21\VBD\1753788|)|VPA|and|( (l_dobj) syndrome_23\NN\5870365|who|subsequently (l_prep) of_24\IN\0|the (l_pobj) secretion_26\NN\13526110|NONE (l_prep) of_27\IN\0|inappropriate (l_pobj) hormone_29\NN\5404728|NONE (l_appos) siadh_31\NNP\0|(|antidiuretic|)
D014635_D007177 CID vpa_16\NNP\0|)|and|developed|( (r_npadvmod) valproate_14\NN\0|of|the (l_conj) developed_21\VBD\1753788|)|VPA|and|( (l_dobj) syndrome_23\NN\5870365|who|subsequently (l_prep) of_24\IN\0|the (l_pobj) secretion_26\NN\13526110|NONE (l_prep) of_27\IN\0|inappropriate (l_pobj) hormone_29\NN\5404728|NONE
D014635_D007177 CID vpa_16\NNP\0|)|and|developed|( (r_npadvmod) valproate_14\NN\0|of|the (l_conj) developed_21\VBD\1753788|)|VPA|and|( (l_dobj) syndrome_23\NN\5870365|who|subsequently (l_prep) of_24\IN\0|the (l_pobj) secretion_26\NN\13526110|NONE (l_prep) of_27\IN\0|inappropriate (l_pobj) hormone_29\NN\5404728|NONE (l_appos) siadh_31\NNP\0|(|antidiuretic|)
D014635_D007177 CID vpa_30\NNP\0|NONE (r_pobj) of_29\IN\0|term|the (r_prep) administration_28\NN\1133281|of|and|a (r_conj) weakness_17\NN\14462666|NONE (r_pobj) including_15\VBG\0|NONE (r_prep) factors_14\NNS\7326557|NONE (r_pobj) of_13\IN\0|a (r_prep) combination_12\NN\7951464|NONE (r_pobj) of_10\IN\0|the (r_prep) result_9\NN\34213|to|episode (r_attr) be_7\VB\14625458|We|. (l_nsubj) episode_3\NN\7283608|to|result (l_prep) of_4\IN\0|this (l_pobj) siadh_5\NNP\0|NONE
D014635_D002493 NONE vpa_30\NNP\0|NONE (r_pobj) of_29\IN\0|term|the (r_prep) administration_28\NN\1133281|of|and|a (r_conj) weakness_17\NN\14462666|NONE (l_prep) of_18\IN\0|administration|and|a (l_pobj) system_22\NN\3575240|NONE
2334179
D010396_D011507 CID penicillamine_2\NN\3740161|syndrome|in (r_nsubj) caused_3\VBD\1617192|insufficiency|;|none|. (l_prep) in_6\IN\13603305|Penicillamine|syndrome (l_pobj) patient_8\NN\9898892|NONE (l_conj) proteinuria_12\NN\14299637||and
D010396_D012594 NONE penicillamine_2\NN\3740161|NONE (l_prep) in_3\IN\13603305|D|.| (l_pobj) treatment_5\NN\654885|NONE (l_prep) of_6\IN\0|the (l_pobj) scleroderma_8\NN\14187378|NONE
D010396_D012594 NONE penicillamine_17\NN\3740161|NONE (r_pobj) with_14\IN\0|who|were (r_prep) treated_13\VBN\2376958|with| (r_relcl) patients_4\NNS\9898892|NONE (l_prep) with_5\IN\0|treated| (l_pobj) scleroderma_10\NN\14187378|NONE
D010396_D012594 NONE penicillamine_6\NN\3740161|may|that|effective (r_nsubj) be_8\VB\14625458|data|. (l_acomp) effective_9\JJ\0|may|that|penicillamine (l_prep) in_10\IN\13603305|NONE (l_pobj) cases_12\NNS\7283608|NONE (l_prep) of_13\IN\0|severe (l_pobj) scleroderma_15\NN\14187378|NONE
D010396_D009404 CID penicillamine_2\NN\3740161|syndrome|in (r_nsubj) caused_3\VBD\1617192|insufficiency|;|none|. (l_dobj) syndrome_5\NN\5870365|Penicillamine|in
D010396_D051437 NONE penicillamine_2\NN\3740161|syndrome|in (r_nsubj) caused_3\VBD\1617192|insufficiency|;|none|. (r_ccomp) developed_19\VBD\1753788|NONE (l_dobj) insufficiency_21\NN\14462946|;|caused|none|.
18657397
D010400_D004827 CID potassium_20\NN\14625458|recorded|into (r_dobj) injecting_14\VBG\81072|NONE (r_pcomp) by_13\IN\0|After|was|.|focus|, (r_prep) induced_12\VBN\1627355|NONE (l_nsubjpass) focus_10\NN\5704266|by|After|was|.|, (l_amod) epileptic_9\JJ\10595647|NONE
D010406_D004827 NONE penicillin_5\NN\2716866| (r_npadvmod) induced_7\VBN\1627355|in|epileptiform (r_amod) activity_9\NN\30358|NONE
D010406_D004827 NONE penicillin_0\NNP\2716866|NONE (r_compound) model_1\NN\5888929|model|. (r_nsubj) is_2\VBZ\0|NONE (l_attr) model_7\NN\5888929|.|model (l_prep) for_8\IN\0|a|experimental|used (l_pobj) research_10\NN\633864|NONE (l_compound) epilepsy_9\NN\14085708|NONE
D010406_D004827 NONE penicillin_13\NN\2716866| (r_npadvmod) induced_15\VBN\1627355|epileptiform (r_amod) activity_17\NN\30358|NONE
D010406_D004827 NONE penicillin_7\NN\2716866| (r_npadvmod) induced_9\VBN\1627355|activity|the (r_amod) periods_12\NNS\13575869|latent|and (l_compound) activity_11\NN\30358|induced|the
9270571
D004298_D010300 NONE dopamine_4\NN\14807737|NONE (r_pobj) of_3\IN\0|clinical|The|agonists (r_prep) utility_2\NN\8186047|.|unclear|still (l_appos) agonists_10\NNS\0|of|clinical|The (l_prep) in_11\IN\13603305|receptor|D|)|(|DA (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the (l_pobj) disease_17\NN\14061805|NONE
D004298_D010300 NONE dopamine_4\NN\14807737|NONE (r_pobj) of_3\IN\0|clinical|The|agonists (r_prep) utility_2\NN\8186047|.|unclear|still (l_appos) agonists_10\NNS\0|of|clinical|The (l_prep) in_11\IN\13603305|receptor|D|)|(|DA (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the (l_pobj) disease_17\NN\14061805|NONE (l_appos) pd_19\NNP\14625458|(|)|Parkinson
D004298_D010300 NONE da_6\NNP\10484858|in|receptor|D|)|( (r_nmod) agonists_10\NNS\0|of|clinical|The (l_prep) in_11\IN\13603305|receptor|D|)|(|DA (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the (l_pobj) disease_17\NN\14061805|NONE
D004298_D010300 NONE da_6\NNP\10484858|in|receptor|D|)|( (r_nmod) agonists_10\NNS\0|of|clinical|The (l_prep) in_11\IN\13603305|receptor|D|)|(|DA (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|the (l_pobj) disease_17\NN\14061805|NONE (l_appos) pd_19\NNP\14625458|(|)|Parkinson
D004298_D010300 NONE da_1\NNP\10484858|Potent (r_compound) d1_2\NN\0|receptor|with|A (r_compound) agents_4\NNS\7347|tools|. (r_nsubj) are_23\VBP\13600404|NONE (l_attr) tools_26\NNS\3563967|.|agents (l_prep) in_27\IN\13603305|and|therapeutic|merit|potential (l_pobj) pd_28\NNP\14625458|NONE
D007980_D004409 CID levodopa_20\RB\14604959| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore
D007980_D004409 CID levodopa_20\RB\14604959| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore (r_dobj) conducted_2\VBD\2436349|NONE (l_advcl) evaluate_25\VB\670261|We|study|dyskinesias|.|therefore (l_dobj) effects_30\NNS\13245626|to (l_amod) locomotor_27\NN\0|on|the (l_conj) dyskinetic_29\JJ\0|and
D007980_D004409 CID levodopa_14\NN\14604959|NONE (r_pobj) as_13\IN\14622893|parkinsonism (r_prep) alleviating_8\VBG\205885|NONE (r_pcomp) in_7\IN\13603305|as (r_prep) efficacious_6\JJ\0|but|administration|.|A|was|, (r_acomp) was_4\VBD\0|NONE (l_conj) was_19\VBD\0|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ\0|NONE (l_xcomp) reproduce_23\VB\1621555|less (l_dobj) dyskinesias_28\NNS\14084880|than|to
D007980_D004409 CID levodopa_25\RB\14604959| (r_npadvmod) induced_27\VBN\1627355|the|in (r_amod) dyskinesias_28\NNS\14084880|than|to
D007980_D004409 CID levodopa_40\NN\14604959|NONE (r_pobj) of_39\IN\0|LY (r_prep) challenge_38\NN\13927383|NONE (r_pobj) with_33\IN\0|NONE (r_prep) than_32\IN\0|dyskinesias|to (r_prep) reproduce_23\VB\1621555|less (l_dobj) dyskinesias_28\NNS\14084880|than|to
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE (r_pobj) in_10\IN\13603305|response|the|acute|present (r_prep) study_9\NN\635850|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD\2436349|NONE (l_dobj) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE (r_pobj) in_10\IN\13603305|response|the|acute|present (r_prep) study_9\NN\635850|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD\2436349|NONE (l_advcl) evaluate_25\VB\670261|We|study|dyskinesias|.|therefore (l_dobj) effects_30\NNS\13245626|to (l_amod) locomotor_27\NN\0|on|the (l_conj) dyskinetic_29\JJ\0|and
D015632_D004409 NONE mptp)-exposed_14\VBN\0|cynomolgus|primed|( (r_amod) monkeys_16\NNS\2469914|four (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE (r_pobj) in_10\IN\13603305|response|the|acute|present (r_prep) study_9\NN\635850|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD\2436349|NONE (l_dobj) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore
D015632_D004409 NONE mptp)-exposed_14\VBN\0|cynomolgus|primed|( (r_amod) monkeys_16\NNS\2469914|four (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE (r_pobj) in_10\IN\13603305|response|the|acute|present (r_prep) study_9\NN\635850|We|dyskinesias|evaluate|.|therefore (r_dobj) conducted_2\VBD\2436349|NONE (l_advcl) evaluate_25\VB\670261|We|study|dyskinesias|.|therefore (l_dobj) effects_30\NNS\13245626|to (l_amod) locomotor_27\NN\0|on|the (l_conj) dyskinetic_29\JJ\0|and
D015632_D004409 NONE mptp_9\NNP\0| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) parkinsonism_12\NN\14085708|as (r_dobj) alleviating_8\VBG\205885|NONE (r_pcomp) in_7\IN\13603305|as (r_prep) efficacious_6\JJ\0|but|administration|.|A|was|, (r_acomp) was_4\VBD\0|NONE (l_conj) was_19\VBD\0|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ\0|NONE (l_xcomp) reproduce_23\VB\1621555|less (l_dobj) dyskinesias_28\NNS\14084880|than|to
C095427_D010300 NONE a-86929_13\NNS\0|receptor|with|D (r_punct) agents_4\NNS\7347|tools|. (r_nsubj) are_23\VBP\13600404|NONE (l_attr) tools_26\NNS\3563967|.|agents (l_prep) in_27\IN\13603305|and|therapeutic|merit|potential (l_pobj) pd_28\NNP\14625458|NONE
C095427_D020734 NONE a-86929_0\NNS\0|NONE (l_dep) study_4\NN\635850|.|: (l_prep) in_5\IN\13603305|an|acute (l_pobj) monkeys_10\NNS\2469914|NONE (l_amod) parkinsonian_6\JJ\0|primed
C095427_D020734 NONE a-86929_3\NNS\0|but|administration|.|efficacious|was|, (r_punct) was_4\VBD\0|NONE (l_acomp) efficacious_6\JJ\0|but|administration|.|A|was|, (l_prep) in_7\IN\13603305|as (l_pcomp) alleviating_8\VBG\205885|NONE (l_dobj) parkinsonism_12\NN\14085708|as
C095427_D004409 NONE a-86929_44\NNS\0|) (r_punct) ,_57\,\0|from|four|)|of|(|agonist (r_punct) doses_35\NNS\3740161|NONE (r_pobj) with_33\IN\0|NONE (r_prep) challenge_32\NN\13927383|NONE (r_pobj) on_31\IN\0|locomotor|the (r_prep) effects_30\NNS\13245626|to (r_dobj) evaluate_25\VB\670261|We|study|dyskinesias|.|therefore (r_advcl) conducted_2\VBD\2436349|NONE (l_dobj) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore
C095427_D004409 NONE a-86929_44\NNS\0|) (r_punct) ,_57\,\0|from|four|)|of|(|agonist (r_punct) doses_35\NNS\3740161|NONE (r_pobj) with_33\IN\0|NONE (r_prep) challenge_32\NN\13927383|NONE (r_pobj) on_31\IN\0|locomotor|the (r_prep) effects_30\NNS\13245626|to (l_amod) locomotor_27\NN\0|on|the (l_conj) dyskinetic_29\JJ\0|and
C095427_D004409 NONE 10-diol_55\JJ\0|NONE (r_punct) )_56\-RRB-\0|A (r_punct) ,_57\,\0|from|four|)|of|(|agonist (r_punct) doses_35\NNS\3740161|NONE (r_pobj) with_33\IN\0|NONE (r_prep) challenge_32\NN\13927383|NONE (r_pobj) on_31\IN\0|locomotor|the (r_prep) effects_30\NNS\13245626|to (r_dobj) evaluate_25\VB\670261|We|study|dyskinesias|.|therefore (r_advcl) conducted_2\VBD\2436349|NONE (l_dobj) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore
C095427_D004409 NONE 10-diol_55\JJ\0|NONE (r_punct) )_56\-RRB-\0|A (r_punct) ,_57\,\0|from|four|)|of|(|agonist (r_punct) doses_35\NNS\3740161|NONE (r_pobj) with_33\IN\0|NONE (r_prep) challenge_32\NN\13927383|NONE (r_pobj) on_31\IN\0|locomotor|the (r_prep) effects_30\NNS\13245626|to (l_amod) locomotor_27\NN\0|on|the (l_conj) dyskinetic_29\JJ\0|and
C095427_D004409 NONE a-86929_3\NNS\0|but|administration|.|efficacious|was|, (r_punct) was_4\VBD\0|NONE (l_conj) was_19\VBD\0|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ\0|NONE (l_xcomp) reproduce_23\VB\1621555|less (l_dobj) dyskinesias_28\NNS\14084880|than|to
D007980_D020734 NONE levodopa_7\NN\14604959| (r_npadvmod) primed_9\VBN\406243|parkinsonian (r_amod) monkeys_10\NNS\2469914|NONE (l_amod) parkinsonian_6\JJ\0|primed
D007980_D020734 NONE levodopa_14\NN\14604959|NONE (r_pobj) as_13\IN\14622893|parkinsonism (r_prep) alleviating_8\VBG\205885|NONE (l_dobj) parkinsonism_12\NN\14085708|as
D007980_D020734 NONE levodopa_25\RB\14604959| (r_npadvmod) induced_27\VBN\1627355|the|in (r_amod) dyskinesias_28\NNS\14084880|than|to (r_dobj) reproduce_23\VB\1621555|less (r_xcomp) likely_21\JJ\0|NONE (r_acomp) was_19\VBD\0|but|administration|.|A|efficacious|, (r_conj) was_4\VBD\0|NONE (l_acomp) efficacious_6\JJ\0|but|administration|.|A|was|, (l_prep) in_7\IN\13603305|as (l_pcomp) alleviating_8\VBG\205885|NONE (l_dobj) parkinsonism_12\NN\14085708|as
D007980_D020734 NONE levodopa_40\NN\14604959|NONE (r_pobj) of_39\IN\0|LY (r_prep) challenge_38\NN\13927383|NONE (r_pobj) with_33\IN\0|NONE (r_prep) than_32\IN\0|dyskinesias|to (r_prep) reproduce_23\VB\1621555|less (r_xcomp) likely_21\JJ\0|NONE (r_acomp) was_19\VBD\0|but|administration|.|A|efficacious|, (r_conj) was_4\VBD\0|NONE (l_acomp) efficacious_6\JJ\0|but|administration|.|A|was|, (l_prep) in_7\IN\13603305|as (l_pcomp) alleviating_8\VBG\205885|NONE (l_dobj) parkinsonism_12\NN\14085708|as
D015632_D020734 CID mptp_9\NNP\0| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) parkinsonism_12\NN\14085708|as
D004298_D004409 NONE da_62\NNP\10484858|a|selective|Dlike|with|receptor (r_compound) agonist_65\NN\0|from|four|)|of|(|, (r_appos) doses_35\NNS\3740161|NONE (r_pobj) with_33\IN\0|NONE (r_prep) challenge_32\NN\13927383|NONE (r_pobj) on_31\IN\0|locomotor|the (r_prep) effects_30\NNS\13245626|to (r_dobj) evaluate_25\VB\670261|We|study|dyskinesias|.|therefore (r_advcl) conducted_2\VBD\2436349|NONE (l_dobj) dyskinesias_23\NNS\14084880|We|study|evaluate|.|therefore
D004298_D004409 NONE da_62\NNP\10484858|a|selective|Dlike|with|receptor (r_compound) agonist_65\NN\0|from|four|)|of|(|, (r_appos) doses_35\NNS\3740161|NONE (r_pobj) with_33\IN\0|NONE (r_prep) challenge_32\NN\13927383|NONE (r_pobj) on_31\IN\0|locomotor|the (r_prep) effects_30\NNS\13245626|to (l_amod) locomotor_27\NN\0|on|the (l_conj) dyskinetic_29\JJ\0|and
C416545_D020734 NONE ly-171555_16\NNP\0|and (r_conj) levodopa_14\NN\14604959|NONE (r_pobj) as_13\IN\14622893|parkinsonism (r_prep) alleviating_8\VBG\205885|NONE (l_dobj) parkinsonism_12\NN\14085708|as
C416545_D020734 NONE ly-171555_35\NNP\0|of (r_amod) challenge_38\NN\13927383|NONE (r_pobj) with_33\IN\0|NONE (r_prep) than_32\IN\0|dyskinesias|to (r_prep) reproduce_23\VB\1621555|less (r_xcomp) likely_21\JJ\0|NONE (r_acomp) was_19\VBD\0|but|administration|.|A|efficacious|, (r_conj) was_4\VBD\0|NONE (l_acomp) efficacious_6\JJ\0|but|administration|.|A|was|, (l_prep) in_7\IN\13603305|as (l_pcomp) alleviating_8\VBG\205885|NONE (l_dobj) parkinsonism_12\NN\14085708|as
C416545_D004409 NONE ly-171555_16\NNP\0|and (r_conj) levodopa_14\NN\14604959|NONE (r_pobj) as_13\IN\14622893|parkinsonism (r_prep) alleviating_8\VBG\205885|NONE (r_pcomp) in_7\IN\13603305|as (r_prep) efficacious_6\JJ\0|but|administration|.|A|was|, (r_acomp) was_4\VBD\0|NONE (l_conj) was_19\VBD\0|but|administration|.|A|efficacious|, (l_acomp) likely_21\JJ\0|NONE (l_xcomp) reproduce_23\VB\1621555|less (l_dobj) dyskinesias_28\NNS\14084880|than|to
C416545_D004409 NONE ly-171555_35\NNP\0|of (r_amod) challenge_38\NN\13927383|NONE (r_pobj) with_33\IN\0|NONE (r_prep) than_32\IN\0|dyskinesias|to (r_prep) reproduce_23\VB\1621555|less (l_dobj) dyskinesias_28\NNS\14084880|than|to
8305357
D003630_D000163 NONE daunorubicin_18\NN\0|NONE (r_pobj) of_16\IN\0|NONE (r_prep) safety_15\NN\13920835|the|and|in (r_conj) efficacy_13\NN\5199286|to (l_prep) in_22\IN\13603305|the|and|safety (l_pobj) treatment_24\NN\654885|NONE (l_prep) of_25\IN\0|the (l_pobj) aids_26\NNP\13974317|NONE
D003630_D012514 NONE daunorubicin_1\NN\0|NONE (l_dobj) sarcoma_6\NN\14239918|.|in|Liposomal
D003630_D012514 NONE daunorubicin_18\NN\0|NONE (r_pobj) of_16\IN\0|NONE (r_prep) safety_15\NN\13920835|the|and|in (r_conj) efficacy_13\NN\5199286|to (r_dobj) assess_11\VB\5220461|randomized|II|clinical|a (r_relcl) trial_9\NN\786195|We|.|related (r_dobj) report_1\VBP\6470073|NONE (l_ccomp) related_27\VBD\628491|We|.|trial (l_dobj) sarcoma_30\NN\14239918|NONE
D003630_D012514 NONE daunorubicin_7\NN\0|,|agent|.|In (r_nsubj) was_8\VBD\0|NONE (l_attr) agent_14\NN\7347|,|daunorubicin|.|In (l_prep) in_15\IN\13603305|an|effective (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) sarcoma_21\NN\14239918|NONE
15985056
D003907_D006606 NONE dexamethasone_2\NN\2721538|benzodiazepines|(|)|, (r_appos) corticosteroids_0\NNS\14745635|have|agents|. (r_nsubj) been_15\VBN\0|NONE (l_attr) agents_18\NNS\7347|have|.|Corticosteroids (l_acl) mentioned_19\VBD\730052|the|specific (l_prep) as_25\IN\14622893|frequently|in (l_pcomp) associated_27\VBN\628491|NONE (l_prep) with_28\IN\0|being (l_pobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) hiccups_32\NNS\863513|NONE
D017963_D006606 CID azithromycin_1\RB\2716205| (r_advmod) associated_3\VBN\628491|.|Possible (r_amod) hiccups_4\NNS\863513|NONE
D017963_D006606 CID azithromycin_9\CD\2716205|NONE (r_amod) therapy_10\NN\657604|NONE (r_pobj) by_8\IN\0|NONE (r_agent) associated_7\VBN\628491|persistent (r_acl) hiccups_6\NNS\863513|NONE
D017963_D006606 CID azithromycin_11\RB\2716205|for (r_advmod) beginning_10\VBG\7283608|NONE (r_pcomp) after_9\IN\0|man|.|with (r_prep) presented_5\VBN\2137132|NONE (l_prep) with_6\IN\0|man|after|. (l_pobj) hiccups_8\NNS\863513|NONE
D017963_D006606 CID azithromycin_2\NNP\2716205|NONE (r_pobj) of_1\IN\0|and|therapy (r_prep) discontinuation_0\NN\209943|hiccups|.|finally (r_nsubj) resolved_8\VBD\352826|NONE (l_dobj) hiccups_9\NNS\863513|Discontinuation|.|finally
D017963_D006606 CID azithromycin_9\WP\2716205|NONE (r_pobj) by_8\IN\0|NONE (r_agent) mediated_7\VBN\761713|a|vagal (r_acl) mechanism_6\NN\13446390|that|pathogenesis|could (r_nsubj) be_11\VB\14625458|hypothesis|. (l_attr) pathogenesis_13\NN\13533470|that|could|mechanism (l_prep) of_14\IN\0|the (l_pobj) hiccups_15\NNS\863513|NONE
D008775_D006606 NONE methylprednisolone_4\NN\0|and (r_conj) dexamethasone_2\NN\2721538|benzodiazepines|(|)|, (r_appos) corticosteroids_0\NNS\14745635|have|agents|. (r_nsubj) been_15\VBN\0|NONE (l_attr) agents_18\NNS\7347|have|.|Corticosteroids (l_acl) mentioned_19\VBD\730052|the|specific (l_prep) as_25\IN\14622893|frequently|in (l_pcomp) associated_27\VBN\628491|NONE (l_prep) with_28\IN\0|being (l_pobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) hiccups_32\NNS\863513|NONE
D001569_D006606 NONE benzodiazepines_7\NNS\3771443|(|dexamethasone|)|, (r_appos) corticosteroids_0\NNS\14745635|have|agents|. (r_nsubj) been_15\VBN\0|NONE (l_attr) agents_18\NNS\7347|have|.|Corticosteroids (l_acl) mentioned_19\VBD\730052|the|specific (l_prep) as_25\IN\14622893|frequently|in (l_pcomp) associated_27\VBN\628491|NONE (l_prep) with_28\IN\0|being (l_pobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) hiccups_32\NNS\863513|NONE
D001418_D006606 CID baclofen_6\NN\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) therapy_4\NN\657604|and|of (r_conj) discontinuation_0\NN\209943|hiccups|.|finally (r_nsubj) resolved_8\VBD\352826|NONE (l_dobj) hiccups_9\NNS\863513|Discontinuation|.|finally
D018942_D006606 NONE macrolide_12\NN\0|NONE (r_amod) antimicrobials_13\NNS\14778436|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|cases|been|have|. (r_oprd) reported_9\VBN\831651|NONE (l_nsubjpass) cases_1\NNS\7283608|related|been|have|. (l_prep) of_2\IN\0|Few (l_pobj) hiccups_6\NNS\863513|NONE
D018942_D006606 NONE macrolides_36\NNS\0|NONE (r_pobj) with_34\IN\0|this|absence|and (r_prep) reaction_33\NN\13446390|NONE (l_conj) absence_39\NN\14449405|with|this|and (l_prep) of_40\IN\0|the (l_pobj) explanation_43\NN\6722453|NONE (l_prep) for_44\IN\0|alternative|any (l_pobj) hiccups_45\NNS\863513|NONE
D018942_D006606 NONE macrolide_2\NN\0|NONE (r_amod) antimicrobials_3\NNS\14778436|.|,|been|explain|However|have|associated (r_nsubjpass) reported_6\VBN\831651|NONE (l_xcomp) associated_9\VBN\628491|.|,|been|explain|However|have|antimicrobials (l_prep) with_10\IN\0|be|to (l_pobj) mechanism_14\NN\13446390|NONE (l_nmod) hiccups_11\NNS\863513|vagal
D017963_D010612 NONE azithromycin_11\RB\2716205|for (r_advmod) beginning_10\VBG\7283608|NONE (l_prep) for_12\IN\0|azithromycin (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|the (l_pobj) pharyngitis_16\NN\14171682|NONE
D008874_D006606 NONE midazolam_9\NN\2830852|(|anaesthesia (r_appos) benzodiazepines_7\NNS\3771443|(|dexamethasone|)|, (r_appos) corticosteroids_0\NNS\14745635|have|agents|. (r_nsubj) been_15\VBN\0|NONE (l_attr) agents_18\NNS\7347|have|.|Corticosteroids (l_acl) mentioned_19\VBD\730052|the|specific (l_prep) as_25\IN\14622893|frequently|in (l_pcomp) associated_27\VBN\628491|NONE (l_prep) with_28\IN\0|being (l_pobj) development_30\NN\248977|NONE (l_prep) of_31\IN\0|the (l_pobj) hiccups_32\NNS\863513|NONE
6794356
D008094_D001282 NONE lithium_18\NN\14625458|high|a (r_compound) level_19\NN\4916342|and|heart|, (r_conj) failure_12\NN\66216|atrial|, (r_conj) flutter_8\JJ\331950|massive|tricuspid|,
D008094_D001282 NONE lithium_26\NN\14625458|NONE (r_compound) compounds_27\NNS\5869584|NONE (r_pobj) to_25\IN\0|in (r_prep) exposed_24\VBN\2110927|NONE (r_acl) infants_23\NNS\9918248|NONE (r_pobj) among_22\IN\0|cardiac (r_prep) disease_21\NN\14061805|NONE (r_pobj) with_19\IN\0|NONE (r_prep) patient_18\NN\9898892|th|. (r_dobj) described_17\VBN\1001294|,|patient|and|This (r_conj) is_1\VBZ\0|NONE (l_attr) patient_4\NN\9898892|,|and|described|This (l_relcl) manifest_7\VB\6479665|first|the (l_dobj) regurgitation_9\NN\7406350|initially|to (l_conj) flutter_12\NN\331950|and|tricuspid
D008094_D014262 NONE lithium_18\NN\14625458|high|a (r_compound) level_19\NN\4916342|and|heart|, (r_conj) failure_12\NN\66216|atrial|, (r_conj) flutter_8\JJ\331950|massive|tricuspid|, (r_conj) regurgitation_5\NN\7406350|NONE
D008094_D014262 NONE lithium_26\NN\14625458|NONE (r_compound) compounds_27\NNS\5869584|NONE (r_pobj) to_25\IN\0|in (r_prep) exposed_24\VBN\2110927|NONE (r_acl) infants_23\NNS\9918248|NONE (r_pobj) among_22\IN\0|cardiac (r_prep) disease_21\NN\14061805|NONE (r_pobj) with_19\IN\0|NONE (r_prep) patient_18\NN\9898892|th|. (r_dobj) described_17\VBN\1001294|,|patient|and|This (r_conj) is_1\VBZ\0|NONE (l_attr) patient_4\NN\9898892|,|and|described|This (l_relcl) manifest_7\VB\6479665|first|the (l_dobj) regurgitation_9\NN\7406350|initially|to
D008094_D006331 NONE lithium_26\NN\14625458|NONE (r_compound) compounds_27\NNS\5869584|NONE (r_pobj) to_25\IN\0|in (r_prep) exposed_24\VBN\2110927|NONE (r_acl) infants_23\NNS\9918248|NONE (r_pobj) among_22\IN\0|cardiac (r_prep) disease_21\NN\14061805|NONE
D016651_D014262 NONE carbonate_5\NN\15010703|NONE (r_compound) toxicity_6\NN\13576101|valve|.|Tricuspid|in|and (r_conj) regurgitation_2\NN\7406350|NONE
D016651_D006331 NONE carbonate_1\NN\15010703|in|may|.|factor|taken (r_nsubj) be_3\VB\14625458|NONE (l_prep) in_6\IN\13603305|carbonate|may|.|factor|taken (l_pobj) incidence_9\NN\13821570|NONE (l_prep) of_10\IN\0|the|increasing (l_pobj) disease_13\NN\14061805|NONE
D016651_D064420 NONE carbonate_5\NN\15010703|NONE (r_compound) toxicity_6\NN\13576101|valve|.|Tricuspid|in|and
D008094_D006333 NONE lithium_18\NN\14625458|high|a (r_compound) level_19\NN\4916342|and|heart|, (r_conj) failure_12\NN\66216|atrial|,
11999899
D016291_D014202 NONE mk-801_16\NNP\0|also|tremor|Reserpine|. (r_punct) produced_2\VBD\1617192|NONE (l_dobj) tremor_3\NN\345926|MK|also|Reserpine|.
D016291_D014202 NONE mk-801_2\NNP\0|However|injection|.|,|increase (r_punct) produced_4\VBD\1617192|NONE (l_dobj) increase_7\NN\13576355|However|injection|.|,|MK (l_prep) of_8\IN\0|a|in|significant (l_pobj) tremor_9\NN\345926|NONE
D016291_D014202 NONE mk-801_17\NNP\0|On|.|compared|reserpine|increases|, (r_punct) induced_6\VBN\1627355|NONE (l_dobj) increases_7\NNS\13576355|MK|On|.|compared|reserpine|, (l_prep) in_8\IN\13603305|NONE (l_pobj) tremor_9\NN\345926|NONE
D016291_D014202 NONE mk-801_33\NNP\0|)|mg/kg (r_punct) injection_38\NN\320852| (r_nsubj) min_40\NN\15154774|effects|test|whereas|before (r_nsubj) reversed_44\VBD\109660|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD\1617192|with (l_conj) increases_26\NNS\13576355|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN\13603305|NONE (l_pobj) tremor_28\NN\345926|NONE
D012110_D004409 CID reserpine_0\NN\2721160|increases|. (r_nsubj) produced_15\VBD\1617192|NONE (l_dobj) increases_16\NNS\13576355|.|Reserpine (l_prep) in_17\IN\13603305|NONE (l_pobj) dyskinesia_19\NN\14084880|NONE (l_relcl) are_30\VBP\13600404|protrusion|,|,|orofacial (l_attr) signs_31\NNS\6643763|which (l_amod) indicative_32\JJ\13801424|NONE (l_prep) of_33\IN\0|NONE (l_pobj) dyskinesia_35\NN\14084880|NONE
D012110_D004409 CID reserpine_4\NN\2721160|that|movements (r_nsubj) produces_5\VBZ\7555863|results|. (l_dobj) movements_9\NNS\191142|that|reserpine
D012110_D004409 CID reserpine_4\NN\2721160|that|movements (r_nsubj) produces_5\VBZ\7555863|results|. (l_dobj) movements_9\NNS\191142|that|reserpine (l_relcl) related_13\VBN\628491|different|, (l_conj) considered_22\VBN\689344|which|are|and|to (l_prep) as_23\IN\14622893|be|can (l_pobj) signs_30\NNS\6643763|NONE (l_compound) dsykinesia_29\NN\0|parkinsonian
D016202_D002375 NONE nmda_5\NNP\0|NONE (r_pobj) by_4\IN\0|NONE (r_agent) produced_3\VBN\1617192|The|glutamatergic (r_acl) blockage_2\NN\14034177|.|signs|according|can (r_nsubj) restore_7\VB\1631072|NONE (l_dobj) signs_9\NNS\6643763|.|blockage|according|can (l_prep) as_12\IN\14622893|these|, (l_pobj) movements_15\NNS\191142|such (l_conj) protrusions_18\NNS\13919685|chewing|,|vacuous (l_conj) catalepsy_20\NN\14023236|tongue|,
D016291_D002375 NONE mk-801_16\NNP\0|also|tremor|Reserpine|. (r_punct) produced_2\VBD\1617192|NONE (l_dobj) tremor_3\NN\345926|MK|also|Reserpine|. (l_conj) catalepsy_5\NN\14023236|,|and|are
D016291_D002375 NONE mk-801_17\NNP\0|On|.|compared|reserpine|increases|, (r_punct) induced_6\VBN\1627355|NONE (l_dobj) increases_7\NNS\13576355|MK|On|.|compared|reserpine|, (l_prep) in_8\IN\13603305|NONE (l_pobj) tremor_9\NN\345926|NONE (l_conj) catalepsy_11\NN\14023236|and
D016291_D002375 NONE mk-801_33\NNP\0|)|mg/kg (r_punct) injection_38\NN\320852| (r_nsubj) min_40\NN\15154774|effects|test|whereas|before (r_nsubj) reversed_44\VBD\109660|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD\1617192|with (l_conj) increases_26\NNS\13576355|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN\13603305|NONE (l_pobj) tremor_28\NN\345926|NONE (l_conj) catalepsy_30\NN\14023236|and
D012110_D014202 CID reserpine_0\NN\2721160|MK|also|tremor|. (r_nsubj) produced_2\VBD\1617192|NONE (l_dobj) tremor_3\NN\345926|MK|also|Reserpine|.
D012110_D014202 CID reserpine_11\NN\2721160| (r_npadvmod) treated_13\VBN\2376958|NONE (r_amod) mice_14\NNS\2329401|NONE (r_pobj) in_10\IN\13603305|of|a|significant (r_prep) increase_7\NN\13576355|However|injection|.|,|MK (l_prep) of_8\IN\0|a|in|significant (l_pobj) tremor_9\NN\345926|NONE
D012110_D014202 CID reserpine_5\NN\2721160|MK|On|.|compared|increases|, (r_nsubj) induced_6\VBN\1627355|NONE (l_dobj) increases_7\NNS\13576355|MK|On|.|compared|reserpine|, (l_prep) in_8\IN\13603305|NONE (l_pobj) tremor_9\NN\345926|NONE
D012110_D014202 CID reserpine_12\NN\2721160|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|tremor|the|and (r_acl) catalepsy_7\NN\14023236|.|administration|( (l_conj) tremor_9\NN\345926|the|and|induced
D012110_D014202 CID reserpine_2\NN\2721160|NONE (r_pobj) with_1\IN\0|produced (r_prep) pretreatment_0\NN\0|NONE (l_acl) produced_13\VBD\1617192|with (l_conj) increases_26\NNS\13576355|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN\13603305|NONE (l_pobj) tremor_28\NN\345926|NONE
D012110_D014202 CID reserpine_48\NN\2721160|NONE (r_pobj) of_47\IN\0|the (r_prep) effects_46\NNS\13245626|test|whereas|before|min (r_dobj) reversed_44\VBD\109660|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD\1617192|with (l_conj) increases_26\NNS\13576355|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN\13603305|NONE (l_pobj) tremor_28\NN\345926|NONE
D012110_D009069 NONE reserpine_0\NN\2721160|increases|. (r_nsubj) produced_15\VBD\1617192|NONE (l_dobj) increases_16\NNS\13576355|.|Reserpine (l_prep) in_17\IN\13603305|NONE (l_pobj) dyskinesia_19\NN\14084880|NONE
D012110_D009069 NONE reserpine_0\NN\2721160|and|followed|before (r_nsubj) administered_6\VBN\2436349|,|in|not|did|dyskinesia|. (r_ccomp) produce_29\VB\7555863|NONE (l_dobj) dyskinesia_31\NN\14084880|,|administered|in|not|did|.
D001058_D009069 NONE apomophine_15\JJ\0|min (r_amod) injection_16\NN\320852|NONE (r_pobj) by_14\IN\0|NONE (r_agent) followed_13\VBN\1835496|and|before|Reserpine (r_conj) administered_6\VBN\2436349|,|in|not|did|dyskinesia|. (r_ccomp) produce_29\VB\7555863|NONE (l_dobj) dyskinesia_31\NN\14084880|,|administered|in|not|did|.
D016202_D014202 NONE nmda_5\NNP\0|NONE (r_pobj) by_4\IN\0|NONE (r_agent) produced_3\VBN\1617192|The|glutamatergic (r_acl) blockage_2\NN\14034177|.|signs|according|can (r_nsubj) restore_7\VB\1631072|NONE (l_dobj) signs_9\NNS\6643763|.|blockage|according|can (l_prep) as_12\IN\14622893|these|, (l_pobj) movements_15\NNS\191142|such (l_conj) protrusions_18\NNS\13919685|chewing|,|vacuous (l_conj) catalepsy_20\NN\14023236|tongue|, (l_conj) tremor_22\NN\345926|and
D016291_D010300 NONE mk-801_16\NNP\0|also|tremor|Reserpine|. (r_punct) produced_2\VBD\1617192|NONE (l_dobj) tremor_3\NN\345926|MK|also|Reserpine|. (l_relcl) are_8\VBP\13600404|,|and|catalepsy (l_attr) signs_9\NNS\6643763|which (l_amod) suggestive_10\JJ\0|NONE (l_prep) of_11\IN\0|NONE (l_pobj) disease_14\NN\14061805|NONE
D012110_D010300 NONE reserpine_0\NN\2721160|MK|also|tremor|. (r_nsubj) produced_2\VBD\1617192|NONE (l_dobj) tremor_3\NN\345926|MK|also|Reserpine|. (l_relcl) are_8\VBP\13600404|,|and|catalepsy (l_attr) signs_9\NNS\6643763|which (l_amod) suggestive_10\JJ\0|NONE (l_prep) of_11\IN\0|NONE (l_pobj) disease_14\NN\14061805|NONE
D012110_D010300 NONE reserpine_4\NN\2721160|that|movements (r_nsubj) produces_5\VBZ\7555863|results|. (l_dobj) movements_9\NNS\191142|that|reserpine (l_relcl) related_13\VBN\628491|different|, (l_conj) considered_22\VBN\689344|which|are|and|to (l_prep) as_23\IN\14622893|be|can (l_pobj) signs_30\NNS\6643763|NONE (l_amod) parkinsonian_24\JJ\0|dsykinesia
D012110_D002375 CID reserpine_0\NN\2721160|MK|also|tremor|. (r_nsubj) produced_2\VBD\1617192|NONE (l_dobj) tremor_3\NN\345926|MK|also|Reserpine|. (l_conj) catalepsy_5\NN\14023236|,|and|are
D012110_D002375 CID reserpine_25\NN\2721160|NONE (r_pobj) by_24\IN\0|NONE (r_agent) induced_23\VBN\1627355|vacuous|the|,|chewing|protrusions (r_acl) movements_17\NNS\191142|mg/kg|. (l_conj) protrusions_20\NNS\13919685|vacuous|the|induced|,|chewing (l_conj) catalepsy_22\NN\14023236|and|tongue
D012110_D002375 CID reserpine_5\NN\2721160|MK|On|.|compared|increases|, (r_nsubj) induced_6\VBN\1627355|NONE (l_dobj) increases_7\NNS\13576355|MK|On|.|compared|reserpine|, (l_prep) in_8\IN\13603305|NONE (l_pobj) tremor_9\NN\345926|NONE (l_conj) catalepsy_11\NN\14023236|and
D012110_D002375 CID reserpine_12\NN\2721160|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|tremor|the|and (r_acl) catalepsy_7\NN\14023236|.|administration|(
D012110_D002375 CID reserpine_2\NN\2721160|NONE (r_pobj) with_1\IN\0|produced (r_prep) pretreatment_0\NN\0|NONE (l_acl) produced_13\VBD\1617192|with (l_conj) increases_26\NNS\13576355|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN\13603305|NONE (l_pobj) tremor_28\NN\345926|NONE (l_conj) catalepsy_30\NN\14023236|and
D012110_D002375 CID reserpine_48\NN\2721160|NONE (r_pobj) of_47\IN\0|the (r_prep) effects_46\NNS\13245626|test|whereas|before|min (r_dobj) reversed_44\VBD\109660|test|,|(|.|,|increases|before|as|h|increases|mg/kg (r_advcl) produced_13\VBD\1617192|with (l_conj) increases_26\NNS\13576355|test|,|(|.|,|increases|before|reversed|as|h|mg/kg (l_prep) in_27\IN\13603305|NONE (l_pobj) tremor_28\NN\345926|NONE (l_conj) catalepsy_30\NN\14023236|and
9205462
D013629_D001943 NONE tamoxifen_9\NN\2714883|NONE (r_pobj) with_8\IN\0|for|.|was|woman (r_prep) treated_7\VBN\2376958|NONE (l_prep) for_10\IN\0|with|.|was|woman (l_pobj) carcinoma_18\NN\14239918|NONE
D013629_D017093 CID tamoxifen_2\NN\2714883| (r_npadvmod) induced_4\VBN\1627355|liver (r_amod) dysfunction_6\NN\14204950|NONE
D013629_D017093 CID tamoxifen_20\NN\2714883|NONE (r_compound) metabolism_21\NN\13526110|NONE (r_pobj) in_19\IN\13603305|NONE (r_prep) alterations_18\NNS\7283608|of (r_pobj) because_16\IN\0|at|Patients|.|may (r_prep) be_8\VB\14625458|NONE (l_nsubj) patients_0\NNS\9898892|at|.|may|because (l_prep) with_1\IN\0|NONE (l_pobj) dysfunction_6\NN\14204950|NONE
D013629_D009369 NONE tamoxifen_8\NN\2714883|and|tumors (r_compound) use_9\NN\407535|NONE (l_conj) tumors_12\NNS\14234074|and|tamoxifen
D013629_C537296 CID tamoxifen_9\NN\2714883|antecedent (r_compound) use_10\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491|the (r_acl) ovary_5\NN\11675842|NONE
D004967_D001943 NONE estrogen_13\NN\14745635|II|positive|stage|breast (r_compound) carcinoma_18\NN\14239918|NONE
D013629_D006106 NONE tamoxifen_2\NN\2714883| (r_npadvmod) induced_4\VBN\1627355|liver (r_amod) dysfunction_6\NN\14204950|NONE (r_pobj) with_1\IN\0|NONE (r_prep) patients_0\NNS\9898892|at|.|may|because (r_nsubj) be_8\VB\14625458|NONE (l_prep) at_9\IN\14622893|Patients|.|may|because (l_pobj) risk_11\NN\14541044|NONE (l_prep) for_12\IN\0|increased (l_pobj) tumors_15\NNS\14234074|NONE
D013629_D006106 NONE tamoxifen_20\NN\2714883|NONE (r_compound) metabolism_21\NN\13526110|NONE (r_pobj) in_19\IN\13603305|NONE (r_prep) alterations_18\NNS\7283608|of (r_pobj) because_16\IN\0|at|Patients|.|may (r_prep) be_8\VB\14625458|NONE (l_prep) at_9\IN\14622893|Patients|.|may|because (l_pobj) risk_11\NN\14541044|NONE (l_prep) for_12\IN\0|increased (l_pobj) tumors_15\NNS\14234074|NONE
19105845
D016642_D012640 CID hydrochloride_8\NN\14817592| (r_npadvmod) induced_10\VBN\1627355|in (r_amod) seizures_11\NNS\14081375|NONE
D016642_D012640 CID bupropion_15\NN\0| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) seizures_18\NNS\14081375|NONE
D016642_D012640 CID hcl_12\NNP\0|NONE (r_pobj) of_10\IN\0|infusion|the|intraperitoneal (r_prep) rates_9\NNS\13308999|mg/kg (r_dobj) varying_5\VBG\0|NONE (r_pcomp) of_4\IN\0|,|the|CD (r_prep) effect_3\NN\34213|We|on|.|, (l_appos) cd50_22\NNP\0|of|,|the (l_amod) convulsive_18\JJ\0|dose|)|a|(
D016642_D012640 CID hcl_12\NNP\0|NONE (r_pobj) of_10\IN\0|infusion|the|intraperitoneal (r_prep) rates_9\NNS\13308999|mg/kg (r_dobj) varying_5\VBG\0|NONE (r_pcomp) of_4\IN\0|,|the|CD (r_prep) effect_3\NN\34213|We|on|.|, (r_dobj) investigated_1\VBD\644583|NONE (l_prep) on_25\IN\0|We|.|effect|, (l_pobj) incidence_27\NN\13821570|NONE (l_prep) of_30\IN\0|and|the|severity (l_pobj) convulsions_34\NNS\14081375|NONE
D016642_D012640 CID bupropion_31\NN\0| (r_npadvmod) induced_33\VBN\1627355|in (r_amod) convulsions_34\NNS\14081375|NONE (r_pobj) of_30\IN\0|and|the|severity (r_prep) incidence_27\NN\13821570|NONE (r_pobj) on_25\IN\0|We|.|effect|, (r_prep) investigated_1\VBD\644583|NONE (l_dobj) effect_3\NN\34213|We|on|.|, (l_appos) cd50_22\NNP\0|of|,|the (l_amod) convulsive_18\JJ\0|dose|)|a|(
D016642_D012640 CID bupropion_31\NN\0| (r_npadvmod) induced_33\VBN\1627355|in (r_amod) convulsions_34\NNS\14081375|NONE
D016642_D012640 CID hcl_9\NNP\0|.|results|by|mg/kg|:|induced|% (r_ccomp) showed_3\VBD\2137132|NONE (l_advcl) induced_15\VBD\1627355|.|results|by|mg/kg|:|%|HCl (l_dobj) convulsions_16\NNS\14081375|NONE
D016642_D012640 CID hcl_27\NNP\0|NONE (r_pobj) of_25\IN\0|the|infusion (r_prep) time_24\NN\7308889|mg/kg (r_dobj) increasing_20\VBG\169651|odds|=|)|and|;|. (r_conj) ratio_15\NN\13815152|was|with|compared (r_nsubjpass) associated_31\VBN\628491|analysis|was|. (l_prep) with_32\IN\0|ratio|was|compared (l_pobj) odds_37\NNS\4756635|NONE (l_prep) of_38\IN\0|reduced|%|a (l_pobj) convulsions_39\NNS\14081375|NONE
D016642_D012640 CID bupropion_19\NN\0|NONE (r_pobj) of_18\IN\0|and|fixed|a|risk (r_prep) dose_17\NN\3740161|NONE (l_amod) fixed_14\JJ\205885|and|of|a|risk (l_conj) convulsive_16\JJ\0|and
D016642_D012640 CID bupropion_19\NN\0|NONE (r_pobj) of_18\IN\0|and|fixed|a|risk (r_prep) dose_17\NN\3740161|NONE (l_conj) risk_22\NN\14541044|and|of|fixed|a (l_prep) of_23\IN\0|the (l_pobj) convulsions_24\NNS\14081375|NONE
9067481
D002251_D064420 NONE tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
D000082_D066126 NONE acetaminophen_35\RB\2707683|CCl|,|, (l_conj) against_39\IN\0|and|and|galactosamine (l_pobj) lethal_41\JJ\0|NONE (l_conj) effect_47\NN\34213|(|and|the (l_amod) cardiotoxic_45\JJ\0|)|of
D005688_D064420 NONE galactosamine_52\NN\0| (r_npadvmod) induced_54\VBN\1627355|and (r_conj) chloroform-_50\JJ\0|NONE (r_nmod) toxicity_55\NN\13576101|,|carbon|acetaminophen
D004317_D066126 CID adriamycin_49\NNS\0|NONE (r_amod) administration_50\NN\1133281|NONE (r_pobj) of_48\IN\0|cardiotoxic|) (r_prep) effect_47\NN\34213|(|and|the (l_amod) cardiotoxic_45\JJ\0|)|of
C103872_D064420 NONE acid_35\NN\14818238|, (l_conj) salt_38\NN\14818238|cholesteryloxybutyric|, (l_prep) against_42\IN\0|tris|CSE (l_pobj) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
D002725_D064420 NONE chloroform-_50\JJ\0|NONE (r_nmod) toxicity_55\NN\13576101|,|carbon|acetaminophen
D004317_D056486 NONE adriamycin_49\NNS\0|NONE (r_amod) administration_50\NN\1133281|NONE (r_pobj) of_48\IN\0|cardiotoxic|) (r_prep) effect_47\NN\34213|(|and|the (r_conj) lethal_41\JJ\0|NONE (r_pobj) against_39\IN\0|and|and|galactosamine (r_conj) acetaminophen_35\RB\2707683|CCl|,|, (r_conj) chcl3_33\NNP\0|NONE (r_pobj) of_30\IN\0|hepatotoxic|the (r_prep) effects_29\NNS\13245626|NONE (l_amod) hepatotoxic_28\JJ\0|the|of
D004317_D064420 NONE adriamycin-_45\JJ\0|,|, (r_conj) acetaminophen-_43\NN\0|,|carbon|toxicity (r_nmod) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
D002251_D066126 NONE ccl4_31\NNP\0|acetaminophen|,|, (r_nmod) chcl3_33\NNP\0|NONE (l_conj) acetaminophen_35\RB\2707683|CCl|,|, (l_conj) against_39\IN\0|and|and|galactosamine (l_pobj) lethal_41\JJ\0|NONE (l_conj) effect_47\NN\34213|(|and|the (l_amod) cardiotoxic_45\JJ\0|)|of
D002725_D056486 CID chcl3_33\NNP\0|NONE (r_pobj) of_30\IN\0|hepatotoxic|the (r_prep) effects_29\NNS\13245626|NONE (l_amod) hepatotoxic_28\JJ\0|the|of
D005688_D056486 CID galactosamine_37\NN\0|against|and|and (r_conj) acetaminophen_35\RB\2707683|CCl|,|, (r_conj) chcl3_33\NNP\0|NONE (r_pobj) of_30\IN\0|hepatotoxic|the (r_prep) effects_29\NNS\13245626|NONE (l_amod) hepatotoxic_28\JJ\0|the|of
D005688_D056486 CID galactosamine_30\NN\0|NONE (r_amod) hepatotoxicity_31\NN\0|NONE
D000082_D064420 NONE acetaminophen-_43\NN\0|,|carbon|toxicity (r_nmod) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
D002725_D066126 NONE chcl3_33\NNP\0|NONE (l_conj) acetaminophen_35\RB\2707683|CCl|,|, (l_conj) against_39\IN\0|and|and|galactosamine (l_pobj) lethal_41\JJ\0|NONE (l_conj) effect_47\NN\34213|(|and|the (l_amod) cardiotoxic_45\JJ\0|)|of
D002251_D056486 CID tetrachloride_35\NN\14818238|CCl|hepatotoxic|the|of (r_advmod) effects_32\NNS\13245626|NONE (l_amod) hepatotoxic_31\JJ\0|CCl|tetrachloride|the|of
D002251_D056486 CID ccl4_37\NNP\0|tetrachloride|hepatotoxic|the|of (r_appos) effects_32\NNS\13245626|NONE (l_amod) hepatotoxic_31\JJ\0|CCl|tetrachloride|the|of
D002251_D056486 CID ccl4_31\NNP\0|acetaminophen|,|, (r_nmod) chcl3_33\NNP\0|NONE (r_pobj) of_30\IN\0|hepatotoxic|the (r_prep) effects_29\NNS\13245626|NONE (l_amod) hepatotoxic_28\JJ\0|the|of
-1_D056486 NONE salt_17\NN\14818238|)|tris|(|CS (r_nmod) administration_21\NN\1133281|,|cholesteryl (r_conj) hemisuccinate_14\NN\0|,|of|stabilizer (r_conj) rigidifier_9\NN\0|NONE (r_pobj) as_5\IN\14622893|its (r_prep) use_4\NN\407535|NONE (r_pobj) to_2\IN\0|NONE (r_prep) addition_1\NN\3081021|NONE (r_pobj) in_0\IN\13603305|.|also|protect|been|has (r_prep) shown_25\VBN\2137132|NONE (l_xcomp) protect_27\VB\1127795|.|also|been|In|has (l_prep) from_29\IN\0|to|rats (l_pobj) effects_32\NNS\13245626|NONE (l_amod) hepatotoxic_31\JJ\0|CCl|tetrachloride|the|of
-1_D056486 NONE cs_19\NNP\14625458|)|tris|salt|( (r_nmod) administration_21\NN\1133281|,|cholesteryl (r_conj) hemisuccinate_14\NN\0|,|of|stabilizer (r_conj) rigidifier_9\NN\0|NONE (r_pobj) as_5\IN\14622893|its (r_prep) use_4\NN\407535|NONE (r_pobj) to_2\IN\0|NONE (r_prep) addition_1\NN\3081021|NONE (r_pobj) in_0\IN\13603305|.|also|protect|been|has (r_prep) shown_25\VBN\2137132|NONE (l_xcomp) protect_27\VB\1127795|.|also|been|In|has (l_prep) from_29\IN\0|to|rats (l_pobj) effects_32\NNS\13245626|NONE (l_amod) hepatotoxic_31\JJ\0|CCl|tetrachloride|the|of
-1_D056486 NONE cs_13\NNP\14625458|mg|)|(|i.p.|/|, (r_nmod) kg_17\NNS\13717155|NONE (r_pobj) of_12\IN\0|single|a (r_prep) dose_11\NN\3740161|NONE (r_pobj) with_8\IN\0|of|h|A (r_prep) pretreatment_2\NN\0|,|in|. (r_nsubj) resulted_22\VBD\2633881|NONE (l_prep) in_23\IN\13603305|,|pretreatment|. (l_pobj) protection_25\NN\407535|NONE (l_prep) against_26\IN\0|significant (l_pobj) effects_29\NNS\13245626|NONE (l_amod) hepatotoxic_28\JJ\0|the|of
-1_D056486 NONE cs_3\NNP\14625458|NONE (r_compound) protection_4\NN\407535|NONE (r_pobj) of_2\IN\0|The (r_prep) mechanism_1\NN\13446390|does|not|be|.|) (r_nsubj) appear_7\VB\2604760|NONE (l_xcomp) be_9\VB\14625458|does|not|.|mechanism|) (l_acomp) dependent_10\JJ\9627906|to (l_prep) on_11\IN\0|NONE (l_pobj) inhibition_13\NN\1068773|NONE (l_prep) to_17\IN\0|the|of (l_pobj) in_23\IN\13603305|NONE (l_pobj) light_24\NN\11421401|intermediate|( (l_prep) of_25\IN\0|NONE (l_pobj) protection_27\NN\407535|NONE (l_acl) observed_28\VBN\2163746|the (l_prep) against_29\IN\0|NONE (l_pobj) hepatotoxicity_31\NN\0|NONE
-1_D064420 NONE cs_8\NNP\14625458|NONE (r_compound) cytoprotection_9\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) mechanism_6\NN\13446390|NONE (r_pobj) of_4\IN\0|our (r_prep) understanding_3\NN\5804793|To (r_dobj) further_1\VB\2554922|we|mice|.|,|and|in (r_advmod) examined_12\VBD\0|NONE (l_conj) mice_16\NNS\2329401|we|.|further|,|and|in (l_dobj) abilities_19\NNS\4723816|NONE (l_prep) of_20\IN\0|protective|the (l_pobj) cs_21\NNP\14625458|NONE (l_conj) form_28\NN\6286395|and (l_prep) of_29\IN\0|hydrolyzable|ether|the (l_pobj) cs_30\NNP\14625458|NONE (l_conj) acid_35\NN\14818238|, (l_conj) salt_38\NN\14818238|cholesteryloxybutyric|, (l_prep) against_42\IN\0|tris|CSE (l_pobj) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
-1_D064420 NONE cs_21\NNP\14625458|NONE (l_conj) form_28\NN\6286395|and (l_prep) of_29\IN\0|hydrolyzable|ether|the (l_pobj) cs_30\NNP\14625458|NONE (l_conj) acid_35\NN\14818238|, (l_conj) salt_38\NN\14818238|cholesteryloxybutyric|, (l_prep) against_42\IN\0|tris|CSE (l_pobj) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
-1_D064420 NONE cs_30\NNP\14625458|NONE (l_conj) acid_35\NN\14818238|, (l_conj) salt_38\NN\14818238|cholesteryloxybutyric|, (l_prep) against_42\IN\0|tris|CSE (l_pobj) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
-1_D064420 NONE salt_38\NN\14818238|cholesteryloxybutyric|, (l_prep) against_42\IN\0|tris|CSE (l_pobj) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
-1_D064420 NONE cse_40\NNP\8342039|tris|against (r_appos) salt_38\NN\14818238|cholesteryloxybutyric|, (l_prep) against_42\IN\0|tris|CSE (l_pobj) tetrachloride-_48\NN\0|NONE (l_appos) toxicity_55\NN\13576101|,|carbon|acetaminophen
D000082_D056486 CID acetaminophen_35\RB\2707683|CCl|,|, (r_conj) chcl3_33\NNP\0|NONE (r_pobj) of_30\IN\0|hepatotoxic|the (r_prep) effects_29\NNS\13245626|NONE (l_amod) hepatotoxic_28\JJ\0|the|of
C013440_D056486 NONE hemisuccinate_14\NN\0|,|of|stabilizer (r_conj) rigidifier_9\NN\0|NONE (r_pobj) as_5\IN\14622893|its (r_prep) use_4\NN\407535|NONE (r_pobj) to_2\IN\0|NONE (r_prep) addition_1\NN\3081021|NONE (r_pobj) in_0\IN\13603305|.|also|protect|been|has (r_prep) shown_25\VBN\2137132|NONE (l_xcomp) protect_27\VB\1127795|.|also|been|In|has (l_prep) from_29\IN\0|to|rats (l_pobj) effects_32\NNS\13245626|NONE (l_amod) hepatotoxic_31\JJ\0|CCl|tetrachloride|the|of
-1_D066126 NONE cs_13\NNP\14625458|mg|)|(|i.p.|/|, (r_nmod) kg_17\NNS\13717155|NONE (r_pobj) of_12\IN\0|single|a (r_prep) dose_11\NN\3740161|NONE (r_pobj) with_8\IN\0|of|h|A (r_prep) pretreatment_2\NN\0|,|in|. (r_nsubj) resulted_22\VBD\2633881|NONE (l_prep) in_23\IN\13603305|,|pretreatment|. (l_pobj) protection_25\NN\407535|NONE (l_prep) against_26\IN\0|significant (l_pobj) effects_29\NNS\13245626|NONE (l_prep) of_30\IN\0|hepatotoxic|the (l_pobj) chcl3_33\NNP\0|NONE (l_conj) acetaminophen_35\RB\2707683|CCl|,|, (l_conj) against_39\IN\0|and|and|galactosamine (l_pobj) lethal_41\JJ\0|NONE (l_conj) effect_47\NN\34213|(|and|the (l_amod) cardiotoxic_45\JJ\0|)|of
D005688_D066126 NONE galactosamine_37\NN\0|against|and|and (r_conj) acetaminophen_35\RB\2707683|CCl|,|, (l_conj) against_39\IN\0|and|and|galactosamine (l_pobj) lethal_41\JJ\0|NONE (l_conj) effect_47\NN\34213|(|and|the (l_amod) cardiotoxic_45\JJ\0|)|of
2422478
D012701_D006973 NONE serotonin_19\NN\14807737|midline|the|cell|in (r_compound) group_21\NN\2137|NONE (r_pobj) of_15\IN\0|the (r_prep) area_14\NN\8630985|NONE (r_pobj) into_12\IN\0|of (r_prep) microinjection_9\NN\0|,|hypertensive|prone|, (r_conj) rats_7\NNS\2329401|NONE (l_amod) hypertensive_2\JJ\10405694|,|microinjection|prone|,
D012701_D006973 NONE serotonin_51\NN\14807737|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_prep) in_0\IN\13603305|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS\2329401|NONE (l_amod) hypertensive_2\JJ\10405694|,|microinjection|prone|,
D012701_D020521 NONE serotonin_19\NN\14807737|midline|the|cell|in (r_compound) group_21\NN\2137|NONE (r_pobj) of_15\IN\0|the (r_prep) area_14\NN\8630985|NONE (r_pobj) into_12\IN\0|of (r_prep) microinjection_9\NN\0|,|hypertensive|prone|, (r_conj) rats_7\NNS\2329401|NONE (l_amod) prone_6\JJ\0|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN\556313|
D012701_D020521 NONE serotonin_51\NN\14807737|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_prep) in_0\IN\13603305|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS\2329401|NONE (l_amod) prone_6\JJ\0|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN\556313|
D015116_D020521 NONE 5,7-dihydroxytryptamine_53\CD\0|serotonin|the (r_appos) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_prep) in_0\IN\13603305|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS\2329401|NONE (l_amod) prone_6\JJ\0|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN\556313|
D015116_D020521 NONE 5,7-dht_55\NNP\0|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD\0|serotonin|the (r_appos) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_prep) in_0\IN\13603305|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS\2329401|NONE (l_amod) prone_6\JJ\0|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN\556313|
D008750_D007022 CID methyldopa_13\NN\2721160|NONE (r_pobj) of_12\IN\0|hypotensive (r_prep) effect_11\NN\34213|NONE (l_amod) hypotensive_10\JJ\10405694|of
D008750_D007022 CID methyldopa_10\NN\2721160|NONE (r_pobj) of_9\IN\0|onto (r_prep) microinjection_8\NN\0|that|response (r_nsubj) elicits_23\VBZ\1617192|.|have|experiments (l_dobj) response_26\NN\11410625|that|microinjection (l_amod) hypotensive_25\JJ\10405694|mediated|a
D008750_D007022 CID methyldopa_11\NN\2721160|NONE (r_pobj) of_10\IN\0|into (r_prep) microinjection_9\NN\0|,|hypertensive|prone|, (r_conj) rats_7\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|hypotension|and|abolished|h|. (r_prep) caused_26\VBD\1617192|NONE (l_dobj) hypotension_29\NN\14057371|and|abolished|h|.|In
D008750_D007022 CID methyldopa_14\NN\2721160| (r_npadvmod) induced_16\VBN\1627355|a (r_amod) hypotension_17\NN\14057371|which|via
D008750_D007022 CID methyldopa_14\NN\2721160| (r_npadvmod) induced_16\VBN\1627355|a (r_amod) hypotension_17\NN\14057371|which|via (r_dobj) mediate_12\VBP\761713|the|ventrolateral|B (r_relcl) cells_10\NNS\3080309|NONE (r_pobj) unlike_6\IN\0|,|that|cells|by|,|,|to (r_prep) contribute_30\VB\126264|It|.|therefore|is (l_prep) to_31\IN\0|,|that|cells|by|unlike|,|, (l_pobj) action_34\NN\30358|NONE (l_amod) hypotensive_33\JJ\10405694|the|of
D008750_D007022 CID methyldopa_36\NN\2721160|NONE (r_pobj) of_35\IN\0|the|hypotensive (r_prep) action_34\NN\30358|NONE (r_pobj) to_31\IN\0|,|that|cells|by|unlike|,|, (r_prep) contribute_30\VB\126264|It|.|therefore|is (l_prep) unlike_6\IN\0|,|that|cells|by|,|,|to (l_pobj) cells_10\NNS\3080309|NONE (l_relcl) mediate_12\VBP\761713|the|ventrolateral|B (l_dobj) hypotension_17\NN\14057371|which|via
D008750_D007022 CID methyldopa_36\NN\2721160|NONE (r_pobj) of_35\IN\0|the|hypotensive (r_prep) action_34\NN\30358|NONE (l_amod) hypotensive_33\JJ\10405694|the|of
D008750_D006973 NONE methyldopa_11\NN\2721160|NONE (r_pobj) of_10\IN\0|into (r_prep) microinjection_9\NN\0|,|hypertensive|prone|, (r_conj) rats_7\NNS\2329401|NONE (l_amod) hypertensive_2\JJ\10405694|,|microinjection|prone|,
D008750_D020521 NONE methyldopa_11\NN\2721160|NONE (r_pobj) of_10\IN\0|into (r_prep) microinjection_9\NN\0|,|hypertensive|prone|, (r_conj) rats_7\NNS\2329401|NONE (l_amod) prone_6\JJ\0|,|hypertensive|microinjection|, (l_npadvmod) stroke_4\NN\556313|
D015116_D006973 NONE 5,7-dihydroxytryptamine_53\CD\0|serotonin|the (r_appos) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_prep) in_0\IN\13603305|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS\2329401|NONE (l_amod) hypertensive_2\JJ\10405694|,|microinjection|prone|,
D015116_D006973 NONE 5,7-dht_55\NNP\0|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD\0|serotonin|the (r_appos) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_prep) in_0\IN\13603305|hypotension|and|abolished|h|. (l_pobj) rats_7\NNS\2329401|NONE (l_amod) hypertensive_2\JJ\10405694|,|microinjection|prone|,
D012701_D007022 NONE serotonin_2\NN\14807737|in (r_compound) nerves_3\NNS\14373582|are|.|in (r_nsubjpass) involved_8\VBN\2676054|NONE (l_prep) in_9\IN\13603305|are|.|nerves (l_pobj) effect_11\NN\34213|NONE (l_amod) hypotensive_10\JJ\10405694|of
D012701_D007022 NONE serotonin_18\NN\14807737|the (r_compound) neurons_19\NNS\5430628|NONE (r_pobj) of_15\IN\0|in|the|ventrolateral (r_prep) cells_14\NNS\3080309|NONE (r_pobj) onto_11\IN\0|of (r_prep) microinjection_8\NN\0|that|response (r_nsubj) elicits_23\VBZ\1617192|.|have|experiments (l_dobj) response_26\NN\11410625|that|microinjection (l_amod) hypotensive_25\JJ\10405694|mediated|a
D012701_D007022 NONE serotonin_19\NN\14807737|midline|the|cell|in (r_compound) group_21\NN\2137|NONE (r_pobj) of_15\IN\0|the (r_prep) area_14\NN\8630985|NONE (r_pobj) into_12\IN\0|of (r_prep) microinjection_9\NN\0|,|hypertensive|prone|, (r_conj) rats_7\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|hypotension|and|abolished|h|. (r_prep) caused_26\VBD\1617192|NONE (l_dobj) hypotension_29\NN\14057371|and|abolished|h|.|In
D012701_D007022 NONE serotonin_51\NN\14807737|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_dobj) hypotension_29\NN\14057371|and|abolished|h|.|In
D012701_D007022 NONE serotonin_15\NN\14807737|in (r_compound) projections_16\NNS\5775081|only (r_dobj) descending_14\VBG\1835496|NONE (r_pcomp) of_12\IN\0|selective|a (r_prep) lesion_11\NN\14204950|to (r_dobj) produce_7\VB\7555863|intraspinal|of (r_relcl) injection_3\NN\320852|not|did|,|hypotension|However|. (r_nsubj) affect_23\VB\26192|NONE (l_dobj) hypotension_25\NN\14057371|not|did|,|injection|However|.
D012701_D007022 NONE serotonin_24\NN\14807737|in|the|midline|B (r_compound) cells_26\NNS\3080309|,|that|by|unlike|,|,|to (r_nsubj) contribute_30\VB\126264|It|.|therefore|is (l_prep) unlike_6\IN\0|,|that|cells|by|,|,|to (l_pobj) cells_10\NNS\3080309|NONE (l_relcl) mediate_12\VBP\761713|the|ventrolateral|B (l_dobj) hypotension_17\NN\14057371|which|via
D012701_D007022 NONE serotonin_24\NN\14807737|in|the|midline|B (r_compound) cells_26\NNS\3080309|,|that|by|unlike|,|,|to (r_nsubj) contribute_30\VB\126264|It|.|therefore|is (l_prep) to_31\IN\0|,|that|cells|by|unlike|,|, (l_pobj) action_34\NN\30358|NONE (l_amod) hypotensive_33\JJ\10405694|the|of
D015116_D007022 NONE 5,7-dihydroxytryptamine_53\CD\0|serotonin|the (r_appos) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_dobj) hypotension_29\NN\14057371|and|abolished|h|.|In
D015116_D007022 NONE 5,7-dht_55\NNP\0|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD\0|serotonin|the (r_appos) neurotoxin_52\NN\15034074|NONE (r_pobj) by_49\IN\0|was|injected (r_agent) abolished_48\VBN\0|hypotension|and|h|.|In (r_conj) caused_26\VBD\1617192|NONE (l_dobj) hypotension_29\NN\14057371|and|abolished|h|.|In
D015116_D007022 NONE 5,7-dht_5\CD\0|NONE (r_pobj) of_4\IN\0|produce|intraspinal (r_prep) injection_3\NN\320852|not|did|,|hypotension|However|. (r_nsubj) affect_23\VB\26192|NONE (l_dobj) hypotension_25\NN\14057371|not|did|,|injection|However|.
7421734
D004967_D009369 NONE estrogens_4\NNS\14745635|NONE (r_pobj) on_2\IN\0|Young (r_prep) women_1\NNS\9605289|after|therapy|have|also|and|.|may|risk|examined (r_nsubj) increased_14\VBN\169651|NONE (l_nsubj) therapy_10\NN\657604|after|have|also|women|and|.|may|risk|examined (l_compound) cancer_9\NN\14239425|NONE
D004967_D016889 CID estrogens_16\NNS\14745635|treatment (r_dobj) received_14\VBD\2210855|.|failure|and|She|, (l_npadvmod) treatment_19\NN\654885|estrogens (l_acl) implicated_20\VBN\2677097|a|, (l_prep) in_21\IN\13603305|NONE (l_pobj) development_23\NN\248977|NONE (l_prep) of_24\IN\0|the (l_pobj) cancer_26\NN\14239425|NONE
D004967_D016889 CID estrogens_4\NNS\14745635|NONE (r_pobj) on_2\IN\0|Young (r_prep) women_1\NNS\9605289|after|therapy|have|also|and|.|may|risk|examined (r_nsubj) increased_14\VBN\169651|NONE (l_dobj) risk_15\NN\14541044|after|therapy|have|also|women|and|.|may|examined (l_prep) of_16\IN\0|NONE (l_pobj) carcinoma_18\NN\14239918|NONE
D004967_D010049 NONE estrogens_16\NNS\14745635|treatment (r_dobj) received_14\VBD\2210855|.|failure|and|She|, (r_conj) had_1\VBD\0|NONE (l_dobj) failure_3\NN\66216|.|and|She|,|received
D004967_D010049 NONE estrogens_4\NNS\14745635|NONE (l_prep) for_5\IN\0|replacement (l_pobj) failure_7\NN\66216|NONE
D004967_D006689 NONE estrogens_16\NNS\14745635|treatment (r_dobj) received_14\VBD\2210855|.|failure|and|She|, (r_conj) had_1\VBD\0|NONE (l_dobj) failure_3\NN\66216|.|and|She|,|received (l_prep) after_4\IN\0|ovarian (l_pobj) irradiation_6\NN\13920835|NONE (l_prep) for_9\IN\0|abdominal|and|chemotherapy (l_pobj) disease_11\NN\14061805|NONE
7843916
D013256_D005901 NONE steroid_0\NN\14727670|NONE (r_compound) treatment_1\NN\654885|.|in (r_nsubj) resulted_2\VBD\2633881|NONE (l_prep) in_3\IN\13603305|.|treatment (l_pobj) changes_5\NNS\7283608|NONE (l_prep) in_6\IN\13603305|morphologic (l_pobj) meshwork_9\NN\3309808|NONE (l_amod) similar_10\JJ\0|the|trabecular (l_prep) to_11\IN\0|NONE (l_pobj) those_12\DT\0|NONE (l_acl) reported_13\VBN\831651|NONE (l_prep) for_14\IN\0|NONE (l_pobj) glaucoma_16\NN\14252864|NONE
D003907_D009798 CID dexamethasone_0\NN\2721538|hypertension|.| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) hypertension_4\NN\14057371|.||Dexamethasone
D003907_D009798 CID dexamethasone_4\NN\2721538| (r_npadvmod) treated_6\VBN\2376958|hypertensive|the (r_amod) eyes_8\NNS\5945642|had|,|.|beams|,|decreased|In
D003907_D009798 CID dexamethasone_0\NN\2721538|of (r_compound) treatment_1\NN\654885|.|to (r_nsubj) led_10\VBD\3202760|NONE (l_prep) to_11\IN\0|treatment|. (l_pobj) generation_13\NN\7942152|NONE (l_prep) of_14\IN\0|the|in (l_pobj) hypertension_16\NN\14057371|NONE
D003907_D009798 CID dexamethasone_23\NN\2721538| (r_npadvmod) treated_25\VBN\2376958|the (r_amod) eyes_26\NNS\5945642|NONE (r_pobj) of_21\IN\0| (r_prep) %_20\NN\0|NONE (r_pobj) in_17\IN\13603305|the|of (r_prep) generation_13\NN\7942152|NONE (l_prep) of_14\IN\0|the|in (l_pobj) hypertension_16\NN\14057371|NONE
D013256_D005902 NONE steroid_0\NN\14727670|NONE (r_compound) treatment_1\NN\654885|.|in (r_nsubj) resulted_2\VBD\2633881|NONE (l_prep) in_3\IN\13603305|.|treatment (l_pobj) changes_5\NNS\7283608|NONE (l_prep) in_6\IN\13603305|morphologic (l_pobj) meshwork_9\NN\3309808|NONE (l_amod) similar_10\JJ\0|the|trabecular (l_prep) to_11\IN\0|NONE (l_pobj) those_12\DT\0|NONE (l_acl) reported_13\VBN\831651|NONE (l_prep) for_14\IN\0|NONE (l_pobj) glaucoma_16\NN\14252864|NONE (l_conj) glaucoma_20\NN\14252864|and|corticosteroid
6415512
D002220_D004831 CID carbamazepine_10\NN\0|NONE (r_compound) therapy_11\NN\657604|NONE (r_pobj) of_9\IN\0|in (r_prep) institution_8\NN\8008335|NONE (r_dobj) following_7\VBG\8180190|Myoclonic|. (r_prep) seizures_6\NNS\14081375|NONE
D002220_D004831 CID carbamazepine_11\NN\0|NONE (r_pobj) with_10\IN\0|,|.|children|had (r_prep) treated_9\VBN\2376958|NONE (l_conj) had_15\VBD\0|,|.|children|with (l_dobj) reaction_19\NN\13446390|NONE (l_acl) characterized_20\VBN\609683|acute|aberrant|an (l_agent) by_21\IN\0|NONE (l_pobj) onset_23\NN\7325190|NONE (l_prep) of_24\IN\0|the (l_pobj) absence_28\NN\14449405|NONE (l_conj) seizures_35\NNS\14081375|,|atypical|and/or|myoclonic
D002220_D004832 CID carbamazepine_10\NN\0|NONE (r_compound) therapy_11\NN\657604|NONE (r_pobj) of_9\IN\0|in (r_prep) institution_8\NN\8008335|NONE (r_dobj) following_7\VBG\8180190|Myoclonic|. (r_prep) seizures_6\NNS\14081375|NONE
D002220_D004832 CID carbamazepine_11\NN\0|NONE (r_pobj) with_10\IN\0|,|.|children|had (r_prep) treated_9\VBN\2376958|NONE (l_conj) had_15\VBD\0|,|.|children|with (l_dobj) reaction_19\NN\13446390|NONE (l_acl) characterized_20\VBN\609683|acute|aberrant|an (l_agent) by_21\IN\0|NONE (l_pobj) onset_23\NN\7325190|NONE (l_prep) of_24\IN\0|the (l_pobj) absence_28\NN\14449405|NONE (l_conj) seizures_35\NNS\14081375|,|atypical|and/or|myoclonic
D002220_D012640 NONE carbamazepine_2\NN\0|was|When (r_nsubjpass) discontinued_4\VBN\0|to|,|quickly|two (r_advcl) returned_10\VBD\1835496|and|,|,|two|had|resolve (r_ccomp) had_19\VBD\0|NONE (l_ccomp) resolve_24\VBP\4616059|and|,|,|two|had|returned (l_nsubj) seizures_23\NNS\14081375|in
D002220_D012640 NONE carbamazepine_2\NN\0|was|When (r_nsubjpass) discontinued_4\VBN\0|to|,|quickly|two (r_advcl) returned_10\VBD\1835496|and|,|,|two|had|resolve (r_ccomp) had_19\VBD\0|NONE (l_conj) had_33\VBD\0|and|,|,|two|returned|resolve (l_ccomp) persist_36\VB\118523|.|one (l_nsubj) seizures_35\NNS\14081375|NONE
D002220_D004827 NONE carbamazepine_11\NN\0|NONE (l_prep) for_12\IN\0|NONE (l_pobj) epilepsy_13\NN\14085708|NONE
1969772
D004298_D007022 NONE dopamine-1_4\NNS\0|receptor|causes|selective|a (r_punct) agonist_9\NN\0|.|Fenoldopam (l_relcl) causes_11\VBZ\7323922|receptor|selective|dopamine|a (l_conj) preserves_23\VBZ\7597145|vasodilatation|that|to|and (l_prep) during_29\IN\0|flow (l_pobj) hypotension_31\NN\14057371|NONE
D012964_D007022 NONE sodium_25\NN\14625458|P|)|(|induced (r_amod) hypotension_29\NN\14057371|NONE (r_pobj) during_24\IN\0||+/ (r_prep) decreased_18\VBD\169651|.|and|during|flow (r_conj) increased_6\VBD\169651|NONE (l_prep) during_7\IN\0|.|and|decreased|flow (l_pobj) hypotension_11\NN\14057371|NONE
D012964_D007022 NONE sodium_25\NN\14625458|P|)|(|induced (r_amod) hypotension_29\NN\14057371|NONE
D018818_D007022 CID fenoldopam_9\NN\0|NONE (r_pobj) with_8\IN\0|.|Preservation|in (r_prep) induced_7\VBN\1627355|NONE (l_nsubj) preservation_0\NN\817680|.|with|in (l_prep) during_5\IN\0|of (l_pobj) hypotension_6\NN\14057371|NONE
D018818_D007022 CID fenoldopam_3\NN\0|The (r_relcl) hypothesis_1\NN\7162194|induce|be|could|.|tested (r_nsubjpass) used_6\VBN\0|NONE (l_xcomp) induce_8\VB\1627355|be|could|.|tested|hypothesis (l_dobj) hypotension_9\NN\14057371|and|preserve|to
D018818_D007022 CID fenoldopam_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|+/|| (r_amod) hypotension_11\NN\14057371|NONE
D018818_D007022 CID fenoldopam_8\NN\0| (r_npadvmod) induced_10\VBN\1627355|+/|| (r_amod) hypotension_11\NN\14057371|NONE (r_pobj) during_7\IN\0|.|and|decreased|flow (r_prep) increased_6\VBD\169651|NONE (l_conj) decreased_18\VBD\169651|.|and|during|flow (l_prep) during_24\IN\0||+/ (l_pobj) hypotension_29\NN\14057371|NONE
D009599_D007022 CID nitroprusside_26\RB\0| (r_advmod) induced_28\VBN\1627355|sodium|P|)|( (r_amod) hypotension_29\NN\14057371|NONE (r_pobj) during_24\IN\0||+/ (r_prep) decreased_18\VBD\169651|.|and|during|flow (r_conj) increased_6\VBD\169651|NONE (l_prep) during_7\IN\0|.|and|decreased|flow (l_pobj) hypotension_11\NN\14057371|NONE
D009599_D007022 CID nitroprusside_26\RB\0| (r_advmod) induced_28\VBN\1627355|sodium|P|)|( (r_amod) hypotension_29\NN\14057371|NONE
D009599_D007022 CID nitroprusside_1\NN\0|vasodilator|. (r_nsubj) is_2\VBZ\0|NONE (l_attr) vasodilator_10\NN\3198383|nitroprusside|. (l_relcl) produce_13\VB\7555863|arteriolar|venous (l_prep) during_22\IN\0|that|can|redistribution (l_pobj) hypotension_24\NN\14057371|NONE
3686155
D001971_D011605 CID bromocriptine_4\NN\0|NONE (r_pobj) by_3\IN\0|.|psychosis (r_prep) induced_2\VBN\1627355|NONE (l_nsubj) psychosis_1\NN\14380140|.|by
D001971_D011605 CID bromocriptine_16\NN\0|for|having (r_dobj) received_15\VBN\2210855|,|.|were|with|patients (r_advcl) seen_9\VBN\2106506|NONE (l_prep) with_10\IN\0|received|,|.|were|patients (l_pobj) psychosis_12\NN\14380140|NONE
D001971_D011605 CID bromocriptine_0\NNP\0|been|has|with|. (r_nsubjpass) associated_7\VBN\628491|NONE (l_prep) with_8\IN\0|been|has|Bromocriptine|. (l_pobj) psychosis_9\NN\14380140|NONE
D001971_D011605 CID bromocriptine_4\NN\0|may|psychosis|given (r_nsubj) cause_6\VB\7323922|.|cases (l_dobj) psychosis_7\NN\14380140|bromocriptine|may|given
D001971_D010300 NONE bromocriptine_0\NNP\0|been|has|with|. (r_nsubjpass) associated_7\VBN\628491|NONE (l_prep) with_8\IN\0|been|has|Bromocriptine|. (l_pobj) psychosis_9\NN\14380140|NONE (l_prep) in_10\IN\13603305|NONE (l_pobj) patients_11\NNS\9898892|NONE (l_acl) receiving_12\VBG\2210855|NONE (l_dobj) drug_14\NN\14778436|NONE (l_prep) for_15\IN\0|the (l_pobj) disease_18\NN\14061805|NONE
D001971_D001523 NONE bromocriptine_16\NN\0|for|having (r_dobj) received_15\VBN\2210855|,|.|were|with|patients (r_advcl) seen_9\VBN\2106506|NONE (l_nsubjpass) patients_2\NNS\9898892|received|,|.|were|with (l_prep) with_3\IN\0|multigravida|Two (l_pobj) history_7\NN\15120823|NONE (l_amod) psychiatric_6\JJ\0|prior|no
D001971_D007775 NONE bromocriptine_16\NN\0|for|having (r_dobj) received_15\VBN\2210855|,|.|were|with|patients (l_prep) for_17\IN\0|having|bromocriptine (l_pobj) inhibition_18\NN\1068773|NONE (l_prep) of_19\IN\0|NONE (l_pobj) lactation_20\NN\15113229|NONE
3120485
982002
D012293_D058186 CID rifampicin_8\NNS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) administration_6\NN\1133281|NONE (r_pobj) to_4\IN\0|NONE (r_prep) subsequent_3\JJ\0|.|renal|Acute (r_amod) failure_2\NN\66216|NONE
D012293_D051437 NONE rifampicin_12\NNS\0|NONE (r_pobj) of_11\IN\0|intermittent|the (r_prep) administration_10\NN\1133281|NONE (r_pobj) after_7\IN\0|failure|had|.|patients (r_prep) developed_3\VBN\1753788|NONE (l_dobj) failure_6\NN\66216|had|.|after|patients
3950060
D000583_D007674 CID amikacin_10\JJ\0|NONE (r_dobj) receiving_9\VBG\2210855|NONE (r_acl) patients_8\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|outcome|and (r_prep) nephrotoxicity_3\NN\0|NONE
D000583_D007674 CID amikacin_6\JJ\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) treated_4\VBN\2376958| (r_acl) patients_3\NNS\9898892|NONE (r_pobj) from_1\IN\0|NONE (r_prep) data_0\NNS\7951464|.|were|for (r_nsubjpass) analyzed_8\VBN\0|NONE (l_prep) for_9\IN\0|.|Data|were (l_pobj) factors_10\NNS\7326557|NONE (l_acl) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|NONE (l_pobj) nephrotoxicity_13\NN\0|NONE
16574713
D018817_D008569 CID mdma_12\NNP\3054098|moderate (r_compound) users_13\NNS\7846|NONE (r_pobj) in_10\IN\13603305|.|,|evidence|In|was (r_prep) observed_9\VBN\2163746|NONE (l_nsubjpass) evidence_4\NN\5816287|.|,|in|In|was (l_prep) of_5\IN\0|no (l_pobj) impairment_7\NN\7296428|NONE
D018817_D008569 CID mdma_4\NNP\3054098|NONE (r_pobj) of_3\IN\0|in|the (r_prep) use_2\NN\407535|.|to|use|may|While (l_prep) in_5\IN\13603305|of|the (l_pobj) quantities_6\NNS\2137|NONE (l_relcl) considered_10\VBN\689344|NONE (l_oprd) associated_16\VBN\628491|be|may|that (l_prep) with_17\IN\0|is|not|"|" (l_pobj) functioning_20\VBG\29677|NONE
D018817_D008569 CID mdma_4\NNP\3054098|NONE (r_pobj) of_3\IN\0|in|the (r_prep) use_2\NN\407535|.|to|use|may|While (r_nsubj) lead_28\VB\5155821|NONE (l_prep) to_29\IN\0|.|use|may|use|While (l_pobj) impairments_33\NNS\7296428|NONE
D018817_D008569 CID mdma_25\NNP\3054098|NONE (r_compound) use_26\NN\407535|NONE (r_pobj) of_24\IN\0|heavy (r_prep) use_23\NN\407535|.|to|may|use|While (r_nsubj) lead_28\VB\5155821|NONE (l_nsubj) use_2\NN\407535|.|to|use|may|While (l_prep) in_5\IN\13603305|of|the (l_pobj) quantities_6\NNS\2137|NONE (l_relcl) considered_10\VBN\689344|NONE (l_oprd) associated_16\VBN\628491|be|may|that (l_prep) with_17\IN\0|is|not|"|" (l_pobj) functioning_20\VBG\29677|NONE
D018817_D008569 CID mdma_25\NNP\3054098|NONE (r_compound) use_26\NN\407535|NONE (r_pobj) of_24\IN\0|heavy (r_prep) use_23\NN\407535|.|to|may|use|While (r_nsubj) lead_28\VB\5155821|NONE (l_prep) to_29\IN\0|.|use|may|use|While (l_pobj) impairments_33\NNS\7296428|NONE
D012701_D020258 NONE serotonin_13\NN\14807737|to (r_dobj) damage_11\VB\7296428|MDMA|has|,methylenedioxymethamphetamine|Although|been (r_xcomp) shown_9\VBN\2137132|,|is|about|.|little (r_advcl) known_26\VBN\0|NONE (l_prep) about_27\IN\0|,|is|shown|.|little (l_pobj) consequences_32\NNS\34213|NONE (l_prep) of_33\IN\0|the|term (l_pobj) lesions_39\NNS\14204950|NONE
D012701_D020258 NONE 5-ht_15\CD\0|in|humans|(|)|and (r_nmod) neurons_17\NNS\5430628|brain (r_appos) serotonin_13\NN\14807737|to (r_dobj) damage_11\VB\7296428|MDMA|has|,methylenedioxymethamphetamine|Although|been (r_xcomp) shown_9\VBN\2137132|,|is|about|.|little (r_advcl) known_26\VBN\0|NONE (l_prep) about_27\IN\0|,|is|shown|.|little (l_pobj) consequences_32\NNS\34213|NONE (l_prep) of_33\IN\0|the|term (l_pobj) lesions_39\NNS\14204950|NONE
D012701_D020258 NONE 5-ht_37\CD\0|neurotoxic|on|induced (r_nummod) lesions_39\NNS\14204950|NONE
D012701_D020258 NONE 5-ht_44\CD\0|in|is (r_nsubjpass) involved_46\VBN\2676054|,|as (r_relcl) functions_41\NNS\13783581|NONE (r_pobj) on_40\IN\0|neurotoxic|induced|HT (r_prep) lesions_39\NNS\14204950|NONE
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1\CD\0|MDMA|damage|has|Although|been (r_nsubjpass) shown_9\VBN\2137132|,|is|about|.|little (r_advcl) known_26\VBN\0|NONE (l_prep) about_27\IN\0|,|is|shown|.|little (l_pobj) consequences_32\NNS\34213|NONE (l_prep) of_33\IN\0|the|term (l_pobj) lesions_39\NNS\14204950|NONE
D018817_D020258 NONE mdma_3\NNP\3054098|damage|has|,methylenedioxymethamphetamine|Although|been (r_nsubjpass) shown_9\VBN\2137132|,|is|about|.|little (r_advcl) known_26\VBN\0|NONE (l_prep) about_27\IN\0|,|is|shown|.|little (l_pobj) consequences_32\NNS\34213|NONE (l_prep) of_33\IN\0|the|term (l_pobj) lesions_39\NNS\14204950|NONE
D018817_D020258 NONE ecstasy_5\NN\13985818|or|(|) (r_conj) mdma_3\NNP\3054098|damage|has|,methylenedioxymethamphetamine|Although|been (r_nsubjpass) shown_9\VBN\2137132|,|is|about|.|little (r_advcl) known_26\VBN\0|NONE (l_prep) about_27\IN\0|,|is|shown|.|little (l_pobj) consequences_32\NNS\34213|NONE (l_prep) of_33\IN\0|the|term (l_pobj) lesions_39\NNS\14204950|NONE
D018817_D020258 NONE mdma_34\NNP\3054098| (r_npadvmod) induced_36\VBN\1627355|neurotoxic|on|HT (r_amod) lesions_39\NNS\14204950|NONE
4038130
D008619_D009135 CID mepivacaine_19\NN\0|NONE (r_pobj) to_18\IN\0|NONE (r_prep) exposure_17\NN\5042871|especially (r_pobj) after_16\IN\0|.|was|also|,|in|In|damage|, (r_prep) seen_10\VBN\2106506|NONE (l_prep) in_0\IN\13603305|.|was|after|also|,|in|damage|, (l_pobj) addition_1\NN\3081021|NONE (l_prep) to_2\IN\0|NONE (l_pobj) damage_4\NN\7296428|NONE
D008012_D009135 CID lidocaine_21\NN\3681148|plus|epinephrine|and (r_conj) mepivacaine_19\NN\0|NONE (r_pobj) to_18\IN\0|NONE (r_prep) exposure_17\NN\5042871|especially (r_pobj) after_16\IN\0|.|was|also|,|in|In|damage|, (r_prep) seen_10\VBN\2106506|NONE (l_prep) in_0\IN\13603305|.|was|after|also|,|in|damage|, (l_pobj) addition_1\NN\3081021|NONE (l_prep) to_2\IN\0|NONE (l_pobj) damage_4\NN\7296428|NONE
D004837_D009135 NONE epinephrine_23\NN\14807929|plus|lidocaine|and (r_conj) mepivacaine_19\NN\0|NONE (r_pobj) to_18\IN\0|NONE (r_prep) exposure_17\NN\5042871|especially (r_pobj) after_16\IN\0|.|was|also|,|in|In|damage|, (r_prep) seen_10\VBN\2106506|NONE (l_prep) in_0\IN\13603305|.|was|after|also|,|in|damage|, (l_pobj) addition_1\NN\3081021|NONE (l_prep) to_2\IN\0|NONE (l_pobj) damage_4\NN\7296428|NONE
8800187
D003891_D064420 NONE desipramine_8\JJ\4482543|in (r_amod) toxicity_9\NN\13576101|NONE
D015761_D064420 NONE 4-aminopyridine_5\CD\0|on (r_compound) therapy_6\NN\657604|and|calcium (l_prep) on_7\IN\0|aminopyridine (l_pobj) toxicity_9\NN\13576101|NONE
D002122_D007022 NONE cacl2_3\NNP\0|or (r_pobj) of_2\IN\0|The (r_prep) administration_1\NN\1133281|hypotension|.|not|did (r_nsubj) reverse_8\VB\13854649|NONE (l_dobj) hypotension_13\NN\14057371|.|not|administration|did
D003891_D001919 CID desipramine_6\NN\4482543|antidepressant|the (r_compound) ip_7\NNP\5999797|rats|produce|. (r_dobj) received_2\VBD\2210855|NONE (l_advcl) produce_9\VB\7555863|rats|IP|. (l_dobj) prolongation_13\NN\1017987|,|to|hypotension (l_conj) bradycardia_16\NN\14110674|and|QRS|,
D002118_D007022 NONE calcium_7\NN\14625458|NONE (r_compound) channel_8\NN\6251781|in (r_compound) blockade_9\NN\952963|NONE (l_prep) in_10\IN\13603305|channel (l_pobj) hypotension_15\NN\14057371|NONE
D002118_D007022 NONE calcium_8\NN\14625458|NONE (r_compound) channel_9\NN\6251781|in (r_compound) inhibition_10\NN\1068773|NONE (l_prep) in_11\IN\13603305|channel (l_pobj) pathogenesis_13\NN\13533470|NONE (l_prep) of_14\IN\0|the (l_pobj) hypotension_19\NN\14057371|NONE
D015761_D007022 NONE 4-aminopyridine_5\NN\0|NONE (r_punct) did_6\VBD\0|hypotension|.|not|administration (r_aux) reverse_8\VB\13854649|NONE (l_dobj) hypotension_13\NN\14057371|.|not|administration|did
D002122_D001145 CID cacl2_19\NNP\0|the (r_compound) group_20\NN\2137|NONE (r_pobj) in_17\IN\13603305|.|(|) (r_prep) seizures_11\NNS\14081375|ventricular|.|and (r_conj) arrhythmias_4\NNS\14103288|NONE
D002122_D002318 NONE cacl2_0\NNP\0|NONE (r_compound) therapy_1\NN\657604|may|toxicity|possibly|. (r_nsubj) worsen_4\VB\146138|NONE (l_dobj) toxicity_11\NN\13576101|may|therapy|possibly|.
D002118_D062787 NONE calcium_14\NN\14625458|NONE (r_compound) channel_15\NN\6251781|blocker (r_compound) overdose_17\NN\84738|NONE
D002122_D002493 NONE cacl2_0\NNP\0|NONE (r_compound) therapy_1\NN\657604|may|toxicity|possibly|. (r_nsubj) worsen_4\VB\146138|NONE (l_dobj) toxicity_11\NN\13576101|may|therapy|possibly|.
D017693_D007022 NONE nahco3_0\NNP\0|.|hypotension (r_nsubj) reversed_6\VBD\109660|NONE (l_dobj) hypotension_7\NN\14057371|.|NaHCO
D002122_D012640 NONE cacl2_19\NNP\0|the (r_compound) group_20\NN\2137|NONE (r_pobj) in_17\IN\13603305|.|(|) (r_prep) seizures_11\NNS\14081375|ventricular|.|and
D002122_D064420 NONE chloride_3\NN\14818238|NONE (l_conj) therapy_6\NN\657604|and|calcium (l_prep) on_7\IN\0|aminopyridine (l_pobj) toxicity_9\NN\13576101|NONE
D003891_D007022 CID desipramine_6\NN\4482543|antidepressant|the (r_compound) ip_7\NNP\5999797|rats|produce|. (r_dobj) received_2\VBD\2210855|NONE (l_advcl) produce_9\VB\7555863|rats|IP|. (l_dobj) hypotension_10\NN\14057371|,|to|prolongation
8546130
D017291_D007676 NONE clarithromycin_0\NN\0| (r_npadvmod) associated_2\VBN\628491|in|visual|. (r_amod) hallucinations_4\NNS\14376855|NONE (l_prep) in_5\IN\13603305|visual|associated|. (l_pobj) patient_7\NN\9898892|NONE (l_prep) with_8\IN\0|a (l_pobj) failure_11\NN\66216|NONE
D017291_D007676 NONE clarithromycin_8\NN\0|NONE (r_pobj) of_7\IN\0|a|high|in|in (r_prep) dose_6\NN\3740161|NONE (l_prep) in_9\IN\13603305|of|a|high|in (l_pobj) face_10\NN\5225090|NONE (l_prep) of_11\IN\0|NONE (l_pobj) failure_14\NN\66216|NONE
D017291_D020258 NONE clarithromycin_8\NN\0|NONE (r_pobj) of_7\IN\0|a|high|in|in (r_prep) dose_6\NN\3740161|NONE (r_pobj) of_2\IN\0|,|with|,|The (r_prep) combination_1\NN\7951464|.|appearance|have|may (r_nsubj) facilitated_28\VBN\2547586|NONE (l_dobj) appearance_30\NN\4723816|.|have|combination|may (l_prep) of_31\IN\0|the (l_pobj) effect_35\NN\34213|NONE (l_amod) neurotoxic_33\JJ\0|this|side
D018942_D006212 NONE macrolide_13\NN\0|,|clarithromycin|the|new (r_amod) antibiotic_14\NN\2716205|NONE (r_pobj) with_10\IN\0|NONE (r_prep) association_9\NN\8008335|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) occurring_7\VBG\0|visual (r_acl) hallucinations_6\NNS\14376855|in|is|.
D000535_D020258 NONE aluminum_23\NN\14625458|underlying (r_compound) intoxication_24\NN\14034177|NONE (r_pobj) with_21\IN\0|,|,|The|of (r_prep) combination_1\NN\7951464|.|appearance|have|may (r_nsubj) facilitated_28\VBN\2547586|NONE (l_dobj) appearance_30\NN\4723816|.|have|combination|may (l_prep) of_31\IN\0|the (l_pobj) effect_35\NN\34213|NONE (l_amod) neurotoxic_33\JJ\0|this|side
D017291_D006212 CID clarithromycin_0\NN\0| (r_npadvmod) associated_2\VBN\628491|in|visual|. (r_amod) hallucinations_4\NNS\14376855|NONE
D017291_D006212 CID clarithromycin_16\NN\0|,|the|macrolide|new (r_appos) antibiotic_14\NN\2716205|NONE (r_pobj) with_10\IN\0|NONE (r_prep) association_9\NN\8008335|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) occurring_7\VBG\0|visual (r_acl) hallucinations_6\NNS\14376855|in|is|.
D000535_D007676 NONE aluminum_23\NN\14625458|underlying (r_compound) intoxication_24\NN\14034177|NONE (r_pobj) with_21\IN\0|,|,|The|of (r_prep) combination_1\NN\7951464|.|appearance|have|may (l_prep) of_2\IN\0|,|with|,|The (l_pobj) dose_6\NN\3740161|NONE (l_prep) in_9\IN\13603305|of|a|high|in (l_pobj) face_10\NN\5225090|NONE (l_prep) of_11\IN\0|NONE (l_pobj) failure_14\NN\66216|NONE
9121607
D016202_D012640 NONE aspartate_6\NNP\0|NONE (l_appos) seizures_9\NNS\14081375|methyl||D|.
D016202_D012640 NONE nmda)-induced_8\JJ\0|in|( (r_amod) seizures_9\NNS\14081375|methyl||D|.
D016202_D012640 NONE nmda_10\NNP\0|NONE (r_pobj) in_9\IN\13603305|dependent|(|mg/kg|a (r_prep) delay_8\NN\15271008|but|,|also|protect|.|steroids (r_dobj) caused_3\VBD\1617192|NONE (l_conj) protect_22\VB\1127795|but|,|also|.|steroids|delay (l_prep) against_23\IN\0|not|completely|did (l_pobj) seizures_25\NNS\14081375|NONE
D016202_D012640 NONE nmda_24\NNP\0|lethality|or (r_compound) seizures_25\NNS\14081375|NONE
D007608_D013226 CID acid_7\NN\14818238| (r_npadvmod) induced_9\VBN\1627355|limbic|status|and|pilocarpine (r_amod) seizures_11\NNS\14081375|NONE (r_pobj) against_3\IN\0|.|epilepticus|steroids (r_prep) protect_2\VBP\1127795|NONE (l_advcl) epilepticus_14\NN\0|.|steroids|against
D007608_D013226 CID acid_23\NN\14818238| (r_npadvmod) induced_25\VBN\1627355|and|limbic|kainic|epilepticus (r_amod) seizures_27\NNS\14081375|NONE (l_conj) epilepticus_30\NN\0|and|induced|limbic|kainic
D007608_D013226 CID acid_14\NN\14818238| (r_npadvmod) induced_16\VBN\1627355|status|and|pilocarpine (r_amod) seizures_17\NNS\14081375|NONE (r_pobj) against_10\IN\0|NONE (r_prep) protecting_9\VBG\1127795|NONE (r_pcomp) in_8\IN\13603305|highly (r_prep) effective_7\JJ\0|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP\13600404|We|. (l_advcl) epilepticus_20\NN\0|and|that|be|steroids|effective|,
D007608_D013226 CID acid_14\NN\14818238| (r_npadvmod) induced_16\VBN\1627355|status|and|pilocarpine (r_amod) seizures_17\NNS\14081375|NONE (r_pobj) against_10\IN\0|NONE (r_prep) protecting_9\VBG\1127795|NONE (r_pcomp) in_8\IN\13603305|highly (r_prep) effective_7\JJ\0|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP\13600404|We|. (l_conj) be_26\VB\14625458|and|that|steroids|epilepticus|effective|, (l_advmod) epilepticus_37\NN\0|may|of|in
D013256_D012640 NONE steroids_1\NNS\14727670|.|epilepticus|against (r_nsubj) protect_2\VBP\1127795|NONE (l_prep) against_3\IN\0|.|epilepticus|steroids (l_pobj) seizures_11\NNS\14081375|NONE
D013256_D012640 NONE steroids_0\NNS\14727670|effective|.|values|mg/kg (r_nsubj) were_19\VBD\0|NONE (l_parataxis) mg/kg_28\NNS\0|effective|.|values|Steroids (l_conj) s.c.)-induced_30\VBN\0|,||( (l_dobj) seizures_33\NNS\14081375|NONE
D013256_D012640 NONE steroids_3\NNS\14727670|Although|potent (r_nsubj) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ\0|Although|steroids (l_advcl) clonazepam_11\NN\0|less (l_prep) in_12\IN\13603305|benzodiazepine|the|than (l_pcomp) protecting_13\VBG\1127795|NONE (l_prep) against_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D013256_D012640 NONE steroids_3\NNS\14727670|Although|potent (r_nsubj) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D013256_D012640 NONE steroids_18\NNS\14727670|clonazepam|values|,|,|indicating|.|were (r_nsubj) had_26\VBD\0|NONE (l_advcl) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ\0|Although|steroids (l_advcl) clonazepam_11\NN\0|less (l_prep) in_12\IN\13603305|benzodiazepine|the|than (l_pcomp) protecting_13\VBG\1127795|NONE (l_prep) against_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D013256_D012640 NONE steroids_18\NNS\14727670|clonazepam|values|,|,|indicating|.|were (r_nsubj) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D013256_D012640 NONE steroids_52\NNS\14727670|that|may|toxicity (r_nsubj) have_54\VB\7846|NONE (r_ccomp) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (r_advcl) had_26\VBD\0|NONE (l_advcl) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ\0|Although|steroids (l_advcl) clonazepam_11\NN\0|less (l_prep) in_12\IN\13603305|benzodiazepine|the|than (l_pcomp) protecting_13\VBG\1127795|NONE (l_prep) against_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D013256_D012640 NONE steroids_52\NNS\14727670|that|may|toxicity (r_nsubj) have_54\VB\7846|NONE (r_ccomp) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (r_advcl) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D013256_D012640 NONE steroids_0\NNS\14727670|configurations|delay|also|,|but|protect|. (r_nsubj) produced_13\VBD\1617192|NONE (l_dobj) delay_18\NN\15271008|configurations|also|,|but|protect|.|Steroids (l_prep) in_19\IN\13603305|a|dependent|induced (l_pobj) onset_21\NN\7325190|NONE (l_prep) of_22\IN\0|the (l_pobj) seizures_24\NNS\14081375|NONE
D013256_D012640 NONE steroids_0\NNS\14727670|configurations|delay|also|,|but|protect|. (r_nsubj) produced_13\VBD\1617192|NONE (l_conj) protect_40\VB\1127795|configurations|delay|also|,|but|.|Steroids (l_prep) against_41\IN\0|did|completely|not (l_pobj) seizures_43\NNS\14081375|NONE
D013256_D012640 NONE steroid_8\NN\14727670|NONE (r_pobj) of_6\IN\0|second|a (r_prep) dose_5\NN\3740161|when|was (r_nsubjpass) administered_10\VBN\2436349||,|However|after (r_advcl) hr_12\NN\15154774|,|complete|from (r_nmod) protection_19\NN\407535|.|was (l_prep) from_20\IN\0|hr|,|complete (l_pobj) seizures_27\NNS\14081375|NONE
D013256_D012640 NONE steroids_1\NNS\14727670|but|,|also|protect|.|delay (r_nsubj) caused_3\VBD\1617192|NONE (l_conj) protect_22\VB\1127795|but|,|also|.|steroids|delay (l_prep) against_23\IN\0|not|completely|did (l_pobj) seizures_25\NNS\14081375|NONE
D013256_D012640 NONE steroids_4\NNS\14727670|and|that|be|epilepticus|effective|, (r_nsubj) are_5\VBP\13600404|We|. (l_acomp) effective_7\JJ\0|and|that|be|steroids|epilepticus|, (l_prep) in_8\IN\13603305|highly (l_pcomp) protecting_9\VBG\1127795|NONE (l_prep) against_10\IN\0|NONE (l_pobj) seizures_17\NNS\14081375|NONE
D001569_D012640 NONE benzodiazepine_10\JJ\3771443|in|the|than (r_amod) clonazepam_11\NN\0|less (l_prep) in_12\IN\13603305|benzodiazepine|the|than (l_pcomp) protecting_13\VBG\1127795|NONE (l_prep) against_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D001569_D012640 NONE benzodiazepine_10\JJ\3771443|in|the|than (r_amod) clonazepam_11\NN\0|less (r_advcl) potent_7\JJ\0|Although|steroids (r_acomp) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D013256_D013226 NONE steroids_1\NNS\14727670|.|epilepticus|against (r_nsubj) protect_2\VBP\1127795|NONE (l_advcl) epilepticus_14\NN\0|.|steroids|against
D013256_D013226 NONE steroids_0\NNS\14727670|effective|.|values|mg/kg (r_nsubj) were_19\VBD\0|NONE (l_npadvmod) values_39\NNS\5941423|effective|.|mg/kg|Steroids (l_amod) epilepticus_36\NN\0|(|mg/kg|)|,|ED
D013256_D013226 NONE steroid_8\NN\14727670|NONE (r_pobj) of_6\IN\0|second|a (r_prep) dose_5\NN\3740161|when|was (r_nsubjpass) administered_10\VBN\2436349||,|However|after (r_advcl) hr_12\NN\15154774|,|complete|from (r_nmod) protection_19\NN\407535|.|was (l_prep) from_20\IN\0|hr|,|complete (l_pobj) seizures_27\NNS\14081375|NONE (l_conj) epilepticus_30\NN\0|and|induced|limbic|kainic
D013256_D013226 NONE steroids_4\NNS\14727670|and|that|be|epilepticus|effective|, (r_nsubj) are_5\VBP\13600404|We|. (l_advcl) epilepticus_20\NN\0|and|that|be|steroids|effective|,
D013256_D013226 NONE steroids_4\NNS\14727670|and|that|be|epilepticus|effective|, (r_nsubj) are_5\VBP\13600404|We|. (l_conj) be_26\VB\14625458|and|that|steroids|epilepticus|effective|, (l_advmod) epilepticus_37\NN\0|may|of|in
D010862_D013226 CID pilocarpine-_4\NN\0|induced|limbic|status|and (r_nmod) seizures_11\NNS\14081375|NONE (r_pobj) against_3\IN\0|.|epilepticus|steroids (r_prep) protect_2\VBP\1127795|NONE (l_advcl) epilepticus_14\NN\0|.|steroids|against
D010862_D013226 CID pilocarpine_25\NN\14712692|NONE (r_pobj) against_24\IN\0|NONE (r_prep) protecting_23\VBG\1127795|NONE (r_pcomp) in_22\IN\13603305|highly (r_prep) effective_21\JJ\0|.|values|mg/kg|Steroids (r_acomp) were_19\VBD\0|NONE (l_npadvmod) values_39\NNS\5941423|effective|.|mg/kg|Steroids (l_amod) epilepticus_36\NN\0|(|mg/kg|)|,|ED
D010862_D013226 CID pilocarpine-_11\NN\0|status|and|induced (r_nmod) seizures_17\NNS\14081375|NONE (r_pobj) against_10\IN\0|NONE (r_prep) protecting_9\VBG\1127795|NONE (r_pcomp) in_8\IN\13603305|highly (r_prep) effective_7\JJ\0|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP\13600404|We|. (l_advcl) epilepticus_20\NN\0|and|that|be|steroids|effective|,
D010862_D013226 CID pilocarpine-_11\NN\0|status|and|induced (r_nmod) seizures_17\NNS\14081375|NONE (r_pobj) against_10\IN\0|NONE (r_prep) protecting_9\VBG\1127795|NONE (r_pcomp) in_8\IN\13603305|highly (r_prep) effective_7\JJ\0|and|that|be|steroids|epilepticus|, (r_acomp) are_5\VBP\13600404|We|. (l_conj) be_26\VB\14625458|and|that|steroids|epilepticus|effective|, (l_advmod) epilepticus_37\NN\0|may|of|in
D001569_D064420 NONE benzodiazepine_10\JJ\3771443|in|the|than (r_amod) clonazepam_11\NN\0|less (r_advcl) potent_7\JJ\0|Although|steroids (r_acomp) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_advcl) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
D013256_D064420 NONE steroids_3\NNS\14727670|Although|potent (r_nsubj) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_advcl) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
D013256_D064420 NONE steroids_18\NNS\14727670|clonazepam|values|,|,|indicating|.|were (r_nsubj) had_26\VBD\0|NONE (l_advcl) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
D013256_D064420 NONE steroids_52\NNS\14727670|that|may|toxicity (r_nsubj) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
D002998_D064420 NONE clonazepam_11\NN\0|less (r_advcl) potent_7\JJ\0|Although|steroids (r_acomp) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_advcl) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
D002998_D064420 NONE clonazepam_46\NN\0|values|steroids|,|,|indicating|.|were (r_advcl) had_26\VBD\0|NONE (l_advcl) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
D002998_D012640 NONE clonazepam_11\NN\0|less (l_prep) in_12\IN\13603305|benzodiazepine|the|than (l_pcomp) protecting_13\VBG\1127795|NONE (l_prep) against_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D002998_D012640 NONE clonazepam_11\NN\0|less (r_advcl) potent_7\JJ\0|Although|steroids (r_acomp) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D002998_D012640 NONE clonazepam_46\NN\0|values|steroids|,|,|indicating|.|were (r_advcl) had_26\VBD\0|NONE (l_advcl) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (l_acomp) potent_7\JJ\0|Although|steroids (l_advcl) clonazepam_11\NN\0|less (l_prep) in_12\IN\13603305|benzodiazepine|the|than (l_pcomp) protecting_13\VBG\1127795|NONE (l_prep) against_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D002998_D012640 NONE clonazepam_46\NN\0|values|steroids|,|,|indicating|.|were (r_advcl) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D010862_D012640 CID pilocarpine-_4\NN\0|induced|limbic|status|and (r_nmod) seizures_11\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_25\NN\14712692|NONE (r_pobj) against_24\IN\0|NONE (r_prep) protecting_23\VBG\1127795|NONE (r_pcomp) in_22\IN\13603305|highly (r_prep) effective_21\JJ\0|.|values|mg/kg|Steroids (r_acomp) were_19\VBD\0|NONE (l_parataxis) mg/kg_28\NNS\0|effective|.|values|Steroids (l_conj) s.c.)-induced_30\VBN\0|,||( (l_dobj) seizures_33\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_15\NN\14712692|NONE (r_amod) seizures_16\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_15\NN\14712692|NONE (r_amod) seizures_16\NNS\14081375|NONE (r_pobj) against_14\IN\0|NONE (r_prep) protecting_13\VBG\1127795|NONE (r_pcomp) in_12\IN\13603305|benzodiazepine|the|than (r_prep) clonazepam_11\NN\0|less (r_advcl) potent_7\JJ\0|Although|steroids (r_acomp) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_dobj) values_32\NNS\5941423|clonazepam|steroids|,|,|indicating|.|were (l_appos) td50_34\NNP\0|comparable|protective|)|(|index (l_acl) divided_38\VBN\140123|for (l_prep) for_41\IN\0|by (l_pobj) protection_43\NN\407535|NONE (l_compound) seizure_42\NN\14081375|NONE
D010862_D012640 CID pilocarpine-_11\NN\0|status|and|induced (r_nmod) seizures_17\NNS\14081375|NONE
D007608_D012640 CID acid_7\NN\14818238| (r_npadvmod) induced_9\VBN\1627355|limbic|status|and|pilocarpine (r_amod) seizures_11\NNS\14081375|NONE
D007608_D012640 CID acid_28\NN\14818238|NONE (r_pobj) by_26\IN\0|NONE (r_agent) induced_25\VBN\1627355|a|in|dependent (r_acl) delay_18\NN\15271008|configurations|also|,|but|protect|.|Steroids (l_prep) in_19\IN\13603305|a|dependent|induced (l_pobj) onset_21\NN\7325190|NONE (l_prep) of_22\IN\0|the (l_pobj) seizures_24\NNS\14081375|NONE
D007608_D012640 CID acid_28\NN\14818238|NONE (r_pobj) by_26\IN\0|NONE (r_agent) induced_25\VBN\1627355|a|in|dependent (r_acl) delay_18\NN\15271008|configurations|also|,|but|protect|.|Steroids (r_dobj) produced_13\VBD\1617192|NONE (l_conj) protect_40\VB\1127795|configurations|delay|also|,|but|.|Steroids (l_prep) against_41\IN\0|did|completely|not (l_pobj) seizures_43\NNS\14081375|NONE
D007608_D012640 CID acid_23\NN\14818238| (r_npadvmod) induced_25\VBN\1627355|and|limbic|kainic|epilepticus (r_amod) seizures_27\NNS\14081375|NONE
D007608_D012640 CID acid_14\NN\14818238| (r_npadvmod) induced_16\VBN\1627355|status|and|pilocarpine (r_amod) seizures_17\NNS\14081375|NONE
D010862_D064420 NONE pilocarpine_15\NN\14712692|NONE (r_amod) seizures_16\NNS\14081375|NONE (r_pobj) against_14\IN\0|NONE (r_prep) protecting_13\VBG\1127795|NONE (r_pcomp) in_12\IN\13603305|benzodiazepine|the|than (r_prep) clonazepam_11\NN\0|less (r_advcl) potent_7\JJ\0|Although|steroids (r_acomp) were_4\VBD\0|clonazepam|values|steroids|,|,|indicating|. (r_advcl) had_26\VBD\0|NONE (l_advcl) indicating_48\VBG\952524|clonazepam|values|steroids|,|,|.|were (l_ccomp) have_54\VB\7846|NONE (l_dobj) toxicity_57\NN\13576101|steroids|that|may
9226773
D008094_D018500 CID lithium_5\NN\14625458|NONE (r_compound) therapy_6\NN\657604|NONE (r_dobj) following_4\VBG\8180190|.|diabetes (r_prep) insipidus_3\NN\0|NONE
D008094_D018500 CID lithium_9\NN\14625458| (r_npadvmod) induced_11\VBN\1627355|diabetes (r_amod) insipidus_14\NN\0|to
D008094_D018500 CID lithium_17\NN\14625458|NONE (r_compound) therapy_18\NN\657604|.|had|been (r_nsubjpass) discontinued_21\VBN\0|have|had|previously|and|,|he|years|been (r_conj) diagnosed_6\VBN\644583|NONE (l_xcomp) have_8\VB\7846|discontinued|had|previously|and|,|he|years|been (l_dobj) insipidus_14\NN\0|to
D008094_D018500 CID lithium_8\NN\14625458|NONE (r_pobj) of_7\IN\0|NONE (r_prep) cessation_6\NN\7365849|NONE (r_pobj) despite_5\IN\7501545|NONE (r_prep) polyuric_4\JJ\0|and (r_conj) thirsty_2\JJ\0|.|showed|He (r_acomp) remained_1\VBD\2604760|NONE (l_conj) showed_13\VBD\2137132|.|thirsty|He (l_ccomp) have_16\VB\7846|NONE (l_prep) with_24\IN\0|to|thirst|,|him (l_pobj) evidence_26\NN\5816287|NONE (l_prep) of_27\IN\0|clear (l_pobj) insipidus_30\NN\0|NONE
D008094_D018500 CID lithium_0\NN\14625458|insipidus (r_nsubj) induced_1\VBD\1627355|.|is|be (l_dobj) insipidus_4\NN\0|Lithium
D008094_D018500 CID lithium_24\NN\14625458|after|was (r_nsubjpass) stopped_26\VBN\0|reversible|to (r_advcl) be_8\VB\14625458|.|induced|is (r_xcomp) considered_6\VBN\689344|NONE (l_csubjpass) induced_1\VBD\1627355|.|is|be (l_dobj) insipidus_4\NN\0|Lithium
D008094_D018500 CID lithium_14\NN\14625458| (r_npadvmod) induced_16\VBN\1627355|diabetes (r_amod) insipidus_19\NN\0|NONE
D008094_D011141 CID lithium_8\NN\14625458|NONE (r_pobj) of_7\IN\0|NONE (r_prep) cessation_6\NN\7365849|NONE (r_pobj) despite_5\IN\7501545|NONE (r_prep) polyuric_4\JJ\0|and
D008094_D011141 CID lithium_0\NN\14625458|insipidus (r_nsubj) induced_1\VBD\1627355|.|is|be (r_csubjpass) considered_6\VBN\689344|NONE (l_xcomp) be_8\VB\14625458|.|induced|is (l_acomp) reversible_9\JJ\3419014|to|stopped (l_prep) on_10\IN\0|NONE (l_pobj) cessation_11\NN\7365849|NONE (l_prep) of_12\IN\0|persisted (l_pobj) therapy_13\NN\657604|NONE (l_conj) polyuria_15\NN\14113228|but
D008094_D011141 CID lithium_24\NN\14625458|after|was (r_nsubjpass) stopped_26\VBN\0|reversible|to (r_advcl) be_8\VB\14625458|.|induced|is (l_acomp) reversible_9\JJ\3419014|to|stopped (l_prep) on_10\IN\0|NONE (l_pobj) cessation_11\NN\7365849|NONE (l_prep) of_12\IN\0|persisted (l_pobj) therapy_13\NN\657604|NONE (l_conj) polyuria_15\NN\14113228|but
D014667_D011141 NONE vasopressin_21\NN\5407119|NONE (r_compound) secretion_22\NN\13526110|and|normal|osmoregulated (r_conj) thirst_19\NN\14035298|to|,|with|him (r_dobj) have_16\VB\7846|NONE (r_ccomp) showed_13\VBD\2137132|.|thirsty|He (r_conj) remained_1\VBD\2604760|NONE (l_acomp) thirsty_2\JJ\0|.|showed|He (l_conj) polyuric_4\JJ\0|and
D014667_D018500 NONE vasopressin_21\NN\5407119|NONE (r_compound) secretion_22\NN\13526110|and|normal|osmoregulated (r_conj) thirst_19\NN\14035298|to|,|with|him (r_dobj) have_16\VB\7846|NONE (l_prep) with_24\IN\0|to|thirst|,|him (l_pobj) evidence_26\NN\5816287|NONE (l_prep) of_27\IN\0|clear (l_pobj) insipidus_30\NN\0|NONE
3780697
D005283_D009127 CID fentanyl_5\NN\2707683|NONE (r_compound) administration_6\NN\1133281|NONE (r_pobj) after_4\IN\0|operative|. (r_prep) rigidity_3\NN\5023233|NONE
D005283_D009127 CID fentanyl_29\NN\2707683|NONE (r_pobj) of_28\IN\0|a|moderate (r_prep) dose_27\NN\3740161|who (r_dobj) received_24\VBD\2210855|elderly|an (r_relcl) patient_22\NN\9898892|NONE (r_pobj) in_19\IN\13603305|the|operative (r_prep) period_18\NN\13575869|NONE (r_pobj) in_13\IN\13603305|.|is|case (r_prep) described_12\VBN\1001294|NONE (l_nsubjpass) case_1\NN\7283608|.|is|in (l_prep) of_2\IN\0|A (l_pobj) rigidity_6\NN\5023233|NONE
D005283_D012131 NONE fentanyl_29\NN\2707683|NONE (r_pobj) of_28\IN\0|a|moderate (r_prep) dose_27\NN\3740161|who (r_dobj) received_24\VBD\2210855|elderly|an (r_relcl) patient_22\NN\9898892|NONE (r_pobj) in_19\IN\13603305|the|operative (r_prep) period_18\NN\13575869|NONE (r_pobj) in_13\IN\13603305|.|is|case (r_prep) described_12\VBN\1001294|NONE (l_nsubjpass) case_1\NN\7283608|.|is|in (l_prep) of_2\IN\0|A (l_pobj) rigidity_6\NN\5023233|NONE (l_acl) leading_7\VBG\4339291|abdominal (l_prep) to_8\IN\0|NONE (l_pobj) failure_10\NN\66216|NONE
19203554
D013256_D010996 NONE steroid_32\NN\14727670|NONE (r_compound) therapy_33\NN\657604|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD\1617192|NONE (l_advcl) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE (l_appos) eyes_12\NNS\5945642|, (l_conj) pain_15\NN\14299637|,|red (l_conj) titer_17\NN\5038593|chest|, (l_prep) of_18\IN\0|NONE (l_pobj) protein_22\NN\14944888|NONE (l_prep) of_25\IN\0|volume|and|reactive (l_pobj) effusions_28\NNS\6880249|NONE
D013256_D010996 NONE steroid_32\NN\14727670|NONE (r_compound) therapy_33\NN\657604|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD\1617192|NONE (l_conj) increased_45\VBD\169651|rose|,|,|we|resulted|therapy (l_conj) remained_56\VBD\2604760|count|,|,|and|to (l_nsubj) effusion_55\NN\6880249|.
D013256_D010996 NONE steroid_3\NN\14727670|NONE (r_compound) therapy_4\NN\657604|month (r_pobj) after_2\IN\0|effusion|,|and|,|normalized (r_prep) disappeared_9\VBD\0|NONE (l_nsubj) effusion_8\NN\6880249|after|,|and|,|normalized
D012460_D005334 CID sulphasalazine_3\NN\0|NONE (r_compound) treatment_4\NN\654885|NONE (r_pobj) of_2\IN\0|NONE (r_prep) cessation_1\NN\7365849|Although|in (r_nsubj) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE
D012460_D005921 NONE sulphasalazine_10\JJ\0|NONE (r_compound) treatment_11\NN\654885|NONE (r_dobj) restarting_9\VBG\1857717|NONE (r_pcomp) after_8\IN\0|cytoplasmic|glomerulonephritis|.|Proteinase|antineutrophil (r_prep) antibody-(pr3-anca_3\NNS\0|NONE (l_appos) glomerulonephritis_7\NN\14113798|cytoplasmic|after|.|Proteinase|antineutrophil
D012460_D005921 NONE sulphasalazine_4\NN\0|glomerulonephritis|that|can (r_nsubj) induce_6\VB\1627355|case|. (l_dobj) glomerulonephritis_11\NN\14113798|that|sulphasalazine|can
D012460_D002637 NONE sulphasalazine_3\NN\0|NONE (r_compound) treatment_4\NN\654885|NONE (r_pobj) of_2\IN\0|NONE (r_prep) cessation_1\NN\7365849|Although|in (r_nsubj) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE (l_appos) eyes_12\NNS\5945642|, (l_conj) pain_15\NN\14299637|,|red
D013256_D005128 NONE steroid_32\NN\14727670|NONE (r_compound) therapy_33\NN\657604|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD\1617192|NONE (l_advcl) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE (l_appos) eyes_12\NNS\5945642|,
D012460_D004802 NONE sulphasalazine_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) of_21\IN\0|NONE (r_prep) restarting_20\VBG\1857717|NONE (r_pcomp) after_19\IN\0|woman|eyes|. (r_prep) developed_8\VBD\1753788|NONE (l_dobj) eyes_10\NNS\5945642|woman|after|. (l_conj) effusion_13\NN\6880249|,|red (l_conj) eosinophilia_15\NN\14299637|pleural|,
D012460_D003093 NONE sulphasalazine_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) of_21\IN\0|NONE (r_prep) restarting_20\VBG\1857717|NONE (r_pcomp) after_19\IN\0|woman|eyes|. (r_prep) developed_8\VBD\1753788|NONE (l_nsubj) woman_4\NN\9605289|after|eyes|. (l_prep) with_5\IN\0|A|old (l_pobj) colitis_7\NN\14336539|NONE
D012460_D001745 NONE sulphasalazine_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) of_21\IN\0|NONE (r_prep) restarting_20\VBG\1857717|NONE (r_pcomp) after_19\IN\0|woman|eyes|. (r_prep) developed_8\VBD\1753788|NONE (l_dobj) eyes_10\NNS\5945642|woman|after|. (l_conj) effusion_13\NN\6880249|,|red (l_conj) eosinophilia_15\NN\14299637|pleural|, (l_conj) abnormalities_18\NNS\14034177|and
D012460_D005128 NONE sulphasalazine_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) of_21\IN\0|NONE (r_prep) restarting_20\VBG\1857717|NONE (r_pcomp) after_19\IN\0|woman|eyes|. (r_prep) developed_8\VBD\1753788|NONE (l_dobj) eyes_10\NNS\5945642|woman|after|.
D012460_D005128 NONE sulphasalazine_3\NN\0|NONE (r_compound) treatment_4\NN\654885|NONE (r_pobj) of_2\IN\0|NONE (r_prep) cessation_1\NN\7365849|Although|in (r_nsubj) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE (l_appos) eyes_12\NNS\5945642|,
D013256_D005334 NONE steroid_32\NN\14727670|NONE (r_compound) therapy_33\NN\657604|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD\1617192|NONE (l_advcl) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE
D012460_D010996 CID sulphasalazine_22\JJ\0|NONE (r_compound) treatment_23\NN\654885|NONE (r_pobj) of_21\IN\0|NONE (r_prep) restarting_20\VBG\1857717|NONE (r_pcomp) after_19\IN\0|woman|eyes|. (r_prep) developed_8\VBD\1753788|NONE (l_dobj) eyes_10\NNS\5945642|woman|after|. (l_conj) effusion_13\NN\6880249|,|red
D012460_D010996 CID sulphasalazine_3\NN\0|NONE (r_compound) treatment_4\NN\654885|NONE (r_pobj) of_2\IN\0|NONE (r_prep) cessation_1\NN\7365849|Although|in (r_nsubj) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE (l_appos) eyes_12\NNS\5945642|, (l_conj) pain_15\NN\14299637|,|red (l_conj) titer_17\NN\5038593|chest|, (l_prep) of_18\IN\0|NONE (l_pobj) protein_22\NN\14944888|NONE (l_prep) of_25\IN\0|volume|and|reactive (l_pobj) effusions_28\NNS\6880249|NONE
D012460_D010996 CID sulphasalazine_3\NN\0|NONE (r_compound) treatment_4\NN\654885|NONE (r_pobj) of_2\IN\0|NONE (r_prep) cessation_1\NN\7365849|Although|in (r_nsubj) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (r_advcl) initiated_31\VBD\1617192|NONE (l_conj) increased_45\VBD\169651|rose|,|,|we|resulted|therapy (l_conj) remained_56\VBD\2604760|count|,|,|and|to (l_nsubj) effusion_55\NN\6880249|.
D013256_D002637 NONE steroid_32\NN\14727670|NONE (r_compound) therapy_33\NN\657604|rose|,|,|increased|we|resulted (r_dobj) initiated_31\VBD\1617192|NONE (l_advcl) resulted_5\VBD\2633881|rose|,|,|increased|we|therapy (l_prep) in_6\IN\13603305|Although|cessation (l_pobj) improvements_7\NNS\7359599|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) fever_9\NN\14299637|NONE (l_appos) eyes_12\NNS\5945642|, (l_conj) pain_15\NN\14299637|,|red
12842176
D000431_D064420 NONE ethanol_35\NN\14708720|or (r_conj) pb_33\NNP\14625458|P|inducible (r_nmod) isoenzymes_38\NNS\0|NONE (r_pobj) by_32\IN\0|NONE (r_agent) formed_31\VBN\1617192|its (r_acl) metabolites_30\NNS\20090|per|or (r_conj) lindane_25\NN\14919948|are|in|that (r_nsubjpass) involved_40\VBN\2676054|NONE (l_prep) in_41\IN\13603305|are|lindane|that (l_pobj) toxicity_44\NN\13576101|NONE
D001556_D064420 NONE lindane_7\NN\14919948|NONE (r_pobj) of_6\IN\0|Pmediated|the (r_prep) metabolism_5\NN\13526110|was|by|when (r_nsubjpass) blocked_9\VBN\1476483|was|indicating|Similarly|.|in|, (r_advcl) increased_17\VBN\169651|NONE (l_advcl) indicating_23\VBG\952524|blocked|was|Similarly|.|in|, (l_ccomp) involved_40\VBN\2676054|NONE (l_prep) in_41\IN\13603305|are|lindane|that (l_pobj) toxicity_44\NN\13576101|NONE
D001556_D064420 NONE lindane_22\NN\14919948|NONE (r_pobj) with_21\IN\0|NONE (r_prep) treated_20\VBN\2376958|NONE (r_acl) animals_19\NNS\4475|NONE (r_pobj) in_18\IN\13603305|blocked|was|indicating|Similarly|.|, (r_prep) increased_17\VBN\169651|NONE (l_advcl) indicating_23\VBG\952524|blocked|was|Similarly|.|in|, (l_ccomp) involved_40\VBN\2676054|NONE (l_prep) in_41\IN\13603305|are|lindane|that (l_pobj) toxicity_44\NN\13576101|NONE
D001556_D064420 NONE lindane_25\NN\14919948|are|in|that (r_nsubjpass) involved_40\VBN\2676054|NONE (l_prep) in_41\IN\13603305|are|lindane|that (l_pobj) toxicity_44\NN\13576101|NONE
D000431_D012640 NONE ethanol_46\NN\14708720|inducer|,|B/B|of|or|an (r_conj) inducer_41\NN\14778436|PB|,|)|( (r_appos) phenobarbital_35\JJ\2792049|NONE (r_pobj) with_34\IN\0|NONE (r_prep) pretreatment_33\NN\0|, (r_conj) convulsions_31\NNS\14081375|that|produce
D000431_D012640 NONE ethanol_46\NN\14708720|inducer|,|B/B|of|or|an (r_conj) inducer_41\NN\14778436|PB|,|)|( (r_appos) phenobarbital_35\JJ\2792049|NONE (r_pobj) with_34\IN\0|NONE (r_prep) pretreatment_33\NN\0|, (r_conj) convulsions_31\NNS\14081375|that|produce (r_dobj) induced_30\VBN\1627355|further|studies|have (r_ccomp) shown_4\VBN\2137132|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD\169651|NONE (l_advcl) induced_62\VBN\1627355|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS\14081375|NONE
D000431_D012640 NONE ethanol_35\NN\14708720|or (r_conj) pb_33\NNP\14625458|P|inducible (r_nmod) isoenzymes_38\NNS\0|NONE (r_pobj) by_32\IN\0|NONE (r_agent) formed_31\VBN\1617192|its (r_acl) metabolites_30\NNS\20090|per|or (r_conj) lindane_25\NN\14919948|are|in|that (r_nsubjpass) involved_40\VBN\2676054|NONE (r_ccomp) indicating_23\VBG\952524|blocked|was|Similarly|.|in|, (r_advcl) increased_17\VBN\169651|NONE (l_advcl) blocked_9\VBN\1476483|was|indicating|Similarly|.|in|, (l_agent) by_10\IN\0|was|when|metabolism (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|chloride (l_pobj) convulsions_15\NNS\14081375|NONE
C018021_D012640 NONE chloride_12\NN\14818238|of (r_compound) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|chloride (l_pobj) convulsions_15\NNS\14081375|NONE
D008748_D012640 NONE 3-methylcholanthrene_9\NN\0|MC (r_pobj) of_8\IN\0|inducer|, (r_prep) pretreatment_7\NN\0|,|not|did|effect|while (r_nsubj) produce_21\VB\7555863|that|convulsions (r_advcl) induced_30\VBN\1627355|further|studies|have (l_dobj) convulsions_31\NNS\14081375|that|produce
D008748_D012640 NONE 3-methylcholanthrene_9\NN\0|MC (r_pobj) of_8\IN\0|inducer|, (r_prep) pretreatment_7\NN\0|,|not|did|effect|while (r_nsubj) produce_21\VB\7555863|that|convulsions (r_advcl) induced_30\VBN\1627355|further|studies|have (r_ccomp) shown_4\VBN\2137132|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD\169651|NONE (l_advcl) induced_62\VBN\1627355|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS\14081375|NONE
D008748_D012640 NONE mc_11\NNP\15286249|methylcholanthrene (r_pobj) of_8\IN\0|inducer|, (r_prep) pretreatment_7\NN\0|,|not|did|effect|while (r_nsubj) produce_21\VB\7555863|that|convulsions (r_advcl) induced_30\VBN\1627355|further|studies|have (l_dobj) convulsions_31\NNS\14081375|that|produce
D008748_D012640 NONE mc_11\NNP\15286249|methylcholanthrene (r_pobj) of_8\IN\0|inducer|, (r_prep) pretreatment_7\NN\0|,|not|did|effect|while (r_nsubj) produce_21\VB\7555863|that|convulsions (r_advcl) induced_30\VBN\1627355|further|studies|have (r_ccomp) shown_4\VBN\2137132|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD\169651|NONE (l_advcl) induced_62\VBN\1627355|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS\14081375|NONE
D010634_D012640 NONE phenobarbital_35\JJ\2792049|NONE (r_pobj) with_34\IN\0|NONE (r_prep) pretreatment_33\NN\0|, (r_conj) convulsions_31\NNS\14081375|that|produce
D010634_D012640 NONE phenobarbital_35\JJ\2792049|NONE (r_pobj) with_34\IN\0|NONE (r_prep) pretreatment_33\NN\0|, (r_conj) convulsions_31\NNS\14081375|that|produce (r_dobj) induced_30\VBN\1627355|further|studies|have (r_ccomp) shown_4\VBN\2137132|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD\169651|NONE (l_advcl) induced_62\VBN\1627355|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS\14081375|NONE
D001556_D020258 NONE lindane_2\NN\14919948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) effect_0\NN\34213|influence|.|neurotoxicity (r_nsubj) induced_16\VBN\1627355|NONE (l_dobj) neurotoxicity_17\NN\0|Effect|influence|.
D001556_D020258 NONE lindane_15\NN\14919948|NONE (r_pobj) in_14\IN\13603305|P (r_prep) modulation_13\NN\7044917|NONE (r_pobj) of_11\IN\0|NONE (r_prep) influence_10\NN\5190804|Effect|.|neurotoxicity (r_nsubj) induced_16\VBN\1627355|NONE (l_dobj) neurotoxicity_17\NN\0|Effect|influence|.
C018021_D064420 NONE chloride_12\NN\14818238|of (r_compound) incidence_13\NN\13821570|NONE (r_pobj) by_10\IN\0|was|when|metabolism (r_agent) blocked_9\VBN\1476483|was|indicating|Similarly|.|in|, (r_advcl) increased_17\VBN\169651|NONE (l_advcl) indicating_23\VBG\952524|blocked|was|Similarly|.|in|, (l_ccomp) involved_40\VBN\2676054|NONE (l_prep) in_41\IN\13603305|are|lindane|that (l_pobj) toxicity_44\NN\13576101|NONE
D001556_D012640 CID lindane_29\NN\14919948|NONE (r_pobj) of_28\IN\0|the (r_prep) incidence_27\NN\13821570|NONE (r_pobj) in_25\IN\13603305|any|significant (r_prep) effect_24\NN\34213|,|not|pretreatment|did|while (r_dobj) produce_21\VB\7555863|that|convulsions (r_advcl) induced_30\VBN\1627355|further|studies|have (l_dobj) convulsions_31\NNS\14081375|that|produce
D001556_D012640 CID lindane_29\NN\14919948|NONE (r_pobj) of_28\IN\0|the (r_prep) incidence_27\NN\13821570|NONE (r_pobj) in_25\IN\13603305|any|significant (r_prep) effect_24\NN\34213|,|not|pretreatment|did|while (r_dobj) produce_21\VB\7555863|that|convulsions (r_advcl) induced_30\VBN\1627355|further|studies|have (r_ccomp) shown_4\VBN\2137132|significantly|.|incidence|induced|, (r_ccomp) increased_57\VBD\169651|NONE (l_advcl) induced_62\VBN\1627355|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS\14081375|NONE
D001556_D012640 CID lindane_61\NN\14919948|NONE (r_pobj) of_60\IN\0|the (r_prep) incidence_59\NN\13821570|significantly|shown|.|induced|, (r_dobj) increased_57\VBD\169651|NONE (l_ccomp) shown_4\VBN\2137132|significantly|.|incidence|induced|, (l_ccomp) induced_30\VBN\1627355|further|studies|have (l_dobj) convulsions_31\NNS\14081375|that|produce
D001556_D012640 CID lindane_61\NN\14919948|NONE (r_pobj) of_60\IN\0|the (r_prep) incidence_59\NN\13821570|significantly|shown|.|induced|, (r_dobj) increased_57\VBD\169651|NONE (l_advcl) induced_62\VBN\1627355|significantly|shown|.|incidence|, (l_dobj) convulsions_63\NNS\14081375|NONE
D001556_D012640 CID lindane_7\NN\14919948|NONE (r_pobj) of_6\IN\0|Pmediated|the (r_prep) metabolism_5\NN\13526110|was|by|when (r_nsubjpass) blocked_9\VBN\1476483|was|indicating|Similarly|.|in|, (l_agent) by_10\IN\0|was|when|metabolism (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|chloride (l_pobj) convulsions_15\NNS\14081375|NONE
D001556_D012640 CID lindane_22\NN\14919948|NONE (r_pobj) with_21\IN\0|NONE (r_prep) treated_20\VBN\2376958|NONE (r_acl) animals_19\NNS\4475|NONE (r_pobj) in_18\IN\13603305|blocked|was|indicating|Similarly|.|, (r_prep) increased_17\VBN\169651|NONE (l_advcl) blocked_9\VBN\1476483|was|indicating|Similarly|.|in|, (l_agent) by_10\IN\0|was|when|metabolism (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|chloride (l_pobj) convulsions_15\NNS\14081375|NONE
D001556_D012640 CID lindane_25\NN\14919948|are|in|that (r_nsubjpass) involved_40\VBN\2676054|NONE (r_ccomp) indicating_23\VBG\952524|blocked|was|Similarly|.|in|, (r_advcl) increased_17\VBN\169651|NONE (l_advcl) blocked_9\VBN\1476483|was|indicating|Similarly|.|in|, (l_agent) by_10\IN\0|was|when|metabolism (l_pobj) incidence_13\NN\13821570|NONE (l_prep) of_14\IN\0|chloride (l_pobj) convulsions_15\NNS\14081375|NONE
6699841
D012459_D007681 NONE salicylates_22\NNS\3828465|fenoprofen|, (r_conj) calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man
D012459_D007681 NONE salicylates_22\NNS\3828465|fenoprofen|, (r_conj) calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man (l_appos) rpn_32\NNP\0|(|papillary|renal|)
D013467_D007681 NONE sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man
D013467_D007681 NONE sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man (l_appos) rpn_32\NNP\0|(|papillary|renal|)
D013467_D007681 NONE sulindac_15\NN\3828465|NONE (r_pobj) of_14\IN\0|possible (r_prep) advantages_13\NNS\5154517|NONE (r_dobj) discuss_11\VB\7466557|RPN|and|to (r_conj) linking_4\VBG\628491|previous (l_dobj) rpn_5\NNP\0|and|to|discuss
D009288_D001172 NONE naproxen_39\NN\3828465|NONE (r_compound) therapy_40\NN\657604|NONE (r_pobj) of_38\IN\0|NONE (r_prep) institution_37\NN\8008335|months (r_pobj) after_36\IN\0|necrosis|.|man (r_prep) developed_27\VBD\1753788|NONE (l_nsubj) man_4\NN\9605289|after|necrosis|. (l_prep) with_5\IN\0|,|A|old|treated|, (l_pobj) arthritis_7\NN\14171682|NONE
D006046_D001172 NONE gold_24\NN\13371489|NONE (r_compound) salts_25\NNS\14818238|and|high|dose (r_conj) salicylates_22\NNS\3828465|fenoprofen|, (r_conj) calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (l_prep) with_5\IN\0|,|A|old|treated|, (l_pobj) arthritis_7\NN\14171682|NONE
D005279_D001172 NONE calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (l_prep) with_5\IN\0|,|A|old|treated|, (l_pobj) arthritis_7\NN\14171682|NONE
D005279_D007681 NONE calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man
D005279_D007681 NONE calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man (l_appos) rpn_32\NNP\0|(|papillary|renal|)
D013467_D007674 NONE sulindac_15\NN\3828465|NONE (l_prep) in_16\IN\13603305|NONE (l_pobj) patients_17\NNS\9898892|NONE (l_relcl) experienced_20\VBN\2108377|NONE (l_dobj) toxicity_22\NN\13576101|who|have
D009288_D007681 CID naproxen_5\NN\3828465|to (r_pobj) due_3\IN\5174653|Renal|.|papillary (r_prep) necrosis_2\NN\11444117|NONE
D009288_D007681 CID naproxen_39\NN\3828465|NONE (r_compound) therapy_40\NN\657604|NONE (r_pobj) of_38\IN\0|NONE (r_prep) institution_37\NN\8008335|months (r_pobj) after_36\IN\0|necrosis|.|man (r_prep) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man
D009288_D007681 CID naproxen_39\NN\3828465|NONE (r_compound) therapy_40\NN\657604|NONE (r_pobj) of_38\IN\0|NONE (r_prep) institution_37\NN\8008335|months (r_pobj) after_36\IN\0|necrosis|.|man (r_prep) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man (l_appos) rpn_32\NNP\0|(|papillary|renal|)
D006046_D007681 NONE gold_24\NN\13371489|NONE (r_compound) salts_25\NNS\14818238|and|high|dose (r_conj) salicylates_22\NNS\3828465|fenoprofen|, (r_conj) calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man
D006046_D007681 NONE gold_24\NN\13371489|NONE (r_compound) salts_25\NNS\14818238|and|high|dose (r_conj) salicylates_22\NNS\3828465|fenoprofen|, (r_conj) calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (r_nsubj) developed_27\VBD\1753788|NONE (l_dobj) necrosis_30\NN\11444117|after|.|man (l_appos) rpn_32\NNP\0|(|papillary|renal|)
D013467_D001172 NONE sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (l_prep) with_5\IN\0|,|A|old|treated|, (l_pobj) arthritis_7\NN\14171682|NONE
D012459_D001172 NONE salicylates_22\NNS\3828465|fenoprofen|, (r_conj) calcium_18\NN\14625458|, (r_conj) sulindac_15\NN\3828465|NONE (r_pobj) with_14\IN\0|had|been|who|previously (r_prep) treated_13\VBN\2376958|with|,|A|old|, (r_relcl) man_4\NN\9605289|after|necrosis|. (l_prep) with_5\IN\0|,|A|old|treated|, (l_pobj) arthritis_7\NN\14171682|NONE
1545575
D015080_D006470 NONE mesna_19\NN\0|NONE (r_pobj) with_18\IN\0|,|a|of|feasibility|neutralizes (r_prep) trial_15\NN\786195|,|.|we|In (l_relcl) neutralizes_22\VBZ\126264|,|a|of|with|feasibility (l_dobj) metabolite_25\NN\20090|which (l_relcl) causes_29\VBZ\7323922|hepatic|of|the (l_dobj) cystitis_31\NN\14566129|that
D015080_D006470 NONE mesna_10\JJ\0|NONE (r_amod) uroprophylaxis_11\NNS\0|who|before (r_dobj) received_9\VBD\2210855|consecutive|four (r_relcl) patients_7\NNS\9898892|,|In|cystitis|.|for (r_nsubj) had_17\VBD\0|NONE (l_dobj) cystitis_20\NN\14566129|,|In|patients|.|for
D003520_D006470 CID cyclophosphamide_11\NN\0|administered|dose (r_compound) therapy_12\NN\657604|NONE (r_pobj) of_7\IN\0|serious|a (r_prep) complication_6\NN\1073995|cystitis|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) cystitis_1\NN\14566129|complication|.
D003520_D006470 CID cyclophosphamide_27\NN\0|NONE (r_pobj) of_26\IN\0|causes|hepatic|the (r_prep) metabolite_25\NN\20090|which (l_relcl) causes_29\VBZ\7323922|hepatic|of|the (l_dobj) cystitis_31\NN\14566129|that
D015080_D003556 NONE mesna_19\NN\0|NONE (r_pobj) with_18\IN\0|,|a|of|feasibility|neutralizes (r_prep) trial_15\NN\786195|,|.|we|In (l_relcl) neutralizes_22\VBZ\126264|,|a|of|with|feasibility (l_dobj) metabolite_25\NN\20090|which (l_relcl) causes_29\VBZ\7323922|hepatic|of|the (l_dobj) cystitis_31\NN\14566129|that
D015080_D003556 NONE mesna_10\JJ\0|NONE (r_amod) uroprophylaxis_11\NNS\0|who|before (r_dobj) received_9\VBD\2210855|consecutive|four (r_relcl) patients_7\NNS\9898892|,|In|cystitis|.|for (r_nsubj) had_17\VBD\0|NONE (l_dobj) cystitis_20\NN\14566129|,|In|patients|.|for
D003520_D003556 CID cyclophosphamide_11\NN\0|administered|dose (r_compound) therapy_12\NN\657604|NONE (r_pobj) of_7\IN\0|serious|a (r_prep) complication_6\NN\1073995|cystitis|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) cystitis_1\NN\14566129|complication|.
D003520_D003556 CID cyclophosphamide_27\NN\0|NONE (r_pobj) of_26\IN\0|causes|hepatic|the (r_prep) metabolite_25\NN\20090|which (l_relcl) causes_29\VBZ\7323922|hepatic|of|the (l_dobj) cystitis_31\NN\14566129|that
12452237
D008012_D063806 NONE lidocaine_9\JJ\3681148|on (r_compound) pretreatment_10\NN\0|NONE (l_prep) on_11\IN\0|lidocaine (l_pobj) reduction_12\NN\351485|NONE (l_prep) of_13\IN\0|NONE (l_pobj) myalgia_17\NN\14322699|NONE
D013390_D010149 CID succinylcholine_3\NN\3800001|?|Can|lidocaine|induced (r_dobj) reduce_2\VB\441445|NONE (l_conj) induced_4\VBD\1627355|succinylcholine|?|Can|lidocaine (l_dobj) myalgia_6\NN\14322699|NONE
D013390_D010149 CID succinylcholine_4\NN\3800001|where|is (r_nsubjpass) used_6\VBN\0|be|lidocaine|is|,|,|In|. (r_advcl) proven_10\VBN\2604760|NONE (l_xcomp) be_12\VB\14625458|lidocaine|used|is|,|,|In|. (l_attr) agent_16\NN\7347|to (l_prep) for_17\IN\0|useful|pretreatment|the (l_pobj) reduction_19\NN\351485|NONE (l_prep) of_20\IN\0|the (l_pobj) myalgia_22\NN\14322699|NONE
D008012_D010149 NONE lidocaine_1\RB\3681148|succinylcholine|?|Can|induced (r_nsubj) reduce_2\VB\441445|NONE (l_conj) induced_4\VBD\1627355|succinylcholine|?|Can|lidocaine (l_dobj) myalgia_6\NN\14322699|NONE
D008012_D010149 NONE lidocaine_8\NN\3681148|be|used|is|,|,|In|. (r_nsubjpass) proven_10\VBN\2604760|NONE (l_xcomp) be_12\VB\14625458|lidocaine|used|is|,|,|In|. (l_attr) agent_16\NN\7347|to (l_prep) for_17\IN\0|useful|pretreatment|the (l_pobj) reduction_19\NN\351485|NONE (l_prep) of_20\IN\0|the (l_pobj) myalgia_22\NN\14322699|NONE
D013390_D063806 NONE succinylcholine_14\NN\3800001| (r_npadvmod) induced_16\VBN\1627355|in (r_amod) myalgia_17\NN\14322699|NONE
16826348
D003561_D010523 CID arabinoside_8\NN\0|in|dose|cytosine (r_amod) treatment_9\NN\654885|NONE (r_pobj) by_3\IN\0|NONE (r_agent) caused_2\VBN\1617192|.|Peripheral (r_acl) neuropathy_1\NNS\14204950|NONE
D003561_D010523 CID arabinoside_14\NN\0|therapy|,|play|and|are|, (r_nsubj) is_15\VBZ\0|NONE (l_advcl) are_6\VBP\13600404|therapy|,|arabinoside|play|and|, (l_nsubj) mechanisms_2\NNS\13446390|Although|unclear|still (l_prep) of_3\IN\0|the (l_pobj) neuropathy_5\NN\14204950|NONE
D003561_D015470 NONE arabinoside_8\NN\0|in|dose|cytosine (r_amod) treatment_9\NN\654885|NONE (l_prep) in_10\IN\13603305|arabinoside|dose|cytosine (l_pobj) patient_12\NN\9898892|NONE (l_prep) with_13\IN\0|a (l_pobj) leukemia_16\NN\14239918|NONE
D003561_D006987 NONE arabinoside_8\NN\0|NONE (r_pobj) of_3\IN\0|first|The (r_prep) course_2\NN\883297|but|,|in|complained (r_nsubj) resulted_9\VBD\2633881|NONE (l_conj) complained_28\VBD\0|course|but|,|in (l_prep) of_29\IN\0|.|on|patient|in|, (l_pobj) numbness_30\NN\14299637|NONE
D008775_D006086 NONE methylprednisolone_38\NN\0|NONE (r_pobj) to_37\IN\0|subsequently|symptoms|. (r_prep) responded_36\VBD\2367363|received|and|,|symptoms|with|,|, (r_conj) worsened_19\VBD\146138|NONE (l_prep) with_21\IN\0|responded|received|and|,|symptoms|,|, (l_pobj) development_23\NN\248977|NONE (l_prep) of_24\IN\0|the (l_pobj) disease_30\NN\14061805|NONE
D003561_D064420 NONE arabinoside_10\NN\0|NONE (r_pobj) of_5\IN\0|The|system|central (r_prep) toxicity_4\NN\13576101|but|is|well|,|reported
D003561_D064420 NONE arabinoside_10\NN\0|NONE (r_pobj) of_5\IN\0|The|system|central (r_prep) toxicity_4\NN\13576101|but|is|well|,|reported (r_nsubjpass) recognized_13\VBN\686447|NONE (l_conj) reported_29\VBN\831651|but|toxicity|is|well|, (l_nsubjpass) toxicity_17\NN\13576101|has|infrequently|been|.
D003561_D064420 NONE arabinoside_20\NN\0|NONE (r_pobj) of_18\IN\0|the (r_prep) toxicity_17\NN\13576101|has|infrequently|been|. (r_nsubjpass) reported_29\VBN\831651|but|toxicity|is|well|, (r_conj) recognized_13\VBN\686447|NONE (l_nsubjpass) toxicity_4\NN\13576101|but|is|well|,|reported
D003561_D064420 NONE arabinoside_20\NN\0|NONE (r_pobj) of_18\IN\0|the (r_prep) toxicity_17\NN\13576101|has|infrequently|been|.
D008775_D009422 NONE methylprednisolone_38\NN\0|NONE (r_pobj) to_37\IN\0|subsequently|symptoms|. (r_prep) responded_36\VBD\2367363|received|and|,|symptoms|with|,|, (r_conj) worsened_19\VBD\146138|NONE (l_ccomp) received_11\VBD\2210855|responded|and|,|symptoms|with|,|, (l_ccomp) resolving_4\VBG\5781800|;|after|transplantation|patient|,|however (l_nsubj) neuropathy_1\NN\14204950|was|gradually
3123611
D003276_D002819 CID contraception_4\NN\851994|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBN\628491|. (r_acl) chorea_0\NNP\14253124|NONE
D003276_D002819 CID contraceptives_7\NNS\3183080|while (r_dobj) receiving_5\VBG\2210855|.|patients|chorea (r_advcl) developed_2\VBD\1753788|NONE (l_dobj) chorea_3\NN\14253124|receiving|.|patients
D003276_D002819 CID contraception_12\NN\851994|NONE (r_pobj) after_9\IN\0|chorea|patient|. (r_prep) had_3\VBD\0|NONE (l_dobj) chorea_8\NN\14253124|after|patient|.
D000661_D002819 CID amphetamine_5\NN\3248958| (r_npadvmod) induced_7\VBN\1627355|acute (r_amod) chorea_8\NN\14253124|after|patient|.
10411803
D015313_D000743 CID cefotetan_9\NN\0|NONE (r_pobj) of_8\IN\0|prophylactic|in (r_prep) use_7\NN\407535|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|.|immune|Severe|hemolytic (r_acl) anemia_3\NN\14189204|NONE
D015313_D000743 CID cefotetan_8\JJ\0|generation|,|, (r_appos) cephalosporins_5\NNS\2716866|and (r_conj) second-_0\NNP\0|are|.|with|increasingly (r_nsubjpass) associated_12\VBN\628491|NONE (l_prep) with_13\IN\0|Second|are|.|increasingly (l_pobj) anemia_20\NN\14189204|NONE
D015313_D000743 CID cefotetan_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|hemolytic (r_amod) anemias_13\NNS\14189204|NONE
D015313_D000743 CID cefotetan_20\JJ\0|had|who|for|prophylactically (r_dobj) received_19\VBN\2210855|NONE (r_relcl) patients_16\NNS\9898892|NONE (r_pobj) in_15\IN\13603305|that| (r_prep) were_14\VBD\0|We|. (l_nsubj) 10_3\CD\13745420|in|that (l_prep) of_4\IN\0|NONE (l_pobj) cases_7\NNS\7283608|NONE (l_prep) of_8\IN\0|our| (l_pobj) anemias_13\NNS\14189204|NONE
D002511_D000743 NONE cephalosporins_5\NNS\2716866|and (r_conj) second-_0\NNP\0|are|.|with|increasingly (r_nsubjpass) associated_12\VBN\628491|NONE (l_prep) with_13\IN\0|Second|are|.|increasingly (l_pobj) anemia_20\NN\14189204|NONE
16596970
D010862_D012640 NONE pilocarpine_0\NNP\14712692|NONE (r_amod) seizures_1\NNS\14081375|.|impairment
D010862_D012640 NONE pilocarpine_0\NN\14712692|status|epilepticus (r_nsubj) induced_4\VBN\1627355|.|epilepticus|;|had|,|in (r_ccomp) resulted_12\VBD\2633881|NONE (l_prep) in_13\IN\13603305|.|epilepticus|;|had|,|induced (l_pobj) loss_16\NN\13252973|NONE (l_conj) seizures_19\NNS\14081375|CA|cell|and
D010862_D012640 NONE pilocarpine_0\NN\14712692|status|epilepticus (r_nsubj) induced_4\VBN\1627355|.|epilepticus|;|had|,|in (r_ccomp) resulted_12\VBD\2633881|NONE (l_advcl) had_24\VBD\0|.|epilepticus|;|,|induced|in (l_dobj) loss_27\NN\13252973|whereas|rats (l_conj) seizures_30\NNS\14081375|or|cell|no
D010862_D001308 CID pilocarpine_0\NNP\14712692|NONE (r_amod) seizures_1\NNS\14081375|.|impairment (r_nsubj) cause_2\IN\7323922|NONE (l_dobj) impairment_6\NN\7296428|seizures|. (l_prep) in_7\IN\13603305|dependent (l_pobj) discrimination_10\NN\1123598|NONE
D010862_D013226 CID pilocarpine_0\NN\14712692|status|epilepticus (r_nsubj) induced_4\VBN\1627355|.|epilepticus|;|had|,|in (l_advmod) epilepticus_6\NN\0|Pilocarpine|status
D010862_D013226 CID pilocarpine_0\NN\14712692|status|epilepticus (r_nsubj) induced_4\VBN\1627355|.|epilepticus|;|had|,|in (r_ccomp) resulted_12\VBD\2633881|NONE (l_nsubj) epilepticus_9\NN\0|.|;|had|,|induced|in
2576810
D009627_D006948 CID nomifensine_4\NN\0|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|The (r_acl) hyperactivity_1\NN\14052403|.|unaffected
D016666_D006948 CID fluvoxamine_4\NNP\0|NONE (r_pobj) with_3\IN\0|(|daily|)|A|repeated (r_prep) treatment_2\NN\654885|.|hyperactivity|in|weaker (r_nsubj) potentiated_12\VBN\229605|NONE (l_dobj) hyperactivity_25\NN\14052403|.|in|treatment|weaker
D016666_D006948 CID fluvoxamine_10\NN\0|NONE (r_pobj) by_9\IN\0|NONE (r_prep) unaffected_8\JJ\0|.|hyperactivity (r_acomp) remained_7\VBD\2604760|NONE (l_nsubj) hyperactivity_1\NN\14052403|.|unaffected
D000661_D006948 CID amphetamine_22\NN\3248958| (r_npadvmod) induced_24\VBN\1627355|the (r_amod) hyperactivity_25\NN\14052403|.|in|treatment|weaker
12091028
D003975_D006212 NONE diazepam_0\NNP\2830852|drug|.|,|contraindicated|, (r_nsubj) remains_7\VBZ\2684|NONE (l_attr) drug_12\NN\14778436|.|,|contraindicated|,|Diazepam (l_relcl) ketamine_14\NN\3054098|only|necessary|the|complementary (l_advcl) buffers_17\VBZ\14818238|to (l_conj) decreases_22\VBZ\7296428|and|as|it|response (l_dobj) duration_24\NN\15113229|NONE (l_prep) of_27\IN\0|intensity|the|and (l_pobj) hallucinations_31\NNS\14376855|NONE
D007649_D006212 CID ketamine_14\NN\3054098|only|necessary|the|complementary (l_advcl) buffers_17\VBZ\14818238|to (l_conj) decreases_22\VBZ\7296428|and|as|it|response (l_dobj) duration_24\NN\15113229|NONE (l_prep) of_27\IN\0|intensity|the|and (l_pobj) hallucinations_31\NNS\14376855|NONE
11245434
D016190_D000740 CID carboplatin_8\NN\0|NONE (r_pobj) of_7\IN\0|resulting|i.v.|)|single|a (r_prep) dose_6\NN\3740161|NONE (r_dobj) using_3\VBG\418025|.|was|Anemia (r_xcomp) induced_2\VBN\1627355|NONE (l_nsubjpass) anemia_0\NN\14189204|.|was|using
D016190_D000740 CID carboplatin_29\NN\0|NONE (r_amod) application_30\NN\947128|NONE (r_pobj) before_28\IN\0| (r_prep) days_27\NNS\15140892|NONE (r_dobj) starting_25\VBG\457382|week|s.c. (r_advcl) administered_19\VBN\2436349|by|.|development|In|was|, (r_conj) prevented_10\VBN\0|NONE (l_nsubjpass) development_6\NN\248977|by|.|In|administered|was|, (l_prep) of_7\IN\0|the (l_pobj) anemia_8\NN\14189204|NONE
D003520_D064420 NONE cyclophosphamide_8\NN\0|in (r_compound) cytotoxicity_9\NN\13583478|NONE
D003520_D064420 NONE cyclophosphamide_25\NN\0|NONE (r_pobj) of_24\IN\0|the|in (r_prep) cytotoxicity_23\NN\13583478|NONE
D003520_D064420 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|in (r_prep) cytotoxicity_9\NN\13583478|that|anemia|increases|,
D010100_D064420 NONE oxygen_37\NN\14622893|to|an|improved (r_compound) supply_38\NN\13576355|NONE (r_pobj) of_34\IN\0|a (r_prep) result_33\NN\34213|probably (r_pobj) as_31\IN\14622893|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ\13576355|cytotoxicity|that|anemia|, (r_advcl) reduces_8\VBZ\441445|results|. (l_dobj) cytotoxicity_9\NN\13583478|that|anemia|increases|,
D016190_D009369 NONE carboplatin_3\NN\0|NONE (r_amod) treatment_4\NN\654885|days (r_pobj) after_2\IN\0|tumors|.|s.c.|,|onto|were (r_prep) implanted_16\VBN\1421622|NONE (l_nsubjpass) tumors_6\NNS\14234074|.|s.c.|,|after|onto|were
D016190_D009369 NONE carboplatin_1\NN\0|NONE (l_conj) influenced_5\VBN\137313|.|treatment|Neither|nor (l_dobj) rate_8\NN\13815152|se (l_compound) tumor_6\NN\14234074|growth
D010100_D000740 NONE oxygen_37\NN\14622893|to|an|improved (r_compound) supply_38\NN\13576355|NONE (r_pobj) of_34\IN\0|a (r_prep) result_33\NN\34213|probably (r_pobj) as_31\IN\14622893|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ\13576355|cytotoxicity|that|anemia|, (r_advcl) reduces_8\VBZ\441445|results|. (l_nsubj) anemia_7\NN\14189204|cytotoxicity|that|increases|,
D010100_D000740 NONE oxygen_37\NN\14622893|to|an|improved (r_compound) supply_38\NN\13576355|NONE (r_pobj) of_34\IN\0|a (r_prep) result_33\NN\34213|probably (r_pobj) as_31\IN\14622893|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ\13576355|cytotoxicity|that|anemia|, (l_nsubj) correction_16\NN\248977|,|as|sensitivity|whereas (l_prep) of_17\IN\0|by (l_pobj) anemia_18\NN\14189204|NONE
D010100_D009369 NONE oxygen_37\NN\14622893|to|an|improved (r_compound) supply_38\NN\13576355|NONE (r_pobj) of_34\IN\0|a (r_prep) result_33\NN\34213|probably (r_pobj) as_31\IN\14622893|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ\13576355|cytotoxicity|that|anemia|, (r_advcl) reduces_8\VBZ\441445|results|. (l_dobj) cytotoxicity_9\NN\13583478|that|anemia|increases|, (l_prep) in_12\IN\13603305|of (l_pobj) tumors_13\NNS\14234074|NONE
D010100_D009369 NONE oxygen_37\NN\14622893|to|an|improved (r_compound) supply_38\NN\13576355|NONE (l_prep) to_39\IN\0|oxygen|an|improved (l_pobj) tissue_41\NN\5220461|NONE (l_compound) tumor_40\NN\14234074|NONE
D016190_D012509 NONE carboplatin_3\NN\0|NONE (r_amod) treatment_4\NN\654885|days (r_pobj) after_2\IN\0|tumors|.|s.c.|,|onto|were (r_prep) implanted_16\VBN\1421622|NONE (l_nsubjpass) tumors_6\NNS\14234074|.|s.c.|,|after|onto|were (l_appos) sarcoma_10\NN\14239918|)|(
D003520_D009369 NONE cyclophosphamide_8\NN\0|in (r_compound) cytotoxicity_9\NN\13583478|NONE (l_prep) in_10\IN\13603305|cyclophosphamide (l_pobj) tumors_12\NNS\14234074|NONE
D003520_D009369 NONE cyclophosphamide_25\NN\0|NONE (r_pobj) of_24\IN\0|the|in (r_prep) cytotoxicity_23\NN\13583478|NONE (l_prep) in_26\IN\13603305|of|the (l_pobj) tumors_29\NNS\14234074|NONE
D003520_D009369 NONE cyclophosphamide_9\NN\0|NONE (r_pobj) of_8\IN\0|a|single|(|mg/kg|) (r_prep) dose_7\NN\3740161|NONE (r_pobj) with_4\IN\0|after|were|When|tumors (r_prep) treated_3\VBN\2376958|delay|was|,|. (l_nsubjpass) tumors_1\NNS\14234074|after|with|were|When
D003520_D009369 NONE cyclophosphamide_9\NN\0|NONE (r_pobj) of_8\IN\0|a|single|(|mg/kg|) (r_prep) dose_7\NN\3740161|NONE (r_pobj) with_4\IN\0|after|were|When|tumors (r_prep) treated_3\VBN\2376958|delay|was|,|. (r_advcl) observed_31\VBN\2163746|NONE (l_nsubjpass) delay_22\NN\15271008|treated|was|,|. (l_prep) with_23\IN\0|a|growth (l_pobj) regrowth_26\NN\0|NONE (l_prep) of_27\IN\0|a|subsequent (l_pobj) tumors_29\NNS\14234074|NONE
D003520_D009369 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|in (r_prep) cytotoxicity_9\NN\13583478|that|anemia|increases|, (l_prep) in_12\IN\13603305|of (l_pobj) tumors_13\NNS\14234074|NONE
D003520_D009369 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|in (r_prep) cytotoxicity_9\NN\13583478|that|anemia|increases|, (r_dobj) reduces_8\VBZ\441445|results|. (l_advcl) increases_26\VBZ\13576355|cytotoxicity|that|anemia|, (l_prep) as_31\IN\14622893|,|correction|sensitivity|whereas (l_pobj) result_33\NN\34213|probably (l_prep) of_34\IN\0|a (l_pobj) supply_38\NN\13576355|NONE (l_prep) to_39\IN\0|oxygen|an|improved (l_pobj) tissue_41\NN\5220461|NONE (l_compound) tumor_40\NN\14234074|NONE
D003520_D000740 NONE cyclophosphamide_8\NN\0|in (r_compound) cytotoxicity_9\NN\13583478|NONE (r_pobj) in_7\IN\13603305|induced|the (r_prep) reduction_6\NN\351485|Erythropoietin|. (l_amod) induced_5\VBN\1627355|in|the (l_npadvmod) anemia_3\NN\14189204|
D003520_D000740 NONE cyclophosphamide_25\NN\0|NONE (r_pobj) of_24\IN\0|the|in (r_prep) cytotoxicity_23\NN\13583478|NONE (r_pobj) on_21\IN\0|)|rHuEPO|erythropoietin|( (r_prep) treatment_20\NN\654885|NONE (r_pobj) by_13\IN\0|the|of (r_prep) impact_9\NN\7339329|to (l_prep) of_10\IN\0|the|by (l_pobj) prevention_12\NN\1073995|NONE (l_compound) anemia_11\NN\14189204|NONE
D003520_D000740 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|in (r_prep) cytotoxicity_9\NN\13583478|that|anemia|increases|, (r_dobj) reduces_8\VBZ\441445|results|. (l_nsubj) anemia_7\NN\14189204|cytotoxicity|that|increases|,
D003520_D000740 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|in (r_prep) cytotoxicity_9\NN\13583478|that|anemia|increases|, (r_dobj) reduces_8\VBZ\441445|results|. (l_advcl) increases_26\VBZ\13576355|cytotoxicity|that|anemia|, (l_nsubj) correction_16\NN\248977|,|as|sensitivity|whereas (l_prep) of_17\IN\0|by (l_pobj) anemia_18\NN\14189204|NONE
6203632
D007545_D006332 CID isoproterenol_2\NN\3740161| (r_npadvmod) induced_4\VBN\1627355|cardiac (r_amod) hypertrophy_6\NN\14365950|NONE
D007545_D006332 CID isoproterenol_17\NN\3740161|NONE (r_pobj) of_16\IN\0|)|ISO|subcutaneous|daily|(|weight (r_prep) injections_15\NNS\320852|NONE (r_pobj) following_12\VBG\8180190|in|development|.|was (r_prep) studied_6\VBN\0|NONE (l_nsubjpass) development_1\NN\248977|in|.|was|following (l_prep) of_2\IN\0|The (l_pobj) hypertrophy_4\NN\14365950|NONE
D007545_D006332 CID iso_19\NN\0|)|subcutaneous|daily|(|weight|of (r_appos) injections_15\NNS\320852|NONE (r_pobj) following_12\VBG\8180190|in|development|.|was (r_prep) studied_6\VBN\0|NONE (l_nsubjpass) development_1\NN\248977|in|.|was|following (l_prep) of_2\IN\0|The (l_pobj) hypertrophy_4\NN\14365950|NONE
D007545_D006984 NONE iso_8\NN\0|NONE (r_pobj) to_7\IN\0|adaptive|the (r_prep) response_6\NN\11410625|that|phase (r_nsubj) shows_9\VBZ\429048|.|data (l_dobj) phase_13\NN\15113229|response|that (l_amod) hypertrophic_12\JJ\0|early|(|characterized|)|days|an
8607407
D002110_D006973 CID caffeine_5\NN\14712692|NONE (r_pobj) with_4\IN\0|.|pressure|Acute|in (r_prep) elevations_3\NNS\7445480|NONE (l_prep) in_6\IN\13603305|.|pressure|Acute|with (l_pobj) men_7\NNS\8208016|NONE (l_prep) with_8\IN\0|NONE (l_pobj) hypertension_11\NN\14057371|NONE
D002110_D006973 CID caffeine_5\NN\14712692|NONE (r_pobj) of_4\IN\0|the|vasoconstrictive (r_prep) actions_3\NNS\30358|Whether|in|are (r_nsubjpass) enhanced_7\VBN\227165|.|has|not|been (l_prep) in_8\IN\13603305|actions|Whether|are (l_pobj) persons_10\NNS\7347|NONE (l_amod) hypertensive_9\JJ\10405694|NONE
D002110_D006973 CID caffeine_24\NN\14712692|NONE (r_compound) ingestion_25\NN\13440063|NONE (r_pobj) after_23\IN\0|.|levels|,|Consequently|%|,|exhibited (r_prep) achieved_19\VBD\2524171|NONE (l_dobj) levels_22\NNS\4916342|.|,|Consequently|after|%|,|exhibited (l_amod) hypertensive_20\JJ\10405694|BP
D002110_D006973 CID caffeine_10\NN\14712692|NONE (r_pobj) to_9\IN\0|exaggerated (r_prep) responses_8\NNS\11410625|selective|,|:|.|replicated|Thus|,|consistent|in|, (r_nsubj) were_11\VBD\0|NONE (l_prep) in_2\IN\13603305|responses|selective|,|:|.|replicated|Thus|,|consistent|, (l_pobj) men_5\NNS\8208016|NONE (l_amod) hypertensive_4\JJ\10405694|borderline
D002110_D006973 CID caffeine_10\NN\14712692|NONE (r_pobj) to_9\IN\0|exaggerated (r_prep) responses_8\NNS\11410625|selective|,|:|.|replicated|Thus|,|consistent|in|, (r_nsubj) were_11\VBD\0|NONE (l_advcl) replicated_23\VBN\2035919|responses|selective|,|:|.|Thus|,|consistent|in|, (l_conj) representative_29\NN\10351874|and|,|in (l_prep) of_30\IN\0|NONE (l_pobj) hypertensives_34\NNS\10405694|NONE
8473723
D016666_D012640 CID fluvoxamine_6\NN\0|combined (r_compound) treatment_7\NN\654885|NONE (r_pobj) by_2\IN\0|.|Seizures (r_agent) induced_1\VBN\1627355|NONE (l_nsubj) seizures_0\NNS\14081375|.|by
D016666_D012640 CID fluvoxamine_8\NN\0|combined|induced (r_nmod) seizures_12\NNS\14081375|NONE
D008728_D012640 CID levomepromazine_4\JJ\0| (r_amod) fluvoxamine_6\NN\0|combined (r_compound) treatment_7\NN\654885|NONE (r_pobj) by_2\IN\0|.|Seizures (r_agent) induced_1\VBN\1627355|NONE (l_nsubj) seizures_0\NNS\14081375|.|by
D008728_D012640 CID levomepromazine_6\JJ\0| (r_amod) fluvoxamine_8\NN\0|combined|induced (r_nmod) seizures_12\NNS\14081375|NONE
17194457
D012701_D001523 NONE 5-ht_16\CD\0|NONE (r_pobj) with_13\IN\0|AAS|pubertal (r_prep) users_12\NNS\7846|prone|that|may (r_nsubj) be_18\VB\14625458|,|can|it|.|be|Based (l_acomp) prone_20\JJ\0|that|users|may (l_xcomp) exhibit_22\VB\6733939|especially (l_dobj) behavior_24\NN\407535|to
D013739_D001523 CID t_0\NNP\14999913|effect|but|.|preference (r_nsubj) had_2\VBD\0|NONE (l_dobj) effect_4\NN\34213|but|.|T|preference (l_prep) on_5\IN\0|no (l_pobj) locomotion_6\NN\4773351|NONE (l_conj) irritability_8\NN\7552087|,
D013739_D001523 CID t_0\NNP\14999913|effect|but|.|preference (r_nsubj) had_2\VBD\0|NONE (l_conj) preference_16\NN\7497473|effect|but|.|T (l_conj) aggression_18\NN\4657876|and|partner|increased
-1_D001523 NONE pcpa_3\NNP\0|NONE (r_pobj) to_2\IN\0|alone|Chronic (r_prep) exposure_1\NN\5042871|had|and|activity|.|significantly|but|increased (r_nsubj) decreased_6\VBD\169651|NONE (l_conj) increased_10\VBN\169651|had|and|activity|.|significantly|but|exposure (l_dobj) irritability_11\NN\7552087|NONE
-1_D001523 NONE pcpa_3\NNP\0|NONE (r_pobj) to_2\IN\0|alone|Chronic (r_prep) exposure_1\NN\5042871|had|and|activity|.|significantly|but|increased (r_nsubj) decreased_6\VBD\169651|NONE (l_conj) had_13\VBD\0|and|activity|.|significantly|but|exposure|increased (l_dobj) effect_15\NN\34213|NONE (l_prep) on_16\IN\0|no (l_pobj) behavior_18\NN\407535|NONE (l_conj) preference_21\NN\7497473|,|sexual (l_conj) aggression_24\NN\4657876|or|,|partner
20394767
C015068_D012021 CID mcpp_12\NNS\0|,|suppressed|yohimbine|,|startle|Furthermore (r_advcl) increased_3\VBN\169651|NONE (l_dobj) startle_5\NN\863513|,|mCPP|suppressed|yohimbine|,|Furthermore
C015068_D012021 CID mcpp_12\NNS\0|,|suppressed|yohimbine|,|startle|Furthermore (r_advcl) increased_3\VBN\169651|NONE (l_conj) suppressed_13\VBD\2510337|,|mCPP|yohimbine|,|startle|Furthermore (l_dobj) startle_15\NN\863513|and|suppressed
C015068_D012021 CID mcpp_12\NNS\0|,|suppressed|yohimbine|,|startle|Furthermore (r_advcl) increased_3\VBN\169651|NONE (l_conj) suppressed_13\VBD\2510337|,|mCPP|yohimbine|,|startle|Furthermore (l_conj) suppressed_24\VBD\2510337|and|startle (l_dobj) startle_26\NN\863513|PTZ|.
D015016_D012021 CID yohimbine_2\NN\0|,|mCPP|suppressed|,|startle|Furthermore (r_nsubj) increased_3\VBN\169651|NONE (l_dobj) startle_5\NN\863513|,|mCPP|suppressed|yohimbine|,|Furthermore
D015016_D012021 CID yohimbine_2\NN\0|,|mCPP|suppressed|,|startle|Furthermore (r_nsubj) increased_3\VBN\169651|NONE (l_conj) suppressed_13\VBD\2510337|,|mCPP|yohimbine|,|startle|Furthermore (l_dobj) startle_15\NN\863513|and|suppressed
D015016_D012021 CID yohimbine_2\NN\0|,|mCPP|suppressed|,|startle|Furthermore (r_nsubj) increased_3\VBN\169651|NONE (l_conj) suppressed_13\VBD\2510337|,|mCPP|yohimbine|,|startle|Furthermore (l_conj) suppressed_24\VBD\2510337|and|startle (l_dobj) startle_26\NN\863513|PTZ|.
D010433_D012021 CID ptz_23\NNP\0|startle|. (r_nsubj) suppressed_24\VBD\2510337|and|startle (r_conj) suppressed_13\VBD\2510337|,|mCPP|yohimbine|,|startle|Furthermore (r_conj) increased_3\VBN\169651|NONE (l_dobj) startle_5\NN\863513|,|mCPP|suppressed|yohimbine|,|Furthermore
D010433_D012021 CID ptz_23\NNP\0|startle|. (r_nsubj) suppressed_24\VBD\2510337|and|startle (r_conj) suppressed_13\VBD\2510337|,|mCPP|yohimbine|,|startle|Furthermore (l_dobj) startle_15\NN\863513|and|suppressed
D010433_D012021 CID ptz_23\NNP\0|startle|. (r_nsubj) suppressed_24\VBD\2510337|and|startle (l_dobj) startle_26\NN\863513|PTZ|.
9228650
D012601_D000647 CID scopolamine_6\NN\14712692| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) amnesia_9\NN\5669934|and
D012601_D000647 CID scopolamine_7\NN\14712692| (r_npadvmod) induced_9\VBN\1627355|and|movement (r_amod) amnesia_10\NN\5669934|,|effects|and|compared|.|were
D012601_D000647 CID scopolamine_14\NN\14712692|NONE (r_pobj) by_13\IN\0|in (r_agent) induced_12\VBN\1627355|the (r_acl) amnesia_11\NN\5669934|.|significantly|p.o.|compounds
D012601_D000647 CID scopolamine_17\NN\14712692| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) amnesia_20\NN\5669934|but|affect|NIK|that
C049860_D000647 CID nik-247_2\NNP\0|NONE (l_prep) on_3\IN\0|NONE (l_pobj) cholinesterase_4\NN\14732946|NONE (l_conj) amnesia_9\NN\5669934|and
C049860_D000647 CID nik-247_3\NNP\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effects_1\NNS\13245626|,|and|compared|.|were|amnesia (r_nsubjpass) examined_15\VBN\0|NONE (l_nsubjpass) amnesia_10\NN\5669934|,|effects|and|compared|.|were
C049860_D000647 CID nik-247_4\NNP\0|but|affect|that|amnesia (r_nsubj) improves_16\VBZ\126264|.|findings (l_dobj) amnesia_20\NN\5669934|but|affect|NIK|that
C076946_D000647 CID e-2020_29\NNS\0|and (r_conj) tacrine_27\NN\0|the|cholinesterase|known (r_appos) inhibitors_26\NNS\20090|NONE (r_pobj) of_20\IN\0|NONE (r_prep) those_19\DT\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) compared_17\VBN\644583|,|effects|and|.|were|amnesia (r_conj) examined_15\VBN\0|NONE (l_nsubjpass) amnesia_10\NN\5669934|,|effects|and|compared|.|were
C049860_D000544 NONE nik-247_4\NNP\0|may|that|drug (r_nsubj) be_6\VB\14625458|findings|. (l_attr) drug_9\NN\14778436|may|NIK|that (l_prep) for_10\IN\0|useful|a (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) disease_16\NN\14061805|NONE
D013619_D000647 CID tacrine_27\NN\0|the|cholinesterase|known (r_appos) inhibitors_26\NNS\20090|NONE (r_pobj) of_20\IN\0|NONE (r_prep) those_19\DT\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) compared_17\VBN\644583|,|effects|and|.|were|amnesia (r_conj) examined_15\VBN\0|NONE (l_nsubjpass) amnesia_10\NN\5669934|,|effects|and|compared|.|were
17702969
D005473_D006976 CID fluoxetine_3\NN\4169152|to|hypertension (r_advmod) induces_4\VBZ\1627355|.|Prenatal (l_dobj) hypertension_7\NN\14057371|to|fluoxetine
D005473_D006976 CID fluoxetine_4\NN\4169152|NONE (r_amod) exposure_5\NN\5042871|prevalence|prenatally|that (r_nsubj) increases_7\VBZ\13576355|.|data (l_dobj) prevalence_9\NN\4764412|exposure|prenatally|that (l_prep) of_10\IN\0|the (l_pobj) syndrome_14\NN\5870365|NONE
D005473_D006976 CID fluoxetine_20\NN\4169152|protective|in (r_amod) effect_21\NN\34213|the|of|current (r_appos) evidence_14\NN\5816287|NONE (l_prep) of_15\IN\0|effect|the|current (l_pobj) hypertension_18\NN\14057371|NONE
D005473_D006976 CID fluoxetine_5\NN\4169152|NONE (r_amod) exposure_6\NN\5042871|,|compared|.|in|and|evidenced|by (r_nsubj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|,|exposure|compared|.|and|evidenced|by (l_pobj) hypertension_11\NN\14057371|NONE
D005473_D006976 CID fluoxetine_6\NN\4169152|in (r_amod) exposure_7\NN\5042871|hypertension|as|.|In|, (r_nsubj) induces_10\VBZ\1627355|NONE (l_dobj) hypertension_12\NN\14057371|exposure|as|.|In|,
D005473_D005315 CID fluoxetine_3\NN\4169152|to|hypertension (r_advmod) induces_4\VBZ\1627355|.|Prenatal (l_dobj) hypertension_7\NN\14057371|to|fluoxetine
D005473_D005315 CID fluoxetine_5\NN\4169152|NONE (r_amod) exposure_6\NN\5042871|,|compared|.|in|and|evidenced|by (r_nsubj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|,|exposure|compared|.|and|evidenced|by (l_pobj) hypertension_11\NN\14057371|NONE
17490790
D007501_D009410 NONE iron_6\NN\14625458|peripheral|loss|and (r_compound) overload_7\NN\3679986|NONE (r_pobj) between_4\IN\0|the (r_prep) relationship_3\NN\31921|To (r_dobj) demonstrate_1\VB\2137132|,|in|we|voltammetry|. (r_advcl) used_25\VBD\0|NONE (l_dobj) voltammetry_28\NN\0|,|in|we|.|demonstrate (l_conj) immunohistochemistry_35\NN\791527|fast|cyclic|, (l_conj) staining_40\NN\275424|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN\5708432|Perls|,|and|iron|content (l_acl) study_51\VB\635850|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN\29677|to (l_prep) of_54\IN\0|the (l_pobj) neurons_56\NNS\5430628|NONE
D007501_D009410 NONE iron_39\NN\14625458|Perls|,|detection|and|content (r_compound) staining_40\NN\275424|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN\5708432|Perls|,|and|iron|content (l_acl) study_51\VB\635850|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN\29677|to (l_prep) of_54\IN\0|the (l_pobj) neurons_56\NNS\5430628|NONE
D007501_D009410 NONE iron_59\NN\14625458|in|increased (r_compound) content_60\NN\7951464|Perls|,|detection|and|iron (r_conj) staining_40\NN\275424|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN\5708432|Perls|,|and|iron|content (l_acl) study_51\VB\635850|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN\29677|to (l_prep) of_54\IN\0|the (l_pobj) neurons_56\NNS\5430628|NONE
D007501_D009410 NONE iron_10\NN\14625458|in|causes|the|, (r_compound) level_11\NN\4916342|dextran|that|can (l_relcl) causes_19\VBZ\7323922|in|the|iron|, (l_dobj) degeneration_21\NN\29677|iron|where (l_prep) of_22\IN\0|the (l_pobj) neurons_24\NNS\5430628|NONE
D007501_D009410 NONE iron_18\NN\14625458|degeneration|where (r_nsubj) causes_19\VBZ\7323922|in|the|iron|, (l_dobj) degeneration_21\NN\29677|iron|where (l_prep) of_22\IN\0|the (l_pobj) neurons_24\NNS\5430628|NONE
D014443_D009410 NONE tyrosine_30\NN\14601829|(|hydroxylase|TH|,|staining|) (r_det) immunohistochemistry_35\NN\791527|fast|cyclic|, (l_conj) staining_40\NN\275424|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN\5708432|Perls|,|and|iron|content (l_acl) study_51\VB\635850|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN\29677|to (l_prep) of_54\IN\0|the (l_pobj) neurons_56\NNS\5430628|NONE
D007501_D010300 NONE iron_0\NN\14625458|NONE (r_compound) accumulation_1\NN\13497135|involved|.|is (r_nsubjpass) considered_3\VBN\689344|NONE (l_xcomp) involved_6\VBN\2676054|accumulation|.|is (l_prep) in_7\IN\13603305|to|be (l_pobj) pathogenesis_9\NN\13533470|NONE (l_prep) of_10\IN\0|the (l_pobj) disease_13\NN\14061805|NONE
D007505_D009410 CID dextran_2\NN\0|.|degeneration (r_nsubj) induced_3\VBD\1627355|NONE (l_dobj) degeneration_4\NN\29677|.|dextran (l_prep) of_5\IN\0|NONE (l_pobj) neurons_7\NNS\5430628|NONE
D007505_D009410 CID dextran_66\NN\0|overloaded|iron (r_amod) animals_68\NNS\4475|NONE (r_pobj) of_64\IN\0|the (r_prep) sn_63\NN\14625458|NONE (r_pobj) in_61\IN\13603305|increased|iron (r_prep) content_60\NN\7951464|Perls|,|detection|and|iron (r_conj) staining_40\NN\275424|(|tyrosine|hydroxylase|TH|,|) (l_conj) detection_49\NN\5708432|Perls|,|and|iron|content (l_acl) study_51\VB\635850|and|liquid|electrochemical|performance (l_dobj) degeneration_53\NN\29677|to (l_prep) of_54\IN\0|the (l_pobj) neurons_56\NNS\5430628|NONE
D007505_D009410 CID dextran_6\NN\0|level|that|can (r_nsubj) increase_8\VB\13576355|results|. (l_dobj) level_11\NN\4916342|dextran|that|can (l_relcl) causes_19\VBZ\7323922|in|the|iron|, (l_dobj) degeneration_21\NN\29677|iron|where (l_prep) of_22\IN\0|the (l_pobj) neurons_24\NNS\5430628|NONE
11752998
D002211_D004342 NONE capsaicin_27\NN\15032661| (r_npadvmod) evoked_29\VBN\1617192|mechanical (r_amod) hypersensitivity_31\NN\14531772|noxious|and|acute|both
D002211_D004342 NONE capsaicin_20\NN\15032661|peripheral (r_compound) injection_21\NN\320852|NONE (r_pobj) after_18\IN\0|sensitization|to (r_prep) reflect_13\VB\923793|NONE (r_xcomp) presumed_11\VBN\719734|,|inhibition|.|results (r_advcl) show_2\VBP\429048|NONE (l_dobj) inhibition_4\NN\1068773|,|presumed|.|results (l_prep) by_5\IN\0|selective (l_pobj) adenosine_7\NN\14964367|NONE (l_prep) of_8\IN\0|intrathecal (l_pobj) hypersensitivity_9\NN\14531772|NONE
D002211_D010146 NONE capsaicin_82\NN\15032661|intradermal (r_compound) injection_83\NN\320852|NONE (r_pobj) after_80\IN\0|areas|and|heat|acute (r_prep) stimuli_72\NNS\5816287|NONE (r_pobj) to_69\IN\0|NONE (r_prep) response_68\NN\11410625|NONE (r_pobj) in_67\IN\13603305|pain (r_prep) ratings_66\NNS\5733583|were|. (l_compound) pain_65\NN\14299637|in
D002211_D010146 NONE capsaicin_22\NN\15032661|intradermal (r_compound) injection_23\NN\320852|NONE (r_pobj) from_20\IN\0|NONE (r_prep) allodynia_19\NN\0|mechanical|for|reduced|and (r_conj) hyperalgesia_17\NN\0|but|acute|noxious|thermal (r_conj) stimulation_13\NN\242808|NONE (r_pobj) to_7\IN\0|effect|Adenosine (r_prep) produced_1\VBD\1617192|NONE (l_dobj) effect_3\NN\34213|to|Adenosine (l_prep) on_4\IN\0|no (l_pobj) report_6\NN\6470073|NONE (l_compound) pain_5\NN\14299637|NONE
D000241_D059787 NONE adenosine_4\NN\14964367|NONE (r_pobj) of_2\IN\0|Preclinical (r_prep) studies_1\NNS\635850|be|and|suggests (r_nsubj) suggest_5\VBP\1010118|NONE (l_ccomp) be_8\VB\14625458|studies|and|suggests (l_acomp) effective_9\JJ\0|,|may|it (l_prep) in_10\IN\13603305|NONE (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) pain_17\NN\14299637|NONE
D000241_D059787 NONE adenosine_33\NN\14964367|NONE (r_pobj) of_32\IN\0|Swedish|a (r_prep) formulation_31\NN\14818238|NONE (r_pobj) with_28\IN\0|and|patients (r_prep) volunteers_25\NNS\10582746|NONE (r_pobj) in_24\IN\13603305|preliminary (r_prep) studies_23\NNS\635850|.|be (r_nsubj) suggests_34\VBZ\1010118|studies|be|and (r_conj) suggest_5\VBP\1010118|NONE (l_ccomp) be_8\VB\14625458|studies|and|suggests (l_acomp) effective_9\JJ\0|,|may|it (l_prep) in_10\IN\13603305|NONE (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) pain_17\NN\14299637|NONE
D000241_D006930 NONE adenosine_34\NN\14964367|intrathecal|of|trial|and (r_amod) doses_35\NNS\3740161|NONE (r_pobj) with_32\IN\0|label|an|,|escalating|, (r_prep) trial_31\NN\786195|two|: (r_appos) trials_21\NNS\786195|NONE (r_pobj) in_19\IN\13603305|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN\0|NONE (l_conj) obtained_59\VBN\2210855|volunteers|Following|,|were|in (l_conj) determined_85\VBN\0|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS\5733583|were|. (l_prep) in_67\IN\13603305|pain (l_pobj) response_68\NN\11410625|NONE (l_prep) to_69\IN\0|NONE (l_pobj) stimuli_72\NNS\5816287|NONE (l_conj) areas_74\NNS\8630985|after|and|heat|acute (l_prep) of_75\IN\0|NONE (l_pobj) hyperalgesia_77\NN\0|NONE
D000241_D006930 NONE adenosine_34\NN\14964367|intrathecal|of|trial|and (r_amod) doses_35\NNS\3740161|NONE (r_pobj) with_32\IN\0|label|an|,|escalating|, (r_prep) trial_31\NN\786195|two|: (r_appos) trials_21\NNS\786195|NONE (r_pobj) in_19\IN\13603305|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN\0|NONE (l_conj) obtained_59\VBN\2210855|volunteers|Following|,|were|in (l_conj) determined_85\VBN\0|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS\5733583|were|. (l_prep) in_67\IN\13603305|pain (l_pobj) response_68\NN\11410625|NONE (l_prep) to_69\IN\0|NONE (l_pobj) stimuli_72\NNS\5816287|NONE (l_conj) areas_74\NNS\8630985|after|and|heat|acute (l_prep) of_75\IN\0|NONE (l_pobj) hyperalgesia_77\NN\0|NONE (l_conj) allodynia_79\NN\0|mechanical|and
D000241_D006930 NONE adenosine_52\NN\14964367|NONE (r_pobj) of_51\IN\0|blind|,|a|controlled (r_prep) trial_50\NN\786195|intrathecal|of|adenosine|and (r_conj) doses_35\NNS\3740161|NONE (r_pobj) with_32\IN\0|label|an|,|escalating|, (r_prep) trial_31\NN\786195|two|: (r_appos) trials_21\NNS\786195|NONE (r_pobj) in_19\IN\13603305|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN\0|NONE (l_conj) obtained_59\VBN\2210855|volunteers|Following|,|were|in (l_conj) determined_85\VBN\0|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS\5733583|were|. (l_prep) in_67\IN\13603305|pain (l_pobj) response_68\NN\11410625|NONE (l_prep) to_69\IN\0|NONE (l_pobj) stimuli_72\NNS\5816287|NONE (l_conj) areas_74\NNS\8630985|after|and|heat|acute (l_prep) of_75\IN\0|NONE (l_pobj) hyperalgesia_77\NN\0|NONE
D000241_D006930 NONE adenosine_52\NN\14964367|NONE (r_pobj) of_51\IN\0|blind|,|a|controlled (r_prep) trial_50\NN\786195|intrathecal|of|adenosine|and (r_conj) doses_35\NNS\3740161|NONE (r_pobj) with_32\IN\0|label|an|,|escalating|, (r_prep) trial_31\NN\786195|two|: (r_appos) trials_21\NNS\786195|NONE (r_pobj) in_19\IN\13603305|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN\0|NONE (l_conj) obtained_59\VBN\2210855|volunteers|Following|,|were|in (l_conj) determined_85\VBN\0|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS\5733583|were|. (l_prep) in_67\IN\13603305|pain (l_pobj) response_68\NN\11410625|NONE (l_prep) to_69\IN\0|NONE (l_pobj) stimuli_72\NNS\5816287|NONE (l_conj) areas_74\NNS\8630985|after|and|heat|acute (l_prep) of_75\IN\0|NONE (l_pobj) hyperalgesia_77\NN\0|NONE (l_conj) allodynia_79\NN\0|mechanical|and
D000241_D006930 NONE adenosine_0\NNP\14964367|effect|to (r_nsubj) produced_1\VBD\1617192|NONE (l_prep) to_7\IN\0|effect|Adenosine (l_pobj) stimulation_13\NN\242808|NONE (l_conj) hyperalgesia_17\NN\0|but|acute|noxious|thermal
D000241_D006930 NONE adenosine_0\NNP\14964367|effect|to (r_nsubj) produced_1\VBD\1617192|NONE (l_prep) to_7\IN\0|effect|Adenosine (l_pobj) stimulation_13\NN\242808|NONE (l_conj) hyperalgesia_17\NN\0|but|acute|noxious|thermal (l_conj) allodynia_19\NN\0|mechanical|for|reduced|and
D000241_D009437 NONE adenosine_27\NN\14964367|NONE (r_pobj) of_26\IN\0|in|prolonged (r_prep) residence_25\NN\8491027|to (r_pobj) due_22\JJ\5174653|not (r_acomp) is_20\VBZ\0|effect|consistent|and|. (r_conj) is_5\VBZ\0|NONE (l_acomp) consistent_6\JJ\0|effect|is|and|. (l_prep) with_7\IN\0|NONE (l_pcomp) observed_9\VBN\2163746|NONE (l_prep) in_10\IN\13603305|that (l_pobj) reports_12\NNS\6470073|NONE (l_prep) of_13\IN\0|preliminary (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|NONE (l_pobj) pain_18\NN\14299637|NONE
D000241_D004342 NONE adenosine_4\NN\14964367|NONE (r_pobj) of_2\IN\0|Preclinical (r_prep) studies_1\NNS\635850|be|and|suggests (r_nsubj) suggest_5\VBP\1010118|NONE (l_conj) suggests_34\VBZ\1010118|studies|be|and (l_ccomp) be_37\VB\14625458|.|studies (l_acomp) effective_38\JJ\0|it|with|but|may (l_prep) in_39\IN\13603305|NONE (l_pobj) states_41\NNS\8491826|NONE (l_compound) hypersensitivity_40\NN\14531772|NONE
D000241_D004342 NONE adenosine_33\NN\14964367|NONE (r_pobj) of_32\IN\0|Swedish|a (r_prep) formulation_31\NN\14818238|NONE (r_pobj) with_28\IN\0|and|patients (r_prep) volunteers_25\NNS\10582746|NONE (r_pobj) in_24\IN\13603305|preliminary (r_prep) studies_23\NNS\635850|.|be (r_nsubj) suggests_34\VBZ\1010118|studies|be|and (l_ccomp) be_37\VB\14625458|.|studies (l_acomp) effective_38\JJ\0|it|with|but|may (l_prep) in_39\IN\13603305|NONE (l_pobj) states_41\NNS\8491826|NONE (l_compound) hypersensitivity_40\NN\14531772|NONE
D000241_D004342 NONE adenosine_15\NN\14964367|NONE (r_pobj) of_14\IN\0|a|different (r_prep) formulation_13\NN\14818238|NONE (r_pobj) of_10\IN\0|NONE (r_prep) efficacy_9\NN\5199286|NONE (r_pobj) for_8\IN\0|to|,|using (r_prep) screen_7\VB\4362025|purpose|. (l_advcl) using_21\VBG\418025|for|to|, (l_dobj) stimulation_25\NN\242808|NONE (l_conj) hypersensitivity_31\NN\14531772|noxious|and|acute|both
D000241_D004342 NONE adenosine_7\NN\14964367|NONE (l_prep) of_8\IN\0|intrathecal (l_pobj) hypersensitivity_9\NN\14531772|NONE
D000241_D059350 NONE adenosine_4\NN\14964367|NONE (r_pobj) of_2\IN\0|Preclinical (r_prep) studies_1\NNS\635850|be|and|suggests (r_nsubj) suggest_5\VBP\1010118|NONE (l_ccomp) be_8\VB\14625458|studies|and|suggests (l_acomp) effective_9\JJ\0|,|may|it (l_prep) in_10\IN\13603305|NONE (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) pain_17\NN\14299637|NONE
D000241_D059350 NONE adenosine_33\NN\14964367|NONE (r_pobj) of_32\IN\0|Swedish|a (r_prep) formulation_31\NN\14818238|NONE (r_pobj) with_28\IN\0|and|patients (r_prep) volunteers_25\NNS\10582746|NONE (r_pobj) in_24\IN\13603305|preliminary (r_prep) studies_23\NNS\635850|.|be (r_nsubj) suggests_34\VBZ\1010118|studies|be|and (r_conj) suggest_5\VBP\1010118|NONE (l_ccomp) be_8\VB\14625458|studies|and|suggests (l_acomp) effective_9\JJ\0|,|may|it (l_prep) in_10\IN\13603305|NONE (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) pain_17\NN\14299637|NONE
D000241_D010146 NONE adenosine_34\NN\14964367|intrathecal|of|trial|and (r_amod) doses_35\NNS\3740161|NONE (r_pobj) with_32\IN\0|label|an|,|escalating|, (r_prep) trial_31\NN\786195|two|: (r_appos) trials_21\NNS\786195|NONE (r_pobj) in_19\IN\13603305|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN\0|NONE (l_conj) obtained_59\VBN\2210855|volunteers|Following|,|were|in (l_conj) determined_85\VBN\0|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS\5733583|were|. (l_compound) pain_65\NN\14299637|in
D000241_D010146 NONE adenosine_52\NN\14964367|NONE (r_pobj) of_51\IN\0|blind|,|a|controlled (r_prep) trial_50\NN\786195|intrathecal|of|adenosine|and (r_conj) doses_35\NNS\3740161|NONE (r_pobj) with_32\IN\0|label|an|,|escalating|, (r_prep) trial_31\NN\786195|two|: (r_appos) trials_21\NNS\786195|NONE (r_pobj) in_19\IN\13603305|obtained|volunteers|Following|,|were (r_prep) studied_18\VBN\0|NONE (l_conj) obtained_59\VBN\2210855|volunteers|Following|,|were|in (l_conj) determined_85\VBN\0|was|,|and|for|fluid (l_nsubjpass) ratings_66\NNS\5733583|were|. (l_compound) pain_65\NN\14299637|in
D000241_D010146 NONE adenosine_0\NNP\14964367|effect|to (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) effect_3\NN\34213|to|Adenosine (l_prep) on_4\IN\0|no (l_pobj) report_6\NN\6470073|NONE (l_compound) pain_5\NN\14299637|NONE
D002211_D006930 CID capsaicin_82\NN\15032661|intradermal (r_compound) injection_83\NN\320852|NONE (r_pobj) after_80\IN\0|areas|and|heat|acute (r_prep) stimuli_72\NNS\5816287|NONE (l_conj) areas_74\NNS\8630985|after|and|heat|acute (l_prep) of_75\IN\0|NONE (l_pobj) hyperalgesia_77\NN\0|NONE
D002211_D006930 CID capsaicin_82\NN\15032661|intradermal (r_compound) injection_83\NN\320852|NONE (r_pobj) after_80\IN\0|areas|and|heat|acute (r_prep) stimuli_72\NNS\5816287|NONE (l_conj) areas_74\NNS\8630985|after|and|heat|acute (l_prep) of_75\IN\0|NONE (l_pobj) hyperalgesia_77\NN\0|NONE (l_conj) allodynia_79\NN\0|mechanical|and
D002211_D006930 CID capsaicin_22\NN\15032661|intradermal (r_compound) injection_23\NN\320852|NONE (r_pobj) from_20\IN\0|NONE (r_prep) allodynia_19\NN\0|mechanical|for|reduced|and (r_conj) hyperalgesia_17\NN\0|but|acute|noxious|thermal
D002211_D006930 CID capsaicin_22\NN\15032661|intradermal (r_compound) injection_23\NN\320852|NONE (r_pobj) from_20\IN\0|NONE (r_prep) allodynia_19\NN\0|mechanical|for|reduced|and
11079278
D004280_D017202 CID dobutamine_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|myocardial (r_amod) ischemia_14\NN\14195315|NONE
D004280_D017202 CID dobutamine_1\NN\0|NONE (r_pcomp) during_0\IN\0|metoprolol|,|.|or|eliminates (r_prep) attenuates_6\VBZ\224901|NONE (l_conj) eliminates_8\VBZ\1619929|metoprolol|During|,|.|or (l_dobj) evidence_9\NN\5816287|NONE (l_prep) of_10\IN\0|NONE (l_pobj) ischemia_12\NN\14195315|NONE
D008790_D017202 NONE metoprolol_3\NN\2832168|NONE (l_conj) metoprolol_6\NN\2832168|intravenous|or (l_conj) glucagon_8\NN\5407119|intravenous|plus (l_prep) on_9\IN\0|NONE (l_pobj) ischemia_14\NN\14195315|NONE
D008790_D017202 NONE metoprolol_6\NN\2832168|intravenous|or (l_conj) glucagon_8\NN\5407119|intravenous|plus (l_prep) on_9\IN\0|NONE (l_pobj) ischemia_14\NN\14195315|NONE
D008790_D017202 NONE metoprolol_5\FW\2832168|During|,|.|or|eliminates (r_nsubj) attenuates_6\VBZ\224901|NONE (l_conj) eliminates_8\VBZ\1619929|metoprolol|During|,|.|or (l_dobj) evidence_9\NN\5816287|NONE (l_prep) of_10\IN\0|NONE (l_pobj) ischemia_12\NN\14195315|NONE
7416947
D004077_D020018 CID digoxin_13\NN\15060131|NONE (r_pobj) of_12\IN\0|term (r_prep) administration_11\NN\1133281|NONE (r_pobj) on_7\IN\0|NONE (r_prep) patients_6\NNS\9898892|NONE (r_pobj) of_5\IN\0|sexual (r_prep) dysfunction_4\NN\14204950|NONE
D004077_D012214 NONE digoxin_10\NN\15060131|NONE (r_pobj) without_9\IN\0|the|(|)|study (r_prep) group_7\NN\2137|NONE (r_pobj) of_2\IN\0|The (r_prep) patients_1\NNS\9898892|.|of|selected|and (r_nsubj) were_12\VBD\0|NONE (l_conj) selected_29\VBN\697589|.|of|and|patients (l_prep) from_30\IN\0|randomly|were (l_pobj) patients_35\NNS\9898892|NONE (l_compound) disease_34\NN\14061805|the|rheumatic
19761039
D010936_D004409 NONE sinensis_7\NN\0|NONE (r_pobj) of_4\IN\0|methanolic (r_prep) extract_3\NN\14589223|NONE (r_pobj) of_1\IN\0|)|mg/kg|( (r_prep) effect_0\NN\34213|was|on|. (r_nsubjpass) studied_15\VBN\0|NONE (l_prep) on_16\IN\0|Effect|was|. (l_pobj) dyskinesia_21\JJ\14084880|NONE
D010936_D004409 NONE sinensis_10\NN\0|that|role (r_nsubj) had_11\VBD\0|results|. (l_dobj) role_14\NN\719494|sinensis|that (l_prep) against_15\IN\0|a|protective (l_pobj) dyskinesia_20\JJ\14084880|NONE
D012110_D004409 CID reserpine_17\NN\2721160| (r_npadvmod) induced_19\VBN\1627355|and|alterations|orofacial (r_amod) dyskinesia_21\JJ\14084880|NONE
D012110_D004409 CID reserpine_16\NN\2721160| (r_npadvmod) induced_18\VBN\1627355|stress|and|orofacial (r_amod) dyskinesia_20\JJ\14084880|NONE
12852481
D001241_D005767 NONE asa_20\NNP\0|when|is|on (r_nsubjpass) administered_22\VBN\2436349|to|results (r_advcl) compare_7\VB\4744814|;|Objectives|. (r_xcomp) were_5\VBD\0|NONE (l_nsubj) objectives_0\NNS\5980875|compare|;|. (l_acl) compare_33\VB\4744814|of (l_conj) test_50\VB\5798043|patterns|and|to|; (l_dobj) hypothesis_52\NN\7162194|to (l_acl) confounds_57\VBZ\2604760|the (l_nsubj) toxicity_56\NN\13576101|that|detection|used
D001241_D005767 NONE asa_65\NNP\0|NONE (r_pobj) with_64\IN\0|low|incidence (r_prep) malformations_63\NNS\14213199|NONE (r_pobj) of_60\IN\0|the (r_prep) detection_59\NN\5708432|that|toxicity|used (r_dobj) confounds_57\VBZ\2604760|the (l_nsubj) toxicity_56\NN\13576101|that|detection|used
D001241_D000014 CID aspirin_0\NNP\2707683||induces|(|,|)|,|acid|cyclooxygenase|. (r_nsubj) acetylsalicylic_2\JJ\0|NONE (l_conj) induces_17\VBZ\1627355||(|,|)|,|acid|cyclooxygenase|Aspirin|. (l_dobj) anomalies_19\NNS\14501726|administered
D001241_D000014 CID acid_3\NN\14818238||induces|(|,|)|,|cyclooxygenase|Aspirin|. (r_npadvmod) acetylsalicylic_2\JJ\0|NONE (l_conj) induces_17\VBZ\1627355||(|,|)|,|acid|cyclooxygenase|Aspirin|. (l_dobj) anomalies_19\NNS\14501726|administered
D001241_D000014 CID asa_5\NNP\0|NONE (r_appos) acid_3\NN\14818238||induces|(|,|)|,|cyclooxygenase|Aspirin|. (r_npadvmod) acetylsalicylic_2\JJ\0|NONE (l_conj) induces_17\VBZ\1627355||(|,|)|,|acid|cyclooxygenase|Aspirin|. (l_dobj) anomalies_19\NNS\14501726|administered
D001241_D000014 CID asa_20\NNP\0|when|is|on (r_nsubjpass) administered_22\VBN\2436349|to|results (r_advcl) compare_7\VB\4744814|;|Objectives|. (r_xcomp) were_5\VBD\0|NONE (l_nsubj) objectives_0\NNS\5980875|compare|;|. (l_acl) compare_33\VB\4744814|of (l_conj) test_50\VB\5798043|patterns|and|to|; (l_dobj) hypothesis_52\NN\7162194|to (l_acl) confounds_57\VBZ\2604760|the (l_dobj) detection_59\NN\5708432|that|toxicity|used (l_prep) of_60\IN\0|the (l_pobj) malformations_63\NNS\14213199|NONE
D001241_D000014 CID asa_65\NNP\0|NONE (r_pobj) with_64\IN\0|low|incidence (r_prep) malformations_63\NNS\14213199|NONE
D001241_D000014 CID asa_16\NNP\0|even|though|malformations (r_nsubj) induces_17\VBZ\1627355|,|,|;|hence|,|study|on|)|. (r_advcl) focused_9\VBD\628491|NONE (l_prep) on_10\IN\0|induces|,|,|;|hence|,|study|)|. (l_pobj) malformations_12\NNS\14213199|NONE
D001241_D000014 CID asa_16\NNP\0|even|though|malformations (r_nsubj) induces_17\VBZ\1627355|,|,|;|hence|,|study|on|)|. (l_dobj) malformations_23\NNS\14213199|even|ASA|though
D001241_D000014 CID asa_6\NNP\0|as|when|was (r_nsubjpass) administered_8\VBN\2436349|.|similar|GDs|Variations (r_advcl) were_3\VBD\0|NONE (l_nsubj) variations_0\NNS\7296428|administered|.|similar|GDs (l_conj) malformations_2\NNS\14213199|and
D001241_D000014 CID asa_38\NNP\0|NONE (r_pobj) with_37\IN\0|could|that|,|,|be|malformations|also (r_prep) induced_36\VBN\1627355|.|evident|also|It (l_nsubjpass) malformations_17\NNS\14213199|could|that|,|,|be|with|also
19058474
D014859_D006470 NONE warfarin_26\NN\2718259|NONE (r_pobj) of_25\IN\0|his|usual (r_prep) dosage_24\NN\13576355|while (r_dobj) maintaining_21\VBG\0|who|for|juice (r_advcl) consumed_13\VBD\1168468|elderly|an (r_relcl) man_11\NN\9605289|NONE (r_pobj) in_8\IN\13603305|of|a (r_prep) case_3\NN\7283608|We|. (l_prep) of_4\IN\0|in|a (l_pobj) haemorrhage_7\NN\14285662|NONE
D014859_D010490 NONE warfarin_13\NN\2718259|NONE (r_pobj) with_12\IN\0|possible|of (r_prep) interaction_8\NN\37396|to (r_pobj) due_5\IN\5174653|.|haemopericardium (r_prep) haemorrhage_4\NN\14285662|NONE (l_nmod) haemopericardium_1\NN\0|.|due
D014859_D006471 CID warfarin_13\NN\2718259|NONE (r_pobj) with_12\IN\0|possible|of (r_prep) interaction_8\NN\37396|to (r_pobj) due_5\IN\5174653|.|haemopericardium (r_prep) haemorrhage_4\NN\14285662|NONE
11009181
D001058_D004409 NONE apomorphine_13\NN\3786417|continuous (r_compound) infusions_14\NNS\14589223|NONE (r_pobj) with_10\IN\0|NONE (r_prep) monotherapy_9\NN\0|with|that|is (r_nsubjpass) associated_16\VBN\628491|clinical (l_prep) with_17\IN\0|that|monotherapy|is (l_pobj) reductions_19\NNS\351485|NONE (l_prep) of_20\IN\0|marked (l_pobj) dyskinesias_25\NNS\14084880|NONE
D007980_D004409 CID levodopa_22\NN\14604959| (r_npadvmod) induced_24\VBN\1627355|preexisting (r_amod) dyskinesias_25\NNS\14084880|NONE
D001058_D001523 NONE apomorphine_6\NN\3786417|subcutaneous (r_compound) treatment_7\NN\654885|NONE (r_pobj) of_4\IN\0|side|The|main (r_prep) effects_3\NNS\13245626|are|to|play|.|, (r_nsubjpass) related_9\VBN\628491|NONE (l_advcl) play_20\VBP\7007684|are|to|.|effects|, (l_nsubj) sedation_16\NN\14034177|whereas|role (l_conj) complications_19\NNS\1073995|and (l_amod) psychiatric_18\JJ\0|NONE
D001058_D010300 NONE apomorphine_0\NNP\3786417|NONE (l_appos) therapy_4\NN\657604|.|: (l_prep) for_5\IN\0|underutilized|an (l_pobj) disease_8\NN\14061805|NONE
D001058_D010300 NONE apomorphine_0\NNP\3786417|drug|. (r_nsubj) was_1\VBD\0|NONE (l_attr) drug_5\NN\14778436|Apomorphine|. (l_acl) used_7\VBN\0|the|dopaminergic|first (l_xcomp) treat_9\VB\7570720|ever (l_dobj) symptoms_10\NNS\5823932|to (l_prep) of_11\IN\0|NONE (l_pobj) disease_14\NN\14061805|NONE
D001058_D010300 NONE apomorphine_24\NN\3786417|NONE (r_pobj) of_23\IN\0|subcutaneous (r_prep) administration_22\NN\1133281|NONE (r_pobj) by_20\IN\0|disease (r_prep) treating_15\VBG\2376958|NONE (l_dobj) disease_19\NN\14061805|by
D001058_D010300 NONE apomorphine_8\NN\3786417|subcutaneous|in (r_compound) treatment_9\NN\654885|NONE (l_prep) in_10\IN\13603305|subcutaneous|apomorphine (l_pobj) disease_14\NN\14061805|NONE
15897593
D005047_D015431 CID etoposide_12\RB\0|and (r_conj) daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE (l_conj) loss_8\NN\13252973|reduced|and
D005047_D015431 CID etoposide_12\RB\0|and (r_conj) daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither
D018943_D066126 NONE anthracyclines_1\NNS\0|are|doxorubicin|and (r_nsubj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN\13576101|and
D018943_D066126 NONE anthracycline_9\NN\0| (r_advmod) induced_11\VBN\1627355|NONE (r_amod) cardiotoxicity_12\NN\0|NONE
D003630_D064420 NONE daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither (l_conj) cytotoxicity_39\NN\13583478|,|nor|weight
D005047_D006402 CID etoposide_33\VB\0|NONE (r_pobj) to_32\TO\0|of (r_prep) sensitivity_24\NN\5651971|.|in|was|investigated (r_nsubjpass) determined_42\VBN\0|NONE (l_advcl) investigated_22\VBN\644583|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN\13576101|enhancers|:|was|,|Because
D005047_D006402 CID etoposide_13\NN\0|NONE (r_pobj) of_12\IN\0|dexrazoxane (r_prep) doses_11\NNS\3740161|NONE (r_dobj) combining_7\VBG\7373277|brain (r_acl) metastases_6\NNS\13533470|NONE (r_pobj) with_4\IN\0|NONE (r_prep) patients_3\NNS\9898892|NONE (r_pobj) in_2\IN\13603305|Clinical (r_prep) trials_1\NNS\786195|ongoing|. (r_nsubj) is_14\VBZ\0|NONE (l_acomp) ongoing_15\JJ\0|trials|. (l_prep) with_16\IN\0|NONE (l_pobj) aim_18\NN\5980875|NONE (l_prep) of_19\IN\0|the (l_pcomp) improving_20\VBG\126264|NONE (l_prep) without_22\IN\0|efficacy (l_pcomp) aggravating_23\VBG\126264|NONE (l_dobj) toxicity_25\NN\13576101|NONE
D064730_D006402 NONE dexrazoxane_12\NN\0|NONE (r_pobj) of_11\IN\0|and (r_prep) coadministration_10\NN\0|NONE (r_pobj) following_9\VBG\8180190|hematologic|the (r_prep) toxicity_8\NN\13576101|enhancers|:|was|,|Because
D064730_D006402 NONE dexrazoxane_40\NN\0|NONE (r_dobj) doxorubicin_38\NN\2716866|and|, (r_conj) daunorubicin_35\NNS\0|, (r_conj) etoposide_33\VB\0|NONE (r_pobj) to_32\TO\0|of (r_prep) sensitivity_24\NN\5651971|.|in|was|investigated (r_nsubjpass) determined_42\VBN\0|NONE (l_advcl) investigated_22\VBN\644583|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN\13576101|enhancers|:|was|,|Because
D064730_D006402 NONE dexrazoxane_8\NN\0|of (r_nmod) doses_11\NNS\3740161|NONE (r_dobj) combining_7\VBG\7373277|brain (r_acl) metastases_6\NNS\13533470|NONE (r_pobj) with_4\IN\0|NONE (r_prep) patients_3\NNS\9898892|NONE (r_pobj) in_2\IN\13603305|Clinical (r_prep) trials_1\NNS\786195|ongoing|. (r_nsubj) is_14\VBZ\0|NONE (l_acomp) ongoing_15\JJ\0|trials|. (l_prep) with_16\IN\0|NONE (l_pobj) aim_18\NN\5980875|NONE (l_prep) of_19\IN\0|the (l_pcomp) improving_20\VBG\126264|NONE (l_prep) without_22\IN\0|efficacy (l_pcomp) aggravating_23\VBG\126264|NONE (l_dobj) toxicity_25\NN\13576101|NONE
D011034_D001855 NONE epipodophyllotoxin_7\NN\0|and (r_conj) doxorubicin_4\NN\2716866|anthracyclines|are|and (r_conj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|,
D011034_D066126 NONE epipodophyllotoxin_7\NN\0|and (r_conj) doxorubicin_4\NN\2716866|anthracyclines|are|and (r_conj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN\13576101|and
D003630_D001855 NONE daunorubicin_13\NNS\0|but|and|doxorubicin (r_conj) etoposide_11\NN\0|against|.|Dexrazoxane (r_advmod) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN\0|NONE
D003630_D001855 NONE daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|,
D003630_D001855 NONE daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE
D003630_D001855 NONE daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses
D064730_D064420 NONE dexrazoxane_3\NN\0|NONE (r_npadvmod) reduced_4\VBN\441445|loss|and (r_amod) myelosuppression_5\NN\0|NONE (r_pobj) of_2\IN\0|Nontoxic|from|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither (l_conj) cytotoxicity_39\NN\13583478|,|nor|weight
D064730_D064420 NONE dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither (l_conj) cytotoxicity_39\NN\13583478|,|nor|weight
D004317_D006402 CID doxorubicin_38\NN\2716866|and|, (r_conj) daunorubicin_35\NNS\0|, (r_conj) etoposide_33\VB\0|NONE (r_pobj) to_32\TO\0|of (r_prep) sensitivity_24\NN\5651971|.|in|was|investigated (r_nsubjpass) determined_42\VBN\0|NONE (l_advcl) investigated_22\VBN\644583|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN\13576101|enhancers|:|was|,|Because
D064730_D015431 NONE dexrazoxane_3\NN\0|NONE (r_npadvmod) reduced_4\VBN\441445|loss|and (r_amod) myelosuppression_5\NN\0|NONE (l_conj) loss_8\NN\13252973|reduced|and
D064730_D015431 NONE dexrazoxane_3\NN\0|NONE (r_npadvmod) reduced_4\VBN\441445|loss|and (r_amod) myelosuppression_5\NN\0|NONE (r_pobj) of_2\IN\0|Nontoxic|from|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither
D064730_D015431 NONE dexrazoxane_27\NN\0|NONE (l_nsubj) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE (l_conj) loss_8\NN\13252973|reduced|and
D064730_D015431 NONE dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither
D064730_D066126 NONE dexrazoxane_0\NNP\0|.|for|is (r_nsubjpass) recommended_5\VBN\875394|NONE (l_prep) for_6\IN\0|.|is|Dexrazoxane (l_pobj) protection_7\NN\407535|NONE (l_prep) against_8\IN\0|NONE (l_pobj) cardiotoxicity_12\NN\0|NONE
D064730_D066126 NONE icrf-187_2\NN\0|NONE (r_appos) dexrazoxane_0\NNP\0|.|for|is (r_nsubjpass) recommended_5\VBN\875394|NONE (l_prep) for_6\IN\0|.|is|Dexrazoxane (l_pobj) protection_7\NN\407535|NONE (l_prep) against_8\IN\0|NONE (l_pobj) cardiotoxicity_12\NN\0|NONE
D005047_D066126 NONE etoposide_8\NN\0|the (r_appos) epipodophyllotoxin_7\NN\0|and (r_conj) doxorubicin_4\NN\2716866|anthracyclines|are|and (r_conj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN\13576101|and
D004317_D066126 NONE doxorubicin_4\NN\2716866|anthracyclines|are|and (r_conj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN\13576101|and
D064730_D001855 NONE dexrazoxane_0\NNP\0|against|.|etoposide (r_nsubj) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN\0|NONE
D064730_D001855 NONE dexrazoxane_3\NN\0|NONE (r_npadvmod) reduced_4\VBN\441445|loss|and (r_amod) myelosuppression_5\NN\0|NONE
D064730_D001855 NONE dexrazoxane_3\NN\0|NONE (r_npadvmod) reduced_4\VBN\441445|loss|and (r_amod) myelosuppression_5\NN\0|NONE (r_pobj) of_2\IN\0|Nontoxic|from|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses
D064730_D001855 NONE dexrazoxane_27\NN\0|NONE (l_nsubj) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE
D064730_D001855 NONE dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses
D005047_D064420 NONE etoposide_12\RB\0|and (r_conj) daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither (l_conj) cytotoxicity_39\NN\13583478|,|nor|weight
D064730_D009362 NONE dexrazoxane_8\NN\0|of (r_nmod) doses_11\NNS\3740161|NONE (r_dobj) combining_7\VBG\7373277|brain (r_acl) metastases_6\NNS\13533470|NONE
D005047_D001855 NONE etoposide_11\NN\0|against|.|Dexrazoxane (r_advmod) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN\0|NONE
D005047_D001855 NONE etoposide_8\NN\0|the (r_appos) epipodophyllotoxin_7\NN\0|and (r_conj) doxorubicin_4\NN\2716866|anthracyclines|are|and (r_conj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|,
D005047_D001855 NONE etoposide_12\RB\0|and (r_conj) daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE
D005047_D001855 NONE etoposide_12\RB\0|and (r_conj) daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses
D004317_D064420 NONE doxorubicin_41\NN\2716866|NONE (r_pobj) from_40\IN\0|the|vitro (r_prep) cytotoxicity_39\NN\13583478|,|nor|weight
D005047_D009362 NONE etoposide_13\NN\0|NONE (r_pobj) of_12\IN\0|dexrazoxane (r_prep) doses_11\NNS\3740161|NONE (r_dobj) combining_7\VBG\7373277|brain (r_acl) metastases_6\NNS\13533470|NONE
D004317_D015431 CID doxorubicin_41\NN\2716866|NONE (r_pobj) from_40\IN\0|the|vitro (r_prep) cytotoxicity_39\NN\13583478|,|nor|weight (r_conj) loss_33\NN\13252973|,|reduced|neither (r_conj) myelosuppression_30\NN\0|however|,|;|.|doses (r_dobj) dexrazoxane_27\NN\0|NONE (l_nsubj) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE (l_conj) loss_8\NN\13252973|reduced|and
D004317_D015431 CID doxorubicin_41\NN\2716866|NONE (r_pobj) from_40\IN\0|the|vitro (r_prep) cytotoxicity_39\NN\13583478|,|nor|weight (r_conj) loss_33\NN\13252973|,|reduced|neither
D018943_D001855 NONE anthracyclines_1\NNS\0|are|doxorubicin|and (r_nsubj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|,
D003630_D006402 CID daunorubicin_35\NNS\0|, (r_conj) etoposide_33\VB\0|NONE (r_pobj) to_32\TO\0|of (r_prep) sensitivity_24\NN\5651971|.|in|was|investigated (r_nsubjpass) determined_42\VBN\0|NONE (l_advcl) investigated_22\VBN\644583|.|in|was|Sensitivity (l_nsubjpass) toxicity_8\NN\13576101|enhancers|:|was|,|Because
D003630_D066126 NONE daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|, (l_conj) toxicity_29\NN\13576101|and
D004317_D001855 NONE doxorubicin_16\RB\2716866|but|and|daunorubicin (r_conj) etoposide_11\NN\0|against|.|Dexrazoxane (r_advmod) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|.|Dexrazoxane|etoposide (l_pobj) myelosuppression_3\NN\0|NONE
D004317_D001855 NONE doxorubicin_4\NN\2716866|anthracyclines|are|and (r_conj) daunorubicin_2\NN\0|myelosuppression|;|.|however|use|, (r_ccomp) limit_30\VBP\5123416|NONE (l_nsubj) myelosuppression_26\NN\0|;|daunorubicin|.|however|use|,
D004317_D001855 NONE doxorubicin_41\NN\2716866|NONE (r_pobj) from_40\IN\0|the|vitro (r_prep) cytotoxicity_39\NN\13583478|,|nor|weight (r_conj) loss_33\NN\13252973|,|reduced|neither (r_conj) myelosuppression_30\NN\0|however|,|;|.|doses (r_dobj) dexrazoxane_27\NN\0|NONE (l_nsubj) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE
D004317_D001855 NONE doxorubicin_41\NN\2716866|NONE (r_pobj) from_40\IN\0|the|vitro (r_prep) cytotoxicity_39\NN\13583478|,|nor|weight (r_conj) loss_33\NN\13252973|,|reduced|neither (r_conj) myelosuppression_30\NN\0|however|,|;|.|doses
D003630_D015431 CID daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (l_prep) of_2\IN\0|Nontoxic|from|in|antagonized|and (l_pobj) myelosuppression_5\NN\0|NONE (l_conj) loss_8\NN\13252973|reduced|and
D003630_D015431 CID daunorubicin_10\NN\0|NONE (r_pobj) from_9\IN\0|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS\3740161|however|myelosuppression|,|;|. (r_nsubj) dexrazoxane_27\NN\0|NONE (l_dobj) myelosuppression_30\NN\0|however|,|;|.|doses (l_conj) loss_33\NN\13252973|,|reduced|neither
1595783
D000638_D011014 CID amiodarone_0\NN\2715941|agent|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_5\NN\7347|Amiodarone|. (l_appos) being_19\VBG\24720|antiarrhythmic|limited|effective|,|an (l_attr) pneumonitis_20\NN\14336539|problematic|the
D000638_D008171 NONE amiodarone_0\NN\2715941|pulmonary|. (r_amod) toxicity_2\NN\13576101|NONE
D000638_D008171 NONE amiodarone_4\NN\2715941|NONE (r_pobj) of_3\IN\0|pulmonary|The (r_prep) toxicity_2\NN\13576101|is|.|result
D000638_D008171 NONE amiodarone_6\NN\2715941| (r_npadvmod) induced_8\VBN\1627355|pulmonary (r_amod) toxicity_10\NN\13576101|NONE
D000638_D004342 NONE amiodarone_4\NN\2715941|NONE (r_pobj) of_3\IN\0|pulmonary|The (r_prep) toxicity_2\NN\13576101|is|.|result (r_nsubjpass) thought_6\VBN\5809192|NONE (l_xcomp) result_8\VB\34213|toxicity|is|. (l_prep) from_9\IN\0|to (l_pobj) injury_11\NN\14052046|NONE (l_acl) related_12\VBN\628491|direct (l_prep) to_13\IN\0|NONE (l_pobj) accumulation_16\NN\13497135|NONE (l_prep) of_17\IN\0|the|intracellular (l_pobj) pneumonitis_25\NN\14336539|NONE
D000638_D000542 NONE amiodarone_4\NN\2715941|NONE (r_pobj) of_3\IN\0|pulmonary|The (r_prep) toxicity_2\NN\13576101|is|.|result (r_nsubjpass) thought_6\VBN\5809192|NONE (l_xcomp) result_8\VB\34213|toxicity|is|. (l_prep) from_9\IN\0|to (l_pobj) injury_11\NN\14052046|NONE (l_acl) related_12\VBN\628491|direct (l_prep) to_13\IN\0|NONE (l_pobj) accumulation_16\NN\13497135|NONE (l_prep) of_17\IN\0|the|intracellular (l_pobj) pneumonitis_25\NN\14336539|NONE
3952818
D005472_D066126 NONE 5-fluorouracil_3\CD\0|NONE (r_punct) ._4\.\0|Cardiac|of (r_punct) toxicity_1\NN\13576101|NONE
D005472_D066126 NONE 5-fu_14\CD\0|NONE (r_pobj) to_13\IN\0|NONE (r_pcomp) due_12\JJ\5174653|cause|,|that|and|used|may|spasm (r_prep) be_7\VB\14625458|.|data (l_attr) cause_9\NN\7323922|due|,|that|and|used|may|spasm (l_prep) of_10\IN\0|the (l_pobj) cardiotoxicity_11\NN\0|NONE
D005472_D066126 NONE 5-fu_14\CD\0|NONE (r_pobj) to_13\IN\0|NONE (r_pcomp) due_12\JJ\5174653|cause|,|that|and|used|may|spasm (r_prep) be_7\VB\14625458|.|data (l_conj) used_23\VBN\0|cause|due|,|that|and|may|spasm (l_prep) in_24\IN\13603305|probably|be|that|antagonists|may (l_pobj) prevention_26\NN\1073995|NONE (l_prep) of_29\IN\0|the|or|treatment (l_pobj) cardiotoxicity_31\NN\0|NONE
D005472_D066126 NONE 5-fu_30\CD\0|NONE (r_compound) cardiotoxicity_31\NN\0|NONE (r_pobj) of_29\IN\0|the|or|treatment (r_prep) prevention_26\NN\1073995|NONE (r_pobj) in_24\IN\13603305|probably|be|that|antagonists|may (r_prep) used_23\VBN\0|cause|due|,|that|and|may|spasm (r_conj) be_7\VB\14625458|.|data (l_attr) cause_9\NN\7323922|due|,|that|and|used|may|spasm (l_prep) of_10\IN\0|the (l_pobj) cardiotoxicity_11\NN\0|NONE
D005472_D066126 NONE 5-fu_30\CD\0|NONE (r_compound) cardiotoxicity_31\NN\0|NONE
D009543_D000788 NONE nifedipine_19\NN\2938514|NONE (r_pobj) with_18\IN\0|promptly|.|pain (r_prep) resolved_17\VBD\352826|,|similar|and|evolution (r_conj) was_3\VBD\0|NONE (l_acomp) similar_4\JJ\0|,|and|resolved|evolution (l_prep) to_5\IN\0|NONE (l_pobj) that_6\DT\0|NONE (l_acl) observed_7\VBN\2163746|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) angina_11\NN\14171682|NONE
D005472_D002637 CID 5-fluorouracil_18\CD\0|(|)|FU (r_punct) administration_22\NN\1133281|NONE (r_pobj) after_17\IN\0|who|pain (r_prep) presented_14\VBD\2137132|a|with (l_dobj) pain_16\NN\14299637|who|after
D005472_D002637 CID 5-fu_20\CD\0|fluorouracil|(|) (r_nmod) administration_22\NN\1133281|NONE (r_pobj) after_17\IN\0|who|pain (r_prep) presented_14\VBD\2137132|a|with (l_dobj) pain_16\NN\14299637|who|after
D009543_D002637 NONE nifedipine_19\NN\2938514|NONE (r_pobj) with_18\IN\0|promptly|.|pain (r_prep) resolved_17\VBD\352826|,|similar|and|evolution (l_nsubj) pain_15\NN\14299637|promptly|.|with
D005472_D009362 NONE 5-fluorouracil_18\CD\0|(|)|FU (r_punct) administration_22\NN\1133281|NONE (r_pobj) after_17\IN\0|who|pain (r_prep) presented_14\VBD\2137132|a|with (r_relcl) patient_6\NN\9898892|NONE (l_prep) with_7\IN\0|a|presented (l_pobj) carcinoma_9\NN\14239918|NONE (l_conj) metastasis_12\NN\13533470|colon|and
D005472_D009362 NONE 5-fu_20\CD\0|fluorouracil|(|) (r_nmod) administration_22\NN\1133281|NONE (r_pobj) after_17\IN\0|who|pain (r_prep) presented_14\VBD\2137132|a|with (r_relcl) patient_6\NN\9898892|NONE (l_prep) with_7\IN\0|a|presented (l_pobj) carcinoma_9\NN\14239918|NONE (l_conj) metastasis_12\NN\13533470|colon|and
D005472_D003329 NONE 5-fu_14\CD\0|NONE (r_pobj) to_13\IN\0|NONE (r_pcomp) due_12\JJ\5174653|cause|,|that|and|used|may|spasm (r_prep) be_7\VB\14625458|.|data (l_nsubj) spasm_5\NN\14299637|cause|due|,|that|and|used|may
D005472_D003329 NONE 5-fu_30\CD\0|NONE (r_compound) cardiotoxicity_31\NN\0|NONE (r_pobj) of_29\IN\0|the|or|treatment (r_prep) prevention_26\NN\1073995|NONE (r_pobj) in_24\IN\13603305|probably|be|that|antagonists|may (r_prep) used_23\VBN\0|cause|due|,|that|and|may|spasm (r_conj) be_7\VB\14625458|.|data (l_nsubj) spasm_5\NN\14299637|cause|due|,|that|and|used|may
D005472_D003110 NONE 5-fluorouracil_18\CD\0|(|)|FU (r_punct) administration_22\NN\1133281|NONE (r_pobj) after_17\IN\0|who|pain (r_prep) presented_14\VBD\2137132|a|with (r_relcl) patient_6\NN\9898892|NONE (l_prep) with_7\IN\0|a|presented (l_pobj) carcinoma_9\NN\14239918|NONE
D005472_D003110 NONE 5-fu_20\CD\0|fluorouracil|(|) (r_nmod) administration_22\NN\1133281|NONE (r_pobj) after_17\IN\0|who|pain (r_prep) presented_14\VBD\2137132|a|with (r_relcl) patient_6\NN\9898892|NONE (l_prep) with_7\IN\0|a|presented (l_pobj) carcinoma_9\NN\14239918|NONE
D002118_D066126 NONE calcium_18\NN\14625458|NONE (r_compound) antagonists_19\NNS\7846|probably|be|that|in|may (r_nsubjpass) used_23\VBN\0|cause|due|,|that|and|may|spasm (r_conj) be_7\VB\14625458|.|data (l_attr) cause_9\NN\7323922|due|,|that|and|used|may|spasm (l_prep) of_10\IN\0|the (l_pobj) cardiotoxicity_11\NN\0|NONE
D002118_D066126 NONE calcium_18\NN\14625458|NONE (r_compound) antagonists_19\NNS\7846|probably|be|that|in|may (r_nsubjpass) used_23\VBN\0|cause|due|,|that|and|may|spasm (l_prep) in_24\IN\13603305|probably|be|that|antagonists|may (l_pobj) prevention_26\NN\1073995|NONE (l_prep) of_29\IN\0|the|or|treatment (l_pobj) cardiotoxicity_31\NN\0|NONE
D002118_D003329 NONE calcium_18\NN\14625458|NONE (r_compound) antagonists_19\NNS\7846|probably|be|that|in|may (r_nsubjpass) used_23\VBN\0|cause|due|,|that|and|may|spasm (r_conj) be_7\VB\14625458|.|data (l_nsubj) spasm_5\NN\14299637|cause|due|,|that|and|used|may
8475949
D008274_C537153 NONE magnesium_11\NN\14625458|serum|hypomagnesemia|and (r_compound) levels_12\NNS\4916342|NONE (l_conj) hypomagnesemia_14\NN\0|serum|and|magnesium
D008274_D008133 NONE magnesium_8\NN\14625458|early (r_compound) supplementation_9\NN\5108947|,|observed|is|. (r_nsubjpass) advocated_11\VBN\875394|NONE (l_advcl) observed_5\VBN\2163746|,|supplementation|is|. (l_nsubjpass) prolongation_3\NN\1017987|is|When
D008274_D016171 NONE magnesium_11\NN\14625458|serum|hypomagnesemia|and (r_compound) levels_12\NNS\4916342|NONE (r_pobj) to_9\IN\0|be|induce|pointes|may|. (r_prep) related_8\VBN\628491|NONE (l_nsubjpass) pointes_5\FW\831651|be|induce|may|.|to
D010419_D017180 NONE pentamidine_3\NN\0|NONE (l_conj) tachycardia_7\NN\14110674|and
D010419_D017180 NONE isethionate_1\NN\0|been|has|.|with (r_nsubjpass) associated_4\VBN\628491|NONE (l_prep) with_5\IN\0|been|has|isethionate|. (l_pobj) tachyarrhythmias_7\NNS\0|NONE
D010419_D016171 CID isethionate_1\NN\0|been|has|.|with (r_nsubjpass) associated_4\VBN\628491|NONE (l_prep) with_5\IN\0|been|has|isethionate|. (l_pobj) tachyarrhythmias_7\NNS\0|NONE (l_prep) including_9\VBG\0|,|ventricular (l_pobj) pointes_12\FW\831651|NONE
D010419_D016171 CID pentamidine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) torsade_3\NN\0|de (r_nmod) pointes_5\FW\831651|be|induce|may|.|to
D010419_D016171 CID pentamidine_13\NN\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatment_11\NN\654885|NONE (r_pobj) of_10\IN\0| (r_prep) days_9\NNS\15140892|NONE (r_pobj) of_7\IN\0|an (r_prep) average_6\NN\6021499|NONE (r_pobj) after_4\IN\0|.|pointes (r_prep) occurred_3\VBD\0|NONE (l_nsubj) pointes_2\NNS\831651|.|after
D010419_D016171 CID pentamidine_14\NN\0|NONE (r_pobj) of_13\IN\0|NONE (r_prep) discontinuation_12\NN\209943|possibly (r_pobj) without_11\IN\0|when|early|, (r_prep) recognized_7\VBN\686447|be|can|pointes|. (r_advcl) treated_5\VBN\2376958|NONE (l_nsubjpass) pointes_2\FW\831651|recognized|be|can|.
D010419_C537153 NONE pentamidine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) torsade_3\NN\0|de (r_nmod) pointes_5\FW\831651|be|induce|may|.|to (r_nsubjpass) related_8\VBN\628491|NONE (l_prep) to_9\IN\0|be|induce|pointes|may|. (l_pobj) levels_12\NNS\4916342|NONE (l_conj) hypomagnesemia_14\NN\0|serum|and|magnesium
11860495
D012601_D000647 CID scopolamine_21\NN\14712692| (r_npadvmod) induced_23\VBN\1627355|NONE (r_amod) amnesia_24\NN\5669934|NONE
D012601_D000647 CID scopolamine_25\NN\14712692| (r_npadvmod) induced_27\VBN\1627355|NONE (r_amod) amnesia_28\NN\5669934|NONE
D005680_D000647 NONE gaba(a)r_15\NNP\0|NONE (r_compound) ligands_16\NNS\20090|and (r_conj) nmdar_13\NNP\0|NONE (r_pobj) of_12\IN\0|the|like (r_prep) effects_11\NNS\13245626|to (l_amod) like_10\JJ\5839024|the|of (l_amod) amnesic_8\JJ\10158756|
C018370_D000647 NONE sulphate_13\NN\15010703|NONE (r_pobj) of_11\IN\0|amnesic|the|in (r_prep) effects_10\NNS\13245626|.|structure (l_amod) amnesic_9\JJ\10158756|the|in|of
C018370_D000647 NONE pregs_2\NNP\0|.|able|,|Moreover (r_nsubj) is_3\VBZ\0|NONE (l_acomp) able_4\JJ\0|PREGS|.|,|Moreover (l_xcomp) reverse_6\VB\13854649|NONE (l_dobj) effects_11\NNS\13245626|to (l_amod) like_10\JJ\5839024|the|of (l_amod) amnesic_8\JJ\10158756|
C018370_D000647 NONE pregs_6\NNP\0|NONE (r_pobj) of_5\IN\0|The|enhancing (r_prep) effects_4\NNS\13245626|in|.|were (r_nsubjpass) tested_11\VBN\670261|NONE (l_prep) in_12\IN\13603305|.|effects|were (l_pobj) task_16\NN\575741|NONE (l_acl) using_17\VBG\418025|the|passive|avoidance (l_dobj) model_19\NN\5888929|NONE (l_prep) of_20\IN\0|the (l_pobj) amnesia_24\NN\5669934|NONE
C018370_D000647 NONE pregs_10\NNP\0|NONE (r_pobj) of_8\IN\0|be|the (r_prep) ability_7\NN\4723816|NONE (l_acl) be_12\VB\14625458|of|the (l_attr) order_14\NN\7168131|to (l_amod) effective_18\JJ\0|an|of (l_prep) than_19\IN\0|more (l_pobj) enantiomer_22\NN\14818238|NONE (l_prep) in_23\IN\13603305|synthetic|its (l_pcomp) reversing_24\VBG\109660|NONE (l_dobj) amnesia_28\NN\5669934|NONE
D013256_D000647 NONE steroid_0\NN\14727670|properties|and (r_compound) structure_1\NN\21939|.|effects (r_nsubj) determine_5\VBP\0|NONE (l_dobj) effects_10\NNS\13245626|.|structure (l_amod) amnesic_9\JJ\10158756|the|in|of
2257294
C034753_D001855 NONE benzylacyclouridine_0\NN\0|.|suppression|without (r_nsubj) reverses_1\VBZ\13854649|NONE (l_dobj) suppression_6\NN\13489037|.|Benzylacyclouridine|without
C034753_D001855 NONE bau_11\NNP\0|.|coadministered|toxicity|, (r_nsubj) reduced_12\VBD\441445|NONE (l_dobj) toxicity_17\NN\13576101|.|coadministered|BAU|,
C034753_D064420 NONE benzylacyclouridine_14\NN\0|NONE (r_pobj) of_13\IN\0|effect|the (r_prep) ability_12\NN\4723816|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_prep) because_0\IN\0|ability|in|,|,|anemia|.|,|was (l_pobj) toxicities_4\NNS\13576101|of
C034753_D064420 NONE bau_16\NNP\0|)|( (r_appos) benzylacyclouridine_14\NN\0|NONE (r_pobj) of_13\IN\0|effect|the (r_prep) ability_12\NN\4723816|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_prep) because_0\IN\0|ability|in|,|,|anemia|.|,|was (l_pobj) toxicities_4\NNS\13576101|of
D014529_D000740 NONE urd_8\NNP\0|chronic (r_compound) administration_9\NN\1133281|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|clinical|the (r_acl) toxicities_4\NNS\13576101|of (r_pobj) because_0\IN\0|ability|in|,|,|anemia|.|,|was (r_prep) assessed_31\VBN\670261|NONE (l_nsubjpass) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was
D014529_D064420 NONE urd_8\NNP\0|chronic (r_compound) administration_9\NN\1133281|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|clinical|the (r_acl) toxicities_4\NNS\13576101|of
D014529_D064420 NONE urd_3\NNP\0|NONE (r_compound) catabolism_4\NN\13526110|,|increases|agent|and|. (r_dobj) inhibits_2\VBZ\2510337|NONE (l_conj) increases_10\VBZ\13576355|catabolism|,|agent|and|. (l_prep) without_23\IN\0|in|in|concentration|,|, (l_pobj) toxicity_27\NN\13576101|NONE
D014529_D064420 NONE urd_15\NNP\0|NONE (r_pobj) of_14\IN\0|the|plasma (r_prep) concentration_13\NN\4916342|in|in|without|,|, (r_dobj) increases_10\VBZ\13576355|catabolism|,|agent|and|. (l_prep) without_23\IN\0|in|in|concentration|,|, (l_pobj) toxicity_27\NN\13576101|NONE
D014529_D064420 NONE urd_24\NNP\0| (r_npadvmod) related_26\VBN\628491|NONE (r_amod) toxicity_27\NN\13576101|NONE
C034753_-1 NONE bau_31\NNP\0|mg/kg|(|plus|, (r_conj) azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_conj) increased_67\VBN\169651|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN\126264|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN\0|NONE
D014529_D007970 NONE urd_8\NNP\0|chronic (r_compound) administration_9\NN\1133281|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|clinical|the (r_acl) toxicities_4\NNS\13576101|of (r_pobj) because_0\IN\0|ability|in|,|,|anemia|.|,|was (r_prep) assessed_31\VBN\670261|NONE (l_nsubjpass) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN\14189204|and|induced
D015215_D064420 NONE azt_24\NNP\3834836| (r_npadvmod) induced_26\VBN\1627355|and|leukopenia (r_amod) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_prep) because_0\IN\0|ability|in|,|,|anemia|.|,|was (l_pobj) toxicities_4\NNS\13576101|of
D015215_D001855 CID azidothymidine_2\RB\0| (r_advmod) induced_4\VBN\1627355|marrow (r_amod) suppression_6\NN\13489037|.|Benzylacyclouridine|without
D015215_D001855 CID azt_3\NNP\3834836|NONE (r_pobj) with_2\IN\0|When|from (r_prep) coadministered_1\VBN\0|.|toxicity|BAU|, (r_advcl) reduced_12\VBD\441445|NONE (l_dobj) toxicity_17\NN\13576101|.|coadministered|BAU|,
D015215_D001855 CID azt_13\NNP\3834836| (r_npadvmod) induced_15\VBN\1627355|marrow (r_amod) toxicity_17\NN\13576101|.|coadministered|BAU|,
D014529_D007153 NONE uridine_4\NN\0|NONE (r_pobj) of_3\IN\0|extracellular|Increased (r_prep) concentrations_2\NNS\4916342|.|reduce|been|have (r_nsubjpass) reported_10\VBN\831651|NONE (l_xcomp) reduce_12\VB\441445|concentrations|.|been|have (l_dobj) inhibition_20\NN\1068773|,|to|in (l_prep) without_28\IN\0|AZT)induced|of|( (l_pobj) impairment_29\NN\7296428|NONE (l_prep) of_30\IN\0|NONE (l_pobj) virus_34\NN\9312843|NONE (l_compound) immunodeficiency_33\NN\13973990|its|activity|antihuman
D014529_D007153 NONE urd_6\NNP\0|NONE (r_appos) uridine_4\NN\0|NONE (r_pobj) of_3\IN\0|extracellular|Increased (r_prep) concentrations_2\NNS\4916342|.|reduce|been|have (r_nsubjpass) reported_10\VBN\831651|NONE (l_xcomp) reduce_12\VB\441445|concentrations|.|been|have (l_dobj) inhibition_20\NN\1068773|,|to|in (l_prep) without_28\IN\0|AZT)induced|of|( (l_pobj) impairment_29\NN\7296428|NONE (l_prep) of_30\IN\0|NONE (l_pobj) virus_34\NN\9312843|NONE (l_compound) immunodeficiency_33\NN\13973990|its|activity|antihuman
D015215_D007970 CID azt_24\NNP\3834836| (r_npadvmod) induced_26\VBN\1627355|and|leukopenia (r_amod) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN\14189204|and|induced
D015215_D007970 CID azt_10\NNP\3834836|NONE (r_pobj) of_9\IN\0|the (r_prep) administration_8\NN\1133281|NONE (r_pobj) by_6\IN\0|(|)|mL|for (r_prep) leukopenic_5\JJ\0|anemic|and
D015215_D007970 CID azt_10\NNP\3834836|NONE (r_pobj) of_9\IN\0|the (r_prep) administration_8\NN\1133281|NONE (r_pobj) by_6\IN\0|(|)|mL|for (r_prep) leukopenic_5\JJ\0|anemic|and (r_conj) rendered_2\VBD\120316|NONE (r_acl) mice_1\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (r_prep) reversed_39\VBD\109660|NONE (l_dobj) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN\14189204|and|P|(|reticulocytes|induced
D015215_D007970 CID azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_prep) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS\2329401|NONE (l_acl) rendered_2\VBD\120316|NONE (l_conj) leukopenic_5\JJ\0|anemic|and
D015215_D007970 CID azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_dobj) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN\14189204|and|P|(|reticulocytes|induced
D015215_D007970 CID azt_40\NNP\3834836| (r_npadvmod) induced_42\VBN\1627355|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (r_dobj) reversed_39\VBD\109660|NONE (l_prep) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS\2329401|NONE (l_acl) rendered_2\VBD\120316|NONE (l_conj) leukopenic_5\JJ\0|anemic|and
D015215_D007970 CID azt_40\NNP\3834836| (r_npadvmod) induced_42\VBN\1627355|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN\14189204|and|P|(|reticulocytes|induced
C034753_D000740 NONE benzylacyclouridine_14\NN\0|NONE (r_pobj) of_13\IN\0|effect|the (r_prep) ability_12\NN\4723816|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_nsubjpass) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was
C034753_D000740 NONE bau_16\NNP\0|)|( (r_appos) benzylacyclouridine_14\NN\0|NONE (r_pobj) of_13\IN\0|effect|the (r_prep) ability_12\NN\4723816|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_nsubjpass) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was
C034753_D000740 NONE bau_31\NNP\0|mg/kg|(|plus|, (r_conj) azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_prep) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS\2329401|NONE (l_acl) rendered_2\VBD\120316|NONE (l_oprd) anemic_3\JJ\0|and|leukopenic
C034753_D000740 NONE bau_31\NNP\0|mg/kg|(|plus|, (r_conj) azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_dobj) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|.
C034753_D007153 NONE benzylacyclouridine_0\NN\0|.|suppression|without (r_nsubj) reverses_1\VBZ\13854649|NONE (l_prep) without_7\IN\0|.|suppression|Benzylacyclouridine (l_pobj) impairment_8\NN\7296428|NONE (l_prep) of_9\IN\0|NONE (l_pobj) activity_15\NN\30358|NONE (l_compound) virus_14\NN\9312843|human (l_compound) immunodeficiency_13\NN\13973990|NONE
D015215_D000740 CID azt_24\NNP\3834836| (r_npadvmod) induced_26\VBN\1627355|and|leukopenia (r_amod) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was
D015215_D000740 CID azt_10\NNP\3834836|NONE (r_pobj) of_9\IN\0|the (r_prep) administration_8\NN\1133281|NONE (r_pobj) by_6\IN\0|(|)|mL|for (r_prep) leukopenic_5\JJ\0|anemic|and (r_conj) rendered_2\VBD\120316|NONE (l_oprd) anemic_3\JJ\0|and|leukopenic
D015215_D000740 CID azt_10\NNP\3834836|NONE (r_pobj) of_9\IN\0|the (r_prep) administration_8\NN\1133281|NONE (r_pobj) by_6\IN\0|(|)|mL|for (r_prep) leukopenic_5\JJ\0|anemic|and (r_conj) rendered_2\VBD\120316|NONE (r_acl) mice_1\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (r_prep) reversed_39\VBD\109660|NONE (l_dobj) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|.
D015215_D000740 CID azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_prep) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS\2329401|NONE (l_acl) rendered_2\VBD\120316|NONE (l_oprd) anemic_3\JJ\0|and|leukopenic
D015215_D000740 CID azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_dobj) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|.
D015215_D000740 CID azt_40\NNP\3834836| (r_npadvmod) induced_42\VBN\1627355|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (r_dobj) reversed_39\VBD\109660|NONE (l_prep) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS\2329401|NONE (l_acl) rendered_2\VBD\120316|NONE (l_oprd) anemic_3\JJ\0|and|leukopenic
D015215_D000740 CID azt_40\NNP\3834836| (r_npadvmod) induced_42\VBN\1627355|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|.
C034753_D007970 NONE benzylacyclouridine_14\NN\0|NONE (r_pobj) of_13\IN\0|effect|the (r_prep) ability_12\NN\4723816|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_nsubjpass) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN\14189204|and|induced
C034753_D007970 NONE bau_16\NNP\0|)|( (r_appos) benzylacyclouridine_14\NN\0|NONE (r_pobj) of_13\IN\0|effect|the (r_prep) ability_12\NN\4723816|in|Because|,|,|anemia|.|,|was (r_nsubjpass) assessed_31\VBN\670261|NONE (l_nsubjpass) anemia_27\NN\14189204|ability|in|Because|,|,|.|,|was (l_conj) leukopenia_29\NN\14189204|and|induced
C034753_D007970 NONE bau_31\NNP\0|mg/kg|(|plus|, (r_conj) azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_prep) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (l_pobj) mice_1\NNS\2329401|NONE (l_acl) rendered_2\VBD\120316|NONE (l_conj) leukopenic_5\JJ\0|anemic|and
C034753_D007970 NONE bau_31\NNP\0|mg/kg|(|plus|, (r_conj) azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_dobj) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (l_conj) leukopenia_45\NN\14189204|and|P|(|reticulocytes|induced
D015215_-1 NONE azt_10\NNP\3834836|NONE (r_pobj) of_9\IN\0|the (r_prep) administration_8\NN\1133281|NONE (r_pobj) by_6\IN\0|(|)|mL|for (r_prep) leukopenic_5\JJ\0|anemic|and (r_conj) rendered_2\VBD\120316|NONE (r_acl) mice_1\NNS\2329401|NONE (r_pobj) in_0\IN\13603305|administration|,|increased|)|,|anemia|partially|P|. (r_prep) reversed_39\VBD\109660|NONE (l_conj) increased_67\VBN\169651|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN\126264|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN\0|NONE
D015215_-1 NONE azt_28\NNP\3834836|NONE (r_pobj) of_27\IN\0|continued|orally|the (r_prep) administration_26\NN\1133281|,|increased|)|,|anemia|partially|In|P|. (r_nsubj) reversed_39\VBD\109660|NONE (l_conj) increased_67\VBN\169651|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN\126264|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN\0|NONE
D015215_-1 NONE azt_40\NNP\3834836| (r_npadvmod) induced_42\VBN\1627355|and|P|(|leukopenia|reticulocytes (r_amod) anemia_43\NN\14189204|administration|,|increased|)|,|partially|In|P|. (r_dobj) reversed_39\VBD\109660|NONE (l_conj) increased_67\VBN\169651|administration|,|)|,|anemia|partially|In|P|. (l_conj) improved_74\VBN\126264|,|and|in|cellularity (l_dobj) megaloblastosis_75\NN\0|NONE
D015215_D007153 NONE azidothymidine_2\RB\0| (r_advmod) induced_4\VBN\1627355|marrow (r_amod) suppression_6\NN\13489037|.|Benzylacyclouridine|without (r_dobj) reverses_1\VBZ\13854649|NONE (l_prep) without_7\IN\0|.|suppression|Benzylacyclouridine (l_pobj) impairment_8\NN\7296428|NONE (l_prep) of_9\IN\0|NONE (l_pobj) activity_15\NN\30358|NONE (l_compound) virus_14\NN\9312843|human (l_compound) immunodeficiency_13\NN\13973990|NONE
D015215_D007153 NONE azidothymidine_17\NN\0|, (r_advmod) vitro_15\FW\0|NONE (r_amod) in_14\IN\13603305|,|to|inhibition (r_prep) reduce_12\VB\441445|concentrations|.|been|have (l_dobj) inhibition_20\NN\1068773|,|to|in (l_prep) without_28\IN\0|AZT)induced|of|( (l_pobj) impairment_29\NN\7296428|NONE (l_prep) of_30\IN\0|NONE (l_pobj) virus_34\NN\9312843|NONE (l_compound) immunodeficiency_33\NN\13973990|its|activity|antihuman
D015215_D007153 NONE azt)-induced_19\JJ\0|of|without|( (r_compound) inhibition_20\NN\1068773|,|to|in (l_prep) without_28\IN\0|AZT)induced|of|( (l_pobj) impairment_29\NN\7296428|NONE (l_prep) of_30\IN\0|NONE (l_pobj) virus_34\NN\9312843|NONE (l_compound) immunodeficiency_33\NN\13973990|its|activity|antihuman
20103708
D010100_D003928 NONE oxygen_20\NN\14622893|)|(|ROS|reactive (r_compound) species_21\NNS\7992450|NONE (r_pobj) of_18\IN\0|the (r_prep) production_17\NN\30358|NONE (r_pobj) by_15\IN\0|which|is (r_agent) accompanied_14\VBN\0|,|of|major|the (r_relcl) causes_7\NNS\7323922|NONE (r_pobj) of_4\IN\0|NONE (r_prep) one_3\CD\13741022|.|nephropathy (r_attr) is_2\VBZ\0|NONE (l_nsubj) nephropathy_1\NN\14573196|.|one
D013311_D058186 NONE streptozotocin_13\RB\0| (r_npadvmod) induced_15\VBN\1627355|renal (r_amod) damage_17\NN\7296428|NONE
D010100_D051437 NONE oxygen_20\NN\14622893|)|(|ROS|reactive (r_compound) species_21\NNS\7992450|NONE (r_pobj) of_18\IN\0|the (r_prep) production_17\NN\30358|NONE (r_pobj) by_15\IN\0|which|is (r_agent) accompanied_14\VBN\0|,|of|major|the (r_relcl) causes_7\NNS\7323922|NONE (l_prep) of_8\IN\0|,|accompanied|major|the (l_pobj) failure_10\NN\66216|NONE
D013311_D003928 CID streptozotocin_6\JJ\0| (r_npadvmod) induced_8\VBN\1627355|diabetic (r_amod) nephropathy_10\NN\14573196|NONE
D013311_D003928 CID streptozotocin_22\RB\0| (r_npadvmod) induced_24\VBN\1627355|nephropathy|in|explore|:|.|a|, (r_amod) model_27\NN\5888929|NONE (l_ccomp) explore_2\VBP\789138|nephropathy|in|induced|:|.|a|, (l_dobj) role_5\NN\719494|We (l_prep) against_8\IN\0|of|the|protective (l_pobj) nephropathy_10\NN\14573196|NONE
D013311_D003928 CID streptozotocin_22\RB\0| (r_npadvmod) induced_24\VBN\1627355|nephropathy|in|explore|:|.|a|, (r_amod) model_27\NN\5888929|NONE (l_ccomp) explore_2\VBP\789138|nephropathy|in|induced|:|.|a|, (l_dobj) role_5\NN\719494|We (l_prep) against_8\IN\0|of|the|protective (l_pobj) nephropathy_10\NN\14573196|NONE (l_acl) using_11\VBG\418025|diabetic (l_prep) from_16\IN\0|tissues (l_pobj) patients_19\NNS\9898892|NONE (l_compound) nephropathy_18\NN\14573196|diabetic
D013311_D003928 CID streptozotocin_22\RB\0| (r_npadvmod) induced_24\VBN\1627355|nephropathy|in|explore|:|.|a|, (r_amod) model_27\NN\5888929|NONE (l_compound) nephropathy_26\NN\14573196|in|explore|induced|:|.|a|,
18997632
D002110_D018879 CID caffeine_1\NN\14712692|commonly|and|.|improve|is|tolerated (r_nsubjpass) used_4\VBN\0|NONE (l_conj) tolerated_18\VBN\802318|commonly|and|.|improve|caffeine|is (l_prep) from_20\IN\0|is|well|aside|generally (l_pobj) reports_22\NNS\6470073|NONE (l_prep) of_23\IN\0|occasional (l_pobj) ectopy_27\NN\0|NONE
D002110_D006331 NONE caffeine_25\NN\14712692|NONE (r_compound) administration_26\NN\1133281|NONE (r_pobj) after_24\IN\0|who|bigeminy (r_prep) developed_14\VBD\1753788|or|arrhythmia|cardiac (r_relcl) disease_10\NN\14061805|NONE
D002110_D012640 CID caffeine_1\NN\14712692|commonly|and|.|improve|is|tolerated (r_nsubjpass) used_4\VBN\0|NONE (l_xcomp) improve_6\VB\126264|commonly|and|.|caffeine|is|tolerated (l_dobj) duration_8\NN\15113229|to (l_compound) seizure_7\NN\14081375|quality|and|in
D002110_D017180 CID caffeine_7\NN\14712692|NONE (r_compound) pretreatment_8\NN\0|NONE (r_pobj) to_6\IN\0|NONE (r_prep) related_5\VBN\628491|ventricular (r_acl) tachycardia_4\NN\14110674|NONE
D002110_D017180 CID caffeine_25\NN\14712692|NONE (r_compound) administration_26\NN\1133281|NONE (r_pobj) after_24\IN\0|who|bigeminy (r_prep) developed_14\VBD\1753788|or|arrhythmia|cardiac (l_dobj) bigeminy_16\JJ\0|who|after (l_conj) runs_20\NNS\186634|and|sustained (l_prep) of_21\IN\0||brief (l_pobj) tachycardia_23\NN\14110674|NONE
D002110_D001145 NONE caffeine_25\NN\14712692|NONE (r_compound) administration_26\NN\1133281|NONE (r_pobj) after_24\IN\0|who|bigeminy (r_prep) developed_14\VBD\1753788|or|arrhythmia|cardiac (r_relcl) disease_10\NN\14061805|NONE (l_conj) arrhythmia_12\NN\14103288|or|developed|cardiac
D002110_D001145 NONE caffeine_2\NN\14712692|is|Although|well|generally (r_nsubjpass) tolerated_6\VBN\802318|aware|clinician|,|should|. (r_advcl) be_11\VB\14625458|NONE (l_acomp) aware_12\JJ\0|tolerated|clinician|,|should|. (l_prep) of_13\IN\0|NONE (l_pobj) potential_15\NN\14481929|NONE (l_prep) for_16\IN\0|the (l_pobj) arrhythmias_21\NNS\14103288|NONE
14633084
D015080_D006470 NONE mesna_4\NN\0|NONE (r_pobj) with_3\IN\0|.|for|of (r_prep) use_0\NN\407535|NONE (l_prep) for_5\IN\0|.|with|of (l_pobj) prevention_7\NN\1073995|NONE (l_prep) of_8\IN\0|the (l_pobj) cystitis_13\NN\14566129|NONE
D015080_D006470 NONE mesna_15\NN\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) combination_13\NN\7951464|NONE (r_pobj) in_12\IN\13603305|for|the|of (r_prep) use_9\NN\407535|we|In|.|, (l_prep) for_16\IN\0|in|the|of (l_pobj) prevention_18\NN\1073995|NONE (l_prep) of_19\IN\0|the (l_pobj) hc_23\NN\0|NONE
D015080_D006470 NONE mesna_4\NN\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) combination_2\NN\7951464|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) dexamethasone_0\NN\2721538|.|efficient (r_nsubj) was_5\VBD\0|NONE (l_acomp) efficient_6\JJ\0|Dexamethasone|. (l_prep) in_7\IN\13603305|NONE (l_pcomp) blocking_8\VBG\562280|NONE (l_dobj) hc_12\NN\0|NONE
D015080_D006470 NONE mesna_9\NN\0|NONE (r_pobj) of_8\IN\0|last|two|with (r_prep) doses_7\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) replacement_3\NN\196485|HC|did|,|.|not|However (r_nsubj) prevent_22\VB\0|NONE (l_dobj) hc_23\NN\0|did|,|.|not|However|replacement
D015080_D006470 NONE mesna_16\JJ\0|with|the (r_amod) doses_17\NNS\3740161|NONE (r_pobj) of_14\IN\0|NONE (r_prep) all_13\DT\0|or (r_conj) saline_11\NN\14849367|NONE (r_pobj) with_10\IN\0|last|two|of (r_prep) doses_7\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) replacement_3\NN\196485|HC|did|,|.|not|However (r_nsubj) prevent_22\VB\0|NONE (l_dobj) hc_23\NN\0|did|,|.|not|However|replacement
D015080_D003556 NONE mesna_4\NN\0|NONE (r_pobj) with_3\IN\0|.|for|of (r_prep) use_0\NN\407535|NONE (l_prep) for_5\IN\0|.|with|of (l_pobj) prevention_7\NN\1073995|NONE (l_prep) of_8\IN\0|the (l_pobj) cystitis_13\NN\14566129|NONE
D015080_D003556 NONE mesna_15\NN\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) combination_13\NN\7951464|NONE (r_pobj) in_12\IN\13603305|for|the|of (r_prep) use_9\NN\407535|we|In|.|, (l_prep) for_16\IN\0|in|the|of (l_pobj) prevention_18\NN\1073995|NONE (l_prep) of_19\IN\0|the (l_pobj) hc_23\NN\0|NONE
D015080_D003556 NONE mesna_4\NN\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) combination_2\NN\7951464|NONE (r_pobj) in_1\IN\13603305|NONE (r_prep) dexamethasone_0\NN\2721538|.|efficient (r_nsubj) was_5\VBD\0|NONE (l_acomp) efficient_6\JJ\0|Dexamethasone|. (l_prep) in_7\IN\13603305|NONE (l_pcomp) blocking_8\VBG\562280|NONE (l_dobj) hc_12\NN\0|NONE
D015080_D003556 NONE mesna_9\NN\0|NONE (r_pobj) of_8\IN\0|last|two|with (r_prep) doses_7\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) replacement_3\NN\196485|HC|did|,|.|not|However (r_nsubj) prevent_22\VB\0|NONE (l_dobj) hc_23\NN\0|did|,|.|not|However|replacement
D015080_D003556 NONE mesna_16\JJ\0|with|the (r_amod) doses_17\NNS\3740161|NONE (r_pobj) of_14\IN\0|NONE (r_prep) all_13\DT\0|or (r_conj) saline_11\NN\14849367|NONE (r_pobj) with_10\IN\0|last|two|of (r_prep) doses_7\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) replacement_3\NN\196485|HC|did|,|.|not|However (r_nsubj) prevent_22\VB\0|NONE (l_dobj) hc_23\NN\0|did|,|.|not|However|replacement
D007069_D003556 CID ifosfamide_9\RB\0| (r_advmod) induced_11\VBN\1627355|hemorrhagic (r_amod) cystitis_13\NN\14566129|NONE
D007069_D003556 CID ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|:
D007069_D003556 CID ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|: (l_appos) hc_5\NNP\0|)|(|Hemorrhagic
D007069_D003556 CID ifs_18\NNP\0|(|) (r_appos) ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|:
D007069_D003556 CID ifs_18\NNP\0|(|) (r_appos) ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|: (l_appos) hc_5\NNP\0|)|(|Hemorrhagic
D007069_D003556 CID ifs_20\NNP\0| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) hc_23\NN\0|NONE
D007069_D003556 CID ifs_9\NNP\0| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) hc_12\NN\0|NONE
D007069_D006470 CID ifosfamide_9\RB\0| (r_advmod) induced_11\VBN\1627355|hemorrhagic (r_amod) cystitis_13\NN\14566129|NONE
D007069_D006470 CID ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|:
D007069_D006470 CID ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|: (l_appos) hc_5\NNP\0|)|(|Hemorrhagic
D007069_D006470 CID ifs_18\NNP\0|(|) (r_appos) ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|:
D007069_D006470 CID ifs_18\NNP\0|(|) (r_appos) ifosfamide_16\NN\0|NONE (r_pobj) with_15\IN\0|side|limiting|of|a| (r_prep) effect_12\NN\34213|AIM|. (r_attr) is_7\VBZ\0|NONE (l_nsubj) aim_0\VB\5980875|effect|. (l_appos) cystitis_3\NN\14566129|: (l_appos) hc_5\NNP\0|)|(|Hemorrhagic
D007069_D006470 CID ifs_20\NNP\0| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) hc_23\NN\0|NONE
D007069_D006470 CID ifs_9\NNP\0| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) hc_12\NN\0|NONE
D003907_D006470 NONE dexamethasone_2\NN\2721538|NONE (r_pobj) of_1\IN\0|.|for|with (r_prep) use_0\NN\407535|NONE (l_prep) for_5\IN\0|.|with|of (l_pobj) prevention_7\NN\1073995|NONE (l_prep) of_8\IN\0|the (l_pobj) cystitis_13\NN\14566129|NONE
D003907_D006470 NONE dexamethasone_11\NN\2721538|NONE (r_pobj) of_10\IN\0|in|for|the (r_prep) use_9\NN\407535|we|In|.|, (l_prep) for_16\IN\0|in|the|of (l_pobj) prevention_18\NN\1073995|NONE (l_prep) of_19\IN\0|the (l_pobj) hc_23\NN\0|NONE
D003907_D006470 NONE dexamethasone_0\NN\2721538|.|efficient (r_nsubj) was_5\VBD\0|NONE (l_acomp) efficient_6\JJ\0|Dexamethasone|. (l_prep) in_7\IN\13603305|NONE (l_pcomp) blocking_8\VBG\562280|NONE (l_dobj) hc_12\NN\0|NONE
D003907_D006470 NONE dexamethasone_19\NN\2721538|NONE (r_pobj) with_18\IN\0|mesna|the (r_prep) doses_17\NNS\3740161|NONE (r_pobj) of_14\IN\0|NONE (r_prep) all_13\DT\0|or (r_conj) saline_11\NN\14849367|NONE (r_pobj) with_10\IN\0|last|two|of (r_prep) doses_7\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) replacement_3\NN\196485|HC|did|,|.|not|However (r_nsubj) prevent_22\VB\0|NONE (l_dobj) hc_23\NN\0|did|,|.|not|However|replacement
D003907_D003556 NONE dexamethasone_2\NN\2721538|NONE (r_pobj) of_1\IN\0|.|for|with (r_prep) use_0\NN\407535|NONE (l_prep) for_5\IN\0|.|with|of (l_pobj) prevention_7\NN\1073995|NONE (l_prep) of_8\IN\0|the (l_pobj) cystitis_13\NN\14566129|NONE
D003907_D003556 NONE dexamethasone_11\NN\2721538|NONE (r_pobj) of_10\IN\0|in|for|the (r_prep) use_9\NN\407535|we|In|.|, (l_prep) for_16\IN\0|in|the|of (l_pobj) prevention_18\NN\1073995|NONE (l_prep) of_19\IN\0|the (l_pobj) hc_23\NN\0|NONE
D003907_D003556 NONE dexamethasone_0\NN\2721538|.|efficient (r_nsubj) was_5\VBD\0|NONE (l_acomp) efficient_6\JJ\0|Dexamethasone|. (l_prep) in_7\IN\13603305|NONE (l_pcomp) blocking_8\VBG\562280|NONE (l_dobj) hc_12\NN\0|NONE
D003907_D003556 NONE dexamethasone_19\NN\2721538|NONE (r_pobj) with_18\IN\0|mesna|the (r_prep) doses_17\NNS\3740161|NONE (r_pobj) of_14\IN\0|NONE (r_prep) all_13\DT\0|or (r_conj) saline_11\NN\14849367|NONE (r_pobj) with_10\IN\0|last|two|of (r_prep) doses_7\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) replacement_3\NN\196485|HC|did|,|.|not|However (r_nsubj) prevent_22\VB\0|NONE (l_dobj) hc_23\NN\0|did|,|.|not|However|replacement
19274460
D003907_D009101 NONE dexamethasone_14\NN\2721538|NONE (r_pobj) with_11\IN\0|NONE (r_prep) combination_10\NN\7951464|NONE (r_pobj) in_9\IN\13603305|for|for|dose (r_prep) definition_5\NN\6738281|.|:|XI (l_prep) for_15\IN\0|in|for|dose (l_pobj) induction_17\NN\7450842|NONE (l_prep) in_18\IN\13603305|remission (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|NONE (l_pobj) myeloma_23\NN\14239425|NONE
D003907_D009101 NONE dexamethasone_17\NN\2721538|and (r_conj) bortezomib_15\NNS\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) combination_13\NN\7951464|NONE (r_pobj) in_12\IN\13603305|dose|to|as (r_prep) evaluate_6\VB\670261|trial|was|. (l_prep) as_18\IN\14622893|dose|to|in (l_pobj) treatment_20\NN\654885|NONE (l_prep) before_21\IN\0|induction (l_pobj) transplantation_24\NN\671351|NONE (l_prep) for_25\IN\0|cell (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|younger (l_pobj) myeloma_32\NN\14239425|NONE
D003907_D009101 NONE dexamethasone_17\NN\2721538|and (r_conj) bortezomib_15\NNS\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) combination_13\NN\7951464|NONE (r_pobj) in_12\IN\13603305|dose|to|as (r_prep) evaluate_6\VB\670261|trial|was|. (l_prep) as_18\IN\14622893|dose|to|in (l_pobj) treatment_20\NN\654885|NONE (l_prep) before_21\IN\0|induction (l_pobj) transplantation_24\NN\671351|NONE (l_prep) for_25\IN\0|cell (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|younger (l_pobj) myeloma_32\NN\14239425|NONE (l_appos) mm_34\NNP\13649268|diagnosed|multiple
D003907_D009101 NONE dexamethasone_16\NN\2721538|that|bortezomib|treatment (r_nsubj) is_17\VBZ\0|.|results (l_attr) treatment_21\NN\654885|that|bortezomib|dexamethasone (l_prep) for_22\IN\0|effective|induction|warrants|an (l_pobj) patients_23\NNS\9898892|NONE (l_prep) with_24\IN\0|NONE (l_pobj) mm_27\NNP\13649268|NONE
C400082_D009101 NONE bortezomib_12\NNS\0|/ (r_amod) dexamethasone_14\NN\2721538|NONE (r_pobj) with_11\IN\0|NONE (r_prep) combination_10\NN\7951464|NONE (r_pobj) in_9\IN\13603305|for|for|dose (r_prep) definition_5\NN\6738281|.|:|XI (l_prep) for_15\IN\0|in|for|dose (l_pobj) induction_17\NN\7450842|NONE (l_prep) in_18\IN\13603305|remission (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|NONE (l_pobj) myeloma_23\NN\14239425|NONE
C400082_D009101 NONE bortezomib_15\NNS\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) combination_13\NN\7951464|NONE (r_pobj) in_12\IN\13603305|dose|to|as (r_prep) evaluate_6\VB\670261|trial|was|. (l_prep) as_18\IN\14622893|dose|to|in (l_pobj) treatment_20\NN\654885|NONE (l_prep) before_21\IN\0|induction (l_pobj) transplantation_24\NN\671351|NONE (l_prep) for_25\IN\0|cell (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|younger (l_pobj) myeloma_32\NN\14239425|NONE
C400082_D009101 NONE bortezomib_15\NNS\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) combination_13\NN\7951464|NONE (r_pobj) in_12\IN\13603305|dose|to|as (r_prep) evaluate_6\VB\670261|trial|was|. (l_prep) as_18\IN\14622893|dose|to|in (l_pobj) treatment_20\NN\654885|NONE (l_prep) before_21\IN\0|induction (l_pobj) transplantation_24\NN\671351|NONE (l_prep) for_25\IN\0|cell (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|younger (l_pobj) myeloma_32\NN\14239425|NONE (l_appos) mm_34\NNP\13649268|diagnosed|multiple
C400082_D009101 NONE bortezomib_4\NNS\0|that|dexamethasone|treatment (r_nsubj) is_17\VBZ\0|.|results (l_attr) treatment_21\NN\654885|that|bortezomib|dexamethasone (l_prep) for_22\IN\0|effective|induction|warrants|an (l_pobj) patients_23\NNS\9898892|NONE (l_prep) with_24\IN\0|NONE (l_pobj) mm_27\NNP\13649268|NONE
D003520_D009101 NONE cyclophosphamide_8\NN\0|NONE (r_pobj) for_6\IN\0|for|in|dose (r_prep) definition_5\NN\6738281|.|:|XI (l_prep) for_15\IN\0|in|for|dose (l_pobj) induction_17\NN\7450842|NONE (l_prep) in_18\IN\13603305|remission (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|NONE (l_pobj) myeloma_23\NN\14239425|NONE
D003520_D009101 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|the|recommended (r_prep) dose_9\NN\3740161|to|in|as (r_dobj) evaluate_6\VB\670261|trial|was|. (l_prep) as_18\IN\14622893|dose|to|in (l_pobj) treatment_20\NN\654885|NONE (l_prep) before_21\IN\0|induction (l_pobj) transplantation_24\NN\671351|NONE (l_prep) for_25\IN\0|cell (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|younger (l_pobj) myeloma_32\NN\14239425|NONE
D003520_D009101 NONE cyclophosphamide_11\NN\0|NONE (r_pobj) of_10\IN\0|the|recommended (r_prep) dose_9\NN\3740161|to|in|as (r_dobj) evaluate_6\VB\670261|trial|was|. (l_prep) as_18\IN\14622893|dose|to|in (l_pobj) treatment_20\NN\654885|NONE (l_prep) before_21\IN\0|induction (l_pobj) transplantation_24\NN\671351|NONE (l_prep) for_25\IN\0|cell (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|younger (l_pobj) myeloma_32\NN\14239425|NONE (l_appos) mm_34\NNP\13649268|diagnosed|multiple
D003520_D009101 NONE cyclophosphamide_8\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) combination_6\NN\7951464|NONE (r_pobj) in_5\IN\13603305|at|and (r_prep) bortezomib_4\NNS\0|that|dexamethasone|treatment (r_nsubj) is_17\VBZ\0|.|results (l_attr) treatment_21\NN\654885|that|bortezomib|dexamethasone (l_prep) for_22\IN\0|effective|induction|warrants|an (l_pobj) patients_23\NNS\9898892|NONE (l_prep) with_24\IN\0|NONE (l_pobj) mm_27\NNP\13649268|NONE
6769133
D004317_D006333 CID adriamycin_13\NNS\0|average|m|below|considered|cumulative|an (r_compound) dose_14\NN\3740161|NONE (r_pobj) at_9\IN\14622893|.||failure (r_prep) developed_5\VBD\1753788|NONE (l_dobj) failure_8\NN\66216|at|.|
D018943_D009202 NONE anthracycline_10\NN\0| (r_amod) induced_12\VBN\1627355|human (r_amod) cardiomyopathy_13\NN\14103288|NONE
D004317_D066126 NONE adriamycin_6\NNS\0|NONE (r_pobj) of_5\IN\0|leukemogenic|in|possible (r_prep) effects_4\NNS\13245626|and|. (r_conj) cardiotoxic_0\NNP\0|NONE
D018943_D001768 NONE anthracycline_10\NN\0| (r_amod) induced_12\VBN\1627355|human (r_amod) cardiomyopathy_13\NN\14103288|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) found_7\VBN\13279262|NONE (r_acl) those_6\DT\0|.|,|Histologically|lesions (r_dobj) resembled_5\VBD\2657219|NONE (l_nsubj) lesions_4\NNS\14204950|.|those|,|Histologically
D004317_D015470 CID adriamycin_16\NNS\0|NONE (r_pobj) of_15\IN\0|/|mg| (r_prep) m2_14\CD\13357178|NONE (r_dobj) receiving_10\VBG\2210855|NONE (r_pcomp) after_9\IN\0|leukemia| (r_prep) developed_5\VBD\1753788|alive|monkey|after|.|; (l_dobj) leukemia_8\NN\14239918|after|
D004317_D007938 NONE adriamycin_4\NN\0|that|than|be|and|cardiotoxin|, (r_nsubj) is_5\VBZ\0|.|results (l_conj) be_20\VB\14625458|that|adriamycin|than|and|cardiotoxin|, (l_nsubj) leukemia_18\NN\14239918|may|that|consequence
3762968
D013835_D014899 NONE pyrophosphate_42\NN\15010703|NONE (r_pobj) for_40\IN\0|]|high|[ (r_prep) km_39\NNP\13649268|transketolase (r_appos) abnormality_36\NN\14034177|,|reported|patient|if|also (r_dobj) had_34\VBD\0|to (r_ccomp) delineate_29\VB\2137132|NONE (r_acl) order_27\NN\7168131|NONE (r_pobj) in_26\IN\13603305|We|enzyme|from|,|. (r_prep) studied_1\VBD\0|NONE (l_prep) from_10\IN\0|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS\5447757|NONE (l_prep) of_12\IN\0|NONE (l_pobj) patient_15\NN\9898892|NONE (l_relcl) developed_17\VBD\1753788|diabetic|a (l_dobj) encephalopathy_20\NN\14084880|treated|who
D013835_D014899 NONE tpp_44\NNP\0|thiamine|)|( (r_appos) pyrophosphate_42\NN\15010703|NONE (r_pobj) for_40\IN\0|]|high|[ (r_prep) km_39\NNP\13649268|transketolase (r_appos) abnormality_36\NN\14034177|,|reported|patient|if|also (r_dobj) had_34\VBD\0|to (r_ccomp) delineate_29\VB\2137132|NONE (r_acl) order_27\NN\7168131|NONE (r_pobj) in_26\IN\13603305|We|enzyme|from|,|. (r_prep) studied_1\VBD\0|NONE (l_prep) from_10\IN\0|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS\5447757|NONE (l_prep) of_12\IN\0|NONE (l_pobj) patient_15\NN\9898892|NONE (l_relcl) developed_17\VBD\1753788|diabetic|a (l_dobj) encephalopathy_20\NN\14084880|treated|who
D013835_D014899 NONE tpp_30\NNP\0|NONE (r_pobj) for_29\IN\0|its (r_prep) km_28\NNP\13649268|NONE (r_pobj) by_26\IN\0|as (r_agent) determined_25\VBN\0|patient|that|transketolase (r_advcl) had_21\VBD\0|.|We (l_nsubj) patient_7\NN\9898892|that|transketolase|determined (l_prep) with_14\IN\0|the|and|mentioned|one (l_pobj) history_16\NN\15120823|NONE (l_prep) of_17\IN\0|no (l_pobj) encephalopathy_20\NN\14084880|NONE
D014042_D020915 NONE tolazamide_24\NN\4353189|NONE (r_pobj) with_23\IN\0|when (r_prep) treated_22\VBN\2376958|encephalopathy|who (r_advcl) developed_17\VBD\1753788|diabetic|a (r_relcl) patient_15\NN\9898892|NONE (r_pobj) of_12\IN\0|NONE (r_prep) fibroblasts_11\NNS\5447757|NONE (r_pobj) from_10\IN\0|We|enzyme|in|,|. (r_prep) studied_1\VBD\0|NONE (l_prep) in_26\IN\13603305|We|enzyme|from|,|. (l_pobj) order_27\NN\7168131|NONE (l_acl) delineate_29\VB\2137132|NONE (l_ccomp) had_34\VBD\0|to (l_advcl) reported_50\VBN\831651|,|abnormality|patient|if|also (l_prep) in_51\IN\13603305|previously|as (l_pobj) syndrome_56\NN\5870365|NONE
D014042_D020915 NONE tolazamide_15\NN\4353189| (r_npadvmod) induced_17\VBN\1627355|from|Wernicke (r_amod) encephalopathy_20\NN\14084880|NONE (r_pobj) with_14\IN\0|the (r_prep) patient_13\NN\9898892|postalcoholic|Korsakoff|and (r_conj) syndrome_10\NN\5870365|NONE
D013831_D014899 NONE thiamine_3\NN\15090742| (r_npadvmod) dependent_5\JJ\9627906|,|,|a|transketolase (r_amod) enzyme_6\NN\14723628|We|from|in|,|. (r_dobj) studied_1\VBD\0|NONE (l_prep) from_10\IN\0|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS\5447757|NONE (l_prep) of_12\IN\0|NONE (l_pobj) patient_15\NN\9898892|NONE (l_relcl) developed_17\VBD\1753788|diabetic|a (l_dobj) encephalopathy_20\NN\14084880|treated|who
D013835_D003920 NONE pyrophosphate_42\NN\15010703|NONE (r_pobj) for_40\IN\0|]|high|[ (r_prep) km_39\NNP\13649268|transketolase (r_appos) abnormality_36\NN\14034177|,|reported|patient|if|also (r_dobj) had_34\VBD\0|to (r_ccomp) delineate_29\VB\2137132|NONE (r_acl) order_27\NN\7168131|NONE (r_pobj) in_26\IN\13603305|We|enzyme|from|,|. (r_prep) studied_1\VBD\0|NONE (l_prep) from_10\IN\0|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS\5447757|NONE (l_prep) of_12\IN\0|NONE (l_pobj) patient_15\NN\9898892|NONE (l_amod) diabetic_14\JJ\10595647|developed|a
D013835_D003920 NONE tpp_44\NNP\0|thiamine|)|( (r_appos) pyrophosphate_42\NN\15010703|NONE (r_pobj) for_40\IN\0|]|high|[ (r_prep) km_39\NNP\13649268|transketolase (r_appos) abnormality_36\NN\14034177|,|reported|patient|if|also (r_dobj) had_34\VBD\0|to (r_ccomp) delineate_29\VB\2137132|NONE (r_acl) order_27\NN\7168131|NONE (r_pobj) in_26\IN\13603305|We|enzyme|from|,|. (r_prep) studied_1\VBD\0|NONE (l_prep) from_10\IN\0|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS\5447757|NONE (l_prep) of_12\IN\0|NONE (l_pobj) patient_15\NN\9898892|NONE (l_amod) diabetic_14\JJ\10595647|developed|a
D013835_D003920 NONE tpp_30\NNP\0|NONE (r_pobj) for_29\IN\0|its (r_prep) km_28\NNP\13649268|NONE (r_pobj) by_26\IN\0|as (r_agent) determined_25\VBN\0|patient|that|transketolase (r_advcl) had_21\VBD\0|.|We (l_nsubj) patient_7\NN\9898892|that|transketolase|determined (l_conj) one_9\CD\13741022|the|and|with|mentioned (l_prep) of_10\IN\0|NONE (l_pobj) kindreds_13\NNS\7950920|NONE (l_amod) diabetic_12\JJ\10595647|the
D013831_D020915 NONE thiamine_3\NN\15090742| (r_npadvmod) dependent_5\JJ\9627906|,|,|a|transketolase (r_amod) enzyme_6\NN\14723628|We|from|in|,|. (r_dobj) studied_1\VBD\0|NONE (l_prep) in_26\IN\13603305|We|enzyme|from|,|. (l_pobj) order_27\NN\7168131|NONE (l_acl) delineate_29\VB\2137132|NONE (l_ccomp) had_34\VBD\0|to (l_advcl) reported_50\VBN\831651|,|abnormality|patient|if|also (l_prep) in_51\IN\13603305|previously|as (l_pobj) syndrome_56\NN\5870365|NONE
D013835_D020915 NONE pyrophosphate_42\NN\15010703|NONE (r_pobj) for_40\IN\0|]|high|[ (r_prep) km_39\NNP\13649268|transketolase (r_appos) abnormality_36\NN\14034177|,|reported|patient|if|also (r_dobj) had_34\VBD\0|to (l_advcl) reported_50\VBN\831651|,|abnormality|patient|if|also (l_prep) in_51\IN\13603305|previously|as (l_pobj) syndrome_56\NN\5870365|NONE
D013835_D020915 NONE tpp_44\NNP\0|thiamine|)|( (r_appos) pyrophosphate_42\NN\15010703|NONE (r_pobj) for_40\IN\0|]|high|[ (r_prep) km_39\NNP\13649268|transketolase (r_appos) abnormality_36\NN\14034177|,|reported|patient|if|also (r_dobj) had_34\VBD\0|to (l_advcl) reported_50\VBN\831651|,|abnormality|patient|if|also (l_prep) in_51\IN\13603305|previously|as (l_pobj) syndrome_56\NN\5870365|NONE
D014042_D014899 CID tolazamide_3\NN\4353189| (r_npadvmod) induced_5\VBN\1627355|Wernicke (r_amod) encephalopathy_8\NN\14084880|NONE
D014042_D014899 CID tolazamide_24\NN\4353189|NONE (r_pobj) with_23\IN\0|when (r_prep) treated_22\VBN\2376958|encephalopathy|who (r_advcl) developed_17\VBD\1753788|diabetic|a (l_dobj) encephalopathy_20\NN\14084880|treated|who
D014042_D014899 CID tolazamide_15\NN\4353189| (r_npadvmod) induced_17\VBN\1627355|from|Wernicke (r_amod) encephalopathy_20\NN\14084880|NONE
D014042_D003920 NONE tolazamide_24\NN\4353189|NONE (r_pobj) with_23\IN\0|when (r_prep) treated_22\VBN\2376958|encephalopathy|who (r_advcl) developed_17\VBD\1753788|diabetic|a (r_relcl) patient_15\NN\9898892|NONE (l_amod) diabetic_14\JJ\10595647|developed|a
D013831_D003920 NONE thiamine_3\NN\15090742| (r_npadvmod) dependent_5\JJ\9627906|,|,|a|transketolase (r_amod) enzyme_6\NN\14723628|We|from|in|,|. (r_dobj) studied_1\VBD\0|NONE (l_prep) from_10\IN\0|We|enzyme|in|,|. (l_pobj) fibroblasts_11\NNS\5447757|NONE (l_prep) of_12\IN\0|NONE (l_pobj) patient_15\NN\9898892|NONE (l_amod) diabetic_14\JJ\10595647|developed|a
3732088
D000584_D003324 NONE amiloride_30\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0| (r_prep) weeks_20\NNS\15113229|NONE (r_pobj) after_18\IN\0|disease|) (r_prep) known_14\VBN\0|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN\14061805|)|after
D011188_D001145 NONE potassium_2\NN\14625458|.|,|in (l_conj) arrhythmias_4\NNS\14103288|and
D011188_D001145 NONE potassium_9\NN\14625458|NONE (r_pobj) in_7\IN\13603305|modest (r_prep) changes_6\NNS\7283608|can|tendency|that (r_nsubj) alter_11\VB\0|.|It|been|has (l_dobj) tendency_13\NN\6193203|can|changes|that (l_prep) towards_14\IN\0|the (l_pobj) arrhythmias_16\NNS\14103288|NONE
D002752_D006973 NONE chlorthalidone_43\NN\3214670|NONE (r_pobj) on_36\IN\0|a|similar|in (r_prep) period_35\NN\13575869|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN\697589|NONE (l_prep) in_7\IN\13603305|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
D011188_D003324 NONE potassium_25\NN\14625458| (r_npadvmod) conserving_27\VBG\2681795|NONE (r_amod) diuretic_28\JJ\3247620|a|( (r_amod) amiloride_30\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0| (r_prep) weeks_20\NNS\15113229|NONE (r_pobj) after_18\IN\0|disease|) (r_prep) known_14\VBN\0|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN\14061805|)|after
D011188_D003324 NONE potassium_38\NN\14625458| (r_npadvmod) losing_40\VBG\0|diuretic|(|)|a (r_amod) chlorthalidone_43\NN\3214670|NONE (r_pobj) on_36\IN\0|a|similar|in (r_prep) period_35\NN\13575869|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN\697589|NONE (l_conj) known_14\VBN\0|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN\14061805|)|after
D002752_D018879 CID chlorthalidone_6\NN\3214670|the (r_compound) phase_7\NN\15113229|period|increased|.|Compared|and|with|,|,|was (r_nsubjpass) associated_9\VBN\628491|NONE (l_prep) with_10\IN\0|period|increased|.|phase|Compared|and|,|,|was (l_pobj) frequency_13\NN\15286249|NONE (l_prep) of_14\IN\0|grading|an|and|increased (l_pobj) beats_17\NNS\8289449|NONE
D011188_D003327 NONE potassium_2\NN\14625458|.|,|in (r_conj) diuretics_0\NNS\3247620|NONE (l_prep) in_5\IN\13603305|.|,|potassium (l_pobj) disease_8\NN\14061805|NONE
D000584_D006973 NONE amiloride_30\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0| (r_prep) weeks_20\NNS\15113229|NONE (r_pobj) after_18\IN\0|disease|) (r_prep) known_14\VBN\0|was|excitability|and|,|in|period|Thus|and|. (r_conj) measured_6\VBN\697589|NONE (l_prep) in_7\IN\13603305|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
D011188_D006973 NONE potassium_2\NN\14625458|.|,|in (r_conj) diuretics_0\NNS\3247620|NONE (l_prep) in_5\IN\13603305|.|,|potassium (l_pobj) disease_8\NN\14061805|NONE (l_amod) hypertensive_6\JJ\10405694|coronary
D011188_D006973 NONE potassium_25\NN\14625458| (r_npadvmod) conserving_27\VBG\2681795|NONE (r_amod) diuretic_28\JJ\3247620|a|( (r_amod) amiloride_30\NN\0|NONE (r_pobj) with_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) of_21\IN\0| (r_prep) weeks_20\NNS\15113229|NONE (r_pobj) after_18\IN\0|disease|) (r_prep) known_14\VBN\0|was|excitability|and|,|in|period|Thus|and|. (r_conj) measured_6\VBN\697589|NONE (l_prep) in_7\IN\13603305|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
D011188_D006973 NONE potassium_38\NN\14625458| (r_npadvmod) losing_40\VBG\0|diuretic|(|)|a (r_amod) chlorthalidone_43\NN\3214670|NONE (r_pobj) on_36\IN\0|a|similar|in (r_prep) period_35\NN\13575869|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN\697589|NONE (l_prep) in_7\IN\13603305|was|excitability|and|,|period|Thus|and|.|known (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) hypertension_12\NN\14057371|NONE
D002752_D003324 NONE chlorthalidone_43\NN\3214670|NONE (r_pobj) on_36\IN\0|a|similar|in (r_prep) period_35\NN\13575869|was|excitability|and|,|in|Thus|and|.|known (r_conj) measured_6\VBN\697589|NONE (l_conj) known_14\VBN\0|was|excitability|and|,|in|period|Thus|and|. (l_dobj) disease_17\NN\14061805|)|after
D000584_D018879 NONE amiloride_2\NN\0|NONE (r_compound) treatment_3\NN\654885|NONE (r_pobj) to_1\IN\0|NONE (r_prep) compared_0\VBN\644583|period|increased|.|phase|and|with|,|,|was (r_prep) associated_9\VBN\628491|NONE (l_prep) with_10\IN\0|period|increased|.|phase|Compared|and|,|,|was (l_pobj) frequency_13\NN\15286249|NONE (l_prep) of_14\IN\0|grading|an|and|increased (l_pobj) beats_17\NNS\8289449|NONE
D011188_D017202 NONE potassium_6\NN\14625458| (r_npadvmod) losing_8\VBG\0|diuretic (r_amod) therapy_10\NN\657604|can|because|excitability (r_nsubj) increase_12\VB\13576355|minor|that|in|, (l_dobj) excitability_15\NN\5653575|can|therapy|because (l_prep) in_16\IN\13603305|electrical|myocardial (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|NONE (l_pobj) disease_21\NN\14061805|NONE
D011188_D017202 NONE potassium_28\NN\14625458|plasma (r_compound) concentrations_29\NNS\4916342|NONE (r_pobj) in_26\IN\13603305|increase|minor|that|, (r_prep) falls_25\VBZ\11692265|.|avoided|results (l_advcl) increase_12\VB\13576355|minor|that|in|, (l_dobj) excitability_15\NN\5653575|can|therapy|because (l_prep) in_16\IN\13603305|electrical|myocardial (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|NONE (l_pobj) disease_21\NN\14061805|NONE
3137399
D016685_D066126 NONE c._12\NNP\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|on|A|prospective (r_acl) study_2\NN\635850|NONE (l_prep) on_3\IN\0|A|prospective|induced (l_pobj) dependency_6\NN\24720|NONE (l_prep) of_7\IN\0|the|dose (l_pobj) cardiotoxicity_8\NN\0|NONE
D016685_D066126 NONE c_3\NNP\13714184|combined|Since|be|been|,|.|has (r_nsubjpass) suggested_9\VBN\1010118|NONE (l_xcomp) be_11\VB\14625458|combined|Since|been|,|.|has|C (l_acomp) cardiotoxic_12\JJ\0|to
D016685_D066126 NONE mmc_5\NN\0|mitomycin (r_appos) c_3\NNP\13714184|combined|Since|be|been|,|.|has (r_nsubjpass) suggested_9\VBN\1010118|NONE (l_xcomp) be_11\VB\14625458|combined|Since|been|,|.|has|C (l_acomp) cardiotoxic_12\JJ\0|to
D016685_D066126 NONE mmc_16\NN\0| (r_npadvmod) related_18\VBN\628491|NONE (r_amod) cardiotoxicity_19\NN\0|occurring|dependent|that|,|,|in
D016685_D006333 CID mmc_11\NNP\0|NONE (r_pobj) after_7\IN\0|One|.|failure (r_prep) developed_4\VBD\1753788|NONE (l_dobj) failure_6\NN\66216|One|after|.
D004317_D006333 CID doxorubicin_17\NN\2716866|m|and||mg (r_conj) mmc_11\NNP\0|NONE (r_pobj) after_7\IN\0|One|.|failure (r_prep) developed_4\VBD\1753788|NONE (l_dobj) failure_6\NN\66216|One|after|.
D004317_D066126 NONE doxorubicin_21\NN\2716866|NONE (r_dobj) following_20\VBG\8180190|NONE (r_pcomp) given_19\VBN\5892096|when|or|with|especially (r_conj) combined_16\VBN\2630189|Since|be|been|,|.|has|C (r_advcl) suggested_9\VBN\1010118|NONE (l_xcomp) be_11\VB\14625458|combined|Since|been|,|.|has|C (l_acomp) cardiotoxic_12\JJ\0|to
D004317_D066126 NONE doxorubicin_47\NN\2716866|NONE (r_pobj) with_46\IN\0|)|also|(|previously (r_prep) treated_45\VBN\2376958|NONE (r_acl) patients_38\NNS\9898892|mainly (r_pobj) in_37\IN\13603305|occurring|dependent|that|cardiotoxicity|,|, (r_prep) is_20\VBZ\0|we|Based|.|, (l_nsubj) cardiotoxicity_19\NN\0|occurring|dependent|that|,|,|in
761833
D000641_D003128 NONE ammonia_2\NN\14940386|in (r_compound) coma_3\NN\5678932|NONE
D000641_D003128 NONE ammonia_0\NN\14940386|NONE (r_compound) coma_1\NN\5678932|.|was|in
D000641_D003128 NONE ammonia_18\NN\14940386|the (r_compound) coma_19\NN\5678932|nor|affect|not|did
D000641_D003128 NONE ammonia_26\NN\14940386|the|blood (r_compound) concentrations_27\NNS\4916342|NONE (r_dobj) affect_21\VB\26192|nor|coma|not|did (r_conj) prevent_16\VB\0|infusion|.|raise (l_dobj) coma_19\NN\5678932|nor|affect|not|did
D000641_D003128 NONE ammonia_14\NN\14940386|NONE (r_pobj) on_10\IN\0||coma|L|and (r_prep) dopa_9\NN\14601829|NONE (l_conj) coma_18\NN\5678932||L|and|on
D000641_D003128 NONE ammonia_17\NN\14940386|the (r_compound) coma_18\NN\5678932||L|and|on
D000641_D003128 NONE ammonia_8\NN\14940386|NONE (r_pobj) in_4\IN\13603305|the|and|prevention (r_prep) reduction_3\NN\351485|be|can|.|for|Thus|by|,|, (l_conj) prevention_11\NN\1073995|in|the|and (l_prep) of_12\IN\0|the|after (l_pobj) coma_14\NN\5678932|NONE
D000641_D003128 NONE ammonia_13\NN\14940386|NONE (r_compound) coma_14\NN\5678932|NONE
D064751_D003128 NONE salt_19\NN\14818238|the (r_compound) injection_20\NN\320852|minutes (r_pobj) before_16\IN\0|coma|was|.|with (r_prep) prevented_3\VBN\0|NONE (l_nsubjpass) coma_1\NN\5678932|was|before|.|with
D007980_D001927 NONE dopa_18\NNP\14601829|NONE (r_dobj) receiving_15\VBG\2210855|encephalopathic|some (r_acl) patients_14\NNS\9898892|NONE (l_amod) encephalopathic_13\JJ\0|some|receiving
D000643_D003128 CID nh4cl_17\NN\0|NONE (r_pobj) of_14\IN\0|an (r_prep) intraperitonealinjection_13\NN\0|NONE (r_pobj) of_11\IN\0| (r_prep) minutes_10\NNS\6502378|NONE (r_pobj) within_6\IN\0|NONE (r_prep) rats_5\NNS\2329401|NONE (r_pobj) in_4\IN\13603305|.|was|coma (r_prep) produced_3\VBN\1617192|NONE (l_nsubjpass) coma_1\NN\5678932|.|was|in
D007980_D003128 NONE dopa_9\NNP\14601829|NONE (r_pobj) by_6\IN\0|NONE (r_prep) rats_5\NNS\2329401|NONE (r_pobj) in_4\IN\13603305|ammonia (r_prep) coma_3\NN\5678932|NONE
D007980_D003128 NONE dopa_9\NN\14601829|NONE (r_pobj) with_4\IN\0|coma|was|before|. (r_prep) prevented_3\VBN\0|NONE (l_nsubjpass) coma_1\NN\5678932|was|before|.|with
D007980_D003128 NONE dopa_9\NN\14601829|NONE (l_conj) coma_18\NN\5678932||L|and|on
D007980_D003128 NONE dopa_18\NNP\14601829|NONE (r_pobj) after_15\IN\0|the|of (r_prep) prevention_11\NN\1073995|in|the|and (l_prep) of_12\IN\0|the|after (l_pobj) coma_14\NN\5678932|NONE
D004298_D003128 NONE dopamine_3\NN\14807737|NONE (r_pobj) of_2\IN\0|Intraventricular (r_prep) infusion_1\NN\14589223|prevent|.|raise (r_nsubj) sufficient_4\JJ\0|NONE (l_conj) prevent_16\VB\0|infusion|.|raise (l_dobj) coma_19\NN\5678932|nor|affect|not|did
D004298_D003128 NONE dopamine_9\NN\14807737|to|to (r_dobj) raise_6\VB\5108947|prevent|infusion|. (r_xcomp) sufficient_4\JJ\0|NONE (l_conj) prevent_16\VB\0|infusion|.|raise (l_dobj) coma_19\NN\5678932|nor|affect|not|did
D004298_D003128 NONE dopamine_29\NN\14807737|NONE (r_pobj) of_28\IN\0|the|on|peripheral (r_prep) effect_27\NN\34213|NONE (r_pobj) by_24\IN\0|be|can|.|for|Thus|reduction|,|, (r_agent) accounted_22\VBN\2604760|NONE (l_nsubjpass) reduction_3\NN\351485|be|can|.|for|Thus|by|,|, (l_conj) prevention_11\NN\1073995|in|the|and (l_prep) of_12\IN\0|the|after (l_pobj) coma_14\NN\5678932|NONE
8278214
D009020_D006930 CID morphine_11\NN\2707683|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treated_7\VBN\2376958|terminal|cancer (r_acl) patients_6\NNS\9898892|NONE (r_pobj) in_3\IN\13603305|NONE (r_prep) myoclonus_2\NN\14360459|.|and (r_conj) hyperalgesia_0\NNP\0|NONE
D009020_D006930 CID morphine_16\NN\2707683|NONE (r_pobj) of_14\IN\0|high (r_prep) doses_13\NNS\3740161|NONE (r_pobj) with_11\IN\0|patients|developed|. (r_prep) treated_10\VBN\2376958|NONE (l_advcl) developed_17\VBN\1753788|patients|with|. (l_dobj) hyperalgesia_18\NN\0|NONE
D009020_D006930 CID morphine_16\NN\2707683|NONE (r_pobj) of_15\IN\0|high (r_prep) doses_14\NNS\3740161|and|/|hyperalgesia (r_conj) myoclonus_11\NN\14360459|NONE (l_nmod) hyperalgesia_9\NN\0|doses|and|/
D009020_D006930 CID morphine_27\NN\2707683|role|that|,|for (r_nsubj) plays_33\VBZ\7007684|support|.|,|are (r_ccomp) indicates_25\VBZ\952524|NONE (l_advcl) are_17\VBP\13600404|support|.|,|plays (l_nsubj) descriptions_4\NNS\6722453|Although|available (l_prep) of_5\IN\0|clinical|few (l_pobj) relationship_7\NN\31921|NONE (l_prep) between_8\IN\0|the (l_pobj) myoclonus_11\NN\14360459|NONE (l_nmod) hyperalgesia_9\NN\0|doses|and|/
D009020_D009369 NONE morphine_11\NN\2707683|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treated_7\VBN\2376958|terminal|cancer (r_acl) patients_6\NNS\9898892|NONE (l_compound) cancer_5\NN\14239425|terminal|treated
D009020_D009369 NONE morphine_16\NN\2707683|NONE (r_pobj) of_14\IN\0|high (r_prep) doses_13\NNS\3740161|NONE (r_pobj) with_11\IN\0|patients|developed|. (r_prep) treated_10\VBN\2376958|NONE (l_nsubj) patients_2\NNS\9898892|with|developed|. (l_compound) cancer_1\NN\14239425|in|Eight
D009020_D009207 CID morphine_11\NN\2707683|NONE (r_pobj) with_8\IN\0|NONE (r_prep) treated_7\VBN\2376958|terminal|cancer (r_acl) patients_6\NNS\9898892|NONE (r_pobj) in_3\IN\13603305|NONE (r_prep) myoclonus_2\NN\14360459|.|and
D009020_D009207 CID morphine_16\NN\2707683|NONE (r_pobj) of_15\IN\0|high (r_prep) doses_14\NNS\3740161|and|/|hyperalgesia (r_conj) myoclonus_11\NN\14360459|NONE
D009020_D009207 CID morphine_27\NN\2707683|role|that|,|for (r_nsubj) plays_33\VBZ\7007684|support|.|,|are (r_ccomp) indicates_25\VBZ\952524|NONE (l_advcl) are_17\VBP\13600404|support|.|,|plays (l_nsubj) descriptions_4\NNS\6722453|Although|available (l_prep) of_5\IN\0|clinical|few (l_pobj) relationship_7\NN\31921|NONE (l_prep) between_8\IN\0|the (l_pobj) myoclonus_11\NN\14360459|NONE
10728962
D014667_D006333 NONE vasopressin_0\NN\5407119|NONE (l_prep) in_1\IN\13603305|. (l_pobj) treatment_3\NN\654885|NONE (l_prep) of_4\IN\0|the (l_pobj) hypotension_8\NN\14057371|NONE (l_prep) in_9\IN\13603305|induced (l_pobj) failure_12\NN\66216|NONE
D014667_D006333 NONE vasopressin_16\NN\5407119|NONE (r_pobj) of_15\IN\0|low (r_prep) doses_14\NNS\3740161|In|pressure|.|without (r_nsubj) restored_17\VBD\1631072|NONE (l_prep) in_0\IN\13603305|doses|pressure|.|without (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) failure_5\NN\66216|NONE
D020105_D006333 NONE milrinone_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|in (r_amod) hypotension_8\NN\14057371|NONE (l_prep) in_9\IN\13603305|induced (l_pobj) failure_12\NN\66216|NONE
D020105_D006333 NONE milrinone_7\NN\0|such (l_prep) in_8\IN\13603305|NONE (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_11\IN\0|the (l_pobj) failure_14\NN\66216|NONE
D020105_D006333 NONE milrinone_11\NN\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) after_8\IN\0|NONE (r_prep) hypotension_7\NN\14057371|NONE (r_pobj) with_6\IN\0|decompensated|heart (r_prep) failure_5\NN\66216|NONE
D020105_D006333 NONE milrinone_26\NN\0|NONE (r_pobj) of_25\IN\0|the|inotropic (r_prep) effect_24\NN\34213|NONE (r_dobj) inhibiting_21\VBG\2510337|NONE (r_pcomp) without_20\IN\0|doses|In|pressure|. (r_prep) restored_17\VBD\1631072|NONE (l_prep) in_0\IN\13603305|doses|pressure|.|without (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) failure_5\NN\66216|NONE
D020105_D007022 CID milrinone_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|in (r_amod) hypotension_8\NN\14057371|NONE
D020105_D007022 CID milrinone_7\NN\0|such (r_pobj) as_6\IN\14622893|phosphodiesterase (r_prep) inhibitors_4\NNS\20090|NONE (r_pobj) of_2\IN\0|The (r_prep) use_1\NN\407535|is|frequently|.|cause (r_nsubjpass) restricted_17\VBN\235368|NONE (l_advcl) cause_20\VBP\7323922|is|use|frequently|. (l_dobj) vasodilation_21\NN\365995|because|they (l_conj) hypotension_23\NN\14057371|and
D020105_D007022 CID milrinone_11\NN\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) after_8\IN\0|NONE (r_prep) hypotension_7\NN\14057371|NONE
D020105_D007022 CID milrinone_26\NN\0|NONE (r_pobj) of_25\IN\0|the|inotropic (r_prep) effect_24\NN\34213|NONE (r_dobj) inhibiting_21\VBG\2510337|NONE (r_pcomp) without_20\IN\0|doses|In|pressure|. (r_prep) restored_17\VBD\1631072|NONE (l_prep) in_0\IN\13603305|doses|pressure|.|without (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) failure_5\NN\66216|NONE (l_prep) with_6\IN\0|decompensated|heart (l_pobj) hypotension_7\NN\14057371|NONE
D014667_D007022 CID vasopressin_0\NN\5407119|NONE (l_prep) in_1\IN\13603305|. (l_pobj) treatment_3\NN\654885|NONE (l_prep) of_4\IN\0|the (l_pobj) hypotension_8\NN\14057371|NONE
D014667_D007022 CID vasopressin_16\NN\5407119|NONE (r_pobj) of_15\IN\0|low (r_prep) doses_14\NNS\3740161|In|pressure|.|without (r_nsubj) restored_17\VBD\1631072|NONE (l_prep) in_0\IN\13603305|doses|pressure|.|without (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) failure_5\NN\66216|NONE (l_prep) with_6\IN\0|decompensated|heart (l_pobj) hypotension_7\NN\14057371|NONE
343678
D006514_D006509 NONE antigen_43\NN\20090|HBsAG)positive|( (r_nmod) donors_46\NNS\9608709|NONE (r_pobj) to_39\IN\0|stick (r_prep) exposure_38\NN\5042871|NONE (r_pobj) after_34\IN\0|hepatitis (r_prep) preventing_30\VBG\0|NONE (r_pcomp) in_29\IN\13603305|relative|their (r_prep) efficacies_28\NNS\5199286|to (r_dobj) assess_25\VB\5220461|were|globulin|.|in (r_advcl) examined_15\VBN\0|NONE (l_nsubjpass) globulin_3\NN\14736972|were|assess|.|in (l_compound) b_1\NN\1355326|globulin|and|HBIG|immune
D006514_D006509 NONE antigen_43\NN\20090|HBsAG)positive|( (r_nmod) donors_46\NNS\9608709|NONE (r_pobj) to_39\IN\0|stick (r_prep) exposure_38\NN\5042871|NONE (r_pobj) after_34\IN\0|hepatitis (r_prep) preventing_30\VBG\0|NONE (l_dobj) hepatitis_33\NN\14127211|after
D006514_D006509 NONE hbsag)-positive_45\JJ\0|(|antigen (r_compound) donors_46\NNS\9608709|NONE (r_pobj) to_39\IN\0|stick (r_prep) exposure_38\NN\5042871|NONE (r_pobj) after_34\IN\0|hepatitis (r_prep) preventing_30\VBG\0|NONE (r_pcomp) in_29\IN\13603305|relative|their (r_prep) efficacies_28\NNS\5199286|to (r_dobj) assess_25\VB\5220461|were|globulin|.|in (r_advcl) examined_15\VBN\0|NONE (l_nsubjpass) globulin_3\NN\14736972|were|assess|.|in (l_compound) b_1\NN\1355326|globulin|and|HBIG|immune
D006514_D006509 NONE hbsag)-positive_45\JJ\0|(|antigen (r_compound) donors_46\NNS\9608709|NONE (r_pobj) to_39\IN\0|stick (r_prep) exposure_38\NN\5042871|NONE (r_pobj) after_34\IN\0|hepatitis (r_prep) preventing_30\VBG\0|NONE (l_dobj) hepatitis_33\NN\14127211|after
430165
D010672_D064420 NONE diphenylhydantoin_7\JJ\3550533|NONE (r_compound) toxicity_8\NN\13576101|NONE
D010672_D064420 NONE dph_13\NNP\6702458|NONE (r_compound) toxicity_14\NN\13576101|to|as
D010672_D002526 CID diphenylhydantoin_6\NN\3550533|(|DPH|) (r_nmod) overdose_10\NN\84738|NONE (r_pobj) of_5\IN\0|the|common|side (r_prep) effects_4\NNS\13245626|NONE (r_pobj) among_0\IN\0|signs|.|,|those (r_prep) are_18\VBP\13600404|NONE (l_nsubj) those_19\DT\0|signs|.|,|Among (l_prep) of_20\IN\0|NONE (l_pobj) dysfunction_22\NN\14204950|NONE
D010672_D002526 CID dph_8\NNP\6702458|(|)|diphenylhydantoin (r_nmod) overdose_10\NN\84738|NONE (r_pobj) of_5\IN\0|the|common|side (r_prep) effects_4\NNS\13245626|NONE (r_pobj) among_0\IN\0|signs|.|,|those (r_prep) are_18\VBP\13600404|NONE (l_nsubj) those_19\DT\0|signs|.|,|Among (l_prep) of_20\IN\0|NONE (l_pobj) dysfunction_22\NN\14204950|NONE
D010672_D062787 CID diphenylhydantoin_6\NN\3550533|(|DPH|) (r_nmod) overdose_10\NN\84738|NONE
D010672_D062787 CID dph_8\NNP\6702458|(|)|diphenylhydantoin (r_nmod) overdose_10\NN\84738|NONE
D010672_D062787 CID dph_10\NNP\6702458|NONE (r_compound) overdose_11\NN\84738|to
D010672_D010291 CID diphenylhydantoin_7\JJ\3550533|NONE (r_compound) toxicity_8\NN\13576101|NONE (r_pobj) of_6\IN\0|rare|a (r_prep) manifestation_5\NN\7321772|Transient|.|: (r_appos) hemiparesis_1\NN\0|NONE
D010672_D010291 CID dph_10\NNP\6702458|NONE (r_compound) overdose_11\NN\84738|to (r_pobj) due_8\IN\5174653|who|hemiparesis (r_prep) suffered_5\VBD\2110220|.|are|patients (l_dobj) hemiparesis_7\NN\0|who|due
D010672_D001927 NONE dph_13\NNP\6702458|NONE (r_compound) toxicity_14\NN\13576101|to|as (r_dobj) manifest_12\VB\6479665|NONE (r_xcomp) liable_10\JJ\0|patients|that (r_acomp) are_9\VBP\13600404|It|.|is (l_nsubj) patients_4\NNS\9898892|liable|that (l_prep) with_5\IN\0|NONE (l_pobj) damage_8\NN\7296428|NONE
1628552
D002738_D006327 NONE chloroquine_0\NNP\2721948|:|block (r_nsubj) related_1\VBD\628491|case|. (l_dobj) block_4\NN\21939|Chloroquine|:
D002738_D006327 NONE chloroquine_5\NN\2721948|NONE (r_amod) retinopathy_6\NN\14252864|NONE (r_pobj) of_4\IN\0|NONE (r_prep) features_3\NNS\5849040|assessment (r_dobj) revealed_2\VBD\2137132|,|.|assessment|features (r_ccomp) revealed_10\VBD\2137132|NONE (l_dobj) features_11\NNS\5849040|,|.|assessment|revealed (l_conj) block_19\NN\21939|and|of
D002738_D006327 NONE chloroquine_15\NN\2721948|NONE (r_amod) discontinuation_16\NN\209943|NONE (r_dobj) following_14\VBG\8180190|failure|spontaneously|. (r_prep) resolved_12\VBD\352826|by|block|was|and (r_conj) treated_4\VBN\2376958|NONE (l_nsubjpass) block_2\NN\21939|by|resolved|was|and
D002738_D015354 NONE chloroquine_9\NN\2721948|regular (r_amod) ingestion_10\NN\13440063|NONE (r_pobj) of_7\IN\0|NONE (r_prep) history_6\NN\15120823|NONE (r_pobj) with_5\IN\0|African|A|old|year (r_prep) woman_4\NN\9605289|with|. (r_nsubj) presented_11\VBN\2137132|NONE (l_prep) with_12\IN\0|woman|. (l_pobj) deterioration_14\NN\14560612|NONE (l_prep) of_15\IN\0|progressive|fatiguability|, (l_pobj) vision_16\NN\5767733|NONE
D002738_D013575 CID chloroquine_9\NN\2721948|regular (r_amod) ingestion_10\NN\13440063|NONE (r_pobj) of_7\IN\0|NONE (r_prep) history_6\NN\15120823|NONE (r_pobj) with_5\IN\0|African|A|old|year (r_prep) woman_4\NN\9605289|with|. (r_nsubj) presented_11\VBN\2137132|NONE (l_prep) with_12\IN\0|woman|. (l_pobj) deterioration_14\NN\14560612|NONE (l_conj) fatiguability_19\NN\0|progressive|,|of (l_conj) dyspnoea_21\NN\14299637|,|easy (l_conj) dizziness_23\NN\14299637|, (l_acl) progressing_24\VBG\252019|NONE (l_prep) to_25\IN\0|NONE (l_pobj) attacks_27\NNS\955060|NONE
D002738_D004417 CID chloroquine_9\NN\2721948|regular (r_amod) ingestion_10\NN\13440063|NONE (r_pobj) of_7\IN\0|NONE (r_prep) history_6\NN\15120823|NONE (r_pobj) with_5\IN\0|African|A|old|year (r_prep) woman_4\NN\9605289|with|. (r_nsubj) presented_11\VBN\2137132|NONE (l_prep) with_12\IN\0|woman|. (l_pobj) deterioration_14\NN\14560612|NONE (l_conj) fatiguability_19\NN\0|progressive|,|of (l_conj) dyspnoea_21\NN\14299637|,|easy
D002738_D004244 CID chloroquine_9\NN\2721948|regular (r_amod) ingestion_10\NN\13440063|NONE (r_pobj) of_7\IN\0|NONE (r_prep) history_6\NN\15120823|NONE (r_pobj) with_5\IN\0|African|A|old|year (r_prep) woman_4\NN\9605289|with|. (r_nsubj) presented_11\VBN\2137132|NONE (l_prep) with_12\IN\0|woman|. (l_pobj) deterioration_14\NN\14560612|NONE (l_conj) fatiguability_19\NN\0|progressive|,|of (l_conj) dyspnoea_21\NN\14299637|,|easy (l_conj) dizziness_23\NN\14299637|,
D002738_D005221 CID chloroquine_9\NN\2721948|regular (r_amod) ingestion_10\NN\13440063|NONE (r_pobj) of_7\IN\0|NONE (r_prep) history_6\NN\15120823|NONE (r_pobj) with_5\IN\0|African|A|old|year (r_prep) woman_4\NN\9605289|with|. (r_nsubj) presented_11\VBN\2137132|NONE (l_prep) with_12\IN\0|woman|. (l_pobj) deterioration_14\NN\14560612|NONE (l_conj) fatiguability_19\NN\0|progressive|,|of
D002738_D001766 CID chloroquine_0\NNP\2721948|:|block (r_nsubj) related_1\VBD\628491|case|. (l_dobj) block_4\NN\21939|Chloroquine|: (l_prep) with_5\IN\0|heart|complete (l_pobj) blindness_6\NN\14552802|NONE
D002738_D006333 CID chloroquine_5\NN\2721948|NONE (r_amod) retinopathy_6\NN\14252864|NONE (r_pobj) of_4\IN\0|NONE (r_prep) features_3\NNS\5849040|assessment (r_dobj) revealed_2\VBD\2137132|,|.|assessment|features (r_ccomp) revealed_10\VBD\2137132|NONE (l_dobj) features_11\NNS\5849040|,|.|assessment|revealed (l_prep) of_12\IN\0|block|and (l_pobj) failure_14\NN\66216|NONE
D002738_D006333 CID chloroquine_15\NN\2721948|NONE (r_amod) discontinuation_16\NN\209943|NONE (r_dobj) following_14\VBG\8180190|failure|spontaneously|. (r_prep) resolved_12\VBD\352826|by|block|was|and (l_nsubj) failure_11\NN\66216|following|spontaneously|.
D002738_D002037 CID chloroquine_5\NN\2721948|NONE (r_amod) retinopathy_6\NN\14252864|NONE (r_pobj) of_4\IN\0|NONE (r_prep) features_3\NNS\5849040|assessment (r_dobj) revealed_2\VBD\2137132|,|.|assessment|features (r_ccomp) revealed_10\VBD\2137132|NONE (l_dobj) features_11\NNS\5849040|,|.|assessment|revealed (l_conj) block_19\NN\21939|and|of (l_prep) with_20\IN\0|heart|a|complete (l_pobj) pattern_25\NN\5726345|NONE (l_compound) block_24\NN\21939|bundle|right
D002738_D012164 CID chloroquine_5\NN\2721948|NONE (r_amod) retinopathy_6\NN\14252864|NONE
1445986
D015313_D000743 CID cefotetan_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|hemolytic|immune|. (r_amod) anemia_5\NN\14189204|NONE
D010406_D000743 NONE penicillins_17\NNS\2716866|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|has|.|primarily|been|anemia (r_prep) described_12\VBN\1001294|NONE (l_nsubjpass) anemia_2\NN\14189204|in|has|.|primarily|been
D002511_D000743 NONE cephalosporins_22\NNS\2716866|and (r_conj) penicillins_17\NNS\2716866|NONE (r_dobj) receiving_16\VBG\2210855|NONE (r_acl) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|has|.|primarily|been|anemia (r_prep) described_12\VBN\1001294|NONE (l_nsubjpass) anemia_2\NN\14189204|in|has|.|primarily|been
D015313_D000740 NONE cefotetan_10\NN\0|while (r_dobj) receiving_8\VBG\2210855|anemia|who (r_advcl) developed_5\VBD\1753788|a (l_dobj) anemia_6\NN\14189204|receiving|who
20042557
D015742_D011183 CID propofol_4\NN\0|light (r_amod) sedation_5\NN\14034177|NONE (r_pobj) of_2\IN\0|The (r_prep) use_1\NN\407535|prevalence|. (r_nsubj) decreased_6\VBD\169651|NONE (l_dobj) prevalence_8\NN\4764412|.|use (l_prep) of_9\IN\0|by|the|compared (l_pobj) delirium_11\NN\14391660|NONE
D015742_D003704 NONE propofol_39\NN\0|NONE (r_amod) sedation_40\NN\14034177|NONE (r_pobj) with_38\IN\0|spinal (r_prep) anesthesia_37\NN\14034177|NONE (r_pobj) under_35\IN\0|fracture (r_prep) repair_34\NN\248977|who (r_dobj) underwent_31\VBD\109660|or|dementia|preoperative (r_relcl) delirium_26\NN\14391660|NONE (l_conj) dementia_29\NN\14395018|or|underwent|preoperative
D015742_D006620 NONE propofol_39\NN\0|NONE (r_amod) sedation_40\NN\14034177|NONE (r_pobj) with_38\IN\0|spinal (r_prep) anesthesia_37\NN\14034177|NONE (r_pobj) under_35\IN\0|fracture (r_prep) repair_34\NN\248977|who (l_compound) fracture_33\NN\14285662|under
D015742_D003693 CID propofol_39\NN\0|NONE (r_amod) sedation_40\NN\14034177|NONE (r_pobj) with_38\IN\0|spinal (r_prep) anesthesia_37\NN\14034177|NONE (r_pobj) under_35\IN\0|fracture (r_prep) repair_34\NN\248977|who (r_dobj) underwent_31\VBD\109660|or|dementia|preoperative (r_relcl) delirium_26\NN\14391660|NONE
D015742_D003693 CID propofol_4\NN\0|light (r_amod) sedation_5\NN\14034177|NONE (r_pobj) of_2\IN\0|The (r_prep) use_1\NN\407535|prevalence|. (r_nsubj) decreased_6\VBD\169651|NONE (l_dobj) prevalence_8\NN\4764412|.|use (l_prep) of_9\IN\0|by|the|compared (l_pobj) delirium_11\NN\14391660|NONE
10840460
D009020_D001523 NONE morphine_0\NNP\2707683|.|disorders|dependently (r_nsubj) reversed_4\VBD\109660|NONE (l_dobj) disorders_7\NNS\14034177|.|Morphine|dependently
D009020_D004487 NONE morphine_6\NN\2707683|NONE (r_pobj) of_5\IN\0|,|modifications (r_prep) administration_4\NN\1133281|NONE (l_appos) modifications_9\NNS\191142|of|, (l_prep) as_16\IN\14622893|histological|of|, (l_pobj) edema_21\NN\14315192|such
D003520_D059265 NONE cyclophosphamide_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|in|.|approach|: (r_amod) cystitis_3\NN\14566129|NONE (l_appos) approach_12\NN\940842|in|.|induced|: (l_prep) to_13\IN\0|behavioral (l_pobj) model_16\NN\5888929|NONE (l_prep) of_17\IN\0|a|new (l_pobj) pain_19\NN\14299637|NONE
D003520_D059265 NONE cp_10\NNP\0| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) cystitis_13\NN\14566129|NONE (r_pobj) of_9\IN\0|this|experimental (r_prep) model_8\NN\5888929|that|,|may|allowing|model (r_nsubj) be_15\VB\14625458|,|Overall|results|. (l_attr) model_20\NN\5888929|that|,|model|may|allowing (l_prep) of_21\IN\0|new|interesting|an|behavioral (l_pobj) pain_24\NN\14299637|NONE
D003520_D010146 CID cp_10\NNP\0| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) cystitis_13\NN\14566129|NONE (r_pobj) of_9\IN\0|this|experimental (r_prep) model_8\NN\5888929|that|,|may|allowing|model (r_nsubj) be_15\VB\14625458|,|Overall|results|. (l_advcl) allowing_26\VBG\0|that|,|model|may|model (l_dobj) understanding_29\NN\5804793|NONE (l_prep) of_30\IN\0|a|better|approach|and (l_pobj) syndromes_33\NNS\5870365|NONE
D000171_D003556 NONE acrolein_22\NN\14584765|NONE (r_pobj) through_17\IN\0|to|effects (r_prep) produce_10\VB\7555863|NONE (r_xcomp) known_8\VBN\0|antitumoral|an (r_acl) agent_7\NN\7347|,|CP|, (r_appos) cyclophosphamide_0\NNP\0|was|induce|. (r_nsubjpass) used_25\VBN\0|NONE (l_xcomp) induce_27\VB\1627355|Cyclophosphamide|was|. (l_dobj) cystitis_28\NN\14566129|to
D003520_D003556 CID cyclophosphamide_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|in|.|approach|: (r_amod) cystitis_3\NN\14566129|NONE
D003520_D003556 CID cyclophosphamide_0\NNP\0|was|induce|. (r_nsubjpass) used_25\VBN\0|NONE (l_xcomp) induce_27\VB\1627355|Cyclophosphamide|was|. (l_dobj) cystitis_28\NN\14566129|to
D003520_D003556 CID cp_2\NNP\0|,|,|agent (r_appos) cyclophosphamide_0\NNP\0|was|induce|. (r_nsubjpass) used_25\VBN\0|NONE (l_xcomp) induce_27\VB\1627355|Cyclophosphamide|was|. (l_dobj) cystitis_28\NN\14566129|to
D003520_D003556 CID cp_10\NNP\0| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) cystitis_13\NN\14566129|NONE
11860278
D004298_D004827 NONE dopamine_0\NNP\14807737|role|.|in|, (r_nsubj) plays_12\VBZ\7007684|NONE (l_prep) in_16\IN\13603305|role|.|Dopamine|, (l_pobj) control_18\NN\5190804|NONE (l_prep) of_19\IN\0|the (l_pobj) seizures_21\NNS\14081375|NONE
D004298_D004827 NONE da_2\NNP\10484858|through|, (r_appos) dopamine_0\NNP\14807737|role|.|in|, (r_nsubj) plays_12\VBZ\7007684|NONE (l_prep) in_16\IN\13603305|role|.|Dopamine|, (l_pobj) control_18\NN\5190804|NONE (l_prep) of_19\IN\0|the (l_pobj) seizures_21\NNS\14081375|NONE
D004298_D004827 NONE da_11\NNP\10484858|NONE (r_compound) receptors_12\NNS\5225602|NONE (r_pobj) of_10\IN\0|in|the (r_prep) role_9\NN\719494|NONE (l_prep) in_13\IN\13603305|the|of (l_pobj) occurrence_15\NN\29378|NONE (l_prep) of_16\IN\0|the (l_pobj) death_22\NN\7296428|NONE (l_amod) induced_19\VBN\1627355|cell|neuronal (l_npadvmod) epilepsy_17\NN\14085708|
D000109_D012640 NONE acetylcholine_16\NN\14807558|both|and (r_conj) glutamate_14\NN\15010703|NONE (r_pobj) by_12\IN\0|NONE (r_agent) induced_11\VBN\1627355|NONE (r_acl) seizures_10\NNS\14081375|NONE
D010862_D020258 NONE pilocarpine_18\NN\14712692|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|/|DR (r_acl) mice_12\NNS\2329401|NONE (r_pobj) in_9\IN\13603305|neurotoxicity|and (r_prep) seizures_6\NNS\14081375|NONE (l_conj) neurotoxicity_8\NN\0|and|in
D010862_D012640 CID pilocarpine_18\NN\14712692|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|/|DR (r_acl) mice_12\NNS\2329401|NONE (r_pobj) in_9\IN\13603305|neurotoxicity|and (r_prep) seizures_6\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_2\NN\14712692| (r_npadvmod) induced_4\VBN\1627355|NONE (r_amod) seizures_5\NNS\14081375|in|,|.|However
D018698_D012640 NONE glutamate_14\NN\15010703|NONE (r_pobj) by_12\IN\0|NONE (r_agent) induced_11\VBN\1627355|NONE (r_acl) seizures_10\NNS\14081375|NONE
D007608_D012640 CID ka_23\NNP\0|NONE (r_pobj) to_22\IN\0|NONE (r_prep) comparison_21\NN\635850|NONE (r_pobj) in_20\IN\13603305|widespread|neuronal|a|in (r_prep) death_12\NN\7296428|NONE (r_pobj) in_7\IN\13603305|seizures|,|.|However (r_prep) result_6\VBP\34213|NONE (l_nsubj) seizures_5\NNS\14081375|in|,|.|However
2819587
11302406
D015725_D017180 NONE fluconazole_4\NN\0|was|when (r_nsubjpass) discontinued_6\VBN\0|TDP (r_advcl) resolved_2\VBD\352826|tachycardia|and|:|patient|,|however|until|have|; (r_ccomp) continued_12\VBD\2367363|NONE (l_conj) tachycardia_21\NN\14110674|resolved|and|:|patient|,|however|until|have|;
D015725_D017180 NONE fluconazole_4\NN\0|was|when (r_nsubjpass) discontinued_6\VBN\0|TDP (r_advcl) resolved_2\VBD\352826|tachycardia|and|:|patient|,|however|until|have|; (r_ccomp) continued_12\VBD\2367363|NONE (l_conj) tachycardia_21\NN\14110674|resolved|and|:|patient|,|however|until|have|; (l_appos) nsvt_23\NNP\0|)|nonsustained|ventricular|(
D015725_D017180 NONE fluconazole_22\NN\0|.|strongly|as|followed (r_dobj) suggests_21\VBZ\1010118|NONE (l_csubj) followed_9\VBN\1835496|.|strongly|fluconazole|as (l_nsubj) disappearance_2\NN\42757|stopped|by (l_prep) of_3\IN\0|complete|contractions|The|and (l_pobj) nsvt_4\NNP\0|NONE
D011188_D003866 NONE potassium_10\NN\14625458|rectifier (r_compound) currents_11\NNS\11449002|rapidly (r_dobj) activating_7\VBG\407535|NONE (r_pcomp) of_5\IN\0|NONE (r_prep) depression_4\NN\14373582|.|mechanism
D015725_D016171 CID fluconazole_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) torsade_3\NN\0|de|. (r_nmod) pointes_5\FW\831651|NONE
D015725_D016171 CID fluconazole_5\NN\0| (r_advmod) associated_7\VBN\628491|de|(|)|torsade|TDP (r_amod) pointes_10\FW\831651|NONE
D015725_D016171 CID fluconazole_5\NN\0| (r_advmod) associated_7\VBN\628491|de|(|)|torsade|TDP (r_amod) pointes_10\FW\831651|NONE (l_appos) tdp_12\NNP\0|de|(|)|torsade|associated
D015725_D016171 CID fluconazole_5\NN\0| (r_advmod) associated_7\VBN\628491|de|(|)|torsade|TDP (r_amod) pointes_10\FW\831651|NONE (r_pobj) of_4\IN\0|a (r_prep) case_3\NN\7283608|To|discuss|and|. (r_dobj) present_1\VB\28270|NONE (l_conj) discuss_15\VB\7466557|To|case|and|. (l_dobj) role_18\NN\719494|NONE (l_prep) in_19\IN\13603305|fluconazole (l_pcomp) causing_20\VBG\30358|NONE (l_dobj) tdp_21\NNP\0|NONE
D015725_D016171 CID fluconazole_16\NN\0|in (r_poss) role_18\NN\719494|NONE (r_dobj) discuss_15\VB\7466557|To|case|and|. (r_conj) present_1\VB\28270|NONE (l_dobj) case_3\NN\7283608|To|discuss|and|. (l_prep) of_4\IN\0|a (l_pobj) pointes_10\FW\831651|NONE
D015725_D016171 CID fluconazole_16\NN\0|in (r_poss) role_18\NN\719494|NONE (r_dobj) discuss_15\VB\7466557|To|case|and|. (r_conj) present_1\VB\28270|NONE (l_dobj) case_3\NN\7283608|To|discuss|and|. (l_prep) of_4\IN\0|a (l_pobj) pointes_10\FW\831651|NONE (l_appos) tdp_12\NNP\0|de|(|)|torsade|associated
D015725_D016171 CID fluconazole_16\NN\0|in (r_poss) role_18\NN\719494|NONE (l_prep) in_19\IN\13603305|fluconazole (l_pcomp) causing_20\VBG\30358|NONE (l_dobj) tdp_21\NNP\0|NONE
D015725_D016171 CID fluconazole_21\NN\0|NONE (r_dobj) commencing_19\VBG\0|days (r_pcomp) after_18\IN\0|woman|isolated (r_prep) glabrata_8\NNS\0|NONE (l_xcomp) isolated_9\VBN\2512305|after|woman (l_prep) from_10\IN\0|NONE (l_pobj) abscess_13\NN\14299637|NONE (l_acl) developed_14\VBD\1753788|presacral|a (l_dobj) tdp_15\NNP\0|NONE
D015725_D016171 CID fluconazole_33\NN\0|NONE (r_pobj) of_32\IN\0|the (r_prep) initiation_31\NN\7450842|NONE (r_pobj) between_29\IN\0|a|temporal (r_prep) association_28\NN\8008335|There (r_attr) was_25\VBD\0|,|for|no|other|including|risk (r_relcl) factors_6\NNS\7326557|patient|. (l_prep) for_7\IN\0|,|was|no|other|including|risk (l_pobj) tdp_8\NNP\0|NONE
D015725_D016171 CID fluconazole_33\NN\0|NONE (l_conj) tdp_35\NNP\0|and
D015725_D016171 CID fluconazole_4\NN\0|was|when (r_nsubjpass) discontinued_6\VBN\0|TDP (r_advcl) resolved_2\VBD\352826|tachycardia|and|:|patient|,|however|until|have|; (l_nsubj) tdp_1\NNP\0|discontinued
D015725_D016171 CID fluconazole_14\NN\0|NONE (r_pobj) of_13\IN\0|development|and|the (r_prep) use_12\NN\407535|NONE (l_conj) development_17\NN\248977|of|and|the (l_prep) of_18\IN\0|the (l_pobj) tdp_19\NNP\0|NONE
D015725_D016171 CID fluconazole_5\NN\0|, (r_ccomp) aware_3\JJ\0|at|Clinicians|,|should|cause|. (r_acomp) be_2\VB\14625458|NONE (l_conj) cause_13\VB\7323922|at|Clinicians|,|should|aware|. (l_advcl) leading_20\VBG\4339291|,|may|prolongation (l_prep) to_21\IN\0|NONE (l_pobj) tdp_22\NNP\0|NONE
D015725_D009202 NONE fluconazole_33\NN\0|NONE (r_pobj) of_32\IN\0|the (r_prep) initiation_31\NN\7450842|NONE (r_pobj) between_29\IN\0|a|temporal (r_prep) association_28\NN\8008335|There (r_attr) was_25\VBD\0|,|for|no|other|including|risk (r_relcl) factors_6\NNS\7326557|patient|. (l_prep) including_10\VBG\0|,|was|for|no|other|risk (l_pobj) disease_13\NN\14061805|NONE (l_amod) cardiomyopathy_15\NN\14103288|coronary|artery|,
D015725_D006333 NONE fluconazole_33\NN\0|NONE (r_pobj) of_32\IN\0|the (r_prep) initiation_31\NN\7450842|NONE (r_pobj) between_29\IN\0|a|temporal (r_prep) association_28\NN\8008335|There (r_attr) was_25\VBD\0|,|for|no|other|including|risk (r_relcl) factors_6\NNS\7326557|patient|. (l_prep) including_10\VBG\0|,|was|for|no|other|risk (l_pobj) disease_13\NN\14061805|NONE (l_amod) cardiomyopathy_15\NN\14103288|coronary|artery|, (l_conj) failure_19\NN\66216|,
D015725_D008133 NONE fluconazole_5\NN\0|, (r_ccomp) aware_3\JJ\0|at|Clinicians|,|should|cause|. (r_acomp) be_2\VB\14625458|NONE (l_conj) cause_13\VB\7323922|at|Clinicians|,|should|aware|. (l_dobj) prolongation_14\NN\1017987|,|may|leading (l_prep) of_15\IN\0|NONE (l_pobj) interval_18\NN\33615|NONE
D015725_D003324 NONE fluconazole_33\NN\0|NONE (r_pobj) of_32\IN\0|the (r_prep) initiation_31\NN\7450842|NONE (r_pobj) between_29\IN\0|a|temporal (r_prep) association_28\NN\8008335|There (r_attr) was_25\VBD\0|,|for|no|other|including|risk (r_relcl) factors_6\NNS\7326557|patient|. (l_prep) including_10\VBG\0|,|was|for|no|other|risk (l_pobj) disease_13\NN\14061805|NONE
D015725_D018879 NONE fluconazole_4\NN\0|was|when (r_nsubjpass) discontinued_6\VBN\0|TDP (r_advcl) resolved_2\VBD\352826|tachycardia|and|:|patient|,|however|until|have|; (r_ccomp) continued_12\VBD\2367363|NONE (l_xcomp) have_14\VB\7846|resolved|tachycardia|and|:|patient|,|however|until|; (l_dobj) contractions_17\NNS\358931|to
D015725_D018879 NONE fluconazole_22\NN\0|.|strongly|as|followed (r_dobj) suggests_21\VBZ\1010118|NONE (l_csubj) followed_9\VBN\1835496|.|strongly|fluconazole|as (l_nsubj) disappearance_2\NN\42757|stopped|by (l_conj) contractions_8\NNS\358931|complete|of|The|and
D015725_D001145 NONE fluconazole_7\NN\0|is|when|in (r_nsubjpass) administered_9\VBN\2436349|be|monitoring|.|may (l_prep) in_10\IN\13603305|fluconazole|is|when (l_pobj) patients_11\NNS\9898892|NONE (l_relcl) are_13\VBP\13600404|NONE (l_prep) at_14\IN\14622893|who (l_pobj) risk_15\NN\14541044|NONE (l_prep) for_16\IN\0|NONE (l_pobj) arrhythmias_18\NNS\14103288|NONE
11271907
D003520_D009205 CID cyclophosphamide_5\NN\0|NONE (r_compound) therapy_6\NN\657604|NONE (r_pobj) to_4\IN\0|myocarditis|haemorrhagic (r_prep) secondary_3\JJ\8426461|. (l_amod) myocarditis_2\NN\14338942|haemorrhagic|to
D003520_D009205 CID cyclophosphamide_9\NN\0|NONE (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|rare|a (r_prep) complication_7\NN\1073995|.|myocarditis (r_attr) is_2\VBZ\0|NONE (l_nsubj) myocarditis_1\NN\14338942|.|complication
D003520_D006470 CID cyclophosphamide_5\NN\0|NONE (r_compound) therapy_6\NN\657604|NONE (r_pobj) to_4\IN\0|myocarditis|haemorrhagic (r_prep) secondary_3\JJ\8426461|. (l_amod) myocarditis_2\NN\14338942|haemorrhagic|to
D003520_D006470 CID cyclophosphamide_9\NN\0|NONE (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|rare|a (r_prep) complication_7\NN\1073995|.|myocarditis (r_attr) is_2\VBZ\0|NONE (l_nsubj) myocarditis_1\NN\14338942|.|complication
20304337
D003042_-1 NONE cocaine_8\NN\3492717|NONE (r_pobj) to_7\IN\0|.|prenatally|dysgenesis (r_prep) exposed_6\VBN\2110927|NONE (l_nsubj) dysgenesis_1\NN\14045507|.|prenatally|to
1255900
D006493_D013924 NONE heparin_8\JJ\2718259|NONE (r_compound) therapy_9\NN\657604|NONE (r_pobj) of_7\IN\0|the|for (r_prep) initiation_6\NN\7450842|NONE (l_prep) for_10\IN\0|the|of (l_pobj) thrombophlebitis_13\NN\14352890|NONE
18405372
D012460_D001168 NONE sulfasalazine_3\NN\0|NONE (l_prep) in_4\IN\13603305|NONE (l_pobj) arthritis_6\NN\14171682|NONE
D012460_D056486 CID sulfasalazine_3\NN\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBN\628491|: (r_acl) hepatotoxicity_0\NN\0|NONE
D012460_D056486 CID sulfasalazine_7\NN\0|NONE (r_pobj) on_6\IN\0|who|met|and|hepatotoxicity (r_prep) had_4\VBD\0|,|'|, (l_dobj) hepatotoxicity_5\NN\0|who|on|met|and
D012460_D056486 CID sulfasalazine_6\NN\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) hepatotoxicity_4\NN\0|NONE
D012460_D056486 CID sulfasalazine_7\NN\0|NONE (r_pobj) with_6\IN\0|serious (r_prep) hepatotoxicity_5\NN\0|NONE
D012460_D056486 CID sulfasalazine_4\NN\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBN\628491|Serious (r_acl) hepatotoxicity_1\NN\0|be|is|.
7565311
D016190_D018233 NONE carboplatin_15\NN\0|NONE (r_pobj) with_11\IN\0|was|for|who (r_prep) treated_10\VBN\2376958|a||old (l_prep) for_16\IN\0|was|with|who (l_pobj) rhabdomyosarcoma_20\NN\14246359|NONE
D016190_D058186 CID carboplatin_6\NN\0|dose|high (r_compound) chemotherapy_7\NN\661091|NONE (r_pobj) in_3\IN\13603305|.|renal|Acute (r_prep) failure_2\NN\66216|NONE
D016190_D058186 CID carboplatin_0\NNP\0|has|cause|.|been (r_nsubjpass) reported_3\VBN\831651|NONE (l_xcomp) cause_5\VB\7323922|Carboplatin|has|.|been (l_dobj) failure_8\NN\66216|administered|to
6695415
D010665_D002543 CID phenylpropanolamine_4\NN\2682038|NONE (r_pobj) with_3\IN\0|in (r_prep) associated_2\VBN\628491|Cerebral|. (r_acl) hemorrhage_1\NN\14285662|NONE
D010665_D002543 CID ppa_4\NNP\0|/ (r_nmod) caffeine_6\NN\14712692|that|administered|to|can (r_nsubj) lead_8\VB\5155821|results|. (l_prep) to_9\IN\0|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN\14285662|NONE
D002110_D006973 CID caffeine_7\NN\14712692|if|to|in|can (r_nsubj) lead_9\VB\5155821|to (l_prep) in_12\IN\13603305|caffeine|if|to|can (l_pobj) rats_16\NNS\2329401|NONE (l_amod) normotensive_13\NN\0|NONE (l_conj) hypertensive_15\JJ\10405694|and/or
D002110_D006973 CID caffeine_4\NN\14712692|)|single|A|dose|( (r_compound) administration_5\NN\1133281|.|to (r_nsubj) lead_10\NN\5155821|NONE (l_prep) to_11\IN\0|.|administration (l_pobj) hypertension_13\NN\14057371|NONE
D002110_D006973 CID caffeine_4\NN\14712692|)|single|A|dose|( (r_compound) administration_5\NN\1133281|.|to (r_nsubj) lead_10\NN\5155821|NONE (l_prep) to_11\IN\0|.|administration (l_pobj) hypertension_13\NN\14057371|NONE (l_prep) in_14\IN\13603305|acute (l_pobj) animals_20\NNS\4475|NONE (l_amod) normotensive_17\NN\0|the|both (l_conj) hypertensive_19\JJ\10405694|and
D002110_D006973 CID caffeine_6\NN\14712692|that|administered|to|can (r_nsubj) lead_8\VB\5155821|results|. (l_prep) to_9\IN\0|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN\14285662|NONE (l_prep) in_12\IN\13603305|cerebral (l_pobj) animals_15\NNS\4475|NONE (l_amod) hypertensive_14\JJ\10405694|NONE
D002110_D002543 CID caffeine_8\NN\14712692|NONE (r_pobj) with_7\IN\0|NONE (r_prep) combination_6\NN\7951464|NONE (r_pobj) in_5\IN\13603305|with (r_prep) associated_2\VBN\628491|Cerebral|. (r_acl) hemorrhage_1\NN\14285662|NONE
D002110_D002543 CID caffeine_6\NN\14712692|that|administered|to|can (r_nsubj) lead_8\VB\5155821|results|. (l_prep) to_9\IN\0|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN\14285662|NONE
D010665_D006973 CID ppa_5\NNP\0|/ (r_nmod) caffeine_7\NN\14712692|if|to|in|can (r_nsubj) lead_9\VB\5155821|to (l_prep) in_12\IN\13603305|caffeine|if|to|can (l_pobj) rats_16\NNS\2329401|NONE (l_amod) normotensive_13\NN\0|NONE (l_conj) hypertensive_15\JJ\10405694|and/or
D010665_D006973 CID ppa_2\NNP\0|/ (r_nmod) caffeine_4\NN\14712692|)|single|A|dose|( (r_compound) administration_5\NN\1133281|.|to (r_nsubj) lead_10\NN\5155821|NONE (l_prep) to_11\IN\0|.|administration (l_pobj) hypertension_13\NN\14057371|NONE
D010665_D006973 CID ppa_2\NNP\0|/ (r_nmod) caffeine_4\NN\14712692|)|single|A|dose|( (r_compound) administration_5\NN\1133281|.|to (r_nsubj) lead_10\NN\5155821|NONE (l_prep) to_11\IN\0|.|administration (l_pobj) hypertension_13\NN\14057371|NONE (l_prep) in_14\IN\13603305|acute (l_pobj) animals_20\NNS\4475|NONE (l_amod) normotensive_17\NN\0|the|both (l_conj) hypertensive_19\JJ\10405694|and
D010665_D006973 CID ppa_4\NNP\0|/ (r_nmod) caffeine_6\NN\14712692|that|administered|to|can (r_nsubj) lead_8\VB\5155821|results|. (l_prep) to_9\IN\0|that|administered|caffeine|can (l_pobj) hemorrhage_11\NN\14285662|NONE (l_prep) in_12\IN\13603305|cerebral (l_pobj) animals_15\NNS\4475|NONE (l_amod) hypertensive_14\JJ\10405694|NONE
D002110_D020521 NONE caffeine_7\NN\14712692|if|to|in|can (r_nsubj) lead_9\VB\5155821|to (l_prep) to_10\IN\0|caffeine|if|in|can (l_pobj) stroke_11\NN\556313|NONE
D010665_D020521 CID phenylpropanolamine_0\NNP\2682038|.|drug (r_nsubj) is_4\VBZ\0|NONE (l_attr) drug_6\NN\14778436|Phenylpropanolamine|. (l_relcl) associated_10\VBN\628491|a (l_prep) with_11\IN\0|has|been|that (l_pobj) effects_14\NNS\13245626|NONE (l_prep) including_15\VBG\0|serious|side (l_pobj) stroke_16\NN\556313|NONE
D010665_D020521 CID ppa_2\NNP\0|(|) (r_appos) phenylpropanolamine_0\NNP\2682038|.|drug (r_nsubj) is_4\VBZ\0|NONE (l_attr) drug_6\NN\14778436|Phenylpropanolamine|. (l_relcl) associated_10\VBN\628491|a (l_prep) with_11\IN\0|has|been|that (l_pobj) effects_14\NNS\13245626|NONE (l_prep) including_15\VBG\0|serious|side (l_pobj) stroke_16\NN\556313|NONE
D010665_D020521 CID ppa_5\NNP\0|/ (r_nmod) caffeine_7\NN\14712692|if|to|in|can (r_nsubj) lead_9\VB\5155821|to (l_prep) to_10\IN\0|caffeine|if|in|can (l_pobj) stroke_11\NN\556313|NONE
7596955
D000242_D001791 NONE camp_19\NNS\3763727|NONE (r_pobj) of_17\IN\0|NONE (r_prep) determination_16\NN\43195|ex|platelet|and (r_conj) aggregation_14\NN\31264|NONE
C045645_D005483 CID clz_25\NNP\0|NONE (r_pobj) of_24\IN\0|NONE (r_prep) ingestion_23\NN\13440063|especially (r_pobj) after_22\IN\0|,|flush|in (r_prep) accompanying_11\VBG\0|a|short (l_dobj) flush_13\NN\15113229|,|in|after
C045645_D006261 CID clz_25\NNP\0|NONE (r_pobj) of_24\IN\0|NONE (r_prep) ingestion_23\NN\13440063|especially (r_pobj) after_22\IN\0|,|flush|in (r_prep) accompanying_11\VBG\0|a|short (r_acl) duration_10\NN\15113229|NONE (r_pobj) of_7\IN\0|NONE (r_prep) headache_6\NN\5829480|.|subjects
C045645_D009325 CID clz_25\NNP\0|NONE (r_pobj) of_24\IN\0|NONE (r_prep) ingestion_23\NN\13440063|especially (r_pobj) after_22\IN\0|,|flush|in (r_prep) accompanying_11\VBG\0|a|short (l_dobj) flush_13\NN\15113229|,|in|after (l_prep) in_14\IN\13603305|facial (l_pobj) one_15\CD\13741022|NONE (l_conj) nausea_17\NN\14299637|and
20510337
C024989_D058186 NONE q10_5\NNP\0|NONE (r_pobj) of_3\IN\0|nephroprotective|The (r_prep) effect_2\NN\34213|.|was|in|induced (r_nsubjpass) investigated_7\VBN\644583|NONE (l_prep) in_8\IN\13603305|.|was|induced|effect (l_pobj) mice_9\NNS\2329401|NONE (l_prep) with_10\IN\0|NONE (l_pobj) injury_13\NN\14052046|NONE
D002945_D009369 NONE cisplatin_55\JJ\0|NONE (r_amod) administration_56\NN\1133281|NONE (r_pobj) from_54\IN\0|NONE (r_prep) resulted_53\VBD\2633881|reductions (r_advcl) attenuated_42\VBD\224901|elevations|and|, (r_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
D002945_D007674 NONE cisplatin_5\NN\0|in|acute (r_amod) nephrotoxicity_6\NN\0|treatment|.
D002945_D007674 NONE cisplatin_8\NN\0|NONE (r_pobj) by_7\IN\0|NONE (r_agent) mediated_6\VBN\761713|renal|tissue|histopathological (r_acl) damage_5\NN\7296428|Also|.|,|was|by
D002945_D007674 NONE cisplatin_15\NN\0|acute|encountered (r_amod) nephrotoxicity_16\NN\0|NONE
C024989_D009336 NONE q10_1\NNP\0|,|.|decreased|(|)|suppressed|deficits|,|level|significantly (r_nsubj) compensated_3\VBD\2673134|NONE (l_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D005978_D009369 NONE glutathione_12\NN\0|and|reduced|activity (r_compound) level_13\NN\4916342|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD\2673134|NONE (l_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
D013481_D009336 NONE superoxide_15\NN\14971519|dismutase (r_amod) activity_17\NN\30358|glutathione|and|reduced (r_conj) level_13\NN\4916342|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD\2673134|NONE (l_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D012643_D009336 NONE selenium_46\NN\14724645|in (r_nmod) ions_49\NNS\9386422|NONE (r_pobj) of_45\IN\0|the (r_prep) reductions_44\NNS\351485|resulted (r_dobj) attenuated_42\VBD\224901|elevations|and|, (r_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D010984_D009369 NONE platinum_37\NN\14627081|NONE (r_compound) ion_38\NN\9386422|NONE (r_compound) concentration_39\NN\4916342|nitric|and (r_conj) oxide_35\NN\14818238|,| (r_conj) alpha_32\NN\6828818|necrosis|tumor (r_appos) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
C024989_D009369 NONE q10_1\NNP\0|,|.|decreased|(|)|suppressed|deficits|,|level|significantly (r_nsubj) compensated_3\VBD\2673134|NONE (l_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
D010984_D009336 NONE platinum_37\NN\14627081|NONE (r_compound) ion_38\NN\9386422|NONE (r_compound) concentration_39\NN\4916342|nitric|and (r_conj) oxide_35\NN\14818238|,| (r_conj) alpha_32\NN\6828818|necrosis|tumor (r_appos) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
C024989_D007674 NONE q10_1\NNP\0|Coenzyme (r_compound) treatment_2\NN\654885|nephrotoxicity|. (r_nsubj) ameliorates_3\VBZ\126264|NONE (l_dobj) nephrotoxicity_6\NN\0|treatment|.
C024989_D007674 NONE q10_13\NNP\0|coenzyme (r_compound) treatment_14\NN\654885|NONE (r_pobj) by_11\IN\0|Also|.|damage|,|was (r_agent) ameliorated_10\VBN\126264|NONE (l_nsubjpass) damage_5\NN\7296428|Also|.|,|was|by
C024989_D007674 NONE q10_5\NNP\0|option|that (r_nsubj) represents_6\VBZ\2664769|.|was|It (l_dobj) option_10\NN\6480506|Q|that (l_acl) protect_12\VB\1127795|therapeutic|a|potential (l_prep) against_13\IN\0|to (l_pobj) nephrotoxicity_16\NN\0|NONE
D009569_D009336 NONE oxide_35\NN\14818238|,| (r_conj) alpha_32\NN\6828818|necrosis|tumor (r_appos) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D015032_D009369 NONE zinc_48\NN\14625458|and (r_conj) selenium_46\NN\14724645|in (r_nmod) ions_49\NNS\9386422|NONE (r_pobj) of_45\IN\0|the (r_prep) reductions_44\NNS\351485|resulted (r_dobj) attenuated_42\VBD\224901|elevations|and|, (r_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
D005978_D009336 NONE glutathione_12\NN\0|and|reduced|activity (r_compound) level_13\NN\4916342|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD\2673134|NONE (l_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D013481_D009369 NONE superoxide_15\NN\14971519|dismutase (r_amod) activity_17\NN\30358|glutathione|and|reduced (r_conj) level_13\NN\4916342|,|.|decreased|(|)|suppressed|deficits|Q|,|significantly (r_dobj) compensated_3\VBD\2673134|NONE (l_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
D015032_D009336 NONE zinc_48\NN\14625458|and (r_conj) selenium_46\NN\14724645|in (r_nmod) ions_49\NNS\9386422|NONE (r_pobj) of_45\IN\0|the (r_prep) reductions_44\NNS\351485|resulted (r_dobj) attenuated_42\VBD\224901|elevations|and|, (r_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D002945_D058186 CID cisplatin_21\NN\0|NONE (r_pobj) of_20\IN\0|i.p.|)|mg/kg|(|a|single (r_prep) injection_19\NN\320852|NONE (r_pobj) by_15\IN\0|NONE (r_agent) induced_14\VBN\1627355|.|was|in|effect (r_advcl) investigated_7\VBN\644583|NONE (l_prep) in_8\IN\13603305|.|was|induced|effect (l_pobj) mice_9\NNS\2329401|NONE (l_prep) with_10\IN\0|NONE (l_pobj) injury_13\NN\14052046|NONE
D012643_D009369 NONE selenium_46\NN\14724645|in (r_nmod) ions_49\NNS\9386422|NONE (r_pobj) of_45\IN\0|the (r_prep) reductions_44\NNS\351485|resulted (r_dobj) attenuated_42\VBD\224901|elevations|and|, (r_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
D002945_D009336 NONE cisplatin_55\JJ\0|NONE (r_amod) administration_56\NN\1133281|NONE (r_pobj) from_54\IN\0|NONE (r_prep) resulted_53\VBD\2633881|reductions (r_advcl) attenuated_42\VBD\224901|elevations|and|, (r_conj) decreased_24\VBD\169651|,|.|(|)|suppressed|deficits|Q|,|level|significantly (l_dobj) elevations_26\NNS\7445480|and|attenuated|, (l_prep) of_27\IN\0|the (l_pobj) factor_30\NN\7326557|NONE (l_compound) necrosis_29\NN\11444117|alpha|tumor
D009569_D009369 NONE oxide_35\NN\14818238|,| (r_conj) alpha_32\NN\6828818|necrosis|tumor (r_appos) factor_30\NN\7326557|NONE (l_compound) tumor_28\NN\14234074|alpha|necrosis
17511042
C417083_D063726 CID alpha-2b_16\NN\0|NONE (r_pobj) during_13\IN\0|in|delusional (r_prep) parasitosis_6\NN\0|NONE
C417083_D063726 CID alpha-2b_17\CD\0|.|We|woman (r_prep) present_1\VBP\28270|NONE (l_dobj) woman_6\NN\9605289|alphab|.|We (l_relcl) developed_8\VBD\1753788|old|a (l_dobj) parasitosis_11\NN\0|who
D012254_D019698 NONE ribavirin_18\JJ\2725367|NONE (r_compound) treatment_19\NN\654885|and|interferon|pegylated (r_conj) alpha-2b_16\NN\0|NONE (r_pobj) during_13\IN\0|in|delusional (r_prep) parasitosis_6\NN\0|NONE (l_prep) in_7\IN\13603305|during|delusional (l_pobj) patient_12\NN\9898892|NONE (l_compound) c_11\NN\13714184|chronic|a
D012254_D019698 NONE ribavirin_10\RB\2725367|and (r_conj) interferon_8\NN\2725367|NONE (r_pobj) with_7\IN\0|chronic|C (r_prep) patients_6\NNS\9898892|NONE (l_compound) c_5\NNP\13714184|with|chronic
D012254_D063726 CID ribavirin_18\JJ\2725367|NONE (r_compound) treatment_19\NN\654885|and|interferon|pegylated (r_conj) alpha-2b_16\NN\0|NONE (r_pobj) during_13\IN\0|in|delusional (r_prep) parasitosis_6\NN\0|NONE
D012254_D063726 CID ribavirin_20\RB\2725367|and (r_conj) weekly_18\RB\6593803|NONE (r_amod) alpha-2b_17\CD\0|.|We|woman (r_prep) present_1\VBP\28270|NONE (l_dobj) woman_6\NN\9605289|alphab|.|We (l_relcl) developed_8\VBD\1753788|old|a (l_dobj) parasitosis_11\NN\0|who
C417083_D019698 NONE alpha-2b_16\NN\0|NONE (r_pobj) during_13\IN\0|in|delusional (r_prep) parasitosis_6\NN\0|NONE (l_prep) in_7\IN\13603305|during|delusional (l_pobj) patient_12\NN\9898892|NONE (l_compound) c_11\NN\13714184|chronic|a
1928887
D009270_D062787 NONE naloxone_0\NN\3808977|of|due|. (r_compound) reversal_1\NN\199130|NONE (l_prep) due_4\IN\5174653|Naloxone|of|. (l_pobj) overdose_7\NN\84738|to
D009270_D062787 NONE naloxone_22\NN\3808977|NONE (r_pobj) of_21\IN\0|the (r_prep) administration_20\NN\1133281|NONE (r_pobj) with_18\IN\0|that|promptly|, (r_prep) resolved_16\VBD\352826|case|.|We|,|manifested (r_ccomp) report_1\VBP\6470073|NONE (l_dobj) case_3\NN\7283608|.|We|resolved|,|manifested (l_prep) of_4\IN\0|a (l_pobj) overdose_8\NN\84738|NONE
D002216_D062787 NONE captopril_6\NN\2673637|NONE (r_compound) overdose_7\NN\84738|to
D002216_D062787 NONE captopril_7\NN\2673637|intentional|an (r_compound) overdose_8\NN\84738|NONE
D002216_D007022 NONE captopril_6\NN\2673637|NONE (r_compound) overdose_7\NN\84738|to (r_pobj) due_4\IN\5174653|Naloxone|of|. (r_prep) reversal_1\NN\199130|NONE (l_prep) of_2\IN\0|Naloxone|due|. (l_pobj) hypotension_3\NN\14057371|NONE
D002216_D007022 NONE captopril_15\NN\2673637|NONE (r_pobj) of_14\IN\0|hypotensive|the (r_prep) actions_13\NNS\30358|NONE (l_amod) hypotensive_12\JJ\10405694|of|the
D002216_D007022 NONE captopril_7\NN\2673637|intentional|an (r_compound) overdose_8\NN\84738|NONE (r_pobj) of_4\IN\0|a (r_prep) case_3\NN\7283608|.|We|resolved|,|manifested (r_dobj) report_1\VBP\6470073|NONE (l_advcl) manifested_10\VBN\1015244|case|.|We|resolved|, (l_agent) by_11\IN\0|NONE (l_pobj) hypotension_13\NN\14057371|NONE
D002216_D007022 NONE captopril_11\NN\2673637| (r_npadvmod) induced_13\VBN\1627355|treated (r_amod) hypotension_14\NN\14057371|NONE
D002216_D007022 NONE captopril_15\NN\2673637|NONE (r_pobj) from_14\IN\0|NONE (r_prep) resulting_13\VBG\2633881|NONE (r_acl) hypotension_12\NN\14057371|NONE
D009270_D007022 NONE naloxone_0\NN\3808977|of|due|. (r_compound) reversal_1\NN\199130|NONE (l_prep) of_2\IN\0|Naloxone|due|. (l_pobj) hypotension_3\NN\14057371|NONE
D009270_D007022 NONE naloxone_3\NN\3808977|opioid|The (r_appos) antagonist_2\NN\7846|.|has|block|been (r_nsubjpass) shown_6\VBN\2137132|NONE (l_xcomp) block_8\VB\21939|.|has|been|antagonist (l_conj) reverse_10\VB\13854649|or|to (l_dobj) actions_13\NNS\30358|NONE (l_amod) hypotensive_12\JJ\10405694|of|the
D009270_D007022 NONE naloxone_22\NN\3808977|NONE (r_pobj) of_21\IN\0|the (r_prep) administration_20\NN\1133281|NONE (r_pobj) with_18\IN\0|that|promptly|, (r_prep) resolved_16\VBD\352826|case|.|We|,|manifested (r_ccomp) report_1\VBP\6470073|NONE (l_advcl) manifested_10\VBN\1015244|case|.|We|resolved|, (l_agent) by_11\IN\0|NONE (l_pobj) hypotension_13\NN\14057371|NONE
D009270_D007022 NONE naloxone_17\NN\3808977|NONE (r_pobj) with_16\IN\0|NONE (r_prep) treated_15\VBN\2376958|induced (r_acl) hypotension_14\NN\14057371|NONE
D009270_D007022 NONE naloxone_7\NN\3808977|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) reversal_10\NN\199130|NONE (l_prep) of_11\IN\0|the (l_pobj) hypotension_12\NN\14057371|NONE
10354657
D008094_D007037 CID lithium_22\NN\14625458|NONE (r_compound) therapy_23\NN\657604|NONE (r_pobj) of_21\IN\0|NONE (r_prep) onset_20\NN\7325190|years (r_pobj) after_19\IN\0|.|patients|compared|onset|after|)|)|(|had (r_prep) accelerated_12\VBN\226566|NONE (l_dobj) onset_13\NN\7325190|.|patients|compared|after|)|)|(|had|after (l_prep) of_14\IN\0|( (l_pobj) hypothyroidism_15\NN\14059928|NONE
D008094_D007037 CID lithium_38\NN\14625458|NONE (r_compound) therapy_39\NN\657604|NONE (r_pobj) of_37\IN\0|NONE (r_prep) onset_36\NN\7325190|years (r_pobj) after_35\IN\0|.|patients|compared|onset|)|)|(|had|after (r_prep) accelerated_12\VBN\226566|NONE (l_dobj) onset_13\NN\7325190|.|patients|compared|after|)|)|(|had|after (l_prep) of_14\IN\0|( (l_pobj) hypothyroidism_15\NN\14059928|NONE
D008094_D007037 CID lithium_12\NN\14625458|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_11\IN\0|for|risk|a (r_prep) factor_6\NN\7326557|illness|. (l_prep) for_7\IN\0|risk|during|a (l_pobj) hypothyroidism_8\NN\14059928|NONE
D008094_D006934 NONE lithium_12\NN\14625458|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_11\IN\0|for|risk|a (r_prep) factor_6\NN\7326557|illness|. (l_prep) for_7\IN\0|risk|during|a (l_pobj) hypothyroidism_8\NN\14059928|NONE (l_conj) hypercalcemia_10\NN\14299637|and
D008094_D013959 NONE lithium_9\NN\14625458|,|age (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|the (r_prep) duration_7\NN\15113229|NONE (r_pobj) to_5\IN\0|NONE (r_prep) respect_4\NN\5817845|NONE (r_pobj) with_3\IN\0|were|had|These|. (r_prep) evaluated_2\VBN\670261|NONE (l_parataxis) had_25\VBD\0|were|These|.|with (l_dobj) relative_30\NN\7846|not|or|)|(|whether|patient (l_prep) with_31\IN\0|degree|a (l_pobj) disease_33\NN\14061805|NONE
D008094_D013959 NONE lithium_22\NN\14625458|NONE (r_compound) therapy_23\NN\657604|NONE (r_pobj) of_21\IN\0|NONE (r_prep) onset_20\NN\7325190|years (r_pobj) after_19\IN\0|.|patients|compared|onset|after|)|)|(|had (r_prep) accelerated_12\VBN\226566|NONE (l_nsubj) patients_1\NNS\9898892|.|compared|onset|after|)|)|(|had|after (l_acl) having_2\VBG\0|All (l_dobj) relatives_6\NNS\7846|NONE (l_acl) affected_7\VBN\126264|degree (l_agent) by_8\IN\0|NONE (l_pobj) illness_10\NN\14052046|NONE
D008094_D013959 NONE lithium_38\NN\14625458|NONE (r_compound) therapy_39\NN\657604|NONE (r_pobj) of_37\IN\0|NONE (r_prep) onset_36\NN\7325190|years (r_pobj) after_35\IN\0|.|patients|compared|onset|)|)|(|had|after (r_prep) accelerated_12\VBN\226566|NONE (l_nsubj) patients_1\NNS\9898892|.|compared|onset|after|)|)|(|had|after (l_acl) having_2\VBG\0|All (l_dobj) relatives_6\NNS\7846|NONE (l_acl) affected_7\VBN\126264|degree (l_agent) by_8\IN\0|NONE (l_pobj) illness_10\NN\14052046|NONE
D008094_D013959 NONE lithium_12\NN\14625458|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_11\IN\0|for|risk|a (r_prep) factor_6\NN\7326557|illness|. (r_attr) is_3\VBZ\0|NONE (l_nsubj) illness_2\NN\14052046|.|factor
D008094_D001714 NONE lithium_16\NN\14625458|maintenance|ranging (r_compound) therapy_18\NN\657604|disorder (r_dobj) receiving_15\VBG\2210855|NONE (l_nsubj) disorder_14\NN\14034177|therapy
18086064
D020927_D009203 NONE dexmedetomidine_0\NNP\0|was|with (r_nsubjpass) associated_2\VBN\628491|infarction|CI|%|,|;|(|cause (r_ccomp) mortality_14\NN\5054863|NONE (l_appos) infarction_35\NN\14204950|associated|CI|%|,|;|(|cause
1899352
D015080_D006417 NONE mesna_22\NNP\0|to (r_dobj) adding_21\VBG\156601|.|monitoring|,|essential (r_advcl) is_18\VBZ\0|precise|and|,|frequency|not (r_conj) are_6\VBP\13600404|NONE (l_nsubj) frequency_1\NN\15286249|precise|and|is|,|not (l_conj) predictability_3\NN\4753455|and|The (l_prep) of_4\IN\0|NONE (l_pobj) hematuria_5\NN\14299637|NONE
D015080_D006417 NONE mesna_22\NNP\0|to (r_dobj) adding_21\VBG\156601|.|monitoring|,|essential (l_prep) to_23\IN\0|Mesna (l_pobj) infusate_25\NN\0|NONE (l_prep) in_26\IN\13603305|the (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|NONE (l_pobj) hematuria_30\NN\14299637|NONE
16725121
D003891_D012640 NONE desipramine_12\NN\4482543|NONE (r_pobj) of_11\IN\0|chronic (r_prep) administration_10\NN\1133281|NONE (r_pobj) by_8\IN\0|linking (r_agent) induced_7\VBN\1627355|.||Down|of (l_xcomp) linking_13\VBG\628491|by (l_prep) to_14\IN\0|NONE (l_pobj) alteration_16\NN\7283608|NONE (l_prep) of_17\IN\0|counteraction|and|the (l_pobj) sensitivity_18\NN\5651971|NONE (l_prep) of_19\IN\0|NONE (l_pobj) convulsions_25\NNS\14081375|NONE
D003891_D012640 NONE desipramine_3\NN\4482543|NONE (r_pobj) of_2\IN\0|Daily (r_prep) administration_1\NN\1133281|.|decreased|incidence|and (r_nsubj) increased_4\VBD\169651|NONE (l_dobj) incidence_6\NN\13821570|.|administration|decreased|and (l_prep) of_7\IN\0|the (l_pobj) appearance_8\NN\4723816|NONE (l_prep) of_9\IN\0|NONE (l_pobj) convulsions_13\NNS\14081375|NONE
D003891_D012640 NONE desipramine_3\NN\4482543|NONE (r_pobj) of_2\IN\0|Daily (r_prep) administration_1\NN\1133281|.|decreased|incidence|and (r_nsubj) increased_4\VBD\169651|NONE (l_conj) decreased_15\VBD\169651|.|administration|incidence|and (l_dobj) that_16\DT\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) convulsions_21\NNS\14081375|NONE
D003891_D012640 NONE desipramine_6\NN\4482543|NONE (r_pobj) with_5\IN\0|NONE (r_prep) lidocaine_4\NN\3681148|NONE (r_pobj) of_3\IN\0|Co| (r_prep) administration_2\NN\1133281|.|changes (r_nsubj) reversed_7\VBD\109660|NONE (l_dobj) changes_9\NNS\7283608|administration|. (l_prep) of_10\IN\0|induced|the (l_pobj) activity_12\NN\30358|NONE (l_amod) convulsive_11\JJ\0|of
D003891_D012640 NONE desipramine_22\NN\4482543|NONE (r_pobj) of_21\IN\0|repeated (r_prep) administration_20\NN\1133281|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|of|the (r_acl) changes_9\NNS\7283608|administration|. (l_prep) of_10\IN\0|induced|the (l_pobj) activity_12\NN\30358|NONE (l_amod) convulsive_11\JJ\0|of
D003891_D012640 NONE desipramine_15\NN\4482543|NONE (r_pobj) of_14\IN\0|chronic (r_prep) administration_13\NN\1133281|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355||down|of (r_acl) regulation_6\NN\6652242|relevant|that|may (r_nsubj) be_17\VB\14625458|results|. (l_acomp) relevant_18\JJ\0|regulation|that|may (l_prep) to_19\IN\0|NONE (l_pobj) sensitization_23\NN\14531772|NONE (l_prep) of_24\IN\0|induced (l_pobj) convulsions_26\NNS\14081375|NONE
D003891_D012640 NONE desipramine_20\NN\4482543| (r_advmod) induced_22\VBN\1627355|of (r_amod) sensitization_23\NN\14531772|NONE (l_prep) of_24\IN\0|induced (l_pobj) convulsions_26\NNS\14081375|NONE
D003891_D012640 NONE desipramine_0\NN\4482543| (r_nsubj) induced_2\VBN\1627355|of (r_amod) sensitization_3\NN\14531772|.|may|mechanism (l_prep) of_4\IN\0|induced (l_pobj) seizures_6\NNS\14081375|NONE
D009638_D012640 NONE norepinephrine_4\NN\14807929|transporter (r_amod) function_6\NN\13783581|NONE (r_pobj) of_3\IN\0|induced|.||Down (r_prep) regulation_2\NN\6652242|NONE (l_acl) induced_7\VBN\1627355|.||Down|of (l_xcomp) linking_13\VBG\628491|by (l_prep) to_14\IN\0|NONE (l_pobj) alteration_16\NN\7283608|NONE (l_prep) of_17\IN\0|counteraction|and|the (l_pobj) sensitivity_18\NN\5651971|NONE (l_prep) of_19\IN\0|NONE (l_pobj) convulsions_25\NNS\14081375|NONE
D009638_D012640 NONE norepinephrine_2\NN\14807929|NET|) (r_compound) transporter_3\NN\4490091|by (r_nmod) function_7\NN\13783581|NONE (l_prep) by_8\IN\0|transporter (l_pobj) inhibition_10\NN\1068773|NONE (l_prep) in_13\IN\13603305|chronic|of (l_pobj) relation_14\NN\2137|NONE (l_prep) to_15\IN\0|NONE (l_pobj) sensitization_16\NN\14531772|NONE (l_prep) to_17\IN\0|NONE (l_pobj) seizures_18\NNS\14081375|NONE
D003042_D012640 CID cocaine_21\NN\3492717|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induce_19\VB\1627355|NONE (r_acl) seizures_18\NNS\14081375|NONE
D003042_D012640 CID cocaine_18\NN\3492717| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) convulsions_21\NNS\14081375|NONE (r_pobj) of_17\IN\0|NONE (r_prep) that_16\DT\0|NONE (r_dobj) decreased_15\VBD\169651|.|administration|incidence|and (r_conj) increased_4\VBD\169651|NONE (l_dobj) incidence_6\NN\13821570|.|administration|decreased|and (l_prep) of_7\IN\0|the (l_pobj) appearance_8\NN\4723816|NONE (l_prep) of_9\IN\0|NONE (l_pobj) convulsions_13\NNS\14081375|NONE
D003042_D012640 CID cocaine_18\NN\3492717| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) convulsions_21\NNS\14081375|NONE
D003042_D012640 CID cocaine_16\NN\3492717|and (r_conj) lidocaine_14\NN\3681148|NONE (r_pobj) of_13\IN\0|convulsive (r_prep) activity_12\NN\30358|NONE (l_amod) convulsive_11\JJ\0|of
D003042_D012640 CID cocaine_19\NN\3492717|NONE (r_pobj) of_18\IN\0|repeated (r_prep) administration_17\NN\1133281|NONE (r_pobj) from_15\IN\0|NONE (r_prep) resulting_14\VBG\2633881|NONE (r_acl) kindling_13\VBG\15101361|NONE (r_pobj) from_12\IN\0|NONE (r_prep) distinct_11\JJ\0|a (r_amod) mechanism_10\NN\13446390|.|sensitization|may (r_dobj) have_8\VB\7846|NONE (l_nsubj) sensitization_3\NN\14531772|.|may|mechanism (l_prep) of_4\IN\0|induced (l_pobj) seizures_6\NNS\14081375|NONE
D008012_D012640 CID lidocaine_10\NN\3681148| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) convulsions_13\NNS\14081375|NONE
D008012_D012640 CID lidocaine_10\NN\3681148| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) convulsions_13\NNS\14081375|NONE (r_pobj) of_9\IN\0|NONE (r_prep) appearance_8\NN\4723816|NONE (r_pobj) of_7\IN\0|the (r_prep) incidence_6\NN\13821570|.|administration|decreased|and (r_dobj) increased_4\VBD\169651|NONE (l_conj) decreased_15\VBD\169651|.|administration|incidence|and (l_dobj) that_16\DT\0|NONE (l_prep) of_17\IN\0|NONE (l_pobj) convulsions_21\NNS\14081375|NONE
D008012_D012640 CID lidocaine_4\NN\3681148|NONE (r_pobj) of_3\IN\0|Co| (r_prep) administration_2\NN\1133281|.|changes (r_nsubj) reversed_7\VBD\109660|NONE (l_dobj) changes_9\NNS\7283608|administration|. (l_prep) of_10\IN\0|induced|the (l_pobj) activity_12\NN\30358|NONE (l_amod) convulsive_11\JJ\0|of
D008012_D012640 CID lidocaine_14\NN\3681148|NONE (r_pobj) of_13\IN\0|convulsive (r_prep) activity_12\NN\30358|NONE (l_amod) convulsive_11\JJ\0|of
D008012_D012640 CID lidocaine_25\NN\3681148|NONE (r_compound) convulsions_26\NNS\14081375|NONE
D008012_D012640 CID lidocaine_5\NN\3681148|NONE (r_compound) seizures_6\NNS\14081375|NONE
2917114
D004491_D001919 CID edrophonium_17\NN\0|NONE (r_pobj) before_15\IN\0| (r_prep) min_14\NN\15154774|,|,|was (r_dobj) given_12\VBN\5892096|micrograms|of|. (l_conj) was_19\VBD\0|,|,|min (l_acomp) sufficient_20\JJ\0|NONE (l_xcomp) minimize_22\VB\441445|NONE (l_dobj) bradycardias_28\NNS\14110674|to
D004491_D001919 CID edrophonium_25\NN\0| (r_npadvmod) induced_27\VBN\1627355|early|, (r_amod) bradycardias_28\NNS\14110674|to
D006024_D001919 NONE glycopyrronium_2\NN\0|NONE (r_pobj) of_1\IN\0|micrograms|given|. (r_prep) use_0\NN\407535|NONE (l_acl) given_12\VBN\5892096|micrograms|of|. (l_conj) was_19\VBD\0|,|,|min (l_acomp) sufficient_20\JJ\0|NONE (l_xcomp) minimize_22\VB\441445|NONE (l_dobj) bradycardias_28\NNS\14110674|to
19139001
D013467_D034381 CID sulindac_14\NN\3828465|the|experienced|DFMO (r_compound) group_15\NN\2137|NONE (l_relcl) experienced_17\VBD\2108377|sulindac|the|DFMO (l_dobj) loss_21\NN\13252973|who|compared
D013467_D015179 NONE sulindac_15\NN\3828465|and (l_prep) for_16\IN\0|NONE (l_pobj) prevention_17\NN\1073995|NONE (l_prep) of_18\IN\0|NONE (l_pobj) adenomas_21\NNS\14236226|NONE
D000518_D015179 NONE difluoromethylornithine_13\NN\0|NONE (l_conj) sulindac_15\NN\3828465|and (l_prep) for_16\IN\0|NONE (l_pobj) prevention_17\NN\1073995|NONE (l_prep) of_18\IN\0|NONE (l_pobj) adenomas_21\NNS\14236226|NONE
D000518_D064420 NONE dfmo_10\NN\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) treatment_8\NN\654885|NONE (r_pobj) of_7\IN\0|,|known|a (r_prep) toxicity_6\NN\13576101|developed|.|loss
D000518_D034381 NONE dfmo_10\NN\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) treatment_8\NN\654885|NONE (r_pobj) of_7\IN\0|,|known|a (r_prep) toxicity_6\NN\13576101|developed|.|loss (r_attr) is_3\VBZ\0|NONE (l_nsubj) loss_2\NN\13252973|developed|toxicity|.
D000518_D034381 NONE dfmo_12\NN\0|sulindac|the|experienced (r_nmod) group_15\NN\2137|NONE (l_relcl) experienced_17\VBD\2108377|sulindac|the|DFMO (l_dobj) loss_21\NN\13252973|who|compared
D013467_D018256 NONE sulindac_22\NN\3828465|plus|(|DFMO|) (r_conj) difluoromethylornithine_17\NN\0|NONE (r_pobj) with_16\IN\0| (r_prep) months_15\NNS\15113229|NONE (r_pobj) for_13\IN\0|NONE (r_prep) treatment_12\NN\654885|NONE (r_pobj) after_11\IN\0|adenomatous (r_prep) polyps_10\NNS\14234074|NONE
D000518_D018256 NONE difluoromethylornithine_17\NN\0|NONE (r_pobj) with_16\IN\0| (r_prep) months_15\NNS\15113229|NONE (r_pobj) for_13\IN\0|NONE (r_prep) treatment_12\NN\654885|NONE (r_pobj) after_11\IN\0|adenomatous (r_prep) polyps_10\NNS\14234074|NONE
D000518_D018256 NONE dfmo_19\NN\0|plus|(|sulindac|) (r_appos) difluoromethylornithine_17\NN\0|NONE (r_pobj) with_16\IN\0| (r_prep) months_15\NNS\15113229|NONE (r_pobj) for_13\IN\0|NONE (r_prep) treatment_12\NN\654885|NONE (r_pobj) after_11\IN\0|adenomatous (r_prep) polyps_10\NNS\14234074|NONE
14745746
8854309
D003042_D010259 CID cocaine_9\NN\3492717| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) paranoia_12\NN\14398067|NONE
D003042_D010259 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|(|)|CIP (r_amod) paranoia_3\NN\14398067|model|.
D003042_D010259 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|(|)|CIP (r_amod) paranoia_3\NN\14398067|model|. (l_appos) cip_5\NNP\0|induced|(|)
D003042_D010259 CID cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|(|)|CIP (r_amod) paranoia_3\NN\14398067|model|. (r_nsubj) remains_7\VBZ\2684|NONE (l_attr) model_13\NN\5888929|.|paranoia (l_prep) of_14\IN\0|an|induced|important (l_pobj) paranoia_16\NN\14398067|NONE
D016578_D010259 NONE cocaine_14\NN\3492717|endorsing|crack (r_compound) abusers_15\NNS\9633969|NONE (l_acl) endorsing_16\VBG\806502|cocaine|crack (l_prep) past_17\IN\28270|from (l_pobj) cip_18\NNP\0|NONE
D016578_D010259 NONE cocaine_14\NN\3492717|endorsing|crack (r_compound) abusers_15\NNS\9633969|NONE (l_acl) endorsing_16\VBG\806502|cocaine|crack (l_prep) from_24\IN\0|past (l_pobj) group_26\NN\2137|NONE (l_relcl) denied_31\VBD\823436|another|of (l_prep) past_32\IN\28270|who (l_pobj) cip_33\NNP\0|NONE
D016578_D010259 NONE crack_28\NN\9379111|NONE (r_compound) addicts_29\NNS\10059582|NONE (r_pobj) of_27\IN\0|another|denied (r_prep) group_26\NN\2137|NONE (r_pobj) from_24\IN\0|past (r_prep) endorsing_16\VBG\806502|cocaine|crack (l_prep) past_17\IN\28270|from (l_pobj) cip_18\NNP\0|NONE
D016578_D010259 NONE crack_28\NN\9379111|NONE (r_compound) addicts_29\NNS\10059582|NONE (r_pobj) of_27\IN\0|another|denied (r_prep) group_26\NN\2137|NONE (l_relcl) denied_31\VBD\823436|another|of (l_prep) past_32\IN\28270|who (l_pobj) cip_33\NNP\0|NONE
D016578_D011681 NONE cocaine_14\NN\3492717|endorsing|crack (r_compound) abusers_15\NNS\9633969|NONE (r_pobj) of_11\IN\0|a (r_prep) group_10\NN\2137|significantly|to (r_dobj) distinguish_8\VB\618878|NONE (r_xcomp) able_5\JJ\0|.|Measures (r_acomp) were_4\VBD\0|NONE (l_nsubj) measures_0\NNS\168237|.|able (l_prep) of_1\IN\0|NONE (l_pobj) oscillation_3\NN\13518963|NONE
D016578_D011681 NONE crack_28\NN\9379111|NONE (r_compound) addicts_29\NNS\10059582|NONE (r_pobj) of_27\IN\0|another|denied (r_prep) group_26\NN\2137|NONE (r_pobj) from_24\IN\0|past (r_prep) endorsing_16\VBG\806502|cocaine|crack (r_acl) abusers_15\NNS\9633969|NONE (r_pobj) of_11\IN\0|a (r_prep) group_10\NN\2137|significantly|to (r_dobj) distinguish_8\VB\618878|NONE (r_xcomp) able_5\JJ\0|.|Measures (r_acomp) were_4\VBD\0|NONE (l_nsubj) measures_0\NNS\168237|.|able (l_prep) of_1\IN\0|NONE (l_pobj) oscillation_3\NN\13518963|NONE
D003042_D011681 CID cocaine_9\NN\3492717| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) paranoia_12\NN\14398067|NONE (r_pobj) of_8\IN\0|a (r_prep) marker_7\NN\21939|NONE (r_pobj) as_5\IN\14622893|A|of|. (r_prep) measure_1\NN\168237|NONE (l_prep) of_2\IN\0|A|as|. (l_pobj) oscillation_4\NN\13518963|NONE
9321531
D007980_D004409 CID levodopa_11\RB\14604959| (r_npadvmod) induced_13\VBN\1627355|disability|and (r_amod) dyskinesias_14\NNS\14084880|pallidotomy|significantly|In|,|.
D007980_D010300 NONE levodopa_11\RB\14604959| (r_npadvmod) induced_13\VBN\1627355|disability|and (r_amod) dyskinesias_14\NNS\14084880|pallidotomy|significantly|In|,|. (r_dobj) reduces_10\VBZ\441445|NONE (l_prep) in_0\IN\13603305|pallidotomy|significantly|dyskinesias|,|. (l_pobj) disease_6\NN\14061805|NONE
8617710
D020280_D003072 NONE sertraline_4\NN\4169152|NONE (r_pobj) of_3\IN\0|on (r_prep) effect_2\NN\34213|NONE (l_prep) on_5\IN\0|of (l_pobj) sensitization_9\NN\14531772|NONE (l_prep) of_10\IN\0|based (l_pobj) impairment_12\NN\7296428|NONE
D020280_D003072 NONE sertraline_14\NN\4169152|concomitant (r_compound) administration_15\NN\1133281|NONE (r_pobj) by_12\IN\0|not|was|that (r_agent) worsened_11\VBN\146138|clear|a|of (r_relcl) profile_4\NN\6999802|Haloperidol|. (l_prep) of_5\IN\0|clear|a|worsened (l_pobj) impairment_7\NN\7296428|NONE
D006220_D003072 CID haloperidol_14\NN\3713736|NONE (r_pobj) with_13\IN\0|cognitive (r_prep) impairment_12\NN\7296428|NONE
D006220_D003072 CID haloperidol_13\NN\3713736|NONE (r_pobj) of_12\IN\0|NONE (r_prep) administration_11\NN\1133281|hours (r_pobj) after_10\IN\0|Impairment|.|but|was|was|on (r_prep) observed_5\VBN\2163746|NONE (l_nsubjpass) impairment_0\NN\7296428|after|.|but|was|was|on (l_prep) of_1\IN\0|NONE (l_pobj) function_3\NN\13783581|NONE
D006220_D003072 CID haloperidol_0\NNP\3713736|profile|. (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) profile_4\NN\6999802|Haloperidol|. (l_prep) of_5\IN\0|clear|a|worsened (l_pobj) impairment_7\NN\7296428|NONE
384871
D004977_D064420 NONE ethambutol_8\NN\0|to (r_pobj) due_6\IN\5174653|of|The (r_amod) hazards_1\NNS\14541044|.|are (l_prep) of_2\IN\0|due|The (l_pobj) toxicity_5\NN\13576101|NONE
D004977_D009901 CID ethambutol_6\NN\0|NONE (r_nmod) treatment_9\NN\654885|to (r_pobj) due_3\IN\5174653|.|optic (r_prep) neuropathy_2\NN\14204950|NONE
D007538_D009901 CID isoniazid_8\NN\2716205|combined|and (r_conj) ethambutol_6\NN\0|NONE (r_nmod) treatment_9\NN\654885|to (r_pobj) due_3\IN\5174653|.|optic (r_prep) neuropathy_2\NN\14204950|NONE
16629641
C026956_D000743 NONE viramidine_0\NNP\0|potential (r_nsubj) has_10\VBZ\13888491|NONE (l_dobj) potential_12\NN\14481929|Viramidine (l_acl) maintain_14\VB\0|the (l_advcl) decreasing_21\VBG\169651|to|efficacy (l_dobj) risk_23\NN\14541044|while (l_prep) of_24\IN\0|the (l_pobj) anemia_26\NN\14189204|NONE
D012254_D007674 NONE ribavirin_8\RB\2725367| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hemolysis_11\NN\13509528|NONE (r_pobj) of_7\IN\0|a (r_prep) result_6\NN\34213|mainly (r_pobj) as_4\IN\14622893|,|be|concentrations|and (r_prep) decrease_2\VBP\7296428|NONE (l_conj) be_17\VB\14625458|,|as|concentrations|and (l_conj) comorbid_29\VBN\0|.|problematic|anemia|can|in (l_dobj) disorders_33\NNS\14034177|have|those
D007372_D006526 NONE interferon_12\NN\2725367|NONE (r_pobj) with_10\IN\0|combination (r_prep) therapy_9\NN\657604|.|treatment (r_attr) is_7\VBZ\0|NONE (l_nsubj) treatment_3\NN\654885|.|therapy (l_prep) for_4\IN\0|The|current|best (l_pobj) infection_6\NN\14052046|NONE
D012254_D002318 NONE ribavirin_8\RB\2725367| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hemolysis_11\NN\13509528|NONE (r_pobj) of_7\IN\0|a (r_prep) result_6\NN\34213|mainly (r_pobj) as_4\IN\14622893|,|be|concentrations|and (r_prep) decrease_2\VBP\7296428|NONE (l_conj) be_17\VB\14625458|,|as|concentrations|and (l_conj) comorbid_29\VBN\0|.|problematic|anemia|can|in (l_dobj) disorders_33\NNS\14034177|have|those
D012254_D000740 NONE ribavirin_8\RB\2725367| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hemolysis_11\NN\13509528|NONE (r_pobj) of_7\IN\0|a (r_prep) result_6\NN\34213|mainly (r_pobj) as_4\IN\14622893|,|be|concentrations|and (r_prep) decrease_2\VBP\7296428|NONE (l_conj) be_17\VB\14625458|,|as|concentrations|and (l_nsubj) anemia_15\NN\14189204|.|comorbid|problematic|can|in
D012254_D000740 NONE ribavirin_1\RB\2725367| (r_npadvmod) associated_3\VBN\628491|NONE (r_amod) anemia_4\NN\14189204|by|can|be|Although
D012254_D000740 NONE ribavirin_8\RB\2725367| (r_npadvmod) associated_10\VBN\628491|NONE (r_amod) anemia_11\NN\14189204|to
D012254_D019698 NONE ribavirin_8\NN\2725367|NONE (r_pobj) of_7\IN\0|a|targeting (r_prep) prodrug_6\NN\0|,|, (r_appos) viramidine_0\NNP\0|potential (r_nsubj) has_10\VBZ\13888491|NONE (l_dobj) potential_12\NN\14481929|Viramidine (l_acl) maintain_14\VB\0|the (l_advcl) decreasing_21\VBG\169651|to|efficacy (l_dobj) risk_23\NN\14541044|while (l_prep) of_24\IN\0|the (l_pobj) anemia_26\NN\14189204|NONE (l_prep) in_27\IN\13603305|hemolytic (l_pobj) patients_28\NNS\9898892|NONE (l_prep) with_29\IN\0|NONE (l_pobj) c._32\NNP\0|NONE
D012254_D019698 NONE ribavirin_19\RB\2725367|NONE (r_pobj) of_18\IN\0|virologic|the (r_prep) efficacy_17\NN\5199286|to|decreasing (r_dobj) maintain_14\VB\0|the (l_advcl) decreasing_21\VBG\169651|to|efficacy (l_dobj) risk_23\NN\14541044|while (l_prep) of_24\IN\0|the (l_pobj) anemia_26\NN\14189204|NONE (l_prep) in_27\IN\13603305|hemolytic (l_pobj) patients_28\NNS\9898892|NONE (l_prep) with_29\IN\0|NONE (l_pobj) c._32\NNP\0|NONE
D012254_D006461 NONE ribavirin_8\RB\2725367| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hemolysis_11\NN\13509528|NONE
D012254_D000743 CID ribavirin_8\NN\2725367|NONE (r_pobj) of_7\IN\0|a|targeting (r_prep) prodrug_6\NN\0|,|, (r_appos) viramidine_0\NNP\0|potential (r_nsubj) has_10\VBZ\13888491|NONE (l_dobj) potential_12\NN\14481929|Viramidine (l_acl) maintain_14\VB\0|the (l_advcl) decreasing_21\VBG\169651|to|efficacy (l_dobj) risk_23\NN\14541044|while (l_prep) of_24\IN\0|the (l_pobj) anemia_26\NN\14189204|NONE
D012254_D000743 CID ribavirin_19\RB\2725367|NONE (r_pobj) of_18\IN\0|virologic|the (r_prep) efficacy_17\NN\5199286|to|decreasing (r_dobj) maintain_14\VB\0|the (l_advcl) decreasing_21\VBG\169651|to|efficacy (l_dobj) risk_23\NN\14541044|while (l_prep) of_24\IN\0|the (l_pobj) anemia_26\NN\14189204|NONE
D012254_D006526 NONE ribavirin_14\NN\2725367|pegylated|and (r_conj) interferon_12\NN\2725367|NONE (r_pobj) with_10\IN\0|combination (r_prep) therapy_9\NN\657604|.|treatment (r_attr) is_7\VBZ\0|NONE (l_nsubj) treatment_3\NN\654885|.|therapy (l_prep) for_4\IN\0|The|current|best (l_pobj) infection_6\NN\14052046|NONE
D012254_D006526 NONE ribavirin_8\RB\2725367| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hemolysis_11\NN\13509528|NONE (r_pobj) of_7\IN\0|a (r_prep) result_6\NN\34213|mainly (r_pobj) as_4\IN\14622893|,|be|concentrations|and (r_prep) decrease_2\VBP\7296428|NONE (l_conj) be_17\VB\14625458|,|as|concentrations|and (l_prep) in_19\IN\13603305|.|comorbid|problematic|anemia|can (l_pobj) patients_20\NNS\9898892|NONE (l_prep) with_21\IN\0|NONE (l_pobj) infection_23\NN\14052046|NONE
C026956_D019698 NONE viramidine_0\NNP\0|potential (r_nsubj) has_10\VBZ\13888491|NONE (l_dobj) potential_12\NN\14481929|Viramidine (l_acl) maintain_14\VB\0|the (l_advcl) decreasing_21\VBG\169651|to|efficacy (l_dobj) risk_23\NN\14541044|while (l_prep) of_24\IN\0|the (l_pobj) anemia_26\NN\14189204|NONE (l_prep) in_27\IN\13603305|hemolytic (l_pobj) patients_28\NNS\9898892|NONE (l_prep) with_29\IN\0|NONE (l_pobj) c._32\NNP\0|NONE
16132524
D017239_D001929 CID paclitaxel_9\NN\0|suffered|.|and|Six (r_dobj) received_4\VBD\2210855|NONE (l_conj) suffered_11\VBD\2110220|paclitaxel|.|and|Six (l_prep) from_12\IN\0|received|, (l_prep) to_14\TO\0|moderate (l_pobj) edema_17\NN\14315192|NONE
D017239_D001929 CID paclitaxel_30\NN\0|NONE (r_pobj) of_27\IN\0|a|only (r_prep) total_26\NN\3553|patients|while (r_dobj) received_23\VBD\2210855|from|, (r_advcl) suffered_11\VBD\2110220|paclitaxel|.|and|Six (l_prep) from_12\IN\0|received|, (l_prep) to_14\TO\0|moderate (l_pobj) edema_17\NN\14315192|NONE
D017239_D005909 NONE paclitaxel_3\NN\0|/ (r_nmod) carboplatin_5\VB\0|)|crystalline|cubic|for|liquid (r_amod) phases_9\NNS\15113229|(|.|Intracavitary (l_prep) for_11\IN\0|)|crystalline|cubic|liquid|carboplatin (l_pobj) glioblastoma_13\NN\14236743|NONE
D017239_D005909 NONE paclitaxel_21\NN\0|NONE (r_pobj) of_20\IN\0|surgical|intracavitary|a (r_prep) application_19\NN\947128|NONE (r_pobj) of_15\IN\0|and|encapsulated|term (r_prep) effects_14\NNS\13245626|,|and (r_conj) safety_8\NN\13920835|the|, (r_conj) feasibility_6\NN\5152150|,|.|are|For|in (r_nsubjpass) examined_31\VBN\0|NONE (l_prep) for_0\IN\0|feasibility|,|.|are|in (l_pobj) recurrences_3\NNS\7342049|NONE (l_compound) glioblastoma_2\NN\14236743|human
D017239_D005909 NONE paclitaxel_22\NN\0|NONE (r_pobj) of_21\IN\0|an|intracavitary (r_prep) application_20\NN\947128|phases|and (r_dobj) received_17\VBD\2210855|and (r_conj) underwent_12\VBN\109660|a|glioblastoma (r_acl) multiforme_11\NN\0|NONE (l_compound) glioblastoma_10\NN\14236743|a|underwent
D016190_D005909 NONE carboplatin_5\VB\0|)|crystalline|cubic|for|liquid (r_amod) phases_9\NNS\15113229|(|.|Intracavitary (l_prep) for_11\IN\0|)|crystalline|cubic|liquid|carboplatin (l_pobj) glioblastoma_13\NN\14236743|NONE
D016190_D005909 NONE carboplatin_23\NN\0|by (r_advmod) encapsulated_24\VBN\1587062|and|of|term (r_conj) effects_14\NNS\13245626|,|and (r_conj) safety_8\NN\13920835|the|, (r_conj) feasibility_6\NN\5152150|,|.|are|For|in (r_nsubjpass) examined_31\VBN\0|NONE (l_prep) for_0\IN\0|feasibility|,|.|are|in (l_pobj) recurrences_3\NNS\7342049|NONE (l_compound) glioblastoma_2\NN\14236743|human
D016190_D005909 NONE carboplatin_24\VB\0|cubic|in (r_amod) phases_26\NNS\15113229|application|and (r_conj) received_17\VBD\2210855|and (r_conj) underwent_12\VBN\109660|a|glioblastoma (r_acl) multiforme_11\NN\0|NONE (l_compound) glioblastoma_10\NN\14236743|a|underwent
8841157
D000804_D006973 NONE ii_5\CD\13741022|angiotensin|for|a (r_compound) antagonist_6\NN\7846|,|.|study|: (l_prep) for_7\IN\0|angiotensin|II|a (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) hypertension_12\NN\14057371|NONE
C081489_D006973 NONE valsartan_0\NNP\2712393|NONE (l_appos) antagonist_6\NN\7846|,|.|study|: (l_prep) for_7\IN\0|angiotensin|II|a (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) hypertension_12\NN\14057371|NONE
C081489_D006973 NONE valsartan_27\NN\2712393|to (r_dobj) receive_24\VB\2210855|were|outpatients|in|randomly|. (r_advcl) allocated_14\VBN\2228698|NONE (l_nsubjpass) outpatients_6\NNS\10405694|were|receive|in|randomly|. (l_prep) with_7\IN\0|hundred|adult|eight (l_pobj) hypertension_11\NN\14057371|NONE
C081489_D006973 NONE valsartan_4\NN\2712393|effective|that (r_nsubj) is_5\VBZ\0|.|data (l_acomp) effective_9\JJ\0|valsartan|that (l_prep) as_10\IN\14622893|as|least (l_pobj) amlodipine_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|the (l_pobj) hypertension_19\NN\14057371|NONE
D017311_D004487 CID amlodipine_13\NN\0|the (r_compound) group_14\NN\2137|NONE (r_pobj) in_11\IN\13603305|.|at|incidence|%|higher|, (r_prep) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|at|in|%|higher|, (l_prep) of_2\IN\0|The (l_pobj) edema_7\NN\14315192|NONE
D017311_D004487 CID amlodipine_38\NN\0|NONE (r_pobj) for_35\IN\0|%|;|)|.|;|% (r_prep) %_34\NN\0|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|at|in|%|higher|, (l_prep) of_2\IN\0|The (l_pobj) edema_7\NN\14315192|NONE
D017311_D004487 CID amlodipine_47\NN\0|for|plus| (r_conj) %_41\NN\0|;|)|.|;|%|for (r_conj) %_34\NN\0|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|at|in|%|higher|, (l_prep) of_2\IN\0|The (l_pobj) edema_7\NN\14315192|NONE
D017311_D004487 CID amlodipine_54\NN\0|NONE (r_pobj) for_51\IN\0|. (r_prep) %_50\NN\0|%|;|)|.|;|for (r_appos) %_34\NN\0|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|at|in|%|higher|, (l_prep) of_2\IN\0|The (l_pobj) edema_7\NN\14315192|NONE
D017311_D006973 NONE amlodipine_23\NN\0|NONE (r_pobj) against_22\IN\0|NONE (r_prep) safety_21\NN\13920835|and|the (r_conj) efficacy_19\NN\5199286|NONE (r_pobj) of_17\IN\0|comparative|a (r_prep) study_16\NN\635850|antagonist|,|.|: (r_appos) valsartan_0\NNP\2712393|NONE (l_appos) antagonist_6\NN\7846|,|.|study|: (l_prep) for_7\IN\0|angiotensin|II|a (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) hypertension_12\NN\14057371|NONE
D017311_D006973 NONE amlodipine_31\NN\0|mg|or| (r_conj) valsartan_27\NN\2712393|to (r_dobj) receive_24\VB\2210855|were|outpatients|in|randomly|. (r_advcl) allocated_14\VBN\2228698|NONE (l_nsubjpass) outpatients_6\NNS\10405694|were|receive|in|randomly|. (l_prep) with_7\IN\0|hundred|adult|eight (l_pobj) hypertension_11\NN\14057371|NONE
D017311_D006973 NONE amlodipine_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|the (l_pobj) hypertension_19\NN\14057371|NONE
C081489_D004487 CID valsartan_31\NN\2712393|NONE (r_pobj) for_28\IN\0|. (r_prep) %_27\NN\0|;|a|of|( (r_appos) dose_19\NN\3740161|particularly (r_pobj) at_17\IN\14622893|.|in|incidence|%|higher|, (r_prep) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|at|in|%|higher|, (l_prep) of_2\IN\0|The (l_pobj) edema_7\NN\14315192|NONE
C081489_D004487 CID valsartan_43\NN\2712393|NONE (r_pobj) for_42\IN\0|amlodipine|plus| (r_prep) %_41\NN\0|;|)|.|;|%|for (r_conj) %_34\NN\0|.|at|in|incidence|higher|, (r_npadvmod) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|at|in|%|higher|, (l_prep) of_2\IN\0|The (l_pobj) edema_7\NN\14315192|NONE
12180796
D009569_D001167 NONE oxide_21\NN\14818238|(|factor|nitric|iNOS|,|) (r_compound) synthase_22\NN\0|NONE (r_pobj) of_19\IN\0|inducible (r_prep) type_18\NN\5839024|NONE (r_pobj) of_16\IN\0|NONE (r_prep) expressions_15\NNS\4679549|NONE (r_pobj) for_14\IN\0|was|immunohistochemically|,|. (r_prep) examined_12\VBN\0|Arteritis|fenoldopam|in|, (r_conj) induced_1\VBN\1627355|NONE (l_nsubj) arteritis_0\NNP\14336539|examined|fenoldopam|in|,
D018818_D001167 CID fenoldopam_12\NN\0|NONE (r_pobj) by_11\IN\0|NONE (r_prep) rats_10\NNS\2329401|NONE (r_pobj) in_9\IN\13603305|beta|,|.|vasodilators (r_prep) induced_8\VBN\1627355|NONE (l_nsubj) beta1_0\NNP\0|in|,|.|vasodilators (l_prep) in_6\IN\13603305|(|)|beta (l_pobj) arteritis_7\NN\14336539|NONE
D018818_D001167 CID fenoldopam_7\NN\0|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN\1627355|NONE (l_nsubj) arteritis_0\NNP\14336539|examined|fenoldopam|in|,
D013806_D001167 CID theophylline_14\NN\2905612|and (r_conj) fenoldopam_12\NN\0|NONE (r_pobj) by_11\IN\0|NONE (r_prep) rats_10\NNS\2329401|NONE (r_pobj) in_9\IN\13603305|beta|,|.|vasodilators (r_prep) induced_8\VBN\1627355|NONE (l_nsubj) beta1_0\NNP\0|in|,|.|vasodilators (l_prep) in_6\IN\13603305|(|)|beta (l_pobj) arteritis_7\NN\14336539|NONE
D013806_D001167 CID theophylline_9\NN\2905612|and (r_conj) fenoldopam_7\NN\0|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN\1627355|NONE (l_nsubj) arteritis_0\NNP\14336539|examined|fenoldopam|in|,
D013806_D009369 NONE theophylline_9\NN\2905612|and (r_conj) fenoldopam_7\NN\0|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN\1627355|NONE (l_conj) examined_12\VBN\0|Arteritis|fenoldopam|in|, (l_prep) for_14\IN\0|was|immunohistochemically|,|. (l_pobj) expressions_15\NNS\4679549|NONE (l_prep) of_16\IN\0|NONE (l_pobj) type_18\NN\5839024|NONE (l_prep) of_19\IN\0|inducible (l_pobj) synthase_22\NN\0|NONE (l_appos) factor_30\NN\7326557|(|oxide|nitric|iNOS|,|) (l_conj) beta1_39\NNP\0|growth|)|basic|(|bFGF|and (l_compound) factor_37\NN\7326557|beta|(|) (l_compound) tumor_35\NN\14234074|growth|
D018818_D009369 NONE fenoldopam_7\NN\0|Arteritis|examined|in|, (r_npadvmod) induced_1\VBN\1627355|NONE (l_conj) examined_12\VBN\0|Arteritis|fenoldopam|in|, (l_prep) for_14\IN\0|was|immunohistochemically|,|. (l_pobj) expressions_15\NNS\4679549|NONE (l_prep) of_16\IN\0|NONE (l_pobj) type_18\NN\5839024|NONE (l_prep) of_19\IN\0|inducible (l_pobj) synthase_22\NN\0|NONE (l_appos) factor_30\NN\7326557|(|oxide|nitric|iNOS|,|) (l_conj) beta1_39\NNP\0|growth|)|basic|(|bFGF|and (l_compound) factor_37\NN\7326557|beta|(|) (l_compound) tumor_35\NN\14234074|growth|
D009569_D009369 NONE oxide_7\NN\14818238|NONE (l_appos) factor_15\NN\7326557|iNOS|)|nitric|(|, (l_conj) growth_21\NN\13526110|growth|)|and|basic|(|bFGF (l_compound) tumor_20\NN\14234074|NONE
D009569_D009369 NONE oxide_21\NN\14818238|(|factor|nitric|iNOS|,|) (r_compound) synthase_22\NN\0|NONE (l_appos) factor_30\NN\7326557|(|oxide|nitric|iNOS|,|) (l_conj) beta1_39\NNP\0|growth|)|basic|(|bFGF|and (l_compound) factor_37\NN\7326557|beta|(|) (l_compound) tumor_35\NN\14234074|growth|
9431903
D005996_D046628 NONE trinitrate_3\NN\0|NONE (l_prep) on_4\IN\0|glyceryl (l_pobj) sphincter_6\NN\5289297|NONE (l_prep) of_7\IN\0|the (l_pobj) spasm_9\NN\14299637|NONE
D005996_D046628 NONE trinitrate_9\NN\0|NONE (l_prep) on_10\IN\0|glyceryl (l_pobj) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|the|induced (l_pobj) spasm_20\NN\14299637|NONE
D005996_D046628 NONE trinitrate_9\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effect_6\NN\34213|.|OBJECTIVE|:|with|in|In|was (r_nsubjpass) evaluated_22\VBN\670261|NONE (l_prep) with_27\IN\0|.|OBJECTIVE|:|in|In|was|effect (l_pobj) sphincter_28\NN\5289297|NONE (l_prep) of_29\IN\0|NONE (l_pobj) dyskinesia_31\NN\14084880|NONE
D005996_D046628 NONE trinitrate_11\NN\0|NONE (l_prep) on_12\IN\0|glyceryl (l_pobj) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|induced|the (l_pobj) spasm_20\NN\14299637|NONE
D005996_D046628 NONE trinitrate_2\NN\0|able|Since (r_nsubj) is_3\VBZ\0|of|in|.|,|might|it (r_advcl) be_16\VB\14625458|NONE (l_prep) in_19\IN\13603305|of|.|,|is|might|it (l_pobj) treatment_21\NN\654885|NONE (l_prep) of_22\IN\0|the (l_pobj) sphincter_23\NN\5289297|NONE (l_prep) of_24\IN\0|NONE (l_pobj) dyskinesia_26\NN\14084880|NONE
D009388_D013035 CID prostigmine_12\JJ\0| (r_compound) morphine_14\NN\2707683|NONE (r_compound) administration_15\NN\1133281|NONE (r_pobj) by_11\IN\0|NONE (r_agent) evoked_10\VBN\1617192|Oddi (r_acl) spasm_9\NN\14299637|NONE
D009388_D013035 CID prostigmine_12\JJ\0| (r_compound) morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|the|induced (l_pobj) spasm_20\NN\14299637|NONE
D009388_D013035 CID prostigmine_7\JJ\0| (r_compound) morphine_9\NN\2707683|prostigmine (r_compound) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009388_D013035 CID prostigmine_14\NN\0|morphine (r_parataxis) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009388_D013035 CID prostigmine_1\JJ\0| (r_compound) morphine_3\NN\2707683|NONE (r_compound) provocation_4\NN\1221611|:|indicating|.|)|and|.|increases|+/ (r_nsubj) caused_5\VBD\1617192|NONE (l_advcl) indicating_97\VBG\952524|:|.|provocation|)|and|.|increases|+/ (l_dobj) spasm_100\NN\14299637|NONE
D009388_D046628 CID prostigmine_12\JJ\0| (r_compound) morphine_14\NN\2707683|NONE (r_compound) administration_15\NN\1133281|NONE (r_pobj) by_11\IN\0|NONE (r_agent) evoked_10\VBN\1617192|Oddi (r_acl) spasm_9\NN\14299637|NONE
D009388_D046628 CID prostigmine_12\JJ\0| (r_compound) morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|the|induced (l_pobj) spasm_20\NN\14299637|NONE
D009388_D046628 CID prostigmine_12\JJ\0| (r_compound) morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (r_pobj) on_10\IN\0|glyceryl (r_prep) trinitrate_9\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effect_6\NN\34213|.|OBJECTIVE|:|with|in|In|was (r_nsubjpass) evaluated_22\VBN\670261|NONE (l_prep) with_27\IN\0|.|OBJECTIVE|:|in|In|was|effect (l_pobj) sphincter_28\NN\5289297|NONE (l_prep) of_29\IN\0|NONE (l_pobj) dyskinesia_31\NN\14084880|NONE
D009388_D046628 CID prostigmine_7\JJ\0| (r_compound) morphine_9\NN\2707683|prostigmine (r_compound) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009388_D046628 CID prostigmine_14\NN\0|morphine (r_parataxis) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009020_D013035 CID morphine_14\NN\2707683|NONE (r_compound) administration_15\NN\1133281|NONE (r_pobj) by_11\IN\0|NONE (r_agent) evoked_10\VBN\1617192|Oddi (r_acl) spasm_9\NN\14299637|NONE
D009020_D013035 CID morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|the|induced (l_pobj) spasm_20\NN\14299637|NONE
D009020_D013035 CID morphine_9\NN\2707683|prostigmine (r_compound) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009020_D013035 CID morphine_19\NN\2707683|(|subcutaneously|and|mg|intramuscularly|) (r_conj) prostigmine_14\NN\0|morphine (r_parataxis) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009020_D013035 CID morphine_3\NN\2707683|NONE (r_compound) provocation_4\NN\1221611|:|indicating|.|)|and|.|increases|+/ (r_nsubj) caused_5\VBD\1617192|NONE (l_advcl) indicating_97\VBG\952524|:|.|provocation|)|and|.|increases|+/ (l_dobj) spasm_100\NN\14299637|NONE
D009020_D013035 CID morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|induced|the (l_pobj) spasm_20\NN\14299637|NONE
D005996_D013035 NONE trinitrate_3\NN\0|NONE (l_prep) on_4\IN\0|glyceryl (l_pobj) sphincter_6\NN\5289297|NONE (l_prep) of_7\IN\0|the (l_pobj) spasm_9\NN\14299637|NONE
D005996_D013035 NONE trinitrate_9\NN\0|NONE (l_prep) on_10\IN\0|glyceryl (l_pobj) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|the|induced (l_pobj) spasm_20\NN\14299637|NONE
D005996_D013035 NONE trinitrate_11\NN\0|NONE (l_prep) on_12\IN\0|glyceryl (l_pobj) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|induced|the (l_pobj) spasm_20\NN\14299637|NONE
D009020_D046628 CID morphine_14\NN\2707683|NONE (r_compound) administration_15\NN\1133281|NONE (r_pobj) by_11\IN\0|NONE (r_agent) evoked_10\VBN\1617192|Oddi (r_acl) spasm_9\NN\14299637|NONE
D009020_D046628 CID morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|the|induced (l_pobj) spasm_20\NN\14299637|NONE
D009020_D046628 CID morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (r_pobj) on_10\IN\0|glyceryl (r_prep) trinitrate_9\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effect_6\NN\34213|.|OBJECTIVE|:|with|in|In|was (r_nsubjpass) evaluated_22\VBN\670261|NONE (l_prep) with_27\IN\0|.|OBJECTIVE|:|in|In|was|effect (l_pobj) sphincter_28\NN\5289297|NONE (l_prep) of_29\IN\0|NONE (l_pobj) dyskinesia_31\NN\14084880|NONE
D009020_D046628 CID morphine_9\NN\2707683|prostigmine (r_compound) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009020_D046628 CID morphine_19\NN\2707683|(|subcutaneously|and|mg|intramuscularly|) (r_conj) prostigmine_14\NN\0|morphine (r_parataxis) administration_10\NN\1133281|NONE (r_pobj) by_6\IN\0|visualized|.|spasm|was|and (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) spasm_3\NN\14299637|visualized|.|by|was|and
D009020_D046628 CID morphine_14\NN\2707683| (r_npadvmod) induced_16\VBN\1627355|the|of (r_amod) sphincter_17\NN\5289297|NONE (l_prep) of_18\IN\0|induced|the (l_pobj) spasm_20\NN\14299637|NONE
D009020_D046628 CID morphine_12\NN\2707683|NONE (r_pobj) of_11\IN\0|even|drastic|the (r_prep) effect_10\NN\34213|to (r_dobj) overcome_6\VB\0|NONE (r_xcomp) able_4\JJ\0|Since|trinitrate (r_acomp) is_3\VBZ\0|of|in|.|,|might|it (r_advcl) be_16\VB\14625458|NONE (l_prep) in_19\IN\13603305|of|.|,|is|might|it (l_pobj) treatment_21\NN\654885|NONE (l_prep) of_22\IN\0|the (l_pobj) sphincter_23\NN\5289297|NONE (l_prep) of_24\IN\0|NONE (l_pobj) dyskinesia_26\NN\14084880|NONE
3015327
D007538_D009422 CID isoniazid_6\NN\2716205|in (r_compound) neuropathy_7\NN\14204950|NONE
D007538_D009422 CID isoniazid_8\NN\2716205|NONE (r_pobj) of_7\IN\0|in|single|a (r_prep) dose_6\NN\3740161|NONE (r_pobj) by_3\IN\0|NONE (r_agent) caused_2\VBN\1617192|The (r_acl) neuropathy_1\NN\14204950|.|was|with
9201797
D002354_D002375 NONE hydrochloride_5\NN\14817592|NONE (r_pobj) of_3\IN\0|on|attenuating|The|. (r_prep) effect_2\NN\34213|NONE (l_prep) on_13\IN\0|attenuating|The|.|of (l_pobj) catalepsy_17\NN\14023236|NONE
D002354_D002375 NONE carteolol_5\NN\0|NONE (r_pobj) of_4\IN\0|the|,|antagonist (r_prep) effects_3\NNS\13245626|and|,|were|Therefore|behaviorally|.|compared (l_appos) antagonist_11\NN\7846|the|,|of (l_prep) on_13\IN\0|a|,|adrenoceptor (l_pobj) catalepsy_17\NN\14023236|NONE
D002354_D002375 NONE carteolol_0\NNP\0|NONE (l_conj) propranolol_5\NN\0|as|,|. (l_conj) inhibited_9\VBD\2510337|,|and|biperiden (l_dobj) catalepsy_14\NN\14023236|NONE
D002354_D002375 NONE carteolol_5\NN\0|that|expected|catalepsy|via|and (r_nsubj) improves_6\VBZ\126264|strongly|results|. (l_dobj) catalepsy_10\NN\14023236|that|carteolol|expected|via|and
D006220_D002375 CID haloperidol_14\NN\3713736| (r_npadvmod) induced_16\VBN\1627355|in (r_amod) catalepsy_17\NN\14023236|NONE
D006220_D002375 CID haloperidol_11\NN\3713736| (r_npadvmod) induced_13\VBN\1627355|the (r_amod) catalepsy_14\NN\14023236|NONE
D006220_D002375 CID haloperidol_7\NN\3713736| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) catalepsy_10\NN\14023236|that|carteolol|expected|via|and
D004298_D017109 NONE dopamine_40\NN\14807737|NONE (r_nmod) receptor_41\NN\5225602|antagonistic|its|postsynaptic (r_nmod) activity_43\NN\30358|NONE (r_pobj) to_37\IN\0|NONE (r_pcomp) due_36\IN\5174653|effects (r_prep) attenuating_30\VBG\224901|NONE (r_pcomp) without_29\IN\0|the|of (r_prep) treatment_26\NN\654885|NONE (l_prep) of_27\IN\0|without|the (l_pobj) akathisia_28\NN\0|NONE
D002354_D009069 NONE carteolol_0\NNP\0|signs|not|did|. (r_nsubj) evoke_3\VB\1617192|NONE (l_dobj) signs_10\NNS\6643763|not|Carteolol|did|. (l_prep) as_12\IN\14622893|dopamine|behavioral|postsynaptic|stimulating (l_pobj) stereotypy_13\NN\0|such (l_conj) hyperlocomotion_15\NN\0|and|in
D004298_D009069 NONE dopamine_5\NN\14807737|behavioral|as|postsynaptic|stimulating (r_nmod) signs_10\NNS\6643763|not|Carteolol|did|. (l_prep) as_12\IN\14622893|dopamine|behavioral|postsynaptic|stimulating (l_pobj) stereotypy_13\NN\0|such (l_conj) hyperlocomotion_15\NN\0|and|in
D004298_D002375 NONE dopamine_40\NN\14807737|NONE (r_nmod) receptor_41\NN\5225602|antagonistic|its|postsynaptic (r_nmod) activity_43\NN\30358|NONE (r_pobj) to_37\IN\0|NONE (r_pcomp) due_36\IN\5174653|effects (r_prep) attenuating_30\VBG\224901|NONE (r_pcomp) without_29\IN\0|the|of (r_prep) treatment_26\NN\654885|NONE (r_pobj) in_24\IN\13603305|NONE (r_prep) effective_23\JJ\0|to (r_acomp) be_22\VB\14625458|is (r_xcomp) expected_20\VBN\670261|that|carteolol|catalepsy|via|and (r_conj) improves_6\VBZ\126264|strongly|results|. (l_dobj) catalepsy_10\NN\14023236|that|carteolol|expected|via|and
D006220_D017109 NONE haloperidol_7\NN\3713736| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) catalepsy_10\NN\14023236|that|carteolol|expected|via|and (r_dobj) improves_6\VBZ\126264|strongly|results|. (l_conj) expected_20\VBN\670261|that|carteolol|catalepsy|via|and (l_xcomp) be_22\VB\14625458|is (l_acomp) effective_23\JJ\0|to (l_prep) in_24\IN\13603305|NONE (l_pobj) treatment_26\NN\654885|NONE (l_prep) of_27\IN\0|without|the (l_pobj) akathisia_28\NN\0|NONE
D001712_D002375 NONE biperiden_30\VBN\0|and (r_conj) propranolol_28\NN\0|NONE (r_pobj) of_27\IN\0|,|antagonist (r_prep) those_26\DT\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) compared_24\VBN\644583|and|effects|,|were|Therefore|behaviorally|. (r_conj) studied_22\VBN\0|NONE (l_nsubjpass) effects_3\NNS\13245626|and|,|were|Therefore|behaviorally|.|compared (l_appos) antagonist_11\NN\7846|the|,|of (l_prep) on_13\IN\0|a|,|adrenoceptor (l_pobj) catalepsy_17\NN\14023236|NONE
D001712_D002375 NONE biperiden_7\RB\0|,|and|inhibited (r_conj) propranolol_5\NN\0|as|,|. (l_conj) inhibited_9\VBD\2510337|,|and|biperiden (l_dobj) catalepsy_14\NN\14023236|NONE
D011433_D002375 NONE propranolol_28\NN\0|NONE (r_pobj) of_27\IN\0|,|antagonist (r_prep) those_26\DT\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) compared_24\VBN\644583|and|effects|,|were|Therefore|behaviorally|. (r_conj) studied_22\VBN\0|NONE (l_nsubjpass) effects_3\NNS\13245626|and|,|were|Therefore|behaviorally|.|compared (l_appos) antagonist_11\NN\7846|the|,|of (l_prep) on_13\IN\0|a|,|adrenoceptor (l_pobj) catalepsy_17\NN\14023236|NONE
D011433_D002375 NONE propranolol_5\NN\0|as|,|. (l_conj) inhibited_9\VBD\2510337|,|and|biperiden (l_dobj) catalepsy_14\NN\14023236|NONE
D002354_D017109 NONE carteolol_5\NN\0|that|expected|catalepsy|via|and (r_nsubj) improves_6\VBZ\126264|strongly|results|. (l_conj) expected_20\VBN\670261|that|carteolol|catalepsy|via|and (l_xcomp) be_22\VB\14625458|is (l_acomp) effective_23\JJ\0|to (l_prep) in_24\IN\13603305|NONE (l_pobj) treatment_26\NN\654885|NONE (l_prep) of_27\IN\0|without|the (l_pobj) akathisia_28\NN\0|NONE
15042318
D004317_D009136 NONE doxorubicin_34\NN\2716866| (r_npadvmod) based_36\VBN\0|NONE (r_amod) chemotherapy_37\NN\661091|NONE (r_pobj) of_33\IN\0|one (r_prep) cycle_32\NN\15269513|in (r_pobj) following_30\VBG\8180190|atrial|sudden (r_prep) fibrillation_29\NN\14361664|,|and|of|common|the (r_conj) form_20\NN\6286395|lymphoma|diffuse|, (l_prep) of_21\IN\0|,|and|common|the|fibrillation (l_pobj) dystrophy_24\NN\14151139|NONE
D004317_C535648 NONE doxorubicin_34\NN\2716866| (r_npadvmod) based_36\VBN\0|NONE (r_amod) chemotherapy_37\NN\661091|NONE (r_pobj) of_33\IN\0|one (r_prep) cycle_32\NN\15269513|in (r_pobj) following_30\VBG\8180190|atrial|sudden (r_prep) fibrillation_29\NN\14361664|,|and|of|common|the (r_conj) form_20\NN\6286395|lymphoma|diffuse|, (r_appos) dystrophy_15\NN\14151139|NONE (l_nmod) lymphoma_12\NN\14239918|form|diffuse|,
D004317_D009223 NONE doxorubicin_34\NN\2716866| (r_npadvmod) based_36\VBN\0|NONE (r_amod) chemotherapy_37\NN\661091|NONE (r_pobj) of_33\IN\0|one (r_prep) cycle_32\NN\15269513|in (r_pobj) following_30\VBG\8180190|atrial|sudden (r_prep) fibrillation_29\NN\14361664|,|and|of|common|the (r_conj) form_20\NN\6286395|lymphoma|diffuse|, (r_appos) dystrophy_15\NN\14151139|NONE
D004317_D001281 CID doxorubicin_34\NN\2716866| (r_npadvmod) based_36\VBN\0|NONE (r_amod) chemotherapy_37\NN\661091|NONE (r_pobj) of_33\IN\0|one (r_prep) cycle_32\NN\15269513|in (r_pobj) following_30\VBG\8180190|atrial|sudden (r_prep) fibrillation_29\NN\14361664|,|and|of|common|the
8492347
D011188_D013746 NONE potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS\14299637|NONE (l_conj) tetany_16\NN\14304060|muscle|and
D008274_D013746 NONE magnesium_10\NN\14625458|NONE (r_compound) supplementation_11\NN\5108947|NONE (r_pobj) of_9\IN\0|NONE (r_prep) importance_8\NN\5138488|rhabdomyolysis||due|and|. (r_appos) tetany_0\NNP\14304060|NONE
D011188_D007008 NONE potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_advcl) cause_4\VB\7323922|corrected|hypomagnesemia|.|,|is|with (l_nsubj) hypokalemia_2\NN\14299637|weakness|While|may
D002118_C537153 NONE calcium_25\NN\14625458|and (r_conj) potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_nsubjpass) hypomagnesemia_9\NN\0|corrected|.|cause|,|is|with
D008274_D007008 NONE magnesium_27\NN\14625458|NONE (r_compound) depletion_28\NN\351638|NONE (r_pobj) of_26\IN\0|the (r_prep) effects_25\NNS\13245626|not|were|in|. (r_nsubjpass) noted_31\VBN\1009240|but|(|)|was|,|in (r_conj) observed_19\VBN\2163746|(|hypokalemia|and|has|)||been|in (r_conj) reported_4\VBN\831651|NONE (l_nsubjpass) hypokalemia_1\NN\14299637|observed|(|and|has|)||been|in
D008274_D006996 NONE magnesium_27\NN\14625458|NONE (r_compound) depletion_28\NN\351638|NONE (r_pobj) of_26\IN\0|the (r_prep) effects_25\NNS\13245626|not|were|in|. (r_nsubjpass) noted_31\VBN\1009240|but|(|)|was|,|in (r_conj) observed_19\VBN\2163746|(|hypokalemia|and|has|)||been|in (l_prep) in_14\IN\13603305|but|(|)|noted|was|, (l_pobj) hypocalcemia_17\NN\14299637|NONE
D011188_C537153 NONE potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_nsubjpass) hypomagnesemia_9\NN\0|corrected|.|cause|,|is|with
D011188_D018908 NONE potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_advcl) cause_4\VB\7323922|corrected|hypomagnesemia|.|,|is|with (l_dobj) weakness_6\NN\14462666|hypokalemia|While|may
D002118_D013746 NONE calcium_25\NN\14625458|and (r_conj) potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS\14299637|NONE (l_conj) tetany_16\NN\14304060|muscle|and
D005665_D012206 CID furosemide_6\NN\3214670|to (r_pobj) due_3\JJ\5174653|rhabdomyolysis||importance|and|. (r_prep) tetany_0\NNP\14304060|NONE (l_conj) rhabdomyolysis_2\NN\0||importance|due|and|.
D005665_D013746 CID furosemide_6\NN\3214670|to (r_pobj) due_3\JJ\5174653|rhabdomyolysis||importance|and|. (r_prep) tetany_0\NNP\14304060|NONE
D008274_D012206 NONE magnesium_10\NN\14625458|NONE (r_compound) supplementation_11\NN\5108947|NONE (r_pobj) of_9\IN\0|NONE (r_prep) importance_8\NN\5138488|rhabdomyolysis||due|and|. (r_appos) tetany_0\NNP\14304060|NONE (l_conj) rhabdomyolysis_2\NN\0||importance|due|and|.
D002118_D007008 NONE calcium_25\NN\14625458|and (r_conj) potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_advcl) cause_4\VB\7323922|corrected|hypomagnesemia|.|,|is|with (l_nsubj) hypokalemia_2\NN\14299637|weakness|While|may
D002118_D013035 NONE calcium_25\NN\14625458|and (r_conj) potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS\14299637|NONE
D002118_D018908 NONE calcium_25\NN\14625458|and (r_conj) potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_advcl) cause_4\VB\7323922|corrected|hypomagnesemia|.|,|is|with (l_dobj) weakness_6\NN\14462666|hypokalemia|While|may
D011188_D013035 NONE potassium_23\NN\14625458|alone (r_nmod) supplementation_26\NN\5108947|NONE (r_pobj) by_22\IN\0|can|which|not|be (r_agent) corrected_21\VBN\138508|hypomagnesemia|.|cause|,|is|with (r_ccomp) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|corrected|hypomagnesemia|.|cause|,|is (l_pobj) spasms_14\NNS\14299637|NONE
10414674
D000082_D001791 NONE acetaminophen_9\NN\2707683|the (r_compound) group_10\NN\2137|NONE (r_pobj) in_7\IN\13603305|.|aggregation|,|In|on|compared (r_prep) increased_6\VBD\169651|NONE (l_nsubj) aggregation_5\NN\31264|in|.|,|In|on|compared
D000082_D001791 NONE acetaminophen_9\NN\2707683|the (r_compound) group_10\NN\2137|NONE (r_pobj) in_7\IN\13603305|.|aggregation|,|In|on|compared (r_prep) increased_6\VBD\169651|NONE (l_advcl) compared_17\VBN\644583|in|.|aggregation|,|In|on (l_prep) with_18\IN\0|as (l_pobj) results_23\NNS\34213|NONE (l_compound) aggregation_22\NN\31264|P|(|the|)
D000082_D013345 NONE acetaminophen_35\RB\2707683|,|weak|a|, (r_advmod) nsaid_33\NNP\2721538|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|(|.|receive|were|) (l_prep) with_1\IN\0|NONE (l_pobj) hemorrhage_4\NN\14285662|NONE
D000082_D013345 NONE acetaminophen_35\RB\2707683|,|weak|a|, (r_advmod) nsaid_33\NNP\2721538|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_punct) (_5\-LRB-\0|.|receive|were|Patients|) (l_preconj) sah_6\NNP\0|NONE
D000082_D013345 NONE acetaminophen_35\RB\2707683|,|weak|a|, (r_advmod) nsaid_33\NNP\2721538|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (l_parataxis) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE
D000082_D013345 NONE acetaminophen_45\NN\2707683||n|, (r_compound) group_46\NN\2137|(|immediately|after (r_nsubj) starting_52\VBG\457382|ketoprofen|times|group|to (r_parataxis) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|(|.|receive|were|) (l_prep) with_1\IN\0|NONE (l_pobj) hemorrhage_4\NN\14285662|NONE
D000082_D013345 NONE acetaminophen_45\NN\2707683||n|, (r_compound) group_46\NN\2137|(|immediately|after (r_nsubj) starting_52\VBG\457382|ketoprofen|times|group|to (r_parataxis) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_punct) (_5\-LRB-\0|.|receive|were|Patients|) (l_preconj) sah_6\NNP\0|NONE
D000082_D013345 NONE acetaminophen_45\NN\2707683||n|, (r_compound) group_46\NN\2137|(|immediately|after (r_nsubj) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE
D000082_D013345 NONE acetaminophen_3\RB\2707683|but (l_dobj) function_6\NN\13783581|.|not (l_prep) in_7\IN\13603305|impaired|platelet (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) sah_10\NNP\0|NONE
D007660_D006470 NONE ketoprofen_1\NN\3828465|If|before|is|on (r_nsubjpass) used_3\VBN\0|factor|may|it|.|, (r_advcl) pose_13\VB\4787763|NONE (l_dobj) factor_17\NN\7326557|may|it|.|used|, (l_prep) for_18\IN\0|additional|risk|an (l_pobj) hemorrhage_19\NN\14285662|NONE
D007660_D001791 CID ketoprofen_14\NN\3828465|NONE (r_pobj) of_13\IN\0|NONE (r_prep) administration_12\NN\1133281|NONE (r_pobj) after_11\IN\0|NONE (r_prep) decreased_10\VBD\169651|.|by|aggregation (r_conj) induced_3\VBN\1627355|NONE (l_nsubj) aggregation_2\NN\31264|.|by|decreased
D007660_D013345 NONE ketoprofen_13\JJ\3828465|times|group|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|(|.|receive|were|) (l_prep) with_1\IN\0|NONE (l_pobj) hemorrhage_4\NN\14285662|NONE
D007660_D013345 NONE ketoprofen_13\JJ\3828465|times|group|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_punct) (_5\-LRB-\0|.|receive|were|Patients|) (l_preconj) sah_6\NNP\0|NONE
D007660_D013345 NONE ketoprofen_13\JJ\3828465|times|group|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (l_parataxis) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE
D007660_D013345 NONE ketoprofen_23\JJ\3828465|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|(|.|receive|were|) (l_prep) with_1\IN\0|NONE (l_pobj) hemorrhage_4\NN\14285662|NONE
D007660_D013345 NONE ketoprofen_23\JJ\3828465|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (r_xcomp) randomized_9\VBN\278117|NONE (l_punct) (_5\-LRB-\0|.|receive|were|Patients|) (l_preconj) sah_6\NNP\0|NONE
D007660_D013345 NONE ketoprofen_23\JJ\3828465|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (l_parataxis) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE
D007660_D013345 NONE ketoprofen_0\NNP\3828465|NONE (l_conj) acetaminophen_3\RB\2707683|but (l_dobj) function_6\NN\13783581|.|not (l_prep) in_7\IN\13603305|impaired|platelet (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) sah_10\NNP\0|NONE
D007660_D017542 NONE ketoprofen_13\JJ\3828465|times|group|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (l_parataxis) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE (l_amod) aneurysmal_58\JJ\0|NONE
D007660_D017542 NONE ketoprofen_23\JJ\3828465|(|,|,|)|g|times||NSAID|or|n (r_compound) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (l_parataxis) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE (l_amod) aneurysmal_58\JJ\0|NONE
D000082_D017542 NONE acetaminophen_35\RB\2707683|,|weak|a|, (r_advmod) nsaid_33\NNP\2721538|(|,|,|)|g|times||or|ketoprofen|n (r_conj) group_24\NN\2137|ketoprofen|times|starting|to (r_dobj) receive_11\VB\2210855|(|.|were|Patients|) (l_parataxis) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE (l_amod) aneurysmal_58\JJ\0|NONE
D000082_D017542 NONE acetaminophen_45\NN\2707683||n|, (r_compound) group_46\NN\2137|(|immediately|after (r_nsubj) starting_52\VBG\457382|ketoprofen|times|group|to (l_prep) after_54\IN\0|(|group|immediately (l_pobj) diagnosis_56\NN\152018|NONE (l_prep) of_57\IN\0|the (l_pobj) sah_59\NNP\0|NONE (l_amod) aneurysmal_58\JJ\0|NONE
D007660_D006406 CID ketoprofen_4\JJ\3828465|the (r_compound) group_5\NN\2137|NONE (r_pobj) in_2\IN\13603305|One (r_prep) patient_1\NN\9898892|hematoma|. (r_nsubj) developed_6\VBD\1753788|NONE (l_dobj) hematoma_10\NN\14317720|.|patient
D000244_D001791 NONE diphosphate_9\NN\0|NONE (r_pobj) of_7\IN\0| (r_prep) microm_6\NNS\0|NONE (r_pobj) by_4\IN\0|.|aggregation|decreased (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) aggregation_2\NN\31264|.|by|decreased
D007660_D002532 NONE ketoprofen_1\NN\3828465|If|before|is|on (r_nsubjpass) used_3\VBN\0|factor|may|it|.|, (l_prep) on_6\IN\0|If|before|is|ketoprofen (l_pobj) aneurysms_9\NNS\14057371|NONE
8643966
D017239_D001943 NONE paclitaxel_0\NNP\0|activity|has|. (r_nsubj) demonstrated_15\VBN\2137132|NONE (l_dobj) activity_18\NN\30358|Paclitaxel|has|. (l_prep) against_19\IN\0|significant|antineoplastic (l_pobj) types_22\NNS\5839024|NONE (l_appos) carcinoma_28\NN\14239918|different|,|tumor
D017239_D001943 NONE taxol_2\NNP\0|Company (r_appos) paclitaxel_0\NNP\0|activity|has|. (r_nsubj) demonstrated_15\VBN\2137132|NONE (l_dobj) activity_18\NN\30358|Paclitaxel|has|. (l_prep) against_19\IN\0|significant|antineoplastic (l_pobj) types_22\NNS\5839024|NONE (l_appos) carcinoma_28\NN\14239918|different|,|tumor
D017239_D010051 NONE paclitaxel_0\NNP\0|activity|has|. (r_nsubj) demonstrated_15\VBN\2137132|NONE (l_dobj) activity_18\NN\30358|Paclitaxel|has|. (l_prep) against_19\IN\0|significant|antineoplastic (l_pobj) types_22\NNS\5839024|NONE (l_appos) carcinoma_28\NN\14239918|different|,|tumor
D017239_D010051 NONE taxol_2\NNP\0|Company (r_appos) paclitaxel_0\NNP\0|activity|has|. (r_nsubj) demonstrated_15\VBN\2137132|NONE (l_dobj) activity_18\NN\30358|Paclitaxel|has|. (l_prep) against_19\IN\0|significant|antineoplastic (l_pobj) types_22\NNS\5839024|NONE (l_appos) carcinoma_28\NN\14239918|different|,|tumor
D017239_D064420 NONE paclitaxel_9\NN\0|a|in|hour (r_compound) infusion_10\NN\14589223|NONE (r_pobj) of_6\IN\0|the|toxicity|and (r_prep) efficacy_3\NN\5199286|We|. (l_conj) toxicity_5\NN\13576101|the|of|and
D017239_D064420 NONE paclitaxel_0\NNP\0|,|agent|with|.|thus (r_nsubj) is_1\VBZ\0|NONE (l_prep) with_12\IN\0|,|agent|.|Paclitaxel|thus (l_pobj) infusion_15\NN\14589223|NONE (l_acl) proving_16\VBG\2604760|a|hour (l_oprd) effective_18\JJ\0|NONE (l_prep) to_19\IN\0|comparably (l_pobj) infusion_22\NN\14589223|NONE (l_conj) superior_24\JJ\9623038|a|hour|and (l_prep) in_25\IN\13603305|NONE (l_pobj) terms_26\NNS\13945919|NONE (l_prep) of_27\IN\0|NONE (l_pobj) incidence_29\NN\13821570|NONE (l_prep) of_30\IN\0|the (l_pobj) toxicity_34\NN\13576101|NONE
D017239_D002289 NONE paclitaxel_11\NN\0|NONE (r_pobj) with_10\IN\0|lung|inoperable|small|advanced (r_prep) cancer_9\NN\14239425|NONE
D017239_D002289 NONE paclitaxel_6\NN\0|in|hour (r_compound) infusions_7\NNS\14589223|NONE (l_prep) in_8\IN\13603305|hour|paclitaxel (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|naive (l_pobj) iiib_15\NNS\0|NONE (l_conj) cancer_23\NN\14239425|or|stage
D017239_D002289 NONE paclitaxel_6\NN\0|in|hour (r_compound) infusions_7\NNS\14589223|NONE (l_prep) in_8\IN\13603305|hour|paclitaxel (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|naive (l_pobj) iiib_15\NNS\0|NONE (l_conj) cancer_23\NN\14239425|or|stage (l_appos) nsclc_25\NNP\0|IV|)|lung|small|(
D017239_D002289 NONE paclitaxel_9\NN\0|a|in|hour (r_compound) infusion_10\NN\14589223|NONE (l_prep) in_11\IN\13603305|a|paclitaxel|hour (l_pobj) trial_15\NN\786195|NONE (l_prep) in_16\IN\13603305|II|phase (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|NONE (l_pobj) iiib_21\NNS\0|NONE (l_conj) nsclc_24\NNP\0|stage|or
D017239_D002289 NONE paclitaxel_5\NN\0|NONE (r_pobj) with_4\IN\0|combined|II (r_prep) studies_3\NNS\635850|Further (l_acl) combined_6\VBN\2630189|with|II (l_prep) with_7\IN\0|NONE (l_pobj) drugs_9\NNS\14778436|NONE (l_amod) active_10\JJ\14779550|other (l_prep) against_11\IN\0|NONE (l_pobj) nsclc_12\NNP\0|NONE
D017239_D002289 NONE paclitaxel_21\NN\0|with (r_dobj) comparing_20\VBG\635850|III (r_acl) studies_19\NNS\635850|remain (r_dobj) phase_17\NN\15113229|and|are|,|phase|. (r_conj) indicated_14\VBN\952524|NONE (l_nsubjpass) phase_1\NN\15113229|phase|and|are|,|. (l_dobj) studies_3\NNS\635850|Further (l_acl) combined_6\VBN\2630189|with|II (l_prep) with_7\IN\0|NONE (l_pobj) drugs_9\NNS\14778436|NONE (l_amod) active_10\JJ\14779550|other (l_prep) against_11\IN\0|NONE (l_pobj) nsclc_12\NNP\0|NONE
D017239_D009369 NONE paclitaxel_0\NNP\0|activity|has|. (r_nsubj) demonstrated_15\VBN\2137132|NONE (l_dobj) activity_18\NN\30358|Paclitaxel|has|. (l_prep) against_19\IN\0|significant|antineoplastic (l_pobj) types_22\NNS\5839024|NONE (l_compound) tumor_21\NN\14234074|carcinoma|different|,
D017239_D009369 NONE taxol_2\NNP\0|Company (r_appos) paclitaxel_0\NNP\0|activity|has|. (r_nsubj) demonstrated_15\VBN\2137132|NONE (l_dobj) activity_18\NN\30358|Paclitaxel|has|. (l_prep) against_19\IN\0|significant|antineoplastic (l_pobj) types_22\NNS\5839024|NONE (l_compound) tumor_21\NN\14234074|carcinoma|different|,
9041081
D013256_D009798 NONE steroid_13\NN\14727670| (r_npadvmod) induced_15\VBN\1627355|IOP|(|intraocular|elevated (r_amod) pressure_18\NN\11419404|patients|During|,|.
D013256_D009798 NONE steroid_2\NN\14727670| (r_npadvmod) induced_4\VBN\1627355|IOP (r_amod) rise_6\NN\7324673|cause|did|not|.
D000305_D009798 CID corticosteroid_25\NN\14745635|NONE (r_compound) therapy_26\NN\657604|after|was (r_nsubjpass) discontinued_28\VBN\0|that (r_advcl) resolved_23\VBD\352826|) (r_relcl) iop_20\NNP\11495041|(|induced|intraocular|elevated (r_appos) pressure_18\NN\11419404|patients|During|,|.
16710500
D004977_D014376 NONE ethambutol_2\NNP\0|:|is|in|INTRODUCTION|,|associated|and|. (r_nsubjpass) used_4\VBN\0|NONE (l_prep) in_5\IN\13603305|:|is|INTRODUCTION|,|associated|and|.|Ethambutol (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the|,|is (l_pobj) tuberculosis_9\NN\14127211|NONE
D004977_D009901 CID ethambutol_0\NN\0| (r_npadvmod) associated_2\VBN\628491|.|optic (r_amod) neuropathy_4\NN\14204950|NONE
D004977_D009901 CID ethambutol_3\NN\0| (r_npadvmod) associated_5\VBN\628491|optic (r_amod) neuropathy_8\NNS\14204950|NONE
D004977_D014786 CID ethambutol_2\NNP\0|:|is|in|INTRODUCTION|,|associated|and|. (r_nsubjpass) used_4\VBN\0|NONE (l_conj) associated_22\VBN\628491|:|is|in|INTRODUCTION|,|and|.|Ethambutol (l_prep) with_23\IN\0|be|can (l_pobj) loss_26\NN\13252973|NONE
D004977_D014786 CID ethambutol_0\NNP\0|NONE (r_compound) usage_1\NN\407535|.|is|avoided|with|and (r_nsubjpass) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|.|is|avoided|and|usage (l_pobj) loss_7\NN\13252973|NONE
12093990
C059262_D009503 CID cidofovir_2\NN\0|NONE (r_pobj) of_1\IN\0|in (r_prep) use_0\NN\407535|was|.|with (r_nsubjpass) associated_7\VBN\628491|NONE (l_prep) with_8\IN\0|was|Use|. (l_pobj) failure_11\NN\66216|NONE (l_conj) neutropenia_13\NN\14196405|progressive|and|renal
D012254_D000257 NONE ribavirin_1\JJ\2725367|.|Intravenous|in|for (r_compound) treatment_2\NN\654885|NONE (l_prep) for_3\IN\0|.|Intravenous|in|ribavirin (l_pobj) disease_6\NN\14061805|NONE
D012254_D000257 NONE ribavirin_7\NN\2725367|intravenous (r_compound) therapy_8\NN\657604|NONE (r_pobj) with_5\IN\0|our|for|in (r_prep) experience_4\NN\5984287|and|:|review|We|. (l_prep) for_9\IN\0|our|in|with (l_pobj) disease_12\NN\14061805|NONE
D012254_D000257 NONE ribavirin_12\RB\2725367|NONE (r_pobj) with_10\IN\0|for (r_prep) treated_9\VBN\2376958| (l_prep) for_13\IN\0|with (l_pobj) disease_17\NN\14061805|NONE
D012254_D000257 NONE ribavirin_2\NN\2725367|effective|not|Although (r_nsubj) was_3\VBD\0|therapy|.|begun|,|unlikely (l_acomp) effective_5\JJ\0|not|Although|ribavirin (l_prep) for_6\IN\0|NONE (l_pobj) children_8\NNS\9622049|NONE (l_prep) with_9\IN\0|all (l_pobj) disease_12\NN\14061805|NONE
D012254_D000257 NONE ribavirin_11\RB\2725367|NONE (r_pobj) with_9\IN\0|recovered|.|children (r_prep) treated_8\VBN\2376958|NONE (l_nsubj) children_3\NNS\9622049|recovered|with|. (l_prep) with_4\IN\0| (l_pobj) disease_7\NN\14061805|NONE
D012254_D000257 NONE ribavirin_33\NN\2725367|such (r_pobj) as_31\IN\14622893|,|adenoviral|useful|, (r_prep) therapies_28\NNS\657604|NONE (r_pobj) of_22\IN\0|,|clinical|multicenter|a|large (r_prep) trial_21\NN\786195|especially|, (r_conj) children_14\NNS\9622049|,|certain (r_appos) hosts_11\NNS\9605289|NONE (r_pobj) in_9\IN\13603305|of (r_prep) prevalence_5\NN\4764412|the|increasing|and (l_prep) of_6\IN\0|in (l_pobj) disease_8\NN\14061805|NONE
C059262_D000257 NONE cidofovir_3\NN\0|NONE (r_pobj) of_2\IN\0|The|in (r_prep) use_1\NN\407535|has|been|by (l_prep) in_4\IN\13603305|The|of (l_pobj) infection_7\NN\14052046|NONE
D012254_D000740 NONE ribavirin_7\RB\2725367|NONE (r_pobj) of_5\IN\0|common|adverse|The (r_prep) effect_4\NN\34213|anemia|. (r_nsubj) is_8\VBZ\0|NONE (l_attr) anemia_11\NN\14189204|.|effect
D012254_D006482 NONE ribavirin_0\NNP\2725367|is|in|is|and|,|treat|. (r_nsubjpass) licensed_2\VBN\803325|NONE (l_conj) is_27\VBZ\0|in|is|and|,|Ribavirin|treat|. (l_attr) treatment_29\NN\654885|NONE (l_prep) for_32\IN\0|the|of (l_pobj) infection_33\NN\14052046|NONE (l_prep) with_34\IN\0|NONE (l_pobj) viruses_37\NNS\9312843|NONE
D012254_D006482 NONE ribavirin_26\RB\2725367|to|in (r_dobj) treat_22\VB\7570720|is|in|is|and|,|Ribavirin|. (r_conj) licensed_2\VBN\803325|NONE (l_conj) is_27\VBZ\0|in|is|and|,|Ribavirin|treat|. (l_attr) treatment_29\NN\654885|NONE (l_prep) for_32\IN\0|the|of (l_pobj) infection_33\NN\14052046|NONE (l_prep) with_34\IN\0|NONE (l_pobj) viruses_37\NNS\9312843|NONE
D012254_D007239 NONE ribavirin_2\NN\2725367|effective|not|Although (r_nsubj) was_3\VBD\0|therapy|.|begun|,|unlikely (r_advcl) is_22\VBZ\0|NONE (l_advcl) begun_29\VBN\0|therapy|.|was|,|unlikely (l_prep) in_31\IN\13603305|if (l_pobj) course_33\NN\883297|late (l_prep) of_34\IN\0|the (l_pobj) infection_36\NN\14052046|NONE
C059262_D058186 CID cidofovir_2\NN\0|NONE (r_pobj) of_1\IN\0|in (r_prep) use_0\NN\407535|was|.|with (r_nsubjpass) associated_7\VBN\628491|NONE (l_prep) with_8\IN\0|was|Use|. (l_pobj) failure_11\NN\66216|NONE
D012254_D006526 NONE ribavirin_0\NNP\2725367|is|in|is|and|,|treat|. (r_nsubjpass) licensed_2\VBN\803325|NONE (l_conj) treat_22\VB\7570720|is|in|is|and|,|Ribavirin|. (l_dobj) ribavirin_26\RB\2725367|to|in (l_compound) intravenous_25\NNP\0|NONE (l_compound) c._24\NNP\0|hepatitis
D012254_D006526 NONE ribavirin_26\RB\2725367|to|in (l_compound) intravenous_25\NNP\0|NONE (l_compound) c._24\NNP\0|hepatitis
D012254_D018357 NONE ribavirin_0\NNP\2725367|is|in|is|and|,|treat|. (r_nsubjpass) licensed_2\VBN\803325|NONE (l_prep) in_3\IN\13603305|is|is|and|,|Ribavirin|treat|. (l_pobj) form_5\NN\6286395|NONE (l_prep) for_6\IN\0|aerosol (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) infection_13\NN\14052046|NONE
D012254_D018357 NONE ribavirin_26\RB\2725367|to|in (r_dobj) treat_22\VB\7570720|is|in|is|and|,|Ribavirin|. (r_conj) licensed_2\VBN\803325|NONE (l_prep) in_3\IN\13603305|is|is|and|,|Ribavirin|treat|. (l_pobj) form_5\NN\6286395|NONE (l_prep) for_6\IN\0|aerosol (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) infection_13\NN\14052046|NONE
C059262_D007674 NONE cidofovir_3\NN\0|NONE (r_pobj) of_2\IN\0|The|in (r_prep) use_1\NN\407535|has|been|by (r_nsubjpass) limited_10\VBN\4019101|.|,|nephrotoxicity|significant (r_ccomp) is_20\VBZ\0|NONE (l_attr) nephrotoxicity_21\NN\0|.|,|limited|significant
17049862
D010672_D001919 CID phenytoin_1\JJ\3550533|NONE (r_compound) administration_2\NN\1133281|NONE (r_pobj) following_0\VBG\8180190|,|refractory|.|bradycardia|,|patient (r_prep) developed_6\VBD\1753788|NONE (l_dobj) bradycardia_9\NN\14110674|,|Following|refractory|.|,|patient
D001285_D001919 NONE atropine_13\NN\14712692|NONE (r_pobj) to_12\IN\0|NONE (r_prep) refractory_11\JJ\3673767|,|Following|.|bradycardia|,|patient (r_advcl) developed_6\VBD\1753788|NONE (l_dobj) bradycardia_9\NN\14110674|,|Following|refractory|.|,|patient
D010672_D012640 NONE phenytoin_1\NN\3550533|during|was|. (r_nsubjpass) administered_3\VBN\2436349|NONE (l_prep) during_4\IN\0|was|phenytoin|. (l_pobj) part_7\NN\31921|NONE (l_prep) of_8\IN\0|later|the (l_pobj) surgery_10\NN\6045562|NONE (l_prep) for_11\IN\0|the (l_pobj) prophylaxis_13\NN\1077350|NONE (l_compound) seizure_12\NN\14081375|NONE
D004837_D001919 NONE adrenaline_15\NN\14807929|and (r_conj) atropine_13\NN\14712692|NONE (r_pobj) to_12\IN\0|NONE (r_prep) refractory_11\JJ\3673767|,|Following|.|bradycardia|,|patient (r_advcl) developed_6\VBD\1753788|NONE (l_dobj) bradycardia_9\NN\14110674|,|Following|refractory|.|,|patient
D010672_D007035 NONE phenytoin_1\JJ\3550533|NONE (r_compound) administration_2\NN\1133281|?|safe (r_nsubj) is_0\VBZ\0|NONE (l_acomp) safe_3\JJ\4340750|administration|? (l_prep) in_4\IN\13603305|NONE (l_pobj) child_7\NN\9622049|NONE (l_amod) hypothermic_6\JJ\0|a
D010672_D007035 NONE phenytoin_5\NN\3550533|NONE (l_conj) hypothermia_7\NN\14034177|and
D010672_D007035 NONE phenytoin_2\NN\3550533|NONE (r_pobj) of_1\IN\0|in (r_prep) administration_0\NN\1133281|to|.|may (l_prep) in_3\IN\13603305|of (l_pobj) presence_5\NN\13954253|NONE (l_prep) of_6\IN\0|the (l_pobj) hypothermia_7\NN\14034177|NONE
11063349
D016572_D064420 NONE cyclosporine_16\NN\0|NONE (l_appos) csa_18\NNP\0|NONE (l_conj) toxicity_25\NN\13576101|(|or|)
D016572_D064420 NONE csa_18\NNP\0|NONE (l_conj) toxicity_25\NN\13576101|(|or|)
D016572_D064420 NONE csa_6\NNP\0|indications|. (l_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) csa_15\NNP\0|disorder||Tac|,|, (l_conj) toxicity_18\NN\13576101|,|or||dysmorphism|acute
D016572_D064420 NONE csa_15\NNP\0|disorder||Tac|,|, (l_conj) toxicity_18\NN\13576101|,|or||dysmorphism|acute
D003404_D007674 NONE creatinine_17\NN\0|NONE (r_pobj) in_15\IN\13603305|+/|significant|a|to|at (r_prep) decrease_14\NN\7296428|there|:|In|.|] (r_attr) was_11\VBD\0|NONE (l_prep) in_1\IN\13603305|there|decrease|:|.|] (l_pobj) patients_4\NNS\9898892|NONE (l_acl) switched_5\VBD\138508||the (l_prep) because_6\IN\0|NONE (l_pobj) nephrotoxicity_9\NN\0|of
D016572_D056486 NONE csa_6\NNP\0|indications|. (l_conj) hepatotoxicity_43\NN\0|in|chronic|or|and|nephrotoxicity|,
D016572_D056486 NONE csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (r_conj) csa_6\NNP\0|indications|. (l_conj) hepatotoxicity_43\NN\0|in|chronic|or|and|nephrotoxicity|,
D020123_D011014 NONE rapa_0\NNP\0|,|in|PTLD|because|.|was (r_nsubjpass) discontinued_2\VBN\0|NONE (l_prep) because_7\IN\0|,|in|PTLD|.|RAPA|was (l_pobj) pneumonia_9\NN\14145095|of
D016559_-1 NONE tac_8\NNP\0|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) csa_15\NNP\0|disorder||Tac|,|, (l_conj) dysmorphism_25\NN\0|toxicity|,|or||acute
D016559_-1 NONE tac_17\NNP\0|NONE (r_compound) toxicity_18\NN\13576101|,|or||dysmorphism|acute (r_conj) csa_15\NNP\0|disorder||Tac|,|, (l_conj) dysmorphism_25\NN\0|toxicity|,|or||acute
D016572_D007674 CID csa_6\NNP\0|indications|. (l_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|,
D016572_D007674 CID csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|,
D016572_D008232 NONE csa_6\NNP\0|indications|. (l_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|,
D016572_D008232 NONE csa_6\NNP\0|indications|. (l_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|, (l_appos) ptld_34\NN\0|(|)|lymphoproliferative|posttransplant
D016572_D008232 NONE csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|,
D016572_D008232 NONE csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|, (l_appos) ptld_34\NN\0|(|)|lymphoproliferative|posttransplant
D020123_D013281 NONE rapa_0\NNP\0|,|in|PTLD|because|.|was (r_nsubjpass) discontinued_2\VBN\0|NONE (l_appos) ptld_13\NN\0|,|in|because|.|RAPA|was (l_conj) ulcers_20\NNS\14211294|in|,|,|and
D016572_-1 NONE csa_6\NNP\0|indications|. (l_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) csa_15\NNP\0|disorder||Tac|,|, (l_conj) dysmorphism_25\NN\0|toxicity|,|or||acute
D016572_-1 NONE csa_15\NNP\0|disorder||Tac|,|, (l_conj) dysmorphism_25\NN\0|toxicity|,|or||acute
D016559_D007674 CID tac_8\NNP\0|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|,
D016559_D007674 CID tac_17\NNP\0|NONE (r_compound) toxicity_18\NN\13576101|,|or||dysmorphism|acute (r_conj) csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|,
D016559_D008232 NONE tac_8\NNP\0|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|,
D016559_D008232 NONE tac_8\NNP\0|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|, (l_appos) ptld_34\NN\0|(|)|lymphoproliferative|posttransplant
D016559_D008232 NONE tac_17\NNP\0|NONE (r_compound) toxicity_18\NN\13576101|,|or||dysmorphism|acute (r_conj) csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|,
D016559_D008232 NONE tac_17\NNP\0|NONE (r_compound) toxicity_18\NN\13576101|,|or||dysmorphism|acute (r_conj) csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) disorder_32\NN\14034177|CsA||Tac|,|, (l_appos) ptld_34\NN\0|(|)|lymphoproliferative|posttransplant
D020123_D008232 NONE rapa_0\NNP\0|,|in|PTLD|because|.|was (r_nsubjpass) discontinued_2\VBN\0|NONE (l_appos) ptld_13\NN\0|,|in|because|.|RAPA|was
D020123_D011020 NONE rapa_6\NNP\0|drug (r_compound) levels_8\NNS\4916342|NONE (r_pobj) to_5\IN\0|when|patients (r_prep) converting_3\VBG\126264|,|should|avoid|However|be|over (r_csubjpass) monitored_11\VBN\2169352|prophylaxis|.|should|be (r_advcl) given_27\VBN\5892096|NONE (l_nsubjpass) prophylaxis_24\NN\1077350|monitored|.|should|be (l_compound) pneumonia_23\NN\14145095|NONE
D020123_D064420 NONE rapa_11\NNP\0|in (r_compound) conversion_12\NN\7359599|NONE (l_prep) in_13\IN\13603305|RAPA (l_pobj) patients_14\NNS\9898892|NONE (l_acl) undergoing_15\VBG\109660|NONE (l_dobj) cyclosporine_16\NN\0|NONE (l_appos) csa_18\NNP\0|NONE (l_conj) toxicity_25\NN\13576101|(|or|)
D016559_D064420 NONE tacrolimus_21\NN\0|(|Tac|) (r_nmod) toxicity_25\NN\13576101|(|or|)
D016559_D064420 NONE tac_23\NN\0|(|tacrolimus|) (r_nmod) toxicity_25\NN\13576101|(|or|)
D016559_D064420 NONE tac_8\NNP\0|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (l_conj) csa_15\NNP\0|disorder||Tac|,|, (l_conj) toxicity_18\NN\13576101|,|or||dysmorphism|acute
D016559_D064420 NONE tac_17\NNP\0|NONE (r_compound) toxicity_18\NN\13576101|,|or||dysmorphism|acute
D016559_D056486 NONE tac_8\NNP\0|disorder|CsA||,|, (r_compound) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (r_conj) csa_6\NNP\0|indications|. (l_conj) hepatotoxicity_43\NN\0|in|chronic|or|and|nephrotoxicity|,
D016559_D056486 NONE tac_17\NNP\0|NONE (r_compound) toxicity_18\NN\13576101|,|or||dysmorphism|acute (r_conj) csa_15\NNP\0|disorder||Tac|,|, (r_conj) nephrotoxicity_9\NN\0|in|chronic|or|hepatotoxicity|and|, (r_conj) csa_6\NNP\0|indications|. (l_conj) hepatotoxicity_43\NN\0|in|chronic|or|and|nephrotoxicity|,
11900788
D018738_D002375 NONE hexamethonium_10\NN\0|and|, (r_conj) mecamylamine_7\NN\0|, (r_conj) naloxone_5\NN\3808977|of|Intraperitoneal|,|catalepsy|. (r_appos) administration_1\NN\1133281|NONE (l_appos) catalepsy_14\NN\14023236|naloxone|of|Intraperitoneal|,|.
D018738_D002375 NONE hexamethonium_5\NN\0|, (r_conj) atropine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|Intracerebroventricular (r_prep) injection_1\NN\320852|also|.|catalepsy (r_nsubj) decreased_10\VBD\169651|NONE (l_dobj) catalepsy_11\NN\14023236|injection|also|.
D001285_D002375 NONE atropine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|naloxone|Intraperitoneal|,|catalepsy|. (r_prep) administration_1\NN\1133281|NONE (l_appos) catalepsy_14\NN\14023236|naloxone|of|Intraperitoneal|,|.
D001285_D002375 NONE atropine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|Intracerebroventricular (r_prep) injection_1\NN\320852|also|.|catalepsy (r_nsubj) decreased_10\VBD\169651|NONE (l_dobj) catalepsy_11\NN\14023236|injection|also|.
D008464_D002375 NONE mecamylamine_7\NN\0|, (r_conj) naloxone_5\NN\3808977|of|Intraperitoneal|,|catalepsy|. (r_appos) administration_1\NN\1133281|NONE (l_appos) catalepsy_14\NN\14023236|naloxone|of|Intraperitoneal|,|.
D009538_D002375 CID nicotine_0\NN\14712692|of|.|in (r_compound) potentiation_1\NN\13564910|NONE (l_prep) of_2\IN\0|.|Nicotine|in (l_pobj) catalepsy_6\NN\14023236|NONE
D009538_D002375 CID nicotine_7\NN\14712692|NONE (r_pobj) of_6\IN\0|induced|on (r_prep) effects_5\NNS\13245626|have|,|In|.|been (l_prep) on_8\IN\0|of|induced (l_pobj) catalepsy_9\NN\14023236|NONE
D009538_D002375 CID nicotine_3\NN\14712692|but (r_conj) morphine_0\NNP\2707683|.|catalepsy (r_nsubj) induced_4\VBD\1627355|NONE (l_dobj) catalepsy_9\NN\14023236|.|Morphine
D009538_D002375 CID nicotine_22\NN\14712692|NONE (r_pobj) with_21\IN\0|a|of (r_prep) combination_18\NN\7951464|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|reduced (r_acl) catalepsy_14\NN\14023236|naloxone|of|Intraperitoneal|,|.
D009538_D002375 CID nicotine_16\NN\14712692|plus (r_conj) morphine_14\NN\2707683|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|NONE (r_acl) catalepsy_11\NN\14023236|injection|also|.
D009538_D002375 CID nicotine_22\NN\14712692|NONE (r_pobj) by_21\IN\0|NONE (r_agent) induced_20\VBN\1627355|the|of (r_acl) potentiation_17\NN\13564910|be|through|also|may (r_nsubjpass) mediated_26\VBN\761713|be|by|catalepsy|can|,|and|that (r_conj) elicited_8\VBN\1617192|was|It|. (l_nsubjpass) catalepsy_5\NN\14023236|be|by|can|,|and|that|mediated
D009020_D002375 CID morphine_3\NN\2707683| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) catalepsy_6\NN\14023236|NONE
D009020_D002375 CID morphine_12\NN\2707683|NONE (r_pobj) by_11\IN\0|in (r_agent) induced_10\VBN\1627355|of|on (r_acl) effects_5\NNS\13245626|have|,|In|.|been (l_prep) on_8\IN\0|of|induced (l_pobj) catalepsy_9\NN\14023236|NONE
D009020_D002375 CID morphine_0\NNP\2707683|.|catalepsy (r_nsubj) induced_4\VBD\1627355|NONE (l_dobj) catalepsy_9\NN\14023236|.|Morphine
D009020_D002375 CID morphine_20\NN\2707683|NONE (r_pobj) of_19\IN\0|a|with (r_prep) combination_18\NN\7951464|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|reduced (r_acl) catalepsy_14\NN\14023236|naloxone|of|Intraperitoneal|,|.
D009020_D002375 CID morphine_14\NN\2707683|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|NONE (r_acl) catalepsy_11\NN\14023236|injection|also|.
D009020_D002375 CID morphine_4\NN\2707683|NONE (r_compound) catalepsy_5\NN\14023236|be|by|can|,|and|that|mediated
D009020_D002375 CID morphine_19\NN\2707683|NONE (r_pobj) of_18\IN\0|the|induced (r_prep) potentiation_17\NN\13564910|be|through|also|may (r_nsubjpass) mediated_26\VBN\761713|be|by|catalepsy|can|,|and|that (r_conj) elicited_8\VBN\1617192|was|It|. (l_nsubjpass) catalepsy_5\NN\14023236|be|by|can|,|and|that|mediated
D009270_D002375 NONE naloxone_5\NN\3808977|of|Intraperitoneal|,|catalepsy|. (r_appos) administration_1\NN\1133281|NONE (l_appos) catalepsy_14\NN\14023236|naloxone|of|Intraperitoneal|,|.
D009270_D002375 NONE naloxone_8\NN\3808977|and|, (r_conj) hexamethonium_5\NN\0|, (r_conj) atropine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|Intracerebroventricular (r_prep) injection_1\NN\320852|also|.|catalepsy (r_nsubj) decreased_10\VBD\169651|NONE (l_dobj) catalepsy_11\NN\14023236|injection|also|.
11583940
C063008_D007674 NONE mofetil_7\NNS\0|have|,|.|agents (r_dobj) mycophenolate_6\VB\0|NONE (l_dep) have_14\VBP\7846|,|.|agents|mofetil (l_dobj) nephrotoxicity_16\NN\0|NONE
D020123_D007674 NONE sirolimus_9\NN\0|rapamycin|and (r_conj) mofetil_7\NNS\0|have|,|.|agents (r_dobj) mycophenolate_6\VB\0|NONE (l_dep) have_14\VBP\7846|,|.|agents|mofetil (l_dobj) nephrotoxicity_16\NN\0|NONE
D020123_D007674 NONE rapamycin_11\NNS\0|sirolimus|and (r_appos) mofetil_7\NNS\0|have|,|.|agents (r_dobj) mycophenolate_6\VB\0|NONE (l_dep) have_14\VBP\7846|,|.|agents|mofetil (l_dobj) nephrotoxicity_16\NN\0|NONE
1700207
D006221_D001145 NONE halothane_17\NN\3570838| (r_npadvmod) anesthetized_19\VBN\84738|NONE (r_amod) dogs_20\NNS\2083346|NONE (r_pobj) in_16\IN\13603305|adrenaline (r_prep) infusion_15\NN\14589223|NONE (r_pobj) by_13\IN\0|was|.|arrhythmia (r_agent) induced_12\VBN\1627355|NONE (l_nsubjpass) arrhythmia_1\NN\14103288|by|was|.
D012964_D001145 NONE na_7\NNP\14625458|channel (r_compound) blockers_9\NNS\10101634|NONE (r_pobj) by_6\IN\0|is|which (r_agent) suppressed_5\VBN\2510337|,|Digitalis|, (r_relcl) arrhythmia_1\NN\14103288|by|was|.
D010042_D001145 CID ouabain_21\NN\0|NONE (r_pobj) of_20\IN\0|in|)|i.v.|( (r_prep) injection_19\NN\320852|intermittent (r_appos) intravenous_15\JJ\0|NONE (r_pobj) by_13\IN\0|arrhythmia|was|. (r_agent) induced_12\VBN\1627355|NONE (l_nsubjpass) arrhythmia_1\NN\14103288|by|was|.
C032151_D001145 NONE cibenzoline_6\NN\0|NONE (l_prep) on_7\IN\0|NONE (l_pobj) arrhythmias_10\NNS\14103288|NONE
C032151_D001145 NONE -cibenzoline_6\:\0|(|+ (r_conj) of_2\IN\0|and|Antiarrhythmic|examined (r_prep) effects_1\NNS\13245626|NONE (l_conj) examined_11\VBN\0|and|Antiarrhythmic|of (l_advcl) using_12\VBG\418025|)cibenzoline|were|.|( (l_dobj) models_17\NNS\5888929|NONE (l_compound) arrhythmia_16\NN\14103288|canine|two
C032151_D001145 NONE -)-cibenzoline_9\:\0|were|using|.|( (r_nsubjpass) examined_11\VBN\0|and|Antiarrhythmic|of (l_advcl) using_12\VBG\418025|)cibenzoline|were|.|( (l_dobj) models_17\NNS\5888929|NONE (l_compound) arrhythmia_16\NN\14103288|canine|two
C032151_D001145 NONE -cibenzoline_8\,\0|) (r_punct) suppressed_9\VBN\2510337|,|.|digitalis|i.v.|respectively (r_amod) arrhythmias_15\NNS\14103288|NONE
C032151_D001145 NONE -cibenzoline_9\:\0|arrhythmias (r_punct) for_10\IN\0|of|The|effective|minimum|plasma (l_pobj) arrhythmias_16\NNS\14103288|cibenzoline
C032151_D001145 NONE -)-cibenzoline_9\NNP\0|,|arrhythmia|( (r_nsubj) suppressed_10\VBD\2510337|NONE (l_dobj) arrhythmia_15\NN\14103288|,|)cibenzoline|(
C032151_D001145 NONE -)-cibenzoline_9\NNP\0|,|arrhythmia|( (r_nsubj) suppressed_10\VBD\2510337|NONE (r_pcomp) of_7\IN\0|NONE (r_prep) i.v._6\NN\0|lower|A|of (r_appos) dose_2\NN\3740161|mg/kg|suppress|was|whereas|. (r_nsubjpass) needed_22\VBN\0|NONE (l_advcl) suppress_24\VB\2510337|dose|mg/kg|was|whereas|. (l_dobj) arrhythmias_28\NNS\14103288|to
C032151_D001145 NONE -)-cibenzoline_7\:\0|effective|minimum|of|The|plasma (l_prep) for_8\IN\0|( (l_pobj) arrhythmia_14\NN\14103288|NONE
D004837_D001145 CID adrenaline_14\NN\14807929|in (r_amod) infusion_15\NN\14589223|NONE (r_pobj) by_13\IN\0|was|.|arrhythmia (r_agent) induced_12\VBN\1627355|NONE (l_nsubjpass) arrhythmia_1\NN\14103288|by|was|.
D004837_D001145 CID adrenaline_12\NN\14807929| (r_npadvmod) induced_14\VBN\1627355|and (r_conj) digitalis-_10\NN\0|,|suppressed|.|i.v.|respectively (r_amod) arrhythmias_15\NNS\14103288|NONE
D004837_D001145 CID adrenaline_13\NN\14807929| (r_npadvmod) induced_15\VBN\1627355|and (r_conj) digitalis-_11\NN\0|NONE (r_amod) arrhythmias_16\NNS\14103288|cibenzoline
D004837_D001145 CID adrenaline_25\NN\14807929| (r_npadvmod) induced_27\VBN\1627355|NONE (r_amod) arrhythmias_28\NNS\14103288|to (r_dobj) suppress_24\VB\2510337|dose|mg/kg|was|whereas|. (r_advcl) needed_22\VBN\0|NONE (l_nsubjpass) dose_2\NN\3740161|mg/kg|suppress|was|whereas|. (l_appos) i.v._6\NN\0|lower|A|of (l_prep) of_7\IN\0|NONE (l_pcomp) suppressed_10\VBD\2510337|NONE (l_dobj) arrhythmia_15\NN\14103288|,|)cibenzoline|(
D004837_D001145 CID adrenaline_25\NN\14807929| (r_npadvmod) induced_27\VBN\1627355|NONE (r_amod) arrhythmias_28\NNS\14103288|to
D004837_D001145 CID adrenaline_11\NN\14807929| (r_npadvmod) induced_13\VBN\1627355|and (r_conj) digitalis-_9\NN\0|NONE (r_amod) arrhythmia_14\NN\14103288|NONE
D010424_D001145 NONE pentobarbital_23\NN\2792049| (r_npadvmod) anesthetized_25\VBN\84738|NONE (r_amod) dogs_26\NNS\2083346|NONE (r_pobj) in_22\IN\13603305|of|)|i.v.|( (r_prep) injection_19\NN\320852|intermittent (r_appos) intravenous_15\JJ\0|NONE (r_pobj) by_13\IN\0|arrhythmia|was|. (r_agent) induced_12\VBN\1627355|NONE (l_nsubjpass) arrhythmia_1\NN\14103288|by|was|.
D002118_D001145 NONE ca_7\NNP\14625458|NONE (r_aux) channel_8\NN\6251781|NONE (r_compound) blockers_9\NNS\10101634|NONE (r_pobj) by_6\IN\0|is|which (r_agent) suppressed_5\VBN\2510337|,|Adrenaline|, (r_relcl) arrhythmia_1\NN\14103288|by|was|.
D004070_D001145 NONE digitalis_0\NNP\15059939|,|,|suppressed (r_compound) arrhythmia_1\NN\14103288|by|was|.
D004070_D001145 NONE digitalis-_10\NN\0|,|suppressed|.|i.v.|respectively (r_amod) arrhythmias_15\NNS\14103288|NONE
D004070_D001145 NONE digitalis-_11\NN\0|NONE (r_amod) arrhythmias_16\NNS\14103288|cibenzoline
D004070_D001145 NONE digitalis_12\NN\15059939| (r_npadvmod) induced_14\VBN\1627355|the (r_amod) arrhythmia_15\NN\14103288|,|)cibenzoline|(
D004070_D001145 NONE digitalis_12\NN\15059939| (r_npadvmod) induced_14\VBN\1627355|the (r_amod) arrhythmia_15\NN\14103288|,|)cibenzoline|( (r_dobj) suppressed_10\VBD\2510337|NONE (r_pcomp) of_7\IN\0|NONE (r_prep) i.v._6\NN\0|lower|A|of (r_appos) dose_2\NN\3740161|mg/kg|suppress|was|whereas|. (r_nsubjpass) needed_22\VBN\0|NONE (l_advcl) suppress_24\VB\2510337|dose|mg/kg|was|whereas|. (l_dobj) arrhythmias_28\NNS\14103288|to
D004070_D001145 NONE digitalis-_9\NN\0|NONE (r_amod) arrhythmia_14\NN\14103288|NONE
6118280
D002998_D009207 NONE clonazepam_4\NN\0|,|.|Of|be|was (r_nsubjpass) found_12\VBN\13279262|NONE (l_xcomp) be_14\VB\14625458|,|clonazepam|.|Of|was (l_prep) in_27\IN\13603305|potent|mg/kg|to (l_pcomp) blocking_28\VBG\562280|NONE (l_dobj) jerks_31\NNS\10322238|NONE
D009118_D009207 CID muscimol_7\NNS\0|in|.|jerks||drugs (r_npadvmod) induced_9\VBN\1627355|NONE (l_dobj) jerks_11\NNS\10322238|in|.|muscimol||drugs
D009118_D009207 CID muscimol_5\NNS\0|In|,|.|jerks (r_nsubj) produced_6\VBD\1617192|NONE (l_dobj) jerks_8\NNS\10322238|In|muscimol|,|.
D009118_D009207 CID muscimol_22\NN\0| (r_npadvmod) induced_24\VBN\1627355|the (r_amod) myoclonus_25\NN\14360459|clinical|, (r_appos) myoclonus_19\NN\14360459|NONE
D009118_D009207 CID muscimol_22\NN\0| (r_npadvmod) induced_24\VBN\1627355|the (r_amod) myoclonus_25\NN\14360459|clinical|,
D001418_D009207 NONE baclofen_5\JJ\0|NONE (r_compound) block_6\NN\21939|and (r_conj) benzodiazepines_3\NNS\3771443|,|Serotonergic (r_conj) drugs_1\NNS\14778436|in|.|muscimol|jerks| (r_nsubj) induced_9\VBN\1627355|NONE (l_dobj) jerks_11\NNS\10322238|in|.|muscimol||drugs
D001418_D009207 NONE -)-baclofen_11\:\0|management (r_punct) in_12\IN\13603305|possible|the|of (l_pobj) management_14\NN\1123598|)baclofen (l_prep) of_15\IN\0|the (l_pobj) myoclonus_17\NN\14360459|NONE
D003975_D009207 NONE diazepam_20\NN\2830852|NONE (r_pobj) than_19\IN\0|fold|more (r_prep) potent_18\JJ\0|in|mg/kg|to (r_acomp) be_14\VB\14625458|,|clonazepam|.|Of|was (l_prep) in_27\IN\13603305|potent|mg/kg|to (l_pcomp) blocking_28\VBG\562280|NONE (l_dobj) jerks_31\NNS\10322238|NONE
D001569_D009207 NONE benzodiazepines_3\NNS\3771443|,|Serotonergic (r_conj) drugs_1\NNS\14778436|in|.|muscimol|jerks| (r_nsubj) induced_9\VBN\1627355|NONE (l_dobj) jerks_11\NNS\10322238|in|.|muscimol||drugs
D001569_D009207 NONE benzodiazepines_2\NNS\3771443|NONE (r_pobj) of_0\IN\0|,|clonazepam|.|be|was (r_prep) found_12\VBN\13279262|NONE (l_xcomp) be_14\VB\14625458|,|clonazepam|.|Of|was (l_prep) in_27\IN\13603305|potent|mg/kg|to (l_pcomp) blocking_28\VBG\562280|NONE (l_dobj) jerks_31\NNS\10322238|NONE
D001569_D009207 NONE benzodiazepines_7\NNS\3771443|and (r_conj) 5-htp_4\NN\0|that|been|be|have (r_nsubjpass) found_10\VBN\13279262|the (l_xcomp) be_12\VB\14625458|that|HTP|been|have (l_acomp) beneficial_13\JJ\0|to (l_prep) in_14\IN\13603305|NONE (l_pobj) management_16\NN\1123598|NONE (l_prep) of_17\IN\0|the (l_pobj) myoclonus_19\NN\14360459|NONE
D001569_D009207 NONE benzodiazepines_7\NNS\3771443|and (r_conj) 5-htp_4\NN\0|that|been|be|have (r_nsubjpass) found_10\VBN\13279262|the (l_xcomp) be_12\VB\14625458|that|HTP|been|have (l_acomp) beneficial_13\JJ\0|to (l_prep) in_14\IN\13603305|NONE (l_pobj) management_16\NN\1123598|NONE (l_prep) of_17\IN\0|the (l_pobj) myoclonus_19\NN\14360459|NONE (l_appos) myoclonus_25\NN\14360459|clinical|,
D006916_D009207 NONE 5-htp_4\NN\0|that|been|be|have (r_nsubjpass) found_10\VBN\13279262|the (l_xcomp) be_12\VB\14625458|that|HTP|been|have (l_acomp) beneficial_13\JJ\0|to (l_prep) in_14\IN\13603305|NONE (l_pobj) management_16\NN\1123598|NONE (l_prep) of_17\IN\0|the (l_pobj) myoclonus_19\NN\14360459|NONE
D006916_D009207 NONE 5-htp_4\NN\0|that|been|be|have (r_nsubjpass) found_10\VBN\13279262|the (l_xcomp) be_12\VB\14625458|that|HTP|been|have (l_acomp) beneficial_13\JJ\0|to (l_prep) in_14\IN\13603305|NONE (l_pobj) management_16\NN\1123598|NONE (l_prep) of_17\IN\0|the (l_pobj) myoclonus_19\NN\14360459|NONE (l_appos) myoclonus_25\NN\14360459|clinical|,
C014896_D009207 NONE mk-212_8\NNP\0|NONE (r_punct) and_9\CC\0|( (r_punct) -)-baclofen_11\:\0|management (r_punct) in_12\IN\13603305|possible|the|of (l_pobj) management_14\NN\1123598|)baclofen (l_prep) of_15\IN\0|the (l_pobj) myoclonus_17\NN\14360459|NONE
20552622
D000420_D013617 CID salbutamol_7\NN\0|NONE (r_pobj) by_6\IN\0|NONE (r_agent) triggered_5\VBN\1641914|induced|report|atrial (r_acl) tachyarrhythmia_4\NN\0|NONE
D000420_D013617 CID salbutamol_0\NNP\0|.|as|is|here (r_nsubjpass) presented_2\VBN\2137132|NONE (l_prep) as_4\IN\14622893|.|Salbutamol|is|here (l_pobj) trigger_7\NN\3659292|NONE (l_prep) for_8\IN\0|possible|a (l_pobj) siat_9\NNP\0|NONE
D001262_D013610 NONE atenolol_51\NN\2832168|such (r_pobj) as_50\IN\14622893||beta|a (r_prep) blocker_48\NN\10101634|may|that|it (r_nsubj) relieve_60\VB\205885|and|while (r_conj) swallowing_42\VBG\1156834|may|agonist|that|trigger (r_advcl) be_31\VB\14625458|to (l_nsubj) agonist_21\NN\0|may|swallowing|that|trigger (l_acl) known_25\VBN\0|like|beta||a (l_xcomp) induce_27\VB\1627355|)|( (l_dobj) tachycardia_28\NN\14110674|to
D001262_D001145 NONE atenolol_6\NN\2832168|NONE (r_pobj) with_5\IN\0|arrhythmia|,|but|after|recurred|. (r_prep) resolved_2\VBD\352826|NONE (l_nsubj) arrhythmia_1\NN\14103288|,|but|after|with|recurred|.
D001262_D001145 NONE atenolol_13\NN\2832168|NONE (r_pobj) with_11\IN\0|a (r_prep) week_10\NN\15113229|NONE (r_pobj) after_8\IN\0|,|After|arrhythmia|. (r_prep) disappeared_17\VBD\0|NONE (l_nsubj) arrhythmia_16\NN\14103288|,|After|after|.
D000420_D013610 NONE salbutamol_23\NN\0|NONE (r_pobj) like_22\IN\5839024|beta||known|a (r_prep) agonist_21\NN\0|may|swallowing|that|trigger (l_acl) known_25\VBN\0|like|beta||a (l_xcomp) induce_27\VB\1627355|)|( (l_dobj) tachycardia_28\NN\14110674|to
11282081
D002698_D001281 NONE chloralose_21\NN\0|anesthetized (r_amod) dogs_23\NNS\2083346|NONE (r_pobj) to_18\IN\0|evaluate|we|,|.|verapamil (r_prep) administered_16\VBD\2436349|NONE (l_advcl) evaluate_1\VB\670261|we|,|.|verapamil|to (l_dobj) mechanisms_4\NNS\13446390|To (l_prep) of_5\IN\0|potential|the (l_pobj) promotion_7\NN\6598915|NONE (l_compound) af_6\NNP\0|by
D004110_D001281 NONE diltiazem_0\NNP\2938514|,|produced|did|but|ERP|not|. (r_nsubj) affect_3\VB\26192|NONE (l_dobj) erp_4\NNP\0|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN\5093581|, (l_compound) af_6\NNP\0|cycle|or|duration
D004110_D001281 NONE diltiazem_0\NNP\2938514|,|produced|did|but|ERP|not|. (r_nsubj) affect_3\VB\26192|NONE (l_dobj) erp_4\NNP\0|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN\5093581|, (l_conj) duration_11\NN\15113229|AF|cycle|or (l_compound) af_10\NNP\0|NONE
D004110_D001281 NONE diltiazem_23\NN\2938514|NONE (r_pobj) by_22\IN\0|not (r_agent) shared_21\VBN\2660631|an|and|dependent (r_conj) effect_13\NN\34213|,|Verapamil|in|.|by|AF (r_dobj) promotes_1\VBZ\2556126|NONE (l_dobj) af_2\NNP\0|,|effect|Verapamil|in|.|by
D009020_D001281 NONE morphine_19\NN\2707683| (r_npadvmod) chloralose_21\NN\0|anesthetized (r_amod) dogs_23\NNS\2083346|NONE (r_pobj) to_18\IN\0|evaluate|we|,|.|verapamil (r_prep) administered_16\VBD\2436349|NONE (l_advcl) evaluate_1\VB\670261|we|,|.|verapamil|to (l_dobj) mechanisms_4\NNS\13446390|To (l_prep) of_5\IN\0|potential|the (l_pobj) promotion_7\NN\6598915|NONE (l_compound) af_6\NNP\0|by
D002118_D013617 NONE ca(2_23\NNP\0|NONE (r_dobj) decreases_19\VBZ\7296428|and|occurrence|tachycardia (r_conj) promotes_7\VBZ\2556126|.|: (l_nsubj) tachycardia_3\NN\14110674|decreases|and|occurrence
D002118_D001281 NONE ca(2_23\NNP\0|NONE (r_dobj) decreases_19\VBZ\7296428|and|occurrence|tachycardia (r_conj) promotes_7\VBZ\2556126|.|: (l_dobj) occurrence_9\NN\29378|decreases|and|tachycardia (l_prep) of_12\IN\0|and|the|maintenance (l_pobj) fibrillation_14\NN\14361664|NONE
D002118_D001281 NONE ca(2_23\NNP\0|NONE (r_dobj) decreases_19\VBZ\7296428|and|occurrence|tachycardia (r_conj) promotes_7\VBZ\2556126|.|: (l_dobj) occurrence_9\NN\29378|decreases|and|tachycardia (l_prep) of_12\IN\0|and|the|maintenance (l_pobj) fibrillation_14\NN\14361664|NONE (l_appos) af_16\NNP\0|)|atrial|(
D002118_D001281 NONE ca(2_11\NN\0|) (r_nmod) channel_13\NN\6251781|acute|type (r_compound) blockade_14\NN\952963|,|can|AF|that|consistent (r_nsubj) promote_16\VB\2556126|clinical|a (l_dobj) af_17\NNP\0|,|can|that|blockade|consistent
D002118_D001281 NONE ca(2_11\NN\0|) (r_nmod) channel_13\NN\6251781|acute|type (r_compound) blockade_14\NN\952963|,|can|AF|that|consistent (r_nsubj) promote_16\VB\2556126|clinical|a (l_advcl) consistent_19\JJ\0|,|can|AF|that|blockade (l_prep) with_20\IN\0|NONE (l_pobj) effect_24\NN\34213|NONE (l_compound) af_22\NNP\0|of|an|promoting
D002118_D001281 NONE ca(2_26\NNP\0|channel (r_nmod) inhibition_30\NN\1068773|NONE (r_pobj) of_25\IN\0|an|AF|promoting (r_prep) effect_24\NN\34213|NONE (r_pobj) with_20\IN\0|NONE (r_prep) consistent_19\JJ\0|,|can|AF|that|blockade (r_advcl) promote_16\VB\2556126|clinical|a (l_dobj) af_17\NNP\0|,|can|that|blockade|consistent
D002118_D001281 NONE ca(2_26\NNP\0|channel (r_nmod) inhibition_30\NN\1068773|NONE (r_pobj) of_25\IN\0|an|AF|promoting (r_prep) effect_24\NN\34213|NONE (l_compound) af_22\NNP\0|of|an|promoting
D002118_D001281 NONE ca(2_9\NNP\0|channel (r_nmod) blockers_13\NNS\10101634|NONE (r_pobj) by_8\IN\0|AF (r_prep) promotion_7\NN\6598915|NONE (l_compound) af_6\NNP\0|by
D014700_D001281 CID verapamil_2\NN\2938514|NONE (r_pobj) of_1\IN\0|.|determinants|and|on (r_prep) effects_0\NNS\13245626|NONE (l_prep) on_3\IN\0|.|determinants|and|of (l_pobj) fibrillation_5\NN\14361664|NONE
D014700_D001281 CID verapamil_17\NN\2938514|evaluate|we|,|.|to (r_dobj) administered_16\VBD\2436349|NONE (l_advcl) evaluate_1\VB\670261|we|,|.|verapamil|to (l_dobj) mechanisms_4\NNS\13446390|To (l_prep) of_5\IN\0|potential|the (l_pobj) promotion_7\NN\6598915|NONE (l_compound) af_6\NNP\0|by
D014700_D001281 CID verapamil_1\NNP\2938514|increasing|:|,|promotion|in (r_nsubj) caused_2\VBD\1617192|NONE (l_dobj) promotion_4\NN\6598915|increasing|:|,|Verapamil|in (l_compound) af_3\NNP\0|NONE
D014700_D001281 CID verapamil_1\NNP\2938514|increasing|:|,|promotion|in (r_nsubj) caused_2\VBD\1617192|NONE (l_advcl) increasing_9\VBG\169651|:|,|Verapamil|promotion|in (l_dobj) duration_11\NN\15113229|NONE (l_prep) of_12\IN\0|induced|mean (l_pobj) af_13\NNP\0|NONE
D014700_D001281 CID verapamil_4\NN\2938514|,|from|period|,|mean|accelerated|.|,|decreased|In (r_nsubj) shortened_5\VBN\429060|NONE (l_conj) accelerated_43\VBN\226566|,|from|period|,|mean|.|,|decreased|In|verapamil (l_conj) decreased_47\VBD\169651|heterogeneously|conduction|and (l_dobj) length_50\NN\5093581|to (l_prep) of_51\IN\0|cycle|the (l_pobj) 94+/-4_54\CD\0|NONE (l_nmod) af_52\NNP\0|(
D014700_D001281 CID verapamil_22\NNP\2938514|( (r_nmod) n=5_24\NNS\0|NONE (r_pobj) by_21\IN\0|NONE (r_agent) caused_20\VBN\1617192|NONE (r_acl) that_19\DT\0|NONE (r_pobj) to_18\IN\0|NONE (r_prep) similar_17\JJ\0|conduction (r_amod) acceleration_16\NN\7296428|) (r_dobj) produced_14\VBD\1617192|,|did|but|ERP|not|Diltiazem|. (r_conj) affect_3\VB\26192|NONE (l_dobj) erp_4\NNP\0|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN\5093581|, (l_compound) af_6\NNP\0|cycle|or|duration
D014700_D001281 CID verapamil_22\NNP\2938514|( (r_nmod) n=5_24\NNS\0|NONE (r_pobj) by_21\IN\0|NONE (r_agent) caused_20\VBN\1617192|NONE (r_acl) that_19\DT\0|NONE (r_pobj) to_18\IN\0|NONE (r_prep) similar_17\JJ\0|conduction (r_amod) acceleration_16\NN\7296428|) (r_dobj) produced_14\VBD\1617192|,|did|but|ERP|not|Diltiazem|. (r_conj) affect_3\VB\26192|NONE (l_dobj) erp_4\NNP\0|,|produced|did|but|not|Diltiazem|. (l_conj) length_8\NN\5093581|, (l_conj) duration_11\NN\15113229|AF|cycle|or (l_compound) af_10\NNP\0|NONE
D014700_D001281 CID verapamil_7\NN\2938514|refractoriness|promote|In|.|, (r_nsubj) failed_8\VBD\0|NONE (l_xcomp) promote_10\VB\2556126|refractoriness|verapamil|In|.|, (l_dobj) af_11\NNP\0|increased|and|to
D014700_D001281 CID verapamil_4\NN\2938514|by|that|AF (r_nsubj) promoted_5\VBD\2556126|.|mapping (l_dobj) af_6\NNP\0|by|verapamil|that
D014700_D001281 CID verapamil_0\NNP\2938514|,|effect|in|.|by|AF (r_nsubj) promotes_1\VBZ\2556126|NONE (l_dobj) af_2\NNP\0|,|effect|Verapamil|in|.|by
7650771
D004456_D064420 NONE iodide_8\NN\14904359|eye|echothiophate (r_compound) drops_10\VBZ\13899200|NONE (r_pobj) of_6\IN\0|ocular (r_prep) instillation_5\NN\320852|NONE (r_pobj) from_3\IN\0|NONE (r_prep) resulting_2\VBG\2633881|.|Cholinergic (r_acl) toxicity_1\NN\13576101|NONE
D004456_D018908 CID iodide_12\NN\14904359|echothiophate|ophthalmic (r_nmod) drops_14\NNS\13899200|NONE (r_pobj) of_10\IN\0|the (r_prep) use_9\NN\407535|NONE (r_pobj) from_7\IN\0|a|cholinergic|severe (r_prep) syndrome_6\NN\5870365|.|,|presented|patient (r_dobj) developed_2\VBD\1753788|NONE (l_conj) presented_16\VBN\2137132|syndrome|.|,|patient (l_prep) with_17\IN\0|given|and (l_pobj) weakness_20\NN\14462666|NONE
D004456_D009157 NONE iodide_12\NN\14904359|echothiophate|ophthalmic (r_nmod) drops_14\NNS\13899200|NONE (r_pobj) of_10\IN\0|the (r_prep) use_9\NN\407535|NONE (r_pobj) from_7\IN\0|a|cholinergic|severe (r_prep) syndrome_6\NN\5870365|.|,|presented|patient (r_dobj) developed_2\VBD\1753788|NONE (l_conj) presented_16\VBN\2137132|syndrome|.|,|patient (l_conj) given_24\VBN\5892096|with|and (l_dobj) diagnosis_26\NN\152018|initially|was (l_prep) of_27\IN\0|the (l_pobj) gravis_29\NN\0|NONE
19893084
D005839_D058186 CID gentamicin_12\NN\2716866|NONE (r_pcomp) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|renal|acute (r_acl) failure_9\NN\66216|NONE
7066357
D011692_D009404 CID aminonucleoside_18\RB\0|Plasma|.|by|in (r_advmod) induced_12\VBN\1627355|NONE (l_nsubj) plasma_0\NN\5398023|.|by|aminonucleoside|in (l_prep) during_6\IN\0|and|lipids (l_pobj) development_8\NN\248977|NONE (l_prep) of_9\IN\0|the (l_pobj) syndrome_11\NN\5870365|NONE
D011692_D009404 CID aminonucleoside_19\NN\0|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|of|the (r_acl) alterations_8\NNS\7283608|to|,|whether|,|due|or (l_prep) of_9\IN\0|induced|the (l_pobj) lipoproteins_11\NNS\14731135|NONE (l_acl) found_12\VBN\13279262|plasma (l_prep) in_13\IN\13603305|NONE (l_pobj) syndrome_15\NN\5870365|NONE
D011692_D009404 CID aminonucleoside_19\NN\0|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|of|the (r_acl) alterations_8\NNS\7283608|to|,|whether|,|due|or (r_nsubj) were_20\VBD\0|to (l_acomp) due_21\JJ\5174653|alterations|to|,|whether|,|or (l_prep) to_22\IN\0|NONE (l_pobj) syndrome_24\NN\5870365|NONE
D011692_D009404 CID aminonucleoside_37\NN\0|NONE (r_pobj) to_35\IN\0|alterations|,|whether|,|due|or (r_prep) were_20\VBD\0|to (l_nsubj) alterations_8\NNS\7283608|to|,|whether|,|due|or (l_prep) of_9\IN\0|induced|the (l_pobj) lipoproteins_11\NNS\14731135|NONE (l_acl) found_12\VBN\13279262|plasma (l_prep) in_13\IN\13603305|NONE (l_pobj) syndrome_15\NN\5870365|NONE
D011692_D009404 CID aminonucleoside_37\NN\0|NONE (r_pobj) to_35\IN\0|alterations|,|whether|,|due|or (r_prep) were_20\VBD\0|to (l_acomp) due_21\JJ\5174653|alterations|to|,|whether|,|or (l_prep) to_22\IN\0|NONE (l_pobj) syndrome_24\NN\5870365|NONE
D011692_D009404 CID aminonucleoside_21\NN\0|purpose|investigate|. (l_conj) development_32\NN\248977|and|mg/kg (l_prep) of_33\IN\0|subsequent|the (l_pobj) syndrome_35\NN\5870365|NONE
D005227_D009404 NONE acids_10\NNS\14818238|NONE (r_pobj) of_8\IN\0|plasma|the (r_prep) level_7\NN\4916342|remained|.|In (r_nsubj) decreased_15\VBD\169651|NONE (l_prep) in_0\IN\13603305|remained|.|level (l_pobj) stage_4\NN\15113229|NONE (l_amod) nephrotic_3\JJ\0|NONE
D002788_D009404 NONE esters_22\NNS\14727670|while|constant|that (r_nsubj) remained_25\VBD\2604760|.|level|In (r_advcl) decreased_15\VBD\169651|NONE (l_prep) in_0\IN\13603305|remained|.|level (l_pobj) stage_4\NN\15113229|NONE (l_amod) nephrotic_3\JJ\0|NONE
D014280_D009404 NONE triacylglycerol_12\NN\0|fatty|, (r_conj) acids_10\NNS\14818238|NONE (r_pobj) of_8\IN\0|plasma|the (r_prep) level_7\NN\4916342|remained|.|In (r_nsubj) decreased_15\VBD\169651|NONE (l_prep) in_0\IN\13603305|remained|.|level (l_pobj) stage_4\NN\15113229|NONE (l_amod) nephrotic_3\JJ\0|NONE
3962737
D000638_D056486 CID amiodarone_2\NN\2715941|NONE (r_pobj) of_1\IN\0|. (r_prep) hepatotoxicity_0\NN\0|NONE
D000638_D056486 CID amiodarone_7\NN\2715941|NONE (r_compound) treatment_8\NN\654885|A|due|with (r_appos) patient_1\NN\9898892|is|below|given|and (l_prep) with_2\IN\0|treatment|A|due (l_pobj) hepatitis_4\NN\14127211|NONE
D000638_D056486 CID amiodarone_7\NN\2715941|NONE (r_compound) treatment_8\NN\654885|A|due|with (r_appos) patient_1\NN\9898892|is|below|given|and (r_nsubjpass) presented_10\VBN\2137132|NONE (l_conj) given_21\VBN\5892096|is|below|and|patient (l_nsubjpass) review_14\NN\5733583|is|. (l_prep) of_15\IN\0|a (l_pobj) hepatotoxicity_17\NN\0|NONE
D000638_D056486 CID amiodarone_19\NN\2715941|NONE (r_pobj) of_18\IN\0|the (r_prep) hepatotoxicity_17\NN\0|NONE (r_pobj) of_15\IN\0|a (r_prep) review_14\NN\5733583|is|. (r_nsubjpass) given_21\VBN\5892096|is|below|and|patient (r_conj) presented_10\VBN\2137132|NONE (l_nsubjpass) patient_1\NN\9898892|is|below|given|and (l_prep) with_2\IN\0|treatment|A|due (l_pobj) hepatitis_4\NN\14127211|NONE
D000638_D056486 CID amiodarone_19\NN\2715941|NONE (r_pobj) of_18\IN\0|the (r_prep) hepatotoxicity_17\NN\0|NONE
D000638_D056486 CID amiodarone_12\NN\2715941|,|,|including (r_compound) treatment_13\NN\654885|NONE (r_pobj) to_11\IN\0|alterations (r_pcomp) due_10\IN\5174653|evidence|that|of (r_prep) exists_6\VBZ\0|.|It|is (l_prep) of_7\IN\0|evidence|that|due (l_pobj) injury_9\NN\14052046|NONE
D000638_D056486 CID amiodarone_12\NN\2715941|,|,|including (r_compound) treatment_13\NN\654885|NONE (r_pobj) to_11\IN\0|alterations (r_pcomp) due_10\IN\5174653|evidence|that|of (l_pobj) alterations_18\NNS\7283608|to (l_acl) resembling_19\VBG\2657219|NONE (l_dobj) hepatitis_21\NN\14127211|NONE (l_appos) cirrhosis_27\NN\14116321|alcoholic|, (l_nmod) hepatitis_24\NN\14127211|cholestatic|of
D000638_D013610 NONE amiodarone_0\NNP\2715941|.|effective|has|in (r_nsubj) proved_2\VBN\2604760|NONE (l_prep) in_5\IN\13603305|.|effective|has|Amiodarone (l_pobj) treatment_7\NN\654885|NONE (l_prep) of_8\IN\0|the (l_pobj) tachyarrhythmias_12\NNS\0|NONE
D000638_D006519 NONE amiodarone_12\NN\2715941|,|,|including (r_compound) treatment_13\NN\654885|NONE (r_pobj) to_11\IN\0|alterations (r_pcomp) due_10\IN\5174653|evidence|that|of (l_pobj) alterations_18\NNS\7283608|to (l_acl) resembling_19\VBG\2657219|NONE (l_dobj) hepatitis_21\NN\14127211|NONE
D000638_D008103 CID amiodarone_12\NN\2715941|,|,|including (r_compound) treatment_13\NN\654885|NONE (r_pobj) to_11\IN\0|alterations (r_pcomp) due_10\IN\5174653|evidence|that|of (l_pobj) alterations_18\NNS\7283608|to (l_acl) resembling_19\VBG\2657219|NONE (l_dobj) hepatitis_21\NN\14127211|NONE (l_appos) cirrhosis_27\NN\14116321|alcoholic|, (l_prep) of_28\IN\0|hepatitis|cholestatic (l_pobj) liver_30\NN\5298729|NONE
D000638_D002779 CID amiodarone_7\NN\2715941|NONE (r_compound) treatment_8\NN\654885|A|due|with (r_appos) patient_1\NN\9898892|is|below|given|and (l_prep) with_2\IN\0|treatment|A|due (l_pobj) hepatitis_4\NN\14127211|NONE
D000638_D002779 CID amiodarone_19\NN\2715941|NONE (r_pobj) of_18\IN\0|the (r_prep) hepatotoxicity_17\NN\0|NONE (r_pobj) of_15\IN\0|a (r_prep) review_14\NN\5733583|is|. (r_nsubjpass) given_21\VBN\5892096|is|below|and|patient (r_conj) presented_10\VBN\2137132|NONE (l_nsubjpass) patient_1\NN\9898892|is|below|given|and (l_prep) with_2\IN\0|treatment|A|due (l_pobj) hepatitis_4\NN\14127211|NONE
D000638_D002779 CID amiodarone_12\NN\2715941|,|,|including (r_compound) treatment_13\NN\654885|NONE (r_pobj) to_11\IN\0|alterations (r_pcomp) due_10\IN\5174653|evidence|that|of (l_pobj) alterations_18\NNS\7283608|to (l_acl) resembling_19\VBG\2657219|NONE (l_dobj) hepatitis_21\NN\14127211|NONE (l_appos) cirrhosis_27\NN\14116321|alcoholic|, (l_nmod) hepatitis_24\NN\14127211|cholestatic|of
D000638_D005234 CID amiodarone_12\NN\2715941|,|,|including (r_compound) treatment_13\NN\654885|NONE (l_prep) including_15\VBG\0|amiodarone|,|, (l_pobj) steatosis_16\NN\0|NONE
15096016
D007980_D018476 NONE levodopa_20\RB\14604959| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) dyskinesias_23\NNS\14084880|NONE (r_dobj) improving_19\VBG\126264|NONE (r_pcomp) in_18\IN\13603305|to (r_prep) be_17\VB\14625458|.|strength|;|,|however|improves (r_xcomp) seems_15\VBZ\2604760|NONE (l_ccomp) improves_2\VBZ\126264|.|strength|;|,|however|be (l_dobj) bradykinesia_3\JJ\0|stimulation|to
D007980_D009127 NONE levodopa_20\RB\14604959| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) dyskinesias_23\NNS\14084880|NONE (r_dobj) improving_19\VBG\126264|NONE (r_pcomp) in_18\IN\13603305|to (r_prep) be_17\VB\14625458|.|strength|;|,|however|improves (r_xcomp) seems_15\VBZ\2604760|NONE (l_ccomp) improves_2\VBZ\126264|.|strength|;|,|however|be (l_dobj) bradykinesia_3\JJ\0|stimulation|to (l_conj) rigidity_5\NN\5023233|and
D007980_D004409 CID levodopa_20\RB\14604959| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) dyskinesias_23\NNS\14084880|NONE
8586822
D017673_D006973 CID chloride_31\NN\14818238|dietary (r_compound) supplementation_32\NN\5108947|NONE (r_pobj) of_28\IN\0|hypertensive|the (r_prep) effect_27\NN\34213|NONE (r_pobj) to_24\IN\0|importantly|test|system|,|. (r_prep) contributes_22\VBZ\126264|NONE (l_advcl) test_1\VB\5798043|to|importantly|system|,|. (l_dobj) hypothesis_3\NN\7162194|To (l_relcl) treated_10\VBN\2376958|the (l_dobj) rats_13\NNS\2329401|captopril||in|spontaneously|that|, (l_amod) hypertensive_12\JJ\10405694|)|SHR|(
D017673_D006973 CID chloride_31\NN\14818238|dietary (r_compound) supplementation_32\NN\5108947|NONE (r_pobj) of_28\IN\0|hypertensive|the (r_prep) effect_27\NN\34213|NONE (l_amod) hypertensive_26\JJ\10405694|of|the
D017673_D006973 CID chloride_19\NN\14818238| (r_npadvmod) induced_21\VBN\1627355|the|sodium|in|in (r_amod) increase_22\NN\13576355|that (l_prep) in_23\IN\13603305|the|sodium|in|induced (l_pobj) map_24\NNP\4076846|NONE
D002216_D006973 NONE captopril_12\FW\2673637|rats||.|Contribution (r_npadvmod) treated_14\VBN\2376958|NONE (l_dobj) rats_17\NNS\2329401||.|Contribution|captopril (l_amod) hypertensive_16\JJ\10405694|NONE
D002216_D006973 NONE captopril_8\FW\2673637||in|rats|spontaneously|that|, (r_npadvmod) treated_10\VBN\2376958|the (l_dobj) rats_13\NNS\2329401|captopril||in|spontaneously|that|, (l_amod) hypertensive_12\JJ\10405694|)|SHR|(
D002216_D006973 NONE captopril_8\FW\2673637||in|rats|spontaneously|that|, (r_npadvmod) treated_10\VBN\2376958|the (r_relcl) hypothesis_3\NN\7162194|To (r_dobj) test_1\VB\5798043|to|importantly|system|,|. (r_advcl) contributes_22\VBZ\126264|NONE (l_prep) to_24\IN\0|importantly|test|system|,|. (l_pobj) effect_27\NN\34213|NONE (l_amod) hypertensive_26\JJ\10405694|of|the
D018738_D006973 NONE hexamethonium_6\NN\0|NONE (r_pobj) of_2\IN\0|Intravenous (r_prep) infusion_1\NN\14589223|in|. (r_nsubj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|.|infusion (l_pobj) decline_11\NN\13458571|NONE (l_relcl) eliminated_15\VBD\1619929|rapid|a|in (l_dobj) increase_22\NN\13576355|that (l_prep) in_23\IN\13603305|the|sodium|in|induced (l_pobj) map_24\NNP\4076846|NONE
7651879
D001569_D012131 NONE benzodiazepine_3\JJ\3771443|used|receptor|a (r_amod) antagonist_5\NN\7846|.|Flumazenil (l_acl) used_6\VBD\0|receptor|a|benzodiazepine (l_xcomp) reverse_8\VB\13854649|NONE (l_dobj) sedation_9\NN\14034177|to (l_conj) depression_12\NN\14373582|induced|and
D001569_D012131 NONE benzodiazepines_15\NNS\3771443|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|depression|and (r_acl) sedation_9\NN\14034177|to (l_conj) depression_12\NN\14373582|induced|and
D005442_D012131 NONE flumazenil_0\NNP\0|antagonist|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) antagonist_5\NN\7846|.|Flumazenil (l_acl) used_6\VBD\0|receptor|a|benzodiazepine (l_xcomp) reverse_8\VB\13854649|NONE (l_dobj) sedation_9\NN\14034177|to (l_conj) depression_12\NN\14373582|induced|and
D005442_D012640 CID flumazenil_2\JJ\0|in (r_compound) administration_3\NN\1133281|NONE (r_pobj) after_1\IN\0|. (r_prep) seizure_0\NN\14081375|NONE
D005442_D012640 CID flumazenil_19\JJ\0|NONE (r_pobj) of_18\IN\0|the (r_prep) administration_17\NN\1133281|NONE (r_pobj) following_15\VBG\8180190|pediatric|a (r_acl) patient_14\NN\9898892|NONE (r_pobj) in_11\IN\13603305|clonic|generalized|a (r_prep) seizure_10\NN\14081375|NONE
6402369
D015080_D064420 NONE mesna_7\NNP\0|series|and|the (r_compound) series_8\NN\8456993|NONE (l_conj) series_13\NN\8456993|MESNA|and|the (l_prep) with_14\IN\0|conventional|the|prophylaxis (l_pobj) respect_15\NN\5817845|NONE (l_prep) to_16\IN\0|NONE (l_pobj) toxicity_21\NN\13576101|NONE
D015080_D008175 NONE sulphonate_13\JJ\0|NONE (r_pobj) of_10\IN\0|oral (r_prep) administration_9\NN\1133281|NONE (r_pobj) by_7\IN\0|urothelial|induced (r_prep) toxicity_6\NN\13576101|NONE (r_pobj) of_1\IN\0|to|. (r_prep) treatment_0\NN\654885|NONE (l_prep) to_17\IN\0|of|. (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) cancer_22\NN\14239425|NONE
D015080_D008175 NONE mesna_15\NNP\0|sodium|mercaptoethane (r_appos) sulphonate_13\JJ\0|NONE (r_pobj) of_10\IN\0|oral (r_prep) administration_9\NN\1133281|NONE (r_pobj) by_7\IN\0|urothelial|induced (r_prep) toxicity_6\NN\13576101|NONE (r_pobj) of_1\IN\0|to|. (r_prep) treatment_0\NN\654885|NONE (l_prep) to_17\IN\0|of|. (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) cancer_22\NN\14239425|NONE
D015080_D008175 NONE sulphonate_12\JJ\0|NONE (r_pobj) of_6\IN\0|oral (r_prep) administration_5\NN\1133281|NONE (r_pobj) of_3\IN\0|against|The|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN\670261|NONE (l_prep) in_27\IN\13603305|)|was|as|.|(|effect|IF (l_pobj) group_29\NN\2137|NONE (l_prep) of_30\IN\0|a (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0| (l_pobj) cancer_36\NN\14239425|NONE
D015080_D008175 NONE mesna_14\NNP\0|mercaptoethane|sodium|the|compound|thiol (r_appos) sulphonate_12\JJ\0|NONE (r_pobj) of_6\IN\0|oral (r_prep) administration_5\NN\1133281|NONE (r_pobj) of_3\IN\0|against|The|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN\670261|NONE (l_prep) in_27\IN\13603305|)|was|as|.|(|effect|IF (l_pobj) group_29\NN\2137|NONE (l_prep) of_30\IN\0|a (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0| (l_pobj) cancer_36\NN\14239425|NONE
D013438_D001745 NONE thiol_8\JJ\0|mercaptoethane|sodium|the|compound|MESNA (r_compound) sulphonate_12\JJ\0|NONE (r_pobj) of_6\IN\0|oral (r_prep) administration_5\NN\1133281|NONE (r_pobj) of_3\IN\0|against|The|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (l_prep) against_16\IN\0|The|of|protective (l_pobj) toxicity_18\NN\13576101|NONE
D013438_D008175 NONE thiol_8\JJ\0|mercaptoethane|sodium|the|compound|MESNA (r_compound) sulphonate_12\JJ\0|NONE (r_pobj) of_6\IN\0|oral (r_prep) administration_5\NN\1133281|NONE (r_pobj) of_3\IN\0|against|The|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN\670261|NONE (l_prep) in_27\IN\13603305|)|was|as|.|(|effect|IF (l_pobj) group_29\NN\2137|NONE (l_prep) of_30\IN\0|a (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0| (l_pobj) cancer_36\NN\14239425|NONE
D015080_D001745 NONE sulphonate_13\JJ\0|NONE (r_pobj) of_10\IN\0|oral (r_prep) administration_9\NN\1133281|NONE (r_pobj) by_7\IN\0|urothelial|induced (r_prep) toxicity_6\NN\13576101|NONE
D015080_D001745 NONE mesna_15\NNP\0|sodium|mercaptoethane (r_appos) sulphonate_13\JJ\0|NONE (r_pobj) of_10\IN\0|oral (r_prep) administration_9\NN\1133281|NONE (r_pobj) by_7\IN\0|urothelial|induced (r_prep) toxicity_6\NN\13576101|NONE
D015080_D001745 NONE sulphonate_12\JJ\0|NONE (r_pobj) of_6\IN\0|oral (r_prep) administration_5\NN\1133281|NONE (r_pobj) of_3\IN\0|against|The|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (l_prep) against_16\IN\0|The|of|protective (l_pobj) toxicity_18\NN\13576101|NONE
D015080_D001745 NONE mesna_14\NNP\0|mercaptoethane|sodium|the|compound|thiol (r_appos) sulphonate_12\JJ\0|NONE (r_pobj) of_6\IN\0|oral (r_prep) administration_5\NN\1133281|NONE (r_pobj) of_3\IN\0|against|The|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (l_prep) against_16\IN\0|The|of|protective (l_pobj) toxicity_18\NN\13576101|NONE
D007069_D001745 CID ifosfamide_2\RB\0| (r_advmod) induced_4\VBN\1627355|by|urothelial (r_amod) toxicity_6\NN\13576101|NONE
D007069_D001745 CID ifosfamide_21\NN\0|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|urothelial (r_acl) toxicity_18\NN\13576101|NONE
D007069_D001745 CID if_23\IN\0|)|in|was|as|.|(|effect (r_mark) tested_26\VBN\670261|NONE (l_nsubjpass) effect_2\NN\34213|)|in|was|as|.|(|IF (l_prep) against_16\IN\0|The|of|protective (l_pobj) toxicity_18\NN\13576101|NONE
D007069_D001745 CID if_40\IN\0|)|/|on|mg||( (r_mark) m2_45\NN\13357178|NONE (r_pobj) with_39\IN\0|NONE (r_prep) treatment_38\NN\654885|NONE (r_pobj) under_37\IN\0|lung|inoperable (r_prep) cancer_36\NN\14239425|NONE (r_pobj) with_33\IN\0| (r_prep) patients_32\NNS\9898892|NONE (r_pobj) of_30\IN\0|a (r_prep) group_29\NN\2137|NONE (r_pobj) in_27\IN\13603305|)|was|as|.|(|effect|IF (r_prep) tested_26\VBN\670261|NONE (l_nsubjpass) effect_2\NN\34213|)|in|was|as|.|(|IF (l_prep) against_16\IN\0|The|of|protective (l_pobj) toxicity_18\NN\13576101|NONE
D007069_D008175 NONE ifosfamide_2\RB\0| (r_advmod) induced_4\VBN\1627355|by|urothelial (r_amod) toxicity_6\NN\13576101|NONE (r_pobj) of_1\IN\0|to|. (r_prep) treatment_0\NN\654885|NONE (l_prep) to_17\IN\0|of|. (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) cancer_22\NN\14239425|NONE
D007069_D008175 NONE ifosfamide_21\NN\0|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|urothelial (r_acl) toxicity_18\NN\13576101|NONE (r_pobj) against_16\IN\0|The|of|protective (r_prep) effect_2\NN\34213|)|in|was|as|.|(|IF (r_nsubjpass) tested_26\VBN\670261|NONE (l_prep) in_27\IN\13603305|)|was|as|.|(|effect|IF (l_pobj) group_29\NN\2137|NONE (l_prep) of_30\IN\0|a (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0| (l_pobj) cancer_36\NN\14239425|NONE
D007069_D008175 NONE if_23\IN\0|)|in|was|as|.|(|effect (r_mark) tested_26\VBN\670261|NONE (l_prep) in_27\IN\13603305|)|was|as|.|(|effect|IF (l_pobj) group_29\NN\2137|NONE (l_prep) of_30\IN\0|a (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0| (l_pobj) cancer_36\NN\14239425|NONE
D007069_D008175 NONE if_40\IN\0|)|/|on|mg||( (r_mark) m2_45\NN\13357178|NONE (r_pobj) with_39\IN\0|NONE (r_prep) treatment_38\NN\654885|NONE (r_pobj) under_37\IN\0|lung|inoperable (r_prep) cancer_36\NN\14239425|NONE
8958188
C045894_D009369 NONE lometrexol_9\NN\0|that|activity (r_nsubj) has_10\VBZ\13888491|data|have|. (l_dobj) activity_11\NN\30358|that|lometrexol (l_prep) against_12\IN\0|NONE (l_pobj) tumours_13\NNS\14234074|NONE
D005492_D064420 NONE acid_16\NN\14818238|folic|dose|,|low (r_compound) administration_17\NN\1133281|NONE (r_pobj) by_12\IN\0|be|following|toxicity|can|that|for (r_agent) prevented_11\VBN\0|.|studies (l_nsubjpass) toxicity_6\NN\13576101|be|following|by|can|that|for
D005492_D064420 NONE acid_13\NN\14818238|folic|confirmed (r_compound) supplementation_14\NN\5108947|NONE (l_relcl) confirmed_17\VBN\0|acid|folic (l_ccomp) reduced_26\VBN\441445|has|which (l_nsubjpass) toxicity_20\NN\13576101|be|can|markedly|by|that
D005492_D064420 NONE acid_29\NN\14818238|folic (r_compound) supplementation_30\NN\5108947|NONE (r_pobj) by_27\IN\0|be|toxicity|can|markedly|that (r_agent) reduced_26\VBN\441445|has|which (l_nsubjpass) toxicity_20\NN\13576101|be|can|markedly|by|that
D005492_D064420 NONE folate_13\JJ\15090742|plasma (r_compound) elevation_14\NN\7445480|NONE (r_pobj) of_11\IN\0|the (r_prep) extent_10\NN\13939892|clinical|and (r_conj) toxicity_7\NN\13576101|NONE
D005492_D064420 NONE acid_12\NN\14818238|folic (r_compound) administration_13\NN\1133281|NONE (r_pobj) by_10\IN\0|that|not|were|indicating|pharmacokinetics (r_agent) altered_9\VBN\0|.|studies (l_advcl) indicating_14\VBG\952524|that|not|were|by|pharmacokinetics (l_ccomp) is_17\VBZ\0|NONE (l_acomp) unlikely_18\JJ\0|that|supplementation (l_xcomp) reduce_20\VB\441445|NONE (l_dobj) toxicity_21\NN\13576101|by|to
D008727_D009369 NONE methotrexate_22\NNP\2722166|other|, (r_appos) drugs_19\NNS\14778436|NONE (r_pobj) to_17\IN\0|NONE (r_prep) refractory_16\JJ\3673767|which (r_acomp) are_15\VBP\13600404|NONE (r_relcl) tumours_13\NNS\14234074|NONE
C045894_D064420 NONE lometrexol_7\NN\0|NONE (r_pobj) of_6\IN\0|clinical|initial|the (r_prep) development_5\NN\248977|was|However|,|because|. (r_nsubjpass) curtailed_9\VBN\235368|NONE (l_prep) because_10\IN\0|was|However|development|,|. (l_pobj) toxicities_16\NNS\13576101|of
C045894_D064420 NONE lometrexol_8\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) toxicity_6\NN\13576101|be|following|by|can|that|for
C045894_D064420 NONE lometrexol_9\NN\0|NONE (r_pobj) of_8\IN\0|I|given|clinical (r_prep) study_7\NN\635850|Phase|observation|. (l_acl) given_10\VBN\5892096|of|I|clinical (l_prep) with_11\IN\0|NONE (l_pobj) supplementation_14\NN\5108947|NONE (l_relcl) confirmed_17\VBN\0|acid|folic (l_ccomp) reduced_26\VBN\441445|has|which (l_nsubjpass) toxicity_20\NN\13576101|be|can|markedly|by|that
C045894_D064420 NONE lometrexol_22\NN\0|NONE (r_pobj) of_21\IN\0|the (r_prep) toxicity_20\NN\13576101|be|can|markedly|by|that
C045894_D064420 NONE lometrexol_4\NN\0|NONE (r_compound) plasma_5\NN\5398023|NONE (r_compound) pharmacokinetics_6\NNS\6054892|that|not|were|indicating|by (r_nsubjpass) altered_9\VBN\0|.|studies (l_advcl) indicating_14\VBG\952524|that|not|were|by|pharmacokinetics (l_ccomp) is_17\VBZ\0|NONE (l_acomp) unlikely_18\JJ\0|that|supplementation (l_xcomp) reduce_20\VB\441445|NONE (l_dobj) toxicity_21\NN\13576101|by|to
C045894_D064420 NONE lometrexol_24\NN\0|NONE (r_compound) plasma_25\NN\5398023|NONE (r_compound) clearance_26\NN\5089947|NONE (r_dobj) enhancing_23\VBG\227165|NONE (r_pcomp) by_22\IN\0|toxicity|to (r_prep) reduce_20\VB\441445|NONE (l_dobj) toxicity_21\NN\13576101|by|to
10743694
1535072
D012701_D001008 NONE serotonin_23\NN\14807737|reuptake (r_compound) blockers_25\NNS\10101634|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) after_20\IN\0|who|effects (r_prep) suffered_16\VBD\2110220|affective (r_relcl) disorders_14\NNS\14034177|,|or (r_conj) anxiety_10\NN\14373582|,
D015016_D020018 NONE yohimbine_0\NNP\0|.|induced|of (r_compound) treatment_1\NN\654885|NONE (l_prep) of_2\IN\0|.|Yohimbine|induced (l_pobj) effects_5\NNS\13245626|NONE
D015016_D020018 NONE yohimbine_6\NN\0|may|treat|that|be (r_nsubjpass) used_9\VBN\0|.|report (l_xcomp) treat_11\VB\7570720|yohimbine|may|that|be (l_dobj) effects_15\NNS\13245626|to
D015016_D020018 NONE yohimbine_3\NN\0|.|as|study (r_dobj) evaluated_2\VBD\670261|NONE (l_prep) as_4\IN\14622893|.|study|yohimbine (l_pobj) treatment_6\NN\654885|NONE (l_prep) for_7\IN\0|a (l_pobj) effects_11\NNS\13245626|NONE
D015016_D020018 NONE yohimbine_28\NN\0|.|on|basis|were|patients (r_dobj) given_27\VBN\5892096|NONE (l_nsubjpass) patients_1\NNS\9898892|.|on|basis|were|yohimbine (l_prep) with_2\IN\0|Six (l_pobj) disorder_6\NN\14034177|NONE (l_conj) trichotillomania_8\NN\9181557|compulsive|obsessive|either|, (l_conj) anxiety_10\NN\14373582|, (l_conj) disorders_14\NNS\14034177|,|or (l_relcl) suffered_16\VBD\2110220|affective (l_dobj) effects_19\NNS\13245626|who|after
D015016_D020018 NONE yohimbine_7\NN\0|treatment|that|may (r_nsubj) be_9\VB\14625458|.|results (l_attr) treatment_12\NN\654885|that|may|yohimbine (l_prep) for_13\IN\0|an|effective (l_pobj) effects_17\NNS\13245626|NONE
D012701_D020018 NONE serotonin_8\NN\14807737|reuptake (r_compound) blockers_10\NNS\10101634|NONE (r_pobj) by_7\IN\0|NONE (r_agent) induced_6\VBN\1627355|.|Yohimbine|of (r_acl) treatment_1\NN\654885|NONE (l_prep) of_2\IN\0|.|Yohimbine|induced (l_pobj) effects_5\NNS\13245626|NONE
D012701_D020018 NONE serotonin_14\NN\14807737|reuptake (r_compound) blockers_16\NNS\10101634|NONE (r_pobj) by_13\IN\0|NONE (r_agent) caused_12\VBN\1617192|side|the|sexual (r_acl) effects_11\NNS\13245626|NONE
D012701_D020018 NONE serotonin_23\NN\14807737|reuptake (r_compound) blockers_25\NNS\10101634|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) after_20\IN\0|who|effects (r_prep) suffered_16\VBD\2110220|affective (l_dobj) effects_19\NNS\13245626|who|after
D012701_D020018 NONE serotonin_20\NN\14807737|reuptake (r_compound) blockers_22\NNS\10101634|NONE (r_pobj) by_19\IN\0|NONE (r_agent) caused_18\VBN\1617192|the|side|sexual (r_acl) effects_17\NNS\13245626|NONE
D015016_D009771 NONE yohimbine_28\NN\0|.|on|basis|were|patients (r_dobj) given_27\VBN\5892096|NONE (l_nsubjpass) patients_1\NNS\9898892|.|on|basis|were|yohimbine (l_prep) with_2\IN\0|Six (l_pobj) disorder_6\NN\14034177|NONE
D012701_D019964 NONE serotonin_23\NN\14807737|reuptake (r_compound) blockers_25\NNS\10101634|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) after_20\IN\0|who|effects (r_prep) suffered_16\VBD\2110220|affective (r_relcl) disorders_14\NNS\14034177|,|or
D015016_D014256 NONE yohimbine_28\NN\0|.|on|basis|were|patients (r_dobj) given_27\VBN\5892096|NONE (l_nsubjpass) patients_1\NNS\9898892|.|on|basis|were|yohimbine (l_prep) with_2\IN\0|Six (l_pobj) disorder_6\NN\14034177|NONE (l_conj) trichotillomania_8\NN\9181557|compulsive|obsessive|either|,
D015016_D007172 NONE yohimbine_6\NN\0|behavior|be|that|and (r_nsubj) facilitates_7\VBZ\2547586|.|studies (l_conj) be_12\VB\14625458|behavior|that|and|yohimbine (l_acomp) helpful_13\JJ\0|may (l_prep) in_14\IN\13603305|NONE (l_pobj) treatment_16\NN\654885|NONE (l_prep) of_17\IN\0|the (l_pobj) impotence_19\NN\4723816|NONE
D012701_D009771 NONE serotonin_23\NN\14807737|reuptake (r_compound) blockers_25\NNS\10101634|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) after_20\IN\0|who|effects (r_prep) suffered_16\VBD\2110220|affective (r_relcl) disorders_14\NNS\14034177|,|or (r_conj) anxiety_10\NN\14373582|, (r_conj) trichotillomania_8\NN\9181557|compulsive|obsessive|either|, (r_conj) disorder_6\NN\14034177|NONE
D002997_D020018 CID clomipramine_17\NN\4482543|NONE (r_pobj) of_16\IN\0|the|side (r_prep) effects_15\NNS\13245626|to
D015016_D019964 NONE yohimbine_28\NN\0|.|on|basis|were|patients (r_dobj) given_27\VBN\5892096|NONE (l_nsubjpass) patients_1\NNS\9898892|.|on|basis|were|yohimbine (l_prep) with_2\IN\0|Six (l_pobj) disorder_6\NN\14034177|NONE (l_conj) trichotillomania_8\NN\9181557|compulsive|obsessive|either|, (l_conj) anxiety_10\NN\14373582|, (l_conj) disorders_14\NNS\14034177|,|or
D012701_D014256 NONE serotonin_23\NN\14807737|reuptake (r_compound) blockers_25\NNS\10101634|NONE (r_pobj) with_22\IN\0|NONE (r_prep) treatment_21\NN\654885|NONE (r_pobj) after_20\IN\0|who|effects (r_prep) suffered_16\VBD\2110220|affective (r_relcl) disorders_14\NNS\14034177|,|or (r_conj) anxiety_10\NN\14373582|, (r_conj) trichotillomania_8\NN\9181557|compulsive|obsessive|either|,
D015016_D001008 NONE yohimbine_28\NN\0|.|on|basis|were|patients (r_dobj) given_27\VBN\5892096|NONE (l_nsubjpass) patients_1\NNS\9898892|.|on|basis|were|yohimbine (l_prep) with_2\IN\0|Six (l_pobj) disorder_6\NN\14034177|NONE (l_conj) trichotillomania_8\NN\9181557|compulsive|obsessive|either|, (l_conj) anxiety_10\NN\14373582|,
D015016_D001008 NONE yohimbine_3\NN\0|NONE (r_pobj) of_2\IN\0|Side (r_prep) effects_1\NNS\13245626|.|sweating (r_nsubj) included_4\VBD\0|NONE (l_dobj) sweating_6\NN\13440063|.|effects (l_conj) anxiety_9\NN\14373582|excessive|,
7880714
7053705
D013866_D006504 CID 6-thioguanine_7\CD\0|NONE (r_pobj) by_6\IN\0|NONE (r_agent) caused_5\VBN\1617192|occlusive|.|Hepatic (r_acl) disease_4\NN\14061805|NONE
D013866_D006504 CID 6-thioguanine_27\CD\0|NONE (r_punct) ._28\.\0|occlusive|reversible|of (r_punct) disease_5\NN\14061805|NONE (l_prep) of_6\IN\0|occlusive|reversible|. (l_pobj) liver_8\NN\5298729|NONE
D013866_D006504 CID 6-thioguanine_35\CD\0|solely (r_pobj) to_34\IN\0|occlusive (r_prep) related_32\VBN\628491|NONE (r_pobj) of_28\IN\0|the|first (r_prep) case_27\NN\7283608|may (r_attr) be_24\VB\14625458|and|,|case|opportunity|. (r_conj) presented_2\VBD\2137132|NONE (l_dobj) opportunity_5\NN\14481929|and|be|,|case|. (l_acl) observe_7\VB\2163746|a|unique (l_dobj) features_10\NNS\5849040|to|over (l_prep) of_11\IN\0|the|histologic (l_pobj) disease_18\NN\14061805|NONE
D013866_D054198 NONE 6-thioguanine_27\CD\0|NONE (r_punct) ._28\.\0|occlusive|reversible|of (r_punct) disease_5\NN\14061805|NONE (l_prep) of_6\IN\0|occlusive|reversible|. (l_pobj) liver_8\NN\5298729|NONE (l_acl) developed_9\VBN\1753788|the (l_prep) in_10\IN\13603305|after|with (l_pobj) man_15\NN\9605289|NONE (l_prep) with_16\IN\0|old|a (l_pobj) leukemia_19\NN\14239918|NONE
8384253
D014750_D008228 NONE vincristine_10\NN\3917455|NONE (r_pobj) with_9\IN\0|investigated|.|between|patients (r_prep) treated_8\VBN\2376958|NONE (l_nsubj) patients_1\NNS\9898892|investigated|with|.|between (l_prep) with_2\IN\0|Forty (l_pobj) lymphoma_7\NNP\14239918|NONE
D014750_D008228 NONE vincristine_37\NN\3917455|NONE (r_pobj) of_36\IN\0|on|the|term (r_prep) effects_35\NNS\13245626|to (r_dobj) evaluate_31\VB\670261|NONE (r_acl) order_29\NN\7168131|NONE (r_pobj) in_28\IN\13603305|(|dose|were (r_prep) investigated_27\VBN\644583|with|.|between|patients (r_parataxis) treated_8\VBN\2376958|NONE (l_nsubj) patients_1\NNS\9898892|investigated|with|.|between (l_prep) with_2\IN\0|Forty (l_pobj) lymphoma_7\NNP\14239918|NONE
D014750_D009422 NONE vincristine_8\NN\3917455|NONE (r_pobj) with_4\IN\0|that|reversible|signs (r_prep) are_17\VBP\13600404|good (l_nsubj) signs_11\NNS\6643763|that|reversible|with (l_conj) symptoms_13\NNS\5823932|dose|and|schedule (l_prep) of_14\IN\0|NONE (l_pobj) neuropathy_16\NN\14204950|NONE
D014750_D009422 NONE vincristine_15\NN\3917455|NONE (r_compound) neuropathy_16\NN\14204950|NONE
8111719
D007069_D006212 CID ifosfamide_2\RB\0| (r_advmod) induced_4\VBN\1627355|NONE (r_amod) neurotoxicity_5\NN\0|.|and (r_conj) hallucinations_0\NNS\14376855|NONE
D007069_D006212 CID ifosfamide_16\NN\0|NONE (r_pobj) of_15\IN\0|side|known|a (r_prep) effect_14\NN\34213|.|Hallucinations (r_attr) are_7\VBP\13600404|NONE (l_nsubj) hallucinations_0\NNS\14376855|.|effect
D007069_D006212 CID ifosfamide_3\RB\0| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) hallucinations_6\NNS\14376855|NONE
D007069_D006212 CID ifosfamide_6\RB\0| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) hallucinations_9\NNS\14376855|NONE
D007069_D006212 CID ifosfamide_7\RB\0| (r_npadvmod) induced_9\VBN\1627355|possible|occur|, (r_amod) hallucinations_10\NNS\14376855|NONE
D007069_D020258 NONE ifosfamide_2\RB\0| (r_advmod) induced_4\VBN\1627355|NONE (r_amod) neurotoxicity_5\NN\0|.|and
D007069_D020258 NONE ifosfamide_16\NN\0|NONE (r_pobj) of_15\IN\0|side|known|a (r_prep) effect_14\NN\34213|.|Hallucinations (r_attr) are_7\VBP\13600404|NONE (l_nsubj) hallucinations_0\NNS\14376855|.|effect (l_prep) as_1\IN\14622893|NONE (l_pobj) symptom_3\NN\5823932|NONE (l_prep) of_4\IN\0|a (l_pobj) neurotoxicity_6\NN\0|NONE
D007069_D020258 NONE ifosfamide_7\RB\0| (r_npadvmod) induced_9\VBN\1627355|possible|occur|, (r_amod) hallucinations_10\NNS\14376855|NONE (l_relcl) occur_14\VB\0|possible|induced|, (l_prep) without_15\IN\0|may|which (l_pobj) signs_17\NNS\6643763|NONE (l_prep) of_18\IN\0|other (l_pobj) neurotoxicity_19\NN\0|NONE
D006220_D011595 NONE haloperidol_12\NN\3713736|potency|)|marked|(|, (r_appos) neuroleptics_8\NNS\4470232|may|.|effective (l_amod) marked_3\JJ\1296462|potency|haloperidol|)|(|, (l_auxpass) becomes_2\VBZ\146138|NONE (l_nsubj) agitation_1\NN\14373582|If
9579567
D013629_D016889 CID tamoxifen_9\NN\2714883|treatments|or (r_compound) use_10\NN\407535|and|endometrial (r_conj) cancer_7\NN\14239425|NONE
D013629_D016889 CID tamoxifen_4\NN\2714883|who|had (r_dobj) received_3\VBN\2210855|NONE (r_relcl) women_0\NNS\9605289|likely|. (r_nsubj) were_5\VBD\0|NONE (l_acomp) likely_8\JJ\0|.|Women (l_xcomp) have_10\VB\7846|more (l_dobj) cancer_12\NN\14239425|to
D013629_D016889 CID tamoxifen_8\NN\2714883|had (r_advmod) received_7\VBN\2210855|who|cancer|and (r_conj) had_2\VBD\0|NONE (l_dobj) cancer_4\NN\14239425|who|received|and
D013629_D016889 CID tamoxifen_8\NN\2714883|had (r_advmod) received_7\VBN\2210855|who|cancer|and (r_conj) had_2\VBD\0|NONE (r_relcl) women_0\NNS\9605289|.|disease (r_nsubj) had_9\VBD\0|NONE (l_dobj) disease_12\NN\14061805|.|Women (l_conj) prognosis_15\NN\6748969|advanced|and (l_prep) than_16\IN\0|poorer (l_pobj) those_17\DT\0|NONE (l_prep) with_18\IN\0|received (l_pobj) cancer_20\NN\14239425|NONE
D013629_D016889 CID tamoxifen_7\NN\2714883|NONE (r_pobj) of_6\IN\0|a|in|causal (r_prep) role_5\NN\719494|,|results|used|. (l_prep) in_8\IN\13603305|a|causal|of (l_pobj) cancer_10\NN\14239425|NONE
D013629_D016889 CID tamoxifen_7\NN\2714883|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treated_5\VBN\2376958|NONE (r_acl) women_4\NNS\9605289|NONE (r_pobj) in_3\IN\13603305|NONE (r_prep) diagnosed_2\VBD\644583|Endometrial (r_acl) cancers_1\NNS\14239425|.|prognosis
D013629_D001943 NONE tamoxifen_1\NN\2714883|widely|proposed|in|Since|and|is (r_nsubjpass) used_4\VBN\0|,|effects|carefully|be|must|. (l_prep) in_5\IN\13603305|widely|tamoxifen|proposed|Since|and|is (l_pobj) treatment_8\NN\654885|NONE (l_compound) cancer_7\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_1\NN\2714883|widely|proposed|in|Since|and|is (r_nsubjpass) used_4\VBN\0|,|effects|carefully|be|must|. (l_conj) proposed_12\VBN\1010118|widely|tamoxifen|in|Since|and|is (l_prep) for_13\IN\0|has|been (l_pobj) prevention_15\NN\1073995|NONE (l_prep) of_16\IN\0|the (l_pobj) cancer_18\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_9\NN\2714883|treatments|or (r_compound) use_10\NN\407535|and|endometrial (r_conj) cancer_7\NN\14239425|NONE (r_pobj) between_5\IN\0|treated|the (r_prep) association_4\NN\8008335|have|We|. (l_acl) treated_16\VBN\2376958|the|between (l_prep) for_17\IN\0|in (l_pobj) cancer_19\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_7\NN\2714883|NONE (r_pobj) of_6\IN\0|a|in|causal (r_prep) role_5\NN\719494|,|results|used|. (r_dobj) suggest_2\VBP\1010118|NONE (l_advcl) used_14\VBN\0|role|,|results|. (l_xcomp) proposed_17\VBN\1010118|when|particularly (l_prep) for_18\IN\0|as|currently (l_pobj) prevention_21\NN\1073995|NONE (l_compound) cancer_20\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_3\NN\2714883|who|for (r_dobj) receive_2\VBP\2210855|NONE (l_prep) for_4\IN\0|who|tamoxifen (l_pobj) cancer_6\NN\14239425|NONE
D013629_D001943 NONE tamoxifen_12\NN\2714883|NONE (r_pobj) of_11\IN\0|the|benefit (r_prep) ratio_10\NN\13815152|NONE (r_pobj) of_5\IN\0|term|A|as (r_prep) evaluation_4\NN\874067|clearly|.|is (l_prep) as_13\IN\14622893|term|A|of (l_pobj) treatment_16\NN\654885|NONE (l_prep) for_17\IN\0|a|preventive (l_pobj) cancer_19\NN\14239425|NONE
D013629_D020178 NONE tamoxifen_8\NN\2714883|had (r_advmod) received_7\VBN\2210855|who|cancer|and (r_conj) had_2\VBD\0|NONE (r_relcl) women_0\NNS\9605289|.|disease (r_nsubj) had_9\VBD\0|NONE (l_dobj) disease_12\NN\14061805|.|Women
9669632
D020117_D010146 NONE cisapride_11\NN\0|NONE (r_compound) therapy_12\NN\657604|+/|(|P|cisapride|,|,|[|)|after (r_nmod) score_14\NN\5736149|patients|score|;|pretreatment|. (r_advcl) had_5\VBD\0|NONE (l_dobj) score_9\NN\5736149|patients|score|;|pretreatment|. (l_compound) pain_8\NN\14299637|a|higher
D020117_D010146 NONE cisapride_25\NN\0|+/|(|P|,|,|therapy|[|)|after (r_conj) score_14\NN\5736149|patients|score|;|pretreatment|. (r_advcl) had_5\VBD\0|NONE (l_dobj) score_9\NN\5736149|patients|score|;|pretreatment|. (l_compound) pain_8\NN\14299637|a|higher
D020117_D003248 NONE cisapride_36\NN\0|and (r_conj) before_28\IN\0|patients|)|daily|.|,|;|manometry|, (r_advmod) underwent_23\VBD\109660|NONE (l_nsubj) patients_3\NNS\9898892|before|)|daily|.|,|;|manometry|, (l_prep) with_4\IN\0|eight (l_pobj) ibs_5\NNP\0|NONE (l_appos) predominant_9\JJ\0|( (l_compound) constipation_7\NN\14299637||,
D020117_D003248 NONE cisapride_11\NN\0| (r_npadvmod) treated_13\VBN\2376958|score|predominant|IBS (r_amod) patients_18\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|scores|lower (r_prep) were_8\VBD\0|NONE (l_nsubj) scores_1\NNS\13757724|in|lower (l_acl) relating_2\VBG\628491|Symptom (l_prep) to_3\IN\0|NONE (l_pobj) severity_5\NN\5036394|NONE (l_prep) of_6\IN\0|the (l_pobj) constipation_7\NN\14299637|NONE
D020117_D003248 NONE cisapride_11\NN\0| (r_npadvmod) treated_13\VBN\2376958|score|predominant|IBS (r_amod) patients_18\NNS\9898892|NONE (l_amod) predominant_16\JJ\0|score|treated|IBS (l_compound) constipation_14\NN\14299637|
D020117_D003967 NONE cisapride_36\NN\0|and (r_conj) before_28\IN\0|patients|)|daily|.|,|;|manometry|, (r_advmod) underwent_23\VBD\109660|NONE (l_punct) ;_14\:\0|patients|before|)|daily|.|,|manometry|, (l_preconj) predominant_17\JJ\0|NONE (l_compound) diarrhoea_15\NN\14299637|
D020117_D003967 NONE cisapride_14\NN\0|the (r_nmod) groups_17\NNS\2137|NONE (r_pobj) between_12\IN\0|were|In|differences|. (r_prep) observed_11\VBN\2163746|NONE (l_prep) in_0\IN\13603305|were|between|differences|. (l_pobj) patients_4\NNS\9898892|NONE (l_amod) predominant_3\JJ\0|NONE (l_npadvmod) diarrhoea_1\NN\14299637|
D020117_D003967 NONE cisapride_1\NN\0| (r_npadvmod) treated_3\VBN\2376958|predominant (r_amod) patients_7\NNS\9898892|NONE (l_amod) predominant_6\JJ\0|treated (l_npadvmod) diarrhoea_4\NN\14299637|
D020117_D003967 NONE cisapride_11\NN\0|NONE (r_compound) therapy_12\NN\657604|+/|(|P|cisapride|,|,|[|)|after (r_nmod) score_14\NN\5736149|patients|score|;|pretreatment|. (r_advcl) had_5\VBD\0|NONE (l_nsubj) patients_4\NNS\9898892|score|score|;|pretreatment|. (l_amod) predominant_2\JJ\0|IBS (l_npadvmod) diarrhoea_0\NN\14299637|
D020117_D003967 NONE cisapride_25\NN\0|+/|(|P|,|,|therapy|[|)|after (r_conj) score_14\NN\5736149|patients|score|;|pretreatment|. (r_advcl) had_5\VBD\0|NONE (l_nsubj) patients_4\NNS\9898892|score|score|;|pretreatment|. (l_amod) predominant_2\JJ\0|IBS (l_npadvmod) diarrhoea_0\NN\14299637|
D020117_D043183 NONE cisapride_2\NN\0|NONE (r_pobj) of_1\IN\0|function|.|on|and (r_prep) effects_0\NNS\13245626|NONE (l_conj) function_11\NN\13783581|.|on|of|and (l_prep) in_12\IN\13603305|motor|bowel|postcibal (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) syndrome_17\NN\5870365|NONE
D020117_D043183 NONE cisapride_17\NN\0|to|effects (l_prep) on_19\IN\0|, (l_pobj) motility_22\NN\4773351|NONE (l_prep) in_25\IN\13603305|symptoms|jejunal|and|postprandial (l_pobj) syndrome_29\NN\5870365|NONE
D020117_D043183 NONE cisapride_17\NN\0|to|effects (l_prep) on_19\IN\0|, (l_pobj) motility_22\NN\4773351|NONE (l_prep) in_25\IN\13603305|symptoms|jejunal|and|postprandial (l_pobj) syndrome_29\NN\5870365|NONE (l_appos) ibs_31\NNP\0|(|the|irritable|)|bowel
D020117_D043183 NONE cisapride_36\NN\0|and (r_conj) before_28\IN\0|patients|)|daily|.|,|;|manometry|, (r_advmod) underwent_23\VBD\109660|NONE (l_nsubj) patients_3\NNS\9898892|before|)|daily|.|,|;|manometry|, (l_prep) with_4\IN\0|eight (l_pobj) ibs_5\NNP\0|NONE
D020117_D043183 NONE cisapride_11\NN\0| (r_npadvmod) treated_13\VBN\2376958|score|predominant|IBS (r_amod) patients_18\NNS\9898892|NONE (l_compound) ibs_17\NNP\0|score|treated|predominant
D020117_D043183 NONE cisapride_11\NN\0|NONE (r_compound) therapy_12\NN\657604|+/|(|P|cisapride|,|,|[|)|after (r_nmod) score_14\NN\5736149|patients|score|;|pretreatment|. (r_advcl) had_5\VBD\0|NONE (l_nsubj) patients_4\NNS\9898892|score|score|;|pretreatment|. (l_compound) ibs_3\NNP\0|predominant
D020117_D043183 NONE cisapride_25\NN\0|+/|(|P|,|,|therapy|[|)|after (r_conj) score_14\NN\5736149|patients|score|;|pretreatment|. (r_advcl) had_5\VBD\0|NONE (l_nsubj) patients_4\NNS\9898892|score|score|;|pretreatment|. (l_compound) ibs_3\NNP\0|predominant
D020117_D043183 NONE cisapride_0\NNP\0|characteristics|. (r_nsubj) affects_1\VBZ\26192|NONE (l_dobj) characteristics_4\NNS\5849040|Cisapride|. (l_conj) symptoms_7\NNS\5823932|and|jejunal|contraction (l_prep) in_8\IN\13603305|some (l_pobj) ibs_9\NNP\0|NONE
873132
D004997_D002779 CID estradiol_12\NN\14749794| (r_npadvmod) induced_14\VBN\1627355|in (r_amod) cholestasis_15\NN\14052403|hydroxylation|sulfation|.
D003840_D002779 NONE acid_9\NN\14818238|NONE (r_pobj) of_7\IN\0||in|alpha (r_prep) hydroxylation_6\NN\0|cholestasis|sulfation|. (r_dobj) decreased_3\VBD\169651|NONE (l_dobj) cholestasis_15\NN\14052403|hydroxylation|sulfation|.
20973483
D006220_D002375 CID haloperidol_53\NN\3713736| (r_npadvmod) induced_55\VBN\1627355|,|,|model|model (r_amod) catalepsy_56\NN\14023236|NONE
D015632_D002375 NONE mptp_80\NNP\0| (r_npadvmod) treated_82\VBN\2376958|human|primate (r_amod) model_87\NN\5888929|number|and (r_conj) across_37\IN\0|Compound|after|antagonist|,|,|. (l_pobj) number_39\NN\5107765|and|model (l_prep) of_40\IN\0|a (l_pobj) models_42\NNS\5888929|NONE (l_prep) of_43\IN\0|animal (l_pobj) disease_46\NN\14061805|NONE (l_prep) including_47\VBG\0|Parkinson (l_pobj) models_51\NNS\5888929|NONE (l_prep) of_52\IN\0|mouse (l_pobj) catalepsy_56\NN\14023236|NONE
D006220_D004409 NONE haloperidol_53\NN\3713736| (r_npadvmod) induced_55\VBN\1627355|,|,|model|model (r_amod) catalepsy_56\NN\14023236|NONE (l_appos) model_59\NN\5888929|,|,|model|induced (l_prep) of_60\IN\0|mouse (l_pobj) akinesia_64\NN\14558226|NONE
D058915_D010300 NONE antagonist_11\NN\7846|NONE (l_prep) in_12\IN\13603305|a|adenosine|receptor|A|AA (l_pobj) models_14\NNS\5888929|NONE (l_prep) of_15\IN\0|animal (l_pobj) disease_18\NN\14061805|NONE
D058915_D010300 NONE antagonist_11\NN\7846|NONE (l_prep) in_12\IN\13603305|receptor|adenosine|a|A(A)/A(|) (l_pobj) models_15\NNS\5888929|NONE (l_prep) of_16\IN\0|animal|several (l_pobj) disease_19\NN\14061805|NONE
D015632_D004409 NONE mptp_80\NNP\0| (r_npadvmod) treated_82\VBN\2376958|human|primate (r_amod) model_87\NN\5888929|number|and (r_conj) across_37\IN\0|Compound|after|antagonist|,|,|. (l_pobj) number_39\NN\5107765|and|model (l_prep) of_40\IN\0|a (l_pobj) models_42\NNS\5888929|NONE (l_prep) of_43\IN\0|animal (l_pobj) disease_46\NN\14061805|NONE (l_prep) including_47\VBG\0|Parkinson (l_pobj) models_51\NNS\5888929|NONE (l_prep) of_52\IN\0|mouse (l_pobj) catalepsy_56\NN\14023236|NONE (l_appos) model_59\NN\5888929|,|,|model|induced (l_prep) of_60\IN\0|mouse (l_pobj) akinesia_64\NN\14558226|NONE
D016627_D002375 NONE 6-hydroxydopamine_67\NN\0|(|) (r_nmod) 6-ohda_69\CD\0|,|lesion|of|rat (r_nummod) model_72\NN\5888929|,|,|induced|model (r_appos) catalepsy_56\NN\14023236|NONE
D016627_D002375 NONE 6-ohda_69\CD\0|,|lesion|of|rat (r_nummod) model_72\NN\5888929|,|,|induced|model (r_appos) catalepsy_56\NN\14023236|NONE
D012110_D004409 CID reserpine_61\NN\2721160| (r_npadvmod) induced_63\VBN\1627355|NONE (r_compound) akinesia_64\NN\14558226|NONE
D016627_D010300 NONE 6-hydroxydopamine_67\NN\0|(|) (r_nmod) 6-ohda_69\CD\0|,|lesion|of|rat (r_nummod) model_72\NN\5888929|,|,|induced|model (r_appos) catalepsy_56\NN\14023236|NONE (r_pobj) of_52\IN\0|mouse (r_prep) models_51\NNS\5888929|NONE (r_pobj) including_47\VBG\0|Parkinson (r_prep) disease_46\NN\14061805|NONE
D016627_D010300 NONE 6-ohda_69\CD\0|,|lesion|of|rat (r_nummod) model_72\NN\5888929|,|,|induced|model (r_appos) catalepsy_56\NN\14023236|NONE (r_pobj) of_52\IN\0|mouse (r_prep) models_51\NNS\5888929|NONE (r_pobj) including_47\VBG\0|Parkinson (r_prep) disease_46\NN\14061805|NONE
D012110_D010300 NONE reserpine_61\NN\2721160| (r_npadvmod) induced_63\VBN\1627355|NONE (r_compound) akinesia_64\NN\14558226|NONE (r_pobj) of_60\IN\0|mouse (r_prep) model_59\NN\5888929|,|,|model|induced (r_appos) catalepsy_56\NN\14023236|NONE (r_pobj) of_52\IN\0|mouse (r_prep) models_51\NNS\5888929|NONE (r_pobj) including_47\VBG\0|Parkinson (r_prep) disease_46\NN\14061805|NONE
D012110_D002375 NONE reserpine_61\NN\2721160| (r_npadvmod) induced_63\VBN\1627355|NONE (r_compound) akinesia_64\NN\14558226|NONE (r_pobj) of_60\IN\0|mouse (r_prep) model_59\NN\5888929|,|,|model|induced (r_appos) catalepsy_56\NN\14023236|NONE
D006220_D010300 NONE haloperidol_53\NN\3713736| (r_npadvmod) induced_55\VBN\1627355|,|,|model|model (r_amod) catalepsy_56\NN\14023236|NONE (r_pobj) of_52\IN\0|mouse (r_prep) models_51\NNS\5888929|NONE (r_pobj) including_47\VBG\0|Parkinson (r_prep) disease_46\NN\14061805|NONE
D016627_D004409 NONE 6-hydroxydopamine_67\NN\0|(|) (r_nmod) 6-ohda_69\CD\0|,|lesion|of|rat (r_nummod) model_72\NN\5888929|,|,|induced|model (r_appos) catalepsy_56\NN\14023236|NONE (l_appos) model_59\NN\5888929|,|,|model|induced (l_prep) of_60\IN\0|mouse (l_pobj) akinesia_64\NN\14558226|NONE
D016627_D004409 NONE 6-ohda_69\CD\0|,|lesion|of|rat (r_nummod) model_72\NN\5888929|,|,|induced|model (r_appos) catalepsy_56\NN\14023236|NONE (l_appos) model_59\NN\5888929|,|,|model|induced (l_prep) of_60\IN\0|mouse (l_pobj) akinesia_64\NN\14558226|NONE
D015632_D010300 NONE mptp_80\NNP\0| (r_npadvmod) treated_82\VBN\2376958|human|primate (r_amod) model_87\NN\5888929|number|and (r_conj) across_37\IN\0|Compound|after|antagonist|,|,|. (l_pobj) number_39\NN\5107765|and|model (l_prep) of_40\IN\0|a (l_pobj) models_42\NNS\5888929|NONE (l_prep) of_43\IN\0|animal (l_pobj) disease_46\NN\14061805|NONE
3183120
C033706_D001927 CID tiazofurin_5\NN\0|NONE (r_compound) usage_6\NN\407535|NONE (r_pobj) with_4\IN\0|NONE (r_prep) associated_3\VBN\628491|.|Reversible|:|demonstration|cerebral (r_acl) lesions_2\NNS\14204950|NONE
9549528
D007980_D020734 NONE dopa_9\NN\14601829| (r_npadvmod) induced_11\VBN\1627355|dose (r_amod) dyskinesia_15\NN\14084880|NONE (r_pobj) with_6\IN\0|parkinsonian (r_prep) patients_5\NNS\9898892|NONE (l_amod) parkinsonian_4\JJ\0|with
D007980_D020734 NONE dopa_42\NN\14601829|, (r_compound) medication_43\NN\3247620|NONE (r_pobj) on_39\IN\0|parkinsonian (r_prep) patients_38\NNS\9898892|NONE (l_amod) parkinsonian_37\JJ\0|on
D007980_D020734 NONE dopa_51\NN\14601829|NONE (r_pobj) without_48\IN\0|first|the (r_prep) one_47\NN\13741022|and|dyskinesia|,|of (r_nsubj) induced_52\VBD\1627355|have|We|.|flow (r_conj) studied_2\VBN\0|NONE (l_dobj) flow_7\NN\7311115|have|We|induced|. (l_conj) changes_11\NNS\7283608|(|blood|cerebral|the|rCBF|regional (l_acl) induced_12\VBN\1627355|) (l_agent) by_13\IN\0|NONE (l_pobj) execution_15\NN\1161161|NONE (l_prep) in_26\IN\13603305|the|of (l_pobj) cortex_32\NN\5462674|NONE (l_prep) of_33\IN\0|supplementary|motor|the (l_pobj) groups_35\NNS\2137|NONE (l_prep) of_36\IN\0|two (l_pobj) patients_38\NNS\9898892|NONE (l_amod) parkinsonian_37\JJ\0|on
D007980_D004409 CID dopa_9\NN\14601829| (r_npadvmod) induced_11\VBN\1627355|dose (r_amod) dyskinesia_15\NN\14084880|NONE
D007980_D004409 CID dopa_42\NN\14601829|, (r_compound) medication_43\NN\3247620|NONE (r_pobj) on_39\IN\0|parkinsonian (r_prep) patients_38\NNS\9898892|NONE (r_pobj) of_36\IN\0|two (r_prep) groups_35\NNS\2137|NONE (r_pobj) of_33\IN\0|supplementary|motor|the (r_prep) cortex_32\NN\5462674|NONE (r_pobj) in_26\IN\13603305|the|of (r_prep) execution_15\NN\1161161|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|) (r_acl) changes_11\NNS\7283608|(|blood|cerebral|the|rCBF|regional (r_conj) flow_7\NN\7311115|have|We|induced|. (r_dobj) studied_2\VBN\0|NONE (l_conj) induced_52\VBD\1627355|have|We|.|flow (l_dobj) dyskinesia_53\NN\14084880|one|and|,|of
D007980_D004409 CID dopa_42\NN\14601829|, (r_compound) medication_43\NN\3247620|NONE (r_pobj) on_39\IN\0|parkinsonian (r_prep) patients_38\NNS\9898892|NONE (r_pobj) of_36\IN\0|two (r_prep) groups_35\NNS\2137|NONE (r_pobj) of_33\IN\0|supplementary|motor|the (r_prep) cortex_32\NN\5462674|NONE (r_pobj) in_26\IN\13603305|the|of (r_prep) execution_15\NN\1161161|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|) (r_acl) changes_11\NNS\7283608|(|blood|cerebral|the|rCBF|regional (r_conj) flow_7\NN\7311115|have|We|induced|. (r_dobj) studied_2\VBN\0|NONE (l_conj) induced_52\VBD\1627355|have|We|.|flow (l_dobj) dyskinesia_53\NN\14084880|one|and|,|of (l_conj) other_61\JJ\0||and|)|(|n (l_prep) with_62\IN\0|the (l_pobj) dyskinesia_67\NN\14084880|NONE
D007980_D004409 CID dopa_51\NN\14601829|NONE (r_pobj) without_48\IN\0|first|the (r_prep) one_47\NN\13741022|and|dyskinesia|,|of (r_nsubj) induced_52\VBD\1627355|have|We|.|flow (l_dobj) dyskinesia_53\NN\14084880|one|and|,|of
D007980_D004409 CID dopa_51\NN\14601829|NONE (r_pobj) without_48\IN\0|first|the (r_prep) one_47\NN\13741022|and|dyskinesia|,|of (r_nsubj) induced_52\VBD\1627355|have|We|.|flow (l_dobj) dyskinesia_53\NN\14084880|one|and|,|of (l_conj) other_61\JJ\0||and|)|(|n (l_prep) with_62\IN\0|the (l_pobj) dyskinesia_67\NN\14084880|NONE
D007980_D004409 CID dopa_17\NN\14601829| (r_npadvmod) induced_19\VBN\1627355|dose (r_amod) dyskinesia_22\NN\14084880|NONE (r_pobj) like_14\IN\5839024|hyperkinetic|,|involuntary|abnormal|an (r_prep) movement_12\NN\191142|that|,|due
D007980_D004409 CID dopa_17\NN\14601829| (r_npadvmod) induced_19\VBN\1627355|dose (r_amod) dyskinesia_22\NN\14084880|NONE
D007980_D006948 NONE dopa_17\NN\14601829| (r_npadvmod) induced_19\VBN\1627355|dose (r_amod) dyskinesia_22\NN\14084880|NONE (r_pobj) like_14\IN\5839024|hyperkinetic|,|involuntary|abnormal|an (r_prep) movement_12\NN\191142|that|,|due (l_amod) hyperkinetic_9\JJ\0|,|involuntary|abnormal|like|an
18239197
D014282_D003072 CID trihexyphenidyl_10\JJ\0|NONE (r_pcomp) after_9\IN\0|with (r_prep) associated_3\VBN\628491|.|Increased|mental (r_acl) slowing_2\NN\7296428|NONE
D014282_D003072 CID trihexyphenidyl_5\JJ\0|NONE (r_pobj) of_4\IN\0|oral|A|.mg (r_prep) dose_3\NN\3740161|.|in (r_nsubj) resulted_6\VBD\2633881|NONE (l_prep) in_7\IN\13603305|.|dose (l_pobj) ratings_10\NNS\5733583|NONE (l_prep) of_11\IN\0|subjective|increased (l_pobj) slowness_13\NN\5648247|NONE
D014282_D003072 CID trihexyphenidyl_10\JJ\0|NONE (r_pobj) between_7\IN\0|on|difference (r_prep) scores_6\NNS\13757724|NONE (l_prep) on_13\IN\0|between|difference (l_pobj) ratings_14\NNS\5733583|NONE (l_prep) of_15\IN\0|NONE (l_pobj) slowness_17\NN\5648247|NONE
D014282_D003072 CID trihexyphenidyl_14\JJ\0|anticholinergic (r_amod) challenge_16\NN\13927383|NONE (r_pobj) after_13\IN\0|subjective|mental|increased (r_prep) slowing_12\NN\7296428|NONE
D014282_D003221 NONE trihexyphenidyl_19\NN\0|NONE (l_prep) on_20\IN\0|NONE (l_pobj) measures_21\NNS\168237|NONE (l_acl) reflecting_22\VBG\923793|NONE (l_dobj) sedation_23\NN\14034177|NONE (l_conj) confusion_25\NN\13972797|and
D014282_D003221 NONE trihexyphenidyl_32\NN\0| (r_npadvmod) induced_34\VBN\1627355|subjective|and|performance (r_amod) effects_36\NNS\13245626|NONE (r_pobj) between_31\IN\0|the (r_prep) relationship_30\NN\31921|to (r_dobj) investigate_28\VB\644583|and|to|relationship (r_conj) examine_9\VB\0|objectives|. (l_dobj) relationship_11\NN\31921|and|to|investigate (l_conj) effects_17\NNS\13245626|between|the (l_prep) of_18\IN\0|subjective (l_pobj) trihexyphenidyl_19\NN\0|NONE (l_prep) on_20\IN\0|NONE (l_pobj) measures_21\NNS\168237|NONE (l_acl) reflecting_22\VBG\923793|NONE (l_dobj) sedation_23\NN\14034177|NONE (l_conj) confusion_25\NN\13972797|and
17241657
C107044_D012640 NONE 21_15\CD\13745420|NONE (r_nummod) /-)-sm_14\SYM\0|or|+|( (r_conj) umb24_10\NNP\0|NONE (r_pobj) with_9\IN\0|of (r_prep) pretreatment_4\NN\0|convulsions|.|lethality|,|,|In|significantly|but (r_nsubj) attenuated_17\VBN\224901|NONE (l_dobj) convulsions_21\NNS\14081375|.|lethality|,|,|pretreatment|In|significantly|but
C519696_D012640 NONE umb24_10\NNP\0|NONE (r_pobj) with_9\IN\0|of (r_prep) pretreatment_4\NN\0|convulsions|.|lethality|,|,|In|significantly|but (r_nsubj) attenuated_17\VBN\224901|NONE (l_dobj) convulsions_21\NNS\14081375|.|lethality|,|,|pretreatment|In|significantly|but
D003042_D012640 CID cocaine_21\NN\3492717|NONE (r_pobj) of_20\IN\0|stimulatory|the|lethal|locomotor|,|,|convulsive (r_prep) actions_19\NNS\30358|that|antagonism (l_amod) convulsive_11\JJ\0|stimulatory|the|lethal|locomotor|of|,|,
D003042_D012640 CID cocaine_18\NN\3492717| (r_npadvmod) induced_20\VBN\1627355|activity|and (r_amod) convulsions_21\NNS\14081375|.|lethality|,|,|pretreatment|In|significantly|but
20558148
D006220_D002375 CID haloperidol_12\NN\3713736| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) catalepsy_15\NN\14023236|.|neurotransmission|can
D006220_D002375 CID haloperidol_25\NN\3713736|the|receptor (r_appos) blocker_24\NN\10101634|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|the (r_acl) catalepsy_18\NN\14023236|NONE
D006220_D002375 CID haloperidol_0\NN\3713736| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D006220_D002375 CID haloperidol_15\NN\3713736|NONE (r_pobj) of_14\IN\0|systemic (r_prep) injections_13\NNS\320852|NONE (r_pobj) to_11\IN\0|NONE (r_prep) previous_10\JJ\0|NONE (r_amod) ap7_9\RB\0|and|that|intracollicular|of (r_conj) microinjection_5\NN\0|attenuated|results|. (r_dobj) showed_2\VBD\2137132|NONE (l_ccomp) attenuated_17\VBD\224901|microinjection|results|. (l_dobj) catalepsy_19\NN\14023236|significantly|indicated|,
D006220_D002375 CID haloperidol_17\NN\3713736| (r_npadvmod) induced_19\VBN\1627355|influence (r_amod) catalepsy_20\NN\14023236|NONE
D018698_D002375 NONE glutamate_11\NN\15010703|receptor|, (r_compound) antagonists_14\NNS\7846|NONE (r_pobj) of_10\IN\0|intracollicular|prior (r_prep) microinjections_9\NNS\0|NONE (r_pobj) with_6\IN\0|was|.|)|microl|catalepsy|microl (r_prep) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D018698_D002375 NONE glutamate_4\NN\15010703| (r_npadvmod) mediated_6\VBN\761713|and|participate|in|that (r_amod) mechanisms_7\NNS\13446390|findings|. (l_prep) in_8\IN\13603305|and|participate|mediated|that (l_pobj) circuits_11\NNS\3269401|NONE (l_prep) at_12\IN\14622893|the|neural (l_pobj) catalepsy_20\NN\14023236|NONE
D016291_D002375 NONE mk-801_16\NNP\0|mmol/.||of|AP|)|or|(|and (r_punct) microl_22\NN\0|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D016291_D002375 NONE mk-801_7\NNP\0|NONE (r_punct) and_8\CC\0|AP|that|intracollicular|of (r_cc) microinjection_5\NN\0|attenuated|results|. (r_dobj) showed_2\VBD\2137132|NONE (l_ccomp) attenuated_17\VBD\224901|microinjection|results|. (l_dobj) catalepsy_19\NN\14023236|significantly|indicated|,
C031231_D002375 NONE ap7_25\RB\0|mmol/.||of|)|or|MK|(|and (r_conj) microl_22\NN\0|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
C031231_D002375 NONE ap7_9\RB\0|and|that|intracollicular|of (r_conj) microinjection_5\NN\0|attenuated|results|. (r_dobj) showed_2\VBD\2137132|NONE (l_ccomp) attenuated_17\VBD\224901|microinjection|results|. (l_dobj) catalepsy_19\NN\14023236|significantly|indicated|,
D004298_D002375 NONE dopamine_22\NN\14807737|NONE (r_compound) receptor_23\NN\5225602|the|haloperidol (r_compound) blocker_24\NN\10101634|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|the (r_acl) catalepsy_18\NN\14023236|NONE
D016202_D002375 NONE nmda_4\NNP\0|NONE (r_compound) receptors_5\NNS\5225602|NONE (r_pobj) by_3\IN\0|in (r_agent) mediated_2\VBN\761713|Glutamatergic (r_acl) neurotransmission_1\NN\0|.|catalepsy|can (r_nsubj) modulate_11\VB\1724459|NONE (l_dobj) catalepsy_15\NN\14023236|.|neurotransmission|can
D016202_D002375 NONE nmda_12\NNP\0|NONE (r_compound) receptor_13\NN\5225602|,|glutamate (r_compound) antagonists_14\NNS\7846|NONE (r_pobj) of_10\IN\0|intracollicular|prior (r_prep) microinjections_9\NNS\0|NONE (r_pobj) with_6\IN\0|was|.|)|microl|catalepsy|microl (r_prep) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D016202_D002375 NONE nmda_37\NNP\0|NMDA|the (r_compound) receptor_38\NN\5225602|NONE (r_pobj) of_35\IN\0|mmol/.||AP|)|or|MK|(|and (r_prep) microl_22\NN\0|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D016202_D002375 NONE aspartate_46\NNP\0|agonist|(|, (r_nmod) nmda_48\NNP\0|NMDA|the (r_appos) receptor_38\NN\5225602|NONE (r_pobj) of_35\IN\0|mmol/.||AP|)|or|MK|(|and (r_prep) microl_22\NN\0|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D016202_D002375 NONE nmda_48\NNP\0|NMDA|the (r_appos) receptor_38\NN\5225602|NONE (r_pobj) of_35\IN\0|mmol/.||AP|)|or|MK|(|and (r_prep) microl_22\NN\0|was|with|.|)|catalepsy|microl (r_dobj) challenged_5\VBN\869596|NONE (l_nsubjpass) catalepsy_3\NN\14023236|was|with|.|)|microl|microl
D000596_D002375 NONE acid_9\NN\14818238| (r_npadvmod) mediated_11\VBN\761713|excitatory|amino (r_amod) mechanisms_12\NNS\13446390|NONE (r_pobj) of_6\IN\0|on|the|in (r_prep) influence_5\NN\5190804|study (l_prep) on_16\IN\0|of|the|in (l_pobj) catalepsy_18\NN\14023236|NONE
10027919
D002117_D001851 CID calcitriol_0\NNP\0|NONE (r_compound) therapy_1\NN\657604|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ\2510337|NONE (l_conj) has_17\VBZ\13888491|therapy|.|in|but|levels (l_dobj) drawbacks_19\NNS\5161614|NONE (l_prep) including_21\VBG\0|,|several (l_pobj) hypercalcemia_22\NN\14299637|NONE (l_conj) suppression_25\NN\13489037|and/or (l_prep) of_26\IN\0|marked (l_pobj) turnover_28\NN\13819207|NONE
D002117_D001851 CID calcitriol_0\NNP\0|NONE (r_compound) therapy_1\NN\657604|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ\2510337|NONE (l_conj) has_17\VBZ\13888491|therapy|.|in|but|levels (l_dobj) drawbacks_19\NNS\5161614|NONE (l_prep) including_21\VBG\0|,|several (l_pobj) hypercalcemia_22\NN\14299637|NONE (l_conj) suppression_25\NN\13489037|and/or (l_prep) of_26\IN\0|marked (l_pobj) turnover_28\NN\13819207|NONE (l_relcl) lead_32\VB\5155821|bone|, (l_prep) to_33\IN\0|which|may (l_pobj) disease_36\NN\14061805|NONE
D002117_D006934 CID calcitriol_0\NNP\0|NONE (r_compound) therapy_1\NN\657604|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ\2510337|NONE (l_conj) has_17\VBZ\13888491|therapy|.|in|but|levels (l_dobj) drawbacks_19\NNS\5161614|NONE (l_prep) including_21\VBG\0|,|several (l_pobj) hypercalcemia_22\NN\14299637|NONE
C051883_D001851 NONE 22-oxacalcitriol_0\JJ\0|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ\2510337|NONE (l_prep) without_4\IN\0|oxacalcitriol|.|hyperparathyroidism (l_pcomp) inducing_5\VBG\42311|NONE (l_dobj) turnover_8\NN\13819207|NONE
C051883_D001851 NONE oct_6\NNP\15209706|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB\0|may|in|of|it|that|,|induce (r_advcl) be_24\VB\14625458|results|. (l_advcl) induce_37\VB\1627355|may|in|of|it|that|,|prevent (l_dobj) turnover_40\NN\13819207|it|,|does|because|increase|not|and
C051883_D001851 NONE oct_6\NNP\15209706|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB\0|may|in|of|it|that|,|induce (r_advcl) be_24\VB\14625458|results|. (l_advcl) induce_37\VB\1627355|may|in|of|it|that|,|prevent (l_conj) increase_47\VB\13576355|it|,|does|turnover|because|not|and (l_dobj) risk_49\NN\14541044|not|does|therefore|, (l_prep) of_50\IN\0|the (l_pobj) disease_53\NN\14061805|NONE
C051883_-1 NONE oct_4\NNP\15209706|,|.|formation|,|but|alter|In (r_nsubj) reversed_5\VBD\109660|NONE (l_dobj) formation_8\NN\7938773|,|.|,|but|alter|In|OCT (l_prep) as_11\IN\14622893|bone|,|abnormal (l_pobj) osteoid_13\NN\0|such
C051883_D006934 CID oct_6\NNP\15209706|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB\0|may|in|of|it|that|,|induce (l_dobj) occurrence_12\NN\29378|OCT|though|does|completely|even|not (l_prep) of_13\IN\0|the|in (l_pobj) hypercalcemia_14\NN\14299637|NONE
C051883_D005355 NONE oct_4\NNP\15209706|,|.|formation|,|but|alter|In (r_nsubj) reversed_5\VBD\109660|NONE (l_dobj) formation_8\NN\7938773|,|.|,|but|alter|In|OCT (l_prep) as_11\IN\14622893|bone|,|abnormal (l_pobj) osteoid_13\NN\0|such (l_conj) fibrosis_15\NN\14204950|and|woven
C051883_D006962 NONE 22-oxacalcitriol_0\JJ\0|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ\2510337|NONE (l_dobj) hyperparathyroidism_3\NN\14059928|oxacalcitriol|.|without
C051883_D006962 NONE oct_7\NNP\15209706|.|levels|In|,|during (r_nsubj) stabilized_14\VBD\126264|NONE (l_prep) in_0\IN\13603305|OCT|.|levels|,|during (l_pobj) hyperparathyroidism_5\NN\14059928|NONE
C051883_D006962 NONE oct_6\NNP\15209706|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB\0|may|in|of|it|that|,|induce (r_advcl) be_24\VB\14625458|results|. (l_prep) in_27\IN\13603305|may|of|it|that|,|prevent|induce (l_pobj) management_29\NN\1123598|NONE (l_prep) of_30\IN\0|the (l_pobj) hyperparathyroidism_32\NN\14059928|NONE
D002117_D051437 NONE calcitriol_0\NNP\0|NONE (r_compound) therapy_1\NN\657604|.|in|but|levels|has (r_nsubj) suppresses_2\VBZ\2510337|NONE (l_prep) in_11\IN\13603305|therapy|.|but|levels|has (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|NONE (l_pobj) failure_15\NN\66216|NONE
C051883_D051437 NONE 22-oxacalcitriol_0\JJ\0|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ\2510337|NONE (l_prep) without_4\IN\0|oxacalcitriol|.|hyperparathyroidism (l_pcomp) inducing_5\VBG\42311|NONE (l_dobj) turnover_8\NN\13819207|NONE (l_prep) in_9\IN\13603305|low|bone (l_pobj) dogs_10\NNS\2083346|NONE (l_prep) with_11\IN\0|NONE (l_pobj) failure_13\NN\66216|NONE
C051883_D051437 NONE oct_4\NNP\15209706|after|In|levels|,|significantly|. (r_nsubj) decreased_6\VBD\169651|NONE (l_prep) after_11\IN\0|In|levels|,|significantly|.|OCT (l_pobj) induction_13\NN\7450842|soon (l_prep) of_14\IN\0|the (l_pobj) insufficiency_16\NN\14462946|NONE
C051883_D051437 NONE oct_6\NNP\15209706|though|does|completely|even|occurrence|not (r_nsubj) prevent_10\VB\0|may|in|of|it|that|,|induce (l_dobj) occurrence_12\NN\29378|OCT|though|does|completely|even|not (l_prep) in_15\IN\13603305|the|of (l_pobj) dogs_17\NNS\2083346|NONE (l_prep) with_18\IN\0|experimental (l_pobj) insufficiency_20\NN\14462946|NONE
C051883_D007674 NONE oct_9\NNP\15209706|NONE (r_pobj) of_8\IN\0|the|on (r_prep) effects_7\NNS\13245626|to (l_prep) on_10\IN\0|the|of (l_pobj) levels_13\NNS\4916342|NONE (l_conj) turnover_16\NN\13819207|and|serum|PTH (l_prep) in_17\IN\13603305|bone (l_pobj) states_18\NNS\8491826|NONE (l_prep) of_19\IN\0|NONE (l_pobj) function_24\NN\13783581|NONE
7189975
C004616_D012640 CID chloroprocaine_31\NN\0|the (r_compound) group_32\NN\2137|NONE (r_pobj) of_29\IN\0| (r_prep) %_28\NN\0|and|in|, (r_pobj) in_26\IN\13603305|.|in|fatal|,|dose (r_prep) was_15\VBD\0|NONE (l_nsubj) dose_2\NN\3740161|.|in|in|fatal|, (l_appos) convulsions_8\NNS\14081375|of|)|A|CD
C004616_D012640 CID chloroprocaine_31\NN\0|the (r_compound) group_32\NN\2137|NONE (r_pobj) of_29\IN\0| (r_prep) %_28\NN\0|and|in|, (r_pobj) in_26\IN\13603305|.|in|fatal|,|dose (r_prep) was_15\VBD\0|NONE (l_prep) in_17\IN\13603305|.|in|fatal|,|dose (l_pobj) %_19\NN\0|NONE (l_prep) of_20\IN\0| (l_pobj) seizures_24\NNS\14081375|NONE
D002045_D012640 CID bupivacaine_21\NN\0| (r_npadvmod) induced_23\VBN\1627355|NONE (r_amod) seizures_24\NNS\14081375|NONE (r_pobj) of_20\IN\0| (r_prep) %_19\NN\0|NONE (r_pobj) in_17\IN\13603305|.|in|fatal|,|dose (r_prep) was_15\VBD\0|NONE (l_nsubj) dose_2\NN\3740161|.|in|in|fatal|, (l_appos) convulsions_8\NNS\14081375|of|)|A|CD
D002045_D012640 CID bupivacaine_21\NN\0| (r_npadvmod) induced_23\VBN\1627355|NONE (r_amod) seizures_24\NNS\14081375|NONE
D008012_D012640 CID lidocaine_40\NN\3681148|the (r_compound) group_41\NN\2137|NONE (r_pobj) of_38\IN\0| (r_prep) %_37\NN\0|NONE (r_pobj) in_35\IN\13603305|and|%|, (r_conj) in_26\IN\13603305|.|in|fatal|,|dose (r_prep) was_15\VBD\0|NONE (l_nsubj) dose_2\NN\3740161|.|in|in|fatal|, (l_appos) convulsions_8\NNS\14081375|of|)|A|CD
D008012_D012640 CID lidocaine_40\NN\3681148|the (r_compound) group_41\NN\2137|NONE (r_pobj) of_38\IN\0| (r_prep) %_37\NN\0|NONE (r_pobj) in_35\IN\13603305|and|%|, (r_conj) in_26\IN\13603305|.|in|fatal|,|dose (r_prep) was_15\VBD\0|NONE (l_prep) in_17\IN\13603305|.|in|fatal|,|dose (l_pobj) %_19\NN\0|NONE (l_prep) of_20\IN\0| (l_pobj) seizures_24\NNS\14081375|NONE
7724492
D003487_D007674 NONE cyanoacrylate_7\JJ\0|doxorubicin|adriamycin)loaded|( (r_compound) nanoparticles_8\NNS\0|NONE (r_pobj) of_3\IN\0|Acute|.|renal (r_prep) toxicity_2\NN\13576101|NONE
D004317_D005921 NONE doxorubicin_1\NN\2716866| (r_npadvmod) loaded_3\VBN\452512|NONE (r_amod) nanoparticle_4\NN\0|Acute|renal|DXNP (r_nmod) toxicity_9\NN\13576101|.|in|was (r_nsubjpass) explored_11\VBN\789138|NONE (l_prep) in_12\IN\13603305|.|was|toxicity (l_pobj) rats_15\NNS\2329401|NONE (l_conj) rats_17\NNS\2329401|and|both|normal (l_prep) with_18\IN\0|NONE (l_pobj) glomerulonephritis_20\NN\14113798|NONE
D004317_D005921 NONE dx_10\NNP\0|NONE (r_pobj) given_9\VBN\5892096|/ (r_prep) rats_8\NNS\2329401|,|within|in|,|In|. (r_nsubj) died_11\VBD\146138|NONE (l_prep) in_0\IN\13603305|,|within|in|,|rats|. (l_pobj) rats_1\NNS\2329401|NONE (l_prep) with_2\IN\0|NONE (l_pobj) glomerulonephritis_5\NN\14113798|NONE
D004317_D011507 CID dx_16\NNP\0|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treated_14\VBN\2376958|NONE (r_acl) those_13\DT\0|NONE (r_pobj) in_12\IN\13603305|NONE (r_prep) than_11\IN\0|with (r_prep) treated_8\VBN\2376958|NONE (r_acl) animals_7\NNS\4475|NONE (r_pobj) in_6\IN\13603305|.|proteinuria (r_prep) appeared_5\VBD\2604760|NONE (l_nsubj) proteinuria_4\NN\14299637|.|in
D004317_D011507 CID doxorubicin_22\NN\2716866|day (r_compound) treatment_23\NN\654885|NONE (r_pobj) after_21\IN\0|NONE (r_prep) prolonged_20\VBN\317700|and||.|more (r_conj) intense_13\JJ\0|,|without (r_acomp) was_7\VBD\0|.|Proteinuria|,|in|but (r_conj) appeared_1\VBD\2604760|NONE (l_nsubj) proteinuria_0\NNP\14299637|.|,|was|in|but
D004317_D011507 CID dx_39\NNP\0|and (r_conj) dxnp_37\NNP\0|NONE (r_pobj) between_36\IN\0|significant (r_prep) difference_35\NN\4723816|NONE (r_pobj) without_33\IN\0|,|intense (r_prep) was_7\VBD\0|.|Proteinuria|,|in|but (r_conj) appeared_1\VBD\2604760|NONE (l_nsubj) proteinuria_0\NNP\14299637|.|,|was|in|but
D004317_D007674 NONE doxorubicin_4\NN\2716866|adriamycin)loaded|(|cyanoacrylate (r_nmod) nanoparticles_8\NNS\0|NONE (r_pobj) of_3\IN\0|Acute|.|renal (r_prep) toxicity_2\NN\13576101|NONE
D004317_D007674 NONE adriamycin)-loaded_6\VBN\0|doxorubicin|(|cyanoacrylate (r_amod) nanoparticles_8\NNS\0|NONE (r_pobj) of_3\IN\0|Acute|.|renal (r_prep) toxicity_2\NN\13576101|NONE
D004317_D007674 NONE doxorubicin_1\NN\2716866| (r_npadvmod) loaded_3\VBN\452512|NONE (r_amod) nanoparticle_4\NN\0|Acute|renal|DXNP (r_nmod) toxicity_9\NN\13576101|.|in|was
D004317_D007674 NONE dx_16\NNP\0|NONE (r_pobj) than_14\IN\0|less (r_prep) animals_13\NNS\4475|,|that|DXNP|,|despite|in|, (r_dobj) killed_11\VBD\0|.|results (l_prep) despite_18\IN\7501545|,|that|DXNP|,|animals|in|, (l_prep) of_19\IN\0|NONE (l_pobj) toxicity_23\NN\13576101|NONE
15565293
D004977_D051437 NONE emb_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|optic (r_amod) neuropathy_11\NN\14204950|NONE (r_pobj) of_6\IN\0|NONE (r_prep) management_5\NN\1123598|NONE (r_pobj) of_4\IN\0|NONE (r_prep) terms_3\NNS\13945919|NONE (r_pobj) in_2\IN\13603305|reached|.|important|,|Additionally|it|, (r_prep) is_14\VBZ\0|NONE (l_acomp) important_15\JJ\0|reached|.|,|Additionally|it|in|, (l_xcomp) manage_18\VB\2524171|NONE (l_dobj) dosing_20\VBG\515154|to|properly|achieve|and (l_prep) in_21\IN\13603305|ethambutol (l_pobj) patients_22\NNS\9898892|NONE (l_prep) with_23\IN\0|NONE (l_pobj) impairment_25\NN\7296428|NONE
D004977_D051437 NONE ethambutol_19\NN\0|in (r_amod) dosing_20\VBG\515154|to|properly|achieve|and (l_prep) in_21\IN\13603305|ethambutol (l_pobj) patients_22\NNS\9898892|NONE (l_prep) with_23\IN\0|NONE (l_pobj) impairment_25\NN\7296428|NONE
D004977_D014376 NONE ethambutol_0\NNP\0|agent|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_4\NN\7347|Ethambutol|. (l_acl) used_6\VBD\0|an|antimycobacterial (l_xcomp) treat_8\VB\7570720|often (l_dobj) tuberculosis_9\NN\14127211|to
D004977_D009901 CID ethambutol_10\NN\0| (r_advmod) induced_12\VBN\1627355|optic (r_amod) neuropathy_14\NN\14204950|NONE
D004977_D009901 CID ethambutol_14\NN\0| (r_advmod) induced_16\VBN\1627355|optic (r_amod) neuropathy_18\NN\14204950|NONE
D004977_D009901 CID ethambutol_4\NN\0|NONE (r_pobj) of_3\IN\0|A|serious (r_prep) complication_2\NN\1073995|.|neuropathy (r_nsubj) is_5\VBZ\0|NONE (l_attr) neuropathy_8\NN\14204950|complication|.
D004977_D009901 CID ethambutol_6\NN\0|,|and|(|of|optic (r_amod) neuropathy_10\NN\14204950|NONE
D004977_D009901 CID emb)-induced_8\VBN\0|NONE (r_amod) optic_9\JJ\5299178|,|and|(|ethambutol|of (r_compound) neuropathy_10\NN\14204950|NONE
D004977_D009901 CID emb_6\NNP\0| (r_npadvmod) induced_8\VBN\1627355|optic (r_amod) neuropathy_10\NN\14204950|NONE
D004977_D009901 CID emb_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|optic (r_amod) neuropathy_11\NN\14204950|NONE
D004977_D009901 CID emb_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|optic (r_amod) neuropathy_11\NN\14204950|NONE
D004977_D009901 CID ethambutol_19\NN\0|in (r_amod) dosing_20\VBG\515154|to|properly|achieve|and (r_dobj) manage_18\VB\2524171|NONE (r_xcomp) important_15\JJ\0|reached|.|,|Additionally|it|in|, (r_acomp) is_14\VBZ\0|NONE (l_prep) in_2\IN\13603305|reached|.|important|,|Additionally|it|, (l_pobj) terms_3\NNS\13945919|NONE (l_prep) of_4\IN\0|NONE (l_pobj) management_5\NN\1123598|NONE (l_prep) of_6\IN\0|NONE (l_pobj) neuropathy_11\NN\14204950|NONE
D004977_D009410 NONE ethambutol_14\NN\0| (r_advmod) induced_16\VBN\1627355|optic (r_amod) neuropathy_18\NN\14204950|NONE (r_pobj) in_13\IN\13603305|axonal|using (r_prep) degeneration_12\NN\29677|NONE
D004977_D014786 CID ethambutol_6\NN\0|,|and|(|of|optic (r_amod) neuropathy_10\NN\14204950|NONE (r_pobj) of_5\IN\0|a (r_prep) history_4\NN\15120823|NONE (r_pobj) with_2\IN\0|Three (r_prep) subjects_1\NNS\6598915|.|were|deficits|examination (r_nsubjpass) administered_23\VBN\2436349|NONE (l_nsubjpass) deficits_21\NNS\5113133|.|were|subjects|examination
D004977_D014786 CID emb)-induced_8\VBN\0|NONE (r_amod) optic_9\JJ\5299178|,|and|(|ethambutol|of (r_compound) neuropathy_10\NN\14204950|NONE (r_pobj) of_5\IN\0|a (r_prep) history_4\NN\15120823|NONE (r_pobj) with_2\IN\0|Three (r_prep) subjects_1\NNS\6598915|.|were|deficits|examination (r_nsubjpass) administered_23\VBN\2436349|NONE (l_nsubjpass) deficits_21\NNS\5113133|.|were|subjects|examination
D004977_D014786 CID emb_6\NNP\0| (r_npadvmod) induced_8\VBN\1627355|optic (r_amod) neuropathy_10\NN\14204950|NONE (r_pobj) of_5\IN\0|NONE (r_prep) history_4\NN\15120823|NONE (r_pobj) with_3\IN\0|all (r_prep) subjects_2\NNS\6598915|NONE (r_pobj) in_0\IN\13603305|,|there|loss|,|with|. (r_prep) was_13\VBD\0|NONE (l_attr) loss_16\NN\13252973|,|there|,|In|with|. (l_prep) with_32\IN\0|a|,|in|mean|of|loss|) (l_pobj) recovery_34\NN\7357388|NONE (l_prep) with_48\IN\0|eventual|of (l_pobj) deficits_51\NNS\5113133|NONE
D004977_D014786 CID emb_6\NNP\0| (r_npadvmod) induced_8\VBN\1627355|optic (r_amod) neuropathy_10\NN\14204950|NONE (r_pobj) of_5\IN\0|NONE (r_prep) history_4\NN\15120823|NONE (r_pobj) with_3\IN\0|all (r_prep) subjects_2\NNS\6598915|NONE (r_pobj) in_0\IN\13603305|,|there|loss|,|with|. (r_prep) was_13\VBD\0|NONE (l_attr) loss_16\NN\13252973|,|there|,|In|with|. (l_conj) loss_55\NN\13252973|a|,|in|mean|with|of|) (l_conj) c_58\NN\13714184|%|; (l_prep) with_60\IN\0|,|,|patient|loss (l_pobj) deficits_63\NNS\5113133|NONE
17074608
D014635_D002819 CID valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|encephalopathy|and|. (r_amod) chorea_3\NN\14253124|NONE
D014635_D002819 CID valproate_32\NN\0|NONE (r_amod) therapy_33\NN\657604|NONE (r_pobj) of_31\IN\0|NONE (r_prep) initiation_30\NN\7450842|shortly (r_pobj) after_29\IN\0|with|her (r_prep) presentation_22\NN\1027379|NONE (l_prep) with_23\IN\0|after|her (l_pobj) encephalopathy_25\NN\14084880|NONE (l_conj) chorea_27\NN\14253124|acute|and
D005998_D000592 NONE glycine_15\NN\14601829|the|cleavage (r_compound) system_17\NN\3575240|NONE (r_pobj) in_13\IN\13603305|a (r_prep) defect_12\NN\14462666|to|in (r_nsubj) leads_18\VBZ\5155821|acid (r_relcl) metabolism_8\NN\13526110|NONE
D005998_D000592 NONE glycine_23\NN\14601829|NONE (r_pobj) of_22\IN\0|in|an (r_prep) accumulation_21\NN\13497135|NONE (r_pobj) to_19\IN\0|in|defect (r_prep) leads_18\VBZ\5155821|acid (r_relcl) metabolism_8\NN\13526110|NONE
D005998_D020158 NONE glycine_15\NN\14601829|the|cleavage (r_compound) system_17\NN\3575240|NONE (r_pobj) in_13\IN\13603305|a (r_prep) defect_12\NN\14462666|to|in (r_nsubj) leads_18\VBZ\5155821|acid (r_relcl) metabolism_8\NN\13526110|NONE (r_pobj) of_5\IN\0|a (r_prep) disorder_4\NN\14034177|.|hyperglycinemia (r_attr) is_2\VBZ\0|NONE (l_nsubj) hyperglycinemia_1\NN\0|.|disorder
D005998_D020158 NONE glycine_23\NN\14601829|NONE (r_pobj) of_22\IN\0|in|an (r_prep) accumulation_21\NN\13497135|NONE (r_pobj) to_19\IN\0|in|defect (r_prep) leads_18\VBZ\5155821|acid (r_relcl) metabolism_8\NN\13526110|NONE (r_pobj) of_5\IN\0|a (r_prep) disorder_4\NN\14034177|.|hyperglycinemia (r_attr) is_2\VBZ\0|NONE (l_nsubj) hyperglycinemia_1\NN\0|.|disorder
D014635_D020158 NONE valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|encephalopathy|and|. (r_amod) chorea_3\NN\14253124|NONE (l_conj) encephalopathy_5\JJ\14084880|and|.|induced (l_prep) in_6\IN\13603305|NONE (l_pobj) hyperglycinemia_9\NN\0|NONE
D014635_D020158 NONE valproate_32\NN\0|NONE (r_amod) therapy_33\NN\657604|NONE (r_pobj) of_31\IN\0|NONE (r_prep) initiation_30\NN\7450842|shortly (r_pobj) after_29\IN\0|with|her (r_prep) presentation_22\NN\1027379|NONE (r_pobj) following_20\VBG\8180190|have|was|who (r_prep) found_15\VBN\13279262|and|,|mild|retardation|language (l_xcomp) have_17\VB\7846|following|was|who (l_dobj) hyperglycinemia_19\NN\0|to
D014635_D001927 CID valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|encephalopathy|and|. (r_amod) chorea_3\NN\14253124|NONE (l_conj) encephalopathy_5\JJ\14084880|and|.|induced
D014635_D001927 CID valproate_32\NN\0|NONE (r_amod) therapy_33\NN\657604|NONE (r_pobj) of_31\IN\0|NONE (r_prep) initiation_30\NN\7450842|shortly (r_pobj) after_29\IN\0|with|her (r_prep) presentation_22\NN\1027379|NONE (l_prep) with_23\IN\0|after|her (l_pobj) encephalopathy_25\NN\14084880|NONE
D014635_D008607 NONE valproate_32\NN\0|NONE (r_amod) therapy_33\NN\657604|NONE (r_pobj) of_31\IN\0|NONE (r_prep) initiation_30\NN\7450842|shortly (r_pobj) after_29\IN\0|with|her (r_prep) presentation_22\NN\1027379|NONE (r_pobj) following_20\VBG\8180190|have|was|who (r_prep) found_15\VBN\13279262|and|,|mild|retardation|language (r_relcl) delay_8\NN\15271008|NONE (l_conj) retardation_11\NN\7296428|and|found|,|mild|language
D014635_D007805 NONE valproate_32\NN\0|NONE (r_amod) therapy_33\NN\657604|NONE (r_pobj) of_31\IN\0|NONE (r_prep) initiation_30\NN\7450842|shortly (r_pobj) after_29\IN\0|with|her (r_prep) presentation_22\NN\1027379|NONE (r_pobj) following_20\VBG\8180190|have|was|who (r_prep) found_15\VBN\13279262|and|,|mild|retardation|language (r_relcl) delay_8\NN\15271008|NONE
15580403
D012254_D019698 NONE ribavirin_3\JJ\2725367|in (r_compound) reduction_4\NN\351485|NONE (l_prep) in_5\IN\13603305|ribavirin (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) hemolysis_8\NN\13509528|NONE (l_prep) during_9\IN\0|NONE (l_pobj) therapy_11\NN\657604|NONE (l_prep) for_16\IN\0|of|combination (l_pobj) c._19\NNP\0|NONE
D012254_D019698 NONE ribavirin_15\RB\2725367|and (r_conj) interferon_13\NN\2725367|NONE (r_pobj) of_12\IN\0|for|combination (r_prep) therapy_11\NN\657604|NONE (l_prep) for_16\IN\0|of|combination (l_pobj) c._19\NNP\0|NONE
D007372_D000743 CID interferon_14\NN\2725367|NONE (r_pobj) of_13\IN\0|the|combination (r_prep) therapy_12\NN\657604|NONE (r_pobj) of_9\IN\0|adverse|major|the (r_prep) events_8\NNS\23100|NONE (r_pobj) of_4\IN\0|NONE (r_prep) one_3\CD\13741022|.|anemia (r_attr) is_2\VBZ\0|NONE (l_nsubj) anemia_1\NN\14189204|.|one
D012254_D000740 NONE ribavirin_9\NN\2725367|NONE (r_pobj) of_8\IN\0|NONE (r_prep) reduction_7\NN\351485|NONE (r_pobj) with_6\IN\0| (r_prep) patients_5\NNS\9898892|.|therapy|could|,|decreased|However|not (r_nsubj) continue_12\VB\2367363|NONE (l_advcl) decreased_24\VBD\169651|.|therapy|could|,|However|patients|not (l_conj) occurred_33\VBD\0|because|to|values|or (l_nsubj) effects_32\NNS\13245626|B|) (l_amod) related_29\VBN\628491|severe|side (l_npadvmod) anemia_27\NN\14189204|
D007372_D019698 NONE interferon_13\NN\2725367|NONE (r_pobj) of_12\IN\0|for|combination (r_prep) therapy_11\NN\657604|NONE (l_prep) for_16\IN\0|of|combination (l_pobj) c._19\NNP\0|NONE
D007372_D006461 NONE interferon_13\NN\2725367|NONE (r_pobj) of_12\IN\0|for|combination (r_prep) therapy_11\NN\657604|NONE (r_pobj) during_9\IN\0|NONE (r_prep) hemolysis_8\NN\13509528|NONE
D012254_D006461 NONE ribavirin_3\JJ\2725367|in (r_compound) reduction_4\NN\351485|NONE (l_prep) in_5\IN\13603305|ribavirin (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) hemolysis_8\NN\13509528|NONE
D012254_D006461 NONE ribavirin_15\RB\2725367|and (r_conj) interferon_13\NN\2725367|NONE (r_pobj) of_12\IN\0|for|combination (r_prep) therapy_11\NN\657604|NONE (r_pobj) during_9\IN\0|NONE (r_prep) hemolysis_8\NN\13509528|NONE
D012254_D006461 NONE ribavirin_13\JJ\2725367|in (r_compound) reduction_14\NN\351485|NONE (l_prep) in_15\IN\13603305|ribavirin (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) hemolysis_18\NN\13509528|NONE
D012254_D000743 CID ribavirin_16\NN\2725367|and (r_conj) interferon_14\NN\2725367|NONE (r_pobj) of_13\IN\0|the|combination (r_prep) therapy_12\NN\657604|NONE (r_pobj) of_9\IN\0|adverse|major|the (r_prep) events_8\NNS\23100|NONE (r_pobj) of_4\IN\0|NONE (r_prep) one_3\CD\13741022|.|anemia (r_attr) is_2\VBZ\0|NONE (l_nsubj) anemia_1\NN\14189204|.|one
D012254_D000743 CID ribavirin_2\RB\2725367| (r_npadvmod) related_4\VBN\628491|hemolytic (r_amod) anemia_6\NN\14189204|of
12600698
D013307_D015837 CID streptomycin_5\NN\2716866| (r_npadvmod) induced_7\VBN\1627355|in (r_amod) vestibulotoxicity_8\NN\0|NONE
D013307_D015837 CID streptomycin_5\NNS\2716866| (r_npadvmod) induced_7\VBN\1627355|NONE (r_amod) vestibulotoxicity_8\NN\0|NONE
D013307_D015837 CID streptomycin_6\NN\2716866| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) vestibulotoxicity_9\NN\0|edaravone|that
C005435_D015837 NONE edaravone_3\NN\0|NONE (r_pobj) of_2\IN\0|.|against|Protective (r_prep) effect_1\NN\34213|NONE (l_prep) against_4\IN\0|of|.|Protective (l_pobj) vestibulotoxicity_8\NN\0|NONE
C005435_D015837 NONE edaravone_10\NN\0|NONE (r_pobj) by_9\IN\0|in|of (r_prep) alleviation_3\NN\7492516|.|study (l_prep) of_4\IN\0|by|in (l_pobj) vestibulotoxicity_8\NN\0|NONE
C005435_D015837 NONE edaravone_4\NN\0|vestibulotoxicity|that (r_nsubj) suppresses_5\VBZ\2510337|.|results (l_dobj) vestibulotoxicity_9\NN\0|edaravone|that
C005435_D002544 NONE edaravone_0\NNP\0|and|action|used|. (r_nsubj) has_7\VBZ\13888491|NONE (l_conj) used_15\VBN\0|and|action|.|Edaravone (l_xcomp) treat_20\VB\7570720|is|in (l_dobj) infarction_22\NN\14204950|to
18541230
D011692_D006402 NONE aminonucleoside_6\NN\0| (r_advmod) induced_8\VBN\1627355|hematological (r_amod) abnormalities_10\NNS\14034177|Treatment|.|puromycin
D011692_D009404 NONE aminonucleoside_18\RB\0| (r_advmod) induced_20\VBN\1627355|,|is|puromycin (r_amod) nephrosis_21\NN\14304060|NONE (l_relcl) is_24\VBZ\0|,|puromycin|induced (l_attr) model_27\NN\5888929|which (l_prep) of_28\IN\0|an|experimental (l_pobj) syndrome_31\NN\5870365|NONE
D011692_D009404 NONE aminonucleoside_14\RB\0| (r_advmod) induced_16\VBN\1627355|puromycin|nephrotic (r_amod) syndrome_18\NN\5870365|NONE
D011692_D009401 CID aminonucleoside_6\JJ\0|in (r_amod) nephrosis_7\NN\14304060|puromycin
D011692_D009401 CID aminonucleoside_18\RB\0| (r_advmod) induced_20\VBN\1627355|,|is|puromycin (r_amod) nephrosis_21\NN\14304060|NONE
D011692_D006949 NONE aminonucleoside_1\RB\0| (r_advmod) induced_3\VBN\1627355|renal|hyperlipidemia|and|Puromycin (r_amod) dysfunction_5\NN\14204950|.|were|also (l_conj) hyperlipidemia_7\NN\14299637|renal|and|induced|Puromycin
D011692_D007674 NONE aminonucleoside_1\RB\0| (r_advmod) induced_3\VBN\1627355|renal|hyperlipidemia|and|Puromycin (r_amod) dysfunction_5\NN\14204950|.|were|also
48362
D011802_D056486 CID quinidine_0\NN\2715941|. (r_compound) hepatitis_1\NN\14127211|NONE
D011802_D056486 CID quinidine_6\VBN\2715941|NONE (r_poss) hepatotoxicity_7\NN\0|believe|that|and|patient
17263743
D003000_D001008 NONE clonidine_16\NN\2721160|NONE (r_pobj) of_15\IN\0|three (r_prep) doses_14\NNS\3740161|Without|during|.|before|,|mother|reduce (r_dobj) administered_12\VBD\2436349|NONE (l_advcl) reduce_26\VB\441445|Without|doses|during|.|before|,|mother (l_dobj) anxiety_27\NN\14373582|to
D003000_D004827 NONE clonidine_18\NN\2721160|for (r_dobj) receiving_17\VBG\2210855|We|,|case|. (r_advcl) present_1\VBP\28270|NONE (l_dobj) case_3\NN\7283608|We|receiving|,|. (l_prep) of_4\IN\0|a (l_pobj) child_9\NN\9622049|NONE (l_prep) with_10\IN\0|a|old (l_pobj) disorder_15\NN\14034177|NONE
D001418_D002547 NONE baclofen_28\JJ\0|a (r_compound) pump_29\NN\3736970|NONE (r_pobj) of_26\IN\0|NONE (r_prep) placement_25\NN\5074774|NONE (r_pobj) for_24\IN\0|who (r_prep) presented_23\VBD\2137132|, (r_relcl) restlessness_20\NN\4773351|NONE (r_pobj) for_19\IN\0|clonidine (r_prep) receiving_17\VBG\2210855|We|,|case|. (r_advcl) present_1\VBP\28270|NONE (l_dobj) case_3\NN\7283608|We|receiving|,|. (l_prep) of_4\IN\0|a (l_pobj) child_9\NN\9622049|NONE (l_prep) with_10\IN\0|a|old (l_pobj) disorder_15\NN\14034177|NONE (l_nmod) palsy_12\JJ\14557898|seizure
C009250_D006323 NONE sevoflurane_9\NN\0|of (r_amod) induction_10\NN\7450842|NONE (r_dobj) undergoing_8\VBG\109660|in|Cardiac|. (r_acl) arrest_1\NN\88481|NONE
D003000_D011595 NONE clonidine_18\NN\2721160|for (r_dobj) receiving_17\VBG\2210855|We|,|case|. (l_prep) for_19\IN\0|clonidine (l_pobj) restlessness_20\NN\4773351|NONE
D003000_D006323 CID clonidine_15\NN\2721160|NONE (r_pobj) after_13\IN\0|NONE (r_prep) anesthesia_12\NN\14034177|NONE (r_pobj) of_11\IN\0|sevoflurane (r_prep) induction_10\NN\7450842|NONE (r_dobj) undergoing_8\VBG\109660|in|Cardiac|. (r_acl) arrest_1\NN\88481|NONE
D003000_D006323 CID clonidine_6\NN\2721160| (r_npadvmod) associated_8\VBN\628491|cardiac|in (r_amod) arrest_10\NN\88481|NONE
C009250_D002547 NONE sevoflurane_9\NN\0|of (r_amod) induction_10\NN\7450842|NONE (r_dobj) undergoing_8\VBG\109660|in|Cardiac|. (r_acl) arrest_1\NN\88481|NONE (l_prep) in_2\IN\13603305|Cardiac|.|undergoing (l_pobj) child_4\NN\9622049|NONE (l_prep) with_5\IN\0|a (l_pobj) palsy_7\JJ\14557898|NONE
D003000_D002547 NONE clonidine_15\NN\2721160|NONE (r_pobj) after_13\IN\0|NONE (r_prep) anesthesia_12\NN\14034177|NONE (r_pobj) of_11\IN\0|sevoflurane (r_prep) induction_10\NN\7450842|NONE (r_dobj) undergoing_8\VBG\109660|in|Cardiac|. (r_acl) arrest_1\NN\88481|NONE (l_prep) in_2\IN\13603305|Cardiac|.|undergoing (l_pobj) child_4\NN\9622049|NONE (l_prep) with_5\IN\0|a (l_pobj) palsy_7\JJ\14557898|NONE
D003000_D002547 NONE clonidine_18\NN\2721160|for (r_dobj) receiving_17\VBG\2210855|We|,|case|. (r_advcl) present_1\VBP\28270|NONE (l_dobj) case_3\NN\7283608|We|receiving|,|. (l_prep) of_4\IN\0|a (l_pobj) child_9\NN\9622049|NONE (l_prep) with_10\IN\0|a|old (l_pobj) disorder_15\NN\14034177|NONE (l_nmod) palsy_12\JJ\14557898|seizure
D001418_D011595 NONE baclofen_28\JJ\0|a (r_compound) pump_29\NN\3736970|NONE (r_pobj) of_26\IN\0|NONE (r_prep) placement_25\NN\5074774|NONE (r_pobj) for_24\IN\0|who (r_prep) presented_23\VBD\2137132|, (r_relcl) restlessness_20\NN\4773351|NONE
D001418_D004827 NONE baclofen_28\JJ\0|a (r_compound) pump_29\NN\3736970|NONE (r_pobj) of_26\IN\0|NONE (r_prep) placement_25\NN\5074774|NONE (r_pobj) for_24\IN\0|who (r_prep) presented_23\VBD\2137132|, (r_relcl) restlessness_20\NN\4773351|NONE (r_pobj) for_19\IN\0|clonidine (r_prep) receiving_17\VBG\2210855|We|,|case|. (r_advcl) present_1\VBP\28270|NONE (l_dobj) case_3\NN\7283608|We|receiving|,|. (l_prep) of_4\IN\0|a (l_pobj) child_9\NN\9622049|NONE (l_prep) with_10\IN\0|a|old (l_pobj) disorder_15\NN\14034177|NONE
10910842
D011239_D009468 NONE prednisolone_8\NN\2721538|NONE (r_pobj) after_7\IN\0|the|neuromuscular (r_prep) dysfunction_6\NN\14204950|that|dependent|and|,|derives
D000109_D009133 NONE acetylcholine_22\NN\14807558|receptor (r_compound) expression_24\NN\4679549|NONE (r_pobj) in_21\IN\13603305|NONE (r_prep) changes_20\NNS\7283608|NONE (r_pobj) from_19\IN\0|NONE (r_prep) less_18\JJR\14187378|NONE (r_advmod) derive_17\VB\634472|and|primarily|from (r_conj) derive_11\VBP\634472|dependent|that|effects|and (l_prep) from_13\IN\0|and|primarily|derive (l_pobj) atrophy_15\NN\14299637|NONE
D011239_D009133 CID prednisolone_8\NN\2721538|NONE (r_pobj) after_7\IN\0|the|neuromuscular (r_prep) dysfunction_6\NN\14204950|that|dependent|and|,|derives (r_nsubj) is_9\VBZ\0|results|. (l_conj) derives_15\VBZ\634472|that|dependent|and|dysfunction|, (l_prep) from_17\IN\0|primarily|and|derives (l_pobj) atrophy_19\NN\14299637|NONE
D000109_D001284 NONE acetylcholine_13\NN\14807558|receptor|altered (r_compound) expression_15\NN\4679549|NONE (r_pobj) by_11\IN\0|NONE (r_prep) than_10\IN\0|NONE (r_prep) atrophy_9\NN\14299637|NONE
D014403_D013746 NONE tubocurarine_27\NN\14712692|NONE (r_pobj) of_24\IN\0|the|response|in (r_prep) curves_23\NNS\13863771|,|and (r_conj) fatigability_16\NN\5040275|tetanic|,|and (r_conj) tensions_13\NNS\14375890|twitch|the|,|evoked|peak (l_compound) tetanic_12\JJ\0|,|and|fatigability
D011239_D018908 CID prednisolone_0\NNP\2721538| (r_npadvmod) induced_2\VBN\1627355|muscle (r_amod) dysfunction_4\NN\14204950|is|.|more|by
D000109_D018908 NONE acetylcholine_13\NN\14807558|receptor|altered (r_compound) expression_15\NN\4679549|NONE (r_pobj) by_11\IN\0|NONE (r_prep) than_10\IN\0|NONE (r_prep) atrophy_9\NN\14299637|NONE (r_pobj) by_8\IN\0|is|.|more|dysfunction (r_agent) caused_6\VBN\1617192|NONE (l_nsubjpass) dysfunction_4\NN\14204950|is|.|more|by
D011239_D001284 NONE prednisolone_0\NNP\2721538| (r_npadvmod) induced_2\VBN\1627355|muscle (r_amod) dysfunction_4\NN\14204950|is|.|more|by (r_nsubjpass) caused_6\VBN\1617192|NONE (l_agent) by_8\IN\0|is|.|more|dysfunction (l_pobj) atrophy_9\NN\14299637|NONE
2750819
D008278_D020879 CID sulfate_4\NN\15010703|NONE (r_pobj) with_2\IN\0|.|Neuromuscular (r_prep) blockade_1\NN\952963|NONE
D008278_D020879 CID sulfate_15\NN\15010703|NONE (r_pobj) of_13\IN\0| (r_prep) mg_12\NN\13717155|patient|.|after|was (r_nsubjpass) administered_17\VBN\2436349|NONE (l_nsubjpass) patient_1\NN\9898892|mg|.|after|was (l_relcl) received_3\VBD\2210855|A (l_dobj) tocolysis_4\NN\0|who (l_prep) with_5\IN\0|NONE (l_pobj) blockade_9\NN\952963|NONE
D008274_D064420 NONE magnesium_11\NN\14625458|NONE (r_pobj) of_10\IN\0|the (r_prep) toxicity_9\NN\13576101|that|seriously|nifedipine|can
D009543_D064420 NONE nifedipine_4\NN\2938514|toxicity|that|seriously|can (r_nsubj) potentiate_7\VB\229605|.|reaction (l_dobj) toxicity_9\NN\13576101|that|seriously|nifedipine|can
D009543_D020879 CID nifedipine_6\NN\2938514|and|magnesium (r_conj) sulfate_4\NN\15010703|NONE (r_pobj) with_2\IN\0|.|Neuromuscular (r_prep) blockade_1\NN\952963|NONE
D009543_D020879 CID nifedipine_6\NN\2938514|neuromuscular|developed (r_nmod) blockade_9\NN\952963|NONE
8494478
D002939_D007674 NONE ciprofloxacin_0\NNP\2716866|.|nephrotoxicity| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) nephrotoxicity_3\NN\0|.|Ciprofloxacin|
D002939_D007674 NONE ciprofloxacin_3\NNS\2716866|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBN\628491|NONE (r_acl) nephrotoxicity_0\NN\0|uncommon|.
D002939_D058186 CID ciprofloxacin_13\NNS\2716866|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatment_11\NN\654885|that (r_dobj) followed_10\VBD\1835496|acute|renal (r_relcl) failure_8\NN\66216|who
D002939_D058186 CID ciprofloxacin_18\NNS\2716866| (r_npadvmod) induced_20\VBN\1627355|renal|acute (r_amod) failure_23\NN\66216|NONE
D002939_D009369 NONE ciprofloxacin_0\NNP\2716866|.|nephrotoxicity| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) nephrotoxicity_3\NN\0|.|Ciprofloxacin| (l_prep) in_4\IN\13603305|NONE (l_pobj) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|NONE (l_pobj) cancer_7\NN\14239425|NONE
D002939_D009369 NONE ciprofloxacin_13\NNS\2716866|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treatment_11\NN\654885|that (r_dobj) followed_10\VBD\1835496|acute|renal (r_relcl) failure_8\NN\66216|who (r_dobj) developed_5\VBD\1753788|with|Five (r_relcl) patients_1\NNS\9898892|and|are|reviewed (l_prep) with_2\IN\0|developed|Five (l_pobj) cancer_3\NN\14239425|NONE
10524660
D005996_D008881 NONE gtn_14\NNP\0|as|p=.|during|after (r_compound) infusion_15\NN\14589223|severe|.|Headache (r_advcl) was_1\VBD\0|NONE (l_acomp) severe_3\JJ\0|infusion|.|Headache (l_prep) in_4\IN\13603305|more|than (l_pobj) migraineurs_5\NNS\0|NONE
D005996_D008881 NONE gtn_5\NNP\0| (r_npadvmod) induced_7\VBN\1627355|the (r_amod) headache_8\NN\5829480|gradually|,|In|peak|,|. (r_nsubj) disappeared_10\VBD\0|NONE (l_advcl) peak_15\JJ\13758296|gradually|,|In|headache|,|. (l_prep) in_13\IN\13603305|occurred|whereas (l_pobj) migraineurs_14\NNS\0|NONE
D009569_D020325 NONE no_5\DT\7204911|is|in|that (r_nsubjpass) involved_7\VBN\2676054|results|therefore|. (l_prep) in_8\IN\13603305|is|NO|that (l_pobj) mechanisms_11\NNS\13446390|NONE (l_prep) with_14\IN\0|the|of|pain (l_pobj) aura_15\NN\14299637|NONE
D009569_D020325 NONE no_9\DT\7204911|in|to (r_intj) liberate_8\VB\146138|has|Since|been|depression (r_xcomp) shown_6\VBN\2137132|may|understanding|,|.|finding (r_advcl) help_16\VB\407535|NONE (l_dobj) understanding_18\NN\5804793|may|,|shown|.|finding (l_prep) of_19\IN\0|our (l_pobj) coupling_21\NN\3091374|NONE (l_prep) between_22\IN\0|the (l_pobj) depression_25\NN\14373582|NONE (l_conj) headache_27\NN\5829480|cortical|and|spreading (l_prep) with_30\IN\0|in (l_pobj) aura_31\NN\14299637|NONE
D009569_D010146 NONE oxide_13\NN\14818238|in|that|is (r_nsubjpass) involved_18\VBN\2676054|.|has|,|In|evidence (l_prep) in_19\IN\13603305|oxide|that|is (l_pobj) mechanisms_21\NNS\13446390|NONE (l_compound) pain_20\NN\14299637|without|of
D009569_D010146 NONE no_15\NNP\7204911|nitric|molecule|)|(|the (r_appos) oxide_13\NN\14818238|in|that|is (r_nsubjpass) involved_18\VBN\2676054|.|has|,|In|evidence (l_prep) in_19\IN\13603305|oxide|that|is (l_pobj) mechanisms_21\NNS\13446390|NONE (l_compound) pain_20\NN\14299637|without|of
D009569_D010146 NONE no_5\DT\7204911|is|in|that (r_nsubjpass) involved_7\VBN\2676054|results|therefore|. (l_prep) in_8\IN\13603305|is|NO|that (l_pobj) mechanisms_11\NNS\13446390|NONE (l_compound) pain_10\NN\14299637|the|with|of
D005996_D020326 CID trinitrate_1\NN\0|attacks|. (r_nsubj) induces_2\VBZ\1627355|NONE (l_dobj) attacks_3\NNS\955060|trinitrate|. (l_prep) without_6\IN\0|of (l_pobj) aura_7\NN\14299637|NONE
D005996_D020325 NONE trinitrate_1\NN\0|attacks|. (r_nsubj) induces_2\VBZ\1627355|NONE (l_dobj) attacks_3\NNS\955060|trinitrate|. (l_prep) without_6\IN\0|of (l_pobj) aura_7\NN\14299637|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) sufferers_9\NNS\9630641|NONE (l_prep) with_12\IN\0|of (l_pobj) aura_13\NN\14299637|NONE
D005996_D020325 NONE trinitrate_28\NN\0|NONE (r_pobj) of_26\IN\0|intravenous (r_prep) infusion_25\NN\14589223|NONE (r_pobj) to_23\IN\0|the|headache (r_prep) response_22\NN\11410625|min|we|In|.|,|in (r_dobj) examined_19\VBD\0|NONE (l_prep) in_0\IN\13603305|min|response|we|.|,|in (l_pobj) order_1\NN\7168131|NONE (l_acl) clarify_3\VB\939277|NONE (l_ccomp) is_7\VBZ\0|to (l_acomp) true_8\JJ\5077146|same|whether (l_prep) for_9\IN\0|NONE (l_pobj) migraine_10\NN\14326607|NONE (l_prep) with_11\IN\0|NONE (l_pobj) aura_12\NN\14299637|NONE
D005996_D020325 NONE trinitrate_28\NN\0|NONE (r_pobj) of_26\IN\0|intravenous (r_prep) infusion_25\NN\14589223|NONE (r_pobj) to_23\IN\0|the|headache (r_prep) response_22\NN\11410625|min|we|In|.|,|in (r_dobj) examined_19\VBD\0|NONE (l_parataxis) min_38\NN\15154774|response|we|In|.|,|in (l_prep) in_43\IN\13603305|.|(|)|/|for|microg (l_pobj) sufferers_45\NNS\9630641|NONE (l_prep) with_48\IN\0|of| (l_pobj) aura_49\NN\14299637|NONE
D005996_D020325 NONE gtn_30\NNP\0|(|)|glyceryl (r_appos) trinitrate_28\NN\0|NONE (r_pobj) of_26\IN\0|intravenous (r_prep) infusion_25\NN\14589223|NONE (r_pobj) to_23\IN\0|the|headache (r_prep) response_22\NN\11410625|min|we|In|.|,|in (r_dobj) examined_19\VBD\0|NONE (l_prep) in_0\IN\13603305|min|response|we|.|,|in (l_pobj) order_1\NN\7168131|NONE (l_acl) clarify_3\VB\939277|NONE (l_ccomp) is_7\VBZ\0|to (l_acomp) true_8\JJ\5077146|same|whether (l_prep) for_9\IN\0|NONE (l_pobj) migraine_10\NN\14326607|NONE (l_prep) with_11\IN\0|NONE (l_pobj) aura_12\NN\14299637|NONE
D005996_D020325 NONE gtn_30\NNP\0|(|)|glyceryl (r_appos) trinitrate_28\NN\0|NONE (r_pobj) of_26\IN\0|intravenous (r_prep) infusion_25\NN\14589223|NONE (r_pobj) to_23\IN\0|the|headache (r_prep) response_22\NN\11410625|min|we|In|.|,|in (r_dobj) examined_19\VBD\0|NONE (l_parataxis) min_38\NN\15154774|response|we|In|.|,|in (l_prep) in_43\IN\13603305|.|(|)|/|for|microg (l_pobj) sufferers_45\NNS\9630641|NONE (l_prep) with_48\IN\0|of| (l_pobj) aura_49\NN\14299637|NONE
D009569_D003866 NONE no_9\DT\7204911|in|to (r_intj) liberate_8\VB\146138|has|Since|been|depression (r_xcomp) shown_6\VBN\2137132|may|understanding|,|.|finding (l_nsubjpass) depression_3\NN\14373582|has|Since|been|liberate
D009569_D003866 NONE no_9\DT\7204911|in|to (r_intj) liberate_8\VB\146138|has|Since|been|depression (r_xcomp) shown_6\VBN\2137132|may|understanding|,|.|finding (r_advcl) help_16\VB\407535|NONE (l_dobj) understanding_18\NN\5804793|may|,|shown|.|finding (l_prep) of_19\IN\0|our (l_pobj) coupling_21\NN\3091374|NONE (l_prep) between_22\IN\0|the (l_pobj) depression_25\NN\14373582|NONE
D009569_D020326 CID oxide_13\NN\14818238|in|that|is (r_nsubjpass) involved_18\VBN\2676054|.|has|,|In|evidence (l_prep) in_19\IN\13603305|oxide|that|is (l_pobj) mechanisms_21\NNS\13446390|NONE (l_prep) without_24\IN\0|pain|of (l_pobj) aura_25\NN\14299637|NONE
D009569_D020326 CID no_15\NNP\7204911|nitric|molecule|)|(|the (r_appos) oxide_13\NN\14818238|in|that|is (r_nsubjpass) involved_18\VBN\2676054|.|has|,|In|evidence (l_prep) in_19\IN\13603305|oxide|that|is (l_pobj) mechanisms_21\NNS\13446390|NONE (l_prep) without_24\IN\0|pain|of (l_pobj) aura_25\NN\14299637|NONE
D009569_D006261 NONE no_9\DT\7204911|in|to (r_intj) liberate_8\VB\146138|has|Since|been|depression (r_xcomp) shown_6\VBN\2137132|may|understanding|,|.|finding (r_advcl) help_16\VB\407535|NONE (l_dobj) understanding_18\NN\5804793|may|,|shown|.|finding (l_prep) of_19\IN\0|our (l_pobj) coupling_21\NN\3091374|NONE (l_prep) between_22\IN\0|the (l_pobj) depression_25\NN\14373582|NONE (l_conj) headache_27\NN\5829480|cortical|and|spreading
D005996_D006261 NONE trinitrate_28\NN\0|NONE (r_pobj) of_26\IN\0|intravenous (r_prep) infusion_25\NN\14589223|NONE (r_pobj) to_23\IN\0|the|headache (r_prep) response_22\NN\11410625|min|we|In|.|,|in (l_compound) headache_21\NN\5829480|the|to
D005996_D006261 NONE gtn_30\NNP\0|(|)|glyceryl (r_appos) trinitrate_28\NN\0|NONE (r_pobj) of_26\IN\0|intravenous (r_prep) infusion_25\NN\14589223|NONE (r_pobj) to_23\IN\0|the|headache (r_prep) response_22\NN\11410625|min|we|In|.|,|in (l_compound) headache_21\NN\5829480|the|to
D005996_D006261 NONE gtn_14\NNP\0|as|p=.|during|after (r_compound) infusion_15\NN\14589223|severe|.|Headache (r_advcl) was_1\VBD\0|NONE (l_nsubj) headache_0\NNP\5829480|infusion|severe|.
D005996_D006261 NONE gtn_5\NNP\0| (r_npadvmod) induced_7\VBN\1627355|the (r_amod) headache_8\NN\5829480|gradually|,|In|peak|,|.
D005996_D006261 NONE gtn_5\NNP\0| (r_npadvmod) induced_7\VBN\1627355|the (r_amod) headache_8\NN\5829480|gradually|,|In|peak|,|. (r_nsubj) disappeared_10\VBD\0|NONE (l_advcl) peak_15\JJ\13758296|gradually|,|In|headache|,|. (l_ccomp) occurred_18\VBD\0|in|whereas (l_nsubj) intensity_17\NN\5090441|at (l_compound) headache_16\NN\5829480|NONE
9154656
D000809_D009404 NONE angiotensin_9\NN\4522421|the|system (r_compound) proteins_11\NNS\14944888|NONE (r_pobj) of_5\IN\0|Plasma|and|excretion (r_prep) concentration_1\NN\4916342|are|.|in (r_nsubjpass) altered_13\VBN\0|NONE (l_prep) in_14\IN\13603305|are|.|concentration (l_pobj) rats_15\NNS\2329401|NONE (l_prep) with_16\IN\0|NONE (l_pobj) syndrome_18\NN\5870365|NONE
D000809_D009404 NONE angiotensin_9\NN\4522421|the|system (r_compound) proteins_11\NNS\14944888|NONE (r_pobj) of_5\IN\0|Plasma|and|excretion (r_prep) concentration_1\NN\4916342|are|.|in (r_nsubjpass) altered_13\VBN\0|NONE (l_prep) in_14\IN\13603305|are|.|concentration (l_pobj) rats_15\NNS\2329401|NONE (l_prep) with_16\IN\0|NONE (l_pobj) syndrome_18\NN\5870365|NONE (l_appos) ns_20\NNP\14622893|nephrotic
D011692_D009404 CID nucleoside_11\NN\14887305|puromycin|( (r_nmod) pan_13\NNP\3101986|NONE (r_pobj) of_7\IN\0|single|a (r_prep) injection_6\NN\320852|NONE (r_pobj) by_3\IN\0|was|.|NS|) (r_agent) induced_2\VBN\1627355|NONE (l_nsubjpass) ns_0\NNP\14622893|was|.|by|)
D011692_D009404 CID pan_13\NNP\3101986|NONE (r_pobj) of_7\IN\0|single|a (r_prep) injection_6\NN\320852|NONE (r_pobj) by_3\IN\0|was|.|NS|) (r_agent) induced_2\VBN\1627355|NONE (l_nsubjpass) ns_0\NNP\14622893|was|.|by|)
D011692_D009404 CID pan_19\NNP\3101986|NONE (r_compound) injection_20\NN\320852|NONE (r_pobj) after_18\IN\0|on|excretion|were|Although (r_prep) observed_14\VBN\2163746|.|not|established|did|,|,|levels (r_advcl) change_34\VB\7283608|NONE (l_advcl) established_26\VBN\2426171|.|not|did|observed|,|,|levels (l_nsubjpass) ns_23\NNP\14622893|clearly|when|was
D011692_D009404 CID pan_22\NNP\3101986|NONE (r_pobj) by_21\IN\0|NONE (r_agent) induced_20\VBN\1627355|the|of (r_acl) development_15\NN\248977|NONE (l_prep) of_16\IN\0|the|induced (l_pobj) ns_19\NNP\14622893|NONE
7619765
D005047_D009203 CID etoposide_0\RB\0| (r_npadvmod) related_2\VBN\628491|myocardial|. (r_amod) infarction_4\NN\14204950|NONE
D005047_D009203 CID etoposide_11\RB\0|NONE (r_dobj) containing_10\VBG\2632940|NONE (r_acl) chemotherapy_9\NN\661091|NONE (r_pobj) after_8\IN\0|is|.|in|occurrence|, (r_prep) reported_7\VBN\831651|NONE (l_nsubjpass) occurrence_1\NN\29378|after|is|.|in|, (l_prep) of_2\IN\0|The (l_pobj) infarction_5\NN\14204950|NONE
D005047_D003327 NONE etoposide_11\RB\0|NONE (r_dobj) containing_10\VBG\2632940|NONE (r_acl) chemotherapy_9\NN\661091|NONE (r_pobj) after_8\IN\0|is|.|in|occurrence|, (r_prep) reported_7\VBN\831651|NONE (l_prep) in_13\IN\13603305|after|is|.|occurrence|, (l_pobj) man_15\NN\9605289|NONE (l_prep) with_16\IN\0|a (l_pobj) factors_19\NNS\7326557|NONE (l_prep) for_20\IN\0|risk|no (l_pobj) disease_23\NN\14061805|NONE
12571256
D007472_D007674 CID iohexol_45\NN\0|nonionic (r_pobj) of_33\IN\0|NONE (r_prep) those_32\DT\0|NONE (r_pobj) with_31\IN\0|of|the|nephrotoxic (r_prep) effects_16\NNS\13245626|NONE (l_amod) nephrotoxic_15\JJ\0|with|of|the
C044834_D007674 NONE iodixanol_29\NN\0|osmolar|,|dimeric|nonionic|contrast|,|,|an|, (r_appos) medium_27\NN\3575240|NONE (r_pobj) of_17\IN\0|with|the|nephrotoxic (r_prep) effects_16\NNS\13245626|NONE (l_amod) nephrotoxic_15\JJ\0|with|of|the
C044834_D007674 NONE iodixanol_17\NN\0|than|is|when (r_nsubjpass) used_19\VBN\0|to|in (r_advcl) develop_10\VB\1753788|less (r_xcomp) likely_8\JJ\0|induced|.|may (r_acomp) be_6\VB\14625458|NONE (l_csubj) induced_1\VBN\1627355|likely|.|may (l_nsubj) nephropathy_0\NNP\14573196|by
D003404_D003920 NONE creatinine_9\JJ\0|serum|underwent|of (r_compound) concentrations_10\NNS\4916342|NONE (r_pobj) with_7\IN\0|NONE (r_prep) diabetes_6\NNS\14075199|NONE
1848636
D008790_D007008 NONE metoprolol_8\NN\2832168|NONE (l_prep) of_9\IN\0|NONE (l_pobj) hypokalemia_13\NN\14299637|NONE
D013726_D007008 CID terbutaline_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hypokalemia_13\NN\14299637|NONE
10225068
D008012_D011128 CID lignocaine_10\NN\0|NONE (r_pobj) with_6\IN\0|spinal (r_prep) anaesthesia_5\NN\14034177|NONE (r_pobj) after_3\IN\0|:|equina|review|. (r_prep) syndrome_2\NN\5870365|NONE
D008012_D011128 CID lignocaine_10\NN\0|NONE (r_pobj) with_6\IN\0|spinal (r_prep) anaesthesia_5\NN\14034177|NONE (r_pobj) after_3\IN\0|:|equina|review|. (r_prep) syndrome_2\NN\5870365|NONE (l_appos) review_13\NN\5733583|:|equina|.|after (l_prep) of_14\IN\0|a|reported (l_pobj) cases_16\NNS\7283608|NONE (l_prep) of_17\IN\0|six (l_pobj) syndrome_20\NN\5870365|NONE
D008012_D020258 NONE lignocaine_6\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) dose_1\NN\3740161|from (r_nsubj) ranged_8\VBD\2604760|by|.|likely|were (r_ccomp) caused_21\VBN\1617192|NONE (l_agent) by_22\IN\0|.|ranged|likely|were (l_pobj) neurotoxicity_24\NN\0|NONE
D008012_D020258 NONE lignocaine_29\NN\0|NONE (r_pobj) of_25\IN\0|direct (r_prep) neurotoxicity_24\NN\0|NONE
11284996
D005996_D018781 NONE trinitrate_20\NN\0|NONE (r_pobj) by_15\IN\0|in (r_agent) induced_14\VBN\1627355|NONE (l_prep) in_24\IN\13603305|by (l_pobj) patients_26\NNS\9898892|NONE (l_prep) with_27\IN\0| (l_pobj) headache_32\NN\5829480|NONE
D005996_D018781 NONE gtn_22\NNP\0|glyceryl|)|(|NO|the (r_appos) trinitrate_20\NN\0|NONE (r_pobj) by_15\IN\0|in (r_agent) induced_14\VBN\1627355|NONE (l_prep) in_24\IN\13603305|by (l_pobj) patients_26\NNS\9898892|NONE (l_prep) with_27\IN\0| (l_pobj) headache_32\NN\5829480|NONE
D009569_D006261 CID oxide_8\NN\14818238| (r_npadvmod) induced_10\VBN\1627355|nitric|in (r_amod) headache_11\NN\5829480|NONE
D009569_D006261 CID oxide_6\NN\14818238|associated|that (r_nsubj) induced_10\VBN\1627355|been|.|It|has (l_ccomp) associated_17\VBN\628491|oxide|that (l_nsubjpass) headache_11\NN\5829480|may|with|be
D009569_D006261 CID no_8\NNP\7204911|(|)|nitric (r_intj) oxide_6\NN\14818238|associated|that (r_nsubj) induced_10\VBN\1627355|been|.|It|has (l_ccomp) associated_17\VBN\628491|oxide|that (l_nsubjpass) headache_11\NN\5829480|may|with|be
D009569_D006261 CID no_17\JJ\7204911|glyceryl|)|(|the|GTN (r_det) trinitrate_20\NN\0|NONE (r_pobj) by_15\IN\0|in (r_agent) induced_14\VBN\1627355|NONE (r_acl) headache_13\NN\5829480|NONE
D009569_D006261 CID no_5\RB\7204911| (r_intj) induced_7\VBN\1627355|immediate (r_amod) headache_9\NN\5829480|that|with|not|is
D009569_D051270 NONE oxide_6\NN\14818238|associated|that (r_nsubj) induced_10\VBN\1627355|been|.|It|has (l_ccomp) associated_17\VBN\628491|oxide|that (l_nsubjpass) headache_11\NN\5829480|may|with|be (l_prep) in_12\IN\13603305|NONE (l_pobj) headaches_14\NNS\5829480|NONE
D009569_D051270 NONE no_8\NNP\7204911|(|)|nitric (r_intj) oxide_6\NN\14818238|associated|that (r_nsubj) induced_10\VBN\1627355|been|.|It|has (l_ccomp) associated_17\VBN\628491|oxide|that (l_nsubjpass) headache_11\NN\5829480|may|with|be (l_prep) in_12\IN\13603305|NONE (l_pobj) headaches_14\NNS\5829480|NONE
D009569_D018781 NONE oxide_8\NN\14818238| (r_npadvmod) induced_10\VBN\1627355|nitric|in (r_amod) headache_11\NN\5829480|NONE (l_prep) in_12\IN\13603305|induced|nitric (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) headache_19\NN\5829480|NONE
D009569_D018781 NONE no_17\JJ\7204911|glyceryl|)|(|the|GTN (r_det) trinitrate_20\NN\0|NONE (r_pobj) by_15\IN\0|in (r_agent) induced_14\VBN\1627355|NONE (l_prep) in_24\IN\13603305|by (l_pobj) patients_26\NNS\9898892|NONE (l_prep) with_27\IN\0| (l_pobj) headache_32\NN\5829480|NONE
D005996_D006261 CID trinitrate_20\NN\0|NONE (r_pobj) by_15\IN\0|in (r_agent) induced_14\VBN\1627355|NONE (r_acl) headache_13\NN\5829480|NONE
D005996_D006261 CID gtn_22\NNP\0|glyceryl|)|(|NO|the (r_appos) trinitrate_20\NN\0|NONE (r_pobj) by_15\IN\0|in (r_agent) induced_14\VBN\1627355|NONE (r_acl) headache_13\NN\5829480|NONE
D005996_D006261 CID gtn_13\NNP\0|to (l_conj) placebo_15\NN\3740161|or|min (l_prep) over_16\IN\5867413|NONE (l_pobj) min_18\NN\15154774|NONE (l_prep) on_19\IN\0| (l_pobj) days_24\NNS\15140892|NONE (l_amod) free_23\JJ\7942152|two (l_npadvmod) headache_21\NN\5829480|
D005996_D006261 CID gtn_11\NNP\0|the (r_compound) day_12\NN\15154774|NONE (r_pobj) on_9\IN\0|immediate|stronger|than (r_prep) headache_8\NN\5829480|and|was|patients
D005996_D006261 CID gtn_11\NNP\0|the (r_compound) day_12\NN\15154774|NONE (r_pobj) on_9\IN\0|immediate|stronger|than (r_prep) headache_8\NN\5829480|and|was|patients (r_dobj) developed_4\VBD\1753788|NONE (l_conj) was_21\VBD\0|and|headache|patients (l_nsubj) headache_20\NN\5829480|.|pronounced
921394
D007649_D013610 CID ketamine_18\NN\3054098| (r_npadvmod) induced_20\VBN\1627355|the (r_amod) tachycardia_21\NN\14110674|NONE
D007649_D003866 NONE ketamine_2\NN\3054098|NONE (r_pobj) of_1\IN\0|mg|in|. (r_prep) injections_0\NNS\320852|NONE (l_dep) mg_10\NN\13717155|in|.|of (l_prep) into_11\IN\0|NONE (l_pobj) artery_13\NN\5417975|NONE (l_acl) produced_14\VBD\1617192|the (l_dobj) depression_16\NN\14373582|by
6817363
C036466_D007859 NONE aniracetam_5\RB\0|NONE (l_appos) ro_7\NNP\6894544|novel|compound|the|( (l_prep) upon_12\IN\0||) (l_pobj) learning_14\NN\5701944|NONE (l_conj) memory_16\NN\5926676|and|in|impaired
C036466_D007859 NONE 5057_10\CD\0|NONE (r_prep) 13_8\CD\13745420|upon|) (r_nummod) ro_7\NNP\6894544|novel|compound|the|( (l_prep) upon_12\IN\0||) (l_pobj) learning_14\NN\5701944|NONE (l_conj) memory_16\NN\5926676|and|in|impaired
C036466_D008569 NONE aniracetam_5\RB\0|NONE (l_appos) ro_7\NNP\6894544|novel|compound|the|( (l_prep) upon_12\IN\0||) (l_pobj) learning_14\NN\5701944|NONE (l_conj) memory_16\NN\5926676|and|in|impaired
C036466_D008569 NONE 5057_10\CD\0|NONE (r_prep) 13_8\CD\13745420|upon|) (r_nummod) ro_7\NNP\6894544|novel|compound|the|( (l_prep) upon_12\IN\0||) (l_pobj) learning_14\NN\5701944|NONE (l_conj) memory_16\NN\5926676|and|in|impaired
D003513_D000647 NONE cycloheximide_140\NN\0|or (r_conj) chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (l_prep) of_75\IN\0|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN\5669934|NONE
D003513_D000647 NONE cycloheximide_140\NN\0|or (r_conj) chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
D003513_D000647 NONE cycloheximide_177\NN\0|NONE (r_pobj) by_176\IN\0|NONE (r_agent) induced_175\VBN\1627355|a|passive|avoidance (r_acl) task_174\NN\575741|NONE (r_pobj) of_170\IN\0|or|retrieval (r_prep) retention_167\NN\809465|NONE (r_pobj) in_166\IN\13603305|the (r_prep) deficit_165\NN\5113133|NONE (r_pobj) of_163\IN\0|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN\199130|for|;||)|of|( (r_conj) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (l_prep) of_75\IN\0|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN\5669934|NONE
D003513_D000647 NONE cycloheximide_177\NN\0|NONE (r_pobj) by_176\IN\0|NONE (r_agent) induced_175\VBN\1627355|a|passive|avoidance (r_acl) task_174\NN\575741|NONE (r_pobj) of_170\IN\0|or|retrieval (r_prep) retention_167\NN\809465|NONE (r_pobj) in_166\IN\13603305|the (r_prep) deficit_165\NN\5113133|NONE (r_pobj) of_163\IN\0|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN\199130|for|;||)|of|( (r_conj) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
D003513_D006935 NONE cycloheximide_140\NN\0|or (r_conj) chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
D003513_D006935 NONE cycloheximide_140\NN\0|or (r_conj) chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (l_conj) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
D003513_D006935 NONE cycloheximide_177\NN\0|NONE (r_pobj) by_176\IN\0|NONE (r_agent) induced_175\VBN\1627355|a|passive|avoidance (r_acl) task_174\NN\575741|NONE (r_pobj) of_170\IN\0|or|retrieval (r_prep) retention_167\NN\809465|NONE (r_pobj) in_166\IN\13603305|the (r_prep) deficit_165\NN\5113133|NONE (r_pobj) of_163\IN\0|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN\199130|for|;||)|of|( (r_conj) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
D003513_D006935 NONE cycloheximide_177\NN\0|NONE (r_pobj) by_176\IN\0|NONE (r_agent) induced_175\VBN\1627355|a|passive|avoidance (r_acl) task_174\NN\575741|NONE (r_pobj) of_170\IN\0|or|retrieval (r_prep) retention_167\NN\809465|NONE (r_pobj) in_166\IN\13603305|the (r_prep) deficit_165\NN\5113133|NONE (r_pobj) of_163\IN\0|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
C036466_D006935 NONE aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
C036466_D006935 NONE aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN\1073995|for||complete|against|; (l_conj) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
C036466_D006935 NONE 5057_8\CD\0|NONE (r_prep) 13_6\CD\13745420|,|anisoylpyrrolidinone (r_nummod) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
C036466_D006935 NONE 5057_8\CD\0|NONE (r_prep) 13_6\CD\13745420|,|anisoylpyrrolidinone (r_nummod) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN\1073995|for||complete|against|; (l_conj) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|,| (r_appos) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|,| (r_appos) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN\1073995|for||complete|against|; (l_conj) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
D002701_D000647 NONE chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (l_prep) of_75\IN\0|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN\5669934|NONE
D002701_D000647 NONE chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
D012601_D003072 NONE scopolamine_77\NN\14712692| (r_npadvmod) induced_79\VBN\1627355|term|the (r_amod) amnesia_83\NN\5669934|NONE (r_pobj) of_75\IN\0|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (r_appos) effects_33\NNS\13245626|NONE (r_dobj) produced_30\VBD\1617192|was|on|.|and|effect (r_conj) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
C036466_D000647 NONE aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_prep) of_75\IN\0|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN\5669934|NONE
C036466_D000647 NONE aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
C036466_D000647 NONE 5057_8\CD\0|NONE (r_prep) 13_6\CD\13745420|,|anisoylpyrrolidinone (r_nummod) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_prep) of_75\IN\0|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN\5669934|NONE
C036466_D000647 NONE 5057_8\CD\0|NONE (r_prep) 13_6\CD\13745420|,|anisoylpyrrolidinone (r_nummod) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|,| (r_appos) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_prep) of_75\IN\0|(|for|protection|)|mice|;|complete (l_pobj) amnesia_83\NN\5669934|NONE
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|,| (r_appos) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_conj) produced_30\VBD\1617192|was|on|.|and|effect (l_dobj) effects_33\NNS\13245626|NONE (l_appos) prevention_40\NN\1073995|following|the|: (l_conj) rats_67\NNS\2329401|;|complete||of (l_conj) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
D012601_D006935 NONE scopolamine_77\NN\14712692| (r_npadvmod) induced_79\VBN\1627355|term|the (r_amod) amnesia_83\NN\5669934|NONE (r_pobj) of_75\IN\0|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
D012601_D006935 NONE scopolamine_77\NN\14712692| (r_npadvmod) induced_79\VBN\1627355|term|the (r_amod) amnesia_83\NN\5669934|NONE (r_pobj) of_75\IN\0|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_conj) prevention_116\NN\1073995|for||complete|against|; (l_conj) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
D012601_D000647 CID scopolamine_77\NN\14712692| (r_npadvmod) induced_79\VBN\1627355|term|the (r_amod) amnesia_83\NN\5669934|NONE
D012601_D000647 CID scopolamine_77\NN\14712692| (r_npadvmod) induced_79\VBN\1627355|term|the (r_amod) amnesia_83\NN\5669934|NONE (r_pobj) of_75\IN\0|(|for|protection|)|mice|;|complete (r_prep) prevention_74\NN\1073995|or|)||(|( (l_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (l_prep) against_95\IN\0|for||complete|;|prevention (l_pobj) amnesia_96\NN\5669934|NONE
D002701_D003072 NONE chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (r_appos) effects_33\NNS\13245626|NONE (r_dobj) produced_30\VBD\1617192|was|on|.|and|effect (r_conj) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
C036466_D003072 NONE aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
C036466_D003072 NONE 5057_8\CD\0|NONE (r_prep) 13_6\CD\13745420|,|anisoylpyrrolidinone (r_nummod) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|,| (r_appos) ro_5\NNP\6894544|)|( (r_appos) aniracetam_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|produced|on|.|and (r_nsubjpass) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
C036466_D003072 NONE aniracetam_12\JJ\0|of|oral (r_amod) doses_13\NNS\3740161|NONE (r_pobj) at_10\IN\14622893|were|.|improvements (r_prep) seen_9\VBN\2106506|NONE (l_nsubjpass) improvements_1\NNS\7359599|were|at|. (l_conj) normalizations_3\NNS\1123598|or|These (l_prep) of_4\IN\0|NONE (l_pobj) functions_7\NNS\13783581|NONE
D003513_D003072 NONE cycloheximide_140\NN\0|or (r_conj) chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (r_appos) effects_33\NNS\13245626|NONE (r_dobj) produced_30\VBD\1617192|was|on|.|and|effect (r_conj) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
D003513_D003072 NONE cycloheximide_177\NN\0|NONE (r_pobj) by_176\IN\0|NONE (r_agent) induced_175\VBN\1627355|a|passive|avoidance (r_acl) task_174\NN\575741|NONE (r_pobj) of_170\IN\0|or|retrieval (r_prep) retention_167\NN\809465|NONE (r_pobj) in_166\IN\13603305|the (r_prep) deficit_165\NN\5113133|NONE (r_pobj) of_163\IN\0|;||)|prevention|,|,|h|injected|(|administered (r_prep) reversal_149\NN\199130|for|;||)|of|( (r_conj) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (r_appos) effects_33\NNS\13245626|NONE (r_dobj) produced_30\VBD\1617192|was|on|.|and|effect (r_conj) studied_13\VBN\0|NONE (l_prep) on_14\IN\0|was|produced|.|and|effect (l_pobj) forms_16\NNS\6286395|NONE (l_prep) of_17\IN\0|various|in (l_pobj) functions_21\NNS\13783581|NONE
D002701_D006935 NONE chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (r_conj) protection_94\NN\407535|(|for|)|of|mice|;|complete (r_conj) prevention_74\NN\1073995|or|)||(|( (r_conj) rats_67\NNS\2329401|;|complete||of (r_conj) prevention_40\NN\1073995|following|the|: (l_prep) of_41\IN\0|rats|;|complete| (l_pobj) incapacity_43\NN\5644922|NONE (l_acl) learn_45\VB\0|the (l_dobj) response_49\NN\11410625|to (l_prep) in_50\IN\13603305|a|escape|discrete (l_pobj) rats_51\NNS\2329401|NONE (l_acl) exposed_52\VBN\2110927|NONE (l_prep) to_53\IN\0|before (l_pobj) hypercapnia_55\NN\14034177|NONE
D002701_D006935 NONE chloramphenicol_138\NN\2716866|NONE (r_pobj) by_137\IN\0|in (r_agent) induced_132\VBN\1627355|avoidance|administered|a|passive (r_acl) task_131\NN\575741|NONE (r_pobj) for_127\IN\0|;||)|reversal|of|( (r_prep) prevention_116\NN\1073995|for||complete|against|; (l_conj) reversal_149\NN\199130|for|;||)|of|( (l_conj) prevention_186\NN\1073995|;||)|,|of|,|h|injected|(|administered (l_prep) in_190\IN\13603305|(|)||of (l_pobj) retrieval_192\NN\13450862|NONE (l_prep) of_193\IN\0|the (l_pobj) task_197\NN\575741|NONE (l_acl) induced_198\VBN\1627355|active|applied|avoidance|an (l_agent) by_201\IN\0|in (l_pobj) electroshock_203\NN\662681|NONE (l_conj) hypercapnia_205\NN\14034177|subconvulsant|or
8742498
D000431_D056486 CID ethanol_35\NN\14708720|in|simultaneous (r_compound) consumption_36\NN\13440063|NONE (r_pobj) of_33\IN\0|the (r_prep) influence_32\NN\5190804|NONE (r_dobj) evaluates_30\VBZ\670261|in|,|PARP|on|and (r_conj) acts_20\VBZ\0|the (l_prep) in_22\IN\13603305|,|PARP|evaluates|on|and (l_pobj) mice_25\NNS\2329401|NONE (l_prep) with_26\IN\0|female|NMRI (l_pobj) hepatitis_28\NN\14127211|NONE
D000431_D056486 CID ethanol_25\NN\14708720|NONE (r_pobj) by_24\IN\0|on|in (r_agent) caused_23\VBN\1617192|the (r_acl) exacerbation_22\NN\374224|NONE (r_pobj) unlike_20\IN\0|was|by|damage|.|, (r_prep) inhibited_37\VBN\2510337|increases|were|,|and|In|,|in (l_nsubjpass) damage_35\NN\7296428|was|by|.|,|unlike
D000431_D056486 CID ethanol_42\NN\14708720|NONE (r_pobj) by_41\IN\0| (r_prep) %_40\NN\0|NONE (r_pobj) by_38\IN\0|was|damage|.|,|unlike (r_agent) inhibited_37\VBN\2510337|increases|were|,|and|In|,|in (l_nsubjpass) damage_35\NN\7296428|was|by|.|,|unlike
D000431_D056486 CID ethanol_15\NN\14708720||/|AAP (r_nmod) mice_19\NNS\2329401|NONE (r_pobj) to_14\IN\0|when|was|NAA (r_dative) given_13\VBN\5892096|,|.|reduction|was (r_advcl) observed_8\VBN\2163746|NONE (l_nsubjpass) reduction_4\NN\351485|,|.|given|was (l_prep) of_5\IN\0|A|%|further (l_pobj) hepatitis_6\NN\14127211|NONE
D000431_D056486 CID ethanol_14\NN\14708720|NONE (r_pobj) by_13\IN\0|its (r_prep) exacerbation_12\NN\374224|and|the|induced (r_conj) hepatitis_9\NN\14127211|be|can|that|either|by
D019289_D056486 NONE pyruvate_18\NN\0|(|GPT|) (r_compound) transaminase_19\NN\15077571|(|oxaloacetate|and|)|GOT (r_conj) transaminase_11\NN\15077571|NONE (r_pobj) of_7\IN\0|serum (r_prep) activities_6\NNS\30358|NONE (r_pobj) as_4\IN\14622893|.|were|injuries (r_prep) quantified_3\VBN\947077|NONE (l_nsubjpass) injuries_1\NNS\14052046|.|were|as
D018698_D056486 NONE glutamate_8\NN\15010703| (r_compound) oxaloacetate_10\NN\15010703|(|transaminase|and|)|GOT (r_compound) transaminase_11\NN\15077571|NONE (r_pobj) of_7\IN\0|serum (r_prep) activities_6\NNS\30358|NONE (r_pobj) as_4\IN\14622893|.|were|injuries (r_prep) quantified_3\VBN\947077|NONE (l_nsubjpass) injuries_1\NNS\14052046|.|were|as
D018698_D056486 NONE glutamate_16\NN\15010703| (r_npadvmod) pyruvate_18\NN\0|(|GPT|) (r_compound) transaminase_19\NN\15077571|(|oxaloacetate|and|)|GOT (r_conj) transaminase_11\NN\15077571|NONE (r_pobj) of_7\IN\0|serum (r_prep) activities_6\NNS\30358|NONE (r_pobj) as_4\IN\14622893|.|were|injuries (r_prep) quantified_3\VBN\947077|NONE (l_nsubjpass) injuries_1\NNS\14052046|.|were|as
D009536_D056486 NONE amide_10\NN\14727670|NONE (r_pobj) of_7\IN\0|the|hepatoprotective (r_prep) effects_6\NNS\13245626|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD\2137132|NONE (l_npadvmod) aap)-hepatitis_33\NNP\0|.|,|Recently|,|suggesting|effects|we
D009536_D056486 NONE amide_10\NN\14727670|NONE (r_pobj) of_7\IN\0|the|hepatoprotective (r_prep) effects_6\NNS\13245626|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD\2137132|NONE (l_advcl) suggesting_35\VBG\1010118|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ\2676054|NONE (l_nsubj) injury_42\NN\14052046|that|step
D009536_D056486 NONE naa_11\NNP\0|when|was|to (r_nsubjpass) given_13\VBN\5892096|,|.|reduction|was (r_advcl) observed_8\VBN\2163746|NONE (l_nsubjpass) reduction_4\NN\351485|,|.|given|was (l_prep) of_5\IN\0|A|%|further (l_pobj) hepatitis_6\NN\14127211|NONE
D009536_D056486 NONE naa_27\NNP\0|by|or (r_pobj) by_26\IN\0|product|of (r_prep) inhibition_23\NN\1068773|NONE (r_pobj) by_19\IN\0|be|can|that|hepatitis|either (r_agent) reduced_18\VBN\441445|NONE (l_nsubjpass) hepatitis_9\NN\14127211|be|can|that|either|by
D009536_D056486 NONE naa_6\NNP\0|NONE (r_pobj) of_5\IN\0|the|main (r_prep) application_4\NN\947128|.|We|in|as (r_dobj) see_1\VBP\8647945|NONE (l_prep) in_17\IN\13603305|.|We|as|application (l_pobj) order_18\NN\7168131|NONE (l_acl) avoid_20\VB\0|NONE (l_dobj) damage_22\NN\7296428|to
D011064_D056486 NONE )_19\-RRB-\0|EC|ribose|PARP|)|;|( (r_punct) polymerase_20\NN\14732946|NONE (r_pobj) of_15\IN\0|on|selective|a (r_prep) inhibitor_14\NN\20090|,|nicotinic|acid (r_appos) amide_10\NN\14727670|NONE (r_pobj) of_7\IN\0|the|hepatoprotective (r_prep) effects_6\NNS\13245626|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD\2137132|NONE (l_npadvmod) aap)-hepatitis_33\NNP\0|.|,|Recently|,|suggesting|effects|we
D011064_D056486 NONE )_19\-RRB-\0|EC|ribose|PARP|)|;|( (r_punct) polymerase_20\NN\14732946|NONE (r_pobj) of_15\IN\0|on|selective|a (r_prep) inhibitor_14\NN\20090|,|nicotinic|acid (r_appos) amide_10\NN\14727670|NONE (r_pobj) of_7\IN\0|the|hepatoprotective (r_prep) effects_6\NNS\13245626|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD\2137132|NONE (l_advcl) suggesting_35\VBG\1010118|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ\2676054|NONE (l_nsubj) injury_42\NN\14052046|that|step
D000082_D056486 CID acetaminophen_9\NN\2707683|hepatotoxicity (r_pobj) on_8\IN\0|of (l_pobj) hepatotoxicity_10\NN\0|acetaminophen
D000082_D056486 CID acetaminophen_31\NN\2707683|NONE (r_pobj) from_30\IN\0|mice (r_prep) suffering_29\VBG\14322699|NONE (r_pcomp) on_27\IN\0|selective|of|a (r_prep) inhibitor_14\NN\20090|,|nicotinic|acid (r_appos) amide_10\NN\14727670|NONE (r_pobj) of_7\IN\0|the|hepatoprotective (r_prep) effects_6\NNS\13245626|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD\2137132|NONE (l_npadvmod) aap)-hepatitis_33\NNP\0|.|,|Recently|,|suggesting|effects|we
D000082_D056486 CID acetaminophen_31\NN\2707683|NONE (r_pobj) from_30\IN\0|mice (r_prep) suffering_29\VBG\14322699|NONE (r_pcomp) on_27\IN\0|selective|of|a (r_prep) inhibitor_14\NN\20090|,|nicotinic|acid (r_appos) amide_10\NN\14727670|NONE (r_pobj) of_7\IN\0|the|hepatoprotective (r_prep) effects_6\NNS\13245626|.|,|AAP)hepatitis|Recently|,|suggesting|we (r_dobj) demonstrated_3\VBD\2137132|NONE (l_advcl) suggesting_35\VBG\1010118|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ\2676054|NONE (l_nsubj) injury_42\NN\14052046|that|step
D000082_D056486 CID aap)-hepatitis_33\NNP\0|.|,|Recently|,|suggesting|effects|we
D000082_D056486 CID aap)-hepatitis_33\NNP\0|.|,|Recently|,|suggesting|effects|we (r_npadvmod) demonstrated_3\VBD\2137132|NONE (l_advcl) suggesting_35\VBG\1010118|.|,|AAP)hepatitis|Recently|,|effects|we (l_ccomp) involves_43\VBZ\2676054|NONE (l_nsubj) injury_42\NN\14052046|that|step
D000082_D056486 CID aap_38\NNP\0| (r_npadvmod) induced_40\VBN\1627355|the|liver (r_amod) injury_42\NN\14052046|that|step (r_nsubj) involves_43\VBZ\2676054|NONE (r_ccomp) suggesting_35\VBG\1010118|.|,|AAP)hepatitis|Recently|,|effects|we (r_advcl) demonstrated_3\VBD\2137132|NONE (l_npadvmod) aap)-hepatitis_33\NNP\0|.|,|Recently|,|suggesting|effects|we
D000082_D056486 CID aap_38\NNP\0| (r_npadvmod) induced_40\VBN\1627355|the|liver (r_amod) injury_42\NN\14052046|that|step
D000082_D056486 CID aap_27\NNP\0|NONE (r_compound) hepatitis_28\NN\14127211|NONE
D000082_D056486 CID aap_17\NNP\0|NONE (r_pobj) of_16\IN\0|the (r_prep) presence_15\NN\13954253|NONE (r_pobj) in_13\IN\13603305|increases|were|,|and|inhibited|In|, (r_prep) measured_12\VBN\697589|NONE (l_conj) inhibited_37\VBN\2510337|increases|were|,|and|In|,|in (l_nsubjpass) damage_35\NN\7296428|was|by|.|,|unlike
D000082_D056486 CID aap_17\NNP\0|ethanol||/ (r_compound) mice_19\NNS\2329401|NONE (r_pobj) to_14\IN\0|when|was|NAA (r_dative) given_13\VBN\5892096|,|.|reduction|was (r_advcl) observed_8\VBN\2163746|NONE (l_nsubjpass) reduction_4\NN\351485|,|.|given|was (l_prep) of_5\IN\0|A|%|further (l_pobj) hepatitis_6\NN\14127211|NONE
D000082_D056486 CID aap_6\NNP\0| (r_npadvmod) induced_8\VBN\1627355|and|the|exacerbation (r_amod) hepatitis_9\NN\14127211|be|can|that|either|by
D000082_D056486 CID acetaminophen_16\NN\2707683|NONE (r_pobj) of_15\IN\0|pharmaceutical (r_prep) preparations_14\NNS\407535|NONE (r_pobj) in_12\IN\13603305|the|combinational (r_prep) use_11\NN\407535|NONE (r_pobj) for_8\IN\0|NONE (r_prep) as_7\IN\14622893|.|We|in|application (r_prep) see_1\VBP\8647945|NONE (l_prep) in_17\IN\13603305|.|We|as|application (l_pobj) order_18\NN\7168131|NONE (l_acl) avoid_20\VB\0|NONE (l_dobj) damage_22\NN\7296428|to
D062907_D056486 NONE oxaloacetate_10\NN\15010703|(|transaminase|and|)|GOT (r_compound) transaminase_11\NN\15077571|NONE (r_pobj) of_7\IN\0|serum (r_prep) activities_6\NNS\30358|NONE (r_pobj) as_4\IN\14622893|.|were|injuries (r_prep) quantified_3\VBN\947077|NONE (l_nsubjpass) injuries_1\NNS\14052046|.|were|as
D009243_D056486 NONE nad_5\NNP\14800277| (r_compound) precursors_7\NNS\14580897|NONE (r_pobj) of_4\IN\0|on (r_prep) free_3\JJ\7942152|.|of (l_prep) on_8\IN\0|of (l_pobj) hepatotoxicity_10\NN\0|acetaminophen
D009243_D056486 NONE nad_13\NNP\14800277|NONE (l_appos) substrate_16\NN\19613|, (l_relcl) acts_20\VBZ\0|the (l_prep) in_22\IN\13603305|,|PARP|evaluates|on|and (l_pobj) mice_25\NNS\2329401|NONE (l_prep) with_26\IN\0|female|NMRI (l_pobj) hepatitis_28\NN\14127211|NONE
D009243_D056486 NONE nad_37\NNP\14800277|enzyme (r_appos) substrate_36\NN\19613|NONE (r_pobj) of_32\IN\0|dietary (r_prep) depletion_31\NN\351638|NONE (r_pobj) by_29\IN\0|or|NAA (r_conj) by_26\IN\0|product|of (r_prep) inhibition_23\NN\1068773|NONE (r_pobj) by_19\IN\0|be|can|that|hepatitis|either (r_agent) reduced_18\VBN\441445|NONE (l_nsubjpass) hepatitis_9\NN\14127211|be|can|that|either|by
1415380
D011803_D006463 CID quinine_8\NN\2721948|NONE (r_pobj) of_7\IN\0|NONE (r_prep) ingestion_6\NN\13440063|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|.|uremic (r_acl) syndrome_3\NN\5870365|NONE
D011803_D006463 CID quinine_5\NN\2721948|NONE (r_compound) ingestion_6\NN\13440063|NONE (r_pobj) following_4\VBG\8180190|uremic (r_prep) syndrome_3\NN\5870365|.|,|phenomenon|with
D011803_D006463 CID quinine_0\NN\2721948| (r_npadvmod) associated_2\VBN\628491|uremic (r_amod) syndrome_6\NN\5870365|often|.|probably
8480959
D003401_D009135 NONE creatine_7\NN\14601829|NONE (r_compound) kinase_8\NN\14732946|greater (r_compound) elevations_9\NNS\7445480|NONE (r_pobj) with_6\IN\0|muscle (r_prep) symptoms_5\NNS\5823932|NONE (r_pobj) as_3\IN\14622893|, (r_prep) defined_2\VBN\2604760|NONE (r_acl) myopathy_0\NNP\14204950|,|and|associated|.|rare
D008148_D006937 NONE lovastatin_4\NN\3676175|NONE (r_pobj) of_3\IN\0|and|tolerability|in|. (r_prep) efficacy_0\NN\5199286|NONE (l_prep) in_5\IN\13603305|and|tolerability|of|. (l_pobj) women_7\NNS\9605289|NONE (l_prep) with_8\IN\0| (l_pobj) hypercholesterolemia_10\NN\14299637|NONE
D008148_D006937 NONE lovastatin_7\NN\3676175|NONE (r_pobj) of_6\IN\0|and|the|safety|in (r_prep) efficacy_3\NN\5199286|.|with|To (r_dobj) evaluate_1\VB\670261|NONE (l_prep) with_10\IN\0|.|efficacy|To (l_pobj) hypercholesterolemia_12\NN\14299637|NONE
D008148_D006937 NONE lovastatin_0\NNP\3676175|tolerated|.|effective|and (r_nsubj) is_1\VBZ\0|NONE (l_conj) tolerated_7\VBN\802318|.|effective|Lovastatin|and (l_prep) as_8\IN\14622893|generally|well (l_pobj) therapy_9\NN\657604|NONE (l_prep) for_10\IN\0|NONE (l_pobj) hypercholesterolemia_12\NN\14299637|NONE
D008148_D009135 CID lovastatin_31\NN\3676175|NONE (r_pobj) of_30\IN\0|daily|mg|recommended|the (r_prep) dose_29\NN\3740161|NONE (r_pobj) with_24\IN\0|NONE (r_prep) associated_23\VBN\628491|,|and|.|Myopathy|rare (r_conj) was_20\VBD\0|NONE (l_nsubj) myopathy_0\NNP\14204950|,|and|associated|.|rare
17965424
D004008_D005767 CID diclofenac_14\NNP\0|NONE (r_pobj) than_13\IN\0|NONE (r_prep) etoricoxib_12\NN\0|NONE (r_pobj) with_11\IN\0|significantly (r_prep) lower_10\JJR\2831724|ratio|.|rate|; (r_acomp) was_8\VBD\0|NONE (l_nsubj) rate_3\NN\13815152|ratio|.|lower|; (l_amod) due_4\IN\5174653|discontinuation|cumulative|The (l_pcomp) to_5\IN\0|NONE (l_pobj) aes_7\NNS\0|NONE
D004008_D005767 CID diclofenac_17\NNP\0|from||mg. (r_nmod) discontinuations_20\NNS\209943|NONE (r_pobj) with_16\IN\0|NONE (r_prep) compared_15\VBN\644583|due|treatment (r_prep) discontinuing_9\VBG\0|NONE (l_prep) due_11\IN\5174653|compared|treatment (l_pcomp) to_12\IN\0|NONE (l_pobj) aes_14\NNS\0|NONE
D004008_D005767 CID diclofenac_17\NNP\0|from||mg. (r_nmod) discontinuations_20\NNS\209943|NONE (r_pobj) with_16\IN\0|NONE (r_prep) compared_15\VBN\644583|due|treatment (r_prep) discontinuing_9\VBG\0|NONE (r_pcomp) for_8\IN\0|lower|a (r_prep) risk_7\NN\14541044|common|Etoricoxib|,|mg (r_dobj) demonstrated_3\VBD\2137132|higher|,|. (l_advcl) common_27\JJ\8673395|Etoricoxib|risk|,|mg (l_prep) than_28\IN\0|although|less (l_pobj) discontinuations_29\NNS\209943|NONE (l_prep) from_30\IN\0|NONE (l_pobj) aes_32\NNS\0|NONE
C422649_D004487 CID etoricoxib_17\NN\0|NONE (r_pobj) with_16\IN\0|significantly (r_prep) higher_15\JJR\0|compared|incidence|;|.|p<. (r_acomp) were_13\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|compared|higher|;|.|p<. (l_prep) of_2\IN\0|The (l_pobj) discontinuations_3\NNS\209943|NONE (l_prep) for_4\IN\0|NONE (l_pobj) aes_12\NNS\0|NONE (l_amod) related_7\VBN\628491|NONE (l_conj) related_11\VBN\628491|hypertension|and| (l_npadvmod) oedema_9\NN\14315192|
C422649_D004487 CID etoricoxib_17\NN\0|NONE (r_pobj) with_16\IN\0|significantly (r_prep) higher_15\JJR\0|compared|incidence|;|.|p<. (r_acomp) were_13\VBD\0|NONE (l_dep) p<0.001_37\VB\0|compared|higher|incidence|;|. (l_prep) for_38\IN\0|) (l_pobj) hypertension_39\NN\14057371|NONE (l_conj) p<0.01_41\NN\0|and (l_prep) for_42\IN\0|NONE (l_pobj) oedema_43\NN\14315192|NONE
D004008_D001172 NONE sodium_15\NN\14625458|diclofenac|and|II|trial|gastrointestinal (r_compound) tolerability_17\NN\0|NONE (r_pobj) vs_13\IN\13634784|the (r_prep) etoricoxib_12\NN\0|NONE (r_pobj) of_10\IN\0|) (r_prep) results_9\NNS\34213|of|:|.|Gastrointestinal (r_appos) tolerability_1\NN\0|NONE (l_prep) of_2\IN\0|results|:|.|Gastrointestinal (l_pobj) etoricoxib_3\NN\0|NONE (l_prep) in_4\IN\13603305|NONE (l_pobj) patients_7\NNS\9898892|NONE (l_compound) arthritis_6\NN\14171682|rheumatoid
D004008_D001172 NONE diclofenac_22\NN\0|and (r_conj) etoricoxib_20\NN\0|NONE (r_pobj) of_19\IN\0|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN\0|in|to (r_dobj) compare_8\VB\4744814|A|,|.|blind|randomised (l_prep) in_23\IN\13603305|tolerability|to (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) arthritis_27\NN\14171682|NONE
D004008_D001172 NONE diclofenac_22\NN\0|and (r_conj) etoricoxib_20\NN\0|NONE (r_pobj) of_19\IN\0|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN\0|in|to (r_dobj) compare_8\VB\4744814|A|,|.|blind|randomised (l_prep) in_23\IN\13603305|tolerability|to (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) arthritis_27\NN\14171682|NONE (l_appos) ra_29\NNP\14625458|(|)|rheumatoid
D004008_D001172 NONE diclofenac_28\NN\0| (r_nmod) mg_30\NN\13717155|)||daily (r_compound) twice_31\RB\0|and|received|years|were|or|. (r_conj) enrolled_15\VBN\2471690|NONE (l_nsubjpass) years_9\NNS\15144371|twice|and|received|were|or|. (l_acl) diagnosed_11\VBD\644583|age|.|)|A (l_prep) with_12\IN\0|NONE (l_pobj) ra_13\NNP\14625458|NONE
C422649_D006973 CID etoricoxib_17\NN\0|NONE (r_pobj) with_16\IN\0|significantly (r_prep) higher_15\JJR\0|compared|incidence|;|.|p<. (r_acomp) were_13\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|compared|higher|;|.|p<. (l_prep) of_2\IN\0|The (l_pobj) discontinuations_3\NNS\209943|NONE (l_prep) for_4\IN\0|NONE (l_pobj) aes_12\NNS\0|NONE (l_amod) related_7\VBN\628491|NONE (l_npadvmod) hypertension_5\NN\14057371|related|and|
C422649_D006973 CID etoricoxib_17\NN\0|NONE (r_pobj) with_16\IN\0|significantly (r_prep) higher_15\JJR\0|compared|incidence|;|.|p<. (r_acomp) were_13\VBD\0|NONE (l_dep) p<0.001_37\VB\0|compared|higher|incidence|;|. (l_prep) for_38\IN\0|) (l_pobj) hypertension_39\NN\14057371|NONE
C422649_D001172 NONE etoricoxib_3\NN\0|NONE (l_prep) in_4\IN\13603305|NONE (l_pobj) patients_7\NNS\9898892|NONE (l_compound) arthritis_6\NN\14171682|rheumatoid
C422649_D001172 NONE etoricoxib_12\NN\0|NONE (r_pobj) of_10\IN\0|) (r_prep) results_9\NNS\34213|of|:|.|Gastrointestinal (r_appos) tolerability_1\NN\0|NONE (l_prep) of_2\IN\0|results|:|.|Gastrointestinal (l_pobj) etoricoxib_3\NN\0|NONE (l_prep) in_4\IN\13603305|NONE (l_pobj) patients_7\NNS\9898892|NONE (l_compound) arthritis_6\NN\14171682|rheumatoid
C422649_D001172 NONE etoricoxib_20\NN\0|NONE (r_pobj) of_19\IN\0|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN\0|in|to (r_dobj) compare_8\VB\4744814|A|,|.|blind|randomised (l_prep) in_23\IN\13603305|tolerability|to (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) arthritis_27\NN\14171682|NONE
C422649_D001172 NONE etoricoxib_20\NN\0|NONE (r_pobj) of_19\IN\0|the|safety|)|gastrointestinal|,|GI|( (r_prep) tolerability_14\NN\0|in|to (r_dobj) compare_8\VB\4744814|A|,|.|blind|randomised (l_prep) in_23\IN\13603305|tolerability|to (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) arthritis_27\NN\14171682|NONE (l_appos) ra_29\NNP\14625458|(|)|rheumatoid
C422649_D001172 NONE etoricoxib_18\RB\0|daily (r_dobj) received_17\VBN\2210855|twice|and|years|were|or|. (r_conj) enrolled_15\VBN\2471690|NONE (l_nsubjpass) years_9\NNS\15144371|twice|and|received|were|or|. (l_acl) diagnosed_11\VBD\644583|age|.|)|A (l_prep) with_12\IN\0|NONE (l_pobj) ra_13\NNP\14625458|NONE
C422649_D005767 NONE etoricoxib_12\NN\0|NONE (r_pobj) with_11\IN\0|significantly (r_prep) lower_10\JJR\2831724|ratio|.|rate|; (r_acomp) was_8\VBD\0|NONE (l_nsubj) rate_3\NN\13815152|ratio|.|lower|; (l_amod) due_4\IN\5174653|discontinuation|cumulative|The (l_pcomp) to_5\IN\0|NONE (l_pobj) aes_7\NNS\0|NONE
C422649_D005767 NONE etoricoxib_0\NNP\0|common|risk|,|mg (r_nsubj) demonstrated_3\VBD\2137132|higher|,|. (l_dobj) risk_7\NN\14541044|common|Etoricoxib|,|mg (l_prep) for_8\IN\0|lower|a (l_pcomp) discontinuing_9\VBG\0|NONE (l_prep) due_11\IN\5174653|compared|treatment (l_pcomp) to_12\IN\0|NONE (l_pobj) aes_14\NNS\0|NONE
C422649_D005767 NONE etoricoxib_0\NNP\0|common|risk|,|mg (r_nsubj) demonstrated_3\VBD\2137132|higher|,|. (l_advcl) common_27\JJ\8673395|Etoricoxib|risk|,|mg (l_prep) than_28\IN\0|although|less (l_pobj) discontinuations_29\NNS\209943|NONE (l_prep) from_30\IN\0|NONE (l_pobj) aes_32\NNS\0|NONE
C422649_D005767 NONE etoricoxib_38\NN\0|NONE (r_pobj) with_37\IN\0|significantly (r_prep) higher_36\JJR\0|demonstrated|,|. (r_acomp) were_34\VBD\0|NONE (l_ccomp) demonstrated_3\VBD\2137132|higher|,|. (l_dobj) risk_7\NN\14541044|common|Etoricoxib|,|mg (l_prep) for_8\IN\0|lower|a (l_pcomp) discontinuing_9\VBG\0|NONE (l_prep) due_11\IN\5174653|compared|treatment (l_pcomp) to_12\IN\0|NONE (l_pobj) aes_14\NNS\0|NONE
C422649_D005767 NONE etoricoxib_38\NN\0|NONE (r_pobj) with_37\IN\0|significantly (r_prep) higher_36\JJR\0|demonstrated|,|. (r_acomp) were_34\VBD\0|NONE (l_ccomp) demonstrated_3\VBD\2137132|higher|,|. (l_advcl) common_27\JJ\8673395|Etoricoxib|risk|,|mg (l_prep) than_28\IN\0|although|less (l_pobj) discontinuations_29\NNS\209943|NONE (l_prep) from_30\IN\0|NONE (l_pobj) aes_32\NNS\0|NONE
D004008_D006973 NONE diclofenac_28\NNP\0|NONE (r_pobj) with_27\IN\0|respectively (r_prep) compared_26\VBN\644583|higher|incidence|;|.|p<. (r_prep) were_13\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|compared|higher|;|.|p<. (l_prep) of_2\IN\0|The (l_pobj) discontinuations_3\NNS\209943|NONE (l_prep) for_4\IN\0|NONE (l_pobj) aes_12\NNS\0|NONE (l_amod) related_7\VBN\628491|NONE (l_npadvmod) hypertension_5\NN\14057371|related|and|
D004008_D006973 NONE diclofenac_28\NNP\0|NONE (r_pobj) with_27\IN\0|respectively (r_prep) compared_26\VBN\644583|higher|incidence|;|.|p<. (r_prep) were_13\VBD\0|NONE (l_dep) p<0.001_37\VB\0|compared|higher|incidence|;|. (l_prep) for_38\IN\0|) (l_pobj) hypertension_39\NN\14057371|NONE
D004008_D004487 NONE diclofenac_28\NNP\0|NONE (r_pobj) with_27\IN\0|respectively (r_prep) compared_26\VBN\644583|higher|incidence|;|.|p<. (r_prep) were_13\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|compared|higher|;|.|p<. (l_prep) of_2\IN\0|The (l_pobj) discontinuations_3\NNS\209943|NONE (l_prep) for_4\IN\0|NONE (l_pobj) aes_12\NNS\0|NONE (l_amod) related_7\VBN\628491|NONE (l_conj) related_11\VBN\628491|hypertension|and| (l_npadvmod) oedema_9\NN\14315192|
D004008_D004487 NONE diclofenac_28\NNP\0|NONE (r_pobj) with_27\IN\0|respectively (r_prep) compared_26\VBN\644583|higher|incidence|;|.|p<. (r_prep) were_13\VBD\0|NONE (l_dep) p<0.001_37\VB\0|compared|higher|incidence|;|. (l_prep) for_38\IN\0|) (l_pobj) hypertension_39\NN\14057371|NONE (l_conj) p<0.01_41\NN\0|and (l_prep) for_42\IN\0|NONE (l_pobj) oedema_43\NN\14315192|NONE
6381653
D007980_D004409 CID levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|and|thalamotomy|. (r_amod) dyskinesia_3\JJ\14084880|NONE
D007980_D004409 CID levodopa_0\NNP\14604959|alleviated|.|dyskinesia| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dyskinesia_3\NN\14084880|alleviated|.||Levodopa
D007980_D004409 CID levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|by (r_amod) dyskinesias_5\NNS\14084880|NONE
D007980_D020821 NONE levodopa_0\NNP\14604959|alleviated|.|dyskinesia| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dyskinesia_3\NN\14084880|alleviated|.||Levodopa (l_prep) in_7\IN\13603305|of (l_pobj) cases_9\NNS\7283608|NONE (l_prep) of_10\IN\0|thirteen (l_pobj) parkinsonism_11\NNP\14085708|NONE (l_relcl) was_14\VBD\0|,|, (l_attr) choreic_15\JJ\0|which (l_conj) ballistic_17\JJ\0|,|in (l_conj) dystonic_19\JJ\0|or
D007980_D013786 NONE levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|by (r_amod) dyskinesias_5\NNS\14084880|NONE (l_prep) by_6\IN\0|induced (l_pobj) lesions_8\NNS\14204950|NONE
D007980_D010302 NONE levodopa_0\NNP\14604959|alleviated|.|dyskinesia| (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dyskinesia_3\NN\14084880|alleviated|.||Levodopa (l_prep) in_7\IN\13603305|of (l_pobj) cases_9\NNS\7283608|NONE (l_prep) of_10\IN\0|thirteen (l_pobj) parkinsonism_11\NNP\14085708|NONE
D007980_D010302 NONE levodopa_2\NN\14604959| (r_npadvmod) induced_4\VBN\1627355|by (r_amod) dyskinesias_5\NNS\14084880|NONE (r_pobj) of_1\IN\0|in (r_prep) control_0\NN\5190804|.|is (l_prep) in_9\IN\13603305|of (l_pobj) course_11\NN\883297|NONE (l_prep) of_12\IN\0|the (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|routine (l_pobj) parkinsonism_16\NNP\14085708|NONE
12691807
D007980_D008538 NONE levodopa_10\NN\14604959| (r_npadvmod) induced_12\VBN\1627355|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN\0|NONE
D007980_D008538 NONE levodopa_10\NN\14604959| (r_npadvmod) induced_12\VBN\1627355|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN\0|NONE (l_appos) omd_16\NNP\0|Oromandibular|)|reversible|(|induced
D007980_D004421 CID levodopa_0\NNP\14604959||.|dystonia (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dystonia_4\NN\0|Levodopa||.
D007980_D004409 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) dyskinesias_3\NNS\14084880|in|have|been|.
D007980_D019578 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) dyskinesias_3\NNS\14084880|in|have|been|. (r_nsubjpass) reported_6\VBN\831651|NONE (l_prep) in_7\IN\13603305|dyskinesias|have|been|. (l_pobj) disease_10\NN\14061805|NONE (l_conj) atrophy_14\NN\14299637|and|Parkinson
D007980_D013494 NONE levodopa_0\NNP\14604959||.|dystonia (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dystonia_4\NN\0|Levodopa||. (l_prep) in_5\IN\13603305|oromandibular (l_pobj) palsy_8\JJ\14557898|NONE
D007980_D013494 NONE levodopa_10\NN\14604959| (r_npadvmod) induced_12\VBN\1627355|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN\0|NONE (r_pobj) of_8\IN\0|in|an|unusual (r_prep) case_7\NN\7283608|we|highlight|.|In (l_prep) in_18\IN\13603305|of|an|unusual (l_pobj) patient_21\NN\9898892|NONE (l_compound) psp_20\NNP\0|a
D007980_D013494 NONE levodopa_10\NN\14604959| (r_npadvmod) induced_12\VBN\1627355|Oromandibular|OMD|)|reversible|( (r_amod) dystonia_14\NN\0|NONE (r_pobj) of_8\IN\0|in|an|unusual (r_prep) case_7\NN\7283608|we|highlight|.|In (r_dobj) describe_4\VBP\1001294|NONE (l_advcl) highlight_23\VB\13809920|we|case|.|In (l_dobj) importance_25\NN\5138488|to (l_prep) of_26\IN\0|the (l_pcomp) recognizing_27\VBG\686447|NONE (l_dobj) complication_31\NN\1073995|,|discuss|and (l_prep) in_32\IN\13603305|related|this (l_pobj) management_34\NN\1123598|NONE (l_prep) of_35\IN\0|the (l_pobj) psp_36\NNP\0|NONE
D007980_D010300 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) dyskinesias_3\NNS\14084880|in|have|been|. (r_nsubjpass) reported_6\VBN\831651|NONE (l_prep) in_7\IN\13603305|dyskinesias|have|been|. (l_pobj) disease_10\NN\14061805|NONE
2055425
D018723_D003920 NONE bethanechol_23\NN\0|and|, (r_conj) atp_20\NNP\14964590|,|nerve (r_conj) stimulation_18\NN\242808|NONE (r_pobj) to_16\TO\0|from|of|contractile (r_prep) responses_8\NNS\11410625|NONE (l_prep) from_13\IN\0|of|contractile|to (l_pobj) rats_15\NNS\2329401|NONE (l_amod) diabetic_14\JJ\10595647|NONE
D018723_D003920 NONE bethanechol_22\NN\0|and|, (r_conj) atp_19\NNP\14964590|nerve|, (r_conj) stimulation_17\NN\242808|NONE (r_pobj) to_15\TO\0|from|of|contractile (r_prep) responses_7\NNS\11410625|NONE (l_prep) from_12\IN\0|of|to|contractile (l_pobj) rats_14\NNS\2329401|NONE (l_amod) diabetic_13\JJ\10595647|NONE
D013311_D003920 CID streptozotocin_17\NNS\0| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) diabetes_20\NN\14075199|NONE (r_compound) mellitus_21\NN\0|NONE
D013311_D003920 CID streptozotocin_15\JJ\0| (r_npadvmod) diabetic_17\JJ\10595647|NONE
D013311_D003920 CID streptozotocin_7\NNS\0| (r_npadvmod) induced_9\VBN\1627355|on (r_amod) diabetes_10\NNS\14075199|NONE
D000255_D003920 NONE atp_20\NNP\14964590|,|nerve (r_conj) stimulation_18\NN\242808|NONE (r_pobj) to_16\TO\0|from|of|contractile (r_prep) responses_8\NNS\11410625|NONE (l_prep) from_13\IN\0|of|contractile|to (l_pobj) rats_15\NNS\2329401|NONE (l_amod) diabetic_14\JJ\10595647|NONE
D000255_D003920 NONE atp_19\NNP\14964590|nerve|, (r_conj) stimulation_17\NN\242808|NONE (r_pobj) to_15\TO\0|from|of|contractile (r_prep) responses_7\NNS\11410625|NONE (l_prep) from_12\IN\0|of|to|contractile (l_pobj) rats_14\NNS\2329401|NONE (l_amod) diabetic_13\JJ\10595647|NONE
3769769
D014282_D012559 NONE hydrochloride_12\NN\14817592|NONE (r_dobj) trihexyphenidyl_11\JJ\0|was|with|patient|. (r_conj) treated_5\VBN\2376958|NONE (l_nsubjpass) patient_3\NN\9898892|was|with|trihexyphenidyl|. (l_amod) schizophrenic_2\JJ\10490141|A|chronic
D014282_D001919 CID hydrochloride_4\NN\14817592|to (r_pobj) due_1\JJ\5174653|. (r_amod) bradycardia_0\NNS\14110674|NONE
6674249
D015119_D013345 NONE acid_12\NN\14818238|)|( (r_nmod) eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (l_prep) in_17\IN\13603305|a|short|EACA|aminocaproic (l_pobj) patient_23\NN\9898892|NONE (l_prep) with_24\IN\0|old|a (l_pobj) haemorrhage_26\NN\14285662|NONE
D015119_D013345 NONE acid_12\NN\14818238|)|( (r_nmod) eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (r_pobj) due_5\IN\5174653|myopathy (r_prep) necrotizing_3\VBG\0|NONE (r_pcomp) of_2\IN\0|A (r_prep) case_1\NN\7283608|(|is|.|) (r_nsubjpass) described_31\VBN\1001294|NONE (l_punct) (_27\-LRB-\0|is|case|.|) (l_preconj) sah_28\NNP\0|NONE
D015119_D013345 NONE eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (l_prep) in_17\IN\13603305|a|short|EACA|aminocaproic (l_pobj) patient_23\NN\9898892|NONE (l_prep) with_24\IN\0|old|a (l_pobj) haemorrhage_26\NN\14285662|NONE
D015119_D013345 NONE eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (r_pobj) due_5\IN\5174653|myopathy (r_prep) necrotizing_3\VBG\0|NONE (r_pcomp) of_2\IN\0|A (r_prep) case_1\NN\7283608|(|is|.|) (r_nsubjpass) described_31\VBN\1001294|NONE (l_punct) (_27\-LRB-\0|is|case|.|) (l_preconj) sah_28\NNP\0|NONE
D015119_D009336 CID acid_12\NN\14818238|)|( (r_nmod) eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (r_pobj) due_5\IN\5174653|myopathy (r_prep) necrotizing_3\VBG\0|NONE (l_advmod) myopathy_4\NNS\14204950|due
D015119_D009336 CID eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (r_pobj) due_5\IN\5174653|myopathy (r_prep) necrotizing_3\VBG\0|NONE (l_advmod) myopathy_4\NNS\14204950|due
D015119_D009135 CID acid_5\NN\14818238|in|?|myopathy|may|Why (r_nsubj) induce_9\VBP\1627355|NONE (l_dobj) myopathy_10\NNS\14204950|in|?|acid|may|Why
D015119_D009135 CID eaca_7\NNP\0|aminocaproic (r_appos) acid_5\NN\14818238|in|?|myopathy|may|Why (r_nsubj) induce_9\VBP\1627355|NONE (l_dobj) myopathy_10\NNS\14204950|in|?|acid|may|Why
D015119_D009135 CID acid_12\NN\14818238|)|( (r_nmod) eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (r_pobj) due_5\IN\5174653|myopathy (r_prep) necrotizing_3\VBG\0|NONE (l_advmod) myopathy_4\NNS\14204950|due
D015119_D009135 CID eaca_14\NNP\0|a|short|in|aminocaproic (r_nmod) treatment_16\NN\654885|to (r_pobj) due_5\IN\5174653|myopathy (r_prep) necrotizing_3\VBG\0|NONE (l_advmod) myopathy_4\NNS\14204950|due
15686794
D000638_D001281 NONE amiodarone_0\NNP\2715941|.|drug (r_nsubj) represents_1\VBZ\2664769|NONE (l_dobj) drug_5\NN\14778436|.|Amiodarone (l_prep) for_6\IN\0|effective|antiarrhythmic|an (l_pobj) cardioversion_7\NN\0|NONE (l_prep) of_8\IN\0|NONE (l_pobj) fibrillation_13\NN\14361664|NONE
D000638_D001281 NONE amiodarone_0\NNP\2715941|.|drug (r_nsubj) represents_1\VBZ\2664769|NONE (l_dobj) drug_5\NN\14778436|.|Amiodarone (l_prep) for_6\IN\0|effective|antiarrhythmic|an (l_pobj) cardioversion_7\NN\0|NONE (l_prep) of_8\IN\0|NONE (l_pobj) fibrillation_13\NN\14361664|NONE (l_appos) af_15\NNP\0|onset|(|atrial
D000638_D001281 NONE amiodarone_28\NN\2715941|intravenous (r_compound) loading_29\NN\4571088|NONE (r_pobj) of_26\IN\0|NONE (r_prep) initiation_25\NN\7450842|minutes (r_pobj) after_24\IN\0|who|pain (r_prep) experienced_14\VBD\2108377|atrial|onset|, (r_relcl) fibrillation_11\NN\14361664|NONE
D000638_D017116 CID amiodarone_8\NN\2715941|NONE (r_pobj) of_7\IN\0|intravenous (r_prep) administration_6\NN\1133281|NONE (r_pobj) during_4\IN\0|:|.|report|Acute|back (r_prep) pain_3\NN\14299637|NONE
D000638_D017116 CID amiodarone_28\NN\2715941|intravenous (r_compound) loading_29\NN\4571088|NONE (r_pobj) of_26\IN\0|NONE (r_prep) initiation_25\NN\7450842|minutes (r_pobj) after_24\IN\0|who|pain (r_prep) experienced_14\VBD\2108377|atrial|onset|, (l_dobj) pain_20\NN\14299637|after|who
3413271
D004837_D003866 NONE epinephrine_1\NN\14807929|evidenced|ischemia|. (r_nsubj) produced_4\VBD\1617192|NONE (l_advcl) evidenced_8\VBN\1015244|ischemia|epinephrine|. (l_agent) by_9\IN\0|as (l_pobj) depression_12\NN\14373582|NONE
D010100_D007511 NONE oxygen_8\NN\14622893|increasing|myocardial (r_compound) consumption_9\NN\13440063|.|were|during|signs (r_nsubjpass) compared_11\VBN\644583|NONE (l_nsubjpass) signs_1\NNS\6643763|.|were|during|consumption (l_prep) of_2\IN\0|Objective (l_pobj) ischemia_3\NN\14195315|NONE
D004837_D000787 NONE epinephrine_1\NN\14807929|evidenced|ischemia|. (r_nsubj) produced_4\VBD\1617192|NONE (l_advcl) evidenced_8\VBN\1015244|ischemia|epinephrine|. (l_agent) by_9\IN\0|as (l_pobj) depression_12\NN\14373582|NONE (l_conj) angina_14\NN\14171682|ST|and|segment
D004837_D003324 NONE epinephrine_3\NN\14807929|NONE (r_pobj) of_2\IN\0|The|in (r_prep) role_1\NN\719494|.|was|in (r_nsubjpass) examined_9\VBN\0|NONE (l_prep) in_10\IN\13603305|.|was|role (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) disease_15\NN\14061805|NONE
D004837_D017202 CID epinephrine_6\NN\14807929|NONE (r_pobj) by_5\IN\0|Mechanisms|. (r_prep) induced_4\VBN\1627355|NONE (l_nsubj) mechanisms_0\NNS\13446390|.|by (l_prep) of_1\IN\0|NONE (l_pobj) ischemia_3\NN\14195315|NONE
D004837_D017202 CID epinephrine_3\NN\14807929|NONE (r_pobj) of_2\IN\0|The|in (r_prep) role_1\NN\719494|.|was|in (l_prep) in_4\IN\13603305|of|The (l_pcomp) eliciting_5\VBG\1617192|NONE (l_dobj) ischemia_7\NN\14195315|NONE
D004837_D017202 CID epinephrine_1\NN\14807929|evidenced|ischemia|. (r_nsubj) produced_4\VBD\1617192|NONE (l_dobj) ischemia_6\NN\14195315|evidenced|epinephrine|.
D004837_D017202 CID epinephrine_9\NN\14807929|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|of|the (r_acl) mechanisms_3\NNS\13446390|However|different|,|. (l_prep) of_4\IN\0|induced|the (l_pobj) ischemia_6\NN\14195315|NONE
D004837_D017202 CID epinephrine_28\NN\14807929| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) ischemia_31\NN\14195315|while|was|by (r_nsubjpass) characterized_33\VBN\609683|predominantly|with|by|was|.|ischemia|, (r_advcl) marked_6\VBN\1296462|NONE (l_nsubjpass) ischemia_4\NN\14195315|predominantly|with|characterized|by|was|.|,
D004837_D007511 NONE epinephrine_6\NN\14807929|NONE (l_appos) comparison_8\NN\635850|: (l_prep) with_9\IN\0|NONE (l_pobj) ischemia_13\NN\14195315|NONE
D004837_D007511 NONE epinephrine_13\NN\14807929|exercise|and (r_amod) infusion_14\NN\14589223|NONE (r_pobj) during_12\IN\0|.|were|signs|consumption (r_prep) compared_11\VBN\644583|NONE (l_nsubjpass) signs_1\NNS\6643763|.|were|during|consumption (l_prep) of_2\IN\0|Objective (l_pobj) ischemia_3\NN\14195315|NONE
D004837_D007511 NONE epinephrine_28\NN\14807929| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) ischemia_31\NN\14195315|while|was|by
D004837_D007511 NONE epinephrine_7\NN\14807929|NONE (r_pobj) by_6\IN\0|NONE (r_agent) produced_5\VBN\1617192|that|, (r_acl) ischemia_4\NN\14195315|may|as|during
7161250
D006220_D010302 CID haloperidol_10\NN\3713736|NONE (r_pobj) of_9\IN\0|higher (r_prep) doses_8\NNS\3740161|and|in (r_pobj) at_6\IN\14622893|higher|.|incidence (r_prep) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|higher|at|. (l_prep) of_2\IN\0|The (l_pobj) parkinsonism_3\NN\14085708|NONE
D008140_D017109 NONE lorazepam_6\NN\2830852|NONE (r_pobj) by_3\IN\0|were|.|was|,|Akathisia (r_agent) controlled_2\VBN\0|NONE (l_nsubjpass) akathisia_0\NNP\0|were|.|was|,|by
D001569_D017109 NONE benzodiazepine_5\JJ\3771443|the|in|out (r_amod) lorazepam_6\NN\2830852|NONE (r_pobj) by_3\IN\0|were|.|was|,|Akathisia (r_agent) controlled_2\VBN\0|NONE (l_nsubjpass) akathisia_0\NNP\0|were|.|was|,|by
19996135
D014148_D012640 CID acid_4\NNP\14818238|with|is|. (r_nsubjpass) associated_6\VBN\628491|NONE (l_prep) with_7\IN\0|is|.|Acid (l_pobj) seizures_10\NNS\14081375|NONE
D014148_D012640 CID txa_19\NNP\0|seizures|and (r_compound) usage_20\NN\407535|NONE (l_conj) seizures_22\NNS\14081375|TXA|and
D014148_D012640 CID txa_9\NNP\0|NONE (r_compound) intraoperatively_10\NN\0|NONE (r_pobj) of_8\IN\0|high|ranging (r_prep) doses_7\NNS\3740161|.|had|,|patients (r_dobj) received_5\VBD\2210855|NONE (l_nsubj) patients_2\NNS\9898892|.|had|doses|, (l_prep) with_3\IN\0||All (l_pobj) seizures_4\NNS\14081375|NONE
D014148_D012640 CID txa_9\NN\0|NONE (r_pobj) of_5\IN\0|in|in (r_prep) use_4\NN\407535|that|is|with (r_nsubjpass) associated_25\VBN\628491|results|. (l_prep) with_26\IN\0|that|is|use (l_pobj) seizures_28\NNS\14081375|NONE
